15882284
D001241_D007676 CID BACKGROUND\NN\4921011 :\:\1740 Studies\NNS\635850 on\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 the\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 <e1>aspirin</e1>\NN\2707683 and\CC\1740 other\JJ\1740 analgesic\NN\3740161 and\CC\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 NSAIDs\NNS\2721538 )\-RRB-\1740 and\CC\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 ESRD\NN\1740 )\-RRB-\1740 have\VBP\2108377 given\VBN\2327200 conflicting\JJ\1740 results\NNS\34213 .\.\1740
D001241_D007676 CID BACKGROUND\NN\4921011 :\:\1740 Studies\NNS\635850 on\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 the\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 <e1>aspirin</e1>\NN\2707683 and\CC\1740 other\JJ\1740 analgesic\NN\3740161 and\CC\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 NSAIDs\NNS\2721538 )\-RRB-\1740 and\CC\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 (\-LRB-\1740 <e2>ESRD</e2>\NN\1740 )\-RRB-\1740 have\VBP\2108377 given\VBN\2327200 conflicting\JJ\1740 results\NNS\34213 .\.\1740
D001241_D007676 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>ESRD</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>aspirin</e1>\NN\2707683 was\VBD\836236 related\JJ\1740 to\TO\1740 the\DT\1740 cumulated\JJ\1740 dose\NN\3740161 and\CC\1740 duration\NN\15113229 of\IN\1740 use\NN\407535 ,\,\1740 and\CC\1740 it\PRP\6125041 was\VBD\836236 particularly\RB\1740 high\JJ\1740 among\IN\1740 the\DT\1740 subset\NN\7999699 of\IN\1740 patients\NNS\9898892 with\IN\1740 vascular\JJ\1740 nephropathy\NN\14573196 as\IN\14622893 underlying\VBG\2604760 disease\NN\14061805 [\-LRB-\1740 2.35\CD\1740 (\-LRB-\1740 1.17\CD\1740 -\SYM\1740 4.72\CD\1740 )\-RRB-\1740 ]\-RRB-\1740 .\.\1740
D001241_D007676 CID However\RB\1740 ,\,\1740 the\DT\1740 chronic\JJ\1740 use\NN\407535 of\IN\1740 <e1>aspirin</e1>\NN\2707683 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>ESRD</e2>\NN\1740 .\.\1740
D001241_D007674 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 ESRD\NN\1740 associated\VBN\628491 with\IN\1740 <e1>aspirin</e1>\NN\2707683 was\VBD\836236 related\JJ\1740 to\TO\1740 the\DT\1740 cumulated\JJ\1740 dose\NN\3740161 and\CC\1740 duration\NN\15113229 of\IN\1740 use\NN\407535 ,\,\1740 and\CC\1740 it\PRP\6125041 was\VBD\836236 particularly\RB\1740 high\JJ\1740 among\IN\1740 the\DT\1740 subset\NN\7999699 of\IN\1740 patients\NNS\9898892 with\IN\1740 vascular\JJ\1740 <e2>nephropathy</e2>\NN\14573196 as\IN\14622893 underlying\VBG\2604760 disease\NN\14061805 [\-LRB-\1740 2.35\CD\1740 (\-LRB-\1740 1.17\CD\1740 -\SYM\1740 4.72\CD\1740 )\-RRB-\1740 ]\-RRB-\1740 .\.\1740
17159032
D006886_D014786 CID Early\JJ\1740 paracentral\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 loss</e2>\NN\13252973 in\IN\13603305 patients\NNS\9898892 taking\VBG\2367363 <e1>hydroxychloroquine</e1>\NN\2721538 .\.\1740
D006886_D014786 CID Thirty-five\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 13.4\CD\1740 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 <e2>visual\JJ\1740 field\NN\8673395 abnormalities</e2>\NNS\14034177 ,\,\1740 which\WDT\1740 were\VBD\836236 attributed\VBN\670261 to\TO\1740 <e1>hydroxychloroquine</e1>\NN\2721538 treatment\NN\654885 in\IN\13603305 4\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
7018927
D006220_D006966 CID Pituitary\JJ\1740 response\NN\11410625 to\TO\1740 luteinizing\VBG\1740 hormone-releasing\JJ\1740 hormone\NN\5404728 during\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D006220_D006966 CID During\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 infusions\NNS\14589223 ,\,\1740 significant\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 was\VBD\836236 found\VBN\2426171 ,\,\1740 together\RB\1740 with\IN\1740 an\DT\6697703 abolished\VBN\1740 pituitary\JJ\1740 response\NN\11410625 to\TO\1740 LH-RH\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 with\IN\1740 responses\NNS\11410625 of\IN\1740 control\JJ\1740 subjects\NNS\6598915 .\.\1740
6305660
2553470
D016291_D013226 NONE Anticonvulsant\JJ\1740 actions\NNS\30358 of\IN\1740 <e1>MK-801</e1>\NN\1740 on\IN\1740 the\DT\1740 lithium-pilocarpine\NN\1740 model\NN\5888929 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016291_D013226 NONE Administration\NN\1133281 of\IN\1740 <e1>MK-801</e1>\NN\1740 30\CD\13745420 or\CC\3541091 60\CD\13745420 min\NN\15154774 after\IN\1740 pilocarpine\NN\14712692 ,\,\1740 i.e.\FW\1740 ,\,\1740 during\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 ,\,\1740 gradually\RB\1740 reduced\VBN\441445 electrical\JJ\1740 and\CC\1740 behavioral\JJ\1740 seizure\NN\14081375 activity\NN\30358 and\CC\1740 greatly\RB\1740 enhanced\VBD\227165 the\DT\1740 survival\NN\13961642 rate\NN\13815152 .\.\1740
D008094_D013226 CID Anticonvulsant\JJ\1740 actions\NNS\30358 of\IN\1740 MK-801\NN\1740 on\IN\1740 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008094_D013226 CID Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 pilocarpine\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D008094_D013226 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 NMDA\NN\1740 receptors\NNS\5225602 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 brain\NN\5462674 damage\NN\7296428 in\IN\13603305 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 .\.\1740
D010862_D013226 CID Anticonvulsant\JJ\1740 actions\NNS\30358 of\IN\1740 MK-801\NN\1740 on\IN\1740 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 of\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010862_D013226 CID Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 lithium\NN\14625458 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 pilocarpine\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D010862_D013226 CID Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D010862_D013226 CID Administration\NN\1133281 of\IN\1740 MK-801\NN\1740 30\CD\13745420 or\CC\3541091 60\CD\13745420 min\NN\15154774 after\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 i.e.\FW\1740 ,\,\1740 during\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 ,\,\1740 gradually\RB\1740 reduced\VBN\441445 electrical\JJ\1740 and\CC\1740 behavioral\JJ\1740 seizure\NN\14081375 activity\NN\30358 and\CC\1740 greatly\RB\1740 enhanced\VBD\227165 the\DT\1740 survival\NN\13961642 rate\NN\13815152 .\.\1740
D010862_D013226 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 NMDA\NN\1740 receptors\NNS\5225602 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 brain\NN\5462674 damage\NN\7296428 in\IN\13603305 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 .\.\1740
D010862_D013226 CID This\DT\1740 was\VBD\836236 further\RBR\1740 supported\VBN\2199590 by\IN\1740 results\NNS\34213 showing\VBG\2137132 that\IN\1740 nonconvulsive\JJ\1740 doses\NNS\3740161 of\IN\1740 NMDA\NN\1740 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 were\VBD\836236 synergistic\JJ\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 subsequent\JJ\1740 mortality\NN\5054863 .\.\1740
D016291_D012640 NONE <e1>MK-801</e1>\NN\1740 ,\,\1740 a\DT\13649268 noncompetitive\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 was\VBD\836236 tested\VBN\670261 for\IN\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 using\VBG\1156834 two\CD\13741022 <e2>seizure</e2>\NN\14081375 models\NNS\5888929 ,\,\1740 coadministration\NN\1740 of\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 and\CC\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 .\.\1740
D016291_D012640 NONE First\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>MK-801</e1>\NN\1740 produced\VBD\1617192 an\DT\6697703 effective\JJ\1740 and\CC\1740 dose-dependent\JJ\1740 anticonvulsant\JJ\1740 action\NN\30358 with\IN\1740 the\DT\1740 lithium-pilocarpine\NN\1740 model\NN\5888929 but\CC\1740 not\RB\1740 with\IN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 biochemical\JJ\1740 mechanisms\NNS\13446390 control\VBP\2422663 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 these\DT\1740 two\CD\13741022 models\NNS\5888929 .\.\1740
D016291_D012640 NONE Second\RB\1740 ,\,\1740 the\DT\1740 anticonvulsant\JJ\1740 effect\NN\34213 of\IN\1740 <e1>MK-801</e1>\NN\1740 in\IN\13603305 the\DT\1740 lithium-pilocarpine\NN\1740 model\NN\5888929 only\RB\1740 occurred\VBD\2623529 after\IN\1740 initial\JJ\1740 periods\NNS\13575869 of\IN\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 .\.\1740
D016291_D012640 NONE Administration\NN\1133281 of\IN\1740 <e1>MK-801</e1>\NN\1740 30\CD\13745420 or\CC\3541091 60\CD\13745420 min\NN\15154774 after\IN\1740 pilocarpine\NN\14712692 ,\,\1740 i.e.\FW\1740 ,\,\1740 during\IN\1740 status\NN\24720 epilepticus\NN\1740 ,\,\1740 gradually\RB\1740 reduced\VBN\441445 electrical\JJ\1740 and\CC\1740 behavioral\JJ\1740 <e2>seizure</e2>\NN\14081375 activity\NN\30358 and\CC\1740 greatly\RB\1740 enhanced\VBD\227165 the\DT\1740 survival\NN\13961642 rate\NN\13815152 .\.\1740
D016202_D012640 NONE MK-801\NN\1740 ,\,\1740 a\DT\13649268 noncompetitive\JJ\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 was\VBD\836236 tested\VBN\670261 for\IN\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 using\VBG\1156834 two\CD\13741022 <e2>seizure</e2>\NN\14081375 models\NNS\5888929 ,\,\1740 coadministration\NN\1740 of\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 and\CC\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 .\.\1740
D016202_D012640 NONE MK-801\NN\1740 ,\,\1740 a\DT\13649268 noncompetitive\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 was\VBD\836236 tested\VBN\670261 for\IN\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 using\VBG\1156834 two\CD\13741022 <e2>seizure</e2>\NN\14081375 models\NNS\5888929 ,\,\1740 coadministration\NN\1740 of\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 and\CC\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 .\.\1740
D008094_D012640 NONE MK-801\NN\1740 ,\,\1740 a\DT\13649268 noncompetitive\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 was\VBD\836236 tested\VBN\670261 for\IN\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 using\VBG\1156834 two\CD\13741022 <e2>seizure</e2>\NN\14081375 models\NNS\5888929 ,\,\1740 coadministration\NN\1740 of\IN\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 and\CC\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 .\.\1740
D008094_D012640 NONE First\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 MK-801\NN\1740 produced\VBD\1617192 an\DT\6697703 effective\JJ\1740 and\CC\1740 dose-dependent\JJ\1740 anticonvulsant\JJ\1740 action\NN\30358 with\IN\1740 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 but\CC\1740 not\RB\1740 with\IN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 biochemical\JJ\1740 mechanisms\NNS\13446390 control\VBP\2422663 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 these\DT\1740 two\CD\13741022 models\NNS\5888929 .\.\1740
D008094_D012640 NONE Second\RB\1740 ,\,\1740 the\DT\1740 anticonvulsant\JJ\1740 effect\NN\34213 of\IN\1740 MK-801\NN\1740 in\IN\13603305 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 only\RB\1740 occurred\VBD\2623529 after\IN\1740 initial\JJ\1740 periods\NNS\13575869 of\IN\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 .\.\1740
D008094_D012640 NONE Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 pilocarpine\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 status\NN\24720 epilepticus\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D008094_D012640 NONE Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 pilocarpine\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 status\NN\24720 epilepticus\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 NONE MK-801\NN\1740 ,\,\1740 a\DT\13649268 noncompetitive\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 was\VBD\836236 tested\VBN\670261 for\IN\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 using\VBG\1156834 two\CD\13741022 <e2>seizure</e2>\NN\14081375 models\NNS\5888929 ,\,\1740 coadministration\NN\1740 of\IN\1740 lithium\NN\14625458 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 and\CC\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 .\.\1740
D010862_D012640 NONE MK-801\NN\1740 ,\,\1740 a\DT\13649268 noncompetitive\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 was\VBD\836236 tested\VBN\670261 for\IN\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 using\VBG\1156834 two\CD\13741022 <e2>seizure</e2>\NN\14081375 models\NNS\5888929 ,\,\1740 coadministration\NN\1740 of\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 and\CC\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 alone\RB\1740 .\.\1740
D010862_D012640 NONE First\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 MK-801\NN\1740 produced\VBD\1617192 an\DT\6697703 effective\JJ\1740 and\CC\1740 dose-dependent\JJ\1740 anticonvulsant\JJ\1740 action\NN\30358 with\IN\1740 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 but\CC\1740 not\RB\1740 with\IN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 alone\RB\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 biochemical\JJ\1740 mechanisms\NNS\13446390 control\VBP\2422663 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 these\DT\1740 two\CD\13741022 models\NNS\5888929 .\.\1740
D010862_D012640 NONE First\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 MK-801\NN\1740 produced\VBD\1617192 an\DT\6697703 effective\JJ\1740 and\CC\1740 dose-dependent\JJ\1740 anticonvulsant\JJ\1740 action\NN\30358 with\IN\1740 the\DT\1740 lithium-pilocarpine\NN\1740 model\NN\5888929 but\CC\1740 not\RB\1740 with\IN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>pilocarpine</e1>\NN\14712692 alone\RB\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 biochemical\JJ\1740 mechanisms\NNS\13446390 control\VBP\2422663 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 these\DT\1740 two\CD\13741022 models\NNS\5888929 .\.\1740
D010862_D012640 NONE Second\RB\1740 ,\,\1740 the\DT\1740 anticonvulsant\JJ\1740 effect\NN\34213 of\IN\1740 MK-801\NN\1740 in\IN\13603305 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 only\RB\1740 occurred\VBD\2623529 after\IN\1740 initial\JJ\1740 periods\NNS\13575869 of\IN\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 .\.\1740
D010862_D012640 NONE Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 lithium\NN\14625458 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 pilocarpine\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 status\NN\24720 epilepticus\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D010862_D012640 NONE Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 lithium\NN\14625458 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 pilocarpine\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 status\NN\24720 epilepticus\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 NONE Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 status\NN\24720 epilepticus\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 seizures\NNS\14081375 .\.\1740
D010862_D012640 NONE Third\RB\1740 ,\,\1740 although\IN\1740 it\PRP\6125041 is\VBZ\836236 relatively\RB\1740 easy\JJ\1740 to\TO\1740 block\VB\1476483 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 lithium\NN\14625458 and\CC\1740 pilocarpine\NN\14712692 by\IN\1740 administration\NN\1133281 of\IN\1740 anticonvulsants\NNS\3740161 prior\RB\1740 to\TO\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 it\PRP\6125041 is\VBZ\836236 more\RBR\1740 difficult\JJ\1740 to\TO\1740 terminate\VB\126264 ongoing\JJ\1740 status\NN\24720 epilepticus\NN\1740 and\CC\1740 block\VBP\1476483 the\DT\1740 lethality\NN\4790449 of\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 NONE Administration\NN\1133281 of\IN\1740 MK-801\NN\1740 30\CD\13745420 or\CC\3541091 60\CD\13745420 min\NN\15154774 after\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 i.e.\FW\1740 ,\,\1740 during\IN\1740 status\NN\24720 epilepticus\NN\1740 ,\,\1740 gradually\RB\1740 reduced\VBN\441445 electrical\JJ\1740 and\CC\1740 behavioral\JJ\1740 <e2>seizure</e2>\NN\14081375 activity\NN\30358 and\CC\1740 greatly\RB\1740 enhanced\VBD\227165 the\DT\1740 survival\NN\13961642 rate\NN\13815152 .\.\1740
D016202_D013226 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 <e1>NMDA</e1>\NN\1740 receptors\NNS\5225602 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 brain\NN\5462674 damage\NN\7296428 in\IN\13603305 the\DT\1740 lithium-pilocarpine\NN\1740 model\NN\5888929 .\.\1740
D016202_D013226 NONE This\DT\1740 was\VBD\836236 further\RBR\1740 supported\VBN\2199590 by\IN\1740 results\NNS\34213 showing\VBG\2137132 that\IN\1740 nonconvulsive\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>NMDA</e1>\NN\1740 and\CC\1740 pilocarpine\NN\14712692 were\VBD\836236 synergistic\JJ\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 <e2>status\NN\24720 epilepticus</e2>\NN\1740 and\CC\1740 subsequent\JJ\1740 mortality\NN\5054863 .\.\1740
D016202_D001930 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 <e1>NMDA</e1>\NN\1740 receptors\NNS\5225602 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 status\NN\24720 epilepticus\NN\1740 and\CC\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 in\IN\13603305 the\DT\1740 lithium-pilocarpine\NN\1740 model\NN\5888929 .\.\1740
D008094_D001930 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 NMDA\NN\1740 receptors\NNS\5225602 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 status\NN\24720 epilepticus\NN\1740 and\CC\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 in\IN\13603305 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 .\.\1740
D010862_D001930 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 NMDA\NN\1740 receptors\NNS\5225602 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 status\NN\24720 epilepticus\NN\1740 and\CC\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 in\IN\13603305 the\DT\1740 <e1>lithium-pilocarpine</e1>\NN\1740 model\NN\5888929 .\.\1740
9132810
D008727_D056784 CID This\DT\1740 report\NN\6470073 describes\VBZ\1001294 unique\JJ\1740 contrast\NN\13854649 enhancement\NN\248977 of\IN\1740 the\DT\1740 white\JJ\1740 matter\NN\5670710 on\IN\1740 T1-weighted\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 images\NNS\5926676 of\IN\1740 two\CD\13741022 patients\NNS\9898892 with\IN\1740 disseminated\VBN\954608 necrotizing\NN\1740 <e2>leukoencephalopathy</e2>\IN\1740 ,\,\1740 which\WDT\1740 developed\VBD\1753788 from\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 <e1>methotrexate</e1>\NN\2722166 .\.\1740
D008727_D054198 NONE This\DT\1740 report\NN\6470073 describes\VBZ\1001294 unique\JJ\1740 contrast\NN\13854649 enhancement\NN\248977 of\IN\1740 the\DT\1740 white\JJ\1740 matter\NN\5670710 on\IN\1740 T1-weighted\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 images\NNS\5926676 of\IN\1740 two\CD\13741022 patients\NNS\9898892 with\IN\1740 disseminated\VBN\954608 necrotizing\NN\1740 leukoencephalopathy\IN\1740 ,\,\1740 which\WDT\1740 developed\VBD\1753788 from\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 <e1>methotrexate</e1>\NN\2722166 .\.\1740
10219427
12828076
D000082_D017114 CID Increased\VBN\169651 serum\NN\5397468 soluble\JJ\1740 Fas\NN\14304060 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 due\JJ\1740 to\TO\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 .\.\1740
D000082_D017114 CID Levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 due\JJ\1740 to\TO\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 (\-LRB-\1740 median\NN\6021761 ,\,\1740 28.7\CD\1740 U/mL\NN\1740 ;\:\1740 range\VB\2604760 ,\,\1740 12.8\CD\1740 -\SYM\1740 52.7\CD\1740 U/mL\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 than\IN\1740 those\DT\1740 due\JJ\1740 to\IN\1740 non-A\NN\1740 to\TO\1740 E\NN\14724645 hepatitis\NN\14127211 (\-LRB-\1740 median\NN\6021761 ,\,\1740 12.5\CD\1740 U/mL\NN\1740 ;\:\1740 range\VB\2604760 ,\,\1740 6.9\CD\1740 -\HYPH\1740 46.0\CD\1740 U/mL\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 ,\,\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D000082_D062787 NONE Increased\VBN\169651 serum\NN\5397468 soluble\JJ\1740 Fas\NN\14304060 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 due\JJ\1740 to\TO\1740 <e1>paracetamol</e1>\NN\1740 <e2>overdose</e2>\NN\1740 .\.\1740
D000082_D062787 NONE Levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 due\JJ\1740 to\TO\1740 <e1>paracetamol</e1>\NN\1740 <e2>overdose</e2>\NN\1740 (\-LRB-\1740 median\NN\6021761 ,\,\1740 28.7\CD\1740 U/mL\NN\1740 ;\:\1740 range\VB\2604760 ,\,\1740 12.8\CD\1740 -\SYM\1740 52.7\CD\1740 U/mL\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 than\IN\1740 those\DT\1740 due\JJ\1740 to\IN\1740 non-A\NN\1740 to\TO\1740 E\NN\14724645 hepatitis\NN\14127211 (\-LRB-\1740 median\NN\6021761 ,\,\1740 12.5\CD\1740 U/mL\NN\1740 ;\:\1740 range\VB\2604760 ,\,\1740 6.9\CD\1740 -\HYPH\1740 46.0\CD\1740 U/mL\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 ,\,\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D000082_D056486 NONE Levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 due\JJ\1740 to\TO\1740 <e1>paracetamol</e1>\NN\1740 overdose\NN\1740 (\-LRB-\1740 median\NN\6021761 ,\,\1740 28.7\CD\1740 U/mL\NN\1740 ;\:\1740 range\VB\2604760 ,\,\1740 12.8\CD\1740 -\SYM\1740 52.7\CD\1740 U/mL\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 than\IN\1740 those\DT\1740 due\JJ\1740 to\IN\1740 non-A\NN\1740 to\TO\1740 E\NN\14724645 <e2>hepatitis</e2>\NN\14127211 (\-LRB-\1740 median\NN\6021761 ,\,\1740 12.5\CD\1740 U/mL\NN\1740 ;\:\1740 range\VB\2604760 ,\,\1740 6.9\CD\1740 -\HYPH\1740 46.0\CD\1740 U/mL\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 ,\,\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
11229942
D003042_D066126 NONE <e1>Cocaine</e1>\NNP\3492717 ,\,\1740 ethanol\NN\14708720 ,\,\1740 and\CC\1740 cocaethylene\NN\1740 <e2>cardiotoxity</e2>\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse\NN\418025 .\.\1740
D003042_D066126 NONE Their\PRP$\1740 combined\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 independent\JJ\1740 effects\NNS\13245626 of\IN\1740 each\DT\1740 drug\NN\14778436 ;\:\1740 however\RB\1740 ,\,\1740 they\PRP\1740 may\MD\15209706 also\RB\1740 be\VB\836236 due\JJ\1740 to\TO\1740 cocaethylene\NN\1740 (\-LRB-\1740 CE\NN\14625458 )\-RRB-\1740 ,\,\1740 a\DT\13649268 <e1>cocaine</e1>\NN\3492717 metabolite\NN\20090 formed\VBN\1617192 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 ethanol\NN\14708720 .\.\1740
D003042_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 delineate\VB\2137132 the\DT\1740 role\NN\719494 of\IN\1740 CE\NN\14625458 in\IN\13603305 the\DT\1740 combined\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 ethanol\NN\14708720 in\IN\13603305 a\DT\13649268 model\NN\5888929 simulating\VBG\1736822 their\PRP$\1740 abuse\NN\418025 .\.\1740
D003042_D019970 NONE <e1>Cocaine</e1>\NNP\3492717 ,\,\1740 ethanol\NN\14708720 ,\,\1740 and\CC\1740 cocaethylene\NN\1740 cardiotoxity\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse</e2>\NN\418025 .\.\1740
D003042_D000437 NONE <e1>Cocaine</e1>\NNP\3492717 ,\,\1740 ethanol\NN\14708720 ,\,\1740 and\CC\1740 cocaethylene\NN\1740 cardiotoxity\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse</e2>\NN\418025 .\.\1740
D000431_D066126 NONE Cocaine\NNP\3492717 ,\,\1740 <e1>ethanol</e1>\NN\14708720 ,\,\1740 and\CC\1740 cocaethylene\NN\1740 <e2>cardiotoxity</e2>\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse\NN\418025 .\.\1740
D000431_D066126 NONE Their\PRP$\1740 combined\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 independent\JJ\1740 effects\NNS\13245626 of\IN\1740 each\DT\1740 drug\NN\14778436 ;\:\1740 however\RB\1740 ,\,\1740 they\PRP\1740 may\MD\15209706 also\RB\1740 be\VB\836236 due\JJ\1740 to\TO\1740 cocaethylene\NN\1740 (\-LRB-\1740 CE\NN\14625458 )\-RRB-\1740 ,\,\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 formed\VBN\1617192 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e1>ethanol</e1>\NN\14708720 .\.\1740
D000431_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 delineate\VB\2137132 the\DT\1740 role\NN\719494 of\IN\1740 CE\NN\14625458 in\IN\13603305 the\DT\1740 combined\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>ethanol</e1>\NN\14708720 in\IN\13603305 a\DT\13649268 model\NN\5888929 simulating\VBG\1736822 their\PRP$\1740 abuse\NN\418025 .\.\1740
D000431_D019970 NONE Cocaine\NNP\3492717 ,\,\1740 <e1>ethanol</e1>\NN\14708720 ,\,\1740 and\CC\1740 cocaethylene\NN\1740 cardiotoxity\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse</e2>\NN\418025 .\.\1740
D000431_D000437 NONE Cocaine\NNP\3492717 ,\,\1740 <e1>ethanol</e1>\NN\14708720 ,\,\1740 and\CC\1740 cocaethylene\NN\1740 cardiotoxity\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse</e2>\NN\418025 .\.\1740
C066444_D066126 NONE Cocaine\NNP\3492717 ,\,\1740 ethanol\NN\14708720 ,\,\1740 and\CC\1740 <e1>cocaethylene</e1>\NN\1740 <e2>cardiotoxity</e2>\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse\NN\418025 .\.\1740
C066444_D066126 NONE Their\PRP$\1740 combined\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 independent\JJ\1740 effects\NNS\13245626 of\IN\1740 each\DT\1740 drug\NN\14778436 ;\:\1740 however\RB\1740 ,\,\1740 they\PRP\1740 may\MD\15209706 also\RB\1740 be\VB\836236 due\JJ\1740 to\TO\1740 <e1>cocaethylene</e1>\NN\1740 (\-LRB-\1740 CE\NN\14625458 )\-RRB-\1740 ,\,\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 formed\VBN\1617192 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 ethanol\NN\14708720 .\.\1740
C066444_D066126 NONE Their\PRP$\1740 combined\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 independent\JJ\1740 effects\NNS\13245626 of\IN\1740 each\DT\1740 drug\NN\14778436 ;\:\1740 however\RB\1740 ,\,\1740 they\PRP\1740 may\MD\15209706 also\RB\1740 be\VB\836236 due\JJ\1740 to\TO\1740 cocaethylene\NN\1740 (\-LRB-\1740 <e1>CE</e1>\NN\14625458 )\-RRB-\1740 ,\,\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 formed\VBN\1617192 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 ethanol\NN\14708720 .\.\1740
C066444_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 delineate\VB\2137132 the\DT\1740 role\NN\719494 of\IN\1740 <e1>CE</e1>\NN\14625458 in\IN\13603305 the\DT\1740 combined\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 in\IN\13603305 a\DT\13649268 model\NN\5888929 simulating\VBG\1736822 their\PRP$\1740 abuse\NN\418025 .\.\1740
C066444_D019970 NONE Cocaine\NNP\3492717 ,\,\1740 ethanol\NN\14708720 ,\,\1740 and\CC\1740 <e1>cocaethylene</e1>\NN\1740 cardiotoxity\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse</e2>\NN\418025 .\.\1740
C066444_D000437 NONE Cocaine\NNP\3492717 ,\,\1740 ethanol\NN\14708720 ,\,\1740 and\CC\1740 <e1>cocaethylene</e1>\NN\1740 cardiotoxity\NN\1740 in\IN\13603305 an\DT\6697703 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 and\CC\1740 ethanol\NN\14708720 abuse</e2>\NN\418025 .\.\1740
C066444_D002303 CID Peak\JJ\1740 <e1>CE</e1>\NN\14625458 levels\NNS\4916342 were\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 45\CD\1740 %\NN\1740 (\-LRB-\1740 SD\NN\1740 +/-\CC\1740 22\CD\13745420 %\NN\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 =\JJ\1740 22\CD\13745420 %\NN\1740 to\IN\1740 69\CD\1740 %\NN\1740 )\-RRB-\1740 <e2>decrease\NN\7296428 in\IN\13603305 cardiac\JJ\1740 output</e2>\NN\4007894 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 56\CD\1740 %\NN\1740 (\-LRB-\1740 SD\NN\1740 +/-\CC\1740 23\CD\13745420 %\NN\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 =\JJ\1740 32\CD\1740 %\NN\1740 to\TO\1740 80\CD\13745420 %\NN\1740 )\-RRB-\1740 decrease\NN\7296428 in\IN\13603305 dP/dt(max\NN\1740 )\-RRB-\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 .006\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 a\DT\13649268 23\CD\13745420 %\NN\1740 (\-LRB-\1740 SD\NN\1740 +/-\CC\1740 15\CD\13745420 %\NN\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 =\JJ\1740 7\CD\13741022 %\NN\1740 to\TO\1740 49\CD\1740 %\NN\1740 )\-RRB-\1740 decrease\NN\7296428 in\IN\13603305 SVO(2\NN\1740 )\-RRB-\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.025\CD\1740 )\-RRB-\1740 .\.\1740
C066444_D009202 NONE Peak\JJ\1740 serum\NN\5397468 <e1>cocaethylene</e1>\NN\1740 concentrations\NNS\4916342 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e2>myocardial\JJ\1740 depression</e2>\NN\14373582 .\.\1740
12487093
D004837_D006973 CID <e1>Adrenaline-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 used\VBN\1156834 to\TO\1740 destroy\VB\1619231 the\DT\1740 BBB\NNP\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 triphenyltetrazolium\NN\1740 (\-LRB-\1740 TTC\NN\1740 )\-RRB-\1740 staining\NN\275424 of\IN\1740 the\DT\1740 brain\NN\5462674 slices\NNS\13285176 just\RB\1740 after\IN\1740 giving\VBG\2327200 adrenaline\NN\14807929 for\IN\1740 30\CD\13745420 s.\NN\1740 In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 whole\JJ\1740 brain\NN\5462674 sections\NNS\7020895 exhibited\VBD\2632167 complete\JJ\1740 staining\NN\275424 with\IN\1740 TTC\NN\1740 .\.\1740
D004837_D006973 CID Adrenaline-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 used\VBN\1156834 to\TO\1740 destroy\VB\1619231 the\DT\1740 BBB\NNP\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 triphenyltetrazolium\NN\1740 (\-LRB-\1740 TTC\NN\1740 )\-RRB-\1740 staining\NN\275424 of\IN\1740 the\DT\1740 brain\NN\5462674 slices\NNS\13285176 just\RB\1740 after\IN\1740 giving\VBG\2327200 <e1>adrenaline</e1>\NN\14807929 for\IN\1740 30\CD\13745420 s.\NN\1740 In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 whole\JJ\1740 brain\NN\5462674 sections\NNS\7020895 exhibited\VBD\2632167 complete\JJ\1740 staining\NN\275424 with\IN\1740 TTC\NN\1740 .\.\1740
C009591_D006973 NONE Adrenaline-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 used\VBN\1156834 to\TO\1740 destroy\VB\1619231 the\DT\1740 BBB\NNP\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 <e1>triphenyltetrazolium</e1>\NN\1740 (\-LRB-\1740 TTC\NN\1740 )\-RRB-\1740 staining\NN\275424 of\IN\1740 the\DT\1740 brain\NN\5462674 slices\NNS\13285176 just\RB\1740 after\IN\1740 giving\VBG\2327200 adrenaline\NN\14807929 for\IN\1740 30\CD\13745420 s.\NN\1740 In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 whole\JJ\1740 brain\NN\5462674 sections\NNS\7020895 exhibited\VBD\2632167 complete\JJ\1740 staining\NN\275424 with\IN\1740 TTC\NN\1740 .\.\1740
C009591_D006973 NONE Adrenaline-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 used\VBN\1156834 to\TO\1740 destroy\VB\1619231 the\DT\1740 BBB\NNP\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 triphenyltetrazolium\NN\1740 (\-LRB-\1740 <e1>TTC</e1>\NN\1740 )\-RRB-\1740 staining\NN\275424 of\IN\1740 the\DT\1740 brain\NN\5462674 slices\NNS\13285176 just\RB\1740 after\IN\1740 giving\VBG\2327200 adrenaline\NN\14807929 for\IN\1740 30\CD\13745420 s.\NN\1740 In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 whole\JJ\1740 brain\NN\5462674 sections\NNS\7020895 exhibited\VBD\2632167 complete\JJ\1740 staining\NN\275424 with\IN\1740 TTC\NN\1740 .\.\1740
C009591_D006973 NONE Adrenaline-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 used\VBN\1156834 to\TO\1740 destroy\VB\1619231 the\DT\1740 BBB\NNP\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 evaluated\VBN\670261 using\VBG\1156834 triphenyltetrazolium\NN\1740 (\-LRB-\1740 TTC\NN\1740 )\-RRB-\1740 staining\NN\275424 of\IN\1740 the\DT\1740 brain\NN\5462674 slices\NNS\13285176 just\RB\1740 after\IN\1740 giving\VBG\2327200 adrenaline\NN\14807929 for\IN\1740 30\CD\13745420 s.\NN\1740 In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 whole\JJ\1740 brain\NN\5462674 sections\NNS\7020895 exhibited\VBD\2632167 complete\JJ\1740 staining\NN\275424 with\IN\1740 <e1>TTC</e1>\NN\1740 .\.\1740
256433
D014031_D007239 NONE Continuous\JJ\1740 infusion\NN\14589223 <e1>tobramycin</e1>\NN\2716866 combined\JJ\1740 with\IN\1740 carbenicillin\NN\1740 for\IN\1740 <e2>infections</e2>\NNS\14052046 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D014031_D009369 NONE Continuous\JJ\1740 infusion\NN\14589223 <e1>tobramycin</e1>\NN\2716866 combined\JJ\1740 with\IN\1740 carbenicillin\NN\1740 for\IN\1740 infections\NNS\14052046 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D002228_D007239 NONE Continuous\JJ\1740 infusion\NN\14589223 tobramycin\NN\2716866 combined\JJ\1740 with\IN\1740 <e1>carbenicillin</e1>\NN\1740 for\IN\1740 <e2>infections</e2>\NNS\14052046 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D002228_D009369 NONE Continuous\JJ\1740 infusion\NN\14589223 tobramycin\NN\2716866 combined\JJ\1740 with\IN\1740 <e1>carbenicillin</e1>\NN\1740 for\IN\1740 infections\NNS\14052046 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D014031_D009503 NONE To\TO\1740 overcome\VB\1101913 the\DT\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e2>neutropenia</e2>\NN\14196405 ,\,\1740 <e1>tobramycin</e1>\NN\2716866 was\VBD\836236 given\VBN\2327200 by\IN\1740 continuous\JJ\1740 infusion\NN\14589223 and\CC\1740 combined\VBN\2630189 with\IN\1740 intermittent\JJ\1740 carbenicillin\NN\1740 .\.\1740
D002228_D009503 NONE To\TO\1740 overcome\VB\1101913 the\DT\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e2>neutropenia</e2>\NN\14196405 ,\,\1740 tobramycin\NN\2716866 was\VBD\836236 given\VBN\2327200 by\IN\1740 continuous\JJ\1740 infusion\NN\14589223 and\CC\1740 combined\VBN\2630189 with\IN\1740 intermittent\JJ\1740 <e1>carbenicillin</e1>\NN\1740 .\.\1740
D003404_D053099 NONE Major\JJ\1740 <e2>azotemia</e2>\NN\14204950 (\-LRB-\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 greater\JJR\1740 than\IN\1740 2.5\CD\1740 mg/dl\NN\1740 or\CC\3541091 BUN\NN\7679356 greater\JJR\1740 than\IN\1740 50\CD\13745420 mg/dl\NN\1740 )\-RRB-\1740 occurred\VBD\2623529 in\IN\13603305 only\RB\1740 2\CD\13741022 %\NN\1740 .\.\1740
D014031_D053099 CID <e2>Azotemia</e2>\NNP\14204950 was\VBD\836236 not\RB\1740 related\JJ\1740 to\TO\1740 duration\NN\15113229 of\IN\1740 therapy\NN\657604 or\CC\3541091 serum\NN\5397468 <e1>tobramycin</e1>\NN\2716866 concentration\NN\4916342 .\.\1740
612112
D005045_D009207 CID It\PRP\6125041 is\VBZ\836236 considered\VBN\689344 unlikely\JJ\1740 that\IN\1740 <e1>etomidate</e1>\NN\1740 will\MD\5650329 prove\VB\2604760 to\TO\1740 be\VB\836236 the\DT\1740 hypnotic\NN\3247620 of\IN\1740 choice\NN\5788149 for\IN\1740 a\DT\13649268 totally\RB\1740 intravenous\JJ\1740 anesthetic\JJ\1740 technique\NN\5660268 in\IN\13603305 adults\NNS\7846 because\IN\1740 of\IN\1740 the\DT\1740 high\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>myoclonia</e2>\NN\1740 after\IN\1740 prolonged\JJ\1740 administration\NN\1133281 .\.\1740
12752472
D010862_D004827 CID Here\RB\1740 we\PRP\1740 sought\VBD\1825237 to\TO\1740 generate\VB\1617192 information\NN\6598915 with\IN\1740 regard\NN\5817845 to\TO\1740 the\DT\1740 interictal\JJ\1740 period\NN\13575869 in\IN\13603305 animals\NNS\4475 with\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>epilepsy</e2>\NN\14085708 .\.\1740
D010862_D006985 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 <e2>hyperventilation</e2>\NN\831191 maneuver\NN\955060 caused\VBD\1617192 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 spontaneous\JJ\1740 ventilation\NN\248977 in\IN\13603305 <e1>pilocarpine-treated</e1>\JJ\1740 and\CC\1740 control\NN\5190804 rats\NNS\2329401 .\.\1740
15096374
D016559_D003872 NONE Induction\NN\7450842 of\IN\1740 rosaceiform\NN\1740 <e2>dermatitis</e2>\NN\14226056 during\IN\1740 treatment\NN\654885 of\IN\1740 facial\JJ\1740 inflammatory\JJ\1740 dermatoses\NNS\14219661 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\NN\4074482 .\.\1740
D016559_D003872 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 rosaceiform\NN\1740 <e2>dermatitis</e2>\NN\14226056 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\NN\4074482 .\.\1740
D016559_D003872 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Our\PRP$\1740 observations\NNS\996969 suggest\VBP\1010118 that\IN\1740 the\DT\1740 spectrum\NN\7939382 of\IN\1740 rosaceiform\NN\1740 <e2>dermatitis</e2>\NN\14226056 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\NN\4074482 is\VBZ\836236 heterogeneous\JJ\1740 .\.\1740
D016559_D005148 NONE Induction\NN\7450842 of\IN\1740 rosaceiform\NN\1740 dermatitis\NN\14226056 during\IN\1740 treatment\NN\654885 of\IN\1740 <e2>facial\JJ\1740 inflammatory\JJ\1740 dermatoses</e2>\NNS\14219661 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\NN\4074482 .\.\1740
D016559_D005148 NONE OBSERVATIONS\NN\996969 :\:\1740 Six\CD\13741022 adult\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>inflammatory\JJ\1740 facial\JJ\1740 dermatoses</e2>\NNS\14219661 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 ointment\JJ\1740 because\IN\1740 of\IN\1740 the\DT\1740 ineffectiveness\NN\5204637 of\IN\1740 standard\JJ\1740 treatments\NNS\654885 .\.\1740
D016559_D012393 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Tacrolimus</e1>\NN\1740 ointment\NN\4074482 is\VBZ\836236 increasingly\RB\1740 used\VBN\1156834 for\IN\1740 anti-inflammatory\JJ\1740 treatment\NN\654885 of\IN\1740 sensitive\JJ\1740 areas\NNS\8630985 such\JJ\1740 as\IN\14622893 the\DT\1740 face\NN\5225090 ,\,\1740 and\CC\1740 recent\JJ\1740 observations\NNS\996969 indicate\VBP\952524 that\IN\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 effective\JJ\1740 in\IN\13603305 steroid-aggravated\JJ\1740 <e2>rosacea</e2>\NN\14222112 and\CC\1740 perioral\JJ\1740 dermatitis\NN\14226056 .\.\1740
D016559_D019557 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Tacrolimus</e1>\NN\1740 ointment\NN\4074482 is\VBZ\836236 increasingly\RB\1740 used\VBN\1156834 for\IN\1740 anti-inflammatory\JJ\1740 treatment\NN\654885 of\IN\1740 sensitive\JJ\1740 areas\NNS\8630985 such\JJ\1740 as\IN\14622893 the\DT\1740 face\NN\5225090 ,\,\1740 and\CC\1740 recent\JJ\1740 observations\NNS\996969 indicate\VBP\952524 that\IN\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 effective\JJ\1740 in\IN\13603305 steroid-aggravated\JJ\1740 rosacea\NN\14222112 and\CC\1740 <e2>perioral\JJ\1740 dermatitis</e2>\NN\14226056 .\.\1740
D013256_D012393 NONE BACKGROUND\NN\4921011 :\:\1740 Tacrolimus\NN\1740 ointment\NN\4074482 is\VBZ\836236 increasingly\RB\1740 used\VBN\1156834 for\IN\1740 anti-inflammatory\JJ\1740 treatment\NN\654885 of\IN\1740 sensitive\JJ\1740 areas\NNS\8630985 such\JJ\1740 as\IN\14622893 the\DT\1740 face\NN\5225090 ,\,\1740 and\CC\1740 recent\JJ\1740 observations\NNS\996969 indicate\VBP\952524 that\IN\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 effective\JJ\1740 in\IN\13603305 <e1>steroid-aggravated</e1>\JJ\1740 <e2>rosacea</e2>\NN\14222112 and\CC\1740 perioral\JJ\1740 dermatitis\NN\14226056 .\.\1740
D013256_D019557 NONE BACKGROUND\NN\4921011 :\:\1740 Tacrolimus\NN\1740 ointment\NN\4074482 is\VBZ\836236 increasingly\RB\1740 used\VBN\1156834 for\IN\1740 anti-inflammatory\JJ\1740 treatment\NN\654885 of\IN\1740 sensitive\JJ\1740 areas\NNS\8630985 such\JJ\1740 as\IN\14622893 the\DT\1740 face\NN\5225090 ,\,\1740 and\CC\1740 recent\JJ\1740 observations\NNS\996969 indicate\VBP\952524 that\IN\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 effective\JJ\1740 in\IN\13603305 <e1>steroid-aggravated</e1>\JJ\1740 rosacea\NN\14222112 and\CC\1740 <e2>perioral\JJ\1740 dermatitis</e2>\NN\14226056 .\.\1740
20495512
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 :\:\1740 a\DT\13649268 practical\JJ\1740 review\NN\5733583 .\.\1740
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 remains\VBZ\2604760 under-recognized\JJ\1740 despite\IN\7501545 its\PRP$\6125041 potentially\RB\1740 devastating\VBG\1564144 outcomes\NNS\7291312 .\.\1740
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 remains\VBZ\2604760 under-recognized\JJ\1740 despite\IN\7501545 its\PRP$\6125041 potentially\RB\1740 devastating\VBG\1564144 outcomes\NNS\7291312 .\.\1740
D006493_D013921 CID <e2>HIT</e2>\NN\36762 must\MD\9367203 be\VB\836236 acknowledged\VBN\822367 for\IN\1740 its\PRP$\6125041 intense\JJ\1740 predilection\NN\6200178 for\IN\1740 thrombosis\NN\14100769 and\CC\1740 suspected\VBN\916909 whenever\WRB\1740 thrombosis\NN\14100769 occurs\VBZ\2623529 after\IN\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 .\.\1740
D006493_D013921 CID The\DT\1740 treatment\NN\654885 of\IN\1740 <e2>HIT</e2>\NN\36762 mandates\VBZ\2391803 an\DT\6697703 immediate\JJ\1740 cessation\NN\7365849 of\IN\1740 all\DT\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 and\CC\1740 the\DT\1740 institution\NN\8008335 of\IN\1740 an\DT\6697703 antithrombotic\JJ\1740 therapy\NN\657604 ,\,\1740 most\RBS\1740 commonly\RB\1740 using\VBG\1156834 a\DT\13649268 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 .\.\1740
D006493_D013921 CID Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 are\VBP\836236 appropriate\JJ\1740 ,\,\1740 evidence-based\JJ\1740 alternatives\NNS\5788149 to\TO\1740 <e1>heparin</e1>\NN\2718259 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>HIT</e2>\NN\36762 ,\,\1740 who\WP\8299493 need\VBP\2604760 to\TO\1740 undergo\VB\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 .\.\1740
D006493_D013921 CID As\IN\14622893 <e1>heparin</e1>\NN\2718259 remains\VBZ\2604760 one\CD\13741022 of\IN\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 used\VBN\1156834 medications\NNS\3247620 today\NN\15119536 with\IN\1740 potential\NN\14481929 for\IN\1740 <e2>HIT</e2>\NN\36762 with\IN\1740 every\DT\1740 heparin\NN\2718259 exposure\NN\5042871 ,\,\1740 a\DT\13649268 close\JJ\1740 vigilance\NN\5650579 of\IN\1740 platelet\NN\5432736 counts\NNS\13582013 must\MD\9367203 be\VB\836236 practiced\VBN\599992 whenever\WRB\1740 heparin\NN\2718259 is\VBZ\836236 initiated\VBN\1617192 .\.\1740
D006493_D013921 CID As\IN\14622893 heparin\NN\2718259 remains\VBZ\2604760 one\CD\13741022 of\IN\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 used\VBN\1156834 medications\NNS\3247620 today\NN\15119536 with\IN\1740 potential\NN\14481929 for\IN\1740 <e2>HIT</e2>\NN\36762 with\IN\1740 every\DT\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 ,\,\1740 a\DT\13649268 close\JJ\1740 vigilance\NN\5650579 of\IN\1740 platelet\NN\5432736 counts\NNS\13582013 must\MD\9367203 be\VB\836236 practiced\VBN\599992 whenever\WRB\1740 heparin\NN\2718259 is\VBZ\836236 initiated\VBN\1617192 .\.\1740
D006493_D013921 CID As\IN\14622893 heparin\NN\2718259 remains\VBZ\2604760 one\CD\13741022 of\IN\1740 the\DT\1740 most\RBS\1740 frequently\RB\1740 used\VBN\1156834 medications\NNS\3247620 today\NN\15119536 with\IN\1740 potential\NN\14481929 for\IN\1740 <e2>HIT</e2>\NN\36762 with\IN\1740 every\DT\1740 heparin\NN\2718259 exposure\NN\5042871 ,\,\1740 a\DT\13649268 close\JJ\1740 vigilance\NN\5650579 of\IN\1740 platelet\NN\5432736 counts\NNS\13582013 must\MD\9367203 be\VB\836236 practiced\VBN\599992 whenever\WRB\1740 <e1>heparin</e1>\NN\2718259 is\VBZ\836236 initiated\VBN\1617192 .\.\1740
D006493_D013927 CID HIT\NN\36762 must\MD\9367203 be\VB\836236 acknowledged\VBN\822367 for\IN\1740 its\PRP$\6125041 intense\JJ\1740 predilection\NN\6200178 for\IN\1740 <e2>thrombosis</e2>\NN\14100769 and\CC\1740 suspected\VBN\916909 whenever\WRB\1740 thrombosis\NN\14100769 occurs\VBZ\2623529 after\IN\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 .\.\1740
D006493_D013927 CID HIT\NN\36762 must\MD\9367203 be\VB\836236 acknowledged\VBN\822367 for\IN\1740 its\PRP$\6125041 intense\JJ\1740 predilection\NN\6200178 for\IN\1740 thrombosis\NN\14100769 and\CC\1740 suspected\VBN\916909 whenever\WRB\1740 <e2>thrombosis</e2>\NN\14100769 occurs\VBZ\2623529 after\IN\1740 <e1>heparin</e1>\NN\2718259 exposure\NN\5042871 .\.\1740
D000991_D013921 NONE The\DT\1740 treatment\NN\654885 of\IN\1740 <e2>HIT</e2>\NN\36762 mandates\VBZ\2391803 an\DT\6697703 immediate\JJ\1740 cessation\NN\7365849 of\IN\1740 all\DT\1740 heparin\NN\2718259 exposure\NN\5042871 and\CC\1740 the\DT\1740 institution\NN\8008335 of\IN\1740 an\DT\6697703 antithrombotic\JJ\1740 therapy\NN\657604 ,\,\1740 most\RBS\1740 commonly\RB\1740 using\VBG\1156834 a\DT\13649268 <e1>direct\JJ\1740 thrombin\NN\14735953 inhibitor</e1>\NN\20090 .\.\1740
D000991_D013921 NONE <e1>Direct\JJ\1740 thrombin\NN\14735953 inhibitors</e1>\NNS\20090 are\VBP\836236 appropriate\JJ\1740 ,\,\1740 evidence-based\JJ\1740 alternatives\NNS\5788149 to\TO\1740 heparin\NN\2718259 in\IN\13603305 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>HIT</e2>\NN\36762 ,\,\1740 who\WP\8299493 need\VBP\2604760 to\TO\1740 undergo\VB\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 .\.\1740
8825380
D011692_D007674 CID The\DT\1740 effect\NN\34213 of\IN\1740 recombinant\JJ\1740 human\JJ\1740 insulin-like\JJ\1740 growth\NN\13526110 factor-I\NN\1740 on\IN\1740 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011692_D007674 CID We\PRP\1740 recently\RB\1740 demonstrated\VBD\2137132 that\IN\1740 recombinant\JJ\1740 hGH\NN\1740 exacerbates\NNS\1740 renal\JJ\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 <e2>nephropathy</e2>\RB\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 glomerular\JJ\1740 disease\NN\14061805 .\.\1740
D011692_D007674 CID We\PRP\1740 recently\RB\1740 demonstrated\VBD\2137132 that\IN\1740 recombinant\JJ\1740 hGH\NN\1740 exacerbates\NNS\1740 renal\JJ\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 nephropathy\RB\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>glomerular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D011692_D007674 CID We\PRP\1740 recently\RB\1740 demonstrated\VBD\2137132 that\IN\1740 recombinant\JJ\1740 hGH\NN\1740 exacerbates\NNS\1740 renal\JJ\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 <e2>nephropathy</e2>\RB\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 glomerular\JJ\1740 disease\NN\14061805 .\.\1740
D011692_D007674 CID We\PRP\1740 recently\RB\1740 demonstrated\VBD\2137132 that\IN\1740 recombinant\JJ\1740 hGH\NN\1740 exacerbates\NNS\1740 renal\JJ\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 nephropathy\RB\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>glomerular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D011692_D007674 CID Therefore\RB\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 whether\IN\1740 recombinant\JJ\1740 human\JJ\1740 (\-LRB-\1740 rh\NN\15037339 )\-RRB-\1740 IGF-I\NN\1740 is\VBZ\836236 a\DT\13649268 safer\JJR\1740 alternative\NN\5788149 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 growth\NN\13526110 failure\NN\66216 in\IN\13603305 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 <e1>PAN</e1>\NN\3101986 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D011692_D007674 CID The\DT\1740 <e2>glomerulopathy</e2>\NN\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 seven\CD\13741022 serial\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>PAN</e1>\NN\3101986 over\IN\5867413 12\CD\13745420 wk\NN\1740 .\.\1740
D011692_D007674 CID Urinary\JJ\1740 protein\NN\14944888 excretion\NN\13466586 was\VBD\836236 unaltered\JJ\1740 by\IN\1740 rhIGF-I\NN\1740 treatment\NN\654885 in\IN\13603305 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 <e1>PAN</e1>\NN\3101986 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D011692_D007674 CID After\IN\1740 12\CD\13745420 wk\NN\1740 ,\,\1740 the\DT\1740 inulin\JJ\1740 clearance\NN\5089947 was\VBD\836236 higher\JJR\1740 in\IN\13603305 rhIGF-I-treated\VBN\1740 rats\NNS\2329401 ,\,\1740 0.48\CD\1740 +/-\CC\1740 0.08\CD\1740 versus\CC\1740 0.24\CD\1740 +/-\CC\1740 0.06\CD\1740 mL/min/100\NN\1740 g\NN\13717155 of\IN\1740 body\NN\19128 weight\NN\5009170 in\IN\13603305 untreated\JJ\1740 <e1>PAN</e1>\NN\3101986 <e2>nephropathy</e2>\JJ\1740 animals\NNS\4475 ,\,\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 .\.\1740
D011692_D007674 CID In\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>PAN</e1>\NN\3101986 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 administration\NN\1133281 of\IN\1740 rhIGF-I\NN\1740 increased\VBD\169651 IGF-I\NN\1740 and\CC\1740 GH\NN\1740 receptor\NN\5225602 gene\NN\8459252 expression\NN\4679549 ,\,\1740 without\IN\1740 altering\VBG\126264 the\DT\1740 steady\JJ\1740 state\NN\8491826 level\NN\4916342 of\IN\1740 IGF-I\NN\1740 receptor\NN\5225602 mRNA\NN\14832193 .\.\1740
D011692_D007674 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 administration\NN\1133281 of\IN\1740 rhIGF-I\NN\1740 improves\NNS\1740 growth\NN\13526110 and\CC\1740 GFR\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 <e1>PAN</e1>\NN\3101986 <e2>nephropathy</e2>\NN\14573196 and\CC\1740 2\CD\13741022 )\-RRB-\1740 unlike\IN\1740 rhGH\NN\1740 ,\,\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 rhIGF-I\NN\1740 does\VBZ\1640855 not\RB\1740 worsen\VBN\146138 renal\JJ\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 injury\NN\14052046 in\IN\13603305 this\DT\1740 disease\NN\14061805 model\NN\5888929 .\.\1740
D011692_D006130 NONE Therefore\RB\1740 ,\,\1740 we\PRP\1740 examined\VBD\789138 whether\IN\1740 recombinant\JJ\1740 human\JJ\1740 (\-LRB-\1740 rh\NN\15037339 )\-RRB-\1740 IGF-I\NN\1740 is\VBZ\836236 a\DT\13649268 safer\JJR\1740 alternative\NN\5788149 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>growth\NN\13526110 failure</e2>\NN\66216 in\IN\13603305 rats\NNS\2329401 with\IN\1740 chronic\JJ\1740 <e1>PAN</e1>\NN\3101986 nephropathy\NN\14573196 .\.\1740
D008315_D007674 NONE The\DT\1740 improvement\NN\7359599 in\IN\13603305 GFR\NN\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 enhanced\VBN\227165 <e2>glomerular\JJ\1740 hypertrophy</e2>\NN\14365950 or\CC\3541091 increased\VBN\169651 segmental\JJ\1740 glomerulosclerosis\NN\1740 ,\,\1740 tubulointerstitial\JJ\1740 injury\NN\14052046 ,\,\1740 or\CC\3541091 renal\JJ\1740 cortical\JJ\1740 <e1>malondialdehyde</e1>\NN\1740 content\NN\7951464 .\.\1740
D008315_D007674 NONE In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 with\IN\1740 intact\JJ\1740 kidneys\NNS\5333259 ,\,\1740 rhIGF-I\NN\1740 administration\NN\1133281 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 weight\NN\5009170 gain\NN\13576355 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 GFR\NN\1740 ,\,\1740 glomerular\JJ\1740 planar\NN\1740 area\NN\8630985 ,\,\1740 renal\JJ\1740 cortical\JJ\1740 <e1>malondialdehyde</e1>\NN\1740 content\NN\7951464 ,\,\1740 or\CC\3541091 glomerular\JJ\1740 or\CC\3541091 <e2>tubulointerstitial\JJ\1740 damage</e2>\NN\7296428 ,\,\1740 compared\VBN\644583 with\IN\1740 untreated\JJ\1740 animals\NNS\4475 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 .\.\1740
D008315_D005921 NONE The\DT\1740 improvement\NN\7359599 in\IN\13603305 GFR\NN\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 enhanced\VBN\227165 glomerular\JJ\1740 hypertrophy\NN\14365950 or\CC\3541091 increased\VBN\169651 segmental\JJ\1740 <e2>glomerulosclerosis</e2>\NN\1740 ,\,\1740 tubulointerstitial\JJ\1740 injury\NN\14052046 ,\,\1740 or\CC\3541091 renal\JJ\1740 cortical\JJ\1740 <e1>malondialdehyde</e1>\NN\1740 content\NN\7951464 .\.\1740
D008315_-1 NONE The\DT\1740 improvement\NN\7359599 in\IN\13603305 GFR\NN\1740 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 enhanced\VBN\227165 glomerular\JJ\1740 hypertrophy\NN\14365950 or\CC\3541091 increased\VBN\169651 segmental\JJ\1740 glomerulosclerosis\NN\1740 ,\,\1740 <e2>tubulointerstitial\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 or\CC\3541091 renal\JJ\1740 cortical\JJ\1740 <e1>malondialdehyde</e1>\NN\1740 content\NN\7951464 .\.\1740
D008315_D011507 NONE In\IN\13603305 normal\JJ\1740 rats\NNS\2329401 with\IN\1740 intact\JJ\1740 kidneys\NNS\5333259 ,\,\1740 rhIGF-I\NN\1740 administration\NN\1133281 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 weight\NN\5009170 gain\NN\13576355 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 GFR\NN\1740 ,\,\1740 glomerular\JJ\1740 planar\NN\1740 area\NN\8630985 ,\,\1740 renal\JJ\1740 cortical\JJ\1740 <e1>malondialdehyde</e1>\NN\1740 content\NN\7951464 ,\,\1740 or\CC\3541091 glomerular\JJ\1740 or\CC\3541091 tubulointerstitial\JJ\1740 damage\NN\7296428 ,\,\1740 compared\VBN\644583 with\IN\1740 untreated\JJ\1740 animals\NNS\4475 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 .\.\1740
20192893
D003287_D007674 CID <e1>Contrast\NN\13854649 medium</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 after\IN\1740 renal\JJ\1740 artery\NN\5417975 and\CC\1740 coronary\JJ\1740 angioplasty\NN\671351 .\.\1740
D003287_D007674 CID BACKGROUND\NN\4921011 :\:\1740 <e2>Renal\JJ\1740 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 iodinated\JJ\1740 <e1>contrast\NN\13854649 medium</e1>\NN\3575240 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 administration\NN\1133281 can\MD\3094503 minimize\VB\441445 the\DT\1740 benefit\NN\13278375 of\IN\1740 the\DT\1740 interventional\JJ\1740 procedure\NN\407535 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 renal\JJ\1740 angioplasty\NN\671351 (\-LRB-\1740 PTRA\NN\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID BACKGROUND\NN\4921011 :\:\1740 <e2>Renal\JJ\1740 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 iodinated\JJ\1740 contrast\NN\13854649 medium\NN\3575240 (\-LRB-\1740 <e1>CM</e1>\NN\13649268 )\-RRB-\1740 administration\NN\1133281 can\MD\3094503 minimize\VB\441445 the\DT\1740 benefit\NN\13278375 of\IN\1740 the\DT\1740 interventional\JJ\1740 procedure\NN\407535 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 renal\JJ\1740 angioplasty\NN\671351 (\-LRB-\1740 PTRA\NN\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 compare\VB\644583 the\DT\1740 susceptibility\NN\13920835 to\TO\1740 <e2>nephrotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>CM</e1>\NN\13649268 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 PTRA\NN\1740 with\IN\1740 that\DT\1740 of\IN\1740 patients\NNS\9898892 submitted\VBN\1952898 to\TO\1740 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
D003287_D007674 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 study\NN\635850 patients\NNS\9898892 submitted\VBN\1952898 to\TO\1740 PTRA\NN\1740 showed\VBD\2137132 a\DT\13649268 lower\JJR\1740 susceptibility\NN\13920835 to\TO\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>CM</e1>\NN\13649268 administration\NN\1133281 than\IN\1740 PCI\NN\1740 patients\NNS\9898892 .\.\1740
D003287_D064420 NONE The\DT\1740 effectiveness\NN\5190804 of\IN\1740 PTRA\NN\1740 on\IN\1740 renal\JJ\1740 function\NN\13783581 seems\VBZ\2604760 to\TO\1740 be\VB\836236 barely\RB\1740 influenced\VBN\137313 by\IN\1740 <e1>CM</e1>\NN\13649268 <e2>toxicity</e2>\NN\13576101 .\.\1740
7739955
D002220_D009205 CID Three\CD\13741022 patients\NNS\9898892 had\VBD\2108377 acute\JJ\1740 viral\JJ\1740 <e2>myocarditis</e2>\NN\14338942 ,\,\1740 one\NN\13741022 had\VBD\2108377 a\DT\13649268 <e1>carbamazepine-induced</e1>\JJ\1740 acute\JJ\1740 eosinophilic\JJ\1740 myocarditis\NN\14338942 ,\,\1740 and\CC\1740 one\NN\13741022 had\VBD\2108377 cardiac\JJ\1740 hemosiderosis\NN\14299637 resulting\VBG\2633881 in\IN\13603305 acute\JJ\1740 cardiogenic\JJ\1740 shock\NN\7510495 .\.\1740
D002220_D009205 CID Three\CD\13741022 patients\NNS\9898892 had\VBD\2108377 acute\JJ\1740 viral\JJ\1740 myocarditis\NN\14338942 ,\,\1740 one\NN\13741022 had\VBD\2108377 a\DT\13649268 <e1>carbamazepine-induced</e1>\JJ\1740 acute\JJ\1740 <e2>eosinophilic\JJ\1740 myocarditis</e2>\NN\14338942 ,\,\1740 and\CC\1740 one\NN\13741022 had\VBD\2108377 cardiac\JJ\1740 hemosiderosis\NN\14299637 resulting\VBG\2633881 in\IN\13603305 acute\JJ\1740 cardiogenic\JJ\1740 shock\NN\7510495 .\.\1740
D002220_D004802 CID Three\CD\13741022 patients\NNS\9898892 had\VBD\2108377 acute\JJ\1740 viral\JJ\1740 myocarditis\NN\14338942 ,\,\1740 one\NN\13741022 had\VBD\2108377 a\DT\13649268 <e1>carbamazepine-induced</e1>\JJ\1740 acute\JJ\1740 <e2>eosinophilic\JJ\1740 myocarditis</e2>\NN\14338942 ,\,\1740 and\CC\1740 one\NN\13741022 had\VBD\2108377 cardiac\JJ\1740 hemosiderosis\NN\14299637 resulting\VBG\2633881 in\IN\13603305 acute\JJ\1740 cardiogenic\JJ\1740 shock\NN\7510495 .\.\1740
D002220_D012770 NONE Three\CD\13741022 patients\NNS\9898892 had\VBD\2108377 acute\JJ\1740 viral\JJ\1740 myocarditis\NN\14338942 ,\,\1740 one\NN\13741022 had\VBD\2108377 a\DT\13649268 <e1>carbamazepine-induced</e1>\JJ\1740 acute\JJ\1740 eosinophilic\JJ\1740 myocarditis\NN\14338942 ,\,\1740 and\CC\1740 one\NN\13741022 had\VBD\2108377 cardiac\JJ\1740 hemosiderosis\NN\14299637 resulting\VBG\2633881 in\IN\13603305 acute\JJ\1740 <e2>cardiogenic\JJ\1740 shock</e2>\NN\7510495 .\.\1740
24653743
C042288_D016757 CID A\DT\13649268 Case\NN\7283608 of\IN\1740 <e2>Sudden\NNP\1740 Cardiac\NNP\1740 Death</e2>\NNP\7296428 due\JJ\1740 to\IN\1740 <e1>Pilsicainide-Induced</e1>\JJ\1740 Torsades\NNP\1740 de\NNP\1740 Pointes\NNP\1740 .\.\1740
C042288_D016757 CID An\DT\6697703 84-year-old\JJ\1740 male\JJ\1740 received\VBD\2210855 oral\JJ\1740 <e1>pilsicainide</e1>\NN\1740 ,\,\1740 a\DT\13649268 pure\JJ\1740 sodium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 slow\JJ\1740 recovery\NN\7357388 kinetics\NNS\6100236 ,\,\1740 to\TO\1740 convert\VB\126264 his\PRP$\1740 paroxysmal\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 to\IN\1740 a\DT\13649268 sinus\NN\5248181 rhythm\NN\15122011 ;\:\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 <e2>sudden\JJ\1740 cardiac\JJ\1740 death</e2>\NN\7296428 two\CD\13741022 days\NNS\15140892 later\RB\1740 .\.\1740
C042288_D016171 CID A\DT\13649268 Case\NN\7283608 of\IN\1740 Sudden\NNP\1740 Cardiac\NNP\1740 Death\NNP\7296428 due\JJ\1740 to\IN\1740 <e1>Pilsicainide-Induced</e1>\JJ\1740 <e2>Torsades\NNP\1740 de\NNP\1740 Pointes</e2>\NNP\1740 .\.\1740
C042288_D016171 CID Although\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 renal\JJ\1740 function\NN\13783581 was\VBD\836236 not\RB\1740 highly\RB\1740 impaired\JJ\1740 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>pilsicainide</e1>\NN\1740 was\VBD\836236 low\JJ\1740 ,\,\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 pilsicainide\NN\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 high\JJ\1740 ,\,\1740 which\WDT\1740 can\MD\3094503 produce\VB\1617192 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 in\IN\13603305 the\DT\1740 octogenarian\NN\10376523 .\.\1740
C042288_D016171 CID Although\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 renal\JJ\1740 function\NN\13783581 was\VBD\836236 not\RB\1740 highly\RB\1740 impaired\JJ\1740 and\CC\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 pilsicainide\NN\1740 was\VBD\836236 low\JJ\1740 ,\,\1740 the\DT\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 <e1>pilsicainide</e1>\NN\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 high\JJ\1740 ,\,\1740 which\WDT\1740 can\MD\3094503 produce\VB\1617192 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 in\IN\13603305 the\DT\1740 octogenarian\NN\10376523 .\.\1740
C042288_D001281 NONE An\DT\6697703 84-year-old\JJ\1740 male\JJ\1740 received\VBD\2210855 oral\JJ\1740 <e1>pilsicainide</e1>\NN\1740 ,\,\1740 a\DT\13649268 pure\JJ\1740 sodium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 slow\JJ\1740 recovery\NN\7357388 kinetics\NNS\6100236 ,\,\1740 to\TO\1740 convert\VB\126264 his\PRP$\1740 paroxysmal\JJ\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 to\IN\1740 a\DT\13649268 sinus\NN\5248181 rhythm\NN\15122011 ;\:\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 sudden\JJ\1740 cardiac\JJ\1740 death\NN\7296428 two\CD\13741022 days\NNS\15140892 later\RB\1740 .\.\1740
C042288_D001281 NONE Although\IN\1740 the\DT\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 class\NN\7951464 IC\NN\8339454 drugs\NNS\14778436 ,\,\1740 including\VBG\690614 <e1>pilsicainide</e1>\NN\1740 ,\,\1740 is\VBZ\836236 effective\JJ\1740 to\TO\1740 terminate\VB\126264 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 ,\,\1740 careful\JJ\1740 consideration\NN\5770926 must\MD\9367203 be\VB\836236 taken\VBN\2367363 before\IN\1740 giving\VBG\2327200 these\DT\1740 drugs\NNS\14778436 to\TO\1740 octogenarians\NNS\10376523 .\.\1740
D012964_D001281 NONE An\DT\6697703 84-year-old\JJ\1740 male\JJ\1740 received\VBD\2210855 oral\JJ\1740 pilsicainide\NN\1740 ,\,\1740 a\DT\13649268 pure\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 slow\JJ\1740 recovery\NN\7357388 kinetics\NNS\6100236 ,\,\1740 to\TO\1740 convert\VB\126264 his\PRP$\1740 paroxysmal\JJ\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 to\IN\1740 a\DT\13649268 sinus\NN\5248181 rhythm\NN\15122011 ;\:\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 sudden\JJ\1740 cardiac\JJ\1740 death\NN\7296428 two\CD\13741022 days\NNS\15140892 later\RB\1740 .\.\1740
D012964_D016757 NONE An\DT\6697703 84-year-old\JJ\1740 male\JJ\1740 received\VBD\2210855 oral\JJ\1740 pilsicainide\NN\1740 ,\,\1740 a\DT\13649268 pure\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 slow\JJ\1740 recovery\NN\7357388 kinetics\NNS\6100236 ,\,\1740 to\TO\1740 convert\VB\126264 his\PRP$\1740 paroxysmal\JJ\1740 atrial\JJ\1740 fibrillation\NN\14361664 to\IN\1740 a\DT\13649268 sinus\NN\5248181 rhythm\NN\15122011 ;\:\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 <e2>sudden\JJ\1740 cardiac\JJ\1740 death</e2>\NN\7296428 two\CD\13741022 days\NNS\15140892 later\RB\1740 .\.\1740
9071336
D017239_D001943 NONE <e1>Paclitaxel</e1>\NN\1740 ,\,\1740 5-fluorouracil\NN\1740 ,\,\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 in\IN\13603305 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 :\:\1740 BRE-26\NN\1740 ,\,\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 .\.\1740
D017239_D001943 NONE 5-Fluorouracil\NN\1740 plus\CC\4723816 folinic\JJ\1740 acid\NN\14818238 and\CC\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 are\VBP\836236 effective\JJ\1740 salvage\NN\3076708 therapies\NNS\657604 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D001943 NONE 5-Fluorouracil\NN\1740 plus\CC\4723816 folinic\JJ\1740 acid\NN\14818238 and\CC\1740 paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 are\VBP\836236 effective\JJ\1740 salvage\NN\3076708 therapies\NNS\657604 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D001943 NONE We\PRP\1740 performed\VBD\2367363 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 175\CD\1740 mg/m2\NN\1740 over\IN\5867413 3\CD\13741022 hours\NNS\15118228 on\IN\1740 day\NN\15154774 I\PRP\14622893 followed\VBD\1835496 by\IN\1740 folinic\JJ\1740 acid\NN\14818238 300\CD\1740 mg\NN\13717155 over\IN\5867413 1\CD\13741022 hour\NN\15154774 before\IN\1740 5-fluorouracil\NN\1740 350\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 1\CD\13741022 to\TO\1740 3\CD\13741022 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 TFL\NN\1740 )\-RRB-\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D005472_D001943 NONE Paclitaxel\NN\1740 ,\,\1740 <e1>5-fluorouracil</e1>\NN\1740 ,\,\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 in\IN\13603305 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 :\:\1740 BRE-26\NN\1740 ,\,\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 .\.\1740
D005472_D001943 NONE <e1>5-Fluorouracil</e1>\NN\1740 plus\CC\4723816 folinic\JJ\1740 acid\NN\14818238 and\CC\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 are\VBP\836236 effective\JJ\1740 salvage\NN\3076708 therapies\NNS\657604 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D005472_D001943 NONE We\PRP\1740 performed\VBD\2367363 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 paclitaxel\NN\1740 175\CD\1740 mg/m2\NN\1740 over\IN\5867413 3\CD\13741022 hours\NNS\15118228 on\IN\1740 day\NN\15154774 I\PRP\14622893 followed\VBD\1835496 by\IN\1740 folinic\JJ\1740 acid\NN\14818238 300\CD\1740 mg\NN\13717155 over\IN\5867413 1\CD\13741022 hour\NN\15154774 before\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 350\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 1\CD\13741022 to\TO\1740 3\CD\13741022 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 TFL\NN\1740 )\-RRB-\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D002955_D001943 NONE Paclitaxel\NN\1740 ,\,\1740 5-fluorouracil\NN\1740 ,\,\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 :\:\1740 BRE-26\NN\1740 ,\,\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 .\.\1740
D002955_D001943 NONE 5-Fluorouracil\NN\1740 plus\CC\4723816 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 and\CC\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 are\VBP\836236 effective\JJ\1740 salvage\NN\3076708 therapies\NNS\657604 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D002955_D001943 NONE We\PRP\1740 performed\VBD\2367363 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 paclitaxel\NN\1740 175\CD\1740 mg/m2\NN\1740 over\IN\5867413 3\CD\13741022 hours\NNS\15118228 on\IN\1740 day\NN\15154774 I\PRP\14622893 followed\VBD\1835496 by\IN\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 300\CD\1740 mg\NN\13717155 over\IN\5867413 1\CD\13741022 hour\NN\15154774 before\IN\1740 5-fluorouracil\NN\1740 350\CD\1740 mg/m2\NN\1740 on\IN\1740 days\NNS\15140892 1\CD\13741022 to\TO\1740 3\CD\13741022 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 TFL\NN\1740 )\-RRB-\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D017239_D064420 NONE <e1>Paclitaxel</e1>\NN\1740 and\CC\1740 5-fluorouracil\NN\1740 have\VBP\2108377 additive\JJ\1740 <e2>cytotoxicity</e2>\NN\13583478 in\IN\13603305 MCF-7\NN\1740 cell\NN\3080309 lines\NNS\8426461 .\.\1740
D005472_D064420 NONE Paclitaxel\NN\1740 and\CC\1740 <e1>5-fluorouracil</e1>\NN\1740 have\VBP\2108377 additive\JJ\1740 <e2>cytotoxicity</e2>\NN\13583478 in\IN\13603305 MCF-7\NN\1740 cell\NN\3080309 lines\NNS\8426461 .\.\1740
D016179_D009503 NONE Analysis\NN\633864 is\VBZ\836236 reported\VBN\831651 on\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 minimum\NN\13653902 of\IN\1740 6\CD\13741022 months\NNS\15113229 follow-up\JJ\1740 who\WP\8299493 received\VBD\2210855 a\DT\13649268 total\NN\3553 of\IN\1740 192\CD\1740 cycles\NNS\15269513 of\IN\1740 TFL\NN\1740 :\:\1740 nine\CD\13741022 cycles\NNS\15269513 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 grade\NN\7975026 3/4\CD\1740 <e2>neutropenia</e2>\NN\14196405 requiring\VBG\754942 hospitalization\NN\15113229 ;\:\1740 seven\CD\13741022 (\-LRB-\1740 4\CD\13741022 %\NN\1740 )\-RRB-\1740 cycles\NNS\15269513 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 required\VBD\754942 <e1>granulocyte\NN\5449959 colony-stimulating\JJ\1740 factor</e1>\NN\7326557 due\JJ\1740 to\TO\1740 neutropenia\NN\14196405 ;\:\1740 no\DT\7204911 patient\NN\9898892 required\VBD\754942 platelet\NN\5432736 transfusions\NNS\320852 .\.\1740
D016179_D009503 NONE Analysis\NN\633864 is\VBZ\836236 reported\VBN\831651 on\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 minimum\NN\13653902 of\IN\1740 6\CD\13741022 months\NNS\15113229 follow-up\JJ\1740 who\WP\8299493 received\VBD\2210855 a\DT\13649268 total\NN\3553 of\IN\1740 192\CD\1740 cycles\NNS\15269513 of\IN\1740 TFL\NN\1740 :\:\1740 nine\CD\13741022 cycles\NNS\15269513 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 grade\NN\7975026 3/4\CD\1740 neutropenia\NN\14196405 requiring\VBG\754942 hospitalization\NN\15113229 ;\:\1740 seven\CD\13741022 (\-LRB-\1740 4\CD\13741022 %\NN\1740 )\-RRB-\1740 cycles\NNS\15269513 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 required\VBD\754942 <e1>granulocyte\NN\5449959 colony-stimulating\JJ\1740 factor</e1>\NN\7326557 due\JJ\1740 to\TO\1740 <e2>neutropenia</e2>\NN\14196405 ;\:\1740 no\DT\7204911 patient\NN\9898892 required\VBD\754942 platelet\NN\5432736 transfusions\NNS\320852 .\.\1740
19967075
D012964_D007674 NONE Decreased\VBD\169651 Expression\NN\4679549 of\IN\1740 <e1>Na/K-ATPase</e1>\NN\1740 ,\,\1740 NHE3\NN\1740 ,\,\1740 NBC1\NN\1740 ,\,\1740 AQP1\NN\1740 and\CC\1740 OAT\NN\12141495 in\IN\13603305 Gentamicin-induced\JJ\1740 <e2>Nephropathy</e2>\NNP\14573196 .\.\1740
D012964_D007674 NONE Gentamicin-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 may\MD\15209706 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 be\VB\836236 causally\RB\1740 related\JJ\1740 with\IN\1740 a\DT\13649268 decreased\VBN\169651 expression\NN\4679549 of\IN\1740 <e1>Na(+)/K(+)-ATPase</e1>\NN\1740 ,\,\1740 NHE3\NN\1740 ,\,\1740 NBC1\NN\1740 ,\,\1740 AQP1\NN\1740 and\CC\1740 OAT\NN\12141495 .\.\1740
D011188_D007674 NONE Decreased\VBD\169651 Expression\NN\4679549 of\IN\1740 <e1>Na/K-ATPase</e1>\NN\1740 ,\,\1740 NHE3\NN\1740 ,\,\1740 NBC1\NN\1740 ,\,\1740 AQP1\NN\1740 and\CC\1740 OAT\NN\12141495 in\IN\13603305 Gentamicin-induced\JJ\1740 <e2>Nephropathy</e2>\NNP\14573196 .\.\1740
D011188_D007674 NONE Gentamicin-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 may\MD\15209706 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 be\VB\836236 causally\RB\1740 related\JJ\1740 with\IN\1740 a\DT\13649268 decreased\VBN\169651 expression\NN\4679549 of\IN\1740 <e1>Na(+)/K(+)-ATPase</e1>\NN\1740 ,\,\1740 NHE3\NN\1740 ,\,\1740 NBC1\NN\1740 ,\,\1740 AQP1\NN\1740 and\CC\1740 OAT\NN\12141495 .\.\1740
D005839_D007674 CID Decreased\VBD\169651 Expression\NN\4679549 of\IN\1740 Na/K-ATPase\NN\1740 ,\,\1740 NHE3\NN\1740 ,\,\1740 NBC1\NN\1740 ,\,\1740 AQP1\NN\1740 and\CC\1740 OAT\NN\12141495 in\IN\13603305 <e1>Gentamicin-induced</e1>\JJ\1740 <e2>Nephropathy</e2>\NNP\14573196 .\.\1740
D005839_D007674 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 aimed\VBN\1987160 to\TO\1740 determine\VB\1645601 whether\IN\1740 there\EX\27167 is\VBZ\836236 an\DT\6697703 altered\JJ\1740 regulation\NN\6652242 of\IN\1740 tubular\JJ\1740 transporters\NNS\4490091 in\IN\13603305 <e1>gentamicin-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D005839_D007674 CID <e1>Gentamicin-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 may\MD\15209706 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 be\VB\836236 causally\RB\1740 related\JJ\1740 with\IN\1740 a\DT\13649268 decreased\VBN\169651 expression\NN\4679549 of\IN\1740 Na(+)/K(+)-ATPase\NN\1740 ,\,\1740 NHE3\NN\1740 ,\,\1740 NBC1\NN\1740 ,\,\1740 AQP1\NN\1740 and\CC\1740 OAT\NN\12141495 .\.\1740
17879100
D001241_D005334 NONE He\PRP\14622893 was\VBD\836236 put\VBN\1850315 on\IN\1740 <e1>aspirin</e1>\NN\2707683 following\VBG\1835496 surgery\NN\6045562 and\CC\1740 took\VBD\2367363 ibuprofen\NN\3828465 for\IN\1740 <e2>fever</e2>\NN\14299637 for\IN\1740 nearly\RB\1740 a\DT\13649268 week\NN\15113229 prior\RB\1740 to\IN\1740 presentation\NN\1027379 .\.\1740
D007052_D005334 NONE He\PRP\14622893 was\VBD\836236 put\VBN\1850315 on\IN\1740 aspirin\NN\2707683 following\VBG\1835496 surgery\NN\6045562 and\CC\1740 took\VBD\2367363 <e1>ibuprofen</e1>\NN\3828465 for\IN\1740 <e2>fever</e2>\NN\14299637 for\IN\1740 nearly\RB\1740 a\DT\13649268 week\NN\15113229 prior\RB\1740 to\IN\1740 presentation\NN\1027379 .\.\1740
24999722
D005446_C537630 NONE Safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 intravitreal\VBP\1740 implant\NN\4013729 (\-LRB-\1740 0.59\CD\1740 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 <e2>birdshot\NN\1740 retinochoroidopathy</e2>\NN\1740 .\.\1740
D005446_C537630 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 report\VB\831651 the\DT\1740 treatment\NN\654885 outcomes\NNS\7291312 of\IN\1740 the\DT\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 intravitreal\VBP\1740 implant\NN\4013729 (\-LRB-\1740 0.59\CD\1740 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>birdshot\NN\1740 retinochoroidopathy</e2>\VBD\1740 whose\WP$\1740 disease\NN\14061805 is\VBZ\836236 refractory\JJ\1740 or\CC\3541091 intolerant\JJ\1740 to\TO\1740 conventional\JJ\1740 immunomodulatory\NN\1740 therapy\NN\657604 .\.\1740
D005446_C537630 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 implant\NN\4013729 (\-LRB-\1740 0.59\CD\1740 mg\NN\13717155 )\-RRB-\1740 helps\VBZ\2556126 to\TO\1740 control\VB\2422663 inflammation\NN\14299637 in\IN\13603305 otherwise\JJ\1740 treatment-refractory\JJ\1740 cases\NNS\7283608 of\IN\1740 <e2>birdshot\JJ\1740 retinochoroidopathy</e2>\NN\1740 .\.\1740
D005446_D007249 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>fluocinolone\NN\1740 acetonide</e1>\NN\1740 implant\NN\4013729 (\-LRB-\1740 0.59\CD\1740 mg\NN\13717155 )\-RRB-\1740 helps\VBZ\2556126 to\TO\1740 control\VB\2422663 <e2>inflammation</e2>\NN\14299637 in\IN\13603305 otherwise\JJ\1740 treatment-refractory\JJ\1740 cases\NNS\7283608 of\IN\1740 birdshot\JJ\1740 retinochoroidopathy\NN\1740 .\.\1740
9323412
D017294_D003866 NONE Acute\JJ\1740 severe\JJ\1740 <e2>depression</e2>\NN\14373582 following\VBG\1835496 peri-operative\JJ\1740 <e1>ondansetron</e1>\NN\1740 .\.\1740
D017294_D020250 NONE A\DT\13649268 41-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 a\DT\13649268 strong\JJ\1740 history\NN\15120823 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 presented\VBN\2137132 for\IN\1740 abdominal\JJ\1740 hysterectomy\NN\393369 3\CD\13741022 months\NNS\15113229 after\IN\1740 a\DT\13649268 previous\JJ\1740 anaesthetic\JJ\1740 where\WRB\1740 <e1>ondansetron</e1>\JJ\1740 prophylaxis\NN\1077350 had\VBD\2108377 been\VBN\836236 used\VBN\1156834 .\.\1740
D012701_D003865 NONE She\PRP\1740 had\VBD\2108377 developed\VBN\1753788 a\DT\13649268 severe\JJ\1740 acute\JJ\1740 <e2>major\JJ\1740 depression\NN\14373582 disorder</e2>\NN\14034177 almost\RB\1740 immediately\RB\1740 thereafter\RB\1740 ,\,\1740 possibly\RB\1740 related\JJ\1740 to\TO\1740 the\DT\1740 use\NN\407535 of\IN\1740 a\DT\13649268 <e1>serotonin</e1>\NN\14807737 antagonist\NN\7846 .\.\1740
D015742_D009325 NONE Anaesthesia\NN\14034177 with\IN\1740 a\DT\13649268 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 and\CC\1740 avoidance\NN\203342 of\IN\1740 serotonin\NN\14807737 antagonists\NNS\7846 provided\VBN\2199590 a\DT\13649268 <e2>nausea-free</e2>\JJ\1740 postoperative\JJ\1740 course\NN\883297 without\IN\1740 exacerbation\NN\374224 of\IN\1740 the\DT\1740 depression\NN\14373582 disorder\NN\14034177 .\.\1740
D015742_D003866 NONE Anaesthesia\NN\14034177 with\IN\1740 a\DT\13649268 <e1>propofol</e1>\NN\1740 infusion\NN\14589223 and\CC\1740 avoidance\NN\203342 of\IN\1740 serotonin\NN\14807737 antagonists\NNS\7846 provided\VBN\2199590 a\DT\13649268 nausea-free\JJ\1740 postoperative\JJ\1740 course\NN\883297 without\IN\1740 exacerbation\NN\374224 of\IN\1740 the\DT\1740 <e2>depression\NN\14373582 disorder</e2>\NN\14034177 .\.\1740
D012701_D009325 NONE Anaesthesia\NN\14034177 with\IN\1740 a\DT\13649268 propofol\NN\1740 infusion\NN\14589223 and\CC\1740 avoidance\NN\203342 of\IN\1740 <e1>serotonin</e1>\NN\14807737 antagonists\NNS\7846 provided\VBN\2199590 a\DT\13649268 <e2>nausea-free</e2>\JJ\1740 postoperative\JJ\1740 course\NN\883297 without\IN\1740 exacerbation\NN\374224 of\IN\1740 the\DT\1740 depression\NN\14373582 disorder\NN\14034177 .\.\1740
D012701_D003866 NONE Anaesthesia\NN\14034177 with\IN\1740 a\DT\13649268 propofol\NN\1740 infusion\NN\14589223 and\CC\1740 avoidance\NN\203342 of\IN\1740 <e1>serotonin</e1>\NN\14807737 antagonists\NNS\7846 provided\VBN\2199590 a\DT\13649268 nausea-free\JJ\1740 postoperative\JJ\1740 course\NN\883297 without\IN\1740 exacerbation\NN\374224 of\IN\1740 the\DT\1740 <e2>depression\NN\14373582 disorder</e2>\NN\14034177 .\.\1740
2131034
D013852_D011115 CID Severe\JJ\1740 <e2>polyneuropathy</e2>\JJ\1740 and\CC\1740 motor\NN\3699975 loss\NN\13252973 after\IN\1740 intrathecal\JJ\1740 <e1>thiotepa</e1>\NN\2722458 combination\NN\7951464 chemotherapy\NN\661091 :\:\1740 description\NN\6722453 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
D013852_D020258 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 delayed\VBN\439958 <e2>neurologic\JJ\1740 toxicity</e2>\NN\13576101 related\JJ\1740 to\TO\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 combination\NN\7951464 chemotherapy\NN\661091 including\VBG\690614 <e1>thiotepa</e1>\NN\2722458 (\-LRB-\1740 TSPA\NN\1740 )\-RRB-\1740 are\VBP\836236 presented\VBN\2137132 .\.\1740
D013852_D020258 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 delayed\VBN\439958 <e2>neurologic\JJ\1740 toxicity</e2>\NN\13576101 related\JJ\1740 to\TO\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 combination\NN\7951464 chemotherapy\NN\661091 including\VBG\690614 thiotepa\NN\2722458 (\-LRB-\1740 <e1>TSPA</e1>\NN\1740 )\-RRB-\1740 are\VBP\836236 presented\VBN\2137132 .\.\1740
D013852_D020258 CID <e2>Neurologic\JJ\1740 toxicities</e2>\NNS\13576101 have\VBP\2108377 been\VBN\836236 described\VBN\1001294 with\IN\1740 IT-methotrexate\NN\1740 ,\,\1740 IT-cytosine\NN\1740 arabinoside\NN\1740 and\CC\1740 <e1>IT-TSPA</e1>\NN\1740 .\.\1740
D013852_D020258 CID In\IN\13603305 spite\NN\7550369 of\IN\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 <e1>TSPA</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 useful\JJ\1740 IT\NN\6125041 agent\NN\7347 ,\,\1740 its\PRP$\6125041 combination\NN\7951464 with\IN\1740 MTX\NN\1740 ,\,\1740 ara-C\JJ\1740 and\CC\1740 radiotherapy\NN\661091 could\MD\1740 cause\VB\1617192 severe\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008727_D020258 CID <e2>Neurologic\JJ\1740 toxicities</e2>\NNS\13576101 have\VBP\2108377 been\VBN\836236 described\VBN\1001294 with\IN\1740 <e1>IT-methotrexate</e1>\NN\1740 ,\,\1740 IT-cytosine\NN\1740 arabinoside\NN\1740 and\CC\1740 IT-TSPA\NN\1740 .\.\1740
D008727_D020258 CID In\IN\13603305 spite\NN\7550369 of\IN\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 TSPA\NNP\1740 is\VBZ\836236 a\DT\13649268 useful\JJ\1740 IT\NN\6125041 agent\NN\7347 ,\,\1740 its\PRP$\6125041 combination\NN\7951464 with\IN\1740 <e1>MTX</e1>\NN\1740 ,\,\1740 ara-C\JJ\1740 and\CC\1740 radiotherapy\NN\661091 could\MD\1740 cause\VB\1617192 severe\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D003561_D020258 CID <e2>Neurologic\JJ\1740 toxicities</e2>\NNS\13576101 have\VBP\2108377 been\VBN\836236 described\VBN\1001294 with\IN\1740 IT-methotrexate\NN\1740 ,\,\1740 <e1>IT-cytosine\NN\1740 arabinoside</e1>\NN\1740 and\CC\1740 IT-TSPA\NN\1740 .\.\1740
D003561_D020258 CID In\IN\13603305 spite\NN\7550369 of\IN\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 TSPA\NNP\1740 is\VBZ\836236 a\DT\13649268 useful\JJ\1740 IT\NN\6125041 agent\NN\7347 ,\,\1740 its\PRP$\6125041 combination\NN\7951464 with\IN\1740 MTX\NN\1740 ,\,\1740 <e1>ara-C</e1>\JJ\1740 and\CC\1740 radiotherapy\NN\661091 could\MD\1740 cause\VB\1617192 severe\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
10672628
D009569_D002375 NONE Sub-chronic\JJ\1740 inhibition\NN\1068773 of\IN\1740 <e1>nitric-oxide</e1>\JJ\1740 synthesis\NN\13446390 modifies\VBZ\109660 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 the\DT\1740 number\NN\5107765 of\IN\1740 NADPH-diaphorase\JJ\1740 neurons\NNS\5430628 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009569_D002375 NONE RATIONALE\NN\5793000 :\:\1740 NG-nitro-L-arginine\NN\1740 (\-LRB-\1740 L-NOARG\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 <e1>nitric-oxide</e1>\JJ\1740 synthase\NN\1740 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 induces\VBZ\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 mice\NNS\2329401 .\.\1740
D006220_D002375 CID Sub-chronic\JJ\1740 inhibition\NN\1068773 of\IN\1740 nitric-oxide\JJ\1740 synthesis\NN\13446390 modifies\VBZ\109660 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 the\DT\1740 number\NN\5107765 of\IN\1740 NADPH-diaphorase\JJ\1740 neurons\NNS\5430628 in\IN\13603305 mice\NNS\2329401 .\.\1740
D006220_D002375 CID Neuroleptic\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 <e1>haloperidol</e1>\NN\3713736 ,\,\1740 which\WDT\1740 block\VBP\1476483 dopamine\NN\14807737 receptors\NNS\5225602 ,\,\1740 also\RB\1740 cause\VBP\1617192 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rodents\NNS\1886756 .\.\1740
D006220_D002375 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 subchronic\JJ\1740 L-NOARG\NN\1740 treatment\NN\654885 in\IN\13603305 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 the\DT\1740 number\NN\5107765 of\IN\1740 NOS\NN\7204911 neurons\NNS\5430628 in\IN\13603305 areas\NNS\8630985 related\JJ\1740 to\TO\1740 motor\NN\3699975 control\NN\5190804 .\.\1740
D006220_D002375 CID RESULTS\NNS\34213 :\:\1740 L-NOARG\JJ\1740 sub-chronic\JJ\1740 administration\NN\1133281 produced\VBD\1617192 tolerance\NN\5032565 of\IN\1740 L-NOARG\NN\1740 and\CC\1740 of\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D009249_D002375 NONE Sub-chronic\JJ\1740 inhibition\NN\1068773 of\IN\1740 nitric-oxide\JJ\1740 synthesis\NN\13446390 modifies\VBZ\109660 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 the\DT\1740 number\NN\5107765 of\IN\1740 <e1>NADPH-diaphorase</e1>\JJ\1740 neurons\NNS\5430628 in\IN\13603305 mice\NNS\2329401 .\.\1740
D019335_D002375 NONE RATIONALE\NN\5793000 :\:\1740 <e1>NG-nitro-L-arginine</e1>\NN\1740 (\-LRB-\1740 L-NOARG\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 nitric-oxide\JJ\1740 synthase\NN\1740 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 induces\VBZ\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 mice\NNS\2329401 .\.\1740
D019335_D002375 NONE RATIONALE\NN\5793000 :\:\1740 NG-nitro-L-arginine\NN\1740 (\-LRB-\1740 <e1>L-NOARG</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 nitric-oxide\JJ\1740 synthase\NN\1740 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 induces\VBZ\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 mice\NNS\2329401 .\.\1740
D019335_D002375 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 subchronic\JJ\1740 <e1>L-NOARG</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 the\DT\1740 number\NN\5107765 of\IN\1740 NOS\NN\7204911 neurons\NNS\5430628 in\IN\13603305 areas\NNS\8630985 related\JJ\1740 to\TO\1740 motor\NN\3699975 control\NN\5190804 .\.\1740
D019335_D002375 NONE RESULTS\NNS\34213 :\:\1740 <e1>L-NOARG</e1>\JJ\1740 sub-chronic\JJ\1740 administration\NN\1133281 produced\VBD\1617192 tolerance\NN\5032565 of\IN\1740 L-NOARG\NN\1740 and\CC\1740 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D019335_D002375 NONE RESULTS\NNS\34213 :\:\1740 L-NOARG\JJ\1740 sub-chronic\JJ\1740 administration\NN\1133281 produced\VBD\1617192 tolerance\NN\5032565 of\IN\1740 <e1>L-NOARG</e1>\NN\1740 and\CC\1740 of\IN\1740 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D004298_D002375 NONE Neuroleptic\JJ\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 haloperidol\NN\3713736 ,\,\1740 which\WDT\1740 block\VBP\1476483 <e1>dopamine</e1>\NN\14807737 receptors\NNS\5225602 ,\,\1740 also\RB\1740 cause\VBP\1617192 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rodents\NNS\1886756 .\.\1740
3711722
D003035_D009202 CID In\IN\13603305 the\DT\1740 first\JJ\1740 ,\,\1740 <e1>cobalt</e1>\NN\14625458 <e2>cardiomyopathy</e2>\NN\14103288 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 eight\CD\13741022 dogs\NNS\2083346 ;\:\1740 VIP\NN\10200781 (\-LRB-\1740 by\IN\1740 radioimmunoassay\NN\5740560 )\-RRB-\1740 decreased\VBD\169651 from\IN\1740 35\CD\1740 +/-\CC\1740 11\CD\13745420 pg/mg\NN\1740 protein\NN\14944888 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 )\-RRB-\1740 to\TO\1740 5\CD\13741022 +/-\CC\1740 4\CD\13741022 pg/mg\NN\1740 protein\NN\14944888 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D004317_D006333 CID In\IN\13603305 six\CD\13741022 dogs\NNS\2083346 with\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 VIP\NN\10200781 decreased\VBD\169651 from\IN\1740 31\CD\1740 +/-\CC\1740 7\CD\13741022 to\TO\1740 11\CD\13745420 +/-\CC\1740 4\CD\13741022 pg/mg\NN\1740 protein\NN\14944888 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
19020118
11988250
D007052_D006976 CID <e2>Pulmonary\JJ\1740 hypertension</e2>\NN\14057371 after\IN\1740 <e1>ibuprofen</e1>\NN\3828465 prophylaxis\NN\1077350 in\IN\13603305 very\JJ\1740 preterm\NN\1740 infants\NNS\9918248 .\.\1740
D007052_D000860 CID We\PRP\1740 report\VBP\831651 three\CD\13741022 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 <e2>hypoxaemia</e2>\NN\1740 after\IN\1740 <e1>ibuprofen</e1>\NN\3828465 administration\NN\1133281 during\IN\1740 a\DT\13649268 randomised\VBN\278117 controlled\VBN\2422663 trial\NN\786195 of\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 patent\NN\6470073 ductus\NN\1740 arteriosus\NN\1740 with\IN\1740 ibuprofen\NN\3828465 in\IN\13603305 premature\JJ\1740 infants\NNS\9918248 born\VBN\2630189 at\IN\14622893 less\JJR\1740 than\IN\1740 28\CD\13745420 weeks\NNS\15113229 of\IN\1740 gestation\NN\15116532 .\.\1740
D007052_D000860 CID We\PRP\1740 report\VBP\831651 three\CD\13741022 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 <e2>hypoxaemia</e2>\NN\1740 after\IN\1740 ibuprofen\NN\3828465 administration\NN\1133281 during\IN\1740 a\DT\13649268 randomised\VBN\278117 controlled\VBN\2422663 trial\NN\786195 of\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 patent\NN\6470073 ductus\NN\1740 arteriosus\NN\1740 with\IN\1740 <e1>ibuprofen</e1>\NN\3828465 in\IN\13603305 premature\JJ\1740 infants\NNS\9918248 born\VBN\2630189 at\IN\14622893 less\JJR\1740 than\IN\1740 28\CD\13745420 weeks\NNS\15113229 of\IN\1740 gestation\NN\15116532 .\.\1740
D007052_D000860 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 investigators\NNS\10560637 involved\VBN\2676054 in\IN\13603305 similar\JJ\1740 trials\NNS\786195 pay\VBP\2199590 close\JJ\1740 attention\NN\5701944 to\IN\1740 pulmonary\JJ\1740 pressure\NN\11419404 if\IN\1740 <e2>hypoxaemia</e2>\NN\1740 occurs\VBZ\2623529 after\IN\1740 prophylactic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 .\.\1740
D007052_D004374 NONE We\PRP\1740 report\VBP\831651 three\CD\13741022 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 hypoxaemia\NN\1740 after\IN\1740 <e1>ibuprofen</e1>\NN\3828465 administration\NN\1133281 during\IN\1740 a\DT\13649268 randomised\VBN\278117 controlled\VBN\2422663 trial\NN\786195 of\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>patent\NN\6470073 ductus\NN\1740 arteriosus</e2>\NN\1740 with\IN\1740 ibuprofen\NN\3828465 in\IN\13603305 premature\JJ\1740 infants\NNS\9918248 born\VBN\2630189 at\IN\14622893 less\JJR\1740 than\IN\1740 28\CD\13745420 weeks\NNS\15113229 of\IN\1740 gestation\NN\15116532 .\.\1740
D007052_D004374 NONE We\PRP\1740 report\VBP\831651 three\CD\13741022 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 hypoxaemia\NN\1740 after\IN\1740 ibuprofen\NN\3828465 administration\NN\1133281 during\IN\1740 a\DT\13649268 randomised\VBN\278117 controlled\VBN\2422663 trial\NN\786195 of\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>patent\NN\6470073 ductus\NN\1740 arteriosus</e2>\NN\1740 with\IN\1740 <e1>ibuprofen</e1>\NN\3828465 in\IN\13603305 premature\JJ\1740 infants\NNS\9918248 born\VBN\2630189 at\IN\14622893 less\JJR\1740 than\IN\1740 28\CD\13745420 weeks\NNS\15113229 of\IN\1740 gestation\NN\15116532 .\.\1740
D009569_D000860 NONE <e2>Hypoxaemia</e2>\NNP\1740 resolved\VBD\352826 quickly\RB\1740 on\IN\1740 inhaled\VBN\1198101 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 therapy\NN\657604 .\.\1740
17351238
D005996_D007022 CID A\DT\13649268 dramatic\JJ\1740 <e2>drop\NN\13899200 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 following\VBG\1835496 prehospital\JJ\1740 <e1>GTN</e1>\NN\1740 administration\NN\1133281 .\.\1740
D005996_D007022 CID Several\JJ\1740 minutes\NNS\6502378 after\IN\1740 the\DT\1740 <e1>GTN</e1>\NN\1740 the\DT\1740 patient\NN\9898892 experienced\VBD\2108377 a\DT\13649268 sudden\JJ\1740 <e2>drop\NN\13899200 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 ,\,\1740 this\DT\1740 was\VBD\836236 rectified\VBN\918872 by\IN\1740 atropine\NN\14712692 sulphate\NN\15010703 and\CC\1740 a\DT\13649268 fluid\NN\19613 challenge\NN\13927383 .\.\1740
D001285_D007022 NONE Several\JJ\1740 minutes\NNS\6502378 after\IN\1740 the\DT\1740 GTN\NN\1740 the\DT\1740 patient\NN\9898892 experienced\VBD\2108377 a\DT\13649268 sudden\JJ\1740 <e2>drop\NN\13899200 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 ,\,\1740 this\DT\1740 was\VBD\836236 rectified\VBN\918872 by\IN\1740 <e1>atropine\NN\14712692 sulphate</e1>\NN\15010703 and\CC\1740 a\DT\13649268 fluid\NN\19613 challenge\NN\13927383 .\.\1740
17223814
D015251_D054537 CID Peri-operative\JJ\1740 <e2>atrioventricular\JJ\1740 block</e2>\NN\21939 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>epirubicin</e1>\NN\1740 and\CC\1740 paclitaxel\NN\1740 .\.\1740
D017239_D054537 CID Peri-operative\JJ\1740 <e2>atrioventricular\JJ\1740 block</e2>\NN\21939 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 chemotherapy\NN\661091 with\IN\1740 epirubicin\NN\1740 and\CC\1740 <e1>paclitaxel</e1>\NN\1740 .\.\1740
7457821
25031906
D017311_D004408 CID Is\VBZ\836236 <e2>Dysguesia</e2>\NNP\1740 Going\VBG\2367363 to\TO\1740 be\VB\836236 a\DT\13649268 Rare\JJ\1740 or\CC\3541091 a\DT\13649268 Common\JJ\1740 Side-effect\NN\1740 of\IN\1740 <e1>Amlodipine</e1>\NN\1740 ?\.\1740
D017311_D004408 CID A\DT\13649268 very\RB\1740 rare\JJ\1740 side-effect\NN\1740 of\IN\1740 <e1>amlodipine</e1>\NN\1740 is\VBZ\836236 <e2>dysguesia</e2>\VBN\1740 .\.\1740
D017311_D004408 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>amlodipine</e1>\NN\1740 can\MD\3094503 cause\VB\1617192 <e2>dysguesia</e2>\NN\1740 .\.\1740
D017311_D004408 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 clinical\JJ\1740 presentation\NN\1027379 and\CC\1740 review\VB\644583 the\DT\1740 relevant\JJ\1740 literature\NN\6362953 on\IN\1740 <e1>amlodipine</e1>\NN\1740 and\CC\1740 <e2>dysguesia</e2>\NN\1740 .\.\1740
D017311_D006973 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 about\IN\1740 a\DT\13649268 female\NN\15388 with\IN\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 on\IN\1740 drug\NN\14778436 treatment\NN\654885 with\IN\1740 <e1>amlodipine</e1>\NN\1740 developed\VBD\1753788 loss\NN\13252973 of\IN\1740 taste\NN\5712076 sensation\NN\5708432 .\.\1740
D017311_D012678 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 about\IN\1740 a\DT\13649268 female\NN\15388 with\IN\1740 essential\JJ\1740 hypertension\NN\14057371 on\IN\1740 drug\NN\14778436 treatment\NN\654885 with\IN\1740 <e1>amlodipine</e1>\NN\1740 developed\VBD\1753788 <e2>loss\NN\13252973 of\IN\1740 taste\NN\5712076 sensation</e2>\NN\5708432 .\.\1740
4082192
C026729_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>p-aminophenol</e1>\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
C026729_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>p-aminophenol</e1>\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
C026729_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 <e1>p-aminophenol</e1>\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
C026729_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 <e1>p-aminophenol</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
C026729_D007674 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 <e1>PAP</e1>\NN\6612266 formation\NN\7938773 is\VBZ\836236 a\DT\13649268 requisite\JJ\1740 step\NN\168237 in\IN\13603305 APAP-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
C026729_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 (\-LRB-\1740 BNPP\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 acylamidase\NN\1740 inhibitor\NN\20090 ,\,\1740 on\IN\1740 APAP\NN\1740 and\CC\1740 <e1>PAP</e1>\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 was\VBD\836236 determined\VBN\1645601 .\.\1740
C026729_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 <e1>PAP</e1>\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 nephrotoxicity\NN\1740 .\.\1740
C026729_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 <e1>PAP</e1>\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 nephrotoxicity\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
C026729_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 but\CC\1740 not\RB\1740 <e1>PAP</e1>\NN\6612266 nephrotoxicity\NN\1740 .\.\1740
C026729_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 nephrotoxicity\NN\1740 but\CC\1740 not\RB\1740 <e1>PAP</e1>\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000082_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D000082_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 <e1>acetaminophen-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D000082_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D000082_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 on\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D000082_D007674 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 PAP\NN\6612266 formation\NN\7938773 is\VBZ\836236 a\DT\13649268 requisite\JJ\1740 step\NN\168237 in\IN\13603305 <e1>APAP-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000082_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 (\-LRB-\1740 BNPP\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 acylamidase\NN\1740 inhibitor\NN\20090 ,\,\1740 on\IN\1740 <e1>APAP</e1>\NN\1740 and\CC\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 was\VBD\836236 determined\VBN\1645601 .\.\1740
D000082_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 <e1>APAP</e1>\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 nephrotoxicity\NN\1740 .\.\1740
D000082_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 <e1>APAP</e1>\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 nephrotoxicity\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000082_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 <e1>APAP</e1>\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 nephrotoxicity\NN\1740 .\.\1740
D000082_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 BNPP\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 <e1>APAP</e1>\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 nephrotoxicity\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000082_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 BNPP-induced\JJ\1740 reduction\NN\351485 in\IN\13603305 <e1>APAP-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 due\JJ\1740 to\TO\1740 inhibition\NN\1068773 of\IN\1740 APAP\NN\1740 deacetylation\NN\1740 .\.\1740
D000082_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 BNPP-induced\JJ\1740 reduction\NN\351485 in\IN\13603305 APAP-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 due\JJ\1740 to\TO\1740 inhibition\NN\1068773 of\IN\1740 <e1>APAP</e1>\NN\1740 deacetylation\NN\1740 .\.\1740
C002887_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 <e1>bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate</e1>\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
C002887_D007674 NONE The\DT\1740 role\NN\719494 of\IN\1740 p-aminophenol\NN\1740 in\IN\13603305 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 :\:\1740 effect\NN\34213 of\IN\1740 <e1>bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate</e1>\NN\15010703 on\IN\1740 acetaminophen\NN\2707683 and\CC\1740 p-aminophenol\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
C002887_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate</e1>\NN\15010703 (\-LRB-\1740 BNPP\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 acylamidase\NN\1740 inhibitor\NN\20090 ,\,\1740 on\IN\1740 APAP\NN\1740 and\CC\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 was\VBD\836236 determined\VBN\1645601 .\.\1740
C002887_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 bis(p-nitrophenyl\NN\1740 )\-RRB-\1740 phosphate\NN\15010703 (\-LRB-\1740 <e1>BNPP</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 acylamidase\NN\1740 inhibitor\NN\20090 ,\,\1740 on\IN\1740 APAP\NN\1740 and\CC\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 metabolism\NN\13526110 was\VBD\836236 determined\VBN\1645601 .\.\1740
C002887_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 <e1>BNPP</e1>\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 nephrotoxicity\NN\1740 .\.\1740
C002887_D007674 NONE Pretreatment\NN\1740 of\IN\1740 animals\NNS\4475 with\IN\1740 <e1>BNPP</e1>\NN\1740 prior\RB\1740 to\TO\1740 APAP\NN\1740 or\CC\3541091 PAP\NN\6612266 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 marked\JJ\1740 reduction\NN\351485 of\IN\1740 APAP\NN\1740 (\-LRB-\1740 900\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 nephrotoxicity\NN\1740 but\CC\1740 not\RB\1740 PAP\NN\6612266 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
C002887_D007674 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 <e1>BNPP-induced</e1>\JJ\1740 reduction\NN\351485 in\IN\13603305 APAP-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 due\JJ\1740 to\TO\1740 inhibition\NN\1068773 of\IN\1740 APAP\NN\1740 deacetylation\NN\1740 .\.\1740
D000082_D007683 CID <e1>Acetaminophen</e1>\NN\2707683 (\-LRB-\1740 APAP\NN\1740 )\-RRB-\1740 produces\VBZ\1617192 proximal\JJ\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 (\-LRB-\1740 F344\NN\1740 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D000082_D007683 CID Acetaminophen\NN\2707683 (\-LRB-\1740 <e1>APAP</e1>\NN\1740 )\-RRB-\1740 produces\VBZ\1617192 proximal\JJ\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 in\IN\13603305 Fischer\NNP\1740 344\CD\1740 (\-LRB-\1740 F344\NN\1740 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D000082_D007683 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 PAP\NN\6612266 formation\NN\7938773 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 accounts\NNS\6647206 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 ,\,\1740 for\IN\1740 <e1>APAP-induced</e1>\JJ\1740 <e2>renal\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 .\.\1740
C026729_D007683 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>PAP</e1>\NN\6612266 formation\NN\7938773 ,\,\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 accounts\NNS\6647206 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 part\NN\31921 ,\,\1740 for\IN\1740 APAP-induced\JJ\1740 <e2>renal\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 .\.\1740
6299641
D001262_D013610 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 single\JJ\1740 doses\NNS\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 <e1>atenolol</e1>\NNS\2832168 (\-LRB-\1740 cardioselective\JJ\1740 )\-RRB-\1740 ,\,\1740 40\CD\13745420 mg\NN\13717155 propranolol\NN\1740 (\-LRB-\1740 nonselective\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 placebo\VB\1740 on\RP\1740 both\CC\1740 exercise-\JJ\1740 and\CC\1740 isoproterenol-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 two\CD\13741022 experiments\NNS\641820 involving\VBG\2676054 nine\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D011433_D013610 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 single\JJ\1740 doses\NNS\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 atenolol\NNS\2832168 (\-LRB-\1740 cardioselective\JJ\1740 )\-RRB-\1740 ,\,\1740 40\CD\13745420 mg\NN\13717155 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 nonselective\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 placebo\VB\1740 on\RP\1740 both\CC\1740 exercise-\JJ\1740 and\CC\1740 isoproterenol-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 two\CD\13741022 experiments\NNS\641820 involving\VBG\2676054 nine\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007545_D013610 CID We\PRP\1740 compared\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 single\JJ\1740 doses\NNS\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 atenolol\NNS\2832168 (\-LRB-\1740 cardioselective\JJ\1740 )\-RRB-\1740 ,\,\1740 40\CD\13745420 mg\NN\13717155 propranolol\NN\1740 (\-LRB-\1740 nonselective\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 placebo\VB\1740 on\RP\1740 both\CC\1740 exercise-\JJ\1740 and\CC\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 two\CD\13741022 experiments\NNS\641820 involving\VBG\2676054 nine\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 .\.\1740
D007545_D013610 CID The\DT\1740 effects\NNS\13245626 on\IN\1740 <e1>isoproterenol</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 were\VBD\836236 determined\VBN\1645601 before\IN\1740 and\CC\1740 after\IN\1740 atropine\NN\14712692 (\-LRB-\1740 0.04\CD\1740 mg/kg\NN\1740 IV\CD\13741022 )\-RRB-\1740 .\.\1740
D007545_D013610 CID These\DT\1740 data\NNS\7951464 are\VBP\836236 consistent\JJ\1740 with\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 exercise-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 results\VBZ\2633881 largely\RB\1740 from\IN\1740 beta\NN\6828818 1-receptor\NN\1740 activation\NN\13561719 that\WDT\1740 is\VBZ\836236 blocked\VBN\1476483 by\IN\1740 both\CC\1740 cardioselective\JJ\1740 and\CC\1740 nonselective\JJ\1740 drugs\NNS\14778436 ,\,\1740 whereas\IN\1740 <e1>isoproterenol</e1>\NN\3740161 activates\VBZ\1641914 both\CC\1740 beta\NN\6828818 1-\CD\1740 and\CC\1740 beta\NN\6828818 2-receptors\NNS\1740 so\IN\6868043 that\IN\1740 after\IN\1740 cardioselective\JJ\1740 blockade\NN\952963 there\EX\27167 remains\VBZ\2604760 a\DT\13649268 beta\NN\6828818 2-component\NN\1740 that\WDT\1740 can\MD\3094503 be\VB\836236 blocked\VBN\1476483 with\IN\1740 a\DT\13649268 nonselective\JJ\1740 drug\NN\14778436 .\.\1740
D001285_D013610 NONE The\DT\1740 effects\NNS\13245626 on\IN\1740 isoproterenol\JJ\1740 <e2>tachycardia</e2>\NN\14110674 were\VBD\836236 determined\VBN\1645601 before\IN\1740 and\CC\1740 after\IN\1740 <e1>atropine</e1>\NN\14712692 (\-LRB-\1740 0.04\CD\1740 mg/kg\NN\1740 IV\CD\13741022 )\-RRB-\1740 .\.\1740
24132704
C029036_D006949 NONE <e1>Crocin</e1>\NN\1740 reduced\VBD\441445 inhibition\NN\1068773 of\IN\1740 ERK\NN\1740 activation\NN\13561719 and\CC\1740 diazinon-induced\JJ\1740 <e2>hyperlipemia</e2>\NN\14299637 and\CC\1740 increased\VBD\169651 levels\NNS\4916342 of\IN\1740 LDLr\NN\1740 transcript\NN\6362953 .\.\1740
C029036_D006949 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Crocin</e1>\NN\1740 may\MD\15209706 be\VB\836236 considered\VBN\689344 as\IN\14622893 a\DT\13649268 novel\JJ\1740 protective\JJ\1740 agent\NN\7347 in\IN\13603305 diazinon-induced\JJ\1740 <e2>hyperlipemia</e2>\NN\14299637 through\IN\1740 modulating\NN\1740 of\IN\1740 ERK\NN\1740 pathway\NN\5483677 and\CC\1740 increase\NN\13576355 of\IN\1740 LDLr\NN\1740 expression\NN\4679549 .\.\1740
D003976_D006949 CID Crocin\NN\1740 reduced\VBD\441445 inhibition\NN\1068773 of\IN\1740 ERK\NN\1740 activation\NN\13561719 and\CC\1740 <e1>diazinon-induced</e1>\JJ\1740 <e2>hyperlipemia</e2>\NN\14299637 and\CC\1740 increased\VBD\169651 levels\NNS\4916342 of\IN\1740 LDLr\NN\1740 transcript\NN\6362953 .\.\1740
D003976_D006949 CID CONCLUSIONS\NNS\5837957 :\:\1740 Crocin\NN\1740 may\MD\15209706 be\VB\836236 considered\VBN\689344 as\IN\14622893 a\DT\13649268 novel\JJ\1740 protective\JJ\1740 agent\NN\7347 in\IN\13603305 <e1>diazinon-induced</e1>\JJ\1740 <e2>hyperlipemia</e2>\NN\14299637 through\IN\1740 modulating\NN\1740 of\IN\1740 ERK\NN\1740 pathway\NN\5483677 and\CC\1740 increase\NN\13576355 of\IN\1740 LDLr\NN\1740 expression\NN\4679549 .\.\1740
6321816
D014667_D006973 NONE <e1>Vasopressin</e1>\VB\1740 as\IN\14622893 a\DT\13649268 possible\JJ\1740 contributor\NN\10025730 to\TO\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D014667_D006973 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 as\IN\14622893 a\DT\13649268 pressor\NN\9190918 agent\NN\7347 to\TO\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 process\NN\407535 was\VBD\836236 examined\VBN\789138 .\.\1740
D014667_D006973 NONE <e1>Vasopressin</e1>\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 DOCA-salt\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 lithium-treated\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 after\IN\1740 DOCA-salt\JJ\1740 treatment\NN\654885 .\.\1740
D014667_D006973 NONE Furthermore\RB\1740 ,\,\1740 the\DT\1740 pressor\NN\9190918 action\NN\30358 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 appears\VBZ\2604760 to\TO\1740 be\VB\836236 important\JJ\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 model\NN\5888929 of\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 enhanced\VBN\227165 pressor\NN\9190918 responsiveness\NN\5652926 to\TO\1740 the\DT\1740 hormone\NN\5404728 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 the\DT\1740 initial\JJ\1740 stage\NN\15113229 of\IN\1740 hypertension\NN\14057371 .\.\1740
D014667_D006973 NONE Furthermore\RB\1740 ,\,\1740 the\DT\1740 pressor\NN\9190918 action\NN\30358 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 appears\VBZ\2604760 to\TO\1740 be\VB\836236 important\JJ\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 model\NN\5888929 of\IN\1740 hypertension\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 enhanced\VBN\227165 pressor\NN\9190918 responsiveness\NN\5652926 to\TO\1740 the\DT\1740 hormone\NN\5404728 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 the\DT\1740 initial\JJ\1740 stage\NN\15113229 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D014667_D006973 NONE Increased\VBN\169651 secretion\NN\13526110 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 from\IN\1740 neurohypophysis\NN\5329735 also\RB\1740 promotes\VBZ\2556126 the\DT\1740 function\NN\13783581 of\IN\1740 the\DT\1740 hormone\NN\5404728 as\IN\14622893 a\DT\13649268 pathogenetic\JJ\1740 factor\NN\7326557 in\IN\13603305 <e2>hypertension</e2>\NN\14057371 .\.\1740
D014667_D006973 NONE However\RB\1740 ,\,\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 remains\VBZ\2604760 to\TO\1740 be\VB\836236 determined\VBN\1645601 in\IN\13603305 human\JJ\1740 essential\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D014667_D003919 NONE <e1>Vasopressin</e1>\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 DOCA-salt\JJ\1740 hypertension\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 lithium-treated\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 after\IN\1740 DOCA-salt\JJ\1740 treatment\NN\654885 .\.\1740
D003900_D006973 CID Vasopressin\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e1>DOCA-salt</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 lithium-treated\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 after\IN\1740 DOCA-salt\JJ\1740 treatment\NN\654885 .\.\1740
D003900_D006973 CID Vasopressin\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 DOCA-salt\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 lithium-treated\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 after\IN\1740 <e1>DOCA-salt</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D003900_D003919 NONE Vasopressin\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e1>DOCA-salt</e1>\JJ\1740 hypertension\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 lithium-treated\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 after\IN\1740 DOCA-salt\JJ\1740 treatment\NN\654885 .\.\1740
D003900_D003919 NONE Vasopressin\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 DOCA-salt\JJ\1740 hypertension\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 lithium-treated\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 after\IN\1740 <e1>DOCA-salt</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D008094_D006973 NONE Vasopressin\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 DOCA-salt\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 <e1>lithium-treated</e1>\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 after\IN\1740 DOCA-salt\JJ\1740 treatment\NN\654885 .\.\1740
D008094_D003919 CID Vasopressin\NN\5407119 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 DOCA-salt\JJ\1740 hypertension\NN\14057371 ,\,\1740 since\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 not\RB\1740 substantial\JJ\1740 in\IN\13603305 the\DT\1740 rats\NNS\2329401 with\IN\1740 <e1>lithium-treated</e1>\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 after\IN\1740 DOCA-salt\JJ\1740 treatment\NN\654885 .\.\1740
6884395
D003276_D000784 CID A\DT\13649268 case\NN\7283608 of\IN\1740 nontraumatic\JJ\1740 <e2>dissecting\NN\1740 aneurysm</e2>\NN\14057371 of\IN\1740 the\DT\1740 basilar\JJ\1740 artery\NN\5417975 in\IN\13603305 association\NN\8008335 with\IN\1740 hypertension\NN\14057371 ,\,\1740 smoke\NN\11422597 ,\,\1740 and\CC\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 young\JJ\1740 female\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 locked-in\JJ\1740 syndrome\NN\5870365 .\.\1740
D003276_D006973 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 nontraumatic\JJ\1740 dissecting\NN\1740 aneurysm\NN\14057371 of\IN\1740 the\DT\1740 basilar\JJ\1740 artery\NN\5417975 in\IN\13603305 association\NN\8008335 with\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 smoke\NN\11422597 ,\,\1740 and\CC\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 young\JJ\1740 female\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 locked-in\JJ\1740 syndrome\NN\5870365 .\.\1740
D003276_D011782 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 nontraumatic\JJ\1740 dissecting\NN\1740 aneurysm\NN\14057371 of\IN\1740 the\DT\1740 basilar\JJ\1740 artery\NN\5417975 in\IN\13603305 association\NN\8008335 with\IN\1740 hypertension\NN\14057371 ,\,\1740 smoke\NN\11422597 ,\,\1740 and\CC\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 young\JJ\1740 female\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 <e2>locked-in\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
24739405
D003687_D012559 NONE Effects\NNS\13245626 of\IN\1740 <e1>dehydroepiandrosterone</e1>\NN\1740 in\IN\13603305 amphetamine-induced\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 models\NNS\5888929 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003687_D012559 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>dehydroepiandrosterone</e1>\NN\1740 (\-LRB-\1740 DHEA\NN\1740 )\-RRB-\1740 on\IN\1740 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D003687_D012559 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 dehydroepiandrosterone\NN\1740 (\-LRB-\1740 <e1>DHEA</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D003687_D012559 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 <e1>DHEA</e1>\NN\1740 displays\VBZ\2137132 typical\JJ\1740 neuroleptic-like\JJ\1740 effects\NNS\13245626 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D000661_D012559 CID Effects\NNS\13245626 of\IN\1740 dehydroepiandrosterone\NN\1740 in\IN\13603305 <e1>amphetamine-induced</e1>\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 models\NNS\5888929 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000661_D012559 CID <e1>Amphetamine</e1>\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 hyper\NN\1740 locomotion\NN\4773351 ,\,\1740 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 catalepsy\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D000661_D006948 NONE <e1>Amphetamine</e1>\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 <e2>hyper</e2>\NN\1740 locomotion\NN\4773351 ,\,\1740 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 catalepsy\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 schizophrenia\NN\14398067 .\.\1740
D000661_D002375 NONE <e1>Amphetamine</e1>\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 hyper\NN\1740 locomotion\NN\4773351 ,\,\1740 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 schizophrenia\NN\14398067 .\.\1740
D001058_D006948 NONE Amphetamine\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 <e2>hyper</e2>\NN\1740 locomotion\NN\4773351 ,\,\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 catalepsy\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 schizophrenia\NN\14398067 .\.\1740
D001058_D002375 NONE Amphetamine\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 hyper\NN\1740 locomotion\NN\4773351 ,\,\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 schizophrenia\NN\14398067 .\.\1740
D001058_D012559 CID Amphetamine\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 hyper\NN\1740 locomotion\NN\4773351 ,\,\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 catalepsy\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D006220_D006948 NONE Amphetamine\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 <e2>hyper</e2>\NN\1740 locomotion\NN\4773351 ,\,\1740 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 catalepsy\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 schizophrenia\NN\14398067 .\.\1740
D006220_D002375 CID Amphetamine\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 hyper\NN\1740 locomotion\NN\4773351 ,\,\1740 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 schizophrenia\NN\14398067 .\.\1740
D006220_D002375 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 between\IN\1740 groups\NNS\2137 in\IN\13603305 the\DT\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 test\NN\5798043 (\-LRB-\1740 p<0.05\NN\1740 )\-RRB-\1740 .\.\1740
D006220_D012559 CID Amphetamine\NN\3248958 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 induced\VBN\1627355 hyper\NN\1740 locomotion\NN\4773351 ,\,\1740 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 subcutaneously\RB\1740 [\-LRB-\1740 sc\FW\14625458 ]\-RRB-\1740 )\-RRB-\1740 induced\VBD\1627355 climbing\NN\7445480 ,\,\1740 and\CC\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 sc\NN\14625458 )\-RRB-\1740 induced\JJ\1740 catalepsy\NN\14023236 tests\NNS\5798043 were\VBD\836236 used\VBN\1156834 as\IN\14622893 animal\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D003687_D002375 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 observed\VBD\2163746 that\IN\1740 <e1>DHEA</e1>\NN\1740 reduced\VBD\441445 locomotor\NN\1740 activity\NN\30358 and\CC\1740 increased\VBN\169651 <e2>catalepsy</e2>\NN\14023236 at\IN\14622893 both\DT\1740 doses\NNS\3740161 ,\,\1740 while\IN\15122231 it\PRP\6125041 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 climbing\NN\7445480 behavior\NN\407535 .\.\1740
23871786
C006780_D001008 CID Pubertal\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>Bisphenol\NN\1740 A</e1>\NN\13649268 increases\VBZ\169651 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 and\CC\1740 decreases\VBZ\169651 acetylcholinesterase\NN\1740 activity\NN\30358 of\IN\1740 hippocampus\NN\5462674 in\IN\13603305 adult\JJ\1740 male\JJ\1740 mice\NNS\2329401 .\.\1740
C006780_D001008 CID Results\NNS\34213 from\IN\1740 our\PRP$\1740 behavioral\JJ\1740 phenotyping\NN\1740 indicated\VBD\952524 that\IN\1740 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 was\VBD\836236 increased\VBN\169651 in\IN\13603305 mice\NNS\2329401 exposed\VBN\2110927 to\TO\1740 <e1>BPA</e1>\NN\1740 .\.\1740
C006780_D001008 CID Our\PRP$\1740 findings\NNS\7951464 showed\VBD\2137132 that\IN\1740 pubertal\JJ\1740 <e1>BPA</e1>\NN\1740 exposure\NN\5042871 increased\VBD\169651 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 ,\,\1740 which\WDT\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 decreased\VBN\169651 AChE\NN\14322699 activity\NN\30358 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 in\IN\13603305 adult\JJ\1740 male\JJ\1740 mice\NNS\2329401 .\.\1740
12699527
D002712_D009224 NONE <e2>Myotonia\NN\14544672 congenita</e2>\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 is\VBZ\836236 caused\VBN\1617192 by\IN\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 skeletal\JJ\1740 muscle\NN\5289601 <e1>chloride</e1>\NN\14818238 channel\NN\6251781 function\NN\13783581 ,\,\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 sustained\JJ\1740 membrane\NN\4188643 depolarisation\NN\11412727 .\.\1740
D002712_D009224 NONE Myotonia\NN\14544672 congenita\NN\1740 (\-LRB-\1740 <e2>MC</e2>\NN\15286249 )\-RRB-\1740 is\VBZ\836236 caused\VBN\1617192 by\IN\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 skeletal\JJ\1740 muscle\NN\5289601 <e1>chloride</e1>\NN\14818238 channel\NN\6251781 function\NN\13783581 ,\,\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 sustained\JJ\1740 membrane\NN\4188643 depolarisation\NN\11412727 .\.\1740
D002712_-1 NONE Myotonia\NN\14544672 congenita\NN\1740 (\-LRB-\1740 MC\NN\15286249 )\-RRB-\1740 is\VBZ\836236 caused\VBN\1617192 by\IN\1740 a\DT\13649268 defect\NN\14462666 in\IN\13603305 the\DT\1740 skeletal\JJ\1740 muscle\NN\5289601 <e1>chloride</e1>\NN\14818238 channel\NN\6251781 function\NN\13783581 ,\,\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 <e2>sustained\JJ\1740 membrane\NN\4188643 depolarisation</e2>\NN\11412727 .\.\1740
D013390_D013035 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 previously\RB\1740 healthy\JJ\1740 32-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 life-threatening\JJ\1740 <e2>muscle\NN\5289601 spasm</e2>\NN\14299637 and\CC\1740 secondary\JJ\1740 ventilation\NN\248977 difficulties\NNS\621627 following\VBG\1835496 a\DT\13649268 preoperative\JJ\1740 injection\NN\320852 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 .\.\1740
7315949
D009638_D013035 CID Medial\JJ\1740 changes\NNS\7283608 in\IN\13603305 arterial\JJ\1740 <e2>spasm</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 <e1>L-norepinephrine</e1>\NN\1740 .\.\1740
D009638_D006547 NONE In\IN\13603305 the\DT\1740 media\NNS\3575240 of\IN\1740 the\DT\1740 saphenous\JJ\1740 artery\NN\5417975 and\CC\1740 its\PRP$\6125041 distal\JJ\1740 branch\NN\8220714 ,\,\1740 vasoconstriction\NN\1149911 induced\VBN\1627355 by\IN\1740 <e1>L-norepinephrine</e1>\NN\1740 produced\VBD\1617192 many\JJ\1740 cell-to-cell\JJ\1740 <e2>hernias</e2>\NNS\14295248 within\IN\1740 15\CD\13745420 minutes\NNS\6502378 .\.\1740
3439580
D007099_D006973 CID <e2>Hypertension</e2>\NN\14057371 in\IN\13603305 neuroblastoma\NN\14239425 induced\VBN\1627355 by\IN\1740 <e1>imipramine</e1>\NN\4482543 .\.\1740
D007099_D006973 CID We\PRP\1740 report\VBP\831651 the\DT\1740 occurrence\NN\29378 of\IN\1740 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 blood\NN\5397468 pressure\NN\11419404 190/160\CD\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 4-year-old\JJ\1740 girl\NN\10787470 with\IN\1740 neuroblastoma\NN\14239425 who\WP\8299493 was\VBD\836236 given\VBN\2327200 <e1>Imipramine</e1>\NNP\4482543 to\TO\1740 control\VB\2422663 a\DT\13649268 behavior\NN\407535 disorder\NN\14034177 .\.\1740
D007099_D006973 CID Since\IN\1740 she\PRP\1740 had\VBD\2108377 no\DT\7204911 blood\NN\5397468 pressure\NN\11419404 elevation\NN\7445480 at\IN\14622893 initial\JJ\1740 diagnosis\NN\152018 and\CC\1740 none\NN\15228378 following\VBG\1835496 discontinuation\NN\209943 of\IN\1740 the\DT\1740 <e1>Imipramine</e1>\NNP\4482543 (\-LRB-\1740 when\WRB\1740 she\PRP\1740 was\VBD\836236 in\IN\13603305 florid\NN\1740 relapse\NN\66636 )\-RRB-\1740 ,\,\1740 we\PRP\1740 believe\VBP\686447 that\IN\1740 this\DT\1740 drug\NN\14778436 rather\RB\1740 than\IN\1740 her\PRP$\1740 underlying\VBG\2604760 disease\NN\14061805 alone\RB\1740 caused\VBD\1617192 her\PRP$\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D007099_D009447 NONE Hypertension\NN\14057371 in\IN\13603305 <e2>neuroblastoma</e2>\NN\14239425 induced\VBN\1627355 by\IN\1740 <e1>imipramine</e1>\NN\4482543 .\.\1740
D007099_D009447 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 occurrence\NN\29378 of\IN\1740 severe\JJ\1740 hypertension\NN\14057371 (\-LRB-\1740 blood\NN\5397468 pressure\NN\11419404 190/160\CD\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 4-year-old\JJ\1740 girl\NN\10787470 with\IN\1740 <e2>neuroblastoma</e2>\NN\14239425 who\WP\8299493 was\VBD\836236 given\VBN\2327200 <e1>Imipramine</e1>\NNP\4482543 to\TO\1740 control\VB\2422663 a\DT\13649268 behavior\NN\407535 disorder\NN\14034177 .\.\1740
D007099_D002653 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 occurrence\NN\29378 of\IN\1740 severe\JJ\1740 hypertension\NN\14057371 (\-LRB-\1740 blood\NN\5397468 pressure\NN\11419404 190/160\CD\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 4-year-old\JJ\1740 girl\NN\10787470 with\IN\1740 neuroblastoma\NN\14239425 who\WP\8299493 was\VBD\836236 given\VBN\2327200 <e1>Imipramine</e1>\NNP\4482543 to\TO\1740 control\VB\2422663 a\DT\13649268 <e2>behavior\NN\407535 disorder</e2>\NN\14034177 .\.\1740
17151160
C076029_D012559 NONE Randomized\JJ\1740 comparison\NN\635850 of\IN\1740 <e1>olanzapine</e1>\NN\1740 versus\CC\1740 risperidone\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 first-episode\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 :\:\1740 4-month\JJ\1740 outcomes\NNS\7291312 .\.\1740
C076029_D012559 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 authors\NNS\9610660 compared\VBD\644583 4-month\JJ\1740 treatment\NN\654885 outcomes\NNS\7291312 for\IN\1740 <e1>olanzapine</e1>\NN\1740 versus\CC\1740 risperidone\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 first-episode\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 spectrum\NN\7939382 disorders\NNS\14034177 .\.\1740
C076029_D012559 NONE METHOD\NNP\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 twelve\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 70\CD\13745420 %\NN\1740 male\JJ\1740 ;\:\1740 mean\JJ\1740 age=23.3\JJ\1740 years\NNS\15144371 [\-LRB-\1740 SD\NN\1740 =\JJ\1740 5.1\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 with\IN\1740 first-episode\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 (\-LRB-\1740 75\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 schizophreniform\NN\1740 disorder\NN\14034177 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 8\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>olanzapine</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 risperidone\NN\1740 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 6\CD\13741022 mg/day\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D012559 NONE Randomized\JJ\1740 comparison\NN\635850 of\IN\1740 olanzapine\NN\1740 versus\CC\1740 <e1>risperidone</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 first-episode\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 :\:\1740 4-month\JJ\1740 outcomes\NNS\7291312 .\.\1740
D018967_D012559 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 authors\NNS\9610660 compared\VBD\644583 4-month\JJ\1740 treatment\NN\654885 outcomes\NNS\7291312 for\IN\1740 olanzapine\NN\1740 versus\CC\1740 <e1>risperidone</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 first-episode\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 spectrum\NN\7939382 disorders\NNS\14034177 .\.\1740
D018967_D012559 NONE METHOD\NNP\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 twelve\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 70\CD\13745420 %\NN\1740 male\JJ\1740 ;\:\1740 mean\JJ\1740 age=23.3\JJ\1740 years\NNS\15144371 [\-LRB-\1740 SD\NN\1740 =\JJ\1740 5.1\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 with\IN\1740 first-episode\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 (\-LRB-\1740 75\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 schizophreniform\NN\1740 disorder\NN\14034177 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 8\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 treatment\NN\654885 with\IN\1740 olanzapine\NN\1740 (\-LRB-\1740 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>risperidone</e1>\NN\1740 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 6\CD\13741022 mg/day\NN\1740 )\-RRB-\1740 .\.\1740
C076029_D011618 NONE METHOD\NNP\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 twelve\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 70\CD\13745420 %\NN\1740 male\JJ\1740 ;\:\1740 mean\JJ\1740 age=23.3\JJ\1740 years\NNS\15144371 [\-LRB-\1740 SD\NN\1740 =\JJ\1740 5.1\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 with\IN\1740 first-episode\JJ\1740 schizophrenia\NN\14398067 (\-LRB-\1740 75\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>schizophreniform\NN\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 8\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>olanzapine</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 risperidone\NN\1740 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 6\CD\13741022 mg/day\NN\1740 )\-RRB-\1740 .\.\1740
C076029_D011618 NONE METHOD\NNP\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 twelve\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 70\CD\13745420 %\NN\1740 male\JJ\1740 ;\:\1740 mean\JJ\1740 age=23.3\JJ\1740 years\NNS\15144371 [\-LRB-\1740 SD\NN\1740 =\JJ\1740 5.1\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 with\IN\1740 first-episode\JJ\1740 schizophrenia\NN\14398067 (\-LRB-\1740 75\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 schizophreniform\NN\1740 disorder\NN\14034177 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e2>schizoaffective\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 8\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>olanzapine</e1>\NN\1740 (\-LRB-\1740 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 risperidone\NN\1740 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 6\CD\13741022 mg/day\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D011618 NONE METHOD\NNP\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 twelve\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 70\CD\13745420 %\NN\1740 male\JJ\1740 ;\:\1740 mean\JJ\1740 age=23.3\JJ\1740 years\NNS\15144371 [\-LRB-\1740 SD\NN\1740 =\JJ\1740 5.1\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 with\IN\1740 first-episode\JJ\1740 schizophrenia\NN\14398067 (\-LRB-\1740 75\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>schizophreniform\NN\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 8\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 treatment\NN\654885 with\IN\1740 olanzapine\NN\1740 (\-LRB-\1740 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>risperidone</e1>\NN\1740 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 6\CD\13741022 mg/day\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D011618 NONE METHOD\NNP\5616786 :\:\1740 One\CD\13741022 hundred\CD\13745420 twelve\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 70\CD\13745420 %\NN\1740 male\JJ\1740 ;\:\1740 mean\JJ\1740 age=23.3\JJ\1740 years\NNS\15144371 [\-LRB-\1740 SD\NN\1740 =\JJ\1740 5.1\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 with\IN\1740 first-episode\JJ\1740 schizophrenia\NN\14398067 (\-LRB-\1740 75\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 schizophreniform\NN\1740 disorder\NN\14034177 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e2>schizoaffective\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 8\CD\13741022 %\NN\1740 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 treatment\NN\654885 with\IN\1740 olanzapine\NN\1740 (\-LRB-\1740 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>risperidone</e1>\NN\1740 (\-LRB-\1740 1\CD\13741022 -\SYM\1740 6\CD\13741022 mg/day\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D010302 NONE Negative\JJ\1740 symptom\NN\5823932 outcomes\NNS\7291312 and\CC\1740 measures\NNS\168237 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 and\CC\1740 akathisia\NN\1740 did\VBD\1640855 not\RB\1740 differ\VB\1740 between\IN\1740 medications.\JJ\1740 Extrapyramidal\JJ\1740 symptom\NN\5823932 severity\NN\5036394 scores\NNS\13757724 were\VBD\836236 1.4\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.2\NN\1740 -\HYPH\1740 1.6\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.0\NNP\1740 -\HYPH\1740 1.4\CD\1740 )\-RRB-\1740 with\IN\1740 olanzapine\NN\1740 .\.\1740
D018967_D017109 NONE Negative\JJ\1740 symptom\NN\5823932 outcomes\NNS\7291312 and\CC\1740 measures\NNS\168237 of\IN\1740 parkinsonism\NN\14085708 and\CC\1740 <e2>akathisia</e2>\NN\1740 did\VBD\1640855 not\RB\1740 differ\VB\1740 between\IN\1740 medications.\JJ\1740 Extrapyramidal\JJ\1740 symptom\NN\5823932 severity\NN\5036394 scores\NNS\13757724 were\VBD\836236 1.4\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.2\NN\1740 -\HYPH\1740 1.6\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.0\NNP\1740 -\HYPH\1740 1.4\CD\1740 )\-RRB-\1740 with\IN\1740 olanzapine\NN\1740 .\.\1740
D018967_D001480 CID Negative\JJ\1740 symptom\NN\5823932 outcomes\NNS\7291312 and\CC\1740 measures\NNS\168237 of\IN\1740 parkinsonism\NN\14085708 and\CC\1740 akathisia\NN\1740 did\VBD\1640855 not\RB\1740 differ\VB\1740 between\IN\1740 medications.\JJ\1740 <e2>Extrapyramidal\JJ\1740 symptom</e2>\NN\5823932 severity\NN\5036394 scores\NNS\13757724 were\VBD\836236 1.4\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.2\NN\1740 -\HYPH\1740 1.6\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.0\NNP\1740 -\HYPH\1740 1.4\CD\1740 )\-RRB-\1740 with\IN\1740 olanzapine\NN\1740 .\.\1740
C076029_D010302 NONE Negative\JJ\1740 symptom\NN\5823932 outcomes\NNS\7291312 and\CC\1740 measures\NNS\168237 of\IN\1740 <e2>parkinsonism</e2>\NN\14085708 and\CC\1740 akathisia\NN\1740 did\VBD\1640855 not\RB\1740 differ\VB\1740 between\IN\1740 medications.\JJ\1740 Extrapyramidal\JJ\1740 symptom\NN\5823932 severity\NN\5036394 scores\NNS\13757724 were\VBD\836236 1.4\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.2\NN\1740 -\HYPH\1740 1.6\CD\1740 )\-RRB-\1740 with\IN\1740 risperidone\NN\1740 and\CC\1740 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.0\NNP\1740 -\HYPH\1740 1.4\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>olanzapine</e1>\NN\1740 .\.\1740
C076029_D017109 NONE Negative\JJ\1740 symptom\NN\5823932 outcomes\NNS\7291312 and\CC\1740 measures\NNS\168237 of\IN\1740 parkinsonism\NN\14085708 and\CC\1740 <e2>akathisia</e2>\NN\1740 did\VBD\1640855 not\RB\1740 differ\VB\1740 between\IN\1740 medications.\JJ\1740 Extrapyramidal\JJ\1740 symptom\NN\5823932 severity\NN\5036394 scores\NNS\13757724 were\VBD\836236 1.4\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.2\NN\1740 -\HYPH\1740 1.6\CD\1740 )\-RRB-\1740 with\IN\1740 risperidone\NN\1740 and\CC\1740 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.0\NNP\1740 -\HYPH\1740 1.4\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>olanzapine</e1>\NN\1740 .\.\1740
C076029_D001480 CID Negative\JJ\1740 symptom\NN\5823932 outcomes\NNS\7291312 and\CC\1740 measures\NNS\168237 of\IN\1740 parkinsonism\NN\14085708 and\CC\1740 akathisia\NN\1740 did\VBD\1640855 not\RB\1740 differ\VB\1740 between\IN\1740 medications.\JJ\1740 <e2>Extrapyramidal\JJ\1740 symptom</e2>\NN\5823932 severity\NN\5036394 scores\NNS\13757724 were\VBD\836236 1.4\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.2\NN\1740 -\HYPH\1740 1.6\CD\1740 )\-RRB-\1740 with\IN\1740 risperidone\NN\1740 and\CC\1740 1.2\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=1.0\NNP\1740 -\HYPH\1740 1.4\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>olanzapine</e1>\NN\1740 .\.\1740
C076029_D015430 CID Significantly\RB\1740 more\JJR\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 occurred\VBD\2623529 with\IN\1740 <e1>olanzapine</e1>\NN\1740 than\IN\1740 with\IN\1740 risperidone\NN\1740 :\:\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 weight\NN\5009170 at\IN\14622893 4\CD\13741022 months\NNS\15113229 relative\JJ\1740 to\TO\1740 baseline\NN\7260623 weight\NN\5009170 was\VBD\836236 17.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=14.2%-20.5\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 olanzapine\NN\1740 and\CC\1740 11.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=8.4%-14.3\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 risperidone\NN\1740 .\.\1740
C076029_D015430 CID Significantly\RB\1740 more\JJR\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 occurred\VBD\2623529 with\IN\1740 olanzapine\NN\1740 than\IN\1740 with\IN\1740 risperidone\NN\1740 :\:\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 weight\NN\5009170 at\IN\14622893 4\CD\13741022 months\NNS\15113229 relative\JJ\1740 to\TO\1740 baseline\NN\7260623 weight\NN\5009170 was\VBD\836236 17.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=14.2%-20.5\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>olanzapine</e1>\NN\1740 and\CC\1740 11.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=8.4%-14.3\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 risperidone\NN\1740 .\.\1740
C076029_D015430 CID Both\DT\1740 medications\NNS\3247620 caused\VBD\1617192 substantial\JJ\1740 rapid\JJ\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 ,\,\1740 but\CC\1740 weight\NN\5009170 gain\NN\13576355 was\VBD\836236 greater\JJR\1740 with\IN\1740 <e1>olanzapine</e1>\NN\1740 .\.\1740
C076029_D015430 CID Both\DT\1740 medications\NNS\3247620 caused\VBD\1617192 substantial\JJ\1740 rapid\JJ\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 but\CC\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 was\VBD\836236 greater\JJR\1740 with\IN\1740 <e1>olanzapine</e1>\NN\1740 .\.\1740
D018967_D015430 CID Significantly\RB\1740 more\JJR\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 occurred\VBD\2623529 with\IN\1740 olanzapine\NN\1740 than\IN\1740 with\IN\1740 <e1>risperidone</e1>\NN\1740 :\:\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 weight\NN\5009170 at\IN\14622893 4\CD\13741022 months\NNS\15113229 relative\JJ\1740 to\TO\1740 baseline\NN\7260623 weight\NN\5009170 was\VBD\836236 17.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=14.2%-20.5\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 olanzapine\NN\1740 and\CC\1740 11.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=8.4%-14.3\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 risperidone\NN\1740 .\.\1740
D018967_D015430 CID Significantly\RB\1740 more\JJR\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 occurred\VBD\2623529 with\IN\1740 olanzapine\NN\1740 than\IN\1740 with\IN\1740 risperidone\NN\1740 :\:\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 weight\NN\5009170 at\IN\14622893 4\CD\13741022 months\NNS\15113229 relative\JJ\1740 to\TO\1740 baseline\NN\7260623 weight\NN\5009170 was\VBD\836236 17.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=14.2%-20.5\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 olanzapine\NN\1740 and\CC\1740 11.3\CD\1740 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI=8.4%-14.3\NN\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
439781
D007213_D007022 CID <e1>Indomethacin</e1>\NN\3828465 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 sodium\NN\14625458 and\CC\1740 volume\NN\33615 depleted\VBN\2267060 rats\NNS\2329401 .\.\1740
D012964_D007022 NONE Indomethacin\NN\3828465 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 <e1>sodium</e1>\NN\14625458 and\CC\1740 volume\NN\33615 depleted\VBN\2267060 rats\NNS\2329401 .\.\1740
19419794
D016627_D004409 NONE Increased\VBN\169651 vulnerability\NN\14540765 to\TO\1740 <e1>6-hydroxydopamine</e1>\NN\1740 lesion\NN\14204950 and\CC\1740 reduced\VBD\441445 development\NN\248977 of\IN\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 mice\NNS\2329401 lacking\VBG\1740 CB1\NN\1740 cannabinoid\NN\1740 receptors\NNS\5225602 .\.\1740
C005177_D004409 NONE Treatment\NN\654885 with\IN\1740 <e1>L-DOPA+benserazide</e1>\NN\1740 (\-LRB-\1740 12\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 resulted\VBD\2633881 in\IN\13603305 less\RBR\1740 severe\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 CB1\NN\1740 KO\NNP\1173038 than\IN\1740 in\IN\13603305 WT\NN\1740 mice\NNS\2329401 .\.\1740
D004298_D004409 NONE The\DT\1740 results\NNS\34213 revealed\VBD\2137132 that\IN\1740 the\DT\1740 lack\NN\14449126 of\IN\1740 cannabinoid\JJ\1740 CB1\NN\1740 receptors\NNS\5225602 increased\VBD\169651 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 impairment\NN\7296428 and\CC\1740 <e1>DA</e1>\NN\10484858 lesion\NN\14204950 ,\,\1740 and\CC\1740 reduced\VBD\441445 L-DOPA-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D007980_D004409 CID The\DT\1740 results\NNS\34213 revealed\VBD\2137132 that\IN\1740 the\DT\1740 lack\NN\14449126 of\IN\1740 cannabinoid\JJ\1740 CB1\NN\1740 receptors\NNS\5225602 increased\VBD\169651 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 impairment\NN\7296428 and\CC\1740 DA\NN\10484858 lesion\NN\14204950 ,\,\1740 and\CC\1740 reduced\VBD\441445 <e1>L-DOPA-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D007980_D004409 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 activation\NN\13561719 of\IN\1740 CB1\NN\1740 receptors\NNS\5225602 offers\VBZ\2327200 neuroprotection\NN\1740 against\IN\1740 dopaminergic\JJ\1740 lesion\NN\14204950 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>L-DOPA-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
23864035
C400082_D009101 NONE <e1>Bortezomib</e1>\NNP\1740 and\CC\1740 dexamethasone\NN\2721538 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 :\:\1740 analysis\NN\633864 of\IN\1740 long-term\JJ\1740 clinical\JJ\1740 outcomes\NNS\7291312 .\.\1740
C400082_D009101 NONE <e1>Bortezomib</e1>\NN\1740 (bort)-dexamethasone\NN\1740 (\-LRB-\1740 dex\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
C400082_D009101 NONE <e1>Bortezomib</e1>\NN\1740 (bort)-dexamethasone\NN\1740 (\-LRB-\1740 dex\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
C400082_D009101 NONE Bortezomib\NN\1740 <e1>(bort)-dexamethasone</e1>\NN\1740 (\-LRB-\1740 dex\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
C400082_D009101 NONE Bortezomib\NN\1740 <e1>(bort)-dexamethasone</e1>\NN\1740 (\-LRB-\1740 dex\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
C400082_D009101 NONE 3\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 and\CC\1740 dex\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 on\IN\1740 the\DT\1740 day\NN\15154774 of\IN\1740 and\CC\1740 the\DT\1740 day\NN\15154774 after\IN\1740 <e1>bort</e1>\FW\1740 )\-RRB-\1740 as\IN\14622893 salvage\NN\3076708 treatment\NN\654885 in\IN\13603305 85\CD\1740 patients\NNS\9898892 with\IN\1740 R/R\NN\1740 <e2>MM</e2>\NN\13649268 after\IN\1740 prior\JJ\1740 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 or\CC\3541091 conventional\JJ\1740 chemotherapy\NN\661091 .\.\1740
C400082_D009101 NONE <e1>Bort-dex</e1>\NN\1740 was\VBD\836236 an\DT\6697703 effective\JJ\1740 salvage\NN\3076708 treatment\NN\654885 for\IN\1740 <e2>MM</e2>\NN\13649268 patients\NNS\9898892 ,\,\1740 particularly\RB\1740 for\IN\1740 those\DT\1740 in\IN\13603305 first\JJ\1740 relapse\NN\66636 .\.\1740
D003907_D009101 NONE Bortezomib\NNP\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 :\:\1740 analysis\NN\633864 of\IN\1740 long-term\JJ\1740 clinical\JJ\1740 outcomes\NNS\7291312 .\.\1740
D003907_D009101 NONE Bortezomib\NN\1740 <e1>(bort)-dexamethasone</e1>\NN\1740 (\-LRB-\1740 dex\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
D003907_D009101 NONE Bortezomib\NN\1740 <e1>(bort)-dexamethasone</e1>\NN\1740 (\-LRB-\1740 dex\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
D003907_D009101 NONE Bortezomib\NN\1740 (bort)-dexamethasone\NN\1740 (\-LRB-\1740 <e1>dex</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 MM\NN\13649268 )\-RRB-\1740 .\.\1740
D003907_D009101 NONE Bortezomib\NN\1740 (bort)-dexamethasone\NN\1740 (\-LRB-\1740 <e1>dex</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 therapy\NN\657604 for\IN\1740 relapsed/refractory\JJ\1740 (\-LRB-\1740 R/R\NN\1740 )\-RRB-\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>MM</e2>\NN\13649268 )\-RRB-\1740 .\.\1740
D003907_D009101 NONE 3\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 and\CC\1740 <e1>dex</e1>\NN\1740 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 on\IN\1740 the\DT\1740 day\NN\15154774 of\IN\1740 and\CC\1740 the\DT\1740 day\NN\15154774 after\IN\1740 bort\FW\1740 )\-RRB-\1740 as\IN\14622893 salvage\NN\3076708 treatment\NN\654885 in\IN\13603305 85\CD\1740 patients\NNS\9898892 with\IN\1740 R/R\NN\1740 <e2>MM</e2>\NN\13649268 after\IN\1740 prior\JJ\1740 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 or\CC\3541091 conventional\JJ\1740 chemotherapy\NN\661091 .\.\1740
D003907_D009101 NONE <e1>Bort-dex</e1>\NN\1740 was\VBD\836236 an\DT\6697703 effective\JJ\1740 salvage\NN\3076708 treatment\NN\654885 for\IN\1740 <e2>MM</e2>\NN\13649268 patients\NNS\9898892 ,\,\1740 particularly\RB\1740 for\IN\1740 those\DT\1740 in\IN\13603305 first\JJ\1740 relapse\NN\66636 .\.\1740
7931490
D017829_D009325 NONE Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>granisetron</e1>\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 5-hydroxytryptamine-3\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 induced\VBN\1627355 by\IN\1740 high-dose\JJ\1740 cisplatin\NN\1740 .\.\1740
D017829_D009325 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 antiemetic\JJ\1740 effects\NNS\13245626 and\CC\1740 safety\NN\13920835 profile\NN\6999802 of\IN\1740 four\CD\13741022 different\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>granisetron</e1>\NN\1740 (\-LRB-\1740 Kytril\NNP\1740 ;\:\1740 SmithKline\NNP\1740 Beecham\NNP\1740 Pharmaceuticals\NNP\3740161 ,\,\1740 Philadelphia\NNP\1740 ,\,\1740 PA\NNP\10080869 )\-RRB-\1740 when\WRB\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 dose\NN\3740161 for\IN\1740 prophylaxis\NN\1077350 of\IN\1740 cisplatin-induced\JJ\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
D017829_D009325 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 antiemetic\JJ\1740 effects\NNS\13245626 and\CC\1740 safety\NN\13920835 profile\NN\6999802 of\IN\1740 four\CD\13741022 different\JJ\1740 doses\NNS\3740161 of\IN\1740 granisetron\NN\1740 (\-LRB-\1740 <e1>Kytril</e1>\NNP\1740 ;\:\1740 SmithKline\NNP\1740 Beecham\NNP\1740 Pharmaceuticals\NNP\3740161 ,\,\1740 Philadelphia\NNP\1740 ,\,\1740 PA\NNP\10080869 )\-RRB-\1740 when\WRB\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 dose\NN\3740161 for\IN\1740 prophylaxis\NN\1077350 of\IN\1740 cisplatin-induced\JJ\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
D017829_D014839 NONE Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>granisetron</e1>\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 5-hydroxytryptamine-3\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 induced\VBN\1627355 by\IN\1740 high-dose\JJ\1740 cisplatin\NN\1740 .\.\1740
D017829_D014839 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 antiemetic\JJ\1740 effects\NNS\13245626 and\CC\1740 safety\NN\13920835 profile\NN\6999802 of\IN\1740 four\CD\13741022 different\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>granisetron</e1>\NN\1740 (\-LRB-\1740 Kytril\NNP\1740 ;\:\1740 SmithKline\NNP\1740 Beecham\NNP\1740 Pharmaceuticals\NNP\3740161 ,\,\1740 Philadelphia\NNP\1740 ,\,\1740 PA\NNP\10080869 )\-RRB-\1740 when\WRB\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 dose\NN\3740161 for\IN\1740 prophylaxis\NN\1077350 of\IN\1740 cisplatin-induced\JJ\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 .\.\1740
D017829_D014839 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 antiemetic\JJ\1740 effects\NNS\13245626 and\CC\1740 safety\NN\13920835 profile\NN\6999802 of\IN\1740 four\CD\13741022 different\JJ\1740 doses\NNS\3740161 of\IN\1740 granisetron\NN\1740 (\-LRB-\1740 <e1>Kytril</e1>\NNP\1740 ;\:\1740 SmithKline\NNP\1740 Beecham\NNP\1740 Pharmaceuticals\NNP\3740161 ,\,\1740 Philadelphia\NNP\1740 ,\,\1740 PA\NNP\10080869 )\-RRB-\1740 when\WRB\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 dose\NN\3740161 for\IN\1740 prophylaxis\NN\1077350 of\IN\1740 cisplatin-induced\JJ\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 .\.\1740
D017829_D014839 NONE RESULTS\NNS\34213 :\:\1740 After\IN\1740 <e1>granisetron</e1>\NN\1740 doses\NNS\3740161 of\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 20\CD\13745420 ,\,\1740 and\CC\1740 40\CD\13745420 micrograms/kg\NNS\1740 ,\,\1740 a\DT\13649268 major\JJ\1740 response\NN\11410625 (\-LRB-\1740 <\CD\1740 or\CC\3541091 =\JJ\1740 two\CD\13741022 <e2>vomiting</e2>\NN\116687 or\CC\3541091 retching\NN\1740 episodes\NNS\7283608 ,\,\1740 and\CC\1740 no\DT\7204911 antiemetic\JJ\1740 rescue\NN\45907 )\-RRB-\1740 was\VBD\836236 recorded\VBN\2225492 in\IN\13603305 23\CD\13745420 %\NN\1740 ,\,\1740 57\CD\1740 %\NN\1740 ,\,\1740 58\CD\1740 %\NN\1740 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 complete\JJ\1740 response\NN\11410625 (\-LRB-\1740 no\DT\7204911 vomiting\NN\116687 or\CC\3541091 retching\NN\1740 ,\,\1740 and\CC\1740 no\DT\7204911 antiemetic\JJ\1740 rescue\NN\45907 )\-RRB-\1740 in\IN\13603305 18\CD\13745420 %\NN\1740 ,\,\1740 41\CD\1740 %\NN\1740 ,\,\1740 40\CD\13745420 %\NN\1740 ,\,\1740 and\CC\1740 47\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 .\.\1740
D017829_D014839 NONE RESULTS\NNS\34213 :\:\1740 After\IN\1740 <e1>granisetron</e1>\NN\1740 doses\NNS\3740161 of\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 ,\,\1740 20\CD\13745420 ,\,\1740 and\CC\1740 40\CD\13745420 micrograms/kg\NNS\1740 ,\,\1740 a\DT\13649268 major\JJ\1740 response\NN\11410625 (\-LRB-\1740 <\CD\1740 or\CC\3541091 =\JJ\1740 two\CD\13741022 vomiting\NN\116687 or\CC\3541091 retching\NN\1740 episodes\NNS\7283608 ,\,\1740 and\CC\1740 no\DT\7204911 antiemetic\JJ\1740 rescue\NN\45907 )\-RRB-\1740 was\VBD\836236 recorded\VBN\2225492 in\IN\13603305 23\CD\13745420 %\NN\1740 ,\,\1740 57\CD\1740 %\NN\1740 ,\,\1740 58\CD\1740 %\NN\1740 ,\,\1740 and\CC\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 complete\JJ\1740 response\NN\11410625 (\-LRB-\1740 no\DT\7204911 <e2>vomiting</e2>\NN\116687 or\CC\3541091 retching\NN\1740 ,\,\1740 and\CC\1740 no\DT\7204911 antiemetic\JJ\1740 rescue\NN\45907 )\-RRB-\1740 in\IN\13603305 18\CD\13745420 %\NN\1740 ,\,\1740 41\CD\1740 %\NN\1740 ,\,\1740 40\CD\13745420 %\NN\1740 ,\,\1740 and\CC\1740 47\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 respectively\RB\1740 .\.\1740
D017829_D014839 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 single\JJ\1740 10-\CD\1740 ,\,\1740 20-\CD\1740 ,\,\1740 or\CC\3541091 40-micrograms/kg\NN\1740 dose\NN\3740161 of\IN\1740 <e1>granisetron</e1>\NN\1740 was\VBD\836236 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>vomiting</e2>\NN\116687 in\IN\13603305 57\CD\1740 %\NN\1740 to\IN\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 cisplatin\NN\1740 at\IN\14622893 doses\NNS\3740161 greater\JJR\1740 than\IN\1740 81\CD\1740 mg/m2\NN\1740 and\CC\1740 totally\RB\1740 prevented\VBD\1740 vomiting\NN\116687 in\IN\13603305 40\CD\13745420 %\NN\1740 to\IN\1740 47\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D017829_D014839 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 single\JJ\1740 10-\CD\1740 ,\,\1740 20-\CD\1740 ,\,\1740 or\CC\3541091 40-micrograms/kg\NN\1740 dose\NN\3740161 of\IN\1740 <e1>granisetron</e1>\NN\1740 was\VBD\836236 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 vomiting\NN\116687 in\IN\13603305 57\CD\1740 %\NN\1740 to\IN\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 cisplatin\NN\1740 at\IN\14622893 doses\NNS\3740161 greater\JJR\1740 than\IN\1740 81\CD\1740 mg/m2\NN\1740 and\CC\1740 totally\RB\1740 prevented\VBD\1740 <e2>vomiting</e2>\NN\116687 in\IN\13603305 40\CD\13745420 %\NN\1740 to\IN\1740 47\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D012701_D009325 NONE Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 granisetron\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>5-hydroxytryptamine-3</e1>\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 induced\VBN\1627355 by\IN\1740 high-dose\JJ\1740 cisplatin\NN\1740 .\.\1740
D012701_D014839 NONE Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 granisetron\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>5-hydroxytryptamine-3</e1>\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 induced\VBN\1627355 by\IN\1740 high-dose\JJ\1740 cisplatin\NN\1740 .\.\1740
D002945_D009325 CID Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 granisetron\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 5-hydroxytryptamine-3\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 induced\VBN\1627355 by\IN\1740 high-dose\JJ\1740 <e1>cisplatin</e1>\NN\1740 .\.\1740
D002945_D009325 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 antiemetic\JJ\1740 effects\NNS\13245626 and\CC\1740 safety\NN\13920835 profile\NN\6999802 of\IN\1740 four\CD\13741022 different\JJ\1740 doses\NNS\3740161 of\IN\1740 granisetron\NN\1740 (\-LRB-\1740 Kytril\NNP\1740 ;\:\1740 SmithKline\NNP\1740 Beecham\NNP\1740 Pharmaceuticals\NNP\3740161 ,\,\1740 Philadelphia\NNP\1740 ,\,\1740 PA\NNP\10080869 )\-RRB-\1740 when\WRB\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 dose\NN\3740161 for\IN\1740 prophylaxis\NN\1077350 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 .\.\1740
D002945_D014839 CID Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 granisetron\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 5-hydroxytryptamine-3\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 induced\VBN\1627355 by\IN\1740 high-dose\JJ\1740 <e1>cisplatin</e1>\NN\1740 .\.\1740
D002945_D014839 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 antiemetic\JJ\1740 effects\NNS\13245626 and\CC\1740 safety\NN\13920835 profile\NN\6999802 of\IN\1740 four\CD\13741022 different\JJ\1740 doses\NNS\3740161 of\IN\1740 granisetron\NN\1740 (\-LRB-\1740 Kytril\NNP\1740 ;\:\1740 SmithKline\NNP\1740 Beecham\NNP\1740 Pharmaceuticals\NNP\3740161 ,\,\1740 Philadelphia\NNP\1740 ,\,\1740 PA\NNP\10080869 )\-RRB-\1740 when\WRB\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 dose\NN\3740161 for\IN\1740 prophylaxis\NN\1077350 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 .\.\1740
D002945_D014839 CID CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 single\JJ\1740 10-\CD\1740 ,\,\1740 20-\CD\1740 ,\,\1740 or\CC\3541091 40-micrograms/kg\NN\1740 dose\NN\3740161 of\IN\1740 granisetron\NN\1740 was\VBD\836236 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>vomiting</e2>\NN\116687 in\IN\13603305 57\CD\1740 %\NN\1740 to\IN\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>cisplatin</e1>\NN\1740 at\IN\14622893 doses\NNS\3740161 greater\JJR\1740 than\IN\1740 81\CD\1740 mg/m2\NN\1740 and\CC\1740 totally\RB\1740 prevented\VBD\1740 vomiting\NN\116687 in\IN\13603305 40\CD\13745420 %\NN\1740 to\IN\1740 47\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D002945_D014839 CID CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 single\JJ\1740 10-\CD\1740 ,\,\1740 20-\CD\1740 ,\,\1740 or\CC\3541091 40-micrograms/kg\NN\1740 dose\NN\3740161 of\IN\1740 granisetron\NN\1740 was\VBD\836236 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 vomiting\NN\116687 in\IN\13603305 57\CD\1740 %\NN\1740 to\IN\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>cisplatin</e1>\NN\1740 at\IN\14622893 doses\NNS\3740161 greater\JJR\1740 than\IN\1740 81\CD\1740 mg/m2\NN\1740 and\CC\1740 totally\RB\1740 prevented\VBD\1740 <e2>vomiting</e2>\NN\116687 in\IN\13603305 40\CD\13745420 %\NN\1740 to\IN\1740 47\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
931801
D005937_D007674 NONE Effect\NN\34213 of\IN\1740 <e1>D-Glucarates</e1>\NN\1740 on\IN\1740 basic\JJ\1740 antibiotic-induced\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005937_D007674 NONE <e1>D-Glucarates</e1>\NN\1740 were\VBD\836236 effective\JJ\1740 against\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 peptide\NN\14724264 antibiotics\NNS\2716205 as\RB\1740 well\RB\1740 as\IN\14622893 various\JJ\1740 aminoglycoside\NN\1740 antibitocis\NN\1740 .\.\1740
D005937_D007674 NONE With\IN\1740 a\DT\13649268 <e1>D-glucarate</e1>\NN\1740 of\IN\1740 a\DT\13649268 fixed\JJ\1740 size\NN\5090441 of\IN\1740 dose\NN\3740161 ,\,\1740 approximately\RB\1740 the\DT\1740 same\JJ\1740 degree\NN\4916342 of\IN\1740 protection\NN\407535 was\VBD\836236 obtained\VBN\2210855 against\IN\1740 <e2>renal\JJ\1740 damages</e2>\NNS\13282550 induced\VBN\1627355 by\IN\1740 different\JJ\1740 basic\JJ\1740 antibiotics\NNS\2716205 despite\IN\7501545 large\JJ\1740 disparities\NNS\4752221 in\IN\13603305 administration\NN\1133281 doses\NNS\3740161 of\IN\1740 different\JJ\1740 antibiotics\NNS\2716205 .\.\1740
D005937_D007674 NONE <e1>D-Glucarates</e1>\NN\1740 had\VBD\2108377 the\DT\1740 ability\NN\4723816 to\TO\1740 prevent\VB\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 but\CC\1740 not\RB\1740 to\TO\1740 cure\VB\82081 it\PRP\6125041 .\.\1740
D005937_D007674 NONE The\DT\1740 reduction\NN\351485 effect\NN\34213 of\IN\1740 <e1>D-glucarates</e1>\NNS\1740 against\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 basic\JJ\1740 antibiotics\NNS\2716205 was\VBD\836236 discussed\VBN\1033527 .\.\1740
D000617_D003681 NONE <e2>Dehydrated</e2>\JJ\1740 rats\NNS\2329401 regularly\RB\1740 develop\VBP\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>aminoglycoside</e1>\JJ\1740 antibiotics\NNS\2716205 combined\VBN\2630189 with\IN\1740 dextran\NN\1740 or\CC\3541091 of\IN\1740 antibiotics\NNS\2716205 only\RB\1740 .\.\1740
D000617_D058186 CID Dehydrated\JJ\1740 rats\NNS\2329401 regularly\RB\1740 develop\VBP\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>aminoglycoside</e1>\JJ\1740 antibiotics\NNS\2716205 combined\VBN\2630189 with\IN\1740 dextran\NN\1740 or\CC\3541091 of\IN\1740 antibiotics\NNS\2716205 only\RB\1740 .\.\1740
C038936_D051437 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>2,5-di-O-acetyl-D-glucaro-1,4\CD\1740 -\HYPH\1740 6,3-dilactone</e1>\NN\1740 protected\VBD\1127795 rats\NNS\2329401 against\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 kanamycin-dextran\NN\1740 .\.\1740
D007612_D051437 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 2,5-di-O-acetyl-D-glucaro-1,4\CD\1740 -\HYPH\1740 6,3-dilactone\NN\1740 protected\VBD\1127795 rats\NNS\2329401 against\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>kanamycin-dextran</e1>\NN\1740 .\.\1740
D000617_D007674 NONE D-Glucarates\NN\1740 were\VBD\836236 effective\JJ\1740 against\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 peptide\NN\14724264 antibiotics\NNS\2716205 as\RB\1740 well\RB\1740 as\IN\14622893 various\JJ\1740 <e1>aminoglycoside</e1>\NN\1740 antibitocis\NN\1740 .\.\1740
D009005_D007674 NONE Rats\NNS\2329401 excreted\VBD\104868 acidic\JJ\1740 urine\NN\14853947 when\WRB\1740 they\PRP\1740 were\VBD\836236 spared\VBN\2725714 from\IN\1740 <e2>renal\JJ\1740 lesions</e2>\NNS\14204950 by\IN\1740 <e1>monosaccharides</e1>\NNS\14792703 .\.\1740
7967231
C059447_D020195 NONE <e1>S-312</e1>\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D020195 NONE S-312\NN\1740 ,\,\1740 <e1>S-312-d</e1>\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>S-312-d</e1>\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D012640 NONE <e1>S-312</e1>\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D012640 NONE <e1>S-312</e1>\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D012640 NONE S-312\NN\1740 ,\,\1740 <e1>S-312-d</e1>\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D012640 NONE S-312\NN\1740 ,\,\1740 <e1>S-312-d</e1>\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>S-312-d</e1>\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>S-312-d</e1>\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
-1_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 <e1>S-312-l</e1>\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
-1_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 <e1>S-312-l</e1>\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
-1_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 <e1>S-312-l</e1>\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D002118_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D002118_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D002118_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D005444_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 <e1>flunarizine</e1>\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D005444_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 <e1>flunarizine</e1>\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D005444_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 <e1>flunarizine</e1>\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D010433_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>pentylenetetrazole</e1>\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D010433_D012640 CID S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>pentylenetetrazole</e1>\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D010433_D012640 CID S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>pentylenetetrazole</e1>\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D001534_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>bemegride</e1>\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D001534_D012640 CID S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>bemegride</e1>\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D001534_D012640 CID S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>bemegride</e1>\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D016202_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D016202_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D016202_D012640 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 ,\,\1740 picrotoxin\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D010852_D020195 NONE S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 <e2>audiogenic\JJ\1740 tonic\JJ\1740 convulsions</e2>\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D010852_D012640 CID S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
D010852_D012640 CID S-312\NN\1740 ,\,\1740 S-312-d\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 S-312-l\NN\1740 ,\,\1740 L-type\NN\1740 calcium\NN\14625458 channel\NN\6251781 antagonists\NNS\7846 ,\,\1740 showed\VBD\2137132 anticonvulsant\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 audiogenic\JJ\1740 tonic\JJ\1740 convulsions\NNS\14081375 in\IN\13603305 DBA/2\NN\1740 mice\NNS\2329401 ;\:\1740 and\CC\1740 their\PRP$\1740 ED50\NN\1740 values\NNS\5941423 were\VBD\836236 18.4\CD\1740 (\-LRB-\1740 12.8\CD\1740 -\SYM\1740 27.1\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 and\CC\1740 15.0\CD\1740 (\-LRB-\1740 10.2\CD\1740 -\SYM\1740 23.7\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 that\DT\1740 of\IN\1740 flunarizine\NN\1740 was\VBD\836236 34.0\CD\1740 (\-LRB-\1740 26.0\CD\1740 -\SYM\1740 44.8\CD\1740 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 Although\IN\1740 moderate\JJ\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 S-312-d\NN\1740 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 were\VBD\836236 observed\VBN\2163746 against\IN\1740 the\DT\1740 clonic\JJ\1740 convulsions\NNS\14081375 induced\VBN\1627355 by\IN\1740 pentylenetetrazole\NN\1740 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 ,\,\1740 s.c.\NN\1740 )\-RRB-\1740 or\CC\3541091 bemegride\NN\1740 (\-LRB-\1740 40\CD\13745420 mg/kg\NN\1740 ,\,\1740 s.c.\FW\1740 )\-RRB-\1740 ,\,\1740 no\DT\7204911 effects\NNS\13245626 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 N-methyl-D-aspartate\NN\1740 ,\,\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 or\CC\3541091 electroshock\NN\662681 in\IN\13603305 Slc\NN\1740 :\:\1740 ddY\CD\1740 mice\NNS\2329401 .\.\1740
C059447_D004827 NONE <e1>S-312-d</e1>\NN\1740 may\MD\15209706 be\VB\836236 useful\JJ\1740 in\IN\13603305 the\DT\1740 therapy\NN\657604 of\IN\1740 certain\JJ\1740 types\NNS\5839024 of\IN\1740 human\JJ\1740 <e2>epilepsy</e2>\NN\14085708 .\.\1740
17828434
C002647_D012640 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 <e1>MIP</e1>\NN\1740 synthase\NN\1740 inhibition\NN\1068773 does\VBZ\1640855 not\RB\1740 replicate\VB\2035919 or\CC\3541091 augment\VBP\153263 the\DT\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 in\IN\13603305 the\DT\1740 inositol\NN\15090742 sensitive\JJ\1740 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 model\NN\5888929 .\.\1740
D008094_D012640 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 MIP\NN\1740 synthase\NN\1740 inhibition\NN\1068773 does\VBZ\1640855 not\RB\1740 replicate\VB\2035919 or\CC\3541091 augment\VBP\153263 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 the\DT\1740 inositol\NN\15090742 sensitive\JJ\1740 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 model\NN\5888929 .\.\1740
D007294_D012640 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 MIP\NN\1740 synthase\NN\1740 inhibition\NN\1068773 does\VBZ\1640855 not\RB\1740 replicate\VB\2035919 or\CC\3541091 augment\VBP\153263 the\DT\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 in\IN\13603305 the\DT\1740 <e1>inositol</e1>\NN\15090742 sensitive\JJ\1740 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 model\NN\5888929 .\.\1740
D010862_D012640 CID This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 MIP\NN\1740 synthase\NN\1740 inhibition\NN\1068773 does\VBZ\1640855 not\RB\1740 replicate\VB\2035919 or\CC\3541091 augment\VBP\153263 the\DT\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 in\IN\13603305 the\DT\1740 inositol\NN\15090742 sensitive\JJ\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 model\NN\5888929 .\.\1740
20859899
D000809_D013575 NONE <e2>Syncope</e2>\NNP\7478169 caused\VBN\1617192 by\IN\1740 hyperkalemia\NN\14299637 during\IN\1740 use\NN\407535 of\IN\1740 a\DT\13649268 combined\JJ\1740 therapy\NN\657604 with\IN\1740 the\DT\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 and\CC\1740 spironolactone\NN\2721160 .\.\1740
D000809_D006947 NONE Syncope\NNP\7478169 caused\VBN\1617192 by\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 during\IN\1740 use\NN\407535 of\IN\1740 a\DT\13649268 combined\JJ\1740 therapy\NN\657604 with\IN\1740 the\DT\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 and\CC\1740 spironolactone\NN\2721160 .\.\1740
D013148_D013575 NONE <e2>Syncope</e2>\NNP\7478169 caused\VBN\1617192 by\IN\1740 hyperkalemia\NN\14299637 during\IN\1740 use\NN\407535 of\IN\1740 a\DT\13649268 combined\JJ\1740 therapy\NN\657604 with\IN\1740 the\DT\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 and\CC\1740 <e1>spironolactone</e1>\NN\2721160 .\.\1740
D013148_D006947 CID Syncope\NNP\7478169 caused\VBN\1617192 by\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 during\IN\1740 use\NN\407535 of\IN\1740 a\DT\13649268 combined\JJ\1740 therapy\NN\657604 with\IN\1740 the\DT\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitor\NN\20090 and\CC\1740 <e1>spironolactone</e1>\NN\2721160 .\.\1740
D013148_D006947 CID The\DT\1740 cause\NN\7323922 of\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 was\VBD\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 several\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>spiranolactone</e1>\NN\1740 ,\,\1740 an\DT\6697703 aldosterone\NN\14751863 antagonist\NN\7846 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 long-term\JJ\1740 intake\NN\13440063 of\IN\1740 ramipril\NN\2673637 ,\,\1740 an\DT\6697703 ACE\NN\13741022 inhibitor\NN\20090 .\.\1740
D000450_D006947 NONE The\DT\1740 cause\NN\7323922 of\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 was\VBD\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 several\JJ\1740 doses\NNS\3740161 of\IN\1740 spiranolactone\NN\1740 ,\,\1740 an\DT\6697703 <e1>aldosterone</e1>\NN\14751863 antagonist\NN\7846 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 long-term\JJ\1740 intake\NN\13440063 of\IN\1740 ramipril\NN\2673637 ,\,\1740 an\DT\6697703 ACE\NN\13741022 inhibitor\NN\20090 .\.\1740
D017257_D006947 CID The\DT\1740 cause\NN\7323922 of\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 was\VBD\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 several\JJ\1740 doses\NNS\3740161 of\IN\1740 spiranolactone\NN\1740 ,\,\1740 an\DT\6697703 aldosterone\NN\14751863 antagonist\NN\7846 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 long-term\JJ\1740 intake\NN\13440063 of\IN\1740 <e1>ramipril</e1>\NN\2673637 ,\,\1740 an\DT\6697703 ACE\NN\13741022 inhibitor\NN\20090 .\.\1740
D011188_D006947 NONE Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 alert\JJ\1740 to\TO\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 ,\,\1740 especially\RB\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 using\VBG\1156834 ACE/ARB\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>potassium</e1>\NN\14625458 sparing\NN\1740 agents\NNS\7347 and\CC\1740 who\WP\8299493 have\VBP\2108377 mild\JJ\1740 renal\JJ\1740 disturbance\NN\407535 .\.\1740
D011188_D007674 NONE Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 alert\JJ\1740 to\TO\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 hyperkalemia\NN\14299637 ,\,\1740 especially\RB\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 using\VBG\1156834 ACE/ARB\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>potassium</e1>\NN\14625458 sparing\NN\1740 agents\NNS\7347 and\CC\1740 who\WP\8299493 have\VBP\2108377 mild\JJ\1740 <e2>renal\JJ\1740 disturbance</e2>\NN\407535 .\.\1740
26115410
D001152_D009369 CID There\EX\27167 is\VBZ\836236 considerable\JJ\1740 interest\NN\5682570 in\IN\13603305 identifying\VBG\699815 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 that\WDT\1740 relate\VBP\628491 early-life\JJ\1740 <e1>iAs</e1>\NN\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 these\DT\1740 latent\JJ\1740 diseases\NNS\14061805 ,\,\1740 particularly\RB\1740 in\IN\13603305 relationship\NN\31921 to\TO\1740 <e2>cancer</e2>\NN\14239425 .\.\1740
D001152_D009369 CID OBJECTIVES\NNS\5980875 :\:\1740 This\DT\1740 work\NN\407535 summarizes\VBZ\958334 research\NN\633864 on\IN\1740 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 that\WDT\1740 underlie\VBP\2604760 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>cancer</e2>\NN\14239425 development\NN\248977 in\IN\13603305 adulthood\NN\15144371 that\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 early-life\JJ\1740 <e1>iAs</e1>\NN\1740 exposure\NN\5042871 .\.\1740
D001152_D009369 CID DISCUSSION\NN\6252138 :\:\1740 Epigenetic\JJ\1740 reprogramming\VBG\1740 that\WDT\1740 imparts\VBZ\952524 functional\JJ\1740 changes\NNS\7283608 in\IN\13603305 gene\NN\8459252 expression\NN\4679549 ,\,\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>cancer</e2>\NN\14239425 stem\NN\6290637 cells\NNS\3080309 ,\,\1740 and\CC\1740 immunomodulation\NN\1740 are\VBP\836236 plausible\JJ\1740 underlying\VBG\2604760 mechanisms\NNS\13446390 by\IN\1740 which\WDT\1740 early-life\JJ\1740 <e1>iAs</e1>\NN\1740 exposure\NN\5042871 elicits\VBZ\1617192 latent\JJ\1740 carcinogenic\JJ\1740 effects\NNS\13245626 .\.\1740
D001152_D009369 CID CONCLUSIONS\NNS\5837957 :\:\1740 Evidence\NN\5816287 is\VBZ\836236 mounting\VBG\1296462 that\WDT\1740 relates\VBZ\628491 early-life\JJ\1740 <e1>iAs</e1>\NN\1740 exposure\NN\5042871 and\CC\1740 <e2>cancer</e2>\NN\14239425 development\NN\248977 later\RBR\1740 in\IN\13603305 life\NN\13954253 .\.\1740
1359137
D014150_D006966 CID <e1>Neuroleptic-associated</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D014150_D006966 CID Six\CD\13741022 stable\JJ\1740 psychiatric\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 amenorrhea/oligomenorrhea\NN\1740 associated\VBN\628491 with\IN\1740 their\PRP$\1740 <e1>neuroleptic\JJ\1740 medications</e1>\NNS\3247620 were\VBD\836236 treated\VBN\2376958 with\IN\1740 bromocriptine\NN\1740 .\.\1740
D014150_D006966 CID This\DT\1740 suggests\VBZ\1010118 that\IN\1740 bromocriptine\NN\1740 should\MD\1740 be\VB\836236 further\RB\1740 evaluated\VBN\670261 as\IN\14622893 potential\JJ\1740 therapy\NN\657604 for\IN\1740 <e1>neuroleptic-associated</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 amenorrhea/galactorrhea\NN\1740 .\.\1740
D014150_D000568 CID Six\CD\13741022 stable\JJ\1740 psychiatric\JJ\1740 outpatients\NNS\10405694 with\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>\NN\1740 associated\VBN\628491 with\IN\1740 their\PRP$\1740 <e1>neuroleptic\JJ\1740 medications</e1>\NNS\3247620 were\VBD\836236 treated\VBN\2376958 with\IN\1740 bromocriptine\NN\1740 .\.\1740
D014150_D000568 CID This\DT\1740 suggests\VBZ\1010118 that\IN\1740 bromocriptine\NN\1740 should\MD\1740 be\VB\836236 further\RB\1740 evaluated\VBN\670261 as\IN\14622893 potential\JJ\1740 therapy\NN\657604 for\IN\1740 <e1>neuroleptic-associated</e1>\JJ\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/galactorrhea</e2>\NN\1740 .\.\1740
D014150_D009839 CID Six\CD\13741022 stable\JJ\1740 psychiatric\JJ\1740 outpatients\NNS\10405694 with\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>\NN\1740 associated\VBN\628491 with\IN\1740 their\PRP$\1740 <e1>neuroleptic\JJ\1740 medications</e1>\NNS\3247620 were\VBD\836236 treated\VBN\2376958 with\IN\1740 bromocriptine\NN\1740 .\.\1740
D001971_D006966 NONE Six\CD\13741022 stable\JJ\1740 psychiatric\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 amenorrhea/oligomenorrhea\NN\1740 associated\VBN\628491 with\IN\1740 their\PRP$\1740 neuroleptic\JJ\1740 medications\NNS\3247620 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>bromocriptine</e1>\NN\1740 .\.\1740
D001971_D006966 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>bromocriptine</e1>\NN\1740 should\MD\1740 be\VB\836236 further\RB\1740 evaluated\VBN\670261 as\IN\14622893 potential\JJ\1740 therapy\NN\657604 for\IN\1740 neuroleptic-associated\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 amenorrhea/galactorrhea\NN\1740 .\.\1740
D001971_D000568 NONE Six\CD\13741022 stable\JJ\1740 psychiatric\JJ\1740 outpatients\NNS\10405694 with\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>\NN\1740 associated\VBN\628491 with\IN\1740 their\PRP$\1740 neuroleptic\JJ\1740 medications\NNS\3247620 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>bromocriptine</e1>\NN\1740 .\.\1740
D001971_D000568 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>bromocriptine</e1>\NN\1740 should\MD\1740 be\VB\836236 further\RB\1740 evaluated\VBN\670261 as\IN\14622893 potential\JJ\1740 therapy\NN\657604 for\IN\1740 neuroleptic-associated\JJ\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/galactorrhea</e2>\NN\1740 .\.\1740
D001971_D009839 NONE Six\CD\13741022 stable\JJ\1740 psychiatric\JJ\1740 outpatients\NNS\10405694 with\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/oligomenorrhea</e2>\NN\1740 associated\VBN\628491 with\IN\1740 their\PRP$\1740 neuroleptic\JJ\1740 medications\NNS\3247620 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>bromocriptine</e1>\NN\1740 .\.\1740
D001971_D011618 CID One\CD\13741022 woman\NN\9605289 ,\,\1740 however\RB\1740 ,\,\1740 developed\VBD\1753788 worsened\VBN\146138 <e2>psychiatric\JJ\1740 symptoms</e2>\NNS\5823932 while\IN\15122231 taking\VBG\2367363 <e1>bromocriptine</e1>\NN\1740 ,\,\1740 and\CC\1740 it\PRP\6125041 was\VBD\836236 discontinued\VBN\2609764 .\.\1740
D001971_D005687 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>bromocriptine</e1>\NN\1740 should\MD\1740 be\VB\836236 further\RB\1740 evaluated\VBN\670261 as\IN\14622893 potential\JJ\1740 therapy\NN\657604 for\IN\1740 neuroleptic-associated\JJ\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/galactorrhea</e2>\NN\1740 .\.\1740
D014150_D005687 NONE This\DT\1740 suggests\VBZ\1010118 that\IN\1740 bromocriptine\NN\1740 should\MD\1740 be\VB\836236 further\RB\1740 evaluated\VBN\670261 as\IN\14622893 potential\JJ\1740 therapy\NN\657604 for\IN\1740 <e1>neuroleptic-associated</e1>\JJ\1740 hyperprolactinemia\NN\1740 and\CC\1740 <e2>amenorrhea/galactorrhea</e2>\NN\1740 .\.\1740
24067251
C418563_D007674 NONE An\DT\6697703 investigation\NN\5797597 of\IN\1740 the\DT\1740 pattern\NN\5726345 of\IN\1740 <e2>kidney\NN\5333259 injury</e2>\NN\14052046 in\IN\13603305 HIV-positive\JJ\1740 persons\NNS\7347 exposed\VBN\2110927 to\TO\1740 <e1>tenofovir\NN\1740 disoproxil\NN\1740 fumarate</e1>\NN\1740 :\:\1740 an\DT\6697703 examination\NN\633864 of\IN\1740 a\DT\13649268 large\JJ\1740 population\NN\7942152 database\NN\6634376 (\-LRB-\1740 MHRA\NN\1740 database\NN\6634376 )\-RRB-\1740 .\.\1740
C418563_D007674 NONE Of\IN\1740 the\DT\1740 407\CD\1740 Yellow\NNP\4959672 Card\NNP\14974264 records\NNS\6643408 analysed\VBN\78760 ,\,\1740 106\CD\1740 satisfied\JJ\1740 criteria\NNS\13577171 for\IN\1740 <e1>TDF-related</e1>\JJ\1740 <e2>kidney\NN\5333259 disease</e2>\NN\14061805 ,\,\1740 of\IN\1740 which\WDT\1740 53\CD\1740 (\-LRB-\1740 50\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 features\NNS\5849040 of\IN\1740 kidney\NN\5333259 tubular\JJ\1740 dysfunction\NN\14204950 ,\,\1740 35\CD\1740 (\-LRB-\1740 33\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 features\NNS\5849040 of\IN\1740 glomerular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 18\CD\13745420 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 Fanconi\NN\1740 syndrome\NN\5870365 .\.\1740
C418563_D007674 NONE Of\IN\1740 the\DT\1740 407\CD\1740 Yellow\NNP\4959672 Card\NNP\14974264 records\NNS\6643408 analysed\VBN\78760 ,\,\1740 106\CD\1740 satisfied\JJ\1740 criteria\NNS\13577171 for\IN\1740 <e1>TDF-related</e1>\JJ\1740 kidney\NN\5333259 disease\NN\14061805 ,\,\1740 of\IN\1740 which\WDT\1740 53\CD\1740 (\-LRB-\1740 50\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 features\NNS\5849040 of\IN\1740 <e2>kidney\NN\5333259 tubular\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 35\CD\1740 (\-LRB-\1740 33\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 features\NNS\5849040 of\IN\1740 glomerular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 18\CD\13745420 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 Fanconi\NN\1740 syndrome\NN\5870365 .\.\1740
C418563_D007674 NONE Of\IN\1740 the\DT\1740 407\CD\1740 Yellow\NNP\4959672 Card\NNP\14974264 records\NNS\6643408 analysed\VBN\78760 ,\,\1740 106\CD\1740 satisfied\JJ\1740 criteria\NNS\13577171 for\IN\1740 <e1>TDF-related</e1>\JJ\1740 kidney\NN\5333259 disease\NN\14061805 ,\,\1740 of\IN\1740 which\WDT\1740 53\CD\1740 (\-LRB-\1740 50\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 features\NNS\5849040 of\IN\1740 kidney\NN\5333259 tubular\JJ\1740 dysfunction\NN\14204950 ,\,\1740 35\CD\1740 (\-LRB-\1740 33\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 features\NNS\5849040 of\IN\1740 <e2>glomerular\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 18\CD\13745420 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 Fanconi\NN\1740 syndrome\NN\5870365 .\.\1740
C418563_D005198 CID Of\IN\1740 the\DT\1740 407\CD\1740 Yellow\NNP\4959672 Card\NNP\14974264 records\NNS\6643408 analysed\VBN\78760 ,\,\1740 106\CD\1740 satisfied\JJ\1740 criteria\NNS\13577171 for\IN\1740 <e1>TDF-related</e1>\JJ\1740 kidney\NN\5333259 disease\NN\14061805 ,\,\1740 of\IN\1740 which\WDT\1740 53\CD\1740 (\-LRB-\1740 50\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 features\NNS\5849040 of\IN\1740 kidney\NN\5333259 tubular\JJ\1740 dysfunction\NN\14204950 ,\,\1740 35\CD\1740 (\-LRB-\1740 33\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 features\NNS\5849040 of\IN\1740 glomerular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 18\CD\13745420 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 <e2>Fanconi\NN\1740 syndrome</e2>\NN\5870365 .\.\1740
C418563_D005198 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 hospitalisation\NN\657604 for\IN\1740 <e1>TDF</e1>\NN\1740 kidney\NN\5333259 adverse\JJ\1740 effects\NNS\13245626 was\VBD\836236 high\JJ\1740 ,\,\1740 particularly\RB\1740 amongst\IN\1740 patients\NNS\9898892 with\IN\1740 features\NNS\5849040 of\IN\1740 <e2>Fanconi\NNP\1740 syndrome</e2>\NN\5870365 .\.\1740
8659767
D002045_D001145 NONE Since\IN\1740 <e1>bupivacaine</e1>\NN\1740 and\CC\1740 epinephrine\NN\14807929 may\MD\15209706 both\CC\1740 precipitate\JJ\1740 <e2>dysrhythmias</e2>\NNS\1740 ,\,\1740 circulating\VBG\1835496 bupivacaine\NN\1740 during\IN\1740 regional\JJ\1740 anesthesia\NN\14034177 could\MD\1740 potentiate\VB\229605 dysrhythmogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 epinephrine\NN\14807929 .\.\1740
D002045_D001145 NONE Since\IN\1740 bupivacaine\NN\1740 and\CC\1740 epinephrine\NN\14807929 may\MD\15209706 both\CC\1740 precipitate\JJ\1740 <e2>dysrhythmias</e2>\NNS\1740 ,\,\1740 circulating\VBG\1835496 <e1>bupivacaine</e1>\NN\1740 during\IN\1740 regional\JJ\1740 anesthesia\NN\14034177 could\MD\1740 potentiate\VB\229605 dysrhythmogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 epinephrine\NN\14807929 .\.\1740
D002045_D001145 NONE <e1>Bupivacaine</e1>\NN\1740 antagonizes\VBZ\1787955 epinephrine\NN\14807929 dysrhythmogenicity\NN\1740 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 susceptible\JJ\1740 to\TO\1740 VT\NN\1740 and\CC\1740 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 with\IN\1740 spontaneous\JJ\1740 postinfarct\NN\1740 <e2>dysrhythmias</e2>\NNS\1740 .\.\1740
D004837_D001145 NONE Since\IN\1740 bupivacaine\NN\1740 and\CC\1740 <e1>epinephrine</e1>\NN\14807929 may\MD\15209706 both\CC\1740 precipitate\JJ\1740 <e2>dysrhythmias</e2>\NNS\1740 ,\,\1740 circulating\VBG\1835496 bupivacaine\NN\1740 during\IN\1740 regional\JJ\1740 anesthesia\NN\14034177 could\MD\1740 potentiate\VB\229605 dysrhythmogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 epinephrine\NN\14807929 .\.\1740
D004837_D001145 NONE Since\IN\1740 bupivacaine\NN\1740 and\CC\1740 epinephrine\NN\14807929 may\MD\15209706 both\CC\1740 precipitate\JJ\1740 <e2>dysrhythmias</e2>\NNS\1740 ,\,\1740 circulating\VBG\1835496 bupivacaine\NN\1740 during\IN\1740 regional\JJ\1740 anesthesia\NN\14034177 could\MD\1740 potentiate\VB\229605 dysrhythmogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 .\.\1740
D004837_D001145 NONE Bupivacaine\NN\1740 antagonizes\VBZ\1787955 <e1>epinephrine</e1>\NN\14807929 dysrhythmogenicity\NN\1740 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 susceptible\JJ\1740 to\TO\1740 VT\NN\1740 and\CC\1740 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 with\IN\1740 spontaneous\JJ\1740 postinfarct\NN\1740 <e2>dysrhythmias</e2>\NNS\1740 .\.\1740
D002045_D009203 NONE We\PRP\1740 therefore\RB\1740 examined\VBD\789138 whether\IN\1740 <e1>bupivacaine</e1>\NN\1740 alters\VBZ\126264 the\DT\1740 dysrhythmogenicity\NN\1740 of\IN\1740 subsequent\JJ\1740 administration\NN\1133281 of\IN\1740 epinephrine\NN\14807929 in\IN\13603305 conscious\JJ\1740 ,\,\1740 healthy\JJ\1740 dogs\NNS\2083346 and\CC\1740 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 with\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D004837_D009203 NONE We\PRP\1740 therefore\RB\1740 examined\VBD\789138 whether\IN\1740 bupivacaine\NN\1740 alters\VBZ\126264 the\DT\1740 dysrhythmogenicity\NN\1740 of\IN\1740 subsequent\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 in\IN\13603305 conscious\JJ\1740 ,\,\1740 healthy\JJ\1740 dogs\NNS\2083346 and\CC\1740 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 with\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D004837_D009203 NONE One\CD\13741022 day\NN\15154774 after\IN\1740 experimental\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 ,\,\1740 six\CD\13741022 additional\JJ\1740 halothane-anesthetized\JJ\1740 dogs\NNS\2083346 received\VBD\2210855 4\CD\13741022 micrograms.kg-1.min-1\NN\1740 <e1>epinephrine</e1>\NN\14807929 until\IN\1740 VT\NN\1740 appeared\VBD\2604760 .\.\1740
D006221_D009203 NONE One\CD\13741022 day\NN\15154774 after\IN\1740 experimental\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 ,\,\1740 six\CD\13741022 additional\JJ\1740 <e1>halothane-anesthetized</e1>\JJ\1740 dogs\NNS\2083346 received\VBD\2210855 4\CD\13741022 micrograms.kg-1.min-1\NN\1740 epinephrine\NN\14807929 until\IN\1740 VT\NN\1740 appeared\VBD\2604760 .\.\1740
D006221_D017180 NONE One\CD\13741022 day\NN\15154774 after\IN\1740 experimental\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 six\CD\13741022 additional\JJ\1740 <e1>halothane-anesthetized</e1>\JJ\1740 dogs\NNS\2083346 received\VBD\2210855 4\CD\13741022 micrograms.kg-1.min-1\NN\1740 epinephrine\NN\14807929 until\IN\1740 <e2>VT</e2>\NN\1740 appeared\VBD\2604760 .\.\1740
D004837_D017180 CID One\CD\13741022 day\NN\15154774 after\IN\1740 experimental\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 six\CD\13741022 additional\JJ\1740 halothane-anesthetized\JJ\1740 dogs\NNS\2083346 received\VBD\2210855 4\CD\13741022 micrograms.kg-1.min-1\NN\1740 <e1>epinephrine</e1>\NN\14807929 until\IN\1740 <e2>VT</e2>\NN\1740 appeared\VBD\2604760 .\.\1740
D004837_D017180 CID Bupivacaine\NN\1740 antagonizes\VBZ\1787955 <e1>epinephrine</e1>\NN\14807929 dysrhythmogenicity\NN\1740 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 susceptible\JJ\1740 to\TO\1740 <e2>VT</e2>\NN\1740 and\CC\1740 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 with\IN\1740 spontaneous\JJ\1740 postinfarct\NN\1740 dysrhythmias\NNS\1740 .\.\1740
D002045_D017180 NONE <e1>Bupivacaine</e1>\NN\1740 antagonizes\VBZ\1787955 epinephrine\NN\14807929 dysrhythmogenicity\NN\1740 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 susceptible\JJ\1740 to\TO\1740 <e2>VT</e2>\NN\1740 and\CC\1740 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 with\IN\1740 spontaneous\JJ\1740 postinfarct\NN\1740 dysrhythmias\NNS\1740 .\.\1740
12678199
D000638_D016171 CID <e1>Amiodarone-induced</e1>\JJ\1740 <e2>torsade\NN\1740 de\FW\1740 pointes</e2>\NNS\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 :\:\1740 an\DT\6697703 unusual\JJ\1740 presentation\NN\1027379 --\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D000638_D016171 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 early\JJ\1740 (\-LRB-\1740 within\IN\1740 4\CD\13741022 days\NNS\15140892 )\-RRB-\1740 development\NN\248977 of\IN\1740 <e2>torsade\NN\1740 de\IN\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 oral\JJ\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D016171 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 early\JJ\1740 (\-LRB-\1740 within\IN\1740 4\CD\13741022 days\NNS\15140892 )\-RRB-\1740 development\NN\248977 of\IN\1740 torsade\NN\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 oral\JJ\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D016171 CID Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 <e2>TdP.</e2>\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 bradycardia\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 TdP.\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 amiodarone-induced\JJ\1740 proarrhythmia\NN\1740 .\.\1740
D000638_D016171 CID Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 TdP.\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 bradycardia\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 <e2>TdP.</e2>\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 amiodarone-induced\JJ\1740 proarrhythmia\NN\1740 .\.\1740
D000638_D016171 CID Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 <e2>TdP.</e2>\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 bradycardia\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 TdP.\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 amiodarone\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 <e1>amiodarone-induced</e1>\JJ\1740 proarrhythmia\NN\1740 .\.\1740
D000638_D016171 CID Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 TdP.\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 bradycardia\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 <e2>TdP.</e2>\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 amiodarone\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 <e1>amiodarone-induced</e1>\JJ\1740 proarrhythmia\NN\1740 .\.\1740
D000638_D016171 CID In\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 ,\,\1740 a\DT\13649268 second\JJ\1740 bladder\NN\5515670 irrigation\NN\1057200 did\VBD\1640855 not\RB\1740 induce\VB\1627355 <e2>TdP</e2>\NN\1740 despite\IN\7501545 hypokalemia\NN\14299637 and\CC\1740 hypomagnesemia\NN\1740 .\.\1740
D004077_D016171 NONE Consistent\JJ\1740 with\IN\1740 other\JJ\1740 reports\NNS\6470073 this\DT\1740 case\NN\7283608 of\IN\1740 <e2>TdP</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 multiple\JJ\1740 exacerbating\NN\1740 factors\NNS\7326557 including\VBG\690614 hypokalemia\NN\14299637 and\CC\1740 <e1>digoxin</e1>\NN\15060131 excess\JJ\1740 .\.\1740
D004077_D007008 NONE Consistent\JJ\1740 with\IN\1740 other\JJ\1740 reports\NNS\6470073 this\DT\1740 case\NN\7283608 of\IN\1740 TdP\NN\1740 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 multiple\JJ\1740 exacerbating\NN\1740 factors\NNS\7326557 including\VBG\690614 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 <e1>digoxin</e1>\NN\15060131 excess\JJ\1740 .\.\1740
D000638_D001919 NONE Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 TdP.\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 <e2>bradycardia</e2>\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 TdP.\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 amiodarone-induced\JJ\1740 proarrhythmia\NN\1740 .\.\1740
D000638_D001919 NONE Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 TdP.\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 <e2>bradycardia</e2>\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 TdP.\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 amiodarone\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 <e1>amiodarone-induced</e1>\JJ\1740 proarrhythmia\NN\1740 .\.\1740
D000638_-1 NONE Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 TdP.\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 bradycardia\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 TdP.\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 amiodarone-induced\JJ\1740 <e2>proarrhythmia</e2>\NN\1740 .\.\1740
D000638_-1 NONE Transient\JJ\1740 prolongation\NN\1017987 of\IN\1740 the\DT\1740 QT\NNP\1740 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 prompted\VBD\1645601 the\DT\1740 episode\NN\7283608 of\IN\1740 TdP.\NN\1740 It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 bradycardia\NN\14110674 exacerbates\NNS\1740 acquired\VBD\109660 TdP.\NN\1740 The\DT\1740 authors\NNS\9610660 speculate\VBP\719734 that\IN\1740 the\DT\1740 increased\VBN\169651 vagal\JJ\1740 tone\NN\7071483 during\IN\1740 bladder\NN\5515670 irrigation\NN\1057200 ,\,\1740 a\DT\13649268 vagal\JJ\1740 maneuver\NN\955060 ,\,\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 amiodarone\NN\2715941 therapy\NN\657604 resulted\VBD\2633881 in\IN\13603305 <e1>amiodarone-induced</e1>\JJ\1740 <e2>proarrhythmia</e2>\NN\1740 .\.\1740
D000638_D007008 NONE In\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 ,\,\1740 a\DT\13649268 second\JJ\1740 bladder\NN\5515670 irrigation\NN\1057200 did\VBD\1640855 not\RB\1740 induce\VB\1627355 TdP\NN\1740 despite\IN\7501545 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 hypomagnesemia\NN\1740 .\.\1740
D000638_C537153 NONE In\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 ,\,\1740 a\DT\13649268 second\JJ\1740 bladder\NN\5515670 irrigation\NN\1057200 did\VBD\1640855 not\RB\1740 induce\VB\1627355 TdP\NN\1740 despite\IN\7501545 hypokalemia\NN\14299637 and\CC\1740 <e2>hypomagnesemia</e2>\NN\1740 .\.\1740
20828385
C401859_D020522 NONE Cytostatic\JJ\1740 and\CC\1740 anti-angiogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>temsirolimus</e1>\NN\1740 in\IN\13603305 refractory\JJ\1740 <e2>mantle\NN\6806469 cell\NN\3080309 lymphoma</e2>\NN\14239918 .\.\1740
C401859_D020522 NONE However\RB\1740 ,\,\1740 a\DT\13649268 38\CD\1740 %\NN\1740 remission\NN\7368256 rate\NN\13815152 has\VBZ\2108377 been\VBN\836236 recently\RB\1740 reported\VBN\831651 in\IN\13603305 refractory\JJ\1740 <e2>MCL</e2>\NN\1740 treated\VBN\2376958 with\IN\1740 <e1>temsirolimus</e1>\NN\1740 ,\,\1740 a\DT\13649268 mTOR\NN\1740 inhibitor\NN\20090 .\.\1740
C401859_D020522 NONE Here\RB\1740 we\PRP\1740 had\VBD\2108377 the\DT\1740 opportunity\NN\14481929 to\TO\1740 study\VB\630380 a\DT\13649268 case\NN\7283608 of\IN\1740 refractory\JJ\1740 <e2>MCL</e2>\NN\1740 who\WP\8299493 had\VBD\2108377 tumor\NN\14234074 regression\NN\14501726 two\CD\13741022 months\NNS\15113229 after\IN\1740 <e1>temsirolimus</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 a\DT\13649268 progression-free\JJ\1740 survival\NN\13961642 of\IN\1740 10\CD\13745420 months\NNS\15113229 .\.\1740
C401859_D020522 NONE This\DT\1740 dual\JJ\1740 effect\NN\34213 of\IN\1740 <e1>temsirolimus</e1>\NN\1740 on\IN\1740 tumor\NN\14234074 tissue\NN\5220461 could\MD\1740 contribute\VB\126264 to\TO\1740 its\PRP$\6125041 recently\RB\1740 reported\VBN\831651 efficiency\NN\13819207 in\IN\13603305 refractory\JJ\1740 <e2>MCL</e2>\NN\1740 resistant\JJ\1740 to\TO\1740 conventional\JJ\1740 chemotherapy\NN\661091 .\.\1740
C401859_D009369 NONE Here\RB\1740 we\PRP\1740 had\VBD\2108377 the\DT\1740 opportunity\NN\14481929 to\TO\1740 study\VB\630380 a\DT\13649268 case\NN\7283608 of\IN\1740 refractory\JJ\1740 MCL\NN\1740 who\WP\8299493 had\VBD\2108377 <e2>tumor</e2>\NN\14234074 regression\NN\14501726 two\CD\13741022 months\NNS\15113229 after\IN\1740 <e1>temsirolimus</e1>\NN\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 a\DT\13649268 progression-free\JJ\1740 survival\NN\13961642 of\IN\1740 10\CD\13745420 months\NNS\15113229 .\.\1740
C401859_D009369 NONE Comparison\NN\635850 of\IN\1740 the\DT\1740 two\CD\13741022 biopsies\NNS\5739043 showed\VBD\2137132 that\IN\1740 <e1>temsirolimus</e1>\NN\1740 inhibited\VBD\2510337 <e2>tumor</e2>\NN\14234074 cell\NN\3080309 proliferation\NN\13489037 through\IN\1740 cell\NN\3080309 cycle\NN\15269513 arrest\NN\88481 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 any\DT\1740 change\NN\7283608 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 apoptotic\JJ\1740 tumor\NN\14234074 cells\NNS\3080309 .\.\1740
C401859_D009369 NONE Comparison\NN\635850 of\IN\1740 the\DT\1740 two\CD\13741022 biopsies\NNS\5739043 showed\VBD\2137132 that\IN\1740 <e1>temsirolimus</e1>\NN\1740 inhibited\VBD\2510337 tumor\NN\14234074 cell\NN\3080309 proliferation\NN\13489037 through\IN\1740 cell\NN\3080309 cycle\NN\15269513 arrest\NN\88481 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 any\DT\1740 change\NN\7283608 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 apoptotic\JJ\1740 <e2>tumor</e2>\NN\14234074 cells\NNS\3080309 .\.\1740
C401859_D009369 NONE Apart\RB\1740 from\IN\1740 this\DT\1740 cytostatic\JJ\1740 effect\NN\34213 ,\,\1740 <e1>temsirolimus</e1>\NN\1740 had\VBD\2108377 an\DT\6697703 antiangiogenic\JJ\1740 effect\NN\34213 with\IN\1740 decrease\NN\7296428 of\IN\1740 <e2>tumor</e2>\NN\14234074 microvessel\NN\1740 density\NN\4941325 and\CC\1740 of\IN\1740 VEGF\NN\1740 expression\NN\4679549 .\.\1740
C401859_D009369 NONE Thus\RB\1740 ,\,\1740 <e1>temsirolimus</e1>\NN\1740 reduced\VBD\441445 <e2>tumor</e2>\NN\14234074 burden\NN\5832264 through\IN\1740 associated\VBN\628491 cytostatic\NN\1740 and\CC\1740 anti-angiogenic\JJ\1740 effects\NNS\13245626 .\.\1740
C401859_D009369 NONE This\DT\1740 dual\JJ\1740 effect\NN\34213 of\IN\1740 <e1>temsirolimus</e1>\NN\1740 on\IN\1740 <e2>tumor</e2>\NN\14234074 tissue\NN\5220461 could\MD\1740 contribute\VB\126264 to\TO\1740 its\PRP$\6125041 recently\RB\1740 reported\VBN\831651 efficiency\NN\13819207 in\IN\13603305 refractory\JJ\1740 MCL\NN\1740 resistant\JJ\1740 to\TO\1740 conventional\JJ\1740 chemotherapy\NN\661091 .\.\1740
C401859_D009336 CID Moreover\RB\1740 ,\,\1740 numerous\JJ\1740 patchy\NN\1740 ,\,\1740 well-limited\JJ\1740 fibrotic\JJ\1740 areas\NNS\8630985 ,\,\1740 compatible\JJ\1740 with\IN\1740 <e2>post-necrotic</e2>\JJ\1740 tissue\NN\5220461 repair\NN\248977 ,\,\1740 were\VBD\836236 found\VBN\2426171 after\IN\1740 6-month\JJ\1740 <e1>temsirolimus</e1>\NN\1740 therapy\NN\657604 .\.\1740
15696449
D008558_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 after\IN\1740 high-dose\JJ\1740 <e1>melphalan</e1>\NN\2722458 in\IN\13603305 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 systemic\JJ\1740 amyloidosis\NN\14061805 during\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 .\.\1740
D008558_D058186 CID The\DT\1740 authors\NNS\9610660 have\VBP\2108377 noted\VBN\1009240 the\DT\1740 development\NN\248977 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 immediately\RB\1740 after\IN\1740 <e1>melphalan</e1>\NN\2722458 conditioning\NN\5752544 .\.\1740
D008558_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 (\-LRB-\1740 ARI\NN\1740 )\-RRB-\1740 after\IN\1740 high-dose\JJ\1740 <e1>melphalan</e1>\NN\2722458 was\VBD\836236 defined\VBN\2604760 by\IN\1740 a\DT\13649268 minimum\JJ\1740 increase\NN\13576355 of\IN\1740 0.5\CD\1740 mg/dL\NN\1740 (\-LRB-\1740 44\CD\1740 micromol/L\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 that\WDT\1740 is\VBZ\836236 greater\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 baseline\NN\7260623 immediately\RB\1740 after\IN\1740 conditioning\NN\5752544 .\.\1740
D008558_D058186 CID Acute\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 <e2>ARI</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 high-dose\JJ\1740 <e1>melphalan</e1>\NN\2722458 was\VBD\836236 defined\VBN\2604760 by\IN\1740 a\DT\13649268 minimum\JJ\1740 increase\NN\13576355 of\IN\1740 0.5\CD\1740 mg/dL\NN\1740 (\-LRB-\1740 44\CD\1740 micromol/L\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 serum\NN\5397468 creatinine\NN\1740 level\NN\4916342 that\WDT\1740 is\VBZ\836236 greater\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 baseline\NN\7260623 immediately\RB\1740 after\IN\1740 conditioning\NN\5752544 .\.\1740
D008558_D058186 CID RESULTS\NNS\34213 :\:\1740 Of\IN\1740 the\DT\1740 80\CD\13745420 patients\NNS\9898892 studied\VBN\630380 ,\,\1740 <e2>ARI</e2>\NN\1740 developed\VBD\1753788 in\IN\13603305 18.8\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 patients\NNS\9898892 after\IN\1740 high-dose\JJ\1740 <e1>melphalan</e1>\NN\2722458 .\.\1740
D008558_D058186 CID Patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 <e2>ARI</e2>\NN\1740 after\IN\1740 high-dose\JJ\1740 <e1>melphalan</e1>\NN\2722458 underwent\VBD\109660 dialysis\NN\646833 more\RBR\1740 often\RB\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.007\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 had\VBD\2108377 a\DT\13649268 worse\JJR\1740 1-year\JJ\1740 survival\NN\13961642 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 .\.\1740
D008558_D058186 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 timing\NN\5044673 of\IN\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 strongly\RB\1740 suggests\VBZ\1010118 <e1>melphalan</e1>\NN\2722458 as\IN\14622893 the\DT\1740 causative\JJ\1740 agent\NN\7347 .\.\1740
D008558_D058186 CID Ongoing\JJ\1740 tubular\JJ\1740 injury\NN\14052046 may\MD\15209706 be\VB\836236 a\DT\13649268 prerequisite\NN\1129920 for\IN\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 by\IN\1740 <e1>melphalan</e1>\NN\2722458 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 the\DT\1740 active\JJ\1740 urinary\JJ\1740 sediment\NN\20827 .\.\1740
D008558_C531616 NONE Acute\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 after\IN\1740 high-dose\JJ\1740 <e1>melphalan</e1>\NN\2722458 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>primary\JJ\1740 systemic\JJ\1740 amyloidosis</e2>\NN\14061805 during\IN\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 .\.\1740
D003404_D058186 NONE <e2>Acute\JJ\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 (\-LRB-\1740 ARI\NN\1740 )\-RRB-\1740 after\IN\1740 high-dose\JJ\1740 melphalan\NN\2722458 was\VBD\836236 defined\VBN\2604760 by\IN\1740 a\DT\13649268 minimum\JJ\1740 increase\NN\13576355 of\IN\1740 0.5\CD\1740 mg/dL\NN\1740 (\-LRB-\1740 44\CD\1740 micromol/L\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 level\NN\4916342 that\WDT\1740 is\VBZ\836236 greater\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 baseline\NN\7260623 immediately\RB\1740 after\IN\1740 conditioning\NN\5752544 .\.\1740
D003404_D058186 NONE Acute\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 <e2>ARI</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 high-dose\JJ\1740 melphalan\NN\2722458 was\VBD\836236 defined\VBN\2604760 by\IN\1740 a\DT\13649268 minimum\JJ\1740 increase\NN\13576355 of\IN\1740 0.5\CD\1740 mg/dL\NN\1740 (\-LRB-\1740 44\CD\1740 micromol/L\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 level\NN\4916342 that\WDT\1740 is\VBZ\836236 greater\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 of\IN\1740 baseline\NN\7260623 immediately\RB\1740 after\IN\1740 conditioning\NN\5752544 .\.\1740
D008558_-1 NONE Ongoing\JJ\1740 <e2>tubular\JJ\1740 injury</e2>\NN\14052046 may\MD\15209706 be\VB\836236 a\DT\13649268 prerequisite\NN\1129920 for\IN\1740 renal\JJ\1740 injury\NN\14052046 by\IN\1740 <e1>melphalan</e1>\NN\2722458 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 the\DT\1740 active\JJ\1740 urinary\JJ\1740 sediment\NN\20827 .\.\1740
19139825
D019772_D005909 NONE <e1>Topotecan</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 radiotherapy\NN\661091 in\IN\13603305 unresectable\JJ\1740 <e2>glioblastoma</e2>\NN\14236743 :\:\1740 a\DT\13649268 phase\NN\15113229 2\CD\13741022 study\NN\635850 .\.\1740
D019772_D005909 NONE The\DT\1740 present\JJ\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 combination\NN\7951464 of\IN\1740 radiotherapy\NN\661091 (\-LRB-\1740 60\CD\13745420 Gy/30\NN\1740 fractions/40\NN\1740 days\NNS\15140892 )\-RRB-\1740 and\CC\1740 <e1>topotecan</e1>\JJ\1740 (\-LRB-\1740 0.9\CD\1740 mg/m(2)/day\CD\1740 on\IN\1740 days\NNS\15140892 1\CD\13741022 -\SYM\1740 5\CD\13741022 on\IN\1740 weeks\NNS\15113229 1\CD\13741022 ,\,\1740 3\CD\13741022 and\CC\1740 5\CD\13741022 )\-RRB-\1740 in\IN\13603305 50\CD\13745420 adults\NNS\7846 with\IN\1740 histologically\RB\1740 proven\VBN\2604760 and\CC\1740 untreated\JJ\1740 <e2>GBM</e2>\NN\1740 .\.\1740
D019772_D005910 NONE <e1>Topotecan</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 attractive\JJ\1740 option\NN\6480506 as\IN\14622893 it\PRP\6125041 exhibits\VBZ\2632167 growth\NN\13526110 inhibition\NN\1068773 of\IN\1740 human\JJ\1740 <e2>glioma</e2>\NN\14236743 as\RB\1740 well\RB\1740 as\IN\14622893 brain\NN\5462674 penetration\NN\972621 .\.\1740
3383127
D002945_D007022 CID <e2>Hypotension</e2>\NN\14057371 as\IN\14622893 a\DT\13649268 manifestation\NN\7321772 of\IN\1740 cardiotoxicity\NN\1740 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 <e1>cisplatin</e1>\NN\1740 and\CC\1740 5-fluorouracil\NN\1740 .\.\1740
D002945_D007022 CID Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 <e2>hypotension</e2>\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 colorectal\JJ\1740 carcinoma\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 and\CC\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D007022 CID Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 <e2>hypotension</e2>\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 colorectal\JJ\1740 carcinoma\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 <e1>CDDP</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D066126 NONE Hypotension\NN\14057371 as\IN\14622893 a\DT\13649268 manifestation\NN\7321772 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 <e1>cisplatin</e1>\NN\1740 and\CC\1740 5-fluorouracil\NN\1740 .\.\1740
D002945_D066126 NONE The\DT\1740 presentation\NN\1027379 and\CC\1740 cardiac\JJ\1740 evaluation\NN\874067 (\-LRB-\1740 hemodynamic\JJ\1740 ,\,\1740 echocardiographic\JJ\1740 ,\,\1740 and\CC\1740 scintigraphic\JJ\1740 )\-RRB-\1740 of\IN\1740 these\DT\1740 patients\NNS\9898892 suggest\VBP\1010118 new\JJ\1740 manifestations\NNS\7321772 of\IN\1740 5-FU\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 that\WDT\1740 may\MD\15209706 be\VB\836236 influenced\VBN\137313 by\IN\1740 <e1>CDDP</e1>\NN\1740 .\.\1740
D005472_D007022 CID <e2>Hypotension</e2>\NN\14057371 as\IN\14622893 a\DT\13649268 manifestation\NN\7321772 of\IN\1740 cardiotoxicity\NN\1740 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 cisplatin\NN\1740 and\CC\1740 <e1>5-fluorouracil</e1>\NN\1740 .\.\1740
D005472_D007022 CID Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 <e2>hypotension</e2>\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 colorectal\JJ\1740 carcinoma\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 .\.\1740
D005472_D007022 CID Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 <e2>hypotension</e2>\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 colorectal\JJ\1740 carcinoma\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 and\CC\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D005472_D066126 NONE Hypotension\NN\14057371 as\IN\14622893 a\DT\13649268 manifestation\NN\7321772 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 cisplatin\NN\1740 and\CC\1740 <e1>5-fluorouracil</e1>\NN\1740 .\.\1740
D005472_D066126 NONE The\DT\1740 presentation\NN\1027379 and\CC\1740 cardiac\JJ\1740 evaluation\NN\874067 (\-LRB-\1740 hemodynamic\JJ\1740 ,\,\1740 echocardiographic\JJ\1740 ,\,\1740 and\CC\1740 scintigraphic\JJ\1740 )\-RRB-\1740 of\IN\1740 these\DT\1740 patients\NNS\9898892 suggest\VBP\1010118 new\JJ\1740 manifestations\NNS\7321772 of\IN\1740 <e1>5-FU</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 that\WDT\1740 may\MD\15209706 be\VB\836236 influenced\VBN\137313 by\IN\1740 CDDP\NN\1740 .\.\1740
D002945_D015179 NONE Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 hypotension\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>colorectal\JJ\1740 carcinoma</e2>\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 and\CC\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D015179 NONE Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 hypotension\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>colorectal\JJ\1740 carcinoma</e2>\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 <e1>CDDP</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 .\.\1740
D005472_D015179 NONE Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 hypotension\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>colorectal\JJ\1740 carcinoma</e2>\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 .\.\1740
D005472_D015179 NONE Cardiac\JJ\1740 symptoms\NNS\5823932 ,\,\1740 including\VBG\690614 hypotension\NN\14057371 ,\,\1740 developed\VBD\1753788 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>colorectal\JJ\1740 carcinoma</e2>\NN\14239918 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 CDDP\NN\1740 )\-RRB-\1740 and\CC\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
20431083
D014859_D002543 CID RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 <e2>ICH</e2>\NN\1740 and\CC\1740 3817\CD\1740 IS/TIA\NN\1740 ,\,\1740 MB\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 ICH\NN\1740 vs\CC\13634784 IS/TIA\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002543 CID RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 ICH\NN\1740 and\CC\1740 3817\CD\1740 IS/TIA\NN\1740 ,\,\1740 MB\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 <e2>ICH</e2>\NN\1740 vs\CC\13634784 IS/TIA\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002543 CID There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 <e2>ICH</e2>\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 IS/TIA\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002543 CID There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 <e2>ICH</e2>\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 IS/TIA\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002543 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 <e2>ICH</e2>\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 MB\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 warfarin-associated\JJ\1740 ICH\NN\1740 .\.\1740
D014859_D002543 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 ICH\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 MB\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 warfarin-associated\JJ\1740 <e2>ICH</e2>\NN\1740 .\.\1740
D014859_D002543 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 <e2>ICH</e2>\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 MB\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>warfarin-associated</e1>\JJ\1740 ICH\NN\1740 .\.\1740
D014859_D002543 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 ICH\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 MB\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>warfarin-associated</e1>\JJ\1740 <e2>ICH</e2>\NN\1740 .\.\1740
D014859_D002544 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 ICH\NN\1740 and\CC\1740 3817\CD\1740 <e2>IS/TIA</e2>\NN\1740 ,\,\1740 MB\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 ICH\NN\1740 vs\CC\13634784 IS/TIA\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002544 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 ICH\NN\1740 and\CC\1740 3817\CD\1740 IS/TIA\NN\1740 ,\,\1740 MB\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 ICH\NN\1740 vs\CC\13634784 <e2>IS/TIA</e2>\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002544 NONE There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 ICH\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 <e2>IS/TIA</e2>\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002544 NONE There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 ICH\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 <e2>IS/TIA</e2>\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002546 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 ICH\NN\1740 and\CC\1740 3817\CD\1740 <e2>IS/TIA</e2>\NN\1740 ,\,\1740 MB\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 ICH\NN\1740 vs\CC\13634784 IS/TIA\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002546 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 ICH\NN\1740 and\CC\1740 3817\CD\1740 IS/TIA\NN\1740 ,\,\1740 MB\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 ICH\NN\1740 vs\CC\13634784 <e2>IS/TIA</e2>\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002546 NONE There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 ICH\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 <e2>IS/TIA</e2>\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_D002546 NONE There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 ICH\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 <e2>IS/TIA</e2>\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_-1 NONE RESULTS\NNS\34213 :\:\1740 In\IN\13603305 a\DT\13649268 pooled\JJ\1740 analysis\NN\633864 of\IN\1740 1460\CD\1740 ICH\NN\1740 and\CC\1740 3817\CD\1740 IS/TIA\NN\1740 ,\,\1740 <e2>MB</e2>\NN\13601596 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 ICH\NN\1740 vs\CC\13634784 IS/TIA\NN\1740 in\IN\13603305 all\DT\1740 treatment\NN\654885 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 excess\NN\5119367 increased\VBD\169651 from\IN\1740 2.8\CD\1740 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 ;\:\1740 range\NN\5123416 ,\,\1740 2.3\CD\1740 -\SYM\1740 3.5\CD\1740 )\-RRB-\1740 in\IN\13603305 nonantithrombotic\JJ\1740 users\NNS\7846 to\TO\1740 5.7\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.4\CD\1740 -\SYM\1740 9.7\CD\1740 )\-RRB-\1740 in\IN\13603305 antiplatelet\NN\1740 users\NNS\7846 and\CC\1740 8.0\CD\1740 (\-LRB-\1740 range\NN\5123416 ,\,\1740 3.5\CD\1740 -\SYM\1740 17.8\CD\1740 )\-RRB-\1740 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 (\-LRB-\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_-1 NONE There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 <e2>MB</e2>\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 ICH\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 IS/TIA\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_-1 NONE There\EX\27167 was\VBD\836236 also\RB\1740 an\DT\6697703 excess\NN\5119367 of\IN\1740 <e2>MB</e2>\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 vs\CC\13634784 nonusers\NNS\1740 with\IN\1740 ICH\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.6\CD\1740 -\SYM\1740 4.4\CD\1740 ;\:\1740 P<0.001\NN\1740 )\-RRB-\1740 but\CC\1740 none\NN\15228378 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 IS/TIA\NN\1740 (\-LRB-\1740 OR\NN\3541091 ,\,\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 0.9\CD\1740 -\SYM\1740 1.7\CD\1740 ;\:\1740 P=0.33\NN\1740 ;\:\1740 P\NN\14622893 difference=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D014859_-1 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 <e2>MB</e2>\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 ICH\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 MB\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 warfarin-associated\JJ\1740 ICH\NN\1740 .\.\1740
D014859_-1 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 <e1>warfarin</e1>\NN\2718259 users\NNS\7846 with\IN\1740 ICH\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 <e2>MB</e2>\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 warfarin-associated\JJ\1740 ICH\NN\1740 .\.\1740
D014859_-1 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 <e2>MB</e2>\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 ICH\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 MB\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>warfarin-associated</e1>\JJ\1740 ICH\NN\1740 .\.\1740
D014859_-1 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 excess\NN\5119367 of\IN\1740 MB\NN\13601596 in\IN\13603305 warfarin\NN\2718259 users\NNS\7846 with\IN\1740 ICH\NN\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 groups\NNS\2137 suggests\VBZ\1010118 that\IN\1740 <e2>MB</e2>\NN\13601596 increase\VBP\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>warfarin-associated</e1>\JJ\1740 ICH\NN\1740 .\.\1740
16920333
C416835_D012640 NONE Anticonvulsant\JJ\1740 effect\NN\34213 of\IN\1740 <e1>eslicarbazepine\NN\1740 acetate</e1>\NN\15010703 (\-LRB-\1740 BIA\NN\1740 2\CD\13741022 -\SYM\1740 093\CD\1740 )\-RRB-\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 microperfusion\NN\1740 of\IN\1740 picrotoxin\NN\1740 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 of\IN\1740 freely\RB\1740 moving\VBG\2367363 rats\NNS\2329401 .\.\1740
C416835_D012640 NONE Anticonvulsant\JJ\1740 effect\NN\34213 of\IN\1740 eslicarbazepine\NN\1740 acetate\NN\15010703 (\-LRB-\1740 <e1>BIA\NN\1740 2\CD\13741022 -\SYM\1740 093</e1>\CD\1740 )\-RRB-\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 microperfusion\NN\1740 of\IN\1740 picrotoxin\NN\1740 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 of\IN\1740 freely\RB\1740 moving\VBG\2367363 rats\NNS\2329401 .\.\1740
C416835_D012640 NONE We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>eslicarbazepine\NN\1740 acetate</e1>\NN\15010703 on\IN\1740 a\DT\13649268 whole-animal\JJ\1740 model\NN\5888929 in\IN\13603305 which\WDT\1740 partial\JJ\1740 <e2>seizures</e2>\NNS\14081375 can\MD\3094503 be\VB\836236 elicited\VBN\1617192 repeatedly\RB\1740 on\IN\1740 different\JJ\1740 days\NNS\15140892 without\IN\1740 changes\NNS\7283608 in\IN\13603305 threshold\NN\15265518 or\CC\3541091 seizure\VB\1740 patterns\NNS\5726345 .\.\1740
C416835_D012640 NONE We\PRP\1740 have\VBP\2108377 studied\VBN\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>eslicarbazepine\NN\1740 acetate</e1>\NN\15010703 on\IN\1740 a\DT\13649268 whole-animal\JJ\1740 model\NN\5888929 in\IN\13603305 which\WDT\1740 partial\JJ\1740 seizures\NNS\14081375 can\MD\3094503 be\VB\836236 elicited\VBN\1617192 repeatedly\RB\1740 on\IN\1740 different\JJ\1740 days\NNS\15140892 without\IN\1740 changes\NNS\7283608 in\IN\13603305 threshold\NN\15265518 or\CC\3541091 <e2>seizure</e2>\VB\1740 patterns\NNS\5726345 .\.\1740
D010852_D012640 CID Anticonvulsant\JJ\1740 effect\NN\34213 of\IN\1740 eslicarbazepine\NN\1740 acetate\NN\15010703 (\-LRB-\1740 BIA\NN\1740 2\CD\13741022 -\SYM\1740 093\CD\1740 )\-RRB-\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 microperfusion\NN\1740 of\IN\1740 <e1>picrotoxin</e1>\NN\1740 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 of\IN\1740 freely\RB\1740 moving\VBG\2367363 rats\NNS\2329401 .\.\1740
D010852_D012640 CID In\IN\13603305 the\DT\1740 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 threshold\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 the\DT\1740 average\JJ\1740 number\NN\5107765 of\IN\1740 <e2>seizures</e2>\NNS\14081375 was\VBD\836236 2.3+/-1.2\CD\1740 ,\,\1740 and\CC\1740 average\JJ\1740 seizure\NN\14081375 duration\NN\15113229 was\VBD\836236 39.5+/-8.4s\CD\1740 .\.\1740
D010852_D012640 CID In\IN\13603305 the\DT\1740 animals\NNS\4475 treated\VBN\2376958 with\IN\1740 threshold\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>picrotoxin</e1>\NN\1740 ,\,\1740 the\DT\1740 average\JJ\1740 number\NN\5107765 of\IN\1740 seizures\NNS\14081375 was\VBD\836236 2.3+/-1.2\CD\1740 ,\,\1740 and\CC\1740 average\JJ\1740 <e2>seizure</e2>\NN\14081375 duration\NN\15113229 was\VBD\836236 39.5+/-8.4s\CD\1740 .\.\1740
D010852_D012640 CID Pre-treatment\JJ\1740 with\IN\1740 a\DT\13649268 dose\NN\3740161 of\IN\1740 30\CD\13745420 mg/kg\NN\1740 2h\NN\1740 before\IN\1740 <e1>picrotoxin</e1>\NN\1740 microperfusion\NN\1740 prevented\VBD\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 the\DT\1740 75\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 rats\NNS\2329401 .\.\1740
15482540
D012254_D000740 NONE Factors\NNS\7326557 contributing\VBG\126264 to\TO\1740 <e1>ribavirin-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D012254_D000740 NONE This\DT\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 identify\VB\699815 the\DT\1740 factors\NNS\7326557 contributing\VBG\126264 to\TO\1740 <e1>ribavirin-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D012254_D000740 NONE A\DT\13649268 hemoglobin\NN\14888884 concentration\NN\4916342 of\IN\1740 <\XX\1740 10\CD\13745420 g/dL\NN\1740 was\VBD\836236 defined\VBN\2604760 as\IN\14622893 <e1>ribavirin-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D012254_D000740 NONE RESULTS\NNS\34213 :\:\1740 <e1>Ribavirin-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 occurred\VBD\2623529 in\IN\13603305 18\CD\13745420 (\-LRB-\1740 20.5\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 during\IN\1740 treatment\NN\654885 .\.\1740
D016898_D019698 NONE BACKGROUND\NN\4921011 AND\CC\1740 AIM\NN\5980875 :\:\1740 <e1>Interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 combination\NN\7951464 therapy\NN\657604 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 produces\VBZ\1617192 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D016898_D019698 NONE METHODS\NNS\5616786 :\:\1740 Eighty-eight\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 who\WP\8299493 received\VBD\2210855 <e1>interferon-alpha-2b</e1>\CD\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 6\CD\13741022 MU\NN\6828818 administered\VBN\2436349 intramuscularly\RB\1740 for\IN\1740 24\CD\13745420 weeks\NNS\15113229 in\IN\13603305 combination\NN\7951464 with\IN\1740 ribavirin\NN\2725367 administered\VBN\2436349 orally\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 600\CD\1740 mg\NN\13717155 or\CC\3541091 800\CD\1740 mg\NN\13717155 participated\VBN\2367363 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
D016898_D000743 CID BACKGROUND\NN\4921011 AND\CC\1740 AIM\NN\5980875 :\:\1740 <e1>Interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 combination\NN\7951464 therapy\NN\657604 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 produces\VBZ\1617192 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D012254_D019698 NONE BACKGROUND\NN\4921011 AND\CC\1740 AIM\NN\5980875 :\:\1740 Interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 combination\NN\7951464 therapy\NN\657604 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 produces\VBZ\1617192 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D012254_D019698 NONE METHODS\NNS\5616786 :\:\1740 Eighty-eight\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 who\WP\8299493 received\VBD\2210855 interferon-alpha-2b\CD\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 6\CD\13741022 MU\NN\6828818 administered\VBN\2436349 intramuscularly\RB\1740 for\IN\1740 24\CD\13745420 weeks\NNS\15113229 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>ribavirin</e1>\NN\2725367 administered\VBN\2436349 orally\RB\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 600\CD\1740 mg\NN\13717155 or\CC\3541091 800\CD\1740 mg\NN\13717155 participated\VBN\2367363 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
D012254_D000743 CID BACKGROUND\NN\4921011 AND\CC\1740 AIM\NN\5980875 :\:\1740 Interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 combination\NN\7951464 therapy\NN\657604 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 produces\VBZ\1617192 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
19549709
C107135_D002289 NONE Efficacy\NNP\5199286 of\IN\1740 <e1>everolimus</e1>\NN\1740 (\-LRB-\1740 RAD001\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>NSCLC</e2>\NN\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 chemotherapy\NN\661091 alone\RB\1740 or\CC\3541091 with\IN\1740 chemotherapy\NN\661091 and\CC\1740 EGFR\NN\1740 inhibitors\NNS\20090 .\.\1740
C107135_D002289 NONE Efficacy\NNP\5199286 of\IN\1740 everolimus\NN\1740 (\-LRB-\1740 <e1>RAD001</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>NSCLC</e2>\NN\1740 previously\RB\1740 treated\VBN\2376958 with\IN\1740 chemotherapy\NN\661091 alone\RB\1740 or\CC\3541091 with\IN\1740 chemotherapy\NN\661091 and\CC\1740 EGFR\NN\1740 inhibitors\NNS\20090 .\.\1740
C107135_D002289 NONE <e1>RAD001</e1>\NN\1740 ,\,\1740 an\DT\6697703 oral\JJ\1740 inhibitor\NN\20090 of\IN\1740 the\DT\1740 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 rapamycin\NN\1740 (\-LRB-\1740 mTOR\NN\1740 )\-RRB-\1740 ,\,\1740 has\VBZ\2108377 shown\VBN\2137132 phase\NN\15113229 I\CD\14622893 efficacy\NN\5199286 in\IN\13603305 <e2>NSCLC</e2>\NN\1740 .\.\1740
C107135_D002289 NONE METHODS\NNS\5616786 :\:\1740 Stage\NN\15113229 IIIb\NNS\1740 or\CC\3541091 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 two\CD\13741022 or\CC\3541091 fewer\JJR\1740 prior\JJ\1740 chemotherapy\NN\661091 regimens\NNS\5898568 ,\,\1740 one\CD\13741022 platinum\NN\14627081 based\VBN\2694933 (\-LRB-\1740 stratum\NN\8591680 1\CD\13741022 )\-RRB-\1740 or\CC\3541091 both\CC\1740 chemotherapy\NN\661091 and\CC\1740 epidermal\JJ\1740 growth\NN\13526110 factor\NN\7326557 receptor\NN\5225602 tyrosine\NN\14601829 kinase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 stratum\NN\8591680 2\CD\13741022 )\-RRB-\1740 ,\,\1740 received\VBD\2210855 <e1>RAD001</e1>\NN\1740 10\CD\13745420 mg/day\NN\1740 until\IN\1740 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 toxicity\NN\13576101 .\.\1740
C107135_D002289 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>RAD001</e1>\NN\1740 10\CD\13745420 mg/day\NN\1740 was\VBD\836236 well\RB\1740 tolerated\VBN\802318 ,\,\1740 showing\VBG\2137132 modest\JJ\1740 clinical\JJ\1740 activity\NN\30358 in\IN\13603305 pretreated\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
C107135_D002289 NONE Evaluation\NN\874067 of\IN\1740 <e1>RAD001</e1>\NN\1740 plus\CC\4723816 standard\JJ\1740 therapy\NN\657604 for\IN\1740 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 continues\VBZ\2367363 .\.\1740
D020123_D002289 NONE RAD001\NN\1740 ,\,\1740 an\DT\6697703 oral\JJ\1740 inhibitor\NN\20090 of\IN\1740 the\DT\1740 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 <e1>rapamycin</e1>\NN\1740 (\-LRB-\1740 mTOR\NN\1740 )\-RRB-\1740 ,\,\1740 has\VBZ\2108377 shown\VBN\2137132 phase\NN\15113229 I\CD\14622893 efficacy\NN\5199286 in\IN\13603305 <e2>NSCLC</e2>\NN\1740 .\.\1740
D010984_D002289 NONE METHODS\NNS\5616786 :\:\1740 Stage\NN\15113229 IIIb\NNS\1740 or\CC\3541091 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 two\CD\13741022 or\CC\3541091 fewer\JJR\1740 prior\JJ\1740 chemotherapy\NN\661091 regimens\NNS\5898568 ,\,\1740 one\CD\13741022 <e1>platinum</e1>\NN\14627081 based\VBN\2694933 (\-LRB-\1740 stratum\NN\8591680 1\CD\13741022 )\-RRB-\1740 or\CC\3541091 both\CC\1740 chemotherapy\NN\661091 and\CC\1740 epidermal\JJ\1740 growth\NN\13526110 factor\NN\7326557 receptor\NN\5225602 tyrosine\NN\14601829 kinase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 stratum\NN\8591680 2\CD\13741022 )\-RRB-\1740 ,\,\1740 received\VBD\2210855 RAD001\NN\1740 10\CD\13745420 mg/day\NN\1740 until\IN\1740 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 toxicity\NN\13576101 .\.\1740
D010984_D064420 NONE METHODS\NNS\5616786 :\:\1740 Stage\NN\15113229 IIIb\NNS\1740 or\CC\3541091 IV\CD\13741022 NSCLC\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 two\CD\13741022 or\CC\3541091 fewer\JJR\1740 prior\JJ\1740 chemotherapy\NN\661091 regimens\NNS\5898568 ,\,\1740 one\CD\13741022 <e1>platinum</e1>\NN\14627081 based\VBN\2694933 (\-LRB-\1740 stratum\NN\8591680 1\CD\13741022 )\-RRB-\1740 or\CC\3541091 both\CC\1740 chemotherapy\NN\661091 and\CC\1740 epidermal\JJ\1740 growth\NN\13526110 factor\NN\7326557 receptor\NN\5225602 tyrosine\NN\14601829 kinase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 stratum\NN\8591680 2\CD\13741022 )\-RRB-\1740 ,\,\1740 received\VBD\2210855 RAD001\NN\1740 10\CD\13745420 mg/day\NN\1740 until\IN\1740 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D014443_D002289 NONE METHODS\NNS\5616786 :\:\1740 Stage\NN\15113229 IIIb\NNS\1740 or\CC\3541091 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 two\CD\13741022 or\CC\3541091 fewer\JJR\1740 prior\JJ\1740 chemotherapy\NN\661091 regimens\NNS\5898568 ,\,\1740 one\CD\13741022 platinum\NN\14627081 based\VBN\2694933 (\-LRB-\1740 stratum\NN\8591680 1\CD\13741022 )\-RRB-\1740 or\CC\3541091 both\CC\1740 chemotherapy\NN\661091 and\CC\1740 epidermal\JJ\1740 growth\NN\13526110 factor\NN\7326557 receptor\NN\5225602 <e1>tyrosine</e1>\NN\14601829 kinase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 stratum\NN\8591680 2\CD\13741022 )\-RRB-\1740 ,\,\1740 received\VBD\2210855 RAD001\NN\1740 10\CD\13745420 mg/day\NN\1740 until\IN\1740 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 toxicity\NN\13576101 .\.\1740
D014443_D064420 NONE METHODS\NNS\5616786 :\:\1740 Stage\NN\15113229 IIIb\NNS\1740 or\CC\3541091 IV\CD\13741022 NSCLC\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 two\CD\13741022 or\CC\3541091 fewer\JJR\1740 prior\JJ\1740 chemotherapy\NN\661091 regimens\NNS\5898568 ,\,\1740 one\CD\13741022 platinum\NN\14627081 based\VBN\2694933 (\-LRB-\1740 stratum\NN\8591680 1\CD\13741022 )\-RRB-\1740 or\CC\3541091 both\CC\1740 chemotherapy\NN\661091 and\CC\1740 epidermal\JJ\1740 growth\NN\13526110 factor\NN\7326557 receptor\NN\5225602 <e1>tyrosine</e1>\NN\14601829 kinase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 stratum\NN\8591680 2\CD\13741022 )\-RRB-\1740 ,\,\1740 received\VBD\2210855 RAD001\NN\1740 10\CD\13745420 mg/day\NN\1740 until\IN\1740 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C107135_D064420 NONE METHODS\NNS\5616786 :\:\1740 Stage\NN\15113229 IIIb\NNS\1740 or\CC\3541091 IV\CD\13741022 NSCLC\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 two\CD\13741022 or\CC\3541091 fewer\JJR\1740 prior\JJ\1740 chemotherapy\NN\661091 regimens\NNS\5898568 ,\,\1740 one\CD\13741022 platinum\NN\14627081 based\VBN\2694933 (\-LRB-\1740 stratum\NN\8591680 1\CD\13741022 )\-RRB-\1740 or\CC\3541091 both\CC\1740 chemotherapy\NN\661091 and\CC\1740 epidermal\JJ\1740 growth\NN\13526110 factor\NN\7326557 receptor\NN\5225602 tyrosine\NN\14601829 kinase\NN\14732946 inhibitors\NNS\20090 (\-LRB-\1740 stratum\NN\8591680 2\CD\13741022 )\-RRB-\1740 ,\,\1740 received\VBD\2210855 <e1>RAD001</e1>\NN\1740 10\CD\13745420 mg/day\NN\1740 until\IN\1740 progression\NN\8457976 or\CC\3541091 unacceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
7671401
D000806_D000799 CID Increased\VBN\169651 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>angio-oedema</e2>\NN\1740 related\JJ\1740 to\TO\1740 long-term\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitor</e1>\NN\20090 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 .\.\1740
D000806_D000799 CID Soon\RB\1740 after\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>ACE\NN\13741022 inhibitors</e1>\NNS\20090 ,\,\1740 acute\JJ\1740 bouts\NNS\5867413 of\IN\1740 <e2>angio-oedema</e2>\NN\1740 were\VBD\836236 reported\VBN\831651 in\IN\13603305 association\NN\8008335 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D000806_D000799 CID We\PRP\1740 wish\VBP\1825237 to\TO\1740 draw\VB\1850315 attention\NN\5701944 to\IN\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 adverse\JJ\1740 reactions\NNS\13446390 to\TO\1740 <e1>ACE\NN\13741022 inhibitors</e1>\NNS\20090 after\IN\1740 long-term\JJ\1740 use\NN\407535 and\CC\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 pre-existing\JJ\1740 <e2>angio-oedema</e2>\NN\1740 .\.\1740
D000806_D006973 NONE <e1>Angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitors</e1>\NNS\20090 ,\,\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 <e2>hypertension</e2>\NN\14057371 and\CC\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 were\VBD\836236 introduced\VBN\831651 in\IN\13603305 Europe\NNP\8294696 in\IN\13603305 the\DT\1740 middle\NN\8497294 of\IN\1740 the\DT\1740 eighties\NNS\15204983 ,\,\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 has\VBZ\2108377 increased\VBN\169651 progressively\RB\1740 .\.\1740
D000806_D006333 NONE <e1>Angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitors</e1>\NNS\20090 ,\,\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 hypertension\NN\14057371 and\CC\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 were\VBD\836236 introduced\VBN\831651 in\IN\13603305 Europe\NNP\8294696 in\IN\13603305 the\DT\1740 middle\NN\8497294 of\IN\1740 the\DT\1740 eighties\NNS\15204983 ,\,\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 these\DT\1740 drugs\NNS\14778436 has\VBZ\2108377 increased\VBN\169651 progressively\RB\1740 .\.\1740
24464946
D015251_D066126 CID Two-dimensional\JJ\1740 speckle\NN\4680285 tracking\NN\319939 echocardiography\NN\177127 combined\JJ\1740 with\IN\1740 high-sensitive\JJ\1740 cardiac\NN\1740 troponin\NN\1740 T\NN\14999913 in\IN\13603305 early\JJ\1740 detection\NN\5708432 and\CC\1740 prediction\NN\5772356 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 during\IN\1740 <e1>epirubicine-based</e1>\JJ\1740 chemotherapy\NN\661091 .\.\1740
D015251_D009202 NONE AIMS\NNS\5980875 :\:\1740 To\TO\1740 investigate\VB\644583 whether\IN\1740 alterations\NNS\7283608 of\IN\1740 <e2>myocardial\JJ\1740 strain</e2>\NN\7358060 and\CC\1740 high-sensitive\JJ\1740 cardiac\JJ\1740 troponin\NN\1740 T\NN\14999913 (\-LRB-\1740 cTnT\NN\1740 )\-RRB-\1740 could\MD\1740 predict\VB\916909 future\JJ\1740 cardiac\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 patients\NNS\9898892 after\IN\1740 <e1>epirubicin</e1>\NN\1740 exposure\NN\5042871 .\.\1740
D015251_D006331 NONE AIMS\NNS\5980875 :\:\1740 To\TO\1740 investigate\VB\644583 whether\IN\1740 alterations\NNS\7283608 of\IN\1740 myocardial\JJ\1740 strain\NN\7358060 and\CC\1740 high-sensitive\JJ\1740 cardiac\JJ\1740 troponin\NN\1740 T\NN\14999913 (\-LRB-\1740 cTnT\NN\1740 )\-RRB-\1740 could\MD\1740 predict\VB\916909 future\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 patients\NNS\9898892 after\IN\1740 <e1>epirubicin</e1>\NN\1740 exposure\NN\5042871 .\.\1740
D015251_D008228 NONE METHODS\NNS\5616786 :\:\1740 Seventy-five\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>non-Hodgkin\JJ\1740 lymphoma</e2>\NN\14239918 treated\VBN\2376958 with\IN\1740 <e1>epirubicin</e1>\NN\1740 were\VBD\836236 studied\VBN\630380 .\.\1740
D018943_D006331 NONE CONCLUSIONS\NNS\5837957 :\:\1740 GLS\NN\1740 combined\VBN\2630189 with\IN\1740 cTnT\NN\1740 may\MD\15209706 provide\VB\2199590 a\DT\13649268 reliable\JJ\1740 and\CC\1740 non-invasive\JJ\1740 method\NN\5616786 to\TO\1740 predict\VB\916909 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>anthracycline-based</e1>\JJ\1740 chemotherapy\NN\661091 .\.\1740
1756784
D010862_D001930 CID <e2>Damage\NN\7296428 of\IN\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata</e2>\VBZ\1740 during\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 status\NN\24720 epilepticus\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 immunohistochemical\JJ\1740 study\NN\635850 of\IN\1740 neurons\NNS\5430628 ,\,\1740 astrocytes\NNS\5467432 and\CC\1740 serum-protein\JJ\1740 extravasation\NN\14940100 .\.\1740
D010862_D013226 CID Damage\NN\7296428 of\IN\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\VBZ\1740 during\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 immunohistochemical\JJ\1740 study\NN\635850 of\IN\1740 neurons\NNS\5430628 ,\,\1740 astrocytes\NNS\5467432 and\CC\1740 serum-protein\JJ\1740 extravasation\NN\14940100 .\.\1740
D010862_D013226 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 systemic\JJ\1740 injection\NN\320852 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002118_D009422 NONE Nissl-staining\JJ\1740 and\CC\1740 antibodies\NNS\14728724 against\IN\1740 the\DT\1740 neuron-specific\JJ\1740 <e1>calcium-binding</e1>\JJ\1740 protein\NN\14944888 ,\,\1740 parvalbumin\NN\1740 ,\,\1740 served\VBD\2669789 to\TO\1740 detect\VB\2163746 <e2>neuronal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 SNR\NN\1740 .\.\1740
9570197
D003042_D018487 CID BACKGROUND\NN\4921011 :\:\1740 In\IN\13603305 dogs\NNS\2083346 ,\,\1740 a\DT\13649268 large\JJ\1740 amount\NN\13329641 of\IN\1740 intravenous\JJ\1740 <e1>cocaine</e1>\NN\3492717 causes\VBZ\1617192 a\DT\13649268 profound\JJ\1740 <e2>deterioration\NN\14560612 of\IN\1740 left\JJ\1740 ventricular\NN\1740 (\-LRB-\1740 LV\JJ\1740 )\-RRB-\1740 systolic\JJ\1740 function</e2>\NN\13783581 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 LV\JJ\1740 end-diastolic\JJ\1740 pressure\NN\11419404 .\.\1740
D003042_D018487 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 humans\NNS\31264 ,\,\1740 the\DT\1740 intracoronary\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>cocaine</e1>\NN\3492717 sufficient\JJ\1740 in\IN\13603305 amount\NN\13329641 to\TO\1740 achieve\VB\2524171 a\DT\13649268 high\JJ\1740 drug\NN\14778436 concentration\NN\4916342 in\IN\13603305 coronary\JJ\1740 sinus\NN\5248181 blood\NN\5397468 causes\VBZ\1617192 a\DT\13649268 <e2>deterioration\NN\14560612 of\IN\1740 LV\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 performance</e2>\NN\6619065 .\.\1740
D003042_D002637 NONE METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 In\IN\13603305 20\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 and\CC\1740 6\CD\13741022 women\NNS\9605289 aged\JJ\1740 39\CD\1740 to\TO\1740 72\CD\1740 years\NNS\15144371 )\-RRB-\1740 referred\VBN\730052 for\IN\1740 cardiac\JJ\1740 catheterization\NN\671351 for\IN\1740 the\DT\1740 evaluation\NN\874067 of\IN\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 we\PRP\1740 measured\VBD\697589 heart\NN\5919034 rate\NN\13815152 ,\,\1740 systemic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 ,\,\1740 LV\JJ\1740 pressure\NN\11419404 and\CC\1740 its\PRP$\6125041 first\JJ\1740 derivative\JJ\1740 (\-LRB-\1740 dP/dt\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 LV\JJ\1740 volumes\NNS\33615 and\CC\1740 ejection\NN\45250 fraction\NN\14806838 before\IN\1740 and\CC\1740 during\IN\1740 the\DT\1740 final\JJ\1740 2\CD\13741022 to\TO\1740 3\CD\13741022 minutes\NNS\6502378 of\IN\1740 a\DT\13649268 15-minute\JJ\1740 intracoronary\JJ\1740 infusion\NN\14589223 of\IN\1740 saline\NN\14849367 (\-LRB-\1740 n=10\NN\1740 ,\,\1740 control\JJ\1740 subjects\NNS\6598915 )\-RRB-\1740 or\CC\3541091 <e1>cocaine\NN\3492717 hydrochloride</e1>\NN\14817592 1\CD\13741022 mg/min\NN\1740 (\-LRB-\1740 n=10\NN\1740 )\-RRB-\1740 .\.\1740
24691439
D003907_D012173 NONE Treatment\NN\654885 of\IN\1740 WT\NN\1740 mice\NNS\2329401 with\IN\1740 topical\JJ\1740 ocular\JJ\1740 0.1\CD\1740 %\NN\1740 <e1>dexamethasone</e1>\NN\2721538 led\VBD\1752884 to\TO\1740 elevation\NN\7445480 of\IN\1740 intraocular\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 ,\,\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 loss\NN\13252973 of\IN\1740 <e2>retinal\JJ\1740 ganglion</e2>\NN\5462674 cells\NNS\3080309 ,\,\1740 and\CC\1740 axonal\JJ\1740 degeneration\NN\29677 ,\,\1740 resembling\VBG\2657219 glucocorticoid-induced\JJ\1740 glaucoma\NN\14252864 in\IN\13603305 human\JJ\1740 patients\NNS\9898892 .\.\1740
D003907_D009410 CID Treatment\NN\654885 of\IN\1740 WT\NN\1740 mice\NNS\2329401 with\IN\1740 topical\JJ\1740 ocular\JJ\1740 0.1\CD\1740 %\NN\1740 <e1>dexamethasone</e1>\NN\2721538 led\VBD\1752884 to\TO\1740 elevation\NN\7445480 of\IN\1740 intraocular\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 ,\,\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 loss\NN\13252973 of\IN\1740 retinal\JJ\1740 ganglion\NN\5462674 cells\NNS\3080309 ,\,\1740 and\CC\1740 <e2>axonal\JJ\1740 degeneration</e2>\NN\29677 ,\,\1740 resembling\VBG\2657219 glucocorticoid-induced\JJ\1740 glaucoma\NN\14252864 in\IN\13603305 human\JJ\1740 patients\NNS\9898892 .\.\1740
D003907_D005901 CID Treatment\NN\654885 of\IN\1740 WT\NN\1740 mice\NNS\2329401 with\IN\1740 topical\JJ\1740 ocular\JJ\1740 0.1\CD\1740 %\NN\1740 <e1>dexamethasone</e1>\NN\2721538 led\VBD\1752884 to\TO\1740 elevation\NN\7445480 of\IN\1740 intraocular\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 IOP\NNS\11495041 )\-RRB-\1740 ,\,\1740 functional\JJ\1740 and\CC\1740 structural\JJ\1740 loss\NN\13252973 of\IN\1740 retinal\JJ\1740 ganglion\NN\5462674 cells\NNS\3080309 ,\,\1740 and\CC\1740 axonal\JJ\1740 degeneration\NN\29677 ,\,\1740 resembling\VBG\2657219 glucocorticoid-induced\JJ\1740 <e2>glaucoma</e2>\NN\14252864 in\IN\13603305 human\JJ\1740 patients\NNS\9898892 .\.\1740
D003907_D009798 CID Furthermore\RB\1740 ,\,\1740 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 was\VBD\836236 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 ER\NN\14625458 stress\NN\7083732 of\IN\1740 the\DT\1740 trabecular\JJ\1740 meshwork\NN\3309808 (\-LRB-\1740 TM\NN\14625458 )\-RRB-\1740 .\.\1740
D003907_D009798 CID <e1>Dexamethasone</e1>\NN\2721538 induced\VBD\1627355 the\DT\1740 transcriptional\JJ\1740 factor\NN\7326557 CHOP\NN\11419404 ,\,\1740 a\DT\13649268 marker\NN\21939 for\IN\1740 chronic\JJ\1740 ER\NN\14625458 stress\NN\7083732 ,\,\1740 in\IN\13603305 the\DT\1740 anterior\JJ\1740 segment\NN\3892891 tissues\NNS\5220461 ,\,\1740 and\CC\1740 Chop\NN\11419404 deletion\NN\13508333 reduced\VBD\441445 ER\NN\14625458 stress\NN\7083732 in\IN\13603305 these\DT\1740 tissues\NNS\5220461 and\CC\1740 prevented\VBD\1740 dexamethasone-induced\JJ\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D003907_D009798 CID Dexamethasone\NN\2721538 induced\VBD\1627355 the\DT\1740 transcriptional\JJ\1740 factor\NN\7326557 CHOP\NN\11419404 ,\,\1740 a\DT\13649268 marker\NN\21939 for\IN\1740 chronic\JJ\1740 ER\NN\14625458 stress\NN\7083732 ,\,\1740 in\IN\13603305 the\DT\1740 anterior\JJ\1740 segment\NN\3892891 tissues\NNS\5220461 ,\,\1740 and\CC\1740 Chop\NN\11419404 deletion\NN\13508333 reduced\VBD\441445 ER\NN\14625458 stress\NN\7083732 in\IN\13603305 these\DT\1740 tissues\NNS\5220461 and\CC\1740 prevented\VBD\1740 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D003907_D009798 CID Furthermore\RB\1740 ,\,\1740 reduction\NN\351485 of\IN\1740 ER\NN\14625458 stress\NN\7083732 in\IN\13603305 the\DT\1740 TM\NN\14625458 with\IN\1740 sodium\NN\14625458 4-phenylbutyrate\NN\1740 prevented\VBD\1740 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 WT\NN\1740 mice\NNS\2329401 .\.\1740
C075773_D009798 NONE Furthermore\RB\1740 ,\,\1740 reduction\NN\351485 of\IN\1740 ER\NN\14625458 stress\NN\7083732 in\IN\13603305 the\DT\1740 TM\NN\14625458 with\IN\1740 <e1>sodium\NN\14625458 4-phenylbutyrate</e1>\NN\1740 prevented\VBD\1740 dexamethasone-induced\JJ\1740 <e2>ocular\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 WT\NN\1740 mice\NNS\2329401 .\.\1740
24971338
D020123_D007674 NONE Conversion\NN\7359599 to\TO\1740 <e1>sirolimus</e1>\NN\1740 ameliorates\VBZ\126264 cyclosporine-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 focus\NN\5704266 on\IN\1740 serum\NN\5397468 ,\,\1740 urine\NN\14853947 ,\,\1740 gene\NN\8459252 ,\,\1740 and\CC\1740 protein\NN\14944888 renal\JJ\1740 expression\NN\4679549 biomarkers\NNS\1740 .\.\1740
D020123_D007674 NONE Protocols\NNS\6652242 of\IN\1740 conversion\NN\7359599 from\IN\1740 cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 to\TO\1740 <e1>sirolimus</e1>\NN\1740 (\-LRB-\1740 SRL\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 immunotherapy\NN\661091 after\IN\1740 transplantation\NN\671351 to\TO\1740 prevent\VB\1740 CsA-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 but\CC\1740 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 these\DT\1740 protocols\NNS\6652242 remain\VBP\2604760 nuclear\JJ\1740 .\.\1740
D020123_D007674 NONE Protocols\NNS\6652242 of\IN\1740 conversion\NN\7359599 from\IN\1740 cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 to\TO\1740 sirolimus\NN\1740 (\-LRB-\1740 <e1>SRL</e1>\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 immunotherapy\NN\661091 after\IN\1740 transplantation\NN\671351 to\TO\1740 prevent\VB\1740 CsA-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 but\CC\1740 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 these\DT\1740 protocols\NNS\6652242 remain\VBP\2604760 nuclear\JJ\1740 .\.\1740
D020123_D007674 NONE <e1>SRL-treated</e1>\JJ\1740 rats\NNS\2329401 presented\VBD\2137132 proteinuria\NN\14299637 and\CC\1740 NGAL\NN\1740 (\-LRB-\1740 serum\NN\5397468 and\CC\1740 urinary\JJ\1740 )\-RRB-\1740 as\IN\14622893 the\DT\1740 best\JJS\1740 markers\NNS\21939 of\IN\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 .\.\1740
D020123_D007674 NONE Conversion\NN\7359599 to\TO\1740 <e1>SRL</e1>\NN\1740 prevented\VBD\1740 CsA-induced\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 evolution\NN\29677 (\-LRB-\1740 absent/mild\JJ\1740 grade\NN\7975026 lesions\NNS\14204950 )\-RRB-\1740 ,\,\1740 while\IN\15122231 NGAL\NN\1740 (\-LRB-\1740 serum\NN\5397468 versus\CC\1740 urine\NN\14853947 )\-RRB-\1740 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 feasible\JJ\1740 biomarker\NN\1740 of\IN\1740 CsA\NN\1740 replacement\NN\196485 to\TO\1740 SRL\NNP\1740 .\.\1740
D020123_D007674 NONE Conversion\NN\7359599 to\TO\1740 SRL\NN\1740 prevented\VBD\1740 CsA-induced\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 evolution\NN\29677 (\-LRB-\1740 absent/mild\JJ\1740 grade\NN\7975026 lesions\NNS\14204950 )\-RRB-\1740 ,\,\1740 while\IN\15122231 NGAL\NN\1740 (\-LRB-\1740 serum\NN\5397468 versus\CC\1740 urine\NN\14853947 )\-RRB-\1740 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 feasible\JJ\1740 biomarker\NN\1740 of\IN\1740 CsA\NN\1740 replacement\NN\196485 to\TO\1740 <e1>SRL</e1>\NNP\1740 .\.\1740
D016572_D007674 CID Conversion\NN\7359599 to\TO\1740 sirolimus\NN\1740 ameliorates\VBZ\126264 <e1>cyclosporine-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 focus\NN\5704266 on\IN\1740 serum\NN\5397468 ,\,\1740 urine\NN\14853947 ,\,\1740 gene\NN\8459252 ,\,\1740 and\CC\1740 protein\NN\14944888 renal\JJ\1740 expression\NN\4679549 biomarkers\NNS\1740 .\.\1740
D016572_D007674 CID Protocols\NNS\6652242 of\IN\1740 conversion\NN\7359599 from\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 to\TO\1740 sirolimus\NN\1740 (\-LRB-\1740 SRL\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 immunotherapy\NN\661091 after\IN\1740 transplantation\NN\671351 to\TO\1740 prevent\VB\1740 CsA-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 but\CC\1740 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 these\DT\1740 protocols\NNS\6652242 remain\VBP\2604760 nuclear\JJ\1740 .\.\1740
D016572_D007674 CID Protocols\NNS\6652242 of\IN\1740 conversion\NN\7359599 from\IN\1740 cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 <e1>CsA</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 sirolimus\NN\1740 (\-LRB-\1740 SRL\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 immunotherapy\NN\661091 after\IN\1740 transplantation\NN\671351 to\TO\1740 prevent\VB\1740 CsA-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 but\CC\1740 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 these\DT\1740 protocols\NNS\6652242 remain\VBP\2604760 nuclear\JJ\1740 .\.\1740
D016572_D007674 CID Protocols\NNS\6652242 of\IN\1740 conversion\NN\7359599 from\IN\1740 cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CsA\NN\1740 )\-RRB-\1740 to\TO\1740 sirolimus\NN\1740 (\-LRB-\1740 SRL\NN\1740 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 widely\RB\1740 used\VBN\1156834 in\IN\13603305 immunotherapy\NN\661091 after\IN\1740 transplantation\NN\671351 to\TO\1740 prevent\VB\1740 <e1>CsA-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 but\CC\1740 the\DT\1740 molecular\JJ\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 these\DT\1740 protocols\NNS\6652242 remain\VBP\2604760 nuclear\JJ\1740 .\.\1740
D016572_D007674 CID Short\JJ\1740 <e1>CsA</e1>\NN\1740 treatment\NN\654885 presented\VBD\2137132 slight\JJ\1740 or\CC\3541091 even\RB\1740 absent\JJ\1740 <e2>kidney\NN\5333259 lesions</e2>\NNS\14204950 and\CC\1740 TGF-b\NN\1740 ,\,\1740 NF-\NN\1740 kb\NN\13601596 ,\,\1740 mTOR\NN\1740 ,\,\1740 PCNA\NN\1740 ,\,\1740 TP53\NN\1740 ,\,\1740 KIM-1\NN\1740 ,\,\1740 and\CC\1740 CTGF\NN\1740 as\IN\14622893 relevant\JJ\1740 gene\NN\8459252 and\CC\1740 protein\NN\14944888 changes\NNS\7283608 .\.\1740
D016572_D007674 CID Prolonged\JJ\1740 <e1>CsA</e1>\NN\1740 exposure\NN\5042871 aggravated\VBD\126264 <e2>renal\JJ\1740 damage</e2>\NN\7296428 ,\,\1740 without\IN\1740 clear\JJ\1740 changes\NNS\7283608 on\IN\1740 the\DT\1740 traditional\JJ\1740 markers\NNS\21939 ,\,\1740 but\CC\1740 with\IN\1740 changes\NNS\7283608 in\IN\13603305 serums\NN\5397468 TGF-\NN\1740 b\NN\1355326 and\CC\1740 IL-7\NN\1740 ,\,\1740 TBARs\NNS\1740 clearance\NN\5089947 ,\,\1740 and\CC\1740 kidney\NN\5333259 TGF-b\NN\1740 and\CC\1740 mTOR\NN\1740 .\.\1740
D016572_D007674 CID Conversion\NN\7359599 to\TO\1740 SRL\NN\1740 prevented\VBD\1740 <e1>CsA-induced</e1>\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 evolution\NN\29677 (\-LRB-\1740 absent/mild\JJ\1740 grade\NN\7975026 lesions\NNS\14204950 )\-RRB-\1740 ,\,\1740 while\IN\15122231 NGAL\NN\1740 (\-LRB-\1740 serum\NN\5397468 versus\CC\1740 urine\NN\14853947 )\-RRB-\1740 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 feasible\JJ\1740 biomarker\NN\1740 of\IN\1740 CsA\NN\1740 replacement\NN\196485 to\TO\1740 SRL\NNP\1740 .\.\1740
D016572_D007674 CID Conversion\NN\7359599 to\TO\1740 SRL\NN\1740 prevented\VBD\1740 CsA-induced\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 evolution\NN\29677 (\-LRB-\1740 absent/mild\JJ\1740 grade\NN\7975026 lesions\NNS\14204950 )\-RRB-\1740 ,\,\1740 while\IN\15122231 NGAL\NN\1740 (\-LRB-\1740 serum\NN\5397468 versus\CC\1740 urine\NN\14853947 )\-RRB-\1740 seems\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 feasible\JJ\1740 biomarker\NN\1740 of\IN\1740 <e1>CsA</e1>\NN\1740 replacement\NN\196485 to\TO\1740 SRL\NNP\1740 .\.\1740
D006416_D007674 NONE <e2>Renal\JJ\1740 lesions</e2>\NNS\14204950 were\VBD\836236 analyzed\VBN\78760 in\IN\13603305 <e1>hematoxylin</e1>\NN\1740 and\CC\1740 eosin\NN\14987695 ,\,\1740 periodic\JJ\1740 acid-Schiff\NN\1740 ,\,\1740 and\CC\1740 Masson\NNP\1740 's\POS\1740 trichrome\NN\1740 stains\NNS\4673965 .\.\1740
D004801_D007674 NONE <e2>Renal\JJ\1740 lesions</e2>\NNS\14204950 were\VBD\836236 analyzed\VBN\78760 in\IN\13603305 hematoxylin\NN\1740 and\CC\1740 <e1>eosin</e1>\NN\14987695 ,\,\1740 periodic\JJ\1740 acid-Schiff\NN\1740 ,\,\1740 and\CC\1740 Masson\NNP\1740 's\POS\1740 trichrome\NN\1740 stains\NNS\4673965 .\.\1740
D020123_D011507 CID <e1>SRL-treated</e1>\JJ\1740 rats\NNS\2329401 presented\VBD\2137132 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 NGAL\NN\1740 (\-LRB-\1740 serum\NN\5397468 and\CC\1740 urinary\JJ\1740 )\-RRB-\1740 as\IN\14622893 the\DT\1740 best\JJS\1740 markers\NNS\21939 of\IN\1740 renal\JJ\1740 impairment\NN\7296428 .\.\1740
24671324
C400082_D019115 CID <e2>Necrotising\VBG\1740 fasciitis</e2>\NN\1740 after\IN\1740 <e1>bortezomib</e1>\NN\1740 and\CC\1740 dexamethasone-containing\JJ\1740 regimen\NN\5898568 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 patient\NN\9898892 of\IN\1740 Waldenstrom\NN\1740 macroglobulinaemia\NN\1740 .\.\1740
C400082_D019115 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 with\IN\1740 Waldenstrom\NN\1740 macroglobulinaemia\NN\1740 who\WP\8299493 suffered\VBD\2110220 <e2>necrotising\JJ\1740 fasciitis</e2>\NN\1740 without\IN\1740 neutropenia\NN\14196405 after\IN\1740 the\DT\1740 combination\NN\7951464 treatment\NN\654885 with\IN\1740 <e1>bortezomib</e1>\NN\1740 ,\,\1740 high-dose\JJ\1740 dexamethasone\NN\2721538 and\CC\1740 rituximab\NN\1740 .\.\1740
C400082_D008258 NONE Necrotising\VBG\1740 fasciitis\NN\1740 after\IN\1740 <e1>bortezomib</e1>\NN\1740 and\CC\1740 dexamethasone-containing\JJ\1740 regimen\NN\5898568 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 patient\NN\9898892 of\IN\1740 <e2>Waldenstrom\NN\1740 macroglobulinaemia</e2>\NN\1740 .\.\1740
C400082_D008258 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>Waldenstrom\NN\1740 macroglobulinaemia</e2>\NN\1740 who\WP\8299493 suffered\VBD\2110220 necrotising\JJ\1740 fasciitis\NN\1740 without\IN\1740 neutropenia\NN\14196405 after\IN\1740 the\DT\1740 combination\NN\7951464 treatment\NN\654885 with\IN\1740 <e1>bortezomib</e1>\NN\1740 ,\,\1740 high-dose\JJ\1740 dexamethasone\NN\2721538 and\CC\1740 rituximab\NN\1740 .\.\1740
D003907_D019115 CID <e2>Necrotising\VBG\1740 fasciitis</e2>\NN\1740 after\IN\1740 bortezomib\NN\1740 and\CC\1740 <e1>dexamethasone-containing</e1>\JJ\1740 regimen\NN\5898568 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 patient\NN\9898892 of\IN\1740 Waldenstrom\NN\1740 macroglobulinaemia\NN\1740 .\.\1740
D003907_D019115 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 with\IN\1740 Waldenstrom\NN\1740 macroglobulinaemia\NN\1740 who\WP\8299493 suffered\VBD\2110220 <e2>necrotising\JJ\1740 fasciitis</e2>\NN\1740 without\IN\1740 neutropenia\NN\14196405 after\IN\1740 the\DT\1740 combination\NN\7951464 treatment\NN\654885 with\IN\1740 bortezomib\NN\1740 ,\,\1740 high-dose\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 and\CC\1740 rituximab\NN\1740 .\.\1740
D003907_D008258 NONE Necrotising\VBG\1740 fasciitis\NN\1740 after\IN\1740 bortezomib\NN\1740 and\CC\1740 <e1>dexamethasone-containing</e1>\JJ\1740 regimen\NN\5898568 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 patient\NN\9898892 of\IN\1740 <e2>Waldenstrom\NN\1740 macroglobulinaemia</e2>\NN\1740 .\.\1740
D003907_D008258 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>Waldenstrom\NN\1740 macroglobulinaemia</e2>\NN\1740 who\WP\8299493 suffered\VBD\2110220 necrotising\JJ\1740 fasciitis\NN\1740 without\IN\1740 neutropenia\NN\14196405 after\IN\1740 the\DT\1740 combination\NN\7951464 treatment\NN\654885 with\IN\1740 bortezomib\NN\1740 ,\,\1740 high-dose\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 and\CC\1740 rituximab\NN\1740 .\.\1740
C400082_D001424 NONE <e1>Bortezomib</e1>\NNP\1740 and\CC\1740 high-dose\JJ\1740 dexamethasone-containing\JJ\1740 regimens\NNS\5898568 are\VBP\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 generally\RB\1740 tolerable\JJ\1740 with\IN\1740 few\JJ\1740 severe\JJ\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 B-cell\NN\1740 malignancies\NNS\14070360 .\.\1740
C400082_D001424 NONE Physicians\NNS\10305802 should\MD\1740 recognise\VB\2256109 the\DT\1740 possibility\NN\5944958 of\IN\1740 fatal\JJ\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 related\VBN\628491 to\TO\1740 <e1>bortezomib</e1>\NN\1740 plus\CC\4723816 high-dose\JJ\1740 dexamethasone\NN\2721538 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 we\PRP\1740 believe\VBP\686447 this\DT\1740 case\NN\7283608 warrants\VBZ\1012073 further\JJ\1740 investigation\NN\5797597 .\.\1740
C400082_D009369 NONE <e1>Bortezomib</e1>\NNP\1740 and\CC\1740 high-dose\JJ\1740 dexamethasone-containing\JJ\1740 regimens\NNS\5898568 are\VBP\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 generally\RB\1740 tolerable\JJ\1740 with\IN\1740 few\JJ\1740 severe\JJ\1740 bacterial\JJ\1740 infections\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 B-cell\NN\1740 <e2>malignancies</e2>\NNS\14070360 .\.\1740
D003907_D001424 NONE Bortezomib\NNP\1740 and\CC\1740 high-dose\JJ\1740 <e1>dexamethasone-containing</e1>\JJ\1740 regimens\NNS\5898568 are\VBP\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 generally\RB\1740 tolerable\JJ\1740 with\IN\1740 few\JJ\1740 severe\JJ\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 B-cell\NN\1740 malignancies\NNS\14070360 .\.\1740
D003907_D001424 NONE Physicians\NNS\10305802 should\MD\1740 recognise\VB\2256109 the\DT\1740 possibility\NN\5944958 of\IN\1740 fatal\JJ\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 related\VBN\628491 to\TO\1740 bortezomib\NN\1740 plus\CC\4723816 high-dose\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 we\PRP\1740 believe\VBP\686447 this\DT\1740 case\NN\7283608 warrants\VBZ\1012073 further\JJ\1740 investigation\NN\5797597 .\.\1740
D003907_D009369 NONE Bortezomib\NNP\1740 and\CC\1740 high-dose\JJ\1740 <e1>dexamethasone-containing</e1>\JJ\1740 regimens\NNS\5898568 are\VBP\836236 considered\VBN\689344 to\TO\1740 be\VB\836236 generally\RB\1740 tolerable\JJ\1740 with\IN\1740 few\JJ\1740 severe\JJ\1740 bacterial\JJ\1740 infections\NNS\14052046 in\IN\13603305 patients\NNS\9898892 with\IN\1740 B-cell\NN\1740 <e2>malignancies</e2>\NNS\14070360 .\.\1740
C400082_D009503 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 with\IN\1740 Waldenstrom\NN\1740 macroglobulinaemia\NN\1740 who\WP\8299493 suffered\VBD\2110220 necrotising\JJ\1740 fasciitis\NN\1740 without\IN\1740 <e2>neutropenia</e2>\NN\14196405 after\IN\1740 the\DT\1740 combination\NN\7951464 treatment\NN\654885 with\IN\1740 <e1>bortezomib</e1>\NN\1740 ,\,\1740 high-dose\JJ\1740 dexamethasone\NN\2721538 and\CC\1740 rituximab\NN\1740 .\.\1740
D003907_D009503 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 with\IN\1740 Waldenstrom\NN\1740 macroglobulinaemia\NN\1740 who\WP\8299493 suffered\VBD\2110220 necrotising\JJ\1740 fasciitis\NN\1740 without\IN\1740 <e2>neutropenia</e2>\NN\14196405 after\IN\1740 the\DT\1740 combination\NN\7951464 treatment\NN\654885 with\IN\1740 bortezomib\NN\1740 ,\,\1740 high-dose\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 and\CC\1740 rituximab\NN\1740 .\.\1740
16801510
D008691_D008133 CID Drug-induced\JJ\1740 <e2>long\JJ\1740 QT\NN\1740 syndrome</e2>\NN\5870365 in\IN\13603305 injection\NN\320852 drug\NN\14778436 users\NNS\7846 receiving\VBG\2210855 <e1>methadone</e1>\NN\3808564 :\:\1740 high\JJ\1740 frequency\NN\15286249 in\IN\13603305 hospitalized\VBN\2348568 patients\NNS\9898892 and\CC\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
D008691_D008133 CID In\IN\13603305 the\DT\1740 inpatient\JJ\1740 setting\NN\8567235 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>QT\NN\1740 interval\NN\33615 prolongation</e2>\NN\1017987 with\IN\1740 <e1>methadone</e1>\NN\3808564 treatment\NN\654885 ,\,\1740 its\PRP$\6125041 dose\NN\3740161 dependence\NN\24720 ,\,\1740 and\CC\1740 the\DT\1740 importance\NN\5138488 of\IN\1740 cofactors\NNS\14818238 such\JJ\1740 as\IN\14622893 drug-drug\JJ\1740 interactions\NNS\37396 remain\VBP\2604760 unknown\JJ\1740 .\.\1740
D008691_D008133 CID In\IN\13603305 addition\NN\3081021 to\TO\1740 <e1>methadone</e1>\NN\3808564 dose\NN\3740161 ,\,\1740 15\CD\13745420 demographic\JJ\1740 ,\,\1740 biological\JJ\1740 ,\,\1740 and\CC\1740 pharmacological\JJ\1740 variables\NNS\2452 were\VBD\836236 considered\VBN\689344 as\IN\14622893 potential\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 .\.\1740
D008691_D008133 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e2>QT\NN\1740 interval\NN\33615 prolongation</e2>\NN\1017987 in\IN\13603305 <e1>methadone</e1>\NN\3808564 maintenance\NN\266806 patients\NNS\9898892 hospitalized\VBN\2348568 in\IN\13603305 a\DT\13649268 tertiary\JJ\1740 care\NN\575741 center\NN\8497294 is\VBZ\836236 a\DT\13649268 frequent\JJ\1740 finding\NN\43195 .\.\1740
D008691_D008133 CID <e1>Methadone</e1>\NN\3808564 dose\NN\3740161 ,\,\1740 presence\NN\13954253 of\IN\1740 cytochrome\NN\14888884 P-450\NN\1740 3A4\NN\1740 inhibitors\NNS\20090 ,\,\1740 potassium\NN\14625458 level\NN\4916342 ,\,\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 contribute\VBP\126264 to\TO\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 .\.\1740
D008691_D008133 CID <e2>Long\JJ\1740 QT\NN\1740 syndrome</e2>\NN\5870365 can\MD\3094503 occur\VB\2623529 with\IN\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>methadone</e1>\NN\3808564 .\.\1740
D008691_D016171 NONE Six\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 3.6\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>methadone</e1>\NN\3808564 group\NN\2137 presented\VBD\2137132 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 .\.\1740
D008691_D007008 NONE Multivariate\JJ\1740 regression\NN\14501726 analysis\NN\633864 allowed\VBD\797697 attribution\NN\5732756 of\IN\1740 31.8\CD\1740 %\NN\1740 of\IN\1740 QTc\NN\1740 variability\NN\4733640 to\TO\1740 <e1>methadone</e1>\NN\3808564 dose\NN\3740161 ,\,\1740 cytochrome\NN\14888884 P-450\NN\1740 3A4\NN\1740 drug-drug\NN\1740 interactions\NNS\37396 ,\,\1740 <e2>hypokalemia</e2>\NN\14299637 ,\,\1740 and\CC\1740 altered\JJ\1740 liver\NN\5298729 function\NN\13783581 .\.\1740
D011188_D008133 NONE Methadone\NN\3808564 dose\NN\3740161 ,\,\1740 presence\NN\13954253 of\IN\1740 cytochrome\NN\14888884 P-450\NN\1740 3A4\NN\1740 inhibitors\NNS\20090 ,\,\1740 <e1>potassium</e1>\NN\14625458 level\NN\4916342 ,\,\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 contribute\VBP\126264 to\TO\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 .\.\1740
24158386
C056507_D006689 NONE <e1>GEM-P</e1>\NN\1740 chemotherapy\NN\661091 is\VBZ\836236 active\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 relapsed\JJ\1740 <e2>Hodgkin\NN\1740 lymphoma</e2>\NN\14239918 .\.\1740
C056507_D006689 NONE <e1>Gemcitabine</e1>\NN\1740 and\CC\1740 cisplatin\NN\1740 have\VBP\2108377 activity\NN\30358 in\IN\13603305 <e2>HL</e2>\NN\13616054 ,\,\1740 non-overlapping\JJ\1740 toxicity\NN\13576101 with\IN\1740 first-line\JJ\1740 chemotherapeutics\NNS\1740 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 delivered\VBN\941990 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 setting\NN\8567235 .\.\1740
C056507_D006689 NONE In\IN\13603305 this\DT\1740 retrospective\JJ\1740 single-centre\JJ\1740 analysis\NN\633864 ,\,\1740 patients\NNS\9898892 with\IN\1740 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 <e2>HL</e2>\NN\13616054 treated\VBN\2376958 with\IN\1740 <e1>gemcitabine</e1>\NN\1740 1,000\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 day\NN\15154774 (D)1\-LRB-\1740 ,\,\1740 D8\NN\1740 and\CC\1740 D15\NN\1740 ;\:\1740 methylprednisolone\NN\1740 1,000\CD\1740 mg\NN\13717155 D1\NN\1740 -\HYPH\1740 5\CD\13741022 ;\:\1740 and\CC\1740 cisplatin\NN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 D15\NN\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 GEM-P\NN\1740 )\-RRB-\1740 were\VBD\836236 included\VBN\690614 .\.\1740
C056507_D006689 NONE In\IN\13603305 this\DT\1740 retrospective\JJ\1740 single-centre\JJ\1740 analysis\NN\633864 ,\,\1740 patients\NNS\9898892 with\IN\1740 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 <e2>HL</e2>\NN\13616054 treated\VBN\2376958 with\IN\1740 gemcitabine\NN\1740 1,000\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 day\NN\15154774 (D)1\-LRB-\1740 ,\,\1740 D8\NN\1740 and\CC\1740 D15\NN\1740 ;\:\1740 methylprednisolone\NN\1740 1,000\CD\1740 mg\NN\13717155 D1\NN\1740 -\HYPH\1740 5\CD\13741022 ;\:\1740 and\CC\1740 cisplatin\NN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 D15\NN\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 <e1>GEM-P</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 included\VBN\690614 .\.\1740
C056507_D006689 NONE <e1>GEM-P</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 salvage\JJ\1740 chemotherapy\NN\661091 with\IN\1740 relatively\RB\1740 high\JJ\1740 response\NN\11410625 rates\NNS\13308999 ,\,\1740 leading\VBG\1752884 to\TO\1740 successful\JJ\1740 transplantation\NN\671351 in\IN\13603305 appropriate\JJ\1740 patients\NNS\9898892 ,\,\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 <e2>HL</e2>\NN\13616054 .\.\1740
C056507_D064420 NONE <e1>Gemcitabine</e1>\NN\1740 and\CC\1740 cisplatin\NN\1740 have\VBP\2108377 activity\NN\30358 in\IN\13603305 HL\NN\13616054 ,\,\1740 non-overlapping\JJ\1740 <e2>toxicity</e2>\NN\13576101 with\IN\1740 first-line\JJ\1740 chemotherapeutics\NNS\1740 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 delivered\VBN\941990 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 setting\NN\8567235 .\.\1740
D002945_D006689 NONE Gemcitabine\NN\1740 and\CC\1740 <e1>cisplatin</e1>\NN\1740 have\VBP\2108377 activity\NN\30358 in\IN\13603305 <e2>HL</e2>\NN\13616054 ,\,\1740 non-overlapping\JJ\1740 toxicity\NN\13576101 with\IN\1740 first-line\JJ\1740 chemotherapeutics\NNS\1740 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 delivered\VBN\941990 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 setting\NN\8567235 .\.\1740
D002945_D006689 NONE In\IN\13603305 this\DT\1740 retrospective\JJ\1740 single-centre\JJ\1740 analysis\NN\633864 ,\,\1740 patients\NNS\9898892 with\IN\1740 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 <e2>HL</e2>\NN\13616054 treated\VBN\2376958 with\IN\1740 gemcitabine\NN\1740 1,000\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 day\NN\15154774 (D)1\-LRB-\1740 ,\,\1740 D8\NN\1740 and\CC\1740 D15\NN\1740 ;\:\1740 methylprednisolone\NN\1740 1,000\CD\1740 mg\NN\13717155 D1\NN\1740 -\HYPH\1740 5\CD\13741022 ;\:\1740 and\CC\1740 <e1>cisplatin</e1>\NN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 D15\NN\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 GEM-P\NN\1740 )\-RRB-\1740 were\VBD\836236 included\VBN\690614 .\.\1740
D002945_D064420 NONE Gemcitabine\NN\1740 and\CC\1740 <e1>cisplatin</e1>\NN\1740 have\VBP\2108377 activity\NN\30358 in\IN\13603305 HL\NN\13616054 ,\,\1740 non-overlapping\JJ\1740 <e2>toxicity</e2>\NN\13576101 with\IN\1740 first-line\JJ\1740 chemotherapeutics\NNS\1740 ,\,\1740 and\CC\1740 may\MD\15209706 be\VB\836236 delivered\VBN\941990 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 setting\NN\8567235 .\.\1740
D008775_D006689 NONE In\IN\13603305 this\DT\1740 retrospective\JJ\1740 single-centre\JJ\1740 analysis\NN\633864 ,\,\1740 patients\NNS\9898892 with\IN\1740 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 <e2>HL</e2>\NN\13616054 treated\VBN\2376958 with\IN\1740 gemcitabine\NN\1740 1,000\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 day\NN\15154774 (D)1\-LRB-\1740 ,\,\1740 D8\NN\1740 and\CC\1740 D15\NN\1740 ;\:\1740 <e1>methylprednisolone</e1>\NN\1740 1,000\CD\1740 mg\NN\13717155 D1\NN\1740 -\HYPH\1740 5\CD\13741022 ;\:\1740 and\CC\1740 cisplatin\NN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 D15\NN\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 (\-LRB-\1740 GEM-P\NN\1740 )\-RRB-\1740 were\VBD\836236 included\VBN\690614 .\.\1740
2931989
D015474_D000152 NONE A\DT\13649268 total\NN\3553 of\IN\1740 261\CD\1740 adverse\JJ\1740 ocular\JJ\1740 reactions\NNS\13446390 occurred\VBD\2623529 in\IN\13603305 237\CD\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>isotretinoin</e1>\NN\1740 ,\,\1740 a\DT\13649268 commonly\RB\1740 used\VBN\1156834 drug\NN\14778436 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 severe\JJ\1740 cystic\JJ\1740 <e2>acne</e2>\NN\14171682 .\.\1740
D015474_D000013 NONE <e1>Isotretinoin</e1>\NN\1740 is\VBZ\836236 contraindicated\VBN\872886 in\IN\13603305 pregnancy\NN\14034177 because\IN\1740 of\IN\1740 the\DT\1740 many\JJ\1740 reported\VBN\831651 <e2>congenital\JJ\1740 abnormalities</e2>\NNS\14034177 after\IN\1740 maternal\JJ\1740 use\NN\407535 (\-LRB-\1740 including\VBG\690614 microphthalmos\NN\1740 ,\,\1740 orbital\JJ\1740 hypertelorism\NN\1740 ,\,\1740 and\CC\1740 optic\JJ\1740 nerve\NN\5475681 hypoplasia\NN\14365950 )\-RRB-\1740 .\.\1740
D015474_D008850 NONE <e1>Isotretinoin</e1>\NN\1740 is\VBZ\836236 contraindicated\VBN\872886 in\IN\13603305 pregnancy\NN\14034177 because\IN\1740 of\IN\1740 the\DT\1740 many\JJ\1740 reported\VBN\831651 congenital\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 maternal\JJ\1740 use\NN\407535 (\-LRB-\1740 including\VBG\690614 <e2>microphthalmos</e2>\NN\1740 ,\,\1740 orbital\JJ\1740 hypertelorism\NN\1740 ,\,\1740 and\CC\1740 optic\JJ\1740 nerve\NN\5475681 hypoplasia\NN\14365950 )\-RRB-\1740 .\.\1740
D015474_D006972 NONE <e1>Isotretinoin</e1>\NN\1740 is\VBZ\836236 contraindicated\VBN\872886 in\IN\13603305 pregnancy\NN\14034177 because\IN\1740 of\IN\1740 the\DT\1740 many\JJ\1740 reported\VBN\831651 congenital\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 maternal\JJ\1740 use\NN\407535 (\-LRB-\1740 including\VBG\690614 microphthalmos\NN\1740 ,\,\1740 orbital\JJ\1740 <e2>hypertelorism</e2>\NN\1740 ,\,\1740 and\CC\1740 optic\JJ\1740 nerve\NN\5475681 hypoplasia\NN\14365950 )\-RRB-\1740 .\.\1740
D015474_C563492 NONE <e1>Isotretinoin</e1>\NN\1740 is\VBZ\836236 contraindicated\VBN\872886 in\IN\13603305 pregnancy\NN\14034177 because\IN\1740 of\IN\1740 the\DT\1740 many\JJ\1740 reported\VBN\831651 congenital\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 maternal\JJ\1740 use\NN\407535 (\-LRB-\1740 including\VBG\690614 microphthalmos\NN\1740 ,\,\1740 orbital\JJ\1740 hypertelorism\NN\1740 ,\,\1740 and\CC\1740 <e2>optic\JJ\1740 nerve\NN\5475681 hypoplasia</e2>\NN\14365950 )\-RRB-\1740 .\.\1740
18987260
D004317_D007674 NONE Reduced\VBN\441445 progression\NN\8457976 of\IN\1740 <e1>adriamycin</e1>\NN\1740 <e2>nephropathy</e2>\JJ\1740 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 treated\VBN\2376958 by\IN\1740 losartan\NN\1740 .\.\1740
D004317_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D004317_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D004317_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 <e1>ADR</e1>\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D004317_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 <e1>ADR</e1>\NN\1740 )\-RRB-\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D004317_D007674 NONE Losartan\NNP\1740 reduced\VBD\441445 uraemia\NN\14204950 and\CC\1740 increased\VBN\169651 urea\NN\14727670 clearance\NN\5089947 in\IN\13603305 advanced\JJ\1740 <e1>ADR</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 SHR\NN\1740 .\.\1740
D004317_D007674 NONE Histological\JJ\1740 examination\NN\633864 showed\VBD\2137132 that\IN\1740 losartan\NN\1740 could\MD\1740 prevent\VB\1740 tubular\JJ\1740 atrophy\NN\14299637 ,\,\1740 interstitial\JJ\1740 infiltration\NN\975452 and\CC\1740 fibrosis\NN\14204950 in\IN\13603305 <e1>ADR</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D004317_D006973 NONE Reduced\VBN\441445 progression\NN\8457976 of\IN\1740 <e1>adriamycin</e1>\NN\1740 nephropathy\JJ\1740 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 treated\VBN\2376958 by\IN\1740 losartan\NN\1740 .\.\1740
D004317_D006973 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D004317_D006973 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 <e1>ADR</e1>\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D019808_D007674 NONE Reduced\VBN\441445 progression\NN\8457976 of\IN\1740 adriamycin\NN\1740 <e2>nephropathy</e2>\JJ\1740 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 treated\VBN\2376958 by\IN\1740 <e1>losartan</e1>\NN\1740 .\.\1740
D019808_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 <e1>losartan</e1>\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D019808_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 <e1>losartan</e1>\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D019808_D007674 NONE <e1>Losartan</e1>\NNP\1740 reduced\VBD\441445 uraemia\NN\14204950 and\CC\1740 increased\VBN\169651 urea\NN\14727670 clearance\NN\5089947 in\IN\13603305 advanced\JJ\1740 ADR\NN\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 SHR\NN\1740 .\.\1740
D019808_D007674 NONE Histological\JJ\1740 examination\NN\633864 showed\VBD\2137132 that\IN\1740 <e1>losartan</e1>\NN\1740 could\MD\1740 prevent\VB\1740 tubular\JJ\1740 atrophy\NN\14299637 ,\,\1740 interstitial\JJ\1740 infiltration\NN\975452 and\CC\1740 fibrosis\NN\14204950 in\IN\13603305 ADR\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D019808_D006973 NONE Reduced\VBN\441445 progression\NN\8457976 of\IN\1740 adriamycin\NN\1740 nephropathy\JJ\1740 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 treated\VBN\2376958 by\IN\1740 <e1>losartan</e1>\NN\1740 .\.\1740
D019808_D006973 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 angiotensin\NN\4522421 II\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 <e1>losartan</e1>\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D000804_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D000804_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 <e2>nephropathy</e2>\RB\1740 .\.\1740
D000804_D006973 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 antihypertensive\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 type-1\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 losartan\RB\1740 ,\,\1740 and\CC\1740 its\PRP$\6125041 potential\NN\14481929 in\IN\13603305 slowing\VBG\151689 down\RP\1740 renal\JJ\1740 disease\NN\14061805 progression\NN\8457976 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 with\IN\1740 adriamycin\NN\1740 (\-LRB-\1740 ADR\NN\1740 )\-RRB-\1740 nephropathy\RB\1740 .\.\1740
D019808_D005921 NONE RESULTS\NNS\34213 :\:\1740 Short-term\JJ\1740 <e1>losartan</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 besides\IN\1740 antihypertensive\JJ\1740 effect\NN\34213 ,\,\1740 improved\VBD\126264 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 and\CC\1740 ameliorated\VBD\126264 <e2>glomerulosclerosis</e2>\NN\1740 resulting\VBG\2633881 in\IN\13603305 decreased\VBN\169651 proteinuria\NN\14299637 .\.\1740
D019808_D005921 NONE Prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>losartan</e1>\NN\1740 showed\VBD\2137132 further\JJ\1740 reduction\NN\351485 of\IN\1740 <e2>glomerulosclerosis</e2>\NN\1740 associated\VBN\628491 with\IN\1740 reduced\VBN\441445 progression\NN\8457976 of\IN\1740 tubular\JJ\1740 atrophy\NN\14299637 and\CC\1740 interstitial\JJ\1740 fibrosis\NN\14204950 ,\,\1740 thus\RB\1740 preventing\VBG\1740 heavy\JJ\1740 proteinuria\NN\14299637 and\CC\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D019808_D011507 NONE RESULTS\NNS\34213 :\:\1740 Short-term\JJ\1740 <e1>losartan</e1>\JJ\1740 treatment\NN\654885 ,\,\1740 besides\IN\1740 antihypertensive\JJ\1740 effect\NN\34213 ,\,\1740 improved\VBD\126264 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 and\CC\1740 ameliorated\VBD\126264 glomerulosclerosis\NN\1740 resulting\VBG\2633881 in\IN\13603305 decreased\VBN\169651 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D019808_D011507 NONE Prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>losartan</e1>\NN\1740 showed\VBD\2137132 further\JJ\1740 reduction\NN\351485 of\IN\1740 glomerulosclerosis\NN\1740 associated\VBN\628491 with\IN\1740 reduced\VBN\441445 progression\NN\8457976 of\IN\1740 tubular\JJ\1740 atrophy\NN\14299637 and\CC\1740 interstitial\JJ\1740 fibrosis\NN\14204950 ,\,\1740 thus\RB\1740 preventing\VBG\1740 heavy\JJ\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D019808_D001284 NONE Prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>losartan</e1>\NN\1740 showed\VBD\2137132 further\JJ\1740 reduction\NN\351485 of\IN\1740 glomerulosclerosis\NN\1740 associated\VBN\628491 with\IN\1740 reduced\VBN\441445 progression\NN\8457976 of\IN\1740 tubular\JJ\1740 <e2>atrophy</e2>\NN\14299637 and\CC\1740 interstitial\JJ\1740 fibrosis\NN\14204950 ,\,\1740 thus\RB\1740 preventing\VBG\1740 heavy\JJ\1740 proteinuria\NN\14299637 and\CC\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D019808_D001284 NONE Histological\JJ\1740 examination\NN\633864 showed\VBD\2137132 that\IN\1740 <e1>losartan</e1>\NN\1740 could\MD\1740 prevent\VB\1740 tubular\JJ\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 interstitial\JJ\1740 infiltration\NN\975452 and\CC\1740 fibrosis\NN\14204950 in\IN\13603305 ADR\NN\1740 nephropathy\NN\14573196 .\.\1740
D019808_D005355 NONE Prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>losartan</e1>\NN\1740 showed\VBD\2137132 further\JJ\1740 reduction\NN\351485 of\IN\1740 glomerulosclerosis\NN\1740 associated\VBN\628491 with\IN\1740 reduced\VBN\441445 progression\NN\8457976 of\IN\1740 tubular\JJ\1740 atrophy\NN\14299637 and\CC\1740 <e2>interstitial\JJ\1740 fibrosis</e2>\NN\14204950 ,\,\1740 thus\RB\1740 preventing\VBG\1740 heavy\JJ\1740 proteinuria\NN\14299637 and\CC\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D019808_D005355 NONE Histological\JJ\1740 examination\NN\633864 showed\VBD\2137132 that\IN\1740 <e1>losartan</e1>\NN\1740 could\MD\1740 prevent\VB\1740 tubular\JJ\1740 atrophy\NN\14299637 ,\,\1740 interstitial\JJ\1740 infiltration\NN\975452 and\CC\1740 <e2>fibrosis</e2>\NN\14204950 in\IN\13603305 ADR\NN\1740 nephropathy\NN\14573196 .\.\1740
D019808_D007676 NONE Prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>losartan</e1>\NN\1740 showed\VBD\2137132 further\JJ\1740 reduction\NN\351485 of\IN\1740 glomerulosclerosis\NN\1740 associated\VBN\628491 with\IN\1740 reduced\VBN\441445 progression\NN\8457976 of\IN\1740 tubular\JJ\1740 atrophy\NN\14299637 and\CC\1740 interstitial\JJ\1740 fibrosis\NN\14204950 ,\,\1740 thus\RB\1740 preventing\VBG\1740 heavy\JJ\1740 proteinuria\NN\14299637 and\CC\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D019808_D007676 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Losartan</e1>\NNP\1740 reduces\VBZ\441445 the\DT\1740 rate\NN\13815152 of\IN\1740 progression\NN\8457976 of\IN\1740 ADR-induced\JJ\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 to\TO\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 in\IN\13603305 SHR\NN\1740 .\.\1740
D019808_D014511 NONE <e1>Losartan</e1>\NNP\1740 reduced\VBD\441445 <e2>uraemia</e2>\NN\14204950 and\CC\1740 increased\VBN\169651 urea\NN\14727670 clearance\NN\5089947 in\IN\13603305 advanced\JJ\1740 ADR\NN\1740 nephropathy\NN\14573196 in\IN\13603305 SHR\NN\1740 .\.\1740
D014508_D014511 NONE Losartan\NNP\1740 reduced\VBD\441445 <e2>uraemia</e2>\NN\14204950 and\CC\1740 increased\VBN\169651 <e1>urea</e1>\NN\14727670 clearance\NN\5089947 in\IN\13603305 advanced\JJ\1740 ADR\NN\1740 nephropathy\NN\14573196 in\IN\13603305 SHR\NN\1740 .\.\1740
D014508_D007674 NONE Losartan\NNP\1740 reduced\VBD\441445 uraemia\NN\14204950 and\CC\1740 increased\VBN\169651 <e1>urea</e1>\NN\14727670 clearance\NN\5089947 in\IN\13603305 advanced\JJ\1740 ADR\NN\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 SHR\NN\1740 .\.\1740
D004317_D014511 CID Losartan\NNP\1740 reduced\VBD\441445 <e2>uraemia</e2>\NN\14204950 and\CC\1740 increased\VBN\169651 urea\NN\14727670 clearance\NN\5089947 in\IN\13603305 advanced\JJ\1740 <e1>ADR</e1>\NN\1740 nephropathy\NN\14573196 in\IN\13603305 SHR\NN\1740 .\.\1740
D004317_D001284 NONE Histological\JJ\1740 examination\NN\633864 showed\VBD\2137132 that\IN\1740 losartan\NN\1740 could\MD\1740 prevent\VB\1740 tubular\JJ\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 interstitial\JJ\1740 infiltration\NN\975452 and\CC\1740 fibrosis\NN\14204950 in\IN\13603305 <e1>ADR</e1>\NN\1740 nephropathy\NN\14573196 .\.\1740
D004317_D005355 NONE Histological\JJ\1740 examination\NN\633864 showed\VBD\2137132 that\IN\1740 losartan\NN\1740 could\MD\1740 prevent\VB\1740 tubular\JJ\1740 atrophy\NN\14299637 ,\,\1740 interstitial\JJ\1740 infiltration\NN\975452 and\CC\1740 <e2>fibrosis</e2>\NN\14204950 in\IN\13603305 <e1>ADR</e1>\NN\1740 nephropathy\NN\14573196 .\.\1740
D019808_D005923 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Losartan</e1>\NNP\1740 reduces\VBZ\441445 the\DT\1740 rate\NN\13815152 of\IN\1740 progression\NN\8457976 of\IN\1740 ADR-induced\JJ\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis</e2>\NN\1740 to\TO\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 in\IN\13603305 SHR\NN\1740 .\.\1740
D004317_D005923 CID CONCLUSION\NN\5837957 :\:\1740 Losartan\NNP\1740 reduces\VBZ\441445 the\DT\1740 rate\NN\13815152 of\IN\1740 progression\NN\8457976 of\IN\1740 <e1>ADR-induced</e1>\JJ\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis</e2>\NN\1740 to\TO\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 in\IN\13603305 SHR\NN\1740 .\.\1740
D004317_D007676 NONE CONCLUSION\NN\5837957 :\:\1740 Losartan\NNP\1740 reduces\VBZ\441445 the\DT\1740 rate\NN\13815152 of\IN\1740 progression\NN\8457976 of\IN\1740 <e1>ADR-induced</e1>\JJ\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 to\TO\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 in\IN\13603305 SHR\NN\1740 .\.\1740
1522360
D012293_D006461 CID Intravascular\JJ\1740 <e2>hemolysis</e2>\NN\13509528 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 intermittent\JJ\1740 <e1>rifampin</e1>\NN\2716205 therapy\NN\657604 .\.\1740
D012293_D006461 CID Intravascular\JJ\1740 <e2>hemolysis</e2>\NN\13509528 leading\VBG\1752884 to\TO\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 <e1>rifampin</e1>\NN\2716205 therapy\NN\657604 is\VBZ\836236 extremely\RB\1740 rare\JJ\1740 .\.\1740
D012293_D006461 CID Two\CD\13741022 patients\NNS\9898892 with\IN\1740 leprosy\NN\14127211 who\WP\8299493 developed\VBD\1753788 <e2>hemolysis</e2>\NN\13509528 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 <e1>rifampin</e1>\NN\2716205 are\VBP\836236 reported\VBN\831651 .\.\1740
D012293_D058186 CID Intravascular\JJ\1740 hemolysis\NN\13509528 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 intermittent\JJ\1740 <e1>rifampin</e1>\NN\2716205 therapy\NN\657604 .\.\1740
D012293_D058186 CID Intravascular\JJ\1740 hemolysis\NN\13509528 leading\VBG\1752884 to\TO\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 <e1>rifampin</e1>\NN\2716205 therapy\NN\657604 is\VBZ\836236 extremely\RB\1740 rare\JJ\1740 .\.\1740
D012293_D058186 CID Two\CD\13741022 patients\NNS\9898892 with\IN\1740 leprosy\NN\14127211 who\WP\8299493 developed\VBD\1753788 hemolysis\NN\13509528 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 <e1>rifampin</e1>\NN\2716205 are\VBP\836236 reported\VBN\831651 .\.\1740
D012293_D051437 NONE <e2>Renal\JJ\1740 failure</e2>\NN\66216 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>rifampin</e1>\NN\2716205 .\.\1740
D012293_D007918 NONE Two\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>leprosy</e2>\NN\14127211 who\WP\8299493 developed\VBD\1753788 hemolysis\NN\13509528 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 <e1>rifampin</e1>\NN\2716205 are\VBP\836236 reported\VBN\831651 .\.\1740
24283660
D016559_D012640 CID <e1>Tacrolimus-related</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 after\IN\1740 pediatric\JJ\1740 liver\NN\5298729 transplantation\NN\671351 --\:\1740 a\DT\13649268 single-center\NN\1740 experience\NN\5984287 .\.\1740
D016559_D012640 CID Univariate\NN\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 risk\NN\14541044 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 pediatric\JJ\1740 LT\NN\1740 included\VBD\690614 gender\NN\6309383 ,\,\1740 pediatric\JJ\1740 end-stage\JJ\1740 liver\NN\5298729 disease\NN\14061805 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 Child-Pugh\JJ\1740 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 serum\NN\5397468 total\JJ\1740 bilirubin\NN\14756039 after\IN\1740 surgery\NN\6045562 ,\,\1740 and\CC\1740 trough\NN\9366017 <e1>TAC</e1>\NN\1740 level\NN\4916342 .\.\1740
D016559_D012640 CID Multivariate\JJ\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 trough\NN\9366017 <e1>TAC</e1>\NN\1740 level\NN\4916342 was\VBD\836236 the\DT\1740 only\JJ\1740 independent\JJ\1740 risk\NN\14541044 factor\NN\7326557 associated\VBN\628491 with\IN\1740 the\DT\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D016559_D012640 CID High\JJ\1740 trough\NN\9366017 <e1>TAC</e1>\NN\1740 level\NN\4916342 was\VBD\836236 the\DT\1740 predominant\JJ\1740 factor\NN\7326557 that\WDT\1740 contributed\VBD\126264 to\TO\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 the\DT\1740 early\JJ\1740 post-operative\JJ\1740 period\NN\13575869 after\IN\1740 pediatric\JJ\1740 LT\NN\1740 .\.\1740
D016559_D012640 CID High\JJ\1740 PELD\NN\1740 and\CC\1740 Child-Pugh\JJ\1740 scores\NNS\13757724 before\IN\1740 LT\NN\1740 and\CC\1740 high\JJ\1740 post-operative\JJ\1740 serum\NN\5397468 Tbil\NN\1740 may\MD\15209706 be\VB\836236 contributory\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e1>TAC-related</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D001663_D012640 NONE Univariate\NN\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 risk\NN\14541044 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 pediatric\JJ\1740 LT\NN\1740 included\VBD\690614 gender\NN\6309383 ,\,\1740 pediatric\JJ\1740 end-stage\JJ\1740 liver\NN\5298729 disease\NN\14061805 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 Child-Pugh\JJ\1740 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 serum\NN\5397468 total\JJ\1740 <e1>bilirubin</e1>\NN\14756039 after\IN\1740 surgery\NN\6045562 ,\,\1740 and\CC\1740 trough\NN\9366017 TAC\NN\1740 level\NN\4916342 .\.\1740
D001663_D058625 NONE Univariate\NN\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 risk\NN\14541044 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 seizures\NNS\14081375 after\IN\1740 pediatric\JJ\1740 LT\NN\1740 included\VBD\690614 gender\NN\6309383 ,\,\1740 pediatric\JJ\1740 <e2>end-stage\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 Child-Pugh\JJ\1740 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 serum\NN\5397468 total\JJ\1740 <e1>bilirubin</e1>\NN\14756039 after\IN\1740 surgery\NN\6045562 ,\,\1740 and\CC\1740 trough\NN\9366017 TAC\NN\1740 level\NN\4916342 .\.\1740
D016559_D058625 NONE Univariate\NN\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 risk\NN\14541044 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 seizures\NNS\14081375 after\IN\1740 pediatric\JJ\1740 LT\NN\1740 included\VBD\690614 gender\NN\6309383 ,\,\1740 pediatric\JJ\1740 <e2>end-stage\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 Child-Pugh\JJ\1740 score\NN\5736149 before\IN\1740 surgery\NN\6045562 ,\,\1740 serum\NN\5397468 total\JJ\1740 bilirubin\NN\14756039 after\IN\1740 surgery\NN\6045562 ,\,\1740 and\CC\1740 trough\NN\9366017 <e1>TAC</e1>\NN\1740 level\NN\4916342 .\.\1740
2453942
D001556_D020258 NONE <e1>Lindane</e1>\NN\14919948 (\-LRB-\1740 gamma-hexachlorocyclohexane\JJ\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 organochlorine\NN\1740 insecticide\NN\14980215 with\IN\1740 known\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D001556_D020258 NONE Lindane\NN\14919948 (\-LRB-\1740 <e1>gamma-hexachlorocyclohexane</e1>\JJ\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 organochlorine\NN\1740 insecticide\NN\14980215 with\IN\1740 known\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 .\.\1740
D001556_D012640 CID We\PRP\1740 studied\VBD\630380 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>lindane</e1>\NN\14919948 (\-LRB-\1740 150\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 GABAergic\JJ\1740 and\CC\1740 dopaminergic\JJ\1740 systems\NNS\3575240 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentration\NN\4916342 of\IN\1740 GABA\NN\14601829 ,\,\1740 dopamine\NN\14807737 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 7\CD\13741022 brain\NN\5462674 areas\NNS\8630985 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D001556_D012640 CID All\DT\1740 animals\NNS\4475 suffered\VBD\2110220 tonic\JJ\1740 <e2>convulsions</e2>\NNS\14081375 at\IN\14622893 18.3\CD\1740 +/-\CC\1740 1.4\CD\1740 min\NN\15154774 after\IN\1740 <e1>lindane</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D005680_D012640 NONE We\PRP\1740 studied\VBD\630380 the\DT\1740 effect\NN\34213 of\IN\1740 lindane\NN\14919948 (\-LRB-\1740 150\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 GABAergic\JJ\1740 and\CC\1740 dopaminergic\JJ\1740 systems\NNS\3575240 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentration\NN\4916342 of\IN\1740 <e1>GABA</e1>\NN\14601829 ,\,\1740 dopamine\NN\14807737 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 7\CD\13741022 brain\NN\5462674 areas\NNS\8630985 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D004298_D012640 NONE We\PRP\1740 studied\VBD\630380 the\DT\1740 effect\NN\34213 of\IN\1740 lindane\NN\14919948 (\-LRB-\1740 150\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 GABAergic\JJ\1740 and\CC\1740 dopaminergic\JJ\1740 systems\NNS\3575240 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentration\NN\4916342 of\IN\1740 GABA\NN\14601829 ,\,\1740 <e1>dopamine</e1>\NN\14807737 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 7\CD\13741022 brain\NN\5462674 areas\NNS\8630985 at\IN\14622893 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
20009434
D008727_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 high-dose\JJ\1740 <e1>methotrexate</e1>\NN\2722166 therapy\NN\657604 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 ileostomy\NN\689550 .\.\1740
D008727_D058186 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 <e1>HD-MTX</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 ileostomy\NN\689550 ,\,\1740 The\DT\1740 patient\NN\9898892 was\VBD\836236 a\DT\13649268 3-year-old\JJ\1740 boy\NN\9624168 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 a\DT\13649268 living-related\JJ\1740 liver\NN\5298729 transplantation\NN\671351 for\IN\1740 congenital\JJ\1740 biliary\JJ\1740 atresia\NN\14501726 .\.\1740
D008727_D058186 CID Subsequent\JJ\1740 <e1>HD-MTX</e1>\NN\1740 therapy\NN\657604 caused\VBD\1617192 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 that\WDT\1740 required\VBD\754942 continuous\JJ\1740 hemodialysis\NN\649760 .\.\1740
D008727_D002051 NONE High-dose\JJ\1740 <e1>methotrexate</e1>\NN\2722166 (\-LRB-\1740 HD-MTX\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>Burkitt\NN\1740 lymphoma</e2>\NN\14239918 ,\,\1740 but\CC\1740 can\MD\3094503 cause\VB\1617192 hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 toxicity\NN\13576101 when\WRB\1740 its\PRP$\6125041 clearance\NN\5089947 is\VBZ\836236 delayed\VBN\439958 .\.\1740
D008727_D002051 NONE High-dose\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 <e1>HD-MTX</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>Burkitt\NN\1740 lymphoma</e2>\NN\14239918 ,\,\1740 but\CC\1740 can\MD\3094503 cause\VB\1617192 hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 toxicity\NN\13576101 when\WRB\1740 its\PRP$\6125041 clearance\NN\5089947 is\VBZ\836236 delayed\VBN\439958 .\.\1740
D008727_D056486 NONE High-dose\JJ\1740 <e1>methotrexate</e1>\NN\2722166 (\-LRB-\1740 HD-MTX\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 treatment\NN\654885 for\IN\1740 Burkitt\NN\1740 lymphoma\NN\14239918 ,\,\1740 but\CC\1740 can\MD\3094503 cause\VB\1617192 <e2>hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 toxicity</e2>\NN\13576101 when\WRB\1740 its\PRP$\6125041 clearance\NN\5089947 is\VBZ\836236 delayed\VBN\439958 .\.\1740
D008727_D056486 NONE High-dose\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 <e1>HD-MTX</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 treatment\NN\654885 for\IN\1740 Burkitt\NN\1740 lymphoma\NN\14239918 ,\,\1740 but\CC\1740 can\MD\3094503 cause\VB\1617192 <e2>hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 toxicity</e2>\NN\13576101 when\WRB\1740 its\PRP$\6125041 clearance\NN\5089947 is\VBZ\836236 delayed\VBN\439958 .\.\1740
D008727_D007674 NONE High-dose\JJ\1740 <e1>methotrexate</e1>\NN\2722166 (\-LRB-\1740 HD-MTX\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 treatment\NN\654885 for\IN\1740 Burkitt\NN\1740 lymphoma\NN\14239918 ,\,\1740 but\CC\1740 can\MD\3094503 cause\VB\1617192 <e2>hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 toxicity</e2>\NN\13576101 when\WRB\1740 its\PRP$\6125041 clearance\NN\5089947 is\VBZ\836236 delayed\VBN\439958 .\.\1740
D008727_D007674 NONE High-dose\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 <e1>HD-MTX</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 treatment\NN\654885 for\IN\1740 Burkitt\NN\1740 lymphoma\NN\14239918 ,\,\1740 but\CC\1740 can\MD\3094503 cause\VB\1617192 <e2>hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 toxicity</e2>\NN\13576101 when\WRB\1740 its\PRP$\6125041 clearance\NN\5089947 is\VBZ\836236 delayed\VBN\439958 .\.\1740
D008727_D001656 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 after\IN\1740 <e1>HD-MTX</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 ileostomy\NN\689550 ,\,\1740 The\DT\1740 patient\NN\9898892 was\VBD\836236 a\DT\13649268 3-year-old\JJ\1740 boy\NN\9624168 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 a\DT\13649268 living-related\JJ\1740 liver\NN\5298729 transplantation\NN\671351 for\IN\1740 congenital\JJ\1740 <e2>biliary\JJ\1740 atresia</e2>\NN\14501726 .\.\1740
14616590
D015742_D010146 CID <e2>Pain</e2>\NN\14299637 on\IN\1740 injection\NN\320852 (\-LRB-\1740 80\CD\13745420 vs.\CC\1740 20\CD\13745420 %\NN\1740 ,\,\1740 p\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 and\CC\1740 thrombophlebitis\NN\14352890 (\-LRB-\1740 93.3\CD\1740 vs.\CC\1740 6.6\CD\1740 %\NN\1740 ,\,\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 with\IN\1740 AM149\NN\1740 than\IN\1740 with\IN\1740 <e1>Disoprivan</e1>\NNP\1740 .\.\1740
D015742_D013924 CID Pain\NN\14299637 on\IN\1740 injection\NN\320852 (\-LRB-\1740 80\CD\13745420 vs.\CC\1740 20\CD\13745420 %\NN\1740 ,\,\1740 p\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 and\CC\1740 <e2>thrombophlebitis</e2>\NN\14352890 (\-LRB-\1740 93.3\CD\1740 vs.\CC\1740 6.6\CD\1740 %\NN\1740 ,\,\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 with\IN\1740 AM149\NN\1740 than\IN\1740 with\IN\1740 <e1>Disoprivan</e1>\NNP\1740 .\.\1740
23846525
C055162_D056486 CID Acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 associated\VBN\628491 with\IN\1740 <e1>clopidogrel</e1>\NN\1740 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
C055162_D056486 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>clopidogrel-related</e1>\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
C055162_D056486 CID Reports\NNS\6470073 about\IN\1740 cases\NNS\7283608 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 due\IN\5174653 to\IN\1740 <e1>clopidogrel</e1>\NN\1740 are\VBP\836236 increasing\VBG\169651 in\IN\13603305 the\DT\1740 last\JJ\1740 few\JJ\1740 years\NNS\15144371 ,\,\1740 after\IN\1740 the\DT\1740 increased\VBN\169651 use\NN\407535 of\IN\1740 this\DT\1740 drug\NN\14778436 .\.\1740
C055162_D056486 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 we\PRP\1740 believe\VBP\686447 that\IN\1740 physicians\NNS\10305802 should\MD\1740 carefully\RB\1740 consider\VB\689344 the\DT\1740 risk\NN\14541044 of\IN\1740 drug-induced\JJ\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 when\WRB\1740 <e1>clopidogrel</e1>\NN\1740 is\VBZ\836236 prescribed\VBN\748282 .\.\1740
1779253
D002211_D051474 NONE Topical\JJ\1740 0.025\CD\1740 %\NN\1740 <e1>capsaicin</e1>\NN\15032661 in\IN\13603305 chronic\JJ\1740 <e2>post-herpetic\JJ\1740 neuralgia</e2>\NN\14322699 :\:\1740 efficacy\NN\5199286 ,\,\1740 predictors\NNS\10756433 of\IN\1740 response\NN\11410625 and\CC\1740 long-term\JJ\1740 course\NN\883297 .\.\1740
D002211_D051474 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 ,\,\1740 time-course\RB\1740 of\IN\1740 action\NN\30358 and\CC\1740 predictors\NNS\10756433 of\IN\1740 response\NN\11410625 to\TO\1740 topical\JJ\1740 <e1>capsaicin</e1>\NN\15032661 ,\,\1740 39\CD\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>post-herpetic\JJ\1740 neuralgia</e2>\NN\14322699 (\-LRB-\1740 PHN\NN\1740 )\-RRB-\1740 ,\,\1740 median\JJ\1740 duration\NN\15113229 24\CD\13745420 months\NNS\15113229 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 0.025\CD\1740 %\NN\1740 capsaicin\NN\15032661 cream\NN\8386555 for\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002211_D051474 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 ,\,\1740 time-course\RB\1740 of\IN\1740 action\NN\30358 and\CC\1740 predictors\NNS\10756433 of\IN\1740 response\NN\11410625 to\TO\1740 topical\JJ\1740 <e1>capsaicin</e1>\NN\15032661 ,\,\1740 39\CD\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 post-herpetic\JJ\1740 neuralgia\NN\14322699 (\-LRB-\1740 <e2>PHN</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 median\JJ\1740 duration\NN\15113229 24\CD\13745420 months\NNS\15113229 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 0.025\CD\1740 %\NN\1740 capsaicin\NN\15032661 cream\NN\8386555 for\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002211_D051474 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 ,\,\1740 time-course\RB\1740 of\IN\1740 action\NN\30358 and\CC\1740 predictors\NNS\10756433 of\IN\1740 response\NN\11410625 to\TO\1740 topical\JJ\1740 capsaicin\NN\15032661 ,\,\1740 39\CD\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>post-herpetic\JJ\1740 neuralgia</e2>\NN\14322699 (\-LRB-\1740 PHN\NN\1740 )\-RRB-\1740 ,\,\1740 median\JJ\1740 duration\NN\15113229 24\CD\13745420 months\NNS\15113229 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 0.025\CD\1740 %\NN\1740 <e1>capsaicin</e1>\NN\15032661 cream\NN\8386555 for\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002211_D051474 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 evaluate\VB\670261 the\DT\1740 efficacy\NN\5199286 ,\,\1740 time-course\RB\1740 of\IN\1740 action\NN\30358 and\CC\1740 predictors\NNS\10756433 of\IN\1740 response\NN\11410625 to\TO\1740 topical\JJ\1740 capsaicin\NN\15032661 ,\,\1740 39\CD\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 post-herpetic\JJ\1740 neuralgia\NN\14322699 (\-LRB-\1740 <e2>PHN</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 median\JJ\1740 duration\NN\15113229 24\CD\13745420 months\NNS\15113229 ,\,\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 0.025\CD\1740 %\NN\1740 <e1>capsaicin</e1>\NN\15032661 cream\NN\8386555 for\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002211_D051474 NONE If\IN\1740 confirmed\VBD\1011725 in\IN\13603305 controlled\VBN\2422663 trials\NNS\786195 ,\,\1740 the\DT\1740 long-term\JJ\1740 results\NNS\34213 of\IN\1740 this\DT\1740 open\JJ\1740 ,\,\1740 non-randomized\JJ\1740 study\NN\635850 might\MD\5029706 indicate\VB\952524 that\IN\1740 the\DT\1740 analgesic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>capsaicin</e1>\NN\15032661 in\IN\13603305 <e2>PHN</e2>\NN\1740 is\VBZ\836236 mediated\VBN\761713 by\IN\1740 both\CC\1740 interference\NN\6660942 with\IN\1740 neuropeptide\NN\1740 metabolism\NN\13526110 and\CC\1740 morphological\JJ\1740 changes\NNS\7283608 (\-LRB-\1740 perhaps\RB\1740 degeneration\NN\29677 )\-RRB-\1740 of\IN\1740 nociceptive\JJ\1740 afferents\NNS\5474346 .\.\1740
D002211_D008413 CID Nineteen\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 48.7\CD\1740 %\NN\1740 )\-RRB-\1740 substantially\RB\1740 improved\VBN\126264 after\IN\1740 the\DT\1740 8-week\JJ\1740 trial\NN\786195 ;\:\1740 5\CD\13741022 (\-LRB-\1740 12.8\CD\1740 %\NN\1740 )\-RRB-\1740 discontinued\VBD\2609764 therapy\NN\657604 due\JJ\1740 to\TO\1740 side-effects\NNS\1740 such\JJ\1740 as\IN\14622893 intolerable\JJ\1740 <e1>capsaicin-induced</e1>\JJ\1740 burning\NN\376063 sensations\NNS\5708432 (\-LRB-\1740 4\CD\13741022 )\-RRB-\1740 or\CC\3541091 <e2>mastitis</e2>\NN\14336539 (\-LRB-\1740 1\CD\13741022 )\-RRB-\1740 ;\:\1740 15\CD\13745420 (\-LRB-\1740 38.5\CD\1740 %\NN\1740 )\-RRB-\1740 reported\VBD\831651 no\DT\7204911 benefit\NN\13278375 .\.\1740
573555
D011433_D007003 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 previously\RB\1740 reported\VBD\831651 <e2>hypoglycemia</e2>\NN\14299637 ,\,\1740 hyperbilirubinemia\NN\14204950 ,\,\1740 polycythemia\NN\14189204 ,\,\1740 neonatal\JJ\1740 apnea\NN\14299637 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 are\VBP\836236 not\RB\1740 invariable\JJ\1740 and\CC\1740 can\MD\3094503 not\RB\1740 be\VB\836236 statistically\RB\1740 correlated\VBN\2657219 with\IN\1740 chronic\JJ\1740 <e1>propranolol</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011433_D006932 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 previously\RB\1740 reported\VBD\831651 hypoglycemia\NN\14299637 ,\,\1740 <e2>hyperbilirubinemia</e2>\NN\14204950 ,\,\1740 polycythemia\NN\14189204 ,\,\1740 neonatal\JJ\1740 apnea\NN\14299637 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 are\VBP\836236 not\RB\1740 invariable\JJ\1740 and\CC\1740 can\MD\3094503 not\RB\1740 be\VB\836236 statistically\RB\1740 correlated\VBN\2657219 with\IN\1740 chronic\JJ\1740 <e1>propranolol</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011433_D011086 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 previously\RB\1740 reported\VBD\831651 hypoglycemia\NN\14299637 ,\,\1740 hyperbilirubinemia\NN\14204950 ,\,\1740 <e2>polycythemia</e2>\NN\14189204 ,\,\1740 neonatal\JJ\1740 apnea\NN\14299637 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 are\VBP\836236 not\RB\1740 invariable\JJ\1740 and\CC\1740 can\MD\3094503 not\RB\1740 be\VB\836236 statistically\RB\1740 correlated\VBN\2657219 with\IN\1740 chronic\JJ\1740 <e1>propranolol</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011433_D001049 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 previously\RB\1740 reported\VBD\831651 hypoglycemia\NN\14299637 ,\,\1740 hyperbilirubinemia\NN\14204950 ,\,\1740 polycythemia\NN\14189204 ,\,\1740 <e2>neonatal\JJ\1740 apnea</e2>\NN\14299637 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 are\VBP\836236 not\RB\1740 invariable\JJ\1740 and\CC\1740 can\MD\3094503 not\RB\1740 be\VB\836236 statistically\RB\1740 correlated\VBN\2657219 with\IN\1740 chronic\JJ\1740 <e1>propranolol</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011433_D001919 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 previously\RB\1740 reported\VBD\831651 hypoglycemia\NN\14299637 ,\,\1740 hyperbilirubinemia\NN\14204950 ,\,\1740 polycythemia\NN\14189204 ,\,\1740 neonatal\JJ\1740 apnea\NN\14299637 ,\,\1740 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 are\VBP\836236 not\RB\1740 invariable\JJ\1740 and\CC\1740 can\MD\3094503 not\RB\1740 be\VB\836236 statistically\RB\1740 correlated\VBN\2657219 with\IN\1740 chronic\JJ\1740 <e1>propranolol</e1>\NN\1740 therapy\NN\657604 .\.\1740
7173007
C025504_D009325 CID The\DT\1740 <e1>Dimer-X</e1>\NN\1740 group\NN\2137 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 dizziness\JJ\1740 .\.\1740
C025504_D004244 CID The\DT\1740 <e1>Dimer-X</e1>\NN\1740 group\NN\2137 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 nausea\NN\14299637 and\CC\1740 <e2>dizziness</e2>\JJ\1740 .\.\1740
C006753_D015746 CID The\DT\1740 <e1>Endografine</e1>\NNP\1740 group\NN\2137 had\VBD\2108377 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>abdominal\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D007485_D064420 NONE <e1>Hexabrix</e1>\NN\1740 and\CC\1740 Vasurix\NN\1740 polyvidone\NN\1740 are\VBP\836236 considered\VBN\689344 the\DT\1740 best\JJS\1740 contrast\NN\13854649 media\NNS\3575240 for\IN\1740 hysterosalpingography\NN\1740 and\CC\1740 perhaps\RB\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 Hexabrix\NNP\1740 should\MD\1740 be\VB\836236 preferred\VBN\1777210 .\.\1740
D007485_D064420 NONE Hexabrix\NN\1740 and\CC\1740 Vasurix\NN\1740 polyvidone\NN\1740 are\VBP\836236 considered\VBN\689344 the\DT\1740 best\JJS\1740 contrast\NN\13854649 media\NNS\3575240 for\IN\1740 hysterosalpingography\NN\1740 and\CC\1740 perhaps\RB\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 <e1>Hexabrix</e1>\NNP\1740 should\MD\1740 be\VB\836236 preferred\VBN\1777210 .\.\1740
D000100_D064420 NONE Hexabrix\NN\1740 and\CC\1740 <e1>Vasurix\NN\1740 polyvidone</e1>\NN\1740 are\VBP\836236 considered\VBN\689344 the\DT\1740 best\JJS\1740 contrast\NN\13854649 media\NNS\3575240 for\IN\1740 hysterosalpingography\NN\1740 and\CC\1740 perhaps\RB\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 Hexabrix\NNP\1740 should\MD\1740 be\VB\836236 preferred\VBN\1777210 .\.\1740
D003287_D064420 NONE Hexabrix\NN\1740 and\CC\1740 Vasurix\NN\1740 polyvidone\NN\1740 are\VBP\836236 considered\VBN\689344 the\DT\1740 best\JJS\1740 <e1>contrast\NN\13854649 media</e1>\NNS\3575240 for\IN\1740 hysterosalpingography\NN\1740 and\CC\1740 perhaps\RB\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 Hexabrix\NNP\1740 should\MD\1740 be\VB\836236 preferred\VBN\1777210 .\.\1740
1449452
D004077_D001281 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 <e1>digoxin</e1>\NN\15060131 is\VBZ\836236 beneficial\JJ\1740 for\IN\1740 ventricular\JJ\1740 rate\NN\13815152 control\NN\5190804 .\.\1740
D004077_D001145 CID Also\RB\1740 ,\,\1740 <e1>digoxin</e1>\NN\15060131 has\VBZ\2108377 undesirable\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 increasing\VBG\169651 peripheral\JJ\1740 resistance\NN\37396 and\CC\1740 myocardial\JJ\1740 demands\NNS\6513366 ,\,\1740 and\CC\1740 causing\VBG\1617192 <e2>arrhythmias</e2>\NNS\14103288 .\.\1740
D004077_D009203 NONE Pooled\JJ\1740 analysis\NN\633864 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 inotropic\JJ\1740 drugs\NNS\14778436 shows\VBZ\2137132 an\DT\6697703 excess\JJ\1740 mortality\NN\5054863 and\CC\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 possibility\NN\5944958 that\IN\1740 <e1>digoxin</e1>\NN\15060131 may\MD\15209706 increase\VB\169651 mortality\NN\5054863 after\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 .\.\1740
D004077_D009203 NONE Pooled\JJ\1740 analysis\NN\633864 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 inotropic\JJ\1740 drugs\NNS\14778436 shows\VBZ\2137132 an\DT\6697703 excess\JJ\1740 mortality\NN\5054863 and\CC\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 possibility\NN\5944958 that\IN\1740 <e1>digoxin</e1>\NN\15060131 may\MD\15209706 increase\VB\169651 mortality\NN\5054863 after\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 .\.\1740
9197951
D003042_D001714 NONE A\DT\13649268 30-year-old\JJ\1740 <e1>cocaine-dependent</e1>\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 a\DT\13649268 subject\NN\6598915 in\IN\13603305 a\DT\13649268 study\NN\635850 evaluating\VBG\670261 the\DT\1740 anticraving\VBG\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 stimulant\JJ\1740 medication\NN\3247620 diethylpropion\NN\1740 (\-LRB-\1740 DEP\NN\1740 )\-RRB-\1740 became\VBD\146138 <e2>manic</e2>\JJ\1740 during\IN\1740 his\PRP$\1740 second\JJ\1740 week\NN\15113229 on\IN\1740 the\DT\1740 study\NN\635850 drug\NN\14778436 .\.\1740
D004053_D001714 CID A\DT\13649268 30-year-old\JJ\1740 cocaine-dependent\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 a\DT\13649268 subject\NN\6598915 in\IN\13603305 a\DT\13649268 study\NN\635850 evaluating\VBG\670261 the\DT\1740 anticraving\VBG\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 stimulant\JJ\1740 medication\NN\3247620 <e1>diethylpropion</e1>\NN\1740 (\-LRB-\1740 DEP\NN\1740 )\-RRB-\1740 became\VBD\146138 <e2>manic</e2>\JJ\1740 during\IN\1740 his\PRP$\1740 second\JJ\1740 week\NN\15113229 on\IN\1740 the\DT\1740 study\NN\635850 drug\NN\14778436 .\.\1740
D004053_D001714 CID A\DT\13649268 30-year-old\JJ\1740 cocaine-dependent\JJ\1740 man\NN\9605289 who\WP\8299493 was\VBD\836236 a\DT\13649268 subject\NN\6598915 in\IN\13603305 a\DT\13649268 study\NN\635850 evaluating\VBG\670261 the\DT\1740 anticraving\VBG\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 stimulant\JJ\1740 medication\NN\3247620 diethylpropion\NN\1740 (\-LRB-\1740 <e1>DEP</e1>\NN\1740 )\-RRB-\1740 became\VBD\146138 <e2>manic</e2>\JJ\1740 during\IN\1740 his\PRP$\1740 second\JJ\1740 week\NN\15113229 on\IN\1740 the\DT\1740 study\NN\635850 drug\NN\14778436 .\.\1740
D004053_D001714 CID Pupillometric\JJ\1740 changes\NNS\7283608 while\IN\15122231 on\IN\1740 <e1>DEP</e1>\NN\1740 ,\,\1740 especially\RB\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 total\JJ\1740 power\NN\4723816 of\IN\1740 pupillary\JJ\1740 oscillation\NN\13518963 ,\,\1740 were\VBD\836236 dramatically\RB\1740 different\JJ\1740 than\IN\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 the\DT\1740 eight\CD\13741022 other\JJ\1740 study\NN\635850 subjects\NNS\6598915 who\WP\8299493 did\VBD\1640855 not\RB\1740 become\VB\146138 <e2>manic</e2>\JJ\1740 .\.\1740
D004053_D011681 NONE Pupillometric\JJ\1740 changes\NNS\7283608 while\IN\15122231 on\IN\1740 <e1>DEP</e1>\NN\1740 ,\,\1740 especially\RB\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 total\JJ\1740 power\NN\4723816 of\IN\1740 <e2>pupillary\JJ\1740 oscillation</e2>\NN\13518963 ,\,\1740 were\VBD\836236 dramatically\RB\1740 different\JJ\1740 than\IN\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 the\DT\1740 eight\CD\13741022 other\JJ\1740 study\NN\635850 subjects\NNS\6598915 who\WP\8299493 did\VBD\1640855 not\RB\1740 become\VB\146138 manic\JJ\1740 .\.\1740
25006961
D008094_D018500 CID Absence\NN\14449405 of\IN\1740 PKC-alpha\NN\1740 attenuates\VBZ\224901 <e1>lithium-induced</e1>\JJ\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 .\.\1740
D008094_D018500 CID <e1>Lithium</e1>\FW\14625458 ,\,\1740 an\DT\6697703 effective\JJ\1740 antipsychotic\JJ\1740 ,\,\1740 induces\VBZ\1627355 <e2>nephrogenic\JJ\1740 diabetes\NN\14075199 insipidus</e2>\NN\1740 (\-LRB-\1740 NDI\NN\1740 )\-RRB-\1740 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008094_D018500 CID <e1>Lithium</e1>\FW\14625458 ,\,\1740 an\DT\6697703 effective\JJ\1740 antipsychotic\JJ\1740 ,\,\1740 induces\VBZ\1627355 nephrogenic\JJ\1740 diabetes\NN\14075199 insipidus\NN\1740 (\-LRB-\1740 <e2>NDI</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008094_D018500 CID Our\PRP$\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 ablation\NN\671351 of\IN\1740 PKCa\NN\1740 preserves\VBZ\2681795 AQP2\NN\1740 and\CC\1740 UT-A1\NN\1740 protein\NN\14944888 expression\NN\4679549 and\CC\1740 localization\NN\151497 in\IN\13603305 <e1>lithium-induced</e1>\JJ\1740 <e2>NDI</e2>\NN\1740 ,\,\1740 and\CC\1740 prevents\VBZ\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 severe\JJ\1740 polyuria\NN\14113228 associated\VBN\628491 with\IN\1740 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D018500 CID Our\PRP$\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 ablation\NN\671351 of\IN\1740 PKCa\NN\1740 preserves\VBZ\2681795 AQP2\NN\1740 and\CC\1740 UT-A1\NN\1740 protein\NN\14944888 expression\NN\4679549 and\CC\1740 localization\NN\151497 in\IN\13603305 lithium-induced\JJ\1740 <e2>NDI</e2>\NN\1740 ,\,\1740 and\CC\1740 prevents\VBZ\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 severe\JJ\1740 polyuria\NN\14113228 associated\VBN\628491 with\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D011141 CID Targeting\VBG\1151110 an\DT\6697703 alternative\JJ\1740 signaling\NN\33020 pathway\NN\5483677 ,\,\1740 such\JJ\1740 as\IN\14622893 PKC-mediated\JJ\1740 signaling\NN\33020 ,\,\1740 may\MD\15209706 be\VB\836236 an\DT\6697703 effective\JJ\1740 method\NN\5616786 of\IN\1740 treating\VBG\2376958 <e1>lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 .\.\1740
D008094_D011141 CID Our\PRP$\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 ablation\NN\671351 of\IN\1740 PKCa\NN\1740 preserves\VBZ\2681795 AQP2\NN\1740 and\CC\1740 UT-A1\NN\1740 protein\NN\14944888 expression\NN\4679549 and\CC\1740 localization\NN\151497 in\IN\13603305 <e1>lithium-induced</e1>\JJ\1740 NDI\NN\1740 ,\,\1740 and\CC\1740 prevents\VBZ\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 severe\JJ\1740 <e2>polyuria</e2>\NN\14113228 associated\VBN\628491 with\IN\1740 lithium\NN\14625458 therapy\NN\657604 .\.\1740
D008094_D011141 CID Our\PRP$\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 ablation\NN\671351 of\IN\1740 PKCa\NN\1740 preserves\VBZ\2681795 AQP2\NN\1740 and\CC\1740 UT-A1\NN\1740 protein\NN\14944888 expression\NN\4679549 and\CC\1740 localization\NN\151497 in\IN\13603305 lithium-induced\JJ\1740 NDI\NN\1740 ,\,\1740 and\CC\1740 prevents\VBZ\1740 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 severe\JJ\1740 <e2>polyuria</e2>\NN\14113228 associated\VBN\628491 with\IN\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
6316193
D010852_D012640 CID Structure-activity\JJ\1740 and\CC\1740 dose-effect\JJ\1740 relationships\NNS\31921 of\IN\1740 the\DT\1740 antagonism\NN\24720 of\IN\1740 <e1>picrotoxin-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 by\IN\1740 cholecystokinin\NN\5408684 ,\,\1740 fragments\NNS\9385911 and\CC\1740 analogues\NNS\4743605 of\IN\1740 cholecystokinin\NN\5408684 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010852_D012640 CID Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 sulphate\NN\15010703 ester\NN\14727670 (\-LRB-\1740 CCK-8-SE\NN\1740 )\-RRB-\1740 and\CC\1740 nonsulphated\VBN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 (\-LRB-\1740 CCK-8-NS\NN\1740 )\-RRB-\1740 enhanced\VBD\227165 the\DT\1740 latency\NN\15269513 of\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>picrotoxin</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010852_D012640 CID The\DT\1740 peptide\NN\14724264 CCK-5\NN\1740 -\:\1740 8\CD\13741022 had\VBD\2108377 weak\JJ\1740 anticonvulsant\JJ\1740 activity\NN\30358 in\IN\13603305 comparison\NN\635850 to\IN\1740 the\DT\1740 octapeptides\NNS\1740 ,\,\1740 3.2\CD\1740 mumol/kg\NNS\1740 and\CC\1740 larger\JJR\1740 doses\NNS\3740161 of\IN\1740 the\DT\1740 reference\NN\6765044 drug\NN\14778436 ,\,\1740 diazepam\NN\2830852 ,\,\1740 totally\RB\1740 prevented\VBD\1740 <e1>picrotoxin-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 mortality\NN\5054863 .\.\1740
D002766_D012640 NONE Structure-activity\JJ\1740 and\CC\1740 dose-effect\JJ\1740 relationships\NNS\31921 of\IN\1740 the\DT\1740 antagonism\NN\24720 of\IN\1740 picrotoxin-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 by\IN\1740 <e1>cholecystokinin</e1>\NN\5408684 ,\,\1740 fragments\NNS\9385911 and\CC\1740 analogues\NNS\4743605 of\IN\1740 cholecystokinin\NN\5408684 in\IN\13603305 mice\NNS\2329401 .\.\1740
D002766_D012640 NONE Structure-activity\JJ\1740 and\CC\1740 dose-effect\JJ\1740 relationships\NNS\31921 of\IN\1740 the\DT\1740 antagonism\NN\24720 of\IN\1740 picrotoxin-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 by\IN\1740 cholecystokinin\NN\5408684 ,\,\1740 fragments\NNS\9385911 and\CC\1740 analogues\NNS\4743605 of\IN\1740 <e1>cholecystokinin</e1>\NN\5408684 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012844_D012640 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>cholecystokinin\NN\5408684 octapeptide</e1>\NN\1740 sulphate\NN\15010703 ester\NN\14727670 (\-LRB-\1740 CCK-8-SE\NN\1740 )\-RRB-\1740 and\CC\1740 nonsulphated\VBN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 (\-LRB-\1740 CCK-8-NS\NN\1740 )\-RRB-\1740 enhanced\VBD\227165 the\DT\1740 latency\NN\15269513 of\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 picrotoxin\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012844_D012640 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 sulphate\NN\15010703 ester\NN\14727670 (\-LRB-\1740 <e1>CCK-8-SE</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 nonsulphated\VBN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 (\-LRB-\1740 CCK-8-NS\NN\1740 )\-RRB-\1740 enhanced\VBD\227165 the\DT\1740 latency\NN\15269513 of\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 picrotoxin\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012844_D012640 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 sulphate\NN\15010703 ester\NN\14727670 (\-LRB-\1740 CCK-8-SE\NN\1740 )\-RRB-\1740 and\CC\1740 nonsulphated\VBN\1740 <e1>cholecystokinin\NN\5408684 octapeptide</e1>\NN\1740 (\-LRB-\1740 CCK-8-NS\NN\1740 )\-RRB-\1740 enhanced\VBD\227165 the\DT\1740 latency\NN\15269513 of\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 picrotoxin\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012844_D012640 NONE Intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 sulphate\NN\15010703 ester\NN\14727670 (\-LRB-\1740 CCK-8-SE\NN\1740 )\-RRB-\1740 and\CC\1740 nonsulphated\VBN\1740 cholecystokinin\NN\5408684 octapeptide\NN\1740 (\-LRB-\1740 <e1>CCK-8-NS</e1>\NN\1740 )\-RRB-\1740 enhanced\VBD\227165 the\DT\1740 latency\NN\15269513 of\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 picrotoxin\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003975_D012640 NONE The\DT\1740 peptide\NN\14724264 CCK-5\NN\1740 -\:\1740 8\CD\13741022 had\VBD\2108377 weak\JJ\1740 anticonvulsant\JJ\1740 activity\NN\30358 in\IN\13603305 comparison\NN\635850 to\IN\1740 the\DT\1740 octapeptides\NNS\1740 ,\,\1740 3.2\CD\1740 mumol/kg\NNS\1740 and\CC\1740 larger\JJR\1740 doses\NNS\3740161 of\IN\1740 the\DT\1740 reference\NN\6765044 drug\NN\14778436 ,\,\1740 <e1>diazepam</e1>\NN\2830852 ,\,\1740 totally\RB\1740 prevented\VBD\1740 picrotoxin-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 mortality\NN\5054863 .\.\1740
4631913
D014750_D011552 CID Effect\NN\34213 of\IN\1740 <e1>vincristine\NN\3917455 sulfate</e1>\NN\15010703 on\IN\1740 <e2>Pseudomonas\NN\1352574 infections</e2>\NNS\14052046 in\IN\13603305 monkeys\NNS\2469914 .\.\1740
D014750_D007970 CID Intravenous\JJ\1740 or\CC\3541091 intratracheal\JJ\1740 inoculation\NN\828990 of\IN\1740 2.0\CD\1740 to\TO\1740 2.5\CD\1740 mg\NN\13717155 of\IN\1740 <e1>vincristine\NN\3917455 sulfate</e1>\NN\15010703 was\VBD\836236 followed\VBN\1835496 by\IN\1740 <e2>leukopenia</e2>\NN\14189204 in\IN\13603305 4\CD\13741022 to\TO\1740 5\CD\13741022 days\NNS\15140892 .\.\1740
D014750_D007239 NONE Intravenous\JJ\1740 inoculation\NN\828990 of\IN\1740 4.2\CD\1740 x\CC\13745420 10(10\CD\1740 )\-RRB-\1740 to\TO\1740 7.8\CD\1740 x\CC\13745420 10(10\CD\1740 )\-RRB-\1740 pyocin\NN\1740 type\NN\5839024 6\CD\13741022 Pseudomonas\NN\1352574 organisms\NNS\4258 in\IN\13603305 monkeys\NNS\2469914 given\VBD\2327200 <e1>vincristine\NN\3917455 sulfate</e1>\NN\15010703 4\CD\13741022 days\NNS\15140892 previously\RB\1740 resulted\VBD\2633881 in\IN\13603305 fatal\JJ\1740 <e2>infection</e2>\NN\14052046 in\IN\13603305 11\CD\13745420 of\IN\1740 14\CD\13745420 monkeys\NNS\2469914 ,\,\1740 whereas\IN\1740 none\NN\15228378 of\IN\1740 four\CD\13741022 receiving\VBG\2210855 Pseudomonas\NNP\1352574 alone\RB\1740 died\VBD\146138 .\.\1740
19681452
D003042_D002543 NONE Bilateral\JJ\1740 <e2>haemorrhagic\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus</e2>\NN\1740 after\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 alcohol\NN\7881800 intoxication\NN\14034177 .\.\1740
D003042_D020520 NONE Bilateral\JJ\1740 <e2>haemorrhagic\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus</e2>\NN\1740 after\IN\1740 <e1>cocaine</e1>\NN\3492717 and\CC\1740 alcohol\NN\7881800 intoxication\NN\14034177 .\.\1740
D003042_D020520 NONE Bilateral\JJ\1740 <e2>basal\JJ\1740 ganglia\NN\5462674 infarcts</e2>\NNS\14204950 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>cocaine</e1>\NN\3492717 ,\,\1740 without\IN\1740 concurrent\JJ\1740 heroin\NN\3492717 use\NN\407535 ,\,\1740 have\VBP\2108377 never\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D000431_D002543 NONE Bilateral\JJ\1740 <e2>haemorrhagic\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus</e2>\NN\1740 after\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>alcohol</e1>\NN\7881800 intoxication\NN\14034177 .\.\1740
D000431_D020520 NONE Bilateral\JJ\1740 <e2>haemorrhagic\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus</e2>\NN\1740 after\IN\1740 cocaine\NN\3492717 and\CC\1740 <e1>alcohol</e1>\NN\7881800 intoxication\NN\14034177 .\.\1740
D003042_D002544 NONE <e1>Cocaine</e1>\NNP\3492717 is\VBZ\836236 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 both\CC\1740 <e2>ischemic\JJ\1740 and\CC\1740 haemorrhagic\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D003042_D020521 NONE <e1>Cocaine</e1>\NNP\3492717 is\VBZ\836236 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 both\CC\1740 <e2>ischemic\JJ\1740 and\CC\1740 haemorrhagic\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D000431_D002545 NONE We\PRP\1740 present\VBP\2137132 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 bilateral\JJ\1740 <e2>ischemia\NN\14195315 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus</e2>\NN\1740 after\IN\1740 excessive\JJ\1740 <e1>alcohol</e1>\NN\7881800 and\CC\1740 intranasal\JJ\1740 cocaine\NN\3492717 use\NN\407535 .\.\1740
D003042_D002545 CID We\PRP\1740 present\VBP\2137132 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 31-year-old\JJ\1740 man\NN\9605289 with\IN\1740 bilateral\JJ\1740 <e2>ischemia\NN\14195315 of\IN\1740 the\DT\1740 globus\NN\1740 pallidus</e2>\NN\1740 after\IN\1740 excessive\JJ\1740 alcohol\NN\7881800 and\CC\1740 intranasal\JJ\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003932_D020520 CID Drug-related\JJ\1740 <e2>globus\NN\1740 pallidus\NN\1740 infarctions</e2>\NNS\14204950 are\VBP\836236 most\RBS\1740 often\RB\1740 associated\VBN\628491 with\IN\1740 <e1>heroin</e1>\NN\3492717 .\.\1740
D003932_D020520 CID Bilateral\JJ\1740 <e2>basal\JJ\1740 ganglia\NN\5462674 infarcts</e2>\NNS\14204950 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 cocaine\NN\3492717 ,\,\1740 without\IN\1740 concurrent\JJ\1740 <e1>heroin</e1>\NN\3492717 use\NN\407535 ,\,\1740 have\VBP\2108377 never\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D003042_D001145 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 transient\JJ\1740 <e2>cardiac\JJ\1740 arrhythmia</e2>\NN\14103288 or\CC\3541091 respiratory\JJ\1740 dysfunction\NN\14204950 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 and/or\CC\1740 ethanol\NN\14708720 use\NN\407535 were\VBD\836236 the\DT\1740 most\RBS\1740 likely\JJ\1740 causes\NNS\7323922 of\IN\1740 cerebral\JJ\1740 hypoperfusion\NN\1740 .\.\1740
D003042_D012131 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 transient\JJ\1740 cardiac\JJ\1740 arrhythmia\NN\14103288 or\CC\3541091 <e2>respiratory\JJ\1740 dysfunction</e2>\NN\14204950 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 and/or\CC\1740 ethanol\NN\14708720 use\NN\407535 were\VBD\836236 the\DT\1740 most\RBS\1740 likely\JJ\1740 causes\NNS\7323922 of\IN\1740 cerebral\JJ\1740 hypoperfusion\NN\1740 .\.\1740
D003042_-1 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 transient\JJ\1740 cardiac\JJ\1740 arrhythmia\NN\14103288 or\CC\3541091 respiratory\JJ\1740 dysfunction\NN\14204950 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 and/or\CC\1740 ethanol\NN\14708720 use\NN\407535 were\VBD\836236 the\DT\1740 most\RBS\1740 likely\JJ\1740 causes\NNS\7323922 of\IN\1740 <e2>cerebral\JJ\1740 hypoperfusion</e2>\NN\1740 .\.\1740
D000431_D001145 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 transient\JJ\1740 <e2>cardiac\JJ\1740 arrhythmia</e2>\NN\14103288 or\CC\3541091 respiratory\JJ\1740 dysfunction\NN\14204950 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 and/or\CC\1740 <e1>ethanol</e1>\NN\14708720 use\NN\407535 were\VBD\836236 the\DT\1740 most\RBS\1740 likely\JJ\1740 causes\NNS\7323922 of\IN\1740 cerebral\JJ\1740 hypoperfusion\NN\1740 .\.\1740
D000431_D012131 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 transient\JJ\1740 cardiac\JJ\1740 arrhythmia\NN\14103288 or\CC\3541091 <e2>respiratory\JJ\1740 dysfunction</e2>\NN\14204950 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 and/or\CC\1740 <e1>ethanol</e1>\NN\14708720 use\NN\407535 were\VBD\836236 the\DT\1740 most\RBS\1740 likely\JJ\1740 causes\NNS\7323922 of\IN\1740 cerebral\JJ\1740 hypoperfusion\NN\1740 .\.\1740
D000431_-1 NONE In\IN\13603305 our\PRP$\1740 patient\NN\9898892 ,\,\1740 transient\JJ\1740 cardiac\JJ\1740 arrhythmia\NN\14103288 or\CC\3541091 respiratory\JJ\1740 dysfunction\NN\14204950 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 and/or\CC\1740 <e1>ethanol</e1>\NN\14708720 use\NN\407535 were\VBD\836236 the\DT\1740 most\RBS\1740 likely\JJ\1740 causes\NNS\7323922 of\IN\1740 <e2>cerebral\JJ\1740 hypoperfusion</e2>\NN\1740 .\.\1740
2320485
D008750_D000743 CID <e1>Methyldopa-induced</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 15\CD\13745420 year\NN\15113229 old\JJ\1740 presenting\NN\1740 as\RB\1740 near-syncope\JJ\1740 .\.\1740
D008750_D000743 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>methyldopa-induced</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 15-year-old\JJ\1740 boy\NN\9624168 who\WP\8299493 presented\VBD\2137132 to\IN\1740 the\DT\1740 emergency\NN\7417644 department\NN\8220714 with\IN\1740 near-syncope\NN\1740 .\.\1740
D008750_D013575 NONE <e1>Methyldopa-induced</e1>\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 a\DT\13649268 15\CD\13745420 year\NN\15113229 old\JJ\1740 presenting\NN\1740 as\RB\1740 <e2>near-syncope</e2>\JJ\1740 .\.\1740
D008750_D013575 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>methyldopa-induced</e1>\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 a\DT\13649268 15-year-old\JJ\1740 boy\NN\9624168 who\WP\8299493 presented\VBD\2137132 to\IN\1740 the\DT\1740 emergency\NN\7417644 department\NN\8220714 with\IN\1740 <e2>near-syncope</e2>\NN\1740 .\.\1740
D008750_D000744 NONE <e1>Methyldopa</e1>\NNP\2721160 causes\VBZ\1617192 an\DT\6697703 <e2>autoimmune\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 small\JJ\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 who\WP\8299493 take\VBP\2367363 the\DT\1740 drug\NN\14778436 .\.\1740
D008750_D004630 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>methyldopa-induced</e1>\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 in\IN\13603305 a\DT\13649268 15-year-old\JJ\1740 boy\NN\9624168 who\WP\8299493 presented\VBD\2137132 to\IN\1740 the\DT\1740 <e2>emergency\NN\7417644 department</e2>\NN\8220714 with\IN\1740 near-syncope\NN\1740 .\.\1740
D008750_D014947 NONE The\DT\1740 boy\NN\9624168 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 intravenous\JJ\1740 <e1>methyldopa</e1>\NN\2721160 during\IN\1740 a\DT\13649268 <e2>trauma</e2>\NN\14052046 admission\NN\49003 seven\CD\13741022 weeks\NNS\15113229 prior\RB\1740 to\IN\1740 presentation\NN\1027379 .\.\1740
16092435
D012266_D066126 NONE Morphological\JJ\1740 evaluation\NN\874067 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>d-ribose</e1>\NN\1740 on\IN\1740 adriamycin-evoked\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D012266_D066126 NONE <e1>D-ribose</e1>\NN\1740 in\IN\13603305 the\DT\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 ADR\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE Morphological\JJ\1740 evaluation\NN\874067 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 d-ribose\NN\1740 on\IN\1740 <e1>adriamycin-evoked</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004317_D066126 NONE <e1>Adriamycin</e1>\NN\1740 in\IN\13603305 the\DT\1740 cumulative\JJ\1740 dose\NN\3740161 of\IN\1740 25\CD\13745420 mg/kg\NN\1740 evoked\VBD\1617192 fully\RB\1740 developed\VBD\1753788 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D004317_D066126 NONE D-ribose\NN\1740 in\IN\13603305 the\DT\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 <e1>ADR</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D012266_D009202 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 <e1>d-ribose</e1>\NN\1740 on\IN\1740 adriamycin-induced\JJ\1740 <e2>myocardiopathy</e2>\NN\14103288 in\IN\13603305 rats\NNS\2329401 was\VBD\836236 studied\VBN\630380 .\.\1740
D004317_D009202 CID The\DT\1740 influence\NN\5190804 of\IN\1740 d-ribose\NN\1740 on\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 <e2>myocardiopathy</e2>\NN\14103288 in\IN\13603305 rats\NNS\2329401 was\VBD\836236 studied\VBN\630380 .\.\1740
2782734
D000420_D001249 NONE Tachyphylaxis\NN\1740 to\TO\1740 systemic\VB\1740 but\CC\1740 not\RB\1740 to\TO\1740 airway\NN\3253398 responses\NNS\11410625 during\IN\1740 prolonged\JJ\1740 therapy\NN\657604 with\IN\1740 high\JJ\1740 dose\NN\3740161 inhaled\VBD\1198101 <e1>salbutamol</e1>\NN\1740 in\IN\13603305 <e2>asthmatics</e2>\NNS\7846 .\.\1740
D000420_D001249 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 inhaled\VBN\1198101 <e1>salbutamol</e1>\NN\1740 produce\VBP\1617192 substantial\JJ\1740 improvements\NNS\7359599 in\IN\13603305 airway\NN\3253398 response\NN\11410625 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>asthma</e2>\NN\14145095 ,\,\1740 and\CC\1740 are\VBP\836236 associated\VBN\628491 with\IN\1740 dose-dependent\JJ\1740 systemic\JJ\1740 beta-adrenoceptor\NN\5608868 responses\NNS\11410625 .\.\1740
D000420_D001249 NONE Twelve\CD\13745420 <e2>asthmatic</e2>\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 FEV1\NN\1740 ,\,\1740 81\CD\1740 +/-\CC\1740 4\CD\13741022 %\NN\1740 predicted\VBN\916909 )\-RRB-\1740 ,\,\1740 requiring\VBG\754942 only\RB\1740 occasional\JJ\1740 inhaled\VBN\1198101 beta-agonists\NNS\1740 as\IN\14622893 their\PRP$\1740 sole\NN\8511241 therapy\NN\657604 ,\,\1740 were\VBD\836236 given\VBN\2327200 a\DT\13649268 14-day\JJ\1740 treatment\NN\654885 with\IN\1740 high\JJ\1740 dose\NN\3740161 inhaled\VBD\1198101 <e1>salbutamol</e1>\NN\1740 (\-LRB-\1740 HDS\NN\1740 )\-RRB-\1740 ,\,\1740 4,000\CD\1740 micrograms\NNS\13717155 daily\RB\1740 ,\,\1740 low\JJ\1740 dose\NN\3740161 inhaled\VBD\1198101 salbutamol\NN\1740 (\-LRB-\1740 LDS\NN\1740 )\-RRB-\1740 ,\,\1740 800\CD\1740 micrograms\NNS\13717155 daily\RB\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 PI\NN\13730756 )\-RRB-\1740 by\IN\1740 metered-dose\JJ\1740 inhaler\NN\3210683 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 crossover\NN\13526110 design\NN\927261 .\.\1740
D000420_D001249 NONE Twelve\CD\13745420 <e2>asthmatic</e2>\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 FEV1\NN\1740 ,\,\1740 81\CD\1740 +/-\CC\1740 4\CD\13741022 %\NN\1740 predicted\VBN\916909 )\-RRB-\1740 ,\,\1740 requiring\VBG\754942 only\RB\1740 occasional\JJ\1740 inhaled\VBN\1198101 beta-agonists\NNS\1740 as\IN\14622893 their\PRP$\1740 sole\NN\8511241 therapy\NN\657604 ,\,\1740 were\VBD\836236 given\VBN\2327200 a\DT\13649268 14-day\JJ\1740 treatment\NN\654885 with\IN\1740 high\JJ\1740 dose\NN\3740161 inhaled\VBD\1198101 salbutamol\NN\1740 (\-LRB-\1740 HDS\NN\1740 )\-RRB-\1740 ,\,\1740 4,000\CD\1740 micrograms\NNS\13717155 daily\RB\1740 ,\,\1740 low\JJ\1740 dose\NN\3740161 inhaled\VBD\1198101 <e1>salbutamol</e1>\NN\1740 (\-LRB-\1740 LDS\NN\1740 )\-RRB-\1740 ,\,\1740 800\CD\1740 micrograms\NNS\13717155 daily\RB\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 PI\NN\13730756 )\-RRB-\1740 by\IN\1740 metered-dose\JJ\1740 inhaler\NN\3210683 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 crossover\NN\13526110 design\NN\927261 .\.\1740
D011188_D014202 NONE At\IN\14622893 the\DT\1740 end\NN\8568978 of\IN\1740 each\DT\1740 14-day\JJ\1740 treatment\NN\654885 ,\,\1740 a\DT\13649268 dose-response\JJ\1740 curve\NN\13863771 (\-LRB-\1740 DRC\NN\1740 )\-RRB-\1740 was\VBD\836236 performed\VBN\2367363 ,\,\1740 and\CC\1740 airway\NN\3253398 (\-LRB-\1740 FEV1\NN\1740 ,\,\1740 FEF25\NN\1740 -\HYPH\1740 75\CD\1740 )\-RRB-\1740 chronotropic\JJ\1740 (\-LRB-\1740 HR\NN\15154774 )\-RRB-\1740 ,\,\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 and\CC\1740 metabolic\JJ\1740 (\-LRB-\1740 <e1>K</e1>\NN\13608598 ,\,\1740 Glu\NN\1740 )\-RRB-\1740 responses\NNS\11410625 were\VBD\836236 measured\VBN\697589 at\IN\14622893 each\DT\1740 step\NN\168237 (\-LRB-\1740 from\IN\1740 100\CD\13745420 to\TO\1740 4,000\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 .\.\1740
D005947_D014202 NONE At\IN\14622893 the\DT\1740 end\NN\8568978 of\IN\1740 each\DT\1740 14-day\JJ\1740 treatment\NN\654885 ,\,\1740 a\DT\13649268 dose-response\JJ\1740 curve\NN\13863771 (\-LRB-\1740 DRC\NN\1740 )\-RRB-\1740 was\VBD\836236 performed\VBN\2367363 ,\,\1740 and\CC\1740 airway\NN\3253398 (\-LRB-\1740 FEV1\NN\1740 ,\,\1740 FEF25\NN\1740 -\HYPH\1740 75\CD\1740 )\-RRB-\1740 chronotropic\JJ\1740 (\-LRB-\1740 HR\NN\15154774 )\-RRB-\1740 ,\,\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 and\CC\1740 metabolic\JJ\1740 (\-LRB-\1740 K\NN\13608598 ,\,\1740 <e1>Glu</e1>\NN\1740 )\-RRB-\1740 responses\NNS\11410625 were\VBD\836236 measured\VBN\697589 at\IN\14622893 each\DT\1740 step\NN\168237 (\-LRB-\1740 from\IN\1740 100\CD\13745420 to\TO\1740 4,000\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 .\.\1740
24675088
D004317_D066126 NONE An\DT\6697703 integrated\JJ\1740 characterization\NN\6724763 of\IN\1740 serological\JJ\1740 ,\,\1740 pathological\JJ\1740 ,\,\1740 and\CC\1740 functional\JJ\1740 events\NNS\23100 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D009202 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 have\VBP\2108377 utilized\VBN\161225 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 progressive\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 ,\,\1740 applying\VBG\2676054 multiple\JJ\1740 approaches\NNS\940842 ,\,\1740 including\VBG\690614 cardiac\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 MRI\NN\901083 )\-RRB-\1740 ,\,\1740 to\TO\1740 provide\VB\2199590 the\DT\1740 most\RBS\1740 comprehensive\JJ\1740 characterization\NN\6724763 to\IN\1740 date\NN\15155220 of\IN\1740 the\DT\1740 timecourse\NN\1740 of\IN\1740 serological\JJ\1740 ,\,\1740 pathological\JJ\1740 ,\,\1740 and\CC\1740 functional\JJ\1740 events\NNS\23100 underlying\VBG\2604760 this\DT\1740 toxicity\NN\13576101 .\.\1740
D004317_D009202 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 have\VBP\2108377 utilized\VBN\161225 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 progressive\JJ\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 ,\,\1740 applying\VBG\2676054 multiple\JJ\1740 approaches\NNS\940842 ,\,\1740 including\VBG\690614 cardiac\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 MRI\NN\901083 )\-RRB-\1740 ,\,\1740 to\TO\1740 provide\VB\2199590 the\DT\1740 most\RBS\1740 comprehensive\JJ\1740 characterization\NN\6724763 to\IN\1740 date\NN\15155220 of\IN\1740 the\DT\1740 timecourse\NN\1740 of\IN\1740 serological\JJ\1740 ,\,\1740 pathological\JJ\1740 ,\,\1740 and\CC\1740 functional\JJ\1740 events\NNS\23100 underlying\VBG\2604760 this\DT\1740 toxicity\NN\13576101 .\.\1740
D004317_D064420 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 have\VBP\2108377 utilized\VBN\161225 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 progressive\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\NN\1740 cardiomyopathy\JJ\1740 ,\,\1740 applying\VBG\2676054 multiple\JJ\1740 approaches\NNS\940842 ,\,\1740 including\VBG\690614 cardiac\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 MRI\NN\901083 )\-RRB-\1740 ,\,\1740 to\TO\1740 provide\VB\2199590 the\DT\1740 most\RBS\1740 comprehensive\JJ\1740 characterization\NN\6724763 to\IN\1740 date\NN\15155220 of\IN\1740 the\DT\1740 timecourse\NN\1740 of\IN\1740 serological\JJ\1740 ,\,\1740 pathological\JJ\1740 ,\,\1740 and\CC\1740 functional\JJ\1740 events\NNS\23100 underlying\VBG\2604760 this\DT\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004317_D064420 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 have\VBP\2108377 utilized\VBN\161225 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 progressive\JJ\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\NN\1740 cardiomyopathy\JJ\1740 ,\,\1740 applying\VBG\2676054 multiple\JJ\1740 approaches\NNS\940842 ,\,\1740 including\VBG\690614 cardiac\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 MRI\NN\901083 )\-RRB-\1740 ,\,\1740 to\TO\1740 provide\VB\2199590 the\DT\1740 most\RBS\1740 comprehensive\JJ\1740 characterization\NN\6724763 to\IN\1740 date\NN\15155220 of\IN\1740 the\DT\1740 timecourse\NN\1740 of\IN\1740 serological\JJ\1740 ,\,\1740 pathological\JJ\1740 ,\,\1740 and\CC\1740 functional\JJ\1740 events\NNS\23100 underlying\VBG\2604760 this\DT\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D005682_D018754 NONE Troponin\NN\1740 I\PRP\14622893 levels\NNS\4916342 positively\RB\1740 correlated\VBD\2657219 with\IN\1740 delayed\VBN\439958 and\CC\1740 peak\NN\13758296 <e1>gadolinium</e1>\NN\14625458 contrast\NN\13854649 enhancement\NN\248977 ,\,\1740 histopathological\JJ\1740 grading\NN\1009871 ,\,\1740 and\CC\1740 <e2>diastolic\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
24100055
D006493_D013921 CID Incidence\NN\13821570 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia\NN\14189204 type\NN\5839024 II</e2>\CD\13741022 and\CC\1740 postoperative\JJ\1740 recovery\NN\7357388 of\IN\1740 platelet\NN\5432736 count\NN\13582013 in\IN\13603305 liver\NN\5298729 graft\NN\5267548 recipients\NNS\9764201 :\:\1740 a\DT\13649268 retrospective\JJ\1740 cohort\NN\8184861 analysis\NN\633864 .\.\1740
D006493_D013921 CID The\DT\1740 impact\NN\7339329 of\IN\1740 immune-mediated\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia\NN\14189204 type\NN\5839024 II</e2>\CD\13741022 (\-LRB-\1740 HIT\NN\36762 type\NN\5839024 II\CD\13741022 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 thrombocytopenia\NN\14189204 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 is\VBZ\836236 not\RB\1740 yet\RB\1740 understood\VBN\588888 ,\,\1740 with\IN\1740 few\JJ\1740 literature\NN\6362953 citations\NNS\6696483 reporting\VBG\831651 contradictory\JJ\1740 results\NNS\34213 .\.\1740
D006493_D013921 CID The\DT\1740 impact\NN\7339329 of\IN\1740 immune-mediated\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 type\NN\5839024 II\CD\13741022 (\-LRB-\1740 <e2>HIT\NN\36762 type\NN\5839024 II</e2>\CD\13741022 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 thrombocytopenia\NN\14189204 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 is\VBZ\836236 not\RB\1740 yet\RB\1740 understood\VBN\588888 ,\,\1740 with\IN\1740 few\JJ\1740 literature\NN\6362953 citations\NNS\6696483 reporting\VBG\831651 contradictory\JJ\1740 results\NNS\34213 .\.\1740
D006493_D013921 CID The\DT\1740 impact\NN\7339329 of\IN\1740 immune-mediated\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 type\NN\5839024 II\CD\13741022 (\-LRB-\1740 HIT\NN\36762 type\NN\5839024 II\CD\13741022 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 is\VBZ\836236 not\RB\1740 yet\RB\1740 understood\VBN\588888 ,\,\1740 with\IN\1740 few\JJ\1740 literature\NN\6362953 citations\NNS\6696483 reporting\VBG\831651 contradictory\JJ\1740 results\NNS\34213 .\.\1740
D006493_D013921 CID For\IN\1740 further\JJ\1740 reduction\NN\351485 of\IN\1740 <e2>HIT\NN\36762 type\NN\5839024 II</e2>\CD\13741022 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 intravenous\JJ\1740 <e1>heparin</e1>\NN\2718259 should\MD\1740 be\VB\836236 avoided\VBN\2452885 and\CC\1740 the\DT\1740 prophylactic\JJ\1740 anticoagulation\NN\657604 should\MD\1740 be\VB\836236 performed\VBN\2367363 with\IN\1740 low-molecular-weight\JJ\1740 heparin\NN\2718259 after\IN\1740 normalization\NN\1123598 of\IN\1740 platelet\NN\5432736 count\NN\13582013 .\.\1740
D006493_D013921 CID For\IN\1740 further\JJ\1740 reduction\NN\351485 of\IN\1740 <e2>HIT\NN\36762 type\NN\5839024 II</e2>\CD\13741022 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 intravenous\JJ\1740 heparin\NN\2718259 should\MD\1740 be\VB\836236 avoided\VBN\2452885 and\CC\1740 the\DT\1740 prophylactic\JJ\1740 anticoagulation\NN\657604 should\MD\1740 be\VB\836236 performed\VBN\2367363 with\IN\1740 low-molecular-weight\JJ\1740 <e1>heparin</e1>\NN\2718259 after\IN\1740 normalization\NN\1123598 of\IN\1740 platelet\NN\5432736 count\NN\13582013 .\.\1740
1837756
D012701_D010259 NONE <e1>Serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 ,\,\1740 <e2>paranoia</e2>\RB\1740 ,\,\1740 and\CC\1740 the\DT\1740 ventral\JJ\1740 basal\JJ\1740 ganglia\NN\5462674 .\.\1740
D012701_D010259 NONE Five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>paranoid</e2>\JJ\1740 exacerbation\NN\374224 with\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 fluoxetine\NN\4169152 and\CC\1740 amitriptyline\NN\4482543 are\VBP\836236 reported\VBN\831651 here\RB\1740 .\.\1740
D012701_D010259 NONE Complicated\JJ\1740 depressive\JJ\1740 disorders\NNS\14034177 (\-LRB-\1740 including\VBG\690614 atypicality\NN\14501726 of\IN\1740 course\NN\883297 and\CC\1740 symptomatology\NN\1740 ,\,\1740 chronicity\NN\1740 ,\,\1740 psychosis\NN\14380140 ,\,\1740 bipolarity\NN\1740 ,\,\1740 and\CC\1740 secondary\JJ\1740 onset\NN\7325190 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 a\DT\13649268 primary\JJ\1740 psychosis\NN\14380140 )\-RRB-\1740 may\MD\15209706 present\VB\2137132 particular\JJ\1740 vulnerability\NN\14540765 to\TO\1740 <e2>paranoid</e2>\NN\10490141 exacerbations\NNS\374224 associated\VBN\628491 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 .\.\1740
D012701_D010259 NONE These\DT\1740 cases\NNS\7283608 call\VBP\1029852 attention\NN\5701944 to\IN\1740 possible\JJ\1740 <e2>paranoid</e2>\JJ\1740 exacerbations\NNS\374224 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 in\IN\13603305 select\JJ\1740 patients\NNS\9898892 and\CC\1740 raise\VBP\153263 neurobiological\JJ\1740 considerations\NNS\5770926 regarding\VBG\689344 paranoia\NN\14398067 .\.\1740
D012701_D010259 NONE These\DT\1740 cases\NNS\7283608 call\VBP\1029852 attention\NN\5701944 to\IN\1740 possible\JJ\1740 paranoid\JJ\1740 exacerbations\NNS\374224 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 blockers\NNS\10101634 in\IN\13603305 select\JJ\1740 patients\NNS\9898892 and\CC\1740 raise\VBP\153263 neurobiological\JJ\1740 considerations\NNS\5770926 regarding\VBG\689344 <e2>paranoia</e2>\NN\14398067 .\.\1740
D005473_D010259 CID Five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>paranoid</e2>\JJ\1740 exacerbation\NN\374224 with\IN\1740 the\DT\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 <e1>fluoxetine</e1>\NN\4169152 and\CC\1740 amitriptyline\NN\4482543 are\VBP\836236 reported\VBN\831651 here\RB\1740 .\.\1740
D000639_D010259 CID Five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>paranoid</e2>\JJ\1740 exacerbation\NN\374224 with\IN\1740 the\DT\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 fluoxetine\NN\4169152 and\CC\1740 <e1>amitriptyline</e1>\NN\4482543 are\VBP\836236 reported\VBN\831651 here\RB\1740 .\.\1740
D012701_D003866 NONE Complicated\JJ\1740 <e2>depressive\JJ\1740 disorders</e2>\NNS\14034177 (\-LRB-\1740 including\VBG\690614 atypicality\NN\14501726 of\IN\1740 course\NN\883297 and\CC\1740 symptomatology\NN\1740 ,\,\1740 chronicity\NN\1740 ,\,\1740 psychosis\NN\14380140 ,\,\1740 bipolarity\NN\1740 ,\,\1740 and\CC\1740 secondary\JJ\1740 onset\NN\7325190 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 a\DT\13649268 primary\JJ\1740 psychosis\NN\14380140 )\-RRB-\1740 may\MD\15209706 present\VB\2137132 particular\JJ\1740 vulnerability\NN\14540765 to\TO\1740 paranoid\NN\10490141 exacerbations\NNS\374224 associated\VBN\628491 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 .\.\1740
D012701_D011605 NONE Complicated\JJ\1740 depressive\JJ\1740 disorders\NNS\14034177 (\-LRB-\1740 including\VBG\690614 atypicality\NN\14501726 of\IN\1740 course\NN\883297 and\CC\1740 symptomatology\NN\1740 ,\,\1740 chronicity\NN\1740 ,\,\1740 <e2>psychosis</e2>\NN\14380140 ,\,\1740 bipolarity\NN\1740 ,\,\1740 and\CC\1740 secondary\JJ\1740 onset\NN\7325190 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 a\DT\13649268 primary\JJ\1740 psychosis\NN\14380140 )\-RRB-\1740 may\MD\15209706 present\VB\2137132 particular\JJ\1740 vulnerability\NN\14540765 to\TO\1740 paranoid\NN\10490141 exacerbations\NNS\374224 associated\VBN\628491 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 .\.\1740
D012701_D011605 NONE Complicated\JJ\1740 depressive\JJ\1740 disorders\NNS\14034177 (\-LRB-\1740 including\VBG\690614 atypicality\NN\14501726 of\IN\1740 course\NN\883297 and\CC\1740 symptomatology\NN\1740 ,\,\1740 chronicity\NN\1740 ,\,\1740 psychosis\NN\14380140 ,\,\1740 bipolarity\NN\1740 ,\,\1740 and\CC\1740 secondary\JJ\1740 onset\NN\7325190 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 a\DT\13649268 primary\JJ\1740 <e2>psychosis</e2>\NN\14380140 )\-RRB-\1740 may\MD\15209706 present\VB\2137132 particular\JJ\1740 vulnerability\NN\14540765 to\TO\1740 paranoid\NN\10490141 exacerbations\NNS\374224 associated\VBN\628491 with\IN\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 .\.\1740
D004298_D010259 NONE Although\IN\1740 the\DT\1740 pharmacology\NN\6043075 and\CC\1740 neurobiology\NN\6037666 of\IN\1740 <e2>paranoia</e2>\RB\1740 remain\VBP\2604760 cryptic\JJ\1740 ,\,\1740 several\JJ\1740 mechanisms\NNS\13446390 ,\,\1740 including\VBG\690614 5HT3\NN\1740 receptor-mediated\JJ\1740 <e1>dopamine</e1>\NN\14807737 release\NN\3748886 ,\,\1740 beta-noradrenergic\JJ\1740 receptor\NN\5225602 downregulation\NN\1740 ,\,\1740 or\CC\3541091 GABAB\NN\1740 receptor\NN\5225602 upregulation\NN\1740 acting\VBG\1619354 in\IN\13603305 the\DT\1740 vicinity\NN\8648322 of\IN\1740 the\DT\1740 ventral\JJ\1740 basal\JJ\1740 ganglia\NN\5462674 (\-LRB-\1740 possibly\RB\1740 in\IN\13603305 lateral\JJ\1740 orbitofrontal\JJ\1740 or\CC\3541091 anterior\JJ\1740 cingulate\NN\1740 circuits\NNS\3269401 )\-RRB-\1740 ,\,\1740 might\MD\5029706 apply\VB\2676054 to\IN\1740 this\DT\1740 phenomenon\NN\29677 .\.\1740
3297909
D013827_D001649 NONE Progressive\JJ\1740 <e2>bile\NN\5405946 duct\NN\5248181 injury</e2>\NN\14052046 after\IN\1740 <e1>thiabendazole</e1>\NN\2720201 administration\NN\1133281 .\.\1740
D013827_D007565 NONE A\DT\13649268 27-yr-old\JJ\1740 man\NN\9605289 developed\VBD\1753788 <e2>jaundice</e2>\NN\14299637 2\CD\13741022 wk\NN\1740 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>thiabendazole</e1>\NN\2720201 .\.\1740
6106951
D005479_D064420 NONE Signs\NNS\6643763 of\IN\1740 <e1>FZP</e1>\NN\1740 <e2>toxocity</e2>\NN\1740 in\IN\13603305 cats\NNS\2120997 included\VBD\690614 excessive\JJ\1740 salivation\NN\13553916 ,\,\1740 extreme\JJ\1740 apprehensive\JJ\1740 behavior\NN\407535 ,\,\1740 retching\NN\1740 ,\,\1740 muscle\NN\5289601 tremors\NNS\345926 and\CC\1740 convulsions\NNS\14081375 .\.\1740
D005479_D012798 NONE Signs\NNS\6643763 of\IN\1740 <e1>FZP</e1>\NN\1740 toxocity\NN\1740 in\IN\13603305 cats\NNS\2120997 included\VBD\690614 excessive\JJ\1740 <e2>salivation</e2>\NN\13553916 ,\,\1740 extreme\JJ\1740 apprehensive\JJ\1740 behavior\NN\407535 ,\,\1740 retching\NN\1740 ,\,\1740 muscle\NN\5289601 tremors\NNS\345926 and\CC\1740 convulsions\NNS\14081375 .\.\1740
D005479_D014202 NONE Signs\NNS\6643763 of\IN\1740 <e1>FZP</e1>\NN\1740 toxocity\NN\1740 in\IN\13603305 cats\NNS\2120997 included\VBD\690614 excessive\JJ\1740 salivation\NN\13553916 ,\,\1740 extreme\JJ\1740 apprehensive\JJ\1740 behavior\NN\407535 ,\,\1740 retching\NN\1740 ,\,\1740 <e2>muscle\NN\5289601 tremors</e2>\NNS\345926 and\CC\1740 convulsions\NNS\14081375 .\.\1740
D005479_D012640 CID Signs\NNS\6643763 of\IN\1740 <e1>FZP</e1>\NN\1740 toxocity\NN\1740 in\IN\13603305 cats\NNS\2120997 included\VBD\690614 excessive\JJ\1740 salivation\NN\13553916 ,\,\1740 extreme\JJ\1740 apprehensive\JJ\1740 behavior\NN\407535 ,\,\1740 retching\NN\1740 ,\,\1740 muscle\NN\5289601 tremors\NNS\345926 and\CC\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D005479_D012640 CID As\IN\14622893 a\DT\13649268 function\NN\13783581 of\IN\1740 dose\NN\3740161 ,\,\1740 <e1>FZP</e1>\NN\1740 first\RB\1740 protected\VBD\1127795 against\IN\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 death\NN\7296428
D005479_D012640 CID These\DT\1740 doses\NNS\3740161 of\IN\1740 <e1>FZP</e1>\NN\1740 were\VBD\836236 lower\JJR\1740 than\IN\1740 those\DT\1740 that\WDT\1740 would\MD\1740 alone\RB\1740 cause\VB\1617192 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D005479_D004827 NONE These\DT\1740 results\NNS\34213 may\MD\15209706 be\VB\836236 relevant\JJ\1740 to\TO\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>FZP</e1>\NN\1740 in\IN\13603305 clinical\JJ\1740 situations\NNS\24720 in\IN\13603305 which\WDT\1740 there\EX\27167 is\VBZ\836236 increased\VBN\169651 neural\JJ\1740 excitability\NN\5653575 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>epilepsy</e2>\NN\14085708 or\CC\3541091 sedative-hypnotic\JJ\1740 drug\NN\14778436 withdrawal\NN\7206096 .\.\1740
44072
C024986_D001145 CID Four\CD\13741022 types\NNS\5839024 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 are\VBP\836236 used\VBN\1156834 --\:\1740 with\IN\1740 <e1>BaCl2</e1>\NN\1740 ,\,\1740 with\IN\1740 chloroform-adrenaline\NN\1740 ,\,\1740 with\IN\1740 strophantine\JJ\1740 G\NN\13717155 and\CC\1740 with\IN\1740 aconitine\NN\1740 .\.\1740
C024986_D001145 CID The\DT\1740 compound\NN\5869584 manifests\VBZ\1015244 antiarrhythmic\JJ\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 models\NNS\5888929 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 used\VBN\1156834 ,\,\1740 causing\VBG\1617192 greatest\JJS\1740 inhibition\NN\1068773 on\IN\1740 the\DT\1740 arrhythmia\NN\14103288 induced\VBN\1627355 by\IN\1740 chloroform-adrenaline\NN\1740 (\-LRB-\1740 in\IN\13603305 90\CD\13745420 per\NN\1740 cent\NN\13662703 )\-RRB-\1740 and\CC\1740 with\IN\1740 <e1>BaCl2</e1>\NN\1740 (\-LRB-\1740 in\IN\13603305 84\CD\1740 per\IN\1740 cent\NN\13662703 )\-RRB-\1740 .\.\1740
C024986_D001145 CID The\DT\1740 compound\NN\5869584 manifests\VBZ\1015244 antiarrhythmic\JJ\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 models\NNS\5888929 of\IN\1740 experimental\JJ\1740 arrhythmia\NN\14103288 used\VBN\1156834 ,\,\1740 causing\VBG\1617192 greatest\JJS\1740 inhibition\NN\1068773 on\IN\1740 the\DT\1740 <e2>arrhythmia</e2>\NN\14103288 induced\VBN\1627355 by\IN\1740 chloroform-adrenaline\NN\1740 (\-LRB-\1740 in\IN\13603305 90\CD\13745420 per\NN\1740 cent\NN\13662703 )\-RRB-\1740 and\CC\1740 with\IN\1740 <e1>BaCl2</e1>\NN\1740 (\-LRB-\1740 in\IN\13603305 84\CD\1740 per\IN\1740 cent\NN\13662703 )\-RRB-\1740 .\.\1740
D002725_D001145 CID Four\CD\13741022 types\NNS\5839024 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 are\VBP\836236 used\VBN\1156834 --\:\1740 with\IN\1740 BaCl2\NN\1740 ,\,\1740 with\IN\1740 <e1>chloroform-adrenaline</e1>\NN\1740 ,\,\1740 with\IN\1740 strophantine\JJ\1740 G\NN\13717155 and\CC\1740 with\IN\1740 aconitine\NN\1740 .\.\1740
D002725_D001145 CID The\DT\1740 compound\NN\5869584 manifests\VBZ\1015244 antiarrhythmic\JJ\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 models\NNS\5888929 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 used\VBN\1156834 ,\,\1740 causing\VBG\1617192 greatest\JJS\1740 inhibition\NN\1068773 on\IN\1740 the\DT\1740 arrhythmia\NN\14103288 induced\VBN\1627355 by\IN\1740 <e1>chloroform-adrenaline</e1>\NN\1740 (\-LRB-\1740 in\IN\13603305 90\CD\13745420 per\NN\1740 cent\NN\13662703 )\-RRB-\1740 and\CC\1740 with\IN\1740 BaCl2\NN\1740 (\-LRB-\1740 in\IN\13603305 84\CD\1740 per\IN\1740 cent\NN\13662703 )\-RRB-\1740 .\.\1740
D002725_D001145 CID The\DT\1740 compound\NN\5869584 manifests\VBZ\1015244 antiarrhythmic\JJ\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 models\NNS\5888929 of\IN\1740 experimental\JJ\1740 arrhythmia\NN\14103288 used\VBN\1156834 ,\,\1740 causing\VBG\1617192 greatest\JJS\1740 inhibition\NN\1068773 on\IN\1740 the\DT\1740 <e2>arrhythmia</e2>\NN\14103288 induced\VBN\1627355 by\IN\1740 <e1>chloroform-adrenaline</e1>\NN\1740 (\-LRB-\1740 in\IN\13603305 90\CD\13745420 per\NN\1740 cent\NN\13662703 )\-RRB-\1740 and\CC\1740 with\IN\1740 BaCl2\NN\1740 (\-LRB-\1740 in\IN\13603305 84\CD\1740 per\IN\1740 cent\NN\13662703 )\-RRB-\1740 .\.\1740
D004837_D001145 CID Four\CD\13741022 types\NNS\5839024 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 are\VBP\836236 used\VBN\1156834 --\:\1740 with\IN\1740 BaCl2\NN\1740 ,\,\1740 with\IN\1740 <e1>chloroform-adrenaline</e1>\NN\1740 ,\,\1740 with\IN\1740 strophantine\JJ\1740 G\NN\13717155 and\CC\1740 with\IN\1740 aconitine\NN\1740 .\.\1740
D004837_D001145 CID The\DT\1740 compound\NN\5869584 manifests\VBZ\1015244 antiarrhythmic\JJ\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 models\NNS\5888929 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 used\VBN\1156834 ,\,\1740 causing\VBG\1617192 greatest\JJS\1740 inhibition\NN\1068773 on\IN\1740 the\DT\1740 arrhythmia\NN\14103288 induced\VBN\1627355 by\IN\1740 <e1>chloroform-adrenaline</e1>\NN\1740 (\-LRB-\1740 in\IN\13603305 90\CD\13745420 per\NN\1740 cent\NN\13662703 )\-RRB-\1740 and\CC\1740 with\IN\1740 BaCl2\NN\1740 (\-LRB-\1740 in\IN\13603305 84\CD\1740 per\IN\1740 cent\NN\13662703 )\-RRB-\1740 .\.\1740
D004837_D001145 CID The\DT\1740 compound\NN\5869584 manifests\VBZ\1015244 antiarrhythmic\JJ\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 models\NNS\5888929 of\IN\1740 experimental\JJ\1740 arrhythmia\NN\14103288 used\VBN\1156834 ,\,\1740 causing\VBG\1617192 greatest\JJS\1740 inhibition\NN\1068773 on\IN\1740 the\DT\1740 <e2>arrhythmia</e2>\NN\14103288 induced\VBN\1627355 by\IN\1740 <e1>chloroform-adrenaline</e1>\NN\1740 (\-LRB-\1740 in\IN\13603305 90\CD\13745420 per\NN\1740 cent\NN\13662703 )\-RRB-\1740 and\CC\1740 with\IN\1740 BaCl2\NN\1740 (\-LRB-\1740 in\IN\13603305 84\CD\1740 per\IN\1740 cent\NN\13662703 )\-RRB-\1740 .\.\1740
D010042_D001145 CID Four\CD\13741022 types\NNS\5839024 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 are\VBP\836236 used\VBN\1156834 --\:\1740 with\IN\1740 BaCl2\NN\1740 ,\,\1740 with\IN\1740 chloroform-adrenaline\NN\1740 ,\,\1740 with\IN\1740 <e1>strophantine\JJ\1740 G</e1>\NN\13717155 and\CC\1740 with\IN\1740 aconitine\NN\1740 .\.\1740
D000157_D001145 CID Four\CD\13741022 types\NNS\5839024 of\IN\1740 experimental\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 are\VBP\836236 used\VBN\1156834 --\:\1740 with\IN\1740 BaCl2\NN\1740 ,\,\1740 with\IN\1740 chloroform-adrenaline\NN\1740 ,\,\1740 with\IN\1740 strophantine\JJ\1740 G\NN\13717155 and\CC\1740 with\IN\1740 <e1>aconitine</e1>\NN\1740 .\.\1740
10087562
D004280_D016171 CID <e2>Torsade\NNP\1740 de\NNP\1740 pointes</e2>\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 low\JJ\1740 dose\NN\3740161 intermittent\NN\1740 <e1>dobutamine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 dilated\JJ\1740 cardiomyopathy\JJ\1740 and\CC\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D004280_D016171 CID The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 56-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 chronic\JJ\1740 ,\,\1740 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 secondary\JJ\1740 to\TO\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 absence\NN\14449405 of\IN\1740 significant\JJ\1740 ventricular\NN\1740 arrhythmias\NNS\14103288 who\WP\8299493 developed\VBD\1753788 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 <e2>torsade\VB\1740 de\NN\1740 pointes</e2>\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 one\CD\13741022 cycle\NN\15269513 of\IN\1740 intermittent\JJ\1740 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 2.5\CD\1740 mcg/kg\NN\1740 per\IN\1740 min\NN\15154774 )\-RRB-\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D016171 CID This\DT\1740 report\NN\6470073 of\IN\1740 <e2>torsade\NN\1740 de\FW\1740 pointes</e2>\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 intermittent\JJ\1740 <e1>dobutamine</e1>\NN\1740 supports\VBZ\2199590 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 unpredictable\JJ\1740 fatal\JJ\1740 arrhythmias\NNS\14103288 may\MD\15209706 occur\VB\2623529 even\RB\1740 with\IN\1740 low\JJ\1740 doses\NNS\3740161 and\CC\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 significant\JJ\1740 rhythm\NN\15122011 disturbances\NNS\407535 .\.\1740
D004280_D017180 NONE Torsade\NNP\1740 de\NNP\1740 pointes\VBZ\831651 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 during\IN\1740 low\JJ\1740 dose\NN\3740161 intermittent\NN\1740 <e1>dobutamine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 dilated\JJ\1740 cardiomyopathy\JJ\1740 and\CC\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D004280_D017180 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 56-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 chronic\JJ\1740 ,\,\1740 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 secondary\JJ\1740 to\TO\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 absence\NN\14449405 of\IN\1740 significant\JJ\1740 ventricular\NN\1740 arrhythmias\NNS\14103288 who\WP\8299493 developed\VBD\1753788 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 torsade\VB\1740 de\NN\1740 pointes\VBZ\831651 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 during\IN\1740 one\CD\13741022 cycle\NN\15269513 of\IN\1740 intermittent\JJ\1740 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 2.5\CD\1740 mcg/kg\NN\1740 per\IN\1740 min\NN\15154774 )\-RRB-\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D017180 NONE This\DT\1740 report\NN\6470073 of\IN\1740 torsade\NN\1740 de\FW\1740 pointes\VBZ\831651 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 during\IN\1740 intermittent\JJ\1740 <e1>dobutamine</e1>\NN\1740 supports\VBZ\2199590 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 unpredictable\JJ\1740 fatal\JJ\1740 arrhythmias\NNS\14103288 may\MD\15209706 occur\VB\2623529 even\RB\1740 with\IN\1740 low\JJ\1740 doses\NNS\3740161 and\CC\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 significant\JJ\1740 rhythm\NN\15122011 disturbances\NNS\407535 .\.\1740
D004280_D002311 NONE Torsade\NNP\1740 de\NNP\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 low\JJ\1740 dose\NN\3740161 intermittent\NN\1740 <e1>dobutamine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>dilated\JJ\1740 cardiomyopathy</e2>\JJ\1740 and\CC\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D004280_D002311 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 56-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 chronic\JJ\1740 ,\,\1740 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 secondary\JJ\1740 to\TO\1740 <e2>dilated\VBN\303465 cardiomyopathy</e2>\JJ\1740 and\CC\1740 absence\NN\14449405 of\IN\1740 significant\JJ\1740 ventricular\NN\1740 arrhythmias\NNS\14103288 who\WP\8299493 developed\VBD\1753788 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 torsade\VB\1740 de\NN\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 one\CD\13741022 cycle\NN\15269513 of\IN\1740 intermittent\JJ\1740 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 2.5\CD\1740 mcg/kg\NN\1740 per\IN\1740 min\NN\15154774 )\-RRB-\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D006333 NONE Torsade\NNP\1740 de\NNP\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 low\JJ\1740 dose\NN\3740161 intermittent\NN\1740 <e1>dobutamine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 dilated\JJ\1740 cardiomyopathy\JJ\1740 and\CC\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D004280_D006333 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 56-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 chronic\JJ\1740 ,\,\1740 severe\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 secondary\JJ\1740 to\TO\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 absence\NN\14449405 of\IN\1740 significant\JJ\1740 ventricular\NN\1740 arrhythmias\NNS\14103288 who\WP\8299493 developed\VBD\1753788 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 torsade\VB\1740 de\NN\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 one\CD\13741022 cycle\NN\15269513 of\IN\1740 intermittent\JJ\1740 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 2.5\CD\1740 mcg/kg\NN\1740 per\IN\1740 min\NN\15154774 )\-RRB-\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D001145 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 56-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 chronic\JJ\1740 ,\,\1740 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 secondary\JJ\1740 to\TO\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 absence\NN\14449405 of\IN\1740 significant\JJ\1740 <e2>ventricular\NN\1740 arrhythmias</e2>\NNS\14103288 who\WP\8299493 developed\VBD\1753788 QT\NN\1740 prolongation\NN\1017987 and\CC\1740 torsade\VB\1740 de\NN\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 one\CD\13741022 cycle\NN\15269513 of\IN\1740 intermittent\JJ\1740 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 2.5\CD\1740 mcg/kg\NN\1740 per\IN\1740 min\NN\15154774 )\-RRB-\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
D004280_D001145 NONE This\DT\1740 report\NN\6470073 of\IN\1740 torsade\NN\1740 de\FW\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 intermittent\JJ\1740 <e1>dobutamine</e1>\NN\1740 supports\VBZ\2199590 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 unpredictable\JJ\1740 fatal\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 may\MD\15209706 occur\VB\2623529 even\RB\1740 with\IN\1740 low\JJ\1740 doses\NNS\3740161 and\CC\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 significant\JJ\1740 rhythm\NN\15122011 disturbances\NNS\407535 .\.\1740
D004280_D008133 NONE The\DT\1740 authors\NNS\9610660 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 56-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 chronic\JJ\1740 ,\,\1740 severe\JJ\1740 heart\NN\5919034 failure\NN\66216 secondary\JJ\1740 to\TO\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 absence\NN\14449405 of\IN\1740 significant\JJ\1740 ventricular\NN\1740 arrhythmias\NNS\14103288 who\WP\8299493 developed\VBD\1753788 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 and\CC\1740 torsade\VB\1740 de\NN\1740 pointes\VBZ\831651 ventricular\JJ\1740 tachycardia\NN\14110674 during\IN\1740 one\CD\13741022 cycle\NN\15269513 of\IN\1740 intermittent\JJ\1740 low\JJ\1740 dose\NN\3740161 (\-LRB-\1740 2.5\CD\1740 mcg/kg\NN\1740 per\IN\1740 min\NN\15154774 )\-RRB-\1740 <e1>dobutamine</e1>\NN\1740 .\.\1740
3083835
D010406_D000707 CID <e1>Penicillin</e1>\NNP\2716866 <e2>anaphylaxis</e2>\NN\14533203 .\.\1740
D010406_D000707 CID A\DT\13649268 case\NN\7283608 of\IN\1740 oral\JJ\1740 <e1>penicillin</e1>\NN\2716866 <e2>anaphylaxis</e2>\NN\14533203 is\VBZ\836236 described\VBN\1001294 ,\,\1740 and\CC\1740 the\DT\1740 terminology\NN\6286395 ,\,\1740 occurrence\NN\29378 ,\,\1740 clinical\JJ\1740 manifestations\NNS\7321772 ,\,\1740 pathogenesis\NN\13533470 ,\,\1740 prevention\NN\1073995 ,\,\1740 and\CC\1740 treatment\NN\654885 of\IN\1740 anaphylaxis\NN\14533203 are\VBP\836236 reviewed\VBN\644583 .\.\1740
D010406_D000707 CID A\DT\13649268 case\NN\7283608 of\IN\1740 oral\JJ\1740 <e1>penicillin</e1>\NN\2716866 anaphylaxis\NN\14533203 is\VBZ\836236 described\VBN\1001294 ,\,\1740 and\CC\1740 the\DT\1740 terminology\NN\6286395 ,\,\1740 occurrence\NN\29378 ,\,\1740 clinical\JJ\1740 manifestations\NNS\7321772 ,\,\1740 pathogenesis\NN\13533470 ,\,\1740 prevention\NN\1073995 ,\,\1740 and\CC\1740 treatment\NN\654885 of\IN\1740 <e2>anaphylaxis</e2>\NN\14533203 are\VBP\836236 reviewed\VBN\644583 .\.\1740
D010406_D000707 CID Emergency\NN\7417644 physicians\NNS\10305802 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 oral\JJ\1740 <e1>penicillin</e1>\NN\2716866 <e2>anaphylaxis</e2>\NN\14533203 in\IN\13603305 order\NN\7168131 to\TO\1740 prevent\VB\1740 its\PRP$\6125041 occurrence\NN\29378 by\IN\1740 prescribing\VBG\748282 the\DT\1740 antibiotic\JJ\1740 judiciously\NN\1740 and\CC\1740 knowledgeably\NN\1740 and\CC\1740 to\TO\1740 offer\VB\2327200 optimal\JJ\1740 medical\JJ\1740 therapy\NN\657604 once\IN\1740 this\DT\1740 life-threatening\JJ\1740 reaction\NN\13446390 has\VBZ\2108377 begun\VBN\941990 .\.\1740
2767010
C043114_D012640 NONE <e1>ACC-9653</e1>\NN\1740 and\CC\1740 phenytoin\NN\3550533 sodium\NN\14625458 have\VBP\2108377 equivalent\JJ\1740 anticonvulsant\JJ\1740 activity\NN\30358 against\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 following\VBG\1835496 i.p.\RB\1740 ,\,\1740 oral\JJ\1740 ,\,\1740 or\CC\3541091 i.v.\NN\1740 administration\NN\1133281 .\.\1740
C043114_D012640 NONE ACC-9653\NN\1740 and\CC\1740 <e1>phenytoin\NN\3550533 sodium</e1>\NN\14625458 have\VBP\2108377 equivalent\JJ\1740 anticonvulsant\JJ\1740 activity\NN\30358 against\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 following\VBG\1835496 i.p.\RB\1740 ,\,\1740 oral\JJ\1740 ,\,\1740 or\CC\3541091 i.v.\NN\1740 administration\NN\1133281 .\.\1740
C043114_D017180 NONE <e1>ACC-9653</e1>\NN\1740 and\CC\1740 phenytoin\NN\3550533 sodium\NN\14625458 have\VBP\2108377 similar\JJ\1740 antiarrhythmic\JJ\1740 activity\NN\30358 against\IN\1740 ouabain-induced\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 .\.\1740
C043114_D017180 NONE ACC-9653\NN\1740 and\CC\1740 <e1>phenytoin\NN\3550533 sodium</e1>\NN\14625458 have\VBP\2108377 similar\JJ\1740 antiarrhythmic\JJ\1740 activity\NN\30358 against\IN\1740 ouabain-induced\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 .\.\1740
D010042_D017180 CID ACC-9653\NN\1740 and\CC\1740 phenytoin\NN\3550533 sodium\NN\14625458 have\VBP\2108377 similar\JJ\1740 antiarrhythmic\JJ\1740 activity\NN\30358 against\IN\1740 <e1>ouabain-induced</e1>\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 in\IN\13603305 anesthetized\VBN\84738 dogs\NNS\2083346 .\.\1740
C043114_D001145 NONE The\DT\1740 total\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ACC-9653</e1>\NN\1740 or\CC\3541091 phenytoin\NN\3550533 sodium\NN\14625458 necessary\JJ\1740 to\TO\1740 convert\VB\126264 the\DT\1740 <e2>arrhythmia</e2>\NN\14103288 to\IN\1740 a\DT\13649268 normal\JJ\1740 sinus\NN\5248181 rhythm\NN\15122011 were\VBD\836236 24\CD\13745420 +/-\CC\1740 6\CD\13741022 and\CC\1740 14\CD\13745420 +/-\CC\1740 3\CD\13741022 mg/kg\NN\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C043114_D001145 NONE The\DT\1740 total\JJ\1740 doses\NNS\3740161 of\IN\1740 ACC-9653\NN\1740 or\CC\3541091 <e1>phenytoin\NN\3550533 sodium</e1>\NN\14625458 necessary\JJ\1740 to\TO\1740 convert\VB\126264 the\DT\1740 <e2>arrhythmia</e2>\NN\14103288 to\IN\1740 a\DT\13649268 normal\JJ\1740 sinus\NN\5248181 rhythm\NN\15122011 were\VBD\836236 24\CD\13745420 +/-\CC\1740 6\CD\13741022 and\CC\1740 14\CD\13745420 +/-\CC\1740 3\CD\13741022 mg/kg\NN\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C043114_D001145 NONE Only\RB\1740 <e1>phenytoin\JJ\1740 sodium</e1>\NN\14625458 displayed\VBD\2137132 in\FW\13603305 vitro\FW\1740 antiarrhythmic\JJ\1740 activity\NN\30358 against\IN\1740 strophanthidin-induced\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 in\IN\13603305 guinea\NN\13388245 pig\NN\2395003 right\RB\1740 atria\RB\1740 .\.\1740
D013327_D001145 CID Only\RB\1740 phenytoin\JJ\1740 sodium\NN\14625458 displayed\VBD\2137132 in\FW\13603305 vitro\FW\1740 antiarrhythmic\JJ\1740 activity\NN\30358 against\IN\1740 <e1>strophanthidin-induced</e1>\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 in\IN\13603305 guinea\NN\13388245 pig\NN\2395003 right\RB\1740 atria\RB\1740 .\.\1740
C043114_D064420 NONE Acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 studies\NNS\635850 of\IN\1740 <e1>ACC-9653</e1>\NN\1740 and\CC\1740 phenytoin\NN\3550533 sodium\NN\14625458 were\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 rats\NNS\2329401 ,\,\1740 rabbits\VBZ\1143838 ,\,\1740 and\CC\1740 dogs\NNS\2083346 by\IN\1740 i.v.\NN\1740 ,\,\1740 i.m.\RB\1740 ,\,\1740 and\CC\1740 i.p.\RB\1740 routes\NNS\8593262 of\IN\1740 administration\NN\1133281 .\.\1740
C043114_D064420 NONE Acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 studies\NNS\635850 of\IN\1740 ACC-9653\NN\1740 and\CC\1740 <e1>phenytoin\NN\3550533 sodium</e1>\NN\14625458 were\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 rats\NNS\2329401 ,\,\1740 rabbits\VBZ\1143838 ,\,\1740 and\CC\1740 dogs\NNS\2083346 by\IN\1740 i.v.\NN\1740 ,\,\1740 i.m.\RB\1740 ,\,\1740 and\CC\1740 i.p.\RB\1740 routes\NNS\8593262 of\IN\1740 administration\NN\1133281 .\.\1740
9272404
D002245_D010146 NONE Phasic\JJ\1740 <e2>pain</e2>\NN\14299637 was\VBD\836236 applied\VBN\2676054 by\IN\1740 means\NNS\44150 of\IN\1740 short\JJ\1740 pulses\NNS\7345593 of\IN\1740 <e1>CO2</e1>\NN\14836127 to\TO\1740 the\DT\1740 nasal\JJ\1740 mucosa\NN\5426243 (\-LRB-\1740 stimulus\NN\5816287 duration\NN\15113229 500\CD\13745420 ms\NN\14187378 ,\,\1740 interval\NN\33615 approximately\RB\1740 60\CD\13745420 s\NNS\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 tonic\JJ\1740 pain\NN\14299637 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 the\DT\1740 nasal\JJ\1740 cavity\NN\9304750 by\IN\1740 means\NNS\44150 of\IN\1740 dry\JJ\1740 air\NN\14877585 of\IN\1740 controlled\VBN\2422663 temperature\NN\13575869 ,\,\1740 humidity\NN\14534696 and\CC\1740 flow\NN\7311115 rate\NN\13815152 (\-LRB-\1740 22\CD\13745420 degrees\NNS\4916342 C\NN\13714184 ,\,\1740 0\CD\13741022 %\NN\1740 relative\JJ\1740 humidity\NN\14534696 ,\,\1740 145\CD\1740 ml.s-1\NNS\1740 )\-RRB-\1740 .\.\1740
D002245_D010146 NONE Phasic\JJ\1740 pain\NN\14299637 was\VBD\836236 applied\VBN\2676054 by\IN\1740 means\NNS\44150 of\IN\1740 short\JJ\1740 pulses\NNS\7345593 of\IN\1740 <e1>CO2</e1>\NN\14836127 to\TO\1740 the\DT\1740 nasal\JJ\1740 mucosa\NN\5426243 (\-LRB-\1740 stimulus\NN\5816287 duration\NN\15113229 500\CD\13745420 ms\NN\14187378 ,\,\1740 interval\NN\33615 approximately\RB\1740 60\CD\13745420 s\NNS\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 tonic\JJ\1740 <e2>pain</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 the\DT\1740 nasal\JJ\1740 cavity\NN\9304750 by\IN\1740 means\NNS\44150 of\IN\1740 dry\JJ\1740 air\NN\14877585 of\IN\1740 controlled\VBN\2422663 temperature\NN\13575869 ,\,\1740 humidity\NN\14534696 and\CC\1740 flow\NN\7311115 rate\NN\13815152 (\-LRB-\1740 22\CD\13745420 degrees\NNS\4916342 C\NN\13714184 ,\,\1740 0\CD\13741022 %\NN\1740 relative\JJ\1740 humidity\NN\14534696 ,\,\1740 145\CD\1740 ml.s-1\NNS\1740 )\-RRB-\1740 .\.\1740
D002245_D010146 NONE Both\CC\1740 CSSEPs\NNS\1740 as\IN\14622893 central\JJ\1740 and\CC\1740 NMPs\NNS\1740 as\IN\14622893 peripheral\JJ\1740 correlates\NNS\5857459 of\IN\1740 <e2>pain</e2>\NN\14299637 were\VBD\836236 obtained\VBN\2210855 in\IN\13603305 response\NN\11410625 to\TO\1740 the\DT\1740 <e1>CO2</e1>\NN\14836127 stimuli\NNS\5816287 .\.\1740
D007052_D010146 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 described\VBN\1001294 earlier\RBR\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 tonic\JJ\1740 <e2>pain</e2>\NN\14299637 but-relative\JJ\1740 to\TO\1740 placebo-an\JJ\1740 increase\NN\13576355 in\IN\13603305 correlates\NNS\5857459 of\IN\1740 phasic\JJ\1740 pain\NN\14299637 ,\,\1740 indicating\VBG\952524 a\DT\13649268 specific\JJ\1740 effect\NN\34213 of\IN\1740 ibuprofen\NN\3828465 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 the\DT\1740 pain\NN\14299637 stimuli\NNS\5816287 under\IN\1740 these\DT\1740 special\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D007052_D010146 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 described\VBN\1001294 earlier\RBR\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 tonic\JJ\1740 pain\NN\14299637 but-relative\JJ\1740 to\TO\1740 placebo-an\JJ\1740 increase\NN\13576355 in\IN\13603305 correlates\NNS\5857459 of\IN\1740 phasic\JJ\1740 <e2>pain</e2>\NN\14299637 ,\,\1740 indicating\VBG\952524 a\DT\13649268 specific\JJ\1740 effect\NN\34213 of\IN\1740 ibuprofen\NN\3828465 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 the\DT\1740 pain\NN\14299637 stimuli\NNS\5816287 under\IN\1740 these\DT\1740 special\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D007052_D010146 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 described\VBN\1001294 earlier\RBR\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 tonic\JJ\1740 pain\NN\14299637 but-relative\JJ\1740 to\TO\1740 placebo-an\JJ\1740 increase\NN\13576355 in\IN\13603305 correlates\NNS\5857459 of\IN\1740 phasic\JJ\1740 pain\NN\14299637 ,\,\1740 indicating\VBG\952524 a\DT\13649268 specific\JJ\1740 effect\NN\34213 of\IN\1740 ibuprofen\NN\3828465 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 the\DT\1740 <e2>pain</e2>\NN\14299637 stimuli\NNS\5816287 under\IN\1740 these\DT\1740 special\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D007052_D010146 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 described\VBN\1001294 earlier\RBR\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 ibuprofen\NN\3828465 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 tonic\JJ\1740 <e2>pain</e2>\NN\14299637 but-relative\JJ\1740 to\TO\1740 placebo-an\JJ\1740 increase\NN\13576355 in\IN\13603305 correlates\NNS\5857459 of\IN\1740 phasic\JJ\1740 pain\NN\14299637 ,\,\1740 indicating\VBG\952524 a\DT\13649268 specific\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 the\DT\1740 pain\NN\14299637 stimuli\NNS\5816287 under\IN\1740 these\DT\1740 special\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D007052_D010146 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 described\VBN\1001294 earlier\RBR\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 ibuprofen\NN\3828465 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 tonic\JJ\1740 pain\NN\14299637 but-relative\JJ\1740 to\TO\1740 placebo-an\JJ\1740 increase\NN\13576355 in\IN\13603305 correlates\NNS\5857459 of\IN\1740 phasic\JJ\1740 <e2>pain</e2>\NN\14299637 ,\,\1740 indicating\VBG\952524 a\DT\13649268 specific\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 the\DT\1740 pain\NN\14299637 stimuli\NNS\5816287 under\IN\1740 these\DT\1740 special\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D007052_D010146 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 described\VBN\1001294 earlier\RBR\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 ibuprofen\NN\3828465 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 tonic\JJ\1740 pain\NN\14299637 but-relative\JJ\1740 to\TO\1740 placebo-an\JJ\1740 increase\NN\13576355 in\IN\13603305 correlates\NNS\5857459 of\IN\1740 phasic\JJ\1740 pain\NN\14299637 ,\,\1740 indicating\VBG\952524 a\DT\13649268 specific\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ibuprofen</e1>\NN\3828465 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 the\DT\1740 <e2>pain</e2>\NN\14299637 stimuli\NNS\5816287 under\IN\1740 these\DT\1740 special\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
18340638
D001379_D000740 CID The\DT\1740 side\NN\8630039 effects\NNS\13245626 of\IN\1740 <e1>azathioprine</e1>\NN\3740161 include\VBP\690614 <e2>anemia</e2>\NN\14189204 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 attributed\VBN\670261 to\TO\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 .\.\1740
D001379_D000740 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Azathioprine</e1>\NN\3740161 triggers\VBZ\1641914 suicidal\JJ\1740 erythrocyte\NN\5449268 death\NN\7296428 ,\,\1740 an\DT\6697703 effect\NN\34213 presumably\RB\1740 contributing\VBG\126264 to\TO\1740 azathioprine-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D001379_D000740 CID CONCLUSIONS\NNS\5837957 :\:\1740 Azathioprine\NN\3740161 triggers\VBZ\1641914 suicidal\JJ\1740 erythrocyte\NN\5449268 death\NN\7296428 ,\,\1740 an\DT\6697703 effect\NN\34213 presumably\RB\1740 contributing\VBG\126264 to\TO\1740 <e1>azathioprine-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D010718_D000740 NONE Alternatively\RB\1740 ,\,\1740 <e2>anemia</e2>\NN\14189204 could\MD\1740 result\VB\2633881 from\IN\1740 accelerated\VBN\226566 suicidal\JJ\1740 erythrocyte\NN\5449268 death\NN\7296428 or\CC\3541091 eryptosis\NN\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 exposure\NN\5042871 of\IN\1740 <e1>phosphatidylserine</e1>\NN\1740 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 at\IN\14622893 the\DT\1740 erythrocyte\NN\5449268 surface\NN\21939 and\CC\1740 by\IN\1740 cell\NN\3080309 shrinkage\NN\7355887 .\.\1740
D010718_D000740 NONE Alternatively\RB\1740 ,\,\1740 <e2>anemia</e2>\NN\14189204 could\MD\1740 result\VB\2633881 from\IN\1740 accelerated\VBN\226566 suicidal\JJ\1740 erythrocyte\NN\5449268 death\NN\7296428 or\CC\3541091 eryptosis\NN\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 exposure\NN\5042871 of\IN\1740 phosphatidylserine\NN\1740 (\-LRB-\1740 <e1>PS</e1>\NN\6763273 )\-RRB-\1740 at\IN\14622893 the\DT\1740 erythrocyte\NN\5449268 surface\NN\21939 and\CC\1740 by\IN\1740 cell\NN\3080309 shrinkage\NN\7355887 .\.\1740
10726030
D006493_D013921 CID Clinical\JJ\1740 aspects\NNS\5849789 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 thrombosis\NN\14100769 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013921 CID Clinical\JJ\1740 aspects\NNS\5849789 of\IN\1740 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 thrombosis\NN\14100769 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013921 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D013921 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D013921 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D013921 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D013921 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D013921 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D013921 NONE These\DT\1740 side\NN\8630039 effects\NNS\13245626 are\VBP\836236 relatively\RB\1740 rare\JJ\1740 in\IN\13603305 a\DT\13649268 given\VBN\2327200 individual\JJ\1740 ,\,\1740 but\CC\1740 given\VBN\2327200 the\DT\1740 extremely\RB\1740 widespread\JJ\1740 use\NN\407535 of\IN\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 some\DT\1740 are\VBP\836236 quite\RB\1740 common\JJ\1740 ,\,\1740 particularly\RB\1740 <e2>HITT</e2>\NN\1740 and\CC\1740 osteoporosis\NN\14204950 .\.\1740
D006493_D013927 NONE Clinical\JJ\1740 aspects\NNS\5849789 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>thrombosis</e2>\NN\14100769 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013927 NONE Clinical\JJ\1740 aspects\NNS\5849789 of\IN\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>thrombosis</e2>\NN\14100769 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013927 NONE <e1>Heparin</e1>\NN\2718259 ,\,\1740 first\RB\1740 used\VBN\1156834 to\TO\1740 prevent\VB\1740 the\DT\1740 clotting\NN\13518963 of\IN\1740 blood\NN\5397468 in\FW\13603305 vitro\FW\1740 ,\,\1740 has\VBZ\2108377 been\VBN\836236 clinically\RB\1740 used\VBN\1156834 to\TO\1740 treat\VB\2376958 <e2>thrombosis</e2>\NN\14100769 for\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 years\NNS\15144371 .\.\1740
D006493_D013927 NONE Although\IN\1740 several\JJ\1740 new\JJ\1740 anticoagulant\JJ\1740 drugs\NNS\14778436 are\VBP\836236 in\IN\13603305 development\NN\248977 ,\,\1740 <e1>heparin</e1>\NN\2718259 remains\VBZ\2604760 the\DT\1740 anticoagulant\NN\3740161 of\IN\1740 choice\NN\5788149 to\TO\1740 treat\VB\2376958 acute\JJ\1740 <e2>thrombotic</e2>\JJ\1740 episodes\NNS\7283608 .\.\1740
D006493_D013927 NONE These\DT\1740 side\NN\8630039 effects\NNS\13245626 are\VBP\836236 relatively\RB\1740 rare\JJ\1740 in\IN\13603305 a\DT\13649268 given\VBN\2327200 individual\JJ\1740 ,\,\1740 but\CC\1740 given\VBN\2327200 the\DT\1740 extremely\RB\1740 widespread\JJ\1740 use\NN\407535 of\IN\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 some\DT\1740 are\VBP\836236 quite\RB\1740 common\JJ\1740 ,\,\1740 particularly\RB\1740 <e2>HITT</e2>\NN\1740 and\CC\1740 osteoporosis\NN\14204950 .\.\1740
D006493_D006470 NONE <e2>Bleeding</e2>\NN\14285662 is\VBZ\836236 the\DT\1740 primary\JJ\1740 untoward\JJ\1740 effect\NN\34213 of\IN\1740 <e1>heparin</e1>\NN\2718259 .\.\1740
D006493_D006470 NONE Major\JJ\1740 <e2>bleeding</e2>\NN\14285662 is\VBZ\836236 of\IN\1740 primary\JJ\1740 concern\NN\5682950 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D010024 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 <e2>osteoporosis</e2>\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D010024 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 <e2>osteoporosis</e2>\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D010024 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 <e2>osteoporosis</e2>\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D010024 CID These\DT\1740 side\NN\8630039 effects\NNS\13245626 are\VBP\836236 relatively\RB\1740 rare\JJ\1740 in\IN\13603305 a\DT\13649268 given\VBN\2327200 individual\JJ\1740 ,\,\1740 but\CC\1740 given\VBN\2327200 the\DT\1740 extremely\RB\1740 widespread\JJ\1740 use\NN\407535 of\IN\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 some\DT\1740 are\VBP\836236 quite\RB\1740 common\JJ\1740 ,\,\1740 particularly\RB\1740 HITT\NN\1740 and\CC\1740 <e2>osteoporosis</e2>\NN\14204950 .\.\1740
D006493_D004802 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D004802 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D004802 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D012871 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D012871 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D012871 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D004342 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D004342 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D004342 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D000505 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e2>alopecia</e2>\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D000505 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e2>alopecia</e2>\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D000505 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e2>alopecia</e2>\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D006947 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 <e2>hyperkalemia</e2>\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D006947 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 <e2>hyperkalemia</e2>\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D006947 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 <e2>hyperkalemia</e2>\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D006994 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 <e2>hypoaldosteronism</e2>\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D006994 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 <e2>hypoaldosteronism</e2>\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D006994 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 <e2>hypoaldosteronism</e2>\NN\1740 ,\,\1740 and\CC\1740 priapism\NN\14204950 .\.\1740
D006493_D011317 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 <e2>priapism</e2>\NN\14204950 .\.\1740
D006493_D011317 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 <e2>priapism</e2>\NN\14204950 .\.\1740
D006493_D011317 CID However\RB\1740 ,\,\1740 additional\JJ\1740 important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 include\VBP\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 ,\,\1740 alopecia\NN\14457041 ,\,\1740 transaminasemia\NN\1740 ,\,\1740 hyperkalemia\NN\14299637 ,\,\1740 hypoaldosteronism\NN\1740 ,\,\1740 and\CC\1740 <e2>priapism</e2>\NN\14204950 .\.\1740
10427794
C065757_D056486 CID <e1>Meloxicam-induced</e1>\JJ\1740 <e2>liver\NN\5298729 toxicity</e2>\NN\13576101 .\.\1740
C065757_D056486 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 female\JJ\1740 patient\NN\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 cytolytic\JJ\1740 <e2>hepatitis</e2>\NN\14127211 due\JJ\1740 to\TO\1740 <e1>meloxicam</e1>\VB\1740 .\.\1740
C065757_D056486 CID The\DT\1740 acute\JJ\1740 cytolytic\JJ\1740 <e2>hepatitis</e2>\NN\14127211 occurred\VBD\2623529 rapidly\RB\1740 after\IN\1740 <e1>meloxicam</e1>\JJ\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 antinuclear\JJ\1740 antibodies\NNS\14728724 suggesting\VBG\1010118 a\DT\13649268 hypersensitivity\NN\14531772 mechanism\NN\13446390 .\.\1740
C065757_D056486 CID This\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 <e1>meloxicam</e1>\NN\1740 related\JJ\1740 <e2>liver\NN\5298729 toxicity</e2>\NN\13576101 demonstrates\VBZ\2137132 the\DT\1740 potential\NN\14481929 of\IN\1740 this\DT\1740 drug\NN\14778436 to\TO\1740 induce\VB\1627355 hepatic\JJ\1740 damage\NN\7296428 .\.\1740
C065757_D056486 CID This\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 <e1>meloxicam</e1>\NN\1740 related\JJ\1740 liver\NN\5298729 toxicity\NN\13576101 demonstrates\VBZ\2137132 the\DT\1740 potential\NN\14481929 of\IN\1740 this\DT\1740 drug\NN\14778436 to\TO\1740 induce\VB\1627355 <e2>hepatic\JJ\1740 damage</e2>\NN\7296428 .\.\1740
C065757_D001172 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 female\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 cytolytic\JJ\1740 hepatitis\NN\14127211 due\JJ\1740 to\TO\1740 <e1>meloxicam</e1>\VB\1740 .\.\1740
C065757_D004342 CID The\DT\1740 acute\JJ\1740 cytolytic\JJ\1740 hepatitis\NN\14127211 occurred\VBD\2623529 rapidly\RB\1740 after\IN\1740 <e1>meloxicam</e1>\JJ\1740 administration\NN\1133281 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 antinuclear\JJ\1740 antibodies\NNS\14728724 suggesting\VBG\1010118 a\DT\13649268 <e2>hypersensitivity</e2>\NN\14531772 mechanism\NN\13446390 .\.\1740
19184102
D014635_D065626 CID <e2>Nonalcoholic\JJ\1740 fatty\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 during\IN\1740 <e1>valproate</e1>\NN\1740 therapy\NN\657604 .\.\1740
D014635_D065626 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>nonalcoholic\JJ\1740 fatty\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 (\-LRB-\1740 NAFLD\NN\1740 )\-RRB-\1740 arising\VBG\2623529 in\IN\13603305 a\DT\13649268 child\NN\9622049 who\WP\8299493 developed\VBD\1753788 obesity\NN\4999401 during\IN\1740 <e1>VPA</e1>\NN\1740 treatment\NN\654885 .\.\1740
D014635_D065626 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 nonalcoholic\JJ\1740 fatty\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 <e2>NAFLD</e2>\NN\1740 )\-RRB-\1740 arising\VBG\2623529 in\IN\13603305 a\DT\13649268 child\NN\9622049 who\WP\8299493 developed\VBD\1753788 obesity\NN\4999401 during\IN\1740 <e1>VPA</e1>\NN\1740 treatment\NN\654885 .\.\1740
D014635_D065626 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 obesity\NN\4999401 ,\,\1740 hyperinsulinemia\NN\1740 ,\,\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>VPA</e1>\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>NAFLD</e2>\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 VPA\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D065626 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 obesity\NN\4999401 ,\,\1740 hyperinsulinemia\NN\1740 ,\,\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 VPA\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>NAFLD</e2>\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 <e1>VPA</e1>\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D004827 NONE <e1>Valproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 is\VBZ\836236 effective\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 types\NNS\5839024 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 ,\,\1740 but\CC\1740 its\PRP$\6125041 use\NN\407535 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 body\NN\19128 weight\NN\5009170 .\.\1740
D014635_D004827 NONE Valproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>VPA</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 effective\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 types\NNS\5839024 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 ,\,\1740 but\CC\1740 its\PRP$\6125041 use\NN\407535 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 body\NN\19128 weight\NN\5009170 .\.\1740
D014635_D009765 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 nonalcoholic\JJ\1740 fatty\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 NAFLD\NN\1740 )\-RRB-\1740 arising\VBG\2623529 in\IN\13603305 a\DT\13649268 child\NN\9622049 who\WP\8299493 developed\VBD\1753788 <e2>obesity</e2>\NN\4999401 during\IN\1740 <e1>VPA</e1>\NN\1740 treatment\NN\654885 .\.\1740
D014635_D009765 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 <e2>obesity</e2>\NN\4999401 ,\,\1740 hyperinsulinemia\NN\1740 ,\,\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>VPA</e1>\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 NAFLD\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 VPA\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D009765 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 <e2>obesity</e2>\NN\4999401 ,\,\1740 hyperinsulinemia\NN\1740 ,\,\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 VPA\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 NAFLD\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 <e1>VPA</e1>\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D015431 NONE After\IN\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 <e1>VPA</e1>\NN\1740 therapy\NN\657604 ,\,\1740 our\PRP$\1740 patient\NN\9898892 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 ,\,\1740 a\DT\13649268 decrease\NN\7296428 of\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 ,\,\1740 and\CC\1740 normalization\NN\1123598 of\IN\1740 metabolic\JJ\1740 and\CC\1740 endocrine\JJ\1740 parameters\NNS\5858936 ;\:\1740 moreover\RB\1740 ,\,\1740 ultrasound\JJ\1740 measurements\NNS\407535 showed\VBD\2137132 a\DT\13649268 complete\JJ\1740 normalization\NN\1123598 .\.\1740
D014635_D006946 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 obesity\NN\4999401 ,\,\1740 <e2>hyperinsulinemia</e2>\NN\1740 ,\,\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>VPA</e1>\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 NAFLD\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 VPA\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D006946 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 obesity\NN\4999401 ,\,\1740 <e2>hyperinsulinemia</e2>\NN\1740 ,\,\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 VPA\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 NAFLD\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 <e1>VPA</e1>\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D007333 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 obesity\NN\4999401 ,\,\1740 hyperinsulinemia\NN\1740 ,\,\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>VPA</e1>\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 NAFLD\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 VPA\NN\1740 withdrawal\NN\7206096 .\.\1740
D014635_D007333 CID The\DT\1740 present\JJ\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 obesity\NN\4999401 ,\,\1740 hyperinsulinemia\NN\1740 ,\,\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 ,\,\1740 and\CC\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 VPA\NN\1740 may\MD\15209706 be\VB\836236 all\DT\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 NAFLD\NN\1740 ;\:\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 is\VBZ\836236 reversible\JJ\1740 after\IN\1740 <e1>VPA</e1>\NN\1740 withdrawal\NN\7206096 .\.\1740
18399341
D004837_D007022 NONE Four\CD\13741022 (\-LRB-\1740 10.8\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 conventional\JJ\1740 group\NN\2137 and\CC\1740 1\CD\13741022 (\-LRB-\1740 2.7\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 unilateral\JJ\1740 group\NN\2137 ,\,\1740 P=\NN\1740 0.17\CD\1740 required\VBD\754942 <e1>epinephrine</e1>\NN\14807929 infusion\NN\14589223 to\TO\1740 treat\VB\2376958 <e2>hypotension</e2>\NN\14057371 .\.\1740
24742750
D016593_D016171 CID Finally\RB\1740 ,\,\1740 the\DT\1740 IKr\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>Terfenadine</e1>\NNP\1740 and\CC\1740 Citalopram\NNP\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 reported\VBN\831651 to\TO\1740 cause\VB\1617192 <e2>Torsade\NNP\1740 de\NNP\1740 Pointes</e2>\NNP\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 ,\,\1740 produced\VBN\1617192 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 .\.\1740
D016593_D016171 CID Finally\RB\1740 ,\,\1740 the\DT\1740 IKr\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>Terfenadine</e1>\NNP\1740 and\CC\1740 Citalopram\NNP\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 reported\VBN\831651 to\TO\1740 cause\VB\1617192 Torsade\NNP\1740 de\NNP\1740 Pointes\NNP\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 ,\,\1740 produced\VBN\1617192 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 .\.\1740
D015283_D016171 CID Finally\RB\1740 ,\,\1740 the\DT\1740 IKr\NN\1740 blockers\NNS\10101634 ,\,\1740 Terfenadine\NNP\1740 and\CC\1740 <e1>Citalopram</e1>\NNP\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 reported\VBN\831651 to\TO\1740 cause\VB\1617192 <e2>Torsade\NNP\1740 de\NNP\1740 Pointes</e2>\NNP\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 ,\,\1740 produced\VBN\1617192 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 .\.\1740
D015283_D016171 CID Finally\RB\1740 ,\,\1740 the\DT\1740 IKr\NN\1740 blockers\NNS\10101634 ,\,\1740 Terfenadine\NNP\1740 and\CC\1740 <e1>Citalopram</e1>\NNP\1740 ,\,\1740 which\WDT\1740 are\VBP\836236 reported\VBN\831651 to\TO\1740 cause\VB\1617192 Torsade\NNP\1740 de\NNP\1740 Pointes\NNP\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 clinical\JJ\1740 practice\NN\407535 ,\,\1740 produced\VBN\1617192 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 .\.\1740
2358093
D003613_D054179 NONE The\DT\1740 long-term\JJ\1740 safety\NN\13920835 of\IN\1740 <e1>danazol</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 <e2>hereditary\JJ\1740 angioedema</e2>\NN\14316714 .\.\1740
D003613_D054179 NONE We\PRP\1740 therefore\RB\1740 investigated\VBD\644583 the\DT\1740 long-term\JJ\1740 safety\NN\13920835 of\IN\1740 <e1>danazol</e1>\NN\1740 by\IN\1740 performing\VBG\2367363 a\DT\13649268 retrospective\JJ\1740 chart\NN\6873252 review\NN\5733583 of\IN\1740 60\CD\13745420 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hereditary\JJ\1740 angioedema</e2>\NN\14316714 treated\VBN\2376958 with\IN\1740 danazol\NN\1740 for\IN\1740 a\DT\13649268 continuous\JJ\1740 period\NN\13575869 of\IN\1740 6\CD\13741022 months\NNS\15113229 or\CC\3541091 longer\RBR\1740 .\.\1740
D003613_D054179 NONE We\PRP\1740 therefore\RB\1740 investigated\VBD\644583 the\DT\1740 long-term\JJ\1740 safety\NN\13920835 of\IN\1740 danazol\NN\1740 by\IN\1740 performing\VBG\2367363 a\DT\13649268 retrospective\JJ\1740 chart\NN\6873252 review\NN\5733583 of\IN\1740 60\CD\13745420 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hereditary\JJ\1740 angioedema</e2>\NN\14316714 treated\VBN\2376958 with\IN\1740 <e1>danazol</e1>\NN\1740 for\IN\1740 a\DT\13649268 continuous\JJ\1740 period\NN\13575869 of\IN\1740 6\CD\13741022 months\NNS\15113229 or\CC\3541091 longer\RBR\1740 .\.\1740
15859361
C105934_D003875 NONE Safety\NN\13920835 of\IN\1740 <e1>celecoxib</e1>\NN\3124700 in\IN\13603305 patients\NNS\9898892 with\IN\1740 adverse\JJ\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 to\TO\1740 acetaminophen\VB\1740 (\-LRB-\1740 paracetamol\NN\1740 )\-RRB-\1740 and\CC\1740 nimesulide\NN\1740 associated\VBN\628491 or\CC\3541091 not\RB\1740 with\IN\1740 common\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 .\.\1740
C105934_D003875 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 evaluated\VBD\670261 the\DT\1740 tolerability\NN\1740 of\IN\1740 <e1>CE</e1>\NN\14625458 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 with\IN\1740 documented\VBN\1000214 history\NN\15120823 of\IN\1740 adverse\JJ\1740 <e2>cutaneous\JJ\1740 reactions</e2>\NNS\13446390 to\TO\1740 P\NN\14622893 and\CC\1740 N\NN\14622893 associated\VBN\628491 or\CC\3541091 not\RB\1740 to\TO\1740 classic\JJ\1740 NSAIDs\NNS\2721538 .\.\1740
D000082_D003875 CID Safety\NN\13920835 of\IN\1740 celecoxib\NN\3124700 in\IN\13603305 patients\NNS\9898892 with\IN\1740 adverse\JJ\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 to\TO\1740 <e1>acetaminophen</e1>\VB\1740 (\-LRB-\1740 paracetamol\NN\1740 )\-RRB-\1740 and\CC\1740 nimesulide\NN\1740 associated\VBN\628491 or\CC\3541091 not\RB\1740 with\IN\1740 common\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 .\.\1740
D000082_D003875 CID Safety\NN\13920835 of\IN\1740 celecoxib\NN\3124700 in\IN\13603305 patients\NNS\9898892 with\IN\1740 adverse\JJ\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 to\TO\1740 acetaminophen\VB\1740 (\-LRB-\1740 <e1>paracetamol</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 nimesulide\NN\1740 associated\VBN\628491 or\CC\3541091 not\RB\1740 with\IN\1740 common\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 .\.\1740
D000082_D003875 CID OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 evaluated\VBD\670261 the\DT\1740 tolerability\NN\1740 of\IN\1740 CE\NN\14625458 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 with\IN\1740 documented\VBN\1000214 history\NN\15120823 of\IN\1740 adverse\JJ\1740 <e2>cutaneous\JJ\1740 reactions</e2>\NNS\13446390 to\TO\1740 <e1>P</e1>\NN\14622893 and\CC\1740 N\NN\14622893 associated\VBN\628491 or\CC\3541091 not\RB\1740 to\TO\1740 classic\JJ\1740 NSAIDs\NNS\2721538 .\.\1740
D000082_D003875 CID The\DT\1740 diagnosis\NN\152018 of\IN\1740 <e1>P</e1>\NN\14622893 and\CC\1740 N-induced\JJ\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 was\VBD\836236 based\VBN\2694933 in\FW\13603305 vivo\FW\1740 challenge\NN\13927383 .\.\1740
C012655_D003875 CID Safety\NN\13920835 of\IN\1740 celecoxib\NN\3124700 in\IN\13603305 patients\NNS\9898892 with\IN\1740 adverse\JJ\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 to\TO\1740 acetaminophen\VB\1740 (\-LRB-\1740 paracetamol\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>nimesulide</e1>\NN\1740 associated\VBN\628491 or\CC\3541091 not\RB\1740 with\IN\1740 common\JJ\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 .\.\1740
C012655_D003875 CID OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 evaluated\VBD\670261 the\DT\1740 tolerability\NN\1740 of\IN\1740 CE\NN\14625458 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 with\IN\1740 documented\VBN\1000214 history\NN\15120823 of\IN\1740 adverse\JJ\1740 <e2>cutaneous\JJ\1740 reactions</e2>\NNS\13446390 to\TO\1740 P\NN\14622893 and\CC\1740 <e1>N</e1>\NN\14622893 associated\VBN\628491 or\CC\3541091 not\RB\1740 to\TO\1740 classic\JJ\1740 NSAIDs\NNS\2721538 .\.\1740
C012655_D003875 CID The\DT\1740 diagnosis\NN\152018 of\IN\1740 P\NN\14622893 and\CC\1740 <e1>N-induced</e1>\JJ\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 was\VBD\836236 based\VBN\2694933 in\FW\13603305 vivo\FW\1740 challenge\NN\13927383 .\.\1740
D000082_D004342 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 9\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 <e1>P</e1>\NN\14622893 and\CC\1740 N\NN\14622893 with\IN\1740 or\CC\3541091 without\IN\1740 associated\VBN\628491 reactions\NNS\13446390 to\TO\1740 classic\JJ\1740 NSAIDs\NNS\2721538 .\.\1740
D000082_D004342 NONE CONCLUSION\NN\5837957 :\:\1740 Only\RB\1740 one\CD\13741022 <e2>hypersensitivity</e2>\NN\14531772 reaction\NN\13446390 to\TO\1740 CE\NN\14625458 was\VBD\836236 documented\VBN\1000214 among\IN\1740 9\CD\13741022 <e1>P</e1>\NN\14622893 and\CC\1740 N-highly\JJ\1740 NSAIDs\NN\2721538 intolerant\JJ\1740 patients\NNS\9898892 .\.\1740
C012655_D004342 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 9\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 P\NN\14622893 and\CC\1740 <e1>N</e1>\NN\14622893 with\IN\1740 or\CC\3541091 without\IN\1740 associated\VBN\628491 reactions\NNS\13446390 to\TO\1740 classic\JJ\1740 NSAIDs\NNS\2721538 .\.\1740
C012655_D004342 NONE CONCLUSION\NN\5837957 :\:\1740 Only\RB\1740 one\CD\13741022 <e2>hypersensitivity</e2>\NN\14531772 reaction\NN\13446390 to\TO\1740 CE\NN\14625458 was\VBD\836236 documented\VBN\1000214 among\IN\1740 9\CD\13741022 P\NN\14622893 and\CC\1740 <e1>N-highly</e1>\JJ\1740 NSAIDs\NN\2721538 intolerant\JJ\1740 patients\NNS\9898892 .\.\1740
C105934_D004342 NONE CONCLUSION\NN\5837957 :\:\1740 Only\RB\1740 one\CD\13741022 <e2>hypersensitivity</e2>\NN\14531772 reaction\NN\13446390 to\TO\1740 <e1>CE</e1>\NN\14625458 was\VBD\836236 documented\VBN\1000214 among\IN\1740 9\CD\13741022 P\NN\14622893 and\CC\1740 N-highly\JJ\1740 NSAIDs\NN\2721538 intolerant\JJ\1740 patients\NNS\9898892 .\.\1740
3088653
D012601_D000647 CID Reversal\NN\199130 of\IN\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 of\IN\1740 passive\JJ\1740 avoidance\NN\203342 by\IN\1740 pre-\JJ\1740 and\CC\1740 post-training\JJ\1740 naloxone\NN\3808977 .\.\1740
D012601_D000647 CID <e1>Scopolamine</e1>\NN\14712692 ,\,\1740 but\CC\1740 not\RB\1740 methyl\NN\14617189 scopolamine\NN\14712692 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 induced\VBD\1627355 an\DT\6697703 <e2>amnesia</e2>\NN\5669934 as\IN\14622893 measured\VBN\697589 by\IN\1740 latency\NN\15269513 and\CC\1740 duration\NN\15113229 parameters\NNS\5858936 .\.\1740
D012601_D000647 CID Post-training\JJ\1740 administration\NN\1133281 of\IN\1740 naloxone\NN\3808977 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 single\JJ\1740 or\CC\3541091 as\IN\14622893 a\DT\13649268 split\JJ\1740 dose\NN\3740161 also\RB\1740 attenuated\VBD\224901 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D009270_D000647 NONE Reversal\NN\199130 of\IN\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 of\IN\1740 passive\JJ\1740 avoidance\NN\203342 by\IN\1740 pre-\JJ\1740 and\CC\1740 post-training\JJ\1740 <e1>naloxone</e1>\NN\3808977 .\.\1740
D009270_D000647 NONE Post-training\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>naloxone</e1>\NN\3808977 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 single\JJ\1740 or\CC\3541091 as\IN\14622893 a\DT\13649268 split\JJ\1740 dose\NN\3740161 also\RB\1740 attenuated\VBD\224901 the\DT\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D009270_D008569 NONE In\IN\13603305 a\DT\13649268 series\NN\8456993 of\IN\1740 five\CD\13741022 experiments\NNS\641820 ,\,\1740 the\DT\1740 modulating\VBG\1724459 role\NN\719494 of\IN\1740 <e1>naloxone</e1>\NN\3808977 on\IN\1740 a\DT\13649268 scopolamine-induced\JJ\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 in\IN\13603305 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 paradigm\NN\13803782 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009270_D008569 NONE <e1>Naloxone</e1>\NN\3808977 (\-LRB-\1740 0.3\CD\1740 ,\,\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 and\CC\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 injected\VBN\81072 prior\RB\1740 to\IN\1740 training\NN\407535 attenuated\VBD\224901 the\DT\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 with\IN\1740 a\DT\13649268 peak\NN\13758296 of\IN\1740 activity\NN\30358 at\IN\14622893 3\CD\13741022 mg/kg\NN\1740 .\.\1740
D009270_D008569 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 pain\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 <e1>naloxone</e1>\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 naloxone\NN\3808977 on\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 .\.\1740
D009270_D008569 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 pain\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 <e1>naloxone</e1>\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 naloxone\NN\3808977 on\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 .\.\1740
D009270_D008569 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 pain\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 <e1>naloxone</e1>\NN\3808977 on\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 .\.\1740
D012601_D008569 NONE In\IN\13603305 a\DT\13649268 series\NN\8456993 of\IN\1740 five\CD\13741022 experiments\NNS\641820 ,\,\1740 the\DT\1740 modulating\VBG\1724459 role\NN\719494 of\IN\1740 naloxone\NN\3808977 on\IN\1740 a\DT\13649268 <e1>scopolamine-induced</e1>\JJ\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 in\IN\13603305 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 paradigm\NN\13803782 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012601_D008569 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 pain\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 naloxone\NN\3808977 on\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>retention\NN\809465 deficit</e2>\NN\5113133 .\.\1740
D019832_D000647 NONE Scopolamine\NN\14712692 ,\,\1740 but\CC\1740 not\RB\1740 <e1>methyl\NN\14617189 scopolamine</e1>\NN\14712692 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 induced\VBD\1627355 an\DT\6697703 <e2>amnesia</e2>\NN\5669934 as\IN\14622893 measured\VBN\697589 by\IN\1740 latency\NN\15269513 and\CC\1740 duration\NN\15113229 parameters\NNS\5858936 .\.\1740
D009270_D010146 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e2>pain</e2>\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 <e1>naloxone</e1>\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 naloxone\NN\3808977 on\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 retention\NN\809465 deficit\NN\5113133 .\.\1740
D009270_D010146 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e2>pain</e2>\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 <e1>naloxone</e1>\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 naloxone\NN\3808977 on\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 retention\NN\809465 deficit\NN\5113133 .\.\1740
D009270_D010146 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e2>pain</e2>\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 <e1>naloxone</e1>\NN\3808977 on\IN\1740 the\DT\1740 scopolamine-induced\JJ\1740 retention\NN\809465 deficit\NN\5113133 .\.\1740
D012601_D010146 NONE Control\NN\5190804 experiments\NNS\641820 indicated\VBD\952524 that\IN\1740 neither\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e2>pain</e2>\NN\14299637 sensitivity\NN\5651971 (\-LRB-\1740 pre-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 nor\CC\1740 an\DT\6697703 induced\VBN\1627355 aversive\JJ\1740 state\NN\8491826 (\-LRB-\1740 post-training\JJ\1740 naloxone\NN\3808977 )\-RRB-\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 naloxone\NN\3808977 on\IN\1740 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 retention\NN\809465 deficit\NN\5113133 .\.\1740
8808730
D009569_D001745 NONE Increased\VBN\169651 expression\NN\4679549 of\IN\1740 neuronal\JJ\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 in\IN\13603305 bladder\NN\5515670 afferent\JJ\1740 pathways\NNS\5483677 following\VBG\1835496 chronic\JJ\1740 <e2>bladder\NN\5515670 irritation</e2>\NN\14373582 .\.\1740
D009569_D014570 NONE Immunocytochemical\JJ\1740 techniques\NNS\5660268 were\VBD\836236 used\VBN\1156834 to\TO\1740 examine\VB\789138 alterations\NNS\7283608 in\IN\13603305 the\DT\1740 expression\NN\4679549 of\IN\1740 neuronal\JJ\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 in\IN\13603305 bladder\NN\5515670 pathways\NNS\5483677 following\VBG\1835496 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 <e2>irritation\NN\14373582 of\IN\1740 the\DT\1740 urinary\JJ\1740 tract</e2>\NN\8574314 of\IN\1740 the\DT\1740 rat\NN\2329401 .\.\1740
D003520_D003556 CID Chemical\JJ\1740 <e2>cystitis</e2>\NN\14566129 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 which\WDT\1740 is\VBZ\836236 metabolized\VBN\1740 to\TO\1740 acrolein\NN\14584765 ,\,\1740 an\DT\6697703 irritant\NN\5830059 eliminated\VBN\1619929 in\IN\13603305 the\DT\1740 urine\NN\14853947 .\.\1740
D003520_D003556 CID Chemical\JJ\1740 <e2>cystitis</e2>\NN\14566129 was\VBD\836236 induced\VBN\1627355 by\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CYP</e1>\NN\1740 )\-RRB-\1740 which\WDT\1740 is\VBZ\836236 metabolized\VBN\1740 to\TO\1740 acrolein\NN\14584765 ,\,\1740 an\DT\6697703 irritant\NN\5830059 eliminated\VBN\1619929 in\IN\13603305 the\DT\1740 urine\NN\14853947 .\.\1740
D000171_D003556 NONE Chemical\JJ\1740 <e2>cystitis</e2>\NN\14566129 was\VBD\836236 induced\VBN\1627355 by\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 which\WDT\1740 is\VBZ\836236 metabolized\VBN\1740 to\TO\1740 <e1>acrolein</e1>\NN\14584765 ,\,\1740 an\DT\6697703 irritant\NN\5830059 eliminated\VBN\1619929 in\IN\13603305 the\DT\1740 urine\NN\14853947 .\.\1740
24753331
C106487_D020964 CID BACKGROUND\NN\4921011 :\:\1740 <e1>S-53482</e1>\NN\1740 and\CC\1740 S-23121\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 <e2>embryolethality</e2>\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C106487_D064793 CID BACKGROUND\NN\4921011 :\:\1740 <e1>S-53482</e1>\NN\1740 and\CC\1740 S-23121\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 <e2>teratogenicity</e2>\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C106487_D064793 CID CONCLUSIONS\NNS\5837957 :\:\1740 Based\VBN\2694933 on\IN\1740 the\DT\1740 results\NNS\34213 ,\,\1740 <e1>S-53482</e1>\NN\1740 and\CC\1740 S-23121\NN\1740 were\VBD\836236 <e2>teratogenic</e2>\JJ\1740 when\WRB\1740 administered\VBN\2436349 dermally\RB\1740 to\TO\1740 pregnant\JJ\1740 rats\NNS\2329401 as\IN\14622893 were\VBD\836236 the\DT\1740 compounds\NNS\5869584 administered\VBN\2436349 orally\RB\1740 .\.\1740
C106487_D006345 CID BACKGROUND\NN\4921011 :\:\1740 <e1>S-53482</e1>\NN\1740 and\CC\1740 S-23121\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 <e2>ventricular\JJ\1740 septal\JJ\1740 defects</e2>\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C106487_D005317 CID BACKGROUND\NN\4921011 :\:\1740 <e1>S-53482</e1>\NN\1740 and\CC\1740 S-23121\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>growth\NN\13526110 retardation</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C106487_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>S-53482</e1>\NN\1740 and\CC\1740 S-23121\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 studies\NNS\635850 .\.\1740
C106487_D064420 NONE RESULTS\NNS\34213 :\:\1740 Dermal\JJ\1740 exposure\NN\5042871 of\IN\1740 rats\NNS\2329401 to\TO\1740 <e1>S-53482</e1>\NN\1740 at\IN\14622893 300\CD\1740 mg/kg\NN\1740 produced\VBD\1617192 patterns\NNS\5726345 of\IN\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 similar\JJ\1740 to\TO\1740 those\DT\1740 resulting\VBG\2633881 from\IN\1740 oral\JJ\1740 exposure\NN\5042871 .\.\1740
C083440_D020964 CID BACKGROUND\NN\4921011 :\:\1740 S-53482\NN\1740 and\CC\1740 <e1>S-23121</e1>\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 <e2>embryolethality</e2>\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C083440_D020964 CID Dermal\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>S-23121</e1>\NN\1740 at\IN\14622893 800\CD\1740 mg/kg\NN\1740 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>embryonic\JJ\1740 death</e2>\NN\7296428 and\CC\1740 ventricular\JJ\1740 septal\JJ\1740 defect\NN\14462666 ,\,\1740 but\CC\1740 retarded\VBD\438495 fetal\JJ\1740 growth\NN\13526110 was\VBD\836236 not\RB\1740 observed\VBN\2163746 as\IN\14622893 it\PRP\6125041 was\VBD\836236 following\VBG\1835496 oral\JJ\1740 exposure\NN\5042871 to\IN\1740 S-23121\NN\1740 .\.\1740
C083440_D020964 CID Dermal\JJ\1740 administration\NN\1133281 of\IN\1740 S-23121\NN\1740 at\IN\14622893 800\CD\1740 mg/kg\NN\1740 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>embryonic\JJ\1740 death</e2>\NN\7296428 and\CC\1740 ventricular\JJ\1740 septal\JJ\1740 defect\NN\14462666 ,\,\1740 but\CC\1740 retarded\VBD\438495 fetal\JJ\1740 growth\NN\13526110 was\VBD\836236 not\RB\1740 observed\VBN\2163746 as\IN\14622893 it\PRP\6125041 was\VBD\836236 following\VBG\1835496 oral\JJ\1740 exposure\NN\5042871 to\IN\1740 <e1>S-23121</e1>\NN\1740 .\.\1740
C083440_D064793 CID BACKGROUND\NN\4921011 :\:\1740 S-53482\NN\1740 and\CC\1740 <e1>S-23121</e1>\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 <e2>teratogenicity</e2>\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C083440_D064793 CID CONCLUSIONS\NNS\5837957 :\:\1740 Based\VBN\2694933 on\IN\1740 the\DT\1740 results\NNS\34213 ,\,\1740 S-53482\NN\1740 and\CC\1740 <e1>S-23121</e1>\NN\1740 were\VBD\836236 <e2>teratogenic</e2>\JJ\1740 when\WRB\1740 administered\VBN\2436349 dermally\RB\1740 to\TO\1740 pregnant\JJ\1740 rats\NNS\2329401 as\IN\14622893 were\VBD\836236 the\DT\1740 compounds\NNS\5869584 administered\VBN\2436349 orally\RB\1740 .\.\1740
C083440_D006345 CID BACKGROUND\NN\4921011 :\:\1740 S-53482\NN\1740 and\CC\1740 <e1>S-23121</e1>\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 <e2>ventricular\JJ\1740 septal\JJ\1740 defects</e2>\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C083440_D006345 CID Dermal\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>S-23121</e1>\NN\1740 at\IN\14622893 800\CD\1740 mg/kg\NN\1740 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 embryonic\JJ\1740 death\NN\7296428 and\CC\1740 <e2>ventricular\JJ\1740 septal\JJ\1740 defect</e2>\NN\14462666 ,\,\1740 but\CC\1740 retarded\VBD\438495 fetal\JJ\1740 growth\NN\13526110 was\VBD\836236 not\RB\1740 observed\VBN\2163746 as\IN\14622893 it\PRP\6125041 was\VBD\836236 following\VBG\1835496 oral\JJ\1740 exposure\NN\5042871 to\IN\1740 S-23121\NN\1740 .\.\1740
C083440_D006345 CID Dermal\JJ\1740 administration\NN\1133281 of\IN\1740 S-23121\NN\1740 at\IN\14622893 800\CD\1740 mg/kg\NN\1740 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 embryonic\JJ\1740 death\NN\7296428 and\CC\1740 <e2>ventricular\JJ\1740 septal\JJ\1740 defect</e2>\NN\14462666 ,\,\1740 but\CC\1740 retarded\VBD\438495 fetal\JJ\1740 growth\NN\13526110 was\VBD\836236 not\RB\1740 observed\VBN\2163746 as\IN\14622893 it\PRP\6125041 was\VBD\836236 following\VBG\1835496 oral\JJ\1740 exposure\NN\5042871 to\IN\1740 <e1>S-23121</e1>\NN\1740 .\.\1740
C083440_D005317 CID BACKGROUND\NN\4921011 :\:\1740 S-53482\NN\1740 and\CC\1740 <e1>S-23121</e1>\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>growth\NN\13526110 retardation</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 toxicity\NN\13576101 studies\NNS\635850 .\.\1740
C083440_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 S-53482\NN\1740 and\CC\1740 <e1>S-23121</e1>\NN\1740 are\VBP\836236 N-phenylimide\JJ\1740 herbicides\NNS\14806838 and\CC\1740 produced\VBD\1617192 embryolethality\NN\1740 ,\,\1740 teratogenicity\NN\1740 (\-LRB-\1740 mainly\RB\1740 ventricular\JJ\1740 septal\JJ\1740 defects\NNS\14462666 and\CC\1740 wavy\JJ\1740 ribs\NNS\4359589 )\-RRB-\1740 ,\,\1740 and\CC\1740 growth\NN\13526110 retardation\NN\7296428 in\IN\13603305 rats\NNS\2329401 in\IN\13603305 conventional\JJ\1740 oral\JJ\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 studies\NNS\635850 .\.\1740
24209900
D007069_D001927 NONE <e1>Ifosfamide</e1>\NN\1740 related\JJ\1740 <e2>encephalopathy</e2>\RB\1740 :\:\1740 the\DT\1740 need\NN\13920835 for\IN\1740 a\DT\13649268 timely\RB\1740 EEG\NN\7000195 evaluation\NN\874067 .\.\1740
D007069_D001927 NONE <e2>Encephalopathy</e2>\NNP\14084880 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 10\CD\13745420 -\SYM\1740 40\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 high-dose\JJ\1740 IV\CD\13741022 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D001927 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 highlight\VB\514463 the\DT\1740 role\NN\719494 of\IN\1740 electroencephalogram\NN\7000195 (\-LRB-\1740 EEG\NN\7000195 )\-RRB-\1740 in\IN\13603305 the\DT\1740 early\JJ\1740 detection\NN\5708432 and\CC\1740 management\NN\1123598 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 related\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D007069_D001927 NONE METHODS\NNS\5616786 :\:\1740 Retrospective\JJ\1740 chart\NN\6873252 review\NN\5733583 including\VBG\690614 clinical\JJ\1740 data\NNS\7951464 and\CC\1740 EEG\NN\7000195 recordings\NNS\6791372 was\VBD\836236 done\VBN\1640855 on\IN\1740 five\CD\13741022 patients\NNS\9898892 ,\,\1740 admitted\VBN\822367 to\IN\1740 MD\NNP\14622893 Anderson\NNP\1740 Cancer\NNP\14239425 Center\NNP\8497294 between\IN\1740 years\NNS\15144371 2009\CD\1740 and\CC\1740 2012\CD\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 <e1>ifosfamide</e1>\NN\1740 related\JJ\1740 acute\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D007069_D001927 NONE RESULTS\NNS\34213 :\:\1740 All\DT\1740 five\CD\13741022 patients\NNS\9898892 experienced\VBD\2108377 symptoms\NNS\5823932 of\IN\1740 <e2>encephalopathy</e2>\JJ\1740 soon\RB\1740 after\IN\1740 (\-LRB-\1740 within\IN\1740 12\CD\13745420 h-2\NN\1740 days\NNS\15140892 )\-RRB-\1740 receiving\VBG\2210855 <e1>ifosfamide</e1>\NN\1740 .\.\1740
D007069_D001927 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Severity\NN\5036394 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 related\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 correlates\VBZ\2657219 with\IN\1740 EEG\NN\7000195 changes\NNS\7283608 .\.\1740
D007069_D001927 NONE We\PRP\1740 suggest\VBP\1010118 a\DT\13649268 timely\RB\1740 EEG\NN\7000195 evaluation\NN\874067 for\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>ifosfamide</e1>\NN\1740 who\WP\8299493 develop\VBP\1753788 features\NNS\5849040 of\IN\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D007069_D009369 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Ifosfamide</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 alkylating\VBG\1740 agent\NN\7347 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 wide\JJ\1740 range\NN\5123416 of\IN\1740 <e2>cancers</e2>\NNS\14239425 including\VBG\690614 sarcomas\NNS\14239918 ,\,\1740 lymphoma\NN\14239918 ,\,\1740 gynecologic\NN\1740 and\CC\1740 testicular\JJ\1740 cancers\NNS\14239425 .\.\1740
D007069_D009369 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Ifosfamide</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 alkylating\VBG\1740 agent\NN\7347 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 wide\JJ\1740 range\NN\5123416 of\IN\1740 cancers\NNS\14239425 including\VBG\690614 sarcomas\NNS\14239918 ,\,\1740 lymphoma\NN\14239918 ,\,\1740 <e2>gynecologic\NN\1740 and\CC\1740 testicular\JJ\1740 cancers</e2>\NNS\14239425 .\.\1740
D007069_D009369 NONE METHODS\NNS\5616786 :\:\1740 Retrospective\JJ\1740 chart\NN\6873252 review\NN\5733583 including\VBG\690614 clinical\JJ\1740 data\NNS\7951464 and\CC\1740 EEG\NN\7000195 recordings\NNS\6791372 was\VBD\836236 done\VBN\1640855 on\IN\1740 five\CD\13741022 patients\NNS\9898892 ,\,\1740 admitted\VBN\822367 to\IN\1740 MD\NNP\14622893 Anderson\NNP\1740 <e2>Cancer</e2>\NNP\14239425 Center\NNP\8497294 between\IN\1740 years\NNS\15144371 2009\CD\1740 and\CC\1740 2012\CD\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 <e1>ifosfamide</e1>\NN\1740 related\JJ\1740 acute\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D007069_D012509 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Ifosfamide</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 alkylating\VBG\1740 agent\NN\7347 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 wide\JJ\1740 range\NN\5123416 of\IN\1740 cancers\NNS\14239425 including\VBG\690614 <e2>sarcomas</e2>\NNS\14239918 ,\,\1740 lymphoma\NN\14239918 ,\,\1740 gynecologic\NN\1740 and\CC\1740 testicular\JJ\1740 cancers\NNS\14239425 .\.\1740
D007069_D008223 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Ifosfamide</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 alkylating\VBG\1740 agent\NN\7347 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 wide\JJ\1740 range\NN\5123416 of\IN\1740 cancers\NNS\14239425 including\VBG\690614 sarcomas\NNS\14239918 ,\,\1740 <e2>lymphoma</e2>\NN\14239918 ,\,\1740 gynecologic\NN\1740 and\CC\1740 testicular\JJ\1740 cancers\NNS\14239425 .\.\1740
24733133
C031942_D055499 NONE Use\NN\407535 of\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 catheter-directed\JJ\1740 <e2>thrombolysis</e2>\NN\13509528 with\IN\1740 alteplase\NN\1740 in\IN\13603305 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 with\IN\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 .\.\1740
C031942_D055499 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 <e2>thrombolysis</e2>\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
C031942_D013921 NONE Use\NN\407535 of\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 catheter-directed\JJ\1740 thrombolysis\NN\13509528 with\IN\1740 alteplase\NN\1740 in\IN\13603305 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 with\IN\1740 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 thrombosis\NN\14100769 .\.\1740
C031942_D013921 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
C031942_D013921 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>HITT</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
C031942_D013921 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 and\CC\1740 SVC\NN\1740 syndrome\NN\5870365 secondary\JJ\1740 to\TO\1740 <e2>HITT</e2>\NN\1740 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 CDT\NN\1740 with\IN\1740 alteplase\NN\1740 .\.\1740
C031942_D013927 NONE Use\NN\407535 of\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 catheter-directed\JJ\1740 thrombolysis\NN\13509528 with\IN\1740 alteplase\NN\1740 in\IN\13603305 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 with\IN\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 .\.\1740
C031942_D013927 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
C031942_D013927 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>HITT</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
C031942_D013927 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 and\CC\1740 SVC\NN\1740 syndrome\NN\5870365 secondary\JJ\1740 to\TO\1740 <e2>HITT</e2>\NN\1740 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 CDT\NN\1740 with\IN\1740 alteplase\NN\1740 .\.\1740
D006493_D055499 NONE Use\NN\407535 of\IN\1740 argatroban\NN\1740 and\CC\1740 catheter-directed\JJ\1740 <e2>thrombolysis</e2>\NN\13509528 with\IN\1740 alteplase\NN\1740 in\IN\13603305 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 .\.\1740
D006493_D055499 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 argatroban\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 <e2>thrombolysis</e2>\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D006493_D013921 CID Use\NN\407535 of\IN\1740 argatroban\NN\1740 and\CC\1740 catheter-directed\JJ\1740 thrombolysis\NN\13509528 with\IN\1740 alteplase\NN\1740 in\IN\13603305 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 thrombosis\NN\14100769 .\.\1740
D006493_D013921 CID PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 argatroban\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D006493_D013921 CID SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 undergoing\VBG\109660 peripheral\JJ\1740 blood\NN\5397468 stem\NN\6290637 cell\NN\3080309 collection\NN\31264 for\IN\1740 an\DT\6697703 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplant\NN\5267548 developed\VBD\1753788 extensive\JJ\1740 bilateral\JJ\1740 upper-extremity\NN\1740 deep\JJ\1740 venous\JJ\1740 thrombosis\NN\14100769 (\-LRB-\1740 DVT\NN\1740 )\-RRB-\1740 and\CC\1740 pulmonary\JJ\1740 embolism\NN\15269513 secondary\JJ\1740 to\TO\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D006493_D013921 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>HITT</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 argatroban\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D006493_D013927 NONE Use\NN\407535 of\IN\1740 argatroban\NN\1740 and\CC\1740 catheter-directed\JJ\1740 thrombolysis\NN\13509528 with\IN\1740 alteplase\NN\1740 in\IN\13603305 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 .\.\1740
D006493_D013927 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 argatroban\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D006493_D013927 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 oncology\NN\6043075 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>HITT</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 argatroban\NN\1740 plus\CC\4723816 catheter-directed\JJ\1740 thrombolysis\NN\13509528 (\-LRB-\1740 CDT\NN\1740 )\-RRB-\1740 with\IN\1740 alteplase\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D006493_D000686 NONE SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 <e2>amyloidosis</e2>\NN\14061805 undergoing\VBG\109660 peripheral\JJ\1740 blood\NN\5397468 stem\NN\6290637 cell\NN\3080309 collection\NN\31264 for\IN\1740 an\DT\6697703 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplant\NN\5267548 developed\VBD\1753788 extensive\JJ\1740 bilateral\JJ\1740 upper-extremity\NN\1740 deep\JJ\1740 venous\JJ\1740 thrombosis\NN\14100769 (\-LRB-\1740 DVT\NN\1740 )\-RRB-\1740 and\CC\1740 pulmonary\JJ\1740 embolism\NN\15269513 secondary\JJ\1740 to\TO\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
D006493_D056824 NONE SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 undergoing\VBG\109660 peripheral\JJ\1740 blood\NN\5397468 stem\NN\6290637 cell\NN\3080309 collection\NN\31264 for\IN\1740 an\DT\6697703 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplant\NN\5267548 developed\VBD\1753788 extensive\JJ\1740 bilateral\JJ\1740 <e2>upper-extremity\NN\1740 deep\JJ\1740 venous\JJ\1740 thrombosis</e2>\NN\14100769 (\-LRB-\1740 DVT\NN\1740 )\-RRB-\1740 and\CC\1740 pulmonary\JJ\1740 embolism\NN\15269513 secondary\JJ\1740 to\TO\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
D006493_D020246 CID SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 undergoing\VBG\109660 peripheral\JJ\1740 blood\NN\5397468 stem\NN\6290637 cell\NN\3080309 collection\NN\31264 for\IN\1740 an\DT\6697703 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplant\NN\5267548 developed\VBD\1753788 extensive\JJ\1740 bilateral\JJ\1740 upper-extremity\NN\1740 deep\JJ\1740 venous\JJ\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>DVT</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 pulmonary\JJ\1740 embolism\NN\15269513 secondary\JJ\1740 to\TO\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
D006493_D011655 CID SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 undergoing\VBG\109660 peripheral\JJ\1740 blood\NN\5397468 stem\NN\6290637 cell\NN\3080309 collection\NN\31264 for\IN\1740 an\DT\6697703 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplant\NN\5267548 developed\VBD\1753788 extensive\JJ\1740 bilateral\JJ\1740 upper-extremity\NN\1740 deep\JJ\1740 venous\JJ\1740 thrombosis\NN\14100769 (\-LRB-\1740 DVT\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>pulmonary\JJ\1740 embolism</e2>\NN\15269513 secondary\JJ\1740 to\TO\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
C031942_D004844 NONE The\DT\1740 <e2>epistaxis</e2>\NN\14288235 resolved\VBD\352826 the\DT\1740 next\JJ\1740 day\NN\15154774 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 was\VBD\836236 restarted\VBN\1857717 on\IN\1740 <e1>argatroban</e1>\NN\1740 .\.\1740
C031942_D000686 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 <e2>amyloidosis</e2>\NN\14061805 and\CC\1740 SVC\NN\1740 syndrome\NN\5870365 secondary\JJ\1740 to\TO\1740 HITT\NN\1740 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 CDT\NN\1740 with\IN\1740 alteplase\NN\1740 .\.\1740
C031942_D013479 NONE CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 63-year-old\JJ\1740 man\NN\9605289 with\IN\1740 renal\JJ\1740 amyloidosis\NN\14061805 and\CC\1740 <e2>SVC\NN\1740 syndrome</e2>\NN\5870365 secondary\JJ\1740 to\TO\1740 HITT\NN\1740 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>argatroban</e1>\NN\1740 and\CC\1740 CDT\NN\1740 with\IN\1740 alteplase\NN\1740 .\.\1740
24928523
C400082_D009101 NONE Combination\NN\7951464 of\IN\1740 <e1>bortezomib</e1>\NN\1740 ,\,\1740 thalidomide\VBP\1740 ,\,\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 VTD\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 consolidation\NN\7373803 therapy\NN\657604 after\IN\1740 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 symptomatic\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 in\IN\13603305 Japanese\JJ\1740 patients\NNS\9898892 .\.\1740
C400082_D009101 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 analyzed\VBD\78760 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 combination\NN\7951464 regimen\NN\5898568 of\IN\1740 <e1>bortezomib</e1>\NN\1740 ,\,\1740 thalidomide\VBP\1740 ,\,\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 VTD\NN\1740 )\-RRB-\1740 as\IN\14622893 consolidation\NN\7373803 therapy\NN\657604 in\IN\13603305 24\CD\13745420 Japanese\JJ\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>MM</e2>\NN\13649268 .\.\1740
D013792_D009101 NONE Combination\NN\7951464 of\IN\1740 bortezomib\NN\1740 ,\,\1740 <e1>thalidomide</e1>\VBP\1740 ,\,\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 VTD\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 consolidation\NN\7373803 therapy\NN\657604 after\IN\1740 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 symptomatic\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 in\IN\13603305 Japanese\JJ\1740 patients\NNS\9898892 .\.\1740
D013792_D009101 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 analyzed\VBD\78760 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 combination\NN\7951464 regimen\NN\5898568 of\IN\1740 bortezomib\NN\1740 ,\,\1740 <e1>thalidomide</e1>\VBP\1740 ,\,\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 VTD\NN\1740 )\-RRB-\1740 as\IN\14622893 consolidation\NN\7373803 therapy\NN\657604 in\IN\13603305 24\CD\13745420 Japanese\JJ\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>MM</e2>\NN\13649268 .\.\1740
D003907_D009101 NONE Combination\NN\7951464 of\IN\1740 bortezomib\NN\1740 ,\,\1740 thalidomide\VBP\1740 ,\,\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 (\-LRB-\1740 VTD\NN\1740 )\-RRB-\1740 as\IN\14622893 a\DT\13649268 consolidation\NN\7373803 therapy\NN\657604 after\IN\1740 autologous\JJ\1740 stem\NN\6290637 cell\NN\3080309 transplantation\NN\671351 for\IN\1740 symptomatic\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 in\IN\13603305 Japanese\JJ\1740 patients\NNS\9898892 .\.\1740
D003907_D009101 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 analyzed\VBD\78760 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 combination\NN\7951464 regimen\NN\5898568 of\IN\1740 bortezomib\NN\1740 ,\,\1740 thalidomide\VBP\1740 ,\,\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 (\-LRB-\1740 VTD\NN\1740 )\-RRB-\1740 as\IN\14622893 consolidation\NN\7373803 therapy\NN\657604 in\IN\13603305 24\CD\13745420 Japanese\JJ\1740 patients\NNS\9898892 with\IN\1740 newly\RB\1740 diagnosed\VBN\644583 <e2>MM</e2>\NN\13649268 .\.\1740
2904523
D004837_D006973 CID Support\NN\407535 for\IN\1740 <e2><e1>adrenaline-hypertension</e1></e2>\JJ\1740 hypothesis\NN\7162194 :\:\1740 18\CD\13745420 hour\NN\15154774 pressor\NN\9190918 effect\NN\34213 after\IN\1740 6\CD\13741022 hours\NNS\15118228 adrenaline\NN\14807929 infusion\NN\14589223 .\.\1740
D004837_D006973 CID Support\NN\407535 for\IN\1740 <e2>adrenaline-hypertension</e2>\JJ\1740 hypothesis\NN\7162194 :\:\1740 18\CD\13745420 hour\NN\15154774 pressor\NN\9190918 effect\NN\34213 after\IN\1740 6\CD\13741022 hours\NNS\15118228 <e1>adrenaline</e1>\NN\14807929 infusion\NN\14589223 .\.\1740
D004837_D006973 CID These\DT\1740 findings\NNS\7951464 are\VBP\836236 strong\JJ\1740 support\NN\407535 for\IN\1740 the\DT\1740 <e2><e1>adrenaline-hypertension</e1></e2>\JJ\1740 hypothesis\NN\7162194 in\IN\13603305 man\NN\9605289 .\.\1740
24114426
D018817_D003866 CID <e2>Depression</e2>\NNP\14373582 ,\,\1740 impulsiveness\NN\4661706 ,\,\1740 sleep\NN\14034177 ,\,\1740 and\CC\1740 memory\NN\5926676 in\IN\13603305 past\JJ\1740 and\CC\1740 present\JJ\1740 polydrug\NN\1740 users\NNS\7846 of\IN\1740 <e1>3,4-methylenedioxymethamphetamine</e1>\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 ,\,\1740 ecstasy\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D003866 CID <e2>Depression</e2>\NNP\14373582 ,\,\1740 impulsiveness\NN\4661706 ,\,\1740 sleep\NN\14034177 ,\,\1740 and\CC\1740 memory\NN\5926676 in\IN\13603305 past\JJ\1740 and\CC\1740 present\JJ\1740 polydrug\NN\1740 users\NNS\7846 of\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 <e1>MDMA</e1>\NN\3054098 ,\,\1740 ecstasy\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D003866 CID <e2>Depression</e2>\NNP\14373582 ,\,\1740 impulsiveness\NN\4661706 ,\,\1740 sleep\NN\14034177 ,\,\1740 and\CC\1740 memory\NN\5926676 in\IN\13603305 past\JJ\1740 and\CC\1740 present\JJ\1740 polydrug\NN\1740 users\NNS\7846 of\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 ,\,\1740 <e1>ecstasy</e1>\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D003866 CID CONCLUSIONS\NNS\5837957 :\:\1740 Given\VBN\2327200 this\DT\1740 record\NN\6643408 of\IN\1740 impaired\JJ\1740 memory\NN\5926676 and\CC\1740 clinically\RB\1740 significant\JJ\1740 levels\NNS\4916342 of\IN\1740 <e2>depression</e2>\NN\14373582 ,\,\1740 impulsiveness\NN\4661706 ,\,\1740 and\CC\1740 sleep\NN\14034177 disturbance\NN\407535 ,\,\1740 the\DT\1740 prognosis\NN\6748969 for\IN\1740 the\DT\1740 current\JJ\1740 generation\NN\7942152 of\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 is\VBZ\836236 a\DT\13649268 major\JJ\1740 cause\NN\7323922 for\IN\1740 concern\NN\5682950 .\.\1740
D018817_D010554 CID Depression\NNP\14373582 ,\,\1740 <e2>impulsiveness</e2>\NN\4661706 ,\,\1740 sleep\NN\14034177 ,\,\1740 and\CC\1740 memory\NN\5926676 in\IN\13603305 past\JJ\1740 and\CC\1740 present\JJ\1740 polydrug\NN\1740 users\NNS\7846 of\IN\1740 <e1>3,4-methylenedioxymethamphetamine</e1>\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 ,\,\1740 ecstasy\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D010554 CID Depression\NNP\14373582 ,\,\1740 <e2>impulsiveness</e2>\NN\4661706 ,\,\1740 sleep\NN\14034177 ,\,\1740 and\CC\1740 memory\NN\5926676 in\IN\13603305 past\JJ\1740 and\CC\1740 present\JJ\1740 polydrug\NN\1740 users\NNS\7846 of\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 <e1>MDMA</e1>\NN\3054098 ,\,\1740 ecstasy\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D010554 CID Depression\NNP\14373582 ,\,\1740 <e2>impulsiveness</e2>\NN\4661706 ,\,\1740 sleep\NN\14034177 ,\,\1740 and\CC\1740 memory\NN\5926676 in\IN\13603305 past\JJ\1740 and\CC\1740 present\JJ\1740 polydrug\NN\1740 users\NNS\7846 of\IN\1740 3,4-methylenedioxymethamphetamine\NN\1740 (\-LRB-\1740 MDMA\NN\3054098 ,\,\1740 <e1>ecstasy</e1>\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D010554 CID CONCLUSIONS\NNS\5837957 :\:\1740 Given\VBN\2327200 this\DT\1740 record\NN\6643408 of\IN\1740 impaired\JJ\1740 memory\NN\5926676 and\CC\1740 clinically\RB\1740 significant\JJ\1740 levels\NNS\4916342 of\IN\1740 depression\NN\14373582 ,\,\1740 <e2>impulsiveness</e2>\NN\4661706 ,\,\1740 and\CC\1740 sleep\NN\14034177 disturbance\NN\407535 ,\,\1740 the\DT\1740 prognosis\NN\6748969 for\IN\1740 the\DT\1740 current\JJ\1740 generation\NN\7942152 of\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 is\VBZ\836236 a\DT\13649268 major\JJ\1740 cause\NN\7323922 for\IN\1740 concern\NN\5682950 .\.\1740
D018817_D008569 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Given\VBN\2327200 this\DT\1740 record\NN\6643408 of\IN\1740 <e2>impaired\JJ\1740 memory</e2>\NN\5926676 and\CC\1740 clinically\RB\1740 significant\JJ\1740 levels\NNS\4916342 of\IN\1740 depression\NN\14373582 ,\,\1740 impulsiveness\NN\4661706 ,\,\1740 and\CC\1740 sleep\NN\14034177 disturbance\NN\407535 ,\,\1740 the\DT\1740 prognosis\NN\6748969 for\IN\1740 the\DT\1740 current\JJ\1740 generation\NN\7942152 of\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 is\VBZ\836236 a\DT\13649268 major\JJ\1740 cause\NN\7323922 for\IN\1740 concern\NN\5682950 .\.\1740
D018817_D020920 CID CONCLUSIONS\NNS\5837957 :\:\1740 Given\VBN\2327200 this\DT\1740 record\NN\6643408 of\IN\1740 impaired\JJ\1740 memory\NN\5926676 and\CC\1740 clinically\RB\1740 significant\JJ\1740 levels\NNS\4916342 of\IN\1740 depression\NN\14373582 ,\,\1740 impulsiveness\NN\4661706 ,\,\1740 and\CC\1740 <e2>sleep\NN\14034177 disturbance</e2>\NN\407535 ,\,\1740 the\DT\1740 prognosis\NN\6748969 for\IN\1740 the\DT\1740 current\JJ\1740 generation\NN\7942152 of\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 is\VBZ\836236 a\DT\13649268 major\JJ\1740 cause\NN\7323922 for\IN\1740 concern\NN\5682950 .\.\1740
978847
D006145_D006973 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 <e1>guanethidine</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 <e2>enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure</e2>\NN\11419404 and\CC\1740 the\DT\1740 tachycardia\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D006145_D013610 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 <e1>guanethidine</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure\NN\11419404 and\CC\1740 the\DT\1740 <e2>tachycardia</e2>\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D018738_D006973 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 <e1>hexamethonium</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 <e2>enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure</e2>\NN\11419404 and\CC\1740 the\DT\1740 tachycardia\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D018738_D013610 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 <e1>hexamethonium</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure\NN\11419404 and\CC\1740 the\DT\1740 <e2>tachycardia</e2>\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D010646_D006973 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 <e1>phentolamine</e1>\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 <e2>enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure</e2>\NN\11419404 and\CC\1740 the\DT\1740 tachycardia\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D010646_D013610 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 <e1>phentolamine</e1>\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure\NN\11419404 and\CC\1740 the\DT\1740 <e2>tachycardia</e2>\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D003891_D006973 CID This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 <e1>desmethylimipramine</e1>\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 <e2>enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure</e2>\NN\11419404 and\CC\1740 the\DT\1740 tachycardia\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D003891_D013610 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 <e1>desmethylimipramine</e1>\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure\NN\11419404 and\CC\1740 the\DT\1740 <e2>tachycardia</e2>\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D011433_D006973 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 <e2>enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure</e2>\NN\11419404 and\CC\1740 the\DT\1740 tachycardia\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D011433_D013610 NONE This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure\NN\11419404 and\CC\1740 the\DT\1740 <e2>tachycardia</e2>\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 carbachol\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D002217_D006973 CID This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 <e2>enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure</e2>\NN\11419404 and\CC\1740 the\DT\1740 tachycardia\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 <e1>carbachol</e1>\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
D002217_D013610 CID This\DT\1740 response\NN\11410625 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 the\DT\1740 intravenous\JJ\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 guanethidine\NN\1740 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 hexamethonium\NN\1740 (\-LRB-\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 or\CC\3541091 phentolamine\NN\4537602 (\-LRB-\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 conversely\RB\1740 ,\,\1740 potentiated\VBD\229605 by\IN\1740 i.v.\NN\1740 desmethylimipramine\NN\1740 (\-LRB-\1740 0.3\CD\1740 mg\NN\13717155 )\-RRB-\1740 ,\,\1740 while\IN\15122231 propranolol\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 )\-RRB-\1740 i.v.\RBR\1740 selectively\RB\1740 inhibited\VBD\2510337 the\DT\1740 enlargement\NN\363260 of\IN\1740 pulse\NN\7345593 pressure\NN\11419404 and\CC\1740 the\DT\1740 <e2>tachycardia</e2>\NN\14110674 following\VBG\1835496 i.c.\JJ\1740 <e1>carbachol</e1>\NN\1740 (\-LRB-\1740 1\CD\13741022 mug\NN\13756125 )\-RRB-\1740 .\.\1740
8392553
C056595_D006331 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>clentiazem</e1>\NN\1740 against\IN\1740 epinephrine-induced\JJ\1740 <e2>cardiac\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 rats\NNS\2329401 .\.\1740
C056595_D006331 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>clentiazem</e1>\NN\1740 attenuated\VBD\224901 epinephrine-induced\JJ\1740 <e2>cardiac\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 possibly\RB\1740 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 the\DT\1740 adrenergic\JJ\1740 pathway\NN\5483677 .\.\1740
D004837_D006331 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 clentiazem\NN\1740 against\IN\1740 <e1>epinephrine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004837_D006331 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 clentiazem\NN\1740 attenuated\VBD\224901 <e1>epinephrine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 possibly\RB\1740 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 the\DT\1740 adrenergic\JJ\1740 pathway\NN\5483677 .\.\1740
C056595_D009202 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>clentiazem</e1>\NN\1740 ,\,\1740 a\DT\13649268 1,5-benzothiazepine\NN\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 on\IN\1740 epinephrine-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 in\IN\13603305 rats\NNS\2329401 .\.\1740
C106746_D009202 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 clentiazem\NN\1740 ,\,\1740 a\DT\13649268 <e1>1,5-benzothiazepine</e1>\NN\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 on\IN\1740 epinephrine-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002118_D009202 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 clentiazem\NN\1740 ,\,\1740 a\DT\13649268 1,5-benzothiazepine\NN\1740 <e1>calcium</e1>\NN\14625458 antagonist\NN\7846 ,\,\1740 on\IN\1740 epinephrine-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004837_D009202 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 clentiazem\NN\1740 ,\,\1740 a\DT\13649268 1,5-benzothiazepine\NN\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 on\IN\1740 <e1>epinephrine-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004837_D007511 NONE With\IN\1740 2-week\JJ\1740 chronic\JJ\1740 <e1>epinephrine</e1>\NN\14807929 infusion\NN\14589223 ,\,\1740 16\CD\13745420 of\IN\1740 30\CD\13745420 rats\NNS\2329401 died\VBD\146138 within\IN\1740 4\CD\13741022 days\NNS\15140892 ,\,\1740 and\CC\1740 severe\JJ\1740 <e2>ischemic\JJ\1740 lesions</e2>\NNS\14204950 and\CC\1740 fibrosis\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 ventricles\NNS\5303402 were\VBD\836236 observed\VBN\2163746 .\.\1740
D004837_D007511 NONE Treatment\NN\654885 with\IN\1740 clentiazem\NN\1740 prevented\VBD\1740 <e1>epinephrine-induced</e1>\JJ\1740 death\NN\7296428 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 ventricular\JJ\1740 <e2>ischemic\JJ\1740 lesions</e2>\NNS\14204950 and\CC\1740 fibrosis\NN\14204950 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
D004837_D005355 NONE With\IN\1740 2-week\JJ\1740 chronic\JJ\1740 <e1>epinephrine</e1>\NN\14807929 infusion\NN\14589223 ,\,\1740 16\CD\13745420 of\IN\1740 30\CD\13745420 rats\NNS\2329401 died\VBD\146138 within\IN\1740 4\CD\13741022 days\NNS\15140892 ,\,\1740 and\CC\1740 severe\JJ\1740 ischemic\JJ\1740 lesions\NNS\14204950 and\CC\1740 <e2>fibrosis</e2>\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 ventricles\NNS\5303402 were\VBD\836236 observed\VBN\2163746 .\.\1740
D004837_D005355 NONE Treatment\NN\654885 with\IN\1740 clentiazem\NN\1740 prevented\VBD\1740 <e1>epinephrine-induced</e1>\JJ\1740 death\NN\7296428 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 ventricular\JJ\1740 ischemic\JJ\1740 lesions\NNS\14204950 and\CC\1740 <e2>fibrosis</e2>\NN\14204950 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
C056595_D007511 NONE Treatment\NN\654885 with\IN\1740 <e1>clentiazem</e1>\NN\1740 prevented\VBD\1740 epinephrine-induced\JJ\1740 death\NN\7296428 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 ventricular\JJ\1740 <e2>ischemic\JJ\1740 lesions</e2>\NNS\14204950 and\CC\1740 fibrosis\NN\14204950 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
C056595_D005355 NONE Treatment\NN\654885 with\IN\1740 <e1>clentiazem</e1>\NN\1740 prevented\VBD\1740 epinephrine-induced\JJ\1740 death\NN\7296428 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 attenuated\VBD\224901 the\DT\1740 ventricular\JJ\1740 ischemic\JJ\1740 lesions\NNS\14204950 and\CC\1740 <e2>fibrosis</e2>\NN\14204950 ,\,\1740 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 .\.\1740
7369302
D011803_D000550 CID Abnormalities\NNS\14034177 of\IN\1740 the\DT\1740 pupil\NN\10059162 and\CC\1740 visual-evoked\JJ\1740 potential\NN\14481929 in\IN\13603305 <e1>quinine</e1>\NN\2721948 <e2>amblyopia</e2>\NN\14552802 .\.\1740
D011803_D001766 CID Total\JJ\1740 <e2>blindness</e2>\NN\14552802 with\IN\1740 a\DT\13649268 transient\JJ\1740 tonic\JJ\1740 pupillary\JJ\1740 response\NN\11410625 ,\,\1740 denervation\NN\1740 supersensitivity\NN\1740 ,\,\1740 and\CC\1740 abnormal\JJ\1740 visual-evoked\JJ\1740 potentials\NNS\14481929 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 54-year-old\JJ\1740 man\NN\9605289 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>quinine\NN\2721948 sulfate</e1>\NN\15010703 for\IN\1740 leg\NN\5560244 cramps\NNS\14299637 .\.\1740
D011803_D015845 CID Total\JJ\1740 blindness\NN\14552802 with\IN\1740 a\DT\13649268 transient\JJ\1740 <e2>tonic\JJ\1740 pupillary</e2>\JJ\1740 response\NN\11410625 ,\,\1740 denervation\NN\1740 supersensitivity\NN\1740 ,\,\1740 and\CC\1740 abnormal\JJ\1740 visual-evoked\JJ\1740 potentials\NNS\14481929 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 54-year-old\JJ\1740 man\NN\9605289 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>quinine\NN\2721948 sulfate</e1>\NN\15010703 for\IN\1740 leg\NN\5560244 cramps\NNS\14299637 .\.\1740
D011803_D015845 CID A\DT\13649268 transient\JJ\1740 <e2>tonic\JJ\1740 pupillary</e2>\JJ\1740 response\NN\11410625 ,\,\1740 denervation\NN\1740 supersensitivity\NN\1740 ,\,\1740 and\CC\1740 abnormal\JJ\1740 visual-evoked\JJ\1740 potentials\NNS\14481929 in\IN\13603305 <e1>quinine</e1>\NN\2721948 toxicity\NN\13576101 ,\,\1740 to\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 previously\RB\1740 reported\VBN\831651 .\.\1740
D011803_D009120 NONE Total\JJ\1740 blindness\NN\14552802 with\IN\1740 a\DT\13649268 transient\JJ\1740 tonic\JJ\1740 pupillary\JJ\1740 response\NN\11410625 ,\,\1740 denervation\NN\1740 supersensitivity\NN\1740 ,\,\1740 and\CC\1740 abnormal\JJ\1740 visual-evoked\JJ\1740 potentials\NNS\14481929 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 54-year-old\JJ\1740 man\NN\9605289 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>quinine\NN\2721948 sulfate</e1>\NN\15010703 for\IN\1740 <e2>leg\NN\5560244 cramps</e2>\NNS\14299637 .\.\1740
D011803_D064420 NONE A\DT\13649268 transient\JJ\1740 tonic\JJ\1740 pupillary\JJ\1740 response\NN\11410625 ,\,\1740 denervation\NN\1740 supersensitivity\NN\1740 ,\,\1740 and\CC\1740 abnormal\JJ\1740 visual-evoked\JJ\1740 potentials\NNS\14481929 in\IN\13603305 <e1>quinine</e1>\NN\2721948 <e2>toxicity</e2>\NN\13576101 ,\,\1740 to\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 previously\RB\1740 reported\VBN\831651 .\.\1740
3812624
D002220_D009759 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>downbeat\JJ\1740 nystagmus</e2>\NN\337486 and\CC\1740 oscillopsia\NN\1740 associated\VBN\628491 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 .\.\1740
D002220_D009759 NONE We\PRP\1740 recorded\VBD\2225492 the\DT\1740 eye\NN\5299178 movements\NNS\191142 of\IN\1740 two\CD\13741022 patients\NNS\9898892 with\IN\1740 reversible\JJ\1740 <e2>downbeat\JJ\1740 nystagmus</e2>\NN\337486 related\JJ\1740 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 therapy\NN\657604 .\.\1740
D002220_D009759 NONE The\DT\1740 <e2>nystagmus</e2>\NN\337486 of\IN\1740 both\DT\1740 patients\NNS\9898892 resolved\VBN\352826 after\IN\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 serum\NN\5397468 <e1>carbamazepine</e1>\NN\1740 levels\NNS\4916342 .\.\1740
D002220_D015835 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 downbeat\JJ\1740 nystagmus\NN\337486 and\CC\1740 <e2>oscillopsia</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 .\.\1740
3798047
D008775_D001919 CID <e2>Bradycardia</e2>\NN\14110674 after\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 therapy\NN\657604 .\.\1740
D008775_D001172 NONE In\IN\13603305 5\CD\13741022 consecutive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 who\WP\8299493 received\VBD\2210855 intravenous\JJ\1740 high-dose\JJ\1740 <e1>methylprednisolone</e1>\NN\1740 (\-LRB-\1740 MP\NN\10249459 )\-RRB-\1740 therapy\NN\657604 (\-LRB-\1740 1\CD\13741022 g\NN\13717155 daily\RB\1740 for\IN\1740 2\CD\13741022 or\CC\3541091 3\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 )\-RRB-\1740 ,\,\1740 a\DT\13649268 decline\NN\13458571 in\IN\13603305 pulse\NN\7345593 rate\NN\13815152 was\VBD\836236 observed\VBN\2163746 ,\,\1740 most\RBS\1740 pronounced\VBN\822367 on\IN\1740 day\NN\15154774 4\CD\13741022 .\.\1740
D008775_D001172 NONE In\IN\13603305 5\CD\13741022 consecutive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 who\WP\8299493 received\VBD\2210855 intravenous\JJ\1740 high-dose\JJ\1740 methylprednisolone\NN\1740 (\-LRB-\1740 <e1>MP</e1>\NN\10249459 )\-RRB-\1740 therapy\NN\657604 (\-LRB-\1740 1\CD\13741022 g\NN\13717155 daily\RB\1740 for\IN\1740 2\CD\13741022 or\CC\3541091 3\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 )\-RRB-\1740 ,\,\1740 a\DT\13649268 decline\NN\13458571 in\IN\13603305 pulse\NN\7345593 rate\NN\13815152 was\VBD\836236 observed\VBN\2163746 ,\,\1740 most\RBS\1740 pronounced\VBN\822367 on\IN\1740 day\NN\15154774 4\CD\13741022 .\.\1740
D008775_D006331 NONE High-dose\JJ\1740 <e1>MP</e1>\NN\10249459 may\MD\15209706 be\VB\836236 contraindicated\VBN\872886 in\IN\13603305 patients\NNS\9898892 with\IN\1740 known\JJ\1740 <e2>heart\NN\5919034 disease</e2>\NN\14061805 .\.\1740
17721298
D016578_D003320 CID <e2>Corneal\NN\1740 ulcers</e2>\NNS\14211294 associated\VBN\628491 with\IN\1740 aerosolized\JJ\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D016578_D003320 CID RESULTS\NNS\34213 :\:\1740 Four\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>corneal\NN\1740 ulcers</e2>\NNS\14211294 associated\VBN\628491 with\IN\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 use\NN\407535 were\VBD\836236 reviewed\VBN\644583 .\.\1740
D016578_D003320 CID CONCLUSIONS\NNS\5837957 :\:\1740 Aerosolized\VBN\1376245 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 use\NN\407535 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>corneal\NN\1740 ulcers</e2>\NNS\14211294 .\.\1740
1655018
D000728_D006528 CID <e2>Hepatocellular\JJ\1740 carcinoma</e2>\NN\14239918 in\IN\13603305 Fanconi\NNP\1740 's\POS\1740 anemia\NN\14189204 treated\VBN\2376958 with\IN\1740 <e1>androgen</e1>\NN\14745635 and\CC\1740 corticosteroid\NN\14745635 .\.\1740
D000728_D005199 NONE Hepatocellular\JJ\1740 carcinoma\NN\14239918 in\IN\13603305 <e2>Fanconi\NNP\1740 's\POS\1740 anemia</e2>\NN\14189204 treated\VBN\2376958 with\IN\1740 <e1>androgen</e1>\NN\14745635 and\CC\1740 corticosteroid\NN\14745635 .\.\1740
D000728_D005199 NONE The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 11-year-old\JJ\1740 boy\NN\9624168 is\VBZ\836236 reported\VBN\831651 who\WP\8299493 was\VBD\836236 known\VBN\2110220 to\TO\1740 have\VB\2108377 <e2>Fanconi\NNP\1740 's\POS\1740 anemia</e2>\NN\14189204 for\IN\1740 3\CD\13741022 years\NNS\15144371 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>androgens</e1>\NNS\14745635 ,\,\1740 corticosteroids\NNS\14745635 and\CC\1740 transfusions\NNS\320852 .\.\1740
D000728_D005199 NONE This\DT\1740 case\NN\7283608 contributes\VBZ\126264 to\TO\1740 the\DT\1740 previous\JJ\1740 observations\NNS\996969 that\IN\1740 non-metastasizing\JJ\1740 hepatic\JJ\1740 neoplasms\NNS\14234074 and\CC\1740 peliosis\NN\14189204 can\MD\3094503 develop\VB\1753788 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>androgen-</e1>\NN\1740 and\CC\1740 corticosteroid-treated\JJ\1740 <e2>Fanconi\NNP\1740 's\POS\1740 anemia</e2>\NN\14189204 .\.\1740
D000305_D006528 CID <e2>Hepatocellular\JJ\1740 carcinoma</e2>\NN\14239918 in\IN\13603305 Fanconi\NNP\1740 's\POS\1740 anemia\NN\14189204 treated\VBN\2376958 with\IN\1740 androgen\NN\14745635 and\CC\1740 <e1>corticosteroid</e1>\NN\14745635 .\.\1740
D000305_D005199 NONE Hepatocellular\JJ\1740 carcinoma\NN\14239918 in\IN\13603305 <e2>Fanconi\NNP\1740 's\POS\1740 anemia</e2>\NN\14189204 treated\VBN\2376958 with\IN\1740 androgen\NN\14745635 and\CC\1740 <e1>corticosteroid</e1>\NN\14745635 .\.\1740
D000305_D005199 NONE The\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 11-year-old\JJ\1740 boy\NN\9624168 is\VBZ\836236 reported\VBN\831651 who\WP\8299493 was\VBD\836236 known\VBN\2110220 to\TO\1740 have\VB\2108377 <e2>Fanconi\NNP\1740 's\POS\1740 anemia</e2>\NN\14189204 for\IN\1740 3\CD\13741022 years\NNS\15144371 and\CC\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 androgens\NNS\14745635 ,\,\1740 <e1>corticosteroids</e1>\NNS\14745635 and\CC\1740 transfusions\NNS\320852 .\.\1740
D000305_D005199 NONE This\DT\1740 case\NN\7283608 contributes\VBZ\126264 to\TO\1740 the\DT\1740 previous\JJ\1740 observations\NNS\996969 that\IN\1740 non-metastasizing\JJ\1740 hepatic\JJ\1740 neoplasms\NNS\14234074 and\CC\1740 peliosis\NN\14189204 can\MD\3094503 develop\VB\1753788 in\IN\13603305 patients\NNS\9898892 with\IN\1740 androgen-\NN\1740 and\CC\1740 <e1>corticosteroid-treated</e1>\JJ\1740 <e2>Fanconi\NNP\1740 's\POS\1740 anemia</e2>\NN\14189204 .\.\1740
D000728_D008113 NONE This\DT\1740 case\NN\7283608 contributes\VBZ\126264 to\TO\1740 the\DT\1740 previous\JJ\1740 observations\NNS\996969 that\IN\1740 non-metastasizing\JJ\1740 <e2>hepatic\JJ\1740 neoplasms</e2>\NNS\14234074 and\CC\1740 peliosis\NN\14189204 can\MD\3094503 develop\VB\1753788 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>androgen-</e1>\NN\1740 and\CC\1740 corticosteroid-treated\JJ\1740 Fanconi\NNP\1740 's\POS\1740 anemia\NN\14189204 .\.\1740
D000728_D010382 CID This\DT\1740 case\NN\7283608 contributes\VBZ\126264 to\TO\1740 the\DT\1740 previous\JJ\1740 observations\NNS\996969 that\IN\1740 non-metastasizing\JJ\1740 hepatic\JJ\1740 neoplasms\NNS\14234074 and\CC\1740 <e2>peliosis</e2>\NN\14189204 can\MD\3094503 develop\VB\1753788 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>androgen-</e1>\NN\1740 and\CC\1740 corticosteroid-treated\JJ\1740 Fanconi\NNP\1740 's\POS\1740 anemia\NN\14189204 .\.\1740
D000305_D008113 NONE This\DT\1740 case\NN\7283608 contributes\VBZ\126264 to\TO\1740 the\DT\1740 previous\JJ\1740 observations\NNS\996969 that\IN\1740 non-metastasizing\JJ\1740 <e2>hepatic\JJ\1740 neoplasms</e2>\NNS\14234074 and\CC\1740 peliosis\NN\14189204 can\MD\3094503 develop\VB\1753788 in\IN\13603305 patients\NNS\9898892 with\IN\1740 androgen-\NN\1740 and\CC\1740 <e1>corticosteroid-treated</e1>\JJ\1740 Fanconi\NNP\1740 's\POS\1740 anemia\NN\14189204 .\.\1740
D000305_D010382 CID This\DT\1740 case\NN\7283608 contributes\VBZ\126264 to\TO\1740 the\DT\1740 previous\JJ\1740 observations\NNS\996969 that\IN\1740 non-metastasizing\JJ\1740 hepatic\JJ\1740 neoplasms\NNS\14234074 and\CC\1740 <e2>peliosis</e2>\NN\14189204 can\MD\3094503 develop\VB\1753788 in\IN\13603305 patients\NNS\9898892 with\IN\1740 androgen-\NN\1740 and\CC\1740 <e1>corticosteroid-treated</e1>\JJ\1740 Fanconi\NNP\1740 's\POS\1740 anemia\NN\14189204 .\.\1740
10975596
C118667_D009203 NONE Hemodynamic\JJ\1740 and\CC\1740 antiadrenergic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>dronedarone</e1>\NN\1740 and\CC\1740 amiodarone\JJ\1740 in\IN\13603305 animals\NNS\4475 with\IN\1740 a\DT\13649268 healed\VBN\205046 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
C118667_D009203 NONE The\DT\1740 hemodynamic\JJ\1740 and\CC\1740 antiadrenergic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>dronedarone</e1>\NN\1740 ,\,\1740 a\DT\13649268 noniodinated\JJ\1740 compound\NN\5869584 structurally\RB\1740 related\JJ\1740 to\TO\1740 amiodarone\NN\2715941 ,\,\1740 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 amiodarone\NN\2715941 after\IN\1740 prolonged\JJ\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 both\CC\1740 at\IN\14622893 rest\NN\13809207 and\CC\1740 during\IN\1740 sympathetic\JJ\1740 stimulation\NN\242808 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 with\IN\1740 a\DT\13649268 healed\VBN\205046 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D000638_D009203 NONE Hemodynamic\JJ\1740 and\CC\1740 antiadrenergic\JJ\1740 effects\NNS\13245626 of\IN\1740 dronedarone\NN\1740 and\CC\1740 <e1>amiodarone</e1>\JJ\1740 in\IN\13603305 animals\NNS\4475 with\IN\1740 a\DT\13649268 healed\VBN\205046 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D000638_D009203 NONE The\DT\1740 hemodynamic\JJ\1740 and\CC\1740 antiadrenergic\JJ\1740 effects\NNS\13245626 of\IN\1740 dronedarone\NN\1740 ,\,\1740 a\DT\13649268 noniodinated\JJ\1740 compound\NN\5869584 structurally\RB\1740 related\JJ\1740 to\TO\1740 <e1>amiodarone</e1>\NN\2715941 ,\,\1740 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 amiodarone\NN\2715941 after\IN\1740 prolonged\JJ\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 both\CC\1740 at\IN\14622893 rest\NN\13809207 and\CC\1740 during\IN\1740 sympathetic\JJ\1740 stimulation\NN\242808 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 with\IN\1740 a\DT\13649268 healed\VBN\205046 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D000638_D009203 NONE The\DT\1740 hemodynamic\JJ\1740 and\CC\1740 antiadrenergic\JJ\1740 effects\NNS\13245626 of\IN\1740 dronedarone\NN\1740 ,\,\1740 a\DT\13649268 noniodinated\JJ\1740 compound\NN\5869584 structurally\RB\1740 related\JJ\1740 to\TO\1740 amiodarone\NN\2715941 ,\,\1740 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 after\IN\1740 prolonged\JJ\1740 oral\JJ\1740 administration\NN\1133281 ,\,\1740 both\CC\1740 at\IN\14622893 rest\NN\13809207 and\CC\1740 during\IN\1740 sympathetic\JJ\1740 stimulation\NN\242808 in\IN\13603305 conscious\JJ\1740 dogs\NNS\2083346 with\IN\1740 a\DT\13649268 healed\VBN\205046 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
C118667_D013610 NONE Both\CC\1740 <e1>dronedarone</e1>\NN\1740 and\CC\1740 amiodarone\NN\2715941 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 exercise-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 ,\,\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 ,\,\1740 decreased\VBD\169651 the\DT\1740 isoproterenol-induced\JJ\1740 tachycardia\NN\14110674 .\.\1740
C118667_D013610 NONE Both\CC\1740 <e1>dronedarone</e1>\NN\1740 and\CC\1740 amiodarone\NN\2715941 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 exercise-induced\JJ\1740 tachycardia\NN\14110674 and\CC\1740 ,\,\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 ,\,\1740 decreased\VBD\169651 the\DT\1740 isoproterenol-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
D000638_D013610 NONE Both\CC\1740 dronedarone\NN\1740 and\CC\1740 <e1>amiodarone</e1>\NN\2715941 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 exercise-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 ,\,\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 ,\,\1740 decreased\VBD\169651 the\DT\1740 isoproterenol-induced\JJ\1740 tachycardia\NN\14110674 .\.\1740
D000638_D013610 NONE Both\CC\1740 dronedarone\NN\1740 and\CC\1740 <e1>amiodarone</e1>\NN\2715941 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 exercise-induced\JJ\1740 tachycardia\NN\14110674 and\CC\1740 ,\,\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 ,\,\1740 decreased\VBD\169651 the\DT\1740 isoproterenol-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
D007545_D013610 CID Both\CC\1740 dronedarone\NN\1740 and\CC\1740 amiodarone\NN\2715941 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 exercise-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 ,\,\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 ,\,\1740 decreased\VBD\169651 the\DT\1740 <e1>isoproterenol-induced</e1>\JJ\1740 tachycardia\NN\14110674 .\.\1740
D007545_D013610 CID Both\CC\1740 dronedarone\NN\1740 and\CC\1740 amiodarone\NN\2715941 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 exercise-induced\JJ\1740 tachycardia\NN\14110674 and\CC\1740 ,\,\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 ,\,\1740 decreased\VBD\169651 the\DT\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
C118667_D001145 NONE Consequently\RB\1740 ,\,\1740 <e1>dronedarone</e1>\NN\1740 might\MD\5029706 be\VB\836236 particularly\RB\1740 suitable\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 and\CC\1740 prevention\NN\1073995 of\IN\1740 various\JJ\1740 clinical\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 without\IN\1740 compromising\VBG\1035530 the\DT\1740 left\JJ\1740 ventricular\JJ\1740 function\NN\13783581 .\.\1740
24618873
D008614_D002526 NONE <e2>Cerebellar\JJ\1740 and\CC\1740 oculomotor\NN\5476256 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 rapid\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>pethidine</e1>\NN\1740 .\.\1740
D008614_D005128 NONE <e2>Cerebellar\JJ\1740 and\CC\1740 oculomotor\NN\5476256 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 rapid\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>pethidine</e1>\NN\1740 .\.\1740
D008614_D010146 NONE <e1>Pethidine</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 opioid\NN\1740 that\WDT\1740 gains\VBZ\2238085 its\PRP$\6125041 popularity\NN\4723816 for\IN\1740 the\DT\1740 effective\JJ\1740 <e2>pain</e2>\NN\14299637 control\NN\5190804 through\IN\1740 acting\VBG\1619354 on\IN\1740 the\DT\1740 opioid-receptors\NNS\1740 .\.\1740
D008614_D010146 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 <e2>pain</e2>\NN\14299637 control\NN\5190804 ,\,\1740 <e1>pethidine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 norpethidine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
D008614_D051437 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function</e2>\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 <e1>pethidine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 norpethidine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
D008614_D017093 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function</e2>\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 <e1>pethidine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 norpethidine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
D008614_D020258 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 <e1>pethidine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 <e2>neurotoxic</e2>\JJ\1740 metabolite\NN\20090 ,\,\1740 norpethidine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
D008614_D001523 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 <e1>pethidine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 norpethidine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 <e2>irritability</e2>\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
D008614_D012640 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 <e1>pethidine</e1>\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 norpethidine\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 <e2>seizure</e2>\VB\1740 attack\NN\955060 .\.\1740
C002752_D051437 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function</e2>\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 pethidine\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 <e1>norpethidine</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
C002752_D017093 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function</e2>\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 pethidine\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 <e1>norpethidine</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
C002752_D010146 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 <e2>pain</e2>\NN\14299637 control\NN\5190804 ,\,\1740 pethidine\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 <e1>norpethidine</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
C002752_D020258 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 pethidine\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 <e2>neurotoxic</e2>\JJ\1740 metabolite\NN\20090 ,\,\1740 <e1>norpethidine</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
C002752_D001523 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 pethidine\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 <e1>norpethidine</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 <e2>irritability</e2>\NN\7552087 and\CC\1740 seizure\VB\1740 attack\NN\955060 .\.\1740
C002752_D012640 CID In\IN\13603305 patients\NNS\9898892 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 and\CC\1740 liver\NN\5298729 function\NN\13783581 ,\,\1740 and\CC\1740 those\DT\1740 who\WP\8299493 need\VBP\2604760 long-term\JJ\1740 pain\NN\14299637 control\NN\5190804 ,\,\1740 pethidine\NN\1740 may\MD\15209706 cause\VB\1617192 excitatory\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 effects\NNS\13245626 through\IN\1740 its\PRP$\6125041 neurotoxic\JJ\1740 metabolite\NN\20090 ,\,\1740 <e1>norpethidine</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 irritability\NN\7552087 and\CC\1740 <e2>seizure</e2>\VB\1740 attack\NN\955060 .\.\1740
7411769
D007213_D006947 CID <e1>Indomethacin-induced</e1>\JJ\1740 <e2>hyperkalemia</e2>\NN\14299637 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 gouty\NN\1740 arthritis\NN\14171682 .\.\1740
D007213_D006947 CID We\PRP\1740 describe\VBP\1001294 three\CD\13741022 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 severe\JJ\1740 ,\,\1740 life-threatening\JJ\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 developed\VBD\1753788 after\IN\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 gouty\NN\1740 arthritis\NN\14171682 with\IN\1740 <e1>indomethacin</e1>\NN\3828465 .\.\1740
D007213_D015210 NONE <e1>Indomethacin-induced</e1>\JJ\1740 hyperkalemia\NN\14299637 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>gouty\NN\1740 arthritis</e2>\NN\14171682 .\.\1740
D007213_D015210 NONE We\PRP\1740 describe\VBP\1001294 three\CD\13741022 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 severe\JJ\1740 ,\,\1740 life-threatening\JJ\1740 hyperkalemia\NN\14299637 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 developed\VBD\1753788 after\IN\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 <e2>gouty\NN\1740 arthritis</e2>\NN\14171682 with\IN\1740 <e1>indomethacin</e1>\NN\3828465 .\.\1740
D007213_D051437 CID We\PRP\1740 describe\VBP\1001294 three\CD\13741022 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 severe\JJ\1740 ,\,\1740 life-threatening\JJ\1740 hyperkalemia\NN\14299637 and\CC\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 developed\VBD\1753788 after\IN\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 gouty\NN\1740 arthritis\NN\14171682 with\IN\1740 <e1>indomethacin</e1>\NN\3828465 .\.\1740
D011453_D006994 NONE This\DT\1740 complication\NN\1073995 may\MD\15209706 result\VB\2633881 from\IN\1740 an\DT\6697703 inhibition\NN\1068773 of\IN\1740 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 and\CC\1740 consequent\JJ\1740 <e2>hyporeninemic\JJ\1740 hypoaidosteronism</e2>\NN\1740 .\.\1740
D011188_D003920 NONE Careful\JJ\1740 attention\NN\5701944 to\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 <e1>potassium</e1>\NN\14625458 balance\NN\13934900 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 indomethacin\NN\3828465 or\CC\3541091 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 particularly\RB\1740 in\IN\13603305 those\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 or\CC\3541091 preexisting\JJ\1740 renal\JJ\1740 disease\NN\14061805 ,\,\1740 will\MD\5650329 help\VB\2556126 prevent\VB\1740 this\DT\1740 potentially\RB\1740 serious\JJ\1740 complication\NN\1073995 .\.\1740
D011188_D007674 NONE Careful\JJ\1740 attention\NN\5701944 to\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 <e1>potassium</e1>\NN\14625458 balance\NN\13934900 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 indomethacin\NN\3828465 or\CC\3541091 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 particularly\RB\1740 in\IN\13603305 those\DT\1740 patients\NNS\9898892 with\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 or\CC\3541091 preexisting\JJ\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 will\MD\5650329 help\VB\2556126 prevent\VB\1740 this\DT\1740 potentially\RB\1740 serious\JJ\1740 complication\NN\1073995 .\.\1740
D007213_D003920 NONE Careful\JJ\1740 attention\NN\5701944 to\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 potassium\NN\14625458 balance\NN\13934900 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>indomethacin</e1>\NN\3828465 or\CC\3541091 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 particularly\RB\1740 in\IN\13603305 those\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 or\CC\3541091 preexisting\JJ\1740 renal\JJ\1740 disease\NN\14061805 ,\,\1740 will\MD\5650329 help\VB\2556126 prevent\VB\1740 this\DT\1740 potentially\RB\1740 serious\JJ\1740 complication\NN\1073995 .\.\1740
D007213_D007674 NONE Careful\JJ\1740 attention\NN\5701944 to\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 potassium\NN\14625458 balance\NN\13934900 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>indomethacin</e1>\NN\3828465 or\CC\3541091 other\JJ\1740 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 agents\NNS\7347 ,\,\1740 particularly\RB\1740 in\IN\13603305 those\DT\1740 patients\NNS\9898892 with\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 or\CC\3541091 preexisting\JJ\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 will\MD\5650329 help\VB\2556126 prevent\VB\1740 this\DT\1740 potentially\RB\1740 serious\JJ\1740 complication\NN\1073995 .\.\1740
9061777
D016291_D012640 CID <e1>MK-801</e1>\NN\1740 augments\VBZ\153263 pilocarpine-induced\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 but\CC\1740 protects\VBZ\1127795 against\IN\1740 brain\NN\5462674 damage\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016291_D012640 CID The\DT\1740 authors\NNS\9610660 examined\VBD\789138 the\DT\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>MK-801</e1>\NN\1740 on\IN\1740 the\DT\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 model\NN\5888929 .\.\1740
D016291_D012640 CID Scopolamine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 pentobarbital\JJ\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 pilocarpine-induced\JJ\1740 behavioral\JJ\1740 <e2>seizure</e2>\NN\14081375 but\CC\1740 <e1>MK-801</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 .\.\1740
D016291_D012640 CID Scopolamine\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 ,\,\1740 <e1>MK-801</e1>\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 seizure\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D016291_D012640 CID Scopolamine\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 ,\,\1740 <e1>MK-801</e1>\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 <e2>seizure</e2>\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D016291_D001930 NONE <e1>MK-801</e1>\NN\1740 augments\VBZ\153263 pilocarpine-induced\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 but\CC\1740 protects\VBZ\1127795 against\IN\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016291_D001930 NONE Pentobarbital\JJ\1740 ,\,\1740 scopolamine\NN\14712692 and\CC\1740 <e1>MK-801</e1>\NN\1740 protected\VBD\1127795 the\DT\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 though\IN\1740 in\IN\13603305 the\DT\1740 MK-801-treated\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 pyramidal\JJ\1740 cells\NNS\3080309 of\IN\1740 hippocampus\NN\5462674 appeared\VBD\2604760 darker\JJR\1740 than\IN\1740 normal\JJ\1740 .\.\1740
D016291_D001930 NONE Pentobarbital\JJ\1740 ,\,\1740 scopolamine\NN\14712692 and\CC\1740 MK-801\NN\1740 protected\VBD\1127795 the\DT\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 though\IN\1740 in\IN\13603305 the\DT\1740 <e1>MK-801-treated</e1>\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 pyramidal\JJ\1740 cells\NNS\3080309 of\IN\1740 hippocampus\NN\5462674 appeared\VBD\2604760 darker\JJR\1740 than\IN\1740 normal\JJ\1740 .\.\1740
D010862_D012640 CID MK-801\NN\1740 augments\VBZ\153263 <e1>pilocarpine-induced</e1>\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 but\CC\1740 protects\VBZ\1127795 against\IN\1740 brain\NN\5462674 damage\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010862_D012640 CID The\DT\1740 authors\NNS\9610660 examined\VBD\789138 the\DT\1740 anticonvulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 MK-801\NN\1740 on\IN\1740 the\DT\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 model\NN\5888929 .\.\1740
D010862_D012640 CID Intraperitoneal\JJ\1740 injection\NN\320852 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 400\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>tonic\JJ\1740 and\CC\1740 clonic\NN\1740 seizure</e2>\NN\14081375 .\.\1740
D010862_D012640 CID Scopolamine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 pentobarbital\JJ\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 behavioral\JJ\1740 <e2>seizure</e2>\NN\14081375 but\CC\1740 MK-801\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 .\.\1740
D010862_D012640 CID 2\LS\13741022 .\.\1740 An\DT\6697703 electrical\JJ\1740 <e2>seizure</e2>\NN\14081375 measured\VBN\697589 with\IN\1740 hippocampal\NN\1740 EEG\NN\7000195 appeared\VBD\2604760 in\IN\13603305 the\DT\1740 <e1>pilocarpine-treated</e1>\JJ\1740 group\NN\2137 .\.\1740
D010862_D012640 CID Scopolamine\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 <e1>pilocarpine-induced</e1>\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 seizure\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D010862_D012640 CID Scopolamine\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 <e1>pilocarpine-induced</e1>\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 <e2>seizure</e2>\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D010862_D012640 CID Scopolamine\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 seizure\NN\14081375 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D010862_D012640 CID Scopolamine\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 <e2>seizure</e2>\NN\14081375 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D010862_D001930 NONE MK-801\NN\1740 augments\VBZ\153263 <e1>pilocarpine-induced</e1>\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 but\CC\1740 protects\VBZ\1127795 against\IN\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010862_D001930 NONE Pentobarbital\JJ\1740 ,\,\1740 scopolamine\NN\14712692 and\CC\1740 MK-801\NN\1740 protected\VBD\1127795 the\DT\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 though\IN\1740 in\IN\13603305 the\DT\1740 MK-801-treated\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 pyramidal\JJ\1740 cells\NNS\3080309 of\IN\1740 hippocampus\NN\5462674 appeared\VBD\2604760 darker\JJR\1740 than\IN\1740 normal\JJ\1740 .\.\1740
D010862_D001930 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 status\NN\24720 epilepticus\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 is\VBZ\836236 initiated\VBN\1617192 by\IN\1740 cholinergic\JJ\1740 overstimulation\NN\1740 and\CC\1740 propagated\VBN\2230247 by\IN\1740 glutamatergic\JJ\1740 transmission\NN\121166 ,\,\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 <e2>brain\NN\5462674 damage</e2>\NN\7296428 through\IN\1740 an\DT\6697703 excitatory\JJ\1740 NMDA\NN\1740 receptor-mediated\JJ\1740 mechanism\NN\13446390 .\.\1740
D012601_D012640 NONE <e1>Scopolamine</e1>\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 pentobarbital\JJ\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 pilocarpine-induced\JJ\1740 behavioral\JJ\1740 <e2>seizure</e2>\NN\14081375 but\CC\1740 MK-801\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 .\.\1740
D012601_D012640 NONE <e1>Scopolamine</e1>\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 seizure\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D012601_D012640 NONE <e1>Scopolamine</e1>\NN\14712692 and\CC\1740 pentobarbital\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 <e2>seizure</e2>\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D010424_D012640 NONE Scopolamine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>pentobarbital</e1>\JJ\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 pilocarpine-induced\JJ\1740 behavioral\JJ\1740 <e2>seizure</e2>\NN\14081375 but\CC\1740 MK-801\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 .\.\1740
D010424_D012640 NONE Scopolamine\NN\14712692 and\CC\1740 <e1>pentobarbital</e1>\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 <e2>seizure</e2>\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 seizure\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D010424_D012640 NONE Scopolamine\NN\14712692 and\CC\1740 <e1>pentobarbital</e1>\NN\2792049 blocked\VBD\1476483 the\DT\1740 pilocarpine-induced\JJ\1740 electrographic\NN\1740 seizure\NN\14081375 ,\,\1740 MK-801\NN\1740 treatment\NN\654885 augmented\VBD\153263 the\DT\1740 electrographic\JJ\1740 <e2>seizure</e2>\NN\14081375 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D010862_D009410 CID <e1>Pilocarpine</e1>\NN\14712692 produced\VBD\1617192 <e2>neuronal\JJ\1740 death</e2>\NN\7296428 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 ,\,\1740 which\WDT\1740 showed\VBD\2137132 pyknotic\JJ\1740 changes\NNS\7283608 .\.\1740
D010424_D001930 NONE <e1>Pentobarbital</e1>\JJ\1740 ,\,\1740 scopolamine\NN\14712692 and\CC\1740 MK-801\NN\1740 protected\VBD\1127795 the\DT\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 though\IN\1740 in\IN\13603305 the\DT\1740 MK-801-treated\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 pyramidal\JJ\1740 cells\NNS\3080309 of\IN\1740 hippocampus\NN\5462674 appeared\VBD\2604760 darker\JJR\1740 than\IN\1740 normal\JJ\1740 .\.\1740
D012601_D001930 NONE Pentobarbital\JJ\1740 ,\,\1740 <e1>scopolamine</e1>\NN\14712692 and\CC\1740 MK-801\NN\1740 protected\VBD\1127795 the\DT\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 though\IN\1740 in\IN\13603305 the\DT\1740 MK-801-treated\JJ\1740 group\NN\2137 ,\,\1740 the\DT\1740 pyramidal\JJ\1740 cells\NNS\3080309 of\IN\1740 hippocampus\NN\5462674 appeared\VBD\2604760 darker\JJR\1740 than\IN\1740 normal\JJ\1740 .\.\1740
D010862_D013226 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 is\VBZ\836236 initiated\VBN\1617192 by\IN\1740 cholinergic\JJ\1740 overstimulation\NN\1740 and\CC\1740 propagated\VBN\2230247 by\IN\1740 glutamatergic\JJ\1740 transmission\NN\121166 ,\,\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 brain\NN\5462674 damage\NN\7296428 through\IN\1740 an\DT\6697703 excitatory\JJ\1740 NMDA\NN\1740 receptor-mediated\JJ\1740 mechanism\NN\13446390 .\.\1740
D016202_D013226 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 is\VBZ\836236 initiated\VBN\1617192 by\IN\1740 cholinergic\JJ\1740 overstimulation\NN\1740 and\CC\1740 propagated\VBN\2230247 by\IN\1740 glutamatergic\JJ\1740 transmission\NN\121166 ,\,\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 brain\NN\5462674 damage\NN\7296428 through\IN\1740 an\DT\6697703 excitatory\JJ\1740 <e1>NMDA</e1>\NN\1740 receptor-mediated\JJ\1740 mechanism\NN\13446390 .\.\1740
D016202_D001930 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 status\NN\24720 epilepticus\NN\1740 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 is\VBZ\836236 initiated\VBN\1617192 by\IN\1740 cholinergic\JJ\1740 overstimulation\NN\1740 and\CC\1740 propagated\VBN\2230247 by\IN\1740 glutamatergic\JJ\1740 transmission\NN\121166 ,\,\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 which\WDT\1740 may\MD\15209706 cause\VB\1617192 <e2>brain\NN\5462674 damage</e2>\NN\7296428 through\IN\1740 an\DT\6697703 excitatory\JJ\1740 <e1>NMDA</e1>\NN\1740 receptor-mediated\JJ\1740 mechanism\NN\13446390 .\.\1740
24881749
D013747_D009459 CID <e2>Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 <e1>tetrabenazine</e1>\NN\1740 and\CC\1740 tiapride\NN\1740 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 patient\NN\9898892 with\IN\1740 Huntington\NNP\1740 's\POS\1740 disease\NN\14061805 at\IN\14622893 the\DT\1740 terminal\JJ\1740 stage\NN\15113229 of\IN\1740 recurrent\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D013747_D009459 CID We\PRP\1740 herein\RB\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 81-year-old\JJ\1740 Japanese\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 that\WDT\1740 occurred\VBD\2623529 36\CD\1740 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 tiapride\NN\1740 (\-LRB-\1740 75\CD\1740 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>tetrabenazine</e1>\NN\1740 (\-LRB-\1740 12.5\CD\1740 mg/day\NN\1740 )\-RRB-\1740 for\IN\1740 Huntington\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D013747_D009459 CID To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 due\JJ\1740 to\TO\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 <e1>tetrabenazine</e1>\NN\1740 and\CC\1740 tiapride\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 previously\RB\1740 reported\VBN\831651 .\.\1740
D013747_D006816 NONE Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 <e1>tetrabenazine</e1>\NN\1740 and\CC\1740 tiapride\NN\1740 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>Huntington\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 at\IN\14622893 the\DT\1740 terminal\JJ\1740 stage\NN\15113229 of\IN\1740 recurrent\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D013747_D006816 NONE We\PRP\1740 herein\RB\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 81-year-old\JJ\1740 Japanese\JJ\1740 woman\NN\9605289 with\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 that\WDT\1740 occurred\VBD\2623529 36\CD\1740 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 tiapride\NN\1740 (\-LRB-\1740 75\CD\1740 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>tetrabenazine</e1>\NN\1740 (\-LRB-\1740 12.5\CD\1740 mg/day\NN\1740 )\-RRB-\1740 for\IN\1740 <e2>Huntington\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D013747_D001943 NONE Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 <e1>tetrabenazine</e1>\NN\1740 and\CC\1740 tiapride\NN\1740 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 patient\NN\9898892 with\IN\1740 Huntington\NNP\1740 's\POS\1740 disease\NN\14061805 at\IN\14622893 the\DT\1740 terminal\JJ\1740 stage\NN\15113229 of\IN\1740 recurrent\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D063325_D009459 CID <e2>Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 tetrabenazine\NN\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 patient\NN\9898892 with\IN\1740 Huntington\NNP\1740 's\POS\1740 disease\NN\14061805 at\IN\14622893 the\DT\1740 terminal\JJ\1740 stage\NN\15113229 of\IN\1740 recurrent\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D063325_D009459 CID We\PRP\1740 herein\RB\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 81-year-old\JJ\1740 Japanese\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 that\WDT\1740 occurred\VBD\2623529 36\CD\1740 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 <e1>tiapride</e1>\NN\1740 (\-LRB-\1740 75\CD\1740 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 tetrabenazine\NN\1740 (\-LRB-\1740 12.5\CD\1740 mg/day\NN\1740 )\-RRB-\1740 for\IN\1740 Huntington\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D063325_D009459 CID To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 due\JJ\1740 to\TO\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 tetrabenazine\NN\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 previously\RB\1740 reported\VBN\831651 .\.\1740
D063325_D006816 NONE Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 tetrabenazine\NN\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>Huntington\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 at\IN\14622893 the\DT\1740 terminal\JJ\1740 stage\NN\15113229 of\IN\1740 recurrent\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D063325_D006816 NONE We\PRP\1740 herein\RB\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 an\DT\6697703 81-year-old\JJ\1740 Japanese\JJ\1740 woman\NN\9605289 with\IN\1740 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 that\WDT\1740 occurred\VBD\2623529 36\CD\1740 days\NNS\15140892 after\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 <e1>tiapride</e1>\NN\1740 (\-LRB-\1740 75\CD\1740 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 tetrabenazine\NN\1740 (\-LRB-\1740 12.5\CD\1740 mg/day\NN\1740 )\-RRB-\1740 for\IN\1740 <e2>Huntington\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D063325_D001943 NONE Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 combination\NN\7951464 therapy\NN\657604 with\IN\1740 tetrabenazine\NN\1740 and\CC\1740 <e1>tiapride</e1>\NN\1740 in\IN\13603305 a\DT\13649268 Japanese\JJ\1740 patient\NN\9898892 with\IN\1740 Huntington\NNP\1740 's\POS\1740 disease\NN\14061805 at\IN\14622893 the\DT\1740 terminal\JJ\1740 stage\NN\15113229 of\IN\1740 recurrent\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
3155884
D007545_D066126 NONE Acute\JJ\1740 insulin\NN\5407119 treatment\NN\654885 normalizes\VBZ\109660 the\DT\1740 resistance\NN\37396 to\TO\1740 the\DT\1740 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 in\IN\13603305 streptozotocin\NN\1740 diabetic\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D066126 NONE The\DT\1740 acute\JJ\1740 effect\NN\34213 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 the\DT\1740 earlier\RBR\1740 reported\VBN\831651 protective\JJ\1740 effect\NN\34213 of\IN\1740 streptozotocin\NN\1740 diabetes\NNS\14075199 against\IN\1740 the\DT\1740 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (\-LRB-\1740 ISO\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D066126 NONE The\DT\1740 acute\JJ\1740 effect\NN\34213 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 the\DT\1740 earlier\RBR\1740 reported\VBN\831651 protective\JJ\1740 effect\NN\34213 of\IN\1740 streptozotocin\NN\1740 diabetes\NNS\14075199 against\IN\1740 the\DT\1740 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 isoproterenol\NN\3740161 (\-LRB-\1740 <e1>ISO</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D003920 NONE Acute\JJ\1740 insulin\NN\5407119 treatment\NN\654885 normalizes\VBZ\109660 the\DT\1740 resistance\NN\37396 to\TO\1740 the\DT\1740 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 in\IN\13603305 streptozotocin\NN\1740 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D003920 NONE The\DT\1740 acute\JJ\1740 effect\NN\34213 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 the\DT\1740 earlier\RBR\1740 reported\VBN\831651 protective\JJ\1740 effect\NN\34213 of\IN\1740 streptozotocin\NN\1740 <e2>diabetes</e2>\NNS\14075199 against\IN\1740 the\DT\1740 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (\-LRB-\1740 ISO\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D003920 NONE The\DT\1740 acute\JJ\1740 effect\NN\34213 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 the\DT\1740 earlier\RBR\1740 reported\VBN\831651 protective\JJ\1740 effect\NN\34213 of\IN\1740 streptozotocin\NN\1740 <e2>diabetes</e2>\NNS\14075199 against\IN\1740 the\DT\1740 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 isoproterenol\NN\3740161 (\-LRB-\1740 <e1>ISO</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D003920 NONE The\DT\1740 rapid\JJ\1740 reversion\NN\13286801 after\IN\1740 insulin\NN\5407119 treatment\NN\654885 excludes\VBZ\471711 the\DT\1740 possibility\NN\5944958 that\IN\1740 streptozotocin\NN\1740 in\IN\13603305 itself\PRP\1740 causes\VBZ\1617192 the\DT\1740 <e1>ISO</e1>\NN\1740 resistance\NN\37396 and\CC\1740 points\VBZ\831651 towards\IN\1740 a\DT\13649268 direct\JJ\1740 insulin\NN\5407119 effect\NN\34213 on\IN\1740 myocardial\JJ\1740 catecholamine\NN\5407119 sensitivity\NN\5651971 in\IN\13603305 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D066126 NONE Acute\JJ\1740 insulin\NN\5407119 treatment\NN\654885 normalizes\VBZ\109660 the\DT\1740 resistance\NN\37396 to\TO\1740 the\DT\1740 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 isoproterenol\NN\3740161 in\IN\13603305 <e1>streptozotocin</e1>\NN\1740 diabetic\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D066126 NONE The\DT\1740 acute\JJ\1740 effect\NN\34213 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 the\DT\1740 earlier\RBR\1740 reported\VBN\831651 protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>streptozotocin</e1>\NN\1740 diabetes\NNS\14075199 against\IN\1740 the\DT\1740 <e2>cardiotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 isoproterenol\NN\3740161 (\-LRB-\1740 ISO\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 .\.\1740
D013311_D003920 CID Acute\JJ\1740 insulin\NN\5407119 treatment\NN\654885 normalizes\VBZ\109660 the\DT\1740 resistance\NN\37396 to\TO\1740 the\DT\1740 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 isoproterenol\NN\3740161 in\IN\13603305 <e1>streptozotocin</e1>\NN\1740 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D003920 CID The\DT\1740 acute\JJ\1740 effect\NN\34213 of\IN\1740 insulin\NN\5407119 treatment\NN\654885 on\IN\1740 the\DT\1740 earlier\RBR\1740 reported\VBN\831651 protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>streptozotocin</e1>\NN\1740 <e2>diabetes</e2>\NNS\14075199 against\IN\1740 the\DT\1740 cardiotoxic\JJ\1740 effect\NN\34213 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 isoproterenol\NN\3740161 (\-LRB-\1740 ISO\NN\1740 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 .\.\1740
D013311_D003920 CID The\DT\1740 rapid\JJ\1740 reversion\NN\13286801 after\IN\1740 insulin\NN\5407119 treatment\NN\654885 excludes\VBZ\471711 the\DT\1740 possibility\NN\5944958 that\IN\1740 <e1>streptozotocin</e1>\NN\1740 in\IN\13603305 itself\PRP\1740 causes\VBZ\1617192 the\DT\1740 ISO\NN\1740 resistance\NN\37396 and\CC\1740 points\VBZ\831651 towards\IN\1740 a\DT\13649268 direct\JJ\1740 insulin\NN\5407119 effect\NN\34213 on\IN\1740 myocardial\JJ\1740 catecholamine\NN\5407119 sensitivity\NN\5651971 in\IN\13603305 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D005355 CID A\DT\13649268 morphometric\JJ\1740 study\NN\635850 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 induced\JJ\1740 myocardial\JJ\1740 <e2>fibrosis</e2>\NN\14204950 .\.\1740
D007545_D005355 CID Thirty\CD\13745420 to\TO\1740 135\CD\1740 min\NN\15154774 after\IN\1740 the\DT\1740 injection\NN\320852 of\IN\1740 crystalline\NN\1740 insulin\NN\5407119 ,\,\1740 <e1>ISO</e1>\NN\1740 was\VBD\836236 given\VBN\2327200 subcutaneously\RB\1740 and\CC\1740 when\WRB\1740 ISO\NN\1740 induced\VBD\1627355 <e2>fibrosis</e2>\NN\14204950 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 was\VBD\836236 morphometrically\RB\1740 analyzed\VBN\78760 7\CD\13741022 days\NNS\15140892 later\RB\1740 ,\,\1740 a\DT\13649268 highly\RB\1740 significant\JJ\1740 correlation\NN\13841213 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.83\CD\1740 ,\,\1740 2\CD\13741022 p\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 to\TO\1740 the\DT\1740 slope\NN\9287968 of\IN\1740 the\DT\1740 fall\NN\15236475 in\IN\13603305 blood\NN\5397468 glucose\NN\14710501 after\IN\1740 insulin\NN\5407119 treatment\NN\654885 appeared\VBD\2604760 .\.\1740
D007545_D005355 CID Thirty\CD\13745420 to\TO\1740 135\CD\1740 min\NN\15154774 after\IN\1740 the\DT\1740 injection\NN\320852 of\IN\1740 crystalline\NN\1740 insulin\NN\5407119 ,\,\1740 ISO\NN\1740 was\VBD\836236 given\VBN\2327200 subcutaneously\RB\1740 and\CC\1740 when\WRB\1740 <e1>ISO</e1>\NN\1740 induced\VBD\1627355 <e2>fibrosis</e2>\NN\14204950 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 was\VBD\836236 morphometrically\RB\1740 analyzed\VBN\78760 7\CD\13741022 days\NNS\15140892 later\RB\1740 ,\,\1740 a\DT\13649268 highly\RB\1740 significant\JJ\1740 correlation\NN\13841213 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.83\CD\1740 ,\,\1740 2\CD\13741022 p\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 to\TO\1740 the\DT\1740 slope\NN\9287968 of\IN\1740 the\DT\1740 fall\NN\15236475 in\IN\13603305 blood\NN\5397468 glucose\NN\14710501 after\IN\1740 insulin\NN\5407119 treatment\NN\654885 appeared\VBD\2604760 .\.\1740
D005947_D005355 NONE Thirty\CD\13745420 to\TO\1740 135\CD\1740 min\NN\15154774 after\IN\1740 the\DT\1740 injection\NN\320852 of\IN\1740 crystalline\NN\1740 insulin\NN\5407119 ,\,\1740 ISO\NN\1740 was\VBD\836236 given\VBN\2327200 subcutaneously\RB\1740 and\CC\1740 when\WRB\1740 ISO\NN\1740 induced\VBD\1627355 <e2>fibrosis</e2>\NN\14204950 in\IN\13603305 the\DT\1740 myocardium\NN\5389939 was\VBD\836236 morphometrically\RB\1740 analyzed\VBN\78760 7\CD\13741022 days\NNS\15140892 later\RB\1740 ,\,\1740 a\DT\13649268 highly\RB\1740 significant\JJ\1740 correlation\NN\13841213 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.83\CD\1740 ,\,\1740 2\CD\13741022 p\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 to\TO\1740 the\DT\1740 slope\NN\9287968 of\IN\1740 the\DT\1740 fall\NN\15236475 in\IN\13603305 blood\NN\5397468 <e1>glucose</e1>\NN\14710501 after\IN\1740 insulin\NN\5407119 treatment\NN\654885 appeared\VBD\2604760 .\.\1740
D002395_D003920 NONE The\DT\1740 myocardial\JJ\1740 content\NN\7951464 of\IN\1740 <e1>catecholamines</e1>\NNS\5407119 was\VBD\836236 estimated\VBN\637259 in\IN\13603305 these\DT\1740 8\CD\13741022 day\NN\15154774 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D002395_D003920 NONE The\DT\1740 rapid\JJ\1740 reversion\NN\13286801 after\IN\1740 insulin\NN\5407119 treatment\NN\654885 excludes\VBZ\471711 the\DT\1740 possibility\NN\5944958 that\IN\1740 streptozotocin\NN\1740 in\IN\13603305 itself\PRP\1740 causes\VBZ\1617192 the\DT\1740 ISO\NN\1740 resistance\NN\37396 and\CC\1740 points\VBZ\831651 towards\IN\1740 a\DT\13649268 direct\JJ\1740 insulin\NN\5407119 effect\NN\34213 on\IN\1740 myocardial\JJ\1740 <e1>catecholamine</e1>\NN\5407119 sensitivity\NN\5651971 in\IN\13603305 <e2>diabetic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
25096313
D013256_D009422 NONE Lateral\JJ\1740 antebrachial\NN\1740 cutaneous\JJ\1740 <e2>neuropathy</e2>\NN\14204950 after\IN\1740 <e1>steroid</e1>\NN\14727670 injection\NN\320852 at\IN\14622893 lateral\JJ\1740 epicondyle\NN\5470189 .\.\1740
D013256_D009422 NONE BACKGROUND\NN\4921011 AND\CC\1740 OBJECTIVES\NNS\5980875 :\:\1740 This\DT\1740 report\NN\6470073 aimed\VBN\1987160 to\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 lateral\JJ\1740 antebrachial\JJ\1740 cutaneous\JJ\1740 <e2>neuropathy</e2>\NN\14204950 (\-LRB-\1740 LACNP\NN\1740 )\-RRB-\1740 that\WDT\1740 occurred\VBD\2623529 after\IN\1740 a\DT\13649268 <e1>steroid</e1>\NN\14727670 injection\NN\320852 in\IN\13603305 the\DT\1740 lateral\JJ\1740 epicondyle\NN\5470189 to\TO\1740 treat\VB\2376958 lateral\JJ\1740 epicondylitis\NN\14336539 in\IN\13603305 a\DT\13649268 40-year-old\JJ\1740 woman\NN\9605289 .\.\1740
D013256_D013716 NONE BACKGROUND\NN\4921011 AND\CC\1740 OBJECTIVES\NNS\5980875 :\:\1740 This\DT\1740 report\NN\6470073 aimed\VBN\1987160 to\TO\1740 present\VB\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 lateral\JJ\1740 antebrachial\JJ\1740 cutaneous\JJ\1740 neuropathy\NN\14204950 (\-LRB-\1740 LACNP\NN\1740 )\-RRB-\1740 that\WDT\1740 occurred\VBD\2623529 after\IN\1740 a\DT\13649268 <e1>steroid</e1>\NN\14727670 injection\NN\320852 in\IN\13603305 the\DT\1740 lateral\JJ\1740 epicondyle\NN\5470189 to\TO\1740 treat\VB\2376958 <e2>lateral\JJ\1740 epicondylitis</e2>\NN\14336539 in\IN\13603305 a\DT\13649268 40-year-old\JJ\1740 woman\NN\9605289 .\.\1740
D013256_D013716 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 woman\NN\9605289 with\IN\1740 LACNP\NN\1740 that\WDT\1740 developed\VBD\1753788 after\IN\1740 a\DT\13649268 <e1>steroid</e1>\NN\14727670 injection\NN\320852 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>lateral\JJ\1740 epicondylitis</e2>\NN\14336539 .\.\1740
D013256_D010292 CID MATERIAL\NN\19613 AND\CC\1740 METHOD\NN\5616786 :\:\1740 A\DT\13649268 40-year-old\JJ\1740 woman\NN\9605289 presented\VBN\2137132 with\IN\1740 decreased\VBN\169651 sensation\NN\5708432 and\CC\1740 <e2>paresthesia</e2>\VBD\1740 over\IN\5867413 her\PRP$\1740 right\JJ\1740 lateral\JJ\1740 forearm\NN\5560244 ;\:\1740 the\DT\1740 paresthesia\NN\14299637 had\VBD\2108377 occurred\VBN\2623529 after\IN\1740 a\DT\13649268 <e1>steroid</e1>\NN\14727670 injection\NN\320852 in\IN\13603305 the\DT\1740 right\JJ\1740 lateral\JJ\1740 epicondyle\NN\5470189 3\CD\13741022 months\NNS\15113229 before\RB\1740 .\.\1740
D013256_D010292 CID MATERIAL\NN\19613 AND\CC\1740 METHOD\NN\5616786 :\:\1740 A\DT\13649268 40-year-old\JJ\1740 woman\NN\9605289 presented\VBN\2137132 with\IN\1740 decreased\VBN\169651 sensation\NN\5708432 and\CC\1740 paresthesia\VBD\1740 over\IN\5867413 her\PRP$\1740 right\JJ\1740 lateral\JJ\1740 forearm\NN\5560244 ;\:\1740 the\DT\1740 <e2>paresthesia</e2>\NN\14299637 had\VBD\2108377 occurred\VBN\2623529 after\IN\1740 a\DT\13649268 <e1>steroid</e1>\NN\14727670 injection\NN\320852 in\IN\13603305 the\DT\1740 right\JJ\1740 lateral\JJ\1740 epicondyle\NN\5470189 3\CD\13741022 months\NNS\15113229 before\RB\1740 .\.\1740
24664478
C104457_D020258 NONE <e1>Nelarabine</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 with\IN\1740 concurrent\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 :\:\1740 Case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 literature\NN\6362953 .\.\1740
C104457_D020258 NONE Severe\JJ\1740 <e1>nelarabine</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 concurrent\JJ\1740 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 chemotherapy\NN\661091 is\VBZ\836236 reported\VBN\831651 .\.\1740
C104457_D020258 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 published\VBN\1621555 case\NN\7283608 report\NN\6470073 of\IN\1740 severe\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>nelarabine</e1>\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 concurrent\JJ\1740 IT\NN\6125041 chemotherapy\NN\661091 .\.\1740
24659727
D008130_D008223 NONE Tolerability\NN\1740 of\IN\1740 <e1>lomustine</e1>\NN\2722458 in\IN\13603305 combination\NN\7951464 with\IN\1740 cyclophosphamide\NN\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>lymphoma</e2>\NN\14239918 .\.\1740
D008130_D008223 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 toxicity\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 <e1>lomustine</e1>\NN\2722458 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CTX\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>lymphoma</e2>\NN\14239918 .\.\1740
D008130_D008223 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 toxicity\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 lomustine\NN\2722458 (\-LRB-\1740 <e1>CCNU</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CTX\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>lymphoma</e2>\NN\14239918 .\.\1740
D003520_D008223 NONE Tolerability\NN\1740 of\IN\1740 lomustine\NN\2722458 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>lymphoma</e2>\NN\14239918 .\.\1740
D003520_D008223 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 toxicity\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 lomustine\NN\2722458 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CTX\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>lymphoma</e2>\NN\14239918 .\.\1740
D003520_D008223 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 toxicity\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 lomustine\NN\2722458 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CTX</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 <e2>lymphoma</e2>\NN\14239918 .\.\1740
D008130_D064420 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 <e2>toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 <e1>lomustine</e1>\NN\2722458 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CTX\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 lymphoma\NN\14239918 .\.\1740
D008130_D064420 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 <e2>toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 lomustine\NN\2722458 (\-LRB-\1740 <e1>CCNU</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CTX\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 lymphoma\NN\14239918 .\.\1740
D003520_D064420 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 <e2>toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 lomustine\NN\2722458 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CTX\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 lymphoma\NN\14239918 .\.\1740
D003520_D064420 NONE This\DT\1740 retrospective\JJ\1740 study\NN\635850 describes\VBZ\1001294 <e2>toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 a\DT\13649268 protocol\NN\6652242 of\IN\1740 lomustine\NN\2722458 (\-LRB-\1740 CCNU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CTX</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 lymphoma\NN\14239918 .\.\1740
D008130_D009503 CID <e2>Neutropenia</e2>\NNP\14196405 was\VBD\836236 the\DT\1740 principal\JJ\1740 toxic\JJ\1740 effect\NN\34213 ,\,\1740 and\CC\1740 the\DT\1740 overall\JJ\1740 frequency\NN\15286249 of\IN\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 after\IN\1740 the\DT\1740 first\JJ\1740 treatment\NN\654885 of\IN\1740 <e1>CCNU/CTX</e1>\NN\1740 was\VBD\836236 30\CD\13745420 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 19\CD\13745420 -\SYM\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D009503 CID Neutropenia\NNP\14196405 was\VBD\836236 the\DT\1740 principal\JJ\1740 toxic\JJ\1740 effect\NN\34213 ,\,\1740 and\CC\1740 the\DT\1740 overall\JJ\1740 frequency\NN\15286249 of\IN\1740 grade\NN\7975026 4\CD\13741022 <e2>neutropenia</e2>\NN\14196405 after\IN\1740 the\DT\1740 first\JJ\1740 treatment\NN\654885 of\IN\1740 <e1>CCNU/CTX</e1>\NN\1740 was\VBD\836236 30\CD\13745420 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 19\CD\13745420 -\SYM\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D009503 CID <e2>Neutropenia</e2>\NNP\14196405 was\VBD\836236 the\DT\1740 principal\JJ\1740 toxic\JJ\1740 effect\NN\34213 ,\,\1740 and\CC\1740 the\DT\1740 overall\JJ\1740 frequency\NN\15286249 of\IN\1740 grade\NN\7975026 4\CD\13741022 neutropenia\NN\14196405 after\IN\1740 the\DT\1740 first\JJ\1740 treatment\NN\654885 of\IN\1740 <e1>CCNU/CTX</e1>\NN\1740 was\VBD\836236 30\CD\13745420 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 19\CD\13745420 -\SYM\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D009503 CID Neutropenia\NNP\14196405 was\VBD\836236 the\DT\1740 principal\JJ\1740 toxic\JJ\1740 effect\NN\34213 ,\,\1740 and\CC\1740 the\DT\1740 overall\JJ\1740 frequency\NN\15286249 of\IN\1740 grade\NN\7975026 4\CD\13741022 <e2>neutropenia</e2>\NN\14196405 after\IN\1740 the\DT\1740 first\JJ\1740 treatment\NN\654885 of\IN\1740 <e1>CCNU/CTX</e1>\NN\1740 was\VBD\836236 30\CD\13745420 %\NN\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 19\CD\13745420 -\SYM\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D008130_D009369 NONE On\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 the\DT\1740 findings\NNS\7951464 reported\VBN\831651 herein\RB\1740 ,\,\1740 a\DT\13649268 dose\NN\3740161 of\IN\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>CCNU</e1>\NN\1740 combined\VBN\2630189 with\IN\1740 250\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 CTX\NN\1740 (\-LRB-\1740 divided\VBN\140123 over\RB\1740 5\CD\13741022 days\NNS\15140892 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 wk\NN\1740 is\VBZ\836236 tolerable\JJ\1740 in\IN\13603305 <e2>tumor-bearing</e2>\JJ\1740 dogs\NNS\2083346 .\.\1740
D003520_D009369 NONE On\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 the\DT\1740 findings\NNS\7951464 reported\VBN\831651 herein\RB\1740 ,\,\1740 a\DT\13649268 dose\NN\3740161 of\IN\1740 60\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 CCNU\NN\1740 combined\VBN\2630189 with\IN\1740 250\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>CTX</e1>\NN\1740 (\-LRB-\1740 divided\VBN\140123 over\RB\1740 5\CD\13741022 days\NNS\15140892 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 wk\NN\1740 is\VBZ\836236 tolerable\JJ\1740 in\IN\13603305 <e2>tumor-bearing</e2>\JJ\1740 dogs\NNS\2083346 .\.\1740
15991002
D009538_D001008 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 investigates\VBZ\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>nicotine</e1>\NN\14712692 on\IN\1740 <e2>anxiety</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 caffeine\NN\14712692 and\CC\1740 another\DT\1740 anxiogenic\JJ\1740 drug\NN\14778436 ,\,\1740 pentylenetetrazole\NN\1740 ,\,\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009538_D001008 NONE <e1>Nicotine</e1>\NN\14712692 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 pretreatment\NN\1740 blocked\VBD\1476483 the\DT\1740 caffeine-\NN\1740 but\CC\1740 not\RB\1740 pentylenetetrazole-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D009538_D001008 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 antagonistic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>nicotine</e1>\NN\14712692 on\IN\1740 caffeine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 is\VBZ\836236 specific\JJ\1740 to\TO\1740 caffeine\NN\14712692 ,\,\1740 instead\RB\1740 of\IN\1740 a\DT\13649268 non-specific\JJ\1740 anxiolytic\JJ\1740 effect\NN\34213 .\.\1740
D002110_D001008 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 investigates\VBZ\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 nicotine\NN\14712692 on\IN\1740 <e2>anxiety</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 <e1>caffeine</e1>\NN\14712692 and\CC\1740 another\DT\1740 anxiogenic\JJ\1740 drug\NN\14778436 ,\,\1740 pentylenetetrazole\NN\1740 ,\,\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D002110_D001008 CID Nicotine\NN\14712692 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 pretreatment\NN\1740 blocked\VBD\1476483 the\DT\1740 <e1>caffeine-</e1>\NN\1740 but\CC\1740 not\RB\1740 pentylenetetrazole-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D002110_D001008 CID CONCLUSIONS\NNS\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 antagonistic\JJ\1740 effect\NN\34213 of\IN\1740 nicotine\NN\14712692 on\IN\1740 <e1>caffeine-induced</e1>\JJ\1740 <e2>anxiety</e2>\NN\14373582 is\VBZ\836236 specific\JJ\1740 to\TO\1740 caffeine\NN\14712692 ,\,\1740 instead\RB\1740 of\IN\1740 a\DT\13649268 non-specific\JJ\1740 anxiolytic\JJ\1740 effect\NN\34213 .\.\1740
D002110_D001008 CID CONCLUSIONS\NNS\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 antagonistic\JJ\1740 effect\NN\34213 of\IN\1740 nicotine\NN\14712692 on\IN\1740 caffeine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 is\VBZ\836236 specific\JJ\1740 to\TO\1740 <e1>caffeine</e1>\NN\14712692 ,\,\1740 instead\RB\1740 of\IN\1740 a\DT\13649268 non-specific\JJ\1740 anxiolytic\JJ\1740 effect\NN\34213 .\.\1740
D010433_D001008 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 investigates\VBZ\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 nicotine\NN\14712692 on\IN\1740 <e2>anxiety</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 caffeine\NN\14712692 and\CC\1740 another\DT\1740 anxiogenic\JJ\1740 drug\NN\14778436 ,\,\1740 <e1>pentylenetetrazole</e1>\NN\1740 ,\,\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010433_D001008 CID Nicotine\NN\14712692 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 pretreatment\NN\1740 blocked\VBD\1476483 the\DT\1740 caffeine-\NN\1740 but\CC\1740 not\RB\1740 <e1>pentylenetetrazole-induced</e1>\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
3987172
D011433_D006973 NONE <e1>Propranolol</e1>\JJ\1740 antagonism\NN\24720 of\IN\1740 phenylpropanolamine-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D011433_D006973 NONE We\PRP\1740 studied\VBD\630380 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>propranolol</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 PPA-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D010665_D006973 CID Propranolol\JJ\1740 antagonism\NN\24720 of\IN\1740 <e1>phenylpropanolamine-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D010665_D006973 CID <e1>Phenylpropanolamine</e1>\NN\2682038 (\-LRB-\1740 PPA\NN\1740 )\-RRB-\1740 overdose\NN\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D010665_D006973 CID Phenylpropanolamine\NN\2682038 (\-LRB-\1740 <e1>PPA</e1>\NN\1740 )\-RRB-\1740 overdose\NN\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D010665_D006973 CID We\PRP\1740 studied\VBD\630380 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 propranolol\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>PPA-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D010665_D062787 NONE <e1>Phenylpropanolamine</e1>\NN\2682038 (\-LRB-\1740 PPA\NN\1740 )\-RRB-\1740 <e2>overdose</e2>\NN\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 hypertension\NN\14057371 ,\,\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D010665_D062787 NONE Phenylpropanolamine\NN\2682038 (\-LRB-\1740 <e1>PPA</e1>\NN\1740 )\-RRB-\1740 <e2>overdose</e2>\NN\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 hypertension\NN\14057371 ,\,\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D010665_D002543 NONE <e1>Phenylpropanolamine</e1>\NN\2682038 (\-LRB-\1740 PPA\NN\1740 )\-RRB-\1740 overdose\NN\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 hypertension\NN\14057371 ,\,\1740 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D010665_D002543 NONE Phenylpropanolamine\NN\2682038 (\-LRB-\1740 <e1>PPA</e1>\NN\1740 )\-RRB-\1740 overdose\NN\1740 can\MD\3094503 cause\VB\1617192 severe\JJ\1740 hypertension\NN\14057371 ,\,\1740 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D010665_D020521 NONE Left\JJ\1740 ventricular\JJ\1740 function\NN\13783581 (\-LRB-\1740 assessed\VBN\670261 by\IN\1740 echocardiography\NN\177127 )\-RRB-\1740 showed\VBD\2137132 that\IN\1740 <e1>PPA</e1>\NN\1740 increased\VBD\169651 the\DT\1740 <e2>stroke</e2>\NN\556313 volume\NN\33615 30\CD\13745420 %\NN\1740 (\-LRB-\1740 from\IN\1740 62.5\CD\1740 +/-\CC\1740 20.9\CD\1740 to\TO\1740 80.8\CD\1740 +/-\CC\1740 22.4\CD\1740 ml\NN\13616054 )\-RRB-\1740 ,\,\1740 the\DT\1740 ejection\NN\45250 fraction\NN\14806838 9\CD\13741022 %\NN\1740 (\-LRB-\1740 from\IN\1740 64\CD\1740 %\NN\1740 +/-\CC\1740 10\CD\13745420 %\NN\1740 to\IN\1740 70\CD\13745420 %\NN\1740 +/-\CC\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 cardiac\JJ\1740 output\NN\4007894 14\CD\13745420 %\NN\1740 (\-LRB-\1740 from\IN\1740 3.6\CD\1740 +/-\CC\1740 0.6\CD\1740 to\TO\1740 4.1\CD\1740 +/-\CC\1740 1.0\CD\1740 L/min\NN\1740 )\-RRB-\1740 .\.\1740
20408947
D000082_D017114 CID Medical\JJ\1740 and\CC\1740 psychiatric\JJ\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 :\:\1740 a\DT\13649268 case-control\JJ\1740 study\NN\635850 .\.\1740
D000082_D017114 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Acetaminophen-induced</e1>\JJ\1740 hepatotoxicity\NN\1740 is\VBZ\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 cause\NN\7323922 of\IN\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 (\-LRB-\1740 ALF\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 UK\NNP\1740 .\.\1740
D000082_D017114 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Acetaminophen-induced</e1>\JJ\1740 hepatotoxicity\NN\1740 is\VBZ\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 cause\NN\7323922 of\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 <e2>ALF</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 UK\NNP\1740 .\.\1740
D000082_D017114 CID AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 chronic\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 CLD\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D017114 CID AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 non-acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 chronic\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 CLD\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D017114 CID AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 chronic\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 CLD\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D017114 CID AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 chronic\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 CLD\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D017114 CID RESULTS\NNS\34213 :\:\1740 <e1>Acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 undergoing\VBG\109660 LT\NN\1740 had\VBD\2108377 a\DT\13649268 greater\JJR\1740 severity\NN\5036394 of\IN\1740 pre-LT\JJ\1740 illness\NN\14052046 reflected\VBN\923793 by\IN\1740 higher\JJR\1740 Acute\NNP\6822198 Physiology\NNP\6037666 and\CC\1740 Chronic\NNP\1740 Health\NN\14447525 Evaluation\NN\874067 II\CD\13741022 scores\NNS\13757724 and\CC\1740 requirement\NN\1129920 for\IN\1740 organ\JJ\1740 support\NN\407535 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 two\CD\13741022 groups\NNS\2137 .\.\1740
D000082_D017114 CID Twenty\CD\13745420 (\-LRB-\1740 56\CD\1740 %\NN\1740 )\-RRB-\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 formal\JJ\1740 psychiatric\JJ\1740 diagnosis\NN\152018 before\IN\1740 LT\NN\1740 (\-LRB-\1740 non-acetaminophen-induced\JJ\1740 ALF=0/35\NN\1740 ,\,\1740 CLD=2/34\JJ\1740 ;\:\1740 P<0.01\NN\1740 for\IN\1740 all\DT\1740 )\-RRB-\1740 and\CC\1740 nine\CD\13741022 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 previous\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
D000082_D017114 CID Twenty\CD\13745420 (\-LRB-\1740 56\CD\1740 %\NN\1740 )\-RRB-\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 formal\JJ\1740 psychiatric\JJ\1740 diagnosis\NN\152018 before\IN\1740 LT\NN\1740 (\-LRB-\1740 non-acetaminophen-induced\JJ\1740 <e2>ALF=0/35</e2>\NN\1740 ,\,\1740 CLD=2/34\JJ\1740 ;\:\1740 P<0.01\NN\1740 for\IN\1740 all\DT\1740 )\-RRB-\1740 and\CC\1740 nine\CD\13741022 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 previous\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
D000082_D017114 CID Twenty\CD\13745420 (\-LRB-\1740 56\CD\1740 %\NN\1740 )\-RRB-\1740 acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 formal\JJ\1740 psychiatric\JJ\1740 diagnosis\NN\152018 before\IN\1740 LT\NN\1740 (\-LRB-\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF=0/35\NN\1740 ,\,\1740 CLD=2/34\JJ\1740 ;\:\1740 P<0.01\NN\1740 for\IN\1740 all\DT\1740 )\-RRB-\1740 and\CC\1740 nine\CD\13741022 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 previous\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
D000082_D017114 CID Twenty\CD\13745420 (\-LRB-\1740 56\CD\1740 %\NN\1740 )\-RRB-\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 formal\JJ\1740 psychiatric\JJ\1740 diagnosis\NN\152018 before\IN\1740 LT\NN\1740 (\-LRB-\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 <e2>ALF=0/35</e2>\NN\1740 ,\,\1740 CLD=2/34\JJ\1740 ;\:\1740 P<0.01\NN\1740 for\IN\1740 all\DT\1740 )\-RRB-\1740 and\CC\1740 nine\CD\13741022 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 previous\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
D000082_D017114 CID During\IN\1740 follow-up\JJ\1740 (\-LRB-\1740 median\JJ\1740 5\CD\13741022 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 rejection\NN\30358 (\-LRB-\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 ,\,\1740 graft\NN\5267548 failure\NN\66216 or\CC\3541091 survival\NN\13961642 between\IN\1740 the\DT\1740 groups\NNS\2137 (\-LRB-\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 1\CD\13741022 year\NN\15113229 87\CD\1740 %\NN\1740 ,\,\1740 5\CD\13741022 years\NNS\15144371 75\CD\1740 %\NN\1740 ;\:\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 88\CD\1740 %\NN\1740 ,\,\1740 78\CD\13745420 %\NN\1740 ;\:\1740 CLD\NN\1740 93\CD\1740 %\NN\1740 ,\,\1740 82\CD\1740 %\NN\1740 :\:\1740 P>0.6\NN\1740 log\NN\15098161 rank\NN\8430568 )\-RRB-\1740 .\.\1740
D000082_D017114 CID During\IN\1740 follow-up\JJ\1740 (\-LRB-\1740 median\JJ\1740 5\CD\13741022 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 rejection\NN\30358 (\-LRB-\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 ,\,\1740 graft\NN\5267548 failure\NN\66216 or\CC\3541091 survival\NN\13961642 between\IN\1740 the\DT\1740 groups\NNS\2137 (\-LRB-\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 1\CD\13741022 year\NN\15113229 87\CD\1740 %\NN\1740 ,\,\1740 5\CD\13741022 years\NNS\15144371 75\CD\1740 %\NN\1740 ;\:\1740 non-acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 88\CD\1740 %\NN\1740 ,\,\1740 78\CD\13745420 %\NN\1740 ;\:\1740 CLD\NN\1740 93\CD\1740 %\NN\1740 ,\,\1740 82\CD\1740 %\NN\1740 :\:\1740 P>0.6\NN\1740 log\NN\15098161 rank\NN\8430568 )\-RRB-\1740 .\.\1740
D000082_D017114 CID During\IN\1740 follow-up\JJ\1740 (\-LRB-\1740 median\JJ\1740 5\CD\13741022 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 rejection\NN\30358 (\-LRB-\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 ,\,\1740 graft\NN\5267548 failure\NN\66216 or\CC\3541091 survival\NN\13961642 between\IN\1740 the\DT\1740 groups\NNS\2137 (\-LRB-\1740 acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 1\CD\13741022 year\NN\15113229 87\CD\1740 %\NN\1740 ,\,\1740 5\CD\13741022 years\NNS\15144371 75\CD\1740 %\NN\1740 ;\:\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 88\CD\1740 %\NN\1740 ,\,\1740 78\CD\13745420 %\NN\1740 ;\:\1740 CLD\NN\1740 93\CD\1740 %\NN\1740 ,\,\1740 82\CD\1740 %\NN\1740 :\:\1740 P>0.6\NN\1740 log\NN\15098161 rank\NN\8430568 )\-RRB-\1740 .\.\1740
D000082_D017114 CID During\IN\1740 follow-up\JJ\1740 (\-LRB-\1740 median\JJ\1740 5\CD\13741022 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 rejection\NN\30358 (\-LRB-\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 ,\,\1740 graft\NN\5267548 failure\NN\66216 or\CC\3541091 survival\NN\13961642 between\IN\1740 the\DT\1740 groups\NNS\2137 (\-LRB-\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 1\CD\13741022 year\NN\15113229 87\CD\1740 %\NN\1740 ,\,\1740 5\CD\13741022 years\NNS\15144371 75\CD\1740 %\NN\1740 ;\:\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 88\CD\1740 %\NN\1740 ,\,\1740 78\CD\13745420 %\NN\1740 ;\:\1740 CLD\NN\1740 93\CD\1740 %\NN\1740 ,\,\1740 82\CD\1740 %\NN\1740 :\:\1740 P>0.6\NN\1740 log\NN\15098161 rank\NN\8430568 )\-RRB-\1740 .\.\1740
D000082_D017114 CID Two\CD\13741022 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 patients\NNS\9898892 reattempted\VBD\1740 suicide\NN\219012 post-LT\NN\1740 (\-LRB-\1740 one\CD\13741022 died\VBD\146138 8\CD\13741022 years\NNS\15144371 post-LT\JJ\1740 )\-RRB-\1740 .\.\1740
D000082_D017114 CID CONCLUSIONS\NNS\5837957 :\:\1740 Despite\IN\7501545 a\DT\13649268 high\JJ\1740 prevalence\NN\4764412 of\IN\1740 psychiatric\JJ\1740 disturbance\NN\407535 ,\,\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 emergently\RB\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 were\VBD\836236 comparable\JJ\1740 to\TO\1740 those\DT\1740 transplanted\VBN\2013571 for\IN\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 and\CC\1740 electively\RB\1740 for\IN\1740 CLD\NN\1740 .\.\1740
D000082_D017114 CID CONCLUSIONS\NNS\5837957 :\:\1740 Despite\IN\7501545 a\DT\13649268 high\JJ\1740 prevalence\NN\4764412 of\IN\1740 psychiatric\JJ\1740 disturbance\NN\407535 ,\,\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 emergently\RB\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 were\VBD\836236 comparable\JJ\1740 to\TO\1740 those\DT\1740 transplanted\VBN\2013571 for\IN\1740 non-acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 and\CC\1740 electively\RB\1740 for\IN\1740 CLD\NN\1740 .\.\1740
D000082_D017114 CID CONCLUSIONS\NNS\5837957 :\:\1740 Despite\IN\7501545 a\DT\13649268 high\JJ\1740 prevalence\NN\4764412 of\IN\1740 psychiatric\JJ\1740 disturbance\NN\407535 ,\,\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 emergently\RB\1740 for\IN\1740 acetaminophen-induced\JJ\1740 <e2>ALF</e2>\NN\1740 were\VBD\836236 comparable\JJ\1740 to\TO\1740 those\DT\1740 transplanted\VBN\2013571 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 and\CC\1740 electively\RB\1740 for\IN\1740 CLD\NN\1740 .\.\1740
D000082_D017114 CID CONCLUSIONS\NNS\5837957 :\:\1740 Despite\IN\7501545 a\DT\13649268 high\JJ\1740 prevalence\NN\4764412 of\IN\1740 psychiatric\JJ\1740 disturbance\NN\407535 ,\,\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 emergently\RB\1740 for\IN\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 were\VBD\836236 comparable\JJ\1740 to\TO\1740 those\DT\1740 transplanted\VBN\2013571 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 <e2>ALF</e2>\NN\1740 and\CC\1740 electively\RB\1740 for\IN\1740 CLD\NN\1740 .\.\1740
D000082_D056486 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Acetaminophen-induced</e1>\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 is\VBZ\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 cause\NN\7323922 of\IN\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 ALF\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 UK\NNP\1740 .\.\1740
D000082_D008107 NONE AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 <e2>chronic\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 (\-LRB-\1740 CLD\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D008107 NONE AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 chronic\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 <e2>CLD</e2>\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D008107 NONE AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 <e2>chronic\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 (\-LRB-\1740 CLD\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D008107 NONE AIMS\NNS\5980875 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 severity\NN\5036394 of\IN\1740 pretransplant\JJ\1740 illness\NN\14052046 ,\,\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 ,\,\1740 medical\JJ\1740 and\CC\1740 psychosocial\JJ\1740 outcomes\NNS\7291312 of\IN\1740 all\DT\1740 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 undergone\VBN\109660 liver\NN\5298729 transplantation\NN\671351 (\-LRB-\1740 LT\NN\1740 )\-RRB-\1740 emergently\RB\1740 between\IN\1740 1999\CD\1740 -\SYM\1740 2004\CD\1740 for\IN\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=36\NN\1740 )\-RRB-\1740 with\IN\1740 age-\NN\1740 and\CC\1740 sex-matched\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 emergent\NN\1740 LT\NN\1740 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 (\-LRB-\1740 n=35\NN\1740 )\-RRB-\1740 and\CC\1740 elective\JJ\1740 LT\NN\1740 for\IN\1740 chronic\JJ\1740 liver\NN\5298729 disease\NN\14061805 (\-LRB-\1740 <e2>CLD</e2>\NN\1740 ,\,\1740 n=34\NN\1740 )\-RRB-\1740 .\.\1740
D000082_D008107 NONE Twenty\CD\13745420 (\-LRB-\1740 56\CD\1740 %\NN\1740 )\-RRB-\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 formal\JJ\1740 psychiatric\JJ\1740 diagnosis\NN\152018 before\IN\1740 LT\NN\1740 (\-LRB-\1740 non-acetaminophen-induced\JJ\1740 ALF=0/35\NN\1740 ,\,\1740 <e2>CLD=2/34</e2>\JJ\1740 ;\:\1740 P<0.01\NN\1740 for\IN\1740 all\DT\1740 )\-RRB-\1740 and\CC\1740 nine\CD\13741022 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 previous\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
D000082_D008107 NONE Twenty\CD\13745420 (\-LRB-\1740 56\CD\1740 %\NN\1740 )\-RRB-\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 formal\JJ\1740 psychiatric\JJ\1740 diagnosis\NN\152018 before\IN\1740 LT\NN\1740 (\-LRB-\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF=0/35\NN\1740 ,\,\1740 <e2>CLD=2/34</e2>\JJ\1740 ;\:\1740 P<0.01\NN\1740 for\IN\1740 all\DT\1740 )\-RRB-\1740 and\CC\1740 nine\CD\13741022 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 previous\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
D000082_D008107 NONE During\IN\1740 follow-up\JJ\1740 (\-LRB-\1740 median\JJ\1740 5\CD\13741022 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 rejection\NN\30358 (\-LRB-\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 ,\,\1740 graft\NN\5267548 failure\NN\66216 or\CC\3541091 survival\NN\13961642 between\IN\1740 the\DT\1740 groups\NNS\2137 (\-LRB-\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 1\CD\13741022 year\NN\15113229 87\CD\1740 %\NN\1740 ,\,\1740 5\CD\13741022 years\NNS\15144371 75\CD\1740 %\NN\1740 ;\:\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 88\CD\1740 %\NN\1740 ,\,\1740 78\CD\13745420 %\NN\1740 ;\:\1740 <e2>CLD</e2>\NN\1740 93\CD\1740 %\NN\1740 ,\,\1740 82\CD\1740 %\NN\1740 :\:\1740 P>0.6\NN\1740 log\NN\15098161 rank\NN\8430568 )\-RRB-\1740 .\.\1740
D000082_D008107 NONE During\IN\1740 follow-up\JJ\1740 (\-LRB-\1740 median\JJ\1740 5\CD\13741022 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 significant\JJ\1740 differences\NNS\4723816 in\IN\13603305 rejection\NN\30358 (\-LRB-\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 ,\,\1740 graft\NN\5267548 failure\NN\66216 or\CC\3541091 survival\NN\13961642 between\IN\1740 the\DT\1740 groups\NNS\2137 (\-LRB-\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 1\CD\13741022 year\NN\15113229 87\CD\1740 %\NN\1740 ,\,\1740 5\CD\13741022 years\NNS\15144371 75\CD\1740 %\NN\1740 ;\:\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 88\CD\1740 %\NN\1740 ,\,\1740 78\CD\13745420 %\NN\1740 ;\:\1740 <e2>CLD</e2>\NN\1740 93\CD\1740 %\NN\1740 ,\,\1740 82\CD\1740 %\NN\1740 :\:\1740 P>0.6\NN\1740 log\NN\15098161 rank\NN\8430568 )\-RRB-\1740 .\.\1740
D000082_D008107 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Despite\IN\7501545 a\DT\13649268 high\JJ\1740 prevalence\NN\4764412 of\IN\1740 psychiatric\JJ\1740 disturbance\NN\407535 ,\,\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 emergently\RB\1740 for\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 were\VBD\836236 comparable\JJ\1740 to\TO\1740 those\DT\1740 transplanted\VBN\2013571 for\IN\1740 non-acetaminophen-induced\JJ\1740 ALF\NN\1740 and\CC\1740 electively\RB\1740 for\IN\1740 <e2>CLD</e2>\NN\1740 .\.\1740
D000082_D008107 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Despite\IN\7501545 a\DT\13649268 high\JJ\1740 prevalence\NN\4764412 of\IN\1740 psychiatric\JJ\1740 disturbance\NN\407535 ,\,\1740 outcomes\NNS\7291312 for\IN\1740 patients\NNS\9898892 transplanted\VBN\2013571 emergently\RB\1740 for\IN\1740 acetaminophen-induced\JJ\1740 ALF\NN\1740 were\VBD\836236 comparable\JJ\1740 to\TO\1740 those\DT\1740 transplanted\VBN\2013571 for\IN\1740 <e1>non-acetaminophen-induced</e1>\JJ\1740 ALF\NN\1740 and\CC\1740 electively\RB\1740 for\IN\1740 <e2>CLD</e2>\NN\1740 .\.\1740
1423336
D007980_D007022 CID Pharmacodynamics\NNS\1740 of\IN\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 in\IN\13603305 parkinsonian\JJ\1740 patients\NNS\9898892 .\.\1740
D007980_D007022 CID The\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 was\VBD\836236 concentration\NN\4916342 dependent\JJ\1740 and\CC\1740 was\VBD\836236 fit\JJ\1740 to\TO\1740 an\DT\6697703 Emax\NN\1740 model\NN\5888929 in\IN\13603305 fluctuating\VBG\1850315 responders\NNS\9610660 .\.\1740
D007980_D007022 CID Phenylalanine\NNP\14605787 ,\,\1740 a\DT\13649268 large\JJ\1740 neutral\JJ\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 LNAA\NN\1740 )\-RRB-\1740 competing\VBG\1740 with\IN\1740 <e1>levodopa</e1>\NN\14604959 for\IN\1740 transport\NN\3575240 across\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 reduced\VBD\441445 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 and\CC\1740 antiparkinsonian\JJ\1740 effects\NNS\13245626 of\IN\1740 levodopa\NN\14604959 .\.\1740
D007980_D007022 CID Phenylalanine\NNP\14605787 ,\,\1740 a\DT\13649268 large\JJ\1740 neutral\JJ\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 LNAA\NN\1740 )\-RRB-\1740 competing\VBG\1740 with\IN\1740 levodopa\NN\14604959 for\IN\1740 transport\NN\3575240 across\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 reduced\VBD\441445 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 and\CC\1740 antiparkinsonian\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>levodopa</e1>\NN\14604959 .\.\1740
D007980_D007022 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>levodopa</e1>\NN\14604959 has\VBZ\2108377 a\DT\13649268 central\JJ\1740 <e2>hypotensive</e2>\JJ\1740 action\NN\30358 that\WDT\1740 parallels\VBZ\2657219 the\DT\1740 motor\NN\3699975 effects\NNS\13245626 in\IN\13603305 fluctuating\VBG\1850315 patients\NNS\9898892 .\.\1740
D007980_D010300 NONE Pharmacodynamics\NNS\1740 of\IN\1740 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D007980_D010300 NONE Blood\NN\5397468 pressure\NN\11419404 effects\NNS\13245626 of\IN\1740 i.v.\NN\1740 <e1>levodopa</e1>\NN\14604959 were\VBD\836236 examined\VBN\789138 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 stable\JJ\1740 and\CC\1740 fluctuating\VBG\1850315 responses\NNS\11410625 to\TO\1740 levodopa\VB\1740 .\.\1740
D007980_D010300 NONE Blood\NN\5397468 pressure\NN\11419404 effects\NNS\13245626 of\IN\1740 i.v.\NN\1740 levodopa\NN\14604959 were\VBD\836236 examined\VBN\789138 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 stable\JJ\1740 and\CC\1740 fluctuating\VBG\1850315 responses\NNS\11410625 to\TO\1740 <e1>levodopa</e1>\VB\1740 .\.\1740
D010649_D007022 NONE <e1>Phenylalanine</e1>\NNP\14605787 ,\,\1740 a\DT\13649268 large\JJ\1740 neutral\JJ\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 LNAA\NN\1740 )\-RRB-\1740 competing\VBG\1740 with\IN\1740 levodopa\NN\14604959 for\IN\1740 transport\NN\3575240 across\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 reduced\VBD\441445 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 and\CC\1740 antiparkinsonian\JJ\1740 effects\NNS\13245626 of\IN\1740 levodopa\NN\14604959 .\.\1740
D000596_D007022 NONE Phenylalanine\NNP\14605787 ,\,\1740 a\DT\13649268 large\JJ\1740 neutral\JJ\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 (\-LRB-\1740 LNAA\NN\1740 )\-RRB-\1740 competing\VBG\1740 with\IN\1740 levodopa\NN\14604959 for\IN\1740 transport\NN\3575240 across\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 reduced\VBD\441445 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 and\CC\1740 antiparkinsonian\JJ\1740 effects\NNS\13245626 of\IN\1740 levodopa\NN\14604959 .\.\1740
16906379
D008911_D014657 NONE <e1>Minocycline-induced</e1>\JJ\1740 <e2>vasculitis</e2>\NN\14336539 fulfilling\VBG\484166 the\DT\1740 criteria\NNS\13577171 of\IN\1740 polyarteritis\NN\14258609 nodosa\NNS\1740 .\.\1740
D008911_D014657 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 second\JJ\1740 case\NN\7283608 of\IN\1740 <e1>minocycline-induced</e1>\JJ\1740 <e2>vasculitis</e2>\NN\14336539 satisfying\VBG\2667900 the\DT\1740 criteria\NNS\13577171 .\.\1740
D008911_D010488 CID <e1>Minocycline-induced</e1>\JJ\1740 vasculitis\NN\14336539 fulfilling\VBG\484166 the\DT\1740 criteria\NNS\13577171 of\IN\1740 <e2>polyarteritis\NN\14258609 nodosa</e2>\NNS\1740 .\.\1740
D008911_D011565 NONE A\DT\13649268 47-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>minocycline</e1>\NN\4416530 for\IN\1740 <e2>palmoplantar\NN\1740 pustulosis</e2>\NN\1740 developed\VBD\1753788 fever\NN\14299637 ,\,\1740 myalgias\NNS\14322699 ,\,\1740 polyneuropathy\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 pain\NN\14299637 ,\,\1740 with\IN\1740 elevated\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 (\-LRB-\1740 CRP\NN\14732116 )\-RRB-\1740 .\.\1740
D008911_D005334 NONE A\DT\13649268 47-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>minocycline</e1>\NN\4416530 for\IN\1740 palmoplantar\NN\1740 pustulosis\NN\1740 developed\VBD\1753788 <e2>fever</e2>\NN\14299637 ,\,\1740 myalgias\NNS\14322699 ,\,\1740 polyneuropathy\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 pain\NN\14299637 ,\,\1740 with\IN\1740 elevated\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 (\-LRB-\1740 CRP\NN\14732116 )\-RRB-\1740 .\.\1740
D008911_D063806 NONE A\DT\13649268 47-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>minocycline</e1>\NN\4416530 for\IN\1740 palmoplantar\NN\1740 pustulosis\NN\1740 developed\VBD\1753788 fever\NN\14299637 ,\,\1740 <e2>myalgias</e2>\NNS\14322699 ,\,\1740 polyneuropathy\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 pain\NN\14299637 ,\,\1740 with\IN\1740 elevated\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 (\-LRB-\1740 CRP\NN\14732116 )\-RRB-\1740 .\.\1740
D008911_D011115 NONE A\DT\13649268 47-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>minocycline</e1>\NN\4416530 for\IN\1740 palmoplantar\NN\1740 pustulosis\NN\1740 developed\VBD\1753788 fever\NN\14299637 ,\,\1740 myalgias\NNS\14322699 ,\,\1740 <e2>polyneuropathy</e2>\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 pain\NN\14299637 ,\,\1740 with\IN\1740 elevated\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 (\-LRB-\1740 CRP\NN\14732116 )\-RRB-\1740 .\.\1740
D008911_D013733 NONE A\DT\13649268 47-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>minocycline</e1>\NN\4416530 for\IN\1740 palmoplantar\NN\1740 pustulosis\NN\1740 developed\VBD\1753788 fever\NN\14299637 ,\,\1740 myalgias\NNS\14322699 ,\,\1740 polyneuropathy\JJ\1740 ,\,\1740 and\CC\1740 <e2>testicular\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 with\IN\1740 elevated\JJ\1740 C-reactive\JJ\1740 protein\NN\14944888 (\-LRB-\1740 CRP\NN\14732116 )\-RRB-\1740 .\.\1740
12523489
D003042_D006948 NONE <e1>Cocaine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D003042_D006948 NONE <e1>Cocaine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D003042_D006948 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 and\CC\1740 antagonists\NNS\7846 on\IN\1740 <e1>cocaine-and</e1>\NN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 examined\VBN\789138 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003042_D006948 NONE Similarly\RB\1740 ,\,\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 decreased\VBD\169651 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 but\CC\1740 at\IN\14622893 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 than\IN\1740 those\DT\1740 which\WDT\1740 were\VBD\836236 active\JJ\1740 in\IN\13603305 <e1>cocaine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D003042_D006948 NONE Similarly\RB\1740 ,\,\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 decreased\VBD\169651 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 ,\,\1740 but\CC\1740 at\IN\14622893 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 than\IN\1740 those\DT\1740 which\WDT\1740 were\VBD\836236 active\JJ\1740 in\IN\13603305 <e1>cocaine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D003042_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 <e1>cocaine-</e1>\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D003042_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 <e1>cocaine-</e1>\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D003042_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D003042_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000241_D006948 NONE Cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000241_D006948 NONE Cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000241_D006948 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 and\CC\1740 antagonists\NNS\7846 on\IN\1740 cocaine-and\NN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 examined\VBN\789138 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000241_D006948 NONE Similarly\RB\1740 ,\,\1740 all\DT\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 decreased\VBD\169651 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 but\CC\1740 at\IN\14622893 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 than\IN\1740 those\DT\1740 which\WDT\1740 were\VBD\836236 active\JJ\1740 in\IN\13603305 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000241_D006948 NONE Similarly\RB\1740 ,\,\1740 all\DT\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 decreased\VBD\169651 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 ,\,\1740 but\CC\1740 at\IN\14622893 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 than\IN\1740 those\DT\1740 which\WDT\1740 were\VBD\836236 active\JJ\1740 in\IN\13603305 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000241_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000241_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000241_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000241_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000661_D006948 NONE Cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 than\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000661_D006948 NONE Cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 than\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000661_D006948 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 and\CC\1740 antagonists\NNS\7846 on\IN\1740 cocaine-and\NN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 examined\VBN\789138 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000661_D006948 NONE Similarly\RB\1740 ,\,\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 decreased\VBD\169651 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 but\CC\1740 at\IN\14622893 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 than\IN\1740 those\DT\1740 which\WDT\1740 were\VBD\836236 active\JJ\1740 in\IN\13603305 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000661_D006948 NONE Similarly\RB\1740 ,\,\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 decreased\VBD\169651 <e1>amphetamine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 ,\,\1740 but\CC\1740 at\IN\14622893 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 than\IN\1740 those\DT\1740 which\WDT\1740 were\VBD\836236 active\JJ\1740 in\IN\13603305 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000661_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 <e1>amphetamine-induced</e1>\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000661_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 <e1>amphetamine-induced</e1>\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000661_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D000661_D006948 NONE Our\PRP$\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 all\DT\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 A1\NN\1740 and\CC\1740 A2\NN\1740 )\-RRB-\1740 reduce\VBP\441445 cocaine-\NN\1740 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activity\NN\30358 and\CC\1740 indicate\VBP\952524 that\IN\1740 cocaine-induced\JJ\1740 hyperactivity\NN\14052403 is\VBZ\836236 more\RBR\1740 influenced\VBN\137313 by\IN\1740 adenosine\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 (\-LRB-\1740 particularly\RB\1740 A1\NN\1740 receptors\NNS\5225602 )\-RRB-\1740 than\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D000241_D004409 NONE All\DT\1740 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 agonists\NNS\9613191 significantly\RB\1740 <e2>decreased\VBD\169651 the\DT\1740 locomotor\NN\1740 activity</e2>\NN\30358 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 the\DT\1740 effects\NNS\13245626 were\VBD\836236 dose-dependent\JJ\1740 .\.\1740
6453500
D004221_D056486 CID <e2>Toxic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>disulfiram</e1>\NN\3740161 in\IN\13603305 a\DT\13649268 non-alcoholic\JJ\1740 .\.\1740
D004221_D056486 CID A\DT\13649268 reversible\JJ\1740 <e2>toxic\JJ\1740 liver\NN\5298729 damage</e2>\NN\7296428 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 non-alcoholic\JJ\1740 woman\NN\9605289 treated\VBN\2376958 with\IN\1740 <e1>disulfiram</e1>\NN\3740161 .\.\1740
146391
D010672_D012010 CID <e2>Pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia</e2>\NN\14365950 ,\,\1740 toxic\JJ\1740 dermatitis\NN\14226056 and\CC\1740 lymphadenopathy\NN\14204950 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 <e1>diphenylhydantoin</e1>\NN\3550533 .\.\1740
D010672_D012010 CID A\DT\13649268 patient\NN\9898892 taking\VBG\2367363 <e1>diphenylhydantoin</e1>\NN\3550533 for\IN\1740 3\CD\13741022 weeks\NNS\15113229 developed\VBD\1753788 a\DT\13649268 generalized\JJ\1740 skin\NN\5237755 rash\NN\14321469 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 <e2>pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia</e2>\NN\14365950 .\.\1740
D010672_D012010 CID <e2>Pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia</e2>\NN\14365950 associated\VBN\628491 with\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 medication\NN\3247620 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 .\.\1740
D010672_D012010 CID In\IN\13603305 this\DT\1740 patient\NN\9898892 the\DT\1740 time\NN\7308889 relation\NN\2137 between\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 and\CC\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 the\DT\1740 skin\NN\5237755 rash\NN\14321469 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 <e2>pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia</e2>\NN\14365950 is\VBZ\836236 very\RB\1740 suggestive\JJ\1740 of\IN\1740 a\DT\13649268 direct\JJ\1740 connection\NN\31921 .\.\1740
D010672_D003875 CID Pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia\NN\14365950 ,\,\1740 <e2>toxic\JJ\1740 dermatitis</e2>\NN\14226056 and\CC\1740 lymphadenopathy\NN\14204950 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 <e1>diphenylhydantoin</e1>\NN\3550533 .\.\1740
D010672_D008206 CID Pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia\NN\14365950 ,\,\1740 toxic\JJ\1740 dermatitis\NN\14226056 and\CC\1740 <e2>lymphadenopathy</e2>\NN\14204950 in\IN\13603305 a\DT\13649268 patient\NN\9898892 taking\VBG\2367363 <e1>diphenylhydantoin</e1>\NN\3550533 .\.\1740
D010672_D008206 CID A\DT\13649268 patient\NN\9898892 taking\VBG\2367363 <e1>diphenylhydantoin</e1>\NN\3550533 for\IN\1740 3\CD\13741022 weeks\NNS\15113229 developed\VBD\1753788 a\DT\13649268 generalized\JJ\1740 skin\NN\5237755 rash\NN\14321469 ,\,\1740 <e2>lymphadenopathy</e2>\NN\14204950 and\CC\1740 pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia\NN\14365950 .\.\1740
D010672_D008206 CID Skin\NN\5237755 rash\NN\14321469 is\VBZ\836236 a\DT\13649268 well-known\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 treatment\NN\654885 as\IN\14622893 is\VBZ\836236 benign\JJ\1740 and\CC\1740 malignant\JJ\1740 <e2>lymphadenopathy</e2>\NN\14204950 .\.\1740
D010672_D008206 CID In\IN\13603305 this\DT\1740 patient\NN\9898892 the\DT\1740 time\NN\7308889 relation\NN\2137 between\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 and\CC\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 the\DT\1740 skin\NN\5237755 rash\NN\14321469 ,\,\1740 <e2>lymphadenopathy</e2>\NN\14204950 and\CC\1740 pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia\NN\14365950 is\VBZ\836236 very\RB\1740 suggestive\JJ\1740 of\IN\1740 a\DT\13649268 direct\JJ\1740 connection\NN\31921 .\.\1740
D010672_D005076 NONE A\DT\13649268 patient\NN\9898892 taking\VBG\2367363 <e1>diphenylhydantoin</e1>\NN\3550533 for\IN\1740 3\CD\13741022 weeks\NNS\15113229 developed\VBD\1753788 a\DT\13649268 generalized\JJ\1740 <e2>skin\NN\5237755 rash</e2>\NN\14321469 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia\NN\14365950 .\.\1740
D010672_D005076 NONE <e2>Skin\NN\5237755 rash</e2>\NN\14321469 is\VBZ\836236 a\DT\13649268 well-known\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 treatment\NN\654885 as\IN\14622893 is\VBZ\836236 benign\JJ\1740 and\CC\1740 malignant\JJ\1740 lymphadenopathy\NN\14204950 .\.\1740
D010672_D005076 NONE In\IN\13603305 this\DT\1740 patient\NN\9898892 the\DT\1740 time\NN\7308889 relation\NN\2137 between\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>diphenylhydantoin</e1>\NN\3550533 and\CC\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 the\DT\1740 <e2>skin\NN\5237755 rash</e2>\NN\14321469 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 pure\JJ\1740 red\JJ\1740 cell\NN\3080309 aplasia\NN\14365950 is\VBZ\836236 very\RB\1740 suggestive\JJ\1740 of\IN\1740 a\DT\13649268 direct\JJ\1740 connection\NN\31921 .\.\1740
6673474
D009599_D007022 CID Coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 cardiac\JJ\1740 work\NN\407535 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 under\IN\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (\-LRB-\1740 SNP\NN\11493266 )\-RRB-\1740 and\CC\1740 trimetaphan\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 deliberate\VBP\813978 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 20\CD\13745420 %\NN\1740 and\CC\1740 40\CD\13745420 %\NN\1740 mean\NN\6021761 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 baseline\NN\7260623 )\-RRB-\1740 .\.\1740
D009599_D007022 CID Coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 cardiac\JJ\1740 work\NN\407535 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 under\IN\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 <e1>SNP</e1>\NN\11493266 )\-RRB-\1740 and\CC\1740 trimetaphan\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 deliberate\VBP\813978 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 20\CD\13745420 %\NN\1740 and\CC\1740 40\CD\13745420 %\NN\1740 mean\NN\6021761 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 baseline\NN\7260623 )\-RRB-\1740 .\.\1740
D009599_D007022 CID Regarding\VBG\689344 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 on\IN\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 aortic\JJ\1740 and\CC\1740 coronary\JJ\1740 sinus\NN\5248181 metabolic\JJ\1740 data\NNS\7951464 (\-LRB-\1740 pH\NN\5038959 ,\,\1740 pO2\FW\1740 ,\,\1740 pCO2\NN\1740 )\-RRB-\1740 we\PRP\1740 could\MD\1740 confirm\VB\1011725 that\IN\1740 <e1>nitroprusside</e1>\NN\1740 hypotension\NN\14057371 could\MD\1740 be\VB\836236 safely\RB\1740 used\VBN\1156834 to\IN\1740 30\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 control\NN\5190804 ,\,\1740 trimetaphan\JJ\1740 hypotension\NN\14057371 to\TO\1740 20\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 .\.\1740
D009599_D007022 CID Regarding\VBG\689344 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug-induced\JJ\1740 hypotension\NN\14057371 on\IN\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 aortic\JJ\1740 and\CC\1740 coronary\JJ\1740 sinus\NN\5248181 metabolic\JJ\1740 data\NNS\7951464 (\-LRB-\1740 pH\NN\5038959 ,\,\1740 pO2\FW\1740 ,\,\1740 pCO2\NN\1740 )\-RRB-\1740 we\PRP\1740 could\MD\1740 confirm\VB\1011725 that\IN\1740 <e1>nitroprusside</e1>\NN\1740 <e2>hypotension</e2>\NN\14057371 could\MD\1740 be\VB\836236 safely\RB\1740 used\VBN\1156834 to\IN\1740 30\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 control\NN\5190804 ,\,\1740 trimetaphan\JJ\1740 hypotension\NN\14057371 to\TO\1740 20\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 .\.\1740
D009599_D007022 CID Regarding\VBG\689344 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug-induced\JJ\1740 hypotension\NN\14057371 on\IN\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 aortic\JJ\1740 and\CC\1740 coronary\JJ\1740 sinus\NN\5248181 metabolic\JJ\1740 data\NNS\7951464 (\-LRB-\1740 pH\NN\5038959 ,\,\1740 pO2\FW\1740 ,\,\1740 pCO2\NN\1740 )\-RRB-\1740 we\PRP\1740 could\MD\1740 confirm\VB\1011725 that\IN\1740 <e1>nitroprusside</e1>\NN\1740 hypotension\NN\14057371 could\MD\1740 be\VB\836236 safely\RB\1740 used\VBN\1156834 to\IN\1740 30\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 control\NN\5190804 ,\,\1740 trimetaphan\JJ\1740 <e2>hypotension</e2>\NN\14057371 to\TO\1740 20\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 .\.\1740
D009599_D007022 CID Cardiac\JJ\1740 work\NN\407535 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 during\IN\1740 <e1>SNP</e1>\NN\11493266 <e2>hypotension</e2>\NN\14057371 .\.\1740
D014294_D007022 CID Coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 cardiac\JJ\1740 work\NN\407535 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 under\IN\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 SNP\NN\11493266 )\-RRB-\1740 and\CC\1740 <e1>trimetaphan</e1>\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 deliberate\VBP\813978 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 20\CD\13745420 %\NN\1740 and\CC\1740 40\CD\13745420 %\NN\1740 mean\NN\6021761 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 baseline\NN\7260623 )\-RRB-\1740 .\.\1740
D014294_D007022 CID Coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 cardiac\JJ\1740 work\NN\407535 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 under\IN\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 SNP\NN\11493266 )\-RRB-\1740 and\CC\1740 trimetaphan\NN\1740 (\-LRB-\1740 <e1>TMP</e1>\NN\1740 )\-RRB-\1740 deliberate\VBP\813978 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 20\CD\13745420 %\NN\1740 and\CC\1740 40\CD\13745420 %\NN\1740 mean\NN\6021761 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 baseline\NN\7260623 )\-RRB-\1740 .\.\1740
D014294_D007022 CID Regarding\VBG\689344 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 on\IN\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 aortic\JJ\1740 and\CC\1740 coronary\JJ\1740 sinus\NN\5248181 metabolic\JJ\1740 data\NNS\7951464 (\-LRB-\1740 pH\NN\5038959 ,\,\1740 pO2\FW\1740 ,\,\1740 pCO2\NN\1740 )\-RRB-\1740 we\PRP\1740 could\MD\1740 confirm\VB\1011725 that\IN\1740 nitroprusside\NN\1740 hypotension\NN\14057371 could\MD\1740 be\VB\836236 safely\RB\1740 used\VBN\1156834 to\IN\1740 30\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 control\NN\5190804 ,\,\1740 <e1>trimetaphan</e1>\JJ\1740 hypotension\NN\14057371 to\TO\1740 20\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 .\.\1740
D014294_D007022 CID Regarding\VBG\689344 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug-induced\JJ\1740 hypotension\NN\14057371 on\IN\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 aortic\JJ\1740 and\CC\1740 coronary\JJ\1740 sinus\NN\5248181 metabolic\JJ\1740 data\NNS\7951464 (\-LRB-\1740 pH\NN\5038959 ,\,\1740 pO2\FW\1740 ,\,\1740 pCO2\NN\1740 )\-RRB-\1740 we\PRP\1740 could\MD\1740 confirm\VB\1011725 that\IN\1740 nitroprusside\NN\1740 <e2>hypotension</e2>\NN\14057371 could\MD\1740 be\VB\836236 safely\RB\1740 used\VBN\1156834 to\IN\1740 30\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 control\NN\5190804 ,\,\1740 <e1>trimetaphan</e1>\JJ\1740 hypotension\NN\14057371 to\TO\1740 20\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 .\.\1740
D014294_D007022 CID Regarding\VBG\689344 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug-induced\JJ\1740 hypotension\NN\14057371 on\IN\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 ,\,\1740 aortic\JJ\1740 and\CC\1740 coronary\JJ\1740 sinus\NN\5248181 metabolic\JJ\1740 data\NNS\7951464 (\-LRB-\1740 pH\NN\5038959 ,\,\1740 pO2\FW\1740 ,\,\1740 pCO2\NN\1740 )\-RRB-\1740 we\PRP\1740 could\MD\1740 confirm\VB\1011725 that\IN\1740 nitroprusside\NN\1740 hypotension\NN\14057371 could\MD\1740 be\VB\836236 safely\RB\1740 used\VBN\1156834 to\IN\1740 30\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 from\IN\1740 control\NN\5190804 ,\,\1740 <e1>trimetaphan</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 to\TO\1740 20\CD\13745420 %\NN\1740 mean\NN\6021761 blood\NN\5397468 pressure\NN\11419404 decrease\NN\7296428 .\.\1740
20046642
D008668_D003072 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 explore\VB\789138 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>MT</e1>\NN\14622893 induction\NN\7450842 on\IN\1740 carmustine\NN\1740 (BCNU)-induced\JJ\1740 hippocampal\NN\1740 <e2>cognitive\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002330_D003072 CID The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 explore\VB\789138 the\DT\1740 effect\NN\34213 of\IN\1740 MT\NN\14622893 induction\NN\7450842 on\IN\1740 <e1>carmustine</e1>\NN\1740 (BCNU)-induced\JJ\1740 hippocampal\NN\1740 <e2>cognitive\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002330_D003072 CID The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 explore\VB\789138 the\DT\1740 effect\NN\34213 of\IN\1740 MT\NN\14622893 induction\NN\7450842 on\IN\1740 carmustine\NN\1740 <e1>(BCNU)-induced</e1>\JJ\1740 hippocampal\NN\1740 <e2>cognitive\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D019287_D007859 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>ZnSO(4\NN\1740 )</e1>\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D019287_D008569 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>ZnSO(4\NN\1740 )</e1>\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D002330_D007859 CID Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 <e1>BCNU</e1>\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D002330_D007859 CID Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 <e1>BCNU</e1>\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D002330_D008569 CID Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 <e1>BCNU</e1>\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D002330_D008569 CID Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 <e1>BCNU</e1>\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D005978_D007859 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 <e1>glutathione</e1>\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D005978_D007859 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 <e1>glutathione</e1>\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D005978_D007859 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 <e1>GSH</e1>\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D005978_D008569 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 <e1>glutathione</e1>\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D005978_D008569 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 <e1>glutathione</e1>\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D005978_D008569 NONE Fourth\JJ\1740 group\NN\2137 received\VBD\2210855 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ZnSO(4\NN\1740 )\-RRB-\1740 (\-LRB-\1740 0.1\CD\1740 micromol/10\NN\1740 microl\NN\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 i.c.v\NN\1740 )\-RRB-\1740 then\RB\1740 BCNU\NNS\1740 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.v\NNS\1740 ,\,\1740 once\RB\1740 )\-RRB-\1740 after\IN\1740 24\CD\13745420 h.\NN\1740 The\DT\1740 obtained\VBN\2210855 data\NNS\7951464 revealed\VBD\2137132 that\IN\1740 BCNU\NN\1740 administration\NN\1133281 resulted\VBD\2633881 in\IN\13603305 <e2>deterioration\NN\14560612 of\IN\1740 learning\NN\5701944 and\CC\1740 short-term\JJ\1740 memory</e2>\NN\5926676 (\-LRB-\1740 STM\NN\5760202 )\-RRB-\1740 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 using\VBG\1156834 radial\JJ\1740 arm\NN\5560244 water\NN\14618834 maze\NN\4377057 ,\,\1740 accompanied\VBN\1835496 with\IN\1740 decreased\VBN\169651 hippocampal\NN\1740 glutathione\NN\1740 reductase\NN\14732946 (\-LRB-\1740 GR\NN\1740 )\-RRB-\1740 activity\NN\30358 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 <e1>GSH</e1>\NN\1740 )\-RRB-\1740 content\NN\7951464 .\.\1740
D002330_D009369 NONE Also\RB\1740 ,\,\1740 <e1>BCNU</e1>\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 MT\NN\14622893 and\CC\1740 malondialdehyde\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D002330_D009336 NONE Also\RB\1740 ,\,\1740 <e1>BCNU</e1>\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 MT\NN\14622893 and\CC\1740 malondialdehyde\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008668_D009369 NONE Also\RB\1740 ,\,\1740 BCNU\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 <e1>MT</e1>\NN\14622893 and\CC\1740 malondialdehyde\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008668_D009336 NONE Also\RB\1740 ,\,\1740 BCNU\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 <e1>MT</e1>\NN\14622893 and\CC\1740 malondialdehyde\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008315_D009369 NONE Also\RB\1740 ,\,\1740 BCNU\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 MT\NN\14622893 and\CC\1740 <e1>malondialdehyde</e1>\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008315_D009369 NONE Also\RB\1740 ,\,\1740 BCNU\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 MT\NN\14622893 and\CC\1740 malondialdehyde\NN\1740 (\-LRB-\1740 <e1>MDA</e1>\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008315_D009336 NONE Also\RB\1740 ,\,\1740 BCNU\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 MT\NN\14622893 and\CC\1740 <e1>malondialdehyde</e1>\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008315_D009336 NONE Also\RB\1740 ,\,\1740 BCNU\NNP\1740 administration\NN\1133281 increased\VBD\169651 serum\NN\5397468 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNFalpha\NN\1740 )\-RRB-\1740 ,\,\1740 hippocampal\VBP\1740 MT\NN\14622893 and\CC\1740 malondialdehyde\NN\1740 (\-LRB-\1740 <e1>MDA</e1>\NN\1740 )\-RRB-\1740 contents\NNS\6481320 as\RB\1740 well\RB\1740 as\IN\14622893 caspase-3\NN\1740 activity\NN\30358 in\IN\13603305 addition\NN\3081021 to\TO\1740 histological\JJ\1740 alterations\NNS\7283608 .\.\1740
D008668_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>MT</e1>\NN\14622893 induction\NN\7450842 halts\VBZ\1859221 BCNU-induced\JJ\1740 hippocampal\NN\1740 <e2>toxicity</e2>\NN\13576101 as\IN\14622893 it\PRP\6125041 prevented\VBD\1740 GR\NN\1740 inhibition\NN\1068773 and\CC\1740 GSH\NN\1740 depletion\NN\351638 and\CC\1740 counteracted\VBD\2367363 the\DT\1740 increased\VBN\169651 levels\NNS\4916342 of\IN\1740 TNFalpha\NN\1740 ,\,\1740 MDA\NN\1740 and\CC\1740 caspase-3\NN\1740 activity\NN\30358 with\IN\1740 subsequent\JJ\1740 preservation\NN\817680 of\IN\1740 cognition\NN\23100 .\.\1740
D002330_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 MT\NN\14622893 induction\NN\7450842 halts\VBZ\1859221 <e1>BCNU-induced</e1>\JJ\1740 hippocampal\NN\1740 <e2>toxicity</e2>\NN\13576101 as\IN\14622893 it\PRP\6125041 prevented\VBD\1740 GR\NN\1740 inhibition\NN\1068773 and\CC\1740 GSH\NN\1740 depletion\NN\351638 and\CC\1740 counteracted\VBD\2367363 the\DT\1740 increased\VBN\169651 levels\NNS\4916342 of\IN\1740 TNFalpha\NN\1740 ,\,\1740 MDA\NN\1740 and\CC\1740 caspase-3\NN\1740 activity\NN\30358 with\IN\1740 subsequent\JJ\1740 preservation\NN\817680 of\IN\1740 cognition\NN\23100 .\.\1740
D005978_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 MT\NN\14622893 induction\NN\7450842 halts\VBZ\1859221 BCNU-induced\JJ\1740 hippocampal\NN\1740 <e2>toxicity</e2>\NN\13576101 as\IN\14622893 it\PRP\6125041 prevented\VBD\1740 GR\NN\1740 inhibition\NN\1068773 and\CC\1740 <e1>GSH</e1>\NN\1740 depletion\NN\351638 and\CC\1740 counteracted\VBD\2367363 the\DT\1740 increased\VBN\169651 levels\NNS\4916342 of\IN\1740 TNFalpha\NN\1740 ,\,\1740 MDA\NN\1740 and\CC\1740 caspase-3\NN\1740 activity\NN\30358 with\IN\1740 subsequent\JJ\1740 preservation\NN\817680 of\IN\1740 cognition\NN\23100 .\.\1740
D008315_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 MT\NN\14622893 induction\NN\7450842 halts\VBZ\1859221 BCNU-induced\JJ\1740 hippocampal\NN\1740 <e2>toxicity</e2>\NN\13576101 as\IN\14622893 it\PRP\6125041 prevented\VBD\1740 GR\NN\1740 inhibition\NN\1068773 and\CC\1740 GSH\NN\1740 depletion\NN\351638 and\CC\1740 counteracted\VBD\2367363 the\DT\1740 increased\VBN\169651 levels\NNS\4916342 of\IN\1740 TNFalpha\NN\1740 ,\,\1740 <e1>MDA</e1>\NN\1740 and\CC\1740 caspase-3\NN\1740 activity\NN\30358 with\IN\1740 subsequent\JJ\1740 preservation\NN\817680 of\IN\1740 cognition\NN\23100 .\.\1740
24438483
D002045_D002318 NONE Pre-treatment\JJ\1740 of\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiovascular\JJ\1740 depression</e2>\NN\14373582 using\VBG\1156834 different\JJ\1740 lipid\NN\14944888 formulations\NNS\14818238 of\IN\1740 propofol\NN\1740 .\.\1740
D015742_D002318 NONE Pre-treatment\JJ\1740 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiovascular\JJ\1740 depression</e2>\NN\14373582 using\VBG\1156834 different\JJ\1740 lipid\NN\14944888 formulations\NNS\14818238 of\IN\1740 <e1>propofol</e1>\NN\1740 .\.\1740
D002045_D066126 CID BACKGROUND\NN\4921011 :\:\1740 Pre-treatment\JJ\1740 with\IN\1740 lipid\NN\14944888 emulsions\NNS\14588219 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 increase\VB\169651 lethal\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 lipid\NN\14944888 content\NN\7951464 of\IN\1740 propofol\NN\1740 may\MD\15209706 alleviate\VB\205885 bupivacaine-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D002045_D066126 CID BACKGROUND\NN\4921011 :\:\1740 Pre-treatment\JJ\1740 with\IN\1740 lipid\NN\14944888 emulsions\NNS\14588219 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 increase\VB\169651 lethal\JJ\1740 doses\NNS\3740161 of\IN\1740 bupivacaine\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 lipid\NN\14944888 content\NN\7951464 of\IN\1740 propofol\NN\1740 may\MD\15209706 alleviate\VB\205885 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D002045_D066126 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 or\CC\3541091 medialipid\NN\1740 emulsions\NNS\14588219 on\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D002045_D066126 CID The\DT\1740 cumulative\JJ\1740 <e1>bupivacaine</e1>\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 bupivacaine\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 Bupivacaine\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 propofol\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 bupivacaine\NN\1740 levels\NNS\4916342 .\.\1740
D002045_D066126 CID The\DT\1740 cumulative\JJ\1740 bupivacaine\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 <e1>bupivacaine</e1>\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 Bupivacaine\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 propofol\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 bupivacaine\NN\1740 levels\NNS\4916342 .\.\1740
D002045_D066126 CID The\DT\1740 cumulative\JJ\1740 bupivacaine\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 bupivacaine\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 <e1>Bupivacaine</e1>\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 propofol\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 bupivacaine\NN\1740 levels\NNS\4916342 .\.\1740
D002045_D066126 CID The\DT\1740 cumulative\JJ\1740 bupivacaine\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 bupivacaine\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 Bupivacaine\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 propofol\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 bupivacaine\NN\1740 levels\NNS\4916342 .\.\1740
D002045_D066126 CID The\DT\1740 cumulative\JJ\1740 bupivacaine\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 bupivacaine\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 Bupivacaine\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 propofol\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 <e1>bupivacaine</e1>\NN\1740 levels\NNS\4916342 .\.\1740
D015742_D066126 NONE BACKGROUND\NN\4921011 :\:\1740 Pre-treatment\JJ\1740 with\IN\1740 lipid\NN\14944888 emulsions\NNS\14588219 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 increase\VB\169651 lethal\JJ\1740 doses\NNS\3740161 of\IN\1740 bupivacaine\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 lipid\NN\14944888 content\NN\7951464 of\IN\1740 <e1>propofol</e1>\NN\1740 may\MD\15209706 alleviate\VB\205885 bupivacaine-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D015742_D066126 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>propofol</e1>\NN\1740 in\IN\13603305 intralipid\NN\1740 or\CC\3541091 medialipid\NN\1740 emulsions\NNS\14588219 on\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D015742_D066126 NONE The\DT\1740 cumulative\JJ\1740 bupivacaine\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 bupivacaine\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 Bupivacaine\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 <e1>propofol</e1>\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 propofol\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 bupivacaine\NN\1740 levels\NNS\4916342 .\.\1740
D015742_D066126 NONE The\DT\1740 cumulative\JJ\1740 bupivacaine\NN\1740 dose\NN\3740161 given\VBN\2327200 at\IN\14622893 those\DT\1740 time\NN\7308889 points\NNS\5868954 was\VBD\836236 higher\JJR\1740 in\IN\13603305 Group\NNP\2137 P.\NNP\1740 Plasma\NNP\5398023 bupivacaine\NN\1740 levels\NNS\4916342 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 Bupivacaine\NNP\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 heart\NN\5919034 were\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 Group\NN\2137 P\NN\14622893 and\CC\1740 Group\NNP\2137 L\NN\13616054 than\IN\1740 in\IN\13603305 Group\NNP\2137 C.\NNP\1740 CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pre-treatment\NN\1740 with\IN\1740 propofol\NN\1740 in\IN\13603305 intralipid\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 <e1>propofol</e1>\NN\1740 in\IN\13603305 medialipid\NN\1740 or\CC\3541091 saline\NN\14849367 ,\,\1740 delayed\VBD\439958 the\DT\1740 onset\NN\7325190 of\IN\1740 bupivacaine-induced\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 as\RB\1740 well\RB\1740 as\IN\14622893 reduced\VBN\441445 plasma\NN\5398023 bupivacaine\NN\1740 levels\NNS\4916342 .\.\1740
D002045_D001145 NONE We\PRP\1740 recorded\VBD\2225492 time\NN\7308889 to\IN\1740 first\JJ\1740 <e2>dysrhythmia</e2>\NN\1740 occurrence\NN\29378 ,\,\1740 respective\JJ\1740 times\NNS\15113229 to\IN\1740 25\CD\13745420 %\NN\1740 and\CC\1740 50\CD\13745420 %\NN\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 HR\NN\15154774 )\-RRB-\1740 and\CC\1740 mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 ,\,\1740 and\CC\1740 time\NN\7308889 to\TO\1740 asystole\VB\1740 and\CC\1740 total\JJ\1740 amount\NN\13329641 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 consumption\NN\13440063 .\.\1740
D002045_D006323 CID We\PRP\1740 recorded\VBD\2225492 time\NN\7308889 to\IN\1740 first\JJ\1740 dysrhythmia\NN\1740 occurrence\NN\29378 ,\,\1740 respective\JJ\1740 times\NNS\15113229 to\IN\1740 25\CD\13745420 %\NN\1740 and\CC\1740 50\CD\13745420 %\NN\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 HR\NN\15154774 )\-RRB-\1740 and\CC\1740 mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 ,\,\1740 and\CC\1740 time\NN\7308889 to\TO\1740 <e2>asystole</e2>\VB\1740 and\CC\1740 total\JJ\1740 amount\NN\13329641 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 consumption\NN\13440063 .\.\1740
6695685
D014700_D001145 CID <e2>Accelerated\VBN\226566 junctional\JJ\1740 rhythms</e2>\NNS\15122011 during\IN\1740 oral\JJ\1740 <e1>verapamil</e1>\NN\2938514 therapy\NN\657604 .\.\1740
D014700_D001145 CID This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 frequency\NN\15286249 of\IN\1740 atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 dissociation\NN\383606 and\CC\1740 <e2>accelerated\VBD\226566 junctional\JJ\1740 rhythms</e2>\NNS\15122011 in\IN\13603305 59\CD\1740 patients\NNS\9898892 receiving\VBG\2210855 oral\JJ\1740 <e1>verapamil</e1>\NN\2938514 .\.\1740
D014700_D002637 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 various\JJ\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 syndromes\NNS\5870365 ,\,\1740 <e1>verapamil</e1>\RB\1740 neither\CC\1740 increased\VBD\169651 the\DT\1740 frequency\NN\15286249 of\IN\1740 junctional\JJ\1740 rhythms\NNS\15122011 nor\CC\1740 suppressed\VBD\2510337 their\PRP$\1740 role\NN\719494 as\IN\14622893 escape\NN\46177 rhythms\NNS\15122011 under\IN\1740 physiologically\RB\1740 appropriate\JJ\1740 circumstances\NNS\13920429 .\.\1740
7176945
D013390_D010146 CID <e1>Post-suxamethonium</e1>\JJ\1740 <e2>pains</e2>\VBZ\64643 in\IN\13603305 Nigerian\JJ\1740 surgical\JJ\1740 patients\NNS\9898892 .\.\1740
D013390_D010146 CID Contrary\JJ\1740 to\IN\1740 an\DT\6697703 earlier\JJR\1740 report\NN\6470073 by\IN\1740 Coxon\NNP\1740 ,\,\1740 <e1>scoline</e1>\NN\1740 <e2>pain</e2>\NN\14299637 occurs\VBZ\2623529 in\IN\13603305 African\JJ\1740 negroes\NNS\7846 .\.\1740
D013390_D010146 CID About\RB\1740 62\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 out-patients\JJ\1740 developed\VBD\1753788 <e1>scoline</e1>\NN\1740 <e2>pain</e2>\NN\14299637 as\IN\14622893 compared\VBN\644583 with\IN\1740 about\RB\1740 26\CD\13745420 %\NN\1740 among\IN\1740 the\DT\1740 in-patients\NNS\1740 .\.\1740
D013390_D010146 CID The\DT\1740 abolition\NN\209943 of\IN\1740 muscle\NN\5289601 fasciculations\NNS\14361664 (\-LRB-\1740 by\IN\1740 0.075mg/kg\NN\1740 dose\NN\3740161 of\IN\1740 Fazadinium\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e1>scoline</e1>\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D013390_D010146 CID Neither\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 induction\NN\7450842 agent\NN\7347 (\-LRB-\1740 Althesin\NN\1740 or\CC\3541091 Thiopentone\NN\1740 )\-RRB-\1740 nor\CC\1740 the\DT\1740 salt\NN\14818238 preparation\NN\407535 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 used\VBN\1156834 (\-LRB-\1740 chloride\NN\14818238 or\CC\3541091 bromide\NN\14904359 )\-RRB-\1740 ,\,\1740 affected\VBD\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 scoline\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D013390_D010146 CID Neither\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 induction\NN\7450842 agent\NN\7347 (\-LRB-\1740 Althesin\NN\1740 or\CC\3541091 Thiopentone\NN\1740 )\-RRB-\1740 nor\CC\1740 the\DT\1740 salt\NN\14818238 preparation\NN\407535 of\IN\1740 suxamethonium\NN\1740 used\VBN\1156834 (\-LRB-\1740 chloride\NN\14818238 or\CC\3541091 bromide\NN\14904359 )\-RRB-\1740 ,\,\1740 affected\VBD\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>scoline</e1>\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
C084773_D005207 NONE The\DT\1740 abolition\NN\209943 of\IN\1740 muscle\NN\5289601 <e2>fasciculations</e2>\NNS\14361664 (\-LRB-\1740 by\IN\1740 0.075mg/kg\NN\1740 dose\NN\3740161 of\IN\1740 <e1>Fazadinium</e1>\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 occurrence\NN\29378 of\IN\1740 scoline\JJ\1740 pain\NN\14299637 .\.\1740
C084773_D010146 NONE The\DT\1740 abolition\NN\209943 of\IN\1740 muscle\NN\5289601 fasciculations\NNS\14361664 (\-LRB-\1740 by\IN\1740 0.075mg/kg\NN\1740 dose\NN\3740161 of\IN\1740 <e1>Fazadinium</e1>\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 occurrence\NN\29378 of\IN\1740 scoline\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D013390_D005207 CID The\DT\1740 abolition\NN\209943 of\IN\1740 muscle\NN\5289601 <e2>fasciculations</e2>\NNS\14361664 (\-LRB-\1740 by\IN\1740 0.075mg/kg\NN\1740 dose\NN\3740161 of\IN\1740 Fazadinium\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e1>scoline</e1>\JJ\1740 pain\NN\14299637 .\.\1740
D000530_D010146 NONE Neither\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 induction\NN\7450842 agent\NN\7347 (\-LRB-\1740 <e1>Althesin</e1>\NN\1740 or\CC\3541091 Thiopentone\NN\1740 )\-RRB-\1740 nor\CC\1740 the\DT\1740 salt\NN\14818238 preparation\NN\407535 of\IN\1740 suxamethonium\NN\1740 used\VBN\1156834 (\-LRB-\1740 chloride\NN\14818238 or\CC\3541091 bromide\NN\14904359 )\-RRB-\1740 ,\,\1740 affected\VBD\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 scoline\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D013874_D010146 NONE Neither\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 induction\NN\7450842 agent\NN\7347 (\-LRB-\1740 Althesin\NN\1740 or\CC\3541091 <e1>Thiopentone</e1>\NN\1740 )\-RRB-\1740 nor\CC\1740 the\DT\1740 salt\NN\14818238 preparation\NN\407535 of\IN\1740 suxamethonium\NN\1740 used\VBN\1156834 (\-LRB-\1740 chloride\NN\14818238 or\CC\3541091 bromide\NN\14904359 )\-RRB-\1740 ,\,\1740 affected\VBD\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 scoline\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D002712_D010146 NONE Neither\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 induction\NN\7450842 agent\NN\7347 (\-LRB-\1740 Althesin\NN\1740 or\CC\3541091 Thiopentone\NN\1740 )\-RRB-\1740 nor\CC\1740 the\DT\1740 salt\NN\14818238 preparation\NN\407535 of\IN\1740 suxamethonium\NN\1740 used\VBN\1156834 (\-LRB-\1740 <e1>chloride</e1>\NN\14818238 or\CC\3541091 bromide\NN\14904359 )\-RRB-\1740 ,\,\1740 affected\VBD\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 scoline\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D001965_D010146 NONE Neither\CC\1740 the\DT\1740 type\NN\5839024 of\IN\1740 induction\NN\7450842 agent\NN\7347 (\-LRB-\1740 Althesin\NN\1740 or\CC\3541091 Thiopentone\NN\1740 )\-RRB-\1740 nor\CC\1740 the\DT\1740 salt\NN\14818238 preparation\NN\407535 of\IN\1740 suxamethonium\NN\1740 used\VBN\1156834 (\-LRB-\1740 chloride\NN\14818238 or\CC\3541091 <e1>bromide</e1>\NN\14904359 )\-RRB-\1740 ,\,\1740 affected\VBD\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 scoline\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
26033014
C051786_D009369 NONE <e2>Cancer</e2>\NN\14239425 incidence\NN\13821570 and\CC\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 :\:\1740 An\DT\6697703 update\NN\6642138 .\.\1740
C051786_D009369 NONE We\PRP\1740 evaluated\VBD\670261 <e2>cancer</e2>\NN\14239425 incidence\NN\13821570 through\IN\1740 2010/2011\NN\1740 (\-LRB-\1740 NC/IA\NN\1740 )\-RRB-\1740 for\IN\1740 49,616\CD\1740 applicators\NNS\3183080 ,\,\1740 53\CD\1740 %\NN\1740 of\IN\1740 whom\WP\1740 reported\VBD\831651 ever\RB\1740 using\VBG\1156834 <e1>metolachlor</e1>\NN\1740 .\.\1740
C051786_D009369 NONE We\PRP\1740 used\VBD\1156834 Poisson\NNP\1740 regression\NN\14501726 to\TO\1740 evaluate\VB\670261 relations\NNS\32823 between\IN\1740 two\CD\13741022 metrics\NNS\6169932 of\IN\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 (\-LRB-\1740 lifetime\NN\15113229 days\NNS\15140892 ,\,\1740 intensity-weighted\JJ\1740 lifetime\NN\15113229 days\NNS\15140892 )\-RRB-\1740 and\CC\1740 <e2>cancer</e2>\NN\14239425 incidence\NN\13821570 .\.\1740
C051786_D009369 NONE We\PRP\1740 saw\VBD\1552519 no\DT\7204911 association\NN\8008335 between\IN\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 and\CC\1740 incidence\NN\13821570 of\IN\1740 all\DT\1740 <e2>cancers</e2>\NNS\14239425 combined\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5,701\CD\1740 with\IN\1740 a\DT\13649268 5-year\JJ\1740 lag\NN\1066163 )\-RRB-\1740 or\CC\3541091 most\JJS\1740 site-specific\JJ\1740 cancers\NNS\14239425 .\.\1740
C051786_D009369 NONE We\PRP\1740 saw\VBD\1552519 no\DT\7204911 association\NN\8008335 between\IN\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 and\CC\1740 incidence\NN\13821570 of\IN\1740 all\DT\1740 cancers\NNS\14239425 combined\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5,701\CD\1740 with\IN\1740 a\DT\13649268 5-year\JJ\1740 lag\NN\1066163 )\-RRB-\1740 or\CC\3541091 most\JJS\1740 site-specific\JJ\1740 <e2>cancers</e2>\NNS\14239425 .\.\1740
C051786_D008113 CID UNASSIGNED\NNS\1740 :\:\1740 <e1>Metolachlor</e1>\NNP\1740 ,\,\1740 a\DT\13649268 widely\RB\1740 used\VBN\1156834 herbicide\NN\14806838 ,\,\1740 is\VBZ\836236 classified\VBN\657260 as\IN\14622893 a\DT\13649268 Group\NN\2137 C\NN\13714184 carcinogen\NN\20090 by\IN\1740 the\DT\1740 U.S.\NNP\8052549 Environmental\NNP\1740 Protection\NNP\407535 Agency\NNP\8077292 based\VBN\2694933 on\IN\1740 increased\VBN\169651 <e2>liver\NN\5298729 neoplasms</e2>\NNS\14234074 in\IN\13603305 female\JJ\1740 rats\NNS\2329401 .\.\1740
C051786_D008113 CID This\DT\1740 suggestion\NN\5833840 of\IN\1740 an\DT\6697703 association\NN\8008335 between\IN\1740 <e1>metolachlor</e1>\NN\1740 and\CC\1740 <e2>liver\NN\5298729 cancer</e2>\NN\14239425 among\IN\1740 pesticide\NN\14806838 applicators\NNS\3183080 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 finding\NN\43195 and\CC\1740 echoes\VBZ\983824 observation\NN\996969 of\IN\1740 increased\VBN\169651 liver\NN\5298729 neoplasms\NNS\14234074 in\IN\13603305 some\DT\1740 animal\JJ\1740 studies\NNS\635850 .\.\1740
C051786_D008113 CID This\DT\1740 suggestion\NN\5833840 of\IN\1740 an\DT\6697703 association\NN\8008335 between\IN\1740 <e1>metolachlor</e1>\NN\1740 and\CC\1740 liver\NN\5298729 cancer\NN\14239425 among\IN\1740 pesticide\NN\14806838 applicators\NNS\3183080 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 finding\NN\43195 and\CC\1740 echoes\VBZ\983824 observation\NN\996969 of\IN\1740 increased\VBN\169651 <e2>liver\NN\5298729 neoplasms</e2>\NNS\14234074 in\IN\13603305 some\DT\1740 animal\JJ\1740 studies\NNS\635850 .\.\1740
C051786_D008113 CID However\RB\1740 ,\,\1740 our\PRP$\1740 findings\NNS\7951464 for\IN\1740 both\CC\1740 <e2>liver\NN\5298729 cancer</e2>\NN\14239425 and\CC\1740 follicular\JJ\1740 cell\NN\3080309 lymphoma\NN\14239918 warrant\NN\6552984 follow-up\NN\4599396 to\TO\1740 better\RBR\1740 differentiate\VB\618878 effects\NNS\13245626 of\IN\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 from\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
C051786_D008175 NONE An\DT\6697703 earlier\JJR\1740 suggestion\NN\5833840 of\IN\1740 increased\VBN\169651 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 risk\NN\14541044 at\IN\14622893 high\JJ\1740 levels\NNS\4916342 of\IN\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 in\IN\13603305 this\DT\1740 cohort\NN\8184861 was\VBD\836236 not\RB\1740 confirmed\VBN\1011725 in\IN\13603305 this\DT\1740 update\NN\6642138 .\.\1740
C051786_D008223 NONE However\RB\1740 ,\,\1740 our\PRP$\1740 findings\NNS\7951464 for\IN\1740 both\CC\1740 liver\NN\5298729 cancer\NN\14239425 and\CC\1740 follicular\JJ\1740 cell\NN\3080309 <e2>lymphoma</e2>\NN\14239918 warrant\NN\6552984 follow-up\NN\4599396 to\TO\1740 better\RBR\1740 differentiate\VB\618878 effects\NNS\13245626 of\IN\1740 <e1>metolachlor</e1>\NN\1740 use\NN\407535 from\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
3895875
D008012_D009203 NONE Prophylactic\JJ\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 early\JJ\1740 phase\NN\15113229 of\IN\1740 suspected\VBN\916909 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D008012_D009203 NONE Four\CD\13741022 hundred\CD\13745420 two\CD\13741022 patients\NNS\9898892 with\IN\1740 suspected\VBN\916909 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 seen\VBN\2106506 within\IN\1740 6\CD\13741022 hours\NNS\15118228 of\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 symptoms\NNS\5823932 entered\VBD\2471690 a\DT\13649268 double-blind\JJ\1740 randomized\JJ\1740 trial\NN\786195 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 vs\CC\13634784 placebo\NN\3740161 .\.\1740
D008012_D009203 NONE The\DT\1740 average\JJ\1740 plasma\NN\5398023 <e1>lidocaine</e1>\NN\3681148 level\NN\4916342 10\CD\13745420 minutes\NNS\6502378 after\IN\1740 administration\NN\1133281 for\IN\1740 patients\NNS\9898892 without\IN\1740 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 that\DT\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 acute\JJ\1740 infarction\NN\14204950 .\.\1740
D008012_D009203 NONE We\PRP\1740 can\MD\3094503 not\RB\1740 advocate\VB\875394 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 prophylactically\RB\1740 in\IN\13603305 the\DT\1740 early\JJ\1740 hours\NNS\15118228 of\IN\1740 suspected\VBN\916909 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D008012_D017180 NONE <e1>Lidocaine</e1>\NN\3681148 ,\,\1740 given\VBN\2327200 in\IN\13603305 a\DT\13649268 300\CD\1740 mg\NN\13717155 dose\NN\3740161 intramuscularly\RB\1740 followed\VBN\1835496 by\IN\1740 100\CD\13745420 mg\NN\13717155 intravenously\RB\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 prevent\VB\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 warning\NN\7212190 arrhythmias\NNS\14103288 between\IN\1740 15\CD\13745420 and\CC\1740 45\CD\1740 minutes\NNS\6502378 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D008012_D017180 NONE Lidocaine\NN\3681148 ,\,\1740 given\VBN\2327200 in\IN\13603305 a\DT\13649268 300\CD\1740 mg\NN\13717155 dose\NN\3740161 intramuscularly\RB\1740 followed\VBN\1835496 by\IN\1740 100\CD\13745420 mg\NN\13717155 intravenously\RB\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 prevent\VB\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 warning\NN\7212190 arrhythmias\NNS\14103288 between\IN\1740 15\CD\13745420 and\CC\1740 45\CD\1740 minutes\NNS\6502378 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D008012_D001145 NONE <e1>Lidocaine</e1>\NN\3681148 ,\,\1740 given\VBN\2327200 in\IN\13603305 a\DT\13649268 300\CD\1740 mg\NN\13717155 dose\NN\3740161 intramuscularly\RB\1740 followed\VBN\1835496 by\IN\1740 100\CD\13745420 mg\NN\13717155 intravenously\RB\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 prevent\VB\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 warning\NN\7212190 <e2>arrhythmias</e2>\NNS\14103288 between\IN\1740 15\CD\13745420 and\CC\1740 45\CD\1740 minutes\NNS\6502378 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D008012_D001145 NONE Lidocaine\NN\3681148 ,\,\1740 given\VBN\2327200 in\IN\13603305 a\DT\13649268 300\CD\1740 mg\NN\13717155 dose\NN\3740161 intramuscularly\RB\1740 followed\VBN\1835496 by\IN\1740 100\CD\13745420 mg\NN\13717155 intravenously\RB\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 prevent\VB\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 number\NN\5107765 of\IN\1740 patients\NNS\9898892 with\IN\1740 warning\NN\7212190 <e2>arrhythmias</e2>\NNS\14103288 between\IN\1740 15\CD\13745420 and\CC\1740 45\CD\1740 minutes\NNS\6502378 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D008012_D007238 NONE The\DT\1740 average\JJ\1740 plasma\NN\5398023 <e1>lidocaine</e1>\NN\3681148 level\NN\4916342 10\CD\13745420 minutes\NNS\6502378 after\IN\1740 administration\NN\1133281 for\IN\1740 patients\NNS\9898892 without\IN\1740 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 that\DT\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 acute\JJ\1740 <e2>infarction</e2>\NN\14204950 .\.\1740
D008012_D007022 CID During\IN\1740 the\DT\1740 1-hour\CD\1740 study\NN\635850 period\NN\13575869 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 side\NN\8630039 effects\NNS\13245626 was\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 <e1>lidocaine</e1>\NN\3681148 group\NN\2137 ,\,\1740 <e2>hypotension</e2>\NN\14057371 occurred\VBD\2623529 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 ,\,\1740 nine\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 lidocaine\NN\3681148 ,\,\1740 and\CC\1740 four\CD\13741022 patients\NNS\9898892 died\VBD\146138 from\IN\1740 asystole\NN\14204950 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 had\VBN\2108377 lidocaine\NN\3681148 .\.\1740
D008012_D007022 CID During\IN\1740 the\DT\1740 1-hour\CD\1740 study\NN\635850 period\NN\13575869 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 side\NN\8630039 effects\NNS\13245626 was\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 ,\,\1740 <e2>hypotension</e2>\NN\14057371 occurred\VBD\2623529 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 ,\,\1740 nine\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 <e1>lidocaine</e1>\NN\3681148 ,\,\1740 and\CC\1740 four\CD\13741022 patients\NNS\9898892 died\VBD\146138 from\IN\1740 asystole\NN\14204950 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 had\VBN\2108377 lidocaine\NN\3681148 .\.\1740
D008012_D007022 CID During\IN\1740 the\DT\1740 1-hour\CD\1740 study\NN\635850 period\NN\13575869 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 side\NN\8630039 effects\NNS\13245626 was\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 ,\,\1740 <e2>hypotension</e2>\NN\14057371 occurred\VBD\2623529 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 ,\,\1740 nine\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 lidocaine\NN\3681148 ,\,\1740 and\CC\1740 four\CD\13741022 patients\NNS\9898892 died\VBD\146138 from\IN\1740 asystole\NN\14204950 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 had\VBN\2108377 <e1>lidocaine</e1>\NN\3681148 .\.\1740
D008012_D006323 NONE During\IN\1740 the\DT\1740 1-hour\CD\1740 study\NN\635850 period\NN\13575869 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 side\NN\8630039 effects\NNS\13245626 was\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 <e1>lidocaine</e1>\NN\3681148 group\NN\2137 ,\,\1740 hypotension\NN\14057371 occurred\VBD\2623529 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 ,\,\1740 nine\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 lidocaine\NN\3681148 ,\,\1740 and\CC\1740 four\CD\13741022 patients\NNS\9898892 died\VBD\146138 from\IN\1740 <e2>asystole</e2>\NN\14204950 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 had\VBN\2108377 lidocaine\NN\3681148 .\.\1740
D008012_D006323 NONE During\IN\1740 the\DT\1740 1-hour\CD\1740 study\NN\635850 period\NN\13575869 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 side\NN\8630039 effects\NNS\13245626 was\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 ,\,\1740 hypotension\NN\14057371 occurred\VBD\2623529 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 ,\,\1740 nine\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 <e1>lidocaine</e1>\NN\3681148 ,\,\1740 and\CC\1740 four\CD\13741022 patients\NNS\9898892 died\VBD\146138 from\IN\1740 <e2>asystole</e2>\NN\14204950 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 had\VBN\2108377 lidocaine\NN\3681148 .\.\1740
D008012_D006323 NONE During\IN\1740 the\DT\1740 1-hour\CD\1740 study\NN\635850 period\NN\13575869 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 side\NN\8630039 effects\NNS\13245626 was\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 lidocaine\NN\3681148 group\NN\2137 ,\,\1740 hypotension\NN\14057371 occurred\VBD\2623529 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 ,\,\1740 nine\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 lidocaine\NN\3681148 ,\,\1740 and\CC\1740 four\CD\13741022 patients\NNS\9898892 died\VBD\146138 from\IN\1740 <e2>asystole</e2>\NN\14204950 ,\,\1740 three\CD\13741022 of\IN\1740 whom\WP\1740 had\VBD\2108377 had\VBN\2108377 <e1>lidocaine</e1>\NN\3681148 .\.\1740
16880771
D004298_D020521 NONE Administration\NN\1133281 of\IN\1740 the\DT\1740 <e1>dopamine</e1>\NN\14807737 precursor\NN\14580897 levodopa\NN\14604959 enhances\VBZ\227165 learning\NN\5701944 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 <e2>stroke</e2>\NN\556313 patients\NNS\9898892 .\.\1740
D004298_D020521 NONE Thus\RB\1740 ,\,\1740 phasic\JJ\1740 signaling\NN\33020 seems\VBZ\2604760 to\TO\1740 be\VB\836236 the\DT\1740 critical\JJ\1740 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 <e1>dopamine</e1>\NN\14807737 enhances\VBZ\227165 associative\JJ\1740 learning\NN\5701944 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 <e2>stroke</e2>\NN\556313 patients\NNS\9898892 .\.\1740
D007980_D020521 NONE Administration\NN\1133281 of\IN\1740 the\DT\1740 dopamine\NN\14807737 precursor\NN\14580897 <e1>levodopa</e1>\NN\14604959 enhances\VBZ\227165 learning\NN\5701944 in\IN\13603305 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 <e2>stroke</e2>\NN\556313 patients\NNS\9898892 .\.\1740
D004298_D007859 NONE The\DT\1740 <e1>dopamine</e1>\NN\14807737 agonist\NN\9613191 significantly\RB\1740 <e2>impaired\VBD\258857 novel\JJ\1740 word\NN\6284225 learning</e2>\NN\5701944 compared\VBN\644583 to\TO\1740 placebo\NN\3740161 .\.\1740
7248895
D003520_D010386 NONE Invasive\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis</e2>\NN\5578911 following\VBG\1835496 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 nonmalignant\JJ\1740 disease\NN\14061805 .\.\1740
D003520_D010386 NONE The\DT\1740 present\JJ\1740 case\NN\7283608 is\VBZ\836236 the\DT\1740 first\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis</e2>\NN\5578911 reported\VBN\831651 in\IN\13603305 association\NN\8008335 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 treatment\NN\654885 .\.\1740
D003520_D006869 NONE A\DT\13649268 47-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 right\JJ\1740 <e2>hydroureteronephrosis</e2>\NN\1740 due\IN\5174653 to\TO\1740 ureterovesical\JJ\1740 junction\NN\8664443 obstruction\NN\4341686 had\VBD\2108377 gross\JJ\1740 hematuria\NN\14299637 after\IN\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 five\CD\13741022 years\NNS\15144371 wtih\NN\1740 <e1>cyclophosphamide</e1>\NN\1740 for\IN\1740 cerebral\JJ\1740 vasculitis\NN\14336539 .\.\1740
D003520_D006869 NONE The\DT\1740 association\NN\8008335 of\IN\1740 the\DT\1740 tumor\NN\14234074 with\IN\1740 preexisting\JJ\1740 <e2>hydroureteronephrosis</e2>\NN\1740 suggests\VBZ\1010118 that\IN\1740 stasis\NN\14204950 prolonged\VBD\317700 and\CC\1740 intensified\VBD\153263 exposure\NN\5042871 of\IN\1740 upper\JJ\1740 urinary\JJ\1740 tract\NN\8574314 epithelium\NN\5267548 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D003520_D006417 CID A\DT\13649268 47-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 right\JJ\1740 hydroureteronephrosis\NN\1740 due\IN\5174653 to\TO\1740 ureterovesical\JJ\1740 junction\NN\8664443 obstruction\NN\4341686 had\VBD\2108377 gross\JJ\1740 <e2>hematuria</e2>\NN\14299637 after\IN\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 five\CD\13741022 years\NNS\15144371 wtih\NN\1740 <e1>cyclophosphamide</e1>\NN\1740 for\IN\1740 cerebral\JJ\1740 vasculitis\NN\14336539 .\.\1740
D003520_D020293 NONE A\DT\13649268 47-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 right\JJ\1740 hydroureteronephrosis\NN\1740 due\IN\5174653 to\TO\1740 ureterovesical\JJ\1740 junction\NN\8664443 obstruction\NN\4341686 had\VBD\2108377 gross\JJ\1740 hematuria\NN\14299637 after\IN\1740 being\VBG\836236 treated\VBN\2376958 for\IN\1740 five\CD\13741022 years\NNS\15144371 wtih\NN\1740 <e1>cyclophosphamide</e1>\NN\1740 for\IN\1740 <e2>cerebral\JJ\1740 vasculitis</e2>\NN\14336539 .\.\1740
D003520_D006470 NONE Although\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 to\TO\1740 cause\VB\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 and\CC\1740 urine\NN\14853947 cytologic\JJ\1740 abnormalities\NNS\14034177 indistinguishable\JJ\1740 from\IN\1740 high\JJ\1740 grade\NN\7975026 carcinoma\NN\14239918 is\VBZ\836236 well\RB\1740 known\VBN\2110220 ,\,\1740 it\PRP\6125041 is\VBZ\836236 less\RBR\1740 widely\RB\1740 appreciated\JJ\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 also\RB\1740 associated\VBN\628491 with\IN\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 urinary\JJ\1740 tract\NN\8574314 .\.\1740
D003520_D003556 NONE Although\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 to\TO\1740 cause\VB\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 and\CC\1740 urine\NN\14853947 cytologic\JJ\1740 abnormalities\NNS\14034177 indistinguishable\JJ\1740 from\IN\1740 high\JJ\1740 grade\NN\7975026 carcinoma\NN\14239918 is\VBZ\836236 well\RB\1740 known\VBN\2110220 ,\,\1740 it\PRP\6125041 is\VBZ\836236 less\RBR\1740 widely\RB\1740 appreciated\JJ\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 also\RB\1740 associated\VBN\628491 with\IN\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 urinary\JJ\1740 tract\NN\8574314 .\.\1740
D003520_D002277 CID Although\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 to\TO\1740 cause\VB\1617192 hemorrhagic\JJ\1740 cystitis\NN\14566129 and\CC\1740 urine\NN\14853947 cytologic\JJ\1740 abnormalities\NNS\14034177 indistinguishable\JJ\1740 from\IN\1740 high\JJ\1740 grade\NN\7975026 <e2>carcinoma</e2>\NN\14239918 is\VBZ\836236 well\RB\1740 known\VBN\2110220 ,\,\1740 it\PRP\6125041 is\VBZ\836236 less\RBR\1740 widely\RB\1740 appreciated\JJ\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 also\RB\1740 associated\VBN\628491 with\IN\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 urinary\JJ\1740 tract\NN\8574314 .\.\1740
D003520_D014571 NONE Although\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 to\TO\1740 cause\VB\1617192 hemorrhagic\JJ\1740 cystitis\NN\14566129 and\CC\1740 urine\NN\14853947 cytologic\JJ\1740 abnormalities\NNS\14034177 indistinguishable\JJ\1740 from\IN\1740 high\JJ\1740 grade\NN\7975026 carcinoma\NN\14239918 is\VBZ\836236 well\RB\1740 known\VBN\2110220 ,\,\1740 it\PRP\6125041 is\VBZ\836236 less\RBR\1740 widely\RB\1740 appreciated\JJ\1740 that\IN\1740 it\PRP\6125041 is\VBZ\836236 also\RB\1740 associated\VBN\628491 with\IN\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 urinary\JJ\1740 tract</e2>\NN\8574314 .\.\1740
D003520_D014571 NONE It\PRP\6125041 is\VBZ\836236 the\DT\1740 third\JJ\1740 <e2>urinary\JJ\1740 tract\NN\8574314 cancer</e2>\NN\14239425 reported\VBN\831651 in\IN\13603305 association\NN\8008335 with\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 treatment\NN\654885 for\IN\1740 nonmalignant\JJ\1740 disease\NN\14061805 .\.\1740
D003520_D009369 NONE The\DT\1740 association\NN\8008335 of\IN\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 with\IN\1740 preexisting\JJ\1740 hydroureteronephrosis\NN\1740 suggests\VBZ\1010118 that\IN\1740 stasis\NN\14204950 prolonged\VBD\317700 and\CC\1740 intensified\VBD\153263 exposure\NN\5042871 of\IN\1740 upper\JJ\1740 urinary\JJ\1740 tract\NN\8574314 epithelium\NN\5267548 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D003520_-1 NONE Patients\NNS\9898892 who\WP\8299493 are\VBP\836236 candidates\NNS\10450303 for\IN\1740 long-term\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 treatment\NN\654885 should\MD\1740 be\VB\836236 routinely\RB\1740 evaluated\VBN\670261 for\IN\1740 <e2>obstructive\JJ\1740 uropathy</e2>\JJ\1740 .\.\1740
24345882
D008727_D054198 NONE Neurocognitive\JJ\1740 and\CC\1740 neuroradiologic\NN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 late\JJ\1740 effects\NNS\13245626 in\IN\13603305 children\NNS\9622049 treated\VBN\2376958 on\IN\1740 Pediatric\NNP\1740 Oncology\NNP\6043075 Group\NNP\2137 (\-LRB-\1740 POG\NN\1740 )\-RRB-\1740 P9605\NN\1740 (\-LRB-\1740 standard\JJ\1740 risk\NN\14541044 )\-RRB-\1740 and\CC\1740 P9201\NN\1740 (\-LRB-\1740 lesser\JJR\1740 risk\NN\14541044 )\-RRB-\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 protocols\NNS\6652242 (\-LRB-\1740 ACCL0131\NN\1740 ):\NFP\1740 a\DT\13649268 <e1>methotrexate</e1>\JJ\1740 consequence\NN\34213 ?\.\1740
D008727_D054198 NONE Concerns\NNS\5682950 about\IN\1740 long-term\JJ\1740 <e1>methotrexate</e1>\NN\2722166 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 neurotoxicity\NN\1740 in\IN\13603305 the\DT\1740 1990s\NNS\15204983 led\VBD\1752884 to\TO\1740 modifications\NNS\191142 in\IN\13603305 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 leucovorin\NN\1740 rescue\NN\45907 ,\,\1740 and\CC\1740 frequency\NN\15286249 of\IN\1740 systemic\JJ\1740 MTX\NN\1740 administration\NN\1133281 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D008727_D054198 NONE Concerns\NNS\5682950 about\IN\1740 long-term\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 <e1>MTX</e1>\NN\1740 )\-RRB-\1740 neurotoxicity\NN\1740 in\IN\13603305 the\DT\1740 1990s\NNS\15204983 led\VBD\1752884 to\TO\1740 modifications\NNS\191142 in\IN\13603305 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 leucovorin\NN\1740 rescue\NN\45907 ,\,\1740 and\CC\1740 frequency\NN\15286249 of\IN\1740 systemic\JJ\1740 MTX\NN\1740 administration\NN\1133281 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D008727_D054198 NONE Concerns\NNS\5682950 about\IN\1740 long-term\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 neurotoxicity\NN\1740 in\IN\13603305 the\DT\1740 1990s\NNS\15204983 led\VBD\1752884 to\TO\1740 modifications\NNS\191142 in\IN\13603305 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 leucovorin\NN\1740 rescue\NN\45907 ,\,\1740 and\CC\1740 frequency\NN\15286249 of\IN\1740 systemic\JJ\1740 <e1>MTX</e1>\NN\1740 administration\NN\1133281 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D008727_D020258 NONE Concerns\NNS\5682950 about\IN\1740 long-term\JJ\1740 <e1>methotrexate</e1>\NN\2722166 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 1990s\NNS\15204983 led\VBD\1752884 to\TO\1740 modifications\NNS\191142 in\IN\13603305 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 leucovorin\NN\1740 rescue\NN\45907 ,\,\1740 and\CC\1740 frequency\NN\15286249 of\IN\1740 systemic\JJ\1740 MTX\NN\1740 administration\NN\1133281 in\IN\13603305 children\NNS\9622049 with\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
D008727_D020258 NONE Concerns\NNS\5682950 about\IN\1740 long-term\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 <e1>MTX</e1>\NN\1740 )\-RRB-\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 1990s\NNS\15204983 led\VBD\1752884 to\TO\1740 modifications\NNS\191142 in\IN\13603305 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 leucovorin\NN\1740 rescue\NN\45907 ,\,\1740 and\CC\1740 frequency\NN\15286249 of\IN\1740 systemic\JJ\1740 MTX\NN\1740 administration\NN\1133281 in\IN\13603305 children\NNS\9622049 with\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
D008727_D020258 NONE Concerns\NNS\5682950 about\IN\1740 long-term\JJ\1740 methotrexate\NN\2722166 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 1990s\NNS\15204983 led\VBD\1752884 to\TO\1740 modifications\NNS\191142 in\IN\13603305 intrathecal\JJ\1740 (\-LRB-\1740 IT\NN\6125041 )\-RRB-\1740 therapy\NN\657604 ,\,\1740 leucovorin\NN\1740 rescue\NN\45907 ,\,\1740 and\CC\1740 frequency\NN\15286249 of\IN\1740 systemic\JJ\1740 <e1>MTX</e1>\NN\1740 administration\NN\1133281 in\IN\13603305 children\NNS\9622049 with\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
18945509
-1_D003324 NONE Risk\NN\14541044 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 associated\VBN\628491 with\IN\1740 initial\JJ\1740 <e1>sulphonylurea</e1>\NN\1740 treatment\NN\654885 of\IN\1740 patients\NNS\9898892 with\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 :\:\1740 a\DT\13649268 matched\VBN\2664769 case-control\NN\1740 study\NN\635850 .\.\1740
-1_D003324 NONE AIMS\NNS\5980875 :\:\1740 This\DT\1740 study\NN\635850 sought\VBD\1825237 to\TO\1740 assess\VB\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 (\-LRB-\1740 CAD\NN\10753546 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 initial\JJ\1740 treatment\NN\654885 of\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 with\IN\1740 different\JJ\1740 <e1>sulphonylureas</e1>\NNS\1740 .\.\1740
-1_D003324 NONE AIMS\NNS\5980875 :\:\1740 This\DT\1740 study\NN\635850 sought\VBD\1825237 to\TO\1740 assess\VB\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 (\-LRB-\1740 <e2>CAD</e2>\NN\10753546 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 initial\JJ\1740 treatment\NN\654885 of\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 with\IN\1740 different\JJ\1740 <e1>sulphonylureas</e1>\NNS\1740 .\.\1740
-1_D003924 NONE Risk\NN\14541044 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 associated\VBN\628491 with\IN\1740 initial\JJ\1740 <e1>sulphonylurea</e1>\NN\1740 treatment\NN\654885 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>type\NN\5839024 2\CD\13741022 diabetes</e2>\NNS\14075199 :\:\1740 a\DT\13649268 matched\VBN\2664769 case-control\NN\1740 study\NN\635850 .\.\1740
-1_D003924 NONE AIMS\NNS\5980875 :\:\1740 This\DT\1740 study\NN\635850 sought\VBD\1825237 to\TO\1740 assess\VB\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 (\-LRB-\1740 CAD\NN\10753546 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 initial\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>type\NN\5839024 2\CD\13741022 diabetes</e2>\NNS\14075199 with\IN\1740 different\JJ\1740 <e1>sulphonylureas</e1>\NNS\1740 .\.\1740
D005905_D003324 CID The\DT\1740 hazard\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>CAD</e2>\NN\10753546 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 initial\JJ\1740 treatment\NN\654885 increased\VBN\169651 by\IN\1740 2.4-fold\JJ\1740 (\-LRB-\1740 1.3\CD\1740 -\SYM\1740 4.3\CD\1740 ,\,\1740 P=0.004\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>glibenclamide</e1>\NN\1740 ;\:\1740 2-fold\JJ\1740 (\-LRB-\1740 0.9\CD\1740 -\SYM\1740 4.6\CD\1740 ,\,\1740 P=0.099\NN\1740 )\-RRB-\1740 with\IN\1740 glipizide\NN\2719105 ;\:\1740 2.9-fold\RB\1740 (\-LRB-\1740 1.6\CD\1740 -\SYM\1740 5.1\CD\1740 ,\,\1740 P=0.000\NN\1740 )\-RRB-\1740 with\IN\1740 either\RB\1740 ,\,\1740 and\CC\1740 was\VBD\836236 unchanged\JJ\1740 with\IN\1740 metformin\NN\2719105 .\.\1740
D005905_D003324 CID CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 with\IN\1740 <e1>glibenclamide</e1>\NN\1740 or\CC\3541091 glipizide\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>CAD</e2>\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 gliclazide\VB\1740 or\CC\3541091 glimepiride\NN\1740 .\.\1740
D005913_D003324 NONE The\DT\1740 hazard\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>CAD</e2>\NN\10753546 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 initial\JJ\1740 treatment\NN\654885 increased\VBN\169651 by\IN\1740 2.4-fold\JJ\1740 (\-LRB-\1740 1.3\CD\1740 -\SYM\1740 4.3\CD\1740 ,\,\1740 P=0.004\NN\1740 )\-RRB-\1740 with\IN\1740 glibenclamide\NN\1740 ;\:\1740 2-fold\JJ\1740 (\-LRB-\1740 0.9\CD\1740 -\SYM\1740 4.6\CD\1740 ,\,\1740 P=0.099\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>glipizide</e1>\NN\2719105 ;\:\1740 2.9-fold\RB\1740 (\-LRB-\1740 1.6\CD\1740 -\SYM\1740 5.1\CD\1740 ,\,\1740 P=0.000\NN\1740 )\-RRB-\1740 with\IN\1740 either\RB\1740 ,\,\1740 and\CC\1740 was\VBD\836236 unchanged\JJ\1740 with\IN\1740 metformin\NN\2719105 .\.\1740
D005913_D003324 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 with\IN\1740 glibenclamide\NN\1740 or\CC\3541091 <e1>glipizide</e1>\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>CAD</e2>\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 gliclazide\VB\1740 or\CC\3541091 glimepiride\NN\1740 .\.\1740
D008687_D003324 NONE The\DT\1740 hazard\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>CAD</e2>\NN\10753546 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 initial\JJ\1740 treatment\NN\654885 increased\VBN\169651 by\IN\1740 2.4-fold\JJ\1740 (\-LRB-\1740 1.3\CD\1740 -\SYM\1740 4.3\CD\1740 ,\,\1740 P=0.004\NN\1740 )\-RRB-\1740 with\IN\1740 glibenclamide\NN\1740 ;\:\1740 2-fold\JJ\1740 (\-LRB-\1740 0.9\CD\1740 -\SYM\1740 4.6\CD\1740 ,\,\1740 P=0.099\NN\1740 )\-RRB-\1740 with\IN\1740 glipizide\NN\2719105 ;\:\1740 2.9-fold\RB\1740 (\-LRB-\1740 1.6\CD\1740 -\SYM\1740 5.1\CD\1740 ,\,\1740 P=0.000\NN\1740 )\-RRB-\1740 with\IN\1740 either\RB\1740 ,\,\1740 and\CC\1740 was\VBD\836236 unchanged\JJ\1740 with\IN\1740 <e1>metformin</e1>\NN\2719105 .\.\1740
D005905_D003924 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 <e2>type\NN\5839024 2\CD\13741022 diabetes</e2>\NNS\14075199 with\IN\1740 <e1>glibenclamide</e1>\NN\1740 or\CC\3541091 glipizide\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 CAD\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 gliclazide\VB\1740 or\CC\3541091 glimepiride\NN\1740 .\.\1740
D005913_D003924 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 <e2>type\NN\5839024 2\CD\13741022 diabetes</e2>\NNS\14075199 with\IN\1740 glibenclamide\NN\1740 or\CC\3541091 <e1>glipizide</e1>\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 CAD\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 gliclazide\VB\1740 or\CC\3541091 glimepiride\NN\1740 .\.\1740
D005907_D003924 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 <e2>type\NN\5839024 2\CD\13741022 diabetes</e2>\NNS\14075199 with\IN\1740 glibenclamide\NN\1740 or\CC\3541091 glipizide\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 CAD\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 <e1>gliclazide</e1>\VB\1740 or\CC\3541091 glimepiride\NN\1740 .\.\1740
D005907_D003324 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 with\IN\1740 glibenclamide\NN\1740 or\CC\3541091 glipizide\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>CAD</e2>\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 <e1>gliclazide</e1>\VB\1740 or\CC\3541091 glimepiride\NN\1740 .\.\1740
C057619_D003924 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 <e2>type\NN\5839024 2\CD\13741022 diabetes</e2>\NNS\14075199 with\IN\1740 glibenclamide\NN\1740 or\CC\3541091 glipizide\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 CAD\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 gliclazide\VB\1740 or\CC\3541091 <e1>glimepiride</e1>\NN\1740 .\.\1740
C057619_D003324 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Initiating\VBG\1617192 treatment\NN\654885 of\IN\1740 type\NN\5839024 2\CD\13741022 diabetes\NNS\14075199 with\IN\1740 glibenclamide\NN\1740 or\CC\3541091 glipizide\NN\2719105 is\VBZ\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>CAD</e2>\NN\10753546 in\IN\13603305 comparison\NN\635850 to\TO\1740 gliclazide\VB\1740 or\CC\3541091 <e1>glimepiride</e1>\NN\1740 .\.\1740
15627798
D005839_D009395 CID Inhibition\NN\1068773 of\IN\1740 nuclear\JJ\1740 factor-kappaB\NN\1740 activation\NN\13561719 attenuates\VBZ\224901 <e2>tubulointerstitial\JJ\1740 nephritis</e2>\NN\14113228 induced\VBN\1627355 by\IN\1740 <e1>gentamicin</e1>\NN\2716866 .\.\1740
D005839_D009395 CID CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 inhibition\NN\1068773 of\IN\1740 NF-kappaB\NN\1740 activation\NN\13561719 attenuates\VBZ\224901 <e2>tubulointerstitial\JJ\1740 nephritis</e2>\NN\14113228 induced\VBN\1627355 by\IN\1740 <e1>gentamicin</e1>\NN\2716866 .\.\1740
D005839_D005355 NONE BACKGROUND\NN\4921011 :\:\1740 Animals\NNS\4475 treated\VBN\2376958 with\IN\1740 <e1>gentamicin</e1>\NN\2716866 can\MD\3094503 show\VB\2137132 residual\JJ\1740 areas\NNS\8630985 of\IN\1740 interstitial\JJ\1740 <e2>fibrosis</e2>\NN\14204950 in\IN\13603305 the\DT\1740 renal\JJ\1740 cortex\NN\5462674 .\.\1740
16731636
D007545_D006332 CID Enhanced\VBN\227165 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 hypertrophy</e2>\NN\14365950 in\IN\13603305 transgenic\JJ\1740 rats\NNS\2329401 with\IN\1740 low\JJ\1740 brain\NN\5462674 angiotensinogen\NN\1740 .\.\1740
D007545_D006332 CID <e2>LV\JJ\1740 hypertrophy</e2>\NN\14365950 induced\VBN\1627355 by\IN\1740 <e1>Iso</e1>\NN\1740 treatment\NN\654885 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 in\IN\13603305 TGR\NNP\1740 than\IN\1740 in\IN\13603305 SD\NN\1740 rats\NNS\2329401 (\-LRB-\1740 in\IN\13603305 g\NN\13717155 LV\NN\1740 wt/100\CD\1740 g\NN\13717155 body\NN\19128 wt\NN\1740 ,\,\1740 0.28\CD\1740 +/-\CC\1740 0.004\CD\1740 vs.\CC\1740 0.24\CD\1740 +/-\CC\1740 0.004\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
6985498
D008733_D056486 CID <e2>Hepatitis</e2>\NN\14127211 and\CC\1740 renal\JJ\1740 tubular\JJ\1740 acidosis\NN\14204950 after\IN\1740 anesthesia\NN\14034177 with\IN\1740 <e1>methoxyflurane</e1>\NN\1740 .\.\1740
D008733_D000141 CID Hepatitis\NN\14127211 and\CC\1740 <e2>renal\JJ\1740 tubular\JJ\1740 acidosis</e2>\NN\14204950 after\IN\1740 anesthesia\NN\14034177 with\IN\1740 <e1>methoxyflurane</e1>\NN\1740 .\.\1740
D008733_D000141 CID A\DT\13649268 69-year-old\JJ\1740 man\NN\9605289 operated\VBD\2439501 for\IN\1740 acute\JJ\1740 cholecystitis\NN\14336539 under\IN\1740 <e1>methoxyflurane</e1>\JJ\1740 anesthesia\NN\14034177 developed\VBD\1753788 postoperatively\RB\1740 a\DT\13649268 hepatic\JJ\1740 insufficiency\NN\14462946 syndrome\NN\5870365 and\CC\1740 <e2>renal\JJ\1740 tubular\JJ\1740 acidosis</e2>\NN\14204950 .\.\1740
D008733_D041881 NONE A\DT\13649268 69-year-old\JJ\1740 man\NN\9605289 operated\VBD\2439501 for\IN\1740 <e2>acute\JJ\1740 cholecystitis</e2>\NN\14336539 under\IN\1740 <e1>methoxyflurane</e1>\JJ\1740 anesthesia\NN\14034177 developed\VBD\1753788 postoperatively\RB\1740 a\DT\13649268 hepatic\JJ\1740 insufficiency\NN\14462946 syndrome\NN\5870365 and\CC\1740 renal\JJ\1740 tubular\JJ\1740 acidosis\NN\14204950 .\.\1740
D008733_D048550 NONE A\DT\13649268 69-year-old\JJ\1740 man\NN\9605289 operated\VBD\2439501 for\IN\1740 acute\JJ\1740 cholecystitis\NN\14336539 under\IN\1740 <e1>methoxyflurane</e1>\JJ\1740 anesthesia\NN\14034177 developed\VBD\1753788 postoperatively\RB\1740 a\DT\13649268 <e2>hepatic\JJ\1740 insufficiency\NN\14462946 syndrome</e2>\NN\5870365 and\CC\1740 renal\JJ\1740 tubular\JJ\1740 acidosis\NN\14204950 .\.\1740
8819482
D002118_D017202 NONE Effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 <e1>calcium</e1>\NN\14625458 antagonist\NN\7846 ,\,\1740 CD-832\NN\1740 ,\,\1740 on\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 .\.\1740
D002118_D023921 NONE Effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 <e1>calcium</e1>\NN\14625458 antagonist\NN\7846 ,\,\1740 CD-832\NN\1740 ,\,\1740 on\IN\1740 isoproterenol-induced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 .\.\1740
C082828_D017202 NONE Effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 <e1>CD-832</e1>\NN\1740 ,\,\1740 on\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 .\.\1740
C082828_D017202 NONE Effects\NNS\13245626 of\IN\1740 <e1>CD-832</e1>\NN\1740 on\IN\1740 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
C082828_D017202 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 <e1>CD-832</e1>\NN\1740 improves\VBZ\126264 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 during\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 stenosis\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 CD-832\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 .\.\1740
C082828_D017202 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CD-832\NN\1740 improves\VBZ\126264 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 during\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 stenosis\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 <e1>CD-832</e1>\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 .\.\1740
C082828_D017202 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CD-832\NN\1740 improves\VBZ\126264 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 during\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 stenosis\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 CD-832\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CD-832</e1>\NN\1740 .\.\1740
C082828_D023921 NONE Effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 <e1>CD-832</e1>\NN\1740 ,\,\1740 on\IN\1740 isoproterenol-induced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 .\.\1740
C082828_D023921 NONE Effects\NNS\13245626 of\IN\1740 <e1>CD-832</e1>\NN\1740 on\IN\1740 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 myocardial\JJ\1740 ischemia\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D007545_D017202 CID Effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 CD-832\NN\1740 ,\,\1740 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 .\.\1740
D007545_D017202 CID Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D007545_D017202 CID Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 isoproterenol\NN\3740161 <e1>(ISO)-induced</e1>\VBN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D007545_D017202 CID These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CD-832\NN\1740 improves\VBZ\126264 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 during\IN\1740 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 with\IN\1740 stenosis\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 CD-832\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 .\.\1740
D007545_D023921 NONE Effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 calcium\NN\14625458 antagonist\NN\7846 ,\,\1740 CD-832\NN\1740 ,\,\1740 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 .\.\1740
D007545_D023921 NONE Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (ISO)-induced\VBN\1740 myocardial\JJ\1740 ischemia\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D007545_D023921 NONE Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 isoproterenol\NN\3740161 <e1>(ISO)-induced</e1>\VBN\1740 myocardial\JJ\1740 ischemia\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D007545_D023921 NONE In\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 stenosis</e2>\NN\14204950 ,\,\1740 3-min\JJ\1740 periods\NNS\13575869 of\IN\1740 intracoronary\JJ\1740 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 (\-LRB-\1740 10\CD\13745420 ng/kg/min\NN\1740 )\-RRB-\1740 increased\VBD\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 maximal\JJ\1740 rate\NN\13815152 of\IN\1740 left\JJ\1740 ventricular\JJ\1740 pressure\NN\11419404 rise\NN\7324673 ,\,\1740 which\WDT\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 percentage\NN\13815742 segmental\JJ\1740 shortening\NN\7672135 and\CC\1740 ST-segment\JJ\1740 elevation\NN\7445480 of\IN\1740 the\DT\1740 epicardial\JJ\1740 electrocardiogram\NN\7000195 .\.\1740
D009543_D017202 NONE Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 <e1>nifedipine</e1>\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D009543_D023921 NONE Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 myocardial\JJ\1740 ischemia\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 <e1>nifedipine</e1>\NN\2938514 or\CC\3541091 diltiazem\NN\2938514 .\.\1740
D004110_D017202 NONE Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 coronary\JJ\1740 stenosis\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 <e1>diltiazem</e1>\NN\2938514 .\.\1740
D004110_D023921 NONE Effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 on\IN\1740 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 myocardial\JJ\1740 ischemia\NN\14195315 were\VBD\836236 studied\VBN\630380 in\IN\13603305 dogs\NNS\2083346 with\IN\1740 partial\JJ\1740 <e2>coronary\JJ\1740 stenosis</e2>\NN\14204950 of\IN\1740 the\DT\1740 left\JJ\1740 circumflex\JJ\1740 coronary\JJ\1740 artery\NN\5417975 and\CC\1740 findings\NNS\7951464 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 for\IN\1740 nifedipine\NN\2938514 or\CC\3541091 <e1>diltiazem</e1>\NN\2938514 .\.\1740
D007545_D003251 NONE After\IN\1740 the\DT\1740 control\NN\5190804 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 was\VBD\836236 performed\VBN\2367363 ,\,\1740 equihypotensive\JJ\1740 doses\NNS\3740161 of\IN\1740 CD-832\NN\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 ,\,\1740 nifedipine\NN\2938514 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 diltiazem\NN\2938514 (\-LRB-\1740 10\CD\13745420 and\CC\1740 30\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 were\VBD\836236 infused\VBN\606335 5\CD\13741022 min\NN\15154774 before\IN\1740 and\CC\1740 during\IN\1740 the\DT\1740 second\JJ\1740 and\CC\1740 third\JJ\1740 ISO\NN\1740 infusion\NN\14589223 .\.\1740
D007545_D003251 NONE After\IN\1740 the\DT\1740 control\NN\5190804 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 was\VBD\836236 performed\VBN\2367363 ,\,\1740 equihypotensive\JJ\1740 doses\NNS\3740161 of\IN\1740 CD-832\NN\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 ,\,\1740 nifedipine\NN\2938514 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 diltiazem\NN\2938514 (\-LRB-\1740 10\CD\13745420 and\CC\1740 30\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 were\VBD\836236 infused\VBN\606335 5\CD\13741022 min\NN\15154774 before\IN\1740 and\CC\1740 during\IN\1740 the\DT\1740 second\JJ\1740 and\CC\1740 third\JJ\1740 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 .\.\1740
D007545_D003251 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 nifedipine\NN\2938514 ,\,\1740 CD-832\NN\1740 (\-LRB-\1740 10\CD\13745420 micrograms/kg/min\NN\1740 )\-RRB-\1740 prevented\VBD\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 percentage\NN\13815742 segmental\JJ\1740 shortening\NN\7672135 from\IN\1740 32\CD\1740 +/-\CC\1740 12\CD\13745420 %\NN\1740 to\TO\1740 115\CD\1740 +/-\CC\1740 26\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 value\NN\5856066 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 and\CC\1740 ST-segment\JJ\1740 elevation\NN\7445480 from\IN\1740 5.6\CD\1740 +/-\CC\1740 1.0\CD\1740 mV\NN\13634784 to\IN\1740 1.6\CD\1740 +/-\CC\1740 1.3\CD\1740 mV\NN\13634784 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 at\IN\14622893 3\CD\13741022 min\NN\15154774 after\IN\1740 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 .\.\1740
D007545_D003251 NONE Diltiazem\NNP\2938514 (\-LRB-\1740 30\CD\13745420 micrograms/kg/min\NN\1740 )\-RRB-\1740 also\RB\1740 prevented\VBD\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 percentage\NN\13815742 segmental\JJ\1740 shortening\NN\7672135 from\IN\1740 34\CD\1740 +/-\CC\1740 14\CD\13745420 %\NN\1740 to\TO\1740 63\CD\1740 +/-\CC\1740 18\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 value\NN\5856066 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 and\CC\1740 ST-segment\JJ\1740 elevation\NN\7445480 from\IN\1740 4.7\CD\1740 +/-\CC\1740 0.7\CD\1740 mV\NN\13634784 to\TO\1740 2.1\CD\1740 +/-\CC\1740 0.7\CD\1740 mV\NN\13634784 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 at\IN\14622893 3\CD\13741022 min\NN\15154774 after\IN\1740 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 .\.\1740
D007545_D003251 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CD-832\NN\1740 improves\VBZ\126264 myocardial\JJ\1740 ischemia\NN\14195315 during\IN\1740 <e1>ISO</e1>\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 CD-832\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 .\.\1740
C082828_D003251 NONE After\IN\1740 the\DT\1740 control\NN\5190804 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 was\VBD\836236 performed\VBN\2367363 ,\,\1740 equihypotensive\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>CD-832</e1>\NN\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 ,\,\1740 nifedipine\NN\2938514 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 diltiazem\NN\2938514 (\-LRB-\1740 10\CD\13745420 and\CC\1740 30\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 were\VBD\836236 infused\VBN\606335 5\CD\13741022 min\NN\15154774 before\IN\1740 and\CC\1740 during\IN\1740 the\DT\1740 second\JJ\1740 and\CC\1740 third\JJ\1740 ISO\NN\1740 infusion\NN\14589223 .\.\1740
C082828_D003251 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 nifedipine\NN\2938514 ,\,\1740 <e1>CD-832</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 micrograms/kg/min\NN\1740 )\-RRB-\1740 prevented\VBD\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 percentage\NN\13815742 segmental\JJ\1740 shortening\NN\7672135 from\IN\1740 32\CD\1740 +/-\CC\1740 12\CD\13745420 %\NN\1740 to\TO\1740 115\CD\1740 +/-\CC\1740 26\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 value\NN\5856066 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 and\CC\1740 ST-segment\JJ\1740 elevation\NN\7445480 from\IN\1740 5.6\CD\1740 +/-\CC\1740 1.0\CD\1740 mV\NN\13634784 to\IN\1740 1.6\CD\1740 +/-\CC\1740 1.3\CD\1740 mV\NN\13634784 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 at\IN\14622893 3\CD\13741022 min\NN\15154774 after\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 .\.\1740
C082828_D003251 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 <e1>CD-832</e1>\NN\1740 improves\VBZ\126264 myocardial\JJ\1740 ischemia\NN\14195315 during\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 CD-832\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 .\.\1740
C082828_D003251 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CD-832\NN\1740 improves\VBZ\126264 myocardial\JJ\1740 ischemia\NN\14195315 during\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 <e1>CD-832</e1>\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 CD-832\NN\1740 .\.\1740
C082828_D003251 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CD-832\NN\1740 improves\VBZ\126264 myocardial\JJ\1740 ischemia\NN\14195315 during\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 and\CC\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 negative\JJ\1740 chronotropic\JJ\1740 property\NN\32613 of\IN\1740 CD-832\NN\1740 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>CD-832</e1>\NN\1740 .\.\1740
D009543_D003251 NONE After\IN\1740 the\DT\1740 control\NN\5190804 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 was\VBD\836236 performed\VBN\2367363 ,\,\1740 equihypotensive\JJ\1740 doses\NNS\3740161 of\IN\1740 CD-832\NN\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 ,\,\1740 <e1>nifedipine</e1>\NN\2938514 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 diltiazem\NN\2938514 (\-LRB-\1740 10\CD\13745420 and\CC\1740 30\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 were\VBD\836236 infused\VBN\606335 5\CD\13741022 min\NN\15154774 before\IN\1740 and\CC\1740 during\IN\1740 the\DT\1740 second\JJ\1740 and\CC\1740 third\JJ\1740 ISO\NN\1740 infusion\NN\14589223 .\.\1740
D009543_D003251 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 <e1>nifedipine</e1>\NN\2938514 ,\,\1740 CD-832\NN\1740 (\-LRB-\1740 10\CD\13745420 micrograms/kg/min\NN\1740 )\-RRB-\1740 prevented\VBD\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 percentage\NN\13815742 segmental\JJ\1740 shortening\NN\7672135 from\IN\1740 32\CD\1740 +/-\CC\1740 12\CD\13745420 %\NN\1740 to\TO\1740 115\CD\1740 +/-\CC\1740 26\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 value\NN\5856066 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 and\CC\1740 ST-segment\JJ\1740 elevation\NN\7445480 from\IN\1740 5.6\CD\1740 +/-\CC\1740 1.0\CD\1740 mV\NN\13634784 to\IN\1740 1.6\CD\1740 +/-\CC\1740 1.3\CD\1740 mV\NN\13634784 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 at\IN\14622893 3\CD\13741022 min\NN\15154774 after\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 .\.\1740
D004110_D003251 NONE After\IN\1740 the\DT\1740 control\NN\5190804 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 was\VBD\836236 performed\VBN\2367363 ,\,\1740 equihypotensive\JJ\1740 doses\NNS\3740161 of\IN\1740 CD-832\NN\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 ,\,\1740 nifedipine\NN\2938514 (\-LRB-\1740 1\CD\13741022 and\CC\1740 3\CD\13741022 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 or\CC\3541091 <e1>diltiazem</e1>\NN\2938514 (\-LRB-\1740 10\CD\13745420 and\CC\1740 30\CD\13745420 micrograms/kg/min\NN\1740 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 were\VBD\836236 infused\VBN\606335 5\CD\13741022 min\NN\15154774 before\IN\1740 and\CC\1740 during\IN\1740 the\DT\1740 second\JJ\1740 and\CC\1740 third\JJ\1740 ISO\NN\1740 infusion\NN\14589223 .\.\1740
D004110_D003251 NONE <e1>Diltiazem</e1>\NNP\2938514 (\-LRB-\1740 30\CD\13745420 micrograms/kg/min\NN\1740 )\-RRB-\1740 also\RB\1740 prevented\VBD\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 percentage\NN\13815742 segmental\JJ\1740 shortening\NN\7672135 from\IN\1740 34\CD\1740 +/-\CC\1740 14\CD\13745420 %\NN\1740 to\TO\1740 63\CD\1740 +/-\CC\1740 18\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 value\NN\5856066 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .05\CD\1740 )\-RRB-\1740 and\CC\1740 ST-segment\JJ\1740 elevation\NN\7445480 from\IN\1740 4.7\CD\1740 +/-\CC\1740 0.7\CD\1740 mV\NN\13634784 to\TO\1740 2.1\CD\1740 +/-\CC\1740 0.7\CD\1740 mV\NN\13634784 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .01\CD\1740 )\-RRB-\1740 at\IN\14622893 3\CD\13741022 min\NN\15154774 after\IN\1740 ISO\NN\1740 infusion\NN\14589223 with\IN\1740 <e2>stenosis</e2>\NN\14204950 .\.\1740
12165618
D019469_-1 NONE Persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 in\IN\13603305 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>indinavir</e1>\NN\4013993 .\.\1740
D019469_-1 NONE A\DT\13649268 higher\JJR\1740 cumulative\JJ\1740 incidence\NN\13821570 of\IN\1740 persistent\JJ\1740 <e2>leukocyturia</e2>\NN\1740 was\VBD\836236 found\VBN\2426171 in\IN\13603305 children\NNS\9622049 with\IN\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 >\$\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 or\CC\3541091 a\DT\13649268 peak\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 <e1>indinavir</e1>\NN\4013993 >\$\1740 12\CD\13745420 mg/L.\NNS\1740 In\IN\13603305 4\CD\13741022 children\NNS\9622049 ,\,\1740 indinavir\NN\4013993 was\VBD\836236 discontinued\VBN\2609764 because\IN\1740 of\IN\1740 nephrotoxicity\NN\1740 .\.\1740
D019469_-1 NONE A\DT\13649268 higher\JJR\1740 cumulative\JJ\1740 incidence\NN\13821570 of\IN\1740 persistent\JJ\1740 <e2>leukocyturia</e2>\NN\1740 was\VBD\836236 found\VBN\2426171 in\IN\13603305 children\NNS\9622049 with\IN\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 >\$\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 or\CC\3541091 a\DT\13649268 peak\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 indinavir\NN\4013993 >\$\1740 12\CD\13745420 mg/L.\NNS\1740 In\IN\13603305 4\CD\13741022 children\NNS\9622049 ,\,\1740 <e1>indinavir</e1>\NN\4013993 was\VBD\836236 discontinued\VBN\2609764 because\IN\1740 of\IN\1740 nephrotoxicity\NN\1740 .\.\1740
D019469_-1 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>indinavir</e1>\NN\4013993 have\VBP\2108377 a\DT\13649268 high\JJ\1740 cumulative\JJ\1740 incidence\NN\13821570 of\IN\1740 persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 .\.\1740
D019469_-1 NONE <e1>Indinavir-associated</e1>\JJ\1740 nephrotoxicity\NN\1740 must\MD\9367203 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 ,\,\1740 especially\RB\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 such\JJ\1740 as\IN\14622893 persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 ,\,\1740 age\NN\4916342 <\NN\1740 5.6\CD\1740 years\NNS\15144371 ,\,\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 of\IN\1740 indinavir\NN\4013993 >\NNS\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 ,\,\1740 and\CC\1740 a\DT\13649268 C(max\NN\1740 )\-RRB-\1740 >\NN\1740 12\CD\13745420 mg/L.\NNS\1740
D019469_-1 NONE Indinavir-associated\JJ\1740 nephrotoxicity\NN\1740 must\MD\9367203 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 ,\,\1740 especially\RB\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 such\JJ\1740 as\IN\14622893 persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 ,\,\1740 age\NN\4916342 <\NN\1740 5.6\CD\1740 years\NNS\15144371 ,\,\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 of\IN\1740 <e1>indinavir</e1>\NN\4013993 >\NNS\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 ,\,\1740 and\CC\1740 a\DT\13649268 C(max\NN\1740 )\-RRB-\1740 >\NN\1740 12\CD\13745420 mg/L.\NNS\1740
D019469_D007674 CID Persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>impaired\JJ\1740 renal\JJ\1740 function</e2>\NN\13783581 in\IN\13603305 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>indinavir</e1>\NN\4013993 .\.\1740
D019469_D007674 CID DESIGN\NN\927261 :\:\1740 A\DT\13649268 prospective\JJ\1740 study\NN\635850 to\TO\1740 monitor\VB\2169352 <e1>indinavir-related</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 a\DT\13649268 cohort\NN\8184861 of\IN\1740 30\CD\13745420 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 indinavir\NN\4013993 .\.\1740
D019469_D007674 CID DESIGN\NN\927261 :\:\1740 A\DT\13649268 prospective\JJ\1740 study\NN\635850 to\TO\1740 monitor\VB\2169352 indinavir-related\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 a\DT\13649268 cohort\NN\8184861 of\IN\1740 30\CD\13745420 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>indinavir</e1>\NN\4013993 .\.\1740
D019469_D007674 CID A\DT\13649268 higher\JJR\1740 cumulative\JJ\1740 incidence\NN\13821570 of\IN\1740 persistent\JJ\1740 leukocyturia\NN\1740 was\VBD\836236 found\VBN\2426171 in\IN\13603305 children\NNS\9622049 with\IN\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 >\$\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 or\CC\3541091 a\DT\13649268 peak\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 <e1>indinavir</e1>\NN\4013993 >\$\1740 12\CD\13745420 mg/L.\NNS\1740 In\IN\13603305 4\CD\13741022 children\NNS\9622049 ,\,\1740 indinavir\NN\4013993 was\VBD\836236 discontinued\VBN\2609764 because\IN\1740 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D019469_D007674 CID A\DT\13649268 higher\JJR\1740 cumulative\JJ\1740 incidence\NN\13821570 of\IN\1740 persistent\JJ\1740 leukocyturia\NN\1740 was\VBD\836236 found\VBN\2426171 in\IN\13603305 children\NNS\9622049 with\IN\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 >\$\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 or\CC\3541091 a\DT\13649268 peak\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 indinavir\NN\4013993 >\$\1740 12\CD\13745420 mg/L.\NNS\1740 In\IN\13603305 4\CD\13741022 children\NNS\9622049 ,\,\1740 <e1>indinavir</e1>\NN\4013993 was\VBD\836236 discontinued\VBN\2609764 because\IN\1740 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D019469_D007674 CID <e1>Indinavir-associated</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 must\MD\9367203 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 ,\,\1740 especially\RB\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 such\JJ\1740 as\IN\14622893 persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 ,\,\1740 age\NN\4916342 <\NN\1740 5.6\CD\1740 years\NNS\15144371 ,\,\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 of\IN\1740 indinavir\NN\4013993 >\NNS\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 ,\,\1740 and\CC\1740 a\DT\13649268 C(max\NN\1740 )\-RRB-\1740 >\NN\1740 12\CD\13745420 mg/L.\NNS\1740
D019469_D007674 CID Indinavir-associated\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 must\MD\9367203 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 ,\,\1740 especially\RB\1740 in\IN\13603305 children\NNS\9622049 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 such\JJ\1740 as\IN\14622893 persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 ,\,\1740 age\NN\4916342 <\NN\1740 5.6\CD\1740 years\NNS\15144371 ,\,\1740 an\DT\6697703 area\NN\8630985 under\IN\1740 the\DT\1740 curve\NN\13863771 of\IN\1740 <e1>indinavir</e1>\NN\4013993 >\NNS\1740 19\CD\13745420 mg/L\NN\1740 x\NN\13745420 h\NN\14622893 ,\,\1740 and\CC\1740 a\DT\13649268 C(max\NN\1740 )\-RRB-\1740 >\NN\1740 12\CD\13745420 mg/L.\NNS\1740
D019469_D015658 NONE Persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 in\IN\13603305 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected</e2>\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>indinavir</e1>\NN\4013993 .\.\1740
D019469_D015658 NONE DESIGN\NN\927261 :\:\1740 A\DT\13649268 prospective\JJ\1740 study\NN\635850 to\TO\1740 monitor\VB\2169352 <e1>indinavir-related</e1>\JJ\1740 nephrotoxicity\NN\1740 in\IN\13603305 a\DT\13649268 cohort\NN\8184861 of\IN\1740 30\CD\13745420 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected</e2>\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 indinavir\NN\4013993 .\.\1740
D019469_D015658 NONE DESIGN\NN\927261 :\:\1740 A\DT\13649268 prospective\JJ\1740 study\NN\635850 to\TO\1740 monitor\VB\2169352 indinavir-related\JJ\1740 nephrotoxicity\NN\1740 in\IN\13603305 a\DT\13649268 cohort\NN\8184861 of\IN\1740 30\CD\13745420 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 type\NN\5839024 1-infected</e2>\JJ\1740 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>indinavir</e1>\NN\4013993 .\.\1740
D003404_-1 NONE Persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 was\VBD\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 a\DT\13649268 mild\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 urine\NN\14853947 <e1>albumin/creatinine</e1>\NN\1740 ratio\NN\13815152 and\CC\1740 by\IN\1740 microscopic\JJ\1740 hematuria\NN\14299637 .\.\1740
D003404_-1 NONE Children\NNS\9622049 with\IN\1740 persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 more\RBR\1740 frequently\RB\1740 had\VBD\2108377 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 of\IN\1740 50\CD\13745420 %\NN\1740 above\IN\6392001 normal\JJ\1740 than\IN\1740 those\DT\1740 children\NNS\9622049 without\IN\1740 persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 .\.\1740
D003404_-1 NONE Children\NNS\9622049 with\IN\1740 persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 more\RBR\1740 frequently\RB\1740 had\VBD\2108377 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 of\IN\1740 50\CD\13745420 %\NN\1740 above\IN\6392001 normal\JJ\1740 than\IN\1740 those\DT\1740 children\NNS\9622049 without\IN\1740 persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 .\.\1740
D003404_-1 NONE Subsequently\RB\1740 ,\,\1740 the\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 decreased\VBD\169651 ,\,\1740 the\DT\1740 urine\NN\14853947 albumin/creatinine\NN\1740 ratios\NNS\13815152 returned\VBD\1835496 to\IN\1740 zero\CD\13576982 ,\,\1740 and\CC\1740 the\DT\1740 <e2>leukocyturia</e2>\NN\1740 disappeared\VBD\2609764 within\IN\1740 3\CD\13741022 months\NNS\15113229 .\.\1740
D003404_-1 NONE Subsequently\RB\1740 ,\,\1740 the\DT\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 decreased\VBD\169651 ,\,\1740 the\DT\1740 urine\NN\14853947 <e1>albumin/creatinine</e1>\NN\1740 ratios\NNS\13815152 returned\VBD\1835496 to\IN\1740 zero\CD\13576982 ,\,\1740 and\CC\1740 the\DT\1740 <e2>leukocyturia</e2>\NN\1740 disappeared\VBD\2609764 within\IN\1740 3\CD\13741022 months\NNS\15113229 .\.\1740
D003404_-1 NONE Children\NNS\9622049 with\IN\1740 persistent\JJ\1740 sterile\JJ\1740 <e2>leukocyturia</e2>\NN\1740 more\RBR\1740 frequently\RB\1740 had\VBD\2108377 an\DT\6697703 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 of\IN\1740 >\NN\1740 50\CD\13745420 %\NN\1740 above\IN\6392001 normal\JJ\1740 .\.\1740
D003404_D006417 NONE Persistent\JJ\1740 sterile\JJ\1740 leukocyturia\NN\1740 was\VBD\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 a\DT\13649268 mild\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 urine\NN\14853947 <e1>albumin/creatinine</e1>\NN\1740 ratio\NN\13815152 and\CC\1740 by\IN\1740 microscopic\JJ\1740 <e2>hematuria</e2>\NN\14299637 .\.\1740
16083708
D001663_D017114 NONE Factors\NNS\7326557 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>fulminant\JJ\1740 hepatic\JJ\1740 failure</e2>\NN\66216 were\VBD\836236 female\JJ\1740 sex\NN\13440063 (\-LRB-\1740 OR\NN\3541091 =\JJ\1740 25\CD\13745420 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 4.1\CD\1740 -\SYM\1740 151\CD\1740 ;\:\1740 P\NN\14622893 <\XX\1740 .0001\CD\1740 )\-RRB-\1740 ,\,\1740 hepatocellular\JJ\1740 damage\NN\7296428 (\-LRB-\1740 OR\NN\3541091 =\JJ\1740 7.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 1.6\CD\1740 -\SYM\1740 37\CD\1740 ;\:\1740 P\NN\14622893 <\XX\1740 .009\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 higher\JJR\1740 baseline\NN\7260623 plasma\NN\5398023 <e1>bilirubin</e1>\NN\14756039 value\NN\5856066 (\-LRB-\1740 OR\NN\3541091 =\JJ\1740 1.15\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 1.09\CD\1740 -\SYM\1740 1.22\CD\1740 ;\:\1740 P\NN\14622893 <\XX\1740 .0001\CD\1740 )\-RRB-\1740 .\.\1740
D019980_D056486 CID <e1>Amoxicillin-clavulanate</e1>\NN\1740 stands\VBZ\1545883 out\RP\1740 as\IN\14622893 the\DT\1740 most\RBS\1740 common\JJ\1740 drug\NN\14778436 related\JJ\1740 to\TO\1740 <e2>DILI</e2>\NN\1740 .\.\1740
23872883
D007545_D066126 CID The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 Solidago\NNP\11579418 virgaurea\NN\1740 extract\NN\14589223 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
3833372
D013999_D006973 NONE A\DT\13649268 postmarketing\NN\1740 surveillance\NN\635012 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 a\DT\13649268 fixed-ratio\JJ\1740 combination\NN\7951464 containing\VBG\2632940 10\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>timolol\CD\2832168 maleate</e1>\NN\2718811 and\CC\1740 25\CD\13745420 mg\NN\13717155 of\IN\1740 hydrochlorothiazide\NN\4423288 ,\,\1740 administered\VBN\2436349 twice\RB\1740 daily\RB\1740 for\IN\1740 one\CD\13741022 month\NN\15113229 to\IN\1740 <e2>hypertensive</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D006852_D006973 NONE A\DT\13649268 postmarketing\NN\1740 surveillance\NN\635012 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 a\DT\13649268 fixed-ratio\JJ\1740 combination\NN\7951464 containing\VBG\2632940 10\CD\13745420 mg\NN\13717155 of\IN\1740 timolol\CD\2832168 maleate\NN\2718811 and\CC\1740 25\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>hydrochlorothiazide</e1>\NN\4423288 ,\,\1740 administered\VBN\2436349 twice\RB\1740 daily\RB\1740 for\IN\1740 one\CD\13741022 month\NN\15113229 to\IN\1740 <e2>hypertensive</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
25041770
D019821_D012206 CID <e2>Rhabdomyolysis</e2>\NN\1740 in\IN\13603305 association\NN\8008335 with\IN\1740 <e1>simvastatin</e1>\NN\3676175 and\CC\1740 dosage\NN\13576355 increment\NN\29677 in\IN\13603305 clarithromycin\NN\1740 .\.\1740
D019821_D012206 CID Our\PRP$\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 troponin\NN\1740 elevation\NN\7445480 could\MD\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 <e1>statin</e1>\NN\3740161 induced\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 warrant\VB\1012073 further\JJ\1740 studies\NNS\635850 .\.\1740
D017291_D012206 CID <e2>Rhabdomyolysis</e2>\NN\1740 in\IN\13603305 association\NN\8008335 with\IN\1740 simvastatin\NN\3676175 and\CC\1740 dosage\NN\13576355 increment\NN\29677 in\IN\13603305 <e1>clarithromycin</e1>\NN\1740 .\.\1740
D017291_D012206 CID This\DT\1740 particular\JJ\1740 case\NN\7283608 is\VBZ\836236 of\IN\1740 interest\NN\5682570 as\IN\14622893 <e2>rhabdomyolysis</e2>\NN\1740 only\RB\1740 occurred\VBD\2623529 after\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>clarithromycin</e1>\NN\1740 .\.\1740
11835460
D007980_D015835 CID <e1>Levodopa-induced</e1>\JJ\1740 <e2>ocular\JJ\1740 dyskinesias</e2>\NNS\14084880 in\IN\13603305 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D015835 CID <e1>Levodopa-induced</e1>\JJ\1740 <e2>ocular\JJ\1740 dyskinesias</e2>\NNS\14084880 are\VBP\836236 very\RB\1740 uncommon\JJ\1740 .\.\1740
D007980_D015835 CID We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 leftward\NN\1740 and\CC\1740 upward\JJ\1740 deviations\NNS\7337390 of\IN\1740 gaze\NN\878456 during\IN\1740 the\DT\1740 peak\NN\13758296 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 ,\,\1740 and\CC\1740 hypothesize\VB\719734 that\IN\1740 a\DT\13649268 severe\JJ\1740 dopaminergic\JJ\1740 denervation\NN\1740 in\IN\13603305 the\DT\1740 caudate\NN\5497363 nucleus\NN\5445668 is\VBZ\836236 needed\VBN\2604760 for\IN\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 these\DT\1740 levodopa-induce\JJ\1740 <e2>ocular\JJ\1740 dyskinesias</e2>\NNS\14084880 .\.\1740
D007980_D015835 CID We\PRP\1740 report\VBP\831651 on\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 leftward\NN\1740 and\CC\1740 upward\JJ\1740 deviations\NNS\7337390 of\IN\1740 gaze\NN\878456 during\IN\1740 the\DT\1740 peak\NN\13758296 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 ,\,\1740 and\CC\1740 hypothesize\VB\719734 that\IN\1740 a\DT\13649268 severe\JJ\1740 dopaminergic\JJ\1740 denervation\NN\1740 in\IN\13603305 the\DT\1740 caudate\NN\5497363 nucleus\NN\5445668 is\VBZ\836236 needed\VBN\2604760 for\IN\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 these\DT\1740 <e1>levodopa-induce</e1>\JJ\1740 <e2>ocular\JJ\1740 dyskinesias</e2>\NNS\14084880 .\.\1740
D007980_D010300 NONE <e1>Levodopa-induced</e1>\JJ\1740 ocular\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
9759693
D018170_D017091 CID <e2>Ischemic\JJ\1740 colitis</e2>\NN\14336539 and\CC\1740 <e1>sumatriptan</e1>\JJ\1740 use\NN\407535 .\.\1740
D018170_D017091 CID We\PRP\1740 report\VBP\831651 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 8\CD\13741022 serious\JJ\1740 cases\NNS\7283608 of\IN\1740 <e2>ischemic\JJ\1740 colitis</e2>\NN\14336539 in\IN\13603305 patients\NNS\9898892 with\IN\1740 migraine\NN\14326607 treated\VBN\2376958 with\IN\1740 <e1>sumatriptan</e1>\NN\1740 .\.\1740
D018170_D003329 NONE Cases\NNS\7283608 have\VBP\2108377 been\VBN\836236 published\VBN\1621555 of\IN\1740 <e2>coronary\JJ\1740 vasospasm</e2>\NN\1740 ,\,\1740 myocardial\JJ\1740 ischemia\NN\14195315 ,\,\1740 and\CC\1740 myocardial\JJ\1740 infarction\NN\14204950 occurring\VBG\2623529 after\IN\1740 <e1>sumatriptan</e1>\JJ\1740 use\NN\407535 .\.\1740
D018170_D017202 NONE Cases\NNS\7283608 have\VBP\2108377 been\VBN\836236 published\VBN\1621555 of\IN\1740 coronary\JJ\1740 vasospasm\NN\1740 ,\,\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 ,\,\1740 and\CC\1740 myocardial\JJ\1740 infarction\NN\14204950 occurring\VBG\2623529 after\IN\1740 <e1>sumatriptan</e1>\JJ\1740 use\NN\407535 .\.\1740
D018170_D009203 NONE Cases\NNS\7283608 have\VBP\2108377 been\VBN\836236 published\VBN\1621555 of\IN\1740 coronary\JJ\1740 vasospasm\NN\1740 ,\,\1740 myocardial\JJ\1740 ischemia\NN\14195315 ,\,\1740 and\CC\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 occurring\VBG\2623529 after\IN\1740 <e1>sumatriptan</e1>\JJ\1740 use\NN\407535 .\.\1740
D018170_D008881 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 8\CD\13741022 serious\JJ\1740 cases\NNS\7283608 of\IN\1740 ischemic\JJ\1740 colitis\NN\14336539 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>migraine</e2>\NN\14326607 treated\VBN\2376958 with\IN\1740 <e1>sumatriptan</e1>\NN\1740 .\.\1740
9382023
D004280_D006973 CID <e2>Hypertensive</e2>\JJ\1740 response\NN\11410625 during\IN\1740 <e1>dobutamine</e1>\NN\1740 stress\NN\7083732 echocardiography\NN\177127 .\.\1740
D004280_D006973 CID Among\IN\1740 3,129\CD\1740 <e1>dobutamine</e1>\NN\1740 stress\NN\7083732 echocardiographic\JJ\1740 studies\NNS\635850 ,\,\1740 a\DT\13649268 <e2>hypertensive</e2>\JJ\1740 response\NN\11410625 ,\,\1740 defined\VBN\2604760 as\IN\14622893 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 220\CD\1740 mm\NN\13649268 Hg\NN\14625458 and/or\CC\1740 diastolic\JJ\1740 BP\NN\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 110\CD\1740 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 occurred\VBD\2623529 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 1\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D004280_D006973 CID Patients\NNS\9898892 with\IN\1740 this\DT\1740 response\NN\11410625 more\RBR\1740 often\RB\1740 had\VBD\2108377 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 had\VBD\2108377 higher\JJR\1740 resting\VBG\2604760 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 BP\NN\1740 before\IN\1740 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 .\.\1740
9125676
D013015_-1 NONE Efficacy\NNP\5199286 and\CC\1740 <e2>proarrhythmia</e2>\VB\1740 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 for\IN\1740 sustained\JJ\1740 ventricular\JJ\1740 tachyarrhythmias\NNS\1740 .\.\1740
D013015_D017180 NONE Efficacy\NNP\5199286 and\CC\1740 proarrhythmia\VB\1740 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 for\IN\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachyarrhythmias</e2>\NNS\1740 .\.\1740
D013015_D017180 NONE This\DT\1740 study\NN\635850 prospectively\RB\1740 evaluated\VBD\670261 the\DT\1740 clinical\JJ\1740 efficacy\NN\5199286 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 ,\,\1740 and\CC\1740 the\DT\1740 presumable\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 for\IN\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachyarrhythmias</e2>\NNS\1740 .\.\1740
D013015_D017180 NONE Eighty-one\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 54\CD\1740 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 and\CC\1740 20\CD\13745420 with\IN\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 )\-RRB-\1740 with\IN\1740 inducible\JJ\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 received\VBD\2210855 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 to\TO\1740 prevent\VB\1740 induction\NN\7450842 of\IN\1740 the\DT\1740 ventricular\JJ\1740 tachyarrhythmia\NN\1740 .\.\1740
D013015_D017180 NONE Eighty-one\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 54\CD\1740 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 and\CC\1740 20\CD\13745420 with\IN\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 )\-RRB-\1740 with\IN\1740 inducible\JJ\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 received\VBD\2210855 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 to\TO\1740 prevent\VB\1740 induction\NN\7450842 of\IN\1740 the\DT\1740 <e2>ventricular\JJ\1740 tachyarrhythmia</e2>\NN\1740 .\.\1740
D013015_D017180 NONE Those\DT\1740 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 prevented\VBD\1740 induction\NN\7450842 of\IN\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 were\VBD\836236 discharged\VBN\1640855 with\IN\1740 the\DT\1740 drug\NN\14778436 and\CC\1740 followed\VBD\1835496 up\RP\1740 on\IN\1740 an\DT\6697703 outpatient\JJ\1740 basis\NN\13790712 for\IN\1740 21\CD\13745420 +/-\CC\1740 18\CD\13745420 months\NNS\15113229 .\.\1740
D013015_D017180 NONE Induction\NN\7450842 of\IN\1740 the\DT\1740 <e2>ventricular\NN\1740 tachyarrhythmia</e2>\NN\1740 was\VBD\836236 prevented\VBN\1740 by\IN\1740 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 in\IN\13603305 35\CD\1740 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 the\DT\1740 ventricular\JJ\1740 tachyarrhythmia\NN\1740 remained\VBD\2604760 inducible\JJ\1740 in\IN\13603305 40\CD\13745420 (\-LRB-\1740 49\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 and\CC\1740 two\CD\13741022 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 did\VBD\1640855 not\RB\1740 tolerate\VB\802318 even\RB\1740 40\CD\13745420 mg\NN\13717155 of\IN\1740 d\NN\15089472 ,\,\1740 l-sotalol\NN\1740 once\RB\1740 daily\RB\1740 .\.\1740
D013015_D017180 NONE Induction\NN\7450842 of\IN\1740 the\DT\1740 ventricular\NN\1740 tachyarrhythmia\NN\1740 was\VBD\836236 prevented\VBN\1740 by\IN\1740 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 in\IN\13603305 35\CD\1740 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 the\DT\1740 <e2>ventricular\JJ\1740 tachyarrhythmia</e2>\NN\1740 remained\VBD\2604760 inducible\JJ\1740 in\IN\13603305 40\CD\13745420 (\-LRB-\1740 49\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 and\CC\1740 two\CD\13741022 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 did\VBD\1640855 not\RB\1740 tolerate\VB\802318 even\RB\1740 40\CD\13745420 mg\NN\13717155 of\IN\1740 d\NN\15089472 ,\,\1740 l-sotalol\NN\1740 once\RB\1740 daily\RB\1740 .\.\1740
D013015_D017180 NONE Induction\NN\7450842 of\IN\1740 the\DT\1740 <e2>ventricular\NN\1740 tachyarrhythmia</e2>\NN\1740 was\VBD\836236 prevented\VBN\1740 by\IN\1740 oral\JJ\1740 d\NN\15089472 ,\,\1740 l-sotalol\NN\1740 in\IN\13603305 35\CD\1740 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 the\DT\1740 ventricular\JJ\1740 tachyarrhythmia\NN\1740 remained\VBD\2604760 inducible\JJ\1740 in\IN\13603305 40\CD\13745420 (\-LRB-\1740 49\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 and\CC\1740 two\CD\13741022 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 did\VBD\1640855 not\RB\1740 tolerate\VB\802318 even\RB\1740 40\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 once\RB\1740 daily\RB\1740 .\.\1740
D013015_D017180 NONE Induction\NN\7450842 of\IN\1740 the\DT\1740 ventricular\NN\1740 tachyarrhythmia\NN\1740 was\VBD\836236 prevented\VBN\1740 by\IN\1740 oral\JJ\1740 d\NN\15089472 ,\,\1740 l-sotalol\NN\1740 in\IN\13603305 35\CD\1740 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 the\DT\1740 <e2>ventricular\JJ\1740 tachyarrhythmia</e2>\NN\1740 remained\VBD\2604760 inducible\JJ\1740 in\IN\13603305 40\CD\13745420 (\-LRB-\1740 49\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 ;\:\1740 and\CC\1740 two\CD\13741022 (\-LRB-\1740 2.5\CD\1740 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 did\VBD\1640855 not\RB\1740 tolerate\VB\802318 even\RB\1740 40\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 once\RB\1740 daily\RB\1740 .\.\1740
D013015_D016171 CID This\DT\1740 study\NN\635850 prospectively\RB\1740 evaluated\VBD\670261 the\DT\1740 clinical\JJ\1740 efficacy\NN\5199286 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 ,\,\1740 and\CC\1740 the\DT\1740 presumable\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 for\IN\1740 sustained\JJ\1740 ventricular\JJ\1740 tachyarrhythmias\NNS\1740 .\.\1740
D013015_D016171 CID This\DT\1740 study\NN\635850 prospectively\RB\1740 evaluated\VBD\670261 the\DT\1740 clinical\JJ\1740 efficacy\NN\5199286 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 ,\,\1740 and\CC\1740 the\DT\1740 presumable\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 for\IN\1740 sustained\JJ\1740 ventricular\JJ\1740 tachyarrhythmias\NNS\1740 .\.\1740
D013015_D016171 CID Four\CD\13741022 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 had\VBD\2108377 from\IN\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 during\IN\1740 the\DT\1740 initial\JJ\1740 oral\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 .\.\1740
D013015_D016171 CID However\RB\1740 ,\,\1740 the\DT\1740 oral\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 200\CD\1740 +/-\CC\1740 46\CD\1740 vs.\CC\1740 328\CD\1740 +/-\CC\1740 53\CD\1740 mg/day\NN\1740 ;\:\1740 p\NN\14622893 =\JJ\1740 0.0017\CD\1740 )\-RRB-\1740 .\.\1740
D013015_D016171 CID One\CD\13741022 female\JJ\1740 patient\NN\9898892 with\IN\1740 stable\JJ\1740 cardiac\JJ\1740 disease\NN\14061805 had\VBD\2108377 recurrent\JJ\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 after\IN\1740 2\CD\13741022 years\NNS\15144371 of\IN\1740 successful\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 .\.\1740
D013015_D016171 CID <e2>Torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 occurred\VBD\2623529 early\JJ\1740 during\IN\1740 treatment\NN\654885 even\RB\1740 with\IN\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 .\.\1740
D013015_D016171 CID Pronounced\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 surface\NN\21939 ECG\NN\7000195 (\-LRB-\1740 cycle\NN\15269513 length\NN\5093581 ,\,\1740 QT\NN\1740 ,\,\1740 and\CC\1740 QTc\NNS\1740 )\-RRB-\1740 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 might\MD\5029706 identify\VB\699815 a\DT\13649268 subgroup\NN\31264 of\IN\1740 patients\NNS\9898892 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 .\.\1740
D013015_D016171 CID Other\JJ\1740 ECG\NN\7000195 parameters\NNS\5858936 before\IN\1740 the\DT\1740 application\NN\947128 of\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 did\VBD\1640855 not\RB\1740 identify\VB\699815 patients\NNS\9898892 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 .\.\1740
D013015_D003324 NONE Eighty-one\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 54\CD\1740 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 ,\,\1740 and\CC\1740 20\CD\13745420 with\IN\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 )\-RRB-\1740 with\IN\1740 inducible\JJ\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 received\VBD\2210855 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 to\TO\1740 prevent\VB\1740 induction\NN\7450842 of\IN\1740 the\DT\1740 ventricular\JJ\1740 tachyarrhythmia\NN\1740 .\.\1740
D013015_D002311 NONE Eighty-one\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 54\CD\1740 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 and\CC\1740 20\CD\13745420 with\IN\1740 <e2>dilated\VBN\303465 cardiomyopathy</e2>\JJ\1740 )\-RRB-\1740 with\IN\1740 inducible\JJ\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 received\VBD\2210855 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 to\TO\1740 prevent\VB\1740 induction\NN\7450842 of\IN\1740 the\DT\1740 ventricular\JJ\1740 tachyarrhythmia\NN\1740 .\.\1740
D013015_D014693 NONE Eighty-one\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 54\CD\1740 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 and\CC\1740 20\CD\13745420 with\IN\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 )\-RRB-\1740 with\IN\1740 inducible\JJ\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 received\VBD\2210855 oral\JJ\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 to\TO\1740 prevent\VB\1740 induction\NN\7450842 of\IN\1740 the\DT\1740 ventricular\JJ\1740 tachyarrhythmia\NN\1740 .\.\1740
D013015_D014693 NONE Those\DT\1740 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 prevented\VBD\1740 induction\NN\7450842 of\IN\1740 ventricular\JJ\1740 tachycardia\NN\14110674 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 were\VBD\836236 discharged\VBN\1640855 with\IN\1740 the\DT\1740 drug\NN\14778436 and\CC\1740 followed\VBD\1835496 up\RP\1740 on\IN\1740 an\DT\6697703 outpatient\JJ\1740 basis\NN\13790712 for\IN\1740 21\CD\13745420 +/-\CC\1740 18\CD\13745420 months\NNS\15113229 .\.\1740
D013015_D006331 NONE One\CD\13741022 female\JJ\1740 patient\NN\9898892 with\IN\1740 stable\JJ\1740 <e2>cardiac\JJ\1740 disease</e2>\NN\14061805 had\VBD\2108377 recurrent\JJ\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 after\IN\1740 2\CD\13741022 years\NNS\15144371 of\IN\1740 successful\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>d\NN\15089472 ,\,\1740 l-sotalol</e1>\NN\1740 .\.\1740
1735570
D014294_D007022 CID The\DT\1740 <e1>trimethaphan-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 significant\JJ\1740 bradycardia\NN\14110674 in\IN\13603305 lesioned\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 -32\CD\1740 +/-\CC\1740 13\CD\13745420 beats\NNS\8289449 per\IN\1740 minute\NN\15154774 )\-RRB-\1740 but\CC\1740 a\DT\13649268 tachycardia\NN\14110674 in\IN\13603305 sham\NN\3562126 rats\NNS\2329401 (\-LRB-\1740 +\CC\1740 33\CD\1740 +/-\CC\1740 12\CD\13745420 beats\NNS\8289449 per\IN\1740 minute\NN\15154774 )\-RRB-\1740 1\CD\13741022 day\NN\15154774 postlesion\NN\1740 .\.\1740
D014294_D001919 NONE The\DT\1740 <e1>trimethaphan-induced</e1>\JJ\1740 hypotension\NN\14057371 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 significant\JJ\1740 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 lesioned\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 -32\CD\1740 +/-\CC\1740 13\CD\13745420 beats\NNS\8289449 per\IN\1740 minute\NN\15154774 )\-RRB-\1740 but\CC\1740 a\DT\13649268 tachycardia\NN\14110674 in\IN\13603305 sham\NN\3562126 rats\NNS\2329401 (\-LRB-\1740 +\CC\1740 33\CD\1740 +/-\CC\1740 12\CD\13745420 beats\NNS\8289449 per\IN\1740 minute\NN\15154774 )\-RRB-\1740 1\CD\13741022 day\NN\15154774 postlesion\NN\1740 .\.\1740
D014294_D013610 CID The\DT\1740 <e1>trimethaphan-induced</e1>\JJ\1740 hypotension\NN\14057371 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 significant\JJ\1740 bradycardia\NN\14110674 in\IN\13603305 lesioned\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 -32\CD\1740 +/-\CC\1740 13\CD\13745420 beats\NNS\8289449 per\IN\1740 minute\NN\15154774 )\-RRB-\1740 but\CC\1740 a\DT\13649268 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 sham\NN\3562126 rats\NNS\2329401 (\-LRB-\1740 +\CC\1740 33\CD\1740 +/-\CC\1740 12\CD\13745420 beats\NNS\8289449 per\IN\1740 minute\NN\15154774 )\-RRB-\1740 1\CD\13741022 day\NN\15154774 postlesion\NN\1740 .\.\1740
20169779
D015632_D010302 NONE Neuropsychiatric\JJ\1740 behaviors\NNS\407535 in\IN\13603305 the\DT\1740 <e1>MPTP</e1>\NN\1740 marmoset\NN\2489589 model\NN\5888929 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D015632_D010302 NONE The\DT\1740 levodopa-treated\JJ\1740 <e1>MPTP-lesioned</e1>\JJ\1740 marmoset\NN\2489589 was\VBD\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 model\NN\5888929 of\IN\1740 neuropsychiatric\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 .\.\1740
D015632_D010302 NONE METHODS\NNS\5616786 :\:\1740 Marmosets\NNS\2489589 were\VBD\836236 administered\VBN\2436349 <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>\CD\1740 (\-LRB-\1740 2.0\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 for\IN\1740 five\CD\13741022 days\NNS\15140892 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 stable\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 .\.\1740
D007980_D001523 NONE The\DT\1740 <e1>levodopa-treated</e1>\JJ\1740 MPTP-lesioned\JJ\1740 marmoset\NN\2489589 was\VBD\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 model\NN\5888929 of\IN\1740 <e2>neuropsychiatric\JJ\1740 symptoms</e2>\NNS\5823932 in\IN\13603305 PD\NN\14625458 patients\NNS\9898892 .\.\1740
D007980_D001523 NONE Here\RB\1740 we\PRP\1740 compare\VBP\644583 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 motor\NN\3699975 fluctuations\NNS\7345593 and\CC\1740 <e2>neuropsychiatric-like\JJ\1740 behaviors</e2>\NNS\407535 to\TO\1740 determine\VB\1645601 the\DT\1740 relationship\NN\31921 between\IN\1740 duration\NN\15113229 of\IN\1740 treatment\NN\654885 and\CC\1740 onset\NN\7325190 of\IN\1740 symptoms\NNS\5823932 .\.\1740
D007980_D001523 NONE Animals\NNS\4475 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 parkinsonian\JJ\1740 disability\NN\14547369 ,\,\1740 dyskinesia\NN\14084880 and\CC\1740 on-time\NN\1740 (\-LRB-\1740 motor\NN\3699975 fluctuations\NNS\7345593 )\-RRB-\1740 and\CC\1740 <e2>neuropsychiatric-like\JJ\1740 behaviors</e2>\NNS\407535 on\IN\1740 Day\NN\15154774 0\CD\13741022 (\-LRB-\1740 prior\JJ\1740 to\TO\1740 <e1>levodopa</e1>\NN\14604959 )\-RRB-\1740 and\CC\1740 on\IN\1740 Days\NNS\15140892 1\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 13\CD\13745420 ,\,\1740 27\CD\13745420 and\CC\1740 30\CD\13745420 of\IN\1740 treatment\NN\654885 using\VBG\1156834 post\NN\8621598 hoc\NN\1740 DVD\NN\3851787 analysis\NN\633864 by\IN\1740 a\DT\13649268 trained\VBN\829107 rater\NN\1740 ,\,\1740 blind\JJ\1740 to\IN\1740 the\DT\1740 treatment\NN\654885 day\NN\15154774 .\.\1740
D007980_D001523 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>neuropsychiatric-like\JJ\1740 behaviors</e2>\NNS\407535 were\VBD\836236 present\JJ\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 of\IN\1740 levodopa\NN\14604959 treatment\NN\654885 and\CC\1740 their\PRP$\1740 severity\NN\5036394 did\VBD\1640855 not\RB\1740 correlate\VB\2657219 with\IN\1740 duration\NN\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D007980_D001523 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 levodopa-induced\JJ\1740 <e2>neuropsychiatric-like\JJ\1740 behaviors</e2>\NNS\407535 were\VBD\836236 present\JJ\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 of\IN\1740 <e1>levodopa</e1>\NN\14604959 treatment\NN\654885 and\CC\1740 their\PRP$\1740 severity\NN\5036394 did\VBD\1640855 not\RB\1740 correlate\VB\2657219 with\IN\1740 duration\NN\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D007980_D001523 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e2>neuropsychiatric\JJ\1740 disorders</e2>\NNS\14034177 in\IN\13603305 PD\NN\14625458 are\VBP\836236 more\RBR\1740 likely\JJ\1740 an\DT\6697703 interaction\NN\37396 between\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 the\DT\1740 disease\NN\14061805 state\NN\8491826 than\IN\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 sensitisation\NN\14531772 to\TO\1740 repeated\VBN\952524 dopaminergic\JJ\1740 therapy\NN\657604 .\.\1740
D007980_D010302 NONE The\DT\1740 <e1>levodopa-treated</e1>\JJ\1740 MPTP-lesioned\JJ\1740 marmoset\NN\2489589 was\VBD\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 model\NN\5888929 of\IN\1740 neuropsychiatric\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 .\.\1740
D007980_D010302 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 neuropsychiatric\JJ\1740 disorders\NNS\14034177 in\IN\13603305 <e2>PD</e2>\NN\14625458 are\VBP\836236 more\RBR\1740 likely\JJ\1740 an\DT\6697703 interaction\NN\37396 between\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 the\DT\1740 disease\NN\14061805 state\NN\8491826 than\IN\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 sensitisation\NN\14531772 to\TO\1740 repeated\VBN\952524 dopaminergic\JJ\1740 therapy\NN\657604 .\.\1740
D015632_D001523 NONE The\DT\1740 levodopa-treated\JJ\1740 <e1>MPTP-lesioned</e1>\JJ\1740 marmoset\NN\2489589 was\VBD\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 model\NN\5888929 of\IN\1740 <e2>neuropsychiatric\JJ\1740 symptoms</e2>\NNS\5823932 in\IN\13603305 PD\NN\14625458 patients\NNS\9898892 .\.\1740
D007980_D020734 NONE Animals\NNS\4475 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 <e2>parkinsonian\JJ\1740 disability</e2>\NN\14547369 ,\,\1740 dyskinesia\NN\14084880 and\CC\1740 on-time\NN\1740 (\-LRB-\1740 motor\NN\3699975 fluctuations\NNS\7345593 )\-RRB-\1740 and\CC\1740 neuropsychiatric-like\JJ\1740 behaviors\NNS\407535 on\IN\1740 Day\NN\15154774 0\CD\13741022 (\-LRB-\1740 prior\JJ\1740 to\TO\1740 <e1>levodopa</e1>\NN\14604959 )\-RRB-\1740 and\CC\1740 on\IN\1740 Days\NNS\15140892 1\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 13\CD\13745420 ,\,\1740 27\CD\13745420 and\CC\1740 30\CD\13745420 of\IN\1740 treatment\NN\654885 using\VBG\1156834 post\NN\8621598 hoc\NN\1740 DVD\NN\3851787 analysis\NN\633864 by\IN\1740 a\DT\13649268 trained\VBN\829107 rater\NN\1740 ,\,\1740 blind\JJ\1740 to\IN\1740 the\DT\1740 treatment\NN\654885 day\NN\15154774 .\.\1740
D007980_D004409 CID Animals\NNS\4475 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 parkinsonian\JJ\1740 disability\NN\14547369 ,\,\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 on-time\NN\1740 (\-LRB-\1740 motor\NN\3699975 fluctuations\NNS\7345593 )\-RRB-\1740 and\CC\1740 neuropsychiatric-like\JJ\1740 behaviors\NNS\407535 on\IN\1740 Day\NN\15154774 0\CD\13741022 (\-LRB-\1740 prior\JJ\1740 to\TO\1740 <e1>levodopa</e1>\NN\14604959 )\-RRB-\1740 and\CC\1740 on\IN\1740 Days\NNS\15140892 1\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 13\CD\13745420 ,\,\1740 27\CD\13745420 and\CC\1740 30\CD\13745420 of\IN\1740 treatment\NN\654885 using\VBG\1156834 post\NN\8621598 hoc\NN\1740 DVD\NN\3851787 analysis\NN\633864 by\IN\1740 a\DT\13649268 trained\VBN\829107 rater\NN\1740 ,\,\1740 blind\JJ\1740 to\IN\1740 the\DT\1740 treatment\NN\654885 day\NN\15154774 .\.\1740
D007980_D004409 CID As\IN\14622893 anticipated\VBN\670261 ,\,\1740 animals\NNS\4475 exhibited\VBD\2632167 a\DT\13649268 progressive\JJ\1740 increase\NN\13576355 in\IN\13603305 <e1>levodopa-induced</e1>\JJ\1740 motor\NN\3699975 fluctuations\NNS\7345593 ,\,\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 wearing-off\NN\1740 ,\,\1740 that\WDT\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 .\.\1740
D007980_D004409 CID As\IN\14622893 anticipated\VBN\670261 ,\,\1740 animals\NNS\4475 exhibited\VBD\2632167 a\DT\13649268 progressive\JJ\1740 increase\NN\13576355 in\IN\13603305 levodopa-induced\JJ\1740 motor\NN\3699975 fluctuations\NNS\7345593 ,\,\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 wearing-off\NN\1740 ,\,\1740 that\WDT\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 .\.\1740
24641119
D007654_-1 NONE <e2>Baboon\NNP\2484473 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>ketoconazole</e1>\NN\1740 .\.\1740
D007654_-1 NONE The\DT\1740 patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 with\IN\1740 drug-induced\JJ\1740 <e2>baboon\NN\2484473 syndrome</e2>\NN\5870365 based\VBN\2694933 on\IN\1740 his\PRP$\1740 history\NN\15120823 ,\,\1740 which\WDT\1740 included\VBD\690614 prior\JJ\1740 sensitivity\NN\5651971 to\TO\1740 topical\JJ\1740 <e1>ketoconazole</e1>\NN\1740 ,\,\1740 a\DT\13649268 physical\JJ\1740 examination\NN\633864 ,\,\1740 and\CC\1740 histopathological\JJ\1740 findings\NNS\7951464 .\.\1740
D007654_-1 NONE To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e1>ketoconazole-induced</e1>\JJ\1740 <e2>baboon\NN\2484473 syndrome</e2>\NN\5870365 in\IN\13603305 the\DT\1740 English\NNP\6946823 literature\NN\6362953 .\.\1740
D007654_D003875 CID A\DT\13649268 27-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 a\DT\13649268 <e2>maculopapular\JJ\1740 eruption</e2>\NN\7307754 on\IN\1740 the\DT\1740 flexural\JJ\1740 areas\NNS\8630985 and\CC\1740 buttocks\NNS\5220461 after\IN\1740 using\VBG\1156834 oral\JJ\1740 <e1>ketoconazole</e1>\NN\1740 .\.\1740
24840785
D000157_D001145 CID <e1>Aconitine-induced</e1>\JJ\1740 Ca2\NN\1740 +\CC\1740 overload\NN\3679986 causes\VBZ\1617192 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 triggers\VBZ\1641914 apoptosis\NN\11486178 through\IN\1740 p38\NN\1740 MAPK\NN\1740 signaling\NN\33020 pathway\NN\5483677 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000157_D001145 CID Hence\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>aconitine</e1>\NN\1740 significantly\RB\1740 aggravates\VBZ\126264 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 overload\NN\3679986 and\CC\1740 causes\VBZ\1617192 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 finally\RB\1740 promotes\VBZ\2556126 apoptotic\JJ\1740 development\NN\248977 via\IN\1740 phosphorylation\NN\1740 of\IN\1740 P38\NN\1740 mitogen-activated\JJ\1740 protein\NN\14944888 kinase\NN\14732946 .\.\1740
D002118_D001145 NONE Aconitine-induced\JJ\1740 <e1>Ca2</e1>\NN\1740 +\CC\1740 overload\NN\3679986 causes\VBZ\1617192 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 triggers\VBZ\1641914 apoptosis\NN\11486178 through\IN\1740 p38\NN\1740 MAPK\NN\1740 signaling\NN\33020 pathway\NN\5483677 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002118_D001145 NONE We\PRP\1740 found\VBD\2426171 that\IN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 overload\NN\3679986 lead\VBP\1752884 to\TO\1740 accelerated\VBN\226566 beating\NN\1170962 rhythm\NN\15122011 in\IN\13603305 adult\JJ\1740 rat\NN\2329401 ventricular\NN\1740 myocytes\NNS\1740 and\CC\1740 caused\VBD\1617192 <e2>arrhythmia</e2>\NN\14103288 in\IN\13603305 conscious\JJ\1740 freely\RB\1740 moving\VBG\2367363 rats\NNS\2329401 .\.\1740
D002118_D001145 NONE Hence\RB\1740 ,\,\1740 our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 aconitine\NN\1740 significantly\RB\1740 aggravates\VBZ\126264 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 overload\NN\3679986 and\CC\1740 causes\VBZ\1617192 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 finally\RB\1740 promotes\VBZ\2556126 apoptotic\JJ\1740 development\NN\248977 via\IN\1740 phosphorylation\NN\1740 of\IN\1740 P38\NN\1740 mitogen-activated\JJ\1740 protein\NN\14944888 kinase\NN\14732946 .\.\1740
D012964_D066126 NONE Emerging\VBG\422090 evidence\NN\5816287 indicates\VBZ\952524 that\IN\1740 voltage-dependent\JJ\1740 <e1>Na(+</e1>\CD\1740 )\-RRB-\1740 channels\NNS\6251781 have\VBP\2108377 pivotal\JJ\1740 roles\NNS\719494 in\IN\13603305 the\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 aconitine\NN\1740 .\.\1740
D000157_D066126 CID Emerging\VBG\422090 evidence\NN\5816287 indicates\VBZ\952524 that\IN\1740 voltage-dependent\JJ\1740 Na(+\CD\1740 )\-RRB-\1740 channels\NNS\6251781 have\VBP\2108377 pivotal\JJ\1740 roles\NNS\719494 in\IN\13603305 the\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 <e1>aconitine</e1>\NN\1740 .\.\1740
D002118_D011041 NONE However\RB\1740 ,\,\1740 no\DT\7204911 reports\NNS\6470073 are\VBP\836236 available\JJ\1740 on\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 in\IN\13603305 aconitine\NN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
D002118_D011041 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 importance\NN\5138488 of\IN\1740 pathological\JJ\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 signaling\NN\33020 in\IN\13603305 aconitine\NN\1740 <e2>poisoning</e2>\NN\14034177 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000157_D011041 CID However\RB\1740 ,\,\1740 no\DT\7204911 reports\NNS\6470073 are\VBP\836236 available\JJ\1740 on\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 in\IN\13603305 <e1>aconitine</e1>\NN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
D000157_D011041 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 importance\NN\5138488 of\IN\1740 pathological\JJ\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 signaling\NN\33020 in\IN\13603305 <e1>aconitine</e1>\NN\1740 <e2>poisoning</e2>\NN\14034177 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000157_D009202 NONE To\TO\1740 investigate\VB\644583 effects\NNS\13245626 of\IN\1740 <e1>aconitine</e1>\NN\1740 on\IN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 we\PRP\1740 performed\VBD\2367363 cytotoxicity\NN\13583478 assay\NN\5733583 in\IN\13603305 neonatal\JJ\1740 rat\NN\2329401 ventricular\NN\1740 myocytes\NNS\1740 (\-LRB-\1740 NRVMs\NN\1740 )\-RRB-\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 measured\VBN\697589 lactate\NN\14850483 dehydrogenase\NN\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 culture\NN\7966140 medium\NN\3575240 of\IN\1740 NRVMs\NN\1740 and\CC\1740 activities\NNS\30358 of\IN\1740 serum\NN\5397468 cardiac\JJ\1740 enzymes\NNS\14723628 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000157_D009202 NONE The\DT\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 <e1>aconitine</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 and\CC\1740 reduced\VBD\441445 NRVMs\NN\1740 viability\NN\4916342 dose-dependently\RB\1740 .\.\1740
D000157_D064420 NONE To\TO\1740 investigate\VB\644583 effects\NNS\13245626 of\IN\1740 <e1>aconitine</e1>\NN\1740 on\IN\1740 myocardial\JJ\1740 injury\NN\14052046 ,\,\1740 we\PRP\1740 performed\VBD\2367363 <e2>cytotoxicity</e2>\NN\13583478 assay\NN\5733583 in\IN\13603305 neonatal\JJ\1740 rat\NN\2329401 ventricular\NN\1740 myocytes\NNS\1740 (\-LRB-\1740 NRVMs\NN\1740 )\-RRB-\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 measured\VBN\697589 lactate\NN\14850483 dehydrogenase\NN\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 culture\NN\7966140 medium\NN\3575240 of\IN\1740 NRVMs\NN\1740 and\CC\1740 activities\NNS\30358 of\IN\1740 serum\NN\5397468 cardiac\JJ\1740 enzymes\NNS\14723628 in\IN\13603305 rats\NNS\2329401 .\.\1740
D019344_D009202 NONE To\TO\1740 investigate\VB\644583 effects\NNS\13245626 of\IN\1740 aconitine\NN\1740 on\IN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 we\PRP\1740 performed\VBD\2367363 cytotoxicity\NN\13583478 assay\NN\5733583 in\IN\13603305 neonatal\JJ\1740 rat\NN\2329401 ventricular\NN\1740 myocytes\NNS\1740 (\-LRB-\1740 NRVMs\NN\1740 )\-RRB-\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 measured\VBN\697589 <e1>lactate</e1>\NN\14850483 dehydrogenase\NN\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 culture\NN\7966140 medium\NN\3575240 of\IN\1740 NRVMs\NN\1740 and\CC\1740 activities\NNS\30358 of\IN\1740 serum\NN\5397468 cardiac\JJ\1740 enzymes\NNS\14723628 in\IN\13603305 rats\NNS\2329401 .\.\1740
D019344_D064420 NONE To\TO\1740 investigate\VB\644583 effects\NNS\13245626 of\IN\1740 aconitine\NN\1740 on\IN\1740 myocardial\JJ\1740 injury\NN\14052046 ,\,\1740 we\PRP\1740 performed\VBD\2367363 <e2>cytotoxicity</e2>\NN\13583478 assay\NN\5733583 in\IN\13603305 neonatal\JJ\1740 rat\NN\2329401 ventricular\NN\1740 myocytes\NNS\1740 (\-LRB-\1740 NRVMs\NN\1740 )\-RRB-\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 measured\VBN\697589 <e1>lactate</e1>\NN\14850483 dehydrogenase\NN\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 culture\NN\7966140 medium\NN\3575240 of\IN\1740 NRVMs\NN\1740 and\CC\1740 activities\NNS\30358 of\IN\1740 serum\NN\5397468 cardiac\JJ\1740 enzymes\NNS\14723628 in\IN\13603305 rats\NNS\2329401 .\.\1740
24975837
D002945_D058186 CID Kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 deletion\NN\13508333 and\CC\1740 blockage\NN\14034177 ameliorates\VBZ\126264 <e1>cisplatin-induced</e1>\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 injury</e2>\NN\14052046 .\.\1740
D002945_D058186 CID <e1>Cisplatin</e1>\NN\1740 treatment\NN\654885 has\VBZ\2108377 been\VBN\836236 adopted\VBN\674607 in\IN\13603305 some\DT\1740 chemotherapies\NNS\661091 ;\:\1740 however\RB\1740 ,\,\1740 this\DT\1740 drug\NN\14778436 can\MD\3094503 induce\VB\1627355 <e2>acute\JJ\1740 kidney\NN\5333259 injury</e2>\NN\14052046 due\IN\5174653 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 negatively\RB\1740 affect\VB\126264 renal\JJ\1740 function\NN\13783581 ,\,\1740 augment\VBP\153263 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 urea\NN\14727670 ,\,\1740 increase\VB\169651 the\DT\1740 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 and\CC\1740 up-regulate\VBP\1740 cytokines\NNS\14728724 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 IL-1b\NN\1740 and\CC\1740 TNF-a\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D058186 CID To\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 in\IN\13603305 <e1>cisplatin-induced</e1>\JJ\1740 <e2>acute\JJ\1740 kidney\NN\5333259 injury</e2>\NN\14052046 ,\,\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 knockout\JJ\1740 mice\NNS\2329401 were\VBD\836236 challenged\VBN\869596 with\IN\1740 cisplatin\NN\1740 .\.\1740
D002945_D058186 CID To\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 in\IN\13603305 cisplatin-induced\JJ\1740 <e2>acute\JJ\1740 kidney\NN\5333259 injury</e2>\NN\14052046 ,\,\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 knockout\JJ\1740 mice\NNS\2329401 were\VBD\836236 challenged\VBN\869596 with\IN\1740 <e1>cisplatin</e1>\NN\1740 .\.\1740
D002945_D058186 CID Thus\RB\1740 ,\,\1740 our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 <e1>cisplatin-induced</e1>\JJ\1740 <e2>acute\JJ\1740 kidney\NN\5333259 injury</e2>\NN\14052046 by\IN\1740 mediating\VBG\761713 the\DT\1740 necrotic\JJ\1740 process\NN\407535 and\CC\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 inflammatory\JJ\1740 cytokines\NNS\14728724 ,\,\1740 thus\RB\1740 resulting\VBG\2633881 in\IN\13603305 declined\VBN\146138 renal\JJ\1740 function\NN\13783581 .\.\1740
D002945_D007683 CID <e1>Cisplatin</e1>\NN\1740 treatment\NN\654885 has\VBZ\2108377 been\VBN\836236 adopted\VBN\674607 in\IN\13603305 some\DT\1740 chemotherapies\NNS\661091 ;\:\1740 however\RB\1740 ,\,\1740 this\DT\1740 drug\NN\14778436 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 kidney\NN\5333259 injury\NN\14052046 due\IN\5174653 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 negatively\RB\1740 affect\VB\126264 renal\JJ\1740 function\NN\13783581 ,\,\1740 augment\VBP\153263 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 urea\NN\14727670 ,\,\1740 increase\VB\169651 the\DT\1740 <e2>acute\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 and\CC\1740 up-regulate\VBP\1740 cytokines\NNS\14728724 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 IL-1b\NN\1740 and\CC\1740 TNF-a\NN\1740 )\-RRB-\1740 .\.\1740
D003404_D058186 NONE Cisplatin\NN\1740 treatment\NN\654885 has\VBZ\2108377 been\VBN\836236 adopted\VBN\674607 in\IN\13603305 some\DT\1740 chemotherapies\NNS\661091 ;\:\1740 however\RB\1740 ,\,\1740 this\DT\1740 drug\NN\14778436 can\MD\3094503 induce\VB\1627355 <e2>acute\JJ\1740 kidney\NN\5333259 injury</e2>\NN\14052046 due\IN\5174653 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 negatively\RB\1740 affect\VB\126264 renal\JJ\1740 function\NN\13783581 ,\,\1740 augment\VBP\153263 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 <e1>creatinine</e1>\NN\1740 and\CC\1740 urea\NN\14727670 ,\,\1740 increase\VB\169651 the\DT\1740 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 and\CC\1740 up-regulate\VBP\1740 cytokines\NNS\14728724 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 IL-1b\NN\1740 and\CC\1740 TNF-a\NN\1740 )\-RRB-\1740 .\.\1740
D003404_D007683 NONE Cisplatin\NN\1740 treatment\NN\654885 has\VBZ\2108377 been\VBN\836236 adopted\VBN\674607 in\IN\13603305 some\DT\1740 chemotherapies\NNS\661091 ;\:\1740 however\RB\1740 ,\,\1740 this\DT\1740 drug\NN\14778436 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 kidney\NN\5333259 injury\NN\14052046 due\IN\5174653 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 negatively\RB\1740 affect\VB\126264 renal\JJ\1740 function\NN\13783581 ,\,\1740 augment\VBP\153263 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 <e1>creatinine</e1>\NN\1740 and\CC\1740 urea\NN\14727670 ,\,\1740 increase\VB\169651 the\DT\1740 <e2>acute\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 and\CC\1740 up-regulate\VBP\1740 cytokines\NNS\14728724 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 IL-1b\NN\1740 and\CC\1740 TNF-a\NN\1740 )\-RRB-\1740 .\.\1740
D014508_D058186 NONE Cisplatin\NN\1740 treatment\NN\654885 has\VBZ\2108377 been\VBN\836236 adopted\VBN\674607 in\IN\13603305 some\DT\1740 chemotherapies\NNS\661091 ;\:\1740 however\RB\1740 ,\,\1740 this\DT\1740 drug\NN\14778436 can\MD\3094503 induce\VB\1627355 <e2>acute\JJ\1740 kidney\NN\5333259 injury</e2>\NN\14052046 due\IN\5174653 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 negatively\RB\1740 affect\VB\126264 renal\JJ\1740 function\NN\13783581 ,\,\1740 augment\VBP\153263 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 <e1>urea</e1>\NN\14727670 ,\,\1740 increase\VB\169651 the\DT\1740 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 score\NN\5736149 and\CC\1740 up-regulate\VBP\1740 cytokines\NNS\14728724 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 IL-1b\NN\1740 and\CC\1740 TNF-a\NN\1740 )\-RRB-\1740 .\.\1740
D014508_D007683 NONE Cisplatin\NN\1740 treatment\NN\654885 has\VBZ\2108377 been\VBN\836236 adopted\VBN\674607 in\IN\13603305 some\DT\1740 chemotherapies\NNS\661091 ;\:\1740 however\RB\1740 ,\,\1740 this\DT\1740 drug\NN\14778436 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 kidney\NN\5333259 injury\NN\14052046 due\IN\5174653 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 negatively\RB\1740 affect\VB\126264 renal\JJ\1740 function\NN\13783581 ,\,\1740 augment\VBP\153263 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 <e1>urea</e1>\NN\14727670 ,\,\1740 increase\VB\169651 the\DT\1740 <e2>acute\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 score\NN\5736149 and\CC\1740 up-regulate\VBP\1740 cytokines\NNS\14728724 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 IL-1b\NN\1740 and\CC\1740 TNF-a\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D009336 NONE Thus\RB\1740 ,\,\1740 our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 <e1>cisplatin-induced</e1>\JJ\1740 acute\JJ\1740 kidney\NN\5333259 injury\NN\14052046 by\IN\1740 mediating\VBG\761713 the\DT\1740 <e2>necrotic</e2>\JJ\1740 process\NN\407535 and\CC\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 inflammatory\JJ\1740 cytokines\NNS\14728724 ,\,\1740 thus\RB\1740 resulting\VBG\2633881 in\IN\13603305 declined\VBN\146138 renal\JJ\1740 function\NN\13783581 .\.\1740
D002945_D007674 NONE These\DT\1740 results\NNS\34213 highlight\VBP\514463 the\DT\1740 kinin\NN\14744841 B2\NN\1740 receptor\NN\5225602 antagonist\NN\7846 treatment\NN\654885 in\IN\13603305 amelioration\NN\248977 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>cisplatin</e1>\NN\1740 therapy\NN\657604 .\.\1740
1556529
D015215_D056486 CID <e1>Zidovudine-induced</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D015215_D056486 CID A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>zidovudine</e1>\NN\3834836 in\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 patient\NN\9898892 with\IN\1740 AIDS\NN\13974317 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D015215_D000163 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 hepatitis\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>zidovudine</e1>\NN\3834836 in\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>AIDS</e2>\NN\13974317 is\VBZ\836236 presented\VBN\2137132 .\.\1740
8667442
D002117_D006934 CID <e2>Milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>1,25(OH)2D</e1>\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 hypoparathyroidism\NN\14059928 .\.\1740
D002117_D006934 CID This\DT\1740 article\NN\6367571 presents\VBZ\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 hypoparathyroidism\NN\14059928 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 calcium\NN\14625458 carbonate\NN\15010703 and\CC\1740 <e1>calcitriol</e1>\NN\1740 resulting\VBG\2633881 in\IN\13603305 two\CD\13741022 admissions\NNS\49003 to\IN\1740 the\DT\1740 hospital\NN\3739518 for\IN\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D002117_D007011 NONE Milk-alkali\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>1,25(OH)2D</e1>\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>hypoparathyroidism</e2>\NN\14059928 .\.\1740
D002117_D007011 NONE This\DT\1740 article\NN\6367571 presents\VBZ\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>hypoparathyroidism</e2>\NN\14059928 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 calcium\NN\14625458 carbonate\NN\15010703 and\CC\1740 <e1>calcitriol</e1>\NN\1740 resulting\VBG\2633881 in\IN\13603305 two\CD\13741022 admissions\NNS\49003 to\IN\1740 the\DT\1740 hospital\NN\3739518 for\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 .\.\1740
D002118_D006934 CID <e2>Milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 was\VBD\836236 first\RB\1740 described\VBN\1001294 70\CD\13745420 years\NNS\15144371 ago\RB\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 peptic\JJ\1740 ulcer\NN\14211294 disease\NN\14061805 with\IN\1740 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>calcium</e1>\NN\14625458 and\CC\1740 alkali\JJ\1740 .\.\1740
D002118_D010437 NONE Milk-alkali\JJ\1740 syndrome\NN\5870365 was\VBD\836236 first\RB\1740 described\VBN\1001294 70\CD\13745420 years\NNS\15144371 ago\RB\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>peptic\JJ\1740 ulcer\NN\14211294 disease</e2>\NN\14061805 with\IN\1740 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>calcium</e1>\NN\14625458 and\CC\1740 alkali\JJ\1740 .\.\1740
D000468_D006934 CID <e2>Milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 was\VBD\836236 first\RB\1740 described\VBN\1001294 70\CD\13745420 years\NNS\15144371 ago\RB\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 peptic\JJ\1740 ulcer\NN\14211294 disease\NN\14061805 with\IN\1740 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 calcium\NN\14625458 and\CC\1740 <e1>alkali</e1>\JJ\1740 .\.\1740
D000468_D010437 NONE Milk-alkali\JJ\1740 syndrome\NN\5870365 was\VBD\836236 first\RB\1740 described\VBN\1001294 70\CD\13745420 years\NNS\15144371 ago\RB\1740 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>peptic\JJ\1740 ulcer\NN\14211294 disease</e2>\NN\14061805 with\IN\1740 large\JJ\1740 amounts\NNS\13329641 of\IN\1740 calcium\NN\14625458 and\CC\1740 <e1>alkali</e1>\JJ\1740 .\.\1740
D009853_D014456 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 <e2>ulcer</e2>\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>omeprazole</e1>\NN\14778019 ,\,\1740 and\CC\1740 sucralfate\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D009853_D006934 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>omeprazole</e1>\NN\14778019 ,\,\1740 and\CC\1740 sucralfate\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D009853_D006934 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>omeprazole</e1>\NN\14778019 ,\,\1740 and\CC\1740 sucralfate\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D009853_D000471 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>omeprazole</e1>\NN\14778019 ,\,\1740 and\CC\1740 sucralfate\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 <e2>alkalosis</e2>\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D009853_D051437 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 <e1>omeprazole</e1>\NN\14778019 ,\,\1740 and\CC\1740 sucralfate\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D013392_D014456 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 <e2>ulcer</e2>\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 and\CC\1740 <e1>sucralfate</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D013392_D006934 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 and\CC\1740 <e1>sucralfate</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D013392_D006934 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 and\CC\1740 <e1>sucralfate</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D013392_D000471 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 and\CC\1740 <e1>sucralfate</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 <e2>alkalosis</e2>\NN\14204950 ,\,\1740 and\CC\1740 renal\JJ\1740 impairment\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D013392_D051437 NONE Although\IN\1740 with\IN\1740 current\JJ\1740 ulcer\NN\14211294 therapy\NN\657604 (\-LRB-\1740 H-2\NN\1740 blockers\NNS\10101634 ,\,\1740 omeprazole\NN\14778019 ,\,\1740 and\CC\1740 <e1>sucralfate</e1>\JJ\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 has\VBZ\2108377 decreased\VBN\169651 significantly\RB\1740 ,\,\1740 the\DT\1740 classic\JJ\1740 triad\NN\13741022 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 alkalosis\NN\14204950 ,\,\1740 and\CC\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 remains\VBZ\2604760 the\DT\1740 hallmark\NN\4731497 of\IN\1740 the\DT\1740 syndrome\NN\5870365 .\.\1740
D002119_D007011 NONE This\DT\1740 article\NN\6367571 presents\VBZ\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>hypoparathyroidism</e2>\NN\14059928 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>calcium\NN\14625458 carbonate</e1>\NN\15010703 and\CC\1740 calcitriol\NN\1740 resulting\VBG\2633881 in\IN\13603305 two\CD\13741022 admissions\NNS\49003 to\IN\1740 the\DT\1740 hospital\NN\3739518 for\IN\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 .\.\1740
D002119_D006934 CID This\DT\1740 article\NN\6367571 presents\VBZ\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 hypoparathyroidism\NN\14059928 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>calcium\NN\14625458 carbonate</e1>\NN\15010703 and\CC\1740 calcitriol\NN\1740 resulting\VBG\2633881 in\IN\13603305 two\CD\13741022 admissions\NNS\49003 to\IN\1740 the\DT\1740 hospital\NN\3739518 for\IN\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
C019248_D006934 NONE This\DT\1740 illustrates\VBZ\955601 intravenous\JJ\1740 <e1>pamidronate</e1>\NN\1740 as\IN\14622893 a\DT\13649268 valuable\JJ\1740 therapeutic\JJ\1740 tool\NN\3563967 when\WRB\1740 <e2>milk-alkali\JJ\1740 syndrome</e2>\NN\5870365 presents\VBZ\2137132 as\IN\14622893 hypercalcemic\JJ\1740 emergency\NN\7417644 .\.\1740
C019248_D006934 NONE This\DT\1740 illustrates\VBZ\955601 intravenous\JJ\1740 <e1>pamidronate</e1>\NN\1740 as\IN\14622893 a\DT\13649268 valuable\JJ\1740 therapeutic\JJ\1740 tool\NN\3563967 when\WRB\1740 milk-alkali\JJ\1740 syndrome\NN\5870365 presents\VBZ\2137132 as\IN\14622893 <e2>hypercalcemic\JJ\1740 emergency</e2>\NN\7417644 .\.\1740
10986547
C076029_D001714 NONE Efficacy\NNP\5199286 of\IN\1740 <e1>olanzapine</e1>\NN\1740 in\IN\13603305 acute\JJ\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 :\:\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 study\NN\635850 .\.\1740
C076029_D001714 NONE BACKGROUND\NN\4921011 :\:\1740 We\PRP\1740 compared\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>olanzapine</e1>\NN\1740 vs\CC\13634784 placebo\VB\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 .\.\1740
C076029_D001714 NONE A\DT\13649268 total\NN\3553 of\IN\1740 115\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 DSM-IV\NN\1740 diagnosis\NN\152018 of\IN\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 manic\JJ\1740 or\CC\3541091 mixed\JJ\1740 ,\,\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 <e1>olanzapine</e1>\NN\1740 ,\,\1740 5\CD\13741022 to\TO\1740 20\CD\13745420 mg/d\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 55\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 60\CD\13745420 )\-RRB-\1740 .\.\1740
C076029_D001714 NONE A\DT\13649268 total\NN\3553 of\IN\1740 115\CD\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 DSM-IV\NN\1740 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 ,\,\1740 <e2>manic</e2>\JJ\1740 or\CC\3541091 mixed\JJ\1740 ,\,\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 <e1>olanzapine</e1>\NN\1740 ,\,\1740 5\CD\13741022 to\TO\1740 20\CD\13745420 mg/d\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 55\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 60\CD\13745420 )\-RRB-\1740 .\.\1740
C076029_D001714 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Olanzapine</e1>\NNP\1740 demonstrated\VBD\2137132 greater\JJR\1740 efficacy\NN\5199286 than\IN\1740 placebo\NN\3740161 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 and\CC\1740 was\VBD\836236 generally\RB\1740 well\RB\1740 tolerated\VBN\802318 .\.\1740
C076029_D015430 CID However\RB\1740 ,\,\1740 <e1>olanzapine-treated</e1>\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 greater\JJR\1740 mean\NN\6021761 (\-LRB-\1740 +/-\CC\1740 SD\NN\1740 )\-RRB-\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 than\IN\1740 placebo-treated\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 2.1\CD\1740 +/-\CC\1740 2.8\CD\1740 vs\CC\13634784 0.45\CD\1740 +/-\CC\1740 2.3\CD\1740 kg\NN\13717155 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 and\CC\1740 also\RB\1740 experienced\VBD\2108377 more\RBR\1740 treatment-emergent\JJ\1740 somnolence\NN\14015731 (\-LRB-\1740 21\CD\13745420 patients\NNS\9898892 [\-LRB-\1740 38.2\CD\1740 %\NN\1740 ]\-RRB-\1740 vs\CC\13634784 5\CD\13741022 [\-LRB-\1740 8.3\CD\1740 %\NN\1740 ]\-RRB-\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
C076029_D006970 CID However\RB\1740 ,\,\1740 <e1>olanzapine-treated</e1>\JJ\1740 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 greater\JJR\1740 mean\NN\6021761 (\-LRB-\1740 +/-\CC\1740 SD\NN\1740 )\-RRB-\1740 weight\NN\5009170 gain\NN\13576355 than\IN\1740 placebo-treated\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 2.1\CD\1740 +/-\CC\1740 2.8\CD\1740 vs\CC\13634784 0.45\CD\1740 +/-\CC\1740 2.3\CD\1740 kg\NN\13717155 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 and\CC\1740 also\RB\1740 experienced\VBD\2108377 more\RBR\1740 treatment-emergent\JJ\1740 <e2>somnolence</e2>\NN\14015731 (\-LRB-\1740 21\CD\13745420 patients\NNS\9898892 [\-LRB-\1740 38.2\CD\1740 %\NN\1740 ]\-RRB-\1740 vs\CC\13634784 5\CD\13741022 [\-LRB-\1740 8.3\CD\1740 %\NN\1740 ]\-RRB-\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
17356399
C042705_D020803 NONE <e2>Acute\JJ\1740 encephalopathy</e2>\JJ\1740 and\CC\1740 cerebral\JJ\1740 vasospasm\NN\1740 after\IN\1740 multiagent\JJ\1740 chemotherapy\NN\661091 including\VBG\690614 <e1>PEG-asparaginase</e1>\NN\1740 and\CC\1740 intrathecal\JJ\1740 cytarabine\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
C042705_D020301 CID Acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 <e2>cerebral\JJ\1740 vasospasm</e2>\NN\1740 after\IN\1740 multiagent\JJ\1740 chemotherapy\NN\661091 including\VBG\690614 <e1>PEG-asparaginase</e1>\NN\1740 and\CC\1740 intrathecal\JJ\1740 cytarabine\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
C042705_D054198 NONE Acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 cerebral\JJ\1740 vasospasm\NN\1740 after\IN\1740 multiagent\JJ\1740 chemotherapy\NN\661091 including\VBG\690614 <e1>PEG-asparaginase</e1>\NN\1740 and\CC\1740 intrathecal\JJ\1740 cytarabine\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D003561_D020803 NONE <e2>Acute\JJ\1740 encephalopathy</e2>\JJ\1740 and\CC\1740 cerebral\JJ\1740 vasospasm\NN\1740 after\IN\1740 multiagent\JJ\1740 chemotherapy\NN\661091 including\VBG\690614 PEG-asparaginase\NN\1740 and\CC\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
D003561_D020803 NONE The\DT\1740 patient\NN\9898892 developed\VBD\1753788 <e2>acute\JJ\1740 encephalopathy</e2>\RB\1740 evidenced\VBN\1015244 by\IN\1740 behavioral\JJ\1740 changes\NNS\7283608 ,\,\1740 aphasia\NN\14085708 ,\,\1740 incontinence\NN\13473097 ,\,\1740 visual\JJ\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 right-sided\JJ\1740 weakness\NN\14462666 with\IN\1740 diffuse\JJ\1740 cerebral\JJ\1740 vasospasm\NN\1740 on\IN\1740 magnetic\JJ\1740 resonance\NN\11419404 angiography\NN\904623 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 .\.\1740
D003561_D020301 CID Acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 <e2>cerebral\JJ\1740 vasospasm</e2>\NN\1740 after\IN\1740 multiagent\JJ\1740 chemotherapy\NN\661091 including\VBG\690614 PEG-asparaginase\NN\1740 and\CC\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 .\.\1740
D003561_D020301 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 encephalopathy\RB\1740 evidenced\VBN\1015244 by\IN\1740 behavioral\JJ\1740 changes\NNS\7283608 ,\,\1740 aphasia\NN\14085708 ,\,\1740 incontinence\NN\13473097 ,\,\1740 visual\JJ\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 right-sided\JJ\1740 weakness\NN\14462666 with\IN\1740 diffuse\JJ\1740 <e2>cerebral\JJ\1740 vasospasm</e2>\NN\1740 on\IN\1740 magnetic\JJ\1740 resonance\NN\11419404 angiography\NN\904623 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 .\.\1740
D003561_D054198 NONE Acute\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 cerebral\JJ\1740 vasospasm\NN\1740 after\IN\1740 multiagent\JJ\1740 chemotherapy\NN\661091 including\VBG\690614 PEG-asparaginase\NN\1740 and\CC\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D003561_D001037 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 encephalopathy\RB\1740 evidenced\VBN\1015244 by\IN\1740 behavioral\JJ\1740 changes\NNS\7283608 ,\,\1740 <e2>aphasia</e2>\NN\14085708 ,\,\1740 incontinence\NN\13473097 ,\,\1740 visual\JJ\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 right-sided\JJ\1740 weakness\NN\14462666 with\IN\1740 diffuse\JJ\1740 cerebral\JJ\1740 vasospasm\NN\1740 on\IN\1740 magnetic\JJ\1740 resonance\NN\11419404 angiography\NN\904623 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 .\.\1740
D003561_D014549 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 encephalopathy\RB\1740 evidenced\VBN\1015244 by\IN\1740 behavioral\JJ\1740 changes\NNS\7283608 ,\,\1740 aphasia\NN\14085708 ,\,\1740 <e2>incontinence</e2>\NN\13473097 ,\,\1740 visual\JJ\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 right-sided\JJ\1740 weakness\NN\14462666 with\IN\1740 diffuse\JJ\1740 cerebral\JJ\1740 vasospasm\NN\1740 on\IN\1740 magnetic\JJ\1740 resonance\NN\11419404 angiography\NN\904623 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 .\.\1740
D003561_D006212 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 encephalopathy\RB\1740 evidenced\VBN\1015244 by\IN\1740 behavioral\JJ\1740 changes\NNS\7283608 ,\,\1740 aphasia\NN\14085708 ,\,\1740 incontinence\NN\13473097 ,\,\1740 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 ,\,\1740 and\CC\1740 right-sided\JJ\1740 weakness\NN\14462666 with\IN\1740 diffuse\JJ\1740 cerebral\JJ\1740 vasospasm\NN\1740 on\IN\1740 magnetic\JJ\1740 resonance\NN\11419404 angiography\NN\904623 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 .\.\1740
D003561_D018908 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 acute\JJ\1740 encephalopathy\RB\1740 evidenced\VBN\1015244 by\IN\1740 behavioral\JJ\1740 changes\NNS\7283608 ,\,\1740 aphasia\NN\14085708 ,\,\1740 incontinence\NN\13473097 ,\,\1740 visual\JJ\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 right-sided\JJ\1740 <e2>weakness</e2>\NN\14462666 with\IN\1740 diffuse\JJ\1740 cerebral\JJ\1740 vasospasm\NN\1740 on\IN\1740 magnetic\JJ\1740 resonance\NN\11419404 angiography\NN\904623 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 intrathecal\JJ\1740 <e1>cytarabine</e1>\NN\1740 .\.\1740
3533179
D003520_D066126 NONE <e1>Cyclophosphamide</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 :\:\1740 an\DT\6697703 analysis\NN\633864 of\IN\1740 dosing\NN\1740 as\IN\14622893 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 .\.\1740
D003520_D066126 NONE At\IN\14622893 these\DT\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>CYA</e1>\NN\1740 ,\,\1740 serious\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 may\MD\15209706 occur\VB\2623529 ,\,\1740 but\CC\1740 definitive\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 such\JJ\1740 cardiotoxicity\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 described\VBN\1001294 .\.\1740
D003520_D066126 NONE At\IN\14622893 these\DT\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>CYA</e1>\NN\1740 ,\,\1740 serious\JJ\1740 cardiotoxicity\NN\1740 may\MD\15209706 occur\VB\2623529 ,\,\1740 but\CC\1740 definitive\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 such\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 described\VBN\1001294 .\.\1740
D003520_D066126 NONE Since\IN\1740 chemotherapeutic\JJ\1740 agent\NN\7347 toxicity\NN\13576101 generally\RB\1740 correlates\VBZ\2657219 with\IN\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 calculated\VBD\632627 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>CYA</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 transplanted\VBN\2013571 at\IN\14622893 our\PRP$\1740 institution\NN\8008335 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 CYA\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 .\.\1740
D003520_D066126 NONE Since\IN\1740 chemotherapeutic\JJ\1740 agent\NN\7347 toxicity\NN\13576101 generally\RB\1740 correlates\VBZ\2657219 with\IN\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 calculated\VBD\632627 the\DT\1740 dose\NN\3740161 of\IN\1740 CYA\NN\1740 in\IN\13603305 patients\NNS\9898892 transplanted\VBN\2013571 at\IN\14622893 our\PRP$\1740 institution\NN\8008335 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>CYA</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 .\.\1740
D003520_D066126 NONE Fourteen\CD\13745420 of\IN\1740 84\CD\1740 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 had\VBD\2108377 symptoms\NNS\5823932 and\CC\1740 signs\NNS\6643763 consistent\JJ\1740 with\IN\1740 <e1>CYA</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 within\IN\1740 ten\CD\13745420 days\NNS\15140892 of\IN\1740 receiving\VBG\2210855 1\CD\13741022 to\TO\1740 4\CD\13741022 doses\NNS\3740161 of\IN\1740 CYA\NNP\1740 .\.\1740
D003520_D066126 NONE Fourteen\CD\13745420 of\IN\1740 84\CD\1740 (\-LRB-\1740 17\CD\13745420 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 had\VBD\2108377 symptoms\NNS\5823932 and\CC\1740 signs\NNS\6643763 consistent\JJ\1740 with\IN\1740 CYA\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 within\IN\1740 ten\CD\13745420 days\NNS\15140892 of\IN\1740 receiving\VBG\2210855 1\CD\13741022 to\TO\1740 4\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>CYA</e1>\NNP\1740 .\.\1740
D003520_D066126 NONE <e2>Cardiotoxicity</e2>\NN\1740 that\WDT\1740 was\VBD\836236 thought\VBN\670261 to\TO\1740 be\VB\836236 related\JJ\1740 to\TO\1740 <e1>CYA</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 1/32\CD\1740 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 in\IN\13603305 Group\NN\2137 1\CD\13741022 and\CC\1740 in\IN\13603305 13/52\CD\1740 (\-LRB-\1740 25\CD\13745420 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 in\IN\13603305 Group\NN\2137 2\CD\13741022 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.025\CD\1740 )\-RRB-\1740 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 <e1>CYA</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 <e1>CYA</e1>\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 correlates\VBZ\2657219 with\IN\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 <e1>CYA</e1>\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 <e1>CYA</e1>\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D066126 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D064420 NONE Since\IN\1740 chemotherapeutic\JJ\1740 agent\NN\7347 <e2>toxicity</e2>\NN\13576101 generally\RB\1740 correlates\VBZ\2657219 with\IN\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 calculated\VBD\632627 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>CYA</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 transplanted\VBN\2013571 at\IN\14622893 our\PRP$\1740 institution\NN\8008335 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 .\.\1740
D003520_D064420 NONE Since\IN\1740 chemotherapeutic\JJ\1740 agent\NN\7347 <e2>toxicity</e2>\NN\13576101 generally\RB\1740 correlates\VBZ\2657219 with\IN\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 we\PRP\1740 retrospectively\RB\1740 calculated\VBD\632627 the\DT\1740 dose\NN\3740161 of\IN\1740 CYA\NN\1740 in\IN\13603305 patients\NNS\9898892 transplanted\VBN\2013571 at\IN\14622893 our\PRP$\1740 institution\NN\8008335 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>CYA</e1>\NN\1740 cardiotoxicity\NN\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 dose\NN\3740161 per\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 .\.\1740
D003520_D000741 NONE Eighty\CD\13745420 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 to\TO\1740 receive\VB\2210855 <e1>CYA</e1>\NN\1740 50\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 as\IN\14622893 preparation\NN\407535 for\IN\1740 marrow\NN\5286536 grafting\NN\379422 underwent\VBD\109660 a\DT\13649268 total\NN\3553 of\IN\1740 84\CD\1740 transplants\NNS\5267548 for\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 Wiskott-Aldrich\NN\1740 syndrome\NN\5870365 ,\,\1740 or\CC\3541091 severe\JJ\1740 combined\JJ\1740 immunodeficiency\NN\13973990 syndrome\NN\5870365 .\.\1740
D003520_D000741 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 <e1>CYA</e1>\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D000741 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D000741 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 <e1>CYA</e1>\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D000741 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 immunodeficiencies\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D014923 NONE Eighty\CD\13745420 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 to\TO\1740 receive\VB\2210855 <e1>CYA</e1>\NN\1740 50\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 as\IN\14622893 preparation\NN\407535 for\IN\1740 marrow\NN\5286536 grafting\NN\379422 underwent\VBD\109660 a\DT\13649268 total\NN\3553 of\IN\1740 84\CD\1740 transplants\NNS\5267548 for\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 ,\,\1740 <e2>Wiskott-Aldrich\NN\1740 syndrome</e2>\NN\5870365 ,\,\1740 or\CC\3541091 severe\JJ\1740 combined\JJ\1740 immunodeficiency\NN\13973990 syndrome\NN\5870365 .\.\1740
D003520_D016511 NONE Eighty\CD\13745420 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 to\TO\1740 receive\VB\2210855 <e1>CYA</e1>\NN\1740 50\CD\13745420 mg/kg/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 as\IN\14622893 preparation\NN\407535 for\IN\1740 marrow\NN\5286536 grafting\NN\379422 underwent\VBD\109660 a\DT\13649268 total\NN\3553 of\IN\1740 84\CD\1740 transplants\NNS\5267548 for\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 ,\,\1740 Wiskott-Aldrich\NN\1740 syndrome\NN\5870365 ,\,\1740 or\CC\3541091 <e2>severe\JJ\1740 combined\JJ\1740 immunodeficiency\NN\13973990 syndrome</e2>\NN\5870365 .\.\1740
D003520_D007153 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 <e1>CYA</e1>\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>immunodeficiencies</e2>\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D007153 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>immunodeficiencies</e2>\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D007153 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>immunodeficiencies</e2>\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 <e1>CYA</e1>\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 CYA\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
D003520_D007153 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 CYA\NN\1740 cardiotoxicity\NN\1740 correlates\VBZ\2657219 with\IN\1740 CYA\NN\1740 dosage\NN\13576355 as\IN\14622893 calculated\VBN\632627 by\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 and\CC\1740 that\IN\1740 patients\NNS\9898892 with\IN\1740 aplastic\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>immunodeficiencies</e2>\NNS\13973990 can\MD\3094503 be\VB\836236 effectively\RB\1740 prepared\VBN\126264 for\IN\1740 bone\NN\5286536 marrow\NN\5286536 grafting\VBG\1291069 at\IN\14622893 a\DT\13649268 CYA\NN\1740 dose\NN\3740161 of\IN\1740 1.55\CD\1740 g/m2/d\NN\1740 for\IN\1740 four\CD\13741022 days\NNS\15140892 with\IN\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 cardiotoxicity\NN\1740 than\IN\1740 patients\NNS\9898892 whose\WP$\1740 <e1>CYA</e1>\NN\1740 dosage\NN\13576355 is\VBZ\836236 calculated\VBN\632627 based\VBN\2694933 on\IN\1740 weight\NN\5009170 .\.\1740
20589632
D014295_D000743 CID <e1>Trimethoprim-induced</e1>\JJ\1740 immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 pediatric\JJ\1740 oncology\NN\6043075 patient\NN\9898892 presenting\VBG\2137132 as\IN\14622893 an\DT\6697703 acute\JJ\1740 hemolytic\JJ\1740 transfusion\NN\320852 reaction\NN\13446390 .\.\1740
15018178
D015662_D000743 CID We\PRP\1740 present\VBP\2137132 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 findings\NNS\7951464 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 girl\NN\10787470 who\WP\8299493 had\VBD\2108377 a\DT\13649268 rapidly\RB\1740 installing\VBG\1494310 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 crisis\NN\14411243 induced\VBN\1627355 by\IN\1740 <e1>trimethoprim-sulfomethoxazole</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 cerebral\JJ\1740 anoxia\NN\14041256 leading\VBG\1752884 to\TO\1740 permanent\JJ\1740 damage\NN\7296428 .\.\1740
D015662_D002534 NONE We\PRP\1740 present\VBP\2137132 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 findings\NNS\7951464 of\IN\1740 a\DT\13649268 5-year-old\JJ\1740 girl\NN\10787470 who\WP\8299493 had\VBD\2108377 a\DT\13649268 rapidly\RB\1740 installing\VBG\1494310 hemolytic\JJ\1740 anemia\NN\14189204 crisis\NN\14411243 induced\VBN\1627355 by\IN\1740 <e1>trimethoprim-sulfomethoxazole</e1>\NN\1740 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 <e2>cerebral\JJ\1740 anoxia</e2>\NN\14041256 leading\VBG\1752884 to\TO\1740 permanent\JJ\1740 damage\NN\7296428 .\.\1740
23666265
D003520_D003556 CID The\DT\1740 function\NN\13783581 of\IN\1740 P2X3\NN\1740 receptor\NN\5225602 and\CC\1740 NK1\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 on\IN\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003520_D003556 CID PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 explore\VB\789138 the\DT\1740 function\NN\13783581 of\IN\1740 P2X3\NN\1740 and\CC\1740 NK1\NN\1740 receptors\NNS\5225602 antagonists\NNS\7846 on\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (CYP)-induced\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003520_D003556 CID PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 explore\VB\789138 the\DT\1740 function\NN\13783581 of\IN\1740 P2X3\NN\1740 and\CC\1740 NK1\NN\1740 receptors\NNS\5225602 antagonists\NNS\7846 on\IN\1740 cyclophosphamide\NN\1740 <e1>(CYP)-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003520_D003556 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 <e1>CYP-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 ,\,\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 P2X3\NN\1740 and\CC\1740 NK1\NN\1740 receptors\NNS\5225602 increased\VBD\169651 in\IN\13603305 urothelium\NN\1740 and/or\CC\1740 suburothelium\NN\1740 .\.\1740
D003520_D010146 CID Spontaneous\JJ\1740 <e2>pain</e2>\NN\14299637 behaviors\NNS\407535 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>CYP</e1>\NN\1740 were\VBD\836236 observed\VBN\2163746 .\.\1740
D003520_D010146 CID RESULTS\NNS\34213 :\:\1740 <e1>Cyclophosphamide</e1>\NN\1740 treatment\NN\654885 increased\VBD\169651 the\DT\1740 spontaneous\JJ\1740 <e2>pain</e2>\NN\14299637 behaviors\NNS\407535 scores\NNS\13757724 .\.\1740
9578276
15366550
D008094_D059606 NONE The\DT\1740 nursing\NN\654885 staff\NN\8208016 ,\,\1740 by\IN\1740 reviewing\VBG\644583 the\DT\1740 patient\NN\9898892 's\POS\1740 health\NN\14447525 history\NN\15120823 with\IN\1740 his\PRP$\1740 family\NN\8189659 ,\,\1740 discovered\VBD\2163746 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 long-standing\JJ\1740 <e1>lithium</e1>\NN\14625458 use\NN\407535 .\.\1740
D008094_D018500 CID <e1>Lithium</e1>\NNP\14625458 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 drug-induced\JJ\1740 <e2>nephrogenic\JJ\1740 DI</e2>\NN\1740 ,\,\1740 and\CC\1740 because\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 not\RB\1740 received\VBN\2210855 lithium\NN\14625458 since\IN\1740 being\VBG\836236 admitted\VBN\822367 to\IN\1740 the\DT\1740 hospital\NN\3739518 ,\,\1740 his\PRP$\1740 treatment\NN\654885 changed\VBN\46534 to\TO\1740 focus\VB\628491 on\IN\1740 nephrogenic\JJ\1740 DI\NN\1740 .\.\1740
D008094_D018500 CID <e1>Lithium</e1>\NNP\14625458 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 drug-induced\JJ\1740 nephrogenic\JJ\1740 DI\NN\1740 ,\,\1740 and\CC\1740 because\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 not\RB\1740 received\VBN\2210855 lithium\NN\14625458 since\IN\1740 being\VBG\836236 admitted\VBN\822367 to\IN\1740 the\DT\1740 hospital\NN\3739518 ,\,\1740 his\PRP$\1740 treatment\NN\654885 changed\VBN\46534 to\TO\1740 focus\VB\628491 on\IN\1740 <e2>nephrogenic\JJ\1740 DI</e2>\NN\1740 .\.\1740
D008094_D018500 CID Lithium\NNP\14625458 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 drug-induced\JJ\1740 <e2>nephrogenic\JJ\1740 DI</e2>\NN\1740 ,\,\1740 and\CC\1740 because\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 not\RB\1740 received\VBN\2210855 <e1>lithium</e1>\NN\14625458 since\IN\1740 being\VBG\836236 admitted\VBN\822367 to\IN\1740 the\DT\1740 hospital\NN\3739518 ,\,\1740 his\PRP$\1740 treatment\NN\654885 changed\VBN\46534 to\TO\1740 focus\VB\628491 on\IN\1740 nephrogenic\JJ\1740 DI\NN\1740 .\.\1740
D008094_D018500 CID Lithium\NNP\14625458 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 drug-induced\JJ\1740 nephrogenic\JJ\1740 DI\NN\1740 ,\,\1740 and\CC\1740 because\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 not\RB\1740 received\VBN\2210855 <e1>lithium</e1>\NN\14625458 since\IN\1740 being\VBG\836236 admitted\VBN\822367 to\IN\1740 the\DT\1740 hospital\NN\3739518 ,\,\1740 his\PRP$\1740 treatment\NN\654885 changed\VBN\46534 to\TO\1740 focus\VB\628491 on\IN\1740 <e2>nephrogenic\JJ\1740 DI</e2>\NN\1740 .\.\1740
D008094_D018500 CID By\IN\1740 combining\VBG\2630189 information\NN\6598915 from\IN\1740 the\DT\1740 patient\NN\9898892 history\NN\15120823 ,\,\1740 the\DT\1740 physical\JJ\1740 examination\NN\633864 ,\,\1740 and\CC\1740 radiologic\JJ\1740 and\CC\1740 laboratory\NN\4602044 studies\NNS\635850 ,\,\1740 the\DT\1740 critical\JJ\1740 care\NN\575741 team\NN\8189659 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 been\VBN\836236 self-treating\JJ\1740 his\PRP$\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>nephrogenic\JJ\1740 DI</e2>\NN\1740 and\CC\1740 developed\VBD\1753788 neurogenic\JJ\1740 DI\NN\1740 secondary\JJ\1740 to\TO\1740 brain\NN\5462674 trauma\NN\14052046 .\.\1740
D008094_D018500 CID By\IN\1740 combining\VBG\2630189 information\NN\6598915 from\IN\1740 the\DT\1740 patient\NN\9898892 history\NN\15120823 ,\,\1740 the\DT\1740 physical\JJ\1740 examination\NN\633864 ,\,\1740 and\CC\1740 radiologic\JJ\1740 and\CC\1740 laboratory\NN\4602044 studies\NNS\635850 ,\,\1740 the\DT\1740 critical\JJ\1740 care\NN\575741 team\NN\8189659 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 been\VBN\836236 self-treating\JJ\1740 his\PRP$\1740 <e1>lithium-induced</e1>\JJ\1740 nephrogenic\JJ\1740 DI\NN\1740 and\CC\1740 developed\VBD\1753788 <e2>neurogenic\JJ\1740 DI</e2>\NN\1740 secondary\JJ\1740 to\TO\1740 brain\NN\5462674 trauma\NN\14052046 .\.\1740
D008094_D001930 NONE By\IN\1740 combining\VBG\2630189 information\NN\6598915 from\IN\1740 the\DT\1740 patient\NN\9898892 history\NN\15120823 ,\,\1740 the\DT\1740 physical\JJ\1740 examination\NN\633864 ,\,\1740 and\CC\1740 radiologic\JJ\1740 and\CC\1740 laboratory\NN\4602044 studies\NNS\635850 ,\,\1740 the\DT\1740 critical\JJ\1740 care\NN\575741 team\NN\8189659 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 been\VBN\836236 self-treating\JJ\1740 his\PRP$\1740 <e1>lithium-induced</e1>\JJ\1740 nephrogenic\JJ\1740 DI\NN\1740 and\CC\1740 developed\VBD\1753788 neurogenic\JJ\1740 DI\NN\1740 secondary\JJ\1740 to\TO\1740 <e2>brain\NN\5462674 trauma</e2>\NN\14052046 .\.\1740
10713017
D005277_D006976 CID However\RB\1740 ,\,\1740 of\IN\1740 the\DT\1740 medications\NNS\3247620 surveyed\VBN\644583 ,\,\1740 only\RB\1740 the\DT\1740 <e1>fenfluramines</e1>\NNS\1740 had\VBD\2108377 a\DT\13649268 significant\JJ\1740 preferential\JJ\1740 association\NN\8008335 with\IN\1740 <e2>PPH</e2>\NN\1740 as\IN\14622893 compared\VBN\644583 with\IN\1740 SPH\NN\1740 (\-LRB-\1740 adjusted\VBN\126264 odds\NNS\4756635 ratio\NN\13815152 for\IN\1740 use\NN\407535 >\NN\1740 6\CD\13741022 months\NNS\15113229 ,\,\1740 7.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.7\CD\1740 to\TO\1740 32.4\CD\1740 )\-RRB-\1740 .\.\1740
D005277_D006976 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 association\NN\8008335 with\IN\1740 <e2>PPH</e2>\NN\1740 ,\,\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 association\NN\8008335 with\IN\1740 increasing\VBG\169651 duration\NN\15113229 of\IN\1740 use\NN\407535 ,\,\1740 and\CC\1740 the\DT\1740 specificity\NN\4762633 for\IN\1740 <e1>fenfluramines</e1>\NNS\1740 are\VBP\836236 consistent\JJ\1740 with\IN\1740 previous\JJ\1740 studies\NNS\635850 indicating\VBG\952524 that\IN\1740 fenfluramines\NNS\1740 are\VBP\836236 causally\RB\1740 related\JJ\1740 to\TO\1740 PPH\NN\1740 .\.\1740
D005277_D006976 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 association\NN\8008335 with\IN\1740 PPH\NN\1740 ,\,\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 association\NN\8008335 with\IN\1740 increasing\VBG\169651 duration\NN\15113229 of\IN\1740 use\NN\407535 ,\,\1740 and\CC\1740 the\DT\1740 specificity\NN\4762633 for\IN\1740 <e1>fenfluramines</e1>\NNS\1740 are\VBP\836236 consistent\JJ\1740 with\IN\1740 previous\JJ\1740 studies\NNS\635850 indicating\VBG\952524 that\IN\1740 fenfluramines\NNS\1740 are\VBP\836236 causally\RB\1740 related\JJ\1740 to\TO\1740 <e2>PPH</e2>\NN\1740 .\.\1740
D005277_D006976 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 association\NN\8008335 with\IN\1740 <e2>PPH</e2>\NN\1740 ,\,\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 association\NN\8008335 with\IN\1740 increasing\VBG\169651 duration\NN\15113229 of\IN\1740 use\NN\407535 ,\,\1740 and\CC\1740 the\DT\1740 specificity\NN\4762633 for\IN\1740 fenfluramines\NNS\1740 are\VBP\836236 consistent\JJ\1740 with\IN\1740 previous\JJ\1740 studies\NNS\635850 indicating\VBG\952524 that\IN\1740 <e1>fenfluramines</e1>\NNS\1740 are\VBP\836236 causally\RB\1740 related\JJ\1740 to\TO\1740 PPH\NN\1740 .\.\1740
D005277_D006976 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 association\NN\8008335 with\IN\1740 PPH\NN\1740 ,\,\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 association\NN\8008335 with\IN\1740 increasing\VBG\169651 duration\NN\15113229 of\IN\1740 use\NN\407535 ,\,\1740 and\CC\1740 the\DT\1740 specificity\NN\4762633 for\IN\1740 fenfluramines\NNS\1740 are\VBP\836236 consistent\JJ\1740 with\IN\1740 previous\JJ\1740 studies\NNS\635850 indicating\VBG\952524 that\IN\1740 <e1>fenfluramines</e1>\NNS\1740 are\VBP\836236 causally\RB\1740 related\JJ\1740 to\TO\1740 <e2>PPH</e2>\NN\1740 .\.\1740
2818777
D010672_D056486 NONE <e1>Phenytoin</e1>\NN\3550533 induced\VBD\1627355 fatal\JJ\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 .\.\1740
D010672_D017093 CID A\DT\13649268 61\CD\1740 year\NN\15113229 old\JJ\1740 female\NN\15388 developed\VBD\1753788 fatal\JJ\1740 <e2>hepatic\JJ\1740 failure</e2>\NN\66216 after\IN\1740 <e1>phenytoin</e1>\NN\3550533 administration\NN\1133281 .\.\1740
25986755
D002110_D005921 NONE Low\JJ\1740 functional\JJ\1740 programming\NN\1144133 of\IN\1740 renal\JJ\1740 AT2R\NN\1740 mediates\VBZ\761713 the\DT\1740 developmental\JJ\1740 origin\NN\8620061 of\IN\1740 <e2>glomerulosclerosis</e2>\NN\1740 in\IN\13603305 adult\JJ\1740 offspring\NN\10235549 induced\VBN\1627355 by\IN\1740 prenatal\JJ\1740 <e1>caffeine</e1>\NN\14712692 exposure\NN\5042871 .\.\1740
D002110_D005317 CID UNASSIGNED\NNS\1740 :\:\1740 Our\PRP$\1740 previous\JJ\1740 study\NN\635850 has\VBZ\2108377 indicated\VBN\952524 that\IN\1740 prenatal\JJ\1740 <e1>caffeine</e1>\NN\14712692 exposure\NN\5042871 (\-LRB-\1740 PCE\NN\1740 )\-RRB-\1740 could\MD\1740 induce\VB\1627355 <e2>intrauterine\NN\1740 growth\NN\13526110 retardation</e2>\NN\7296428 (\-LRB-\1740 IUGR\NN\1740 )\-RRB-\1740 of\IN\1740 offspring\NN\10235549 .\.\1740
D002110_D005317 CID UNASSIGNED\NNS\1740 :\:\1740 Our\PRP$\1740 previous\JJ\1740 study\NN\635850 has\VBZ\2108377 indicated\VBN\952524 that\IN\1740 prenatal\JJ\1740 <e1>caffeine</e1>\NN\14712692 exposure\NN\5042871 (\-LRB-\1740 PCE\NN\1740 )\-RRB-\1740 could\MD\1740 induce\VB\1627355 intrauterine\NN\1740 growth\NN\13526110 retardation\NN\7296428 (\-LRB-\1740 <e2>IUGR</e2>\NN\1740 )\-RRB-\1740 of\IN\1740 offspring\NN\10235549 .\.\1740
D003404_D005921 NONE The\DT\1740 results\NNS\34213 revealed\VBD\2137132 that\IN\1740 the\DT\1740 adult\JJ\1740 offspring\NN\10235549 kidneys\NNS\5333259 in\IN\13603305 the\DT\1740 PCE\NN\1740 group\NN\2137 exhibited\VBD\2632167 <e2>glomerulosclerosis</e2>\NN\1740 as\RB\1740 well\RB\1740 as\IN\14622893 interstitial\JJ\1740 fibrosis\NN\14204950 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 and\CC\1740 urine\NN\14853947 protein\NN\14944888 .\.\1740
D003404_D005355 NONE The\DT\1740 results\NNS\34213 revealed\VBD\2137132 that\IN\1740 the\DT\1740 adult\JJ\1740 offspring\NN\10235549 kidneys\NNS\5333259 in\IN\13603305 the\DT\1740 PCE\NN\1740 group\NN\2137 exhibited\VBD\2632167 glomerulosclerosis\NN\1740 as\RB\1740 well\RB\1740 as\IN\14622893 <e2>interstitial\JJ\1740 fibrosis</e2>\NN\14204950 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 and\CC\1740 urine\NN\14853947 protein\NN\14944888 .\.\1740
2217015
D008528_D009503 CID <e1>Mefenamic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>neutropenia</e2>\NN\14196405 and\CC\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 elderly\JJ\1740 females\NNS\15388 with\IN\1740 hypothyroidism\NN\14059928 .\.\1740
D008528_D009503 CID We\PRP\1740 report\VBP\831651 <e1>mefenamic\JJ\1740 acid-induced</e1>\JJ\1740 non-oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 severe\JJ\1740 <e2>neutropenia</e2>\NN\14196405 occurring\VBG\2623529 simultaneously\RB\1740 in\IN\13603305 two\CD\13741022 elderly\JJ\1740 females\NNS\15388 .\.\1740
D008528_D051437 CID <e1>Mefenamic\JJ\1740 acid-induced</e1>\JJ\1740 neutropenia\NN\14196405 and\CC\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 elderly\JJ\1740 females\NNS\15388 with\IN\1740 hypothyroidism\NN\14059928 .\.\1740
D008528_D051437 CID We\PRP\1740 report\VBP\831651 <e1>mefenamic\JJ\1740 acid-induced</e1>\JJ\1740 non-oliguric\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 severe\JJ\1740 neutropenia\NN\14196405 occurring\VBG\2623529 simultaneously\RB\1740 in\IN\13603305 two\CD\13741022 elderly\JJ\1740 females\NNS\15388 .\.\1740
D008528_D007037 NONE <e1>Mefenamic\JJ\1740 acid-induced</e1>\JJ\1740 neutropenia\NN\14196405 and\CC\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 elderly\JJ\1740 females\NNS\15388 with\IN\1740 <e2>hypothyroidism</e2>\NN\14059928 .\.\1740
D008528_D007037 NONE However\RB\1740 ,\,\1740 it\PRP\6125041 would\MD\1740 seem\VB\2604760 prudent\JJ\1740 not\RB\1740 to\TO\1740 use\VB\1156834 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 <e2>hypothyroid</e2>\JJ\1740 patients\NNS\9898892 until\IN\1740 the\DT\1740 hypothyroidism\NN\14059928 has\VBZ\2108377 been\VBN\836236 corrected\VBN\138508 .\.\1740
D008528_D007037 NONE However\RB\1740 ,\,\1740 it\PRP\6125041 would\MD\1740 seem\VB\2604760 prudent\JJ\1740 not\RB\1740 to\TO\1740 use\VB\1156834 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 hypothyroid\JJ\1740 patients\NNS\9898892 until\IN\1740 the\DT\1740 <e2>hypothyroidism</e2>\NN\14059928 has\VBZ\2108377 been\VBN\836236 corrected\VBN\138508 .\.\1740
15609701
D013015_D003329 CID <e1>Sotalol-induced</e1>\JJ\1740 <e2>coronary\JJ\1740 spasm</e2>\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 dilated\JJ\1740 cardiomyopathy\NN\14103288 associated\VBN\628491 with\IN\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 .\.\1740
D013015_D003329 CID <e2>Coronary\JJ\1740 vasospasm</e2>\NN\1740 may\MD\15209706 be\VB\836236 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-selective\JJ\1740 beta-blocking\JJ\1740 properties\NNS\32613 of\IN\1740 <e1>sotalol</e1>\NNS\1740 .\.\1740
D013015_D002311 NONE <e1>Sotalol-induced</e1>\JJ\1740 coronary\JJ\1740 spasm\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>dilated\JJ\1740 cardiomyopathy</e2>\NN\14103288 associated\VBN\628491 with\IN\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 .\.\1740
D013015_D017180 NONE <e1>Sotalol-induced</e1>\JJ\1740 coronary\JJ\1740 spasm\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 dilated\JJ\1740 cardiomyopathy\NN\14103288 associated\VBN\628491 with\IN\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 .\.\1740
D013015_D017180 NONE An\DT\6697703 alternate\JJ\1740 class\NN\7951464 III\CD\13741022 agent\NN\7347 ,\,\1740 <e1>sotalol</e1>\NNS\1740 ,\,\1740 was\VBD\836236 also\RB\1740 effective\JJ\1740 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>VT</e2>\NN\1740 .\.\1740
C076259_D017180 NONE After\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>nifekalant\JJ\1740 hydrochloride</e1>\NN\14817592 ,\,\1740 sustained\JJ\1740 <e2>VT</e2>\NN\1740 was\VBD\836236 terminated\VBN\126264 .\.\1740
23433219
D008694_D011605 CID The\DT\1740 risk\NN\14541044 and\CC\1740 associated\VBN\628491 factors\NNS\7326557 of\IN\1740 <e1>methamphetamine</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 methamphetamine-dependent\JJ\1740 patients\NNS\9898892 in\IN\13603305 Malaysia\NNP\1740 .\.\1740
D008694_D011605 CID The\DT\1740 risk\NN\14541044 and\CC\1740 associated\VBN\628491 factors\NNS\7326557 of\IN\1740 methamphetamine\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 <e1>methamphetamine-dependent</e1>\JJ\1740 patients\NNS\9898892 in\IN\13603305 Malaysia\NNP\1740 .\.\1740
D008694_D011605 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 risk\NN\14541044 of\IN\1740 lifetime\NN\15113229 and\CC\1740 current\JJ\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 patients\NNS\9898892 with\IN\1740 methamphetamine\NN\2704153 dependence\NN\24720 .\.\1740
D008694_D011605 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 risk\NN\14541044 of\IN\1740 lifetime\NN\15113229 and\CC\1740 current\JJ\1740 methamphetamine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>methamphetamine</e1>\NN\2704153 dependence\NN\24720 .\.\1740
D008694_D011605 CID The\DT\1740 association\NN\8008335 between\IN\1740 psychiatric\JJ\1740 co-morbidity\NN\1740 and\CC\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 was\VBD\836236 also\RB\1740 studied\VBN\630380 .\.\1740
D008694_D011605 CID Patients\NNS\9898892 with\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 based\VBN\2694933 on\IN\1740 DSM-IV\NN\1740 were\VBD\836236 interviewed\VBN\964694 using\VBG\1156834 the\DT\1740 Mini\NNP\4230808 International\NNP\8366202 Neuropsychiatric\NNP\1740 Interview\NNP\7193958 (\-LRB-\1740 M.I.N.I.\NNP\1740 )\-RRB-\1740 for\IN\1740 methamphetamine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 and\CC\1740 other\JJ\1740 Axis\NN\8593262 I\CD\14622893 psychiatric\JJ\1740 disorders\NNS\14034177 .\.\1740
D008694_D011605 CID Patients\NNS\9898892 with\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 methamphetamine\NN\2704153 based\VBN\2694933 on\IN\1740 DSM-IV\NN\1740 were\VBD\836236 interviewed\VBN\964694 using\VBG\1156834 the\DT\1740 Mini\NNP\4230808 International\NNP\8366202 Neuropsychiatric\NNP\1740 Interview\NNP\7193958 (\-LRB-\1740 M.I.N.I.\NNP\1740 )\-RRB-\1740 for\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 and\CC\1740 other\JJ\1740 Axis\NN\8593262 I\CD\14622893 psychiatric\JJ\1740 disorders\NNS\14034177 .\.\1740
D008694_D011605 CID Co-morbid\JJ\1740 major\JJ\1740 depressive\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 bipolar\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 disorder\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 methamphetamine-induced\JJ\1740 <e2>psychosis</e2>\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D011605 CID Co-morbid\JJ\1740 major\JJ\1740 depressive\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 bipolar\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 disorder\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 methamphetamine\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D011605 CID CONCLUSION\NN\5837957 :\:\1740 There\EX\27167 was\VBD\836236 a\DT\13649268 high\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>psychosis</e2>\NN\14380140 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>methamphetamine</e1>\NN\2704153 dependence\NN\24720 .\.\1740
D008694_D011605 CID It\PRP\6125041 is\VBZ\836236 recommended\VBN\875394 that\IN\1740 all\DT\1740 cases\NNS\7283608 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 dependence\NN\24720 should\MD\1740 be\VB\836236 screened\VBN\2533282 for\IN\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
D008694_D001523 NONE Patients\NNS\9898892 with\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 based\VBN\2694933 on\IN\1740 DSM-IV\NN\1740 were\VBD\836236 interviewed\VBN\964694 using\VBG\1156834 the\DT\1740 Mini\NNP\4230808 International\NNP\8366202 Neuropsychiatric\NNP\1740 Interview\NNP\7193958 (\-LRB-\1740 M.I.N.I.\NNP\1740 )\-RRB-\1740 for\IN\1740 methamphetamine-induced\JJ\1740 psychosis\NN\14380140 and\CC\1740 other\JJ\1740 Axis\NN\8593262 I\CD\14622893 <e2>psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D008694_D001523 NONE Patients\NNS\9898892 with\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 methamphetamine\NN\2704153 based\VBN\2694933 on\IN\1740 DSM-IV\NN\1740 were\VBD\836236 interviewed\VBN\964694 using\VBG\1156834 the\DT\1740 Mini\NNP\4230808 International\NNP\8366202 Neuropsychiatric\NNP\1740 Interview\NNP\7193958 (\-LRB-\1740 M.I.N.I.\NNP\1740 )\-RRB-\1740 for\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 psychosis\NN\14380140 and\CC\1740 other\JJ\1740 Axis\NN\8593262 I\CD\14622893 <e2>psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D008694_D003866 NONE Co-morbid\JJ\1740 major\JJ\1740 <e2>depressive\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 bipolar\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 disorder\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 methamphetamine-induced\JJ\1740 psychosis\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D003866 NONE Co-morbid\JJ\1740 major\JJ\1740 <e2>depressive\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 bipolar\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 disorder\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 methamphetamine\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 <e1>methamphetamine-induced</e1>\JJ\1740 psychosis\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D001714 CID Co-morbid\JJ\1740 major\JJ\1740 depressive\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 disorder\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 methamphetamine-induced\JJ\1740 psychosis\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D001714 CID Co-morbid\JJ\1740 major\JJ\1740 depressive\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 disorder\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 methamphetamine\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 <e1>methamphetamine-induced</e1>\JJ\1740 psychosis\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D000987 CID Co-morbid\JJ\1740 major\JJ\1740 depressive\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 bipolar\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>antisocial\JJ\1740 personality\NN\24264 disorder</e2>\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 methamphetamine-induced\JJ\1740 psychosis\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D000987 CID Co-morbid\JJ\1740 major\JJ\1740 depressive\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=7.18\NN\1740 ,\,\1740 95\CD\1740 CI=2.612\NN\1740 -\HYPH\1740 19.708\CD\1740 )\-RRB-\1740 ,\,\1740 bipolar\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 OR=13.807\NN\1740 ,\,\1740 95\CD\1740 CI=5.194\CD\1740 -\HYPH\1740 36.706\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>antisocial\JJ\1740 personality\NN\24264 disorder</e2>\NN\14034177 (\-LRB-\1740 OR=12.619\NN\1740 ,\,\1740 95\CD\1740 CI=6.702\CD\1740 -\:\1740 23.759\CD\1740 )\-RRB-\1740 and\CC\1740 heavy\JJ\1740 methamphetamine\NN\2704153 uses\NNS\407535 were\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 lifetime\NN\15113229 <e1>methamphetamine-induced</e1>\JJ\1740 psychosis\NN\14380140 after\IN\1740 adjusted\VBN\126264 for\IN\1740 other\JJ\1740 factors\NNS\7326557 .\.\1740
D008694_D000987 CID It\PRP\6125041 was\VBD\836236 associated\VBN\628491 with\IN\1740 co-morbid\JJ\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 <e2>antisocial\JJ\1740 personality</e2>\NN\24264 ,\,\1740 and\CC\1740 heavy\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 use\NN\407535 .\.\1740
D008694_D019964 NONE It\PRP\6125041 was\VBD\836236 associated\VBN\628491 with\IN\1740 co-morbid\JJ\1740 <e2>affective\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 antisocial\JJ\1740 personality\NN\24264 ,\,\1740 and\CC\1740 heavy\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 use\NN\407535 .\.\1740
16112787
D014640_D007674 CID In\FW\13603305 vivo\FW\1740 evidences\NNS\5816287 suggesting\VBG\1010118 the\DT\1740 role\NN\719494 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 pathogenesis\NN\13533470 of\IN\1740 <e1>vancomycin-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 protection\NN\407535 by\IN\1740 erdosteine\NN\1740 .\.\1740
D014640_D007674 CID The\DT\1740 aims\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 <e1>vancomycin</e1>\NN\2716866 (VCM)-induced\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 that\WDT\1740 promotes\VBZ\2556126 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 role\NN\719494 of\IN\1740 erdosteine\NN\1740 ,\,\1740 an\DT\6697703 expectorant\JJ\1740 agent\NN\7347 ,\,\1740 which\WDT\1740 has\VBZ\2108377 also\RB\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 on\IN\1740 kidney\NN\5333259 tissue\NN\5220461 against\IN\1740 the\DT\1740 possible\JJ\1740 VCM-induced\JJ\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014640_D007674 CID The\DT\1740 aims\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 vancomycin\NN\2716866 <e1>(VCM)-induced</e1>\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 that\WDT\1740 promotes\VBZ\2556126 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 role\NN\719494 of\IN\1740 erdosteine\NN\1740 ,\,\1740 an\DT\6697703 expectorant\JJ\1740 agent\NN\7347 ,\,\1740 which\WDT\1740 has\VBZ\2108377 also\RB\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 on\IN\1740 kidney\NN\5333259 tissue\NN\5220461 against\IN\1740 the\DT\1740 possible\JJ\1740 VCM-induced\JJ\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014640_D007674 CID The\DT\1740 aims\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 vancomycin\NN\2716866 (VCM)-induced\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 that\WDT\1740 promotes\VBZ\2556126 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 role\NN\719494 of\IN\1740 erdosteine\NN\1740 ,\,\1740 an\DT\6697703 expectorant\JJ\1740 agent\NN\7347 ,\,\1740 which\WDT\1740 has\VBZ\2108377 also\RB\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 on\IN\1740 kidney\NN\5333259 tissue\NN\5220461 against\IN\1740 the\DT\1740 possible\JJ\1740 <e1>VCM-induced</e1>\JJ\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014640_D007674 CID <e1>VCM</e1>\NN\1740 administration\NN\1133281 to\TO\1740 control\NN\5190804 rats\NNS\2329401 significantly\RB\1740 increased\VBD\169651 renal\JJ\1740 malondialdehyde\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 and\CC\1740 urinary\JJ\1740 N-acetyl-beta-d-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 ,\,\1740 a\DT\13649268 marker\NN\21939 of\IN\1740 <e2>renal\JJ\1740 tubular\JJ\1740 injury</e2>\NN\14052046 )\-RRB-\1740 excretion\NN\13466586 but\CC\1740 decreased\VBD\169651 superoxide\NN\14971519 dismutase\NN\1740 (\-LRB-\1740 SOD\NN\9335240 )\-RRB-\1740 and\CC\1740 catalase\NN\14732946 (\-LRB-\1740 CAT\NN\2120997 )\-RRB-\1740 activities\NNS\30358 .\.\1740
D014640_D007674 CID Erdosteine\NNP\1740 showed\VBD\2137132 histopathological\JJ\1740 protection\NN\407535 against\IN\1740 <e1>VCM-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D014640_D007674 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 oxidative\JJ\1740 tubular\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e1>VCM-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 the\DT\1740 modulation\NN\7044917 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 with\IN\1740 erdosteine\NN\1740 reduces\VBZ\441445 the\DT\1740 VCM-induced\JJ\1740 kidney\NN\5333259 damage\NN\7296428 both\CC\1740 at\IN\14622893 the\DT\1740 biochemical\JJ\1740 and\CC\1740 histological\JJ\1740 levels\NNS\4916342 .\.\1740
D014640_D007674 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 oxidative\JJ\1740 tubular\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e1>VCM-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 modulation\NN\7044917 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 with\IN\1740 erdosteine\NN\1740 reduces\VBZ\441445 the\DT\1740 VCM-induced\JJ\1740 <e2>kidney\NN\5333259 damage</e2>\NN\7296428 both\CC\1740 at\IN\14622893 the\DT\1740 biochemical\JJ\1740 and\CC\1740 histological\JJ\1740 levels\NNS\4916342 .\.\1740
D014640_D007674 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 oxidative\JJ\1740 tubular\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 VCM-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 the\DT\1740 modulation\NN\7044917 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 with\IN\1740 erdosteine\NN\1740 reduces\VBZ\441445 the\DT\1740 <e1>VCM-induced</e1>\JJ\1740 kidney\NN\5333259 damage\NN\7296428 both\CC\1740 at\IN\14622893 the\DT\1740 biochemical\JJ\1740 and\CC\1740 histological\JJ\1740 levels\NNS\4916342 .\.\1740
D014640_D007674 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 oxidative\JJ\1740 tubular\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 VCM-induced\JJ\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 modulation\NN\7044917 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 with\IN\1740 erdosteine\NN\1740 reduces\VBZ\441445 the\DT\1740 <e1>VCM-induced</e1>\JJ\1740 <e2>kidney\NN\5333259 damage</e2>\NN\7296428 both\CC\1740 at\IN\14622893 the\DT\1740 biochemical\JJ\1740 and\CC\1740 histological\JJ\1740 levels\NNS\4916342 .\.\1740
C048498_D007674 NONE In\FW\13603305 vivo\FW\1740 evidences\NNS\5816287 suggesting\VBG\1010118 the\DT\1740 role\NN\719494 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 pathogenesis\NN\13533470 of\IN\1740 vancomycin-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 protection\NN\407535 by\IN\1740 <e1>erdosteine</e1>\NN\1740 .\.\1740
C048498_D007674 NONE The\DT\1740 aims\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 vancomycin\NN\2716866 (VCM)-induced\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 that\WDT\1740 promotes\VBZ\2556126 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 role\NN\719494 of\IN\1740 <e1>erdosteine</e1>\NN\1740 ,\,\1740 an\DT\6697703 expectorant\JJ\1740 agent\NN\7347 ,\,\1740 which\WDT\1740 has\VBZ\2108377 also\RB\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 on\IN\1740 kidney\NN\5333259 tissue\NN\5220461 against\IN\1740 the\DT\1740 possible\JJ\1740 VCM-induced\JJ\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
C048498_D007674 NONE <e1>Erdosteine</e1>\NNP\1740 showed\VBD\2137132 histopathological\JJ\1740 protection\NN\407535 against\IN\1740 VCM-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
C048498_D007674 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 oxidative\JJ\1740 tubular\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 VCM-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 the\DT\1740 modulation\NN\7044917 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 with\IN\1740 <e1>erdosteine</e1>\NN\1740 reduces\VBZ\441445 the\DT\1740 VCM-induced\JJ\1740 kidney\NN\5333259 damage\NN\7296428 both\CC\1740 at\IN\14622893 the\DT\1740 biochemical\JJ\1740 and\CC\1740 histological\JJ\1740 levels\NNS\4916342 .\.\1740
C048498_D007674 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 oxidative\JJ\1740 tubular\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 VCM-induced\JJ\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 modulation\NN\7044917 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 with\IN\1740 <e1>erdosteine</e1>\NN\1740 reduces\VBZ\441445 the\DT\1740 VCM-induced\JJ\1740 <e2>kidney\NN\5333259 damage</e2>\NN\7296428 both\CC\1740 at\IN\14622893 the\DT\1740 biochemical\JJ\1740 and\CC\1740 histological\JJ\1740 levels\NNS\4916342 .\.\1740
D010100_D007674 NONE The\DT\1740 aims\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 examine\VB\789138 vancomycin\NN\2716866 (VCM)-induced\JJ\1740 oxidative\JJ\1740 stress\NN\7083732 that\WDT\1740 promotes\VBZ\2556126 production\NN\30358 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 (\-LRB-\1740 ROS\NN\6894544 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 role\NN\719494 of\IN\1740 erdosteine\NN\1740 ,\,\1740 an\DT\6697703 expectorant\JJ\1740 agent\NN\7347 ,\,\1740 which\WDT\1740 has\VBZ\2108377 also\RB\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 on\IN\1740 kidney\NN\5333259 tissue\NN\5220461 against\IN\1740 the\DT\1740 possible\JJ\1740 VCM-induced\JJ\1740 <e2>renal\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008315_D007674 NONE VCM\NN\1740 administration\NN\1133281 to\TO\1740 control\NN\5190804 rats\NNS\2329401 significantly\RB\1740 increased\VBD\169651 renal\JJ\1740 <e1>malondialdehyde</e1>\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 and\CC\1740 urinary\JJ\1740 N-acetyl-beta-d-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 ,\,\1740 a\DT\13649268 marker\NN\21939 of\IN\1740 <e2>renal\JJ\1740 tubular\JJ\1740 injury</e2>\NN\14052046 )\-RRB-\1740 excretion\NN\13466586 but\CC\1740 decreased\VBD\169651 superoxide\NN\14971519 dismutase\NN\1740 (\-LRB-\1740 SOD\NN\9335240 )\-RRB-\1740 and\CC\1740 catalase\NN\14732946 (\-LRB-\1740 CAT\NN\2120997 )\-RRB-\1740 activities\NNS\30358 .\.\1740
D008315_D007674 NONE VCM\NN\1740 administration\NN\1133281 to\TO\1740 control\NN\5190804 rats\NNS\2329401 significantly\RB\1740 increased\VBD\169651 renal\JJ\1740 malondialdehyde\NN\1740 (\-LRB-\1740 <e1>MDA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 urinary\JJ\1740 N-acetyl-beta-d-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 ,\,\1740 a\DT\13649268 marker\NN\21939 of\IN\1740 <e2>renal\JJ\1740 tubular\JJ\1740 injury</e2>\NN\14052046 )\-RRB-\1740 excretion\NN\13466586 but\CC\1740 decreased\VBD\169651 superoxide\NN\14971519 dismutase\NN\1740 (\-LRB-\1740 SOD\NN\9335240 )\-RRB-\1740 and\CC\1740 catalase\NN\14732946 (\-LRB-\1740 CAT\NN\2120997 )\-RRB-\1740 activities\NNS\30358 .\.\1740
D013481_D007674 NONE VCM\NN\1740 administration\NN\1133281 to\TO\1740 control\NN\5190804 rats\NNS\2329401 significantly\RB\1740 increased\VBD\169651 renal\JJ\1740 malondialdehyde\NN\1740 (\-LRB-\1740 MDA\NN\1740 )\-RRB-\1740 and\CC\1740 urinary\JJ\1740 N-acetyl-beta-d-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 ,\,\1740 a\DT\13649268 marker\NN\21939 of\IN\1740 <e2>renal\JJ\1740 tubular\JJ\1740 injury</e2>\NN\14052046 )\-RRB-\1740 excretion\NN\13466586 but\CC\1740 decreased\VBD\169651 <e1>superoxide</e1>\NN\14971519 dismutase\NN\1740 (\-LRB-\1740 SOD\NN\9335240 )\-RRB-\1740 and\CC\1740 catalase\NN\14732946 (\-LRB-\1740 CAT\NN\2120997 )\-RRB-\1740 activities\NNS\30358 .\.\1740
D014640_D001284 NONE There\EX\27167 were\VBD\836236 a\DT\13649268 significant\JJ\1740 dilatation\NN\14034177 of\IN\1740 tubular\JJ\1740 lumens\NNS\13639927 ,\,\1740 extensive\JJ\1740 epithelial\JJ\1740 cell\NN\3080309 vacuolization\NN\13920835 ,\,\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 desquamation\NN\11418750 ,\,\1740 and\CC\1740 necrosis\NN\11444117 in\IN\13603305 <e1>VCM-treated</e1>\JJ\1740 rats\NNS\2329401 more\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 control\NN\5190804 and\CC\1740 the\DT\1740 erdosteine\NN\1740 groups\NNS\2137 .\.\1740
D014640_-1 NONE There\EX\27167 were\VBD\836236 a\DT\13649268 significant\JJ\1740 dilatation\NN\14034177 of\IN\1740 tubular\JJ\1740 lumens\NNS\13639927 ,\,\1740 extensive\JJ\1740 epithelial\JJ\1740 cell\NN\3080309 vacuolization\NN\13920835 ,\,\1740 atrophy\NN\14299637 ,\,\1740 <e2>desquamation</e2>\NN\11418750 ,\,\1740 and\CC\1740 necrosis\NN\11444117 in\IN\13603305 <e1>VCM-treated</e1>\JJ\1740 rats\NNS\2329401 more\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 control\NN\5190804 and\CC\1740 the\DT\1740 erdosteine\NN\1740 groups\NNS\2137 .\.\1740
D014640_D009336 NONE There\EX\27167 were\VBD\836236 a\DT\13649268 significant\JJ\1740 dilatation\NN\14034177 of\IN\1740 tubular\JJ\1740 lumens\NNS\13639927 ,\,\1740 extensive\JJ\1740 epithelial\JJ\1740 cell\NN\3080309 vacuolization\NN\13920835 ,\,\1740 atrophy\NN\14299637 ,\,\1740 desquamation\NN\11418750 ,\,\1740 and\CC\1740 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 <e1>VCM-treated</e1>\JJ\1740 rats\NNS\2329401 more\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 control\NN\5190804 and\CC\1740 the\DT\1740 erdosteine\NN\1740 groups\NNS\2137 .\.\1740
C048498_D001284 NONE There\EX\27167 were\VBD\836236 a\DT\13649268 significant\JJ\1740 dilatation\NN\14034177 of\IN\1740 tubular\JJ\1740 lumens\NNS\13639927 ,\,\1740 extensive\JJ\1740 epithelial\JJ\1740 cell\NN\3080309 vacuolization\NN\13920835 ,\,\1740 <e2>atrophy</e2>\NN\14299637 ,\,\1740 desquamation\NN\11418750 ,\,\1740 and\CC\1740 necrosis\NN\11444117 in\IN\13603305 VCM-treated\JJ\1740 rats\NNS\2329401 more\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 control\NN\5190804 and\CC\1740 the\DT\1740 <e1>erdosteine</e1>\NN\1740 groups\NNS\2137 .\.\1740
C048498_-1 NONE There\EX\27167 were\VBD\836236 a\DT\13649268 significant\JJ\1740 dilatation\NN\14034177 of\IN\1740 tubular\JJ\1740 lumens\NNS\13639927 ,\,\1740 extensive\JJ\1740 epithelial\JJ\1740 cell\NN\3080309 vacuolization\NN\13920835 ,\,\1740 atrophy\NN\14299637 ,\,\1740 <e2>desquamation</e2>\NN\11418750 ,\,\1740 and\CC\1740 necrosis\NN\11444117 in\IN\13603305 VCM-treated\JJ\1740 rats\NNS\2329401 more\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 control\NN\5190804 and\CC\1740 the\DT\1740 <e1>erdosteine</e1>\NN\1740 groups\NNS\2137 .\.\1740
C048498_D009336 NONE There\EX\27167 were\VBD\836236 a\DT\13649268 significant\JJ\1740 dilatation\NN\14034177 of\IN\1740 tubular\JJ\1740 lumens\NNS\13639927 ,\,\1740 extensive\JJ\1740 epithelial\JJ\1740 cell\NN\3080309 vacuolization\NN\13920835 ,\,\1740 atrophy\NN\14299637 ,\,\1740 desquamation\NN\11418750 ,\,\1740 and\CC\1740 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 VCM-treated\JJ\1740 rats\NNS\2329401 more\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 control\NN\5190804 and\CC\1740 the\DT\1740 <e1>erdosteine</e1>\NN\1740 groups\NNS\2137 .\.\1740
11439380
D013792_D009422 NONE <e1>Thalidomide</e1>\VB\1740 <e2>neuropathy</e2>\NN\14204950 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 for\IN\1740 metastatic\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 .\.\1740
D013792_D009422 NONE We\PRP\1740 prospectively\RB\1740 evaluated\VBD\670261 <e1>thalidomide-induced</e1>\JJ\1740 <e2>neuropathy</e2>\JJ\1740 using\VBG\1156834 electrodiagnostic\JJ\1740 studies\NNS\635850 .\.\1740
D013792_D009422 NONE <e2>Neuropathy</e2>\NNP\14204950 may\MD\15209706 thus\RB\1740 be\VB\836236 a\DT\13649268 common\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 .\.\1740
D013792_D011471 NONE <e1>Thalidomide</e1>\VB\1740 neuropathy\NN\14204950 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 for\IN\1740 metastatic\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D013792_D011471 NONE Sixty-seven\JJ\1740 men\NNS\8208016 with\IN\1740 metastatic\JJ\1740 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 in\IN\13603305 an\DT\6697703 open-label\JJ\1740 trial\NN\786195 of\IN\1740 oral\JJ\1740 <e1>thalidomide</e1>\NN\4166841 underwent\VBD\109660 neurologic\JJ\1740 examinations\NNS\633864 and\CC\1740 nerve\NN\5475681 conduction\NN\11419404 studies\NNS\635850 (\-LRB-\1740 NCS\NN\1740 )\-RRB-\1740 prior\RB\1740 to\TO\1740 and\CC\1740 at\IN\14622893 3-month\JJ\1740 intervals\NNS\33615 during\IN\1740 treatment\NN\654885 .\.\1740
D000728_D011471 NONE Sixty-seven\JJ\1740 men\NNS\8208016 with\IN\1740 metastatic\JJ\1740 <e1>androgen-independent</e1>\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 in\IN\13603305 an\DT\6697703 open-label\JJ\1740 trial\NN\786195 of\IN\1740 oral\JJ\1740 thalidomide\NN\4166841 underwent\VBD\109660 neurologic\JJ\1740 examinations\NNS\633864 and\CC\1740 nerve\NN\5475681 conduction\NN\11419404 studies\NNS\635850 (\-LRB-\1740 NCS\NN\1740 )\-RRB-\1740 prior\RB\1740 to\TO\1740 and\CC\1740 at\IN\14622893 3-month\JJ\1740 intervals\NNS\33615 during\IN\1740 treatment\NN\654885 .\.\1740
24842192
D008687_D018487 NONE Chronic\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>metformin</e1>\NN\2719105 suppresses\VBZ\2510337 toll-like\JJ\1740 receptor\NN\5225602 4\CD\13741022 signaling\NN\33020 and\CC\1740 attenuates\VBZ\224901 <e2>left\JJ\1740 ventricular\NN\1740 dysfunction</e2>\NN\14204950 following\VBG\1835496 myocardial\JJ\1740 infarction\NN\14204950 .\.\1740
D008687_D018487 NONE The\DT\1740 <e2>left\JJ\1740 ventricular\NN\1740 dysfunction</e2>\NN\14204950 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 in\IN\13603305 the\DT\1740 groups\NNS\2137 treated\VBN\2376958 with\IN\1740 25\CD\13745420 and\CC\1740 50mg/kg\NN\1740 of\IN\1740 <e1>metformin</e1>\NN\2719105 .\.\1740
D008687_D009203 NONE Chronic\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>metformin</e1>\NN\2719105 suppresses\VBZ\2510337 toll-like\JJ\1740 receptor\NN\5225602 4\CD\13741022 signaling\NN\33020 and\CC\1740 attenuates\VBZ\224901 left\JJ\1740 ventricular\NN\1740 dysfunction\NN\14204950 following\VBG\1835496 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D008687_D009203 NONE Acute\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>metformin</e1>\NN\2719105 has\VBZ\2108377 a\DT\13649268 protective\JJ\1740 effect\NN\34213 in\IN\13603305 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 by\IN\1740 suppression\NN\13489037 of\IN\1740 inflammatory\JJ\1740 responses\NNS\11410625 due\JJ\1740 to\TO\1740 activation\NN\13561719 of\IN\1740 AMP-activated\JJ\1740 protein\NN\14944888 kinase\NN\14732946 (\-LRB-\1740 AMPK\NN\1740 )\-RRB-\1740 .\.\1740
D008687_D009203 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 chronic\JJ\1740 pre-treatment\NN\1740 with\IN\1740 <e1>metformin</e1>\NN\2719105 on\IN\1740 cardiac\JJ\1740 dysfunction\NN\14204950 and\CC\1740 toll-like\JJ\1740 receptor\NN\5225602 4\CD\13741022 (\-LRB-\1740 TLR4\NN\1740 )\-RRB-\1740 activities\NNS\30358 following\VBG\1835496 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 their\PRP$\1740 relation\NN\2137 with\IN\1740 AMPK\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
D008687_D009203 NONE Chronic\JJ\1740 pre-treatment\NN\1740 with\IN\1740 <e1>metformin</e1>\NN\2719105 reduces\VBZ\441445 <e2>post-myocardial\JJ\1740 infarction</e2>\NN\14204950 cardiac\NN\1740 dysfunction\NN\14204950 and\CC\1740 suppresses\VBZ\2510337 inflammatory\JJ\1740 responses\NNS\11410625 ,\,\1740 possibly\RB\1740 through\IN\1740 inhibition\NN\1068773 of\IN\1740 TLR4\NN\1740 activities\NNS\30358 .\.\1740
D000667_D009203 NONE Acute\JJ\1740 treatment\NN\654885 with\IN\1740 metformin\NN\2719105 has\VBZ\2108377 a\DT\13649268 protective\JJ\1740 effect\NN\34213 in\IN\13603305 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 by\IN\1740 suppression\NN\13489037 of\IN\1740 inflammatory\JJ\1740 responses\NNS\11410625 due\JJ\1740 to\TO\1740 activation\NN\13561719 of\IN\1740 <e1>AMP-activated</e1>\JJ\1740 protein\NN\14944888 kinase\NN\14732946 (\-LRB-\1740 AMPK\NN\1740 )\-RRB-\1740 .\.\1740
D008687_D006331 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 chronic\JJ\1740 pre-treatment\NN\1740 with\IN\1740 <e1>metformin</e1>\NN\2719105 on\IN\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 toll-like\JJ\1740 receptor\NN\5225602 4\CD\13741022 (\-LRB-\1740 TLR4\NN\1740 )\-RRB-\1740 activities\NNS\30358 following\VBG\1835496 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 their\PRP$\1740 relation\NN\2137 with\IN\1740 AMPK\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
D007545_D009203 CID <e1>Isoproterenol</e1>\NN\3740161 (\-LRB-\1740 100mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 injected\VBN\81072 subcutaneously\RB\1740 on\IN\1740 the\DT\1740 13th\NN\1740 and\CC\1740 14th\JJ\1740 days\NNS\15140892 to\TO\1740 induce\VB\1627355 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D007545_D009369 NONE Metfromin\NN\1740 markedly\RB\1740 lowered\VBD\1850315 <e1>isoproterenol-induced</e1>\JJ\1740 elevation\NN\7445480 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 TLR4\NN\1740 mRNA\NN\14832193 ,\,\1740 myeloid\JJ\1740 differentiation\NN\5748054 protein\NN\14944888 88\CD\1740 (\-LRB-\1740 MyD88\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>tumor</e2>\NN\14234074 necrosis\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNF-a\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 interleukin\NN\14943950 6\CD\13741022 (\-LRB-\1740 IL-6\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 heart\NN\5919034 tissues\NNS\5220461 .\.\1740
D007545_D009336 NONE Metfromin\NN\1740 markedly\RB\1740 lowered\VBD\1850315 <e1>isoproterenol-induced</e1>\JJ\1740 elevation\NN\7445480 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 TLR4\NN\1740 mRNA\NN\14832193 ,\,\1740 myeloid\JJ\1740 differentiation\NN\5748054 protein\NN\14944888 88\CD\1740 (\-LRB-\1740 MyD88\NN\1740 )\-RRB-\1740 ,\,\1740 tumor\NN\14234074 <e2>necrosis</e2>\NN\11444117 factor-alpha\NN\1740 (\-LRB-\1740 TNF-a\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 interleukin\NN\14943950 6\CD\13741022 (\-LRB-\1740 IL-6\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 heart\NN\5919034 tissues\NNS\5220461 .\.\1740
9646784
D006493_D013921 CID <e1>Heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 paradoxical\JJ\1740 thromboembolism\NN\14100769 ,\,\1740 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013921 CID Heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 paradoxical\JJ\1740 thromboembolism\NN\14100769 ,\,\1740 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013921 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D013921 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D013921 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D013921 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D013921 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D013921 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D013923 CID <e1>Heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 paradoxical\JJ\1740 <e2>thromboembolism</e2>\NN\14100769 ,\,\1740 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D013923 CID Heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 paradoxical\JJ\1740 <e2>thromboembolism</e2>\NN\14100769 ,\,\1740 and\CC\1740 other\JJ\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 .\.\1740
D006493_D010024 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 <e2>osteoporosis</e2>\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D010024 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 <e2>osteoporosis</e2>\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D010024 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 <e2>osteoporosis</e2>\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D004802 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D004802 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D004802 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D012871 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D012871 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D012871 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>skin\NN\5237755 reactions</e2>\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D004342 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D004342 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D004342 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 alopecia\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D000505 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>heparin</e1>\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>alopecia</e2>\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D000505 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 heparin-associated\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>alopecia</e2>\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
D006493_D000505 CID Important\JJ\1740 untoward\JJ\1740 effects\NNS\13245626 of\IN\1740 heparin\NN\2718259 therapy\NN\657604 including\VBG\690614 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 ,\,\1740 <e1>heparin-associated</e1>\JJ\1740 osteoporosis\NN\14204950 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 skin\NN\5237755 reactions\NNS\13446390 ,\,\1740 allergic\JJ\1740 reactions\NNS\13446390 other\JJ\1740 than\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>alopecia</e2>\NN\14457041 will\MD\5650329 be\VB\836236 discussed\VBN\1033527 in\IN\13603305 this\DT\1740 article\NN\6367571 .\.\1740
24582773
C069541_D011595 CID Paradoxical\JJ\1740 severe\JJ\1740 <e2>agitation</e2>\NN\14373582 induced\VBN\1627355 by\IN\1740 add-on\JJ\1740 high-doses\JJ\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 schizo-affective\JJ\1740 disorder\NN\14034177 .\.\1740
C069541_D011595 CID Within\IN\1740 the\DT\1740 48\CD\1740 h\NN\14622893 following\VBG\1835496 the\DT\1740 gradual\JJ\1740 introduction\NN\235435 of\IN\1740 <e1>quetiapine</e1>\NN\1740 (\-LRB-\1740 up\RB\1740 to\TO\1740 600\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 severe\JJ\1740 <e2>agitation</e2>\NN\14373582 without\IN\1740 an\DT\6697703 environmental\JJ\1740 explanation\NN\6722453 ,\,\1740 contrasting\VBG\650353 with\IN\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 aggressiveness\NN\4835724 or\CC\3541091 personality\NN\24264 disorder\NN\14034177 .\.\1740
C069541_D011595 CID The\DT\1740 withdrawal\NN\7206096 and\CC\1740 the\DT\1740 gradual\JJ\1740 reintroduction\NN\7217349 of\IN\1740 <e1>quetiapine</e1>\NN\1740 2\CD\13741022 weeks\NNS\15113229 later\RBR\1740 ,\,\1740 which\WDT\1740 led\VBD\1752884 to\IN\1740 another\DT\1740 severe\JJ\1740 <e2>agitation</e2>\NN\14373582 ,\,\1740 enabled\VBD\126264 us\PRP\14964590 to\TO\1740 attribute\VB\670261 the\DT\1740 agitation\NN\14373582 specifically\RB\1740 to\TO\1740 quetiapine\NN\1740 .\.\1740
C069541_D011595 CID The\DT\1740 withdrawal\NN\7206096 and\CC\1740 the\DT\1740 gradual\JJ\1740 reintroduction\NN\7217349 of\IN\1740 <e1>quetiapine</e1>\NN\1740 2\CD\13741022 weeks\NNS\15113229 later\RBR\1740 ,\,\1740 which\WDT\1740 led\VBD\1752884 to\IN\1740 another\DT\1740 severe\JJ\1740 agitation\NN\14373582 ,\,\1740 enabled\VBD\126264 us\PRP\14964590 to\TO\1740 attribute\VB\670261 the\DT\1740 <e2>agitation</e2>\NN\14373582 specifically\RB\1740 to\TO\1740 quetiapine\NN\1740 .\.\1740
C069541_D011595 CID The\DT\1740 withdrawal\NN\7206096 and\CC\1740 the\DT\1740 gradual\JJ\1740 reintroduction\NN\7217349 of\IN\1740 quetiapine\NN\1740 2\CD\13741022 weeks\NNS\15113229 later\RBR\1740 ,\,\1740 which\WDT\1740 led\VBD\1752884 to\IN\1740 another\DT\1740 severe\JJ\1740 <e2>agitation</e2>\NN\14373582 ,\,\1740 enabled\VBD\126264 us\PRP\14964590 to\TO\1740 attribute\VB\670261 the\DT\1740 agitation\NN\14373582 specifically\RB\1740 to\TO\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
C069541_D011595 CID The\DT\1740 withdrawal\NN\7206096 and\CC\1740 the\DT\1740 gradual\JJ\1740 reintroduction\NN\7217349 of\IN\1740 quetiapine\NN\1740 2\CD\13741022 weeks\NNS\15113229 later\RBR\1740 ,\,\1740 which\WDT\1740 led\VBD\1752884 to\IN\1740 another\DT\1740 severe\JJ\1740 agitation\NN\14373582 ,\,\1740 enabled\VBD\126264 us\PRP\14964590 to\TO\1740 attribute\VB\670261 the\DT\1740 <e2>agitation</e2>\NN\14373582 specifically\RB\1740 to\TO\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
C069541_D011618 NONE Paradoxical\JJ\1740 severe\JJ\1740 agitation\NN\14373582 induced\VBN\1627355 by\IN\1740 add-on\JJ\1740 high-doses\JJ\1740 <e1>quetiapine</e1>\NN\1740 in\IN\13603305 <e2>schizo-affective\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D003006_D011618 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 35-year-old\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 <e2>schizo-affective\JJ\1740 disorder</e2>\NN\14034177 since\IN\1740 the\DT\1740 age\NN\4916342 of\IN\1740 19\CD\13745420 years\NNS\15144371 ,\,\1740 treated\VBN\2376958 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 first-generation\NN\1740 antipsychotics\NNS\4470232 ,\,\1740 <e1>zuclopenthixol</e1>\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 lithium\NN\14625458 (\-LRB-\1740 1200\CD\1740 mg/day\NN\1740 )\-RRB-\1740 (\-LRB-\1740 serum\NN\5397468 lithium=0.85\NN\1740 mEq/l\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D011618 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 35-year-old\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 <e2>schizo-affective\JJ\1740 disorder</e2>\NN\14034177 since\IN\1740 the\DT\1740 age\NN\4916342 of\IN\1740 19\CD\13745420 years\NNS\15144371 ,\,\1740 treated\VBN\2376958 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 first-generation\NN\1740 antipsychotics\NNS\4470232 ,\,\1740 zuclopenthixol\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>lithium</e1>\NN\14625458 (\-LRB-\1740 1200\CD\1740 mg/day\NN\1740 )\-RRB-\1740 (\-LRB-\1740 serum\NN\5397468 lithium=0.85\NN\1740 mEq/l\NN\1740 )\-RRB-\1740 .\.\1740
D008094_D011618 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 35-year-old\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 <e2>schizo-affective\JJ\1740 disorder</e2>\NN\14034177 since\IN\1740 the\DT\1740 age\NN\4916342 of\IN\1740 19\CD\13745420 years\NNS\15144371 ,\,\1740 treated\VBN\2376958 by\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 first-generation\NN\1740 antipsychotics\NNS\4470232 ,\,\1740 zuclopenthixol\NN\1740 (\-LRB-\1740 100\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 and\CC\1740 lithium\NN\14625458 (\-LRB-\1740 1200\CD\1740 mg/day\NN\1740 )\-RRB-\1740 (\-LRB-\1740 serum\NN\5397468 <e1>lithium=0.85</e1>\NN\1740 mEq/l\NN\1740 )\-RRB-\1740 .\.\1740
C069541_D010554 NONE Within\IN\1740 the\DT\1740 48\CD\1740 h\NN\14622893 following\VBG\1835496 the\DT\1740 gradual\JJ\1740 introduction\NN\235435 of\IN\1740 <e1>quetiapine</e1>\NN\1740 (\-LRB-\1740 up\RB\1740 to\TO\1740 600\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 severe\JJ\1740 agitation\NN\14373582 without\IN\1740 an\DT\6697703 environmental\JJ\1740 explanation\NN\6722453 ,\,\1740 contrasting\VBG\650353 with\IN\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>aggressiveness</e2>\NN\4835724 or\CC\3541091 personality\NN\24264 disorder\NN\14034177 .\.\1740
C069541_D010554 NONE Within\IN\1740 the\DT\1740 48\CD\1740 h\NN\14622893 following\VBG\1835496 the\DT\1740 gradual\JJ\1740 introduction\NN\235435 of\IN\1740 <e1>quetiapine</e1>\NN\1740 (\-LRB-\1740 up\RB\1740 to\TO\1740 600\CD\1740 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 severe\JJ\1740 agitation\NN\14373582 without\IN\1740 an\DT\6697703 environmental\JJ\1740 explanation\NN\6722453 ,\,\1740 contrasting\VBG\650353 with\IN\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 aggressiveness\NN\4835724 or\CC\3541091 <e2>personality\NN\24264 disorder</e2>\NN\14034177 .\.\1740
24459006
D015725_D000380 CID <e1>Fluconazole</e1>\NNP\1740 associated\VBD\628491 <e2>agranulocytosis</e2>\NN\14189204 and\CC\1740 thrombocytopenia\NN\14189204 .\.\1740
D015725_D000380 CID CASE\LS\7283608 :\:\1740 We\PRP\1740 describe\VBP\1001294 a\DT\13649268 second\JJ\1740 case\NN\7283608 of\IN\1740 <e1>fluconazole</e1>\NN\1740 associated\VBN\628491 <e2>agranulocytosis</e2>\NN\14189204 with\IN\1740 thrombocytopenia\NN\14189204 and\CC\1740 recovery\NN\7357388 upon\IN\1740 discontinuation\NN\209943 of\IN\1740 therapy\NN\657604 .\.\1740
D015725_D000380 CID CONCLUSION\NN\5837957 :\:\1740 According\VBG\2657219 to\IN\1740 Naranjo\NNP\1740 's\POS\1740 algorithm\NN\5846932 the\DT\1740 likelihood\NN\4756172 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 <e2>agranulocytosis</e2>\NN\14189204 and\CC\1740 thrombocytopenia\NN\14189204 occurred\VBD\2623529 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>fluconazole</e1>\NN\1740 is\VBZ\836236 probable\JJ\1740 ,\,\1740 with\IN\1740 a\DT\13649268 total\NN\3553 of\IN\1740 six\CD\13741022 points\NNS\5868954 .\.\1740
D015725_D013921 CID <e1>Fluconazole</e1>\NNP\1740 associated\VBD\628491 agranulocytosis\NN\14189204 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D015725_D013921 CID CASE\LS\7283608 :\:\1740 We\PRP\1740 describe\VBP\1001294 a\DT\13649268 second\JJ\1740 case\NN\7283608 of\IN\1740 <e1>fluconazole</e1>\NN\1740 associated\VBN\628491 agranulocytosis\NN\14189204 with\IN\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 recovery\NN\7357388 upon\IN\1740 discontinuation\NN\209943 of\IN\1740 therapy\NN\657604 .\.\1740
D015725_D013921 CID CONCLUSION\NN\5837957 :\:\1740 According\VBG\2657219 to\IN\1740 Naranjo\NNP\1740 's\POS\1740 algorithm\NN\5846932 the\DT\1740 likelihood\NN\4756172 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 agranulocytosis\NN\14189204 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 occurred\VBD\2623529 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>fluconazole</e1>\NN\1740 is\VBZ\836236 probable\JJ\1740 ,\,\1740 with\IN\1740 a\DT\13649268 total\NN\3553 of\IN\1740 six\CD\13741022 points\NNS\5868954 .\.\1740
D015725_D001855 NONE In\IN\13603305 particular\JJ\1740 the\DT\1740 temporal\JJ\1740 relationship\NN\31921 of\IN\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 to\TO\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>fluconazole</e1>\NN\1740 and\CC\1740 the\DT\1740 abatement\NN\7367812 of\IN\1740 symptoms\NNS\5823932 that\WDT\1740 rapidly\RB\1740 reversed\VBD\109660 immediately\RB\1740 following\VBG\1835496 discontinuation\NN\209943 .\.\1740
24234943
C086816_D007177 CID <e2>Syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 antidiuretic\JJ\1740 hormone</e2>\NN\5404728 secretion\NN\13526110 associated\VBN\628491 with\IN\1740 <e1>desvenlafaxine</e1>\NN\1740 .\.\1740
C086816_D007177 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 anti-diuretic\JJ\1740 hormone</e2>\NN\5404728 (\-LRB-\1740 SIADH\NN\1740 )\-RRB-\1740 secretion\NN\13526110 associated\VBN\628491 with\IN\1740 <e1>desvenlafaxine</e1>\NN\1740 .\.\1740
C086816_D007177 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 anti-diuretic\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 <e2>SIADH</e2>\NN\1740 )\-RRB-\1740 secretion\NN\13526110 associated\VBN\628491 with\IN\1740 <e1>desvenlafaxine</e1>\NN\1740 .\.\1740
C086816_D009325 CID Her\PRP$\1740 medications\NNS\3247620 included\VBD\690614 <e1>desvenlafaxine</e1>\NN\1740 ,\,\1740 and\CC\1740 symptoms\NNS\5823932 included\VBD\690614 <e2>nausea</e2>\NN\14299637 ,\,\1740 anxiety\NN\14373582 and\CC\1740 confusion\NN\13972797 .\.\1740
C086816_D001008 CID Her\PRP$\1740 medications\NNS\3247620 included\VBD\690614 <e1>desvenlafaxine</e1>\NN\1740 ,\,\1740 and\CC\1740 symptoms\NNS\5823932 included\VBD\690614 nausea\NN\14299637 ,\,\1740 <e2>anxiety</e2>\NN\14373582 and\CC\1740 confusion\NN\13972797 .\.\1740
C086816_D003221 CID Her\PRP$\1740 medications\NNS\3247620 included\VBD\690614 <e1>desvenlafaxine</e1>\NN\1740 ,\,\1740 and\CC\1740 symptoms\NNS\5823932 included\VBD\690614 nausea\NN\14299637 ,\,\1740 anxiety\NN\14373582 and\CC\1740 <e2>confusion</e2>\NN\13972797 .\.\1740
D012964_D007177 NONE The\DT\1740 serum\NN\5397468 <e1>sodium</e1>\NN\14625458 at\IN\14622893 this\DT\1740 time\NN\7308889 was\VBD\836236 120\CD\13745420 mmol/L\NN\1740 ,\,\1740 serum\NN\5397468 osmolality\NN\1740 was\VBD\836236 263\CD\1740 mosmol/kg\NNS\1740 ,\,\1740 urine\NN\14853947 osmolality\NN\1740 410\CD\1740 mosmol/kg\NN\1740 and\CC\1740 urine\NN\14853947 sodium\NN\14625458 63\CD\1740 mmol/L\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 <e2>SIADH</e2>\NN\1740 .\.\1740
D012964_D007177 NONE The\DT\1740 serum\NN\5397468 sodium\NN\14625458 at\IN\14622893 this\DT\1740 time\NN\7308889 was\VBD\836236 120\CD\13745420 mmol/L\NN\1740 ,\,\1740 serum\NN\5397468 osmolality\NN\1740 was\VBD\836236 263\CD\1740 mosmol/kg\NNS\1740 ,\,\1740 urine\NN\14853947 osmolality\NN\1740 410\CD\1740 mosmol/kg\NN\1740 and\CC\1740 urine\NN\14853947 <e1>sodium</e1>\NN\14625458 63\CD\1740 mmol/L\NN\1740 ,\,\1740 consistent\JJ\1740 with\IN\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 <e2>SIADH</e2>\NN\1740 .\.\1740
C086816_D007010 CID This\DT\1740 case\NN\7283608 report\NN\6470073 suggests\VBZ\1010118 that\IN\1740 <e1>desvenlafaxine</e1>\NN\1740 might\MD\5029706 cause\VB\1617192 clinically\RB\1740 significant\JJ\1740 <e2>hyponatremia</e2>\NN\14299637 .\.\1740
8829135
C058876_D000647 NONE <e1>Nefiracetam</e1>\NN\1740 (\-LRB-\1740 DM-9384\NN\1740 )\-RRB-\1740 reverses\VBZ\109660 apomorphine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 response\NN\11410625 :\:\1740 delayed\VBN\439958 emergence\NN\7290905 of\IN\1740 the\DT\1740 memory\NN\5926676 retention\NN\809465 effects\NNS\13245626 .\.\1740
C058876_D000647 NONE Nefiracetam\NN\1740 (\-LRB-\1740 <e1>DM-9384</e1>\NN\1740 )\-RRB-\1740 reverses\VBZ\109660 apomorphine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 response\NN\11410625 :\:\1740 delayed\VBN\439958 emergence\NN\7290905 of\IN\1740 the\DT\1740 memory\NN\5926676 retention\NN\809465 effects\NNS\13245626 .\.\1740
C058876_D000647 NONE Given\VBN\2327200 that\DT\1740 apomorphine\NN\3786417 inhibits\VBZ\2510337 passive\JJ\1740 avoidance\NN\203342 retention\NN\809465 when\WRB\1740 given\VBN\2327200 during\IN\1740 training\NN\407535 or\CC\3541091 in\IN\13603305 a\DT\13649268 defined\VBN\2604760 10\CD\13745420 -\HYPH\1740 12h\NN\1740 post-training\JJ\1740 period\NN\13575869 ,\,\1740 we\PRP\1740 evaluated\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>nefiracetam</e1>\NN\1740 to\TO\1740 attenuate\VB\224901 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 dopaminergic\JJ\1740 agonism\NN\1740 .\.\1740
C058876_D000647 NONE However\RB\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 <e1>nefiracetam</e1>\NN\1740 during\IN\1740 training\NN\407535 completely\RB\1740 reversed\VBD\109660 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 apomorphine\NN\3786417 at\IN\14622893 the\DT\1740 10h\NN\1740 post-training\JJ\1740 time\NN\7308889 and\CC\1740 the\DT\1740 converse\NN\6750804 was\VBD\836236 also\RB\1740 true\JJ\1740 .\.\1740
D001058_D000647 CID Nefiracetam\NN\1740 (\-LRB-\1740 DM-9384\NN\1740 )\-RRB-\1740 reverses\VBZ\109660 <e1>apomorphine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 of\IN\1740 a\DT\13649268 passive\JJ\1740 avoidance\NN\203342 response\NN\11410625 :\:\1740 delayed\VBN\439958 emergence\NN\7290905 of\IN\1740 the\DT\1740 memory\NN\5926676 retention\NN\809465 effects\NNS\13245626 .\.\1740
D001058_D000647 CID Given\VBN\2327200 that\DT\1740 <e1>apomorphine</e1>\NN\3786417 inhibits\VBZ\2510337 passive\JJ\1740 avoidance\NN\203342 retention\NN\809465 when\WRB\1740 given\VBN\2327200 during\IN\1740 training\NN\407535 or\CC\3541091 in\IN\13603305 a\DT\13649268 defined\VBN\2604760 10\CD\13745420 -\HYPH\1740 12h\NN\1740 post-training\JJ\1740 period\NN\13575869 ,\,\1740 we\PRP\1740 evaluated\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 nefiracetam\NN\1740 to\TO\1740 attenuate\VB\224901 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 dopaminergic\JJ\1740 agonism\NN\1740 .\.\1740
D001058_D000647 CID However\RB\1740 ,\,\1740 administration\NN\1133281 of\IN\1740 nefiracetam\NN\1740 during\IN\1740 training\NN\407535 completely\RB\1740 reversed\VBD\109660 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 <e1>apomorphine</e1>\NN\3786417 at\IN\14622893 the\DT\1740 10h\NN\1740 post-training\JJ\1740 time\NN\7308889 and\CC\1740 the\DT\1740 converse\NN\6750804 was\VBD\836236 also\RB\1740 true\JJ\1740 .\.\1740
C058876_D007859 NONE <e1>Nefiracetam</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 pyrrolidone\NN\1740 derivative\JJ\1740 which\WDT\1740 attenuates\VBZ\224901 scopolamine-induced\JJ\1740 <e2>learning\NN\5701944 and\CC\1740 post-training\JJ\1740 consolidation\NN\7373803 deficits</e2>\NNS\5113133 .\.\1740
D011760_D007859 NONE Nefiracetam\NNP\1740 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 <e1>pyrrolidone</e1>\NN\1740 derivative\JJ\1740 which\WDT\1740 attenuates\VBZ\224901 scopolamine-induced\JJ\1740 <e2>learning\NN\5701944 and\CC\1740 post-training\JJ\1740 consolidation\NN\7373803 deficits</e2>\NNS\5113133 .\.\1740
D012601_D007859 CID Nefiracetam\NNP\1740 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 pyrrolidone\NN\1740 derivative\JJ\1740 which\WDT\1740 attenuates\VBZ\224901 <e1>scopolamine-induced</e1>\JJ\1740 <e2>learning\NN\5701944 and\CC\1740 post-training\JJ\1740 consolidation\NN\7373803 deficits</e2>\NNS\5113133 .\.\1740
24709919
D036145_D006930 NONE Effects\NNS\13245626 of\IN\1740 <e1>ginsenosides</e1>\NNS\1740 on\IN\1740 opioid-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C049864_D006930 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>Re\NN\14625458 ,\,\1740 Rg1\NN\1740 ,\,\1740 and\CC\1740 Rb1\NN\1740 ginsenosides</e1>\VBZ\1740 ,\,\1740 the\DT\1740 bioactive\JJ\1740 components\NNS\5867413 of\IN\1740 ginseng\NN\13125117 ,\,\1740 on\IN\1740 <e2>OIH</e2>\NNP\1740 .\.\1740
C049864_D006930 NONE <e1>Re</e1>\IN\14625458 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 inhibited\VBD\2510337 <e2>OIH</e2>\NN\1740 in\IN\13603305 both\CC\1740 the\DT\1740 thermal\JJ\1740 sensitivity\NN\5651971 test\NN\5798043 and\CC\1740 the\DT\1740 acetic\JJ\1740 acid-induced\JJ\1740 writhing\NN\1740 test\NN\5798043 .\.\1740
C049864_D006930 NONE Our\PRP$\1740 data\NNS\7951464 suggested\VBD\1010118 that\IN\1740 the\DT\1740 <e1>ginsenoside\NN\1740 Re</e1>\IN\14625458 ,\,\1740 but\CC\1740 not\RB\1740 Rg1\NN\1740 or\CC\3541091 Rb1\NN\1740 ,\,\1740 may\MD\15209706 contribute\VB\126264 toward\IN\1740 reversal\NN\199130 of\IN\1740 <e2>OIH</e2>\NNP\1740 .\.\1740
C035054_D006930 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>Re\NN\14625458 ,\,\1740 Rg1\NN\1740 ,\,\1740 and\CC\1740 Rb1\NN\1740 ginsenosides</e1>\VBZ\1740 ,\,\1740 the\DT\1740 bioactive\JJ\1740 components\NNS\5867413 of\IN\1740 ginseng\NN\13125117 ,\,\1740 on\IN\1740 <e2>OIH</e2>\NNP\1740 .\.\1740
C035054_D006930 NONE However\RB\1740 ,\,\1740 the\DT\1740 <e1>Rg1\NN\1740 and\CC\1740 Rb1\NN\1740 ginsenosides</e1>\VBZ\1740 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 <e2>OIH</e2>\NNP\1740 in\IN\13603305 either\DT\1740 test\NN\5798043 .\.\1740
C035054_D006930 NONE Furthermore\RB\1740 ,\,\1740 <e1>Rg1</e1>\NN\1740 showed\VBD\2137132 a\DT\13649268 tendency\NN\6193203 to\TO\1740 aggravate\VB\126264 <e2>OIH</e2>\NNP\1740 in\IN\13603305 the\DT\1740 acetic\JJ\1740 acid-induced\JJ\1740 writhing\NN\1740 test\NN\5798043 .\.\1740
C035054_D006930 NONE Our\PRP$\1740 data\NNS\7951464 suggested\VBD\1010118 that\IN\1740 the\DT\1740 ginsenoside\NN\1740 Re\IN\14625458 ,\,\1740 but\CC\1740 not\RB\1740 <e1>Rg1</e1>\NN\1740 or\CC\3541091 Rb1\NN\1740 ,\,\1740 may\MD\15209706 contribute\VB\126264 toward\IN\1740 reversal\NN\199130 of\IN\1740 <e2>OIH</e2>\NNP\1740 .\.\1740
C442759_D006930 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>Re\NN\14625458 ,\,\1740 Rg1\NN\1740 ,\,\1740 and\CC\1740 Rb1\NN\1740 ginsenosides</e1>\VBZ\1740 ,\,\1740 the\DT\1740 bioactive\JJ\1740 components\NNS\5867413 of\IN\1740 ginseng\NN\13125117 ,\,\1740 on\IN\1740 <e2>OIH</e2>\NNP\1740 .\.\1740
C442759_D006930 NONE However\RB\1740 ,\,\1740 the\DT\1740 <e1>Rg1\NN\1740 and\CC\1740 Rb1\NN\1740 ginsenosides</e1>\VBZ\1740 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 <e2>OIH</e2>\NNP\1740 in\IN\13603305 either\DT\1740 test\NN\5798043 .\.\1740
C442759_D006930 NONE Our\PRP$\1740 data\NNS\7951464 suggested\VBD\1010118 that\IN\1740 the\DT\1740 ginsenoside\NN\1740 Re\IN\14625458 ,\,\1740 but\CC\1740 not\RB\1740 Rg1\NN\1740 or\CC\3541091 <e1>Rb1</e1>\NN\1740 ,\,\1740 may\MD\15209706 contribute\VB\126264 toward\IN\1740 reversal\NN\199130 of\IN\1740 <e2>OIH</e2>\NNP\1740 .\.\1740
D009020_D006930 CID <e2>OIH</e2>\NNP\1740 was\VBD\836236 achieved\VBN\2524171 in\IN\13603305 mice\NNS\2329401 after\IN\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>morphine</e1>\NN\2707683 for\IN\1740 7\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 three\CD\13741022 times\NNS\15113229 per\IN\1740 day\NN\15154774 .\.\1740
D019342_D006930 NONE Re\IN\14625458 (\-LRB-\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 inhibited\VBD\2510337 <e2>OIH</e2>\NN\1740 in\IN\13603305 both\CC\1740 the\DT\1740 thermal\JJ\1740 sensitivity\NN\5651971 test\NN\5798043 and\CC\1740 the\DT\1740 <e1>acetic\JJ\1740 acid-induced</e1>\JJ\1740 writhing\NN\1740 test\NN\5798043 .\.\1740
D019342_D006930 NONE Furthermore\RB\1740 ,\,\1740 Rg1\NN\1740 showed\VBD\2137132 a\DT\13649268 tendency\NN\6193203 to\TO\1740 aggravate\VB\126264 <e2>OIH</e2>\NNP\1740 in\IN\13603305 the\DT\1740 <e1>acetic\JJ\1740 acid-induced</e1>\JJ\1740 writhing\NN\1740 test\NN\5798043 .\.\1740
689020
D005280_D014202 CID After\IN\1740 the\DT\1740 end\NN\8568978 of\IN\1740 <e1>fenoterol-hydrobromide</e1>\JJ\1740 infusion\NN\14589223 ,\,\1740 <e2>tremor</e2>\NN\345926 amplitudes\NNS\7444668 decreased\VBD\169651 significantly\RB\1740 faster\JJR\1740 than\IN\1740 those\DT\1740 following\VBG\1835496 ritodrin-HCl\NN\1740 infusion\NN\14589223 .\.\1740
D012312_D014202 CID After\IN\1740 the\DT\1740 end\NN\8568978 of\IN\1740 fenoterol-hydrobromide\JJ\1740 infusion\NN\14589223 ,\,\1740 <e2>tremor</e2>\NN\345926 amplitudes\NNS\7444668 decreased\VBD\169651 significantly\RB\1740 faster\JJR\1740 than\IN\1740 those\DT\1740 following\VBG\1835496 <e1>ritodrin-HCl</e1>\NN\1740 infusion\NN\14589223 .\.\1740
19392810
D003932_D012206 CID <e2>Rhabdomyolysis</e2>\NN\1740 and\CC\1740 brain\NN\5462674 ischemic\JJ\1740 stroke\NN\556313 in\IN\13603305 a\DT\13649268 <e1>heroin-dependent</e1>\JJ\1740 male\NN\15388 under\IN\1740 methadone\NN\3808564 maintenance\NN\266806 therapy\NN\657604 .\.\1740
D003932_D012206 CID RESULTS\NNS\34213 :\:\1740 A\DT\13649268 33-year-old\JJ\1740 man\NN\9605289 presented\VBN\2137132 with\IN\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 cerebral\JJ\1740 ischemic\JJ\1740 stroke\NN\556313 after\IN\1740 intravenous\JJ\1740 <e1>heroin</e1>\NN\3492717 .\.\1740
D003932_D012206 CID CONCLUSION\NN\5837957 :\:\1740 Those\DT\1740 using\VBG\1156834 methadone\NN\3808564 and\CC\1740 <e1>heroin</e1>\NN\3492717 simultaneously\RB\1740 may\MD\15209706 increase\VB\169651 risk\NN\14541044 of\IN\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 ischemic\JJ\1740 stroke\NN\556313 .\.\1740
D003932_D012206 CID Hypotheses\NNS\7162194 of\IN\1740 <e1>heroin-related</e1>\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 stroke\NN\556313 in\IN\13603305 heroin\NN\3492717 abusers\NNS\9633969 are\VBP\836236 discussed\VBN\1033527 .\.\1740
D003932_D012206 CID Hypotheses\NNS\7162194 of\IN\1740 heroin-related\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 stroke\NN\556313 in\IN\13603305 <e1>heroin</e1>\NN\3492717 abusers\NNS\9633969 are\VBP\836236 discussed\VBN\1033527 .\.\1740
D003932_D002544 NONE Rhabdomyolysis\NN\1740 and\CC\1740 brain\NN\5462674 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 in\IN\13603305 a\DT\13649268 <e1>heroin-dependent</e1>\JJ\1740 male\NN\15388 under\IN\1740 methadone\NN\3808564 maintenance\NN\266806 therapy\NN\657604 .\.\1740
D003932_D002544 NONE RESULTS\NNS\34213 :\:\1740 A\DT\13649268 33-year-old\JJ\1740 man\NN\9605289 presented\VBN\2137132 with\IN\1740 rhabdomyolysis\NN\1740 and\CC\1740 cerebral\JJ\1740 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 after\IN\1740 intravenous\JJ\1740 <e1>heroin</e1>\NN\3492717 .\.\1740
D003932_D002544 NONE CONCLUSION\NN\5837957 :\:\1740 Those\DT\1740 using\VBG\1156834 methadone\NN\3808564 and\CC\1740 <e1>heroin</e1>\NN\3492717 simultaneously\RB\1740 may\MD\15209706 increase\VB\169651 risk\NN\14541044 of\IN\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D008691_D012206 CID <e2>Rhabdomyolysis</e2>\NN\1740 and\CC\1740 brain\NN\5462674 ischemic\JJ\1740 stroke\NN\556313 in\IN\13603305 a\DT\13649268 heroin-dependent\JJ\1740 male\NN\15388 under\IN\1740 <e1>methadone</e1>\NN\3808564 maintenance\NN\266806 therapy\NN\657604 .\.\1740
D008691_D012206 CID CONCLUSION\NN\5837957 :\:\1740 Those\DT\1740 using\VBG\1156834 <e1>methadone</e1>\NN\3808564 and\CC\1740 heroin\NN\3492717 simultaneously\RB\1740 may\MD\15209706 increase\VB\169651 risk\NN\14541044 of\IN\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 ischemic\JJ\1740 stroke\NN\556313 .\.\1740
D008691_D002544 NONE Rhabdomyolysis\NN\1740 and\CC\1740 brain\NN\5462674 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 in\IN\13603305 a\DT\13649268 heroin-dependent\JJ\1740 male\NN\15388 under\IN\1740 <e1>methadone</e1>\NN\3808564 maintenance\NN\266806 therapy\NN\657604 .\.\1740
D008691_D002544 NONE CONCLUSION\NN\5837957 :\:\1740 Those\DT\1740 using\VBG\1156834 <e1>methadone</e1>\NN\3808564 and\CC\1740 heroin\NN\3492717 simultaneously\RB\1740 may\MD\15209706 increase\VB\169651 risk\NN\14541044 of\IN\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D003932_D020521 CID Hypotheses\NNS\7162194 of\IN\1740 <e1>heroin-related</e1>\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>stroke</e2>\NN\556313 in\IN\13603305 heroin\NN\3492717 abusers\NNS\9633969 are\VBP\836236 discussed\VBN\1033527 .\.\1740
D003932_D020521 CID Hypotheses\NNS\7162194 of\IN\1740 heroin-related\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>stroke</e2>\NN\556313 in\IN\13603305 <e1>heroin</e1>\NN\3492717 abusers\NNS\9633969 are\VBP\836236 discussed\VBN\1033527 .\.\1740
24451297
C065180_D056486 CID <e2>Drug-Induced\JJ\1740 Acute\NNP\6822198 Liver\NNP\5298729 Injury</e2>\NNP\14052046 Within\IN\1740 12\CD\13745420 Hours\NNS\15118228 After\IN\1740 <e1>Fluvastatin</e1>\NNP\3676175 Therapy\NNP\657604 .\.\1740
C065180_D056486 CID A\DT\13649268 52-year-old\JJ\1740 Chinese\JJ\1740 man\NN\9605289 reported\VBN\831651 with\IN\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 ,\,\1740 which\WDT\1740 appeared\VBD\2604760 12\CD\13745420 hours\NNS\15118228 after\IN\1740 beginning\VBG\941990 treatment\NN\654885 with\IN\1740 <e1>fluvastatin</e1>\NN\3676175 .\.\1740
D019161_D056486 NONE Although\IN\1740 <e1>statins</e1>\NNS\3740161 are\VBP\836236 generally\RB\1740 well-tolerated\JJ\1740 drugs\NNS\14778436 ,\,\1740 recent\JJ\1740 cases\NNS\7283608 of\IN\1740 <e2>drug-induced\JJ\1740 liver\NN\5298729 injury</e2>\NN\14052046 associated\VBN\628491 with\IN\1740 their\PRP$\1740 use\NN\407535 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
15229250
D008694_D001930 CID We\PRP\1740 visualize\VBP\1636397 ,\,\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 ,\,\1740 the\DT\1740 profile\NN\6999802 of\IN\1740 <e2>structural\JJ\1740 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 human\JJ\1740 brain</e2>\NN\5462674 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 (\-LRB-\1740 MA\NN\10332385 )\-RRB-\1740 abuse\NN\418025 .\.\1740
D008694_D001930 CID We\PRP\1740 visualize\VBP\1636397 ,\,\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 ,\,\1740 the\DT\1740 profile\NN\6999802 of\IN\1740 <e2>structural\JJ\1740 deficits\NNS\5113133 in\IN\13603305 the\DT\1740 human\JJ\1740 brain</e2>\NN\5462674 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 methamphetamine\NN\2704153 (\-LRB-\1740 <e1>MA</e1>\NN\10332385 )\-RRB-\1740 abuse\NN\418025 .\.\1740
D008694_D001930 CID We\PRP\1740 used\VBD\1156834 high-resolution\JJ\1740 MRI\NN\901083 and\CC\1740 surface-based\JJ\1740 computational\JJ\1740 image\NN\5926676 analyses\NNS\633864 to\TO\1740 map\VB\1686132 regional\JJ\1740 <e2>abnormalities\NNS\14034177 in\IN\13603305 the\DT\1740 cortex\NN\5462674 ,\,\1740 hippocampus\NN\5462674 ,\,\1740 white\JJ\1740 matter\NN\5670710 ,\,\1740 and\CC\1740 ventricles</e2>\NNS\5303402 in\IN\13603305 22\CD\13745420 human\JJ\1740 subjects\NNS\6598915 who\WP\8299493 used\VBD\1156834 <e1>MA</e1>\NN\10332385 and\CC\1740 21\CD\13745420 age-matched\JJ\1740 ,\,\1740 healthy\JJ\1740 controls\NNS\5190804 .\.\1740
D008694_D001930 CID These\DT\1740 brain\NN\5462674 substrates\NNS\19613 may\MD\15209706 help\VB\2556126 account\NN\6647206 for\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e1>MA</e1>\NN\10332385 abuse\NN\418025 ,\,\1740 providing\VBG\2199590 therapeutic\JJ\1740 targets\NNS\7258332 for\IN\1740 drug-induced\JJ\1740 <e2>brain\NN\5462674 injury</e2>\NN\14052046 .\.\1740
D008694_D008659 NONE Studies\NNS\635850 of\IN\1740 human\JJ\1740 subjects\NNS\6598915 who\WP\8299493 have\VBP\2108377 used\VBN\1156834 <e1>MA</e1>\NNP\10332385 chronically\RB\1740 have\VBP\2108377 revealed\VBN\2137132 deficits\NNS\5113133 in\IN\13603305 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 systems\NNS\3575240 and\CC\1740 cerebral\JJ\1740 <e2>metabolic\JJ\1740 abnormalities</e2>\NNS\14034177 .\.\1740
D008694_D003072 NONE Using\VBG\1156834 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 MRI\NN\901083 )\-RRB-\1740 and\CC\1740 new\JJ\1740 computational\JJ\1740 brain-mapping\JJ\1740 techniques\NNS\5660268 ,\,\1740 we\PRP\1740 determined\VBD\1645601 the\DT\1740 pattern\NN\5726345 of\IN\1740 structural\JJ\1740 brain\NN\5462674 alterations\NNS\7283608 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 <e1>MA</e1>\NN\10332385 abuse\NN\418025 in\IN\13603305 human\JJ\1740 subjects\NNS\6598915 and\CC\1740 related\VBN\628491 these\DT\1740 deficits\NNS\5113133 to\TO\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 .\.\1740
D008694_D006984 NONE On\IN\1740 average\JJ\1740 ,\,\1740 <e1>MA</e1>\NN\10332385 abusers\NNS\9633969 had\VBD\2108377 7.8\CD\1740 %\NN\1740 smaller\JJR\1740 hippocampal\NN\1740 volumes\NNS\33615 than\IN\1740 control\JJ\1740 subjects\NNS\6598915 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.01\CD\1740 ;\:\1740 left\VBN\120316 ,\,\1740 p\NN\14622893 =\JJ\1740 0.01\CD\1740 ;\:\1740 right\UH\5854150 ,\,\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 significant\JJ\1740 white-matter\NN\1740 <e2>hypertrophy</e2>\NN\14365950 (\-LRB-\1740 7.0\CD\1740 %\NN\1740 ;\:\1740 p\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D008694_D008569 CID MRI-based\JJ\1740 maps\NNS\4076846 suggest\VBP\1010118 that\IN\1740 chronic\JJ\1740 <e1>methamphetamine</e1>\NN\2704153 abuse\NN\418025 causes\VBZ\1617192 a\DT\13649268 selective\JJ\1740 pattern\NN\5726345 of\IN\1740 cerebral\JJ\1740 deterioration\NN\14560612 that\WDT\1740 contributes\VBZ\126264 to\TO\1740 <e2>impaired\JJ\1740 memory\NN\5926676 performance</e2>\NN\6619065 .\.\1740
16867246
D002746_D001480 CID Association\NN\8008335 of\IN\1740 DRD2\NN\1740 polymorphisms\NNS\11418750 and\CC\1740 <e1>chlorpromazine-induced</e1>\JJ\1740 <e2>extrapyramidal\JJ\1740 syndrome</e2>\NN\5870365 in\IN\13603305 Chinese\JJ\1740 schizophrenic\JJ\1740 patients\NNS\9898892 .\.\1740
D002746_D001480 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 evaluate\VBP\670261 the\DT\1740 role\NN\719494 DRD2\NN\1740 plays\VBZ\1072262 in\IN\13603305 <e1>chlorpromazine-induced</e1>\JJ\1740 <e2>EPS</e2>\NN\1740 in\IN\13603305 schizophrenic\JJ\1740 patients\NNS\9898892 .\.\1740
D002746_D001480 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 identified\VBD\699815 seven\CD\13741022 SNP(single\NN\1740 nucleotide\NN\14850483 polymorphism\NN\11418750 )\-RRB-\1740 (\-LRB-\1740 -141Cins\NNS\1740 >\NN\1740 del\NN\1740 ,\,\1740 TaqIB\FW\1740 ,\,\1740 TaqID\NN\1740 ,\,\1740 Ser311Cys\NNP\1740 ,\,\1740 rs6275\NN\1740 ,\,\1740 rs6277\NN\1740 and\CC\1740 TaqIA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 DRD2\NN\1740 gene\NN\8459252 in\IN\13603305 146\CD\1740 schizophrenic\JJ\1740 inpatients\NNS\10405694 (\-LRB-\1740 59\CD\1740 with\IN\1740 <e2>EPS</e2>\NN\1740 and\CC\1740 87\CD\1740 without\IN\1740 EPS\NN\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 Simpson-Angus\JJ\1740 Scale\NN\7260623 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>chlorpromazine</e1>\NN\3713736 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002746_D001480 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 identified\VBD\699815 seven\CD\13741022 SNP(single\NN\1740 nucleotide\NN\14850483 polymorphism\NN\11418750 )\-RRB-\1740 (\-LRB-\1740 -141Cins\NNS\1740 >\NN\1740 del\NN\1740 ,\,\1740 TaqIB\FW\1740 ,\,\1740 TaqID\NN\1740 ,\,\1740 Ser311Cys\NNP\1740 ,\,\1740 rs6275\NN\1740 ,\,\1740 rs6277\NN\1740 and\CC\1740 TaqIA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 DRD2\NN\1740 gene\NN\8459252 in\IN\13603305 146\CD\1740 schizophrenic\JJ\1740 inpatients\NNS\10405694 (\-LRB-\1740 59\CD\1740 with\IN\1740 EPS\NN\1740 and\CC\1740 87\CD\1740 without\IN\1740 <e2>EPS</e2>\NN\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 Simpson-Angus\JJ\1740 Scale\NN\7260623 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>chlorpromazine</e1>\NN\3713736 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002746_D012559 NONE Association\NN\8008335 of\IN\1740 DRD2\NN\1740 polymorphisms\NNS\11418750 and\CC\1740 <e1>chlorpromazine-induced</e1>\JJ\1740 extrapyramidal\JJ\1740 syndrome\NN\5870365 in\IN\13603305 Chinese\JJ\1740 <e2>schizophrenic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D002746_D012559 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 evaluate\VBP\670261 the\DT\1740 role\NN\719494 DRD2\NN\1740 plays\VBZ\1072262 in\IN\13603305 <e1>chlorpromazine-induced</e1>\JJ\1740 EPS\NN\1740 in\IN\13603305 <e2>schizophrenic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D002746_D012559 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 identified\VBD\699815 seven\CD\13741022 SNP(single\NN\1740 nucleotide\NN\14850483 polymorphism\NN\11418750 )\-RRB-\1740 (\-LRB-\1740 -141Cins\NNS\1740 >\NN\1740 del\NN\1740 ,\,\1740 TaqIB\FW\1740 ,\,\1740 TaqID\NN\1740 ,\,\1740 Ser311Cys\NNP\1740 ,\,\1740 rs6275\NN\1740 ,\,\1740 rs6277\NN\1740 and\CC\1740 TaqIA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 DRD2\NN\1740 gene\NN\8459252 in\IN\13603305 146\CD\1740 <e2>schizophrenic</e2>\JJ\1740 inpatients\NNS\10405694 (\-LRB-\1740 59\CD\1740 with\IN\1740 EPS\NN\1740 and\CC\1740 87\CD\1740 without\IN\1740 EPS\NN\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 Simpson-Angus\JJ\1740 Scale\NN\7260623 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>chlorpromazine</e1>\NN\3713736 after\IN\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D002746_D012559 NONE CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 did\VBD\1640855 not\RB\1740 lend\VB\126264 strong\JJ\1740 support\NN\407535 to\IN\1740 the\DT\1740 view\NN\6208021 that\IN\1740 the\DT\1740 genetic\JJ\1740 variation\NN\7296428 of\IN\1740 the\DT\1740 DRD2\NN\1740 gene\NN\8459252 plays\VBZ\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 individually\RB\1740 variable\JJ\1740 adverse\JJ\1740 effect\NN\34213 induced\VBN\1627355 by\IN\1740 <e1>chlorpromazine</e1>\NN\3713736 ,\,\1740 at\IN\14622893 least\JJS\1740 in\IN\13603305 Chinese\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
611664
D011433_C544351 NONE Use\NN\407535 of\IN\1740 <e1>propranolol</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>idiopathic\JJ\1740 orthostatic\JJ\1740 hypotension</e2>\NN\14057371 .\.\1740
D011433_C544351 NONE The\DT\1740 studies\NNS\635850 suggest\VBP\1010118 that\IN\1740 <e1>propranolol</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 useful\JJ\1740 drug\NN\14778436 in\IN\13603305 selected\VBN\697589 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 <e2>idiopathic\JJ\1740 orthostatic\JJ\1740 hypotension</e2>\NN\14057371 .\.\1740
D002395_D004342 NONE They\PRP\1740 all\DT\1740 exhibited\VBD\2632167 markedly\RB\1740 reduced\VBN\441445 plasma\NN\5398023 <e1>catecholamines</e1>\NNS\5407119 and\CC\1740 plasma\NN\5398023 renin\NN\14999106 activity\NN\30358 in\IN\13603305 both\CC\1740 recumbent\JJ\1740 and\CC\1740 upright\JJ\1740 positions\NNS\8620061 and\CC\1740 had\VBD\2108377 marked\JJ\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 infused\JJ\1740 norepinephrine\NN\14807929 .\.\1740
D009638_D004342 NONE They\PRP\1740 all\DT\1740 exhibited\VBD\2632167 markedly\RB\1740 reduced\VBN\441445 plasma\NN\5398023 catecholamines\NNS\5407119 and\CC\1740 plasma\NN\5398023 renin\NN\14999106 activity\NN\30358 in\IN\13603305 both\CC\1740 recumbent\JJ\1740 and\CC\1740 upright\JJ\1740 positions\NNS\8620061 and\CC\1740 had\VBD\2108377 marked\JJ\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 the\DT\1740 pressor\NN\9190918 effects\NNS\13245626 of\IN\1740 infused\JJ\1740 <e1>norepinephrine</e1>\NN\14807929 .\.\1740
D011433_D006973 CID In\IN\13603305 1\CD\13741022 patient\NN\9898892 ,\,\1740 marked\JJ\1740 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 the\DT\1740 drug\NN\14778436 had\VBD\2108377 to\TO\1740 be\VB\836236 withdrawn\VBN\1835496 .\.\1740
20513036
C542870_D010243 NONE Abductor\JJ\1740 <e2>paralysis</e2>\NN\14557898 after\IN\1740 <e1>botox</e1>\NN\14587688 injection\NN\320852 for\IN\1740 adductor\NN\5289861 spasmodic\NN\1740 dysphonia\NN\14400677 .\.\1740
C542870_D010243 NONE Here\RB\1740 we\PRP\1740 report\VBP\831651 multiple\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 abductor\JJ\1740 <e2>paralysis</e2>\NN\14557898 following\VBG\1835496 <e1>Botox</e1>\NNP\14587688 injections\NNS\320852 for\IN\1740 ADSD\NN\1740 ,\,\1740 a\DT\13649268 complication\NN\1073995 previously\RB\1740 unreported\VBD\1740 .\.\1740
C542870_D010243 NONE For\IN\1740 patients\NNS\9898892 with\IN\1740 bilateral\JJ\1740 abductor\NN\9609561 <e2>paralysis</e2>\NN\14557898 ,\,\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 paralytic\JJ\1740 <e1>Botox</e1>\NN\14587688 dose\NN\3740161 ,\,\1740 prior\JJ\1740 Botox\NNP\14587688 dose\NN\3740161 ,\,\1740 and\CC\1740 course\NN\883297 following\VBG\1835496 paralysis\NN\14557898 were\VBD\836236 noted\VBN\1009240 .\.\1740
C542870_D010243 NONE For\IN\1740 patients\NNS\9898892 with\IN\1740 bilateral\JJ\1740 abductor\NN\9609561 paralysis\NN\14557898 ,\,\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 paralytic\JJ\1740 <e1>Botox</e1>\NN\14587688 dose\NN\3740161 ,\,\1740 prior\JJ\1740 Botox\NNP\14587688 dose\NN\3740161 ,\,\1740 and\CC\1740 course\NN\883297 following\VBG\1835496 <e2>paralysis</e2>\NN\14557898 were\VBD\836236 noted\VBN\1009240 .\.\1740
C542870_D010243 NONE For\IN\1740 patients\NNS\9898892 with\IN\1740 bilateral\JJ\1740 abductor\NN\9609561 <e2>paralysis</e2>\NN\14557898 ,\,\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 paralytic\JJ\1740 Botox\NN\14587688 dose\NN\3740161 ,\,\1740 prior\JJ\1740 <e1>Botox</e1>\NNP\14587688 dose\NN\3740161 ,\,\1740 and\CC\1740 course\NN\883297 following\VBG\1835496 paralysis\NN\14557898 were\VBD\836236 noted\VBN\1009240 .\.\1740
C542870_D010243 NONE For\IN\1740 patients\NNS\9898892 with\IN\1740 bilateral\JJ\1740 abductor\NN\9609561 paralysis\NN\14557898 ,\,\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 paralytic\JJ\1740 Botox\NN\14587688 dose\NN\3740161 ,\,\1740 prior\JJ\1740 <e1>Botox</e1>\NNP\14587688 dose\NN\3740161 ,\,\1740 and\CC\1740 course\NN\883297 following\VBG\1835496 <e2>paralysis</e2>\NN\14557898 were\VBD\836236 noted\VBN\1009240 .\.\1740
C542870_D010243 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 abductor\JJ\1740 <e2>paralysis</e2>\NN\14557898 after\IN\1740 <e1>Botox</e1>\NNP\14587688 injection\NN\320852 for\IN\1740 ADSD\NN\1740 was\VBD\836236 0.34\CD\1740 %\NN\1740 .\.\1740
C542870_D010243 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Bilateral\JJ\1740 abductor\JJ\1740 <e2>paralysis</e2>\NN\14557898 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>Botox</e1>\NNP\14587688 injections\NNS\320852 for\IN\1740 ADSD\NN\1740 ,\,\1740 causing\VBG\1617192 difficulty\NN\621627 with\IN\1740 breathing\NN\13440063 upon\IN\1740 exertion\NN\620752 .\.\1740
C542870_D010243 NONE The\DT\1740 likely\JJ\1740 mechanism\NN\13446390 of\IN\1740 <e2>paralysis</e2>\NN\14557898 is\VBZ\836236 diffusion\NN\13518963 of\IN\1740 <e1>Botox</e1>\NNP\14587688 around\IN\1740 the\DT\1740 muscular\JJ\1740 process\NN\407535 of\IN\1740 the\DT\1740 arytenoid\NN\5288091 to\IN\1740 the\DT\1740 posterior\JJ\1740 cricoarytenoid\JJ\1740 muscles\NNS\5289601 .\.\1740
C542870_D014826 CID Abductor\JJ\1740 paralysis\NN\14557898 after\IN\1740 <e1>botox</e1>\NN\14587688 injection\NN\320852 for\IN\1740 <e2>adductor\NN\5289861 spasmodic\NN\1740 dysphonia</e2>\NN\14400677 .\.\1740
C542870_D014826 CID OBJECTIVES/HYPOTHESIS\JJ\1740 :\:\1740 Botulinum\NN\1355326 toxin\NN\15032376 (\-LRB-\1740 <e1>Botox</e1>\NN\14587688 )\-RRB-\1740 injections\NNS\320852 into\IN\1740 the\DT\1740 thyroarytenoid\JJ\1740 muscles\NNS\5289601 are\VBP\836236 the\DT\1740 current\JJ\1740 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 <e2>adductor\NN\5289861 spasmodic\JJ\1740 dysphonia</e2>\NN\14400677 (\-LRB-\1740 ADSD\NN\1740 )\-RRB-\1740 .\.\1740
C542870_D014826 CID OBJECTIVES/HYPOTHESIS\JJ\1740 :\:\1740 Botulinum\NN\1355326 toxin\NN\15032376 (\-LRB-\1740 <e1>Botox</e1>\NN\14587688 )\-RRB-\1740 injections\NNS\320852 into\IN\1740 the\DT\1740 thyroarytenoid\JJ\1740 muscles\NNS\5289601 are\VBP\836236 the\DT\1740 current\JJ\1740 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 adductor\NN\5289861 spasmodic\JJ\1740 dysphonia\NN\14400677 (\-LRB-\1740 <e2>ADSD</e2>\NN\1740 )\-RRB-\1740 .\.\1740
C542870_D014826 CID Here\RB\1740 we\PRP\1740 report\VBP\831651 multiple\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 abductor\JJ\1740 paralysis\NN\14557898 following\VBG\1835496 <e1>Botox</e1>\NNP\14587688 injections\NNS\320852 for\IN\1740 <e2>ADSD</e2>\NN\1740 ,\,\1740 a\DT\13649268 complication\NN\1073995 previously\RB\1740 unreported\VBD\1740 .\.\1740
C542870_D014826 CID RESULTS\NNS\34213 :\:\1740 From\IN\1740 a\DT\13649268 database\NN\6634376 of\IN\1740 452\CD\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>Botox</e1>\NNP\14587688 ,\,\1740 352\CD\1740 patients\NNS\9898892 had\VBD\2108377 been\VBN\836236 diagnosed\VBN\644583 with\IN\1740 <e2>ADSD</e2>\NN\1740 .\.\1740
C542870_D014826 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 abductor\JJ\1740 paralysis\NN\14557898 after\IN\1740 <e1>Botox</e1>\NNP\14587688 injection\NN\320852 for\IN\1740 <e2>ADSD</e2>\NN\1740 was\VBD\836236 0.34\CD\1740 %\NN\1740 .\.\1740
C542870_D014826 CID CONCLUSIONS\NNS\5837957 :\:\1740 Bilateral\JJ\1740 abductor\JJ\1740 paralysis\NN\14557898 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>Botox</e1>\NNP\14587688 injections\NNS\320852 for\IN\1740 <e2>ADSD</e2>\NN\1740 ,\,\1740 causing\VBG\1617192 difficulty\NN\621627 with\IN\1740 breathing\NN\13440063 upon\IN\1740 exertion\NN\620752 .\.\1740
C542870_D055154 NONE METHODS\NNS\5616786 :\:\1740 Patients\NNS\9898892 that\WDT\1740 received\VBD\2210855 <e1>Botox</e1>\NNP\14587688 injections\NNS\320852 for\IN\1740 <e2>spasmodic\JJ\1740 dysphonia</e2>\NN\14400677 between\IN\1740 January\NNP\15209706 2000\CD\1740 and\CC\1740 October\NNP\15209706 2009\CD\1740 were\VBD\836236 evaluated\VBN\670261 .\.\1740
2614930
D009543_D001919 CID <e1>Nifedipine</e1>\NN\2938514 induced\VBD\1627355 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D009543_D009422 NONE <e1>Nifedipine</e1>\NN\2938514 induced\VBD\1627355 bradycardia\NN\14110674 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>autonomic\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
D009543_D001282 NONE He\PRP\14622893 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 at\IN\14622893 a\DT\13649268 ventricular\JJ\1740 rate\NN\13815152 of\IN\1740 70/min\NN\1740 which\WDT\1740 slowed\VBD\151689 down\RP\1740 to\IN\1740 30\CD\13745420 -\HYPH\1740 40/min\NN\1740 when\WRB\1740 <e1>nifedipine</e1>\NN\2938514 (\-LRB-\1740 60\CD\13745420 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 3\CD\13741022 divided\JJ\1740 doses\NNS\3740161 ,\,\1740 during\IN\1740 which\WDT\1740 he\PRP\14622893 was\VBD\836236 paced\VBN\1904930 at\IN\14622893 a\DT\13649268 rate\NN\13815152 of\IN\1740 70/min\NNP\1740 .\.\1740
D009543_D013610 CID This\DT\1740 is\VBZ\836236 inconsistent\JJ\1740 with\IN\1740 the\DT\1740 well-established\JJ\1740 finding\NN\43195 that\IN\1740 <e1>nifedipine</e1>\NN\2938514 induces\VBZ\1627355 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 normally\RB\1740 innervated\VBN\2327200 hearts\NNS\496167 .\.\1740
24614773
D014635_D001927 NONE Normoammonemic\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 :\:\1740 solely\RB\1740 <e1>valproate</e1>\VBP\1740 induced\VBN\1627355 or\CC\3541091 multiple\JJ\1740 mechanisms\NNS\13446390 ?\.\1740
D014635_D001927 NONE The\DT\1740 possible\JJ\1740 aetiologies\NNS\7326557 of\IN\1740 <e1>valproate-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 and\CC\1740 NMDA\NN\1740 receptor-associated\JJ\1740 encephalitis\NN\14336539 present\VBP\2137132 a\DT\13649268 diagnostic\JJ\1740 dilemma\NN\5685363 .\.\1740
D014635_D010291 NONE In\IN\13603305 the\DT\1740 preceding\VBG\2690708 months\NNS\15113229 ,\,\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 a\DT\13649268 number\NN\5107765 of\IN\1740 admissions\NNS\49003 with\IN\1740 transient\JJ\1740 unilateral\JJ\1740 <e2>hemiparesis</e2>\NN\1740 with\IN\1740 facial\JJ\1740 droop\NN\13896369 ,\,\1740 and\CC\1740 had\VBD\2108377 been\VBN\836236 started\VBN\2009433 on\IN\1740 <e1>valproate</e1>\NN\1740 for\IN\1740 presumed\VBN\719734 hemiplegic\JJ\1740 migraine\NN\14326607 .\.\1740
D014635_D020325 NONE In\IN\13603305 the\DT\1740 preceding\VBG\2690708 months\NNS\15113229 ,\,\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 a\DT\13649268 number\NN\5107765 of\IN\1740 admissions\NNS\49003 with\IN\1740 transient\JJ\1740 unilateral\JJ\1740 hemiparesis\NN\1740 with\IN\1740 facial\JJ\1740 droop\NN\13896369 ,\,\1740 and\CC\1740 had\VBD\2108377 been\VBN\836236 started\VBN\2009433 on\IN\1740 <e1>valproate</e1>\NN\1740 for\IN\1740 presumed\VBN\719734 <e2>hemiplegic\JJ\1740 migraine</e2>\NN\14326607 .\.\1740
D016202_D001927 NONE EEG\NN\7000195 undertaken\VBN\1641914 during\IN\1740 inpatient\JJ\1740 stay\NN\30358 showed\VBD\2137132 changes\NNS\7283608 consistent\JJ\1740 with\IN\1740 <e2>encephalopathy</e2>\JJ\1740 ,\,\1740 and\CC\1740 low\JJ\1740 titre\NN\5038593 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antibodies\NNS\14728724 were\VBD\836236 present\JJ\1740 in\IN\13603305 this\DT\1740 patient\NN\9898892 .\.\1740
D016202_D001927 NONE EEG\NN\7000195 undertaken\VBN\1641914 during\IN\1740 inpatient\JJ\1740 stay\NN\30358 showed\VBD\2137132 changes\NNS\7283608 consistent\JJ\1740 with\IN\1740 <e2>encephalopathy</e2>\JJ\1740 ,\,\1740 and\CC\1740 low\JJ\1740 titre\NN\5038593 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antibodies\NNS\14728724 were\VBD\836236 present\JJ\1740 in\IN\13603305 this\DT\1740 patient\NN\9898892 .\.\1740
D016202_D001927 NONE The\DT\1740 possible\JJ\1740 aetiologies\NNS\7326557 of\IN\1740 valproate-induced\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 and\CC\1740 <e1>NMDA</e1>\NN\1740 receptor-associated\JJ\1740 encephalitis\NN\14336539 present\VBP\2137132 a\DT\13649268 diagnostic\JJ\1740 dilemma\NN\5685363 .\.\1740
D014635_D004660 NONE The\DT\1740 possible\JJ\1740 aetiologies\NNS\7326557 of\IN\1740 <e1>valproate-induced</e1>\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 NMDA\NN\1740 receptor-associated\JJ\1740 <e2>encephalitis</e2>\NN\14336539 present\VBP\2137132 a\DT\13649268 diagnostic\JJ\1740 dilemma\NN\5685363 .\.\1740
D016202_D004660 NONE The\DT\1740 possible\JJ\1740 aetiologies\NNS\7326557 of\IN\1740 valproate-induced\JJ\1740 encephalopathy\JJ\1740 and\CC\1740 <e1>NMDA</e1>\NN\1740 receptor-associated\JJ\1740 <e2>encephalitis</e2>\NN\14336539 present\VBP\2137132 a\DT\13649268 diagnostic\JJ\1740 dilemma\NN\5685363 .\.\1740
17042797
D010862_D013226 CID Stereological\JJ\1740 methods\NNS\5616786 reveal\VBP\2137132 the\DT\1740 robust\JJ\1740 size\NN\5090441 and\CC\1740 stability\NN\4777852 of\IN\1740 ectopic\JJ\1740 hilar\JJ\1740 granule\NN\9290777 cells\NNS\3080309 after\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 in\IN\13603305 the\DT\1740 adult\JJ\1740 rat\NN\2329401 .\.\1740
D010862_D013226 CID To\TO\1740 quantify\VB\947077 this\DT\1740 population\NN\7942152 ,\,\1740 the\DT\1740 total\JJ\1740 number\NN\5107765 of\IN\1740 ectopic\JJ\1740 hilar\JJ\1740 granule\NN\9290777 cells\NNS\3080309 was\VBD\836236 estimated\VBN\637259 using\VBG\1156834 unbiased\JJ\1740 stereology\NN\1740 at\IN\14622893 different\JJ\1740 times\NNS\15113229 after\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
D010862_D004833 CID The\DT\1740 results\NNS\34213 provide\VBP\2199590 new\JJ\1740 insight\NN\5710020 into\IN\1740 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 ectopic\JJ\1740 hilar\JJ\1740 granule\NN\9290777 cells\NNS\3080309 in\IN\13603305 the\DT\1740 <e1>pilocarpine</e1>\NN\14712692 model\NN\5888929 of\IN\1740 <e2>temporal\JJ\1740 lobe\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
7378868
D013390_D014313 CID <e1>Suxamethonium-induced</e1>\JJ\1740 <e2>jaw\NN\5269901 stiffness</e2>\NN\5023233 and\CC\1740 myalgia\NN\14322699 associated\VBN\628491 with\IN\1740 atypical\JJ\1740 cholinesterase\NN\14732946 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
D013390_D014313 CID The\DT\1740 case\NN\7283608 shows\VBZ\2137132 that\IN\1740 <e2>prolonged\JJ\1740 jaw\NN\5269901 rigidity</e2>\NN\5023233 and\CC\1740 myalgia\NN\14322699 may\MD\15209706 occur\VB\2623529 after\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 cholinesterase\NN\14732946 despite\IN\7501545 pretreatment\NN\1740 with\IN\1740 pancuronium\NN\1740 .\.\1740
D013390_D063806 CID <e1>Suxamethonium-induced</e1>\JJ\1740 jaw\NN\5269901 stiffness\NN\5023233 and\CC\1740 <e2>myalgia</e2>\NN\14322699 associated\VBN\628491 with\IN\1740 atypical\JJ\1740 cholinesterase\NN\14732946 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
D013390_D063806 CID The\DT\1740 case\NN\7283608 shows\VBZ\2137132 that\IN\1740 prolonged\JJ\1740 jaw\NN\5269901 rigidity\NN\5023233 and\CC\1740 <e2>myalgia</e2>\NN\14322699 may\MD\15209706 occur\VB\2623529 after\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 cholinesterase\NN\14732946 despite\IN\7501545 pretreatment\NN\1740 with\IN\1740 pancuronium\NN\1740 .\.\1740
D010197_D014313 NONE The\DT\1740 case\NN\7283608 shows\VBZ\2137132 that\IN\1740 <e2>prolonged\JJ\1740 jaw\NN\5269901 rigidity</e2>\NN\5023233 and\CC\1740 myalgia\NN\14322699 may\MD\15209706 occur\VB\2623529 after\IN\1740 suxamethonium\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 cholinesterase\NN\14732946 despite\IN\7501545 pretreatment\NN\1740 with\IN\1740 <e1>pancuronium</e1>\NN\1740 .\.\1740
D010197_D063806 NONE The\DT\1740 case\NN\7283608 shows\VBZ\2137132 that\IN\1740 prolonged\JJ\1740 jaw\NN\5269901 rigidity\NN\5023233 and\CC\1740 <e2>myalgia</e2>\NN\14322699 may\MD\15209706 occur\VB\2623529 after\IN\1740 suxamethonium\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 cholinesterase\NN\14732946 despite\IN\7501545 pretreatment\NN\1740 with\IN\1740 <e1>pancuronium</e1>\NN\1740 .\.\1740
9869655
D004997_D002780 CID This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 <e1>17alpha-ethinylestradiol</e1>\NN\1740 (EE)-induced\VBD\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 inhibition\NN\1068773 of\IN\1740 the\DT\1740 neutral\JJ\1740 pathway\NN\5483677 of\IN\1740 bile\NN\5405946 salt\NN\14818238 (\-LRB-\1740 BS\NN\6698252 )\-RRB-\1740 synthesis\NN\13446390 .\.\1740
D004997_D002780 CID This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 17alpha-ethinylestradiol\NN\1740 <e1>(EE)-induced</e1>\VBD\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 inhibition\NN\1068773 of\IN\1740 the\DT\1740 neutral\JJ\1740 pathway\NN\5483677 of\IN\1740 bile\NN\5405946 salt\NN\14818238 (\-LRB-\1740 BS\NN\6698252 )\-RRB-\1740 synthesis\NN\13446390 .\.\1740
D001647_D002780 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 17alpha-ethinylestradiol\NN\1740 (EE)-induced\VBD\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 inhibition\NN\1068773 of\IN\1740 the\DT\1740 neutral\JJ\1740 pathway\NN\5483677 of\IN\1740 <e1>bile\NN\5405946 salt</e1>\NN\14818238 (\-LRB-\1740 BS\NN\6698252 )\-RRB-\1740 synthesis\NN\13446390 .\.\1740
D001647_D002780 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 17alpha-ethinylestradiol\NN\1740 (EE)-induced\VBD\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 inhibition\NN\1068773 of\IN\1740 the\DT\1740 neutral\JJ\1740 pathway\NN\5483677 of\IN\1740 bile\NN\5405946 salt\NN\14818238 (\-LRB-\1740 <e1>BS</e1>\NN\6698252 )\-RRB-\1740 synthesis\NN\13446390 .\.\1740
11366874
D019888_D001145 NONE <e1>Viracept</e1>\NNP\4013993 and\CC\1740 <e2>irregular\JJ\1740 heartbeat</e2>\NN\7296190 warning\NN\7212190 .\.\1740
D019888_D001145 NONE A\DT\13649268 group\NN\2137 of\IN\1740 doctors\NNS\10305802 in\IN\13603305 Boston\NNP\1740 warn\VBP\831651 that\IN\1740 the\DT\1740 protease\NN\14732946 inhibitor\NN\20090 <e1>Viracept</e1>\NNP\4013993 may\MD\15209706 cause\VB\1617192 an\DT\6697703 <e2>irregular\JJ\1740 heart\NN\5919034 beat</e2>\VBN\1108148 ,\,\1740 known\VBN\2110220 as\IN\14622893 bradycardia\NN\14110674 ,\,\1740 in\IN\13603305 people\NNS\31264 with\IN\1740 HIV\NN\14186340 .\.\1740
D019888_D001919 CID A\DT\13649268 group\NN\2137 of\IN\1740 doctors\NNS\10305802 in\IN\13603305 Boston\NNP\1740 warn\VBP\831651 that\IN\1740 the\DT\1740 protease\NN\14732946 inhibitor\NN\20090 <e1>Viracept</e1>\NNP\4013993 may\MD\15209706 cause\VB\1617192 an\DT\6697703 irregular\JJ\1740 heart\NN\5919034 beat\VBN\1108148 ,\,\1740 known\VBN\2110220 as\IN\14622893 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 in\IN\13603305 people\NNS\31264 with\IN\1740 HIV\NN\14186340 .\.\1740
D019888_D001919 CID <e2>Bradycardia</e2>\NNP\14110674 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 <e1>Viracept</e1>\NNP\4013993 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 anti-HIV\JJ\1740 drugs\NNS\14778436 .\.\1740
11423811
D004280_D002637 NONE A\DT\13649268 pilot\NN\9826204 study\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 <e1>dobutamine</e1>\NN\1740 stress\NN\7083732 echocardiography\NN\177127 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 evaluation\NN\874067 of\IN\1740 cocaine-associated\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D004280_D002637 NONE Because\IN\1740 of\IN\1740 the\DT\1740 theoretical\JJ\1740 concern\NN\5682950 regarding\VBG\689344 administration\NN\1133281 of\IN\1740 <e1>dobutamine</e1>\NN\1740 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine\NN\3492717 use\NN\407535 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 pilot\NN\9826204 study\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 DSE\NN\1740 in\IN\13603305 emergency\NN\7417644 department\NN\8220714 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D004280_D002637 NONE CONCLUSION\NN\5837957 :\:\1740 No\DT\7204911 exaggerated\JJ\1740 adrenergic\JJ\1740 response\NN\11410625 was\VBD\836236 detected\VBN\2163746 when\WRB\1740 <e1>dobutamine</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 with\IN\1740 cocaine-related\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 CID A\DT\13649268 pilot\NN\9826204 study\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 dobutamine\NN\1740 stress\NN\7083732 echocardiography\NN\177127 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 evaluation\NN\874067 of\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 <e2>Chest\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 poses\NNS\4787763 a\DT\13649268 diagnostic\JJ\1740 dilemma\NN\5685363 .\.\1740
D003042_D002637 CID Because\IN\1740 of\IN\1740 the\DT\1740 theoretical\JJ\1740 concern\NN\5682950 regarding\VBG\689344 administration\NN\1133281 of\IN\1740 dobutamine\NN\1740 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 pilot\NN\9826204 study\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 DSE\NN\1740 in\IN\13603305 emergency\NN\7417644 department\NN\8220714 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 CID Because\IN\1740 of\IN\1740 the\DT\1740 theoretical\JJ\1740 concern\NN\5682950 regarding\VBG\689344 administration\NN\1133281 of\IN\1740 dobutamine\NN\1740 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine\NN\3492717 use\NN\407535 ,\,\1740 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 pilot\NN\9826204 study\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 DSE\NN\1740 in\IN\13603305 emergency\NN\7417644 department\NN\8220714 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 CID Patients\NNS\9898892 were\VBD\836236 eligible\JJ\1740 for\IN\1740 DSE\NN\1740 if\IN\1740 they\PRP\1740 had\VBD\2108377 used\VBN\1156834 <e1>cocaine</e1>\NN\3492717 within\IN\1740 24\CD\13745420 hours\NNS\15118228 preceding\VBG\2690708 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 had\VBD\2108377 a\DT\13649268 normal\JJ\1740 ECG\NN\7000195 and\CC\1740 tropinin\NN\1740
D003042_D002637 CID CONCLUSION\NN\5837957 :\:\1740 No\DT\7204911 exaggerated\JJ\1740 adrenergic\JJ\1740 response\NN\11410625 was\VBD\836236 detected\VBN\2163746 when\WRB\1740 dobutamine\NN\1740 was\VBD\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine-related</e1>\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D004280_D007511 NONE <e1>Dobutamine</e1>\JJ\1740 stress\NN\7083732 echocardiography\NN\177127 (\-LRB-\1740 DSE\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 widely\RB\1740 available\JJ\1740 and\CC\1740 sensitive\JJ\1740 test\NN\5798043 for\IN\1740 evaluating\VBG\670261 cardiac\JJ\1740 <e2>ischemia</e2>\NN\14195315 .\.\1740
D003042_D064420 NONE Patients\NNS\9898892 exhibiting\VBG\2632167 signs\NNS\6643763 of\IN\1740 continuing\VBG\2367363 <e1>cocaine</e1>\NN\3492717 <e2>toxicity</e2>\NN\13576101 were\VBD\836236 excluded\VBN\471711 from\IN\1740 the\DT\1740 study\NN\635850 .\.\1740
17255138
D052246_D009203 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 AMI\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>COX-2\NN\14737847 inhibitors</e1>\NNS\20090 may\MD\15209706 offset\VB\2673134 their\PRP$\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 benefit\NN\13278375 compared\VBN\644583 with\IN\1740 non-selective\JJ\1740 (\-LRB-\1740 NS\NN\14622893 )\-RRB-\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 NSAIDs\NNS\2721538 )\-RRB-\1740 .\.\1740
D052246_D009203 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>AMI</e2>\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>COX-2\NN\14737847 inhibitors</e1>\NNS\20090 may\MD\15209706 offset\VB\2673134 their\PRP$\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 benefit\NN\13278375 compared\VBN\644583 with\IN\1740 non-selective\JJ\1740 (\-LRB-\1740 NS\NN\14622893 )\-RRB-\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 (\-LRB-\1740 NSAIDs\NNS\2721538 )\-RRB-\1740 .\.\1740
D052246_D009203 CID We\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 risks\NNS\14541044 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI</e2>\NN\1740 and\CC\1740 GI\NN\13634615 bleeding\VBG\104868 among\IN\1740 elderly\JJ\1740 patients\NNS\9898892 using\VBG\1156834 <e1>COX-2\NN\14737847 inhibitors</e1>\NNS\20090 ,\,\1740 NS-NSAIDs\NN\1740 and\CC\1740 acetaminophen\RB\1740 .\.\1740
D000894_D009203 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 AMI\NN\1740 )\-RRB-\1740 with\IN\1740 COX-2\NN\14737847 inhibitors\NNS\20090 may\MD\15209706 offset\VB\2673134 their\PRP$\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 benefit\NN\13278375 compared\VBN\644583 with\IN\1740 non-selective\JJ\1740 (\-LRB-\1740 NS\NN\14622893 )\-RRB-\1740 <e1>non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs</e1>\NNS\14778436 (\-LRB-\1740 NSAIDs\NNS\2721538 )\-RRB-\1740 .\.\1740
D000894_D009203 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>AMI</e2>\NN\1740 )\-RRB-\1740 with\IN\1740 COX-2\NN\14737847 inhibitors\NNS\20090 may\MD\15209706 offset\VB\2673134 their\PRP$\1740 gastrointestinal\NN\1740 (\-LRB-\1740 GI\NN\13634615 )\-RRB-\1740 benefit\NN\13278375 compared\VBN\644583 with\IN\1740 non-selective\JJ\1740 (\-LRB-\1740 NS\NN\14622893 )\-RRB-\1740 <e1>non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs</e1>\NNS\14778436 (\-LRB-\1740 NSAIDs\NNS\2721538 )\-RRB-\1740 .\.\1740
D052246_D006471 NONE We\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 risks\NNS\14541044 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 AMI\NN\1740 and\CC\1740 <e2>GI\NN\13634615 bleeding</e2>\VBG\104868 among\IN\1740 elderly\JJ\1740 patients\NNS\9898892 using\VBG\1156834 <e1>COX-2\NN\14737847 inhibitors</e1>\NNS\20090 ,\,\1740 NS-NSAIDs\NN\1740 and\CC\1740 acetaminophen\RB\1740 .\.\1740
D000082_D009203 NONE We\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 risks\NNS\14541044 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI</e2>\NN\1740 and\CC\1740 GI\NN\13634615 bleeding\VBG\104868 among\IN\1740 elderly\JJ\1740 patients\NNS\9898892 using\VBG\1156834 COX-2\NN\14737847 inhibitors\NNS\20090 ,\,\1740 NS-NSAIDs\NN\1740 and\CC\1740 <e1>acetaminophen</e1>\RB\1740 .\.\1740
D000082_D009203 NONE Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 <e1>acetaminophen</e1>\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
D000082_D009203 NONE The\DT\1740 <e2>AMI/GI</e2>\NN\1740 toxicity\NN\13576101 of\IN\1740 celecoxib\NN\3124700 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 better\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 rofecoxib\NN\3124700 and\CC\1740 NS-NSAIDs\NN\1740 .\.\1740
D000082_D006471 NONE We\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 risks\NNS\14541044 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 AMI\NN\1740 and\CC\1740 <e2>GI\NN\13634615 bleeding</e2>\VBG\104868 among\IN\1740 elderly\JJ\1740 patients\NNS\9898892 using\VBG\1156834 COX-2\NN\14737847 inhibitors\NNS\20090 ,\,\1740 NS-NSAIDs\NN\1740 and\CC\1740 <e1>acetaminophen</e1>\RB\1740 .\.\1740
D001241_D009203 NONE Among\IN\1740 non-users\NNS\1740 of\IN\1740 <e1>aspirin</e1>\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
D001241_D009203 NONE Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 <e1>aspirin</e1>\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
D001241_D009203 NONE CONCLUSION\NN\5837957 :\:\1740 Among\IN\1740 non-users\NNS\1740 of\IN\1740 <e1>aspirin</e1>\NN\2707683 ,\,\1740 naproxen\NN\3828465 seemed\VBD\2604760 to\TO\1740 carry\VB\1850315 the\DT\1740 highest\JJS\1740 risk\NN\14541044 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 bleeding\VBG\104868 .\.\1740
C116926_D009203 CID Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 <e1>rofecoxib</e1>\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
C116926_D009203 CID The\DT\1740 <e2>AMI/GI</e2>\NN\1740 toxicity\NN\13576101 of\IN\1740 celecoxib\NN\3124700 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 better\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 <e1>rofecoxib</e1>\NN\3124700 and\CC\1740 NS-NSAIDs\NN\1740 .\.\1740
C105934_D009203 NONE Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 <e1>celecoxib</e1>\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
C105934_D009203 NONE The\DT\1740 <e2>AMI/GI</e2>\NN\1740 toxicity\NN\13576101 of\IN\1740 <e1>celecoxib</e1>\NN\3124700 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 better\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 rofecoxib\NN\3124700 and\CC\1740 NS-NSAIDs\NN\1740 .\.\1740
D009288_D009203 CID Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 <e1>naproxen</e1>\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
D009288_D009203 CID CONCLUSION\NN\5837957 :\:\1740 Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 <e1>naproxen</e1>\NN\3828465 seemed\VBD\2604760 to\TO\1740 carry\VB\1850315 the\DT\1740 highest\JJS\1740 risk\NN\14541044 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 bleeding\VBG\104868 .\.\1740
D004008_D009203 NONE Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 <e1>diclofenac</e1>\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 ibuprofen\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
D007052_D009203 NONE Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 the\DT\1740 adjusted\VBN\126264 hazard\NN\14541044 ratios\NNS\13815152 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 )\-RRB-\1740 of\IN\1740 hospitalization\NN\15113229 for\IN\1740 <e2>AMI/GI</e2>\NN\1740 vs\CC\13634784 the\DT\1740 acetaminophen\NN\2707683 (\-LRB-\1740 with\IN\1740 no\DT\7204911 aspirin\NN\2707683 )\-RRB-\1740 group\NN\2137 were\VBD\836236 :\:\1740 rofecoxib\NN\3124700 1.27\CD\1740 (\-LRB-\1740 1.13\CD\1740 ,\,\1740 1.42\CD\1740 )\-RRB-\1740 ,\,\1740 celecoxib\NN\3124700 0.93\CD\1740 (\-LRB-\1740 0.83\CD\1740 ,\,\1740 1.03\CD\1740 )\-RRB-\1740 ,\,\1740 naproxen\NN\3828465 1.59\CD\1740 (\-LRB-\1740 1.31\CD\1740 ,\,\1740 1.93\CD\1740 )\-RRB-\1740 ,\,\1740 diclofenac\VBD\1740 1.17\CD\1740 (\-LRB-\1740 0.99\CD\1740 ,\,\1740 1.38\CD\1740 )\-RRB-\1740 and\CC\1740 <e1>ibuprofen</e1>\NN\3828465 1.05\CD\1740 (\-LRB-\1740 0.74\CD\1740 ,\,\1740 1.51\CD\1740 )\-RRB-\1740 .\.\1740
D001241_D006471 NONE CONCLUSION\NN\5837957 :\:\1740 Among\IN\1740 non-users\NNS\1740 of\IN\1740 <e1>aspirin</e1>\NN\2707683 ,\,\1740 naproxen\NN\3828465 seemed\VBD\2604760 to\TO\1740 carry\VB\1850315 the\DT\1740 highest\JJS\1740 risk\NN\14541044 for\IN\1740 <e2>AMI/GI\NN\1740 bleeding</e2>\VBG\104868 .\.\1740
D009288_D006471 CID CONCLUSION\NN\5837957 :\:\1740 Among\IN\1740 non-users\NNS\1740 of\IN\1740 aspirin\NN\2707683 ,\,\1740 <e1>naproxen</e1>\NN\3828465 seemed\VBD\2604760 to\TO\1740 carry\VB\1850315 the\DT\1740 highest\JJS\1740 risk\NN\14541044 for\IN\1740 <e2>AMI/GI\NN\1740 bleeding</e2>\VBG\104868 .\.\1740
C105934_D064420 NONE The\DT\1740 AMI/GI\NN\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>celecoxib</e1>\NN\3124700 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 better\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 rofecoxib\NN\3124700 and\CC\1740 NS-NSAIDs\NN\1740 .\.\1740
D000082_D064420 NONE The\DT\1740 AMI/GI\NN\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 celecoxib\NN\3124700 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 better\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 rofecoxib\NN\3124700 and\CC\1740 NS-NSAIDs\NN\1740 .\.\1740
C116926_D064420 NONE The\DT\1740 AMI/GI\NN\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 celecoxib\NN\3124700 was\VBD\836236 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 acetaminophen\NN\2707683 and\CC\1740 seemed\VBD\2604760 to\TO\1740 be\VB\836236 better\JJR\1740 than\IN\1740 those\DT\1740 of\IN\1740 <e1>rofecoxib</e1>\NN\3124700 and\CC\1740 NS-NSAIDs\NN\1740 .\.\1740
15953230
C012052_D062787 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>amisulpride</e1>\JJ\1740 <e2>overdose</e2>\NN\1740 :\:\1740 a\DT\13649268 cause\NN\7323922 for\IN\1740 prolonged\JJ\1740 QT\NN\1740 syndrome\NN\5870365 .\.\1740
C012052_D008133 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>amisulpride</e1>\JJ\1740 overdose\NN\1740 :\:\1740 a\DT\13649268 cause\NN\7323922 for\IN\1740 <e2>prolonged\JJ\1740 QT\NN\1740 syndrome</e2>\NN\5870365 .\.\1740
C012052_D011041 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 deliberate\NN\1740 <e2>self-poisoning</e2>\NN\1740 with\IN\1740 5\CD\13741022 g\NN\13717155 and\CC\1740 3.6\CD\1740 g\NN\13717155 of\IN\1740 <e1>amisulpride</e1>\RB\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 are\VBP\836236 reported\VBN\831651 .\.\1740
D002125_D008133 NONE The\DT\1740 <e2>QT\NNP\1740 prolongation</e2>\NN\1017987 appeared\VBD\2604760 to\TO\1740 respond\VB\2367363 to\TO\1740 administration\NN\1133281 of\IN\1740 i.v.\NN\1740 <e1>calcium\NN\14625458 gluconate</e1>\NN\1740 .\.\1740
12498738
C043211_D009202 NONE <e1>Carvedilol</e1>\NNP\2832168 protects\VBZ\1127795 against\IN\1740 doxorubicin-induced\JJ\1740 mitochondrial\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
C043211_D009202 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 this\DT\1740 protection\NN\407535 by\IN\1740 <e1>carvedilol</e1>\NNS\2832168 against\IN\1740 both\CC\1740 the\DT\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 cardiac\JJ\1740 tissue\NN\5220461 damage\NN\7296428 may\MD\15209706 afford\VB\2267060 significant\JJ\1740 clinical\JJ\1740 advantage\NN\5154517 in\IN\13603305 minimizing\VBG\441445 the\DT\1740 dose-limiting\JJ\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>cardiomyopathy</e2>\NN\14103288 that\WDT\1740 accompanies\VBZ\1835496 long-term\JJ\1740 doxorubicin\NN\2716866 therapy\NN\657604 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D004317_D009202 CID Carvedilol\NNP\2832168 protects\VBZ\1127795 against\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 mitochondrial\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D009202 CID Several\JJ\1740 cytopathic\JJ\1740 mechanisms\NNS\13446390 have\VBP\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 mediate\VB\761713 the\DT\1740 dose-limiting\JJ\1740 cumulative\JJ\1740 and\CC\1740 irreversible\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 caused\VBN\1617192 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D009202 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 this\DT\1740 protection\NN\407535 by\IN\1740 carvedilol\NNS\2832168 against\IN\1740 both\CC\1740 the\DT\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 cardiac\JJ\1740 tissue\NN\5220461 damage\NN\7296428 may\MD\15209706 afford\VB\2267060 significant\JJ\1740 clinical\JJ\1740 advantage\NN\5154517 in\IN\13603305 minimizing\VBG\441445 the\DT\1740 dose-limiting\JJ\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>cardiomyopathy</e2>\NN\14103288 that\WDT\1740 accompanies\VBZ\1835496 long-term\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 therapy\NN\657604 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
C043211_D064420 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 investigation\NN\5797597 was\VBD\836236 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 <e1>carvedilol</e1>\NN\2832168 ,\,\1740 a\DT\13649268 nonselective\JJ\1740 beta-adrenergic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 potent\JJ\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 protects\VBZ\1127795 against\IN\1740 the\DT\1740 cardiac\JJ\1740 and\CC\1740 hepatic\JJ\1740 mitochondrial\JJ\1740 bioenergetic\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 subchronic\JJ\1740 doxorubicin\NN\2716866 <e2>toxicity</e2>\NN\13576101 .\.\1740
D004317_D064420 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 investigation\NN\5797597 was\VBD\836236 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 carvedilol\NN\2832168 ,\,\1740 a\DT\13649268 nonselective\JJ\1740 beta-adrenergic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 potent\JJ\1740 antioxidant\JJ\1740 properties\NNS\32613 ,\,\1740 protects\VBZ\1127795 against\IN\1740 the\DT\1740 cardiac\JJ\1740 and\CC\1740 hepatic\JJ\1740 mitochondrial\JJ\1740 bioenergetic\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 subchronic\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 <e2>toxicity</e2>\NN\13576101 .\.\1740
C043211_D028361 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 this\DT\1740 protection\NN\407535 by\IN\1740 <e1>carvedilol</e1>\NNS\2832168 against\IN\1740 both\CC\1740 the\DT\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 cardiac\JJ\1740 tissue\NN\5220461 damage\NN\7296428 may\MD\15209706 afford\VB\2267060 significant\JJ\1740 clinical\JJ\1740 advantage\NN\5154517 in\IN\13603305 minimizing\VBG\441445 the\DT\1740 dose-limiting\JJ\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 cardiomyopathy\NN\14103288 that\WDT\1740 accompanies\VBZ\1835496 long-term\JJ\1740 doxorubicin\NN\2716866 therapy\NN\657604 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
C043211_D009369 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 this\DT\1740 protection\NN\407535 by\IN\1740 <e1>carvedilol</e1>\NNS\2832168 against\IN\1740 both\CC\1740 the\DT\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 cardiac\JJ\1740 tissue\NN\5220461 damage\NN\7296428 may\MD\15209706 afford\VB\2267060 significant\JJ\1740 clinical\JJ\1740 advantage\NN\5154517 in\IN\13603305 minimizing\VBG\441445 the\DT\1740 dose-limiting\JJ\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 and\CC\1740 cardiomyopathy\NN\14103288 that\WDT\1740 accompanies\VBZ\1835496 long-term\JJ\1740 doxorubicin\NN\2716866 therapy\NN\657604 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D004317_D028361 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 this\DT\1740 protection\NN\407535 by\IN\1740 carvedilol\NNS\2832168 against\IN\1740 both\CC\1740 the\DT\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 cardiac\JJ\1740 tissue\NN\5220461 damage\NN\7296428 may\MD\15209706 afford\VB\2267060 significant\JJ\1740 clinical\JJ\1740 advantage\NN\5154517 in\IN\13603305 minimizing\VBG\441445 the\DT\1740 dose-limiting\JJ\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 cardiomyopathy\NN\14103288 that\WDT\1740 accompanies\VBZ\1835496 long-term\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 therapy\NN\657604 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D004317_D009369 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 this\DT\1740 protection\NN\407535 by\IN\1740 carvedilol\NNS\2832168 against\IN\1740 both\CC\1740 the\DT\1740 structural\JJ\1740 and\CC\1740 functional\JJ\1740 cardiac\JJ\1740 tissue\NN\5220461 damage\NN\7296428 may\MD\15209706 afford\VB\2267060 significant\JJ\1740 clinical\JJ\1740 advantage\NN\5154517 in\IN\13603305 minimizing\VBG\441445 the\DT\1740 dose-limiting\JJ\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 and\CC\1740 cardiomyopathy\NN\14103288 that\WDT\1740 accompanies\VBZ\1835496 long-term\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 therapy\NN\657604 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
19515070
D019343_D064420 NONE Systemic\JJ\1740 anticoagulation\NN\657604 is\VBZ\836236 unsafe\JJ\1740 and\CC\1740 regional\JJ\1740 <e1>citrate</e1>\NN\14850483 anticoagulation\NN\657604 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 a\DT\13649268 functional\JJ\1740 liver\NN\5298729 carries\VBZ\1850315 the\DT\1740 risk\NN\14541044 of\IN\1740 citrate\NN\14850483 <e2>toxicity</e2>\NN\13576101 .\.\1740
D019343_D064420 NONE Systemic\JJ\1740 anticoagulation\NN\657604 is\VBZ\836236 unsafe\JJ\1740 and\CC\1740 regional\JJ\1740 citrate\NN\14850483 anticoagulation\NN\657604 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 a\DT\13649268 functional\JJ\1740 liver\NN\5298729 carries\VBZ\1850315 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>citrate</e1>\NN\14850483 <e2>toxicity</e2>\NN\13576101 .\.\1740
D019343_D064420 NONE The\DT\1740 patient\NN\9898892 tolerated\VBD\802318 the\DT\1740 procedure\NN\407535 well\RB\1740 without\IN\1740 any\DT\1740 signs\NNS\6643763 of\IN\1740 <e1>citrate</e1>\NN\14850483 <e2>toxicity</e2>\NN\13576101 and\CC\1740 maintained\VBD\2202928 adequate\JJ\1740 anticoagulation\NN\657604 for\IN\1740 patency\NN\5083905 of\IN\1740 the\DT\1740 dialysis\NN\646833 circuit\NN\3269401 .\.\1740
D000082_D017114 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 40-year-old\JJ\1740 female\NN\15388 with\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>fulminant\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 with\IN\1740 associated\VBN\628491 AKI\NN\1740 who\WP\8299493 underwent\VBD\109660 intraoperative\JJ\1740 dialytic\JJ\1740 support\NN\407535 during\IN\1740 liver\NN\5298729 transplantation\NN\671351 anticoagulated\VBN\1740 with\IN\1740 citrate\NN\14850483 dialysate\NN\1740 during\IN\1740 the\DT\1740 entire\JJ\1740 procedure\NN\407535 .\.\1740
D000082_D058186 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 40-year-old\JJ\1740 female\NN\15388 with\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 fulminant\JJ\1740 liver\NN\5298729 failure\NN\66216 with\IN\1740 associated\VBN\628491 <e2>AKI</e2>\NN\1740 who\WP\8299493 underwent\VBD\109660 intraoperative\JJ\1740 dialytic\JJ\1740 support\NN\407535 during\IN\1740 liver\NN\5298729 transplantation\NN\671351 anticoagulated\VBN\1740 with\IN\1740 citrate\NN\14850483 dialysate\NN\1740 during\IN\1740 the\DT\1740 entire\JJ\1740 procedure\NN\407535 .\.\1740
D019343_D017114 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 40-year-old\JJ\1740 female\NN\15388 with\IN\1740 acetaminophen-induced\JJ\1740 <e2>fulminant\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 with\IN\1740 associated\VBN\628491 AKI\NN\1740 who\WP\8299493 underwent\VBD\109660 intraoperative\JJ\1740 dialytic\JJ\1740 support\NN\407535 during\IN\1740 liver\NN\5298729 transplantation\NN\671351 anticoagulated\VBN\1740 with\IN\1740 <e1>citrate</e1>\NN\14850483 dialysate\NN\1740 during\IN\1740 the\DT\1740 entire\JJ\1740 procedure\NN\407535 .\.\1740
D019343_D017114 NONE <e1>Citrate</e1>\NN\14850483 dialysate\NN\1740 is\VBZ\836236 a\DT\13649268 safe\JJ\1740 alternative\NN\5788149 for\IN\1740 intradialytic\JJ\1740 support\NN\407535 of\IN\1740 liver\NN\5298729 transplantation\NN\671351 in\IN\13603305 <e2>fulminant\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 .\.\1740
D019343_D058186 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 40-year-old\JJ\1740 female\NN\15388 with\IN\1740 acetaminophen-induced\JJ\1740 fulminant\JJ\1740 liver\NN\5298729 failure\NN\66216 with\IN\1740 associated\VBN\628491 <e2>AKI</e2>\NN\1740 who\WP\8299493 underwent\VBD\109660 intraoperative\JJ\1740 dialytic\JJ\1740 support\NN\407535 during\IN\1740 liver\NN\5298729 transplantation\NN\671351 anticoagulated\VBN\1740 with\IN\1740 <e1>citrate</e1>\NN\14850483 dialysate\NN\1740 during\IN\1740 the\DT\1740 entire\JJ\1740 procedure\NN\407535 .\.\1740
9889429
D009543_D006973 NONE Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 adverse\JJ\1740 event\NN\23100 of\IN\1740 <e1>nifedipine</e1>\NN\2938514 sustained-release\NN\1740 tablets\NNS\4233405 for\IN\1740 cyclosporin\NN\1740 A-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 patients\NNS\9898892 with\IN\1740 psoriasis\NN\14219661 .\.\1740
D009543_D006973 NONE Thirteen\CD\13745420 psoriatic\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hypertension</e2>\NN\14057371 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 cyclosporin\NN\1740 A\NN\13649268 therapy\NN\657604 were\VBD\836236 treated\VBN\2376958 for\IN\1740 25\CD\13745420 months\NNS\15113229 with\IN\1740 a\DT\13649268 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 sustained-release\JJ\1740 <e1>nifedipine</e1>\NN\2938514 ,\,\1740 to\TO\1740 study\VB\630380 the\DT\1740 clinical\JJ\1740 antihypertensive\JJ\1740 effects\NNS\13245626 and\CC\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 treatment\NN\654885 with\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D009543_D006973 NONE Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 sustained-release\JJ\1740 <e1>nifedipine</e1>\NN\2938514 is\VBZ\836236 useful\JJ\1740 for\IN\1740 <e2>hypertensive</e2>\JJ\1740 psoriatic\JJ\1740 patients\NNS\9898892 under\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 ,\,\1740 but\CC\1740 that\IN\1740 these\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 gingival\JJ\1740 hyperplasia\NN\14365950 .\.\1740
D009543_D011565 NONE Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 adverse\JJ\1740 event\NN\23100 of\IN\1740 <e1>nifedipine</e1>\NN\2938514 sustained-release\NN\1740 tablets\NNS\4233405 for\IN\1740 cyclosporin\NN\1740 A-induced\JJ\1740 hypertension\NN\14057371 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 .\.\1740
D009543_D011565 NONE Thirteen\CD\13745420 <e2>psoriatic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 hypertension\NN\14057371 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 cyclosporin\NN\1740 A\NN\13649268 therapy\NN\657604 were\VBD\836236 treated\VBN\2376958 for\IN\1740 25\CD\13745420 months\NNS\15113229 with\IN\1740 a\DT\13649268 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 sustained-release\JJ\1740 <e1>nifedipine</e1>\NN\2938514 ,\,\1740 to\TO\1740 study\VB\630380 the\DT\1740 clinical\JJ\1740 antihypertensive\JJ\1740 effects\NNS\13245626 and\CC\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 treatment\NN\654885 with\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D009543_D011565 NONE Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 sustained-release\JJ\1740 <e1>nifedipine</e1>\NN\2938514 is\VBZ\836236 useful\JJ\1740 for\IN\1740 hypertensive\JJ\1740 <e2>psoriatic</e2>\JJ\1740 patients\NNS\9898892 under\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 ,\,\1740 but\CC\1740 that\IN\1740 these\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 gingival\JJ\1740 hyperplasia\NN\14365950 .\.\1740
D016572_D006973 CID Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 adverse\JJ\1740 event\NN\23100 of\IN\1740 nifedipine\NN\2938514 sustained-release\NN\1740 tablets\NNS\4233405 for\IN\1740 <e1>cyclosporin\NN\1740 A-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 patients\NNS\9898892 with\IN\1740 psoriasis\NN\14219661 .\.\1740
D016572_D006973 CID Thirteen\CD\13745420 psoriatic\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hypertension</e2>\NN\14057371 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 therapy\NN\657604 were\VBD\836236 treated\VBN\2376958 for\IN\1740 25\CD\13745420 months\NNS\15113229 with\IN\1740 a\DT\13649268 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 ,\,\1740 to\TO\1740 study\VB\630380 the\DT\1740 clinical\JJ\1740 antihypertensive\JJ\1740 effects\NNS\13245626 and\CC\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 treatment\NN\654885 with\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D016572_D006973 CID Seven\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 had\VBD\2108377 exhibited\VBN\2632167 a\DT\13649268 subclinical\JJ\1740 <e2>hypertensive</e2>\NN\10405694 state\NN\8491826 before\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 therapy\NN\657604 .\.\1740
D016572_D006973 CID Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 is\VBZ\836236 useful\JJ\1740 for\IN\1740 <e2>hypertensive</e2>\JJ\1740 psoriatic\JJ\1740 patients\NNS\9898892 under\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 ,\,\1740 but\CC\1740 that\IN\1740 these\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 gingival\JJ\1740 hyperplasia\NN\14365950 .\.\1740
D016572_D011565 NONE Long-term\JJ\1740 efficacy\NN\5199286 and\CC\1740 adverse\JJ\1740 event\NN\23100 of\IN\1740 nifedipine\NN\2938514 sustained-release\NN\1740 tablets\NNS\4233405 for\IN\1740 <e1>cyclosporin\NN\1740 A-induced</e1>\JJ\1740 hypertension\NN\14057371 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>psoriasis</e2>\NN\14219661 .\.\1740
D016572_D011565 NONE Thirteen\CD\13745420 <e2>psoriatic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 hypertension\NN\14057371 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 therapy\NN\657604 were\VBD\836236 treated\VBN\2376958 for\IN\1740 25\CD\13745420 months\NNS\15113229 with\IN\1740 a\DT\13649268 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 ,\,\1740 to\TO\1740 study\VB\630380 the\DT\1740 clinical\JJ\1740 antihypertensive\JJ\1740 effects\NNS\13245626 and\CC\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 treatment\NN\654885 with\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D016572_D011565 NONE Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 is\VBZ\836236 useful\JJ\1740 for\IN\1740 hypertensive\JJ\1740 <e2>psoriatic</e2>\JJ\1740 patients\NNS\9898892 under\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 ,\,\1740 but\CC\1740 that\IN\1740 these\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 gingival\JJ\1740 hyperplasia\NN\14365950 .\.\1740
D002118_D011565 NONE Thirteen\CD\13745420 <e2>psoriatic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 hypertension\NN\14057371 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 cyclosporin\NN\1740 A\NN\13649268 therapy\NN\657604 were\VBD\836236 treated\VBN\2376958 for\IN\1740 25\CD\13745420 months\NNS\15113229 with\IN\1740 a\DT\13649268 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 ,\,\1740 to\TO\1740 study\VB\630380 the\DT\1740 clinical\JJ\1740 antihypertensive\JJ\1740 effects\NNS\13245626 and\CC\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 treatment\NN\654885 with\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D002118_D006973 NONE Thirteen\CD\13745420 psoriatic\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hypertension</e2>\NN\14057371 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 cyclosporin\NN\1740 A\NN\13649268 therapy\NN\657604 were\VBD\836236 treated\VBN\2376958 for\IN\1740 25\CD\13745420 months\NNS\15113229 with\IN\1740 a\DT\13649268 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 ,\,\1740 to\TO\1740 study\VB\630380 the\DT\1740 clinical\JJ\1740 antihypertensive\JJ\1740 effects\NNS\13245626 and\CC\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 treatment\NN\654885 with\IN\1740 both\DT\1740 drugs\NNS\14778436 .\.\1740
D016572_D005885 CID The\DT\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 and\CC\1740 nifedipine\NN\2938514 included\VBD\690614 an\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 urea\NN\14727670 nitrogen\NN\14622893 levels\NNS\4916342 in\IN\13603305 9\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 and\CC\1740 development\NN\248977 of\IN\1740 <e2>gingival\JJ\1740 hyperplasia</e2>\NN\14365950 in\IN\13603305 2\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 .\.\1740
D016572_D005885 CID Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 sustained-release\JJ\1740 nifedipine\NN\2938514 is\VBZ\836236 useful\JJ\1740 for\IN\1740 hypertensive\JJ\1740 psoriatic\JJ\1740 patients\NNS\9898892 under\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 ,\,\1740 but\CC\1740 that\IN\1740 these\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 <e2>gingival\JJ\1740 hyperplasia</e2>\NN\14365950 .\.\1740
D009543_D005885 CID The\DT\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 and\CC\1740 <e1>nifedipine</e1>\NN\2938514 included\VBD\690614 an\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 urea\NN\14727670 nitrogen\NN\14622893 levels\NNS\4916342 in\IN\13603305 9\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 and\CC\1740 development\NN\248977 of\IN\1740 <e2>gingival\JJ\1740 hyperplasia</e2>\NN\14365950 in\IN\13603305 2\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 .\.\1740
D009543_D005885 CID Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 sustained-release\JJ\1740 <e1>nifedipine</e1>\NN\2938514 is\VBZ\836236 useful\JJ\1740 for\IN\1740 hypertensive\JJ\1740 psoriatic\JJ\1740 patients\NNS\9898892 under\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 ,\,\1740 but\CC\1740 that\IN\1740 these\DT\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 monitored\VBN\2169352 for\IN\1740 <e2>gingival\JJ\1740 hyperplasia</e2>\NN\14365950 .\.\1740
D001806_D005885 NONE The\DT\1740 adverse\JJ\1740 events\NNS\23100 during\IN\1740 combined\JJ\1740 therapy\NN\657604 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 and\CC\1740 nifedipine\NN\2938514 included\VBD\690614 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e1>blood\NN\5397468 urea\NN\14727670 nitrogen</e1>\NN\14622893 levels\NNS\4916342 in\IN\13603305 9\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 and\CC\1740 development\NN\248977 of\IN\1740 <e2>gingival\JJ\1740 hyperplasia</e2>\NN\14365950 in\IN\13603305 2\CD\13741022 of\IN\1740 the\DT\1740 13\CD\13745420 patients\NNS\9898892 .\.\1740
17554526
D003042_D001925 CID <e2>Impaired\JJ\1740 fear\NN\7480068 recognition</e2>\NN\13932421 in\IN\13603305 regular\JJ\1740 recreational\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 .\.\1740
D003042_D001925 CID The\DT\1740 selective\JJ\1740 <e2>deficit\NN\5113133 in\IN\13603305 fear\NN\7480068 recognition</e2>\NN\13932421 accuracy\NN\4723816 manifested\VBN\1015244 by\IN\1740 the\DT\1740 RC\NN\1740 group\NN\2137 can\MD\3094503 not\RB\1740 be\VB\836236 explained\VBN\831651 by\IN\1740 the\DT\1740 subacute\NN\1740 effects\NNS\13245626 of\IN\1740 <e1>cocaine</e1>\NN\3492717 ,\,\1740 or\CC\3541091 ecstasy\VB\1740 ,\,\1740 because\IN\1740 recent\JJ\1740 and\CC\1740 less\RBR\1740 recent\JJ\1740 users\NNS\7846 of\IN\1740 these\DT\1740 drugs\NNS\14778436 within\IN\1740 this\DT\1740 group\NN\2137 were\VBD\836236 similarly\RB\1740 impaired\JJ\1740 .\.\1740
D018817_D001925 NONE The\DT\1740 selective\JJ\1740 <e2>deficit\NN\5113133 in\IN\13603305 fear\NN\7480068 recognition</e2>\NN\13932421 accuracy\NN\4723816 manifested\VBN\1015244 by\IN\1740 the\DT\1740 RC\NN\1740 group\NN\2137 can\MD\3094503 not\RB\1740 be\VB\836236 explained\VBN\831651 by\IN\1740 the\DT\1740 subacute\NN\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 ,\,\1740 or\CC\3541091 <e1>ecstasy</e1>\VB\1740 ,\,\1740 because\IN\1740 recent\JJ\1740 and\CC\1740 less\RBR\1740 recent\JJ\1740 users\NNS\7846 of\IN\1740 these\DT\1740 drugs\NNS\14778436 within\IN\1740 this\DT\1740 group\NN\2137 were\VBD\836236 similarly\RB\1740 impaired\JJ\1740 .\.\1740
920167
D014859_D005315 NONE The\DT\1740 baby\NN\9918248 showed\VBD\2137132 <e1>warfarin-induced</e1>\JJ\1740 <e2>embryopathy</e2>\NN\1740 with\IN\1740 nasal\JJ\1740 hypoplasia\NN\14365950 and\CC\1740 stippled\JJ\1740 epiphyses\NNS\5275651 (\-LRB-\1740 chondrodysplasia\NN\1740 punctata\NNS\1740 )\-RRB-\1740 .\.\1740
D014859_-1 NONE The\DT\1740 baby\NN\9918248 showed\VBD\2137132 <e1>warfarin-induced</e1>\JJ\1740 embryopathy\NN\1740 with\IN\1740 <e2>nasal\JJ\1740 hypoplasia</e2>\NN\14365950 and\CC\1740 stippled\JJ\1740 epiphyses\NNS\5275651 (\-LRB-\1740 chondrodysplasia\NN\1740 punctata\NNS\1740 )\-RRB-\1740 .\.\1740
D014859_-1 NONE <e2>Nasal\JJ\1740 hypoplasia</e2>\NN\14365950 with\IN\1740 or\CC\3541091 without\IN\1740 stippled\JJ\1740 epiphyses\NNS\5275651 has\VBZ\2108377 now\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 11\CD\13745420 infants\NNS\9918248 born\VBN\2630189 to\TO\1740 mothers\NNS\10399491 treated\VBN\2376958 with\IN\1740 <e1>warfarin</e1>\NN\2718259 during\IN\1740 the\DT\1740 first\JJ\1740 trimester\NN\15113229 ,\,\1740 and\CC\1740 a\DT\13649268 causal\JJ\1740 association\NN\8008335 is\VBZ\836236 probable\JJ\1740 .\.\1740
D014859_D002806 CID The\DT\1740 baby\NN\9918248 showed\VBD\2137132 <e1>warfarin-induced</e1>\JJ\1740 embryopathy\NN\1740 with\IN\1740 nasal\JJ\1740 hypoplasia\NN\14365950 and\CC\1740 <e2>stippled\JJ\1740 epiphyses</e2>\NNS\5275651 (\-LRB-\1740 chondrodysplasia\NN\1740 punctata\NNS\1740 )\-RRB-\1740 .\.\1740
D014859_D002806 CID The\DT\1740 baby\NN\9918248 showed\VBD\2137132 <e1>warfarin-induced</e1>\JJ\1740 embryopathy\NN\1740 with\IN\1740 nasal\JJ\1740 hypoplasia\NN\14365950 and\CC\1740 stippled\JJ\1740 epiphyses\NNS\5275651 (\-LRB-\1740 <e2>chondrodysplasia\NN\1740 punctata</e2>\NNS\1740 )\-RRB-\1740 .\.\1740
D014859_D002806 CID Nasal\JJ\1740 hypoplasia\NN\14365950 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>stippled\JJ\1740 epiphyses</e2>\NNS\5275651 has\VBZ\2108377 now\RB\1740 been\VBN\836236 reported\VBN\831651 in\IN\13603305 11\CD\13745420 infants\NNS\9918248 born\VBN\2630189 to\TO\1740 mothers\NNS\10399491 treated\VBN\2376958 with\IN\1740 <e1>warfarin</e1>\NN\2718259 during\IN\1740 the\DT\1740 first\JJ\1740 trimester\NN\15113229 ,\,\1740 and\CC\1740 a\DT\13649268 causal\JJ\1740 association\NN\8008335 is\VBZ\836236 probable\JJ\1740 .\.\1740
25054547
D013390_D001049 CID Characterization\NN\6724763 of\IN\1740 a\DT\13649268 novel\JJ\1740 BCHE\NN\1740 "\``\1740 silent\JJ\1740 "\''\1740 allele\NN\5436752 :\:\1740 point\NN\5868954 mutation\NN\4475 (\-LRB-\1740 p.\NN\1740 Val204Asp\NN\1740 )\-RRB-\1740 causes\VBZ\1617192 loss\NN\13252973 of\IN\1740 activity\NN\30358 and\CC\1740 prolonged\VBD\317700 <e2>apnea</e2>\NN\14299637 with\IN\1740 <e1>suxamethonium</e1>\NN\1740 .\.\1740
D013390_D001049 CID Butyrylcholinesterase\NN\1740 deficiency\NN\14449126 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 (\-LRB-\1740 <e1>suxamethonium</e1>\NN\1740 or\CC\3541091 mivacurium\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 mutations\NNS\4475 in\IN\13603305 the\DT\1740 BCHE\NN\1740 gene\NN\8459252 .\.\1740
D013390_C537417 CID <e2>Butyrylcholinesterase\NN\1740 deficiency</e2>\NN\14449126 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 prolonged\JJ\1740 apnea\NN\14299637 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 (\-LRB-\1740 <e1>suxamethonium</e1>\NN\1740 or\CC\3541091 mivacurium\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 mutations\NNS\4475 in\IN\13603305 the\DT\1740 BCHE\NN\1740 gene\NN\8459252 .\.\1740
C049430_C537417 CID <e2>Butyrylcholinesterase\NN\1740 deficiency</e2>\NN\14449126 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 prolonged\JJ\1740 apnea\NN\14299637 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 (\-LRB-\1740 suxamethonium\NN\1740 or\CC\3541091 <e1>mivacurium</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 mutations\NNS\4475 in\IN\13603305 the\DT\1740 BCHE\NN\1740 gene\NN\8459252 .\.\1740
C049430_D001049 CID Butyrylcholinesterase\NN\1740 deficiency\NN\14449126 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 muscle\NN\5289601 relaxants\NNS\3247620 (\-LRB-\1740 suxamethonium\NN\1740 or\CC\3541091 <e1>mivacurium</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 mutations\NNS\4475 in\IN\13603305 the\DT\1740 BCHE\NN\1740 gene\NN\8459252 .\.\1740
10677406
D004280_D018487 CID Prolonged\JJ\1740 <e2>left\VBD\120316 ventricular\NN\1740 dysfunction</e2>\NN\14204950 occurs\VBZ\2623529 in\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 after\IN\1740 both\CC\1740 <e1>dobutamine</e1>\NN\1740 and\CC\1740 exercise\NN\621627 induced\JJ\1740 myocardial\JJ\1740 ischaemia\NN\14195315 .\.\1740
D004280_D018487 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 <e1>dobutamine</e1>\NN\1740 induced\VBD\1627355 ischaemia\NN\14195315 results\NNS\34213 in\IN\13603305 prolonged\JJ\1740 reversible\JJ\1740 <e2>left\JJ\1740 ventricular\NN\1740 dysfunction</e2>\NN\14204950 ,\,\1740 presumed\VBN\719734 to\TO\1740 be\VB\836236 myocardial\JJ\1740 stunning\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 that\DT\1740 seen\VBN\2106506 after\IN\1740 exercise\NN\621627 .\.\1740
D004280_D003324 NONE Prolonged\JJ\1740 left\VBD\120316 ventricular\NN\1740 dysfunction\NN\14204950 occurs\VBZ\2623529 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 after\IN\1740 both\CC\1740 <e1>dobutamine</e1>\NN\1740 and\CC\1740 exercise\NN\621627 induced\JJ\1740 myocardial\JJ\1740 ischaemia\NN\14195315 .\.\1740
D004280_D003324 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 ,\,\1740 <e1>dobutamine</e1>\NN\1740 induced\VBD\1627355 ischaemia\NN\14195315 results\NNS\34213 in\IN\13603305 prolonged\JJ\1740 reversible\JJ\1740 left\JJ\1740 ventricular\NN\1740 dysfunction\NN\14204950 ,\,\1740 presumed\VBN\719734 to\TO\1740 be\VB\836236 myocardial\JJ\1740 stunning\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 that\DT\1740 seen\VBN\2106506 after\IN\1740 exercise\NN\621627 .\.\1740
D004280_D003324 NONE <e1>Dobutamine</e1>\NNP\1740 induced\VBD\1627355 ischaemia\NN\14195315 could\MD\1740 therefore\RB\1740 be\VB\836236 used\VBN\1156834 to\TO\1740 study\VB\630380 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 this\DT\1740 phenomenon\NN\29677 further\RBR\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D004280_D017202 NONE Prolonged\JJ\1740 left\VBD\120316 ventricular\NN\1740 dysfunction\NN\14204950 occurs\VBZ\2623529 in\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 after\IN\1740 both\CC\1740 <e1>dobutamine</e1>\NN\1740 and\CC\1740 exercise\NN\621627 induced\JJ\1740 <e2>myocardial\JJ\1740 ischaemia</e2>\NN\14195315 .\.\1740
D004280_D007511 NONE DESIGN\NN\927261 :\:\1740 A\DT\13649268 randomised\JJ\1740 crossover\NN\13526110 study\NN\635850 of\IN\1740 recovery\NN\7357388 time\NN\7308889 of\IN\1740 systolic\JJ\1740 and\CC\1740 diastolic\JJ\1740 left\JJ\1740 ventricular\JJ\1740 function\NN\13783581 after\IN\1740 exercise\NN\621627 and\CC\1740 <e1>dobutamine</e1>\NN\1740 induced\JJ\1740 <e2>ischaemia</e2>\NN\14195315 .\.\1740
D004280_D007511 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 <e1>dobutamine</e1>\NN\1740 induced\VBD\1627355 <e2>ischaemia</e2>\NN\14195315 results\NNS\34213 in\IN\13603305 prolonged\JJ\1740 reversible\JJ\1740 left\JJ\1740 ventricular\NN\1740 dysfunction\NN\14204950 ,\,\1740 presumed\VBN\719734 to\TO\1740 be\VB\836236 myocardial\JJ\1740 stunning\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 that\DT\1740 seen\VBN\2106506 after\IN\1740 exercise\NN\621627 .\.\1740
D004280_D007511 NONE <e1>Dobutamine</e1>\NNP\1740 induced\VBD\1627355 <e2>ischaemia</e2>\NN\14195315 could\MD\1740 therefore\RB\1740 be\VB\836236 used\VBN\1156834 to\TO\1740 study\VB\630380 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 this\DT\1740 phenomenon\NN\29677 further\RBR\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 .\.\1740
D004280_D017682 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 ,\,\1740 <e1>dobutamine</e1>\NN\1740 induced\VBD\1627355 ischaemia\NN\14195315 results\NNS\34213 in\IN\13603305 prolonged\JJ\1740 reversible\JJ\1740 left\JJ\1740 ventricular\NN\1740 dysfunction\NN\14204950 ,\,\1740 presumed\VBN\719734 to\TO\1740 be\VB\836236 <e2>myocardial\JJ\1740 stunning</e2>\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 that\DT\1740 seen\VBN\2106506 after\IN\1740 exercise\NN\621627 .\.\1740
1361574
D002243_D012640 NONE Moreover\RB\1740 ,\,\1740 0.05\CD\1740 mg/kg\NN\1740 of\IN\1740 this\DT\1740 <e1>beta-carboline</e1>\NN\1740 reduced\VBD\441445 markedly\RB\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 [35S]TBPS\NN\1740 binding\NN\4688246 and\CC\1740 the\DT\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 isoniazid\NNS\2716205 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 .\.\1740
C037476_D012640 NONE Moreover\RB\1740 ,\,\1740 0.05\CD\1740 mg/kg\NN\1740 of\IN\1740 this\DT\1740 beta-carboline\NN\1740 reduced\VBD\441445 markedly\RB\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 <e1>[35S]TBPS</e1>\NN\1740 binding\NN\4688246 and\CC\1740 the\DT\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 isoniazid\NNS\2716205 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 .\.\1740
D007538_D012640 CID Moreover\RB\1740 ,\,\1740 0.05\CD\1740 mg/kg\NN\1740 of\IN\1740 this\DT\1740 beta-carboline\NN\1740 reduced\VBD\441445 markedly\RB\1740 the\DT\1740 increase\NN\13576355 of\IN\1740 [35S]TBPS\NN\1740 binding\NN\4688246 and\CC\1740 the\DT\1740 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>isoniazid</e1>\NNS\2716205 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 .\.\1740
6687006
D003913_D006948 CID The\DT\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>D-amphetamine</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mumol/kg\NNS\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 DSP4\NN\1740 pretreatment\NN\1740 .\.\1740
C012102_D006948 NONE The\DT\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 D-amphetamine\NN\1740 (\-LRB-\1740 10\CD\13745420 mumol/kg\NNS\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 reduced\VBN\441445 by\IN\1740 <e1>DSP4</e1>\NN\1740 pretreatment\NN\1740 .\.\1740
C012102_D006948 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>DSP4</e1>\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 neurotoxic\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
C012102_D006948 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 neurotoxic\JJ\1740 action\NN\30358 of\IN\1740 <e1>DSP4</e1>\NN\1740 .\.\1740
D000661_D019956 NONE However\RB\1740 ,\,\1740 the\DT\1740 increased\VBN\169651 rearings\NNS\4921754 and\CC\1740 the\DT\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>stereotypies</e2>\NNS\1740 were\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 DSP4\NN\1740 .\.\1740
C012102_D019956 NONE However\RB\1740 ,\,\1740 the\DT\1740 increased\VBN\169651 rearings\NNS\4921754 and\CC\1740 the\DT\1740 amphetamine-induced\JJ\1740 <e2>stereotypies</e2>\NNS\1740 were\VBD\836236 not\RB\1740 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>DSP4</e1>\NN\1740 .\.\1740
D000661_D006948 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 neurotoxic\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
D000661_D020258 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
C012102_D020258 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>DSP4</e1>\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
C012102_D020258 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 <e1>DSP4</e1>\NN\1740 .\.\1740
D009638_D006948 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 <e1>noradrenaline-uptake</e1>\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 neurotoxic\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
D009638_D020258 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 <e1>noradrenaline-uptake</e1>\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 desipramine\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
D003891_D006948 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 <e1>desipramine</e1>\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 neurotoxic\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
D003891_D020258 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 amphetamine\NN\3248958 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 DSP4\NN\1740 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 noradrenaline-uptake\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 <e1>desipramine</e1>\NN\4482543 ,\,\1740 which\WDT\1740 prevents\VBZ\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 DSP4\NN\1740 .\.\1740
10770468
D008094_D001714 NONE Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 <e2>bipolar</e2>\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D001714 NONE Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D001714 NONE Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 <e2>bipolar</e2>\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 lithium\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D001714 NONE Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 lithium\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D001714 NONE Thus\RB\1740 ,\,\1740 two\CD\13741022 control\NN\5190804 groups\NNS\2137 were\VBD\836236 generated\VBN\1617192 :\:\1740 group\NN\2137 C1\NN\1740 ,\,\1740 which\WDT\1740 included\VBD\690614 age-\NN\1740 and\CC\1740 sex-comparable\JJ\1740 <e1>lithium-treated</e1>\JJ\1740 <e2>bipolar</e2>\JJ\1740 normocalcemic\JJ\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 group\NN\2137 C2\NN\1740 ,\,\1740 which\WDT\1740 included\VBD\690614 bipolar\JJ\1740 normocalcemic\JJ\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 anticonvulsant\JJ\1740 mood\NN\26192 stabilizers\NNS\14806838 .\.\1740
D008094_D001714 NONE Thus\RB\1740 ,\,\1740 two\CD\13741022 control\NN\5190804 groups\NNS\2137 were\VBD\836236 generated\VBN\1617192 :\:\1740 group\NN\2137 C1\NN\1740 ,\,\1740 which\WDT\1740 included\VBD\690614 age-\NN\1740 and\CC\1740 sex-comparable\JJ\1740 <e1>lithium-treated</e1>\JJ\1740 bipolar\JJ\1740 normocalcemic\JJ\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 group\NN\2137 C2\NN\1740 ,\,\1740 which\WDT\1740 included\VBD\690614 <e2>bipolar</e2>\JJ\1740 normocalcemic\JJ\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 anticonvulsant\JJ\1740 mood\NN\26192 stabilizers\NNS\14806838 .\.\1740
D008094_D001714 NONE Patients\NNS\9898892 with\IN\1740 hypercalcemia\NN\14299637 resulting\VBG\2633881 from\IN\1740 medical\JJ\1740 diseases\NNS\14061805 and\CC\1740 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 had\VBD\2108377 significantly\RB\1740 higher\JJR\1740 frequencies\NNS\15286249 of\IN\1740 conduction\NN\11419404 defects\NNS\14462666 .\.\1740
D008094_D006934 CID Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 <e2>hypercalcemia</e2>\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D006934 CID Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 .\.\1740
D008094_D006934 CID Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 lithium\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 <e2>hypercalcemia</e2>\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D006934 CID Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 lithium\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 .\.\1740
D008094_D006934 CID After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 <e2>hypercalcemias</e2>\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 <e1>non-lithium-treated</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 hypercalcemias\NNS\14299637 related\JJ\1740 to\TO\1740 malignancies\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D006934 CID After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 hypercalcemias\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 <e1>non-lithium-treated</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hypercalcemias</e2>\NNS\14299637 related\JJ\1740 to\TO\1740 malignancies\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D006934 CID After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 hypercalcemias\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 <e1>non-lithium-treated</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 hypercalcemias\NNS\14299637 related\JJ\1740 to\TO\1740 malignancies\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D006934 CID After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 <e2>hypercalcemias</e2>\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 non-lithium-treated\JJ\1740 patients\NNS\9898892 with\IN\1740 hypercalcemias\NNS\14299637 related\JJ\1740 to\TO\1740 malignancies\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D006934 CID After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 hypercalcemias\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 non-lithium-treated\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hypercalcemias</e2>\NNS\14299637 related\JJ\1740 to\TO\1740 malignancies\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D006934 CID After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 hypercalcemias\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 non-lithium-treated\JJ\1740 patients\NNS\9898892 with\IN\1740 hypercalcemias\NNS\14299637 related\JJ\1740 to\TO\1740 malignancies\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D006934 CID Patients\NNS\9898892 with\IN\1740 <e2>hypercalcemia</e2>\NN\14299637 resulting\VBG\2633881 from\IN\1740 medical\JJ\1740 diseases\NNS\14061805 and\CC\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 had\VBD\2108377 significantly\RB\1740 higher\JJR\1740 frequencies\NNS\15286249 of\IN\1740 conduction\NN\11419404 defects\NNS\14462666 .\.\1740
D008094_D006934 CID Patients\NNS\9898892 with\IN\1740 hypercalcemia\NN\14299637 resulting\VBG\2633881 from\IN\1740 medical\JJ\1740 diseases\NNS\14061805 and\CC\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 had\VBD\2108377 significantly\RB\1740 higher\JJR\1740 frequencies\NNS\15286249 of\IN\1740 conduction\NN\11419404 defects\NNS\14462666 .\.\1740
D008094_D001919 NONE Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 <e2>bradyarrhythmia</e2>\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D001919 NONE Recent\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 receiving\VBG\2210855 maintenance\NN\266806 lithium\NN\14625458 therapy\NN\657604 who\WP\8299493 developed\VBD\1753788 hypercalcemia\NN\14299637 and\CC\1740 severe\JJ\1740 <e2>bradyarrhythmia</e2>\NN\1740 prompted\VBD\1645601 the\DT\1740 authors\NNS\9610660 to\TO\1740 conduct\VB\2436349 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 bipolar\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 .\.\1740
D008094_D009369 NONE After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 hypercalcemias\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 <e1>non-lithium-treated</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 hypercalcemias\NNS\14299637 related\JJ\1740 to\TO\1740 <e2>malignancies</e2>\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 lithium-associated\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
D008094_D009369 NONE After\IN\1740 eliminating\VBG\1619929 spurious\JJ\1740 hypercalcemias\NNS\14299637 or\CC\3541091 those\DT\1740 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 fluids\NNS\19613 ,\,\1740 the\DT\1740 authors\NNS\9610660 identified\VBD\699815 18\CD\13745420 non-lithium-treated\JJ\1740 patients\NNS\9898892 with\IN\1740 hypercalcemias\NNS\14299637 related\JJ\1740 to\TO\1740 <e2>malignancies</e2>\NNS\14070360 and\CC\1740 other\JJ\1740 medical\JJ\1740 conditions\NNS\14512817 (\-LRB-\1740 group\NN\2137 A\NN\13649268 )\-RRB-\1740 and\CC\1740 12\CD\13745420 patients\NNS\9898892 with\IN\1740 <e1>lithium-associated</e1>\JJ\1740 hypercalcemia\NN\14299637 (\-LRB-\1740 group\NN\2137 B\NN\1355326 )\-RRB-\1740 .\.\1740
18025637
D005473_D012170 CID Branch\NN\8220714 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 and\CC\1740 <e1>fluoxetine</e1>\NN\4169152 .\.\1740
D005473_D012170 CID A\DT\13649268 case\NN\7283608 of\IN\1740 branch\NN\8220714 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 associated\VBN\628491 with\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 secondary\JJ\1740 hypertension\NN\14057371 is\VBZ\836236 described\VBN\1001294 .\.\1740
D005473_D006973 CID A\DT\13649268 case\NN\7283608 of\IN\1740 branch\NN\8220714 retinal\JJ\1740 vein\NN\5417975 occlusion\NN\14081375 associated\VBN\628491 with\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 secondary\JJ\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 described\VBN\1001294 .\.\1740
D012701_D006973 NONE Although\IN\1740 an\DT\6697703 infrequent\JJ\1740 complication\NN\1073995 of\IN\1740 selective\JJ\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 therapy\NN\657604 ,\,\1740 it\PRP\6125041 is\VBZ\836236 important\JJ\1740 that\IN\1740 ophthalmologists\NNS\10632576 are\VBP\836236 aware\JJ\1740 that\IN\1740 these\DT\1740 agents\NNS\7347 can\MD\3094503 cause\VB\1617192 <e2>hypertension</e2>\NN\14057371 because\IN\1740 this\DT\1740 class\NN\7951464 of\IN\1740 drugs\NNS\14778436 is\VBZ\836236 widely\RB\1740 prescribed\VBN\748282 .\.\1740
16309808
D004294_D012148 NONE Does\VBZ\1640855 <e1>domperidone</e1>\RB\1740 potentiate\VB\229605 mirtazapine-associated\JJ\1740 <e2>restless\NN\1740 legs\NNS\5032918 syndrome</e2>\NN\5870365 ?\.\1740
D004294_D012148 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 previous\JJ\1740 report\NN\6470073 regarding\VBG\689344 whether\IN\1740 <e1>domperidone</e1>\NN\1740 ,\,\1740 a\DT\13649268 peripheral\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 can\MD\3094503 also\RB\1740 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NNP\1740 .\.\1740
D004294_D012148 NONE The\DT\1740 authors\NNS\9610660 report\VBP\831651 here\RB\1740 a\DT\13649268 depressed\JJ\1740 patient\NN\9898892 comorbid\NN\1740 with\IN\1740 postprandial\JJ\1740 dyspepsia\NN\14299637 who\WP\8299493 developed\VBD\1753788 <e2>RLS</e2>\NN\1740 after\IN\1740 mirtazapine\NN\1740 had\VBD\2108377 been\VBN\836236 added\VBN\156601 to\IN\1740 his\PRP$\1740 <e1>domperidone</e1>\NN\1740 therapy\NN\657604 .\.\1740
D004294_D012148 NONE Such\JJ\1740 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 mirtazapine\NN\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 did\VBD\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 potentiating\NN\1740 effect\NN\34213 of\IN\1740 <e1>domperione</e1>\NN\1740 on\IN\1740 mirtazapine-associated\JJ\1740 RLS\NN\1740 .\.\1740
D004294_D012148 NONE Such\JJ\1740 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 mirtazapine\NN\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 did\VBD\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 potentiating\NN\1740 effect\NN\34213 of\IN\1740 <e1>domperione</e1>\NN\1740 on\IN\1740 mirtazapine-associated\JJ\1740 <e2>RLS</e2>\NN\1740 .\.\1740
C035133_D012148 CID Does\VBZ\1640855 domperidone\RB\1740 potentiate\VB\229605 <e1>mirtazapine-associated</e1>\JJ\1740 <e2>restless\NN\1740 legs\NNS\5032918 syndrome</e2>\NN\5870365 ?\.\1740
C035133_D012148 CID <e1>Mirtazapine</e1>\NNP\1740 ,\,\1740 the\DT\1740 first\JJ\1740 noradrenergic\JJ\1740 and\CC\1740 specific\JJ\1740 serotonergic\NN\1740 antidepressant\NN\3740161 (\-LRB-\1740 NaSSA\NN\1740 )\-RRB-\1740 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e2>RLS</e2>\NN\1740 in\IN\13603305 several\JJ\1740 recent\JJ\1740 publications\NNS\4599396 .\.\1740
C035133_D012148 CID The\DT\1740 authors\NNS\9610660 report\VBP\831651 here\RB\1740 a\DT\13649268 depressed\JJ\1740 patient\NN\9898892 comorbid\NN\1740 with\IN\1740 postprandial\JJ\1740 dyspepsia\NN\14299637 who\WP\8299493 developed\VBD\1753788 <e2>RLS</e2>\NN\1740 after\IN\1740 <e1>mirtazapine</e1>\NN\1740 had\VBD\2108377 been\VBN\836236 added\VBN\156601 to\IN\1740 his\PRP$\1740 domperidone\NN\1740 therapy\NN\657604 .\.\1740
C035133_D012148 CID Our\PRP$\1740 patient\NN\9898892 started\VBD\2009433 to\TO\1740 have\VB\2108377 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 only\RB\1740 after\IN\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>mirtazapine</e1>\NN\1740 ,\,\1740 and\CC\1740 his\PRP$\1740 RLS\NN\1740 symptoms\NNS\5823932 resolved\VBD\352826 completely\RB\1740 upon\IN\1740 discontinuation\NN\209943 of\IN\1740 his\PRP$\1740 mirtazapine\NN\1740 .\.\1740
C035133_D012148 CID Our\PRP$\1740 patient\NN\9898892 started\VBD\2009433 to\TO\1740 have\VB\2108377 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 only\RB\1740 after\IN\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>mirtazapine</e1>\NN\1740 ,\,\1740 and\CC\1740 his\PRP$\1740 <e2>RLS</e2>\NN\1740 symptoms\NNS\5823932 resolved\VBD\352826 completely\RB\1740 upon\IN\1740 discontinuation\NN\209943 of\IN\1740 his\PRP$\1740 mirtazapine\NN\1740 .\.\1740
C035133_D012148 CID Our\PRP$\1740 patient\NN\9898892 started\VBD\2009433 to\TO\1740 have\VB\2108377 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 only\RB\1740 after\IN\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 mirtazapine\NN\1740 ,\,\1740 and\CC\1740 his\PRP$\1740 RLS\NN\1740 symptoms\NNS\5823932 resolved\VBD\352826 completely\RB\1740 upon\IN\1740 discontinuation\NN\209943 of\IN\1740 his\PRP$\1740 <e1>mirtazapine</e1>\NN\1740 .\.\1740
C035133_D012148 CID Our\PRP$\1740 patient\NN\9898892 started\VBD\2009433 to\TO\1740 have\VB\2108377 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 only\RB\1740 after\IN\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 with\IN\1740 mirtazapine\NN\1740 ,\,\1740 and\CC\1740 his\PRP$\1740 <e2>RLS</e2>\NN\1740 symptoms\NNS\5823932 resolved\VBD\352826 completely\RB\1740 upon\IN\1740 discontinuation\NN\209943 of\IN\1740 his\PRP$\1740 <e1>mirtazapine</e1>\NN\1740 .\.\1740
C035133_D012148 CID Such\JJ\1740 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>mirtazapine</e1>\NN\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 did\VBD\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 potentiating\NN\1740 effect\NN\34213 of\IN\1740 domperione\NN\1740 on\IN\1740 mirtazapine-associated\JJ\1740 RLS\NN\1740 .\.\1740
C035133_D012148 CID Such\JJ\1740 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>mirtazapine</e1>\NN\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 did\VBD\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 potentiating\NN\1740 effect\NN\34213 of\IN\1740 domperione\NN\1740 on\IN\1740 mirtazapine-associated\JJ\1740 <e2>RLS</e2>\NN\1740 .\.\1740
C035133_D012148 CID Such\JJ\1740 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 mirtazapine\NN\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 did\VBD\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 potentiating\NN\1740 effect\NN\34213 of\IN\1740 domperione\NN\1740 on\IN\1740 <e1>mirtazapine-associated</e1>\JJ\1740 RLS\NN\1740 .\.\1740
C035133_D012148 CID Such\JJ\1740 a\DT\13649268 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 mirtazapine\NN\1740 and\CC\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 did\VBD\1640855 not\RB\1740 support\VB\2199590 a\DT\13649268 potentiating\NN\1740 effect\NN\34213 of\IN\1740 domperione\NN\1740 on\IN\1740 <e1>mirtazapine-associated</e1>\JJ\1740 <e2>RLS</e2>\NN\1740 .\.\1740
C035133_D012148 CID However\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 possibility\NN\5944958 that\IN\1740 <e1>mirtazapine</e1>\NN\1740 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 <e2>RLS</e2>\NN\1740 in\IN\13603305 some\DT\1740 individuals\NNS\7347 ,\,\1740 especially\RB\1740 those\DT\1740 receiving\VBG\2210855 concomitant\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 .\.\1740
D007980_D012148 NONE For\IN\1740 example\NN\5816287 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 can\MD\3094503 be\VB\836236 dramatically\RB\1740 improved\VBN\126264 by\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 dopamine\NN\14807737 agonists\NNS\9613191 ,\,\1740 whereas\IN\1740 central\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 can\MD\3094503 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 RLS\NN\1740 symptoms\NNS\5823932 .\.\1740
D007980_D012148 NONE For\IN\1740 example\NN\5816287 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 can\MD\3094503 be\VB\836236 dramatically\RB\1740 improved\VBN\126264 by\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 dopamine\NN\14807737 agonists\NNS\9613191 ,\,\1740 whereas\IN\1740 central\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 can\MD\3094503 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 <e2>RLS</e2>\NN\1740 symptoms\NNS\5823932 .\.\1740
D004298_D012148 NONE For\IN\1740 example\NN\5816287 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 can\MD\3094503 be\VB\836236 dramatically\RB\1740 improved\VBN\126264 by\IN\1740 levodopa\NN\14604959 and\CC\1740 <e1>dopamine</e1>\NN\14807737 agonists\NNS\9613191 ,\,\1740 whereas\IN\1740 central\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 can\MD\3094503 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 RLS\NN\1740 symptoms\NNS\5823932 .\.\1740
D004298_D012148 NONE For\IN\1740 example\NN\5816287 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 can\MD\3094503 be\VB\836236 dramatically\RB\1740 improved\VBN\126264 by\IN\1740 levodopa\NN\14604959 and\CC\1740 <e1>dopamine</e1>\NN\14807737 agonists\NNS\9613191 ,\,\1740 whereas\IN\1740 central\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 can\MD\3094503 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 <e2>RLS</e2>\NN\1740 symptoms\NNS\5823932 .\.\1740
D004298_D012148 NONE For\IN\1740 example\NN\5816287 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NN\1740 can\MD\3094503 be\VB\836236 dramatically\RB\1740 improved\VBN\126264 by\IN\1740 levodopa\NN\14604959 and\CC\1740 dopamine\NN\14807737 agonists\NNS\9613191 ,\,\1740 whereas\IN\1740 central\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 can\MD\3094503 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 RLS\NN\1740 symptoms\NNS\5823932 .\.\1740
D004298_D012148 NONE For\IN\1740 example\NN\5816287 ,\,\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 RLS\NN\1740 can\MD\3094503 be\VB\836236 dramatically\RB\1740 improved\VBN\126264 by\IN\1740 levodopa\NN\14604959 and\CC\1740 dopamine\NN\14807737 agonists\NNS\9613191 ,\,\1740 whereas\IN\1740 central\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 can\MD\3094503 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 <e2>RLS</e2>\NN\1740 symptoms\NNS\5823932 .\.\1740
D004298_D012148 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 previous\JJ\1740 report\NN\6470073 regarding\VBG\689344 whether\IN\1740 domperidone\NN\1740 ,\,\1740 a\DT\13649268 peripheral\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 can\MD\3094503 also\RB\1740 induce\VB\1627355 or\CC\3541091 aggravate\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>RLS</e2>\NNP\1740 .\.\1740
D004298_D012148 NONE However\RB\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 possibility\NN\5944958 that\IN\1740 mirtazapine\NN\1740 can\MD\3094503 be\VB\836236 associated\VBN\628491 with\IN\1740 <e2>RLS</e2>\NN\1740 in\IN\13603305 some\DT\1740 individuals\NNS\7347 ,\,\1740 especially\RB\1740 those\DT\1740 receiving\VBG\2210855 concomitant\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 .\.\1740
C035133_D004415 NONE The\DT\1740 authors\NNS\9610660 report\VBP\831651 here\RB\1740 a\DT\13649268 depressed\JJ\1740 patient\NN\9898892 comorbid\NN\1740 with\IN\1740 <e2>postprandial\JJ\1740 dyspepsia</e2>\NN\14299637 who\WP\8299493 developed\VBD\1753788 RLS\NN\1740 after\IN\1740 <e1>mirtazapine</e1>\NN\1740 had\VBD\2108377 been\VBN\836236 added\VBN\156601 to\IN\1740 his\PRP$\1740 domperidone\NN\1740 therapy\NN\657604 .\.\1740
D004294_D004415 NONE The\DT\1740 authors\NNS\9610660 report\VBP\831651 here\RB\1740 a\DT\13649268 depressed\JJ\1740 patient\NN\9898892 comorbid\NN\1740 with\IN\1740 <e2>postprandial\JJ\1740 dyspepsia</e2>\NN\14299637 who\WP\8299493 developed\VBD\1753788 RLS\NN\1740 after\IN\1740 mirtazapine\NN\1740 had\VBD\2108377 been\VBN\836236 added\VBN\156601 to\IN\1740 his\PRP$\1740 <e1>domperidone</e1>\NN\1740 therapy\NN\657604 .\.\1740
3832950
D002998_D004827 NONE <e1>Clonazepam</e1>\NN\1740 monotherapy\NN\1740 for\IN\1740 <e2>epilepsy</e2>\NN\14085708 in\IN\13603305 childhood\NN\15144371 .\.\1740
D002998_D004827 NONE Sixty\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 age-range\JJ\1740 one\CD\13741022 month\NN\15113229 to\IN\1740 14\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 other\JJ\1740 types\NNS\5839024 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 than\IN\1740 infantile\JJ\1740 spasms\NNS\14299637 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>clonazepam</e1>\NN\1740 .\.\1740
D002998_D013036 NONE Sixty\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 age-range\JJ\1740 one\CD\13741022 month\NN\15113229 to\IN\1740 14\CD\13745420 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 other\JJ\1740 types\NNS\5839024 of\IN\1740 epilepsy\NN\14085708 than\IN\1740 <e2>infantile\JJ\1740 spasms</e2>\NNS\14299637 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>clonazepam</e1>\NN\1740 .\.\1740
4010471
D009538_D012640 CID Relationship\NN\31921 between\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 hippocampal\NN\1740 nicotinic\JJ\1740 receptors\NNS\5225602 .\.\1740
D009538_D012640 CID Using\VBG\1156834 mice\NNS\2329401 derived\VBN\634472 from\IN\1740 a\DT\13649268 classical\JJ\1740 F2\NN\1740 and\CC\1740 backcross\NN\1740 genetic\JJ\1740 design\NN\927261 ,\,\1740 a\DT\13649268 relationship\NN\31921 between\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 alpha-bungarotoxin\JJ\1740 nicotinic\JJ\1740 receptor\NN\5225602 concentration\NN\4916342 was\VBD\836236 found\VBN\2426171 .\.\1740
D009538_D012640 CID Mice\NNS\2329401 sensitive\JJ\1740 to\TO\1740 the\DT\1740 convulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>nicotine</e1>\NN\14712692 had\VBD\2108377 greater\JJR\1740 alpha-bungarotoxin\NN\1740 binding\NN\4688246 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 than\IN\1740 <e2>seizure</e2>\JJ\1740 insensitive\JJ\1740 mice\NNS\2329401 .\.\1740
D004229_D012640 NONE The\DT\1740 binding\VBG\1290422 sites\NNS\8673395 from\IN\1740 <e2>seizure</e2>\JJ\1740 sensitive\JJ\1740 and\CC\1740 resistant\JJ\1740 mice\NNS\2329401 were\VBD\836236 equally\RB\1740 affected\VBN\126264 by\IN\1740 treatment\NN\654885 with\IN\1740 <e1>dithiothreitol</e1>\NN\1740 ,\,\1740 trypsin\NN\14732946 or\CC\3541091 heat\NN\11452218 .\.\1740
7644931
D017239_D002289 NONE <e1>Paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 by\IN\1740 3-hour\CD\1740 infusion\NN\14589223 was\VBD\836236 combined\VBN\2630189 with\IN\1740 carboplatin\NN\1740 in\IN\13603305 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 study\NN\635850 directed\VBN\746718 to\TO\1740 patients\NNS\9898892 with\IN\1740 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
D017239_D002289 NONE Paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 by\IN\1740 3-hour\CD\1740 infusion\NN\14589223 was\VBD\836236 combined\VBN\2630189 with\IN\1740 carboplatin\NN\1740 in\IN\13603305 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 study\NN\635850 directed\VBN\746718 to\TO\1740 patients\NNS\9898892 with\IN\1740 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
D016190_D002289 NONE Paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NNP\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 by\IN\1740 3-hour\CD\1740 infusion\NN\14589223 was\VBD\836236 combined\VBN\2630189 with\IN\1740 <e1>carboplatin</e1>\NN\1740 in\IN\13603305 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 study\NN\635850 directed\VBN\746718 to\TO\1740 patients\NNS\9898892 with\IN\1740 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
D017239_D064420 NONE <e2>Toxicities</e2>\NNS\13576101 were\VBD\836236 compared\VBN\644583 with\IN\1740 a\DT\13649268 cohort\NN\8184861 of\IN\1740 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 phase\NN\15113229 I\CD\14622893 trial\NN\786195 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 alone\RB\1740 at\IN\14622893 identical\JJ\1740 dose\NN\3740161 levels\NNS\4916342 .\.\1740
D016190_D006402 NONE <e1>Carboplatin</e1>\NNP\1740 did\VBD\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 add\VB\156601 to\IN\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicities</e2>\NNS\13576101 observed\VBN\2163746 ,\,\1740 and\CC\1740 the\DT\1740 paclitaxel/carboplatin\NN\1740 combination\NN\7951464 could\MD\1740 be\VB\836236 dosed\VBN\515154 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 .\.\1740
D016190_D006402 NONE Carboplatin\NNP\1740 did\VBD\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 add\VB\156601 to\IN\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicities</e2>\NNS\13576101 observed\VBN\2163746 ,\,\1740 and\CC\1740 the\DT\1740 <e1>paclitaxel/carboplatin</e1>\NN\1740 combination\NN\7951464 could\MD\1740 be\VB\836236 dosed\VBN\515154 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 .\.\1740
D017239_D006402 CID Carboplatin\NNP\1740 did\VBD\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 add\VB\156601 to\IN\1740 the\DT\1740 <e2>hematologic\JJ\1740 toxicities</e2>\NNS\13576101 observed\VBN\2163746 ,\,\1740 and\CC\1740 the\DT\1740 <e1>paclitaxel/carboplatin</e1>\NN\1740 combination\NN\7951464 could\MD\1740 be\VB\836236 dosed\VBN\515154 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 .\.\1740
1280054
D014750_D001927 CID Fatal\JJ\1740 <e2>myeloencephalopathy</e2>\NN\1740 due\JJ\1740 to\TO\1740 intrathecal\JJ\1740 <e1>vincristine</e1>\NN\3917455 administration\NN\1133281 .\.\1740
D014750_D001927 CID <e1>Vincristine</e1>\NN\3917455 was\VBD\836236 accidentally\RB\1740 given\VBN\2327200 intrathecally\RB\1740 to\IN\1740 a\DT\13649268 child\NN\9622049 with\IN\1740 leukaemia\NN\14239918 ,\,\1740 producing\VBG\1617192 sensory\JJ\1740 and\CC\1740 motor\NN\3699975 dysfunction\NN\14204950 followed\VBN\1835496 by\IN\1740 <e2>encephalopathy</e2>\JJ\1740 and\CC\1740 death\NN\7296428 .\.\1740
D014750_D007938 NONE <e1>Vincristine</e1>\NN\3917455 was\VBD\836236 accidentally\RB\1740 given\VBN\2327200 intrathecally\RB\1740 to\IN\1740 a\DT\13649268 child\NN\9622049 with\IN\1740 <e2>leukaemia</e2>\NN\14239918 ,\,\1740 producing\VBG\1617192 sensory\JJ\1740 and\CC\1740 motor\NN\3699975 dysfunction\NN\14204950 followed\VBN\1835496 by\IN\1740 encephalopathy\JJ\1740 and\CC\1740 death\NN\7296428 .\.\1740
D014750_D007049 CID <e1>Vincristine</e1>\NN\3917455 was\VBD\836236 accidentally\RB\1740 given\VBN\2327200 intrathecally\RB\1740 to\IN\1740 a\DT\13649268 child\NN\9622049 with\IN\1740 leukaemia\NN\14239918 ,\,\1740 producing\VBG\1617192 <e2>sensory\JJ\1740 and\CC\1740 motor\NN\3699975 dysfunction</e2>\NN\14204950 followed\VBN\1835496 by\IN\1740 encephalopathy\JJ\1740 and\CC\1740 death\NN\7296428 .\.\1740
895432
D007545_D009203 CID Effects\NNS\13245626 of\IN\1740 exercise\NN\621627 on\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D007545_D009203 CID The\DT\1740 effect\NN\34213 of\IN\1740 exercise\NN\621627 on\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D007238 NONE The\DT\1740 results\NNS\34213 indicated\VBD\952524 that\IN\1740 exercise\NN\621627 reduced\VBD\441445 the\DT\1740 mortality\NN\5054863 associated\VBN\628491 with\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 large\JJ\1740 dosages\NNS\13576355 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 but\CC\1740 had\VBD\2108377 little\JJ\1740 on\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 the\DT\1740 <e2>infarction</e2>\NN\14204950 .\.\1740
19815465
D020888_D014786 CID <e2>Binasal\JJ\1740 visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 are\VBP\836236 not\RB\1740 specific\JJ\1740 to\TO\1740 <e1>vigabatrin</e1>\NN\1740 .\.\1740
D020888_D014786 CID This\DT\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 <e2>visual\JJ\1740 defects</e2>\NNS\14462666 associated\VBN\628491 with\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 <e1>vigabatrin</e1>\NN\1740 (\-LRB-\1740 VGB\NN\1740 )\-RRB-\1740 .\.\1740
D020888_D014786 CID This\DT\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 <e2>visual\JJ\1740 defects</e2>\NNS\14462666 associated\VBN\628491 with\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 vigabatrin\NN\1740 (\-LRB-\1740 <e1>VGB</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D020888_D004827 NONE Two\CD\13741022 hundred\CD\13745420 four\CD\13741022 people\NNS\31264 with\IN\1740 <e2>epilepsy</e2>\NN\14085708 were\VBD\836236 grouped\VBN\654625 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 antiepileptic\JJ\1740 drug\NN\14778436 therapy\NN\657604 (\-LRB-\1740 current\JJ\1740 ,\,\1740 previous\JJ\1740 ,\,\1740 or\CC\3541091 no\DT\7204911 exposure\NN\5042871 to\TO\1740 <e1>VGB</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D020888_D012164 CID Assessment\NN\5732756 by\IN\1740 conventional\JJ\1740 static\JJ\1740 perimetry\NN\1740 may\MD\15209706 neither\CC\1740 be\VB\836236 sufficiently\RB\1740 sensitive\JJ\1740 nor\CC\1740 specific\JJ\1740 to\TO\1740 reliably\RB\1740 identify\VB\699815 <e2>retinal\JJ\1740 toxicity</e2>\NN\13576101 associated\VBN\628491 with\IN\1740 <e1>VGB</e1>\NN\1740 .\.\1740
16565833
C522803_D066126 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 time\NN\7308889 interval\NN\33615 between\IN\1740 <e1>monoHER</e1>\NN\1740 and\CC\1740 doxorubicin\NN\2716866 administration\NN\1133281 on\IN\1740 the\DT\1740 protection\NN\407535 against\IN\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C522803_D066126 NONE The\DT\1740 semisynthetic\JJ\1740 flavonoid\NN\14983143 <e1>monohydroxyethylrutoside</e1>\NN\1740 (\-LRB-\1740 monoHER\NN\1740 )\-RRB-\1740 showed\VBD\2137132 cardioprotection\NN\1740 against\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 through\IN\1740 its\PRP$\6125041 radical\JJ\1740 scavenging\NN\1740 and\CC\1740 iron\NN\14625458 chelating\NN\1740 properties\NNS\32613 .\.\1740
C522803_D066126 NONE The\DT\1740 semisynthetic\JJ\1740 flavonoid\NN\14983143 monohydroxyethylrutoside\NN\1740 (\-LRB-\1740 <e1>monoHER</e1>\NN\1740 )\-RRB-\1740 showed\VBD\2137132 cardioprotection\NN\1740 against\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 through\IN\1740 its\PRP$\6125041 radical\JJ\1740 scavenging\NN\1740 and\CC\1740 iron\NN\14625458 chelating\NN\1740 properties\NNS\32613 .\.\1740
D004317_D066126 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 time\NN\7308889 interval\NN\33615 between\IN\1740 monoHER\NN\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 administration\NN\1133281 on\IN\1740 the\DT\1740 protection\NN\407535 against\IN\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D066126 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 time\NN\7308889 interval\NN\33615 between\IN\1740 monoHER\NN\1740 and\CC\1740 doxorubicin\NN\2716866 administration\NN\1133281 on\IN\1740 the\DT\1740 protection\NN\407535 against\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 Despite\IN\7501545 its\PRP$\6125041 well-known\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 the\DT\1740 anthracyclin\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 continues\VBZ\2367363 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 widely\RB\1740 used\VBN\1156834 chemotherapeutic\JJ\1740 agent\NN\7347 .\.\1740
D004317_D066126 NONE PURPOSE\NNP\5980875 :\:\1740 Despite\IN\7501545 its\PRP$\6125041 well-known\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 the\DT\1740 anthracyclin\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 continues\VBZ\2367363 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 widely\RB\1740 used\VBN\1156834 chemotherapeutic\JJ\1740 agent\NN\7347 .\.\1740
D004317_D066126 NONE The\DT\1740 semisynthetic\JJ\1740 flavonoid\NN\14983143 monohydroxyethylrutoside\NN\1740 (\-LRB-\1740 monoHER\NN\1740 )\-RRB-\1740 showed\VBD\2137132 cardioprotection\NN\1740 against\IN\1740 <e1>DOX-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 through\IN\1740 its\PRP$\6125041 radical\JJ\1740 scavenging\NN\1740 and\CC\1740 iron\NN\14625458 chelating\NN\1740 properties\NNS\32613 .\.\1740
D004317_D006331 NONE <e1>DOX-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 presumably\RB\1740 results\VBZ\2633881 from\IN\1740 the\DT\1740 formation\NN\7938773 of\IN\1740 free\JJ\1740 radicals\NNS\9465459 by\IN\1740 DOX\NN\1740 .\.\1740
D004317_D006331 NONE DOX-induced\JJ\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 presumably\RB\1740 results\VBZ\2633881 from\IN\1740 the\DT\1740 formation\NN\7938773 of\IN\1740 free\JJ\1740 radicals\NNS\9465459 by\IN\1740 <e1>DOX</e1>\NN\1740 .\.\1740
D004317_D006331 NONE Microscopic\JJ\1740 evaluation\NN\874067 revealed\VBD\2137132 that\IN\1740 treatment\NN\654885 with\IN\1740 <e1>DOX</e1>\NN\1740 alone\RB\1740 induced\VBD\1627355 significant\JJ\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 comparison\NN\635850 to\TO\1740 the\DT\1740 saline\NN\14849367 control\NN\5190804 group\NN\2137 (\-LRB-\1740 P<0.001\NN\1740 )\-RRB-\1740 .\.\1740
D005419_D066126 NONE The\DT\1740 semisynthetic\JJ\1740 <e1>flavonoid</e1>\NN\14983143 monohydroxyethylrutoside\NN\1740 (\-LRB-\1740 monoHER\NN\1740 )\-RRB-\1740 showed\VBD\2137132 cardioprotection\NN\1740 against\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 through\IN\1740 its\PRP$\6125041 radical\JJ\1740 scavenging\NN\1740 and\CC\1740 iron\NN\14625458 chelating\NN\1740 properties\NNS\32613 .\.\1740
D007501_D066126 NONE The\DT\1740 semisynthetic\JJ\1740 flavonoid\NN\14983143 monohydroxyethylrutoside\NN\1740 (\-LRB-\1740 monoHER\NN\1740 )\-RRB-\1740 showed\VBD\2137132 cardioprotection\NN\1740 against\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 through\IN\1740 its\PRP$\6125041 radical\JJ\1740 scavenging\NN\1740 and\CC\1740 <e1>iron</e1>\NN\14625458 chelating\NN\1740 properties\NNS\32613 .\.\1740
20682692
D013311_D003928 CID Blockade\NN\952963 of\IN\1740 endothelial-mesenchymal\JJ\1740 transition\NN\199130 by\IN\1740 a\DT\13649268 Smad3\NN\1740 inhibitor\NN\20090 delays\VBZ\439958 the\DT\1740 early\JJ\1740 development\NN\248977 of\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 .\.\1740
D013311_D003928 CID Blocking\NN\562280 studies\NNS\635850 using\VBG\1156834 receptor\NN\5225602 for\IN\1740 AGE\NN\4916342 siRNA\NN\1740 and\CC\1740 a\DT\13649268 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 Smad3\NN\1740 (\-LRB-\1740 SIS3\NN\1740 )\-RRB-\1740 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 MMECs\NNS\1740 and\CC\1740 in\IN\13603305 <e1>STZ-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 in\IN\13603305 Tie2-Cre;Loxp-EGFP\NN\1740 mice\NNS\2329401 .\.\1740
D013311_D003928 CID Immunoprecipitation/Western\NN\1740 blotting\NN\1740 showed\VBD\2137132 that\IN\1740 Smad3\NN\1740 was\VBD\836236 activated\VBN\1641914 by\IN\1740 AGEs\NN\4916342 but\CC\1740 was\VBD\836236 inhibited\VBN\2510337 by\IN\1740 SIS3\NN\1740 in\IN\13603305 MMECs\NNS\1740 and\CC\1740 in\IN\13603305 <e1>STZ-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 .\.\1740
D000804_D003922 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 multicenter\NN\1740 ,\,\1740 controlled\VBN\2422663 trial\NN\786195 showed\VBD\2137132 that\IN\1740 early\JJ\1740 blockade\NN\952963 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>type\NN\5839024 1\CD\13741022 diabetes</e2>\NNS\14075199 and\CC\1740 normoalbuminuria\NN\1740 did\VBD\1640855 not\RB\1740 retard\VB\438495 the\DT\1740 progression\NN\8457976 of\IN\1740 nephropathy\NN\14573196 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 other\JJ\1740 mechanism(s\NN\1740 )\-RRB-\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 early\JJ\1740 diabetic\JJ\1740 nephropathy\NN\14573196 (\-LRB-\1740 diabetic\JJ\1740 nephropathy\NN\14573196 )\-RRB-\1740 .\.\1740
D000804_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 multicenter\NN\1740 ,\,\1740 controlled\VBN\2422663 trial\NN\786195 showed\VBD\2137132 that\IN\1740 early\JJ\1740 blockade\NN\952963 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 in\IN\13603305 patients\NNS\9898892 with\IN\1740 type\NN\5839024 1\CD\13741022 diabetes\NNS\14075199 and\CC\1740 normoalbuminuria\NN\1740 did\VBD\1640855 not\RB\1740 retard\VB\438495 the\DT\1740 progression\NN\8457976 of\IN\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 other\JJ\1740 mechanism(s\NN\1740 )\-RRB-\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 early\JJ\1740 diabetic\JJ\1740 nephropathy\NN\14573196 (\-LRB-\1740 diabetic\JJ\1740 nephropathy\NN\14573196 )\-RRB-\1740 .\.\1740
D000804_D003928 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 multicenter\NN\1740 ,\,\1740 controlled\VBN\2422663 trial\NN\786195 showed\VBD\2137132 that\IN\1740 early\JJ\1740 blockade\NN\952963 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 in\IN\13603305 patients\NNS\9898892 with\IN\1740 type\NN\5839024 1\CD\13741022 diabetes\NNS\14075199 and\CC\1740 normoalbuminuria\NN\1740 did\VBD\1640855 not\RB\1740 retard\VB\438495 the\DT\1740 progression\NN\8457976 of\IN\1740 nephropathy\NN\14573196 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 other\JJ\1740 mechanism(s\NN\1740 )\-RRB-\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 early\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 (\-LRB-\1740 diabetic\JJ\1740 nephropathy\NN\14573196 )\-RRB-\1740 .\.\1740
D000804_D003928 NONE OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 multicenter\NN\1740 ,\,\1740 controlled\VBN\2422663 trial\NN\786195 showed\VBD\2137132 that\IN\1740 early\JJ\1740 blockade\NN\952963 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 in\IN\13603305 patients\NNS\9898892 with\IN\1740 type\NN\5839024 1\CD\13741022 diabetes\NNS\14075199 and\CC\1740 normoalbuminuria\NN\1740 did\VBD\1640855 not\RB\1740 retard\VB\438495 the\DT\1740 progression\NN\8457976 of\IN\1740 nephropathy\NN\14573196 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 other\JJ\1740 mechanism(s\NN\1740 )\-RRB-\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 early\JJ\1740 diabetic\JJ\1740 nephropathy\NN\14573196 (\-LRB-\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 )\-RRB-\1740 .\.\1740
D013311_D005355 NONE We\PRP\1740 have\VBP\2108377 previously\RB\1740 demonstrated\VBN\2137132 that\IN\1740 endothelial-mesenchymal-transition\NN\1740 (\-LRB-\1740 EndoMT\NN\1740 )\-RRB-\1740 contributes\VBZ\126264 to\TO\1740 the\DT\1740 early\JJ\1740 development\NN\248977 of\IN\1740 renal\JJ\1740 interstitial\JJ\1740 <e2>fibrosis</e2>\NN\14204950 independently\RB\1740 of\IN\1740 microalbuminuria\NN\1740 in\IN\13603305 mice\NNS\2329401 with\IN\1740 <e1>streptozotocin</e1>\NN\1740 (STZ)-induced\VBN\1740 diabetes\NNS\14075199 .\.\1740
D013311_D005355 NONE We\PRP\1740 have\VBP\2108377 previously\RB\1740 demonstrated\VBN\2137132 that\IN\1740 endothelial-mesenchymal-transition\NN\1740 (\-LRB-\1740 EndoMT\NN\1740 )\-RRB-\1740 contributes\VBZ\126264 to\TO\1740 the\DT\1740 early\JJ\1740 development\NN\248977 of\IN\1740 renal\JJ\1740 interstitial\JJ\1740 <e2>fibrosis</e2>\NN\14204950 independently\RB\1740 of\IN\1740 microalbuminuria\NN\1740 in\IN\13603305 mice\NNS\2329401 with\IN\1740 streptozotocin\NN\1740 <e1>(STZ)-induced</e1>\VBN\1740 diabetes\NNS\14075199 .\.\1740
D013311_D003920 NONE We\PRP\1740 have\VBP\2108377 previously\RB\1740 demonstrated\VBN\2137132 that\IN\1740 endothelial-mesenchymal-transition\NN\1740 (\-LRB-\1740 EndoMT\NN\1740 )\-RRB-\1740 contributes\VBZ\126264 to\TO\1740 the\DT\1740 early\JJ\1740 development\NN\248977 of\IN\1740 renal\JJ\1740 interstitial\JJ\1740 fibrosis\NN\14204950 independently\RB\1740 of\IN\1740 microalbuminuria\NN\1740 in\IN\13603305 mice\NNS\2329401 with\IN\1740 <e1>streptozotocin</e1>\NN\1740 (STZ)-induced\VBN\1740 <e2>diabetes</e2>\NNS\14075199 .\.\1740
D013311_D003920 NONE We\PRP\1740 have\VBP\2108377 previously\RB\1740 demonstrated\VBN\2137132 that\IN\1740 endothelial-mesenchymal-transition\NN\1740 (\-LRB-\1740 EndoMT\NN\1740 )\-RRB-\1740 contributes\VBZ\126264 to\TO\1740 the\DT\1740 early\JJ\1740 development\NN\248977 of\IN\1740 renal\JJ\1740 interstitial\JJ\1740 fibrosis\NN\14204950 independently\RB\1740 of\IN\1740 microalbuminuria\NN\1740 in\IN\13603305 mice\NNS\2329401 with\IN\1740 streptozotocin\NN\1740 <e1>(STZ)-induced</e1>\VBN\1740 <e2>diabetes</e2>\NNS\14075199 .\.\1740
18189308
D003520_D003556 CID p75NTR\NN\1740 expression\NN\4679549 in\IN\13603305 rat\NN\2329401 urinary\JJ\1740 bladder\NN\5515670 sensory\JJ\1740 neurons\NNS\5430628 and\CC\1740 spinal\JJ\1740 cord\NN\3670849 with\IN\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID The\DT\1740 present\JJ\1740 studies\NNS\635850 examine\VBP\789138 the\DT\1740 expression\NN\4679549 and\CC\1740 regulation\NN\6652242 of\IN\1740 another\DT\1740 receptor\NN\5225602 known\VBN\2110220 to\TO\1740 bind\VB\1290422 NGF\NN\14734348 ,\,\1740 p75(NTR\NN\1740 )\-RRB-\1740 ,\,\1740 after\IN\1740 various\JJ\1740 durations\NNS\15113229 of\IN\1740 <e2>bladder\NN\5515670 inflammation</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CYP\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D003556 CID The\DT\1740 present\JJ\1740 studies\NNS\635850 examine\VBP\789138 the\DT\1740 expression\NN\4679549 and\CC\1740 regulation\NN\6652242 of\IN\1740 another\DT\1740 receptor\NN\5225602 known\VBN\2110220 to\TO\1740 bind\VB\1290422 NGF\NN\14734348 ,\,\1740 p75(NTR\NN\1740 )\-RRB-\1740 ,\,\1740 after\IN\1740 various\JJ\1740 durations\NNS\15113229 of\IN\1740 <e2>bladder\NN\5515670 inflammation</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CYP</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D003520_D003556 CID <e1>CYP-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 increased\VBD\169651 (\-LRB-\1740 P\NN\14622893 <\NN\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 p75(NTR\FW\1740 )\-RRB-\1740 expression\NN\4679549 in\IN\13603305 the\DT\1740 superficial\JJ\1740 lateral\JJ\1740 and\CC\1740 medial\JJ\1740 dorsal\NN\1740 horn\NN\3827536 in\IN\13603305 L1-L2\NN\1740 and\CC\1740 L6-S1\JJ\1740 spinal\JJ\1740 segments\NNS\3892891 .\.\1740
D003520_D003556 CID The\DT\1740 number\NN\5107765 of\IN\1740 p75(NTR)-immunoreactive\NN\1740 (\-LRB-\1740 -IR\NN\1740 )\-RRB-\1740 cells\NNS\3080309 in\IN\13603305 the\DT\1740 lumbosacral\JJ\1740 dorsal\NN\1740 root\NN\13087625 ganglia\NN\5462674 (\-LRB-\1740 DRG\NN\1740 )\-RRB-\1740 also\RB\1740 increased\VBD\169651 (\-LRB-\1740 P\NN\14622893 <\NN\1740 or\CC\3541091 =\JJ\1740 0.05\CD\1740 )\-RRB-\1740 with\IN\1740 <e1>CYP-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 (\-LRB-\1740 acute\JJ\1740 ,\,\1740 intermediate\JJ\1740 ,\,\1740 and\CC\1740 chronic\JJ\1740 )\-RRB-\1740 .\.\1740
D003520_D003556 CID Quantitative\JJ\1740 ,\,\1740 real-time\JJ\1740 polymerase\NN\14732946 chain\NN\8457976 reaction\NN\13446390 also\RB\1740 demonstrated\VBD\2137132 significant\JJ\1740 increases\NNS\13576355 (\-LRB-\1740 P\NN\14622893 <\NN\1740 or\CC\3541091 =\JJ\1740 0.01\CD\1740 )\-RRB-\1740 in\IN\13603305 p75(NTR\NN\1740 )\-RRB-\1740 mRNA\NN\14832193 in\IN\13603305 DRG\NN\1740 with\IN\1740 intermediate\JJ\1740 and\CC\1740 chronic\JJ\1740 <e1>CYP-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D014443_D003556 NONE Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 the\DT\1740 expression\NN\4679549 and\CC\1740 regulation\NN\6652242 of\IN\1740 <e1>tyrosine</e1>\NN\14601829 kinase\NN\14732946 receptors\NNS\5225602 (\-LRB-\1740 Trks\NNS\1740 )\-RRB-\1740 in\IN\13603305 micturition\NN\13473097 reflexes\NNS\859001 with\IN\1740 <e2>urinary\JJ\1740 bladder\NN\5515670 inflammation</e2>\NN\14299637 .\.\1740
9428298
D000420_D001249 NONE Continuously\RB\1740 nebulized\JJ\1740 <e1>albuterol</e1>\NN\2905612 in\IN\13603305 severe\JJ\1740 exacerbations\NNS\374224 of\IN\1740 <e2>asthma</e2>\NN\14145095 in\IN\13603305 adults\NNS\7846 :\:\1740 a\DT\13649268 case-controlled\JJ\1740 study\NN\635850 .\.\1740
D000420_D001249 NONE A\DT\13649268 retrospective\JJ\1740 ,\,\1740 case-controlled\JJ\1740 analysis\NN\633864 comparing\VBG\644583 patients\NNS\9898892 admitted\VBN\822367 to\TO\1740 a\DT\13649268 medical\JJ\1740 intensive\JJ\1740 care\NN\575741 unit\NN\13576101 with\IN\1740 severe\JJ\1740 exacerbations\NNS\374224 of\IN\1740 <e2>asthma</e2>\NN\14145095 who\WP\8299493 received\VBD\2210855 continuously\RB\1740 nebulized\JJ\1740 <e1>albuterol</e1>\NN\2905612 (\-LRB-\1740 CNA\NN\1740 )\-RRB-\1740 versus\CC\1740 intermittent\JJ\1740 albuterol\NN\2905612 (\-LRB-\1740 INA\NN\1740 )\-RRB-\1740 treatments\NNS\654885 is\VBZ\836236 reported\VBN\831651 .\.\1740
D000420_D001249 NONE A\DT\13649268 retrospective\JJ\1740 ,\,\1740 case-controlled\JJ\1740 analysis\NN\633864 comparing\VBG\644583 patients\NNS\9898892 admitted\VBN\822367 to\TO\1740 a\DT\13649268 medical\JJ\1740 intensive\JJ\1740 care\NN\575741 unit\NN\13576101 with\IN\1740 severe\JJ\1740 exacerbations\NNS\374224 of\IN\1740 <e2>asthma</e2>\NN\14145095 who\WP\8299493 received\VBD\2210855 continuously\RB\1740 nebulized\JJ\1740 albuterol\NN\2905612 (\-LRB-\1740 CNA\NN\1740 )\-RRB-\1740 versus\CC\1740 intermittent\JJ\1740 <e1>albuterol</e1>\NN\2905612 (\-LRB-\1740 INA\NN\1740 )\-RRB-\1740 treatments\NNS\654885 is\VBZ\836236 reported\VBN\831651 .\.\1740
16369751
D005472_D066126 NONE <e1>5-Fluorouracil</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 alpha-fluoro-beta-alanine\NN\1740 .\.\1740
D005472_D066126 NONE <e2>Cardiotoxicity</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 occurring\VBG\2623529 during\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 treatment\NN\654885 for\IN\1740 malignancies\NNS\14070360 .\.\1740
D005472_D066126 NONE <e2>Cardiotoxicity</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 occurring\VBG\2623529 during\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 for\IN\1740 malignancies\NNS\14070360 .\.\1740
D005472_D066126 NONE We\PRP\1740 herein\RB\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 70-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e1>5-FU-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 in\IN\13603305 whom\WP\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 alpha-fluoro-beta-alanine\NN\1740 (\-LRB-\1740 FBAL\RB\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 .\.\1740
D005472_D066126 NONE As\IN\14622893 the\DT\1740 precordial\JJ\1740 pain\NN\14299637 in\IN\13603305 this\DT\1740 patient\NN\9898892 was\VBD\836236 considered\VBN\689344 to\TO\1740 have\VB\2108377 been\VBN\836236 due\JJ\1740 to\TO\1740 <e1>5-FU-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 5-FU\NN\1740 was\VBD\836236 abandoned\VBN\2222318 .\.\1740
D005472_D066126 NONE As\IN\14622893 the\DT\1740 precordial\JJ\1740 pain\NN\14299637 in\IN\13603305 this\DT\1740 patient\NN\9898892 was\VBD\836236 considered\VBN\689344 to\TO\1740 have\VB\2108377 been\VBN\836236 due\JJ\1740 to\TO\1740 5-FU-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>5-FU</e1>\NN\1740 was\VBD\836236 abandoned\VBN\2222318 .\.\1740
D005472_D066126 NONE The\DT\1740 experience\NN\5984287 of\IN\1740 this\DT\1740 case\NN\7283608 ,\,\1740 together\RB\1740 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 suggests\VBZ\1010118 that\IN\1740 FBAL\DT\1740 is\VBZ\836236 related\JJ\1740 to\TO\1740 <e1>5-FU-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D005472_D066126 NONE S-1\NN\1740 may\MD\15209706 be\VB\836236 administered\VBN\2436349 safely\RB\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 <e1>5-FU-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
C032348_D066126 NONE 5-Fluorouracil\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>alpha-fluoro-beta-alanine</e1>\NN\1740 .\.\1740
C032348_D066126 NONE We\PRP\1740 herein\RB\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 70-year-old\JJ\1740 man\NN\9605289 with\IN\1740 5-FU-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 in\IN\13603305 whom\WP\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 <e1>alpha-fluoro-beta-alanine</e1>\NN\1740 (\-LRB-\1740 FBAL\RB\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 .\.\1740
C032348_D066126 NONE We\PRP\1740 herein\RB\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 70-year-old\JJ\1740 man\NN\9605289 with\IN\1740 5-FU-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 in\IN\13603305 whom\WP\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 level\NN\4916342 of\IN\1740 alpha-fluoro-beta-alanine\NN\1740 (\-LRB-\1740 <e1>FBAL</e1>\RB\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 .\.\1740
C032348_D066126 NONE The\DT\1740 experience\NN\5984287 of\IN\1740 this\DT\1740 case\NN\7283608 ,\,\1740 together\RB\1740 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 suggests\VBZ\1010118 that\IN\1740 <e1>FBAL</e1>\DT\1740 is\VBZ\836236 related\JJ\1740 to\TO\1740 5-FU-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D005472_D009369 NONE Cardiotoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 occurring\VBG\2623529 during\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 treatment\NN\654885 for\IN\1740 <e2>malignancies</e2>\NNS\14070360 .\.\1740
D005472_D009369 NONE Cardiotoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 occurring\VBG\2623529 during\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 for\IN\1740 <e2>malignancies</e2>\NNS\14070360 .\.\1740
D005472_D002637 CID After\IN\1740 admission\NN\49003 ,\,\1740 the\DT\1740 patient\NN\9898892 received\VBD\2210855 a\DT\13649268 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-FU</e1>\NN\1740 (\-LRB-\1740 1000\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 <e2>precordial\JJ\1740 pain</e2>\NN\14299637 with\IN\1740 right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 occurred\VBD\2623529 concomitantly\RB\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 FBAL\NN\1740 concentration\NN\4916342 of\IN\1740 1955\CD\1740 ng/ml\NN\1740 .\.\1740
D005472_D002637 CID Both\CC\1740 the\DT\1740 <e2>precordial\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 the\DT\1740 electrocardiographic\JJ\1740 changes\NNS\7283608 disappeared\VBD\2609764 spontaneously\RB\1740 after\IN\1740 the\DT\1740 discontinuation\NN\209943 of\IN\1740 <e1>5-FU</e1>\NN\1740 .\.\1740
D005472_D002637 CID As\IN\14622893 the\DT\1740 <e2>precordial\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 this\DT\1740 patient\NN\9898892 was\VBD\836236 considered\VBN\689344 to\TO\1740 have\VB\2108377 been\VBN\836236 due\JJ\1740 to\TO\1740 <e1>5-FU-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 ,\,\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 5-FU\NN\1740 was\VBD\836236 abandoned\VBN\2222318 .\.\1740
D005472_D002637 CID As\IN\14622893 the\DT\1740 <e2>precordial\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 this\DT\1740 patient\NN\9898892 was\VBD\836236 considered\VBN\689344 to\TO\1740 have\VB\2108377 been\VBN\836236 due\JJ\1740 to\TO\1740 5-FU-induced\JJ\1740 cardiotoxicity\NN\1740 ,\,\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>5-FU</e1>\NN\1740 was\VBD\836236 abandoned\VBN\2222318 .\.\1740
D005472_D002037 CID After\IN\1740 admission\NN\49003 ,\,\1740 the\DT\1740 patient\NN\9898892 received\VBD\2210855 a\DT\13649268 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-FU</e1>\NN\1740 (\-LRB-\1740 1000\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 precordial\JJ\1740 pain\NN\14299637 with\IN\1740 <e2>right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 occurred\VBD\2623529 concomitantly\RB\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 FBAL\NN\1740 concentration\NN\4916342 of\IN\1740 1955\CD\1740 ng/ml\NN\1740 .\.\1740
C032348_D002637 NONE After\IN\1740 admission\NN\49003 ,\,\1740 the\DT\1740 patient\NN\9898892 received\VBD\2210855 a\DT\13649268 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-FU\NN\1740 (\-LRB-\1740 1000\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 <e2>precordial\JJ\1740 pain</e2>\NN\14299637 with\IN\1740 right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block\NN\21939 occurred\VBD\2623529 concomitantly\RB\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 <e1>FBAL</e1>\NN\1740 concentration\NN\4916342 of\IN\1740 1955\CD\1740 ng/ml\NN\1740 .\.\1740
C032348_D002037 NONE After\IN\1740 admission\NN\49003 ,\,\1740 the\DT\1740 patient\NN\9898892 received\VBD\2210855 a\DT\13649268 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-FU\NN\1740 (\-LRB-\1740 1000\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 precordial\JJ\1740 pain\NN\14299637 with\IN\1740 <e2>right\JJ\1740 bundle\NN\7951464 branch\NN\8220714 block</e2>\NN\21939 occurred\VBD\2623529 concomitantly\RB\1740 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 <e1>FBAL</e1>\NN\1740 concentration\NN\4916342 of\IN\1740 1955\CD\1740 ng/ml\NN\1740 .\.\1740
3708328
D010862_D012640 CID Susceptibility\NN\13920835 to\TO\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 in\IN\13603305 rats\NNS\2329401 after\IN\1740 microinjection\NN\1740 of\IN\1740 isoniazid\NNS\2716205 or\CC\3541091 gamma-vinyl-GABA\NN\1740 into\IN\1740 the\DT\1740 substantia\NN\1740 nigra\JJ\1740 .\.\1740
D010862_D012640 CID <e1>Pilocarpine</e1>\NN\14712692 ,\,\1740 given\VBN\2327200 intraperitoneally\RB\1740 to\TO\1740 rats\NNS\2329401 ,\,\1740 reproduces\VBZ\1621555 the\DT\1740 neuropathological\JJ\1740 sequelae\NN\14501726 of\IN\1740 temporal\JJ\1740 lobe\VBN\1740 epilepsy\NN\14085708 and\CC\1740 provides\VBZ\2199590 a\DT\13649268 relevant\JJ\1740 animal\NN\4475 model\NN\5888929 for\IN\1740 studying\VBG\630380 mechanisms\NNS\13446390 of\IN\1740 buildup\NN\372013 of\IN\1740 <e2>convulsive</e2>\JJ\1740 activity\NN\30358 and\CC\1740 pathways\NNS\5483677 operative\JJ\1740 in\IN\13603305 the\DT\1740 generalization\NN\5764197 and\CC\1740 propagation\NN\6253140 of\IN\1740 seizures\NNS\14081375 within\IN\1740 the\DT\1740 forebrain\NN\5462674 .\.\1740
D010862_D012640 CID <e1>Pilocarpine</e1>\NN\14712692 ,\,\1740 given\VBN\2327200 intraperitoneally\RB\1740 to\TO\1740 rats\NNS\2329401 ,\,\1740 reproduces\VBZ\1621555 the\DT\1740 neuropathological\JJ\1740 sequelae\NN\14501726 of\IN\1740 temporal\JJ\1740 lobe\VBN\1740 epilepsy\NN\14085708 and\CC\1740 provides\VBZ\2199590 a\DT\13649268 relevant\JJ\1740 animal\NN\4475 model\NN\5888929 for\IN\1740 studying\VBG\630380 mechanisms\NNS\13446390 of\IN\1740 buildup\NN\372013 of\IN\1740 convulsive\JJ\1740 activity\NN\30358 and\CC\1740 pathways\NNS\5483677 operative\JJ\1740 in\IN\13603305 the\DT\1740 generalization\NN\5764197 and\CC\1740 propagation\NN\6253140 of\IN\1740 <e2>seizures</e2>\NNS\14081375 within\IN\1740 the\DT\1740 forebrain\NN\5462674 .\.\1740
D010862_D012640 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 manipulating\VBG\2536557 the\DT\1740 activity\NN\30358 of\IN\1740 the\DT\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (GABA)-mediated\JJ\1740 synaptic\JJ\1740 inhibition\NN\1068773 within\IN\1740 the\DT\1740 substantia\NN\1740 nigra\JJ\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 in\IN\13603305 rats\NNS\2329401 ,\,\1740 were\VBD\836236 investigated\VBN\644583 .\.\1740
D010862_D012640 CID In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 isoniazid\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 GABA-synthesizing\JJ\1740 enzyme\NN\14723628 ,\,\1740 L-glutamic\JJ\1740 acid\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 .\.\1740
D010862_D012640 CID Electroencephalographic\NNP\1740 and\CC\1740 behavioral\JJ\1740 monitoring\NN\879759 revealed\VBD\2137132 a\DT\13649268 profound\JJ\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 threshold\NN\15265518 for\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D010862_D012640 CID Morphological\JJ\1740 analysis\NN\633864 of\IN\1740 frontal\JJ\1740 forebrain\NN\5462674 sections\NNS\7020895 with\IN\1740 light\JJ\1740 microscopy\NN\636921 revealed\VBD\2137132 <e2>seizure-related</e2>\JJ\1740 damage\NN\7296428 to\IN\1740 the\DT\1740 hippocampal\NN\1740 formation\NN\7938773 ,\,\1740 thalamus\NN\5462674 ,\,\1740 amygdala\JJ\1740 ,\,\1740 olfactory\JJ\1740 cortex\NN\5462674 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 and\CC\1740 neocortex\NN\5486510 ,\,\1740 which\WDT\1740 is\VBZ\836236 typically\RB\1740 observed\VBN\2163746 with\IN\1740 <e1>pilocarpine</e1>\NN\14712692 in\IN\13603305 doses\NNS\3740161 exceeding\VBG\2673965 350\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID Bilateral\JJ\1740 intrastriatal\JJ\1740 injections\NNS\320852 of\IN\1740 isoniazid\NNS\2716205 did\VBD\1640855 not\RB\1740 augment\VB\153263 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 200\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID Application\NN\947128 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 GABA\NN\14601829 transaminase\NN\15077571 ,\,\1740 gamma-vinyl-GABA\NN\1740 (\-LRB-\1740 D\NN\15089472 ,\,\1740 L-4-amino-hex-5-enoic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 5\CD\13741022 micrograms\NNS\13717155 ,\,\1740 into\IN\1740 the\DT\1740 SNR\NN\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 suppressed\VBD\2510337 the\DT\1740 appearance\NN\4723816 of\IN\1740 electrographic\JJ\1740 and\CC\1740 behavioral\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID Microinjections\NNS\1740 of\IN\1740 gamma-vinyl-GABA\NN\1740 ,\,\1740 5\CD\13741022 micrograms\NNS\13717155 ,\,\1740 into\IN\1740 the\DT\1740 dorsal\NN\1740 striatum\NN\5497363 ,\,\1740 bilaterally\RB\1740 ,\,\1740 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID The\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 the\DT\1740 threshold\NN\15265518 for\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 subjected\VBN\137313 to\TO\1740 the\DT\1740 regulation\NN\6652242 of\IN\1740 the\DT\1740 GABA-mediated\JJ\1740 synaptic\JJ\1740 inhibition\NN\1068773 within\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 .\.\1740
D007538_D012640 NONE Susceptibility\NN\13920835 to\TO\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 in\IN\13603305 rats\NNS\2329401 after\IN\1740 microinjection\NN\1740 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 or\CC\3541091 gamma-vinyl-GABA\NN\1740 into\IN\1740 the\DT\1740 substantia\NN\1740 nigra\JJ\1740 .\.\1740
D007538_D012640 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 GABA-synthesizing\JJ\1740 enzyme\NN\14723628 ,\,\1740 L-glutamic\JJ\1740 acid\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 .\.\1740
D007538_D012640 NONE Bilateral\JJ\1740 intrastriatal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 did\VBD\1640855 not\RB\1740 augment\VB\153263 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 200\CD\1740 mg/kg\NN\1740 .\.\1740
D020888_D012640 NONE Susceptibility\NN\13920835 to\TO\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 in\IN\13603305 rats\NNS\2329401 after\IN\1740 microinjection\NN\1740 of\IN\1740 isoniazid\NNS\2716205 or\CC\3541091 <e1>gamma-vinyl-GABA</e1>\NN\1740 into\IN\1740 the\DT\1740 substantia\NN\1740 nigra\JJ\1740 .\.\1740
D020888_D012640 NONE Application\NN\947128 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 GABA\NN\14601829 transaminase\NN\15077571 ,\,\1740 <e1>gamma-vinyl-GABA</e1>\NN\1740 (\-LRB-\1740 D\NN\15089472 ,\,\1740 L-4-amino-hex-5-enoic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 5\CD\13741022 micrograms\NNS\13717155 ,\,\1740 into\IN\1740 the\DT\1740 SNR\NN\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 suppressed\VBD\2510337 the\DT\1740 appearance\NN\4723816 of\IN\1740 electrographic\JJ\1740 and\CC\1740 behavioral\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D020888_D012640 NONE Application\NN\947128 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 GABA\NN\14601829 transaminase\NN\15077571 ,\,\1740 gamma-vinyl-GABA\NN\1740 (\-LRB-\1740 <e1>D\NN\15089472 ,\,\1740 L-4-amino-hex-5-enoic\JJ\1740 acid</e1>\NN\14818238 )\-RRB-\1740 ,\,\1740 5\CD\13741022 micrograms\NNS\13717155 ,\,\1740 into\IN\1740 the\DT\1740 SNR\NN\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 suppressed\VBD\2510337 the\DT\1740 appearance\NN\4723816 of\IN\1740 electrographic\JJ\1740 and\CC\1740 behavioral\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D020888_D012640 NONE Microinjections\NNS\1740 of\IN\1740 <e1>gamma-vinyl-GABA</e1>\NN\1740 ,\,\1740 5\CD\13741022 micrograms\NNS\13717155 ,\,\1740 into\IN\1740 the\DT\1740 dorsal\NN\1740 striatum\NN\5497363 ,\,\1740 bilaterally\RB\1740 ,\,\1740 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D004833 NONE <e1>Pilocarpine</e1>\NN\14712692 ,\,\1740 given\VBN\2327200 intraperitoneally\RB\1740 to\TO\1740 rats\NNS\2329401 ,\,\1740 reproduces\VBZ\1621555 the\DT\1740 neuropathological\JJ\1740 sequelae\NN\14501726 of\IN\1740 <e2>temporal\JJ\1740 lobe\VBN\1740 epilepsy</e2>\NN\14085708 and\CC\1740 provides\VBZ\2199590 a\DT\13649268 relevant\JJ\1740 animal\NN\4475 model\NN\5888929 for\IN\1740 studying\VBG\630380 mechanisms\NNS\13446390 of\IN\1740 buildup\NN\372013 of\IN\1740 convulsive\JJ\1740 activity\NN\30358 and\CC\1740 pathways\NNS\5483677 operative\JJ\1740 in\IN\13603305 the\DT\1740 generalization\NN\5764197 and\CC\1740 propagation\NN\6253140 of\IN\1740 seizures\NNS\14081375 within\IN\1740 the\DT\1740 forebrain\NN\5462674 .\.\1740
D005680_D012640 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 manipulating\VBG\2536557 the\DT\1740 activity\NN\30358 of\IN\1740 the\DT\1740 <e1>gamma-aminobutyric\JJ\1740 acid</e1>\NN\14818238 (GABA)-mediated\JJ\1740 synaptic\JJ\1740 inhibition\NN\1068773 within\IN\1740 the\DT\1740 substantia\NN\1740 nigra\JJ\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 in\IN\13603305 rats\NNS\2329401 ,\,\1740 were\VBD\836236 investigated\VBN\644583 .\.\1740
D005680_D012640 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 manipulating\VBG\2536557 the\DT\1740 activity\NN\30358 of\IN\1740 the\DT\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 <e1>(GABA)-mediated</e1>\JJ\1740 synaptic\JJ\1740 inhibition\NN\1068773 within\IN\1740 the\DT\1740 substantia\NN\1740 nigra\JJ\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 in\IN\13603305 rats\NNS\2329401 ,\,\1740 were\VBD\836236 investigated\VBN\644583 .\.\1740
D005680_D012640 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 isoniazid\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 <e1>GABA-synthesizing</e1>\JJ\1740 enzyme\NN\14723628 ,\,\1740 L-glutamic\JJ\1740 acid\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 .\.\1740
D005680_D012640 NONE Application\NN\947128 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 <e1>GABA</e1>\NN\14601829 transaminase\NN\15077571 ,\,\1740 gamma-vinyl-GABA\NN\1740 (\-LRB-\1740 D\NN\15089472 ,\,\1740 L-4-amino-hex-5-enoic\JJ\1740 acid\NN\14818238 )\-RRB-\1740 ,\,\1740 5\CD\13741022 micrograms\NNS\13717155 ,\,\1740 into\IN\1740 the\DT\1740 SNR\NN\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 suppressed\VBD\2510337 the\DT\1740 appearance\NN\4723816 of\IN\1740 electrographic\JJ\1740 and\CC\1740 behavioral\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D005680_D012640 NONE The\DT\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 the\DT\1740 threshold\NN\15265518 for\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 rats\NNS\2329401 is\VBZ\836236 subjected\VBN\137313 to\TO\1740 the\DT\1740 regulation\NN\6652242 of\IN\1740 the\DT\1740 <e1>GABA-mediated</e1>\JJ\1740 synaptic\JJ\1740 inhibition\NN\1068773 within\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 .\.\1740
D007538_D013226 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 <e1>isoniazid</e1>\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 GABA-synthesizing\JJ\1740 enzyme\NN\14723628 ,\,\1740 L-glutamic\JJ\1740 acid\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
D005680_D013226 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 isoniazid\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 <e1>GABA-synthesizing</e1>\JJ\1740 enzyme\NN\14723628 ,\,\1740 L-glutamic\JJ\1740 acid\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
D018698_D012640 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 isoniazid\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 GABA-synthesizing\JJ\1740 enzyme\NN\14723628 ,\,\1740 <e1>L-glutamic\JJ\1740 acid</e1>\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 .\.\1740
D018698_D013226 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 isoniazid\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 GABA-synthesizing\JJ\1740 enzyme\NN\14723628 ,\,\1740 <e1>L-glutamic\JJ\1740 acid</e1>\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
D010862_D013226 NONE In\IN\13603305 animals\NNS\4475 pretreated\VBN\1740 with\IN\1740 microinjections\NNS\1740 of\IN\1740 isoniazid\NNS\2716205 ,\,\1740 150\CD\1740 micrograms\NNS\13717155 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 activity\NN\30358 of\IN\1740 the\DT\1740 GABA-synthesizing\JJ\1740 enzyme\NN\14723628 ,\,\1740 L-glutamic\JJ\1740 acid\NN\14818238 decarboxylase\NN\14732946 ,\,\1740 into\IN\1740 the\DT\1740 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NN\1740 (\-LRB-\1740 SNR\NN\1740 )\-RRB-\1740 ,\,\1740 bilaterally\RB\1740 ,\,\1740 non-convulsant\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 100\CD\13745420 and\CC\1740 200\CD\1740 mg/kg\NN\1740 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 severe\JJ\1740 motor\NN\3699975 limbic\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
4082466
D009020_D012640 CID <e1>Morphine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 newborn\JJ\1740 infants\NNS\9918248 .\.\1740
D009020_D012640 CID Two\CD\13741022 neonates\NNS\9827683 suffered\VBN\2110220 from\IN\1740 generalized\JJ\1740 <e2>seizures</e2>\NNS\14081375 during\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 intravenous\JJ\1740 <e1>morphine\NN\2707683 sulfate</e1>\NN\15010703 for\IN\1740 post-operative\JJ\1740 analgesia\NN\14034177 .\.\1740
D009020_D012640 CID They\PRP\1740 received\VBD\2210855 <e1>morphine</e1>\NN\2707683 in\IN\13603305 doses\NNS\3740161 of\IN\1740 32\CD\1740 micrograms/kg/hr\NN\1740 and\CC\1740 40\CD\13745420 micrograms/kg/hr\NN\1740 larger\JJR\1740 than\IN\1740 a\DT\13649268 group\NN\2137 of\IN\1740 10\CD\13745420 neonates\NNS\9827683 who\WP\8299493 received\VBD\2210855 6\CD\13741022 -\SYM\1740 24\CD\13745420 micrograms/kg/hr\NN\1740 and\CC\1740 had\VBD\2108377 no\DT\7204911 <e2>seizures</e2>\NNS\14081375 .\.\1740
D009020_D012640 CID Other\JJ\1740 known\JJ\1740 reasons\NNS\9178821 for\IN\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 ruled\VBN\2441022 out\RP\1740 and\CC\1740 the\DT\1740 convulsions\NNS\14081375 stopped\VBD\2452885 a\DT\13649268 few\JJ\1740 hours\NNS\15118228 after\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 did\VBD\1640855 not\RB\1740 reoccur\VB\1740 in\IN\13603305 the\DT\1740 subsequent\JJ\1740 8\CD\13741022 months\NNS\15113229 .\.\1740
D009020_D012640 CID Other\JJ\1740 known\JJ\1740 reasons\NNS\9178821 for\IN\1740 seizures\NNS\14081375 were\VBD\836236 ruled\VBN\2441022 out\RP\1740 and\CC\1740 the\DT\1740 <e2>convulsions</e2>\NNS\14081375 stopped\VBD\2452885 a\DT\13649268 few\JJ\1740 hours\NNS\15118228 after\IN\1740 cessation\NN\7365849 of\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 did\VBD\1640855 not\RB\1740 reoccur\VB\1740 in\IN\13603305 the\DT\1740 subsequent\JJ\1740 8\CD\13741022 months\NNS\15113229 .\.\1740
2933998
D017265_D001249 NONE <e1>Procaterol</e1>\NN\1740 and\CC\1740 terbutaline\NN\1740 in\IN\13603305 <e2>bronchial\JJ\1740 asthma</e2>\NN\14145095 .\.\1740
D017265_D001249 NONE <e1>Procaterol</e1>\NNP\1740 ,\,\1740 a\DT\13649268 new\JJ\1740 beta-2\NN\1740 adrenoceptor\NN\1740 stimulant\JJ\1740 ,\,\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 cross-over\JJ\1740 trial\NN\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>bronchial\JJ\1740 asthma</e2>\NN\14145095 .\.\1740
D017265_D001249 NONE Both\CC\1740 <e2>anti-asthmatic</e2>\JJ\1740 and\CC\1740 tremorgenic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>procaterol</e1>\NN\1740 were\VBD\836236 dose-related\JJ\1740 .\.\1740
D013726_D001249 NONE Procaterol\NN\1740 and\CC\1740 <e1>terbutaline</e1>\NN\1740 in\IN\13603305 <e2>bronchial\JJ\1740 asthma</e2>\NN\14145095 .\.\1740
D017265_D014202 CID Both\CC\1740 anti-asthmatic\JJ\1740 and\CC\1740 <e2>tremorgenic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>procaterol</e1>\NN\1740 were\VBD\836236 dose-related\JJ\1740 .\.\1740
24778426
D002945_D007674 NONE Rates\NNS\13308999 of\IN\1740 <e2>Renal\NNP\1740 Toxicity</e2>\NNP\13576101 in\IN\13603305 Cancer\NN\14239425 Patients\NNS\9898892 Receiving\NNP\1740 <e1>Cisplatin</e1>\NNP\1740 With\IN\1740 and\CC\1740 Without\IN\1740 Mannitol\NNP\3214670 .\.\1740
D002945_D007674 NONE One\CD\13741022 of\IN\1740 the\DT\1740 major\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>cisplatin</e1>\NN\1740 use\NN\407535 is\VBZ\836236 dose-limiting\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D002945_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 aimed\VBD\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 rates\NNS\13308999 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 cisplatin\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 mannitol\NN\3214670 .\.\1740
D002945_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 aimed\VBD\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 rates\NNS\13308999 of\IN\1740 cisplatin-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 <e1>cisplatin</e1>\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 mannitol\NN\3214670 .\.\1740
D002945_D007674 NONE Our\PRP$\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 those\DT\1740 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 dosing\NN\1740 schedule\NN\5898568 of\IN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 <e1>cisplatin</e1>\NN\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 and\CC\1740 those\DT\1740 with\IN\1740 hypertension\NN\14057371 are\VBP\836236 at\IN\14622893 the\DT\1740 greatest\JJS\1740 risk\NN\14541044 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 would\MD\1740 benefit\VB\2210855 from\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 mannitol\NN\3214670 .\.\1740
D002945_D009369 NONE Rates\NNS\13308999 of\IN\1740 Renal\NNP\1740 Toxicity\NNP\13576101 in\IN\13603305 <e2>Cancer</e2>\NN\14239425 Patients\NNS\9898892 Receiving\NNP\1740 <e1>Cisplatin</e1>\NNP\1740 With\IN\1740 and\CC\1740 Without\IN\1740 Mannitol\NNP\3214670 .\.\1740
D002945_D009369 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 aimed\VBD\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 rates\NNS\13308999 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 cisplatin\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 mannitol\NN\3214670 .\.\1740
D002945_D009369 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 aimed\VBD\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 rates\NNS\13308999 of\IN\1740 cisplatin-induced\JJ\1740 nephrotoxicity\NN\1740 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 <e1>cisplatin</e1>\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 mannitol\NN\3214670 .\.\1740
D002945_D009369 NONE Data\NNS\7951464 were\VBD\836236 collected\VBN\2281093 on\IN\1740 adult\JJ\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 <e1>cisplatin</e1>\NN\1740 as\IN\14622893 an\DT\6697703 outpatient\NN\10405694 from\IN\1740 January\NNP\15209706 2011\CD\1740 to\IN\1740 September\NNP\15209706 2012\CD\1740 .\.\1740
D002945_D009369 NONE RESULTS\NNS\34213 :\:\1740 We\PRP\1740 evaluated\VBD\670261 143\CD\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 single-agent\JJ\1740 <e1>cisplatin</e1>\NN\1740 ;\:\1740 97.2\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 had\VBD\2108377 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer\NN\14239425 as\IN\14622893 their\PRP$\1740 primary\JJ\1740 <e2>malignancy</e2>\NN\14070360 .\.\1740
D008353_D007674 NONE Rates\NNS\13308999 of\IN\1740 <e2>Renal\NNP\1740 Toxicity</e2>\NNP\13576101 in\IN\13603305 Cancer\NN\14239425 Patients\NNS\9898892 Receiving\NNP\1740 Cisplatin\NNP\1740 With\IN\1740 and\CC\1740 Without\IN\1740 <e1>Mannitol</e1>\NNP\3214670 .\.\1740
D008353_D007674 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 aimed\VBD\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 rates\NNS\13308999 of\IN\1740 cisplatin-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 cisplatin\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 <e1>mannitol</e1>\NN\3214670 .\.\1740
D008353_D007674 NONE Patients\NNS\9898892 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 <e1>mannitol</e1>\NN\3214670 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 develop\VB\1753788 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 odds\NNS\4756635 ratio\NN\13815152 [\-LRB-\1740 OR\NN\3541091 ]\-RRB-\1740 =\JJ\1740 2.646\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 =\JJ\1740 1.008\CD\1740 ,\,\1740 6.944\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 0.048\CD\1740 )\-RRB-\1740 .\.\1740
D008353_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 When\WRB\1740 limited\JJ\1740 quantities\NNS\2137 of\IN\1740 <e1>mannitol</e1>\NN\3214670 are\VBP\836236 available\JJ\1740 ,\,\1740 it\PRP\6125041 should\MD\1740 preferentially\RB\1740 be\VB\836236 given\VBN\2327200 to\TO\1740 patients\NNS\9898892 at\IN\14622893 particularly\RB\1740 high\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D008353_D007674 NONE Our\PRP$\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 those\DT\1740 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 dosing\NN\1740 schedule\NN\5898568 of\IN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 cisplatin\NN\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 and\CC\1740 those\DT\1740 with\IN\1740 hypertension\NN\14057371 are\VBP\836236 at\IN\14622893 the\DT\1740 greatest\JJS\1740 risk\NN\14541044 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 would\MD\1740 benefit\VB\2210855 from\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>mannitol</e1>\NN\3214670 .\.\1740
D008353_D009369 NONE Rates\NNS\13308999 of\IN\1740 Renal\NNP\1740 Toxicity\NNP\13576101 in\IN\13603305 <e2>Cancer</e2>\NN\14239425 Patients\NNS\9898892 Receiving\NNP\1740 Cisplatin\NNP\1740 With\IN\1740 and\CC\1740 Without\IN\1740 <e1>Mannitol</e1>\NNP\3214670 .\.\1740
D008353_D009369 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 aimed\VBD\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 rates\NNS\13308999 of\IN\1740 cisplatin-induced\JJ\1740 nephrotoxicity\NN\1740 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 receiving\VBG\2210855 single-agent\JJ\1740 cisplatin\NN\1740 with\IN\1740 and\CC\1740 without\IN\1740 <e1>mannitol</e1>\NN\3214670 .\.\1740
D008353_D064420 NONE There\EX\27167 are\VBP\836236 many\JJ\1740 strategies\NNS\5902545 to\TO\1740 prevent\VB\1740 this\DT\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 including\VBG\690614 the\DT\1740 use\NN\407535 of\IN\1740 <e1>mannitol</e1>\NN\3214670 as\IN\14622893 a\DT\13649268 nephroprotectant\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 hydration\NN\13435152 .\.\1740
D002945_D006258 NONE RESULTS\NNS\34213 :\:\1740 We\PRP\1740 evaluated\VBD\670261 143\CD\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 single-agent\JJ\1740 <e1>cisplatin</e1>\NN\1740 ;\:\1740 97.2\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 had\VBD\2108377 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 as\IN\14622893 their\PRP$\1740 primary\JJ\1740 malignancy\NN\14070360 .\.\1740
D002945_D006973 NONE Our\PRP$\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 those\DT\1740 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 dosing\NN\1740 schedule\NN\5898568 of\IN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 <e1>cisplatin</e1>\NN\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 and\CC\1740 those\DT\1740 with\IN\1740 <e2>hypertension</e2>\NN\14057371 are\VBP\836236 at\IN\14622893 the\DT\1740 greatest\JJS\1740 risk\NN\14541044 of\IN\1740 nephrotoxicity\NN\1740 and\CC\1740 would\MD\1740 benefit\VB\2210855 from\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 mannitol\NN\3214670 .\.\1740
D008353_D006973 NONE Our\PRP$\1740 analysis\NN\633864 suggests\VBZ\1010118 that\IN\1740 those\DT\1740 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 dosing\NN\1740 schedule\NN\5898568 of\IN\1740 100\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 cisplatin\NN\1740 every\DT\1740 3\CD\13741022 weeks\NNS\15113229 and\CC\1740 those\DT\1740 with\IN\1740 <e2>hypertension</e2>\NN\14057371 are\VBP\836236 at\IN\14622893 the\DT\1740 greatest\JJS\1740 risk\NN\14541044 of\IN\1740 nephrotoxicity\NN\1740 and\CC\1740 would\MD\1740 benefit\VB\2210855 from\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>mannitol</e1>\NN\3214670 .\.\1740
20447294
D009020_D009437 NONE Studies\NNS\635850 of\IN\1740 synergy\NN\13518963 between\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 a\DT\13649268 novel\JJ\1740 sodium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 CNSB002\NN\1740 ,\,\1740 in\IN\13603305 rat\NN\2329401 models\NNS\5888929 of\IN\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D009020_D009437 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 antihyperalgesic\JJ\1740 effect\NN\34213 of\IN\1740 CNSB002\NN\1740 ,\,\1740 a\DT\13649268 sodium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 antioxidant\JJ\1740 properties\NNS\32613 given\VBN\2327200 alone\RB\1740 and\CC\1740 in\IN\13603305 combinations\NNS\7951464 with\IN\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 rat\NN\2329401 models\NNS\5888929 of\IN\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D012964_D009437 NONE Studies\NNS\635850 of\IN\1740 synergy\NN\13518963 between\IN\1740 morphine\NN\2707683 and\CC\1740 a\DT\13649268 novel\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 CNSB002\NN\1740 ,\,\1740 in\IN\13603305 rat\NN\2329401 models\NNS\5888929 of\IN\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D012964_D009437 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 antihyperalgesic\JJ\1740 effect\NN\34213 of\IN\1740 CNSB002\NN\1740 ,\,\1740 a\DT\13649268 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 antioxidant\JJ\1740 properties\NNS\32613 given\VBN\2327200 alone\RB\1740 and\CC\1740 in\IN\13603305 combinations\NNS\7951464 with\IN\1740 morphine\NN\2707683 in\IN\13603305 rat\NN\2329401 models\NNS\5888929 of\IN\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
C401121_D009437 NONE Studies\NNS\635850 of\IN\1740 synergy\NN\13518963 between\IN\1740 morphine\NN\2707683 and\CC\1740 a\DT\13649268 novel\JJ\1740 sodium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 <e1>CNSB002</e1>\NN\1740 ,\,\1740 in\IN\13603305 rat\NN\2329401 models\NNS\5888929 of\IN\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
C401121_D009437 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 determined\VBD\1645601 the\DT\1740 antihyperalgesic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>CNSB002</e1>\NN\1740 ,\,\1740 a\DT\13649268 sodium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 with\IN\1740 antioxidant\JJ\1740 properties\NNS\32613 given\VBN\2327200 alone\RB\1740 and\CC\1740 in\IN\13603305 combinations\NNS\7951464 with\IN\1740 morphine\NN\2707683 in\IN\13603305 rat\NN\2329401 models\NNS\5888929 of\IN\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D009020_D010146 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 <e2>pain</e2>\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D009020_D007249 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 <e2>inflammation</e2>\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D009020_D003929 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
C401121_D010146 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 <e1>CNSB002</e1>\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 <e2>pain</e2>\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
C401121_D007249 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 <e1>CNSB002</e1>\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 <e2>inflammation</e2>\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
C401121_D003929 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 <e1>CNSB002</e1>\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D002351_D010146 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 <e2>pain</e2>\NN\14299637 models\NNS\5888929 :\:\1740 <e1>carrageenan-induced</e1>\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D002351_D007249 CID DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 <e1>carrageenan-induced</e1>\JJ\1740 paw\NN\2153445 <e2>inflammation</e2>\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D002351_D003929 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 <e1>carrageenan-induced</e1>\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D013311_D010146 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 <e2>pain</e2>\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 <e1>streptozotocin</e1>\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D013311_D010146 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 <e2>pain</e2>\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 <e1>(STZ)-induced</e1>\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D013311_D007249 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 <e2>inflammation</e2>\NN\14299637 and\CC\1740 <e1>streptozotocin</e1>\NN\1740 (STZ)-induced\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D013311_D007249 NONE DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 <e2>inflammation</e2>\NN\14299637 and\CC\1740 streptozotocin\NN\1740 <e1>(STZ)-induced</e1>\JJ\1740 diabetic\JJ\1740 neuropathy\JJ\1740 .\.\1740
D013311_D003929 CID DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 <e1>streptozotocin</e1>\NN\1740 (STZ)-induced\JJ\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D013311_D003929 CID DESIGN\NN\927261 :\:\1740 Dose\NN\3740161 response\NN\11410625 curves\NNS\13863771 for\IN\1740 nonsedating\NN\1740 doses\NNS\3740161 of\IN\1740 morphine\NN\2707683 and\CC\1740 CNSB002\NN\1740 given\VBN\2327200 intraperitoneally\RB\1740 alone\RB\1740 and\CC\1740 together\RB\1740 in\IN\13603305 combinations\NNS\7951464 were\VBD\836236 constructed\VBN\1617192 for\IN\1740 antihyperalgesic\JJ\1740 effect\NN\34213 using\VBG\1156834 paw\NN\2153445 withdrawal\NN\7206096 from\IN\1740 noxious\JJ\1740 heat\NN\11452218 in\IN\13603305 two\CD\13741022 rat\NN\2329401 pain\NN\14299637 models\NNS\5888929 :\:\1740 carrageenan-induced\JJ\1740 paw\NN\2153445 inflammation\NN\14299637 and\CC\1740 streptozotocin\NN\1740 <e1>(STZ)-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D002351_D006930 CID The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>carrageenan</e1>\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 STZ-induced\JJ\1740 neuropathy\JJ\1740 model\NN\5888929 for\IN\1740 CNSB002\NN\1740 and\CC\1740 morphine\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D002351_D009422 NONE The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 hyperalgesia\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>carrageenan</e1>\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 STZ-induced\JJ\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 for\IN\1740 CNSB002\NN\1740 and\CC\1740 morphine\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D002351_D009422 NONE The\DT\1740 ED50\NN\1740 values\NNS\5941423 for\IN\1740 morphine\NN\2707683 when\WRB\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 CNSB002\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 were\VBD\836236 less\JJR\1740 than\IN\1740 the\DT\1740 maximum\NN\13653902 nonsedating\NN\1740 dose\NN\3740161 :\:\1740 0.56\CD\1740 (\-LRB-\1740 1.55\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>carrageenan</e1>\NN\14898470 model\NN\5888929 and\CC\1740 1.37\CD\1740 (\-LRB-\1740 1.23\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D013311_D006930 CID The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>STZ-induced</e1>\JJ\1740 neuropathy\JJ\1740 model\NN\5888929 for\IN\1740 CNSB002\NN\1740 and\CC\1740 morphine\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D013311_D009422 NONE The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 hyperalgesia\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>STZ-induced</e1>\JJ\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 for\IN\1740 CNSB002\NN\1740 and\CC\1740 morphine\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
C401121_D006930 NONE The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 STZ-induced\JJ\1740 neuropathy\JJ\1740 model\NN\5888929 for\IN\1740 <e1>CNSB002</e1>\NN\1740 and\CC\1740 morphine\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
C401121_D006930 NONE The\DT\1740 antinociception\NN\1740 after\IN\1740 morphine\NN\2707683 (\-LRB-\1740 3.2\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 co-administration\NN\1740 with\IN\1740 <e1>CNSB002</e1>\NN\1740 from\IN\1740 28.0\CD\1740 and\CC\1740 31.7\CD\1740 %\NN\1740 to\IN\1740 114.6\CD\1740 and\CC\1740 56.9\CD\1740 %\NN\1740 reversal\NN\199130 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 the\DT\1740 inflammatory\JJ\1740 and\CC\1740 neuropathic\JJ\1740 models\NNS\5888929 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 ;\:\1740 one-way\JJ\1740 analysis\NN\633864 of\IN\1740 variance-significantly\RB\1740 greater\JJR\1740 than\IN\1740 either\DT\1740 drug\NN\14778436 given\VBN\2327200 alone\RB\1740 )\-RRB-\1740 .\.\1740
C401121_D009422 NONE The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 hyperalgesia\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 STZ-induced\JJ\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 for\IN\1740 <e1>CNSB002</e1>\NN\1740 and\CC\1740 morphine\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
C401121_D009422 NONE The\DT\1740 ED50\NN\1740 values\NNS\5941423 for\IN\1740 morphine\NN\2707683 when\WRB\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>CNSB002</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 were\VBD\836236 less\JJR\1740 than\IN\1740 the\DT\1740 maximum\NN\13653902 nonsedating\NN\1740 dose\NN\3740161 :\:\1740 0.56\CD\1740 (\-LRB-\1740 1.55\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 1.37\CD\1740 (\-LRB-\1740 1.23\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
C401121_D009422 NONE The\DT\1740 antinociception\NN\1740 after\IN\1740 morphine\NN\2707683 (\-LRB-\1740 3.2\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 co-administration\NN\1740 with\IN\1740 <e1>CNSB002</e1>\NN\1740 from\IN\1740 28.0\CD\1740 and\CC\1740 31.7\CD\1740 %\NN\1740 to\IN\1740 114.6\CD\1740 and\CC\1740 56.9\CD\1740 %\NN\1740 reversal\NN\199130 of\IN\1740 hyperalgesia\NN\1740 in\IN\13603305 the\DT\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic</e2>\JJ\1740 models\NNS\5888929 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 ;\:\1740 one-way\JJ\1740 analysis\NN\633864 of\IN\1740 variance-significantly\RB\1740 greater\JJR\1740 than\IN\1740 either\DT\1740 drug\NN\14778436 given\VBN\2327200 alone\RB\1740 )\-RRB-\1740 .\.\1740
D009020_D006930 NONE The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 STZ-induced\JJ\1740 neuropathy\JJ\1740 model\NN\5888929 for\IN\1740 CNSB002\NN\1740 and\CC\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D009020_D006930 NONE The\DT\1740 antinociception\NN\1740 after\IN\1740 <e1>morphine</e1>\NN\2707683 (\-LRB-\1740 3.2\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 co-administration\NN\1740 with\IN\1740 CNSB002\NN\1740 from\IN\1740 28.0\CD\1740 and\CC\1740 31.7\CD\1740 %\NN\1740 to\IN\1740 114.6\CD\1740 and\CC\1740 56.9\CD\1740 %\NN\1740 reversal\NN\199130 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 the\DT\1740 inflammatory\JJ\1740 and\CC\1740 neuropathic\JJ\1740 models\NNS\5888929 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 ;\:\1740 one-way\JJ\1740 analysis\NN\633864 of\IN\1740 variance-significantly\RB\1740 greater\JJR\1740 than\IN\1740 either\DT\1740 drug\NN\14778436 given\VBN\2327200 alone\RB\1740 )\-RRB-\1740 .\.\1740
D009020_D009422 NONE The\DT\1740 doses\NNS\3740161 calculated\VBN\632627 to\TO\1740 cause\VB\1617192 50\CD\13745420 %\NN\1740 reversal\NN\199130 of\IN\1740 hyperalgesia\NN\1740 (\-LRB-\1740 ED50\NN\1740 )\-RRB-\1740 were\VBD\836236 7.54\CD\1740 (\-LRB-\1740 1.81\CD\1740 )\-RRB-\1740 and\CC\1740 4.83\CD\1740 (\-LRB-\1740 1.54\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 44.18\CD\1740 (\-LRB-\1740 1.37\CD\1740 )\-RRB-\1740 and\CC\1740 9.14\CD\1740 (\-LRB-\1740 1.24\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 STZ-induced\JJ\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 for\IN\1740 CNSB002\NN\1740 and\CC\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D009020_D009422 NONE The\DT\1740 ED50\NN\1740 values\NNS\5941423 for\IN\1740 <e1>morphine</e1>\NN\2707683 when\WRB\1740 given\VBN\2327200 in\IN\13603305 combination\NN\7951464 with\IN\1740 CNSB002\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 were\VBD\836236 less\JJR\1740 than\IN\1740 the\DT\1740 maximum\NN\13653902 nonsedating\NN\1740 dose\NN\3740161 :\:\1740 0.56\CD\1740 (\-LRB-\1740 1.55\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 carrageenan\NN\14898470 model\NN\5888929 and\CC\1740 1.37\CD\1740 (\-LRB-\1740 1.23\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e2>neuropathy</e2>\JJ\1740 model\NN\5888929 (\-LRB-\1740 mg/kg\NN\1740 ;\:\1740 mean\NN\6021761 ,\,\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D009020_D009422 NONE The\DT\1740 antinociception\NN\1740 after\IN\1740 <e1>morphine</e1>\NN\2707683 (\-LRB-\1740 3.2\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 increased\VBN\169651 by\IN\1740 co-administration\NN\1740 with\IN\1740 CNSB002\NN\1740 from\IN\1740 28.0\CD\1740 and\CC\1740 31.7\CD\1740 %\NN\1740 to\IN\1740 114.6\CD\1740 and\CC\1740 56.9\CD\1740 %\NN\1740 reversal\NN\199130 of\IN\1740 hyperalgesia\NN\1740 in\IN\13603305 the\DT\1740 inflammatory\JJ\1740 and\CC\1740 <e2>neuropathic</e2>\JJ\1740 models\NNS\5888929 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 ;\:\1740 one-way\JJ\1740 analysis\NN\633864 of\IN\1740 variance-significantly\RB\1740 greater\JJR\1740 than\IN\1740 either\DT\1740 drug\NN\14778436 given\VBN\2327200 alone\RB\1740 )\-RRB-\1740 .\.\1740
22836123
D016559_D007674 NONE Late-onset\JJ\1740 <e2>scleroderma\NN\14187378 renal\JJ\1740 crisis</e2>\NN\14411243 induced\VBN\1627355 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 prednisolone\NN\2721538 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D016559_D007674 NONE In\IN\13603305 this\DT\1740 article\NN\6367571 ,\,\1740 we\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>SRC</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 corticosteroids\NNS\14745635 .\.\1740
D011239_D007674 NONE Late-onset\JJ\1740 <e2>scleroderma\NN\14187378 renal\JJ\1740 crisis</e2>\NN\14411243 induced\VBN\1627355 by\IN\1740 tacrolimus\NN\1740 and\CC\1740 <e1>prednisolone</e1>\NN\2721538 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D000305_D007674 NONE Moderate\JJ\1740 to\TO\1740 high\JJ\1740 dose\NN\3740161 <e1>corticosteroid</e1>\NN\14745635 use\NN\407535 is\VBZ\836236 recognized\VBN\686447 as\IN\14622893 a\DT\13649268 major\JJ\1740 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>SRC</e2>\NN\1740 .\.\1740
D000305_D007674 NONE In\IN\13603305 this\DT\1740 article\NN\6367571 ,\,\1740 we\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>SRC</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 tacrolimus\NN\1740 and\CC\1740 <e1>corticosteroids</e1>\NNS\14745635 .\.\1740
D016572_D057049 CID Furthermore\RB\1740 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 precipitated\VBN\1642924 by\IN\1740 <e1>cyclosporine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 SSc\NN\1740 .\.\1740
D016572_D012595 NONE Furthermore\RB\1740 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 reports\NNS\6470073 of\IN\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 precipitated\VBN\1642924 by\IN\1740 <e1>cyclosporine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>SSc</e2>\NN\1740 .\.\1740
D016559_D012595 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 work\NN\407535 is\VBZ\836236 to\TO\1740 call\VB\1029852 attention\NN\5701944 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e1>tacrolimus</e1>\NN\1740 use\NN\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>SSc</e2>\NN\1740 .\.\1740
12559315
D007213_D018856 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Indomethacin</e1>\NN\3828465 resulted\VBD\2633881 in\IN\13603305 histopathologic\JJ\1740 findings\NNS\7951464 typical\JJ\1740 of\IN\1740 <e2>interstitial\JJ\1740 cystitis</e2>\NN\14566129 ,\,\1740 such\JJ\1740 as\IN\14622893 leaky\NNS\1740 bladder\NN\5515670 epithelium\NN\5267548 and\CC\1740 mucosal\JJ\1740 mastocytosis\NN\1740 .\.\1740
D007213_D008415 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Indomethacin</e1>\NN\3828465 resulted\VBD\2633881 in\IN\13603305 histopathologic\JJ\1740 findings\NNS\7951464 typical\JJ\1740 of\IN\1740 interstitial\JJ\1740 cystitis\NN\14566129 ,\,\1740 such\JJ\1740 as\IN\14622893 leaky\NNS\1740 bladder\NN\5515670 epithelium\NN\5267548 and\CC\1740 mucosal\JJ\1740 <e2>mastocytosis</e2>\NN\1740 .\.\1740
753803
D014810_D009135 NONE <e2>Myopathy</e2>\NNP\14204950 due\JJ\1740 to\TO\1740 lack\NN\14449126 of\IN\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 and\CC\1740 myopathy\NN\14204950 induced\VBN\1627355 by\IN\1740 certain\JJ\1740 viruses\NNS\9312843 have\VBP\2108377 much\JJ\1740 in\IN\13603305 common\JJ\1740 anatomically\RB\1740 and\CC\1740 pathologically\RB\1740 with\IN\1740 the\DT\1740 human\JJ\1740 form\NN\6286395 .\.\1740
D014810_D009135 NONE Myopathy\NNP\14204950 due\JJ\1740 to\TO\1740 lack\NN\14449126 of\IN\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 and\CC\1740 <e2>myopathy</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 certain\JJ\1740 viruses\NNS\9312843 have\VBP\2108377 much\JJ\1740 in\IN\13603305 common\JJ\1740 anatomically\RB\1740 and\CC\1740 pathologically\RB\1740 with\IN\1740 the\DT\1740 human\JJ\1740 form\NN\6286395 .\.\1740
D014810_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 <e2>myopathic</e2>\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 <e1>vitamin\NN\7570720 E.</e1>\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D014810_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 <e2>myopathic</e2>\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 <e1>vitamin\NN\7570720 E.</e1>\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D014810_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 <e1>vitamin\NN\7570720 E.</e1>\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 <e2>myopathic</e2>\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D014810_D009135 NONE The\DT\1740 authors\NNS\9610660 conclude\VBP\628491 by\IN\1740 affirming\VBG\1010118 the\DT\1740 undoubted\JJ\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 anabolizing\NN\1740 steroids\NNS\14727670 in\IN\13603305 experimental\JJ\1740 <e2>myopathic\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 but\CC\1740 they\PRP\1740 have\VBP\2108377 reservations\NNS\8491826 as\IN\14622893 to\IN\1740 the\DT\1740 transfer\NN\280586 of\IN\1740 the\DT\1740 results\NNS\34213 into\IN\1740 the\DT\1740 human\JJ\1740 field\NN\8673395 ,\,\1740 where\WRB\1740 high\JJ\1740 dosage\NN\13576355 can\MD\3094503 not\RB\1740 be\VB\836236 carried\VBN\1850315 out\RP\1740 continuously\RB\1740 because\IN\1740 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 drug\NN\14778436 on\IN\1740 virility\NN\5008227 ;\:\1740 because\IN\1740 the\DT\1740 tissue\NN\5220461 injury\NN\14052046 too\RB\1740 often\RB\1740 occurs\VBZ\2623529 at\IN\14622893 an\DT\6697703 irreversible\JJ\1740 stage\NN\15113229 vis-a-vis\FW\5695554 the\DT\1740 "\``\1740 regeneration\NN\13526110 "\''\1740 of\IN\1740 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ;\:\1740 and\CC\1740 finally\RB\1740 because\IN\1740 the\DT\1740 dystrophic\JJ\1740 injurious\JJ\1740 agent\NN\7347 is\VBZ\836236 certainly\RB\1740 not\RB\1740 the\DT\1740 lack\NN\14449126 of\IN\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 but\CC\1740 something\NN\1740 as\IN\14622893 yet\RB\1740 unknown\JJ\1740 .\.\1740
D014810_D009136 CID The\DT\1740 authors\NNS\9610660 induced\VBD\1627355 <e2>myodystrophy</e2>\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 by\IN\1740 giving\VBG\2327200 it\PRP\6125041 a\DT\13649268 diet\NN\7560652 lacking\VBG\1740 in\IN\13603305 <e1>vitamin\NN\7570720 E.</e1>\NN\1740 The\DT\1740 pharmacological\JJ\1740 characteristics\NNS\5849040 of\IN\1740 vitamin\NN\7570720 E\NN\14724645 and\CC\1740 the\DT\1740 degenerative\JJ\1740 changes\NNS\7283608 brought\VBN\1449974 about\RB\1740 by\IN\1740 its\PRP$\6125041 deficiency\NN\14449126 ,\,\1740 especially\RB\1740 in\IN\13603305 the\DT\1740 muscles\NNS\5289601 ,\,\1740 are\VBP\836236 illustrated\VBN\955601 .\.\1740
D014810_D009136 CID The\DT\1740 authors\NNS\9610660 induced\VBD\1627355 <e2>myodystrophy</e2>\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 by\IN\1740 giving\VBG\2327200 it\PRP\6125041 a\DT\13649268 diet\NN\7560652 lacking\VBG\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 The\DT\1740 pharmacological\JJ\1740 characteristics\NNS\5849040 of\IN\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 and\CC\1740 the\DT\1740 degenerative\JJ\1740 changes\NNS\7283608 brought\VBN\1449974 about\RB\1740 by\IN\1740 its\PRP$\6125041 deficiency\NN\14449126 ,\,\1740 especially\RB\1740 in\IN\13603305 the\DT\1740 muscles\NNS\5289601 ,\,\1740 are\VBP\836236 illustrated\VBN\955601 .\.\1740
D013256_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 <e2>myopathic</e2>\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 <e1>steroids</e1>\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D013256_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 <e1>steroids</e1>\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 <e2>myopathic</e2>\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D013256_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 <e1>steroids</e1>\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 <e2>myopathic</e2>\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D013256_D009135 NONE The\DT\1740 authors\NNS\9610660 conclude\VBP\628491 by\IN\1740 affirming\VBG\1010118 the\DT\1740 undoubted\JJ\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 anabolizing\NN\1740 <e1>steroids</e1>\NNS\14727670 in\IN\13603305 experimental\JJ\1740 <e2>myopathic\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 but\CC\1740 they\PRP\1740 have\VBP\2108377 reservations\NNS\8491826 as\IN\14622893 to\IN\1740 the\DT\1740 transfer\NN\280586 of\IN\1740 the\DT\1740 results\NNS\34213 into\IN\1740 the\DT\1740 human\JJ\1740 field\NN\8673395 ,\,\1740 where\WRB\1740 high\JJ\1740 dosage\NN\13576355 can\MD\3094503 not\RB\1740 be\VB\836236 carried\VBN\1850315 out\RP\1740 continuously\RB\1740 because\IN\1740 of\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 drug\NN\14778436 on\IN\1740 virility\NN\5008227 ;\:\1740 because\IN\1740 the\DT\1740 tissue\NN\5220461 injury\NN\14052046 too\RB\1740 often\RB\1740 occurs\VBZ\2623529 at\IN\14622893 an\DT\6697703 irreversible\JJ\1740 stage\NN\15113229 vis-a-vis\FW\5695554 the\DT\1740 "\``\1740 regeneration\NN\13526110 "\''\1740 of\IN\1740 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ;\:\1740 and\CC\1740 finally\RB\1740 because\IN\1740 the\DT\1740 dystrophic\JJ\1740 injurious\JJ\1740 agent\NN\7347 is\VBZ\836236 certainly\RB\1740 not\RB\1740 the\DT\1740 lack\NN\14449126 of\IN\1740 vitamin\NN\7570720 E\NN\14724645 but\CC\1740 something\NN\1740 as\IN\14622893 yet\RB\1740 unknown\JJ\1740 .\.\1740
D008696_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 <e2>myopathic</e2>\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 <e1>Dianabol</e1>\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D008696_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 <e1>Dianabol</e1>\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 <e2>myopathic</e2>\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
D008696_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 <e1>Dianabol</e1>\NN\1740 ,\,\1740 CIBA\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 <e2>myopathic</e2>\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
-1_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 <e2>myopathic</e2>\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 <e1>CIBA</e1>\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
-1_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 <e1>CIBA</e1>\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 <e2>myopathic</e2>\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 myopathic\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
-1_D009135 NONE The\DT\1740 encouraging\JJ\1740 results\NNS\34213 obtained\VBN\2210855 in\IN\13603305 various\JJ\1740 authoratative\JJ\1740 departments\NNS\8220714 in\IN\13603305 myopathic\JJ\1740 patients\NNS\9898892 by\IN\1740 using\VBG\1156834 anabolizing\NN\1740 steroids\NNS\14727670 have\VBP\2108377 encouraged\VBN\2556126 the\DT\1740 authors\NNS\9610660 to\TO\1740 investigate\VB\644583 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 one\CD\13741022 anabolizing\NN\1740 agent\NN\7347 (\-LRB-\1740 Dianabol\NN\1740 ,\,\1740 <e1>CIBA</e1>\NNP\1740 )\-RRB-\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 in\IN\13603305 rats\NNS\2329401 rendered\VBN\120316 myopathic\JJ\1740 by\IN\1740 a\DT\13649268 diet\JJ\1740 deficient\NN\1740 in\IN\13603305 vitamin\NN\7570720 E.\NN\1740 In\IN\13603305 this\DT\1740 way\NN\4916342 they\PRP\1740 obtained\VBD\2210855 appreciable\JJ\1740 changes\NNS\7283608 in\IN\13603305 body\NN\19128 weight\NN\5009170 (\-LRB-\1740 increased\VBD\169651 from\IN\1740 50\CD\13745420 to\TO\1740 70\CD\13745420 g\NN\13717155 after\IN\1740 forty\CD\13745420 days\NNS\15140892 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 5\CD\13741022 mg\NN\13717155 per\IN\1740 day\NN\15154774 of\IN\1740 anabolizing\VBG\1740 agent\NN\7347 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 of\IN\1740 all\DT\1740 they\PRP\1740 found\VBD\2426171 histological\JJ\1740 changes\NNS\7283608 due\JJ\1740 to\TO\1740 "\``\1740 regenerative\JJ\1740 "\''\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 muscle\NN\5289601 tissue\NN\5220461 ,\,\1740 which\WDT\1740 however\RB\1740 maintained\VBD\2202928 its\PRP$\6125041 <e2>myopathic</e2>\JJ\1740 characteristics\NNS\5849040 in\IN\13603305 the\DT\1740 control\NN\5190804 animals\NNS\4475 that\WDT\1740 were\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 the\DT\1740 anabolizing\NN\1740 agent\NN\7347 .\.\1740
1760851
D004317_D066126 CID Reduced\VBN\441445 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 given\VBN\2327200 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 N-(2-hydroxypropyl)methacrylamide\NN\1740 conjugates\NNS\14589223 :\:\1740 and\CC\1740 experimental\JJ\1740 study\NN\635850 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D004317_D066126 CID A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 toxicity\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 N-(2-hydroxypropyl)methacrylamide\NN\1740 (\-LRB-\1740 HPMA\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
D004317_D066126 CID A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 toxicity\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 N-(2-hydroxypropyl)methacrylamide\NN\1740 (\-LRB-\1740 HPMA\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
D004317_D066126 CID Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 <e2>cardiotoxicity</e2>\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 <e1>DOX</e1>\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 HPMA\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 DOX\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 DOX-induced\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D066126 CID Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 cardiotoxicity\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 <e1>DOX</e1>\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 HPMA\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 DOX\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 CID Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 <e2>cardiotoxicity</e2>\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 DOX\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 HPMA\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 <e1>DOX</e1>\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 DOX-induced\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D066126 CID Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 cardiotoxicity\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 DOX\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 HPMA\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 <e1>DOX</e1>\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 CID Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 <e2>cardiotoxicity</e2>\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 DOX\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 HPMA\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 DOX\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 <e1>DOX-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D066126 CID Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 cardiotoxicity\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 DOX\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 HPMA\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 DOX\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 <e1>DOX-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
C032976_D066126 NONE Reduced\VBN\441445 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 doxorubicin\NN\2716866 given\VBN\2327200 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 <e1>N-(2-hydroxypropyl)methacrylamide</e1>\NN\1740 conjugates\NNS\14589223 :\:\1740 and\CC\1740 experimental\JJ\1740 study\NN\635850 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
C032976_D066126 NONE A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 toxicity\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 <e1>N-(2-hydroxypropyl)methacrylamide</e1>\NN\1740 (\-LRB-\1740 HPMA\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
C032976_D066126 NONE A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 toxicity\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 N-(2-hydroxypropyl)methacrylamide\NN\1740 (\-LRB-\1740 <e1>HPMA</e1>\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
C032976_D066126 NONE Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 <e2>cardiotoxicity</e2>\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 DOX\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 <e1>HPMA</e1>\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 DOX\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 DOX-induced\JJ\1740 cardiotoxicity\NN\1740 .\.\1740
C032976_D066126 NONE Throughout\IN\1740 the\DT\1740 study\NN\635850 (\-LRB-\1740 20\CD\13745420 weeks\NNS\15113229 )\-RRB-\1740 ,\,\1740 deaths\NNS\7296428 related\JJ\1740 to\TO\1740 cardiotoxicity\NN\1740 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 either\CC\1740 free\JJ\1740 DOX\NN\1740 or\CC\3541091 the\DT\1740 mixture\NN\19613 of\IN\1740 <e1>HPMA</e1>\NN\1740 copolymer\NN\14994328 and\CC\1740 free\JJ\1740 DOX\NN\1740 ;\:\1740 in\IN\13603305 these\DT\1740 cases\NNS\7283608 ,\,\1740 histological\JJ\1740 investigations\NNS\5797597 revealed\VBD\2137132 marked\JJ\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 heart\NN\5919034 that\WDT\1740 were\VBD\836236 consistent\JJ\1740 with\IN\1740 DOX-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D064420 NONE A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 cardiotoxicity\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 N-(2-hydroxypropyl)methacrylamide\NN\1740 (\-LRB-\1740 HPMA\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
D004317_D064420 NONE A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 cardiotoxicity\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 N-(2-hydroxypropyl)methacrylamide\NN\1740 (\-LRB-\1740 HPMA\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
C032976_D064420 NONE A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 cardiotoxicity\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 <e1>N-(2-hydroxypropyl)methacrylamide</e1>\NN\1740 (\-LRB-\1740 HPMA\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
C032976_D064420 NONE A\DT\13649268 rat\NN\2329401 model\NN\5888929 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 general\JJ\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 the\DT\1740 late\JJ\1740 cardiotoxicity\NN\1740 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 given\VBN\2327200 either\CC\1740 as\IN\14622893 free\JJ\1740 drug\NN\14778436 or\CC\3541091 in\IN\13603305 the\DT\1740 form\NN\6286395 of\IN\1740 three\CD\13741022 N-(2-hydroxypropyl)methacrylamide\NN\1740 (\-LRB-\1740 <e1>HPMA</e1>\NN\1740 )\-RRB-\1740 copolymer\NN\14994328 conjugates\NNS\14589223 .\.\1740
17879217
D012293_D005921 CID <e1>Rifampicin-associated</e1>\JJ\1740 segmental\JJ\1740 necrotizing\NN\1740 <e2>glomerulonephritis</e2>\NN\14113798 in\IN\13603305 staphylococcal\JJ\1740 endocarditis\NN\14338942 .\.\1740
D012293_D005921 CID Segmental\JJ\1740 necrotising\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 complication\NN\1073995 of\IN\1740 <e1>rifampicin</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 treatment\NN\654885 for\IN\1740 tuberculosis\NN\14127211 .\.\1740
D012293_D005921 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 Staphylococcal\JJ\1740 IE\NN\1740 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>rifampicin</e1>\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 rifampicin\NN\1740 therapy\NN\657604 .\.\1740
D012293_D005921 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 Staphylococcal\JJ\1740 IE\NN\1740 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 rifampicin\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 <e1>rifampicin</e1>\NN\1740 therapy\NN\657604 .\.\1740
D012293_D013203 NONE <e1>Rifampicin-associated</e1>\JJ\1740 segmental\JJ\1740 necrotizing\NN\1740 glomerulonephritis\NN\14113798 in\IN\13603305 <e2>staphylococcal\JJ\1740 endocarditis</e2>\NN\14338942 .\.\1740
D012293_D013203 NONE Changing\VBG\46534 epidemiology\NN\6043075 of\IN\1740 infections\NNS\14052046 such\JJ\1740 as\IN\14622893 infective\JJ\1740 endocarditis\NN\14338942 (\-LRB-\1740 IE\NN\1740 )\-RRB-\1740 has\VBZ\2108377 led\VBN\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 use\NN\407535 of\IN\1740 <e1>rifampicin</e1>\NN\1740 for\IN\1740 <e2>Staphylococcal\JJ\1740 infections</e2>\NNS\14052046 .\.\1740
D012293_D013203 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>Staphylococcal\JJ\1740 IE</e2>\NN\1740 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>rifampicin</e1>\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 rifampicin\NN\1740 therapy\NN\657604 .\.\1740
D012293_D013203 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>Staphylococcal\JJ\1740 IE</e2>\NN\1740 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 rifampicin\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 <e1>rifampicin</e1>\NN\1740 therapy\NN\657604 .\.\1740
D012293_D004696 NONE <e1>Rifampicin-associated</e1>\JJ\1740 segmental\JJ\1740 necrotizing\NN\1740 glomerulonephritis\NN\14113798 in\IN\13603305 <e2>staphylococcal\JJ\1740 endocarditis</e2>\NN\14338942 .\.\1740
D012293_D004696 NONE Changing\VBG\46534 epidemiology\NN\6043075 of\IN\1740 infections\NNS\14052046 such\JJ\1740 as\IN\14622893 <e2>infective\JJ\1740 endocarditis</e2>\NN\14338942 (\-LRB-\1740 IE\NN\1740 )\-RRB-\1740 has\VBZ\2108377 led\VBN\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 use\NN\407535 of\IN\1740 <e1>rifampicin</e1>\NN\1740 for\IN\1740 Staphylococcal\JJ\1740 infections\NNS\14052046 .\.\1740
D012293_D004696 NONE Changing\VBG\46534 epidemiology\NN\6043075 of\IN\1740 infections\NNS\14052046 such\JJ\1740 as\IN\14622893 infective\JJ\1740 endocarditis\NN\14338942 (\-LRB-\1740 <e2>IE</e2>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 led\VBN\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 use\NN\407535 of\IN\1740 <e1>rifampicin</e1>\NN\1740 for\IN\1740 Staphylococcal\JJ\1740 infections\NNS\14052046 .\.\1740
D012293_D004696 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>Staphylococcal\JJ\1740 IE</e2>\NN\1740 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>rifampicin</e1>\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 rifampicin\NN\1740 therapy\NN\657604 .\.\1740
D012293_D004696 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>Staphylococcal\JJ\1740 IE</e2>\NN\1740 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 rifampicin\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 <e1>rifampicin</e1>\NN\1740 therapy\NN\657604 .\.\1740
D012293_D014376 NONE Segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 complication\NN\1073995 of\IN\1740 <e1>rifampicin</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 treatment\NN\654885 for\IN\1740 <e2>tuberculosis</e2>\NN\14127211 .\.\1740
D012293_D007239 NONE Changing\VBG\46534 epidemiology\NN\6043075 of\IN\1740 <e2>infections</e2>\NNS\14052046 such\JJ\1740 as\IN\14622893 infective\JJ\1740 endocarditis\NN\14338942 (\-LRB-\1740 IE\NN\1740 )\-RRB-\1740 has\VBZ\2108377 led\VBN\1752884 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 use\NN\407535 of\IN\1740 <e1>rifampicin</e1>\NN\1740 for\IN\1740 Staphylococcal\JJ\1740 infections\NNS\14052046 .\.\1740
D012293_D058186 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 Staphylococcal\JJ\1740 IE\NN\1740 who\WP\8299493 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>rifampicin</e1>\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 rifampicin\NN\1740 therapy\NN\657604 .\.\1740
D012293_D058186 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 Staphylococcal\JJ\1740 IE\NN\1740 who\WP\8299493 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 secondary\JJ\1740 to\TO\1740 a\DT\13649268 segmental\JJ\1740 necrotising\JJ\1740 glomerulonephritis\NN\14113798 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 rifampicin\NN\1740 ,\,\1740 and\CC\1740 review\VB\644583 the\DT\1740 literature\NN\6362953 regarding\VBG\689344 this\DT\1740 complication\NN\1073995 of\IN\1740 <e1>rifampicin</e1>\NN\1740 therapy\NN\657604 .\.\1740
8957205
D000324_D006935 NONE Human\JJ\1740 <e1>corticotropin-releasing</e1>\JJ\1740 hormone\NN\5404728 and\CC\1740 thyrotropin-releasing\JJ\1740 hormone\NN\5404728 modulate\VBP\1724459 the\DT\1740 <e2>hypercapnic</e2>\JJ\1740 ventilatory\JJ\1740 response\NN\11410625 in\IN\13603305 humans\NNS\31264 .\.\1740
D013972_D006935 NONE Human\JJ\1740 corticotropin-releasing\JJ\1740 hormone\NN\5404728 and\CC\1740 <e1>thyrotropin-releasing</e1>\JJ\1740 hormone\NN\5404728 modulate\VBP\1724459 the\DT\1740 <e2>hypercapnic</e2>\JJ\1740 ventilatory\JJ\1740 response\NN\11410625 in\IN\13603305 humans\NNS\31264 .\.\1740
24816962
D008795_D001927 CID <e1>Metronidazole-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\RB\1740 :\:\1740 an\DT\6697703 uncommon\JJ\1740 scenario\NN\7009946 .\.\1740
D008795_D001927 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 where\WRB\1740 a\DT\13649268 patient\NN\9898892 developed\VBD\1753788 features\NNS\5849040 of\IN\1740 <e2>encephalopathy</e2>\JJ\1740 following\VBG\1835496 prolonged\JJ\1740 <e1>metronidazole</e1>\NN\2723292 intake\NN\13440063 .\.\1740
D008795_D064420 NONE The\DT\1740 diagnosis\NN\152018 of\IN\1740 <e1>metronidazole</e1>\NN\2723292 <e2>toxicity</e2>\NN\13576101 was\VBD\836236 made\VBN\126264 by\IN\1740 the\DT\1740 MRI\NN\901083 findings\NNS\7951464 and\CC\1740 supported\VBD\2199590 clinically\RB\1740 .\.\1740
12950111
D006024_D013547 NONE Treatment\NN\654885 of\IN\1740 compensatory\JJ\1740 <e2>gustatory\NN\1740 hyperhidrosis</e2>\NN\13535261 with\IN\1740 topical\JJ\1740 <e1>glycopyrrolate</e1>\NN\1740 .\.\1740
D006024_D013547 NONE After\IN\1740 applying\VBG\2676054 topical\JJ\1740 <e1>glycopyrrolate</e1>\NN\1740 ,\,\1740 the\DT\1740 subjective\JJ\1740 effect\NN\34213 was\VBD\836236 excellent\JJ\1740 (\-LRB-\1740 no\DT\7204911 <e2>sweating</e2>\NN\13440063 after\IN\1740 eating\VBG\1156834 hot\JJ\1740 spicy\JJ\1740 food\NN\20090 )\-RRB-\1740 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 77\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 fair\JJ\1740 (\-LRB-\1740 clearly\RB\1740 reduced\VBN\441445 sweating\NN\13440063 )\-RRB-\1740 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 23\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D013547 NONE After\IN\1740 applying\VBG\2676054 topical\JJ\1740 <e1>glycopyrrolate</e1>\NN\1740 ,\,\1740 the\DT\1740 subjective\JJ\1740 effect\NN\34213 was\VBD\836236 excellent\JJ\1740 (\-LRB-\1740 no\DT\7204911 sweating\NN\13440063 after\IN\1740 eating\VBG\1156834 hot\JJ\1740 spicy\JJ\1740 food\NN\20090 )\-RRB-\1740 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 77\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 fair\JJ\1740 (\-LRB-\1740 clearly\RB\1740 reduced\VBN\441445 <e2>sweating</e2>\NN\13440063 )\-RRB-\1740 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 23\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D013547 NONE The\DT\1740 topical\JJ\1740 application\NN\947128 of\IN\1740 a\DT\13649268 <e1>glycopyrrolate</e1>\NN\1740 pad\NN\14974264 appeared\VBD\2604760 to\TO\1740 be\VB\836236 safe\JJ\1740 ,\,\1740 efficacious\JJ\1740 ,\,\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 and\CC\1740 a\DT\13649268 convenient\JJ\1740 method\NN\5616786 of\IN\1740 treatment\NN\654885 for\IN\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>gustatory\JJ\1740 hyperhidrosis</e2>\NN\13535261 in\IN\13603305 post\NN\8621598 transthoracic\NN\1740 endoscopic\JJ\1740 sympathectomy\NN\393369 or\CC\3541091 sympathicotomy\NN\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 few\JJ\1740 side\NN\8630039 effects\NNS\13245626 .\.\1740
D006024_D014987 NONE Adverse\JJ\1740 effects\NNS\13245626 included\VBD\690614 a\DT\13649268 mildly\RB\1740 <e2>dry\JJ\1740 mouth</e2>\NN\5610008 and\CC\1740 a\DT\13649268 sore\JJ\1740 throat\NN\5548726 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 light\JJ\1740 headache\NN\5829480 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 glycopyrrolate\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D014987 NONE Adverse\JJ\1740 effects\NNS\13245626 included\VBD\690614 a\DT\13649268 mildly\RB\1740 <e2>dry\JJ\1740 mouth</e2>\NN\5610008 and\CC\1740 a\DT\13649268 sore\JJ\1740 throat\NN\5548726 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 glycopyrrolate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 light\JJ\1740 headache\NN\5829480 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D010612 CID Adverse\JJ\1740 effects\NNS\13245626 included\VBD\690614 a\DT\13649268 mildly\RB\1740 dry\JJ\1740 mouth\NN\5610008 and\CC\1740 a\DT\13649268 <e2>sore\JJ\1740 throat</e2>\NN\5548726 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 light\JJ\1740 headache\NN\5829480 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 glycopyrrolate\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D010612 CID Adverse\JJ\1740 effects\NNS\13245626 included\VBD\690614 a\DT\13649268 mildly\RB\1740 dry\JJ\1740 mouth\NN\5610008 and\CC\1740 a\DT\13649268 <e2>sore\JJ\1740 throat</e2>\NN\5548726 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 glycopyrrolate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 light\JJ\1740 headache\NN\5829480 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D006261 CID Adverse\JJ\1740 effects\NNS\13245626 included\VBD\690614 a\DT\13649268 mildly\RB\1740 dry\JJ\1740 mouth\NN\5610008 and\CC\1740 a\DT\13649268 sore\JJ\1740 throat\NN\5548726 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 light\JJ\1740 <e2>headache</e2>\NN\5829480 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 glycopyrrolate\NN\1740 )\-RRB-\1740 .\.\1740
D006024_D006261 CID Adverse\JJ\1740 effects\NNS\13245626 included\VBD\690614 a\DT\13649268 mildly\RB\1740 dry\JJ\1740 mouth\NN\5610008 and\CC\1740 a\DT\13649268 sore\JJ\1740 throat\NN\5548726 in\IN\13603305 2\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 glycopyrrolate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 light\JJ\1740 <e2>headache</e2>\NN\5829480 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 1.5\CD\1740 %\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 )\-RRB-\1740 .\.\1740
20024739
D000431_D015658 NONE Longitudinal\JJ\1740 association\NN\8008335 of\IN\1740 <e1>alcohol</e1>\NN\7881800 use\NN\407535 with\IN\1740 <e2>HIV\NN\14186340 disease</e2>\NN\14061805 progression\NN\8457976 and\CC\1740 psychological\JJ\1740 health\NN\14447525 of\IN\1740 women\NNS\9605289 with\IN\1740 HIV\NN\14186340 .\.\1740
D000431_D015658 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 association\NN\8008335 of\IN\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 and\CC\1740 depression\NN\14373582 ,\,\1740 and\CC\1740 their\PRP$\1740 effects\NNS\13245626 on\IN\1740 <e2>HIV\NN\14186340 disease</e2>\NN\14061805 progression\NN\8457976 among\IN\1740 women\NNS\9605289 with\IN\1740 HIV\NN\14186340 .\.\1740
D000431_D003866 CID We\PRP\1740 evaluated\VBD\670261 the\DT\1740 association\NN\8008335 of\IN\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 and\CC\1740 <e2>depression</e2>\NN\14373582 ,\,\1740 and\CC\1740 their\PRP$\1740 effects\NNS\13245626 on\IN\1740 HIV\NN\14186340 disease\NN\14061805 progression\NN\8457976 among\IN\1740 women\NNS\9605289 with\IN\1740 HIV\NN\14186340 .\.\1740
D000431_D003866 CID The\DT\1740 participants\NNS\9816771 had\VBD\2108377 physical\JJ\1740 examination\NN\633864 ,\,\1740 medical\JJ\1740 record\NN\6643408 extraction\NN\13518963 ,\,\1740 and\CC\1740 venipuncture\VB\1740 ,\,\1740 CD4+T-cell\JJ\1740 counts\NNS\13582013 determination\NN\43195 ,\,\1740 measurement\NN\407535 of\IN\1740 <e2>depression</e2>\NN\14373582 symptoms\NNS\5823932 (\-LRB-\1740 using\VBG\1156834 the\DT\1740 self-report\JJ\1740 Center\NNP\8497294 for\IN\1740 Epidemiological\NNP\1740 Studies-Depression\NN\1740 Scale\NN\7260623 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>alcohol</e1>\NN\7881800 use\VBP\1156834 assessment\NN\5732756 at\IN\14622893 enrollment\NN\49003 ,\,\1740 and\CC\1740 semiannually\RB\1740 until\IN\1740 March\NNP\15209706 2000\CD\1740 .\.\1740
D000431_D003866 CID The\DT\1740 participants\NNS\9816771 had\VBD\2108377 physical\JJ\1740 examination\NN\633864 ,\,\1740 medical\JJ\1740 record\NN\6643408 extraction\NN\13518963 ,\,\1740 and\CC\1740 venipuncture\VB\1740 ,\,\1740 CD4+T-cell\JJ\1740 counts\NNS\13582013 determination\NN\43195 ,\,\1740 measurement\NN\407535 of\IN\1740 depression\NN\14373582 symptoms\NNS\5823932 (\-LRB-\1740 using\VBG\1156834 the\DT\1740 self-report\JJ\1740 Center\NNP\8497294 for\IN\1740 Epidemiological\NNP\1740 <e2>Studies-Depression</e2>\NN\1740 Scale\NN\7260623 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>alcohol</e1>\NN\7881800 use\VBP\1156834 assessment\NN\5732756 at\IN\14622893 enrollment\NN\49003 ,\,\1740 and\CC\1740 semiannually\RB\1740 until\IN\1740 March\NNP\15209706 2000\CD\1740 .\.\1740
D000431_D003866 CID The\DT\1740 association\NN\8008335 between\IN\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 and\CC\1740 <e2>depression</e2>\NN\14373582 was\VBD\836236 significant\JJ\1740 (\-LRB-\1740 p<0.001\NN\1740 )\-RRB-\1740 .\.\1740
D000431_D003866 CID Our\PRP$\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 has\VBZ\2108377 a\DT\13649268 direct\JJ\1740 association\NN\8008335 with\IN\1740 <e2>depression</e2>\NN\14373582 .\.\1740
24717468
D020927_D007022 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 <e1>dexmedetomidine</e1>\NN\1740 or\CC\3541091 propofol\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 hypotension\NN\14057371 or\CC\3541091 bradycardia\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D020927_D007022 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 <e1>dexmedetomidine</e1>\NN\1740 or\CC\3541091 propofol\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 <e2>hypotension</e2>\NN\14057371 or\CC\3541091 bradycardia\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D020927_D001919 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 <e1>dexmedetomidine</e1>\NN\1740 or\CC\3541091 propofol\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 hypotension\NN\14057371 or\CC\3541091 bradycardia\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D020927_D001919 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 <e1>dexmedetomidine</e1>\NN\1740 or\CC\3541091 propofol\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 hypotension\NN\14057371 or\CC\3541091 <e2>bradycardia</e2>\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D015742_D007022 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 dexmedetomidine\NN\1740 or\CC\3541091 <e1>propofol</e1>\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 hypotension\NN\14057371 or\CC\3541091 bradycardia\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D015742_D007022 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 dexmedetomidine\NN\1740 or\CC\3541091 <e1>propofol</e1>\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 <e2>hypotension</e2>\NN\14057371 or\CC\3541091 bradycardia\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D015742_D001919 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 dexmedetomidine\NN\1740 or\CC\3541091 <e1>propofol</e1>\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 hypotension\NN\14057371 or\CC\3541091 bradycardia\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
D015742_D001919 CID CONCLUSIONS\NNS\5837957 :\:\1740 Severe\JJ\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 occur\VBP\2623529 at\IN\14622893 similar\JJ\1740 prevalence\NN\4764412 in\IN\13603305 neurocritical\JJ\1740 care\NN\575741 patients\NNS\9898892 who\WP\8299493 receive\VBP\2210855 dexmedetomidine\NN\1740 or\CC\3541091 <e1>propofol</e1>\NN\1740 .\.\1740 Providers\NNS\9882716 should\MD\1740 similarly\RB\1740 consider\VB\689344 the\DT\1740 likelihood\NN\4756172 of\IN\1740 hypotension\NN\14057371 or\CC\3541091 <e2>bradycardia</e2>\NN\14110674 before\IN\1740 starting\VBG\2009433 either\CC\1740 sedative\JJ\1740 .\.\1740
8985298
D019259_D006509 NONE <e1>Lamivudine</e1>\NN\3834836 is\VBZ\836236 effective\JJ\1740 in\IN\13603305 suppressing\VBG\2510337 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 DNA\NN\14994328 in\IN\13603305 Chinese\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen\NN\20090 carriers\NNS\9629752 :\:\1740 a\DT\13649268 placebo-controlled\JJ\1740 trial\NN\786195 .\.\1740
D019259_D006509 NONE <e1>Lamivudine</e1>\NN\3834836 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 2',3'-dideoxy\NN\1740 cytosine\NN\14999913 analogue\NN\4743605 that\WDT\1740 has\VBZ\2108377 potent\JJ\1740 inhibitory\JJ\1740 effects\NNS\13245626 on\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 replication\NN\1019524 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D019259_D006509 NONE Lamivudine\NN\3834836 is\VBZ\836236 a\DT\13649268 novel\JJ\1740 <e1>2',3'-dideoxy\NN\1740 cytosine</e1>\NN\14999913 analogue\NN\4743605 that\WDT\1740 has\VBZ\2108377 potent\JJ\1740 inhibitory\JJ\1740 effects\NNS\13245626 on\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 replication\NN\1019524 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D019259_D006509 NONE All\DT\1740 36\CD\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>lamivudine</e1>\NN\3834836 had\VBD\2108377 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 DNA\NN\14994328 values\NNS\5941423 of\IN\1740 >\NN\1740 90\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 .001\CD\1740 compared\VBN\644583 with\IN\1740 placebo\NN\3740161 )\-RRB-\1740 .\.\1740
D006514_D006509 CID Lamivudine\NN\3834836 is\VBZ\836236 effective\JJ\1740 in\IN\13603305 suppressing\VBG\2510337 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 DNA\NN\14994328 in\IN\13603305 Chinese\JJ\1740 <e1>hepatitis\NN\14127211 B\NN\1355326 surface\NN\21939 antigen</e1>\NN\20090 carriers\NNS\9629752 :\:\1740 a\DT\13649268 placebo-controlled\JJ\1740 trial\NN\786195 .\.\1740
24927617
C486464_D012206 CID <e2>Rhabdomyolysis</e2>\NN\1740 in\IN\13603305 a\DT\13649268 hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infected\JJ\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>telaprevir</e1>\NN\1740 and\CC\1740 simvastatin\NN\3676175 .\.\1740
C486464_D006526 NONE Rhabdomyolysis\NN\1740 in\IN\13603305 a\DT\13649268 <e2>hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infected</e2>\JJ\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>telaprevir</e1>\NN\1740 and\CC\1740 simvastatin\NN\3676175 .\.\1740
C486464_D006526 NONE A\DT\13649268 46-year\JJ\1740 old\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 chronic\JJ\1740 <e2>hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infection</e2>\NN\14052046 received\VBD\2210855 triple\JJ\1740 therapy\NN\657604 with\IN\1740 ribavirin\NN\2725367 ,\,\1740 pegylated\JJ\1740 interferon\NN\2725367 and\CC\1740 <e1>telaprevir</e1>\NN\1740 .\.\1740
D019821_D012206 CID <e2>Rhabdomyolysis</e2>\NN\1740 in\IN\13603305 a\DT\13649268 hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infected\JJ\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 telaprevir\NN\1740 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 .\.\1740
D019821_D006526 NONE Rhabdomyolysis\NN\1740 in\IN\13603305 a\DT\13649268 <e2>hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infected</e2>\JJ\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 telaprevir\NN\1740 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 .\.\1740
D012254_D006526 NONE A\DT\13649268 46-year\JJ\1740 old\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 chronic\JJ\1740 <e2>hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infection</e2>\NN\14052046 received\VBD\2210855 triple\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>ribavirin</e1>\NN\2725367 ,\,\1740 pegylated\JJ\1740 interferon\NN\2725367 and\CC\1740 telaprevir\NN\1740 .\.\1740
C417083_D006526 NONE A\DT\13649268 46-year\JJ\1740 old\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 chronic\JJ\1740 <e2>hepatitis\NN\14127211 C\NN\13714184 virus\NN\9312843 infection</e2>\NN\14052046 received\VBD\2210855 triple\JJ\1740 therapy\NN\657604 with\IN\1740 ribavirin\NN\2725367 ,\,\1740 <e1>pegylated\JJ\1740 interferon</e1>\NN\2725367 and\CC\1740 telaprevir\NN\1740 .\.\1740
D019821_D064420 NONE At\IN\14622893 admission\NN\49003 <e1>simvastatin</e1>\NN\3676175 and\CC\1740 all\DT\1740 antiviral\JJ\1740 drugs\NNS\14778436 were\VBD\836236 discontinued\VBN\2609764 because\IN\1740 <e2>toxicity</e2>\NN\13576101 due\IN\5174653 to\TO\1740 a\DT\13649268 drug-drug\JJ\1740 interaction\NN\37396 was\VBD\836236 suspected\VBN\916909 .\.\1740
D019821_D009135 CID <e1>Simvastatin</e1>\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 increased\VBD\169651 30\CD\13745420 times\NNS\15113229 in\IN\13603305 this\DT\1740 patient\NN\9898892 and\CC\1740 statin\NN\3740161 induced\JJ\1740 <e2>muscle\NN\5289601 toxicity</e2>\NN\13576101 is\VBZ\836236 related\JJ\1740 to\TO\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 the\DT\1740 statin\NN\3740161 in\IN\13603305 blood\NN\5397468 .\.\1740
D019821_D009135 CID Simvastatin\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 increased\VBD\169651 30\CD\13745420 times\NNS\15113229 in\IN\13603305 this\DT\1740 patient\NN\9898892 and\CC\1740 <e1>statin</e1>\NN\3740161 induced\JJ\1740 <e2>muscle\NN\5289601 toxicity</e2>\NN\13576101 is\VBZ\836236 related\JJ\1740 to\TO\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 the\DT\1740 statin\NN\3740161 in\IN\13603305 blood\NN\5397468 .\.\1740
D019821_D009135 CID Simvastatin\JJ\1740 plasma\NN\5398023 concentration\NN\4916342 increased\VBD\169651 30\CD\13745420 times\NNS\15113229 in\IN\13603305 this\DT\1740 patient\NN\9898892 and\CC\1740 statin\NN\3740161 induced\JJ\1740 <e2>muscle\NN\5289601 toxicity</e2>\NN\13576101 is\VBZ\836236 related\JJ\1740 to\TO\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 the\DT\1740 <e1>statin</e1>\NN\3740161 in\IN\13603305 blood\NN\5397468 .\.\1740
11474137
D003300_D034381 NONE Overexpression\NN\1740 of\IN\1740 <e1>copper/zinc-superoxide</e1>\JJ\1740 dismutase\NN\1740 protects\VBZ\1127795 from\IN\1740 kanamycin-induced\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D015032_D034381 NONE Overexpression\NN\1740 of\IN\1740 <e1>copper/zinc-superoxide</e1>\JJ\1740 dismutase\NN\1740 protects\VBZ\1127795 from\IN\1740 kanamycin-induced\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D013481_D034381 NONE Overexpression\NN\1740 of\IN\1740 <e1>copper/zinc-superoxide</e1>\JJ\1740 dismutase\NN\1740 protects\VBZ\1127795 from\IN\1740 kanamycin-induced\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D007612_D034381 CID Overexpression\NN\1740 of\IN\1740 copper/zinc-superoxide\JJ\1740 dismutase\NN\1740 protects\VBZ\1127795 from\IN\1740 <e1>kanamycin-induced</e1>\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D010100_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 <e2>ototoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 aminoglycoside-iron\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 ototoxicity\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D010100_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 ototoxicity\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 aminoglycoside-iron\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 <e2>ototoxicity</e2>\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000617_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 <e1>aminoglycoside-induced</e1>\JJ\1740 <e2>ototoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 aminoglycoside-iron\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 ototoxicity\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000617_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 <e1>aminoglycoside-induced</e1>\JJ\1740 ototoxicity\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 aminoglycoside-iron\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 <e2>ototoxicity</e2>\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000617_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 <e2>ototoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 <e1>aminoglycoside-iron</e1>\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 ototoxicity\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000617_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 ototoxicity\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 <e1>aminoglycoside-iron</e1>\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 <e2>ototoxicity</e2>\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D000617_D006311 NONE The\DT\1740 protection\NN\407535 by\IN\1740 overexpression\NN\1740 of\IN\1740 superoxide\NN\14971519 dismutase\NN\1740 supports\VBZ\2199590 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 oxidant\JJ\1740 stress\NN\7083732 plays\VBZ\1072262 a\DT\13649268 significant\JJ\1740 role\NN\719494 in\IN\13603305 <e1>aminoglycoside-induced</e1>\JJ\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D007501_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 <e2>ototoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 <e1>aminoglycoside-iron</e1>\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 ototoxicity\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D007501_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 ototoxicity\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 <e1>aminoglycoside-iron</e1>\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 superoxide\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 <e2>ototoxicity</e2>\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D013481_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 <e2>ototoxicity</e2>\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 aminoglycoside-iron\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 <e1>superoxide</e1>\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 ototoxicity\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D013481_D006311 NONE The\DT\1740 participation\NN\1080366 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 in\IN\13603305 aminoglycoside-induced\JJ\1740 ototoxicity\NN\1740 has\VBZ\2108377 been\VBN\836236 deduced\VBN\634472 from\IN\1740 observations\NNS\996969 that\IN\1740 aminoglycoside-iron\JJ\1740 complexes\NNS\5869584 catalyze\VBP\146138 the\DT\1740 formation\NN\7938773 of\IN\1740 <e1>superoxide</e1>\NN\14971519 radicals\NNS\9465459 in\FW\13603305 vitro\FW\1740 and\CC\1740 that\IN\1740 antioxidants\NNS\14724436 attenuate\VBP\224901 <e2>ototoxicity</e2>\NN\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D013481_D006311 NONE We\PRP\1740 therefore\RB\1740 hypothesized\VBD\719734 that\IN\1740 overexpression\NN\1740 of\IN\1740 <e1>Cu/Zn-superoxide</e1>\JJ\1740 dismutase\NN\1740 (\-LRB-\1740 h-SOD1\NN\1740 )\-RRB-\1740 should\MD\1740 protect\VB\1127795 transgenic\JJ\1740 mice\NNS\2329401 from\IN\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D013481_D006311 NONE The\DT\1740 protection\NN\407535 by\IN\1740 overexpression\NN\1740 of\IN\1740 <e1>superoxide</e1>\NN\14971519 dismutase\NN\1740 supports\VBZ\2199590 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 oxidant\JJ\1740 stress\NN\7083732 plays\VBZ\1072262 a\DT\13649268 significant\JJ\1740 role\NN\719494 in\IN\13603305 aminoglycoside-induced\JJ\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D003300_D006311 NONE We\PRP\1740 therefore\RB\1740 hypothesized\VBD\719734 that\IN\1740 overexpression\NN\1740 of\IN\1740 <e1>Cu/Zn-superoxide</e1>\JJ\1740 dismutase\NN\1740 (\-LRB-\1740 h-SOD1\NN\1740 )\-RRB-\1740 should\MD\1740 protect\VB\1127795 transgenic\JJ\1740 mice\NNS\2329401 from\IN\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D015032_D006311 NONE We\PRP\1740 therefore\RB\1740 hypothesized\VBD\719734 that\IN\1740 overexpression\NN\1740 of\IN\1740 <e1>Cu/Zn-superoxide</e1>\JJ\1740 dismutase\NN\1740 (\-LRB-\1740 h-SOD1\NN\1740 )\-RRB-\1740 should\MD\1740 protect\VB\1127795 transgenic\JJ\1740 mice\NNS\2329401 from\IN\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
24897009
D004977_D010523 NONE Optochiasmatic\JJ\1740 and\CC\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 due\JJ\1740 to\IN\1740 <e1>ethambutol</e1>\JJ\1740 overtreatment\NN\1740 .\.\1740
D004977_D009901 CID <e1>Ethambutol</e1>\NNP\1740 is\VBZ\836236 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 and\CC\1740 ,\,\1740 more\RBR\1740 rarely\RB\1740 ,\,\1740 axonal\JJ\1740 polyneuropathy\NN\1740 .\.\1740
D004977_D011115 CID <e1>Ethambutol</e1>\NNP\1740 is\VBZ\836236 known\VBN\2110220 to\TO\1740 cause\VB\1617192 optic\JJ\1740 neuropathy\JJ\1740 and\CC\1740 ,\,\1740 more\RBR\1740 rarely\RB\1740 ,\,\1740 axonal\JJ\1740 <e2>polyneuropathy</e2>\NN\1740 .\.\1740
D004977_D014786 CID We\PRP\1740 characterize\VBP\609683 the\DT\1740 clinical\JJ\1740 ,\,\1740 neurophysiological\JJ\1740 ,\,\1740 and\CC\1740 neuroimaging\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 72-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 developed\VBD\1753788 <e2>visual\JJ\1740 loss</e2>\NN\13252973 and\CC\1740 paresthesias\NNS\14299637 after\IN\1740 11\CD\13745420 weeks\NNS\15113229 of\IN\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 supratherapeutic\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>ethambutol</e1>\NN\1740 .\.\1740
D004977_D010292 CID We\PRP\1740 characterize\VBP\609683 the\DT\1740 clinical\JJ\1740 ,\,\1740 neurophysiological\JJ\1740 ,\,\1740 and\CC\1740 neuroimaging\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 72-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 developed\VBD\1753788 visual\JJ\1740 loss\NN\13252973 and\CC\1740 <e2>paresthesias</e2>\NNS\14299637 after\IN\1740 11\CD\13745420 weeks\NNS\15113229 of\IN\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 supratherapeutic\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>ethambutol</e1>\NN\1740 .\.\1740
D004977_D064420 NONE This\DT\1740 case\NN\7283608 demonstrates\VBZ\2137132 the\DT\1740 selective\JJ\1740 vulnerability\NN\14540765 of\IN\1740 the\DT\1740 anterior\JJ\1740 visual\JJ\1740 pathways\NNS\5483677 and\CC\1740 peripheral\JJ\1740 nerves\NNS\14373582 to\TO\1740 <e1>ethambutol</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
25071004
C039726_D000740 NONE Delayed\VBN\439958 <e2>anemia</e2>\NN\14189204 after\IN\1740 treatment\NN\654885 with\IN\1740 injectable\JJ\1740 <e1>artesunate</e1>\NN\1740 in\IN\13603305 the\DT\1740 Democratic\NNP\1740 Republic\NNP\8367880 of\IN\1740 the\DT\1740 Congo\NNP\7934530 :\:\1740 a\DT\13649268 manageable\JJ\1740 issue\NN\5809192 .\.\1740
C039726_D000743 CID Cases\NNS\7283608 of\IN\1740 delayed\VBN\439958 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 have\VBP\2108377 been\VBN\836236 described\VBN\1001294 after\IN\1740 treatment\NN\654885 with\IN\1740 injectable\JJ\1740 <e1>artesunate</e1>\NN\1740 ,\,\1740 the\DT\1740 current\JJ\1740 World\NNP\19128 Health\NNP\14447525 Organization\NNP\7950920 (WHO)-recommended\VBD\1740 first-line\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 severe\JJ\1740 malaria\NN\14178913 .\.\1740
C039726_D008288 NONE Cases\NNS\7283608 of\IN\1740 delayed\VBN\439958 hemolytic\JJ\1740 anemia\NN\14189204 have\VBP\2108377 been\VBN\836236 described\VBN\1001294 after\IN\1740 treatment\NN\654885 with\IN\1740 injectable\JJ\1740 <e1>artesunate</e1>\NN\1740 ,\,\1740 the\DT\1740 current\JJ\1740 World\NNP\19128 Health\NNP\14447525 Organization\NNP\7950920 (WHO)-recommended\VBD\1740 first-line\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 severe\JJ\1740 <e2>malaria</e2>\NN\14178913 .\.\1740
C039726_D008288 NONE A\DT\13649268 total\NN\3553 of\IN\1740 350\CD\1740 patients\NNS\9898892 (\-LRB-\1740 215\CD\1740 [\-LRB-\1740 61.4\CD\1740 %\NN\1740 ]\-RRB-\1740 <\XX\1740 5\CD\13741022 years\NNS\15144371 of\IN\1740 age\NN\4916342 and\CC\1740 135\CD\1740 [\-LRB-\1740 38.6\CD\1740 %\NN\1740 ]\-RRB-\1740 >\NNS\1740 5\CD\13741022 years\NNS\15144371 of\IN\1740 age\NN\4916342 )\-RRB-\1740 were\VBD\836236 followed-up\JJ\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 injectable\JJ\1740 <e1>artesunate</e1>\NN\1740 for\IN\1740 severe\JJ\1740 <e2>malaria</e2>\NN\14178913 in\IN\13603305 hospitals\NNS\3739518 and\CC\1740 health\NN\14447525 centers\NNS\8497294 of\IN\1740 the\DT\1740 Democratic\NNP\1740 Republic\NNP\8367880 of\IN\1740 the\DT\1740 Congo\NNP\7934530 .\.\1740
19914299
D005473_D008569 NONE <e1>Fluoxetine</e1>\NN\4169152 improves\VBZ\126264 the\DT\1740 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 caused\VBN\1617192 by\IN\1740 the\DT\1740 chemotherapy\NN\661091 agent\NN\7347 5-fluorouracil\NN\1740 .\.\1740
D005472_D008569 CID Fluoxetine\NN\4169152 improves\VBZ\126264 the\DT\1740 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 caused\VBN\1617192 by\IN\1740 the\DT\1740 chemotherapy\NN\661091 agent\NN\7347 <e1>5-fluorouracil</e1>\NN\1740 .\.\1740
11745287
D016190_D002294 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 <e1>carboplatin</e1>\NN\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 in\IN\13603305 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 cervix</e2>\NN\5225090 .\.\1740
D016190_D002294 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 <e1>carboplatin</e1>\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma</e2>\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxicity\NN\13576101 profile\NN\6999802 .\.\1740
D016190_D002583 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 <e1>carboplatin</e1>\NN\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 in\IN\13603305 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 cervix</e2>\NN\5225090 .\.\1740
D016190_D002583 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 activity\NN\30358 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>carboplatin</e1>\NN\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>cervical\JJ\1740 carcinoma</e2>\NN\14239918 .\.\1740
D016190_D002583 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 <e1>carboplatin</e1>\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma</e2>\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxicity\NN\13576101 profile\NN\6999802 .\.\1740
D016190_D002583 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 <e1>carboplatin</e1>\NN\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 has\VBZ\2108377 modest\JJ\1740 activity\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>cervical\JJ\1740 carcinoma</e2>\NN\14239918 .\.\1740
D004317_D002294 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 carboplatin\NN\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 cervix</e2>\NN\5225090 .\.\1740
D004317_D002294 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma</e2>\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxicity\NN\13576101 profile\NN\6999802 .\.\1740
D004317_D002294 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma</e2>\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxicity\NN\13576101 profile\NN\6999802 .\.\1740
D004317_D002583 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 carboplatin\NN\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 cervix</e2>\NN\5225090 .\.\1740
D004317_D002583 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 activity\NN\30358 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 was\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>cervical\JJ\1740 carcinoma</e2>\NN\14239918 .\.\1740
D004317_D002583 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma</e2>\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxicity\NN\13576101 profile\NN\6999802 .\.\1740
D004317_D002583 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma</e2>\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxicity\NN\13576101 profile\NN\6999802 .\.\1740
D004317_D002583 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 has\VBZ\2108377 modest\JJ\1740 activity\NN\30358 in\IN\13603305 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 <e2>cervical\JJ\1740 carcinoma</e2>\NN\14239918 .\.\1740
D016190_D064420 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 <e1>carboplatin</e1>\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 <e2>toxicity</e2>\NN\13576101 profile\NN\6999802 .\.\1740
D004317_D064420 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 <e2>toxicity</e2>\NN\13576101 profile\NN\6999802 .\.\1740
D004317_D064420 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 carboplatin\NN\1740 (\-LRB-\1740 area\NN\8630985 under\IN\1740 the\DT\1740 concentration\NN\4916342 curve\NN\13863771 [\-LRB-\1740 AUC\NN\1740 ]\-RRB-\1740 ,\,\1740 5\LS\13741022 )\-RRB-\1740 and\CC\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 ;\:\1740 starting\VBG\2009433 dose\NN\3740161 ,\,\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravenously\RB\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 to\IN\1740 37\CD\1740 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 squamous\JJ\1740 cell\NN\3080309 cervical\JJ\1740 carcinoma\NN\14239918 to\TO\1740 determine\VB\1645601 antitumor\NN\1740 activity\NN\30358 and\CC\1740 <e2>toxicity</e2>\NN\13576101 profile\NN\6999802 .\.\1740
10510854
D006220_D002375 CID 7e\NNP\1740 exhibits\VBZ\2632167 a\DT\13649268 high\JJ\1740 reversal\NN\199130 of\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 indicating\VBG\952524 its\PRP$\6125041 atypical\JJ\1740 antipsychotic\JJ\1740 nature\NN\4723816 .\.\1740
1943082
D005978_D007511 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 hepatic\JJ\1740 tissue\NN\5220461 total\JJ\1740 <e1>glutathione</e1>\NN\1740 following\VBG\1835496 intestinal\JJ\1740 <e2>ischemia-reperfusion</e2>\NN\1740 injury\NN\14052046 .\.\1740
D005978_D015427 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 hepatic\JJ\1740 tissue\NN\5220461 total\JJ\1740 <e1>glutathione</e1>\NN\1740 following\VBG\1835496 intestinal\JJ\1740 <e2>ischemia-reperfusion\NN\1740 injury</e2>\NN\14052046 .\.\1740
3074291
C017590_D001249 NONE Comparison\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>oxitropium\NN\1740 bromide</e1>\NN\14904359 and\CC\1740 of\IN\1740 slow-release\JJ\1740 theophylline\NN\2905612 on\IN\1740 nocturnal\JJ\1740 <e2>asthma</e2>\NN\14145095 .\.\1740
C017590_D001249 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 inhaled\VBN\1198101 antimuscarinic\JJ\1740 drug\NN\14778436 ,\,\1740 <e1>oxitropium\NN\1740 bromide</e1>\NN\14904359 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 slow-release\JJ\1740 theophylline\NN\2905612 preparation\NN\407535 upon\IN\1740 nocturnal\JJ\1740 <e2>asthma</e2>\NN\14145095 were\VBD\836236 compared\VBN\644583 in\IN\13603305 a\DT\13649268 placebo-controlled\JJ\1740 double-blind\JJ\1740 study\NN\635850 .\.\1740
C017590_D001249 NONE <e1>Oxitropium</e1>\NN\1740 proves\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 valuable\JJ\1740 alternative\NN\5788149 to\IN\1740 theophylline\NN\2905612 in\IN\13603305 nocturnal\JJ\1740 <e2>asthma</e2>\NN\14145095 ,\,\1740 since\IN\1740 it\PRP\6125041 is\VBZ\836236 equally\RB\1740 potent\JJ\1740 ,\,\1740 safer\JJR\1740 and\CC\1740 does\VBZ\1640855 not\RB\1740 require\VB\754942 the\DT\1740 titration\NN\647713 of\IN\1740 dosage\NN\13576355 .\.\1740
D013806_D001249 NONE Comparison\NN\635850 of\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 oxitropium\NN\1740 bromide\NN\14904359 and\CC\1740 of\IN\1740 slow-release\JJ\1740 <e1>theophylline</e1>\NN\2905612 on\IN\1740 nocturnal\JJ\1740 <e2>asthma</e2>\NN\14145095 .\.\1740
D013806_D001249 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 new\JJ\1740 inhaled\VBN\1198101 antimuscarinic\JJ\1740 drug\NN\14778436 ,\,\1740 oxitropium\NN\1740 bromide\NN\14904359 ,\,\1740 and\CC\1740 of\IN\1740 a\DT\13649268 slow-release\JJ\1740 <e1>theophylline</e1>\NN\2905612 preparation\NN\407535 upon\IN\1740 nocturnal\JJ\1740 <e2>asthma</e2>\NN\14145095 were\VBD\836236 compared\VBN\644583 in\IN\13603305 a\DT\13649268 placebo-controlled\JJ\1740 double-blind\JJ\1740 study\NN\635850 .\.\1740
D013806_D001249 NONE Oxitropium\NN\1740 proves\VBZ\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 valuable\JJ\1740 alternative\NN\5788149 to\IN\1740 <e1>theophylline</e1>\NN\2905612 in\IN\13603305 nocturnal\JJ\1740 <e2>asthma</e2>\NN\14145095 ,\,\1740 since\IN\1740 it\PRP\6125041 is\VBZ\836236 equally\RB\1740 potent\JJ\1740 ,\,\1740 safer\JJR\1740 and\CC\1740 does\VBZ\1640855 not\RB\1740 require\VB\754942 the\DT\1740 titration\NN\647713 of\IN\1740 dosage\NN\13576355 .\.\1740
C017590_D009325 NONE No\DT\7204911 subject\NN\6598915 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>oxitropium</e1>\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 three\CD\13741022 subjects\NNS\6598915 reporting\VBG\831651 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 and\CC\1740 tremors\NNS\345926 after\IN\1740 theophylline\NN\2905612 .\.\1740
C017590_D014839 NONE No\DT\7204911 subject\NN\6598915 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>oxitropium</e1>\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 three\CD\13741022 subjects\NNS\6598915 reporting\VBG\831651 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 and\CC\1740 tremors\NNS\345926 after\IN\1740 theophylline\NN\2905612 .\.\1740
C017590_D014202 NONE No\DT\7204911 subject\NN\6598915 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>oxitropium</e1>\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 three\CD\13741022 subjects\NNS\6598915 reporting\VBG\831651 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 and\CC\1740 <e2>tremors</e2>\NNS\345926 after\IN\1740 theophylline\NN\2905612 .\.\1740
D013806_D009325 CID No\DT\7204911 subject\NN\6598915 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 oxitropium\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 three\CD\13741022 subjects\NNS\6598915 reporting\VBG\831651 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 and\CC\1740 tremors\NNS\345926 after\IN\1740 <e1>theophylline</e1>\NN\2905612 .\.\1740
D013806_D014839 CID No\DT\7204911 subject\NN\6598915 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 oxitropium\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 three\CD\13741022 subjects\NNS\6598915 reporting\VBG\831651 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 and\CC\1740 tremors\NNS\345926 after\IN\1740 <e1>theophylline</e1>\NN\2905612 .\.\1740
D013806_D014202 CID No\DT\7204911 subject\NN\6598915 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 oxitropium\NN\1740 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 three\CD\13741022 subjects\NNS\6598915 reporting\VBG\831651 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 and\CC\1740 <e2>tremors</e2>\NNS\345926 after\IN\1740 <e1>theophylline</e1>\NN\2905612 .\.\1740
19263707
D002231_D056648 CID <e1>Carbimazole</e1>\NNP\1740 induced\VBD\1627355 <e2>ANCA\NN\1740 positive\JJ\1740 vasculitis</e2>\NN\14336539 .\.\1740
D013956_D006980 NONE <e1>Anti-thyroid\JJ\1740 drugs</e1>\NNS\14778436 ,\,\1740 like\UH\5839024 carbimazole\NN\1740 and\CC\1740 propylthiouracil\NN\14727670 (\-LRB-\1740 PTU\NN\1740 )\-RRB-\1740 are\VBP\836236 commonly\RB\1740 prescribed\VBN\748282 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 .\.\1740
D002231_D006980 NONE Anti-thyroid\JJ\1740 drugs\NNS\14778436 ,\,\1740 like\UH\5839024 <e1>carbimazole</e1>\NN\1740 and\CC\1740 propylthiouracil\NN\14727670 (\-LRB-\1740 PTU\NN\1740 )\-RRB-\1740 are\VBP\836236 commonly\RB\1740 prescribed\VBN\748282 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 .\.\1740
D011441_D006980 NONE Anti-thyroid\JJ\1740 drugs\NNS\14778436 ,\,\1740 like\UH\5839024 carbimazole\NN\1740 and\CC\1740 <e1>propylthiouracil</e1>\NN\14727670 (\-LRB-\1740 PTU\NN\1740 )\-RRB-\1740 are\VBP\836236 commonly\RB\1740 prescribed\VBN\748282 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 .\.\1740
D011441_D006980 NONE Anti-thyroid\JJ\1740 drugs\NNS\14778436 ,\,\1740 like\UH\5839024 carbimazole\NN\1740 and\CC\1740 propylthiouracil\NN\14727670 (\-LRB-\1740 <e1>PTU</e1>\NN\1740 )\-RRB-\1740 are\VBP\836236 commonly\RB\1740 prescribed\VBN\748282 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 .\.\1740
D013956_D056648 CID One\PRP\13741022 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 side\NN\8630039 effects\NNS\13245626 of\IN\1740 <e1>antithyroid\NN\1740 medications.</e1>\NN\1740 <e2>Antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (ANCA)--associated\-LRB-\1740 vasculitis</e2>\NN\14336539 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 life-threatening\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 antithyroidmedications\NNS\1740 .\.\1740
D013956_D056648 CID One\PRP\13741022 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 side\NN\8630039 effects\NNS\13245626 of\IN\1740 antithyroid\NN\1740 medications.\NN\1740 <e2>Antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (ANCA)--associated\-LRB-\1740 vasculitis</e2>\NN\14336539 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 life-threatening\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>antithyroidmedications</e1>\NNS\1740 .\.\1740
D002231_D006111 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 who\WP\8299493 developed\VBD\1753788 ANCA\NN\1740 positive\JJ\1740 <e1>carbimazole</e1>\NN\1740 induced\JJ\1740 vasculitis\NN\14336539 .\.\1740
D002231_D014657 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 with\IN\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 who\WP\8299493 developed\VBD\1753788 ANCA\NN\1740 positive\JJ\1740 <e1>carbimazole</e1>\NN\1740 induced\JJ\1740 <e2>vasculitis</e2>\NN\14336539 .\.\1740
D002231_D014657 NONE To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 ANCA\NN\1740 positive\JJ\1740 <e1>carbimazole</e1>\NN\1740 induced\JJ\1740 <e2>vasculitis</e2>\NN\14336539 case\NN\7283608 reported\VBN\831651 from\IN\1740 India\NNP\1740 .\.\1740
816141
D002512_D000743 CID <e1>Cephalothin-induced</e1>\JJ\1740 immune\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D002512_D000743 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 renal\JJ\1740 disease\NN\14061805 developed\VBD\1753788 Coombs-positive\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 while\IN\15122231 receiving\VBG\2210855 <e1>cephalothin</e1>\NN\2996840 therapy\NN\657604 .\.\1740
D002512_D007674 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 developed\VBD\1753788 Coombs-positive\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 while\IN\15122231 receiving\VBG\2210855 <e1>cephalothin</e1>\NN\2996840 therapy\NN\657604 .\.\1740
10960401
D009020_D009759 CID <e2>Downbeat\JJ\1740 nystagmus</e2>\NN\337486 associated\VBN\628491 with\IN\1740 intravenous\JJ\1740 patient-controlled\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>morphine</e1>\NN\2707683 .\.\1740
D009020_D009759 CID IMPLICATIONS\NN\5774614 :\:\1740 This\DT\1740 case\NN\7283608 documents\VBZ\1000214 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 dizziness\NN\14299637 with\IN\1740 <e2>downbeating\VBG\1740 nystagmus</e2>\NN\337486 while\IN\15122231 receiving\VBG\2210855 a\DT\13649268 relatively\RB\1740 large\JJ\1740 dose\NN\3740161 of\IN\1740 IV\CD\13741022 patient-controlled\JJ\1740 analgesia\NN\14034177 <e1>morphine</e1>\NN\2707683 .\.\1740
D009020_D004244 CID IMPLICATIONS\NN\5774614 :\:\1740 This\DT\1740 case\NN\7283608 documents\VBZ\1000214 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>dizziness</e2>\NN\14299637 with\IN\1740 downbeating\VBG\1740 nystagmus\NN\337486 while\IN\15122231 receiving\VBG\2210855 a\DT\13649268 relatively\RB\1740 large\JJ\1740 dose\NN\3740161 of\IN\1740 IV\CD\13741022 patient-controlled\JJ\1740 analgesia\NN\14034177 <e1>morphine</e1>\NN\2707683 .\.\1740
891494
D010672_D001927 CID <e1>Phenytoin</e1>\NN\3550533 <e2>encephalopathy</e2>\JJ\1740 as\IN\14622893 probable\JJ\1740 idiosyncratic\JJ\1740 reaction\NN\13446390 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
D010672_D001927 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 (\-LRB-\1740 DPH\NN\6702458 )\-RRB-\1740 <e2>encephalopathy</e2>\RB\1740 with\IN\1740 increasing\VBG\169651 seizures\NNS\14081375 and\CC\1740 EEG\NN\7000195 and\CC\1740 mental\JJ\1740 changes\NNS\7283608 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010672_D001927 CID A\DT\13649268 case\NN\7283608 of\IN\1740 phenytoin\NN\3550533 (\-LRB-\1740 <e1>DPH</e1>\NN\6702458 )\-RRB-\1740 <e2>encephalopathy</e2>\RB\1740 with\IN\1740 increasing\VBG\169651 seizures\NNS\14081375 and\CC\1740 EEG\NN\7000195 and\CC\1740 mental\JJ\1740 changes\NNS\7283608 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010672_D012640 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 (\-LRB-\1740 DPH\NN\6702458 )\-RRB-\1740 encephalopathy\RB\1740 with\IN\1740 increasing\VBG\169651 <e2>seizures</e2>\NNS\14081375 and\CC\1740 EEG\NN\7000195 and\CC\1740 mental\JJ\1740 changes\NNS\7283608 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010672_D012640 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 phenytoin\NN\3550533 (\-LRB-\1740 <e1>DPH</e1>\NN\6702458 )\-RRB-\1740 encephalopathy\RB\1740 with\IN\1740 increasing\VBG\169651 <e2>seizures</e2>\NNS\14081375 and\CC\1740 EEG\NN\7000195 and\CC\1740 mental\JJ\1740 changes\NNS\7283608 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010672_D012640 NONE The\DT\1740 authors\NNS\9610660 conclude\VBP\628491 that\IN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 starting\VBG\2009433 <e1>DPH</e1>\NN\6702458 treatment\NN\654885 an\DT\6697703 unexpected\JJ\1740 increase\NN\13576355 in\IN\13603305 <e2>seizures</e2>\NNS\14081375 ,\,\1740 with\IN\1740 EEG\NN\7000195 and\CC\1740 mental\JJ\1740 changes\NNS\7283608 occurring\VBG\2623529 simultaneously\RB\1740 ,\,\1740 should\MD\1740 alert\VB\870213 the\DT\1740 physician\NN\10305802 to\IN\1740 the\DT\1740 possible\JJ\1740 need\NN\13920835 for\IN\1740 eliminating\VBG\1619929 DPH\NN\6702458 from\IN\1740 the\DT\1740 therapeutic\JJ\1740 regimen\NN\5898568 ,\,\1740 even\RB\1740 if\IN\1740 plasma\NN\5398023 concentrations\NNS\4916342 are\VBP\836236 low\JJ\1740 .\.\1740
D010672_D012640 NONE The\DT\1740 authors\NNS\9610660 conclude\VBP\628491 that\IN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 starting\VBG\2009433 DPH\NN\6702458 treatment\NN\654885 an\DT\6697703 unexpected\JJ\1740 increase\NN\13576355 in\IN\13603305 <e2>seizures</e2>\NNS\14081375 ,\,\1740 with\IN\1740 EEG\NN\7000195 and\CC\1740 mental\JJ\1740 changes\NNS\7283608 occurring\VBG\2623529 simultaneously\RB\1740 ,\,\1740 should\MD\1740 alert\VB\870213 the\DT\1740 physician\NN\10305802 to\IN\1740 the\DT\1740 possible\JJ\1740 need\NN\13920835 for\IN\1740 eliminating\VBG\1619929 <e1>DPH</e1>\NN\6702458 from\IN\1740 the\DT\1740 therapeutic\JJ\1740 regimen\NN\5898568 ,\,\1740 even\RB\1740 if\IN\1740 plasma\NN\5398023 concentrations\NNS\4916342 are\VBP\836236 low\JJ\1740 .\.\1740
D010672_D005076 NONE In\IN\13603305 fact\NN\5816287 the\DT\1740 concentration\NN\4916342 of\IN\1740 free\JJ\1740 <e1>DPH</e1>\NN\6702458 was\VBD\836236 normal\JJ\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 a\DT\13649268 retarded\VBN\438495 morbilliform\NN\1740 <e2>rash</e2>\NN\14321469 during\IN\1740 DPH\NN\6702458 treatment\NN\654885 ,\,\1740 the\DT\1740 protidogram\NN\1740 was\VBD\836236 normal\JJ\1740 ,\,\1740 and\CC\1740 an\DT\6697703 intradermic\JJ\1740 DPH\NN\6702458 injection\NN\320852 had\VBD\2108377 no\DT\7204911 local\JJ\1740 effect\NN\34213 .\.\1740
D010672_D005076 NONE In\IN\13603305 fact\NN\5816287 the\DT\1740 concentration\NN\4916342 of\IN\1740 free\JJ\1740 DPH\NN\6702458 was\VBD\836236 normal\JJ\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 a\DT\13649268 retarded\VBN\438495 morbilliform\NN\1740 <e2>rash</e2>\NN\14321469 during\IN\1740 <e1>DPH</e1>\NN\6702458 treatment\NN\654885 ,\,\1740 the\DT\1740 protidogram\NN\1740 was\VBD\836236 normal\JJ\1740 ,\,\1740 and\CC\1740 an\DT\6697703 intradermic\JJ\1740 DPH\NN\6702458 injection\NN\320852 had\VBD\2108377 no\DT\7204911 local\JJ\1740 effect\NN\34213 .\.\1740
D010672_D005076 NONE In\IN\13603305 fact\NN\5816287 the\DT\1740 concentration\NN\4916342 of\IN\1740 free\JJ\1740 DPH\NN\6702458 was\VBD\836236 normal\JJ\1740 ,\,\1740 the\DT\1740 patient\NN\9898892 presented\VBD\2137132 a\DT\13649268 retarded\VBN\438495 morbilliform\NN\1740 <e2>rash</e2>\NN\14321469 during\IN\1740 DPH\NN\6702458 treatment\NN\654885 ,\,\1740 the\DT\1740 protidogram\NN\1740 was\VBD\836236 normal\JJ\1740 ,\,\1740 and\CC\1740 an\DT\6697703 intradermic\JJ\1740 <e1>DPH</e1>\NN\6702458 injection\NN\320852 had\VBD\2108377 no\DT\7204911 local\JJ\1740 effect\NN\34213 .\.\1740
11915580
D005996_D004412 NONE A\DT\13649268 comparison\NN\635850 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 with\IN\1740 diclofenac\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 :\:\1740 an\DT\6697703 open\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 cross-over\JJ\1740 trial\NN\786195 .\.\1740
D005996_D004412 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>glyceryl\NN\14621446 trinitrate</e1>\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 NO\NN\7204911 donor\NN\9608709 ,\,\1740 in\IN\13603305 the\DT\1740 resolution\NN\6470073 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 in\IN\13603305 comparison\NN\635850 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 DCF\NNP\1740 )\-RRB-\1740 .\.\1740
D005996_D004412 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 efficacy\NN\5199286 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 <e1>GTN</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 NO\NN\7204911 donor\NN\9608709 ,\,\1740 in\IN\13603305 the\DT\1740 resolution\NN\6470073 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 in\IN\13603305 comparison\NN\635850 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 DCF\NNP\1740 )\-RRB-\1740 .\.\1740
D005996_D004412 NONE These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>GTN</e1>\NN\1740 has\VBZ\2108377 a\DT\13649268 reduced\VBN\441445 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 by\IN\1740 comparison\NN\635850 with\IN\1740 DCF\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 .\.\1740
D004008_D004412 NONE A\DT\13649268 comparison\NN\635850 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 with\IN\1740 <e1>diclofenac</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 :\:\1740 an\DT\6697703 open\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 cross-over\JJ\1740 trial\NN\786195 .\.\1740
D004008_D004412 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 efficacy\NN\5199286 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 NO\NN\7204911 donor\NN\9608709 ,\,\1740 in\IN\13603305 the\DT\1740 resolution\NN\6470073 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 in\IN\13603305 comparison\NN\635850 with\IN\1740 <e1>diclofenac</e1>\NN\1740 (\-LRB-\1740 DCF\NNP\1740 )\-RRB-\1740 .\.\1740
D004008_D004412 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 efficacy\NN\5199286 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 NO\NN\7204911 donor\NN\9608709 ,\,\1740 in\IN\13603305 the\DT\1740 resolution\NN\6470073 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 in\IN\13603305 comparison\NN\635850 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 <e1>DCF</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D004008_D004412 NONE These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 GTN\NN\1740 has\VBZ\2108377 a\DT\13649268 reduced\VBN\441445 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 by\IN\1740 comparison\NN\635850 with\IN\1740 <e1>DCF</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 .\.\1740
D011453_D004412 NONE Primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 is\VBZ\836236 a\DT\13649268 syndrome\NN\5870365 characterized\VBN\609683 by\IN\1740 painful\JJ\1740 uterine\NN\1740 contractility\NN\5200169 caused\VBN\1617192 by\IN\1740 a\DT\13649268 hypersecretion\NN\13553916 of\IN\1740 endometrial\JJ\1740 <e1>prostaglandins</e1>\NNS\5414534 ;\:\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 are\VBP\836236 the\DT\1740 first\JJ\1740 choice\NN\5788149 for\IN\1740 its\PRP$\6125041 treatment\NN\654885 .\.\1740
D009569_D004412 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 efficacy\NN\5199286 of\IN\1740 glyceryl\NN\14621446 trinitrate\NN\1740 (\-LRB-\1740 GTN\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 <e1>NO</e1>\NN\7204911 donor\NN\9608709 ,\,\1740 in\IN\13603305 the\DT\1740 resolution\NN\6470073 of\IN\1740 primary\JJ\1740 <e2>dysmenorrhea</e2>\NN\14322699 in\IN\13603305 comparison\NN\635850 with\IN\1740 diclofenac\NN\1740 (\-LRB-\1740 DCF\NNP\1740 )\-RRB-\1740 .\.\1740
D004008_D017699 NONE However\RB\1740 ,\,\1740 <e1>DCF</e1>\NNP\1740 continued\VBD\2367363 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 reducing\VBG\441445 <e2>pelvic\JJ\1740 pain</e2>\NN\14299637 for\IN\1740 two\CD\13741022 hours\NNS\15118228 ,\,\1740 whereas\IN\1740 GTN\NN\1740 scores\NNS\13757724 remained\VBD\2604760 more\RBR\1740 or\CC\3541091 less\RBR\1740 stable\JJ\1740 after\IN\1740 30\CD\13745420 min\NN\15154774 and\CC\1740 significantly\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 for\IN\1740 DFC\NN\1740 (\-LRB-\1740 after\IN\1740 one\CD\13741022 hour\NN\15154774 :\:\1740 GTN\NN\1740 ,\,\1740 -12.8\NN\1740 +/-\CC\1740 17.9\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -18.9\NN\1740 +/-\CC\1740 16.6\CD\1740 and\CC\1740 after\IN\1740 two\CD\13741022 hours\NNS\15118228 :\:\1740 GTN\NN\1740 ,\,\1740 -23.7\NNS\1740 +/-\CC\1740 20.5\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -59.7\CD\1740 +/-\CC\1740 17.9\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D005996_D017699 NONE However\RB\1740 ,\,\1740 DCF\NNP\1740 continued\VBD\2367363 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 reducing\VBG\441445 <e2>pelvic\JJ\1740 pain</e2>\NN\14299637 for\IN\1740 two\CD\13741022 hours\NNS\15118228 ,\,\1740 whereas\IN\1740 <e1>GTN</e1>\NN\1740 scores\NNS\13757724 remained\VBD\2604760 more\RBR\1740 or\CC\3541091 less\RBR\1740 stable\JJ\1740 after\IN\1740 30\CD\13745420 min\NN\15154774 and\CC\1740 significantly\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 for\IN\1740 DFC\NN\1740 (\-LRB-\1740 after\IN\1740 one\CD\13741022 hour\NN\15154774 :\:\1740 GTN\NN\1740 ,\,\1740 -12.8\NN\1740 +/-\CC\1740 17.9\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -18.9\NN\1740 +/-\CC\1740 16.6\CD\1740 and\CC\1740 after\IN\1740 two\CD\13741022 hours\NNS\15118228 :\:\1740 GTN\NN\1740 ,\,\1740 -23.7\NNS\1740 +/-\CC\1740 20.5\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -59.7\CD\1740 +/-\CC\1740 17.9\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D005996_D017699 NONE However\RB\1740 ,\,\1740 DCF\NNP\1740 continued\VBD\2367363 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 reducing\VBG\441445 <e2>pelvic\JJ\1740 pain</e2>\NN\14299637 for\IN\1740 two\CD\13741022 hours\NNS\15118228 ,\,\1740 whereas\IN\1740 GTN\NN\1740 scores\NNS\13757724 remained\VBD\2604760 more\RBR\1740 or\CC\3541091 less\RBR\1740 stable\JJ\1740 after\IN\1740 30\CD\13745420 min\NN\15154774 and\CC\1740 significantly\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 for\IN\1740 DFC\NN\1740 (\-LRB-\1740 after\IN\1740 one\CD\13741022 hour\NN\15154774 :\:\1740 <e1>GTN</e1>\NN\1740 ,\,\1740 -12.8\NN\1740 +/-\CC\1740 17.9\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -18.9\NN\1740 +/-\CC\1740 16.6\CD\1740 and\CC\1740 after\IN\1740 two\CD\13741022 hours\NNS\15118228 :\:\1740 GTN\NN\1740 ,\,\1740 -23.7\NNS\1740 +/-\CC\1740 20.5\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -59.7\CD\1740 +/-\CC\1740 17.9\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D005996_D017699 NONE However\RB\1740 ,\,\1740 DCF\NNP\1740 continued\VBD\2367363 to\TO\1740 be\VB\836236 effective\JJ\1740 in\IN\13603305 reducing\VBG\441445 <e2>pelvic\JJ\1740 pain</e2>\NN\14299637 for\IN\1740 two\CD\13741022 hours\NNS\15118228 ,\,\1740 whereas\IN\1740 GTN\NN\1740 scores\NNS\13757724 remained\VBD\2604760 more\RBR\1740 or\CC\3541091 less\RBR\1740 stable\JJ\1740 after\IN\1740 30\CD\13745420 min\NN\15154774 and\CC\1740 significantly\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 for\IN\1740 DFC\NN\1740 (\-LRB-\1740 after\IN\1740 one\CD\13741022 hour\NN\15154774 :\:\1740 GTN\NN\1740 ,\,\1740 -12.8\NN\1740 +/-\CC\1740 17.9\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -18.9\NN\1740 +/-\CC\1740 16.6\CD\1740 and\CC\1740 after\IN\1740 two\CD\13741022 hours\NNS\15118228 :\:\1740 <e1>GTN</e1>\NN\1740 ,\,\1740 -23.7\NNS\1740 +/-\CC\1740 20.5\CD\1740 ;\:\1740 DFC\NN\1740 ,\,\1740 -59.7\CD\1740 +/-\CC\1740 17.9\CD\1740 ,\,\1740 p\NN\14622893 =\JJ\1740 0.0001\CD\1740 )\-RRB-\1740 .\.\1740
D005996_D006261 CID <e2>Headache</e2>\NNP\5829480 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 by\IN\1740 <e1>GTN</e1>\NN\1740 but\CC\1740 not\RB\1740 by\IN\1740 DCF\NNP\1740 .\.\1740
D005996_D006261 CID Eight\CD\13741022 patients\NNS\9898892 stopped\VBD\2452885 using\VBG\1156834 <e1>GTN</e1>\NN\1740 because\IN\1740 <e2>headache</e2>\NN\5829480 --\:\1740 attributed\VBN\670261 to\TO\1740 its\PRP$\6125041 use\NN\407535 --\:\1740 became\VBD\146138 intolerable\JJ\1740 .\.\1740
D004008_D006261 NONE <e2>Headache</e2>\NNP\5829480 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 by\IN\1740 GTN\NN\1740 but\CC\1740 not\RB\1740 by\IN\1740 <e1>DCF</e1>\NNP\1740 .\.\1740
24190587
D018817_D008107 NONE RATIONALE\NN\5793000 :\:\1740 <e1>Ecstasy</e1>\NNP\13985818 (\-LRB-\1740 MDMA\NNP\3054098 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 psychostimulant\NN\1740 drug\NN\14778436 which\WDT\1740 is\VBZ\836236 increasingly\RB\1740 associated\VBN\628491 with\IN\1740 <e2>psychobiological\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D018817_D008107 NONE RATIONALE\NN\5793000 :\:\1740 Ecstasy\NNP\13985818 (\-LRB-\1740 <e1>MDMA</e1>\NNP\3054098 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 psychostimulant\NN\1740 drug\NN\14778436 which\WDT\1740 is\VBZ\836236 increasingly\RB\1740 associated\VBN\628491 with\IN\1740 <e2>psychobiological\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D018817_D001008 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 increases\NNS\13576355 in\IN\13603305 <e2>anxiety</e2>\NN\14373582 and\CC\1740 depression\NN\14373582 are\VBP\836236 in\IN\13603305 line\NN\8426461 with\IN\1740 previous\JJ\1740 observations\NNS\996969 in\IN\13603305 recreational\JJ\1740 <e1>ecstasy-polydrug</e1>\JJ\1740 users\NNS\7846 .\.\1740
D018817_D003866 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 increases\NNS\13576355 in\IN\13603305 anxiety\NN\14373582 and\CC\1740 <e2>depression</e2>\NN\14373582 are\VBP\836236 in\IN\13603305 line\NN\8426461 with\IN\1740 previous\JJ\1740 observations\NNS\996969 in\IN\13603305 recreational\JJ\1740 <e1>ecstasy-polydrug</e1>\JJ\1740 users\NNS\7846 .\.\1740
35781
D003000_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 <e1>clonidine</e1>\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003000_D002375 CID Codeine\NN\2707683 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 increased\VBN\169651 by\IN\1740 <e1>clonidine</e1>\NN\2721160 and\CC\1740 decreased\VBN\169651 by\IN\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 .\.\1740
D009278_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 <e1>naphazoline</e1>\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009278_D002375 CID Codeine\NN\2707683 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 increased\VBN\169651 by\IN\1740 clonidine\NN\2721160 and\CC\1740 decreased\VBN\169651 by\IN\1740 <e1>naphazoline</e1>\NN\3809939 and\CC\1740 xylometazoline\NN\1740 .\.\1740
C009695_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 <e1>xylometazoline</e1>\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
C009695_D002375 CID Codeine\NN\2707683 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 increased\VBN\169651 by\IN\1740 clonidine\NN\2721160 and\CC\1740 decreased\VBN\169651 by\IN\1740 naphazoline\NN\3809939 and\CC\1740 <e1>xylometazoline</e1>\NN\1740 .\.\1740
D009020_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009020_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>morphine</e1>\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009020_D002375 CID It\PRP\6125041 was\VBD\836236 found\VBN\2426171 that\IN\1740 three\CD\13741022 drugs\NNS\14778436 stimulating\VBG\137313 central\JJ\1740 NA\NN\14625458 receptors\NNS\5225602 failed\VBD\1798936 to\TO\1740 affect\VB\126264 the\DT\1740 analgesic\JJ\1740 ED50\NN\1740 of\IN\1740 all\DT\1740 antinociceptive\JJ\1740 agents\NNS\7347 and\CC\1740 they\PRP\1740 enhanced\VBD\227165 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 fentanyl\NN\2707683 .\.\1740
D003061_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 <e1>codeine</e1>\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003061_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 <e1>codine</e1>\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003061_D002375 CID <e1>Codeine</e1>\NN\2707683 <e2>catalepsy</e2>\NN\14023236 was\VBD\836236 increased\VBN\169651 by\IN\1740 clonidine\NN\2721160 and\CC\1740 decreased\VBN\169651 by\IN\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 .\.\1740
D005283_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 <e1>fentanyl</e1>\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005283_D002375 CID The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 pentazocine\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 <e1>fentanyl</e1>\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005283_D002375 CID It\PRP\6125041 was\VBD\836236 found\VBN\2426171 that\IN\1740 three\CD\13741022 drugs\NNS\14778436 stimulating\VBG\137313 central\JJ\1740 NA\NN\14625458 receptors\NNS\5225602 failed\VBD\1798936 to\TO\1740 affect\VB\126264 the\DT\1740 analgesic\JJ\1740 ED50\NN\1740 of\IN\1740 all\DT\1740 antinociceptive\JJ\1740 agents\NNS\7347 and\CC\1740 they\PRP\1740 enhanced\VBD\227165 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 and\CC\1740 <e1>fentanyl</e1>\NN\2707683 .\.\1740
D010423_D002375 NONE The\DT\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 ,\,\1740 naphazoline\NN\3809939 and\CC\1740 xylometazoline\NN\1740 on\IN\1740 analgesia\NN\14034177 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 ,\,\1740 codeine\NN\2707683 ,\,\1740 fentanyl\NN\2707683 and\CC\1740 <e1>pentazocine</e1>\NN\2707683 ,\,\1740 and\CC\1740 on\IN\1740 <e2>cataleptic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 ,\,\1740 codine\NN\1740 and\CC\1740 fentanyl\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009638_D002375 NONE It\PRP\6125041 was\VBD\836236 found\VBN\2426171 that\IN\1740 three\CD\13741022 drugs\NNS\14778436 stimulating\VBG\137313 central\JJ\1740 <e1>NA</e1>\NN\14625458 receptors\NNS\5225602 failed\VBD\1798936 to\TO\1740 affect\VB\126264 the\DT\1740 analgesic\JJ\1740 ED50\NN\1740 of\IN\1740 all\DT\1740 antinociceptive\JJ\1740 agents\NNS\7347 and\CC\1740 they\PRP\1740 enhanced\VBD\227165 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 morphine\NN\2707683 and\CC\1740 fentanyl\NN\2707683 .\.\1740
6310832
D016572_D007239 CID Early\JJ\1740 <e2>infections</e2>\NNS\14052046 in\IN\13603305 kidney\NN\5333259 ,\,\1740 heart\NN\5919034 ,\,\1740 and\CC\1740 liver\NN\5298729 transplant\NN\5267548 recipients\NNS\9764201 on\IN\1740 <e1>cyclosporine</e1>\NN\1740 .\.\1740
D016572_D007239 CID The\DT\1740 randomized\JJ\1740 Aza\NN\1740 patients\NNS\9898892 had\VBD\2108377 more\RBR\1740 overall\JJ\1740 <e2>infections</e2>\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 more\JJR\1740 nonviral\JJ\1740 infections\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 than\IN\1740 the\DT\1740 randomized\VBN\278117 <e1>cyclosporine</e1>\NN\1740 patients\NNS\9898892 .\.\1740
D016572_D007239 CID The\DT\1740 randomized\JJ\1740 Aza\NN\1740 patients\NNS\9898892 had\VBD\2108377 more\RBR\1740 overall\JJ\1740 infections\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 more\JJR\1740 nonviral\JJ\1740 <e2>infections</e2>\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 than\IN\1740 the\DT\1740 randomized\VBN\278117 <e1>cyclosporine</e1>\NN\1740 patients\NNS\9898892 .\.\1740
D016572_D007239 CID Heart\NNP\5919034 and\CC\1740 liver\NN\5298729 patients\NNS\9898892 had\VBD\2108377 more\JJR\1740 <e2>infections</e2>\NNS\14052046 than\IN\1740 <e1>cyclosporine</e1>\NN\1740 renal\JJ\1740 patients\NNS\9898892 but\CC\1740 fewer\JJR\1740 infections\NNS\14052046 than\IN\1740 the\DT\1740 Aza\NN\1740 renal\JJ\1740 patients\NNS\9898892 .\.\1740
D016572_D007239 CID Heart\NNP\5919034 and\CC\1740 liver\NN\5298729 patients\NNS\9898892 had\VBD\2108377 more\JJR\1740 infections\NNS\14052046 than\IN\1740 <e1>cyclosporine</e1>\NN\1740 renal\JJ\1740 patients\NNS\9898892 but\CC\1740 fewer\JJR\1740 <e2>infections</e2>\NNS\14052046 than\IN\1740 the\DT\1740 Aza\NN\1740 renal\JJ\1740 patients\NNS\9898892 .\.\1740
D016572_D007239 CID There\EX\27167 were\VBD\836236 no\DT\7204911 infectious\JJ\1740 deaths\NNS\7296428 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 on\IN\1740 <e1>cyclosporine</e1>\NN\1740 or\CC\3541091 Aza\NN\1740 ,\,\1740 but\CC\1740 <e2>infection</e2>\NN\14052046 played\VBD\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 3\CD\13741022 out\IN\66636 of\IN\1740 6\CD\13741022 cardiac\JJ\1740 transplant\NN\5267548 deaths\NNS\7296428 and\CC\1740 in\IN\13603305 8\CD\13741022 out\IN\66636 of\IN\1740 9\CD\13741022 liver\NN\5298729 transplant\NN\5267548 deaths\NNS\7296428 .\.\1740
D016572_D007239 CID Pulmonary\JJ\1740 <e2>infections</e2>\NNS\14052046 were\VBD\836236 less\RBR\1740 common\JJ\1740 in\IN\13603305 <e1>cyclosporine-treated</e1>\JJ\1740 renal\JJ\1740 patients\NNS\9898892 than\IN\1740 in\IN\13603305 Aza-treated\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D001379_D007239 CID The\DT\1740 randomized\JJ\1740 <e1>Aza</e1>\NN\1740 patients\NNS\9898892 had\VBD\2108377 more\RBR\1740 overall\JJ\1740 <e2>infections</e2>\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 more\JJR\1740 nonviral\JJ\1740 infections\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 than\IN\1740 the\DT\1740 randomized\VBN\278117 cyclosporine\NN\1740 patients\NNS\9898892 .\.\1740
D001379_D007239 CID The\DT\1740 randomized\JJ\1740 <e1>Aza</e1>\NN\1740 patients\NNS\9898892 had\VBD\2108377 more\RBR\1740 overall\JJ\1740 infections\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 more\JJR\1740 nonviral\JJ\1740 <e2>infections</e2>\NNS\14052046 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 than\IN\1740 the\DT\1740 randomized\VBN\278117 cyclosporine\NN\1740 patients\NNS\9898892 .\.\1740
D001379_D007239 CID Heart\NNP\5919034 and\CC\1740 liver\NN\5298729 patients\NNS\9898892 had\VBD\2108377 more\JJR\1740 <e2>infections</e2>\NNS\14052046 than\IN\1740 cyclosporine\NN\1740 renal\JJ\1740 patients\NNS\9898892 but\CC\1740 fewer\JJR\1740 infections\NNS\14052046 than\IN\1740 the\DT\1740 <e1>Aza</e1>\NN\1740 renal\JJ\1740 patients\NNS\9898892 .\.\1740
D001379_D007239 CID Heart\NNP\5919034 and\CC\1740 liver\NN\5298729 patients\NNS\9898892 had\VBD\2108377 more\JJR\1740 infections\NNS\14052046 than\IN\1740 cyclosporine\NN\1740 renal\JJ\1740 patients\NNS\9898892 but\CC\1740 fewer\JJR\1740 <e2>infections</e2>\NNS\14052046 than\IN\1740 the\DT\1740 <e1>Aza</e1>\NN\1740 renal\JJ\1740 patients\NNS\9898892 .\.\1740
D001379_D007239 CID There\EX\27167 were\VBD\836236 no\DT\7204911 infectious\JJ\1740 deaths\NNS\7296428 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 on\IN\1740 cyclosporine\NN\1740 or\CC\3541091 <e1>Aza</e1>\NN\1740 ,\,\1740 but\CC\1740 <e2>infection</e2>\NN\14052046 played\VBD\1072262 a\DT\13649268 major\JJ\1740 role\NN\719494 in\IN\13603305 3\CD\13741022 out\IN\66636 of\IN\1740 6\CD\13741022 cardiac\JJ\1740 transplant\NN\5267548 deaths\NNS\7296428 and\CC\1740 in\IN\13603305 8\CD\13741022 out\IN\66636 of\IN\1740 9\CD\13741022 liver\NN\5298729 transplant\NN\5267548 deaths\NNS\7296428 .\.\1740
D001379_D007239 CID Pulmonary\JJ\1740 <e2>infections</e2>\NNS\14052046 were\VBD\836236 less\RBR\1740 common\JJ\1740 in\IN\13603305 cyclosporine-treated\JJ\1740 renal\JJ\1740 patients\NNS\9898892 than\IN\1740 in\IN\13603305 <e1>Aza-treated</e1>\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D016572_D016470 NONE Renal\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>cyclosporine</e1>\NN\1740 had\VBD\2108377 the\DT\1740 fewest\JJS\1740 <e2>bacteremias</e2>\NNS\14204950 .\.\1740
D001379_D013203 NONE <e1>Aza</e1>\NN\1740 patients\NNS\9898892 had\VBD\2108377 significantly\RB\1740 more\RBR\1740 <e2>staphylococcal\JJ\1740 infections</e2>\NNS\14052046 than\IN\1740 all\DT\1740 other\JJ\1740 transplant\NN\5267548 groups\NNS\2137 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 systemic\JJ\1740 fungal\JJ\1740 infections\NNS\14052046 occurred\VBD\2623529 only\RB\1740 in\IN\13603305 the\DT\1740 liver\NN\5298729 transplant\NN\5267548 group\NN\2137 .\.\1740
D001379_D009181 NONE <e1>Aza</e1>\NN\1740 patients\NNS\9898892 had\VBD\2108377 significantly\RB\1740 more\RBR\1740 staphylococcal\JJ\1740 infections\NNS\14052046 than\IN\1740 all\DT\1740 other\JJ\1740 transplant\NN\5267548 groups\NNS\2137 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 systemic\JJ\1740 <e2>fungal\JJ\1740 infections</e2>\NNS\14052046 occurred\VBD\2623529 only\RB\1740 in\IN\13603305 the\DT\1740 liver\NN\5298729 transplant\NN\5267548 group\NN\2137 .\.\1740
D016572_D003586 NONE Of\IN\1740 the\DT\1740 <e1>cyclosporine</e1>\NN\1740 patients\NNS\9898892 ,\,\1740 15\CD\13745420 %\NN\1740 had\VBD\2108377 symptoms\NNS\5823932 related\JJ\1740 to\TO\1740 <e2>CMV\NN\1338685 infection</e2>\NN\14052046 .\.\1740
D016572_D020031 NONE Serological\JJ\1740 evidence\NN\5816287 for\IN\1740 <e2>Epstein\NN\1740 Barr\NN\1740 Virus\NN\9312843 infection</e2>\NN\14052046 was\VBD\836236 found\VBN\2426171 in\IN\13603305 20\CD\13745420 %\NN\1740 of\IN\1740 65\CD\1740 <e1>cyclosporine</e1>\NN\1740 patients\NNS\9898892 studied\VBN\630380 .\.\1740
8096565
D018170_D009203 CID Transmural\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 with\IN\1740 <e1>sumatriptan</e1>\NN\1740 .\.\1740
D018170_D009203 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 47-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 an\DT\6697703 acute\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>sumatriptan</e1>\NN\1740 6\CD\13741022 mg\NN\13717155 subcutaneously\RB\1740 for\IN\1740 cluster\NN\7959269 headache\NN\5829480 .\.\1740
D018170_D003027 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 47-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 an\DT\6697703 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>sumatriptan</e1>\NN\1740 6\CD\13741022 mg\NN\13717155 subcutaneously\RB\1740 for\IN\1740 <e2>cluster\NN\7959269 headache</e2>\NN\5829480 .\.\1740
16876986
D010862_D012640 CID Physical\JJ\1740 training\NN\407535 decreases\VBZ\169651 susceptibility\NN\13920835 to\TO\1740 subsequent\JJ\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D010862_D012640 CID Thereafter\RB\1740 ,\,\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 injections\NNS\320852 in\IN\13603305 trained\VBN\829107 and\CC\1740 non-trained\JJ\1740 control\NN\5190804 groups\NNS\2137 .\.\1740
946593
D008727_D010264 CID <e2>Paraplegia</e2>\NNP\14558226 following\VBG\1835496 intrathecal\JJ\1740 <e1>methotrexate</e1>\NN\2722166 :\:\1740 report\NN\6470073 of\IN\1740 a\DT\13649268 case\NN\7283608 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D008727_D010264 CID A\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>paraplegia</e2>\NN\14558226 following\VBG\1835496 the\DT\1740 intrathecal\JJ\1740 instillation\NN\320852 of\IN\1740 <e1>methotrexate</e1>\NN\2722166 is\VBZ\836236 discribed\VBN\1740 .\.\1740
D008727_D002493 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 <e1>methothexate</e1>\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 methotrexate\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 neurotoxic\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 methotrexate\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 methotrexate\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D002493 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 methothexate\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 <e1>methotrexate</e1>\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 neurotoxic\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 methotrexate\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 methotrexate\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D002493 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 methothexate\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 methotrexate\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 neurotoxic\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 <e1>methotrexate</e1>\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 methotrexate\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D002493 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 methothexate\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 methotrexate\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 neurotoxic\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 methotrexate\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>methotrexate</e1>\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D002493 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 neurotoxicity\NN\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 by\IN\1740 employing\VBG\1740 lower\JJR\1740 doses\NNS\3740161 of\IN\1740 <e1>methotrexate</e1>\NN\2722166 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia</e2>\NN\14239918 ,\,\1740 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ,\,\1740 and\CC\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 epidural\JJ\1740 leakage\NN\7407777 .\.\1740
D008727_D020258 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 <e1>methothexate</e1>\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 methotrexate\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 methotrexate\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 methotrexate\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D020258 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 methothexate\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 <e1>methotrexate</e1>\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 methotrexate\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 methotrexate\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D020258 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 methothexate\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 methotrexate\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 <e1>methotrexate</e1>\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 methotrexate\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D020258 NONE The\DT\1740 following\VBG\1835496 factors\NNS\7326557 appear\VBP\2604760 to\TO\1740 predispose\VB\680841 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 this\DT\1740 complication\NN\1073995 :\:\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 dynamics\NNS\6100236 related\JJ\1740 to\TO\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia\NN\14239918 ,\,\1740 and\CC\1740 epidural\JJ\1740 cerebrospinal\JJ\1740 leakage\NN\7407777 ;\:\1740 elevated\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 methothexate\NN\1740 concentration\NN\4916342 related\JJ\1740 to\TO\1740 abnormal\JJ\1740 cerebrospinal\JJ\1740 fluid\NN\19613 dynamics\NNS\6100236 and\CC\1740 to\TO\1740 inappropriately\RB\1740 high\JJ\1740 methotrexate\NN\2722166 doses\NNS\3740161 based\VBN\2694933 on\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 calculations\NNS\1023820 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ;\:\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 preservatives\NNS\14818238 in\IN\13603305 commercially\RB\1740 available\JJ\1740 methotrexate\NN\2722166 preparations\NNS\407535 and\CC\1740 diluents\NNS\14778436 ;\:\1740 and\CC\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>methotrexate</e1>\JJ\1740 diluents\NNS\14778436 of\IN\1740 unphysiologic\JJ\1740 pH\NN\5038959 ,\,\1740 ionic\JJ\1740 content\NN\7951464 and\CC\1740 osmolarity\NN\1740 .\.\1740
D008727_D020258 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 may\MD\15209706 be\VB\836236 reduced\VBN\441445 by\IN\1740 employing\VBG\1740 lower\JJR\1740 doses\NNS\3740161 of\IN\1740 <e1>methotrexate</e1>\NN\2722166 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 leukemia\NN\14239918 ,\,\1740 in\IN\13603305 older\JJR\1740 children\NNS\9622049 and\CC\1740 adults\NNS\7846 ,\,\1740 and\CC\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 epidural\JJ\1740 leakage\NN\7407777 .\.\1740
D008727_D020258 NONE Periodic\JJ\1740 monitoring\NN\879759 of\IN\1740 cerebruspinal\JJ\1740 fluid\NN\19613 <e1>methotrexate</e1>\NN\2722166 levels\NNS\4916342 may\MD\15209706 be\VB\836236 predictive\JJ\1740 of\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 serious\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008727_C536409 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>methotrexate</e1>\JJ\1740 contaminants\NNS\14580897 ,\,\1740 local\JJ\1740 <e2>folate\NN\15090742 deficiency</e2>\NN\14449126 ,\,\1740 and\CC\1740 cranial\JJ\1740 irradiation\NN\13920835 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 intrathecal\JJ\1740 methotrexate\NN\2722166 toxicity\NN\13576101 is\VBZ\836236 unclear\JJ\1740 .\.\1740
D008727_C536409 NONE The\DT\1740 role\NN\719494 of\IN\1740 methotrexate\JJ\1740 contaminants\NNS\14580897 ,\,\1740 local\JJ\1740 <e2>folate\NN\15090742 deficiency</e2>\NN\14449126 ,\,\1740 and\CC\1740 cranial\JJ\1740 irradiation\NN\13920835 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 intrathecal\JJ\1740 <e1>methotrexate</e1>\NN\2722166 toxicity\NN\13576101 is\VBZ\836236 unclear\JJ\1740 .\.\1740
D008727_D064420 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>methotrexate</e1>\JJ\1740 contaminants\NNS\14580897 ,\,\1740 local\JJ\1740 folate\NN\15090742 deficiency\NN\14449126 ,\,\1740 and\CC\1740 cranial\JJ\1740 irradiation\NN\13920835 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 intrathecal\JJ\1740 methotrexate\NN\2722166 <e2>toxicity</e2>\NN\13576101 is\VBZ\836236 unclear\JJ\1740 .\.\1740
D008727_D064420 NONE The\DT\1740 role\NN\719494 of\IN\1740 methotrexate\JJ\1740 contaminants\NNS\14580897 ,\,\1740 local\JJ\1740 folate\NN\15090742 deficiency\NN\14449126 ,\,\1740 and\CC\1740 cranial\JJ\1740 irradiation\NN\13920835 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 intrathecal\JJ\1740 <e1>methotrexate</e1>\NN\2722166 <e2>toxicity</e2>\NN\13576101 is\VBZ\836236 unclear\JJ\1740 .\.\1740
16034922
D004967_D020521 CID Long-term\JJ\1740 <e1>oestrogen-only</e1>\JJ\1740 HT\NN\1740 also\RB\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>stroke</e2>\NN\556313 and\CC\1740 gallbladder\NN\5512139 disease\NN\14061805 .\.\1740
D004967_D005705 CID Long-term\JJ\1740 <e1>oestrogen-only</e1>\JJ\1740 HT\NN\1740 also\RB\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 stroke\NN\556313 and\CC\1740 <e2>gallbladder\NN\5512139 disease</e2>\NN\14061805 .\.\1740
17445520
D002110_D016584 CID <e1>Caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 in\IN\13603305 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 and\CC\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 .\.\1740
D002110_D016584 CID <e1>Caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 in\IN\13603305 panic\JJ\1740 disorder\NN\14034177 and\CC\1740 depression\NN\14373582 with\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 .\.\1740
D002110_D016584 CID Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 MDP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 CID Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 MDP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 CID Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 (\-LRB-\1740 MDP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 CID Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 MDP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 CID A\DT\13649268 total\NN\3553 of\IN\1740 58.6\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>PD</e2>\NN\14625458 ,\,\1740 44.4\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MDP\NN\1740 ,\,\1740 12.0\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 3\CD\13741022 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 ,\,\1740 and\CC\1740 7.1\CD\1740 %\NN\1740 (\-LRB-\1740 n=\NN\1740 2\CD\13741022 )\-RRB-\1740 of\IN\1740 control\JJ\1740 subjects\NNS\6598915 had\VBD\2108377 a\DT\13649268 panic\NN\7519253 attack\NN\955060 after\IN\1740 the\DT\1740 480-mg\NN\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 (\-LRB-\1740 chi(2)(3\NN\1740 )\-RRB-\1740 =\JJ\1740 16.22\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D016584 CID A\DT\13649268 total\NN\3553 of\IN\1740 58.6\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 ,\,\1740 44.4\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MDP\NN\1740 ,\,\1740 12.0\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 3\CD\13741022 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 ,\,\1740 and\CC\1740 7.1\CD\1740 %\NN\1740 (\-LRB-\1740 n=\NN\1740 2\CD\13741022 )\-RRB-\1740 of\IN\1740 control\JJ\1740 subjects\NNS\6598915 had\VBD\2108377 a\DT\13649268 <e2>panic\NN\7519253 attack</e2>\NN\955060 after\IN\1740 the\DT\1740 480-mg\NN\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 (\-LRB-\1740 chi(2)(3\NN\1740 )\-RRB-\1740 =\JJ\1740 16.22\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D016584 CID The\DT\1740 patients\NNS\9898892 with\IN\1740 <e2>PD</e2>\NN\14625458 and\CC\1740 MDP\NN\1740 were\VBD\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>caffeine</e1>\NN\14712692 than\IN\1740 were\VBD\836236 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 and\CC\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D002110_D016584 CID No\DT\7204911 <e2>panic\NN\7519253 attack</e2>\NN\955060 was\VBD\836236 observed\VBN\2163746 after\IN\1740 the\DT\1740 <e1>caffeine-free</e1>\JJ\1740 solution\NN\14586258 intake\NN\13440063 .\.\1740
D002110_D016584 CID Our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 an\DT\6697703 association\NN\8008335 between\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 ,\,\1740 no\RB\1740 matter\RB\1740 if\IN\1740 associated\VBN\628491 with\IN\1740 PD\NN\14625458 or\CC\3541091 MDP\NN\1740 ,\,\1740 and\CC\1740 hyperreactivity\NN\1740 to\TO\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 CID Our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 an\DT\6697703 association\NN\8008335 between\IN\1740 panic\NN\7519253 attacks\NNS\955060 ,\,\1740 no\RB\1740 matter\RB\1740 if\IN\1740 associated\VBN\628491 with\IN\1740 <e2>PD</e2>\NN\14625458 or\CC\3541091 MDP\NN\1740 ,\,\1740 and\CC\1740 hyperreactivity\NN\1740 to\TO\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 NONE Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 <e2>MDP</e2>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D016584 NONE A\DT\13649268 total\NN\3553 of\IN\1740 58.6\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 ,\,\1740 44.4\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>MDP</e2>\NN\1740 ,\,\1740 12.0\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 3\CD\13741022 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 ,\,\1740 and\CC\1740 7.1\CD\1740 %\NN\1740 (\-LRB-\1740 n=\NN\1740 2\CD\13741022 )\-RRB-\1740 of\IN\1740 control\JJ\1740 subjects\NNS\6598915 had\VBD\2108377 a\DT\13649268 panic\NN\7519253 attack\NN\955060 after\IN\1740 the\DT\1740 480-mg\NN\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 (\-LRB-\1740 chi(2)(3\NN\1740 )\-RRB-\1740 =\JJ\1740 16.22\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D016584 NONE The\DT\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 and\CC\1740 <e2>MDP</e2>\NN\1740 were\VBD\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>caffeine</e1>\NN\14712692 than\IN\1740 were\VBD\836236 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 and\CC\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D002110_D016584 NONE Our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 an\DT\6697703 association\NN\8008335 between\IN\1740 panic\NN\7519253 attacks\NNS\955060 ,\,\1740 no\RB\1740 matter\RB\1740 if\IN\1740 associated\VBN\628491 with\IN\1740 PD\NN\14625458 or\CC\3541091 <e2>MDP</e2>\NN\1740 ,\,\1740 and\CC\1740 hyperreactivity\NN\1740 to\TO\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D003866 NONE <e1>Caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 in\IN\13603305 panic\JJ\1740 disorder\NN\14034177 and\CC\1740 <e2>depression</e2>\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 .\.\1740
D002110_D003865 NONE Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 <e2>major\JJ\1740 depression</e2>\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 MDP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D003865 NONE Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 <e2>MDP</e2>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 Mental\NNP\1740 Disorders\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D003865 NONE A\DT\13649268 total\NN\3553 of\IN\1740 58.6\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 ,\,\1740 44.4\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>MDP</e2>\NN\1740 ,\,\1740 12.0\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 3\CD\13741022 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 ,\,\1740 and\CC\1740 7.1\CD\1740 %\NN\1740 (\-LRB-\1740 n=\NN\1740 2\CD\13741022 )\-RRB-\1740 of\IN\1740 control\JJ\1740 subjects\NNS\6598915 had\VBD\2108377 a\DT\13649268 panic\NN\7519253 attack\NN\955060 after\IN\1740 the\DT\1740 480-mg\NN\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 (\-LRB-\1740 chi(2)(3\NN\1740 )\-RRB-\1740 =\JJ\1740 16.22\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D003865 NONE A\DT\13649268 total\NN\3553 of\IN\1740 58.6\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 17\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 ,\,\1740 44.4\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 MDP\NN\1740 ,\,\1740 12.0\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 3\CD\13741022 )\-RRB-\1740 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>MD</e2>\NN\14622893 ,\,\1740 and\CC\1740 7.1\CD\1740 %\NN\1740 (\-LRB-\1740 n=\NN\1740 2\CD\13741022 )\-RRB-\1740 of\IN\1740 control\JJ\1740 subjects\NNS\6598915 had\VBD\2108377 a\DT\13649268 panic\NN\7519253 attack\NN\955060 after\IN\1740 the\DT\1740 480-mg\NN\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 (\-LRB-\1740 chi(2)(3\NN\1740 )\-RRB-\1740 =\JJ\1740 16.22\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D003865 NONE The\DT\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 and\CC\1740 <e2>MDP</e2>\NN\1740 were\VBD\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>caffeine</e1>\NN\14712692 than\IN\1740 were\VBD\836236 patients\NNS\9898892 with\IN\1740 MD\NN\14622893 and\CC\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D002110_D003865 NONE The\DT\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 and\CC\1740 MDP\NN\1740 were\VBD\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>caffeine</e1>\NN\14712692 than\IN\1740 were\VBD\836236 patients\NNS\9898892 with\IN\1740 <e2>MD</e2>\NN\14622893 and\CC\1740 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
D002110_D003865 NONE Our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 an\DT\6697703 association\NN\8008335 between\IN\1740 panic\NN\7519253 attacks\NNS\955060 ,\,\1740 no\RB\1740 matter\RB\1740 if\IN\1740 associated\VBN\628491 with\IN\1740 PD\NN\14625458 or\CC\3541091 <e2>MDP</e2>\NN\1740 ,\,\1740 and\CC\1740 hyperreactivity\NN\1740 to\TO\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D001523 NONE Our\PRP$\1740 aim\NN\5980875 was\VBD\836236 to\TO\1740 observe\VB\2163746 if\IN\1740 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 (\-LRB-\1740 MDP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 Diagnostic\NNP\1740 and\CC\1740 Statistical\NNP\1740 Manual\NNP\6421301 of\IN\1740 <e2>Mental\NNP\1740 Disorders</e2>\NNPS\14034177 ,\,\1740 Fourth\NNP\14429985 Edition\NNP\6590210 criteria\NNS\13577171 )\-RRB-\1740 respond\VBP\2367363 in\IN\13603305 a\DT\13649268 similar\JJ\1740 way\NN\4916342 to\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 panic\NN\7519253 attacks\NNS\955060 by\IN\1740 an\DT\6697703 oral\JJ\1740 <e1>caffeine</e1>\NN\14712692 challenge\NN\13927383 test\NN\5798043 .\.\1740
D002110_D001008 NONE In\IN\13603305 a\DT\13649268 randomized\JJ\1740 double-blind\JJ\1740 experiment\NN\641820 performed\VBN\2367363 in\IN\13603305 2\CD\13741022 occasions\NNS\5983801 7\CD\13741022 days\NNS\15140892 apart\RB\1740 ,\,\1740 480\CD\1740 mg\NN\13717155 <e1>caffeine</e1>\NN\14712692 and\CC\1740 a\DT\13649268 caffeine-free\NN\1740 (\-LRB-\1740 placebo\NN\3740161 )\-RRB-\1740 solution\NN\14586258 were\VBD\836236 administered\VBN\2436349 in\IN\13603305 a\DT\13649268 coffee\NN\7881800 form\NN\6286395 and\CC\1740 <e2>anxiety</e2>\NN\14373582 scales\NNS\7260623 were\VBD\836236 applied\VBN\2676054 before\IN\1740 and\CC\1740 after\IN\1740 each\DT\1740 test\NN\5798043 .\.\1740
D002110_D001008 NONE In\IN\13603305 a\DT\13649268 randomized\JJ\1740 double-blind\JJ\1740 experiment\NN\641820 performed\VBN\2367363 in\IN\13603305 2\CD\13741022 occasions\NNS\5983801 7\CD\13741022 days\NNS\15140892 apart\RB\1740 ,\,\1740 480\CD\1740 mg\NN\13717155 caffeine\NN\14712692 and\CC\1740 a\DT\13649268 <e1>caffeine-free</e1>\NN\1740 (\-LRB-\1740 placebo\NN\3740161 )\-RRB-\1740 solution\NN\14586258 were\VBD\836236 administered\VBN\2436349 in\IN\13603305 a\DT\13649268 coffee\NN\7881800 form\NN\6286395 and\CC\1740 <e2>anxiety</e2>\NN\14373582 scales\NNS\7260623 were\VBD\836236 applied\VBN\2676054 before\IN\1740 and\CC\1740 after\IN\1740 each\DT\1740 test\NN\5798043 .\.\1740
10462057
D017330_D000741 CID Induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 by\IN\1740 <e1>remoxipride</e1>\NN\1740 metabolites\NNS\20090 in\IN\13603305 HL60\NN\1740 and\CC\1740 CD34+/CD19-\NN\1740 human\JJ\1740 bone\NN\5286536 marrow\NN\5286536 progenitor\NN\9792555 cells\NNS\3080309 :\:\1740 potential\JJ\1740 relevance\NN\13791389 to\TO\1740 remoxipride-induced\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D017330_D000741 CID Induction\NN\7450842 of\IN\1740 apoptosis\NN\11486178 by\IN\1740 remoxipride\NN\1740 metabolites\NNS\20090 in\IN\13603305 HL60\NN\1740 and\CC\1740 CD34+/CD19-\NN\1740 human\JJ\1740 bone\NN\5286536 marrow\NN\5286536 progenitor\NN\9792555 cells\NNS\3080309 :\:\1740 potential\JJ\1740 relevance\NN\13791389 to\TO\1740 <e1>remoxipride-induced</e1>\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D017330_D000741 CID The\DT\1740 antipsychotic\JJ\1740 agent\NN\7347 ,\,\1740 <e1>remoxipride</e1>\NN\1740 [\-LRB-\1740 (S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz\FW\1740 amide\NN\14727670 ]\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D017330_D000741 CID The\DT\1740 antipsychotic\JJ\1740 agent\NN\7347 ,\,\1740 remoxipride\NN\1740 [\-LRB-\1740 <e1>(S)-(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz\FW\1740 amide</e1>\NN\14727670 ]\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D017330_D000741 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 <e1>remoxipride</e1>\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 aplastic\JJ\1740 anemia\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
D017330_D000741 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 <e1>remoxipride</e1>\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 aplastic\JJ\1740 anemia\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
D017330_D000741 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 aplastic\JJ\1740 anemia\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e1>remoxipride</e1>\NN\1740 .\.\1740
D017330_D000741 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 aplastic\JJ\1740 anemia\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e1>remoxipride</e1>\NN\1740 .\.\1740
C084325_D009336 NONE No\DT\7204911 <e2>necrosis</e2>\NN\11444117 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 cells\NNS\3080309 treated\VBN\2376958 with\IN\1740 <e1>NCQ436</e1>\NN\1740 but\CC\1740 NCQ344\NN\1740 had\VBD\2108377 a\DT\13649268 biphasic\JJ\1740 effect\NN\34213 in\IN\13603305 both\DT\1740 cell\NN\3080309 types\NNS\5839024 ,\,\1740 inducing\VBG\1627355 apoptosis\NN\11486178 at\IN\14622893 lower\JJR\1740 concentrations\NNS\4916342 and\CC\1740 necrosis\NN\11444117 at\IN\14622893 higher\JJR\1740 concentrations\NNS\4916342 .\.\1740
C084325_D009336 NONE No\DT\7204911 necrosis\NN\11444117 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 cells\NNS\3080309 treated\VBN\2376958 with\IN\1740 <e1>NCQ436</e1>\NN\1740 but\CC\1740 NCQ344\NN\1740 had\VBD\2108377 a\DT\13649268 biphasic\JJ\1740 effect\NN\34213 in\IN\13603305 both\DT\1740 cell\NN\3080309 types\NNS\5839024 ,\,\1740 inducing\VBG\1627355 apoptosis\NN\11486178 at\IN\14622893 lower\JJR\1740 concentrations\NNS\4916342 and\CC\1740 <e2>necrosis</e2>\NN\11444117 at\IN\14622893 higher\JJR\1740 concentrations\NNS\4916342 .\.\1740
C112341_D009336 NONE No\DT\7204911 <e2>necrosis</e2>\NN\11444117 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 cells\NNS\3080309 treated\VBN\2376958 with\IN\1740 NCQ436\NN\1740 but\CC\1740 <e1>NCQ344</e1>\NN\1740 had\VBD\2108377 a\DT\13649268 biphasic\JJ\1740 effect\NN\34213 in\IN\13603305 both\DT\1740 cell\NN\3080309 types\NNS\5839024 ,\,\1740 inducing\VBG\1627355 apoptosis\NN\11486178 at\IN\14622893 lower\JJR\1740 concentrations\NNS\4916342 and\CC\1740 necrosis\NN\11444117 at\IN\14622893 higher\JJR\1740 concentrations\NNS\4916342 .\.\1740
C112341_D009336 NONE No\DT\7204911 necrosis\NN\11444117 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 cells\NNS\3080309 treated\VBN\2376958 with\IN\1740 NCQ436\NN\1740 but\CC\1740 <e1>NCQ344</e1>\NN\1740 had\VBD\2108377 a\DT\13649268 biphasic\JJ\1740 effect\NN\34213 in\IN\13603305 both\DT\1740 cell\NN\3080309 types\NNS\5839024 ,\,\1740 inducing\VBG\1627355 apoptosis\NN\11486178 at\IN\14622893 lower\JJR\1740 concentrations\NNS\4916342 and\CC\1740 <e2>necrosis</e2>\NN\11444117 at\IN\14622893 higher\JJR\1740 concentrations\NNS\4916342 .\.\1740
D001554_D000741 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 <e1>benzene</e1>\NN\14767996 may\MD\15209706 induce\VB\1627355 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 aplastic\JJ\1740 anemia\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
D001554_D000741 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 <e1>benzene</e1>\NN\14767996 may\MD\15209706 induce\VB\1627355 aplastic\JJ\1740 anemia\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
C084325_D000741 NONE We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>NCQ436</e1>\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 aplastic\JJ\1740 anemia\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
C084325_D000741 NONE We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 aplastic\JJ\1740 anemia\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>NCQ436</e1>\NN\1740 and\CC\1740 NCQ344\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
C112341_D000741 NONE We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 <e1>NCQ344</e1>\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 aplastic\JJ\1740 anemia\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
C112341_D000741 NONE We\PRP\1740 propose\VBP\1010118 that\IN\1740 remoxipride\NN\1740 and\CC\1740 benzene\NN\14767996 may\MD\15209706 induce\VB\1627355 aplastic\JJ\1740 anemia\NN\14189204 via\IN\1740 production\NN\30358 of\IN\1740 similar\JJ\1740 reactive\JJ\1740 metabolites\NNS\20090 and\CC\1740 that\IN\1740 the\DT\1740 ability\NN\4723816 of\IN\1740 NCQ436\NN\1740 and\CC\1740 <e1>NCQ344</e1>\NN\1740 to\TO\1740 induce\VB\1627355 apoptosis\NN\11486178 in\IN\13603305 HBMP\NN\1740 cells\NNS\3080309 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 mechanism\NN\13446390 underlying\VBG\2604760 acquired\VBN\109660 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 that\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 remoxipride\NN\1740 .\.\1740
6627074
D013390_D001049 CID <e1>Succinylcholine</e1>\NN\3800001 <e2>apnoea</e2>\NN\1740 :\:\1740 attempted\VBN\2367363 reversal\NN\199130 with\IN\1740 anticholinesterases\NNS\3740161 .\.\1740
D013390_D001049 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 anticholinesterases\NNS\3740161 are\VBP\836236 only\RB\1740 partially\RB\1740 effective\JJ\1740 in\IN\13603305 restoring\VBG\1631072 neuromuscular\JJ\1740 function\NN\13783581 in\IN\13603305 <e1>succinylcholine</e1>\NN\3800001 <e2>apnoea</e2>\NN\1740 despite\IN\7501545 muscle\NN\5289601 twitch\NN\14360459 activity\NN\30358 typical\JJ\1740 of\IN\1740 phase\NN\15113229 II\CD\13741022 block\NN\21939 .\.\1740
D013390_D020879 NONE Anticholinesterases\NNS\3740161 were\VBD\836236 administered\VBN\2436349 in\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 antagonize\VB\1787955 prolonged\JJ\1740 <e2>neuromuscular\JJ\1740 blockade</e2>\NN\952963 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>succinylcholine</e1>\NN\3800001 in\IN\13603305 a\DT\13649268 patient\NN\9898892 later\RBR\1740 found\VBD\2426171 to\TO\1740 be\VB\836236 homozygous\JJ\1740 for\IN\1740 atypical\JJ\1740 plasma\NN\5398023 cholinesterase\NN\14732946 .\.\1740
3323599
D011692_D009401 NONE The\DT\1740 enhancement\NN\248977 of\IN\1740 <e1>aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 by\IN\1740 the\DT\1740 co-administration\NN\1740 of\IN\1740 protamine\NN\14736972 .\.\1740
D011692_D005923 CID An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis</e2>\NN\14204950 (\-LRB-\1740 FSGS\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>puromycin-aminonucleoside</e1>\NN\1740 (\-LRB-\1740 AMNS\NN\1740 )\-RRB-\1740 and\CC\1740 protamine\NN\14736972 sulfate\NN\15010703 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 .\.\1740
D011692_D005923 CID An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis\NN\14204950 (\-LRB-\1740 <e2>FSGS</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>puromycin-aminonucleoside</e1>\NN\1740 (\-LRB-\1740 AMNS\NN\1740 )\-RRB-\1740 and\CC\1740 protamine\NN\14736972 sulfate\NN\15010703 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 .\.\1740
D011692_D005923 CID An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis</e2>\NN\14204950 (\-LRB-\1740 FSGS\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 puromycin-aminonucleoside\NN\1740 (\-LRB-\1740 <e1>AMNS</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 protamine\NN\14736972 sulfate\NN\15010703 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 .\.\1740
D011692_D005923 CID An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis\NN\14204950 (\-LRB-\1740 <e2>FSGS</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 puromycin-aminonucleoside\NN\1740 (\-LRB-\1740 <e1>AMNS</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 protamine\NN\14736972 sulfate\NN\15010703 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 .\.\1740
D011692_D005923 CID Therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 PS\NN\6763273 enhances\VBZ\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 <e1>AMNS</e1>\NN\1740 on\IN\1740 the\DT\1740 glomerulus\NN\5425910 and\CC\1740 readily\RB\1740 produces\VBZ\1617192 progressive\JJ\1740 <e2>FSGS</e2>\NNS\1740 in\IN\13603305 rats\NNS\2329401 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 .\.\1740
D011479_D005923 NONE An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis</e2>\NN\14204950 (\-LRB-\1740 FSGS\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 puromycin-aminonucleoside\NN\1740 (\-LRB-\1740 AMNS\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>protamine\NN\14736972 sulfate</e1>\NN\15010703 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 .\.\1740
D011479_D005923 NONE An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis\NN\14204950 (\-LRB-\1740 <e2>FSGS</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 puromycin-aminonucleoside\NN\1740 (\-LRB-\1740 AMNS\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>protamine\NN\14736972 sulfate</e1>\NN\15010703 (\-LRB-\1740 PS\NN\6763273 )\-RRB-\1740 .\.\1740
D011479_D005923 NONE An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis</e2>\NN\14204950 (\-LRB-\1740 FSGS\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 puromycin-aminonucleoside\NN\1740 (\-LRB-\1740 AMNS\NN\1740 )\-RRB-\1740 and\CC\1740 protamine\NN\14736972 sulfate\NN\15010703 (\-LRB-\1740 <e1>PS</e1>\NN\6763273 )\-RRB-\1740 .\.\1740
D011479_D005923 NONE An\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerular\JJ\1740 sclerosis\NN\14204950 (\-LRB-\1740 <e2>FSGS</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 by\IN\1740 the\DT\1740 combined\JJ\1740 administration\NN\1133281 of\IN\1740 puromycin-aminonucleoside\NN\1740 (\-LRB-\1740 AMNS\NN\1740 )\-RRB-\1740 and\CC\1740 protamine\NN\14736972 sulfate\NN\15010703 (\-LRB-\1740 <e1>PS</e1>\NN\6763273 )\-RRB-\1740 .\.\1740
D011479_D005923 NONE Therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>PS</e1>\NN\6763273 enhances\VBZ\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 AMNS\NN\1740 on\IN\1740 the\DT\1740 glomerulus\NN\5425910 and\CC\1740 readily\RB\1740 produces\VBZ\1617192 progressive\JJ\1740 <e2>FSGS</e2>\NNS\1740 in\IN\13603305 rats\NNS\2329401 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 .\.\1740
D011479_D064420 NONE Therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>PS</e1>\NN\6763273 enhances\VBZ\227165 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AMNS\NN\1740 on\IN\1740 the\DT\1740 glomerulus\NN\5425910 and\CC\1740 readily\RB\1740 produces\VBZ\1617192 progressive\JJ\1740 FSGS\NNS\1740 in\IN\13603305 rats\NNS\2329401 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 .\.\1740
D011479_D007676 NONE Therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>PS</e1>\NN\6763273 enhances\VBZ\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 AMNS\NN\1740 on\IN\1740 the\DT\1740 glomerulus\NN\5425910 and\CC\1740 readily\RB\1740 produces\VBZ\1617192 progressive\JJ\1740 FSGS\NNS\1740 in\IN\13603305 rats\NNS\2329401 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D011692_D064420 NONE Therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 PS\NN\6763273 enhances\VBZ\227165 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>AMNS</e1>\NN\1740 on\IN\1740 the\DT\1740 glomerulus\NN\5425910 and\CC\1740 readily\RB\1740 produces\VBZ\1617192 progressive\JJ\1740 FSGS\NNS\1740 in\IN\13603305 rats\NNS\2329401 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 .\.\1740
D011692_D007676 CID Therefore\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 PS\NN\6763273 enhances\VBZ\227165 the\DT\1740 toxicity\NN\13576101 of\IN\1740 <e1>AMNS</e1>\NN\1740 on\IN\1740 the\DT\1740 glomerulus\NN\5425910 and\CC\1740 readily\RB\1740 produces\VBZ\1617192 progressive\JJ\1740 FSGS\NNS\1740 in\IN\13603305 rats\NNS\2329401 resulting\VBG\2633881 in\IN\13603305 the\DT\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 .\.\1740
24658375
D014212_D009220 CID <e1>All-trans\JJ\1740 retinoic\JJ\1740 acid-induced</e1>\JJ\1740 inflammatory\JJ\1740 <e2>myositis</e2>\NN\14336539 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 .\.\1740
D014212_D009220 CID Only\RB\1740 a\DT\13649268 handful\NN\13760316 of\IN\1740 cases\NNS\7283608 of\IN\1740 <e1>ATRA-induced</e1>\JJ\1740 <e2>myositis</e2>\NN\14336539 in\IN\13603305 children\NNS\9622049 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 and\CC\1740 none\NN\15228378 in\IN\13603305 the\DT\1740 radiology\NN\6045562 literature\NN\6362953 .\.\1740
D014212_D015473 NONE <e1>All-trans\JJ\1740 retinoic\JJ\1740 acid-induced</e1>\JJ\1740 inflammatory\JJ\1740 myositis\NN\14336539 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D014212_D015473 NONE <e1>All-trans\JJ\1740 retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 component\NN\5867413 of\IN\1740 standard\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 potentially\RB\1740 serious\JJ\1740 but\CC\1740 treatable\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 involving\VBG\2676054 numerous\JJ\1740 organ\NN\5220461 systems\NNS\3575240 ,\,\1740 including\VBG\690614 rare\JJ\1740 skeletal\JJ\1740 muscle\NN\5289601 involvement\NN\1080366 .\.\1740
D014212_D015473 NONE <e1>All-trans\JJ\1740 retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 component\NN\5867413 of\IN\1740 standard\JJ\1740 therapy\NN\657604 for\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 potentially\RB\1740 serious\JJ\1740 but\CC\1740 treatable\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 involving\VBG\2676054 numerous\JJ\1740 organ\NN\5220461 systems\NNS\3575240 ,\,\1740 including\VBG\690614 rare\JJ\1740 skeletal\JJ\1740 muscle\NN\5289601 involvement\NN\1080366 .\.\1740
D014212_D015473 NONE All-trans\JJ\1740 retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 component\NN\5867413 of\IN\1740 standard\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 potentially\RB\1740 serious\JJ\1740 but\CC\1740 treatable\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 involving\VBG\2676054 numerous\JJ\1740 organ\NN\5220461 systems\NNS\3575240 ,\,\1740 including\VBG\690614 rare\JJ\1740 skeletal\JJ\1740 muscle\NN\5289601 involvement\NN\1080366 .\.\1740
D014212_D015473 NONE All-trans\JJ\1740 retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 component\NN\5867413 of\IN\1740 standard\JJ\1740 therapy\NN\657604 for\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 potentially\RB\1740 serious\JJ\1740 but\CC\1740 treatable\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 involving\VBG\2676054 numerous\JJ\1740 organ\NN\5220461 systems\NNS\3575240 ,\,\1740 including\VBG\690614 rare\JJ\1740 skeletal\JJ\1740 muscle\NN\5289601 involvement\NN\1080366 .\.\1740
12535818
D000638_D001919 CID <e1>Amiodarone</e1>\NN\2715941 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>bradyarrhythmia</e2>\NN\1740 requiring\VBG\754942 permanent\JJ\1740 pacemaker\NN\5925366 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 and\CC\1740 prior\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 .\.\1740
D000638_D001919 CID OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 in\IN\13603305 patients\NNS\9898892 with\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>bradyarrhythmia</e2>\NN\1740 requiring\VBG\754942 a\DT\13649268 permanent\JJ\1740 pacemaker\NN\5925366 .\.\1740
D000638_D001919 CID BACKGROUND\NN\4921011 :\:\1740 Reports\NNS\6470073 of\IN\1740 severe\JJ\1740 <e2>bradyarrhythmia</e2>\NN\1740 during\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 are\VBP\836236 infrequent\JJ\1740 and\CC\1740 limited\VBN\2510337 to\IN\1740 studies\NNS\635850 assessing\VBG\670261 the\DT\1740 therapy\NN\657604 's\POS\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 patients\NNS\9898892 with\IN\1740 ventricular\NN\1740 arrhythmias\NNS\14103288 .\.\1740
D000638_D001919 CID CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 AF\NN\1740 and\CC\1740 a\DT\13649268 previous\JJ\1740 MI\NN\14207561 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>bradyarrhythmia</e2>\NN\1740 requiring\VBG\754942 a\DT\13649268 permanent\JJ\1740 pacemaker\NN\5925366 .\.\1740
D000638_D001281 NONE <e1>Amiodarone</e1>\NN\2715941 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 bradyarrhythmia\NN\1740 requiring\VBG\754942 permanent\JJ\1740 pacemaker\NN\5925366 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 and\CC\1740 prior\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 .\.\1740
D000638_D001281 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bradyarrhythmia\NN\1740 requiring\VBG\754942 a\DT\13649268 permanent\JJ\1740 pacemaker\NN\5925366 .\.\1740
D000638_D001281 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 in\IN\13603305 patients\NNS\9898892 with\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 <e2>AF</e2>\NN\1740 )\-RRB-\1740 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bradyarrhythmia\NN\1740 requiring\VBG\754942 a\DT\13649268 permanent\JJ\1740 pacemaker\NN\5925366 .\.\1740
D000638_D001281 NONE CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>AF</e2>\NN\1740 and\CC\1740 a\DT\13649268 previous\JJ\1740 MI\NN\14207561 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bradyarrhythmia\NN\1740 requiring\VBG\754942 a\DT\13649268 permanent\JJ\1740 pacemaker\NN\5925366 .\.\1740
D000638_D009203 NONE <e1>Amiodarone</e1>\NN\2715941 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 bradyarrhythmia\NN\1740 requiring\VBG\754942 permanent\JJ\1740 pacemaker\NN\5925366 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 and\CC\1740 prior\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D000638_D009203 NONE CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 AF\NN\1740 and\CC\1740 a\DT\13649268 previous\JJ\1740 <e2>MI</e2>\NN\14207561 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 bradyarrhythmia\NN\1740 requiring\VBG\754942 a\DT\13649268 permanent\JJ\1740 pacemaker\NN\5925366 .\.\1740
D000638_D001145 NONE BACKGROUND\NN\4921011 :\:\1740 Reports\NNS\6470073 of\IN\1740 severe\JJ\1740 bradyarrhythmia\NN\1740 during\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 are\VBP\836236 infrequent\JJ\1740 and\CC\1740 limited\VBN\2510337 to\IN\1740 studies\NNS\635850 assessing\VBG\670261 the\DT\1740 therapy\NN\657604 's\POS\1740 use\NN\407535 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>ventricular\NN\1740 arrhythmias</e2>\NNS\14103288 .\.\1740
2429800
D006632_D007022 NONE <e1>Histamine</e1>\NN\14739004 antagonists\NNS\7846 and\CC\1740 d-tubocurarine-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 cardiac\JJ\1740 surgical\JJ\1740 patients\NNS\9898892 .\.\1740
D014403_D007022 CID Histamine\NN\14739004 antagonists\NNS\7846 and\CC\1740 <e1>d-tubocurarine-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 cardiac\JJ\1740 surgical\JJ\1740 patients\NNS\9898892 .\.\1740
2765447
D019793_D012640 NONE <e2>Convulsion</e2>\NN\14081375 following\VBG\1835496 intravenous\JJ\1740 <e1>fluorescein</e1>\NN\14598383 angiography\NN\904623 .\.\1740
D019793_D004830 CID <e2>Tonic-clonic\JJ\1740 seizures</e2>\NNS\14081375 followed\VBD\1835496 intravenous\JJ\1740 <e1>fluorescein</e1>\NN\14598383 injection\NN\320852 for\IN\1740 fundus\NN\5225602 angiography\NN\904623 in\IN\13603305 a\DT\13649268 47-year-old\JJ\1740 male\JJ\1740 .\.\1740
3685052
D005481_D012640 NONE <e1>Flurothyl</e1>\NN\1740 <e2>seizure</e2>\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 flurothyl\NN\1740 seizure\JJ\1740 testing\NN\639556 .\.\1740
D005481_D012640 NONE <e1>Flurothyl</e1>\NN\1740 seizure\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 flurothyl\NN\1740 <e2>seizure</e2>\JJ\1740 testing\NN\639556 .\.\1740
D005481_D012640 NONE Flurothyl\NN\1740 <e2>seizure</e2>\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 <e1>flurothyl</e1>\NN\1740 seizure\JJ\1740 testing\NN\639556 .\.\1740
D005481_D012640 NONE Flurothyl\NN\1740 seizure\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 <e1>flurothyl</e1>\NN\1740 <e2>seizure</e2>\JJ\1740 testing\NN\639556 .\.\1740
D005481_D012640 NONE A\DT\13649268 <e1>flurothyl</e1>\NN\1740 ether\RB\1740 <e2>seizure</e2>\VBP\1740 screening\NN\6887726 technique\NN\5660268 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 seizure\JJ\1740 susceptibility\NN\13920835 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 that\WDT\1740 received\VBD\2210855 neonatal\JJ\1740 injections\NNS\320852 of\IN\1740 MSG\NN\7809368 (\-LRB-\1740 4\CD\13741022 mg/g\NN\1740 and\CC\1740 1\CD\13741022 mg/g\NN\1740 )\-RRB-\1740 .\.\1740
D005481_D012640 NONE A\DT\13649268 <e1>flurothyl</e1>\NN\1740 ether\RB\1740 seizure\VBP\1740 screening\NN\6887726 technique\NN\5660268 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 <e2>seizure</e2>\JJ\1740 susceptibility\NN\13920835 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 that\WDT\1740 received\VBD\2210855 neonatal\JJ\1740 injections\NNS\320852 of\IN\1740 MSG\NN\7809368 (\-LRB-\1740 4\CD\13741022 mg/g\NN\1740 and\CC\1740 1\CD\13741022 mg/g\NN\1740 )\-RRB-\1740 .\.\1740
D005481_D012640 NONE <e1>Flurothyl</e1>\NN\1740 ether\NN\14840755 produced\VBD\1617192 hypothermia\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 flurothyl\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 hypothermia\NN\14034177 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D005481_D012640 NONE Flurothyl\NN\1740 ether\NN\14840755 produced\VBD\1617192 hypothermia\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>flurothyl</e1>\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 hypothermia\NN\14034177 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D005481_D012640 NONE <e1>Flurothyl</e1>\NN\1740 <e2>seizure</e2>\NN\14081375 testing\NN\639556 proved\VBD\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 rapid\JJ\1740 and\CC\1740 reliable\JJ\1740 technique\NN\5660268 with\IN\1740 which\WDT\1740 to\TO\1740 evaluate\VB\670261 seizure\JJ\1740 susceptibility\NN\13920835 .\.\1740
D005481_D012640 NONE <e1>Flurothyl</e1>\NN\1740 seizure\NN\14081375 testing\NN\639556 proved\VBD\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 rapid\JJ\1740 and\CC\1740 reliable\JJ\1740 technique\NN\5660268 with\IN\1740 which\WDT\1740 to\TO\1740 evaluate\VB\670261 <e2>seizure</e2>\JJ\1740 susceptibility\NN\13920835 .\.\1740
D012970_D012640 NONE Flurothyl\NN\1740 <e2>seizure</e2>\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>monosodium\NN\1740 glutamate</e1>\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 flurothyl\NN\1740 seizure\JJ\1740 testing\NN\639556 .\.\1740
D012970_D012640 NONE Flurothyl\NN\1740 seizure\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>monosodium\NN\1740 glutamate</e1>\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 flurothyl\NN\1740 <e2>seizure</e2>\JJ\1740 testing\NN\639556 .\.\1740
D012970_D012640 NONE Flurothyl\NN\1740 <e2>seizure</e2>\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 <e1>MSG</e1>\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 flurothyl\NN\1740 seizure\JJ\1740 testing\NN\639556 .\.\1740
D012970_D012640 NONE Flurothyl\NN\1740 seizure\VBD\1740 thresholds\NNS\15265518 in\IN\13603305 mice\NNS\2329401 treated\VBN\2376958 neonatally\RB\1740 with\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 <e1>MSG</e1>\NN\7809368 ):\-RRB-\1740 evaluation\NN\874067 of\IN\1740 experimental\JJ\1740 parameters\NNS\5858936 in\IN\13603305 flurothyl\NN\1740 <e2>seizure</e2>\JJ\1740 testing\NN\639556 .\.\1740
D012970_D012640 NONE <e1>Monosodium\NN\1740 glutamate</e1>\NN\15010703 (\-LRB-\1740 MSG\NN\7809368 )\-RRB-\1740 administration\NN\1133281 to\TO\1740 neonatal\JJ\1740 rodents\NNS\1886756 produces\VBZ\1617192 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 results\VBZ\2633881 in\IN\13603305 numerous\JJ\1740 biochemical\JJ\1740 and\CC\1740 behavioral\JJ\1740 deficits\NNS\5113133 .\.\1740
D012970_D012640 NONE Monosodium\NN\1740 glutamate\NN\15010703 (\-LRB-\1740 <e1>MSG</e1>\NN\7809368 )\-RRB-\1740 administration\NN\1133281 to\TO\1740 neonatal\JJ\1740 rodents\NNS\1886756 produces\VBZ\1617192 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 results\VBZ\2633881 in\IN\13603305 numerous\JJ\1740 biochemical\JJ\1740 and\CC\1740 behavioral\JJ\1740 deficits\NNS\5113133 .\.\1740
D012970_D012640 NONE These\DT\1740 studies\NNS\635850 were\VBD\836236 undertaken\VBN\1641914 to\TO\1740 determine\VB\1645601 if\IN\1740 neonatal\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>MSG</e1>\NN\7809368 produced\VBD\1617192 permanent\JJ\1740 alterations\NNS\7283608 in\IN\13603305 <e2>seizure</e2>\JJ\1740 susceptibility\NN\13920835 ,\,\1740 since\IN\1740 previous\JJ\1740 investigations\NNS\5797597 were\VBD\836236 inconclusive\JJ\1740 .\.\1740
D012970_D012640 NONE A\DT\13649268 flurothyl\NN\1740 ether\RB\1740 <e2>seizure</e2>\VBP\1740 screening\NN\6887726 technique\NN\5660268 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 seizure\JJ\1740 susceptibility\NN\13920835 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 that\WDT\1740 received\VBD\2210855 neonatal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>MSG</e1>\NN\7809368 (\-LRB-\1740 4\CD\13741022 mg/g\NN\1740 and\CC\1740 1\CD\13741022 mg/g\NN\1740 )\-RRB-\1740 .\.\1740
D012970_D012640 NONE A\DT\13649268 flurothyl\NN\1740 ether\RB\1740 seizure\VBP\1740 screening\NN\6887726 technique\NN\5660268 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 <e2>seizure</e2>\JJ\1740 susceptibility\NN\13920835 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 that\WDT\1740 received\VBD\2210855 neonatal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>MSG</e1>\NN\7809368 (\-LRB-\1740 4\CD\13741022 mg/g\NN\1740 and\CC\1740 1\CD\13741022 mg/g\NN\1740 )\-RRB-\1740 .\.\1740
D012970_D012640 NONE <e1>MSG</e1>\NN\7809368 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 significant\JJ\1740 reductions\NNS\351485 in\IN\13603305 whole\JJ\1740 brain\NN\5462674 weight\NN\5009170 but\CC\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 .\.\1740
D012970_D012640 NONE A\DT\13649268 naloxone\NN\3808977 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 challenge\NN\13927383 was\VBD\836236 also\RB\1740 ineffective\JJ\1740 in\IN\13603305 altering\VBG\126264 the\DT\1740 <e2>seizure</e2>\JJ\1740 thresholds\NNS\15265518 of\IN\1740 either\CC\1740 control\NN\5190804 of\IN\1740 <e1>MSG-treated</e1>\JJ\1740 mice\NNS\2329401 .\.\1740
D004986_D012640 NONE A\DT\13649268 flurothyl\NN\1740 <e1>ether</e1>\RB\1740 <e2>seizure</e2>\VBP\1740 screening\NN\6887726 technique\NN\5660268 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 seizure\JJ\1740 susceptibility\NN\13920835 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 that\WDT\1740 received\VBD\2210855 neonatal\JJ\1740 injections\NNS\320852 of\IN\1740 MSG\NN\7809368 (\-LRB-\1740 4\CD\13741022 mg/g\NN\1740 and\CC\1740 1\CD\13741022 mg/g\NN\1740 )\-RRB-\1740 .\.\1740
D004986_D012640 NONE A\DT\13649268 flurothyl\NN\1740 <e1>ether</e1>\RB\1740 seizure\VBP\1740 screening\NN\6887726 technique\NN\5660268 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 <e2>seizure</e2>\JJ\1740 susceptibility\NN\13920835 in\IN\13603305 adult\JJ\1740 mice\NNS\2329401 that\WDT\1740 received\VBD\2210855 neonatal\JJ\1740 injections\NNS\320852 of\IN\1740 MSG\NN\7809368 (\-LRB-\1740 4\CD\13741022 mg/g\NN\1740 and\CC\1740 1\CD\13741022 mg/g\NN\1740 )\-RRB-\1740 .\.\1740
D004986_D012640 NONE Flurothyl\NN\1740 <e1>ether</e1>\NN\14840755 produced\VBD\1617192 hypothermia\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 flurothyl\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 hypothermia\NN\14034177 to\TO\1740 <e2>seizure</e2>\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D009270_D012640 NONE A\DT\13649268 <e1>naloxone</e1>\NN\3808977 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 challenge\NN\13927383 was\VBD\836236 also\RB\1740 ineffective\JJ\1740 in\IN\13603305 altering\VBG\126264 the\DT\1740 <e2>seizure</e2>\JJ\1740 thresholds\NNS\15265518 of\IN\1740 either\CC\1740 control\NN\5190804 of\IN\1740 MSG-treated\JJ\1740 mice\NNS\2329401 .\.\1740
D005481_D007035 CID <e1>Flurothyl</e1>\NN\1740 ether\NN\14840755 produced\VBD\1617192 <e2>hypothermia</e2>\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 flurothyl\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 hypothermia\NN\14034177 to\TO\1740 seizure\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D005481_D007035 CID <e1>Flurothyl</e1>\NN\1740 ether\NN\14840755 produced\VBD\1617192 hypothermia\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 flurothyl\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 <e2>hypothermia</e2>\NN\14034177 to\TO\1740 seizure\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D005481_D007035 CID Flurothyl\NN\1740 ether\NN\14840755 produced\VBD\1617192 <e2>hypothermia</e2>\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>flurothyl</e1>\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 hypothermia\NN\14034177 to\TO\1740 seizure\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D005481_D007035 CID Flurothyl\NN\1740 ether\NN\14840755 produced\VBD\1617192 hypothermia\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>flurothyl</e1>\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 <e2>hypothermia</e2>\NN\14034177 to\TO\1740 seizure\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D004986_D007035 NONE Flurothyl\NN\1740 <e1>ether</e1>\NN\14840755 produced\VBD\1617192 <e2>hypothermia</e2>\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 flurothyl\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 hypothermia\NN\14034177 to\TO\1740 seizure\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
D004986_D007035 NONE Flurothyl\NN\1740 <e1>ether</e1>\NN\14840755 produced\VBD\1617192 hypothermia\NN\14034177 which\WDT\1740 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 flurothyl\NN\1740 exposure\NN\5042871 ;\:\1740 however\RB\1740 ,\,\1740 the\DT\1740 relationship\NN\31921 of\IN\1740 <e2>hypothermia</e2>\NN\14034177 to\TO\1740 seizure\VB\1740 induction\NN\7450842 was\VBD\836236 unclear\JJ\1740 .\.\1740
1360900
D004976_D012640 CID <e1>Ethacrynic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 brain\NN\5462674 neurotransmitters\NNS\14807410 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004976_D012640 CID Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 <e1>ethacrynic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 50\CD\13745420 %\NN\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 ;\:\1740 50\CD\13745420 micrograms/mouse\NN\1740 )\-RRB-\1740 accelerated\VBD\226566 the\DT\1740 synthesis/turnover\NN\1740 of\IN\1740 5-hydroxytryptamine\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 but\CC\1740 suppressed\VBD\2510337 the\DT\1740 synthesis\NN\13446390 of\IN\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 and\CC\1740 acetylcholine\NN\14807558 in\IN\13603305 mouse\NN\2329401 brain\NN\5462674 .\.\1740
D004976_D012640 CID In\IN\13603305 <e1>ethacrynic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 these\DT\1740 neurotransmitter\NN\14807410 systems\NNS\3575240 may\MD\15209706 be\VB\836236 differentially\RB\1740 modulated\VBN\1724459 ,\,\1740 probably\RB\1740 through\IN\1740 activation\NN\13561719 of\IN\1740 glutaminergic\JJ\1740 neurons\NNS\5430628 in\IN\13603305 the\DT\1740 brain\NN\5462674 .\.\1740
D012701_D012640 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 50\CD\13745420 %\NN\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 ;\:\1740 50\CD\13745420 micrograms/mouse\NN\1740 )\-RRB-\1740 accelerated\VBD\226566 the\DT\1740 synthesis/turnover\NN\1740 of\IN\1740 <e1>5-hydroxytryptamine</e1>\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 but\CC\1740 suppressed\VBD\2510337 the\DT\1740 synthesis\NN\13446390 of\IN\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 and\CC\1740 acetylcholine\NN\14807558 in\IN\13603305 mouse\NN\2329401 brain\NN\5462674 .\.\1740
D012701_D012640 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 50\CD\13745420 %\NN\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 ;\:\1740 50\CD\13745420 micrograms/mouse\NN\1740 )\-RRB-\1740 accelerated\VBD\226566 the\DT\1740 synthesis/turnover\NN\1740 of\IN\1740 5-hydroxytryptamine\NN\14807737 (\-LRB-\1740 <e1>5-HT</e1>\NN\1740 )\-RRB-\1740 but\CC\1740 suppressed\VBD\2510337 the\DT\1740 synthesis\NN\13446390 of\IN\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 and\CC\1740 acetylcholine\NN\14807558 in\IN\13603305 mouse\NN\2329401 brain\NN\5462674 .\.\1740
D005680_D012640 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 50\CD\13745420 %\NN\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 ;\:\1740 50\CD\13745420 micrograms/mouse\NN\1740 )\-RRB-\1740 accelerated\VBD\226566 the\DT\1740 synthesis/turnover\NN\1740 of\IN\1740 5-hydroxytryptamine\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 but\CC\1740 suppressed\VBD\2510337 the\DT\1740 synthesis\NN\13446390 of\IN\1740 <e1>gamma-aminobutyric\JJ\1740 acid</e1>\NN\14818238 and\CC\1740 acetylcholine\NN\14807558 in\IN\13603305 mouse\NN\2329401 brain\NN\5462674 .\.\1740
D000109_D012640 NONE Intracerebroventricular\JJ\1740 injection\NN\320852 of\IN\1740 ethacrynic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 50\CD\13745420 %\NN\1740 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 ;\:\1740 50\CD\13745420 micrograms/mouse\NN\1740 )\-RRB-\1740 accelerated\VBD\226566 the\DT\1740 synthesis/turnover\NN\1740 of\IN\1740 5-hydroxytryptamine\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 but\CC\1740 suppressed\VBD\2510337 the\DT\1740 synthesis\NN\13446390 of\IN\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 and\CC\1740 <e1>acetylcholine</e1>\NN\14807558 in\IN\13603305 mouse\NN\2329401 brain\NN\5462674 .\.\1740
11026989
D014331_D015878 CID The\DT\1740 effect\NN\34213 of\IN\1740 <e2>pupil\NN\10059162 dilation</e2>\NN\7138085 with\IN\1740 <e1>tropicamide</e1>\NN\1740 on\IN\1740 vision\NN\5767733 and\CC\1740 driving\NN\571609 simulator\NN\3699975 performance\NN\6619065 .\.\1740
D014331_D015878 CID METHODS\NNS\5616786 :\:\1740 A\DT\13649268 series\NN\8456993 of\IN\1740 tests\NNS\5798043 on\IN\1740 various\JJ\1740 parameters\NNS\5858936 of\IN\1740 visual\JJ\1740 function\NN\13783581 and\CC\1740 driving\NN\571609 simulator\NN\3699975 performance\NN\6619065 were\VBD\836236 performed\VBN\2367363 on\IN\1740 12\CD\13745420 healthy\JJ\1740 drivers\NNS\10378412 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 <e2>pupil\NN\10059162 dilation</e2>\NN\7138085 using\VBG\1156834 guttae\NN\1740 <e1>tropicamide</e1>\NN\1740 1\CD\13741022 %\NN\1740 .\.\1740
24729111
D000638_D007037 CID <e1>Amiodarone-induced</e1>\JJ\1740 <e2>myxoedema\NN\14121276 coma</e2>\NN\5678932 .\.\1740
D000638_D007037 CID The\DT\1740 only\JJ\1740 two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>myxoedema\NN\14121276 coma</e2>\NN\5678932 in\IN\13603305 the\DT\1740 literature\NN\6362953 report\NN\6470073 patient\NN\9898892 death\NN\7296428 despite\IN\7501545 supportive\JJ\1740 therapy\NN\657604 and\CC\1740 thyroid\NN\5329735 hormone\NN\5404728 replacement\NN\196485 .\.\1740
D000638_D007037 CID This\DT\1740 case\NN\7283608 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 thoroughly\RB\1740 investigated\VBN\644583 case\NN\7283608 of\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>myxoedema\NN\14121276 coma</e2>\NN\5678932 with\IN\1740 a\DT\13649268 history\NN\15120823 significant\JJ\1740 for\IN\1740 subclinical\JJ\1740 thyroid\NN\5329735 disease\NN\14061805 .\.\1740
D000638_D003128 CID <e1>Amiodarone-induced</e1>\JJ\1740 <e2>myxoedema\NN\14121276 coma</e2>\NN\5678932 .\.\1740
D000638_D003128 CID The\DT\1740 only\JJ\1740 two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>myxoedema\NN\14121276 coma</e2>\NN\5678932 in\IN\13603305 the\DT\1740 literature\NN\6362953 report\NN\6470073 patient\NN\9898892 death\NN\7296428 despite\IN\7501545 supportive\JJ\1740 therapy\NN\657604 and\CC\1740 thyroid\NN\5329735 hormone\NN\5404728 replacement\NN\196485 .\.\1740
D000638_D003128 CID This\DT\1740 case\NN\7283608 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 thoroughly\RB\1740 investigated\VBN\644583 case\NN\7283608 of\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>myxoedema\NN\14121276 coma</e2>\NN\5678932 with\IN\1740 a\DT\13649268 history\NN\15120823 significant\JJ\1740 for\IN\1740 subclinical\JJ\1740 thyroid\NN\5329735 disease\NN\14061805 .\.\1740
D000638_D001919 CID A\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 hypothermia\NN\14034177 and\CC\1740 respiratory\JJ\1740 failure\NN\66216 3\CD\13741022 weeks\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 .\.\1740
D000638_D007035 CID A\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 bradycardia\NN\14110674 ,\,\1740 <e2>hypothermia</e2>\NN\14034177 and\CC\1740 respiratory\JJ\1740 failure\NN\66216 3\CD\13741022 weeks\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 .\.\1740
D000638_D012131 CID A\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 bradycardia\NN\14110674 ,\,\1740 hypothermia\NN\14034177 and\CC\1740 <e2>respiratory\JJ\1740 failure</e2>\NN\66216 3\CD\13741022 weeks\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 .\.\1740
D000638_D001281 NONE A\DT\13649268 62-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 bradycardia\NN\14110674 ,\,\1740 hypothermia\NN\14034177 and\CC\1740 respiratory\JJ\1740 failure\NN\66216 3\CD\13741022 weeks\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 for\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 .\.\1740
D000638_D013959 NONE This\DT\1740 case\NN\7283608 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 thoroughly\RB\1740 investigated\VBN\644583 case\NN\7283608 of\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 myxoedema\NN\14121276 coma\NN\5678932 with\IN\1740 a\DT\13649268 history\NN\15120823 significant\JJ\1740 for\IN\1740 subclinical\JJ\1740 <e2>thyroid\NN\5329735 disease</e2>\NN\14061805 .\.\1740
15282950
D010936_D009202 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>Terminalia\NNP\1740 chebula</e1>\NN\1740 against\IN\1740 experimental\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 isoproterenol\NN\3740161 .\.\1740
D010936_D009202 NONE Cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ethanolic\JJ\1740 extract\NN\14589223 of\IN\1740 Terminalia\NNP\1740 chebula\NN\1740 fruits</e1>\NNS\11675842 (\-LRB-\1740 500\CD\13745420 mg/kg\NN\1740 body\NN\19128 wt\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 isoproterenol\NN\3740161 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 wt\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009202 CID Protective\JJ\1740 effect\NN\34213 of\IN\1740 Terminalia\NNP\1740 chebula\NN\1740 against\IN\1740 experimental\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>isoproterenol</e1>\NN\3740161 .\.\1740
D007545_D009202 CID Cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 ethanolic\JJ\1740 extract\NN\14589223 of\IN\1740 Terminalia\NNP\1740 chebula\NN\1740 fruits\NNS\11675842 (\-LRB-\1740 500\CD\13745420 mg/kg\NN\1740 body\NN\19128 wt\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 <e1>isoproterenol</e1>\NN\3740161 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 body\NN\19128 wt\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
11105626
D015474_D065817 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 newborn\JJ\1740 infant\NN\9918248 with\IN\1740 multiple\JJ\1740 congenital\JJ\1740 anomalies\NNS\14501726 (\-LRB-\1740 <e2>anotia</e2>\NN\1740 and\CC\1740 Taussig-Bing\JJ\1740 malformation\NN\14213199 )\-RRB-\1740 due\JJ\1740 to\TO\1740 exposure\NN\5042871 to\TO\1740 <e1>isotretinoin</e1>\VB\1740 within\IN\1740 the\DT\1740 first\JJ\1740 trimester\NN\15113229 .\.\1740
D015474_D004310 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 newborn\JJ\1740 infant\NN\9918248 with\IN\1740 multiple\JJ\1740 congenital\JJ\1740 anomalies\NNS\14501726 (\-LRB-\1740 anotia\NN\1740 and\CC\1740 <e2>Taussig-Bing\JJ\1740 malformation</e2>\NN\14213199 )\-RRB-\1740 due\JJ\1740 to\TO\1740 exposure\NN\5042871 to\TO\1740 <e1>isotretinoin</e1>\VB\1740 within\IN\1740 the\DT\1740 first\JJ\1740 trimester\NN\15113229 .\.\1740
1420650
D002220_D020820 NONE <e2>Asterixis</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>carbamazepine</e1>\NN\1740 therapy\NN\657604 .\.\1740
D002220_D020820 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 we\PRP\1740 present\VBP\2137132 four\CD\13741022 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 different\JJ\1740 psychotropic\JJ\1740 drugs\NNS\14778436 ,\,\1740 in\IN\13603305 whom\WP\1740 <e2>asterixis</e2>\NN\1740 was\VBD\836236 triggered\VBN\1641914 either\CC\1740 by\IN\1740 adding\VBG\156601 <e1>carbamazepine</e1>\NN\1740 (\-LRB-\1740 CBZ\NN\1740 )\-RRB-\1740 to\TO\1740 a\DT\13649268 treatment\NN\654885 regimen\NN\5898568 ,\,\1740 or\CC\3541091 by\IN\1740 increasing\VBG\169651 its\PRP$\6125041 dosage\NN\13576355 .\.\1740
D002220_D020820 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 we\PRP\1740 present\VBP\2137132 four\CD\13741022 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 different\JJ\1740 psychotropic\JJ\1740 drugs\NNS\14778436 ,\,\1740 in\IN\13603305 whom\WP\1740 <e2>asterixis</e2>\NN\1740 was\VBD\836236 triggered\VBN\1641914 either\CC\1740 by\IN\1740 adding\VBG\156601 carbamazepine\NN\1740 (\-LRB-\1740 <e1>CBZ</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 a\DT\13649268 treatment\NN\654885 regimen\NN\5898568 ,\,\1740 or\CC\3541091 by\IN\1740 increasing\VBG\169651 its\PRP$\6125041 dosage\NN\13576355 .\.\1740
D002220_D020820 NONE We\PRP\1740 consider\VBP\689344 <e2>asterixis</e2>\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 easily\RB\1740 overlooked\VBN\2127853 sign\NN\6643763 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 even\RB\1740 at\IN\14622893 low\JJ\1740 or\CC\3541091 moderate\JJ\1740 dosage\NN\13576355 levels\NNS\4916342 ,\,\1740 if\IN\1740 certain\JJ\1740 drugs\NNS\14778436 as\IN\14622893 lithium\NN\14625458 or\CC\3541091 clozapine\NN\3713736 are\VBP\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>CBZ</e1>\NN\1740 .\.\1740
D008094_D020820 CID We\PRP\1740 consider\VBP\689344 <e2>asterixis</e2>\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 easily\RB\1740 overlooked\VBN\2127853 sign\NN\6643763 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 even\RB\1740 at\IN\14622893 low\JJ\1740 or\CC\3541091 moderate\JJ\1740 dosage\NN\13576355 levels\NNS\4916342 ,\,\1740 if\IN\1740 certain\JJ\1740 drugs\NNS\14778436 as\IN\14622893 <e1>lithium</e1>\NN\14625458 or\CC\3541091 clozapine\NN\3713736 are\VBP\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 CBZ\NN\1740 .\.\1740
D008094_D020258 NONE We\PRP\1740 consider\VBP\689344 asterixis\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 easily\RB\1740 overlooked\VBN\2127853 sign\NN\6643763 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 even\RB\1740 at\IN\14622893 low\JJ\1740 or\CC\3541091 moderate\JJ\1740 dosage\NN\13576355 levels\NNS\4916342 ,\,\1740 if\IN\1740 certain\JJ\1740 drugs\NNS\14778436 as\IN\14622893 <e1>lithium</e1>\NN\14625458 or\CC\3541091 clozapine\NN\3713736 are\VBP\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 CBZ\NN\1740 .\.\1740
D003024_D020820 CID We\PRP\1740 consider\VBP\689344 <e2>asterixis</e2>\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 easily\RB\1740 overlooked\VBN\2127853 sign\NN\6643763 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 even\RB\1740 at\IN\14622893 low\JJ\1740 or\CC\3541091 moderate\JJ\1740 dosage\NN\13576355 levels\NNS\4916342 ,\,\1740 if\IN\1740 certain\JJ\1740 drugs\NNS\14778436 as\IN\14622893 lithium\NN\14625458 or\CC\3541091 <e1>clozapine</e1>\NN\3713736 are\VBP\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 CBZ\NN\1740 .\.\1740
D003024_D020258 NONE We\PRP\1740 consider\VBP\689344 asterixis\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 easily\RB\1740 overlooked\VBN\2127853 sign\NN\6643763 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 even\RB\1740 at\IN\14622893 low\JJ\1740 or\CC\3541091 moderate\JJ\1740 dosage\NN\13576355 levels\NNS\4916342 ,\,\1740 if\IN\1740 certain\JJ\1740 drugs\NNS\14778436 as\IN\14622893 lithium\NN\14625458 or\CC\3541091 <e1>clozapine</e1>\NN\3713736 are\VBP\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 CBZ\NN\1740 .\.\1740
D002220_D020258 NONE We\PRP\1740 consider\VBP\689344 asterixis\NN\1740 to\TO\1740 be\VB\836236 an\DT\6697703 easily\RB\1740 overlooked\VBN\2127853 sign\NN\6643763 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 occur\VB\2623529 even\RB\1740 at\IN\14622893 low\JJ\1740 or\CC\3541091 moderate\JJ\1740 dosage\NN\13576355 levels\NNS\4916342 ,\,\1740 if\IN\1740 certain\JJ\1740 drugs\NNS\14778436 as\IN\14622893 lithium\NN\14625458 or\CC\3541091 clozapine\NN\3713736 are\VBP\836236 used\VBN\1156834 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>CBZ</e1>\NN\1740 .\.\1740
3746148
D004176_D003324 NONE Non-invasive\JJ\1740 detection\NN\5708432 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 by\IN\1740 body\NN\19128 surface\NN\21939 electrocardiographic\JJ\1740 mapping\NN\13783581 after\IN\1740 <e1>dipyridamole</e1>\NN\1740 infusion\NN\14589223 .\.\1740
D004176_D003324 NONE Electrocardiographic\JJ\1740 changes\NNS\7283608 after\IN\1740 <e1>dipyridamole</e1>\NN\1740 infusion\NN\14589223 (\-LRB-\1740 0.568\CD\1740 mg/kg/4\NN\1740 min\NN\15154774 )\-RRB-\1740 were\VBD\836236 studied\VBN\630380 in\IN\13603305 41\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 and\CC\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 after\IN\1740 submaximal\JJ\1740 treadmill\NN\3302790 exercise\NN\621627 by\IN\1740 use\NN\407535 of\IN\1740 the\DT\1740 body\NN\19128 surface\NN\21939 mapping\NN\13783581 technique\NN\5660268 .\.\1740
D004176_D003324 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 <e1>dipyridamole</e1>\NN\1740 ECG\NNP\7000195 test\NN\5798043 is\VBZ\836236 as\RB\1740 useful\JJ\1740 as\IN\14622893 the\DT\1740 exercise\NN\621627 ECG\NNP\7000195 test\NN\5798043 for\IN\1740 the\DT\1740 assessment\NN\5732756 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D004176_D007511 NONE After\IN\1740 <e1>dipyridamole</e1>\NN\1740 ,\,\1740 <e2>ischemic</e2>\JJ\1740 ST-segment\JJ\1740 depression\NN\14373582 (\-LRB-\1740 0.05\CD\1740 mV\NN\13634784 or\CC\3541091 more\JJR\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 84\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 non-MI\JJ\1740 group\NN\2137 ,\,\1740 29\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 ANT-MI\NN\1740 group\NN\2137 ,\,\1740 63\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 INF-MI\NN\1740 group\NN\2137 and\CC\1740 61\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 .\.\1740
D004176_D003866 NONE After\IN\1740 <e1>dipyridamole</e1>\NN\1740 ,\,\1740 ischemic\JJ\1740 ST-segment\JJ\1740 <e2>depression</e2>\NN\14373582 (\-LRB-\1740 0.05\CD\1740 mV\NN\13634784 or\CC\3541091 more\JJR\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 84\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 non-MI\JJ\1740 group\NN\2137 ,\,\1740 29\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 ANT-MI\NN\1740 group\NN\2137 ,\,\1740 63\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 INF-MI\NN\1740 group\NN\2137 and\CC\1740 61\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 .\.\1740
D004176_D009203 NONE After\IN\1740 <e1>dipyridamole</e1>\NN\1740 ,\,\1740 ischemic\JJ\1740 ST-segment\JJ\1740 depression\NN\14373582 (\-LRB-\1740 0.05\CD\1740 mV\NN\13634784 or\CC\3541091 more\JJR\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 84\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 <e2>non-MI</e2>\JJ\1740 group\NN\2137 ,\,\1740 29\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 ANT-MI\NN\1740 group\NN\2137 ,\,\1740 63\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 INF-MI\NN\1740 group\NN\2137 and\CC\1740 61\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 .\.\1740
D004176_D056988 NONE After\IN\1740 <e1>dipyridamole</e1>\NN\1740 ,\,\1740 ischemic\JJ\1740 ST-segment\JJ\1740 depression\NN\14373582 (\-LRB-\1740 0.05\CD\1740 mV\NN\13634784 or\CC\3541091 more\JJR\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 84\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 non-MI\JJ\1740 group\NN\2137 ,\,\1740 29\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 <e2>ANT-MI</e2>\NN\1740 group\NN\2137 ,\,\1740 63\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 INF-MI\NN\1740 group\NN\2137 and\CC\1740 61\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 .\.\1740
D004176_D056989 NONE After\IN\1740 <e1>dipyridamole</e1>\NN\1740 ,\,\1740 ischemic\JJ\1740 ST-segment\JJ\1740 depression\NN\14373582 (\-LRB-\1740 0.05\CD\1740 mV\NN\13634784 or\CC\3541091 more\JJR\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 84\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 non-MI\JJ\1740 group\NN\2137 ,\,\1740 29\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 ANT-MI\NN\1740 group\NN\2137 ,\,\1740 63\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 <e2>INF-MI</e2>\NN\1740 group\NN\2137 and\CC\1740 61\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 .\.\1740
D004176_D017202 CID The\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 is\VBZ\836236 caused\VBN\1617192 by\IN\1740 the\DT\1740 inhomogenous\JJ\1740 distribution\NN\5726596 of\IN\1740 myocardial\JJ\1740 blood\NN\5397468 flow\NN\7311115 .\.\1740
24055495
D005690_D003072 CID Long-term\JJ\1740 oral\JJ\1740 <e1>galactose</e1>\VBP\1740 treatment\NN\654885 prevents\VBZ\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 treated\VBN\2376958 intracerebroventricularly\RB\1740 with\IN\1740 streptozotocin\NN\1740 .\.\1740
D005690_D003072 CID We\PRP\1740 have\VBP\2108377 investigated\VBN\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 continuous\JJ\1740 daily\RB\1740 oral\JJ\1740 <e1>galactose</e1>\NN\15062778 (\-LRB-\1740 200\CD\1740 mg/kg/day\NN\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 streptozotocin-induced\JJ\1740 (\-LRB-\1740 STZ-icv\NN\1740 )\-RRB-\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 sAD\NN\1740 ,\,\1740 tested\VBN\670261 by\IN\1740 Morris\NNP\1740 Water\NNP\14618834 Maze\NNP\4377057 and\CC\1740 Passive\NNP\13802920 Avoidance\NNP\203342 test\NN\5798043 ,\,\1740 respectively\RB\1740 .\.\1740
D005690_D003072 CID One\CD\13741022 month\NN\15113229 of\IN\1740 oral\JJ\1740 <e1>galactose</e1>\JJ\1740 treatment\NN\654885 initiated\VBN\1617192 immediately\RB\1740 after\IN\1740 the\DT\1740 STZ-icv\NN\1740 administration\NN\1133281 ,\,\1740 successfully\RB\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 the\DT\1740 STZ-icv-induced\VBN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 .\.\1740
D005690_D003072 CID Oral\JJ\1740 <e1>galactose</e1>\JJ\1740 exposure\NN\5042871 might\MD\5029706 have\VB\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 ability\NN\4723816 and\CC\1740 could\MD\1740 be\VB\836236 worth\JJ\1740 investigating\VBG\644583 for\IN\1740 improvement\NN\7359599 of\IN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 associated\VBN\628491 with\IN\1740 glucose\NN\14710501 hypometabolism\NN\1740 in\IN\13603305 AD\NN\7247071 .\.\1740
D013311_D003072 CID Long-term\JJ\1740 oral\JJ\1740 galactose\VBP\1740 treatment\NN\654885 prevents\VBZ\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 treated\VBN\2376958 intracerebroventricularly\RB\1740 with\IN\1740 <e1>streptozotocin</e1>\NN\1740 .\.\1740
D013311_D003072 CID We\PRP\1740 have\VBP\2108377 investigated\VBN\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 continuous\JJ\1740 daily\RB\1740 oral\JJ\1740 galactose\NN\15062778 (\-LRB-\1740 200\CD\1740 mg/kg/day\NN\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 <e1>streptozotocin-induced</e1>\JJ\1740 (\-LRB-\1740 STZ-icv\NN\1740 )\-RRB-\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 sAD\NN\1740 ,\,\1740 tested\VBN\670261 by\IN\1740 Morris\NNP\1740 Water\NNP\14618834 Maze\NNP\4377057 and\CC\1740 Passive\NNP\13802920 Avoidance\NNP\203342 test\NN\5798043 ,\,\1740 respectively\RB\1740 .\.\1740
D013311_D003072 CID We\PRP\1740 have\VBP\2108377 investigated\VBN\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 continuous\JJ\1740 daily\RB\1740 oral\JJ\1740 galactose\NN\15062778 (\-LRB-\1740 200\CD\1740 mg/kg/day\NN\1740 )\-RRB-\1740 treatment\NN\654885 on\IN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 streptozotocin-induced\JJ\1740 (\-LRB-\1740 <e1>STZ-icv</e1>\NN\1740 )\-RRB-\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 sAD\NN\1740 ,\,\1740 tested\VBN\670261 by\IN\1740 Morris\NNP\1740 Water\NNP\14618834 Maze\NNP\4377057 and\CC\1740 Passive\NNP\13802920 Avoidance\NNP\203342 test\NN\5798043 ,\,\1740 respectively\RB\1740 .\.\1740
D013311_D003072 CID One\CD\13741022 month\NN\15113229 of\IN\1740 oral\JJ\1740 galactose\JJ\1740 treatment\NN\654885 initiated\VBN\1617192 immediately\RB\1740 after\IN\1740 the\DT\1740 <e1>STZ-icv</e1>\NN\1740 administration\NN\1133281 ,\,\1740 successfully\RB\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 the\DT\1740 STZ-icv-induced\VBN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 .\.\1740
D013311_D003072 CID One\CD\13741022 month\NN\15113229 of\IN\1740 oral\JJ\1740 galactose\JJ\1740 treatment\NN\654885 initiated\VBN\1617192 immediately\RB\1740 after\IN\1740 the\DT\1740 STZ-icv\NN\1740 administration\NN\1133281 ,\,\1740 successfully\RB\1740 prevented\VBD\1740 development\NN\248977 of\IN\1740 the\DT\1740 <e1>STZ-icv-induced</e1>\VBN\1740 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 .\.\1740
D005947_D003704 NONE Basic\JJ\1740 and\CC\1740 clinical\JJ\1740 research\NN\633864 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 <e2>dementia</e2>\NN\14395018 of\IN\1740 sporadic\JJ\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 sAD\NN\1740 )\-RRB-\1740 type\NN\5839024 is\VBZ\836236 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 of\IN\1740 the\DT\1740 insulin-receptor\NN\1740 (\-LRB-\1740 IR\NN\14625458 )\-RRB-\1740 system\NN\3575240 followed\VBN\1835496 by\IN\1740 decreased\VBN\169651 <e1>glucose</e1>\NN\14710501 transport\NN\3575240 via\IN\1740 glucose\NN\14710501 transporter\NN\4490091 GLUT4\NN\1740 and\CC\1740 decreased\VBD\169651 glucose\NN\14710501 metabolism\NN\13526110 in\IN\13603305 brain\NN\5462674 cells\NNS\3080309 .\.\1740
D005947_D003704 NONE Basic\JJ\1740 and\CC\1740 clinical\JJ\1740 research\NN\633864 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 <e2>dementia</e2>\NN\14395018 of\IN\1740 sporadic\JJ\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 sAD\NN\1740 )\-RRB-\1740 type\NN\5839024 is\VBZ\836236 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 of\IN\1740 the\DT\1740 insulin-receptor\NN\1740 (\-LRB-\1740 IR\NN\14625458 )\-RRB-\1740 system\NN\3575240 followed\VBN\1835496 by\IN\1740 decreased\VBN\169651 glucose\NN\14710501 transport\NN\3575240 via\IN\1740 <e1>glucose</e1>\NN\14710501 transporter\NN\4490091 GLUT4\NN\1740 and\CC\1740 decreased\VBD\169651 glucose\NN\14710501 metabolism\NN\13526110 in\IN\13603305 brain\NN\5462674 cells\NNS\3080309 .\.\1740
D005947_D003704 NONE Basic\JJ\1740 and\CC\1740 clinical\JJ\1740 research\NN\633864 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 <e2>dementia</e2>\NN\14395018 of\IN\1740 sporadic\JJ\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 sAD\NN\1740 )\-RRB-\1740 type\NN\5839024 is\VBZ\836236 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 of\IN\1740 the\DT\1740 insulin-receptor\NN\1740 (\-LRB-\1740 IR\NN\14625458 )\-RRB-\1740 system\NN\3575240 followed\VBN\1835496 by\IN\1740 decreased\VBN\169651 glucose\NN\14710501 transport\NN\3575240 via\IN\1740 glucose\NN\14710501 transporter\NN\4490091 GLUT4\NN\1740 and\CC\1740 decreased\VBD\169651 <e1>glucose</e1>\NN\14710501 metabolism\NN\13526110 in\IN\13603305 brain\NN\5462674 cells\NNS\3080309 .\.\1740
D005947_D000544 CID Basic\JJ\1740 and\CC\1740 clinical\JJ\1740 research\NN\633864 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 dementia\NN\14395018 of\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 sAD\NN\1740 )\-RRB-\1740 type\NN\5839024 is\VBZ\836236 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 of\IN\1740 the\DT\1740 insulin-receptor\NN\1740 (\-LRB-\1740 IR\NN\14625458 )\-RRB-\1740 system\NN\3575240 followed\VBN\1835496 by\IN\1740 decreased\VBN\169651 <e1>glucose</e1>\NN\14710501 transport\NN\3575240 via\IN\1740 glucose\NN\14710501 transporter\NN\4490091 GLUT4\NN\1740 and\CC\1740 decreased\VBD\169651 glucose\NN\14710501 metabolism\NN\13526110 in\IN\13603305 brain\NN\5462674 cells\NNS\3080309 .\.\1740
D005947_D000544 CID Basic\JJ\1740 and\CC\1740 clinical\JJ\1740 research\NN\633864 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 dementia\NN\14395018 of\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 sAD\NN\1740 )\-RRB-\1740 type\NN\5839024 is\VBZ\836236 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 of\IN\1740 the\DT\1740 insulin-receptor\NN\1740 (\-LRB-\1740 IR\NN\14625458 )\-RRB-\1740 system\NN\3575240 followed\VBN\1835496 by\IN\1740 decreased\VBN\169651 glucose\NN\14710501 transport\NN\3575240 via\IN\1740 <e1>glucose</e1>\NN\14710501 transporter\NN\4490091 GLUT4\NN\1740 and\CC\1740 decreased\VBD\169651 glucose\NN\14710501 metabolism\NN\13526110 in\IN\13603305 brain\NN\5462674 cells\NNS\3080309 .\.\1740
D005947_D000544 CID Basic\JJ\1740 and\CC\1740 clinical\JJ\1740 research\NN\633864 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 dementia\NN\14395018 of\IN\1740 sporadic\JJ\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 sAD\NN\1740 )\-RRB-\1740 type\NN\5839024 is\VBZ\836236 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 of\IN\1740 the\DT\1740 insulin-receptor\NN\1740 (\-LRB-\1740 IR\NN\14625458 )\-RRB-\1740 system\NN\3575240 followed\VBN\1835496 by\IN\1740 decreased\VBN\169651 glucose\NN\14710501 transport\NN\3575240 via\IN\1740 glucose\NN\14710501 transporter\NN\4490091 GLUT4\NN\1740 and\CC\1740 decreased\VBD\169651 <e1>glucose</e1>\NN\14710501 metabolism\NN\13526110 in\IN\13603305 brain\NN\5462674 cells\NNS\3080309 .\.\1740
D005690_D008569 NONE Exclusively\RB\1740 parenteral\JJ\1740 daily\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>galactose</e1>\JJ\1740 induce\NN\1740 <e2>memory\NN\5926676 deterioration</e2>\NN\14560612 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 are\VBP\836236 used\VBN\1156834 to\TO\1740 generate\VB\1617192 animal\JJ\1740 aging\NN\13526110 model\NN\5888929 ,\,\1740 but\CC\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 galactose\VBP\1740 treatment\NN\654885 on\IN\1740 cognitive\JJ\1740 functions\NNS\13783581 have\VBP\2108377 never\RB\1740 been\VBN\836236 tested\VBN\670261 .\.\1740
D005690_D008569 NONE Exclusively\RB\1740 parenteral\JJ\1740 daily\JJ\1740 injections\NNS\320852 of\IN\1740 galactose\JJ\1740 induce\NN\1740 <e2>memory\NN\5926676 deterioration</e2>\NN\14560612 in\IN\13603305 rodents\NNS\1886756 and\CC\1740 are\VBP\836236 used\VBN\1156834 to\TO\1740 generate\VB\1617192 animal\JJ\1740 aging\NN\13526110 model\NN\5888929 ,\,\1740 but\CC\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 <e1>galactose</e1>\VBP\1740 treatment\NN\654885 on\IN\1740 cognitive\JJ\1740 functions\NNS\13783581 have\VBP\2108377 never\RB\1740 been\VBN\836236 tested\VBN\670261 .\.\1740
D005690_D018149 NONE Oral\JJ\1740 <e1>galactose</e1>\JJ\1740 exposure\NN\5042871 might\MD\5029706 have\VB\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 ability\NN\4723816 and\CC\1740 could\MD\1740 be\VB\836236 worth\JJ\1740 investigating\VBG\644583 for\IN\1740 improvement\NN\7359599 of\IN\1740 cognitive\JJ\1740 deficits\NNS\5113133 associated\VBN\628491 with\IN\1740 <e2>glucose\NN\14710501 hypometabolism</e2>\NN\1740 in\IN\13603305 AD\NN\7247071 .\.\1740
D005690_D000544 NONE Oral\JJ\1740 <e1>galactose</e1>\JJ\1740 exposure\NN\5042871 might\MD\5029706 have\VB\2108377 beneficial\JJ\1740 effects\NNS\13245626 on\IN\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 ability\NN\4723816 and\CC\1740 could\MD\1740 be\VB\836236 worth\JJ\1740 investigating\VBG\644583 for\IN\1740 improvement\NN\7359599 of\IN\1740 cognitive\JJ\1740 deficits\NNS\5113133 associated\VBN\628491 with\IN\1740 glucose\NN\14710501 hypometabolism\NN\1740 in\IN\13603305 <e2>AD</e2>\NN\7247071 .\.\1740
24220752
D003287_D007674 CID Incidence\NN\13821570 of\IN\1740 <e1>contrast-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 hospitalised\VBN\2348568 patients\NNS\9898892 with\IN\1740 cancer\NN\14239425 .\.\1740
D003287_D007674 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 frequency\NN\15286249 of\IN\1740 and\CC\1740 possible\JJ\1740 factors\NNS\7326557 related\JJ\1740 to\TO\1740 <e1>contrast-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 CIN\NN\1740 )\-RRB-\1740 in\IN\13603305 hospitalised\VBN\2348568 patients\NNS\9898892 with\IN\1740 cancer\NN\14239425 .\.\1740
D003287_D007674 CID <e1>Contrast-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 CIN\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 concern\NN\5682950 for\IN\1740 oncological\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 CT\NN\901316 .\.\1740 .\.\1740
D003287_D009369 NONE Incidence\NN\13821570 of\IN\1740 <e1>contrast-induced</e1>\JJ\1740 nephropathy\NN\14573196 in\IN\13603305 hospitalised\VBN\2348568 patients\NNS\9898892 with\IN\1740 <e2>cancer</e2>\NN\14239425 .\.\1740
D003287_D009369 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 frequency\NN\15286249 of\IN\1740 and\CC\1740 possible\JJ\1740 factors\NNS\7326557 related\JJ\1740 to\TO\1740 <e1>contrast-induced</e1>\JJ\1740 nephropathy\NN\14573196 (\-LRB-\1740 CIN\NN\1740 )\-RRB-\1740 in\IN\13603305 hospitalised\VBN\2348568 patients\NNS\9898892 with\IN\1740 <e2>cancer</e2>\NN\14239425 .\.\1740
-1_D006973 NONE CIN\NN\1740 was\VBD\836236 significantly\RB\1740 more\JJR\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>bevacizumab/irinotecan</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.021\CD\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.044\CD\1740 )\-RRB-\1740 .\.\1740
-1_D006973 NONE <e2>Hypertension</e2>\NN\14057371 and\CC\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>bevacizumab/irinotecan</e1>\NN\1740 may\MD\15209706 be\VB\836236 additional\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 CIN\NN\1740 development\NN\248977 .\.\1740
-1_D006973 NONE <e2>Hypertension</e2>\NN\14057371 and\CC\1740 treatment\NN\654885 with\IN\1740 <e1>bevacizumab</e1>\NN\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 additional\JJ\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
C051890_D006973 NONE CIN\NN\1740 was\VBD\836236 significantly\RB\1740 more\JJR\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>bevacizumab/irinotecan</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.021\CD\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.044\CD\1740 )\-RRB-\1740 .\.\1740
C051890_D006973 NONE <e2>Hypertension</e2>\NN\14057371 and\CC\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>bevacizumab/irinotecan</e1>\NN\1740 may\MD\15209706 be\VB\836236 additional\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 CIN\NN\1740 development\NN\248977 .\.\1740
17069550
D005702_D001321 NONE A\DT\13649268 prospective\JJ\1740 ,\,\1740 open-label\JJ\1740 trial\NN\786195 of\IN\1740 <e1>galantamine</e1>\NN\1740 in\IN\13603305 <e2>autistic\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D005702_D001321 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>galantamine</e1>\NN\1740 ,\,\1740 an\DT\6697703 acetylcholinesterase\NN\1740 inhibitor\NN\20090 and\CC\1740 nicotinic\JJ\1740 receptor\NN\5225602 modulator\NN\1740 ,\,\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 interfering\VBG\2451370 behaviors\NNS\407535 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>autism</e2>\NN\14304060 .\.\1740
D005702_D001321 NONE METHODS\NNS\5616786 :\:\1740 Thirteen\CD\13745420 medication-free\JJ\1740 children\NNS\9622049 with\IN\1740 <e2>autism</e2>\NN\14304060 (\-LRB-\1740 mean\NN\6021761 age\NN\4916342 ,\,\1740 8.8\CD\1740 +/-\CC\1740 3.5\CD\1740 years\NNS\15144371 )\-RRB-\1740 participated\VBN\2367363 in\IN\13603305 a\DT\13649268 12-week\JJ\1740 ,\,\1740 open-label\JJ\1740 trial\NN\786195 of\IN\1740 <e1>galantamine</e1>\NN\1740 .\.\1740
D005702_D001321 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 open\JJ\1740 trial\NN\786195 ,\,\1740 <e1>galantamine</e1>\NN\1740 was\VBD\836236 well-tolerated\JJ\1740 and\CC\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 beneficial\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 interfering\VBG\2451370 behaviors\NNS\407535 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>autism</e2>\NN\14304060 ,\,\1740 particularly\RB\1740 aggression\NN\4657876 ,\,\1740 behavioral\JJ\1740 dyscontrol\NN\1740 ,\,\1740 and\CC\1740 inattention\NN\5701944 .\.\1740
D005702_D006261 CID Overall\RB\1740 ,\,\1740 <e1>galantamine</e1>\NN\1740 was\VBD\836236 well-tolerated\JJ\1740 ,\,\1740 with\IN\1740 no\DT\7204911 significant\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 apart\RB\1740 from\IN\1740 <e2>headaches</e2>\NNS\5829480 in\IN\13603305 one\CD\13741022 patient\NN\9898892 .\.\1740
D005702_D001523 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 open\JJ\1740 trial\NN\786195 ,\,\1740 <e1>galantamine</e1>\NN\1740 was\VBD\836236 well-tolerated\JJ\1740 and\CC\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 beneficial\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 interfering\VBG\2451370 behaviors\NNS\407535 in\IN\13603305 children\NNS\9622049 with\IN\1740 autism\NN\14304060 ,\,\1740 particularly\RB\1740 <e2>aggression</e2>\NN\4657876 ,\,\1740 behavioral\JJ\1740 dyscontrol\NN\1740 ,\,\1740 and\CC\1740 inattention\NN\5701944 .\.\1740
D005702_D002653 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 open\JJ\1740 trial\NN\786195 ,\,\1740 <e1>galantamine</e1>\NN\1740 was\VBD\836236 well-tolerated\JJ\1740 and\CC\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 beneficial\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 interfering\VBG\2451370 behaviors\NNS\407535 in\IN\13603305 children\NNS\9622049 with\IN\1740 autism\NN\14304060 ,\,\1740 particularly\RB\1740 aggression\NN\4657876 ,\,\1740 <e2>behavioral\JJ\1740 dyscontrol</e2>\NN\1740 ,\,\1740 and\CC\1740 inattention\NN\5701944 .\.\1740
D005702_D019958 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 open\JJ\1740 trial\NN\786195 ,\,\1740 <e1>galantamine</e1>\NN\1740 was\VBD\836236 well-tolerated\JJ\1740 and\CC\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 beneficial\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 interfering\VBG\2451370 behaviors\NNS\407535 in\IN\13603305 children\NNS\9622049 with\IN\1740 autism\NN\14304060 ,\,\1740 particularly\RB\1740 aggression\NN\4657876 ,\,\1740 behavioral\JJ\1740 dyscontrol\NN\1740 ,\,\1740 and\CC\1740 <e2>inattention</e2>\NN\5701944 .\.\1740
20595935
D014700_D006966 NONE <e1>Verapamil</e1>\NN\2938514 stimulation\NN\242808 test\NN\5798043 in\IN\13603305 <e2>hyperprolactinemia</e2>\NN\1740 :\:\1740 loss\NN\13252973 of\IN\1740 prolactin\NN\5410315 response\NN\11410625 in\IN\13603305 anatomic\JJ\1740 or\CC\3541091 functional\JJ\1740 stalk\NN\14991712 effect\NN\34213 .\.\1740
D014700_D006966 NONE AIM\NN\5980875 :\:\1740 <e1>Verapamil</e1>\NN\2938514 stimulation\NN\242808 test\NN\5798043 was\VBD\836236 previously\RB\1740 investigated\VBN\644583 as\IN\14622893 a\DT\13649268 tool\NN\3563967 for\IN\1740 differential\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 but\CC\1740 with\IN\1740 conflicting\VBG\2666882 results\NNS\34213 .\.\1740
D014700_D006966 NONE Prolactin\NN\5410315 responses\NNS\11410625 to\TO\1740 <e1>verapamil</e1>\NNS\2938514 in\IN\13603305 65\CD\1740 female\JJ\1740 patients\NNS\9898892 (\-LRB-\1740 age\NN\4916342 :\:\1740 29.9\CD\1740 +/-\CC\1740 8.1\CD\1740 years\NNS\15144371 )\-RRB-\1740 with\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 were\VBD\836236 tested\VBN\670261 in\IN\13603305 a\DT\13649268 descriptive\JJ\1740 ,\,\1740 matched\VBN\2664769 case-control\NN\1740 study\NN\635850 .\.\1740
D014700_D006966 NONE RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 risperidone-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D014700_D006966 NONE ROC\NNP\9492123 curve\NN\13863771 analysis\NN\633864 revealed\VBD\2137132 that\IN\1740 unresponsiveness\NN\4723816 to\TO\1740 <e1>verapamil</e1>\RB\1740 defined\VBN\2604760 as\IN\14622893 PRL\NN\1740 <\XX\1740 7\CD\13741022 %\NN\1740 ,\,\1740 discriminated\VBD\650353 anatomical\JJ\1740 or\CC\3541091 functional\JJ\1740 stalk\NN\14991712 effect\NN\34213 (\-LRB-\1740 sensitivity\NN\5651971 :\:\1740 74\CD\1740 %\NN\1740 ,\,\1740 specificity\NN\4762633 :\:\1740 73\CD\1740 %\NN\1740 ,\,\1740 AUC\NN\1740 :\:\1740 0.855+/-0.04\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 ,\,\1740 CI\NN\13635336 :\:\1740 0.768\CD\1740 -\SYM\1740 0.942\CD\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 pseudoprolactinoma\NN\1740 or\CC\3541091 risperidone-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D014700_D006966 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Verapamil</e1>\NN\2938514 responsiveness\NN\5652926 is\VBZ\836236 not\RB\1740 a\DT\13649268 reliable\JJ\1740 finding\NN\43195 for\IN\1740 the\DT\1740 differential\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D014700_D006966 NONE However\RB\1740 ,\,\1740 <e1>verapamil</e1>\VBZ\1740 unresponsiveness\JJ\1740 discriminates\NNS\1740 stalk\NN\14991712 effect\NN\34213 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 anatomically\RB\1740 or\CC\3541091 functionally\RB\1740 inhibited\VBN\2510337 dopaminergic\JJ\1740 tonus\NN\14544335 )\-RRB-\1740 from\IN\1740 other\JJ\1740 causes\NNS\7323922 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 with\IN\1740 varying\VBG\2666239 degrees\NNS\4916342 of\IN\1740 responsiveness\NN\5652926 .\.\1740
D014700_D015175 NONE Here\RB\1740 ,\,\1740 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 re-investigate\VB\1740 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 <e1>verapamil</e1>\NN\2938514 in\IN\13603305 a\DT\13649268 population\NN\7942152 who\WP\8299493 were\VBD\836236 all\DT\1740 screened\VBN\2533282 for\IN\1740 <e2>macroprolactinemia</e2>\NN\1740 .\.\1740
D014700_D015175 NONE RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>macroprolactinoma</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 risperidone-induced\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D014700_D015175 NONE RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>microprolactinoma</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 risperidone-induced\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D014700_D015175 NONE RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>macroprolactinemia</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 risperidone-induced\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D014700_-1 NONE RESULTS\NNS\34213 :\:\1740 <e1>Verapamil</e1>\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 <e2>pseudoprolactinoma</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 risperidone-induced\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D014700_-1 NONE ROC\NNP\9492123 curve\NN\13863771 analysis\NN\633864 revealed\VBD\2137132 that\IN\1740 unresponsiveness\NN\4723816 to\TO\1740 <e1>verapamil</e1>\RB\1740 defined\VBN\2604760 as\IN\14622893 PRL\NN\1740 <\XX\1740 7\CD\13741022 %\NN\1740 ,\,\1740 discriminated\VBD\650353 anatomical\JJ\1740 or\CC\3541091 functional\JJ\1740 stalk\NN\14991712 effect\NN\34213 (\-LRB-\1740 sensitivity\NN\5651971 :\:\1740 74\CD\1740 %\NN\1740 ,\,\1740 specificity\NN\4762633 :\:\1740 73\CD\1740 %\NN\1740 ,\,\1740 AUC\NN\1740 :\:\1740 0.855+/-0.04\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 ,\,\1740 CI\NN\13635336 :\:\1740 0.768\CD\1740 -\SYM\1740 0.942\CD\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 <e2>pseudoprolactinoma</e2>\NN\1740 or\CC\3541091 risperidone-induced\JJ\1740 hyperprolactinemia\NN\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D018967_D015175 NONE RESULTS\NNS\34213 :\:\1740 Verapamil\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>macroprolactinoma</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>risperidone-induced</e1>\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D015175 NONE RESULTS\NNS\34213 :\:\1740 Verapamil\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>microprolactinoma</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>risperidone-induced</e1>\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D015175 NONE RESULTS\NNS\34213 :\:\1740 Verapamil\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>macroprolactinemia</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>risperidone-induced</e1>\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D018967_-1 NONE RESULTS\NNS\34213 :\:\1740 Verapamil\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 <e2>pseudoprolactinoma</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>risperidone-induced</e1>\JJ\1740 hyperprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D018967_-1 NONE ROC\NNP\9492123 curve\NN\13863771 analysis\NN\633864 revealed\VBD\2137132 that\IN\1740 unresponsiveness\NN\4723816 to\TO\1740 verapamil\RB\1740 defined\VBN\2604760 as\IN\14622893 PRL\NN\1740 <\XX\1740 7\CD\13741022 %\NN\1740 ,\,\1740 discriminated\VBD\650353 anatomical\JJ\1740 or\CC\3541091 functional\JJ\1740 stalk\NN\14991712 effect\NN\34213 (\-LRB-\1740 sensitivity\NN\5651971 :\:\1740 74\CD\1740 %\NN\1740 ,\,\1740 specificity\NN\4762633 :\:\1740 73\CD\1740 %\NN\1740 ,\,\1740 AUC\NN\1740 :\:\1740 0.855+/-0.04\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 ,\,\1740 CI\NN\13635336 :\:\1740 0.768\CD\1740 -\SYM\1740 0.942\CD\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 <e2>pseudoprolactinoma</e2>\NN\1740 or\CC\3541091 <e1>risperidone-induced</e1>\JJ\1740 hyperprolactinemia\NN\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D018967_D006966 CID RESULTS\NNS\34213 :\:\1740 Verapamil\NNS\2938514 significantly\RB\1740 increased\VBD\169651 PRL\NN\1740 levels\NNS\4916342 in\IN\13603305 healthy\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 183\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 7\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 microprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 19\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 21\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 macroprolactinemia\NN\1740 (\-LRB-\1740 N.\NN\1740 23\CD\13745420 ,\,\1740 PRL\NN\1740 :\:\1740 126\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 not\RB\1740 in\IN\13603305 pseudoprolactinoma\NN\1740 (\-LRB-\1740 N.\NN\1740 8\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 0.8\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 (\-LRB-\1740 N.\NN\1740 7\CD\13741022 ,\,\1740 PRL\NN\1740 :\:\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D018967_D006966 CID ROC\NNP\9492123 curve\NN\13863771 analysis\NN\633864 revealed\VBD\2137132 that\IN\1740 unresponsiveness\NN\4723816 to\TO\1740 verapamil\RB\1740 defined\VBN\2604760 as\IN\14622893 PRL\NN\1740 <\XX\1740 7\CD\13741022 %\NN\1740 ,\,\1740 discriminated\VBD\650353 anatomical\JJ\1740 or\CC\3541091 functional\JJ\1740 stalk\NN\14991712 effect\NN\34213 (\-LRB-\1740 sensitivity\NN\5651971 :\:\1740 74\CD\1740 %\NN\1740 ,\,\1740 specificity\NN\4762633 :\:\1740 73\CD\1740 %\NN\1740 ,\,\1740 AUC\NN\1740 :\:\1740 0.855+/-0.04\NN\1740 ,\,\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 ,\,\1740 CI\NN\13635336 :\:\1740 0.768\CD\1740 -\SYM\1740 0.942\CD\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 pseudoprolactinoma\NN\1740 or\CC\3541091 <e1>risperidone-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 respectively\RB\1740 .\.\1740
3339945
D013806_D020258 NONE <e1>Theophylline</e1>\NN\2905612 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 pregnant\JJ\1740 rats\NNS\2329401 .\.\1740
D013806_D020258 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 investigation\NN\5797597 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 <e2>neurotoxicity</e2>\NN\1740 of\IN\1740 <e1>theophylline</e1>\NN\2905612 is\VBZ\836236 altered\VBN\126264 in\IN\13603305 advanced\JJ\1740 pregnancy\NN\14034177 .\.\1740
D013806_D020258 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 advanced\JJ\1740 pregnancy\NN\14034177 has\VBZ\2108377 a\DT\13649268 negligible\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 response\NN\11410625 to\TO\1740 <e1>theophylline</e1>\NN\2905612 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000628_D012640 CID Sprague-Dawley\NN\1740 rats\NNS\2329401 that\WDT\1740 were\VBD\836236 20\CD\13745420 days\NNS\15140892 pregnant\JJ\1740 and\CC\1740 nonpregnant\JJ\1740 rats\NNS\2329401 of\IN\1740 the\DT\1740 same\JJ\1740 age\NN\4916342 and\CC\1740 strain\NN\7358060 received\VBD\2210855 infusions\NNS\14589223 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 until\IN\1740 onset\NN\7325190 of\IN\1740 maximal\JJ\1740 <e2>seizures</e2>\NNS\14081375 which\WDT\1740 occurred\VBD\2623529 after\IN\1740 28\CD\13745420 and\CC\1740 30\CD\13745420 minutes\NNS\6502378 respectively\RB\1740 .\.\1740
6893265
D011441_D056486 CID <e1>Propylthiouracil-induced</e1>\JJ\1740 <e2>hepatic\JJ\1740 damage</e2>\NN\7296428 .\.\1740
D011441_D056486 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>propylthiouracil-induced</e1>\JJ\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 have\VBP\2108377 been\VBN\836236 observed\VBN\2163746 .\.\1740
16810074
D009569_D006973 CID Mechanisms\NNS\13446390 of\IN\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 :\:\1740 focus\VB\628491 on\IN\1740 venous\JJ\1740 function\NN\13783581 .\.\1740
D009569_D006973 CID Mechanisms\NNS\13446390 of\IN\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 :\:\1740 focus\VB\628491 on\IN\1740 venous\JJ\1740 function\NN\13783581 .\.\1740
D009569_D006973 CID Loss\NN\13252973 of\IN\1740 endothelial\JJ\1740 cell-derived\JJ\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 in\IN\13603305 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 a\DT\13649268 hallmark\NN\4731497 of\IN\1740 arterial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D009569_D006973 CID Loss\NN\13252973 of\IN\1740 endothelial\JJ\1740 cell-derived\JJ\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 in\IN\13603305 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 a\DT\13649268 hallmark\NN\4731497 of\IN\1740 arterial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D009569_D006973 CID Experimental\JJ\1740 <e2>hypertension</e2>\NN\14057371 created\VBN\2367363 by\IN\1740 the\DT\1740 removal\NN\383606 of\IN\1740 <e1>NO</e1>\NN\7204911 ,\,\1740 however\RB\1740 ,\,\1740 involves\VBZ\2676054 mechanisms\NNS\13446390 in\IN\13603305 addition\NN\3081021 to\TO\1740 decreased\VBN\169651 arterial\JJ\1740 vasodilator\NN\3198383 activity\NN\30358 .\.\1740
D009569_D006973 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 while\IN\15122231 <e1>NO</e1>\DT\7204911 deficiency\NN\14449126 increases\VBZ\169651 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 sympathetic\JJ\1740 activity\NN\30358 in\IN\13603305 both\CC\1740 arterial\JJ\1740 and\CC\1740 venous\JJ\1740 vessels\NNS\5246511 ,\,\1740 the\DT\1740 impact\NN\7339329 on\IN\1740 veins\NNS\5417975 does\VBZ\1640855 not\RB\1740 make\VB\126264 a\DT\13649268 major\JJ\1740 contribution\NN\786195 to\TO\1740 this\DT\1740 form\NN\6286395 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D009569_D018754 NONE Loss\NN\13252973 of\IN\1740 endothelial\JJ\1740 cell-derived\JJ\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 in\IN\13603305 hypertension\NN\14057371 is\VBZ\836236 a\DT\13649268 hallmark\NN\4731497 of\IN\1740 <e2>arterial\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D009569_D018754 NONE Loss\NN\13252973 of\IN\1740 endothelial\JJ\1740 cell-derived\JJ\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 in\IN\13603305 hypertension\NN\14057371 is\VBZ\836236 a\DT\13649268 hallmark\NN\4731497 of\IN\1740 <e2>arterial\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D019335_D006973 NONE We\PRP\1740 hypothesized\VBD\719734 that\IN\1740 increased\VBD\169651 venous\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 (\-LRB-\1740 venomotor\NN\1740 )\-RRB-\1740 tone\NN\7071483 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 <e1>Nomega-nitro-L-arginine</e1>\NN\1740 (\-LRB-\1740 LNNA\NN\1740 )\-RRB-\1740 <e2>hypertension</e2>\NN\14057371 through\IN\1740 these\DT\1740 mechanisms\NNS\13446390 .\.\1740
D019335_D006973 NONE We\PRP\1740 hypothesized\VBD\719734 that\IN\1740 increased\VBD\169651 venous\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 (\-LRB-\1740 venomotor\NN\1740 )\-RRB-\1740 tone\NN\7071483 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 Nomega-nitro-L-arginine\NN\1740 (\-LRB-\1740 <e1>LNNA</e1>\NN\1740 )\-RRB-\1740 <e2>hypertension</e2>\NN\14057371 through\IN\1740 these\DT\1740 mechanisms\NNS\13446390 .\.\1740
D019335_D006973 NONE Mean\VB\928630 circulatory\JJ\1740 filling\NN\14580897 pressure\NN\11419404 ,\,\1740 an\DT\6697703 in\FW\13603305 vivo\FW\1740 measure\NN\168237 of\IN\1740 venomotor\NN\1740 tone\NN\7071483 ,\,\1740 was\VBD\836236 not\RB\1740 elevated\JJ\1740 in\IN\13603305 <e1>LNNA</e1>\NN\1740 <e2>hypertension</e2>\NN\14057371 at\IN\14622893 1\CD\13741022 or\CC\3541091 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 LNNA\NNP\1740 .\.\1740
D019335_D006973 NONE Mean\VB\928630 circulatory\JJ\1740 filling\NN\14580897 pressure\NN\11419404 ,\,\1740 an\DT\6697703 in\FW\13603305 vivo\FW\1740 measure\NN\168237 of\IN\1740 venomotor\NN\1740 tone\NN\7071483 ,\,\1740 was\VBD\836236 not\RB\1740 elevated\JJ\1740 in\IN\13603305 LNNA\NN\1740 <e2>hypertension</e2>\NN\14057371 at\IN\14622893 1\CD\13741022 or\CC\3541091 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 <e1>LNNA</e1>\NNP\1740 .\.\1740
D019335_D006973 NONE Similarly\RB\1740 ,\,\1740 ganglionic\JJ\1740 blockade\NN\952963 with\IN\1740 hexamethonium\NN\1740 caused\VBD\1617192 a\DT\13649268 significantly\RB\1740 greater\JJR\1740 fall\NN\15236475 in\IN\13603305 <e1>LNNA</e1>\NN\1740 <e2>hypertensive</e2>\NN\10405694 rats\NNS\2329401 (\-LRB-\1740 76\CD\1740 +/-\CC\1740 9\CD\13741022 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 control\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 35\CD\1740 +/-\CC\1740 10\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 )\-RRB-\1740 .\.\1740
D018738_D006973 NONE Similarly\RB\1740 ,\,\1740 ganglionic\JJ\1740 blockade\NN\952963 with\IN\1740 <e1>hexamethonium</e1>\NN\1740 caused\VBD\1617192 a\DT\13649268 significantly\RB\1740 greater\JJR\1740 fall\NN\15236475 in\IN\13603305 LNNA\NN\1740 <e2>hypertensive</e2>\NN\10405694 rats\NNS\2329401 (\-LRB-\1740 76\CD\1740 +/-\CC\1740 9\CD\13741022 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 control\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 35\CD\1740 +/-\CC\1740 10\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 )\-RRB-\1740 .\.\1740
1563460
D014859_D020758 CID <e2>Thoracic\NN\1740 hematomyelia</e2>\NN\1740 secondary\JJ\1740 to\TO\1740 <e1>coumadin</e1>\NN\2718259 anticoagulant\NN\3740161 therapy\NN\657604 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
6529939
D011433_D001146 CID <e2>Alternating\VBG\123170 sinus\NN\5248181 rhythm</e2>\NN\15122011 and\CC\1740 intermittent\JJ\1740 sinoatrial\NN\1740 block\NN\21939 induced\VBN\1627355 by\IN\1740 <e1>propranolol</e1>\NN\1740 .\.\1740
D011433_D001146 CID <e2>Alternating\VBG\123170 sinus\NN\5248181 rhythm</e2>\NN\15122011 and\CC\1740 intermittent\JJ\1740 sinoatrial\NN\1740 (\-LRB-\1740 S-A\NN\1740 )\-RRB-\1740 block\NN\21939 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 ,\,\1740 under\IN\1740 treatment\NN\654885 for\IN\1740 angina\NN\14171682 with\IN\1740 80\CD\13745420 mg\NN\13717155 <e1>propranolol</e1>\NN\1740 daily\RB\1740 .\.\1740
D011433_D012848 CID Alternating\VBG\123170 sinus\NN\5248181 rhythm\NN\15122011 and\CC\1740 intermittent\JJ\1740 <e2>sinoatrial\NN\1740 block</e2>\NN\21939 induced\VBN\1627355 by\IN\1740 <e1>propranolol</e1>\NN\1740 .\.\1740
D011433_D012848 CID Alternating\VBG\123170 sinus\NN\5248181 rhythm\NN\15122011 and\CC\1740 intermittent\JJ\1740 <e2>sinoatrial\NN\1740 (\-LRB-\1740 S-A\NN\1740 )\-RRB-\1740 block</e2>\NN\21939 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 ,\,\1740 under\IN\1740 treatment\NN\654885 for\IN\1740 angina\NN\14171682 with\IN\1740 80\CD\13745420 mg\NN\13717155 <e1>propranolol</e1>\NN\1740 daily\RB\1740 .\.\1740
D011433_D012848 CID The\DT\1740 abnormal\JJ\1740 rhythm\NN\15122011 disappeared\VBD\2609764 with\IN\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 when\WRB\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 restarted\VBN\1857717 a\DT\13649268 2/1\CD\1740 <e2>S-A\JJ\1740 block</e2>\NN\21939 was\VBD\836236 seen\VBN\2106506 .\.\1740
D011433_D000787 NONE Alternating\VBG\123170 sinus\NN\5248181 rhythm\NN\15122011 and\CC\1740 intermittent\JJ\1740 sinoatrial\NN\1740 (\-LRB-\1740 S-A\NN\1740 )\-RRB-\1740 block\NN\21939 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 ,\,\1740 under\IN\1740 treatment\NN\654885 for\IN\1740 <e2>angina</e2>\NN\14171682 with\IN\1740 80\CD\13745420 mg\NN\13717155 <e1>propranolol</e1>\NN\1740 daily\RB\1740 .\.\1740
D011433_D019955 NONE This\DT\1740 was\VBD\836236 accepted\VBN\670261 as\IN\14622893 evidence\NN\5816287 for\IN\1740 <e1>propranolol</e1>\NN\1740 being\VBG\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 this\DT\1740 <e2>conduction\NN\11419404 disorder</e2>\NN\14034177 .\.\1740
24812279
D018943_D066126 NONE P53\NN\1740 inhibition\NN\1068773 exacerbates\VBZ\126264 late-stage\NN\1740 <e1>anthracycline</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D009369 NONE AIMS\NNS\5980875 :\:\1740 <e1>Doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 <e2>anti-cancer</e2>\NN\1740 therapeutic\JJ\1740 ,\,\1740 but\CC\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 both\CC\1740 acute\JJ\1740 and\CC\1740 late-stage\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D009369 NONE AIMS\NNS\5980875 :\:\1740 Doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 <e2>anti-cancer</e2>\NN\1740 therapeutic\JJ\1740 ,\,\1740 but\CC\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 both\CC\1740 acute\JJ\1740 and\CC\1740 late-stage\NN\1740 cardiotoxicity\NN\1740 .\.\1740
D004317_D066126 NONE AIMS\NNS\5980875 :\:\1740 <e1>Doxorubicin</e1>\NN\2716866 (\-LRB-\1740 DOX\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 anti-cancer\NN\1740 therapeutic\JJ\1740 ,\,\1740 but\CC\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 both\CC\1740 acute\JJ\1740 and\CC\1740 late-stage\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE AIMS\NNS\5980875 :\:\1740 Doxorubicin\NN\2716866 (\-LRB-\1740 <e1>DOX</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 anti-cancer\NN\1740 therapeutic\JJ\1740 ,\,\1740 but\CC\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 both\CC\1740 acute\JJ\1740 and\CC\1740 late-stage\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE Here\RB\1740 ,\,\1740 the\DT\1740 impact\NN\7339329 of\IN\1740 p53\NN\1740 inhibition\NN\1068773 on\IN\1740 acute\JJ\1740 vs.\CC\1740 late-stage\NN\1740 <e1>DOX</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 a\DT\13649268 juvenile\NN\7846 model\NN\5888929 .\.\1740
D004317_D006333 CID Children\NNS\9622049 are\VBP\836236 particularly\RB\1740 sensitive\JJ\1740 to\TO\1740 <e1>DOX-induced</e1>\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
3538855
D000617_D007674 CID Studies\NNS\635850 of\IN\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e1>aminoglycoside</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000617_D007674 CID The\DT\1740 epidemiology\NN\6043075 of\IN\1740 <e1>aminoglycoside-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 is\VBZ\836236 not\RB\1740 fully\RB\1740 understood\VBN\588888 .\.\1740
D000617_D007674 CID Experimental\JJ\1740 studies\NNS\635850 in\IN\13603305 healthy\JJ\1740 human\JJ\1740 volunteers\NNS\10582746 indicate\VBP\952524 <e1>aminoglycosides</e1>\NNS\1740 cause\VBP\1617192 proximal\JJ\1740 tubular\JJ\1740 damage\NN\7296428 in\IN\13603305 most\JJS\1740 patients\NNS\9898892 ,\,\1740 but\CC\1740 rarely\RB\1740 ,\,\1740 if\IN\1740 ever\RB\1740 ,\,\1740 cause\VB\1617192 <e2>glomerular\JJ\1740 or\CC\3541091 tubular\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D000617_D007674 CID Further\JJ\1740 analysis\NN\633864 of\IN\1740 these\DT\1740 data\NNS\7951464 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 therapy\NN\657604 ,\,\1740 plasma\NN\5398023 <e1>aminoglycoside</e1>\NN\1740 levels\NNS\4916342 ,\,\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 high\JJ\1740 initial\JJ\1740 estimated\VBN\637259 creatinine\NN\1740 clearance\NN\5089947 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 female\JJ\1740 gender\NN\6309383 all\DT\1740 increase\VBP\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000617_D007674 CID These\DT\1740 models\NNS\5888929 may\MD\15209706 also\RB\1740 be\VB\836236 useful\JJ\1740 in\IN\13603305 developing\VBG\1753788 insights\NNS\5710020 into\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e1>aminoglycoside-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D000617_D058186 NONE Clinical\JJ\1740 trials\NNS\786195 of\IN\1740 <e1>aminoglycosides</e1>\NNS\1740 in\IN\13603305 seriously\RB\1740 ill\JJ\1740 patients\NNS\9898892 indicate\VBP\952524 that\IN\1740 the\DT\1740 relative\JJ\1740 risk\NN\14541044 for\IN\1740 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 during\IN\1740 therapy\NN\657604 ranges\VBZ\2604760 from\IN\1740 8\CD\13741022 to\TO\1740 10\CD\13745420 and\CC\1740 that\IN\1740 the\DT\1740 attributable\JJ\1740 risk\NN\14541044 is\VBZ\836236 70\CD\13745420 %\NN\1740 to\TO\1740 80\CD\13745420 %\NN\1740 .\.\1740
D000617_D008107 NONE Further\JJ\1740 analysis\NN\633864 of\IN\1740 these\DT\1740 data\NNS\7951464 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 therapy\NN\657604 ,\,\1740 plasma\NN\5398023 <e1>aminoglycoside</e1>\NN\1740 levels\NNS\4916342 ,\,\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 ,\,\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 high\JJ\1740 initial\JJ\1740 estimated\VBN\637259 creatinine\NN\1740 clearance\NN\5089947 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 female\JJ\1740 gender\NN\6309383 all\DT\1740 increase\VBP\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 nephrotoxicity\NN\1740 .\.\1740
D003404_D008107 NONE Further\JJ\1740 analysis\NN\633864 of\IN\1740 these\DT\1740 data\NNS\7951464 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 therapy\NN\657604 ,\,\1740 plasma\NN\5398023 aminoglycoside\NN\1740 levels\NNS\4916342 ,\,\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 ,\,\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 high\JJ\1740 initial\JJ\1740 estimated\VBN\637259 <e1>creatinine</e1>\NN\1740 clearance\NN\5089947 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 female\JJ\1740 gender\NN\6309383 all\DT\1740 increase\VBP\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 nephrotoxicity\NN\1740 .\.\1740
D003404_D007674 NONE Further\JJ\1740 analysis\NN\633864 of\IN\1740 these\DT\1740 data\NNS\7951464 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 therapy\NN\657604 ,\,\1740 plasma\NN\5398023 aminoglycoside\NN\1740 levels\NNS\4916342 ,\,\1740 liver\NN\5298729 disease\NN\14061805 ,\,\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 high\JJ\1740 initial\JJ\1740 estimated\VBN\637259 <e1>creatinine</e1>\NN\1740 clearance\NN\5089947 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 female\JJ\1740 gender\NN\6309383 all\DT\1740 increase\VBP\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
15817013
D014859_D001281 NONE People\NNS\31264 aged\VBD\252019 over\IN\5867413 75\CD\1740 in\IN\13603305 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 on\IN\1740 <e1>warfarin</e1>\NN\2718259 :\:\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 stroke\VB\1206218 in\IN\13603305 more\JJR\1740 than\IN\1740 500\CD\13745420 patient-years\NNS\1740 of\IN\1740 follow-up\NN\4599396 .\.\1740
D014859_D001281 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 major\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 stroke\VB\1206218 in\IN\13603305 people\NNS\31264 aged\JJ\1740 76\CD\1740 and\CC\1740 older\JJR\1740 with\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 on\IN\1740 adjusted-dose\JJ\1740 <e1>warfarin</e1>\NN\2718259 who\WP\8299493 had\VBD\2108377 been\VBN\836236 recently\RB\1740 been\VBN\836236 admitted\VBN\822367 to\IN\1740 hospital\NN\3739518 .\.\1740
D014859_D001281 NONE PARTICIPANTS\NNS\9816771 :\:\1740 Two\CD\13741022 hundred\CD\13745420 thirty-five\JJ\1740 patients\NNS\9898892 aged\JJ\1740 76\CD\1740 and\CC\1740 older\JJR\1740 admitted\VBN\822367 to\TO\1740 a\DT\13649268 major\JJ\1740 healthcare\NN\654885 network\NN\8435388 between\IN\1740 July\NNP\15209706 1\CD\13741022 ,\,\1740 2001\CD\1740 ,\,\1740 and\CC\1740 June\NNP\15209706 30\CD\13745420 ,\,\1740 2002\CD\1740 ,\,\1740 with\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 on\IN\1740 <e1>warfarin</e1>\NN\2718259 were\VBD\836236 enrolled\VBN\2471690 .\.\1740
D014859_D006470 CID People\NNS\31264 aged\VBD\252019 over\IN\5867413 75\CD\1740 in\IN\13603305 atrial\JJ\1740 fibrillation\NN\14361664 on\IN\1740 <e1>warfarin</e1>\NN\2718259 :\:\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 <e2>hemorrhage</e2>\NN\14285662 and\CC\1740 stroke\VB\1206218 in\IN\13603305 more\JJR\1740 than\IN\1740 500\CD\13745420 patient-years\NNS\1740 of\IN\1740 follow-up\NN\4599396 .\.\1740
D014859_D006470 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 major\JJ\1740 <e2>hemorrhage</e2>\NN\14285662 and\CC\1740 stroke\VB\1206218 in\IN\13603305 people\NNS\31264 aged\JJ\1740 76\CD\1740 and\CC\1740 older\JJR\1740 with\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 on\IN\1740 adjusted-dose\JJ\1740 <e1>warfarin</e1>\NN\2718259 who\WP\8299493 had\VBD\2108377 been\VBN\836236 recently\RB\1740 been\VBN\836236 admitted\VBN\822367 to\IN\1740 hospital\NN\3739518 .\.\1740
D014859_D006470 CID MEASUREMENTS\NNS\407535 :\:\1740 Information\NN\6598915 regarding\VBG\689344 major\JJ\1740 <e2>bleeding</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 strokes\NNS\556313 ,\,\1740 and\CC\1740 <e1>warfarin</e1>\NN\2718259 use\NN\407535 was\VBD\836236 obtained\VBN\2210855 from\IN\1740 patients\NNS\9898892 ,\,\1740 relatives\NNS\7846 ,\,\1740 primary\JJ\1740 physicians\NNS\10305802 ,\,\1740 and\CC\1740 medical\JJ\1740 records\NNS\6643408 .\.\1740
D014859_D006470 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 <e2>hemorrhage</e2>\NN\14285662 was\VBD\836236 high\JJ\1740 in\IN\13603305 this\DT\1740 old\JJ\1740 ,\,\1740 frail\NN\13608788 group\NN\2137 ,\,\1740 but\CC\1740 excluding\VBG\471711 fatalities\NNS\7355491 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 long-term\JJ\1740 sequelae\NN\14501726 ,\,\1740 and\CC\1740 the\DT\1740 stroke\NN\556313 rate\NN\13815152 on\IN\1740 <e1>warfarin</e1>\NN\2718259 was\VBD\836236 low\JJ\1740 ,\,\1740 demonstrating\VBG\2137132 how\WRB\1740 effective\JJ\1740 warfarin\NN\2718259 treatment\NN\654885 is\VBZ\836236 .\.\1740
D014859_D006470 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 <e2>hemorrhage</e2>\NN\14285662 was\VBD\836236 high\JJ\1740 in\IN\13603305 this\DT\1740 old\JJ\1740 ,\,\1740 frail\NN\13608788 group\NN\2137 ,\,\1740 but\CC\1740 excluding\VBG\471711 fatalities\NNS\7355491 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 long-term\JJ\1740 sequelae\NN\14501726 ,\,\1740 and\CC\1740 the\DT\1740 stroke\NN\556313 rate\NN\13815152 on\IN\1740 warfarin\NN\2718259 was\VBD\836236 low\JJ\1740 ,\,\1740 demonstrating\VBG\2137132 how\WRB\1740 effective\JJ\1740 <e1>warfarin</e1>\NN\2718259 treatment\NN\654885 is\VBZ\836236 .\.\1740
D014859_D020521 NONE People\NNS\31264 aged\VBD\252019 over\IN\5867413 75\CD\1740 in\IN\13603305 atrial\JJ\1740 fibrillation\NN\14361664 on\IN\1740 <e1>warfarin</e1>\NN\2718259 :\:\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 <e2>stroke</e2>\VB\1206218 in\IN\13603305 more\JJR\1740 than\IN\1740 500\CD\13745420 patient-years\NNS\1740 of\IN\1740 follow-up\NN\4599396 .\.\1740
D014859_D020521 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 incidence\NN\13821570 of\IN\1740 major\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 <e2>stroke</e2>\VB\1206218 in\IN\13603305 people\NNS\31264 aged\JJ\1740 76\CD\1740 and\CC\1740 older\JJR\1740 with\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 on\IN\1740 adjusted-dose\JJ\1740 <e1>warfarin</e1>\NN\2718259 who\WP\8299493 had\VBD\2108377 been\VBN\836236 recently\RB\1740 been\VBN\836236 admitted\VBN\822367 to\IN\1740 hospital\NN\3739518 .\.\1740
D014859_D020521 NONE MEASUREMENTS\NNS\407535 :\:\1740 Information\NN\6598915 regarding\VBG\689344 major\JJ\1740 bleeding\JJ\1740 episodes\NNS\7283608 ,\,\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 and\CC\1740 <e1>warfarin</e1>\NN\2718259 use\NN\407535 was\VBD\836236 obtained\VBN\2210855 from\IN\1740 patients\NNS\9898892 ,\,\1740 relatives\NNS\7846 ,\,\1740 primary\JJ\1740 physicians\NNS\10305802 ,\,\1740 and\CC\1740 medical\JJ\1740 records\NNS\6643408 .\.\1740
D014859_D020521 NONE The\DT\1740 annual\JJ\1740 <e2>stroke</e2>\NN\556313 rate\NN\13815152 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>warfarin</e1>\NN\2718259 was\VBD\836236 2.6\CD\1740 %\NN\1740 .\.\1740
D014859_D020521 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 hemorrhage\NN\14285662 was\VBD\836236 high\JJ\1740 in\IN\13603305 this\DT\1740 old\JJ\1740 ,\,\1740 frail\NN\13608788 group\NN\2137 ,\,\1740 but\CC\1740 excluding\VBG\471711 fatalities\NNS\7355491 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 long-term\JJ\1740 sequelae\NN\14501726 ,\,\1740 and\CC\1740 the\DT\1740 <e2>stroke</e2>\NN\556313 rate\NN\13815152 on\IN\1740 <e1>warfarin</e1>\NN\2718259 was\VBD\836236 low\JJ\1740 ,\,\1740 demonstrating\VBG\2137132 how\WRB\1740 effective\JJ\1740 warfarin\NN\2718259 treatment\NN\654885 is\VBZ\836236 .\.\1740
D014859_D020521 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 major\JJ\1740 hemorrhage\NN\14285662 was\VBD\836236 high\JJ\1740 in\IN\13603305 this\DT\1740 old\JJ\1740 ,\,\1740 frail\NN\13608788 group\NN\2137 ,\,\1740 but\CC\1740 excluding\VBG\471711 fatalities\NNS\7355491 ,\,\1740 resulted\VBD\2633881 in\IN\13603305 no\DT\7204911 long-term\JJ\1740 sequelae\NN\14501726 ,\,\1740 and\CC\1740 the\DT\1740 <e2>stroke</e2>\NN\556313 rate\NN\13815152 on\IN\1740 warfarin\NN\2718259 was\VBD\836236 low\JJ\1740 ,\,\1740 demonstrating\VBG\2137132 how\WRB\1740 effective\JJ\1740 <e1>warfarin</e1>\NN\2718259 treatment\NN\654885 is\VBZ\836236 .\.\1740
19178808
D015742_D006470 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 surgical\JJ\1740 conditions\NNS\14512817 ,\,\1740 including\VBG\690614 the\DT\1740 amount\NN\13329641 of\IN\1740 intraoperative\JJ\1740 <e2>bleeding</e2>\NN\14285662 as\RB\1740 well\RB\1740 as\IN\14622893 intraoperative\JJ\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 during\IN\1740 functional\JJ\1740 endoscopic\JJ\1740 sinus\NN\5248181 surgery\NN\6045562 (\-LRB-\1740 FESS\NN\3853734 )\-RRB-\1740 using\VBG\1156834 flexible\JJ\1740 reinforced\VBN\220869 laryngeal\NN\1740 mask\NN\3122748 airway\NN\3253398 (\-LRB-\1740 FRLMA\NN\1740 )\-RRB-\1740 versus\CC\1740 endotracheal\NN\1740 tube\NN\3089014 (\-LRB-\1740 ETT\NN\1740 )\-RRB-\1740 in\IN\13603305 maintaining\VBG\2202928 controlled\VBN\2422663 hypotension\NN\14057371 anesthesia\NN\14034177 induced\VBN\1627355 by\IN\1740 <e1>propofol-remifentanil</e1>\JJ\1740 total\JJ\1740 i.v.\NN\1740 anesthesia\NN\14034177 (\-LRB-\1740 TIVA\NN\1740 )\-RRB-\1740 .\.\1740
D015742_D007022 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 surgical\JJ\1740 conditions\NNS\14512817 ,\,\1740 including\VBG\690614 the\DT\1740 amount\NN\13329641 of\IN\1740 intraoperative\JJ\1740 bleeding\NN\14285662 as\RB\1740 well\RB\1740 as\IN\14622893 intraoperative\JJ\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 during\IN\1740 functional\JJ\1740 endoscopic\JJ\1740 sinus\NN\5248181 surgery\NN\6045562 (\-LRB-\1740 FESS\NN\3853734 )\-RRB-\1740 using\VBG\1156834 flexible\JJ\1740 reinforced\VBN\220869 laryngeal\NN\1740 mask\NN\3122748 airway\NN\3253398 (\-LRB-\1740 FRLMA\NN\1740 )\-RRB-\1740 versus\CC\1740 endotracheal\NN\1740 tube\NN\3089014 (\-LRB-\1740 ETT\NN\1740 )\-RRB-\1740 in\IN\13603305 maintaining\VBG\2202928 controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 anesthesia\NN\14034177 induced\VBN\1627355 by\IN\1740 <e1>propofol-remifentanil</e1>\JJ\1740 total\JJ\1740 i.v.\NN\1740 anesthesia\NN\14034177 (\-LRB-\1740 TIVA\NN\1740 )\-RRB-\1740 .\.\1740
D015742_D007022 CID METHODS\NNS\5616786 :\:\1740 Sixty\CD\13745420 normotensive\NN\1740 American\NNP\9620078 Society\NNP\7950920 of\IN\1740 Anesthesiologists\NNP\10632576 I-II\CD\1740 adult\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 FESS\NN\3853734 under\IN\1740 controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 anesthesia\NN\14034177 caused\VBN\1617192 by\IN\1740 <e1>propofol-remifentanil-TIVA</e1>\NN\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 into\IN\1740 two\CD\13741022 groups\NNS\2137 :\:\1740 group\NN\2137 I\CD\14622893 ,\,\1740 FRLMA\NN\1740 ;\:\1740 group\NN\2137 II\CD\13741022 ,\,\1740 ETT\NN\1740 .\.\1740
C071741_D006470 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 surgical\JJ\1740 conditions\NNS\14512817 ,\,\1740 including\VBG\690614 the\DT\1740 amount\NN\13329641 of\IN\1740 intraoperative\JJ\1740 <e2>bleeding</e2>\NN\14285662 as\RB\1740 well\RB\1740 as\IN\14622893 intraoperative\JJ\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 during\IN\1740 functional\JJ\1740 endoscopic\JJ\1740 sinus\NN\5248181 surgery\NN\6045562 (\-LRB-\1740 FESS\NN\3853734 )\-RRB-\1740 using\VBG\1156834 flexible\JJ\1740 reinforced\VBN\220869 laryngeal\NN\1740 mask\NN\3122748 airway\NN\3253398 (\-LRB-\1740 FRLMA\NN\1740 )\-RRB-\1740 versus\CC\1740 endotracheal\NN\1740 tube\NN\3089014 (\-LRB-\1740 ETT\NN\1740 )\-RRB-\1740 in\IN\13603305 maintaining\VBG\2202928 controlled\VBN\2422663 hypotension\NN\14057371 anesthesia\NN\14034177 induced\VBN\1627355 by\IN\1740 <e1>propofol-remifentanil</e1>\JJ\1740 total\JJ\1740 i.v.\NN\1740 anesthesia\NN\14034177 (\-LRB-\1740 TIVA\NN\1740 )\-RRB-\1740 .\.\1740
C071741_D007022 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 surgical\JJ\1740 conditions\NNS\14512817 ,\,\1740 including\VBG\690614 the\DT\1740 amount\NN\13329641 of\IN\1740 intraoperative\JJ\1740 bleeding\NN\14285662 as\RB\1740 well\RB\1740 as\IN\14622893 intraoperative\JJ\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 during\IN\1740 functional\JJ\1740 endoscopic\JJ\1740 sinus\NN\5248181 surgery\NN\6045562 (\-LRB-\1740 FESS\NN\3853734 )\-RRB-\1740 using\VBG\1156834 flexible\JJ\1740 reinforced\VBN\220869 laryngeal\NN\1740 mask\NN\3122748 airway\NN\3253398 (\-LRB-\1740 FRLMA\NN\1740 )\-RRB-\1740 versus\CC\1740 endotracheal\NN\1740 tube\NN\3089014 (\-LRB-\1740 ETT\NN\1740 )\-RRB-\1740 in\IN\13603305 maintaining\VBG\2202928 controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 anesthesia\NN\14034177 induced\VBN\1627355 by\IN\1740 <e1>propofol-remifentanil</e1>\JJ\1740 total\JJ\1740 i.v.\NN\1740 anesthesia\NN\14034177 (\-LRB-\1740 TIVA\NN\1740 )\-RRB-\1740 .\.\1740
C071741_D007022 CID METHODS\NNS\5616786 :\:\1740 Sixty\CD\13745420 normotensive\NN\1740 American\NNP\9620078 Society\NNP\7950920 of\IN\1740 Anesthesiologists\NNP\10632576 I-II\CD\1740 adult\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 FESS\NN\3853734 under\IN\1740 controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 anesthesia\NN\14034177 caused\VBN\1617192 by\IN\1740 <e1>propofol-remifentanil-TIVA</e1>\NN\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 into\IN\1740 two\CD\13741022 groups\NNS\2137 :\:\1740 group\NN\2137 I\CD\14622893 ,\,\1740 FRLMA\NN\1740 ;\:\1740 group\NN\2137 II\CD\13741022 ,\,\1740 ETT\NN\1740 .\.\1740
C071741_D007022 CID RESULTS\NNS\34213 :\:\1740 Controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 achieved\VBN\2524171 within\IN\1740 a\DT\13649268 shorter\JJR\1740 period\NN\13575869 using\VBG\1156834 laryngeal\JJ\1740 mask\NN\3122748 using\VBG\1156834 lower\JJR\1740 rates\NNS\13308999 of\IN\1740 <e1>remifentanil</e1>\NN\1740 infusion\NN\14589223 and\CC\1740 lower\JJR\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 remifentanil\NN\1740 .\.\1740
C071741_D007022 CID RESULTS\NNS\34213 :\:\1740 Controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 achieved\VBN\2524171 within\IN\1740 a\DT\13649268 shorter\JJR\1740 period\NN\13575869 using\VBG\1156834 laryngeal\JJ\1740 mask\NN\3122748 using\VBG\1156834 lower\JJR\1740 rates\NNS\13308999 of\IN\1740 remifentanil\NN\1740 infusion\NN\14589223 and\CC\1740 lower\JJR\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>remifentanil</e1>\NN\1740 .\.\1740
C071741_D007022 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 summary\NN\6722453 ,\,\1740 our\PRP$\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 airway\NN\3253398 management\NN\1123598 using\VBG\1156834 FRLMA\NN\1740 during\IN\1740 controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 anesthesia\NN\14034177 provided\VBD\2199590 better\JJR\1740 surgical\JJ\1740 conditions\NNS\14512817 in\IN\13603305 terms\NNS\13945919 of\IN\1740 quality\NN\24264 of\IN\1740 operative\JJ\1740 field\NN\8673395 and\CC\1740 blood\NN\5397468 loss\NN\13252973 and\CC\1740 allowed\VBD\797697 for\IN\1740 convenient\JJ\1740 induced\VBN\1627355 hypotension\NN\14057371 with\IN\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>remifentanil</e1>\NN\1740 during\IN\1740 TIVA\NN\1740 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 FESS\NN\3853734 .\.\1740
C071741_D007022 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 summary\NN\6722453 ,\,\1740 our\PRP$\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 airway\NN\3253398 management\NN\1123598 using\VBG\1156834 FRLMA\NN\1740 during\IN\1740 controlled\VBN\2422663 hypotension\NN\14057371 anesthesia\NN\14034177 provided\VBD\2199590 better\JJR\1740 surgical\JJ\1740 conditions\NNS\14512817 in\IN\13603305 terms\NNS\13945919 of\IN\1740 quality\NN\24264 of\IN\1740 operative\JJ\1740 field\NN\8673395 and\CC\1740 blood\NN\5397468 loss\NN\13252973 and\CC\1740 allowed\VBD\797697 for\IN\1740 convenient\JJ\1740 induced\VBN\1627355 <e2>hypotension</e2>\NN\14057371 with\IN\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>remifentanil</e1>\NN\1740 during\IN\1740 TIVA\NN\1740 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 FESS\NN\3853734 .\.\1740
7121659
D012293_D051437 NONE Antirifampicin\NN\1740 antibodies\NNS\14728724 in\IN\13603305 acute\JJ\1740 <e1>rifampicin-associated</e1>\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D012293_D058186 NONE 5\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 3\CD\13741022 with\IN\1740 thrombopenia\NN\14189204 and\CC\1740 hemolysis\NN\13509528 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 reintroduction\NN\7217349 of\IN\1740 <e1>rifampicin</e1>\NN\1740 are\VBP\836236 described\VBN\1001294 .\.\1740
D012293_D013921 CID 5\CD\13741022 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 3\CD\13741022 with\IN\1740 <e2>thrombopenia</e2>\NN\14189204 and\CC\1740 hemolysis\NN\13509528 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 reintroduction\NN\7217349 of\IN\1740 <e1>rifampicin</e1>\NN\1740 are\VBP\836236 described\VBN\1001294 .\.\1740
D012293_D006461 CID 5\CD\13741022 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 3\CD\13741022 with\IN\1740 thrombopenia\NN\14189204 and\CC\1740 <e2>hemolysis</e2>\NN\13509528 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 reintroduction\NN\7217349 of\IN\1740 <e1>rifampicin</e1>\NN\1740 are\VBP\836236 described\VBN\1001294 .\.\1740
12644816
D013792_D011471 NONE An\DT\6697703 open-label\JJ\1740 phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 low-dose\JJ\1740 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D013792_D011471 NONE We\PRP\1740 undertook\VBD\1641914 an\DT\6697703 open-label\JJ\1740 study\NN\635850 using\VBG\1156834 <e1>thalidomide</e1>\NN\4166841 100\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 for\IN\1740 up\RB\1740 to\TO\1740 6\CD\13741022 months\NNS\15113229 in\IN\13603305 20\CD\13745420 men\NNS\8208016 with\IN\1740 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D000728_D011471 NONE An\DT\6697703 open-label\JJ\1740 phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 low-dose\JJ\1740 thalidomide\NN\4166841 in\IN\13603305 <e1>androgen-independent</e1>\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D000728_D011471 NONE We\PRP\1740 undertook\VBD\1641914 an\DT\6697703 open-label\JJ\1740 study\NN\635850 using\VBG\1156834 thalidomide\NN\4166841 100\CD\13745420 mg\NN\13717155 once\RB\1740 daily\RB\1740 for\IN\1740 up\RB\1740 to\TO\1740 6\CD\13741022 months\NNS\15113229 in\IN\13603305 20\CD\13745420 men\NNS\8208016 with\IN\1740 <e1>androgen-independent</e1>\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D013792_D019337 NONE The\DT\1740 antiangiogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 have\VBP\2108377 been\VBN\836236 assessed\VBN\670261 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 various\JJ\1740 solid\JJ\1740 and\CC\1740 <e2>haematological\JJ\1740 malignancies</e2>\NNS\14070360 .\.\1740
D013792_D010523 CID In\IN\13603305 the\DT\1740 seven\CD\13741022 men\NNS\8208016 who\WP\8299493 completed\VBD\352826 six\CD\13741022 months\NNS\15113229 on\IN\1740 <e1>thalidomide</e1>\NN\4166841 ,\,\1740 subclinical\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 was\VBD\836236 found\VBN\2426171 in\IN\13603305 four\CD\13741022 before\IN\1740 treatment\NN\654885 ,\,\1740 but\CC\1740 in\IN\13603305 all\DT\1740 seven\CD\13741022 at\IN\14622893 repeat\NN\7296190 testing\NN\639556 .\.\1740
D013792_D010523 CID The\DT\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>thalidomide</e1>\NN\4166841 may\MD\15209706 be\VB\836236 an\DT\6697703 option\NN\6480506 for\IN\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 failed\VBN\1798936 other\JJ\1740 forms\NNS\6286395 of\IN\1740 therapy\NN\657604 ,\,\1740 provided\VBN\2199590 close\JJ\1740 follow-up\NN\4599396 is\VBZ\836236 maintained\VBN\2202928 for\IN\1740 development\NN\248977 of\IN\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
3990093
D011692_D007674 NONE Mesangial\JJ\1740 function\NN\13783581 and\CC\1740 <e2>glomerular\JJ\1740 sclerosis</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>aminonucleoside</e1>\NN\1740 nephrosis\NN\14304060 .\.\1740
D011692_D007674 NONE The\DT\1740 possible\JJ\1740 relationship\NN\31921 between\IN\1740 <e2>mesangial\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 development\NN\248977 of\IN\1740 glomerular\JJ\1740 sclerosis\NN\14204950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 model\NN\5888929 .\.\1740
D011692_D007674 NONE The\DT\1740 possible\JJ\1740 relationship\NN\31921 between\IN\1740 mesangial\JJ\1740 dysfunction\NN\14204950 and\CC\1740 development\NN\248977 of\IN\1740 <e2>glomerular\JJ\1740 sclerosis</e2>\NN\14204950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 the\DT\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 model\NN\5888929 .\.\1740
D011692_D007674 NONE The\DT\1740 possible\JJ\1740 relationship\NN\31921 between\IN\1740 <e2>mesangial\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 development\NN\248977 of\IN\1740 glomerular\JJ\1740 sclerosis\NN\14204950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 the\DT\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 model\NN\5888929 .\.\1740
D011692_D007674 NONE The\DT\1740 possible\JJ\1740 relationship\NN\31921 between\IN\1740 mesangial\JJ\1740 dysfunction\NN\14204950 and\CC\1740 development\NN\248977 of\IN\1740 <e2>glomerular\JJ\1740 sclerosis</e2>\NN\14204950 was\VBD\836236 studied\VBN\630380 in\IN\13603305 the\DT\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 model\NN\5888929 .\.\1740
D011692_D007674 NONE At\IN\14622893 5\CD\13741022 months\NNS\15113229 <e2>glomerular\JJ\1740 sclerosis</e2>\NN\14204950 was\VBD\836236 found\VBN\2426171 in\IN\13603305 7.6\CD\1740 +/-\CC\1740 3.4\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 glomeruli\NNS\5425910 of\IN\1740 <e1>PAN</e1>\NN\3101986 rats\NNS\2329401 ;\:\1740 glomeruli\NNS\5425910 of\IN\1740 the\DT\1740 controls\NNS\5190804 were\VBD\836236 normal\JJ\1740 .\.\1740
D011692_D007674 NONE Similar\JJ\1740 to\TO\1740 the\DT\1740 remnant\JJ\1740 kidney\NN\5333259 model\NN\5888929 in\IN\13603305 <e1>PAN</e1>\NN\3101986 nephrosis\NN\14304060 the\DT\1740 development\NN\248977 of\IN\1740 <e2>glomerular\JJ\1740 sclerosis</e2>\NN\14204950 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 "\``\1740 mesangial\JJ\1740 overloading\NN\1740 .\.\1740 "\''\1740
D011692_D009401 NONE Mesangial\JJ\1740 function\NN\13783581 and\CC\1740 glomerular\JJ\1740 sclerosis\NN\14204950 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 NONE Similar\JJ\1740 to\TO\1740 the\DT\1740 remnant\JJ\1740 kidney\NN\5333259 model\NN\5888929 in\IN\13603305 <e1>PAN</e1>\NN\3101986 <e2>nephrosis</e2>\NN\14304060 the\DT\1740 development\NN\248977 of\IN\1740 glomerular\JJ\1740 sclerosis\NN\14204950 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 "\``\1740 mesangial\JJ\1740 overloading\NN\1740 .\.\1740 "\''\1740
D011692_D011507 CID After\IN\1740 4\CD\13741022 weeks\NNS\15113229 the\DT\1740 <e1>PAN</e1>\NN\3101986 rats\NNS\2329401 were\VBD\836236 severely\RB\1740 <e2>proteinuric</e2>\JJ\1740 (\-LRB-\1740 190\CD\1740 +/-\CC\1740 80\CD\13745420 mg/24\NNS\1740 hr\NN\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 all\DT\1740 rats\NNS\2329401 were\VBD\836236 given\VBN\2327200 colloidal\JJ\1740 carbon\NN\14622893 (\-LRB-\1740 CC\NN\13616054 )\-RRB-\1740 intravenously\RB\1740 .\.\1740
D002244_D011507 NONE After\IN\1740 4\CD\13741022 weeks\NNS\15113229 the\DT\1740 PAN\NN\3101986 rats\NNS\2329401 were\VBD\836236 severely\RB\1740 <e2>proteinuric</e2>\JJ\1740 (\-LRB-\1740 190\CD\1740 +/-\CC\1740 80\CD\13745420 mg/24\NNS\1740 hr\NN\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 all\DT\1740 rats\NNS\2329401 were\VBD\836236 given\VBN\2327200 colloidal\JJ\1740 <e1>carbon</e1>\NN\14622893 (\-LRB-\1740 CC\NN\13616054 )\-RRB-\1740 intravenously\RB\1740 .\.\1740
D011692_D012598 NONE Since\IN\1740 mesangial\JJ\1740 CC\NN\13616054 clearance\NN\5089947 from\IN\1740 the\DT\1740 mesangium\NN\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 during\IN\1740 chronic\JJ\1740 <e1>PAN</e1>\NN\3101986 treatment\NN\654885 ,\,\1740 we\PRP\1740 conclude\VBP\628491 that\IN\1740 this\DT\1740 preferential\JJ\1740 CC\NN\13616054 localization\NN\151497 within\IN\1740 the\DT\1740 lesions\NNS\14204950 is\VBZ\836236 caused\VBN\1617192 by\IN\1740 an\DT\6697703 increased\VBN\169651 CC\NN\13616054 uptake\NN\13440063 shortly\RB\1740 after\IN\1740 injection\NN\320852 in\IN\13603305 apparent\JJ\1740 vulnerable\JJ\1740 areas\NNS\8630985 where\WRB\1740 <e2>sclerosis</e2>\NN\14204950 will\MD\5650329 develop\VB\1753788 subsequently\RB\1740 .\.\1740
17346443
D010396_D017512 CID <e1>Penicillamine-related</e1>\JJ\1740 <e2>lichenoid\JJ\1740 dermatitis</e2>\NN\14226056 and\CC\1740 utility\NN\8186047 of\IN\1740 zinc\NN\14625458 acetate\NN\15010703 in\IN\13603305 a\DT\13649268 Wilson\NN\1740 disease\NN\14061805 patient\NN\9898892 with\IN\1740 hepatic\JJ\1740 presentation\NN\1027379 ,\,\1740 anxiety\NN\14373582 and\CC\1740 SPECT\NN\1740 abnormalities\NNS\14034177 .\.\1740
D010396_D017512 CID During\IN\1740 the\DT\1740 follow-up\NN\4599396 of\IN\1740 our\PRP$\1740 patient\NN\9898892 ,\,\1740 <e1>penicillamine</e1>\NN\3740161 was\VBD\836236 interrupted\JJ\1740 after\IN\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 a\DT\13649268 <e2>lichenoid\JJ\1740 dermatitis</e2>\NN\14226056 ,\,\1740 and\CC\1740 zinc\NN\14625458 acetate\NN\15010703 permitted\VBD\797697 to\TO\1740 continue\VB\2367363 the\DT\1740 successful\JJ\1740 treatment\NN\654885 of\IN\1740 the\DT\1740 patient\NN\9898892 without\IN\1740 side-effects\NNS\1740 .\.\1740
D010396_D006527 NONE <e1>Penicillamine-related</e1>\JJ\1740 lichenoid\JJ\1740 dermatitis\NN\14226056 and\CC\1740 utility\NN\8186047 of\IN\1740 zinc\NN\14625458 acetate\NN\15010703 in\IN\13603305 a\DT\13649268 <e2>Wilson\NN\1740 disease</e2>\NN\14061805 patient\NN\9898892 with\IN\1740 hepatic\JJ\1740 presentation\NN\1027379 ,\,\1740 anxiety\NN\14373582 and\CC\1740 SPECT\NN\1740 abnormalities\NNS\14034177 .\.\1740
D010396_D006527 NONE In\IN\13603305 our\PRP$\1740 case\NN\7283608 the\DT\1740 therapy\NN\657604 with\IN\1740 zinc\NN\14625458 acetate\NN\15010703 represented\VBD\2664769 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 a\DT\13649268 <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patient\NN\9898892 in\IN\13603305 which\WDT\1740 <e1>penicillamine-related</e1>\JJ\1740 side\NN\8630039 effects\NNS\13245626 appeared\VBD\2604760 .\.\1740
D010396_D006527 NONE Since\IN\1740 most\JJS\1740 of\IN\1740 <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 <e1>penicillamine-treated</e1>\JJ\1740 patients\NNS\9898892 do\VBP\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 develop\VB\1753788 this\DT\1740 skin\NN\5237755 lesion\NN\14204950 ,\,\1740 it\PRP\6125041 could\MD\1740 be\VB\836236 conceivable\JJ\1740 that\IN\1740 a\DT\13649268 specific\JJ\1740 genetic\JJ\1740 factor\NN\7326557 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 drug\NN\14778436 response\NN\11410625 .\.\1740
D010396_D001008 NONE <e1>Penicillamine-related</e1>\JJ\1740 lichenoid\JJ\1740 dermatitis\NN\14226056 and\CC\1740 utility\NN\8186047 of\IN\1740 zinc\NN\14625458 acetate\NN\15010703 in\IN\13603305 a\DT\13649268 Wilson\NN\1740 disease\NN\14061805 patient\NN\9898892 with\IN\1740 hepatic\JJ\1740 presentation\NN\1027379 ,\,\1740 <e2>anxiety</e2>\NN\14373582 and\CC\1740 SPECT\NN\1740 abnormalities\NNS\14034177 .\.\1740
D019345_D017512 NONE Penicillamine-related\JJ\1740 <e2>lichenoid\JJ\1740 dermatitis</e2>\NN\14226056 and\CC\1740 utility\NN\8186047 of\IN\1740 <e1>zinc\NN\14625458 acetate</e1>\NN\15010703 in\IN\13603305 a\DT\13649268 Wilson\NN\1740 disease\NN\14061805 patient\NN\9898892 with\IN\1740 hepatic\JJ\1740 presentation\NN\1027379 ,\,\1740 anxiety\NN\14373582 and\CC\1740 SPECT\NN\1740 abnormalities\NNS\14034177 .\.\1740
D019345_D017512 NONE During\IN\1740 the\DT\1740 follow-up\NN\4599396 of\IN\1740 our\PRP$\1740 patient\NN\9898892 ,\,\1740 penicillamine\NN\3740161 was\VBD\836236 interrupted\JJ\1740 after\IN\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 a\DT\13649268 <e2>lichenoid\JJ\1740 dermatitis</e2>\NN\14226056 ,\,\1740 and\CC\1740 <e1>zinc\NN\14625458 acetate</e1>\NN\15010703 permitted\VBD\797697 to\TO\1740 continue\VB\2367363 the\DT\1740 successful\JJ\1740 treatment\NN\654885 of\IN\1740 the\DT\1740 patient\NN\9898892 without\IN\1740 side-effects\NNS\1740 .\.\1740
D019345_D006527 NONE Penicillamine-related\JJ\1740 lichenoid\JJ\1740 dermatitis\NN\14226056 and\CC\1740 utility\NN\8186047 of\IN\1740 <e1>zinc\NN\14625458 acetate</e1>\NN\15010703 in\IN\13603305 a\DT\13649268 <e2>Wilson\NN\1740 disease</e2>\NN\14061805 patient\NN\9898892 with\IN\1740 hepatic\JJ\1740 presentation\NN\1027379 ,\,\1740 anxiety\NN\14373582 and\CC\1740 SPECT\NN\1740 abnormalities\NNS\14034177 .\.\1740
D019345_D006527 NONE In\IN\13603305 our\PRP$\1740 case\NN\7283608 the\DT\1740 therapy\NN\657604 with\IN\1740 <e1>zinc\NN\14625458 acetate</e1>\NN\15010703 represented\VBD\2664769 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 a\DT\13649268 <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patient\NN\9898892 in\IN\13603305 which\WDT\1740 penicillamine-related\JJ\1740 side\NN\8630039 effects\NNS\13245626 appeared\VBD\2604760 .\.\1740
D019345_D006527 NONE The\DT\1740 safety\NN\13920835 of\IN\1740 the\DT\1740 <e1>zinc\NN\14625458 acetate</e1>\NN\15010703 allowed\VBD\797697 us\PRP\14964590 to\TO\1740 avoid\VB\2452885 other\JJ\1740 potentially\RB\1740 toxic\JJ\1740 chelating\NN\1740 drugs\NNS\14778436 ;\:\1740 this\DT\1740 observation\NN\996969 is\VBZ\836236 in\IN\13603305 line\NN\8426461 with\IN\1740 the\DT\1740 growing\VBG\109660 evidence\NN\5816287 on\IN\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 the\DT\1740 drug\NN\14778436 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D019345_D001008 NONE Penicillamine-related\JJ\1740 lichenoid\JJ\1740 dermatitis\NN\14226056 and\CC\1740 utility\NN\8186047 of\IN\1740 <e1>zinc\NN\14625458 acetate</e1>\NN\15010703 in\IN\13603305 a\DT\13649268 Wilson\NN\1740 disease\NN\14061805 patient\NN\9898892 with\IN\1740 hepatic\JJ\1740 presentation\NN\1027379 ,\,\1740 <e2>anxiety</e2>\NN\14373582 and\CC\1740 SPECT\NN\1740 abnormalities\NNS\14034177 .\.\1740
D003300_D006527 NONE <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 <e1>copper</e1>\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 copper\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders\NNS\14034177 .\.\1740
D003300_D006527 NONE <e2>Wilson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 copper\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 <e1>copper</e1>\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders\NNS\14034177 .\.\1740
D003300_D064420 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 <e1>copper</e1>\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 copper\NN\14821043 accumulation\NN\13497135 and\CC\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders\NNS\14034177 .\.\1740
D003300_D064420 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 copper\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 <e1>copper</e1>\NN\14821043 accumulation\NN\13497135 and\CC\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders\NNS\14034177 .\.\1740
D003300_D056486 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 <e1>copper</e1>\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 copper\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 <e2>hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D003300_D056486 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 copper\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 <e1>copper</e1>\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 <e2>hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D003300_D009422 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 <e1>copper</e1>\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 copper\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 <e2>hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D003300_D009422 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 copper\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 <e1>copper</e1>\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 <e2>hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D003300_D001523 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 <e1>copper</e1>\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 copper\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 <e2>hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D003300_D001523 NONE Wilson\NN\1740 's\POS\1740 disease\NN\14061805 is\VBZ\836236 an\DT\6697703 autosomal\JJ\1740 recessive\JJ\1740 disorder\NN\14034177 of\IN\1740 hepatic\JJ\1740 copper\NN\14821043 metabolism\NN\13526110 with\IN\1740 consequent\JJ\1740 <e1>copper</e1>\NN\14821043 accumulation\NN\13497135 and\CC\1740 toxicity\NN\13576101 in\IN\13603305 many\JJ\1740 tissues\NNS\5220461 and\CC\1740 consequent\JJ\1740 <e2>hepatic\JJ\1740 ,\,\1740 neurologic\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D010396_D012871 NONE Since\IN\1740 most\JJS\1740 of\IN\1740 Wilson\NN\1740 's\POS\1740 disease\NN\14061805 <e1>penicillamine-treated</e1>\JJ\1740 patients\NNS\9898892 do\VBP\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 develop\VB\1753788 this\DT\1740 <e2>skin\NN\5237755 lesion</e2>\NN\14204950 ,\,\1740 it\PRP\6125041 could\MD\1740 be\VB\836236 conceivable\JJ\1740 that\IN\1740 a\DT\13649268 specific\JJ\1740 genetic\JJ\1740 factor\NN\7326557 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 drug\NN\14778436 response\NN\11410625 .\.\1740
3975902
D010424_D002318 NONE <e2>Cardiovascular\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>sodium\NN\14625458 pentobarbital</e1>\NN\2792049 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 barium\NN\14625458 chloride\NN\14818238 ingestion\NN\13440063 .\.\1740
D010424_D004342 NONE Cardiovascular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 <e1>sodium\NN\14625458 pentobarbital</e1>\NN\2792049 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 barium\NN\14625458 chloride\NN\14818238 ingestion\NN\13440063 .\.\1740
D010424_D004342 NONE The\DT\1740 most\RBS\1740 distinctive\JJ\1740 aspect\NN\5849789 of\IN\1740 the\DT\1740 barium\NN\14625458 effect\NN\34213 was\VBD\836236 a\DT\13649268 demonstrated\VBN\2137132 <e2>hypersensitivity</e2>\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 <e1>sodium\NN\14625458 pentobarbital</e1>\JJ\1740 .\.\1740
D010424_D004342 NONE Overall\RB\1740 ,\,\1740 the\DT\1740 altered\JJ\1740 cardiac\JJ\1740 contractility\NN\5200169 and\CC\1740 excitability\NN\5653575 characteristics\NNS\5849040 ,\,\1740 the\DT\1740 myocardial\JJ\1740 metabolic\JJ\1740 disturbances\NNS\407535 ,\,\1740 and\CC\1740 the\DT\1740 <e2>hypersensitivity</e2>\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 <e1>sodium\NN\14625458 pentobarbital</e1>\NN\2792049 suggest\VBP\1010118 the\DT\1740 existence\NN\24720 of\IN\1740 a\DT\13649268 heretofore\RB\1740 undescribed\JJ\1740 cardiomyopathic\JJ\1740 disorder\NN\14034177 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 barium\NN\14625458 exposure\NN\5042871 .\.\1740
C024986_D002318 NONE <e2>Cardiovascular\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 hypersensitivity\NN\14531772 to\TO\1740 sodium\NN\14625458 pentobarbital\NN\2792049 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 <e1>barium\NN\14625458 chloride</e1>\NN\14818238 ingestion\NN\13440063 .\.\1740
C024986_D004342 NONE Cardiovascular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 sodium\NN\14625458 pentobarbital\NN\2792049 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 <e1>barium\NN\14625458 chloride</e1>\NN\14818238 ingestion\NN\13440063 .\.\1740
D001464_D006973 NONE <e1>Barium-supplemented</e1>\JJ\1740 Long-Evans\NNPS\1740 hooded\VBD\1332730 rats\NNS\2329401 were\VBD\836236 characterized\VBN\609683 by\IN\1740 a\DT\13649268 persistent\JJ\1740 <e2>hypertension</e2>\NN\14057371 that\WDT\1740 was\VBD\836236 evident\JJ\1740 after\IN\1740 1\CD\13741022 month\NN\15113229 of\IN\1740 barium\NN\14625458 (\-LRB-\1740 100\CD\13745420 micrograms/ml\NNS\1740 mineral\NN\14580897 fortified\VBD\126264 water\NN\14618834 )\-RRB-\1740 treatment\NN\654885 .\.\1740
D001464_D006973 NONE Barium-supplemented\JJ\1740 Long-Evans\NNPS\1740 hooded\VBD\1332730 rats\NNS\2329401 were\VBD\836236 characterized\VBN\609683 by\IN\1740 a\DT\13649268 persistent\JJ\1740 <e2>hypertension</e2>\NN\14057371 that\WDT\1740 was\VBD\836236 evident\JJ\1740 after\IN\1740 1\CD\13741022 month\NN\15113229 of\IN\1740 <e1>barium</e1>\NN\14625458 (\-LRB-\1740 100\CD\13745420 micrograms/ml\NNS\1740 mineral\NN\14580897 fortified\VBD\126264 water\NN\14618834 )\-RRB-\1740 treatment\NN\654885 .\.\1740
D001464_D002318 NONE Analysis\NN\633864 of\IN\1740 in\FW\13603305 vivo\FW\1740 myocardial\JJ\1740 excitability\NN\5653575 ,\,\1740 contractility\NN\5200169 ,\,\1740 and\CC\1740 metabolic\JJ\1740 characteristics\NNS\5849040 at\IN\14622893 16\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 other\JJ\1740 significant\JJ\1740 <e1>barium-induced</e1>\JJ\1740 <e2>disturbances\NNS\407535 within\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system</e2>\NN\3575240 .\.\1740
D001464_D004342 NONE The\DT\1740 most\RBS\1740 distinctive\JJ\1740 aspect\NN\5849789 of\IN\1740 the\DT\1740 <e1>barium</e1>\NN\14625458 effect\NN\34213 was\VBD\836236 a\DT\13649268 demonstrated\VBN\2137132 <e2>hypersensitivity</e2>\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 sodium\NN\14625458 pentobarbital\JJ\1740 .\.\1740
D001464_D004342 NONE Overall\RB\1740 ,\,\1740 the\DT\1740 altered\JJ\1740 cardiac\JJ\1740 contractility\NN\5200169 and\CC\1740 excitability\NN\5653575 characteristics\NNS\5849040 ,\,\1740 the\DT\1740 myocardial\JJ\1740 metabolic\JJ\1740 disturbances\NNS\407535 ,\,\1740 and\CC\1740 the\DT\1740 <e2>hypersensitivity</e2>\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 sodium\NN\14625458 pentobarbital\NN\2792049 suggest\VBP\1010118 the\DT\1740 existence\NN\24720 of\IN\1740 a\DT\13649268 heretofore\RB\1740 undescribed\JJ\1740 cardiomyopathic\JJ\1740 disorder\NN\14034177 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 <e1>barium</e1>\NN\14625458 exposure\NN\5042871 .\.\1740
D010424_D008659 NONE Overall\RB\1740 ,\,\1740 the\DT\1740 altered\JJ\1740 cardiac\JJ\1740 contractility\NN\5200169 and\CC\1740 excitability\NN\5653575 characteristics\NNS\5849040 ,\,\1740 the\DT\1740 myocardial\JJ\1740 <e2>metabolic\JJ\1740 disturbances</e2>\NNS\407535 ,\,\1740 and\CC\1740 the\DT\1740 hypersensitivity\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 <e1>sodium\NN\14625458 pentobarbital</e1>\NN\2792049 suggest\VBP\1010118 the\DT\1740 existence\NN\24720 of\IN\1740 a\DT\13649268 heretofore\RB\1740 undescribed\JJ\1740 cardiomyopathic\JJ\1740 disorder\NN\14034177 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 barium\NN\14625458 exposure\NN\5042871 .\.\1740
D010424_D009202 NONE Overall\RB\1740 ,\,\1740 the\DT\1740 altered\JJ\1740 cardiac\JJ\1740 contractility\NN\5200169 and\CC\1740 excitability\NN\5653575 characteristics\NNS\5849040 ,\,\1740 the\DT\1740 myocardial\JJ\1740 metabolic\JJ\1740 disturbances\NNS\407535 ,\,\1740 and\CC\1740 the\DT\1740 hypersensitivity\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 <e1>sodium\NN\14625458 pentobarbital</e1>\NN\2792049 suggest\VBP\1010118 the\DT\1740 existence\NN\24720 of\IN\1740 a\DT\13649268 heretofore\RB\1740 undescribed\JJ\1740 <e2>cardiomyopathic\JJ\1740 disorder</e2>\NN\14034177 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 barium\NN\14625458 exposure\NN\5042871 .\.\1740
D001464_D008659 NONE Overall\RB\1740 ,\,\1740 the\DT\1740 altered\JJ\1740 cardiac\JJ\1740 contractility\NN\5200169 and\CC\1740 excitability\NN\5653575 characteristics\NNS\5849040 ,\,\1740 the\DT\1740 myocardial\JJ\1740 <e2>metabolic\JJ\1740 disturbances</e2>\NNS\407535 ,\,\1740 and\CC\1740 the\DT\1740 hypersensitivity\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 sodium\NN\14625458 pentobarbital\NN\2792049 suggest\VBP\1010118 the\DT\1740 existence\NN\24720 of\IN\1740 a\DT\13649268 heretofore\RB\1740 undescribed\JJ\1740 cardiomyopathic\JJ\1740 disorder\NN\14034177 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 <e1>barium</e1>\NN\14625458 exposure\NN\5042871 .\.\1740
D001464_D009202 NONE Overall\RB\1740 ,\,\1740 the\DT\1740 altered\JJ\1740 cardiac\JJ\1740 contractility\NN\5200169 and\CC\1740 excitability\NN\5653575 characteristics\NNS\5849040 ,\,\1740 the\DT\1740 myocardial\JJ\1740 metabolic\JJ\1740 disturbances\NNS\407535 ,\,\1740 and\CC\1740 the\DT\1740 hypersensitivity\NN\14531772 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 system\NN\3575240 to\TO\1740 sodium\NN\14625458 pentobarbital\NN\2792049 suggest\VBP\1010118 the\DT\1740 existence\NN\24720 of\IN\1740 a\DT\13649268 heretofore\RB\1740 undescribed\JJ\1740 <e2>cardiomyopathic\JJ\1740 disorder</e2>\NN\14034177 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 <e1>barium</e1>\NN\14625458 exposure\NN\5042871 .\.\1740
17379047
C081489_D006973 NONE Comparison\NN\635850 of\IN\1740 <e1>valsartan/hydrochlorothiazide</e1>\JJ\1740 combination\NN\7951464 therapy\NN\657604 at\IN\14622893 doses\NNS\3740161 up\IN\1740 to\TO\1740 320/25\NN\1740 mg\NN\13717155 versus\CC\1740 monotherapy\NN\1740 :\:\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 study\NN\635850 followed\VBN\1835496 by\IN\1740 long-term\JJ\1740 combination\NN\7951464 therapy\NN\657604 in\IN\13603305 <e2>hypertensive</e2>\JJ\1740 adults\NNS\7846 .\.\1740
D006852_D006973 NONE Comparison\NN\635850 of\IN\1740 <e1>valsartan/hydrochlorothiazide</e1>\JJ\1740 combination\NN\7951464 therapy\NN\657604 at\IN\14622893 doses\NNS\3740161 up\IN\1740 to\TO\1740 320/25\NN\1740 mg\NN\13717155 versus\CC\1740 monotherapy\NN\1740 :\:\1740 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 study\NN\635850 followed\VBN\1835496 by\IN\1740 long-term\JJ\1740 combination\NN\7951464 therapy\NN\657604 in\IN\13603305 <e2>hypertensive</e2>\JJ\1740 adults\NNS\7846 .\.\1740
C081489_C562386 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 <e1>valsartan</e1>\NN\2712393 (\-LRB-\1740 VAL\NN\1740 )\-RRB-\1740 or\CC\3541091 hydrochlorothiazide\JJ\1740 (HCTZ)-monotherapy\NN\1740 and\CC\1740 higher-dose\JJ\1740 combinations\NNS\7951464 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
C081489_C562386 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 valsartan\NN\2712393 (\-LRB-\1740 <e1>VAL</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 hydrochlorothiazide\JJ\1740 (HCTZ)-monotherapy\NN\1740 and\CC\1740 higher-dose\JJ\1740 combinations\NNS\7951464 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
C081489_C562386 NONE Patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 (\-LRB-\1740 mean\NN\6021761 sitting\VBG\2655135 diastolic\JJ\1740 BP\NN\1740 [\-LRB-\1740 MSDBP\NN\1740 ]\-RRB-\1740 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 95\CD\1740 mm\NN\13649268 Hg\NNP\14625458 and\CC\1740 <\XX\1740 110\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 1\CD\13741022 of\IN\1740 8\CD\13741022 treatment\NN\654885 groups\NNS\2137 :\:\1740 <e1>VAL</e1>\NN\1740 160\CD\1740 or\CC\3541091 320\CD\1740 mg\NN\13717155 ;\:\1740 HCTZ\NN\1740 12.5\CD\1740 or\CC\3541091 25\CD\13745420 mg\NN\13717155 ;\:\1740 VAL/HCTZ\NN\1740 160/12.5\NN\1740 ,\,\1740 320/12.5\NN\1740 ,\,\1740 or\CC\3541091 320/25\NN\1740 mg\NN\13717155 ;\:\1740 or\CC\3541091 placebo\NN\3740161 .\.\1740
C081489_C562386 NONE Patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 (\-LRB-\1740 mean\NN\6021761 sitting\VBG\2655135 diastolic\JJ\1740 BP\NN\1740 [\-LRB-\1740 MSDBP\NN\1740 ]\-RRB-\1740 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 95\CD\1740 mm\NN\13649268 Hg\NNP\14625458 and\CC\1740 <\XX\1740 110\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 1\CD\13741022 of\IN\1740 8\CD\13741022 treatment\NN\654885 groups\NNS\2137 :\:\1740 VAL\NN\1740 160\CD\1740 or\CC\3541091 320\CD\1740 mg\NN\13717155 ;\:\1740 HCTZ\NN\1740 12.5\CD\1740 or\CC\3541091 25\CD\13745420 mg\NN\13717155 ;\:\1740 <e1>VAL/HCTZ</e1>\NN\1740 160/12.5\NN\1740 ,\,\1740 320/12.5\NN\1740 ,\,\1740 or\CC\3541091 320/25\NN\1740 mg\NN\13717155 ;\:\1740 or\CC\3541091 placebo\NN\3740161 .\.\1740
D006852_C562386 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 valsartan\NN\2712393 (\-LRB-\1740 VAL\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>hydrochlorothiazide</e1>\JJ\1740 (HCTZ)-monotherapy\NN\1740 and\CC\1740 higher-dose\JJ\1740 combinations\NNS\7951464 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D006852_C562386 NONE OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 investigated\VBD\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 tolerability\NN\1740 of\IN\1740 valsartan\NN\2712393 (\-LRB-\1740 VAL\NN\1740 )\-RRB-\1740 or\CC\3541091 hydrochlorothiazide\JJ\1740 <e1>(HCTZ)-monotherapy</e1>\NN\1740 and\CC\1740 higher-dose\JJ\1740 combinations\NNS\7951464 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D006852_C562386 NONE Patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 (\-LRB-\1740 mean\NN\6021761 sitting\VBG\2655135 diastolic\JJ\1740 BP\NN\1740 [\-LRB-\1740 MSDBP\NN\1740 ]\-RRB-\1740 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 95\CD\1740 mm\NN\13649268 Hg\NNP\14625458 and\CC\1740 <\XX\1740 110\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 1\CD\13741022 of\IN\1740 8\CD\13741022 treatment\NN\654885 groups\NNS\2137 :\:\1740 VAL\NN\1740 160\CD\1740 or\CC\3541091 320\CD\1740 mg\NN\13717155 ;\:\1740 <e1>HCTZ</e1>\NN\1740 12.5\CD\1740 or\CC\3541091 25\CD\13745420 mg\NN\13717155 ;\:\1740 VAL/HCTZ\NN\1740 160/12.5\NN\1740 ,\,\1740 320/12.5\NN\1740 ,\,\1740 or\CC\3541091 320/25\NN\1740 mg\NN\13717155 ;\:\1740 or\CC\3541091 placebo\NN\3740161 .\.\1740
D006852_C562386 NONE Patients\NNS\9898892 with\IN\1740 <e2>essential\JJ\1740 hypertension</e2>\NN\14057371 (\-LRB-\1740 mean\NN\6021761 sitting\VBG\2655135 diastolic\JJ\1740 BP\NN\1740 [\-LRB-\1740 MSDBP\NN\1740 ]\-RRB-\1740 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 95\CD\1740 mm\NN\13649268 Hg\NNP\14625458 and\CC\1740 <\XX\1740 110\CD\1740 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 1\CD\13741022 of\IN\1740 8\CD\13741022 treatment\NN\654885 groups\NNS\2137 :\:\1740 VAL\NN\1740 160\CD\1740 or\CC\3541091 320\CD\1740 mg\NN\13717155 ;\:\1740 HCTZ\NN\1740 12.5\CD\1740 or\CC\3541091 25\CD\13745420 mg\NN\13717155 ;\:\1740 <e1>VAL/HCTZ</e1>\NN\1740 160/12.5\NN\1740 ,\,\1740 320/12.5\NN\1740 ,\,\1740 or\CC\3541091 320/25\NN\1740 mg\NN\13717155 ;\:\1740 or\CC\3541091 placebo\NN\3740161 .\.\1740
C081489_D007008 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>hypokalemia</e2>\NN\14299637 was\VBD\836236 lower\JJR\1740 with\IN\1740 <e1>VAL/HCTZ</e1>\JJ\1740 combinations\NNS\7951464 (\-LRB-\1740 1.8%-6.1\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 with\IN\1740 HCTZ\NN\1740 monotherapies\NNS\1740 (\-LRB-\1740 7.1%-13.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C081489_D007008 NONE CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 population\NN\7942152 ,\,\1740 combination\NN\7951464 therapies\NNS\657604 with\IN\1740 <e1>VAL/HCTZ</e1>\NN\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 significantly\RB\1740 greater\JJR\1740 BP\NN\1740 reductions\NNS\351485 compared\VBN\644583 with\IN\1740 either\CC\1740 monotherapy\NN\1740 ,\,\1740 were\VBD\836236 well\RB\1740 tolerated\VBN\802318 ,\,\1740 and\CC\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 less\JJR\1740 <e2>hypokalemia</e2>\NN\14299637 than\IN\1740 HCTZ\NN\1740 alone\RB\1740 .\.\1740
D006852_D007008 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>hypokalemia</e2>\NN\14299637 was\VBD\836236 lower\JJR\1740 with\IN\1740 <e1>VAL/HCTZ</e1>\JJ\1740 combinations\NNS\7951464 (\-LRB-\1740 1.8%-6.1\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 with\IN\1740 HCTZ\NN\1740 monotherapies\NNS\1740 (\-LRB-\1740 7.1%-13.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D006852_D007008 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>hypokalemia</e2>\NN\14299637 was\VBD\836236 lower\JJR\1740 with\IN\1740 VAL/HCTZ\JJ\1740 combinations\NNS\7951464 (\-LRB-\1740 1.8%-6.1\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 with\IN\1740 <e1>HCTZ</e1>\NN\1740 monotherapies\NNS\1740 (\-LRB-\1740 7.1%-13.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D006852_D007008 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 population\NN\7942152 ,\,\1740 combination\NN\7951464 therapies\NNS\657604 with\IN\1740 <e1>VAL/HCTZ</e1>\NN\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 significantly\RB\1740 greater\JJR\1740 BP\NN\1740 reductions\NNS\351485 compared\VBN\644583 with\IN\1740 either\CC\1740 monotherapy\NN\1740 ,\,\1740 were\VBD\836236 well\RB\1740 tolerated\VBN\802318 ,\,\1740 and\CC\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 less\JJR\1740 <e2>hypokalemia</e2>\NN\14299637 than\IN\1740 HCTZ\NN\1740 alone\RB\1740 .\.\1740
D006852_D007008 CID CONCLUSIONS\NNS\5837957 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 population\NN\7942152 ,\,\1740 combination\NN\7951464 therapies\NNS\657604 with\IN\1740 VAL/HCTZ\NN\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 significantly\RB\1740 greater\JJR\1740 BP\NN\1740 reductions\NNS\351485 compared\VBN\644583 with\IN\1740 either\CC\1740 monotherapy\NN\1740 ,\,\1740 were\VBD\836236 well\RB\1740 tolerated\VBN\802318 ,\,\1740 and\CC\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 less\JJR\1740 <e2>hypokalemia</e2>\NN\14299637 than\IN\1740 <e1>HCTZ</e1>\NN\1740 alone\RB\1740 .\.\1740
24068571
D013874_D003693 CID The\DT\1740 use\NN\407535 of\IN\1740 <e1>thiopentone</e1>\NN\1740 was\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 an\DT\6697703 eight-fold-higher\NN\1740 risk\NN\14541044 for\IN\1740 <e2>delirium</e2>\NN\14391660 compared\VBN\644583 to\TO\1740 propofol\NN\1740 (\-LRB-\1740 57.1\CD\1740 %\NN\1740 vs.\CC\1740 7.1\CD\1740 %\NN\1740 ,\,\1740 RR\NN\1740 =\JJ\1740 8.0\CD\1740 ,\,\1740 X2\NN\1740 =\JJ\1740 4.256\CD\1740 ;\:\1740 df\NN\1740 =\JJ\1740 1\CD\13741022 ;\:\1740 0.05\CD\1740 <\XX\1740 p\NN\14622893 <\XX\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
D015742_D003693 NONE The\DT\1740 use\NN\407535 of\IN\1740 thiopentone\NN\1740 was\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 an\DT\6697703 eight-fold-higher\NN\1740 risk\NN\14541044 for\IN\1740 <e2>delirium</e2>\NN\14391660 compared\VBN\644583 to\TO\1740 <e1>propofol</e1>\NN\1740 (\-LRB-\1740 57.1\CD\1740 %\NN\1740 vs.\CC\1740 7.1\CD\1740 %\NN\1740 ,\,\1740 RR\NN\1740 =\JJ\1740 8.0\CD\1740 ,\,\1740 X2\NN\1740 =\JJ\1740 4.256\CD\1740 ;\:\1740 df\NN\1740 =\JJ\1740 1\CD\13741022 ;\:\1740 0.05\CD\1740 <\XX\1740 p\NN\14622893 <\XX\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
10933650
D000666_D007674 NONE Attenuation\NN\7427337 of\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 lipid\NN\14944888 nanosphere\RB\1740 (\-LRB-\1740 NS-718\NN\1740 )\-RRB-\1740 incorporating\VBG\1461328 <e1>amphotericin\NN\2716866 B.</e1>\NN\1740
D000666_D007674 NONE Our\PRP$\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 incorporation\NN\1237415 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 into\IN\1740 lipid\NN\14944888 nanospheres\NNS\1740 of\IN\1740 NS-718\NN\1740 attenuates\VBZ\224901 the\DT\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 amphotericin\NN\2716866 B.\NN\1740
D000666_D007674 NONE Our\PRP$\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 incorporation\NN\1237415 of\IN\1740 amphotericin\NN\2716866 B\NN\1355326 into\IN\1740 lipid\NN\14944888 nanospheres\NNS\1740 of\IN\1740 NS-718\NN\1740 attenuates\VBZ\224901 the\DT\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 <e1>amphotericin\NN\2716866 B.</e1>\NN\1740
D000666_D064420 NONE NS-718\NN\1740 ,\,\1740 a\DT\13649268 lipid\NN\14944888 nanosphere\RB\1740 incorporating\VBG\1461328 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 ,\,\1740 is\VBZ\836236 effective\JJ\1740 against\IN\1740 pathogenic\JJ\1740 fungi\NN\7940552 and\CC\1740 has\VBZ\2108377 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D000666_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 NS-718\NN\1740 with\IN\1740 that\DT\1740 of\IN\1740 <e1>Fungizone</e1>\NN\1740 (\-LRB-\1740 amphotericin\NN\2716866 B-sodium\NN\1740 deoxycholate\VBP\1740 ;\:\1740 D-AmB\NN\1740 )\-RRB-\1740 in\FW\13603305 vitro\FW\1740 using\VBG\1156834 renal\JJ\1740 cell\NN\3080309 cultures\NNS\7966140 and\CC\1740 in\FW\13603305 vivo\FW\1740 by\IN\1740 biochemical\JJ\1740 analysis\NN\633864 ,\,\1740 histopathological\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 kidney\NN\5333259 and\CC\1740 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 amphotericin\NN\2716866 B\NN\1355326 following\VBG\1835496 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 the\DT\1740 formulation\NN\14818238 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000666_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 NS-718\NN\1740 with\IN\1740 that\DT\1740 of\IN\1740 Fungizone\NN\1740 (\-LRB-\1740 amphotericin\NN\2716866 B-sodium\NN\1740 deoxycholate\VBP\1740 ;\:\1740 D-AmB\NN\1740 )\-RRB-\1740 in\FW\13603305 vitro\FW\1740 using\VBG\1156834 renal\JJ\1740 cell\NN\3080309 cultures\NNS\7966140 and\CC\1740 in\FW\13603305 vivo\FW\1740 by\IN\1740 biochemical\JJ\1740 analysis\NN\633864 ,\,\1740 histopathological\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 kidney\NN\5333259 and\CC\1740 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 following\VBG\1835496 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 the\DT\1740 formulation\NN\14818238 in\IN\13603305 rats\NNS\2329401 .\.\1740
C059765_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 NS-718\NN\1740 with\IN\1740 that\DT\1740 of\IN\1740 Fungizone\NN\1740 (\-LRB-\1740 <e1>amphotericin\NN\2716866 B-sodium\NN\1740 deoxycholate</e1>\VBP\1740 ;\:\1740 D-AmB\NN\1740 )\-RRB-\1740 in\FW\13603305 vitro\FW\1740 using\VBG\1156834 renal\JJ\1740 cell\NN\3080309 cultures\NNS\7966140 and\CC\1740 in\FW\13603305 vivo\FW\1740 by\IN\1740 biochemical\JJ\1740 analysis\NN\633864 ,\,\1740 histopathological\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 kidney\NN\5333259 and\CC\1740 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 amphotericin\NN\2716866 B\NN\1355326 following\VBG\1835496 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 the\DT\1740 formulation\NN\14818238 in\IN\13603305 rats\NNS\2329401 .\.\1740
C059765_D064420 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 NS-718\NN\1740 with\IN\1740 that\DT\1740 of\IN\1740 Fungizone\NN\1740 (\-LRB-\1740 amphotericin\NN\2716866 B-sodium\NN\1740 deoxycholate\VBP\1740 ;\:\1740 <e1>D-AmB</e1>\NN\1740 )\-RRB-\1740 in\FW\13603305 vitro\FW\1740 using\VBG\1156834 renal\JJ\1740 cell\NN\3080309 cultures\NNS\7966140 and\CC\1740 in\FW\13603305 vivo\FW\1740 by\IN\1740 biochemical\JJ\1740 analysis\NN\633864 ,\,\1740 histopathological\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 kidney\NN\5333259 and\CC\1740 pharmacokinetic\JJ\1740 study\NN\635850 of\IN\1740 amphotericin\NN\2716866 B\NN\1355326 following\VBG\1835496 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 the\DT\1740 formulation\NN\14818238 in\IN\13603305 rats\NNS\2329401 .\.\1740
C059765_D007683 CID Histopathological\JJ\1740 examination\NN\633864 of\IN\1740 the\DT\1740 kidney\NN\5333259 showed\VBD\2137132 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 in\IN\13603305 <e1>D-AmB-treated</e1>\JJ\1740 rats\NNS\2329401 but\CC\1740 no\DT\7204911 change\NN\7283608 in\IN\13603305 NS-718-treated\JJ\1740 rats\NNS\2329401 .\.\1740
9881641
D005905_D007022 NONE <e1>Glibenclamide-sensitive</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 produced\VBN\1617192 by\IN\1740 helodermin\NN\1740 assessed\VBN\670261 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D005905_D007022 NONE <e2>Hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 both\DT\1740 peptides\NNS\14724264 was\VBD\836236 significantly\RB\1740 attenuated\VBN\224901 by\IN\1740 <e1>glibenclamide</e1>\NN\1740 ,\,\1740 which\WDT\1740 abolished\VBD\1740 a\DT\13649268 levcromakalim-produced\JJ\1740 decrease\NN\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 .\.\1740
D005905_D007022 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 helodermin-produced\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 partly\RB\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 <e1>glibenclamide-sensitive</e1>\JJ\1740 K+\NN\1740 channels\NNS\6251781 (\-LRB-\1740 K(ATP\JJ\1740 )\-RRB-\1740 channels\NNS\6251781 )\-RRB-\1740 ,\,\1740 which\WDT\1740 presumably\RB\1740 exist\VBP\1740 on\IN\1740 arterial\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 .\.\1740
C040442_D007022 CID Glibenclamide-sensitive\JJ\1740 <e2>hypotension</e2>\NN\14057371 produced\VBN\1617192 by\IN\1740 <e1>helodermin</e1>\NN\1740 assessed\VBN\670261 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
C040442_D007022 CID <e1>Helodermin</e1>\NNP\1740 produced\VBD\1617192 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 manner\NN\4916342 with\IN\1740 approximately\RB\1740 similar\JJ\1740 potency\NN\5196375 and\CC\1740 duration\NN\15113229 to\TO\1740 VIP\NN\10200781 .\.\1740
C040442_D007022 CID Oxyhemoglobin\NN\15024240 did\VBD\1640855 not\RB\1740 affect\VB\126264 <e1>helodermin-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 whereas\IN\1740 it\PRP\6125041 shortened\VBD\429060 the\DT\1740 duration\NN\15113229 of\IN\1740 acetylcholine\NN\14807558 (ACh)-produced\VBN\1740 hypotension\NN\14057371 .\.\1740
C040442_D007022 CID Oxyhemoglobin\NN\15024240 did\VBD\1640855 not\RB\1740 affect\VB\126264 <e1>helodermin-induced</e1>\JJ\1740 hypotension\NN\14057371 ,\,\1740 whereas\IN\1740 it\PRP\6125041 shortened\VBD\429060 the\DT\1740 duration\NN\15113229 of\IN\1740 acetylcholine\NN\14807558 (ACh)-produced\VBN\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
C040442_D007022 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>helodermin-produced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 partly\RB\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 glibenclamide-sensitive\JJ\1740 K+\NN\1740 channels\NNS\6251781 (\-LRB-\1740 K(ATP\JJ\1740 )\-RRB-\1740 channels\NNS\6251781 )\-RRB-\1740 ,\,\1740 which\WDT\1740 presumably\RB\1740 exist\VBP\1740 on\IN\1740 arterial\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 .\.\1740
D019806_D007022 CID <e2>Hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 both\DT\1740 peptides\NNS\14724264 was\VBD\836236 significantly\RB\1740 attenuated\VBN\224901 by\IN\1740 glibenclamide\NN\1740 ,\,\1740 which\WDT\1740 abolished\VBD\1740 a\DT\13649268 <e1>levcromakalim-produced</e1>\JJ\1740 decrease\NN\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 .\.\1740
D000109_D007022 CID Oxyhemoglobin\NN\15024240 did\VBD\1640855 not\RB\1740 affect\VB\126264 helodermin-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 whereas\IN\1740 it\PRP\6125041 shortened\VBD\429060 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>acetylcholine</e1>\NN\14807558 (ACh)-produced\VBN\1740 hypotension\NN\14057371 .\.\1740
D000109_D007022 CID Oxyhemoglobin\NN\15024240 did\VBD\1640855 not\RB\1740 affect\VB\126264 helodermin-induced\JJ\1740 hypotension\NN\14057371 ,\,\1740 whereas\IN\1740 it\PRP\6125041 shortened\VBD\429060 the\DT\1740 duration\NN\15113229 of\IN\1740 <e1>acetylcholine</e1>\NN\14807558 (ACh)-produced\VBN\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D000109_D007022 CID Oxyhemoglobin\NN\15024240 did\VBD\1640855 not\RB\1740 affect\VB\126264 helodermin-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 whereas\IN\1740 it\PRP\6125041 shortened\VBD\429060 the\DT\1740 duration\NN\15113229 of\IN\1740 acetylcholine\NN\14807558 <e1>(ACh)-produced</e1>\VBN\1740 hypotension\NN\14057371 .\.\1740
D000109_D007022 CID Oxyhemoglobin\NN\15024240 did\VBD\1640855 not\RB\1740 affect\VB\126264 helodermin-induced\JJ\1740 hypotension\NN\14057371 ,\,\1740 whereas\IN\1740 it\PRP\6125041 shortened\VBD\429060 the\DT\1740 duration\NN\15113229 of\IN\1740 acetylcholine\NN\14807558 <e1>(ACh)-produced</e1>\VBN\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D011188_D007022 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 helodermin-produced\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 partly\RB\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 glibenclamide-sensitive\JJ\1740 <e1>K+</e1>\NN\1740 channels\NNS\6251781 (\-LRB-\1740 K(ATP\JJ\1740 )\-RRB-\1740 channels\NNS\6251781 )\-RRB-\1740 ,\,\1740 which\WDT\1740 presumably\RB\1740 exist\VBP\1740 on\IN\1740 arterial\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 .\.\1740
D011188_D007022 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 helodermin-produced\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 partly\RB\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 glibenclamide-sensitive\JJ\1740 K+\NN\1740 channels\NNS\6251781 (\-LRB-\1740 <e1>K(ATP</e1>\JJ\1740 )\-RRB-\1740 channels\NNS\6251781 )\-RRB-\1740 ,\,\1740 which\WDT\1740 presumably\RB\1740 exist\VBP\1740 on\IN\1740 arterial\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 .\.\1740
D000255_D007022 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 helodermin-produced\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 partly\RB\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 glibenclamide-sensitive\JJ\1740 K+\NN\1740 channels\NNS\6251781 (\-LRB-\1740 <e1>K(ATP</e1>\JJ\1740 )\-RRB-\1740 channels\NNS\6251781 )\-RRB-\1740 ,\,\1740 which\WDT\1740 presumably\RB\1740 exist\VBP\1740 on\IN\1740 arterial\JJ\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 .\.\1740
D009569_D007022 NONE EDRF\NN\1740 (\-LRB-\1740 endothelium-derived\JJ\1740 relaxing\VBG\146138 <e1>factor)/nitric\NN\1740 oxide</e1>\NN\14818238 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 play\VB\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 peptide-produced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
1158089
D013752_D005234 CID <e2>Fatty\JJ\1740 liver</e2>\NN\5298729 induced\VBN\1627355 by\IN\1740 <e1>tetracycline</e1>\NN\2716205 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D013752_D005234 CID Dose-response\JJ\1740 relationships\NNS\31921 ,\,\1740 biochemical\JJ\1740 mechanisms\NNS\13446390 ,\,\1740 and\CC\1740 sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 the\DT\1740 experimental\JJ\1740 <e2>fatty\JJ\1740 liver</e2>\NN\5298729 induced\VBN\1627355 by\IN\1740 <e1>tetracycline</e1>\NN\2716205 were\VBD\836236 studied\VBN\630380 in\IN\13603305 the\DT\1740 intact\JJ\1740 rat\NN\2329401 and\CC\1740 with\IN\1740 the\DT\1740 isolated\VBN\2512305 perfused\JJ\1740 rat\NN\2329401 liver\NN\5298729 in\FW\13603305 vitro\FW\1740 .\.\1740
D013752_D005234 CID Depressed\JJ\1740 hepatic\JJ\1740 secretion\NN\13526110 of\IN\1740 triglyceride\NN\14885088 accounted\VBD\2604760 only\RB\1740 for\IN\1740 30\CD\13745420 to\TO\1740 50\CD\13745420 %\NN\1740 of\IN\1740 accumulated\VBN\2281093 hepatic\JJ\1740 triglyceride\NN\14885088 ,\,\1740 indicating\VBG\952524 that\IN\1740 additional\JJ\1740 mechanisms\NNS\13446390 must\MD\9367203 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 the\DT\1740 triglyceride-rich\JJ\1740 <e2>fatty\JJ\1740 liver</e2>\NN\5298729 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>tetracycline</e1>\NN\2716205 .\.\1740
D019301_D003866 NONE With\IN\1740 provision\NN\6755568 of\IN\1740 adequate\JJ\1740 <e1>oleic\JJ\1740 acid</e1>\NN\14818238 as\IN\14622893 a\DT\13649268 substrate\NN\19613 for\IN\1740 the\DT\1740 isolated\VBN\2512305 perfused\JJ\1740 liver\NN\5298729 ,\,\1740 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 was\VBD\836236 observed\VBN\2163746 between\IN\1740 dose\NN\3740161 of\IN\1740 tetracycline\NN\2716205 and\CC\1740 both\CC\1740 accumulation\NN\13497135 of\IN\1740 triglyceride\NN\14885088 in\IN\13603305 the\DT\1740 liver\NN\5298729 and\CC\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 output\NN\4007894 of\IN\1740 triglyceride\NN\14885088 by\IN\1740 livers\NNS\5298729 from\IN\1740 male\JJ\1740 and\CC\1740 female\JJ\1740 rats\NNS\2329401 .\.\1740
D013752_D003866 NONE With\IN\1740 provision\NN\6755568 of\IN\1740 adequate\JJ\1740 oleic\JJ\1740 acid\NN\14818238 as\IN\14622893 a\DT\13649268 substrate\NN\19613 for\IN\1740 the\DT\1740 isolated\VBN\2512305 perfused\JJ\1740 liver\NN\5298729 ,\,\1740 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 was\VBD\836236 observed\VBN\2163746 between\IN\1740 dose\NN\3740161 of\IN\1740 <e1>tetracycline</e1>\NN\2716205 and\CC\1740 both\CC\1740 accumulation\NN\13497135 of\IN\1740 triglyceride\NN\14885088 in\IN\13603305 the\DT\1740 liver\NN\5298729 and\CC\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 output\NN\4007894 of\IN\1740 triglyceride\NN\14885088 by\IN\1740 livers\NNS\5298729 from\IN\1740 male\JJ\1740 and\CC\1740 female\JJ\1740 rats\NNS\2329401 .\.\1740
D013752_D003866 NONE However\RB\1740 ,\,\1740 livers\NNS\5298729 from\IN\1740 female\NN\15388 ,\,\1740 and\CC\1740 especially\RB\1740 pregnant\JJ\1740 female\JJ\1740 rats\NNS\2329401 ,\,\1740 were\VBD\836236 strikingly\RB\1740 resistant\JJ\1740 to\TO\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>tetracycline</e1>\NN\2716205 on\IN\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 output\NN\4007894 of\IN\1740 triglyceride\NN\14885088 under\IN\1740 these\DT\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D014280_D003866 NONE With\IN\1740 provision\NN\6755568 of\IN\1740 adequate\JJ\1740 oleic\JJ\1740 acid\NN\14818238 as\IN\14622893 a\DT\13649268 substrate\NN\19613 for\IN\1740 the\DT\1740 isolated\VBN\2512305 perfused\JJ\1740 liver\NN\5298729 ,\,\1740 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 was\VBD\836236 observed\VBN\2163746 between\IN\1740 dose\NN\3740161 of\IN\1740 tetracycline\NN\2716205 and\CC\1740 both\CC\1740 accumulation\NN\13497135 of\IN\1740 <e1>triglyceride</e1>\NN\14885088 in\IN\13603305 the\DT\1740 liver\NN\5298729 and\CC\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 output\NN\4007894 of\IN\1740 triglyceride\NN\14885088 by\IN\1740 livers\NNS\5298729 from\IN\1740 male\JJ\1740 and\CC\1740 female\JJ\1740 rats\NNS\2329401 .\.\1740
D014280_D003866 NONE With\IN\1740 provision\NN\6755568 of\IN\1740 adequate\JJ\1740 oleic\JJ\1740 acid\NN\14818238 as\IN\14622893 a\DT\13649268 substrate\NN\19613 for\IN\1740 the\DT\1740 isolated\VBN\2512305 perfused\JJ\1740 liver\NN\5298729 ,\,\1740 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 was\VBD\836236 observed\VBN\2163746 between\IN\1740 dose\NN\3740161 of\IN\1740 tetracycline\NN\2716205 and\CC\1740 both\CC\1740 accumulation\NN\13497135 of\IN\1740 triglyceride\NN\14885088 in\IN\13603305 the\DT\1740 liver\NN\5298729 and\CC\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 output\NN\4007894 of\IN\1740 <e1>triglyceride</e1>\NN\14885088 by\IN\1740 livers\NNS\5298729 from\IN\1740 male\JJ\1740 and\CC\1740 female\JJ\1740 rats\NNS\2329401 .\.\1740
D014280_D003866 NONE However\RB\1740 ,\,\1740 livers\NNS\5298729 from\IN\1740 female\NN\15388 ,\,\1740 and\CC\1740 especially\RB\1740 pregnant\JJ\1740 female\JJ\1740 rats\NNS\2329401 ,\,\1740 were\VBD\836236 strikingly\RB\1740 resistant\JJ\1740 to\TO\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 tetracycline\NN\2716205 on\IN\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 output\NN\4007894 of\IN\1740 <e1>triglyceride</e1>\NN\14885088 under\IN\1740 these\DT\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
D014280_D005234 NONE Depressed\JJ\1740 hepatic\JJ\1740 secretion\NN\13526110 of\IN\1740 <e1>triglyceride</e1>\NN\14885088 accounted\VBD\2604760 only\RB\1740 for\IN\1740 30\CD\13745420 to\TO\1740 50\CD\13745420 %\NN\1740 of\IN\1740 accumulated\VBN\2281093 hepatic\JJ\1740 triglyceride\NN\14885088 ,\,\1740 indicating\VBG\952524 that\IN\1740 additional\JJ\1740 mechanisms\NNS\13446390 must\MD\9367203 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 the\DT\1740 triglyceride-rich\JJ\1740 <e2>fatty\JJ\1740 liver</e2>\NN\5298729 in\IN\13603305 response\NN\11410625 to\TO\1740 tetracycline\NN\2716205 .\.\1740
D014280_D005234 NONE Depressed\JJ\1740 hepatic\JJ\1740 secretion\NN\13526110 of\IN\1740 triglyceride\NN\14885088 accounted\VBD\2604760 only\RB\1740 for\IN\1740 30\CD\13745420 to\TO\1740 50\CD\13745420 %\NN\1740 of\IN\1740 accumulated\VBN\2281093 hepatic\JJ\1740 <e1>triglyceride</e1>\NN\14885088 ,\,\1740 indicating\VBG\952524 that\IN\1740 additional\JJ\1740 mechanisms\NNS\13446390 must\MD\9367203 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 the\DT\1740 triglyceride-rich\JJ\1740 <e2>fatty\JJ\1740 liver</e2>\NN\5298729 in\IN\13603305 response\NN\11410625 to\TO\1740 tetracycline\NN\2716205 .\.\1740
D014280_D005234 NONE Depressed\JJ\1740 hepatic\JJ\1740 secretion\NN\13526110 of\IN\1740 triglyceride\NN\14885088 accounted\VBD\2604760 only\RB\1740 for\IN\1740 30\CD\13745420 to\TO\1740 50\CD\13745420 %\NN\1740 of\IN\1740 accumulated\VBN\2281093 hepatic\JJ\1740 triglyceride\NN\14885088 ,\,\1740 indicating\VBG\952524 that\IN\1740 additional\JJ\1740 mechanisms\NNS\13446390 must\MD\9367203 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 the\DT\1740 <e1>triglyceride-rich</e1>\JJ\1740 <e2>fatty\JJ\1740 liver</e2>\NN\5298729 in\IN\13603305 response\NN\11410625 to\TO\1740 tetracycline\NN\2716205 .\.\1740
1289188
D003676_D058186 NONE <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 occurring\VBG\2623529 during\IN\1740 intravenous\JJ\1740 <e1>desferrioxamine</e1>\NN\1740 therapy\NN\657604 :\:\1740 recovery\NN\7357388 after\IN\1740 haemodialysis\NN\649760 .\.\1740
D003676_D058186 NONE From\IN\1740 the\DT\1740 results\NNS\34213 obtained\VBN\2210855 ,\,\1740 haemodialysis\NN\649760 can\MD\3094503 therefore\RB\1740 be\VB\836236 suggested\VBN\1010118 as\IN\14622893 a\DT\13649268 useful\JJ\1740 therapy\NN\657604 in\IN\13603305 rare\JJ\1740 cases\NNS\7283608 of\IN\1740 progressive\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 caused\VBN\1617192 by\IN\1740 <e1>desferrioxamine</e1>\NN\1740 .\.\1740
D003676_D013789 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 transfusion-dependent\JJ\1740 <e2>thalassemia</e2>\NN\14165544 was\VBD\836236 undergoing\VBG\109660 home\NN\8558963 intravenous\JJ\1740 <e1>desferrioxamine</e1>\NN\1740 (\-LRB-\1740 DFX\NN\1740 )\-RRB-\1740 treatment\NN\654885 by\IN\1740 means\NNS\44150 of\IN\1740 a\DT\13649268 totally\RB\1740 implanted\JJ\1740 system\NN\3575240 because\IN\1740 of\IN\1740 his\PRP$\1740 poor\JJ\1740 compliance\NN\1202904 with\IN\1740 the\DT\1740 nightly\RB\1740 subcutaneous\JJ\1740 therapy\NN\657604 .\.\1740
D003676_D013789 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 transfusion-dependent\JJ\1740 <e2>thalassemia</e2>\NN\14165544 was\VBD\836236 undergoing\VBG\109660 home\NN\8558963 intravenous\JJ\1740 desferrioxamine\NN\1740 (\-LRB-\1740 <e1>DFX</e1>\NN\1740 )\-RRB-\1740 treatment\NN\654885 by\IN\1740 means\NNS\44150 of\IN\1740 a\DT\13649268 totally\RB\1740 implanted\JJ\1740 system\NN\3575240 because\IN\1740 of\IN\1740 his\PRP$\1740 poor\JJ\1740 compliance\NN\1202904 with\IN\1740 the\DT\1740 nightly\RB\1740 subcutaneous\JJ\1740 therapy\NN\657604 .\.\1740
24309294
D012844_D000647 NONE We\PRP\1740 have\VBP\2108377 previously\RB\1740 reported\VBN\831651 that\IN\1740 <e1>CCK-8</e1>\NN\1740 significantly\RB\1740 alleviated\VBD\205885 morphine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 reversed\VBN\109660 spine\NN\5585665 density\NN\4941325 decreases\VBZ\169651 in\IN\13603305 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 in\IN\13603305 morphine-treated\JJ\1740 animals\NNS\4475 .\.\1740
D009020_D000647 CID We\PRP\1740 have\VBP\2108377 previously\RB\1740 reported\VBN\831651 that\IN\1740 CCK-8\NN\1740 significantly\RB\1740 alleviated\VBD\205885 <e1>morphine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 reversed\VBN\109660 spine\NN\5585665 density\NN\4941325 decreases\VBZ\169651 in\IN\13603305 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 in\IN\13603305 morphine-treated\JJ\1740 animals\NNS\4475 .\.\1740
D009020_D000647 CID We\PRP\1740 have\VBP\2108377 previously\RB\1740 reported\VBN\831651 that\IN\1740 CCK-8\NN\1740 significantly\RB\1740 alleviated\VBD\205885 morphine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 and\CC\1740 reversed\VBN\109660 spine\NN\5585665 density\NN\4941325 decreases\VBZ\169651 in\IN\13603305 the\DT\1740 CA1\NN\1740 region\NN\27167 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 in\IN\13603305 <e1>morphine-treated</e1>\JJ\1740 animals\NNS\4475 .\.\1740
D012844_D008569 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 <e1>CCK-8</e1>\NN\1740 attenuates\VBZ\224901 the\DT\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 on\IN\1740 hippocampal\NN\1740 LTP\NNP\1740 through\IN\1740 CCK2\NN\1740 receptors\NNS\5225602 and\CC\1740 suggest\VBP\1010118 an\DT\6697703 ameliorative\JJ\1740 function\NN\13783581 of\IN\1740 CCK-8\NN\1740 on\IN\1740 morphine-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
D012844_D008569 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 CCK-8\NN\1740 attenuates\VBZ\224901 the\DT\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 on\IN\1740 hippocampal\NN\1740 LTP\NNP\1740 through\IN\1740 CCK2\NN\1740 receptors\NNS\5225602 and\CC\1740 suggest\VBP\1010118 an\DT\6697703 ameliorative\JJ\1740 function\NN\13783581 of\IN\1740 <e1>CCK-8</e1>\NN\1740 on\IN\1740 morphine-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
D009020_D008569 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 CCK-8\NN\1740 attenuates\VBZ\224901 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>morphine</e1>\NN\2707683 on\IN\1740 hippocampal\NN\1740 LTP\NNP\1740 through\IN\1740 CCK2\NN\1740 receptors\NNS\5225602 and\CC\1740 suggest\VBP\1010118 an\DT\6697703 ameliorative\JJ\1740 function\NN\13783581 of\IN\1740 CCK-8\NN\1740 on\IN\1740 morphine-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
D009020_D008569 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 CCK-8\NN\1740 attenuates\VBZ\224901 the\DT\1740 effect\NN\34213 of\IN\1740 morphine\NN\2707683 on\IN\1740 hippocampal\NN\1740 LTP\NNP\1740 through\IN\1740 CCK2\NN\1740 receptors\NNS\5225602 and\CC\1740 suggest\VBP\1010118 an\DT\6697703 ameliorative\JJ\1740 function\NN\13783581 of\IN\1740 CCK-8\NN\1740 on\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
15630069
D005947_D012559 NONE <e1>Glucose</e1>\NN\14710501 metabolism\NN\13526110 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 treated\VBN\2376958 with\IN\1740 atypical\JJ\1740 antipsychotic\JJ\1740 agents\NNS\7347 :\:\1740 a\DT\13649268 frequently\RB\1740 sampled\VBN\1156834 intravenous\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 test\NN\5798043 and\CC\1740 minimal\JJ\1740 model\NN\5888929 analysis\NN\633864 .\.\1740
D005947_D012559 NONE Glucose\NN\14710501 metabolism\NN\13526110 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 treated\VBN\2376958 with\IN\1740 atypical\JJ\1740 antipsychotic\JJ\1740 agents\NNS\7347 :\:\1740 a\DT\13649268 frequently\RB\1740 sampled\VBN\1156834 intravenous\JJ\1740 <e1>glucose</e1>\NN\14710501 tolerance\NN\5032565 test\NN\5798043 and\CC\1740 minimal\JJ\1740 model\NN\5888929 analysis\NN\633864 .\.\1740
D005947_D012559 NONE BACKGROUND\NN\4921011 :\:\1740 While\IN\15122231 the\DT\1740 incidence\NN\13821570 of\IN\1740 new-onset\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 may\MD\15209706 be\VB\836236 increasing\VBG\169651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 treated\VBN\2376958 with\IN\1740 certain\JJ\1740 atypical\JJ\1740 antipsychotic\JJ\1740 agents\NNS\7347 ,\,\1740 it\PRP\6125041 remains\VBZ\2604760 unclear\JJ\1740 whether\IN\1740 atypical\JJ\1740 agents\NNS\7347 are\VBP\836236 directly\RB\1740 affecting\VBG\126264 <e1>glucose</e1>\NN\14710501 metabolism\NN\13526110 or\CC\3541091 simply\RB\1740 increasing\VBG\169651 known\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 diabetes\NNS\14075199 .\.\1740
D005947_D012559 NONE DESIGN\NN\927261 :\:\1740 A\DT\13649268 cross-sectional\JJ\1740 design\NN\927261 in\IN\13603305 stable\JJ\1740 ,\,\1740 treated\VBN\2376958 patients\NNS\9898892 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 evaluated\VBN\670261 using\VBG\1156834 a\DT\13649268 frequently\RB\1740 sampled\VBN\1156834 intravenous\JJ\1740 <e1>glucose</e1>\NN\14710501 tolerance\NN\5032565 test\NN\5798043 and\CC\1740 the\DT\1740 Bergman\NNP\1740 minimal\JJ\1740 model\NN\5888929 analysis\NN\633864 .\.\1740
D005947_D003920 NONE BACKGROUND\NN\4921011 :\:\1740 While\IN\15122231 the\DT\1740 incidence\NN\13821570 of\IN\1740 new-onset\JJ\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 may\MD\15209706 be\VB\836236 increasing\VBG\169651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 schizophrenia\NN\14398067 treated\VBN\2376958 with\IN\1740 certain\JJ\1740 atypical\JJ\1740 antipsychotic\JJ\1740 agents\NNS\7347 ,\,\1740 it\PRP\6125041 remains\VBZ\2604760 unclear\JJ\1740 whether\IN\1740 atypical\JJ\1740 agents\NNS\7347 are\VBP\836236 directly\RB\1740 affecting\VBG\126264 <e1>glucose</e1>\NN\14710501 metabolism\NN\13526110 or\CC\3541091 simply\RB\1740 increasing\VBG\169651 known\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 diabetes\NNS\14075199 .\.\1740
D005947_D003920 NONE BACKGROUND\NN\4921011 :\:\1740 While\IN\15122231 the\DT\1740 incidence\NN\13821570 of\IN\1740 new-onset\JJ\1740 diabetes\NN\14075199 mellitus\NN\1740 may\MD\15209706 be\VB\836236 increasing\VBG\169651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 schizophrenia\NN\14398067 treated\VBN\2376958 with\IN\1740 certain\JJ\1740 atypical\JJ\1740 antipsychotic\JJ\1740 agents\NNS\7347 ,\,\1740 it\PRP\6125041 remains\VBZ\2604760 unclear\JJ\1740 whether\IN\1740 atypical\JJ\1740 agents\NNS\7347 are\VBP\836236 directly\RB\1740 affecting\VBG\126264 <e1>glucose</e1>\NN\14710501 metabolism\NN\13526110 or\CC\3541091 simply\RB\1740 increasing\VBG\169651 known\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>diabetes</e2>\NNS\14075199 .\.\1740
D003024_D012559 NONE Thirty-six\CD\1740 nonobese\JJ\1740 subjects\NNS\6598915 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 ,\,\1740 matched\VBN\2664769 by\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 and\CC\1740 treated\VBN\2376958 with\IN\1740 either\DT\1740 <e1>clozapine</e1>\NN\3713736 ,\,\1740 olanzapine\NN\1740 ,\,\1740 or\CC\3541091 risperidone\NN\1740 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 analysis\NN\633864 .\.\1740
D003024_D011618 NONE Thirty-six\CD\1740 nonobese\JJ\1740 subjects\NNS\6598915 with\IN\1740 schizophrenia\NN\14398067 or\CC\3541091 <e2>schizoaffective\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 matched\VBN\2664769 by\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 and\CC\1740 treated\VBN\2376958 with\IN\1740 either\DT\1740 <e1>clozapine</e1>\NN\3713736 ,\,\1740 olanzapine\NN\1740 ,\,\1740 or\CC\3541091 risperidone\NN\1740 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 analysis\NN\633864 .\.\1740
C076029_D012559 NONE Thirty-six\CD\1740 nonobese\JJ\1740 subjects\NNS\6598915 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 ,\,\1740 matched\VBN\2664769 by\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 and\CC\1740 treated\VBN\2376958 with\IN\1740 either\DT\1740 clozapine\NN\3713736 ,\,\1740 <e1>olanzapine</e1>\NN\1740 ,\,\1740 or\CC\3541091 risperidone\NN\1740 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 analysis\NN\633864 .\.\1740
C076029_D011618 NONE Thirty-six\CD\1740 nonobese\JJ\1740 subjects\NNS\6598915 with\IN\1740 schizophrenia\NN\14398067 or\CC\3541091 <e2>schizoaffective\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 matched\VBN\2664769 by\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 and\CC\1740 treated\VBN\2376958 with\IN\1740 either\DT\1740 clozapine\NN\3713736 ,\,\1740 <e1>olanzapine</e1>\NN\1740 ,\,\1740 or\CC\3541091 risperidone\NN\1740 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 analysis\NN\633864 .\.\1740
D018967_D012559 NONE Thirty-six\CD\1740 nonobese\JJ\1740 subjects\NNS\6598915 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 or\CC\3541091 schizoaffective\JJ\1740 disorder\NN\14034177 ,\,\1740 matched\VBN\2664769 by\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 and\CC\1740 treated\VBN\2376958 with\IN\1740 either\DT\1740 clozapine\NN\3713736 ,\,\1740 olanzapine\NN\1740 ,\,\1740 or\CC\3541091 <e1>risperidone</e1>\NN\1740 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 analysis\NN\633864 .\.\1740
D018967_D011618 NONE Thirty-six\CD\1740 nonobese\JJ\1740 subjects\NNS\6598915 with\IN\1740 schizophrenia\NN\14398067 or\CC\3541091 <e2>schizoaffective\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 matched\VBN\2664769 by\IN\1740 body\NN\19128 mass\NN\13575869 index\NN\13850304 and\CC\1740 treated\VBN\2376958 with\IN\1740 either\DT\1740 clozapine\NN\3713736 ,\,\1740 olanzapine\NN\1740 ,\,\1740 or\CC\3541091 <e1>risperidone</e1>\NN\1740 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 analysis\NN\633864 .\.\1740
D005947_D007333 NONE MAIN\NNP\9225146 OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Fasting\VBG\1196037 plasma\NN\5398023 <e1>glucose</e1>\NN\14710501 and\CC\1740 fasting\VBG\1196037 serum\NN\5397468 insulin\NN\5407119 levels\NNS\4916342 ,\,\1740 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 ,\,\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 glucose\NN\14710501 effectiveness\NN\5190804 .\.\1740
D005947_D007333 NONE MAIN\NNP\9225146 OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Fasting\VBG\1196037 plasma\NN\5398023 <e1>glucose</e1>\NN\14710501 and\CC\1740 fasting\VBG\1196037 serum\NN\5397468 insulin\NN\5407119 levels\NNS\4916342 ,\,\1740 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 ,\,\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 ,\,\1740 and\CC\1740 glucose\NN\14710501 effectiveness\NN\5190804 .\.\1740
D005947_D007333 NONE MAIN\NNP\9225146 OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Fasting\VBG\1196037 plasma\NN\5398023 glucose\NN\14710501 and\CC\1740 fasting\VBG\1196037 serum\NN\5397468 insulin\NN\5407119 levels\NNS\4916342 ,\,\1740 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 ,\,\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 insulin\NN\5407119 resistance\NN\37396 ,\,\1740 and\CC\1740 <e1>glucose</e1>\NN\14710501 effectiveness\NN\5190804 .\.\1740
D005947_D007333 NONE MAIN\NNP\9225146 OUTCOME\NN\7291312 MEASURES\NN\168237 :\:\1740 Fasting\VBG\1196037 plasma\NN\5398023 glucose\NN\14710501 and\CC\1740 fasting\VBG\1196037 serum\NN\5397468 insulin\NN\5407119 levels\NNS\4916342 ,\,\1740 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 ,\,\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 ,\,\1740 and\CC\1740 <e1>glucose</e1>\NN\14710501 effectiveness\NN\5190804 .\.\1740
D005947_D007333 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Both\DT\1740 nonobese\JJ\1740 clozapine-\NN\1740 and\CC\1740 olanzapine-treated\JJ\1740 groups\NNS\2137 displayed\VBD\2137132 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 and\CC\1740 impairment\NN\7296428 of\IN\1740 <e1>glucose</e1>\NN\14710501 effectiveness\NN\5190804 compared\VBN\644583 with\IN\1740 risperidone-treated\JJ\1740 subjects\NNS\6598915 .\.\1740
D003024_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 <e1>clozapine</e1>\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 <e1>clozapine</e1>\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 >\NN\1740 olanzapine\NN\1740 >\NN\1740 risperidone\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 >\NN\1740 olanzapine\NN\1740 >\NN\1740 risperidone\NN\1740 )\-RRB-\1740 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
D003024_D007333 CID CONCLUSIONS\NNS\5837957 :\:\1740 Both\DT\1740 nonobese\JJ\1740 <e1>clozapine-</e1>\NN\1740 and\CC\1740 olanzapine-treated\JJ\1740 groups\NNS\2137 displayed\VBD\2137132 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 and\CC\1740 impairment\NN\7296428 of\IN\1740 glucose\NN\14710501 effectiveness\NN\5190804 compared\VBN\644583 with\IN\1740 risperidone-treated\JJ\1740 subjects\NNS\6598915 .\.\1740
D003024_D007333 CID Patients\NNS\9898892 taking\VBG\2367363 <e1>clozapine</e1>\NN\3713736 and\CC\1740 olanzapine\NN\1740 must\MD\9367203 be\VB\836236 examined\VBN\789138 for\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 and\CC\1740 its\PRP$\6125041 consequences\NNS\34213 .\.\1740
C076029_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 <e1>olanzapine</e1>\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 <e1>olanzapine</e1>\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 <e1>olanzapine</e1>\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 <e1>olanzapine</e1>\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 <e1>olanzapine</e1>\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 <e1>olanzapine</e1>\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 >\NN\1740 <e1>olanzapine</e1>\NN\1740 >\NN\1740 risperidone\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 >\NN\1740 olanzapine\NN\1740 >\NN\1740 risperidone\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 <e1>olanzapine</e1>\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
C076029_D007333 CID CONCLUSIONS\NNS\5837957 :\:\1740 Both\DT\1740 nonobese\JJ\1740 clozapine-\NN\1740 and\CC\1740 <e1>olanzapine-treated</e1>\JJ\1740 groups\NNS\2137 displayed\VBD\2137132 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 and\CC\1740 impairment\NN\7296428 of\IN\1740 glucose\NN\14710501 effectiveness\NN\5190804 compared\VBN\644583 with\IN\1740 risperidone-treated\JJ\1740 subjects\NNS\6598915 .\.\1740
C076029_D007333 CID Patients\NNS\9898892 taking\VBG\2367363 clozapine\NN\3713736 and\CC\1740 <e1>olanzapine</e1>\NN\1740 must\MD\9367203 be\VB\836236 examined\VBN\789138 for\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 and\CC\1740 its\PRP$\6125041 consequences\NNS\34213 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 <e1>risperidone</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 <e1>risperidone</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>risperidone</e1>\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>risperidone</e1>\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 <e1>risperidone</e1>\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 <e1>risperidone</e1>\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 <e2>insulin\NN\5407119 sensitivity</e2>\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 insulin\NN\5407119 resistance\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 <e1>risperidone</e1>\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 insulin\NN\5407119 sensitivity\NN\5651971 index\NN\13850304 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 10.66\CD\1740 ;\:\1740 P<.001\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 <\XX\1740 olanzapine\NN\1740 <\XX\1740 risperidone\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 received\VBD\2210855 clozapine\NN\3713736 and\CC\1740 olanzapine\NN\1740 exhibiting\VBG\2632167 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 compared\VBN\644583 with\IN\1740 subjects\NNS\6598915 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -4.29\CD\1740 ;\:\1740 P<.001\NN\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 <e1>risperidone</e1>\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 -3.62\NN\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .001\CD\1740 [\-LRB-\1740 P<.001\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 >\NN\1740 olanzapine\NN\1740 >\NN\1740 <e1>risperidone</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 >\NN\1740 olanzapine\NN\1740 >\NN\1740 risperidone\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 <e1>risperidone</e1>\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE The\DT\1740 homeostasis\NN\13934900 model\NN\5888929 assessment\NN\5732756 of\IN\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 also\RB\1740 differed\VBD\1740 significantly\RB\1740 among\IN\1740 groups\NNS\2137 (\-LRB-\1740 F(33\NN\1740 )\-RRB-\1740 =\JJ\1740 4.92\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .01\CD\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 >\NN\1740 olanzapine\NN\1740 >\NN\1740 risperidone\NN\1740 )\-RRB-\1740 (\-LRB-\1740 clozapine\NN\3713736 vs\CC\13634784 risperidone\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.94\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .006\CD\1740 ;\:\1740 olanzapine\NN\1740 vs\CC\13634784 <e1>risperidone</e1>\NN\1740 ,\,\1740 t(33\NN\1740 )\-RRB-\1740 =\JJ\1740 2.42\CD\1740 ;\:\1740 P\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 .\.\1740
D018967_D007333 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Both\DT\1740 nonobese\JJ\1740 clozapine-\NN\1740 and\CC\1740 olanzapine-treated\JJ\1740 groups\NNS\2137 displayed\VBD\2137132 significant\JJ\1740 <e2>insulin\NN\5407119 resistance</e2>\NN\37396 and\CC\1740 impairment\NN\7296428 of\IN\1740 glucose\NN\14710501 effectiveness\NN\5190804 compared\VBN\644583 with\IN\1740 <e1>risperidone-treated</e1>\JJ\1740 subjects\NNS\6598915 .\.\1740
19841052
D016578_D015658 NONE Smoking\NN\831191 of\IN\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 as\IN\14622893 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>HIV\NN\14186340 infection</e2>\NN\14052046 among\IN\1740 people\NNS\31264 who\WP\8299493 use\VBP\1156834 injection\NN\320852 drugs\NNS\14778436 .\.\1740
D016578_D015658 NONE BACKGROUND\NN\4921011 :\:\1740 Little\JJ\1740 is\VBZ\836236 known\VBN\2110220 about\IN\1740 the\DT\1740 possible\JJ\1740 role\NN\719494 that\WDT\1740 smoking\VBG\1156834 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 has\VBZ\2108377 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>HIV\NN\14186340 infection</e2>\NN\14052046 .\.\1740
D016578_D015658 NONE Given\VBN\2327200 the\DT\1740 increasing\VBG\169651 use\NN\407535 of\IN\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 ,\,\1740 we\PRP\1740 sought\VBD\1825237 to\TO\1740 examine\VB\789138 whether\IN\1740 use\NN\407535 of\IN\1740 this\DT\1740 illicit\NN\1740 drug\NN\14778436 has\VBZ\2108377 become\VBN\146138 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>HIV\NN\14186340 infection</e2>\NN\14052046 .\.\1740
D016578_D006679 CID To\TO\1740 determine\VB\1645601 whether\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>HIV\NN\14186340 seroconversion</e2>\NN\1740 among\IN\1740 daily\JJ\1740 smokers\NNS\9612848 of\IN\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 changed\VBD\46534 over\IN\5867413 time\NN\7308889 ,\,\1740 we\PRP\1740 used\VBD\1156834 Cox\NN\14732946 proportional\JJ\1740 hazards\NNS\14541044 regression\NN\14501726 and\CC\1740 divided\VBD\140123 the\DT\1740 study\NN\635850 into\IN\1740 3\CD\13741022 periods\NNS\13575869 :\:\1740 May\NNP\15209706 1\CD\13741022 ,\,\1740 1996-Nov\NN\1740 .\.\1740
D016578_D006679 CID After\IN\1740 adjusting\VBG\126264 for\IN\1740 potential\JJ\1740 confounders\NNS\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>HIV\NN\14186340 seroconversion</e2>\NN\1740 among\IN\1740 participants\NNS\9816771 who\WP\8299493 were\VBD\836236 daily\RB\1740 smokers\NNS\9612848 of\IN\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 increased\VBD\169651 over\IN\5867413 time\NN\7308889 (\-LRB-\1740 period\NN\13575869 1\CD\13741022 :\:\1740 hazard\NN\14541044 ratio\NN\13815152 [\-LRB-\1740 HR\NNP\15154774 ]\-RRB-\1740 1.03\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 0.57\CD\1740 -\SYM\1740 1.85\CD\1740 ;\:\1740 period\NN\13575869 2\CD\13741022 :\:\1740 HR\NNP\15154774 1.68\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.01\CD\1740 -\SYM\1740 2.80\CD\1740 ;\:\1740 and\CC\1740 period\NN\13575869 3\CD\13741022 :\:\1740 HR\NN\15154774 2.74\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NNP\13635336 1.06\CD\1740 -\SYM\1740 7.11\CD\1740 )\-RRB-\1740 .\.\1740
D016578_D006679 CID INTERPRETATION\NN\5926676 :\:\1740 Smoking\NN\831191 of\IN\1740 <e1>crack\NN\9379111 cocaine</e1>\NN\3492717 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 an\DT\6697703 independent\JJ\1740 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>HIV\NN\14186340 seroconversion</e2>\NN\1740 among\IN\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 injection\NN\320852 drug\NN\14778436 users\NNS\7846 .\.\1740
851038
D007980_D010300 NONE Kaliuretic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>L-dopa</e1>\JJ\1740 treatment\NN\654885 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D007980_D010300 NONE Hypokalemia\NNP\14299637 ,\,\1740 sometimes\RB\1740 severe\JJ\1740 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 some\DT\1740 <e1>L-dopa-treated</e1>\JJ\1740 <e2>parkinsonian</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D007980_D007008 CID <e2>Hypokalemia</e2>\NNP\14299637 ,\,\1740 sometimes\RB\1740 severe\JJ\1740 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 some\DT\1740 <e1>L-dopa-treated</e1>\JJ\1740 parkinsonian\JJ\1740 patients\NNS\9898892 .\.\1740
D007980_D007008 CID The\DT\1740 influence\NN\5190804 of\IN\1740 <e1>L-dopa</e1>\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 potassium\NN\14625458 and\CC\1740 sodium\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 ,\,\1740 sodium\NN\14625458 and\CC\1740 aldosterone\NN\14751863 .\.\1740
D011188_D007008 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 <e1>potassium</e1>\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 potassium\NN\14625458 and\CC\1740 sodium\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 ,\,\1740 sodium\NN\14625458 and\CC\1740 aldosterone\NN\14751863 .\.\1740
D011188_D007008 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 <e1>potassium</e1>\NN\14625458 and\CC\1740 sodium\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 ,\,\1740 sodium\NN\14625458 and\CC\1740 aldosterone\NN\14751863 .\.\1740
D011188_D007008 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 potassium\NN\14625458 and\CC\1740 sodium\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 <e1>potassium</e1>\NN\14625458 ,\,\1740 sodium\NN\14625458 and\CC\1740 aldosterone\NN\14751863 .\.\1740
D012964_D007008 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 potassium\NN\14625458 and\CC\1740 <e1>sodium</e1>\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 ,\,\1740 sodium\NN\14625458 and\CC\1740 aldosterone\NN\14751863 .\.\1740
D012964_D007008 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 potassium\NN\14625458 and\CC\1740 sodium\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 ,\,\1740 <e1>sodium</e1>\NN\14625458 and\CC\1740 aldosterone\NN\14751863 .\.\1740
D000450_D007008 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 L-dopa\NN\14604959 on\IN\1740 the\DT\1740 renal\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 was\VBD\836236 studied\VBN\630380 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>hypokalemia</e2>\NN\14299637 and\CC\1740 in\IN\13603305 5\CD\13741022 normokalemic\JJ\1740 patients\NNS\9898892 by\IN\1740 determination\NN\43195 of\IN\1740 renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 ,\,\1740 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 plasma\NN\5398023 concentration\NN\4916342 of\IN\1740 potassium\NN\14625458 and\CC\1740 sodium\NN\14625458 as\RB\1740 well\RB\1740 as\IN\14622893 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 potassium\NN\14625458 ,\,\1740 sodium\NN\14625458 and\CC\1740 <e1>aldosterone</e1>\NN\14751863 .\.\1740
20129423
D002220_D004802 CID Fatal\JJ\1740 <e1>carbamazepine</e1>\NN\1740 induced\JJ\1740 <e2>fulminant\JJ\1740 eosinophilic</e2>\JJ\1740 (\-LRB-\1740 hypersensitivity\NN\14531772 )\-RRB-\1740 myocarditis\NN\14338942 :\:\1740 emphasis\NN\14434681 on\IN\1740 anatomical\JJ\1740 and\CC\1740 histological\JJ\1740 characteristics\NNS\5849040 ,\,\1740 mechanisms\NNS\13446390 and\CC\1740 genetics\NNS\6037666 of\IN\1740 drug\NN\14778436 hypersensitivity\NN\14531772 and\CC\1740 differential\JJ\1740 diagnosis\NN\152018 .\.\1740
D002220_D004342 CID Fatal\JJ\1740 <e1>carbamazepine</e1>\NN\1740 induced\JJ\1740 fulminant\JJ\1740 eosinophilic\JJ\1740 (\-LRB-\1740 <e2>hypersensitivity</e2>\NN\14531772 )\-RRB-\1740 myocarditis\NN\14338942 :\:\1740 emphasis\NN\14434681 on\IN\1740 anatomical\JJ\1740 and\CC\1740 histological\JJ\1740 characteristics\NNS\5849040 ,\,\1740 mechanisms\NNS\13446390 and\CC\1740 genetics\NNS\6037666 of\IN\1740 drug\NN\14778436 hypersensitivity\NN\14531772 and\CC\1740 differential\JJ\1740 diagnosis\NN\152018 .\.\1740
D002220_D004342 CID Fatal\JJ\1740 <e1>carbamazepine</e1>\NN\1740 induced\JJ\1740 fulminant\JJ\1740 eosinophilic\JJ\1740 (\-LRB-\1740 hypersensitivity\NN\14531772 )\-RRB-\1740 myocarditis\NN\14338942 :\:\1740 emphasis\NN\14434681 on\IN\1740 anatomical\JJ\1740 and\CC\1740 histological\JJ\1740 characteristics\NNS\5849040 ,\,\1740 mechanisms\NNS\13446390 and\CC\1740 genetics\NNS\6037666 of\IN\1740 <e2>drug\NN\14778436 hypersensitivity</e2>\NN\14531772 and\CC\1740 differential\JJ\1740 diagnosis\NN\152018 .\.\1740
D002220_D004342 CID A\DT\13649268 frequently\RB\1740 fatal\JJ\1740 ,\,\1740 although\IN\1740 exceptionally\RB\1740 rare\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 is\VBZ\836236 necrotizing\VBG\1740 eosinophilic\JJ\1740 (\-LRB-\1740 <e2>hypersensitivity</e2>\NN\14531772 )\-RRB-\1740 myocarditis\NN\14338942 .\.\1740
D002220_D004342 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>hypersensitivity</e2>\NN\14531772 myocarditis\NN\14338942 secondary\JJ\1740 to\TO\1740 administration\NN\1133281 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 .\.\1740
D002220_D009205 CID Fatal\JJ\1740 <e1>carbamazepine</e1>\NN\1740 induced\JJ\1740 fulminant\JJ\1740 eosinophilic\JJ\1740 (\-LRB-\1740 hypersensitivity\NN\14531772 )\-RRB-\1740 <e2>myocarditis</e2>\NN\14338942 :\:\1740 emphasis\NN\14434681 on\IN\1740 anatomical\JJ\1740 and\CC\1740 histological\JJ\1740 characteristics\NNS\5849040 ,\,\1740 mechanisms\NNS\13446390 and\CC\1740 genetics\NNS\6037666 of\IN\1740 drug\NN\14778436 hypersensitivity\NN\14531772 and\CC\1740 differential\JJ\1740 diagnosis\NN\152018 .\.\1740
D002220_D009205 CID A\DT\13649268 frequently\RB\1740 fatal\JJ\1740 ,\,\1740 although\IN\1740 exceptionally\RB\1740 rare\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 is\VBZ\836236 necrotizing\VBG\1740 eosinophilic\JJ\1740 (\-LRB-\1740 hypersensitivity\NN\14531772 )\-RRB-\1740 <e2>myocarditis</e2>\NN\14338942 .\.\1740
D002220_D009205 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 hypersensitivity\NN\14531772 <e2>myocarditis</e2>\NN\14338942 secondary\JJ\1740 to\TO\1740 administration\NN\1133281 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 .\.\1740
D002220_D009205 CID To\TO\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 this\DT\1740 is\VBZ\836236 the\DT\1740 second\JJ\1740 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e1>carbamazepine</e1>\NN\1740 induced\JJ\1740 <e2>myocarditis</e2>\NN\14338942 reported\VBN\831651 in\IN\13603305 English\NNP\6946823 literature\NN\6362953 .\.\1740
10327032
D005472_D022124 CID Risk\NN\14541044 of\IN\1740 transient\JJ\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\JJ\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 with\IN\1740 the\DT\1740 complication\NN\1073995 of\IN\1740 dehydration\NN\14536438 and\CC\1740 infection\NN\14052046 .\.\1740
D005472_D022124 CID From\IN\1740 1986\CD\1740 to\IN\1740 1998\CD\1740 ,\,\1740 29\CD\13745420 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 32\CD\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\RB\1740 related\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D005472_D022124 CID From\IN\1740 1986\CD\1740 to\IN\1740 1998\CD\1740 ,\,\1740 29\CD\13745420 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 32\CD\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\RB\1740 related\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D005472_D022124 CID Higher\JJR\1740 plasma\NN\5398023 ammonium\NN\14743582 levels\NNS\4916342 and\CC\1740 more\RBR\1740 rapid\JJ\1740 onset\NN\7325190 of\IN\1740 <e2>hyperammonemia</e2>\NN\1740 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 18\CD\13745420 patients\NNS\9898892 with\IN\1740 bacterial\JJ\1740 infections\NNS\14052046 (\-LRB-\1740 p=0.003\NN\1740 and\CC\1740 0.0006\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 nine\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 high\JJ\1740 daily\JJ\1740 doses\NNS\3740161 (\-LRB-\1740 2600\CD\1740 or\CC\3541091 1800\CD\1740 mg/m2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>5-FU</e1>\NN\1740 (\-LRB-\1740 p=0.0001\NN\1740 and\CC\1740 <\XX\1740 0.0001\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D005472_D022124 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\JJ\1740 can\MD\3094503 occur\VB\2623529 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-FU</e1>\NN\1740 .\.\1740
D005472_D001927 CID Risk\NN\14541044 of\IN\1740 transient\JJ\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\JJ\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 with\IN\1740 the\DT\1740 complication\NN\1073995 of\IN\1740 dehydration\NN\14536438 and\CC\1740 infection\NN\14052046 .\.\1740
D005472_D001927 CID From\IN\1740 1986\CD\1740 to\IN\1740 1998\CD\1740 ,\,\1740 29\CD\13745420 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 32\CD\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\RB\1740 related\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D005472_D001927 CID From\IN\1740 1986\CD\1740 to\IN\1740 1998\CD\1740 ,\,\1740 29\CD\13745420 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 32\CD\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\RB\1740 related\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D005472_D001927 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e2>hyperammonemic\JJ\1740 encephalopathy</e2>\JJ\1740 can\MD\3094503 occur\VB\2623529 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-FU</e1>\NN\1740 .\.\1740
D005472_D009369 NONE Risk\NN\14541044 of\IN\1740 transient\JJ\1740 hyperammonemic\JJ\1740 encephalopathy\JJ\1740 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 with\IN\1740 the\DT\1740 complication\NN\1073995 of\IN\1740 dehydration\NN\14536438 and\CC\1740 infection\NN\14052046 .\.\1740
D005472_D009369 NONE From\IN\1740 1986\CD\1740 to\IN\1740 1998\CD\1740 ,\,\1740 29\CD\13745420 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 32\CD\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 hyperammonemic\JJ\1740 encephalopathy\RB\1740 related\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D005472_D009369 NONE From\IN\1740 1986\CD\1740 to\IN\1740 1998\CD\1740 ,\,\1740 29\CD\13745420 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 32\CD\1740 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 hyperammonemic\JJ\1740 encephalopathy\RB\1740 related\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 identified\VBN\699815 .\.\1740
D005472_D003681 NONE Risk\NN\14541044 of\IN\1740 transient\JJ\1740 hyperammonemic\JJ\1740 encephalopathy\JJ\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 with\IN\1740 the\DT\1740 complication\NN\1073995 of\IN\1740 <e2>dehydration</e2>\NN\14536438 and\CC\1740 infection\NN\14052046 .\.\1740
D005472_D007239 NONE Risk\NN\14541044 of\IN\1740 transient\JJ\1740 hyperammonemic\JJ\1740 encephalopathy\JJ\1740 in\IN\13603305 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 with\IN\1740 the\DT\1740 complication\NN\1073995 of\IN\1740 dehydration\NN\14536438 and\CC\1740 <e2>infection</e2>\NN\14052046 .\.\1740
D000644_D022124 NONE Higher\JJR\1740 plasma\NN\5398023 <e1>ammonium</e1>\NN\14743582 levels\NNS\4916342 and\CC\1740 more\RBR\1740 rapid\JJ\1740 onset\NN\7325190 of\IN\1740 <e2>hyperammonemia</e2>\NN\1740 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 18\CD\13745420 patients\NNS\9898892 with\IN\1740 bacterial\JJ\1740 infections\NNS\14052046 (\-LRB-\1740 p=0.003\NN\1740 and\CC\1740 0.0006\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 nine\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 high\JJ\1740 daily\JJ\1740 doses\NNS\3740161 (\-LRB-\1740 2600\CD\1740 or\CC\3541091 1800\CD\1740 mg/m2\NN\1740 )\-RRB-\1740 of\IN\1740 5-FU\NN\1740 (\-LRB-\1740 p=0.0001\NN\1740 and\CC\1740 <\XX\1740 0.0001\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D000644_D001424 NONE Higher\JJR\1740 plasma\NN\5398023 <e1>ammonium</e1>\NN\14743582 levels\NNS\4916342 and\CC\1740 more\RBR\1740 rapid\JJ\1740 onset\NN\7325190 of\IN\1740 hyperammonemia\NN\1740 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 18\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 (\-LRB-\1740 p=0.003\NN\1740 and\CC\1740 0.0006\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 nine\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 high\JJ\1740 daily\JJ\1740 doses\NNS\3740161 (\-LRB-\1740 2600\CD\1740 or\CC\3541091 1800\CD\1740 mg/m2\NN\1740 )\-RRB-\1740 of\IN\1740 5-FU\NN\1740 (\-LRB-\1740 p=0.0001\NN\1740 and\CC\1740 <\XX\1740 0.0001\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D005472_D001424 NONE Higher\JJR\1740 plasma\NN\5398023 ammonium\NN\14743582 levels\NNS\4916342 and\CC\1740 more\RBR\1740 rapid\JJ\1740 onset\NN\7325190 of\IN\1740 hyperammonemia\NN\1740 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 18\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>bacterial\JJ\1740 infections</e2>\NNS\14052046 (\-LRB-\1740 p=0.003\NN\1740 and\CC\1740 0.0006\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 and\CC\1740 in\IN\13603305 nine\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 high\JJ\1740 daily\JJ\1740 doses\NNS\3740161 (\-LRB-\1740 2600\CD\1740 or\CC\3541091 1800\CD\1740 mg/m2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>5-FU</e1>\NN\1740 (\-LRB-\1740 p=0.0001\NN\1740 and\CC\1740 <\XX\1740 0.0001\CD\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
3109094
D003520_D001745 CID Electron\NN\9338013 microscopic\JJ\1740 investigations\NNS\5797597 of\IN\1740 the\DT\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>lesions\NNS\14204950 of\IN\1740 the\DT\1740 urinary\JJ\1740 bladder</e2>\NN\5515670 of\IN\1740 the\DT\1740 rat\NN\2329401 and\CC\1740 their\PRP$\1740 prevention\NN\1073995 by\IN\1740 mesna\NN\1740 .\.\1740
D015080_D001745 NONE Electron\NN\9338013 microscopic\JJ\1740 investigations\NNS\5797597 of\IN\1740 the\DT\1740 cyclophosphamide-induced\JJ\1740 <e2>lesions\NNS\14204950 of\IN\1740 the\DT\1740 urinary\JJ\1740 bladder</e2>\NN\5515670 of\IN\1740 the\DT\1740 rat\NN\2329401 and\CC\1740 their\PRP$\1740 prevention\NN\1073995 by\IN\1740 <e1>mesna</e1>\NN\1740 .\.\1740
D003520_D003556 NONE Fully\RB\1740 developed\VBN\1753788 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 nearly\RB\1740 complete\JJ\1740 detachment\NN\7505676 of\IN\1740 the\DT\1740 urothelium\NN\1740 ,\,\1740 severe\JJ\1740 submucosal\NN\1740 edema\NN\14315192 owing\VBG\2663643 to\TO\1740 damage\NN\7296428 to\IN\1740 the\DT\1740 microvascular\JJ\1740 bed\NN\2821943 and\CC\1740 focal\JJ\1740 muscle\NN\5289601 necroses\NNS\1740 .\.\1740
D003520_D004487 NONE Fully\RB\1740 developed\VBN\1753788 <e1>cyclophosphamide-induced</e1>\JJ\1740 cystitis\NN\14566129 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 nearly\RB\1740 complete\JJ\1740 detachment\NN\7505676 of\IN\1740 the\DT\1740 urothelium\NN\1740 ,\,\1740 severe\JJ\1740 submucosal\NN\1740 <e2>edema</e2>\NN\14315192 owing\VBG\2663643 to\TO\1740 damage\NN\7296428 to\IN\1740 the\DT\1740 microvascular\JJ\1740 bed\NN\2821943 and\CC\1740 focal\JJ\1740 muscle\NN\5289601 necroses\NNS\1740 .\.\1740
D003520_D009336 NONE Fully\RB\1740 developed\VBN\1753788 <e1>cyclophosphamide-induced</e1>\JJ\1740 cystitis\NN\14566129 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 nearly\RB\1740 complete\JJ\1740 detachment\NN\7505676 of\IN\1740 the\DT\1740 urothelium\NN\1740 ,\,\1740 severe\JJ\1740 submucosal\NN\1740 edema\NN\14315192 owing\VBG\2663643 to\TO\1740 damage\NN\7296428 to\IN\1740 the\DT\1740 microvascular\JJ\1740 bed\NN\2821943 and\CC\1740 focal\JJ\1740 muscle\NN\5289601 <e2>necroses</e2>\NNS\1740 .\.\1740
11380496
D011441_D006111 NONE Frequency\NN\15286249 of\IN\1740 appearance\NN\4723816 of\IN\1740 myeloperoxidase-antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (\-LRB-\1740 MPO-ANCA\NN\1740 )\-RRB-\1740 in\IN\13603305 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 and\CC\1740 the\DT\1740 relationship\NN\31921 between\IN\1740 MPO-ANCA\NN\1740 and\CC\1740 clinical\JJ\1740 manifestations\NNS\7321772 .\.\1740
D011441_D006111 NONE OBJECTIVE\NN\5980875 :\:\1740 Myeloperoxidase\NN\1740 antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (MPO-ANCA)-positive\JJ\1740 vasculitis\NN\14336539 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 (\-LRB-\1740 PTU\NN\1740 )\-RRB-\1740 .\.\1740
D011441_D006111 NONE OBJECTIVE\NN\5980875 :\:\1740 Myeloperoxidase\NN\1740 antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (MPO-ANCA)-positive\JJ\1740 vasculitis\NN\14336539 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 propylthiouracil\NN\14727670 (\-LRB-\1740 <e1>PTU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D011441_D006111 NONE Nevertheless\RB\1740 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 no\DT\7204911 studies\NNS\635850 on\IN\1740 the\DT\1740 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 MPO-ANCA\NN\1740 and\CC\1740 vasculitis\NN\14336539 during\IN\1740 <e1>PTU</e1>\NN\1740 therapy\NN\657604 ,\,\1740 or\CC\3541091 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 MPO-ANCA\NN\1740 in\IN\13603305 untreated\JJ\1740 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 .\.\1740
D011441_D006111 NONE PATIENTS\NNS\9898892 :\:\1740 We\PRP\1740 investigated\VBD\644583 102\CD\1740 untreated\JJ\1740 patients\NNS\9898892 with\IN\1740 hyperthyroidism\NN\14059928 due\IN\5174653 to\IN\1740 <e2>Graves\NN\15143477 '\POS\1740 disease</e2>\NN\14061805 for\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 MPO-ANCA\NN\1740 ,\,\1740 and\CC\1740 for\IN\1740 the\DT\1740 development\NN\248977 vasculitis\NN\14336539 after\IN\1740 starting\VBG\2009433 <e1>PTU</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011441_D014657 NONE OBJECTIVE\NN\5980875 :\:\1740 Myeloperoxidase\NN\1740 antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (MPO-ANCA)-positive\JJ\1740 <e2>vasculitis</e2>\NN\14336539 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 (\-LRB-\1740 PTU\NN\1740 )\-RRB-\1740 .\.\1740
D011441_D014657 NONE OBJECTIVE\NN\5980875 :\:\1740 Myeloperoxidase\NN\1740 antineutrophil\NN\1740 cytoplasmic\JJ\1740 antibody\NN\14728724 (MPO-ANCA)-positive\JJ\1740 <e2>vasculitis</e2>\NN\14336539 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 propylthiouracil\NN\14727670 (\-LRB-\1740 <e1>PTU</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D011441_D014657 NONE Nevertheless\RB\1740 ,\,\1740 there\EX\27167 have\VBP\2108377 been\VBN\836236 no\DT\7204911 studies\NNS\635850 on\IN\1740 the\DT\1740 temporal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 MPO-ANCA\NN\1740 and\CC\1740 <e2>vasculitis</e2>\NN\14336539 during\IN\1740 <e1>PTU</e1>\NN\1740 therapy\NN\657604 ,\,\1740 or\CC\3541091 on\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 MPO-ANCA\NN\1740 in\IN\13603305 untreated\JJ\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 patients\NNS\9898892 .\.\1740
D011441_D014657 NONE PATIENTS\NNS\9898892 :\:\1740 We\PRP\1740 investigated\VBD\644583 102\CD\1740 untreated\JJ\1740 patients\NNS\9898892 with\IN\1740 hyperthyroidism\NN\14059928 due\IN\5174653 to\IN\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 for\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 MPO-ANCA\NN\1740 ,\,\1740 and\CC\1740 for\IN\1740 the\DT\1740 development\NN\248977 <e2>vasculitis</e2>\NN\14336539 after\IN\1740 starting\VBG\2009433 <e1>PTU</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011441_D014657 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>PTU</e1>\NN\1740 therapy\NN\657604 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 MPO-ANCA\NN\1740 ,\,\1740 but\CC\1740 MPO-ANCA\NN\1740 does\VBZ\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 be\VB\836236 closely\RB\1740 related\JJ\1740 to\TO\1740 <e2>vasculitis</e2>\NN\14336539 .\.\1740
D011441_D006980 NONE PATIENTS\NNS\9898892 :\:\1740 We\PRP\1740 investigated\VBD\644583 102\CD\1740 untreated\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 due\IN\5174653 to\IN\1740 Graves\NN\15143477 '\POS\1740 disease\NN\14061805 for\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 MPO-ANCA\NN\1740 ,\,\1740 and\CC\1740 for\IN\1740 the\DT\1740 development\NN\248977 vasculitis\NN\14336539 after\IN\1740 starting\VBG\2009433 <e1>PTU</e1>\NN\1740 therapy\NN\657604 .\.\1740
D011441_D014652 NONE In\IN\13603305 two\CD\13741022 of\IN\1740 them\PRP\1740 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titres\NNS\5038593 transiently\RB\1740 increased\VBD\169651 to\TO\1740 12.8\CD\1740 and\CC\1740 15.0\CD\1740 U/ml\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 despite\IN\7501545 continued\JJ\1740 <e1>PTU</e1>\NN\1740 therapy\NN\657604 ,\,\1740 but\CC\1740 no\DT\7204911 <e2>vasculitic\JJ\1740 disorders</e2>\NNS\14034177 developed\VBD\1753788 .\.\1740
D011441_D005334 CID In\IN\13603305 the\DT\1740 third\JJ\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 increased\VBD\169651 to\TO\1740 204\CD\1740 U/ml\NN\1740 and\CC\1740 she\PRP\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 <e2>fever</e2>\NN\14299637 ,\,\1740 oral\JJ\1740 ulcers\NNS\14211294 and\CC\1740 polyarthralgia\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 symptoms\NNS\5823932 resolved\VBD\352826 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 stopping\VBG\2452885 <e1>PTU</e1>\NN\1740 therapy\NN\657604 ,\,\1740 and\CC\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 decreased\VBD\169651 to\TO\1740 20.7\CD\1740 U/ml\NN\1740 by\IN\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 discontinuing\VBG\2609764 PTU\NN\1740 .\.\1740
D011441_D005334 CID In\IN\13603305 the\DT\1740 third\JJ\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 increased\VBD\169651 to\TO\1740 204\CD\1740 U/ml\NN\1740 and\CC\1740 she\PRP\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 <e2>fever</e2>\NN\14299637 ,\,\1740 oral\JJ\1740 ulcers\NNS\14211294 and\CC\1740 polyarthralgia\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 symptoms\NNS\5823932 resolved\VBD\352826 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 stopping\VBG\2452885 PTU\NN\1740 therapy\NN\657604 ,\,\1740 and\CC\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 decreased\VBD\169651 to\TO\1740 20.7\CD\1740 U/ml\NN\1740 by\IN\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 discontinuing\VBG\2609764 <e1>PTU</e1>\NN\1740 .\.\1740
D011441_D019226 CID In\IN\13603305 the\DT\1740 third\JJ\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 increased\VBD\169651 to\TO\1740 204\CD\1740 U/ml\NN\1740 and\CC\1740 she\PRP\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 fever\NN\14299637 ,\,\1740 <e2>oral\JJ\1740 ulcers</e2>\NNS\14211294 and\CC\1740 polyarthralgia\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 symptoms\NNS\5823932 resolved\VBD\352826 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 stopping\VBG\2452885 <e1>PTU</e1>\NN\1740 therapy\NN\657604 ,\,\1740 and\CC\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 decreased\VBD\169651 to\TO\1740 20.7\CD\1740 U/ml\NN\1740 by\IN\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 discontinuing\VBG\2609764 PTU\NN\1740 .\.\1740
D011441_D019226 CID In\IN\13603305 the\DT\1740 third\JJ\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 increased\VBD\169651 to\TO\1740 204\CD\1740 U/ml\NN\1740 and\CC\1740 she\PRP\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 fever\NN\14299637 ,\,\1740 <e2>oral\JJ\1740 ulcers</e2>\NNS\14211294 and\CC\1740 polyarthralgia\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 symptoms\NNS\5823932 resolved\VBD\352826 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 stopping\VBG\2452885 PTU\NN\1740 therapy\NN\657604 ,\,\1740 and\CC\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 decreased\VBD\169651 to\TO\1740 20.7\CD\1740 U/ml\NN\1740 by\IN\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 discontinuing\VBG\2609764 <e1>PTU</e1>\NN\1740 .\.\1740
D011441_D018771 CID In\IN\13603305 the\DT\1740 third\JJ\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 increased\VBD\169651 to\TO\1740 204\CD\1740 U/ml\NN\1740 and\CC\1740 she\PRP\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 fever\NN\14299637 ,\,\1740 oral\JJ\1740 ulcers\NNS\14211294 and\CC\1740 <e2>polyarthralgia</e2>\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 symptoms\NNS\5823932 resolved\VBD\352826 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 stopping\VBG\2452885 <e1>PTU</e1>\NN\1740 therapy\NN\657604 ,\,\1740 and\CC\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 decreased\VBD\169651 to\TO\1740 20.7\CD\1740 U/ml\NN\1740 by\IN\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 discontinuing\VBG\2609764 PTU\NN\1740 .\.\1740
D011441_D018771 CID In\IN\13603305 the\DT\1740 third\JJ\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 increased\VBD\169651 to\TO\1740 204\CD\1740 U/ml\NN\1740 and\CC\1740 she\PRP\1740 developed\VBD\1753788 a\DT\13649268 higher\JJR\1740 fever\NN\14299637 ,\,\1740 oral\JJ\1740 ulcers\NNS\14211294 and\CC\1740 <e2>polyarthralgia</e2>\NN\1740 ,\,\1740 but\CC\1740 the\DT\1740 symptoms\NNS\5823932 resolved\VBD\352826 2\CD\13741022 weeks\NNS\15113229 after\IN\1740 stopping\VBG\2452885 PTU\NN\1740 therapy\NN\657604 ,\,\1740 and\CC\1740 the\DT\1740 MPO-ANCA\NN\1740 titre\NN\5038593 decreased\VBD\169651 to\TO\1740 20.7\CD\1740 U/ml\NN\1740 by\IN\1740 4\CD\13741022 months\NNS\15113229 after\IN\1740 discontinuing\VBG\2609764 <e1>PTU</e1>\NN\1740 .\.\1740
11176729
D000806_D006333 NONE Toleration\NN\4637923 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors</e1>\NNS\20090 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 :\:\1740 results\NNS\34213 from\IN\1740 the\DT\1740 ATLAS\NN\6417598 trial\NN\786195 .\.\1740
D000806_D006333 NONE BACKGROUND\NN\4921011 :\:\1740 Treatment\NN\654885 with\IN\1740 <e1>angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitors</e1>\NNS\20090 reduces\VBZ\441445 mortality\NN\5054863 and\CC\1740 morbidity\NN\13826959 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 affected\VBN\126264 patients\NNS\9898892 are\VBP\836236 not\RB\1740 receiving\VBG\2210855 these\DT\1740 agents\NNS\7347 or\CC\3541091 are\VBP\836236 being\VBG\836236 treated\VBN\2376958 with\IN\1740 doses\NNS\3740161 lower\JJR\1740 than\IN\1740 those\DT\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 efficacious\JJ\1740 in\IN\13603305 trials\NNS\786195 ,\,\1740 primarily\RB\1740 because\IN\1740 of\IN\1740 concerns\NNS\5682950 about\IN\1740 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 these\DT\1740 agents\NNS\7347 ,\,\1740 especially\RB\1740 at\IN\14622893 the\DT\1740 recommended\VBN\875394 doses\NNS\3740161 .\.\1740
D000806_D006333 NONE BACKGROUND\NN\4921011 :\:\1740 Treatment\NN\654885 with\IN\1740 <e1>angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitors</e1>\NNS\20090 reduces\VBZ\441445 mortality\NN\5054863 and\CC\1740 morbidity\NN\13826959 in\IN\13603305 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 <e2>CHF</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 most\JJS\1740 affected\VBN\126264 patients\NNS\9898892 are\VBP\836236 not\RB\1740 receiving\VBG\2210855 these\DT\1740 agents\NNS\7347 or\CC\3541091 are\VBP\836236 being\VBG\836236 treated\VBN\2376958 with\IN\1740 doses\NNS\3740161 lower\JJR\1740 than\IN\1740 those\DT\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 efficacious\JJ\1740 in\IN\13603305 trials\NNS\786195 ,\,\1740 primarily\RB\1740 because\IN\1740 of\IN\1740 concerns\NNS\5682950 about\IN\1740 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 these\DT\1740 agents\NNS\7347 ,\,\1740 especially\RB\1740 at\IN\14622893 the\DT\1740 recommended\VBN\875394 doses\NNS\3740161 .\.\1740
D000806_D006333 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 therapy\NN\657604 in\IN\13603305 most\JJS\1740 patients\NNS\9898892 with\IN\1740 <e2>CHF</e2>\NN\1740 can\MD\3094503 be\VB\836236 successfully\RB\1740 titrated\VBN\489837 to\IN\1740 and\CC\1740 maintained\VBN\2202928 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 ,\,\1740 and\CC\1740 that\IN\1740 more\RBR\1740 aggressive\JJ\1740 use\NN\407535 of\IN\1740 these\DT\1740 agents\NNS\7347 is\VBZ\836236 warranted\VBN\1012073 .\.\1740
D017706_D006333 NONE The\DT\1740 present\JJ\1740 study\NN\635850 examines\VBZ\789138 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 high-\NN\1740 compared\VBN\644583 with\IN\1740 low-dose\JJ\1740 <e1>lisinopril</e1>\NN\2673637 in\IN\13603305 <e2>CHF</e2>\NN\1740 .\.\1740
D000806_D007022 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 405\CD\1740 patients\NNS\9898892 not\RB\1740 previously\RB\1740 receiving\VBG\2210855 an\DT\6697703 <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 ,\,\1740 doses\NNS\3740161 in\IN\13603305 only\RB\1740 4.2\CD\1740 %\NN\1740 could\MD\1740 not\RB\1740 be\VB\836236 titrated\VBN\489837 to\TO\1740 the\DT\1740 medium\NN\3575240 doses\NNS\3740161 required\VBN\754942 for\IN\1740 randomization\NN\1008378 because\IN\1740 of\IN\1740 symptoms\NNS\5823932 possibly\RB\1740 related\JJ\1740 to\TO\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 2.0\CD\1740 %\NN\1740 )\-RRB-\1740 or\CC\3541091 because\IN\1740 of\IN\1740 renal\JJ\1740 dysfunction\NN\14204950 or\CC\3541091 hyperkalemia\NN\14299637 (\-LRB-\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D000806_D007674 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 405\CD\1740 patients\NNS\9898892 not\RB\1740 previously\RB\1740 receiving\VBG\2210855 an\DT\6697703 <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 ,\,\1740 doses\NNS\3740161 in\IN\13603305 only\RB\1740 4.2\CD\1740 %\NN\1740 could\MD\1740 not\RB\1740 be\VB\836236 titrated\VBN\489837 to\TO\1740 the\DT\1740 medium\NN\3575240 doses\NNS\3740161 required\VBN\754942 for\IN\1740 randomization\NN\1008378 because\IN\1740 of\IN\1740 symptoms\NNS\5823932 possibly\RB\1740 related\JJ\1740 to\TO\1740 hypotension\NN\14057371 (\-LRB-\1740 2.0\CD\1740 %\NN\1740 )\-RRB-\1740 or\CC\3541091 because\IN\1740 of\IN\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 or\CC\3541091 hyperkalemia\NN\14299637 (\-LRB-\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D000806_D006947 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 405\CD\1740 patients\NNS\9898892 not\RB\1740 previously\RB\1740 receiving\VBG\2210855 an\DT\6697703 <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 ,\,\1740 doses\NNS\3740161 in\IN\13603305 only\RB\1740 4.2\CD\1740 %\NN\1740 could\MD\1740 not\RB\1740 be\VB\836236 titrated\VBN\489837 to\TO\1740 the\DT\1740 medium\NN\3575240 doses\NNS\3740161 required\VBN\754942 for\IN\1740 randomization\NN\1008378 because\IN\1740 of\IN\1740 symptoms\NNS\5823932 possibly\RB\1740 related\JJ\1740 to\TO\1740 hypotension\NN\14057371 (\-LRB-\1740 2.0\CD\1740 %\NN\1740 )\-RRB-\1740 or\CC\3541091 because\IN\1740 of\IN\1740 renal\JJ\1740 dysfunction\NN\14204950 or\CC\3541091 <e2>hyperkalemia</e2>\NN\14299637 (\-LRB-\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D000806_D003920 NONE Subgroups\NNS\31264 presumed\VBD\719734 to\TO\1740 be\VB\836236 at\IN\14622893 higher\JJR\1740 risk\NN\14541044 for\IN\1740 <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 intolerance\NN\4642596 (\-LRB-\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <\XX\1740 120\CD\13745420 mm\NN\13649268 Hg\NN\14625458 ;\:\1740 creatinine\NN\1740 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 132.6\CD\1740 micromol/L\NN\1740 [\-LRB-\1740 >\CD\1740 or\CC\3541091 =\JJ\1740 1.5\CD\1740 mg/dL\NN\1740 ]\-RRB-\1740 ;\:\1740 age\NN\4916342 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 70\CD\13745420 years\NNS\15144371 ;\:\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 )\-RRB-\1740 generally\RB\1740 tolerated\VBD\802318 the\DT\1740 high-dose\JJ\1740 strategy\NN\5902545 .\.\1740
D003404_D003920 NONE Subgroups\NNS\31264 presumed\VBD\719734 to\TO\1740 be\VB\836236 at\IN\14622893 higher\JJR\1740 risk\NN\14541044 for\IN\1740 ACE\NN\13741022 inhibitor\NN\20090 intolerance\NN\4642596 (\-LRB-\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <\XX\1740 120\CD\13745420 mm\NN\13649268 Hg\NN\14625458 ;\:\1740 <e1>creatinine</e1>\NN\1740 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 132.6\CD\1740 micromol/L\NN\1740 [\-LRB-\1740 >\CD\1740 or\CC\3541091 =\JJ\1740 1.5\CD\1740 mg/dL\NN\1740 ]\-RRB-\1740 ;\:\1740 age\NN\4916342 ,\,\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 70\CD\13745420 years\NNS\15144371 ;\:\1740 and\CC\1740 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 )\-RRB-\1740 generally\RB\1740 tolerated\VBD\802318 the\DT\1740 high-dose\JJ\1740 strategy\NN\5902545 .\.\1740
2383364
C048279_D002056 NONE Patient\NN\9898892 tolerance\NN\5032565 study\NN\635850 of\IN\1740 topical\JJ\1740 <e1>chlorhexidine\NN\2724207 diphosphanilate</e1>\NN\1740 :\:\1740 a\DT\13649268 new\JJ\1740 topical\JJ\1740 agent\NN\7347 for\IN\1740 <e2>burns</e2>\NNS\14322699 .\.\1740
C048279_D002056 NONE <e1>Chlorhexidine\NN\2724207 phosphanilate</e1>\NN\1740 (\-LRB-\1740 CHP\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 new\JJ\1740 broad-spectrum\NN\1740 antimicrobial\JJ\1740 agent\NN\7347 ,\,\1740 has\VBZ\2108377 been\VBN\836236 evaluated\VBN\670261 as\IN\14622893 a\DT\13649268 topical\JJ\1740 <e2>burn</e2>\NN\14322699 wound\NN\14285662 dressing\VBG\109660 in\IN\13603305 cream\NN\8386555 form\NN\6286395 ,\,\1740 but\CC\1740 preliminary\JJ\1740 clinical\JJ\1740 trials\NNS\786195 reported\VBD\831651 that\IN\1740 it\PRP\6125041 was\VBD\836236 painful\JJ\1740 upon\IN\1740 application\NN\947128 .\.\1740
C048279_D002056 NONE Chlorhexidine\NN\2724207 phosphanilate\NN\1740 (\-LRB-\1740 <e1>CHP</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 new\JJ\1740 broad-spectrum\NN\1740 antimicrobial\JJ\1740 agent\NN\7347 ,\,\1740 has\VBZ\2108377 been\VBN\836236 evaluated\VBN\670261 as\IN\14622893 a\DT\13649268 topical\JJ\1740 <e2>burn</e2>\NN\14322699 wound\NN\14285662 dressing\VBG\109660 in\IN\13603305 cream\NN\8386555 form\NN\6286395 ,\,\1740 but\CC\1740 preliminary\JJ\1740 clinical\JJ\1740 trials\NNS\786195 reported\VBD\831651 that\IN\1740 it\PRP\6125041 was\VBD\836236 painful\JJ\1740 upon\IN\1740 application\NN\947128 .\.\1740
C048279_D002056 NONE One\CD\13741022 <e2>burn</e2>\NN\14322699 site\NN\8673395 was\VBD\836236 treated\VBN\2376958 with\IN\1740 each\DT\1740 of\IN\1740 four\CD\13741022 different\JJ\1740 <e1>CHP</e1>\NN\1740 concentrations\NNS\4916342 ,\,\1740 from\IN\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 to\IN\1740 2\CD\13741022 per\NN\1740 cent\NN\13662703 ,\,\1740 their\PRP$\1740 vehicle\NN\3100490 ,\,\1740 and\CC\1740 1\CD\13741022 per\NN\1740 cent\NN\13662703 silver\NN\14821043 sulphadiazine\NN\1740 (\-LRB-\1740 AgSD\NN\1740 )\-RRB-\1740 cream\NN\8386555 ,\,\1740 an\DT\6697703 antimicrobial\JJ\1740 agent\NN\7347 frequently\RB\1740 used\VBN\1156834 for\IN\1740 topical\JJ\1740 treatment\NN\654885 of\IN\1740 burn\NN\14322699 wounds\NNS\14285662 .\.\1740
C048279_D002056 NONE One\CD\13741022 burn\NN\14322699 site\NN\8673395 was\VBD\836236 treated\VBN\2376958 with\IN\1740 each\DT\1740 of\IN\1740 four\CD\13741022 different\JJ\1740 <e1>CHP</e1>\NN\1740 concentrations\NNS\4916342 ,\,\1740 from\IN\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 to\IN\1740 2\CD\13741022 per\NN\1740 cent\NN\13662703 ,\,\1740 their\PRP$\1740 vehicle\NN\3100490 ,\,\1740 and\CC\1740 1\CD\13741022 per\NN\1740 cent\NN\13662703 silver\NN\14821043 sulphadiazine\NN\1740 (\-LRB-\1740 AgSD\NN\1740 )\-RRB-\1740 cream\NN\8386555 ,\,\1740 an\DT\6697703 antimicrobial\JJ\1740 agent\NN\7347 frequently\RB\1740 used\VBN\1156834 for\IN\1740 topical\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>burn</e2>\NN\14322699 wounds\NNS\14285662 .\.\1740
D012837_D002056 NONE One\CD\13741022 <e2>burn</e2>\NN\14322699 site\NN\8673395 was\VBD\836236 treated\VBN\2376958 with\IN\1740 each\DT\1740 of\IN\1740 four\CD\13741022 different\JJ\1740 CHP\NN\1740 concentrations\NNS\4916342 ,\,\1740 from\IN\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 to\IN\1740 2\CD\13741022 per\NN\1740 cent\NN\13662703 ,\,\1740 their\PRP$\1740 vehicle\NN\3100490 ,\,\1740 and\CC\1740 1\CD\13741022 per\NN\1740 cent\NN\13662703 <e1>silver\NN\14821043 sulphadiazine</e1>\NN\1740 (\-LRB-\1740 AgSD\NN\1740 )\-RRB-\1740 cream\NN\8386555 ,\,\1740 an\DT\6697703 antimicrobial\JJ\1740 agent\NN\7347 frequently\RB\1740 used\VBN\1156834 for\IN\1740 topical\JJ\1740 treatment\NN\654885 of\IN\1740 burn\NN\14322699 wounds\NNS\14285662 .\.\1740
D012837_D002056 NONE One\CD\13741022 burn\NN\14322699 site\NN\8673395 was\VBD\836236 treated\VBN\2376958 with\IN\1740 each\DT\1740 of\IN\1740 four\CD\13741022 different\JJ\1740 CHP\NN\1740 concentrations\NNS\4916342 ,\,\1740 from\IN\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 to\IN\1740 2\CD\13741022 per\NN\1740 cent\NN\13662703 ,\,\1740 their\PRP$\1740 vehicle\NN\3100490 ,\,\1740 and\CC\1740 1\CD\13741022 per\NN\1740 cent\NN\13662703 <e1>silver\NN\14821043 sulphadiazine</e1>\NN\1740 (\-LRB-\1740 AgSD\NN\1740 )\-RRB-\1740 cream\NN\8386555 ,\,\1740 an\DT\6697703 antimicrobial\JJ\1740 agent\NN\7347 frequently\RB\1740 used\VBN\1156834 for\IN\1740 topical\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>burn</e2>\NN\14322699 wounds\NNS\14285662 .\.\1740
D012837_D002056 NONE One\CD\13741022 <e2>burn</e2>\NN\14322699 site\NN\8673395 was\VBD\836236 treated\VBN\2376958 with\IN\1740 each\DT\1740 of\IN\1740 four\CD\13741022 different\JJ\1740 CHP\NN\1740 concentrations\NNS\4916342 ,\,\1740 from\IN\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 to\IN\1740 2\CD\13741022 per\NN\1740 cent\NN\13662703 ,\,\1740 their\PRP$\1740 vehicle\NN\3100490 ,\,\1740 and\CC\1740 1\CD\13741022 per\NN\1740 cent\NN\13662703 silver\NN\14821043 sulphadiazine\NN\1740 (\-LRB-\1740 <e1>AgSD</e1>\NN\1740 )\-RRB-\1740 cream\NN\8386555 ,\,\1740 an\DT\6697703 antimicrobial\JJ\1740 agent\NN\7347 frequently\RB\1740 used\VBN\1156834 for\IN\1740 topical\JJ\1740 treatment\NN\654885 of\IN\1740 burn\NN\14322699 wounds\NNS\14285662 .\.\1740
D012837_D002056 NONE One\CD\13741022 burn\NN\14322699 site\NN\8673395 was\VBD\836236 treated\VBN\2376958 with\IN\1740 each\DT\1740 of\IN\1740 four\CD\13741022 different\JJ\1740 CHP\NN\1740 concentrations\NNS\4916342 ,\,\1740 from\IN\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 to\IN\1740 2\CD\13741022 per\NN\1740 cent\NN\13662703 ,\,\1740 their\PRP$\1740 vehicle\NN\3100490 ,\,\1740 and\CC\1740 1\CD\13741022 per\NN\1740 cent\NN\13662703 silver\NN\14821043 sulphadiazine\NN\1740 (\-LRB-\1740 <e1>AgSD</e1>\NN\1740 )\-RRB-\1740 cream\NN\8386555 ,\,\1740 an\DT\6697703 antimicrobial\JJ\1740 agent\NN\7347 frequently\RB\1740 used\VBN\1156834 for\IN\1740 topical\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>burn</e2>\NN\14322699 wounds\NNS\14285662 .\.\1740
C048279_D010146 CID There\EX\27167 was\VBD\836236 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>CHP</e1>\NN\1740 concentration\NN\4916342 and\CC\1740 patients\NNS\9898892 '\POS\1740 ratings\NNS\5733583 of\IN\1740 <e2>pain</e2>\NN\14299637 on\IN\1740 an\DT\6697703 analogue\NN\4743605 scale\NN\7260623 .\.\1740
C048279_D010146 CID The\DT\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 <e1>CHP</e1>\NN\1740 cream\NN\8386555 was\VBD\836236 closest\JJR\1740 to\TO\1740 AgSD\NN\1740 in\IN\13603305 <e2>pain</e2>\NN\14299637 tolerance\NN\5032565 ;\:\1740 however\RB\1740 ,\,\1740 none\NN\15228378 of\IN\1740 the\DT\1740 treatments\NNS\654885 differed\VBD\1740 statistically\RB\1740 from\IN\1740 AgSD\NN\1740 or\CC\3541091 from\IN\1740 each\DT\1740 other\JJ\1740 .\.\1740
D012837_D010146 NONE The\DT\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 CHP\NN\1740 cream\NN\8386555 was\VBD\836236 closest\JJR\1740 to\TO\1740 <e1>AgSD</e1>\NN\1740 in\IN\13603305 <e2>pain</e2>\NN\14299637 tolerance\NN\5032565 ;\:\1740 however\RB\1740 ,\,\1740 none\NN\15228378 of\IN\1740 the\DT\1740 treatments\NNS\654885 differed\VBD\1740 statistically\RB\1740 from\IN\1740 AgSD\NN\1740 or\CC\3541091 from\IN\1740 each\DT\1740 other\JJ\1740 .\.\1740
D012837_D010146 NONE The\DT\1740 0.25\CD\1740 per\IN\1740 cent\NN\13662703 CHP\NN\1740 cream\NN\8386555 was\VBD\836236 closest\JJR\1740 to\TO\1740 AgSD\NN\1740 in\IN\13603305 <e2>pain</e2>\NN\14299637 tolerance\NN\5032565 ;\:\1740 however\RB\1740 ,\,\1740 none\NN\15228378 of\IN\1740 the\DT\1740 treatments\NNS\654885 differed\VBD\1740 statistically\RB\1740 from\IN\1740 <e1>AgSD</e1>\NN\1740 or\CC\3541091 from\IN\1740 each\DT\1740 other\JJ\1740 .\.\1740
9725303
D019469_D014517 NONE Nonopaque\JJ\1740 crystal\JJ\1740 deposition\NN\13424865 causing\VBG\1617192 <e2>ureteric\JJ\1740 obstruction</e2>\NN\4341686 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HIV\NN\14186340 undergoing\VBG\109660 <e1>indinavir</e1>\NN\4013993 therapy\NN\657604 .\.\1740
D019469_D014517 NONE CONCLUSION\NN\5837957 :\:\1740 <e2>Ureteric\NNP\1740 obstruction</e2>\NN\4341686 caused\VBN\1617192 by\IN\1740 precipitated\VBN\1642924 <e1>indinavir</e1>\NN\4013993 crystals\NNS\15046900 may\MD\15209706 be\VB\836236 difficult\JJ\1740 to\TO\1740 diagnose\VB\644583 with\IN\1740 unenhanced\JJ\1740 CT\NN\901316 .\.\1740
D019469_D014517 NONE Images\NNS\5926676 may\MD\15209706 need\VB\2604760 to\TO\1740 be\VB\836236 obtained\VBN\2210855 using\VBG\1156834 i.v.\NN\1740 contrast\NN\13854649 material\NN\19613 to\TO\1740 enable\VB\126264 diagnosis\NN\152018 of\IN\1740 <e2>ureteric\JJ\1740 stones\NNS\19128 or\CC\3541091 obstruction</e2>\NN\4341686 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HIV\NN\14186340 infection\NN\14052046 who\WP\8299493 receive\VBP\2210855 <e1>indinavir</e1>\NN\4013993 therapy\NN\657604 .\.\1740
D019469_D014514 CID OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 describe\VBP\1001294 the\DT\1740 unique\JJ\1740 CT\NN\901316 features\NNS\5849040 of\IN\1740 <e2>ureteric\JJ\1740 calculi</e2>\NNS\9416076 in\IN\13603305 six\CD\13741022 HIV-infected\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>indinavir</e1>\NN\4013993 ,\,\1740 the\DT\1740 most\RBS\1740 commonly\RB\1740 used\VBN\1156834 HIV\NN\14186340 protease\NN\14732946 inhibitor\NN\20090 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 urolithiasis\NN\1740 .\.\1740
D019469_D014514 NONE Images\NNS\5926676 may\MD\15209706 need\VB\2604760 to\TO\1740 be\VB\836236 obtained\VBN\2210855 using\VBG\1156834 i.v.\NN\1740 contrast\NN\13854649 material\NN\19613 to\TO\1740 enable\VB\126264 diagnosis\NN\152018 of\IN\1740 <e2>ureteric\JJ\1740 stones\NNS\19128 or\CC\3541091 obstruction</e2>\NN\4341686 in\IN\13603305 patients\NNS\9898892 with\IN\1740 HIV\NN\14186340 infection\NN\14052046 who\WP\8299493 receive\VBP\2210855 <e1>indinavir</e1>\NN\4013993 therapy\NN\657604 .\.\1740
D019469_D015658 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 describe\VBP\1001294 the\DT\1740 unique\JJ\1740 CT\NN\901316 features\NNS\5849040 of\IN\1740 ureteric\JJ\1740 calculi\NNS\9416076 in\IN\13603305 six\CD\13741022 <e2>HIV-infected</e2>\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>indinavir</e1>\NN\4013993 ,\,\1740 the\DT\1740 most\RBS\1740 commonly\RB\1740 used\VBN\1156834 HIV\NN\14186340 protease\NN\14732946 inhibitor\NN\20090 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 urolithiasis\NN\1740 .\.\1740
D019469_D015658 NONE Images\NNS\5926676 may\MD\15209706 need\VB\2604760 to\TO\1740 be\VB\836236 obtained\VBN\2210855 using\VBG\1156834 i.v.\NN\1740 contrast\NN\13854649 material\NN\19613 to\TO\1740 enable\VB\126264 diagnosis\NN\152018 of\IN\1740 ureteric\JJ\1740 stones\NNS\19128 or\CC\3541091 obstruction\NN\4341686 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>HIV\NN\14186340 infection</e2>\NN\14052046 who\WP\8299493 receive\VBP\2210855 <e1>indinavir</e1>\NN\4013993 therapy\NN\657604 .\.\1740
D019469_D052878 NONE OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 describe\VBP\1001294 the\DT\1740 unique\JJ\1740 CT\NN\901316 features\NNS\5849040 of\IN\1740 ureteric\JJ\1740 calculi\NNS\9416076 in\IN\13603305 six\CD\13741022 HIV-infected\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>indinavir</e1>\NN\4013993 ,\,\1740 the\DT\1740 most\RBS\1740 commonly\RB\1740 used\VBN\1156834 HIV\NN\14186340 protease\NN\14732946 inhibitor\NN\20090 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>urolithiasis</e2>\NN\1740 .\.\1740
10401555
C096012_D007859 NONE <e1>Nociceptin/orphanin</e1>\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D007859 NONE <e1>Nociceptin/orphanin\NN\1740 FQ</e1>\NN\1740 and\CC\1740 nocistatin\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D007859 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 <e1>nociceptin/orphanin</e1>\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D007859 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 <e1>nociceptin/orphanin\NN\1740 FQ</e1>\NN\1740 and\CC\1740 nocistatin\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D008569 NONE <e1>Nociceptin/orphanin</e1>\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D008569 NONE <e1>Nociceptin/orphanin\NN\1740 FQ</e1>\NN\1740 and\CC\1740 nocistatin\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D008569 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 <e1>nociceptin/orphanin</e1>\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
C096012_D008569 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 <e1>nociceptin/orphanin\NN\1740 FQ</e1>\NN\1740 and\CC\1740 nocistatin\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
C111148_D007859 NONE Nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 <e1>nocistatin</e1>\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
C111148_D007859 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 <e1>nocistatin</e1>\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
C111148_D008569 NONE Nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 <e1>nocistatin</e1>\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
C111148_D008569 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 <e1>nocistatin</e1>\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012601_D007859 CID Nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012601_D007859 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012601_D008569 CID Nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 on\IN\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 in\IN\13603305 mice\NNS\2329401 .\.\1740
D012601_D008569 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 whether\IN\1740 nociceptin/orphanin\NN\1740 FQ\NN\1740 and\CC\1740 nocistatin\NN\1740 could\MD\1740 modulate\VB\1724459 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 ,\,\1740 a\DT\13649268 muscarinic\JJ\1740 cholinergic\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 using\VBG\1156834 spontaneous\JJ\1740 alternation\NN\1010458 of\IN\1740 Y-maze\JJ\1740 and\CC\1740 step-down\JJ\1740 type\NN\5839024 passive\JJ\1740 avoidance\NN\203342 tasks\NNS\575741 in\IN\13603305 mice\NNS\2329401 .\.\1740
C111148_D006930 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e1>nocistatin</e1>\NN\1740 is\VBZ\836236 recently\RB\1740 isolated\VBN\2512305 from\IN\1740 the\DT\1740 same\JJ\1740 precursor\NN\14580897 as\IN\14622893 nociceptin\NN\1740 and\CC\1740 blocks\VBZ\1476483 nociceptin-induced\JJ\1740 <e2>allodynia</e2>\NN\1740 and\CC\1740 hyperalgesia\NN\1740 .\.\1740
C111148_D006930 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 <e1>nocistatin</e1>\NN\1740 is\VBZ\836236 recently\RB\1740 isolated\VBN\2512305 from\IN\1740 the\DT\1740 same\JJ\1740 precursor\NN\14580897 as\IN\14622893 nociceptin\NN\1740 and\CC\1740 blocks\VBZ\1476483 nociceptin-induced\JJ\1740 allodynia\NN\1740 and\CC\1740 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
C096012_D006930 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 nocistatin\NN\1740 is\VBZ\836236 recently\RB\1740 isolated\VBN\2512305 from\IN\1740 the\DT\1740 same\JJ\1740 precursor\NN\14580897 as\IN\14622893 <e1>nociceptin</e1>\NN\1740 and\CC\1740 blocks\VBZ\1476483 nociceptin-induced\JJ\1740 <e2>allodynia</e2>\NN\1740 and\CC\1740 hyperalgesia\NN\1740 .\.\1740
C096012_D006930 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 nocistatin\NN\1740 is\VBZ\836236 recently\RB\1740 isolated\VBN\2512305 from\IN\1740 the\DT\1740 same\JJ\1740 precursor\NN\14580897 as\IN\14622893 <e1>nociceptin</e1>\NN\1740 and\CC\1740 blocks\VBZ\1476483 nociceptin-induced\JJ\1740 allodynia\NN\1740 and\CC\1740 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
C096012_D006930 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 nocistatin\NN\1740 is\VBZ\836236 recently\RB\1740 isolated\VBN\2512305 from\IN\1740 the\DT\1740 same\JJ\1740 precursor\NN\14580897 as\IN\14622893 nociceptin\NN\1740 and\CC\1740 blocks\VBZ\1476483 <e1>nociceptin-induced</e1>\JJ\1740 <e2>allodynia</e2>\NN\1740 and\CC\1740 hyperalgesia\NN\1740 .\.\1740
C096012_D006930 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 nocistatin\NN\1740 is\VBZ\836236 recently\RB\1740 isolated\VBN\2512305 from\IN\1740 the\DT\1740 same\JJ\1740 precursor\NN\14580897 as\IN\14622893 nociceptin\NN\1740 and\CC\1740 blocks\VBZ\1476483 <e1>nociceptin-induced</e1>\JJ\1740 allodynia\NN\1740 and\CC\1740 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
3323259
D002118_D002318 NONE Increasing\VBG\169651 recognition\NN\13932421 of\IN\1740 the\DT\1740 importance\NN\5138488 of\IN\1740 <e1>calcium</e1>\NN\14625458 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 has\VBZ\2108377 stimulated\VBN\137313 research\NN\633864 into\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blocking\NN\562280 agents\NNS\7347 for\IN\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 cardiovascular\JJ\1740 diseases\NNS\14061805 .\.\1740
D002118_D002318 NONE Increasing\VBG\169651 recognition\NN\13932421 of\IN\1740 the\DT\1740 importance\NN\5138488 of\IN\1740 <e1>calcium</e1>\NN\14625458 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 has\VBZ\2108377 stimulated\VBN\137313 research\NN\633864 into\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blocking\NN\562280 agents\NNS\7347 for\IN\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 <e2>cardiovascular\JJ\1740 diseases</e2>\NNS\14061805 .\.\1740
D002121_D002318 NONE Increasing\VBG\169651 recognition\NN\13932421 of\IN\1740 the\DT\1740 importance\NN\5138488 of\IN\1740 calcium\NN\14625458 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 has\VBZ\2108377 stimulated\VBN\137313 research\NN\633864 into\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blocking\NN\562280 agents</e1>\NNS\7347 for\IN\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 cardiovascular\JJ\1740 diseases\NNS\14061805 .\.\1740
D002121_D002318 NONE Increasing\VBG\169651 recognition\NN\13932421 of\IN\1740 the\DT\1740 importance\NN\5138488 of\IN\1740 calcium\NN\14625458 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 has\VBZ\2108377 stimulated\VBN\137313 research\NN\633864 into\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blocking\NN\562280 agents</e1>\NNS\7347 for\IN\1740 treatment\NN\654885 of\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 <e2>cardiovascular\JJ\1740 diseases</e2>\NNS\14061805 .\.\1740
C038806_D000787 NONE As\IN\14622893 the\DT\1740 first\JJ\1740 <e1>dihydropyridine</e1>\NN\1740 available\JJ\1740 for\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 ,\,\1740 nifedipine\NN\2938514 controls\VBZ\2422663 <e2>angina</e2>\NN\14171682 and\CC\1740 hypertension\NN\14057371 with\IN\1740 minimal\JJ\1740 depression\NN\14373582 of\IN\1740 cardiac\JJ\1740 function\NN\13783581 .\.\1740
C038806_D006973 NONE As\IN\14622893 the\DT\1740 first\JJ\1740 <e1>dihydropyridine</e1>\NN\1740 available\JJ\1740 for\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 ,\,\1740 nifedipine\NN\2938514 controls\VBZ\2422663 angina\NN\14171682 and\CC\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 minimal\JJ\1740 depression\NN\14373582 of\IN\1740 cardiac\JJ\1740 function\NN\13783581 .\.\1740
D009543_D000787 NONE As\IN\14622893 the\DT\1740 first\JJ\1740 dihydropyridine\NN\1740 available\JJ\1740 for\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 ,\,\1740 <e1>nifedipine</e1>\NN\2938514 controls\VBZ\2422663 <e2>angina</e2>\NN\14171682 and\CC\1740 hypertension\NN\14057371 with\IN\1740 minimal\JJ\1740 depression\NN\14373582 of\IN\1740 cardiac\JJ\1740 function\NN\13783581 .\.\1740
D009543_D006973 NONE As\IN\14622893 the\DT\1740 first\JJ\1740 dihydropyridine\NN\1740 available\JJ\1740 for\IN\1740 use\NN\407535 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 ,\,\1740 <e1>nifedipine</e1>\NN\2938514 controls\VBZ\2422663 angina\NN\14171682 and\CC\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 minimal\JJ\1740 depression\NN\14373582 of\IN\1740 cardiac\JJ\1740 function\NN\13783581 .\.\1740
D009568_D006973 NONE Once\RB\1740 or\CC\3541091 twice\RB\1740 daily\RB\1740 dosage\NN\13576355 possible\JJ\1740 with\IN\1740 <e1>nitrendipine</e1>\JJ\1740 and\CC\1740 nisoldipine\NN\1740 offers\VBZ\2327200 a\DT\13649268 convenient\JJ\1740 administration\NN\1133281 schedule\NN\5898568 ,\,\1740 which\WDT\1740 encourages\VBZ\2556126 patient\NN\9898892 compliance\NN\1202904 in\IN\13603305 long-term\JJ\1740 therapy\NN\657604 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D015737_D006973 NONE Once\RB\1740 or\CC\3541091 twice\RB\1740 daily\RB\1740 dosage\NN\13576355 possible\JJ\1740 with\IN\1740 nitrendipine\JJ\1740 and\CC\1740 <e1>nisoldipine</e1>\NN\1740 offers\VBZ\2327200 a\DT\13649268 convenient\JJ\1740 administration\NN\1133281 schedule\NN\5898568 ,\,\1740 which\WDT\1740 encourages\VBZ\2556126 patient\NN\9898892 compliance\NN\1202904 in\IN\13603305 long-term\JJ\1740 therapy\NN\657604 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D015737_D000787 NONE The\DT\1740 coronary\JJ\1740 vasodilating\NN\1740 properties\NNS\32613 of\IN\1740 <e1>nisoldipine</e1>\NN\1740 have\VBP\2108377 led\VBN\1752884 to\TO\1740 the\DT\1740 investigation\NN\5797597 of\IN\1740 this\DT\1740 agent\NN\7347 for\IN\1740 use\NN\407535 in\IN\13603305 <e2>angina</e2>\NN\14171682 .\.\1740
D009553_D013345 NONE Selectivity\NN\4916342 for\IN\1740 the\DT\1740 cerebrovascular\JJ\1740 bed\NN\2821943 makes\VBZ\126264 <e1>nimodipine</e1>\NN\1740 potentially\RB\1740 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 ,\,\1740 migraine\NN\14326607 headache\NN\5829480 ,\,\1740 dementia\NN\14395018 ,\,\1740 and\CC\1740 stroke\RB\1740 .\.\1740
D009553_D008881 NONE Selectivity\NN\4916342 for\IN\1740 the\DT\1740 cerebrovascular\JJ\1740 bed\NN\2821943 makes\VBZ\126264 <e1>nimodipine</e1>\NN\1740 potentially\RB\1740 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 <e2>migraine\NN\14326607 headache</e2>\NN\5829480 ,\,\1740 dementia\NN\14395018 ,\,\1740 and\CC\1740 stroke\RB\1740 .\.\1740
D009553_D003704 NONE Selectivity\NN\4916342 for\IN\1740 the\DT\1740 cerebrovascular\JJ\1740 bed\NN\2821943 makes\VBZ\126264 <e1>nimodipine</e1>\NN\1740 potentially\RB\1740 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 migraine\NN\14326607 headache\NN\5829480 ,\,\1740 <e2>dementia</e2>\NN\14395018 ,\,\1740 and\CC\1740 stroke\RB\1740 .\.\1740
D009553_D020521 NONE Selectivity\NN\4916342 for\IN\1740 the\DT\1740 cerebrovascular\JJ\1740 bed\NN\2821943 makes\VBZ\126264 <e1>nimodipine</e1>\NN\1740 potentially\RB\1740 useful\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 ,\,\1740 migraine\NN\14326607 headache\NN\5829480 ,\,\1740 dementia\NN\14395018 ,\,\1740 and\CC\1740 <e2>stroke</e2>\RB\1740 .\.\1740
C038806_D006261 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 <e2>headache</e2>\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
C038806_D005483 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 <e2>flushing</e2>\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
C038806_-1 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 <e2>palpitations</e2>\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
C038806_D004487 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 <e2>edema</e2>\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
C038806_D009325 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
C038806_D000855 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 <e2>anorexia</e2>\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
C038806_D004244 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 <e1>dihydropyridine</e1>\NN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 <e2>dizziness</e2>\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_D006261 CID In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 <e2>headache</e2>\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_D005483 CID In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 <e2>flushing</e2>\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_-1 NONE In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 <e2>palpitations</e2>\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_D004487 CID In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 <e2>edema</e2>\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_D009325 CID In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_D000855 CID In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 <e2>anorexia</e2>\NN\14055623 ,\,\1740 and\CC\1740 dizziness\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
D002121_D004244 CID In\IN\13603305 general\JJ\1740 ,\,\1740 the\DT\1740 dihydropyridine\NN\1740 <e1>calcium\NN\14625458 channel\NN\6251781 blockers</e1>\NNS\10101634 are\VBP\836236 usually\RB\1740 well\RB\1740 tolerated\VBN\802318 ,\,\1740 with\IN\1740 headache\NN\5829480 ,\,\1740 facial\JJ\1740 flushing\NN\1740 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 edema\NN\14315192 ,\,\1740 nausea\NN\14299637 ,\,\1740 anorexia\NN\14055623 ,\,\1740 and\CC\1740 <e2>dizziness</e2>\VB\1740 being\VBG\836236 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 .\.\1740
2884595
D006632_D014917 NONE Blockade\NN\952963 of\IN\1740 <e1>histamine</e1>\NN\14739004 H1\NN\1740 receptors\NNS\5225602 may\MD\15209706 reduce\VB\441445 mortality\NN\5054863 in\IN\13603305 <e2>pertussis</e2>\NN\14127211 immunization-induced\JJ\1740 encephalopathy\JJ\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D006632_D001927 NONE Blockade\NN\952963 of\IN\1740 <e1>histamine</e1>\NN\14739004 H1\NN\1740 receptors\NNS\5225602 may\MD\15209706 reduce\VB\441445 mortality\NN\5054863 in\IN\13603305 pertussis\NN\14127211 immunization-induced\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
2710809
D001712_D001919 CID <e2>Bradycardia</e2>\NNP\14110674 due\IN\5174653 to\IN\1740 <e1>biperiden</e1>\JJ\1740 .\.\1740
D001712_D001919 CID <e2>Bradycardia</e2>\NNP\14110674 induced\VBN\1627355 by\IN\1740 <e1>biperiden</e1>\NN\1740 is\VBZ\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 injection\NN\320852 and\CC\1740 to\TO\1740 a\DT\13649268 dose-related\JJ\1740 dual\JJ\1740 effect\NN\34213 of\IN\1740 atropine-like\JJ\1740 drugs\NNS\14778436 on\IN\1740 muscarine\NN\1740 receptors\NNS\5225602 .\.\1740
C036432_D006562 NONE In\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 a\DT\13649268 severe\JJ\1740 <e2>postzosteric</e2>\JJ\1740 trigeminal\JJ\1740 neuralgia\NN\14322699 ,\,\1740 intravenous\JJ\1740 application\NN\947128 of\IN\1740 10\CD\13745420 mg\NN\13717155 <e1>biperiden\JJ\1740 lactate</e1>\NN\14850483 led\VBD\1752884 to\TO\1740 a\DT\13649268 long-lasting\JJ\1740 paradoxical\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 considerable\JJ\1740 bradycardia\NN\14110674 ,\,\1740 dysarthria\NN\14400677 ,\,\1740 and\CC\1740 dysphagia\NN\14052403 .\.\1740
C036432_D014277 NONE In\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 a\DT\13649268 severe\JJ\1740 postzosteric\JJ\1740 <e2>trigeminal\JJ\1740 neuralgia</e2>\NN\14322699 ,\,\1740 intravenous\JJ\1740 application\NN\947128 of\IN\1740 10\CD\13745420 mg\NN\13717155 <e1>biperiden\JJ\1740 lactate</e1>\NN\14850483 led\VBD\1752884 to\TO\1740 a\DT\13649268 long-lasting\JJ\1740 paradoxical\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 considerable\JJ\1740 bradycardia\NN\14110674 ,\,\1740 dysarthria\NN\14400677 ,\,\1740 and\CC\1740 dysphagia\NN\14052403 .\.\1740
C036432_D001919 NONE In\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 a\DT\13649268 severe\JJ\1740 postzosteric\JJ\1740 trigeminal\JJ\1740 neuralgia\NN\14322699 ,\,\1740 intravenous\JJ\1740 application\NN\947128 of\IN\1740 10\CD\13745420 mg\NN\13717155 <e1>biperiden\JJ\1740 lactate</e1>\NN\14850483 led\VBD\1752884 to\TO\1740 a\DT\13649268 long-lasting\JJ\1740 paradoxical\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 considerable\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 dysarthria\NN\14400677 ,\,\1740 and\CC\1740 dysphagia\NN\14052403 .\.\1740
C036432_D004401 NONE In\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 a\DT\13649268 severe\JJ\1740 postzosteric\JJ\1740 trigeminal\JJ\1740 neuralgia\NN\14322699 ,\,\1740 intravenous\JJ\1740 application\NN\947128 of\IN\1740 10\CD\13745420 mg\NN\13717155 <e1>biperiden\JJ\1740 lactate</e1>\NN\14850483 led\VBD\1752884 to\TO\1740 a\DT\13649268 long-lasting\JJ\1740 paradoxical\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 considerable\JJ\1740 bradycardia\NN\14110674 ,\,\1740 <e2>dysarthria</e2>\NN\14400677 ,\,\1740 and\CC\1740 dysphagia\NN\14052403 .\.\1740
C036432_D003680 NONE In\IN\13603305 a\DT\13649268 38-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 suffering\VBG\2110220 from\IN\1740 a\DT\13649268 severe\JJ\1740 postzosteric\JJ\1740 trigeminal\JJ\1740 neuralgia\NN\14322699 ,\,\1740 intravenous\JJ\1740 application\NN\947128 of\IN\1740 10\CD\13745420 mg\NN\13717155 <e1>biperiden\JJ\1740 lactate</e1>\NN\14850483 led\VBD\1752884 to\TO\1740 a\DT\13649268 long-lasting\JJ\1740 paradoxical\JJ\1740 reaction\NN\13446390 characterized\VBN\609683 by\IN\1740 considerable\JJ\1740 bradycardia\NN\14110674 ,\,\1740 dysarthria\NN\14400677 ,\,\1740 and\CC\1740 <e2>dysphagia</e2>\NN\14052403 .\.\1740
D001285_D001919 NONE <e2>Bradycardia</e2>\NNP\14110674 induced\VBN\1627355 by\IN\1740 biperiden\NN\1740 is\VBZ\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 injection\NN\320852 and\CC\1740 to\TO\1740 a\DT\13649268 dose-related\JJ\1740 dual\JJ\1740 effect\NN\34213 of\IN\1740 <e1>atropine-like</e1>\JJ\1740 drugs\NNS\14778436 on\IN\1740 muscarine\NN\1740 receptors\NNS\5225602 .\.\1740
D009116_D001919 NONE <e2>Bradycardia</e2>\NNP\14110674 induced\VBN\1627355 by\IN\1740 biperiden\NN\1740 is\VBZ\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 injection\NN\320852 and\CC\1740 to\TO\1740 a\DT\13649268 dose-related\JJ\1740 dual\JJ\1740 effect\NN\34213 of\IN\1740 atropine-like\JJ\1740 drugs\NNS\14778436 on\IN\1740 <e1>muscarine</e1>\NN\1740 receptors\NNS\5225602 .\.\1740
12865514
D007980_D010300 NONE METHOD\NN\5616786 :\:\1740 Twenty-three\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 severe\JJ\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 Stages\NNS\15113229 III-V\NN\1740 on\IN\1740 Hoehn\NNP\1740 and\CC\1740 Yahr\NNP\1740 scale\NN\7260623 )\-RRB-\1740 and\CC\1740 ,\,\1740 particularly\RB\1740 bradykinesia\NN\1740 ,\,\1740 rigidity\NN\5023233 ,\,\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 underwent\VBD\109660 bilateral\JJ\1740 implantation\NN\13526110 of\IN\1740 electrodes\NNS\3088707 in\IN\13603305 the\DT\1740 STN\NN\1740 .\.\1740
D007980_D018476 NONE METHOD\NN\5616786 :\:\1740 Twenty-three\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 severe\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 Stages\NNS\15113229 III-V\NN\1740 on\IN\1740 Hoehn\NNP\1740 and\CC\1740 Yahr\NNP\1740 scale\NN\7260623 )\-RRB-\1740 and\CC\1740 ,\,\1740 particularly\RB\1740 <e2>bradykinesia</e2>\NN\1740 ,\,\1740 rigidity\NN\5023233 ,\,\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 underwent\VBD\109660 bilateral\JJ\1740 implantation\NN\13526110 of\IN\1740 electrodes\NNS\3088707 in\IN\13603305 the\DT\1740 STN\NN\1740 .\.\1740
D007980_D009127 NONE METHOD\NN\5616786 :\:\1740 Twenty-three\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 severe\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 Stages\NNS\15113229 III-V\NN\1740 on\IN\1740 Hoehn\NNP\1740 and\CC\1740 Yahr\NNP\1740 scale\NN\7260623 )\-RRB-\1740 and\CC\1740 ,\,\1740 particularly\RB\1740 bradykinesia\NN\1740 ,\,\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 underwent\VBD\109660 bilateral\JJ\1740 implantation\NN\13526110 of\IN\1740 electrodes\NNS\3088707 in\IN\13603305 the\DT\1740 STN\NN\1740 .\.\1740
D007980_D004409 CID METHOD\NN\5616786 :\:\1740 Twenty-three\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 severe\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 Stages\NNS\15113229 III-V\NN\1740 on\IN\1740 Hoehn\NNP\1740 and\CC\1740 Yahr\NNP\1740 scale\NN\7260623 )\-RRB-\1740 and\CC\1740 ,\,\1740 particularly\RB\1740 bradykinesia\NN\1740 ,\,\1740 rigidity\NN\5023233 ,\,\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 underwent\VBD\109660 bilateral\JJ\1740 implantation\NN\13526110 of\IN\1740 electrodes\NNS\3088707 in\IN\13603305 the\DT\1740 STN\NN\1740 .\.\1740
D007980_D004409 CID The\DT\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 <e1>levodopa</e1>\NN\14604959 dose\NN\3740161 is\VBZ\836236 useful\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>drug-induced\JJ\1740 dyskinesias</e2>\NNS\14084880 .\.\1740
16323982
D002784_D011471 NONE MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 with\IN\1740 a\DT\13649268 2.5\CD\1740 years\NNS\15144371 follow-up\VBD\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 <e1>cholesterols</e1>\NNS\15058310 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 triglycerides\NNS\14885088 (\-LRB-\1740 TG\NN\1740 )\-RRB-\1740 ,\,\1740 lipoproteins\NNS\14731135 (\-LRB-\1740 LP\NN\3924069 )\-RRB-\1740 ,\,\1740 and\CC\1740 apolipoproteins\NNS\1740 (\-LRB-\1740 Apo\NN\1740 )\-RRB-\1740 B-100\NN\1740 ,\,\1740 A-I\NN\1740 ,\,\1740 and\CC\1740 A-II\JJ\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 of\IN\1740 mean\NN\6021761 age\NN\4916342 60\CD\13745420 years\NNS\15144371 with\IN\1740 low\JJ\1740 risk\NN\14541044 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 (\-LRB-\1740 stage\NN\15113229 :\:\1740 T1cN0M0\NN\1740 ,\,\1740 Gleason\NN\1740 score\NN\5736149 :\:\1740 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 (\-LRB-\1740 CPA\NN\9761403 )\-RRB-\1740 without\IN\1740 surgical\JJ\1740 management\NN\1123598 or\CC\3541091 radiation\NN\11452218 therapy\NN\657604 .\.\1740
D002784_D011471 NONE MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 with\IN\1740 a\DT\13649268 2.5\CD\1740 years\NNS\15144371 follow-up\VBD\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 cholesterols\NNS\15058310 (\-LRB-\1740 <e1>C</e1>\NN\13714184 )\-RRB-\1740 ,\,\1740 triglycerides\NNS\14885088 (\-LRB-\1740 TG\NN\1740 )\-RRB-\1740 ,\,\1740 lipoproteins\NNS\14731135 (\-LRB-\1740 LP\NN\3924069 )\-RRB-\1740 ,\,\1740 and\CC\1740 apolipoproteins\NNS\1740 (\-LRB-\1740 Apo\NN\1740 )\-RRB-\1740 B-100\NN\1740 ,\,\1740 A-I\NN\1740 ,\,\1740 and\CC\1740 A-II\JJ\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 of\IN\1740 mean\NN\6021761 age\NN\4916342 60\CD\13745420 years\NNS\15144371 with\IN\1740 low\JJ\1740 risk\NN\14541044 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 (\-LRB-\1740 stage\NN\15113229 :\:\1740 T1cN0M0\NN\1740 ,\,\1740 Gleason\NN\1740 score\NN\5736149 :\:\1740 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 (\-LRB-\1740 CPA\NN\9761403 )\-RRB-\1740 without\IN\1740 surgical\JJ\1740 management\NN\1123598 or\CC\3541091 radiation\NN\11452218 therapy\NN\657604 .\.\1740
D014280_D011471 NONE MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 with\IN\1740 a\DT\13649268 2.5\CD\1740 years\NNS\15144371 follow-up\VBD\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 cholesterols\NNS\15058310 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 <e1>triglycerides</e1>\NNS\14885088 (\-LRB-\1740 TG\NN\1740 )\-RRB-\1740 ,\,\1740 lipoproteins\NNS\14731135 (\-LRB-\1740 LP\NN\3924069 )\-RRB-\1740 ,\,\1740 and\CC\1740 apolipoproteins\NNS\1740 (\-LRB-\1740 Apo\NN\1740 )\-RRB-\1740 B-100\NN\1740 ,\,\1740 A-I\NN\1740 ,\,\1740 and\CC\1740 A-II\JJ\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 of\IN\1740 mean\NN\6021761 age\NN\4916342 60\CD\13745420 years\NNS\15144371 with\IN\1740 low\JJ\1740 risk\NN\14541044 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 (\-LRB-\1740 stage\NN\15113229 :\:\1740 T1cN0M0\NN\1740 ,\,\1740 Gleason\NN\1740 score\NN\5736149 :\:\1740 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 (\-LRB-\1740 CPA\NN\9761403 )\-RRB-\1740 without\IN\1740 surgical\JJ\1740 management\NN\1123598 or\CC\3541091 radiation\NN\11452218 therapy\NN\657604 .\.\1740
D014280_D011471 NONE MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 with\IN\1740 a\DT\13649268 2.5\CD\1740 years\NNS\15144371 follow-up\VBD\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 cholesterols\NNS\15058310 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 triglycerides\NNS\14885088 (\-LRB-\1740 <e1>TG</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 lipoproteins\NNS\14731135 (\-LRB-\1740 LP\NN\3924069 )\-RRB-\1740 ,\,\1740 and\CC\1740 apolipoproteins\NNS\1740 (\-LRB-\1740 Apo\NN\1740 )\-RRB-\1740 B-100\NN\1740 ,\,\1740 A-I\NN\1740 ,\,\1740 and\CC\1740 A-II\JJ\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 of\IN\1740 mean\NN\6021761 age\NN\4916342 60\CD\13745420 years\NNS\15144371 with\IN\1740 low\JJ\1740 risk\NN\14541044 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 (\-LRB-\1740 stage\NN\15113229 :\:\1740 T1cN0M0\NN\1740 ,\,\1740 Gleason\NN\1740 score\NN\5736149 :\:\1740 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 (\-LRB-\1740 CPA\NN\9761403 )\-RRB-\1740 without\IN\1740 surgical\JJ\1740 management\NN\1123598 or\CC\3541091 radiation\NN\11452218 therapy\NN\657604 .\.\1740
D017373_D011471 NONE MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 with\IN\1740 a\DT\13649268 2.5\CD\1740 years\NNS\15144371 follow-up\VBD\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 cholesterols\NNS\15058310 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 triglycerides\NNS\14885088 (\-LRB-\1740 TG\NN\1740 )\-RRB-\1740 ,\,\1740 lipoproteins\NNS\14731135 (\-LRB-\1740 LP\NN\3924069 )\-RRB-\1740 ,\,\1740 and\CC\1740 apolipoproteins\NNS\1740 (\-LRB-\1740 Apo\NN\1740 )\-RRB-\1740 B-100\NN\1740 ,\,\1740 A-I\NN\1740 ,\,\1740 and\CC\1740 A-II\JJ\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 of\IN\1740 mean\NN\6021761 age\NN\4916342 60\CD\13745420 years\NNS\15144371 with\IN\1740 low\JJ\1740 risk\NN\14541044 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 (\-LRB-\1740 stage\NN\15113229 :\:\1740 T1cN0M0\NN\1740 ,\,\1740 Gleason\NN\1740 score\NN\5736149 :\:\1740 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cyproterone\NN\1740 acetate</e1>\NN\15010703 (\-LRB-\1740 CPA\NN\9761403 )\-RRB-\1740 without\IN\1740 surgical\JJ\1740 management\NN\1123598 or\CC\3541091 radiation\NN\11452218 therapy\NN\657604 .\.\1740
D017373_D011471 NONE MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 We\PRP\1740 studied\VBD\630380 with\IN\1740 a\DT\13649268 2.5\CD\1740 years\NNS\15144371 follow-up\VBD\1740 the\DT\1740 changes\NNS\7283608 in\IN\13603305 plasma\NN\5398023 cholesterols\NNS\15058310 (\-LRB-\1740 C\NN\13714184 )\-RRB-\1740 ,\,\1740 triglycerides\NNS\14885088 (\-LRB-\1740 TG\NN\1740 )\-RRB-\1740 ,\,\1740 lipoproteins\NNS\14731135 (\-LRB-\1740 LP\NN\3924069 )\-RRB-\1740 ,\,\1740 and\CC\1740 apolipoproteins\NNS\1740 (\-LRB-\1740 Apo\NN\1740 )\-RRB-\1740 B-100\NN\1740 ,\,\1740 A-I\NN\1740 ,\,\1740 and\CC\1740 A-II\JJ\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 in\IN\13603305 24\CD\13745420 patients\NNS\9898892 of\IN\1740 mean\NN\6021761 age\NN\4916342 60\CD\13745420 years\NNS\15144371 with\IN\1740 low\JJ\1740 risk\NN\14541044 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 (\-LRB-\1740 stage\NN\15113229 :\:\1740 T1cN0M0\NN\1740 ,\,\1740 Gleason\NN\1740 score\NN\5736149 :\:\1740 2\CD\13741022 -\SYM\1740 5\CD\13741022 )\-RRB-\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 cyproterone\NN\1740 acetate\NN\15010703 (\-LRB-\1740 <e1>CPA</e1>\NN\9761403 )\-RRB-\1740 without\IN\1740 surgical\JJ\1740 management\NN\1123598 or\CC\3541091 radiation\NN\11452218 therapy\NN\657604 .\.\1740
D017373_D003327 NONE After\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 2.5\CD\1740 years\NNS\15144371 on\IN\1740 <e1>CPA</e1>\NN\9761403 treatment\NN\654885 ,\,\1740 four\CD\13741022 patients\NNS\9898892 out\IN\66636 of\IN\1740 twenty-four\NN\13745420 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 affected\VBN\126264 by\IN\1740 <e2>coronary\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 .\.\1740
D017373_D003324 CID CONCLUSIONS\NNS\5837957 :\:\1740 Ischaemic\JJ\1740 <e2>coronary\JJ\1740 arteriosclerosis</e2>\NN\14110411 with\IN\1740 an\DT\6697703 incidence\NN\13821570 rate\NN\13815152 of\IN\1740 16.6\CD\1740 %\NN\1740 as\IN\14622893 caused\VBN\1617192 by\IN\1740 prolonged\JJ\1740 <e1>CPA</e1>\NN\9761403 therapy\NN\657604 is\VBZ\836236 mediated\VBN\761713 through\IN\1740 changes\NNS\7283608 in\IN\13603305 HDL\NN\14939230 cholesterol\NN\15058310 ,\,\1740 Apo\NN\1740 A-I\NN\1740 and\CC\1740 Apo\JJ\1740 A-II\NN\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 ,\,\1740 other\JJ\1740 than\IN\1740 the\DT\1740 well-known\JJ\1740 hyperglyceridemic\JJ\1740 effect\NN\34213 caused\VBN\1617192 by\IN\1740 estrogen\NN\14745635 .\.\1740
D017373_D050171 CID CONCLUSIONS\NNS\5837957 :\:\1740 Ischaemic\JJ\1740 coronary\JJ\1740 arteriosclerosis\NN\14110411 with\IN\1740 an\DT\6697703 incidence\NN\13821570 rate\NN\13815152 of\IN\1740 16.6\CD\1740 %\NN\1740 as\IN\14622893 caused\VBN\1617192 by\IN\1740 prolonged\JJ\1740 <e1>CPA</e1>\NN\9761403 therapy\NN\657604 is\VBZ\836236 mediated\VBN\761713 through\IN\1740 changes\NNS\7283608 in\IN\13603305 HDL\NN\14939230 cholesterol\NN\15058310 ,\,\1740 Apo\NN\1740 A-I\NN\1740 and\CC\1740 Apo\JJ\1740 A-II\NN\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 ,\,\1740 other\JJ\1740 than\IN\1740 the\DT\1740 well-known\JJ\1740 <e2>hyperglyceridemic\JJ\1740 effect</e2>\NN\34213 caused\VBN\1617192 by\IN\1740 estrogen\NN\14745635 .\.\1740
D002784_D003324 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Ischaemic\JJ\1740 <e2>coronary\JJ\1740 arteriosclerosis</e2>\NN\14110411 with\IN\1740 an\DT\6697703 incidence\NN\13821570 rate\NN\13815152 of\IN\1740 16.6\CD\1740 %\NN\1740 as\IN\14622893 caused\VBN\1617192 by\IN\1740 prolonged\JJ\1740 CPA\NN\9761403 therapy\NN\657604 is\VBZ\836236 mediated\VBN\761713 through\IN\1740 changes\NNS\7283608 in\IN\13603305 HDL\NN\14939230 <e1>cholesterol</e1>\NN\15058310 ,\,\1740 Apo\NN\1740 A-I\NN\1740 and\CC\1740 Apo\JJ\1740 A-II\NN\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 ,\,\1740 other\JJ\1740 than\IN\1740 the\DT\1740 well-known\JJ\1740 hyperglyceridemic\JJ\1740 effect\NN\34213 caused\VBN\1617192 by\IN\1740 estrogen\NN\14745635 .\.\1740
D002784_D050171 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Ischaemic\JJ\1740 coronary\JJ\1740 arteriosclerosis\NN\14110411 with\IN\1740 an\DT\6697703 incidence\NN\13821570 rate\NN\13815152 of\IN\1740 16.6\CD\1740 %\NN\1740 as\IN\14622893 caused\VBN\1617192 by\IN\1740 prolonged\JJ\1740 CPA\NN\9761403 therapy\NN\657604 is\VBZ\836236 mediated\VBN\761713 through\IN\1740 changes\NNS\7283608 in\IN\13603305 HDL\NN\14939230 <e1>cholesterol</e1>\NN\15058310 ,\,\1740 Apo\NN\1740 A-I\NN\1740 and\CC\1740 Apo\JJ\1740 A-II\NN\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 ,\,\1740 other\JJ\1740 than\IN\1740 the\DT\1740 well-known\JJ\1740 <e2>hyperglyceridemic\JJ\1740 effect</e2>\NN\34213 caused\VBN\1617192 by\IN\1740 estrogen\NN\14745635 .\.\1740
D004967_D003324 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Ischaemic\JJ\1740 <e2>coronary\JJ\1740 arteriosclerosis</e2>\NN\14110411 with\IN\1740 an\DT\6697703 incidence\NN\13821570 rate\NN\13815152 of\IN\1740 16.6\CD\1740 %\NN\1740 as\IN\14622893 caused\VBN\1617192 by\IN\1740 prolonged\JJ\1740 CPA\NN\9761403 therapy\NN\657604 is\VBZ\836236 mediated\VBN\761713 through\IN\1740 changes\NNS\7283608 in\IN\13603305 HDL\NN\14939230 cholesterol\NN\15058310 ,\,\1740 Apo\NN\1740 A-I\NN\1740 and\CC\1740 Apo\JJ\1740 A-II\NN\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 ,\,\1740 other\JJ\1740 than\IN\1740 the\DT\1740 well-known\JJ\1740 hyperglyceridemic\JJ\1740 effect\NN\34213 caused\VBN\1617192 by\IN\1740 <e1>estrogen</e1>\NN\14745635 .\.\1740
D004967_D050171 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Ischaemic\JJ\1740 coronary\JJ\1740 arteriosclerosis\NN\14110411 with\IN\1740 an\DT\6697703 incidence\NN\13821570 rate\NN\13815152 of\IN\1740 16.6\CD\1740 %\NN\1740 as\IN\14622893 caused\VBN\1617192 by\IN\1740 prolonged\JJ\1740 CPA\NN\9761403 therapy\NN\657604 is\VBZ\836236 mediated\VBN\761713 through\IN\1740 changes\NNS\7283608 in\IN\13603305 HDL\NN\14939230 cholesterol\NN\15058310 ,\,\1740 Apo\NN\1740 A-I\NN\1740 and\CC\1740 Apo\JJ\1740 A-II\NN\1740 pro\JJ\1740 fi\NN\1740 les\NN\14187378 ,\,\1740 other\JJ\1740 than\IN\1740 the\DT\1740 well-known\JJ\1740 <e2>hyperglyceridemic\JJ\1740 effect</e2>\NN\34213 caused\VBN\1617192 by\IN\1740 <e1>estrogen</e1>\NN\14745635 .\.\1740
16723784
D015764_D001281 NONE Clinical\JJ\1740 evaluation\NN\874067 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 during\IN\1740 <e1>bepridil</e1>\JJ\1740 administration\NN\1133281 for\IN\1740 <e2>atrial\JJ\1740 fibrillation\NN\14361664 and\CC\1740 flutter</e2>\NN\331950 .\.\1740
D015764_D001281 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Bepridil\NNP\1740 hydrochloride</e1>\NN\14817592 (\-LRB-\1740 Bpd\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 (\-LRB-\1740 AFL\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001281 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Bepridil\NNP\1740 hydrochloride</e1>\NN\14817592 (\-LRB-\1740 Bpd\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 <e2>AF</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 (\-LRB-\1740 AFL\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001281 NONE BACKGROUND\NN\4921011 :\:\1740 Bepridil\NNP\1740 hydrochloride\NN\14817592 (\-LRB-\1740 <e1>Bpd</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 (\-LRB-\1740 AFL\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001281 NONE BACKGROUND\NN\4921011 :\:\1740 Bepridil\NNP\1740 hydrochloride\NN\14817592 (\-LRB-\1740 <e1>Bpd</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 <e2>AF</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 (\-LRB-\1740 AFL\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001281 NONE <e1>Bpd</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 to\TO\1740 459\CD\1740 patients\NNS\9898892 (\-LRB-\1740 361\CD\1740 males\NNS\15388 ,\,\1740 63+/-12\CD\1740 years\NNS\15144371 old\JJ\1740 )\-RRB-\1740 comprising\VBG\2604760 378\CD\1740 <e2>AF</e2>\NN\1740 and\CC\1740 81\CD\1740 AFL\NN\8303504 cases\NNS\7283608 .\.\1740
D015764_D001282 NONE Clinical\JJ\1740 evaluation\NN\874067 of\IN\1740 adverse\JJ\1740 effects\NNS\13245626 during\IN\1740 <e1>bepridil</e1>\JJ\1740 administration\NN\1133281 for\IN\1740 <e2>atrial\JJ\1740 fibrillation\NN\14361664 and\CC\1740 flutter</e2>\NN\331950 .\.\1740
D015764_D001282 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Bepridil\NNP\1740 hydrochloride</e1>\NN\14817592 (\-LRB-\1740 Bpd\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 (\-LRB-\1740 AFL\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001282 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Bepridil\NNP\1740 hydrochloride</e1>\NN\14817592 (\-LRB-\1740 Bpd\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 (\-LRB-\1740 <e2>AFL</e2>\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001282 NONE BACKGROUND\NN\4921011 :\:\1740 Bepridil\NNP\1740 hydrochloride\NN\14817592 (\-LRB-\1740 <e1>Bpd</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 (\-LRB-\1740 AFL\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001282 NONE BACKGROUND\NN\4921011 :\:\1740 Bepridil\NNP\1740 hydrochloride\NN\14817592 (\-LRB-\1740 <e1>Bpd</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 attracted\VBN\1448100 attention\NN\5701944 as\IN\14622893 an\DT\6697703 effective\JJ\1740 drug\NN\14778436 for\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 (\-LRB-\1740 AF\NN\1740 )\-RRB-\1740 and\CC\1740 atrial\JJ\1740 flutter\NN\331950 (\-LRB-\1740 <e2>AFL</e2>\NN\8303504 )\-RRB-\1740 .\.\1740
D015764_D001282 NONE <e1>Bpd</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 to\TO\1740 459\CD\1740 patients\NNS\9898892 (\-LRB-\1740 361\CD\1740 males\NNS\15388 ,\,\1740 63+/-12\CD\1740 years\NNS\15144371 old\JJ\1740 )\-RRB-\1740 comprising\VBG\2604760 378\CD\1740 AF\NN\1740 and\CC\1740 81\CD\1740 <e2>AFL</e2>\NN\8303504 cases\NNS\7283608 .\.\1740
15321332
D004329_D001008 CID A\DT\13649268 case\NN\7283608 of\IN\1740 postoperative\JJ\1740 <e2>anxiety</e2>\NN\14373582 due\IN\5174653 to\TO\1740 low\JJ\1740 dose\NN\3740161 <e1>droperidol</e1>\NN\1740 used\VBN\1156834 with\IN\1740 patient-controlled\JJ\1740 analgesia\NN\14034177 .\.\1740
D004329_D001008 CID The\DT\1740 diagnosis\NN\152018 of\IN\1740 <e1>droperidol-induced</e1>\JJ\1740 <e2>psychological\JJ\1740 disturbance</e2>\NN\407535 was\VBD\836236 not\RB\1740 made\VBN\126264 straight\RB\1740 away\RB\1740 although\IN\1740 on\IN\1740 subsequent\JJ\1740 close\NN\15266911 questioning\VBG\868591 the\DT\1740 patient\NN\9898892 gave\VBD\2327200 a\DT\13649268 very\RB\1740 clear\JJ\1740 history\NN\15120823 .\.\1740
19920070
D010634_D006529 CID Liver-specific\JJ\1740 ablation\NN\671351 of\IN\1740 integrin-linked\JJ\1740 kinase\NN\14732946 in\IN\13603305 mice\NNS\2329401 results\VBZ\2633881 in\IN\13603305 enhanced\VBN\227165 and\CC\1740 prolonged\JJ\1740 cell\NN\3080309 proliferation\NN\13489037 and\CC\1740 <e2>hepatomegaly</e2>\NN\14501726 after\IN\1740 <e1>phenobarbital</e1>\JJ\1740 administration\NN\1133281 .\.\1740
6806735
D002945_D010051 NONE Treatment\NN\654885 of\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>cis-platinum</e1>\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 and\CC\1740 hexamethylmelamine\NN\1740 .\.\1740
D002945_D010051 NONE During\IN\1740 the\DT\1740 last\JJ\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 ,\,\1740 38\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>cisplatinum</e1>\NN\1740 (\-LRB-\1740 CPDD\NN\1740 )\-RRB-\1740 ,\,\1740 50\CD\13745420 mg/m2\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 30\CD\13745420 mg/m2\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 ;\:\1740 and\CC\1740 hexamethylmelamine\NN\1740 (\-LRB-\1740 HMM\NN\1740 )\-RRB-\1740 ,\,\1740 6\CD\13741022 mg/kg\NN\1740 daily\RB\1740 ,\,\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
D004317_D010051 NONE Treatment\NN\654885 of\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cis-platinum\NN\1740 ,\,\1740 <e1>adriamycin</e1>\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 and\CC\1740 hexamethylmelamine\NN\1740 .\.\1740
D004317_D010051 NONE During\IN\1740 the\DT\1740 last\JJ\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 ,\,\1740 38\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cisplatinum\NN\1740 (\-LRB-\1740 CPDD\NN\1740 )\-RRB-\1740 ,\,\1740 50\CD\13745420 mg/m2\NN\1740 ,\,\1740 <e1>adriamycin</e1>\NN\1740 ,\,\1740 30\CD\13745420 mg/m2\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 ;\:\1740 and\CC\1740 hexamethylmelamine\NN\1740 (\-LRB-\1740 HMM\NN\1740 )\-RRB-\1740 ,\,\1740 6\CD\13741022 mg/kg\NN\1740 daily\RB\1740 ,\,\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
D003520_D010051 NONE Treatment\NN\654885 of\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cis-platinum\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 <e1>cyclophosphamide</e1>\NN\1740 and\CC\1740 hexamethylmelamine\NN\1740 .\.\1740
D003520_D010051 NONE During\IN\1740 the\DT\1740 last\JJ\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 ,\,\1740 38\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cisplatinum\NN\1740 (\-LRB-\1740 CPDD\NN\1740 )\-RRB-\1740 ,\,\1740 50\CD\13745420 mg/m2\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 30\CD\13745420 mg/m2\NN\1740 ,\,\1740 <e1>cyclophosphamide</e1>\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 ;\:\1740 and\CC\1740 hexamethylmelamine\NN\1740 (\-LRB-\1740 HMM\NN\1740 )\-RRB-\1740 ,\,\1740 6\CD\13741022 mg/kg\NN\1740 daily\RB\1740 ,\,\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
D006585_D010051 NONE Treatment\NN\654885 of\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cis-platinum\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 and\CC\1740 <e1>hexamethylmelamine</e1>\NN\1740 .\.\1740
D006585_D010051 NONE During\IN\1740 the\DT\1740 last\JJ\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 ,\,\1740 38\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cisplatinum\NN\1740 (\-LRB-\1740 CPDD\NN\1740 )\-RRB-\1740 ,\,\1740 50\CD\13745420 mg/m2\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 30\CD\13745420 mg/m2\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 ;\:\1740 and\CC\1740 <e1>hexamethylmelamine</e1>\NN\1740 (\-LRB-\1740 HMM\NN\1740 )\-RRB-\1740 ,\,\1740 6\CD\13741022 mg/kg\NN\1740 daily\RB\1740 ,\,\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
D006585_D010051 NONE During\IN\1740 the\DT\1740 last\JJ\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 ,\,\1740 38\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cisplatinum\NN\1740 (\-LRB-\1740 CPDD\NN\1740 )\-RRB-\1740 ,\,\1740 50\CD\13745420 mg/m2\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 30\CD\13745420 mg/m2\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 ;\:\1740 and\CC\1740 hexamethylmelamine\NN\1740 (\-LRB-\1740 <e1>HMM</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 6\CD\13741022 mg/kg\NN\1740 daily\RB\1740 ,\,\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
C034868_D010051 NONE During\IN\1740 the\DT\1740 last\JJ\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 ,\,\1740 38\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 cisplatinum\NN\1740 (\-LRB-\1740 <e1>CPDD</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 50\CD\13745420 mg/m2\NN\1740 ,\,\1740 adriamycin\NN\1740 ,\,\1740 30\CD\13745420 mg/m2\NN\1740 ,\,\1740 cyclophosphamide\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 ;\:\1740 and\CC\1740 hexamethylmelamine\NN\1740 (\-LRB-\1740 HMM\NN\1740 )\-RRB-\1740 ,\,\1740 6\CD\13741022 mg/kg\NN\1740 daily\RB\1740 ,\,\1740 for\IN\1740 14\CD\13745420 days\NNS\15140892 .\.\1740
D006585_D005767 NONE <e1>HMM</e1>\NN\1740 <e2>gastrointestinal\NN\1740 toxicity</e2>\NN\13576101 necessitated\JJ\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 in\IN\13603305 5\CD\13741022 patients\NNS\9898892 .\.\1740
24275640
D004317_D066126 CID Oxidative\JJ\1740 stress\NN\7083732 on\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 single\JJ\1740 and\CC\1740 multiple\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D066126 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 remains\VBZ\2604760 controversial\JJ\1740 .\.\1740
D004317_D066126 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 remains\VBZ\2604760 controversial\JJ\1740 .\.\1740
D004317_D066126 CID Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 oxidative\JJ\1740 damage\NN\7296428 is\VBZ\836236 associated\VBN\628491 with\IN\1740 acute\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>DOX</e1>\NN\1740 only\RB\1740 .\.\1740
D004317_D006331 NONE Single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>DOX</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 <e2>cardiac\JJ\1740 disarrangement</e2>\NN\14499262 ,\,\1740 necrosis\NN\11444117 ,\,\1740 and\CC\1740 DNA\NN\14994328 damage\NN\7296428 (\-LRB-\1740 strand\NN\5930736 breaks\NNS\7283608 (\-LRB-\1740 SBs\NNS\14625458 )\-RRB-\1740 and\CC\1740 oxidized\VBN\109660 pyrimidines\NNS\14618253 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 TAP\NN\7371293 .\.\1740
D004317_D009336 CID Single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>DOX</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 cardiac\JJ\1740 disarrangement\NN\14499262 ,\,\1740 <e2>necrosis</e2>\NN\11444117 ,\,\1740 and\CC\1740 DNA\NN\14994328 damage\NN\7296428 (\-LRB-\1740 strand\NN\5930736 breaks\NNS\7283608 (\-LRB-\1740 SBs\NNS\14625458 )\-RRB-\1740 and\CC\1740 oxidized\VBN\109660 pyrimidines\NNS\14618253 )\-RRB-\1740 and\CC\1740 decreased\VBD\169651 TAP\NN\7371293 .\.\1740
3409843
D002220_D000741 CID Fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 .\.\1740
D002220_D000741 CID A\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 due\JJ\1740 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 an\DT\6697703 epileptic\JJ\1740 woman\NN\9605289 is\VBZ\836236 reported\VBN\831651 .\.\1740
D002220_D004827 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 fatal\JJ\1740 aplastic\JJ\1740 anemia\NN\14189204 due\JJ\1740 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 an\DT\6697703 <e2>epileptic</e2>\JJ\1740 woman\NN\9605289 is\VBZ\836236 reported\VBN\831651 .\.\1740
D002220_D001855 NONE Despite\IN\7501545 concerns\NNS\5682950 of\IN\1740 fatal\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 toxicity</e2>\NN\13576101 due\IN\5174653 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 ,\,\1740 this\DT\1740 is\VBZ\836236 only\RB\1740 the\DT\1740 fourth\JJ\1740 documented\VBN\1000214 and\CC\1740 published\VBN\1621555 report\NN\6470073 .\.\1740
2021990
D002927_D007022 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 an\DT\6697703 H1\NN\1740 antagonist\NN\7846 may\MD\15209706 be\VB\836236 useful\JJ\1740 in\IN\13603305 preventing\VBG\1740 <e2>hypotension</e2>\NN\14057371 caused\VBN\1617192 by\IN\1740 iv\NN\13741022 <e1>cimetidine</e1>\NN\14778019 ,\,\1740 since\IN\1740 the\DT\1740 vasodilating\NN\1740 activity\NN\30358 of\IN\1740 cimetidine\NN\14778019 is\VBZ\836236 mediated\VBN\761713 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 through\IN\1740 the\DT\1740 H1\NN\1740 receptor\NN\5225602 .\.\1740
D002927_D007022 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 an\DT\6697703 H1\NN\1740 antagonist\NN\7846 may\MD\15209706 be\VB\836236 useful\JJ\1740 in\IN\13603305 preventing\VBG\1740 <e2>hypotension</e2>\NN\14057371 caused\VBN\1617192 by\IN\1740 iv\NN\13741022 cimetidine\NN\14778019 ,\,\1740 since\IN\1740 the\DT\1740 vasodilating\NN\1740 activity\NN\30358 of\IN\1740 <e1>cimetidine</e1>\NN\14778019 is\VBZ\836236 mediated\VBN\761713 ,\,\1740 in\IN\13603305 part\NN\31921 ,\,\1740 through\IN\1740 the\DT\1740 H1\NN\1740 receptor\NN\5225602 .\.\1740
8996419
D003276_D054556 CID Population-based\JJ\1740 study\NN\635850 of\IN\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 associated\VBN\628491 with\IN\1740 various\JJ\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 .\.\1740
D003276_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D003276_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D003276_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 <e1>OCs</e1>\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D003276_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 <e1>OCs</e1>\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D003276_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 <e1>OCs</e1>\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D003276_D054556 CID BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 <e1>OCs</e1>\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D003276_D054556 CID The\DT\1740 aim\NN\5980875 of\IN\1740 our\PRP$\1740 study\NN\635850 was\VBD\836236 to\TO\1740 re-examine\VB\788564 the\DT\1740 association\NN\8008335 between\IN\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 and\CC\1740 <e1>OC</e1>\NN\1740 use\NN\407535 with\IN\1740 a\DT\13649268 different\JJ\1740 study\NN\635850 design\NN\927261 and\CC\1740 analysis\NN\633864 to\TO\1740 avoid\VB\2452885 some\DT\1740 of\IN\1740 the\DT\1740 bias\NN\6201136 and\CC\1740 confounding\NN\1740 of\IN\1740 the\DT\1740 earlier\JJR\1740 studies\NNS\635850 .\.\1740
D003276_D054556 CID We\PRP\1740 did\VBD\1640855 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 to\TO\1740 estimate\VB\637259 and\CC\1740 compare\VB\644583 incidence\NN\13821570 of\IN\1740 <e2>VTE</e2>\NN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 the\DT\1740 main\JJ\1740 <e1>OC</e1>\NN\1740 preparations\NNS\407535 ,\,\1740 and\CC\1740 a\DT\13649268 nested\JJ\1740 case-control\NN\1740 study\NN\635850 to\TO\1740 calculate\VB\632627 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 OC\NN\1740 ,\,\1740 after\IN\1740 adjustment\NN\7357388 for\IN\1740 potential\JJ\1740 confounding\VBG\2604760 factors\NNS\7326557 .\.\1740
D003276_D054556 CID We\PRP\1740 did\VBD\1640855 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 to\TO\1740 estimate\VB\637259 and\CC\1740 compare\VB\644583 incidence\NN\13821570 of\IN\1740 VTE\NN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 the\DT\1740 main\JJ\1740 <e1>OC</e1>\NN\1740 preparations\NNS\407535 ,\,\1740 and\CC\1740 a\DT\13649268 nested\JJ\1740 case-control\NN\1740 study\NN\635850 to\TO\1740 calculate\VB\632627 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 OC\NN\1740 ,\,\1740 after\IN\1740 adjustment\NN\7357388 for\IN\1740 potential\JJ\1740 confounding\VBG\2604760 factors\NNS\7326557 .\.\1740
D003276_D054556 CID We\PRP\1740 did\VBD\1640855 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 to\TO\1740 estimate\VB\637259 and\CC\1740 compare\VB\644583 incidence\NN\13821570 of\IN\1740 <e2>VTE</e2>\NN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 the\DT\1740 main\JJ\1740 OC\NN\1740 preparations\NNS\407535 ,\,\1740 and\CC\1740 a\DT\13649268 nested\JJ\1740 case-control\NN\1740 study\NN\635850 to\TO\1740 calculate\VB\632627 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 <e1>OC</e1>\NN\1740 ,\,\1740 after\IN\1740 adjustment\NN\7357388 for\IN\1740 potential\JJ\1740 confounding\VBG\2604760 factors\NNS\7326557 .\.\1740
D003276_D054556 CID We\PRP\1740 did\VBD\1640855 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 to\TO\1740 estimate\VB\637259 and\CC\1740 compare\VB\644583 incidence\NN\13821570 of\IN\1740 VTE\NN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 the\DT\1740 main\JJ\1740 OC\NN\1740 preparations\NNS\407535 ,\,\1740 and\CC\1740 a\DT\13649268 nested\JJ\1740 case-control\NN\1740 study\NN\635850 to\TO\1740 calculate\VB\632627 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 <e1>OC</e1>\NN\1740 ,\,\1740 after\IN\1740 adjustment\NN\7357388 for\IN\1740 potential\JJ\1740 confounding\VBG\2604760 factors\NNS\7326557 .\.\1740
D003276_D054556 CID FINDINGS\NNS\7951464 :\:\1740 85\CD\1740 women\NNS\9605289 met\VBD\1182709 the\DT\1740 inclusion\NN\13927383 criteria\NNS\13577171 for\IN\1740 <e2>VTE</e2>\NN\1740 ,\,\1740 two\CD\13741022 of\IN\1740 whom\WP\1740 were\VBD\836236 users\NNS\7846 of\IN\1740 progestagen-only\JJ\1740 <e1>OCs</e1>\NN\1740 .\.\1740
D003276_D054556 CID Of\IN\1740 the\DT\1740 83\CD\1740 cases\NNS\7283608 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 combined\JJ\1740 <e1>OCs</e1>\NN\1740 ,\,\1740 43\CD\1740 were\VBD\836236 recorded\VBN\2225492 as\IN\14622893 deep-vein\JJ\1740 thrombosis\NN\14100769 ,\,\1740 35\CD\1740 as\IN\14622893 pulmonary\JJ\1740 thrombosis\NN\14100769 ,\,\1740 and\CC\1740 five\CD\13741022 as\IN\14622893 venous\JJ\1740 thrombosis\NN\14100769 not\RB\1740 otherwise\RB\1740 specified\VBD\888786 .\.\1740
D003276_D054556 CID The\DT\1740 crude\JJ\1740 rate\NN\13815152 of\IN\1740 <e2>VTE</e2>\NN\1740 per\IN\1740 10,000\CD\1740 woman-years\NNS\1740 was\VBD\836236 4.10\CD\1740 in\IN\13603305 current\JJ\1740 users\NNS\7846 of\IN\1740 any\DT\1740 <e1>OC</e1>\NNP\1740 ,\,\1740 3.10\CD\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 second-generation\JJ\1740 OCs\NN\1740 ,\,\1740 and\CC\1740 4.96\CD\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 third-generation\JJ\1740 preparations\NNS\407535 .\.\1740
D003276_D054556 CID The\DT\1740 crude\JJ\1740 rate\NN\13815152 of\IN\1740 <e2>VTE</e2>\NN\1740 per\IN\1740 10,000\CD\1740 woman-years\NNS\1740 was\VBD\836236 4.10\CD\1740 in\IN\13603305 current\JJ\1740 users\NNS\7846 of\IN\1740 any\DT\1740 OC\NNP\1740 ,\,\1740 3.10\CD\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 second-generation\JJ\1740 <e1>OCs</e1>\NN\1740 ,\,\1740 and\CC\1740 4.96\CD\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 third-generation\JJ\1740 preparations\NNS\407535 .\.\1740
D003276_D054556 CID After\IN\1740 adjustment\NN\7357388 for\IN\1740 age\NN\4916342 ,\,\1740 the\DT\1740 rate\NN\13815152 ratio\NN\13815152 of\IN\1740 <e2>VTE</e2>\NN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 third-generation\NN\1740 relative\JJ\1740 to\TO\1740 second-generation\JJ\1740 <e1>OCs</e1>\NN\1740 was\VBD\836236 1.68\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.04\CD\1740 -\HYPH\1740 2.75\CD\1740 )\-RRB-\1740 .\.\1740
D003276_D054556 CID Logistic\JJ\1740 regression\NN\14501726 showed\VBD\2137132 no\DT\7204911 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 between\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 and\CC\1740 second-generation\JJ\1740 <e1>OCs</e1>\NN\1740 .\.\1740
D003276_D054556 CID With\IN\1740 all\DT\1740 second-generation\JJ\1740 <e1>OCs</e1>\NN\1740 as\IN\14622893 the\DT\1740 reference\NN\6765044 ,\,\1740 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 for\IN\1740 <e2>VTE</e2>\NN\1740 were\VBD\836236 3.49\CD\1740 (\-LRB-\1740 1.21\CD\1740 -\SYM\1740 10.12\CD\1740 )\-RRB-\1740 for\IN\1740 desogestrel\NN\1740 plus\CC\4723816 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 and\CC\1740 1.18\CD\1740 (\-LRB-\1740 0.66\CD\1740 -\SYM\1740 2.17\CD\1740 )\-RRB-\1740 for\IN\1740 the\DT\1740 other\JJ\1740 third-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D011374_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 <e1>progestagens</e1>\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D011374_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 <e1>progestagens</e1>\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D011374_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 <e1>progestagens</e1>\NNS\1740 .\.\1740
D011374_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 <e1>progestagens</e1>\NNS\1740 .\.\1740
D011374_D054556 NONE Among\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 <e1>progestagens</e1>\NNS\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 desogestrel\NN\1740 with\IN\1740 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 with\IN\1740 30\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 .\.\1740
D011374_D054556 NONE With\IN\1740 all\DT\1740 second-generation\JJ\1740 OCs\NN\1740 as\IN\14622893 the\DT\1740 reference\NN\6765044 ,\,\1740 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 for\IN\1740 <e2>VTE</e2>\NN\1740 were\VBD\836236 3.49\CD\1740 (\-LRB-\1740 1.21\CD\1740 -\SYM\1740 10.12\CD\1740 )\-RRB-\1740 for\IN\1740 desogestrel\NN\1740 plus\CC\4723816 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 and\CC\1740 1.18\CD\1740 (\-LRB-\1740 0.66\CD\1740 -\SYM\1740 2.17\CD\1740 )\-RRB-\1740 for\IN\1740 the\DT\1740 other\JJ\1740 third-generation\NN\1740 <e1>progestagens</e1>\NNS\1740 .\.\1740
C033273_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 <e1>gestodene</e1>\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
C033273_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 <e1>gestodene</e1>\NN\1740 or\CC\3541091 desogestrel\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
C033273_D054556 NONE Among\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 progestagens\NNS\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 desogestrel\NN\1740 with\IN\1740 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 <e1>gestodene</e1>\NN\1740 or\CC\3541091 desogestrel\NN\1740 with\IN\1740 30\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 .\.\1740
D017135_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 <e1>desogestrel</e1>\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D017135_D054556 NONE BACKGROUND\NN\4921011 :\:\1740 Four\CD\13741022 studies\NNS\635850 published\VBN\1621555 since\IN\1740 December\NNP\15209706 ,\,\1740 1995\CD\1740 ,\,\1740 reported\VBD\831651 that\IN\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OCs\NNS\1740 )\-RRB-\1740 containing\VBG\2632940 the\DT\1740 third-generation\NN\1740 progestagens\NNS\1740 gestodene\NN\1740 or\CC\3541091 <e1>desogestrel</e1>\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 OCs\NN\1740 containing\VBG\2632940 second-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D017135_D054556 NONE Among\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 progestagens\NNS\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 <e1>desogestrel</e1>\NN\1740 with\IN\1740 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 with\IN\1740 30\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 .\.\1740
D017135_D054556 NONE Among\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 progestagens\NNS\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 desogestrel\NN\1740 with\IN\1740 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 gestodene\NN\1740 or\CC\3541091 <e1>desogestrel</e1>\NN\1740 with\IN\1740 30\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 .\.\1740
D017135_D054556 NONE With\IN\1740 all\DT\1740 second-generation\JJ\1740 OCs\NN\1740 as\IN\14622893 the\DT\1740 reference\NN\6765044 ,\,\1740 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 for\IN\1740 <e2>VTE</e2>\NN\1740 were\VBD\836236 3.49\CD\1740 (\-LRB-\1740 1.21\CD\1740 -\SYM\1740 10.12\CD\1740 )\-RRB-\1740 for\IN\1740 <e1>desogestrel</e1>\NN\1740 plus\CC\4723816 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 and\CC\1740 1.18\CD\1740 (\-LRB-\1740 0.66\CD\1740 -\SYM\1740 2.17\CD\1740 )\-RRB-\1740 for\IN\1740 the\DT\1740 other\JJ\1740 third-generation\NN\1740 progestagens\NNS\1740 .\.\1740
D011372_D054556 NONE FINDINGS\NNS\7951464 :\:\1740 85\CD\1740 women\NNS\9605289 met\VBD\1182709 the\DT\1740 inclusion\NN\13927383 criteria\NNS\13577171 for\IN\1740 <e2>VTE</e2>\NN\1740 ,\,\1740 two\CD\13741022 of\IN\1740 whom\WP\1740 were\VBD\836236 users\NNS\7846 of\IN\1740 <e1>progestagen-only</e1>\JJ\1740 OCs\NN\1740 .\.\1740
D003276_D020246 NONE Of\IN\1740 the\DT\1740 83\CD\1740 cases\NNS\7283608 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 combined\JJ\1740 <e1>OCs</e1>\NN\1740 ,\,\1740 43\CD\1740 were\VBD\836236 recorded\VBN\2225492 as\IN\14622893 <e2>deep-vein\JJ\1740 thrombosis</e2>\NN\14100769 ,\,\1740 35\CD\1740 as\IN\14622893 pulmonary\JJ\1740 thrombosis\NN\14100769 ,\,\1740 and\CC\1740 five\CD\13741022 as\IN\14622893 venous\JJ\1740 thrombosis\NN\14100769 not\RB\1740 otherwise\RB\1740 specified\VBD\888786 .\.\1740
D003276_D020246 NONE Of\IN\1740 the\DT\1740 83\CD\1740 cases\NNS\7283608 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 combined\JJ\1740 <e1>OCs</e1>\NN\1740 ,\,\1740 43\CD\1740 were\VBD\836236 recorded\VBN\2225492 as\IN\14622893 deep-vein\JJ\1740 thrombosis\NN\14100769 ,\,\1740 35\CD\1740 as\IN\14622893 pulmonary\JJ\1740 thrombosis\NN\14100769 ,\,\1740 and\CC\1740 five\CD\13741022 as\IN\14622893 <e2>venous\JJ\1740 thrombosis</e2>\NN\14100769 not\RB\1740 otherwise\RB\1740 specified\VBD\888786 .\.\1740
D003276_D013927 NONE Of\IN\1740 the\DT\1740 83\CD\1740 cases\NNS\7283608 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 use\NN\407535 of\IN\1740 combined\JJ\1740 <e1>OCs</e1>\NN\1740 ,\,\1740 43\CD\1740 were\VBD\836236 recorded\VBN\2225492 as\IN\14622893 deep-vein\JJ\1740 thrombosis\NN\14100769 ,\,\1740 35\CD\1740 as\IN\14622893 pulmonary\JJ\1740 <e2>thrombosis</e2>\NN\14100769 ,\,\1740 and\CC\1740 five\CD\13741022 as\IN\14622893 venous\JJ\1740 thrombosis\NN\14100769 not\RB\1740 otherwise\RB\1740 specified\VBD\888786 .\.\1740
D004997_D054556 NONE Among\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 progestagens\NNS\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 desogestrel\NN\1740 with\IN\1740 20\CD\13745420 g\NN\13717155 <e1>ethinyloestradiol</e1>\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 with\IN\1740 30\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 .\.\1740
D004997_D054556 NONE Among\IN\1740 users\NNS\7846 of\IN\1740 third-generation\NN\1740 progestagens\NNS\1740 ,\,\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 was\VBD\836236 higher\JJR\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 desogestrel\NN\1740 with\IN\1740 20\CD\13745420 g\NN\13717155 ethinyloestradiol\NN\1740 than\IN\1740 in\IN\13603305 users\NNS\7846 of\IN\1740 gestodene\NN\1740 or\CC\3541091 desogestrel\NN\1740 with\IN\1740 30\CD\13745420 g\NN\13717155 <e1>ethinyloestradiol</e1>\NN\1740 .\.\1740
D004997_D054556 NONE With\IN\1740 all\DT\1740 second-generation\JJ\1740 OCs\NN\1740 as\IN\14622893 the\DT\1740 reference\NN\6765044 ,\,\1740 the\DT\1740 odds\NNS\4756635 ratios\NNS\13815152 for\IN\1740 <e2>VTE</e2>\NN\1740 were\VBD\836236 3.49\CD\1740 (\-LRB-\1740 1.21\CD\1740 -\SYM\1740 10.12\CD\1740 )\-RRB-\1740 for\IN\1740 desogestrel\NN\1740 plus\CC\4723816 20\CD\13745420 g\NN\13717155 <e1>ethinyloestradiol</e1>\NN\1740 and\CC\1740 1.18\CD\1740 (\-LRB-\1740 0.66\CD\1740 -\SYM\1740 2.17\CD\1740 )\-RRB-\1740 for\IN\1740 the\DT\1740 other\JJ\1740 third-generation\NN\1740 progestagens\NNS\1740 .\.\1740
18422462
D000409_D000740 NONE Clinically\RB\1740 significant\JJ\1740 <e2>anemia</e2>\NN\14189204 (\-LRB-\1740 hemoglobin\NN\14888884 <\XX\1740 7\CD\13741022 g/dL\NN\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 5.4\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 (\-LRB-\1740 CD4\NN\14888310 ,\,\1740 165\CD\1740 cells/microL\NN\1740 )\-RRB-\1740 and\CC\1740 hepatitis\NN\14127211 (\-LRB-\1740 clinical\JJ\1740 jaundice\NN\14299637 with\IN\1740 <e1>alanine</e1>\NN\14601829 aminotransferase\NN\15077571 >\NN\1740 5\CD\13741022 times\NNS\15113229 upper\JJ\1740 limits\NNS\5123416 of\IN\1740 normal\JJ\1740 )\-RRB-\1740 in\IN\13603305 3.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 (\-LRB-\1740 CD4\NN\14888310 ,\,\1740 260\CD\1740 cells/microL\CD\1740 )\-RRB-\1740 .\.\1740
D000409_D056486 NONE Clinically\RB\1740 significant\JJ\1740 anemia\NN\14189204 (\-LRB-\1740 hemoglobin\NN\14888884 <\XX\1740 7\CD\13741022 g/dL\NN\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 5.4\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 (\-LRB-\1740 CD4\NN\14888310 ,\,\1740 165\CD\1740 cells/microL\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>hepatitis</e2>\NN\14127211 (\-LRB-\1740 clinical\JJ\1740 jaundice\NN\14299637 with\IN\1740 <e1>alanine</e1>\NN\14601829 aminotransferase\NN\15077571 >\NN\1740 5\CD\13741022 times\NNS\15113229 upper\JJ\1740 limits\NNS\5123416 of\IN\1740 normal\JJ\1740 )\-RRB-\1740 in\IN\13603305 3.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 (\-LRB-\1740 CD4\NN\14888310 ,\,\1740 260\CD\1740 cells/microL\CD\1740 )\-RRB-\1740 .\.\1740
D000409_D007565 NONE Clinically\RB\1740 significant\JJ\1740 anemia\NN\14189204 (\-LRB-\1740 hemoglobin\NN\14888884 <\XX\1740 7\CD\13741022 g/dL\NN\1740 )\-RRB-\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 5.4\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 (\-LRB-\1740 CD4\NN\14888310 ,\,\1740 165\CD\1740 cells/microL\NN\1740 )\-RRB-\1740 and\CC\1740 hepatitis\NN\14127211 (\-LRB-\1740 clinical\JJ\1740 <e2>jaundice</e2>\NN\14299637 with\IN\1740 <e1>alanine</e1>\NN\14601829 aminotransferase\NN\15077571 >\NN\1740 5\CD\13741022 times\NNS\15113229 upper\JJ\1740 limits\NNS\5123416 of\IN\1740 normal\JJ\1740 )\-RRB-\1740 in\IN\13603305 3.5\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 (\-LRB-\1740 CD4\NN\14888310 ,\,\1740 260\CD\1740 cells/microL\CD\1740 )\-RRB-\1740 .\.\1740
D019829_D005076 CID Among\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 1\CD\13741022 year\NN\15113229 of\IN\1740 follow-up\NN\4599396 ,\,\1740 <e1>NVP</e1>\NN\1740 therapy\NN\657604 was\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 developing\VBG\1753788 <e2>rash</e2>\NN\14321469 and\CC\1740 d4\NN\1740 T\NN\14999913 therapy\NN\657604 with\IN\1740 developing\VBG\1753788 peripheral\JJ\1740 neuropathy\NN\14204950 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D019829_D010523 NONE Among\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 1\CD\13741022 year\NN\15113229 of\IN\1740 follow-up\NN\4599396 ,\,\1740 <e1>NVP</e1>\NN\1740 therapy\NN\657604 was\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 developing\VBG\1753788 rash\NN\14321469 and\CC\1740 d4\NN\1740 T\NN\14999913 therapy\NN\657604 with\IN\1740 developing\VBG\1753788 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D018119_D005076 NONE Among\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 1\CD\13741022 year\NN\15113229 of\IN\1740 follow-up\NN\4599396 ,\,\1740 NVP\NN\1740 therapy\NN\657604 was\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 developing\VBG\1753788 <e2>rash</e2>\NN\14321469 and\CC\1740 <e1>d4\NN\1740 T</e1>\NN\14999913 therapy\NN\657604 with\IN\1740 developing\VBG\1753788 peripheral\JJ\1740 neuropathy\NN\14204950 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D018119_D010523 CID Among\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 1\CD\13741022 year\NN\15113229 of\IN\1740 follow-up\NN\4599396 ,\,\1740 NVP\NN\1740 therapy\NN\657604 was\VBD\836236 significantly\RB\1740 associated\VBN\628491 with\IN\1740 developing\VBG\1753788 rash\NN\14321469 and\CC\1740 <e1>d4\NN\1740 T</e1>\NN\14999913 therapy\NN\657604 with\IN\1740 developing\VBG\1753788 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
18450790
D013792_D010523 CID <e1>Thalidomide</e1>\NN\4166841 and\CC\1740 <e2>sensory\JJ\1740 neurotoxicity</e2>\NN\1740 :\:\1740 a\DT\13649268 neurophysiological\JJ\1740 study\NN\635850 .\.\1740
D013792_D010523 CID BACKGROUND\NN\4921011 :\:\1740 Recent\JJ\1740 studies\NNS\635850 confirmed\VBD\1011725 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>sensory\JJ\1740 axonal\JJ\1740 neuropathy</e2>\NN\14204950 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 different\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 .\.\1740
D013792_D008178 NONE The\DT\1740 study\NN\635850 's\POS\1740 aims\NNS\5980875 were\VBD\836236 to\TO\1740 measure\VB\697589 variations\NNS\7296428 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 sensory\JJ\1740 action\NN\30358 potential\NN\14481929 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 amplitude\NN\7444668 in\IN\13603305 patients\NNS\9898892 with\IN\1740 refractory\JJ\1740 <e2>cutaneous\JJ\1740 lupus\NN\14219661 erythematosus</e2>\NN\1740 (\-LRB-\1740 CLE\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 use\VB\1156834 these\DT\1740 findings\NNS\7951464 to\TO\1740 identify\VB\699815 the\DT\1740 neurotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 thalidomide\NN\4166841 and\CC\1740 the\DT\1740 recovery\NN\7357388 capacity\NN\5202497 of\IN\1740 sensory\JJ\1740 fibres\NNS\14580897 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 .\.\1740
D013792_D008178 NONE The\DT\1740 study\NN\635850 's\POS\1740 aims\NNS\5980875 were\VBD\836236 to\TO\1740 measure\VB\697589 variations\NNS\7296428 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 sensory\JJ\1740 action\NN\30358 potential\NN\14481929 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 amplitude\NN\7444668 in\IN\13603305 patients\NNS\9898892 with\IN\1740 refractory\JJ\1740 cutaneous\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 <e2>CLE</e2>\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 use\VB\1156834 these\DT\1740 findings\NNS\7951464 to\TO\1740 identify\VB\699815 the\DT\1740 neurotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 thalidomide\NN\4166841 and\CC\1740 the\DT\1740 recovery\NN\7357388 capacity\NN\5202497 of\IN\1740 sensory\JJ\1740 fibres\NNS\14580897 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 .\.\1740
D013792_D008178 NONE The\DT\1740 study\NN\635850 's\POS\1740 aims\NNS\5980875 were\VBD\836236 to\TO\1740 measure\VB\697589 variations\NNS\7296428 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 sensory\JJ\1740 action\NN\30358 potential\NN\14481929 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 amplitude\NN\7444668 in\IN\13603305 patients\NNS\9898892 with\IN\1740 refractory\JJ\1740 <e2>cutaneous\JJ\1740 lupus\NN\14219661 erythematosus</e2>\NN\1740 (\-LRB-\1740 CLE\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 thalidomide\NN\4166841 and\CC\1740 use\VB\1156834 these\DT\1740 findings\NNS\7951464 to\TO\1740 identify\VB\699815 the\DT\1740 neurotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 the\DT\1740 recovery\NN\7357388 capacity\NN\5202497 of\IN\1740 sensory\JJ\1740 fibres\NNS\14580897 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 .\.\1740
D013792_D008178 NONE The\DT\1740 study\NN\635850 's\POS\1740 aims\NNS\5980875 were\VBD\836236 to\TO\1740 measure\VB\697589 variations\NNS\7296428 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 sensory\JJ\1740 action\NN\30358 potential\NN\14481929 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 amplitude\NN\7444668 in\IN\13603305 patients\NNS\9898892 with\IN\1740 refractory\JJ\1740 cutaneous\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 <e2>CLE</e2>\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 thalidomide\NN\4166841 and\CC\1740 use\VB\1156834 these\DT\1740 findings\NNS\7951464 to\TO\1740 identify\VB\699815 the\DT\1740 neurotoxic\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 the\DT\1740 recovery\NN\7357388 capacity\NN\5202497 of\IN\1740 sensory\JJ\1740 fibres\NNS\14580897 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 .\.\1740
D013792_D008178 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Clinical\JJ\1740 and\CC\1740 electrophysiological\JJ\1740 data\NNS\7951464 in\IN\13603305 12\CD\13745420 female\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>CLE</e2>\NN\1740 during\IN\1740 treatment\NN\654885 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 up\IN\1740 to\TO\1740 47\CD\1740 months\NNS\15113229 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 were\VBD\836236 analysed\VBN\78760 .\.\1740
D013792_D020258 NONE The\DT\1740 study\NN\635850 's\POS\1740 aims\NNS\5980875 were\VBD\836236 to\TO\1740 measure\VB\697589 variations\NNS\7296428 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 sensory\JJ\1740 action\NN\30358 potential\NN\14481929 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 amplitude\NN\7444668 in\IN\13603305 patients\NNS\9898892 with\IN\1740 refractory\JJ\1740 cutaneous\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 CLE\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 use\VB\1156834 these\DT\1740 findings\NNS\7951464 to\TO\1740 identify\VB\699815 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 thalidomide\NN\4166841 and\CC\1740 the\DT\1740 recovery\NN\7357388 capacity\NN\5202497 of\IN\1740 sensory\JJ\1740 fibres\NNS\14580897 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 .\.\1740
D013792_D020258 NONE The\DT\1740 study\NN\635850 's\POS\1740 aims\NNS\5980875 were\VBD\836236 to\TO\1740 measure\VB\697589 variations\NNS\7296428 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 sensory\JJ\1740 action\NN\30358 potential\NN\14481929 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 amplitude\NN\7444668 in\IN\13603305 patients\NNS\9898892 with\IN\1740 refractory\JJ\1740 cutaneous\JJ\1740 lupus\NN\14219661 erythematosus\NN\1740 (\-LRB-\1740 CLE\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 thalidomide\NN\4166841 and\CC\1740 use\VB\1156834 these\DT\1740 findings\NNS\7951464 to\TO\1740 identify\VB\699815 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 and\CC\1740 the\DT\1740 recovery\NN\7357388 capacity\NN\5202497 of\IN\1740 sensory\JJ\1740 fibres\NNS\14580897 after\IN\1740 discontinuation\NN\209943 of\IN\1740 treatment\NN\654885 .\.\1740
D013792_D020258 NONE At\IN\14622893 detection\NN\5708432 of\IN\1740 reduction\NN\351485 in\IN\13603305 sural\JJ\1740 nerve\NN\5475681 SAP\NN\14589223 amplitude\NN\7444668 ,\,\1740 the\DT\1740 median\JJ\1740 <e1>thalidomide</e1>\NN\4166841 cumulative\JJ\1740 dose\NN\3740161 was\VBD\836236 21.4\CD\1740 g.\NN\1740 The\DT\1740 threshold\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 dosage\NN\13576355 is\VBZ\836236 lower\JJR\1740 than\IN\1740 previously\RB\1740 reported\VBN\831651 .\.\1740
D013792_D020258 NONE This\DT\1740 electrophysiological\JJ\1740 parameter\NN\5858936 provides\VBZ\2199590 information\NN\6598915 about\IN\1740 subclinical\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 but\CC\1740 is\VBZ\836236 not\RB\1740 helpful\JJ\1740 in\IN\13603305 predicting\VBG\916909 the\DT\1740 appearance\NN\4723816 of\IN\1740 sensory\JJ\1740 symptoms\NNS\5823932 .\.\1740
24894748
D008790_D001919 CID A\DT\13649268 <e1>metoprolol-terbinafine</e1>\JJ\1740 combination\NN\7951464 induced\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
C041359_D001919 CID A\DT\13649268 <e1>metoprolol-terbinafine</e1>\JJ\1740 combination\NN\7951464 induced\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D008790_D012804 NONE To\TO\1740 report\VB\831651 a\DT\13649268 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 <e1>metoprolol</e1>\NN\2832168 and\CC\1740 terbinafine\JJ\1740 drug-drug\JJ\1740 interaction\NN\37396 and\CC\1740 its\PRP$\6125041 management\NN\1123598 .\.\1740
D008790_D012804 NONE A\DT\13649268 score\NN\5736149 of\IN\1740 7\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 and\CC\1740 the\DT\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 <e1>metoprolol</e1>\NN\2832168 and\CC\1740 terbinafine\NN\2720201 .\.\1740
D008790_D012804 NONE By\IN\1740 inhibiting\VBG\2510337 the\DT\1740 cytochrome\NN\14888884 P450\NN\1740 2D6\NN\1740 ,\,\1740 terbinafine\NN\2720201 had\VBD\2108377 decreased\VBN\169651 <e1>metoprolol</e1>\NN\2832168 's\POS\1740 clearance\NN\5089947 ,\,\1740 leading\VBG\1752884 in\IN\13603305 metoprolol\NN\2832168 accumulation\NN\13497135 which\WDT\1740 has\VBZ\2108377 resulted\VBN\2633881 in\IN\13603305 clinically\RB\1740 significant\JJ\1740 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 .\.\1740
D008790_D012804 NONE By\IN\1740 inhibiting\VBG\2510337 the\DT\1740 cytochrome\NN\14888884 P450\NN\1740 2D6\NN\1740 ,\,\1740 terbinafine\NN\2720201 had\VBD\2108377 decreased\VBN\169651 metoprolol\NN\2832168 's\POS\1740 clearance\NN\5089947 ,\,\1740 leading\VBG\1752884 in\IN\13603305 <e1>metoprolol</e1>\NN\2832168 accumulation\NN\13497135 which\WDT\1740 has\VBZ\2108377 resulted\VBN\2633881 in\IN\13603305 clinically\RB\1740 significant\JJ\1740 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 .\.\1740
C041359_D012804 NONE To\TO\1740 report\VB\831651 a\DT\13649268 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 metoprolol\NN\2832168 and\CC\1740 <e1>terbinafine</e1>\JJ\1740 drug-drug\JJ\1740 interaction\NN\37396 and\CC\1740 its\PRP$\6125041 management\NN\1123598 .\.\1740
C041359_D012804 NONE A\DT\13649268 score\NN\5736149 of\IN\1740 7\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 and\CC\1740 the\DT\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 metoprolol\NN\2832168 and\CC\1740 <e1>terbinafine</e1>\NN\2720201 .\.\1740
C041359_D012804 NONE By\IN\1740 inhibiting\VBG\2510337 the\DT\1740 cytochrome\NN\14888884 P450\NN\1740 2D6\NN\1740 ,\,\1740 <e1>terbinafine</e1>\NN\2720201 had\VBD\2108377 decreased\VBN\169651 metoprolol\NN\2832168 's\POS\1740 clearance\NN\5089947 ,\,\1740 leading\VBG\1752884 in\IN\13603305 metoprolol\NN\2832168 accumulation\NN\13497135 which\WDT\1740 has\VBZ\2108377 resulted\VBN\2633881 in\IN\13603305 clinically\RB\1740 significant\JJ\1740 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 .\.\1740
D008790_D003324 NONE A\DT\13649268 63\CD\1740 year-old\NN\1740 Caucasian\JJ\1740 man\NN\9605289 on\IN\1740 <e1>metoprolol</e1>\NN\2832168 200\CD\1740 mg/day\NN\1740 for\IN\1740 stable\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 was\VBD\836236 prescribed\VBN\748282 a\DT\13649268 90-day\JJ\1740 course\NN\883297 of\IN\1740 oral\JJ\1740 terbinafine\NN\2720201 250\CD\1740 mg/day\NN\1740 for\IN\1740 onychomycosis\NN\1740 .\.\1740
D008790_D014009 NONE A\DT\13649268 63\CD\1740 year-old\NN\1740 Caucasian\JJ\1740 man\NN\9605289 on\IN\1740 <e1>metoprolol</e1>\NN\2832168 200\CD\1740 mg/day\NN\1740 for\IN\1740 stable\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 was\VBD\836236 prescribed\VBN\748282 a\DT\13649268 90-day\JJ\1740 course\NN\883297 of\IN\1740 oral\JJ\1740 terbinafine\NN\2720201 250\CD\1740 mg/day\NN\1740 for\IN\1740 <e2>onychomycosis</e2>\NN\1740 .\.\1740
C041359_D003324 NONE A\DT\13649268 63\CD\1740 year-old\NN\1740 Caucasian\JJ\1740 man\NN\9605289 on\IN\1740 metoprolol\NN\2832168 200\CD\1740 mg/day\NN\1740 for\IN\1740 stable\JJ\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 was\VBD\836236 prescribed\VBN\748282 a\DT\13649268 90-day\JJ\1740 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>terbinafine</e1>\NN\2720201 250\CD\1740 mg/day\NN\1740 for\IN\1740 onychomycosis\NN\1740 .\.\1740
C041359_D014009 NONE A\DT\13649268 63\CD\1740 year-old\NN\1740 Caucasian\JJ\1740 man\NN\9605289 on\IN\1740 metoprolol\NN\2832168 200\CD\1740 mg/day\NN\1740 for\IN\1740 stable\JJ\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 was\VBD\836236 prescribed\VBN\748282 a\DT\13649268 90-day\JJ\1740 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>terbinafine</e1>\NN\2720201 250\CD\1740 mg/day\NN\1740 for\IN\1740 <e2>onychomycosis</e2>\NN\1740 .\.\1740
C041359_D003221 NONE On\IN\1740 the\DT\1740 49th\JJ\1740 day\NN\15154774 of\IN\1740 <e1>terbinafine</e1>\NN\2720201 therapy\NN\657604 ,\,\1740 he\PRP\14622893 was\VBD\836236 brought\VBN\1449974 to\IN\1740 the\DT\1740 emergency\NN\7417644 room\NN\2735688 for\IN\1740 a\DT\13649268 decrease\NN\7296428 of\IN\1740 his\PRP$\1740 global\JJ\1740 health\NN\14447525 status\NN\24720 ,\,\1740 <e2>confusion</e2>\NN\13972797 and\CC\1740 falls\VBZ\1835496 .\.\1740
D008790_D064420 NONE A\DT\13649268 score\NN\5736149 of\IN\1740 7\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 <e2>adverse\JJ\1740 drug\NN\14778436 reaction</e2>\NN\13446390 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 sinus\NN\5248181 bradycardia\NN\14110674 and\CC\1740 the\DT\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 <e1>metoprolol</e1>\NN\2832168 and\CC\1740 terbinafine\NN\2720201 .\.\1740
C041359_D064420 NONE A\DT\13649268 score\NN\5736149 of\IN\1740 7\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 <e2>adverse\JJ\1740 drug\NN\14778436 reaction</e2>\NN\13446390 probability\NN\33615 scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 probable\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 sinus\NN\5248181 bradycardia\NN\14110674 and\CC\1740 the\DT\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 metoprolol\NN\2832168 and\CC\1740 <e1>terbinafine</e1>\NN\2720201 .\.\1740
19715529
12051122
D014750_D007010 CID <e2>Hyponatremia</e2>\NN\14299637 and\CC\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 anti-diuretic\JJ\1740 hormone\NN\5404728 reported\VBN\831651 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>Vincristine</e1>\NN\3917455 :\:\1740 an\DT\6697703 over-representation\NN\1740 of\IN\1740 Asians\NNPS\9620078 ?\.\1740
D014750_D007010 CID PURPOSE\NNP\5980875 :\:\1740 This\DT\1740 retrospective\JJ\1740 study\NN\635850 used\VBD\1156834 a\DT\13649268 pharmaceutical\JJ\1740 company\NN\8053576 's\POS\1740 global\JJ\1740 safety\NN\13920835 database\NN\6634376 to\TO\1740 determine\VB\1645601 the\DT\1740 reporting\NN\6681177 rate\NN\13815152 of\IN\1740 <e2>hyponatremia</e2>\NN\14299637 and/or\CC\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 anti-diuretic\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 SIADH\NN\1740 )\-RRB-\1740 among\IN\1740 <e1>vincristine-treated</e1>\JJ\1740 patients\NNS\9898892 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 possibility\NN\5944958 of\IN\1740 at-risk\JJ\1740 population\NN\7942152 subgroups\NNS\31264 .\.\1740
D014750_D007010 CID METHOD\NNP\5616786 :\:\1740 We\PRP\1740 searched\VBD\2131279 the\DT\1740 Eli\NNP\1740 Lilly\NNP\1740 and\CC\1740 Company\NNP\8053576 's\POS\1740 computerized\VBN\2327200 adverse\JJ\1740 event\NN\23100 database\NN\6634376 for\IN\1740 all\DT\1740 reported\VBN\831651 cases\NNS\7283608 of\IN\1740 <e2>hyponatremia</e2>\NN\14299637 and/or\CC\1740 SIADH\NN\1740 as\IN\14622893 of\IN\1740 1\CD\13741022 November\NNP\15209706 1999\CD\1740 that\WDT\1740 had\VBD\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>vincristine</e1>\NN\3917455 .\.\1740
D014750_D007010 CID RESULTS\NNS\34213 :\:\1740 A\DT\13649268 total\NN\3553 of\IN\1740 76\CD\1740 cases\NNS\7283608 of\IN\1740 <e2>hyponatremia</e2>\NN\14299637 and/or\CC\1740 SIADH\NN\1740 associated\VBN\628491 with\IN\1740 <e1>vincristine</e1>\NN\3917455 use\NN\407535 were\VBD\836236 identified\VBN\699815 .\.\1740
D014750_D007010 CID CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 Asian\JJ\1740 patients\NNS\9898892 may\MD\15209706 be\VB\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>hyponatremia</e2>\NN\14299637 and/or\CC\1740 SIADH\NN\1740 associated\VBN\628491 with\IN\1740 <e1>vincristine</e1>\NN\3917455 use\NN\407535 .\.\1740
D014750_D007177 CID Hyponatremia\NN\14299637 and\CC\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 anti-diuretic\JJ\1740 hormone</e2>\NN\5404728 reported\VBN\831651 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>Vincristine</e1>\NN\3917455 :\:\1740 an\DT\6697703 over-representation\NN\1740 of\IN\1740 Asians\NNPS\9620078 ?\.\1740
D014750_D007177 CID PURPOSE\NNP\5980875 :\:\1740 This\DT\1740 retrospective\JJ\1740 study\NN\635850 used\VBD\1156834 a\DT\13649268 pharmaceutical\JJ\1740 company\NN\8053576 's\POS\1740 global\JJ\1740 safety\NN\13920835 database\NN\6634376 to\TO\1740 determine\VB\1645601 the\DT\1740 reporting\NN\6681177 rate\NN\13815152 of\IN\1740 hyponatremia\NN\14299637 and/or\CC\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 anti-diuretic\JJ\1740 hormone</e2>\NN\5404728 (\-LRB-\1740 SIADH\NN\1740 )\-RRB-\1740 among\IN\1740 <e1>vincristine-treated</e1>\JJ\1740 patients\NNS\9898892 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 possibility\NN\5944958 of\IN\1740 at-risk\JJ\1740 population\NN\7942152 subgroups\NNS\31264 .\.\1740
D014750_D007177 CID PURPOSE\NNP\5980875 :\:\1740 This\DT\1740 retrospective\JJ\1740 study\NN\635850 used\VBD\1156834 a\DT\13649268 pharmaceutical\JJ\1740 company\NN\8053576 's\POS\1740 global\JJ\1740 safety\NN\13920835 database\NN\6634376 to\TO\1740 determine\VB\1645601 the\DT\1740 reporting\NN\6681177 rate\NN\13815152 of\IN\1740 hyponatremia\NN\14299637 and/or\CC\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 anti-diuretic\JJ\1740 hormone\NN\5404728 (\-LRB-\1740 <e2>SIADH</e2>\NN\1740 )\-RRB-\1740 among\IN\1740 <e1>vincristine-treated</e1>\JJ\1740 patients\NNS\9898892 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 possibility\NN\5944958 of\IN\1740 at-risk\JJ\1740 population\NN\7942152 subgroups\NNS\31264 .\.\1740
D014750_D007177 CID METHOD\NNP\5616786 :\:\1740 We\PRP\1740 searched\VBD\2131279 the\DT\1740 Eli\NNP\1740 Lilly\NNP\1740 and\CC\1740 Company\NNP\8053576 's\POS\1740 computerized\VBN\2327200 adverse\JJ\1740 event\NN\23100 database\NN\6634376 for\IN\1740 all\DT\1740 reported\VBN\831651 cases\NNS\7283608 of\IN\1740 hyponatremia\NN\14299637 and/or\CC\1740 <e2>SIADH</e2>\NN\1740 as\IN\14622893 of\IN\1740 1\CD\13741022 November\NNP\15209706 1999\CD\1740 that\WDT\1740 had\VBD\2108377 been\VBN\836236 reported\VBN\831651 during\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>vincristine</e1>\NN\3917455 .\.\1740
D014750_D007177 CID RESULTS\NNS\34213 :\:\1740 A\DT\13649268 total\NN\3553 of\IN\1740 76\CD\1740 cases\NNS\7283608 of\IN\1740 hyponatremia\NN\14299637 and/or\CC\1740 <e2>SIADH</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>vincristine</e1>\NN\3917455 use\NN\407535 were\VBD\836236 identified\VBN\699815 .\.\1740
D014750_D007177 CID CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 Asian\JJ\1740 patients\NNS\9898892 may\MD\15209706 be\VB\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 of\IN\1740 hyponatremia\NN\14299637 and/or\CC\1740 <e2>SIADH</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>vincristine</e1>\NN\3917455 use\NN\407535 .\.\1740
D014750_D007177 CID Although\IN\1740 the\DT\1740 overall\JJ\1740 reported\VBN\831651 rate\NN\13815152 of\IN\1740 <e2>SIADH</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>vincristine</e1>\NN\3917455 is\VBZ\836236 very\RB\1740 low\JJ\1740 ,\,\1740 physicians\NNS\10305802 caring\VBG\1821996 for\IN\1740 Asian\JJ\1740 oncology\NN\6043075 patients\NNS\9898892 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 this\DT\1740 potential\JJ\1740 serious\JJ\1740 but\CC\1740 reversible\JJ\1740 adverse\JJ\1740 event\NN\23100 .\.\1740
15605432
D004317_D028361 CID Oxidative\JJ\1740 damage\NN\7296428 precedes\VBZ\2690708 nitrative\JJ\1740 damage\NN\7296428 in\IN\13603305 <e1>adriamycin-induced</e1>\JJ\1740 cardiac\JJ\1740 <e2>mitochondrial\JJ\1740 injury</e2>\NN\14052046 .\.\1740
D004317_D028361 CID Our\PRP$\1740 data\NNS\7951464 showed\VBD\2137132 <e1>ADR</e1>\NN\1740 induced\JJ\1740 4HNE-protein\NN\1740 adducts\NNS\14818238 in\IN\13603305 mitochondria\NN\5445668 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 point\NN\5868954 as\IN\14622893 when\WRB\1740 <e2>mitochondrial\JJ\1740 injury</e2>\NN\14052046 initially\RB\1740 appeared\VBD\2604760 .\.\1740
D010100_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 elevated\JJ\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 (ROS)/nitrogen\NN\1740 species\NNS\7992450 (\-LRB-\1740 RNS\NN\14622893 )\-RRB-\1740 reported\VBD\831651 to\TO\1740 be\VB\836236 present\JJ\1740 in\IN\13603305 adriamycin\NN\1740 (ADR)-induced\:\1740 <e2>cardiotoxicity</e2>\NN\1740 actually\RB\1740 resulted\VBD\2633881 in\IN\13603305 cardiomyocyte\NN\1740 oxidative/nitrative\JJ\1740 damage\NN\7296428 ,\,\1740 and\CC\1740 to\TO\1740 quantitatively\RB\1740 determine\VB\1645601 the\DT\1740 time\NN\7308889 course\NN\883297 and\CC\1740 subcellular\JJ\1740 localization\NN\151497 of\IN\1740 these\DT\1740 postulated\VBN\756338 damage\NN\7296428 products\NNS\3076708 using\VBG\1156834 an\DT\6697703 in\FW\13603305 vivo\FW\1740 approach\NN\940842 .\.\1740
D009584_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 <e1>(ROS)/nitrogen</e1>\NN\1740 species\NNS\7992450 (\-LRB-\1740 RNS\NN\14622893 )\-RRB-\1740 reported\VBD\831651 to\TO\1740 be\VB\836236 present\JJ\1740 in\IN\13603305 adriamycin\NN\1740 (ADR)-induced\:\1740 <e2>cardiotoxicity</e2>\NN\1740 actually\RB\1740 resulted\VBD\2633881 in\IN\13603305 cardiomyocyte\NN\1740 oxidative/nitrative\JJ\1740 damage\NN\7296428 ,\,\1740 and\CC\1740 to\TO\1740 quantitatively\RB\1740 determine\VB\1645601 the\DT\1740 time\NN\7308889 course\NN\883297 and\CC\1740 subcellular\JJ\1740 localization\NN\151497 of\IN\1740 these\DT\1740 postulated\VBN\756338 damage\NN\7296428 products\NNS\3076708 using\VBG\1156834 an\DT\6697703 in\FW\13603305 vivo\FW\1740 approach\NN\940842 .\.\1740
D004317_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 (ROS)/nitrogen\NN\1740 species\NNS\7992450 (\-LRB-\1740 RNS\NN\14622893 )\-RRB-\1740 reported\VBD\831651 to\TO\1740 be\VB\836236 present\JJ\1740 in\IN\13603305 <e1>adriamycin</e1>\NN\1740 (ADR)-induced\:\1740 <e2>cardiotoxicity</e2>\NN\1740 actually\RB\1740 resulted\VBD\2633881 in\IN\13603305 cardiomyocyte\NN\1740 oxidative/nitrative\JJ\1740 damage\NN\7296428 ,\,\1740 and\CC\1740 to\TO\1740 quantitatively\RB\1740 determine\VB\1645601 the\DT\1740 time\NN\7308889 course\NN\883297 and\CC\1740 subcellular\JJ\1740 localization\NN\151497 of\IN\1740 these\DT\1740 postulated\VBN\756338 damage\NN\7296428 products\NNS\3076708 using\VBG\1156834 an\DT\6697703 in\FW\13603305 vivo\FW\1740 approach\NN\940842 .\.\1740
D004317_D066126 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 elevated\JJ\1740 reactive\JJ\1740 oxygen\NN\14622893 (ROS)/nitrogen\NN\1740 species\NNS\7992450 (\-LRB-\1740 RNS\NN\14622893 )\-RRB-\1740 reported\VBD\831651 to\TO\1740 be\VB\836236 present\JJ\1740 in\IN\13603305 adriamycin\NN\1740 <e1>(ADR)-induced</e1>\:\1740 <e2>cardiotoxicity</e2>\NN\1740 actually\RB\1740 resulted\VBD\2633881 in\IN\13603305 cardiomyocyte\NN\1740 oxidative/nitrative\JJ\1740 damage\NN\7296428 ,\,\1740 and\CC\1740 to\TO\1740 quantitatively\RB\1740 determine\VB\1645601 the\DT\1740 time\NN\7308889 course\NN\883297 and\CC\1740 subcellular\JJ\1740 localization\NN\151497 of\IN\1740 these\DT\1740 postulated\VBN\756338 damage\NN\7296428 products\NNS\3076708 using\VBG\1156834 an\DT\6697703 in\FW\13603305 vivo\FW\1740 approach\NN\940842 .\.\1740
C027576_D028361 NONE Our\PRP$\1740 data\NNS\7951464 showed\VBD\2137132 ADR\NN\1740 induced\JJ\1740 <e1>4HNE-protein</e1>\NN\1740 adducts\NNS\14818238 in\IN\13603305 mitochondria\NN\5445668 at\IN\14622893 the\DT\1740 same\JJ\1740 time\NN\7308889 point\NN\5868954 as\IN\14622893 when\WRB\1740 <e2>mitochondrial\JJ\1740 injury</e2>\NN\14052046 initially\RB\1740 appeared\VBD\2604760 .\.\1740
8184922
D007545_D006332 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 adult\JJ\1740 mouse\NN\2329401 atrial\JJ\1740 and\CC\1740 ventricular\JJ\1740 cardiomyocytes\NNS\1740 do\VBP\1640855 not\RB\1740 synthesize\VB\193486 DNA\NN\14994328 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 hypertrophy</e2>\NN\14365950 .\.\1740
20959502
D017576_D008581 NONE Cerebrospinal\JJ\1740 fluid\NN\19613 penetration\NN\972621 of\IN\1740 high-dose\JJ\1740 <e1>daptomycin</e1>\NN\1740 in\IN\13603305 suspected\VBN\916909 Staphylococcus\FW\1350855 aureus\FW\1740 <e2>meningitis</e2>\NN\14127211 .\.\1740
D017576_D008581 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 methicillin-sensitive\JJ\1740 Staphylococcus\FW\1350855 aureus\FW\1740 (\-LRB-\1740 MSSA\JJ\1740 )\-RRB-\1740 bacteremia\NN\14204950 with\IN\1740 suspected\VBN\916909 MSSA\NN\1740 <e2>meningitis</e2>\NN\14127211 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 <e1>daptomycin</e1>\NN\1740 assessed\VBN\670261 with\IN\1740 concurrent\JJ\1740 serum\NN\5397468 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 (\-LRB-\1740 CSF\NN\1740 )\-RRB-\1740 concentrations\NNS\4916342 .\.\1740
D017576_D008581 NONE Nafcillin\NNP\3910417 was\VBD\836236 discontinued\VBN\2609764 and\CC\1740 <e1>daptomycin</e1>\NN\1740 9\CD\13741022 mg/kg\NN\1740 daily\RB\1740 was\VBD\836236 initiated\VBN\1617192 for\IN\1740 suspected\VBN\916909 <e2>meningitis</e2>\NN\14127211 and\CC\1740 was\VBD\836236 continued\VBN\2367363 until\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 death\NN\7296428 on\IN\1740 day\NN\15154774 16\CD\13745420 .\.\1740
D008712_D016470 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>methicillin-sensitive</e1>\JJ\1740 Staphylococcus\FW\1350855 aureus\FW\1740 (\-LRB-\1740 MSSA\JJ\1740 )\-RRB-\1740 <e2>bacteremia</e2>\NN\14204950 with\IN\1740 suspected\VBN\916909 MSSA\NN\1740 meningitis\NN\14127211 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 daptomycin\NN\1740 assessed\VBN\670261 with\IN\1740 concurrent\JJ\1740 serum\NN\5397468 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 (\-LRB-\1740 CSF\NN\1740 )\-RRB-\1740 concentrations\NNS\4916342 .\.\1740
D008712_D008581 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>methicillin-sensitive</e1>\JJ\1740 Staphylococcus\FW\1350855 aureus\FW\1740 (\-LRB-\1740 MSSA\JJ\1740 )\-RRB-\1740 bacteremia\NN\14204950 with\IN\1740 suspected\VBN\916909 MSSA\NN\1740 <e2>meningitis</e2>\NN\14127211 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 daptomycin\NN\1740 assessed\VBN\670261 with\IN\1740 concurrent\JJ\1740 serum\NN\5397468 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 (\-LRB-\1740 CSF\NN\1740 )\-RRB-\1740 concentrations\NNS\4916342 .\.\1740
D017576_D016470 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 methicillin-sensitive\JJ\1740 Staphylococcus\FW\1350855 aureus\FW\1740 (\-LRB-\1740 MSSA\JJ\1740 )\-RRB-\1740 <e2>bacteremia</e2>\NN\14204950 with\IN\1740 suspected\VBN\916909 MSSA\NN\1740 meningitis\NN\14127211 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 <e1>daptomycin</e1>\NN\1740 assessed\VBN\670261 with\IN\1740 concurrent\JJ\1740 serum\NN\5397468 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 (\-LRB-\1740 CSF\NN\1740 )\-RRB-\1740 concentrations\NNS\4916342 .\.\1740
D017576_D016470 NONE DISCUSSION\NN\6252138 :\:\1740 <e1>Daptomycin</e1>\NNP\1740 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 secondary\JJ\1740 to\TO\1740 possible\JJ\1740 nafcillin-induced\JJ\1740 acute\JJ\1740 interstitial\JJ\1740 nephritis\NN\14113228 and\CC\1740 relapsing\VBG\146138 <e2>bacteremia</e2>\NN\14204950 .\.\1740
D017576_D016470 NONE CONCLUSIONS\NNS\5837957 :\:\1740 High-dose\JJ\1740 <e1>daptomycin</e1>\NN\1740 may\MD\15209706 be\VB\836236 an\DT\6697703 alternative\JJ\1740 option\NN\6480506 for\IN\1740 MSSA\JJ\1740 <e2>bacteremia</e2>\NN\14204950 with\IN\1740 or\CC\3541091 without\IN\1740 a\DT\13649268 CNS\NN\5237227 source\NN\8620061 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 failed\VBN\1798936 or\CC\3541091 can\MD\3094503 not\RB\1740 tolerate\VB\802318 standard\JJ\1740 therapy\NN\657604 .\.\1740
D003404_D058186 NONE On\IN\1740 day\NN\15154774 8\CD\13741022 ,\,\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 1.9\CD\1740 mg/dL\NN\1740 ,\,\1740 increased\VBD\169651 from\IN\1740 1.2\CD\1740 mg/dL\NN\1740 the\DT\1740 previous\JJ\1740 day\NN\15154774 and\CC\1740 0.8\CD\1740 mg/dL\NN\1740 on\IN\1740 admission\NN\49003 )\-RRB-\1740 .\.\1740
D009254_D008581 NONE <e1>Nafcillin</e1>\NNP\3910417 was\VBD\836236 discontinued\VBN\2609764 and\CC\1740 daptomycin\NN\1740 9\CD\13741022 mg/kg\NN\1740 daily\RB\1740 was\VBD\836236 initiated\VBN\1617192 for\IN\1740 suspected\VBN\916909 <e2>meningitis</e2>\NN\14127211 and\CC\1740 was\VBD\836236 continued\VBN\2367363 until\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 death\NN\7296428 on\IN\1740 day\NN\15154774 16\CD\13745420 .\.\1740
D017576_D009395 NONE DISCUSSION\NN\6252138 :\:\1740 <e1>Daptomycin</e1>\NNP\1740 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 secondary\JJ\1740 to\TO\1740 possible\JJ\1740 nafcillin-induced\JJ\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 and\CC\1740 relapsing\VBG\146138 bacteremia\NN\14204950 .\.\1740
D009254_D009395 CID DISCUSSION\NN\6252138 :\:\1740 Daptomycin\NNP\1740 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 secondary\JJ\1740 to\TO\1740 possible\JJ\1740 <e1>nafcillin-induced</e1>\JJ\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 and\CC\1740 relapsing\VBG\146138 bacteremia\NN\14204950 .\.\1740
D009254_D016470 NONE DISCUSSION\NN\6252138 :\:\1740 Daptomycin\NNP\1740 was\VBD\836236 initiated\VBN\1617192 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 secondary\JJ\1740 to\TO\1740 possible\JJ\1740 <e1>nafcillin-induced</e1>\JJ\1740 acute\JJ\1740 interstitial\JJ\1740 nephritis\NN\14113228 and\CC\1740 relapsing\VBG\146138 <e2>bacteremia</e2>\NN\14204950 .\.\1740
89511
D004967_D014591 NONE Prevention\NN\1073995 and\CC\1740 treatment\NN\654885 of\IN\1740 <e2>endometrial\JJ\1740 disease</e2>\NN\14061805 in\IN\13603305 climacteric\JJ\1740 women\NNS\9605289 receiving\VBG\2210855 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 .\.\1740
D004967_D014591 NONE The\DT\1740 treatment\NN\654885 regimens\NNS\5898568 are\VBP\836236 described\VBN\1001294 in\IN\13603305 74\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>endometrial\JJ\1740 disease</e2>\NN\14061805 among\IN\1740 850\CD\1740 climacteric\JJ\1740 women\NNS\9605289 receiving\VBG\2210855 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 .\.\1740
D004967_D006965 CID Cystic\JJ\1740 <e2>hyperplasia</e2>\NN\14365950 was\VBD\836236 associated\VBN\628491 with\IN\1740 unopposed\JJ\1740 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 without\IN\1740 progestagen\NN\1740 .\.\1740
D004967_D006965 CID 4\CD\13741022 cases\NNS\7283608 of\IN\1740 endometrial\JJ\1740 carcinoma\NN\14239918 referred\VBN\730052 from\IN\1740 elsewhere\RB\1740 demonstrated\VBD\2137132 the\DT\1740 problems\NNS\14408086 of\IN\1740 inappropriate\JJ\1740 and\CC\1740 unsupervised\VBD\1740 unopposed\JJ\1740 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 and\CC\1740 the\DT\1740 difficulty\NN\621627 in\IN\13603305 distinguishing\VBG\618878 severe\JJ\1740 <e2>hyperplasia</e2>\NN\14365950 from\IN\1740 malignancy\NN\14070360 .\.\1740
D011372_D006965 NONE Cystic\JJ\1740 <e2>hyperplasia</e2>\NN\14365950 was\VBD\836236 associated\VBN\628491 with\IN\1740 unopposed\JJ\1740 oestrogen\NN\14745635 therapy\NN\657604 without\IN\1740 <e1>progestagen</e1>\NN\1740 .\.\1740
D009640_D006965 NONE Two\CD\13741022 courses\NNS\883297 of\IN\1740 21\CD\13745420 days\NNS\15140892 of\IN\1740 5\CD\13741022 mg\NN\13717155 <e1>norethisterone</e1>\JJ\1740 daily\RB\1740 caused\VBD\1617192 reversion\NN\13286801 to\TO\1740 normal\JJ\1740 in\IN\13603305 all\DT\1740 57\CD\1740 cases\NNS\7283608 of\IN\1740 cystic\JJ\1740 <e2>hyperplasia</e2>\NN\14365950 and\CC\1740 6\CD\13741022 of\IN\1740 the\DT\1740 8\CD\13741022 cases\NNS\7283608 of\IN\1740 atypical\JJ\1740 hyperplasia\NN\14365950 .\.\1740
D009640_D006965 NONE Two\CD\13741022 courses\NNS\883297 of\IN\1740 21\CD\13745420 days\NNS\15140892 of\IN\1740 5\CD\13741022 mg\NN\13717155 <e1>norethisterone</e1>\JJ\1740 daily\RB\1740 caused\VBD\1617192 reversion\NN\13286801 to\TO\1740 normal\JJ\1740 in\IN\13603305 all\DT\1740 57\CD\1740 cases\NNS\7283608 of\IN\1740 cystic\JJ\1740 hyperplasia\NN\14365950 and\CC\1740 6\CD\13741022 of\IN\1740 the\DT\1740 8\CD\13741022 cases\NNS\7283608 of\IN\1740 atypical\JJ\1740 <e2>hyperplasia</e2>\NN\14365950 .\.\1740
D004967_D016889 NONE 4\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>endometrial\JJ\1740 carcinoma</e2>\NN\14239918 referred\VBN\730052 from\IN\1740 elsewhere\RB\1740 demonstrated\VBD\2137132 the\DT\1740 problems\NNS\14408086 of\IN\1740 inappropriate\JJ\1740 and\CC\1740 unsupervised\VBD\1740 unopposed\JJ\1740 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 and\CC\1740 the\DT\1740 difficulty\NN\621627 in\IN\13603305 distinguishing\VBG\618878 severe\JJ\1740 hyperplasia\NN\14365950 from\IN\1740 malignancy\NN\14070360 .\.\1740
D004967_D009369 NONE 4\CD\13741022 cases\NNS\7283608 of\IN\1740 endometrial\JJ\1740 carcinoma\NN\14239918 referred\VBN\730052 from\IN\1740 elsewhere\RB\1740 demonstrated\VBD\2137132 the\DT\1740 problems\NNS\14408086 of\IN\1740 inappropriate\JJ\1740 and\CC\1740 unsupervised\VBD\1740 unopposed\JJ\1740 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 and\CC\1740 the\DT\1740 difficulty\NN\621627 in\IN\13603305 distinguishing\VBG\618878 severe\JJ\1740 hyperplasia\NN\14365950 from\IN\1740 <e2>malignancy</e2>\NN\14070360 .\.\1740
D004967_D004714 NONE Cyclical\JJ\1740 low-dose\JJ\1740 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 with\IN\1740 7\CD\13741022 -\HYPH\1740 -13\CD\1740 days\NNS\15140892 of\IN\1740 progestagen\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>endometrial\JJ\1740 hyperplasia</e2>\NN\14365950 or\CC\3541091 carcinoma\NN\14239918 .\.\1740
D004967_D002277 NONE Cyclical\JJ\1740 low-dose\JJ\1740 <e1>oestrogen</e1>\NN\14745635 therapy\NN\657604 with\IN\1740 7\CD\13741022 -\HYPH\1740 -13\CD\1740 days\NNS\15140892 of\IN\1740 progestagen\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 or\CC\3541091 <e2>carcinoma</e2>\NN\14239918 .\.\1740
D011372_D004714 NONE Cyclical\JJ\1740 low-dose\JJ\1740 oestrogen\NN\14745635 therapy\NN\657604 with\IN\1740 7\CD\13741022 -\HYPH\1740 -13\CD\1740 days\NNS\15140892 of\IN\1740 <e1>progestagen</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>endometrial\JJ\1740 hyperplasia</e2>\NN\14365950 or\CC\3541091 carcinoma\NN\14239918 .\.\1740
D011372_D002277 NONE Cyclical\JJ\1740 low-dose\JJ\1740 oestrogen\NN\14745635 therapy\NN\657604 with\IN\1740 7\CD\13741022 -\HYPH\1740 -13\CD\1740 days\NNS\15140892 of\IN\1740 <e1>progestagen</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 or\CC\3541091 <e2>carcinoma</e2>\NN\14239918 .\.\1740
8748050
D000639_D001927 CID <e2>Encephalopathy</e2>\RB\1740 during\IN\1740 <e1>amitriptyline</e1>\NN\4482543 therapy\NN\657604 :\:\1740 are\VBP\836236 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 and\CC\1740 serotonin\NN\14807737 syndrome\NN\5870365 spectrum\NN\7939382 disorders\NNS\14034177 ?\.\1740
D000639_D001927 CID This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>encephalopathy</e2>\JJ\1740 developed\VBN\1753788 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 <e1>amitriptyline</e1>\NN\4482543 therapy\NN\657604 ,\,\1740 during\IN\1740 a\DT\13649268 remission\NN\7368256 of\IN\1740 unipolar\JJ\1740 depression\NN\14373582 .\.\1740
D000639_D009459 NONE Encephalopathy\RB\1740 during\IN\1740 <e1>amitriptyline</e1>\NN\4482543 therapy\NN\657604 :\:\1740 are\VBP\836236 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 and\CC\1740 serotonin\NN\14807737 syndrome\NN\5870365 spectrum\NN\7939382 disorders\NNS\14034177 ?\.\1740
D000639_D020230 NONE Encephalopathy\RB\1740 during\IN\1740 <e1>amitriptyline</e1>\NN\4482543 therapy\NN\657604 :\:\1740 are\VBP\836236 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 and\CC\1740 <e2>serotonin\NN\14807737 syndrome</e2>\NN\5870365 spectrum\NN\7939382 disorders\NNS\14034177 ?\.\1740
D000639_D003866 NONE This\DT\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 encephalopathy\JJ\1740 developed\VBN\1753788 in\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 <e1>amitriptyline</e1>\NN\4482543 therapy\NN\657604 ,\,\1740 during\IN\1740 a\DT\13649268 remission\NN\7368256 of\IN\1740 <e2>unipolar\JJ\1740 depression</e2>\NN\14373582 .\.\1740
24535067
D005045_D009207 CID Prevention\NN\1073995 of\IN\1740 <e1>etomidate-induced</e1>\JJ\1740 <e2>myoclonus</e2>\NN\14360459 :\:\1740 which\WDT\1740 is\VBZ\836236 superior\JJ\1740 :\:\1740 Fentanyl\NNP\2707683 ,\,\1740 midazolam\NN\2830852 ,\,\1740 or\CC\3541091 a\DT\13649268 combination\NN\7951464 ?\.\1740
D005045_D009207 CID BACKGROUND\NN\4921011 :\:\1740 In\IN\13603305 this\DT\1740 retrospective\JJ\1740 comparative\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 fentanyl\NN\2707683 ,\,\1740 midazolam\NN\2830852 ,\,\1740 and\CC\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 midazolam\NNS\2830852 to\TO\1740 prevent\VB\1740 <e1>etomidate-induced</e1>\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D005045_D009207 CID CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pretreatment\NN\1740 with\IN\1740 fentanyl\NN\2707683 or\CC\3541091 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 midazolam\NN\2830852 was\VBD\836236 effective\JJ\1740 in\IN\13603305 preventing\VBG\1740 <e1>etomidate-induced</e1>\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D005283_D009207 NONE Prevention\NN\1073995 of\IN\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 :\:\1740 which\WDT\1740 is\VBZ\836236 superior\JJ\1740 :\:\1740 <e1>Fentanyl</e1>\NNP\2707683 ,\,\1740 midazolam\NN\2830852 ,\,\1740 or\CC\3541091 a\DT\13649268 combination\NN\7951464 ?\.\1740
D005283_D009207 NONE BACKGROUND\NN\4921011 :\:\1740 In\IN\13603305 this\DT\1740 retrospective\JJ\1740 comparative\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 ,\,\1740 midazolam\NN\2830852 ,\,\1740 and\CC\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 midazolam\NNS\2830852 to\TO\1740 prevent\VB\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D005283_D009207 NONE BACKGROUND\NN\4921011 :\:\1740 In\IN\13603305 this\DT\1740 retrospective\JJ\1740 comparative\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 fentanyl\NN\2707683 ,\,\1740 midazolam\NN\2830852 ,\,\1740 and\CC\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 and\CC\1740 midazolam\NNS\2830852 to\TO\1740 prevent\VB\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D005283_D009207 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>fentanyl</e1>\NN\2707683 or\CC\3541091 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 midazolam\NN\2830852 was\VBD\836236 effective\JJ\1740 in\IN\13603305 preventing\VBG\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D005283_D009207 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pretreatment\NN\1740 with\IN\1740 fentanyl\NN\2707683 or\CC\3541091 combination\NN\7951464 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 and\CC\1740 midazolam\NN\2830852 was\VBD\836236 effective\JJ\1740 in\IN\13603305 preventing\VBG\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D008874_D009207 NONE Prevention\NN\1073995 of\IN\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 :\:\1740 which\WDT\1740 is\VBZ\836236 superior\JJ\1740 :\:\1740 Fentanyl\NNP\2707683 ,\,\1740 <e1>midazolam</e1>\NN\2830852 ,\,\1740 or\CC\3541091 a\DT\13649268 combination\NN\7951464 ?\.\1740
D008874_D009207 NONE BACKGROUND\NN\4921011 :\:\1740 In\IN\13603305 this\DT\1740 retrospective\JJ\1740 comparative\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 fentanyl\NN\2707683 ,\,\1740 <e1>midazolam</e1>\NN\2830852 ,\,\1740 and\CC\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 midazolam\NNS\2830852 to\TO\1740 prevent\VB\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D008874_D009207 NONE BACKGROUND\NN\4921011 :\:\1740 In\IN\13603305 this\DT\1740 retrospective\JJ\1740 comparative\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 compare\VB\644583 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 fentanyl\NN\2707683 ,\,\1740 midazolam\NN\2830852 ,\,\1740 and\CC\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>midazolam</e1>\NNS\2830852 to\TO\1740 prevent\VB\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D008874_D009207 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 pretreatment\NN\1740 with\IN\1740 fentanyl\NN\2707683 or\CC\3541091 combination\NN\7951464 of\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>midazolam</e1>\NN\2830852 was\VBD\836236 effective\JJ\1740 in\IN\13603305 preventing\VBG\1740 etomidate-induced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 .\.\1740
D005045_D009069 NONE <e2>Myoclonic\JJ\1740 movements</e2>\NNS\191142 are\VBP\836236 evaluated\VBN\670261 ,\,\1740 which\WDT\1740 were\VBD\836236 observed\VBN\2163746 and\CC\1740 graded\VBN\670261 according\VBG\2657219 to\IN\1740 clinical\JJ\1740 severity\NN\5036394 during\IN\1740 the\DT\1740 2\CD\13741022 minutes\NNS\6502378 after\IN\1740 <e1>etomidate</e1>\NN\1740 injection\NN\320852 .\.\1740
D005045_D010146 NONE The\DT\1740 severity\NN\5036394 of\IN\1740 <e2>pain</e2>\NN\14299637 due\JJ\1740 to\TO\1740 <e1>etomidate</e1>\JJ\1740 injection\NN\320852 ,\,\1740 mean\VBP\928630 arterial\JJ\1740 pressure\NN\11419404 ,\,\1740 heart\NN\5919034 rate\NN\13815152 ,\,\1740 and\CC\1740 adverse\JJ\1740 effects\NNS\13245626 were\VBD\836236 also\RB\1740 evaluated\VBN\670261 .\.\1740
24802403
D008687_D012640 NONE <e1>Metformin</e1>\NN\2719105 protects\VBZ\1127795 against\IN\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairments\NNS\7296428 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 pentylenetetrazole-induced\JJ\1740 kindling\NN\15101361 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008687_D012640 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 ameliorative\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>metformin</e1>\NN\2719105 on\IN\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 cognitive\JJ\1740 impairment\NN\7296428 and\CC\1740 brain\NN\5462674 oxidative\JJ\1740 stress\NN\7083732 markers\NNS\21939 observed\VBN\2163746 in\IN\13603305 pentylenetetrazole-induced\JJ\1740 kindling\NN\15101361 animals\NNS\4475 .\.\1740
D008687_D012640 NONE Thus\RB\1740 the\DT\1740 present\JJ\1740 study\NN\635850 concluded\VBD\628491 that\IN\1740 <e1>metformin</e1>\NN\2719105 may\MD\15209706 be\VB\836236 a\DT\13649268 potential\JJ\1740 agent\NN\7347 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 epilepsy\NN\14085708 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 protective\JJ\1740 medicine\NN\6045562 against\IN\1740 cognitive\JJ\1740 impairment\NN\7296428 induced\VBN\1627355 by\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D008687_D007859 NONE <e1>Metformin</e1>\NN\2719105 protects\VBZ\1127795 against\IN\1740 seizures\NNS\14081375 ,\,\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairments</e2>\NNS\7296428 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 pentylenetetrazole-induced\JJ\1740 kindling\NN\15101361 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008687_D008569 NONE <e1>Metformin</e1>\NN\2719105 protects\VBZ\1127795 against\IN\1740 seizures\NNS\14081375 ,\,\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairments</e2>\NNS\7296428 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 pentylenetetrazole-induced\JJ\1740 kindling\NN\15101361 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010433_D012640 CID Metformin\NN\2719105 protects\VBZ\1127795 against\IN\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairments\NNS\7296428 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>pentylenetetrazole-induced</e1>\JJ\1740 kindling\NN\15101361 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010433_D012640 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 ameliorative\JJ\1740 effects\NNS\13245626 of\IN\1740 metformin\NN\2719105 on\IN\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 cognitive\JJ\1740 impairment\NN\7296428 and\CC\1740 brain\NN\5462674 oxidative\JJ\1740 stress\NN\7083732 markers\NNS\21939 observed\VBN\2163746 in\IN\13603305 <e1>pentylenetetrazole-induced</e1>\JJ\1740 kindling\NN\15101361 animals\NNS\4475 .\.\1740
D010433_D007859 CID Metformin\NN\2719105 protects\VBZ\1127795 against\IN\1740 seizures\NNS\14081375 ,\,\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairments</e2>\NNS\7296428 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>pentylenetetrazole-induced</e1>\JJ\1740 kindling\NN\15101361 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010433_D008569 CID Metformin\NN\2719105 protects\VBZ\1127795 against\IN\1740 seizures\NNS\14081375 ,\,\1740 <e2>learning\NN\5701944 and\CC\1740 memory\NN\5926676 impairments</e2>\NNS\7296428 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>pentylenetetrazole-induced</e1>\JJ\1740 kindling\NN\15101361 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008687_D003072 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 ameliorative\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>metformin</e1>\NN\2719105 on\IN\1740 seizures\NNS\14081375 ,\,\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 brain\NN\5462674 oxidative\JJ\1740 stress\NN\7083732 markers\NNS\21939 observed\VBN\2163746 in\IN\13603305 pentylenetetrazole-induced\JJ\1740 kindling\NN\15101361 animals\NNS\4475 .\.\1740
D008687_D003072 NONE We\PRP\1740 found\VBD\2426171 that\IN\1740 <e1>metformin</e1>\NN\2719105 suppressed\VBD\2510337 the\DT\1740 progression\NN\8457976 of\IN\1740 kindling\NN\15101361 ,\,\1740 ameliorated\VBD\126264 the\DT\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 decreased\VBD\169651 brain\NN\5462674 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D008687_D003072 NONE Thus\RB\1740 the\DT\1740 present\JJ\1740 study\NN\635850 concluded\VBD\628491 that\IN\1740 <e1>metformin</e1>\NN\2719105 may\MD\15209706 be\VB\836236 a\DT\13649268 potential\JJ\1740 agent\NN\7347 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 epilepsy\NN\14085708 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 protective\JJ\1740 medicine\NN\6045562 against\IN\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 seizures\NNS\14081375 .\.\1740
D010433_D003072 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 ameliorative\JJ\1740 effects\NNS\13245626 of\IN\1740 metformin\NN\2719105 on\IN\1740 seizures\NNS\14081375 ,\,\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 brain\NN\5462674 oxidative\JJ\1740 stress\NN\7083732 markers\NNS\21939 observed\VBN\2163746 in\IN\13603305 <e1>pentylenetetrazole-induced</e1>\JJ\1740 kindling\NN\15101361 animals\NNS\4475 .\.\1740
D008687_D004827 NONE Thus\RB\1740 the\DT\1740 present\JJ\1740 study\NN\635850 concluded\VBD\628491 that\IN\1740 <e1>metformin</e1>\NN\2719105 may\MD\15209706 be\VB\836236 a\DT\13649268 potential\JJ\1740 agent\NN\7347 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 protective\JJ\1740 medicine\NN\6045562 against\IN\1740 cognitive\JJ\1740 impairment\NN\7296428 induced\VBN\1627355 by\IN\1740 seizures\NNS\14081375 .\.\1740
25006369
C061870_D005207 NONE Optimal\JJ\1740 precurarizing\VBG\1740 dose\NN\3740161 of\IN\1740 <e1>rocuronium</e1>\NN\1740 to\TO\1740 decrease\VB\169651 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 following\VBG\1835496 succinylcholine\NN\3800001 administration\NN\1133281 .\.\1740
C061870_D005207 NONE The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>rocuronium</e1>\NN\1740 to\TO\1740 prevent\VB\1740 succinylcholine-induced\JJ\1740 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 rocuronium\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 succinylcholine\NN\3800001 .\.\1740
C061870_D005207 NONE The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 prevent\VB\1740 succinylcholine-induced\JJ\1740 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 <e1>rocuronium</e1>\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 succinylcholine\NN\3800001 .\.\1740
C061870_D005207 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 visible\JJ\1740 <e2>muscle\NN\5289601 fasciculation</e2>\NN\14361664 was\VBD\836236 significantly\RB\1740 less\JJR\1740 with\IN\1740 increasing\VBG\169651 the\DT\1740 amount\NN\13329641 of\IN\1740 precurarizing\VBG\1740 dose\NN\3740161 of\IN\1740 <e1>rocuronium</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C061870_D005207 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Precurarization\NN\1740 with\IN\1740 0.04\CD\1740 mg/kg\NN\1740 <e1>rocuronium</e1>\NN\1740 was\VBD\836236 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 considering\VBG\689344 the\DT\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 with\IN\1740 acceptable\JJ\1740 onset\NN\7325190 time\NN\7308889 ,\,\1740 and\CC\1740 the\DT\1740 safe\JJ\1740 and\CC\1740 effective\JJ\1740 precurarization\NN\1740 .\.\1740
C061870_D063806 NONE Optimal\JJ\1740 precurarizing\VBG\1740 dose\NN\3740161 of\IN\1740 <e1>rocuronium</e1>\NN\1740 to\TO\1740 decrease\VB\169651 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 following\VBG\1835496 succinylcholine\NN\3800001 administration\NN\1133281 .\.\1740
C061870_D063806 NONE The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>rocuronium</e1>\NN\1740 to\TO\1740 prevent\VB\1740 succinylcholine-induced\JJ\1740 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 rocuronium\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 succinylcholine\NN\3800001 .\.\1740
C061870_D063806 NONE The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 prevent\VB\1740 succinylcholine-induced\JJ\1740 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 <e1>rocuronium</e1>\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 succinylcholine\NN\3800001 .\.\1740
C061870_D063806 NONE Those\DT\1740 of\IN\1740 <e2>myalgia</e2>\NN\14322699 tend\VBP\2604760 to\TO\1740 decrease\VB\169651 according\VBG\2657219 to\IN\1740 increasing\VBG\169651 the\DT\1740 amount\NN\13329641 of\IN\1740 precurarizing\VBG\1740 dose\NN\3740161 of\IN\1740 <e1>rocuronium</e1>\NN\1740 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 significance\NN\5168261 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.072\CD\1740 )\-RRB-\1740 .\.\1740
C061870_D063806 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Precurarization\NN\1740 with\IN\1740 0.04\CD\1740 mg/kg\NN\1740 <e1>rocuronium</e1>\NN\1740 was\VBD\836236 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 considering\VBG\689344 the\DT\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 with\IN\1740 acceptable\JJ\1740 onset\NN\7325190 time\NN\7308889 ,\,\1740 and\CC\1740 the\DT\1740 safe\JJ\1740 and\CC\1740 effective\JJ\1740 precurarization\NN\1740 .\.\1740
D013390_D005207 CID Optimal\JJ\1740 precurarizing\VBG\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 decrease\VB\169651 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 following\VBG\1835496 <e1>succinylcholine</e1>\NN\3800001 administration\NN\1133281 .\.\1740
D013390_D005207 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Succinylcholine</e1>\NN\3800001 commonly\RB\1740 produces\VBZ\1617192 frequent\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 ,\,\1740 including\VBG\690614 <e2>muscle\NN\5289601 fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 .\.\1740
D013390_D005207 CID The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 prevent\VB\1740 <e1>succinylcholine-induced</e1>\JJ\1740 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 rocuronium\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 succinylcholine\NN\3800001 .\.\1740
D013390_D005207 CID The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 prevent\VB\1740 succinylcholine-induced\JJ\1740 <e2>fasciculation</e2>\NN\14361664 and\CC\1740 myalgia\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 rocuronium\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 <e1>succinylcholine</e1>\NN\3800001 .\.\1740
D013390_D005207 CID All\DT\1740 patients\NNS\9898892 received\VBD\2210855 <e1>succinylcholine</e1>\NN\3800001 1.5\CD\1740 mg/kg\NN\1740 at\IN\14622893 2\CD\13741022 minutes\NNS\6502378 after\IN\1740 the\DT\1740 precurarization\NN\1740 ,\,\1740 and\CC\1740 were\VBD\836236 assessed\VBN\670261 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>fasciculations</e2>\NNS\14361664 ,\,\1740 while\IN\15122231 myalgia\NN\14322699 was\VBD\836236 assessed\VBN\670261 at\IN\14622893 24\CD\13745420 hours\NNS\15118228 after\IN\1740 surgery\NN\6045562 .\.\1740
D013390_D063806 CID Optimal\JJ\1740 precurarizing\VBG\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 decrease\VB\169651 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 following\VBG\1835496 <e1>succinylcholine</e1>\NN\3800001 administration\NN\1133281 .\.\1740
D013390_D063806 CID BACKGROUND\NN\4921011 :\:\1740 <e1>Succinylcholine</e1>\NN\3800001 commonly\RB\1740 produces\VBZ\1617192 frequent\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 ,\,\1740 including\VBG\690614 muscle\NN\5289601 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 .\.\1740
D013390_D063806 CID The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 prevent\VB\1740 <e1>succinylcholine-induced</e1>\JJ\1740 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 rocuronium\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 succinylcholine\NN\3800001 .\.\1740
D013390_D063806 CID The\DT\1740 current\JJ\1740 study\NN\635850 identified\VBD\699815 the\DT\1740 optimal\JJ\1740 dose\NN\3740161 of\IN\1740 rocuronium\NN\1740 to\TO\1740 prevent\VB\1740 succinylcholine-induced\JJ\1740 fasciculation\NN\14361664 and\CC\1740 <e2>myalgia</e2>\NN\14322699 and\CC\1740 evaluated\VBD\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 rocuronium\NN\1740 on\IN\1740 the\DT\1740 speed\NN\15286249 of\IN\1740 onset\NN\7325190 produced\VBN\1617192 by\IN\1740 <e1>succinylcholine</e1>\NN\3800001 .\.\1740
D013390_D063806 CID All\DT\1740 patients\NNS\9898892 received\VBD\2210855 <e1>succinylcholine</e1>\NN\3800001 1.5\CD\1740 mg/kg\NN\1740 at\IN\14622893 2\CD\13741022 minutes\NNS\6502378 after\IN\1740 the\DT\1740 precurarization\NN\1740 ,\,\1740 and\CC\1740 were\VBD\836236 assessed\VBN\670261 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 fasciculations\NNS\14361664 ,\,\1740 while\IN\15122231 <e2>myalgia</e2>\NN\14322699 was\VBD\836236 assessed\VBN\670261 at\IN\14622893 24\CD\13745420 hours\NNS\15118228 after\IN\1740 surgery\NN\6045562 .\.\1740
8188982
D001127_D006973 CID Central\JJ\1740 cardiovascular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>AVP</e1>\NN\1740 and\CC\1740 ANP\NN\1740 in\IN\13603305 normotensive\NN\1740 and\CC\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D001127_D006973 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 influence\NN\5190804 of\IN\1740 central\JJ\1740 <e1>arginine\NN\14605787 vasopressin</e1>\NN\5407119 (\-LRB-\1740 AVP\NN\1740 )\-RRB-\1740 and\CC\1740 of\IN\1740 atrial\JJ\1740 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 ANP\NN\1740 )\-RRB-\1740 on\IN\1740 control\NN\5190804 of\IN\1740 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 MAP\NN\4076846 )\-RRB-\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 HR\NN\15154774 )\-RRB-\1740 in\IN\13603305 normotensive\NN\1740 (\-LRB-\1740 WKY\NN\1740 )\-RRB-\1740 and\CC\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\NN\10405694 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D001127_D006973 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 influence\NN\5190804 of\IN\1740 central\JJ\1740 arginine\NN\14605787 vasopressin\NN\5407119 (\-LRB-\1740 <e1>AVP</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 of\IN\1740 atrial\JJ\1740 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 ANP\NN\1740 )\-RRB-\1740 on\IN\1740 control\NN\5190804 of\IN\1740 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 MAP\NN\4076846 )\-RRB-\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 HR\NN\15154774 )\-RRB-\1740 in\IN\13603305 normotensive\NN\1740 (\-LRB-\1740 WKY\NN\1740 )\-RRB-\1740 and\CC\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\NN\10405694 (\-LRB-\1740 SHR\NN\1740 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D010656_D006973 CID Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 <e1>phenylephrine</e1>\NN\2682038 (Phe)-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (SN)-induced\VBD\1740 hypotension\NN\14057371 .\.\1740
D010656_D006973 CID Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 phenylephrine\NN\2682038 <e1>(Phe)-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (SN)-induced\VBD\1740 hypotension\NN\14057371 .\.\1740
D010656_D007022 NONE Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 <e1>phenylephrine</e1>\NN\2682038 (Phe)-induced\JJ\1740 hypertension\NN\14057371 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (SN)-induced\VBD\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D010656_D007022 NONE Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 phenylephrine\NN\2682038 <e1>(Phe)-induced</e1>\JJ\1740 hypertension\NN\14057371 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (SN)-induced\VBD\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D009599_D006973 NONE Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 phenylephrine\NN\2682038 (Phe)-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (SN)-induced\VBD\1740 hypotension\NN\14057371 .\.\1740
D009599_D006973 NONE Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 phenylephrine\NN\2682038 (Phe)-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 <e1>(SN)-induced</e1>\VBD\1740 hypotension\NN\14057371 .\.\1740
D009599_D007022 CID Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 phenylephrine\NN\2682038 (Phe)-induced\JJ\1740 hypertension\NN\14057371 and\CC\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (SN)-induced\VBD\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D009599_D007022 CID Sensitivity\NN\5651971 of\IN\1740 cardiac\JJ\1740 component\NN\5867413 of\IN\1740 baroreflex\NN\1740 (\-LRB-\1740 CCB\NN\1740 )\-RRB-\1740 ,\,\1740 expressed\VBN\928630 as\IN\14622893 a\DT\13649268 slope\NN\9287968 of\IN\1740 the\DT\1740 regression\NN\14501726 line\NN\8426461 was\VBD\836236 determined\VBN\1645601 from\IN\1740 relationships\NNS\31921 between\IN\1740 systolic\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 SAP\NN\14589223 )\-RRB-\1740 and\CC\1740 HR\NN\15154774 period\NN\13575869 (\-LRB-\1740 HRp\NNS\1740 )\-RRB-\1740 during\IN\1740 phenylephrine\NN\2682038 (Phe)-induced\JJ\1740 hypertension\NN\14057371 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 <e1>(SN)-induced</e1>\VBD\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D009599_D007022 CID CCB\NN\1740 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 WKY\NN\1740 and\CC\1740 SHR\NN\1740 after\IN\1740 LV\JJ\1740 administration\NN\1133281 of\IN\1740 AVP\NN\1740 during\IN\1740 <e1>SN-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D001127_D007022 NONE CCB\NN\1740 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 WKY\NN\1740 and\CC\1740 SHR\NN\1740 after\IN\1740 LV\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>AVP</e1>\NN\1740 during\IN\1740 SN-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
23892921
C467567_D009101 NONE "\``\1740 Real-world\JJ\1740 "\''\1740 data\NNS\7951464 on\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>lenalidomide</e1>\NN\1740 and\CC\1740 dexamethasone\NN\2721538 in\IN\13603305 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 according\VBG\2657219 to\IN\1740 the\DT\1740 standard\JJ\1740 clinical\JJ\1740 practice\NN\407535 :\:\1740 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 Greek\NNP\6941644 Myeloma\NNP\14239425 Study\NNP\635850 Group\NNP\2137 .\.\1740
C467567_D009101 NONE "\``\1740 Real-world\JJ\1740 "\''\1740 data\NNS\7951464 on\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>lenalidomide</e1>\NN\1740 and\CC\1740 dexamethasone\NN\2721538 in\IN\13603305 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 multiple\JJ\1740 myeloma\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 according\VBG\2657219 to\IN\1740 the\DT\1740 standard\JJ\1740 clinical\JJ\1740 practice\NN\407535 :\:\1740 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 Greek\NNP\6941644 <e2>Myeloma</e2>\NNP\14239425 Study\NNP\635850 Group\NNP\2137 .\.\1740
C467567_D009101 NONE <e1>Lenalidomide</e1>\NN\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 RD\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 RRMM\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
C467567_D009101 NONE <e1>Lenalidomide</e1>\NN\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 RD\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>RRMM</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
C467567_D009101 NONE Lenalidomide\NN\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 <e1>RD</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 RRMM\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
C467567_D009101 NONE Lenalidomide\NN\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 <e1>RD</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>RRMM</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
C467567_D009101 NONE We\PRP\1740 studied\VBD\630380 212\CD\1740 <e2>RRMM</e2>\NN\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>RD</e1>\NNP\1740 in\IN\13603305 RW\NN\1740 .\.\1740
C467567_D009101 NONE Our\PRP$\1740 study\NN\635850 confirms\VBZ\1011725 that\IN\1740 <e1>RD</e1>\NNP\1740 is\VBZ\836236 effective\JJ\1740 and\CC\1740 safe\JJ\1740 in\IN\13603305 <e2>RRMM</e2>\NN\1740 in\IN\13603305 the\DT\1740 RW\NN\1740 ;\:\1740 it\PRP\6125041 produces\VBZ\1617192 durable\JJ\1740 responses\NNS\11410625 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 continue\VBP\2367363 on\IN\1740 treatment\NN\654885 till\IN\14844693 progression\NN\8457976 and\CC\1740 improves\VBZ\126264 humoral\JJ\1740 immunity\NN\13920835 even\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 stable\JJ\1740 disease\NN\14061805 .\.\1740
D003907_D009101 NONE "\``\1740 Real-world\JJ\1740 "\''\1740 data\NNS\7951464 on\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 lenalidomide\NN\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 according\VBG\2657219 to\IN\1740 the\DT\1740 standard\JJ\1740 clinical\JJ\1740 practice\NN\407535 :\:\1740 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 Greek\NNP\6941644 Myeloma\NNP\14239425 Study\NNP\635850 Group\NNP\2137 .\.\1740
D003907_D009101 NONE "\``\1740 Real-world\JJ\1740 "\''\1740 data\NNS\7951464 on\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 lenalidomide\NN\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 multiple\JJ\1740 myeloma\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 according\VBG\2657219 to\IN\1740 the\DT\1740 standard\JJ\1740 clinical\JJ\1740 practice\NN\407535 :\:\1740 a\DT\13649268 study\NN\635850 of\IN\1740 the\DT\1740 Greek\NNP\6941644 <e2>Myeloma</e2>\NNP\14239425 Study\NNP\635850 Group\NNP\2137 .\.\1740
D003907_D009101 NONE Lenalidomide\NN\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 (\-LRB-\1740 RD\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 RRMM\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
D003907_D009101 NONE Lenalidomide\NN\1740 and\CC\1740 <e1>dexamethasone</e1>\NN\2721538 (\-LRB-\1740 RD\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>RRMM</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
D003907_D009101 NONE Lenalidomide\NN\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 <e1>RD</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 (\-LRB-\1740 RRMM\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
D003907_D009101 NONE Lenalidomide\NN\1740 and\CC\1740 dexamethasone\NN\2721538 (\-LRB-\1740 <e1>RD</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 standard\NN\13577171 of\IN\1740 care\NN\575741 for\IN\1740 relapsed/refractory\JJ\1740 multiple\JJ\1740 myeloma\NN\14239425 (\-LRB-\1740 <e2>RRMM</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 there\EX\27167 is\VBZ\836236 limited\JJ\1740 published\VBN\1621555 data\NNS\7951464 on\IN\1740 its\PRP$\6125041 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 in\IN\13603305 the\DT\1740 "\``\1740 real\JJ\1740 world\NN\19128 "\''\1740 (\-LRB-\1740 RW\NN\1740 )\-RRB-\1740 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pharmacoeconomics\NNPS\1740 and\CC\1740 Outcomes\NNP\7291312 Research\NNP\633864 definition\NN\6738281 .\.\1740
D003907_D009101 NONE We\PRP\1740 studied\VBD\630380 212\CD\1740 <e2>RRMM</e2>\NN\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>RD</e1>\NNP\1740 in\IN\13603305 RW\NN\1740 .\.\1740
D003907_D009101 NONE Our\PRP$\1740 study\NN\635850 confirms\VBZ\1011725 that\IN\1740 <e1>RD</e1>\NNP\1740 is\VBZ\836236 effective\JJ\1740 and\CC\1740 safe\JJ\1740 in\IN\13603305 <e2>RRMM</e2>\NN\1740 in\IN\13603305 the\DT\1740 RW\NN\1740 ;\:\1740 it\PRP\6125041 produces\VBZ\1617192 durable\JJ\1740 responses\NNS\11410625 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 continue\VBP\2367363 on\IN\1740 treatment\NN\654885 till\IN\14844693 progression\NN\8457976 and\CC\1740 improves\VBZ\126264 humoral\JJ\1740 immunity\NN\13920835 even\RB\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 stable\JJ\1740 disease\NN\14061805 .\.\1740
12359538
D003042_D002637 NONE Utility\NN\8186047 of\IN\1740 troponin\NN\1740 I\NN\14622893 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 NONE Baseline\NN\7260623 electrocardiogram\NN\7000195 abnormalities\NNS\14034177 and\CC\1740 market\NN\407535 elevations\NNS\7445480 not\RB\1740 associated\VBN\628491 with\IN\1740 myocardial\JJ\1740 necrosis\NN\11444117 make\VB\126264 accurate\JJ\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 difficult\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 outcomes\NNS\7291312 based\VBN\2694933 on\IN\1740 troponin\NN\1740 positivity\NN\13856574 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine</e1>\NN\3492717 <e2>chest\NN\5220461 pain</e2>\NN\14299637 admitted\VBN\822367 for\IN\1740 exclusion\NN\13927383 of\IN\1740 MI\NNP\14207561 .\.\1740
D003042_D002637 NONE Troponin\NNP\1740 appears\VBZ\2604760 to\TO\1740 have\VB\2108377 an\DT\6697703 equivalent\JJ\1740 diagnostic\JJ\1740 accuracy\NN\4723816 compared\VBN\644583 with\IN\1740 CK-MB\NN\1740 for\IN\1740 diagnosing\VBG\644583 necrosis\NN\11444117 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 suspected\VBN\916909 MI\NN\14207561 .\.\1740
D003042_D009202 NONE Baseline\NN\7260623 electrocardiogram\NN\7000195 abnormalities\NNS\14034177 and\CC\1740 market\NN\407535 elevations\NNS\7445480 not\RB\1740 associated\VBN\628491 with\IN\1740 <e2>myocardial\JJ\1740 necrosis</e2>\NN\11444117 make\VB\126264 accurate\JJ\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 difficult\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 chest\NN\5220461 pain\NN\14299637 .\.\1740
D003042_D009203 CID Baseline\NN\7260623 electrocardiogram\NN\7000195 abnormalities\NNS\14034177 and\CC\1740 market\NN\407535 elevations\NNS\7445480 not\RB\1740 associated\VBN\628491 with\IN\1740 myocardial\JJ\1740 necrosis\NN\11444117 make\VB\126264 accurate\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 difficult\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 chest\NN\5220461 pain\NN\14299637 .\.\1740
D003042_D009203 CID Baseline\NN\7260623 electrocardiogram\NN\7000195 abnormalities\NNS\14034177 and\CC\1740 market\NN\407535 elevations\NNS\7445480 not\RB\1740 associated\VBN\628491 with\IN\1740 myocardial\JJ\1740 necrosis\NN\11444117 make\VB\126264 accurate\JJ\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 difficult\JJ\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 chest\NN\5220461 pain\NN\14299637 .\.\1740
D003042_D009203 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 outcomes\NNS\7291312 based\VBN\2694933 on\IN\1740 troponin\NN\1740 positivity\NN\13856574 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine</e1>\NN\3492717 chest\NN\5220461 pain\NN\14299637 admitted\VBN\822367 for\IN\1740 exclusion\NN\13927383 of\IN\1740 <e2>MI</e2>\NNP\14207561 .\.\1740
D003042_D009203 CID METHODS\NNS\5616786 :\:\1740 Outcomes\NNS\7291312 were\VBD\836236 examined\VBN\789138 in\IN\13603305 patients\NNS\9898892 admitted\VBN\822367 for\IN\1740 possible\JJ\1740 <e2>MI</e2>\NN\14207561 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003042_D009203 CID Troponin\NNP\1740 appears\VBZ\2604760 to\TO\1740 have\VB\2108377 an\DT\6697703 equivalent\JJ\1740 diagnostic\JJ\1740 accuracy\NN\4723816 compared\VBN\644583 with\IN\1740 CK-MB\NN\1740 for\IN\1740 diagnosing\VBG\644583 necrosis\NN\11444117 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 chest\JJ\1740 pain\NN\14299637 and\CC\1740 suspected\VBN\916909 <e2>MI</e2>\NN\14207561 .\.\1740
D003042_D009336 NONE Troponin\NNP\1740 appears\VBZ\2604760 to\TO\1740 have\VB\2108377 an\DT\6697703 equivalent\JJ\1740 diagnostic\JJ\1740 accuracy\NN\4723816 compared\VBN\644583 with\IN\1740 CK-MB\NN\1740 for\IN\1740 diagnosing\VBG\644583 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 chest\JJ\1740 pain\NN\14299637 and\CC\1740 suspected\VBN\916909 MI\NN\14207561 .\.\1740
25080425
D001622_D009202 NONE Regulation\NN\6652242 of\IN\1740 signal\NN\33020 transducer\NN\3269401 and\CC\1740 activator\NN\19613 of\IN\1740 transcription\NN\6349220 3\CD\13741022 and\CC\1740 apoptotic\JJ\1740 pathways\NNS\5483677 by\IN\1740 <e1>betaine</e1>\NN\14712692 attenuates\NNS\1740 isoproterenol-induced\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001622_D009202 NONE The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 <e1>betaine</e1>\NN\14712692 on\IN\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 was\VBD\836236 further\RB\1740 confirmed\VBN\1011725 by\IN\1740 histopathological\JJ\1740 examination\NN\633864 .\.\1740
D007545_D009202 NONE Regulation\NN\6652242 of\IN\1740 signal\NN\33020 transducer\NN\3269401 and\CC\1740 activator\NN\19613 of\IN\1740 transcription\NN\6349220 3\CD\13741022 and\CC\1740 apoptotic\JJ\1740 pathways\NNS\5483677 by\IN\1740 betaine\NN\14712692 attenuates\NNS\1740 <e1>isoproterenol-induced</e1>\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001622_D017202 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 cardioprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>betaine</e1>\NN\14712692 on\IN\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 induced\VBN\1627355 experimentally\RB\1740 in\IN\13603305 rats\NNS\2329401 focusing\VBG\628491 on\IN\1740 regulation\NN\6652242 of\IN\1740 signal\NN\33020 transducer\NN\3269401 and\CC\1740 activator\NN\19613 of\IN\1740 transcription\NN\6349220 3\CD\13741022 (\-LRB-\1740 STAT3\NN\1740 )\-RRB-\1740 and\CC\1740 apoptotic\JJ\1740 pathways\NNS\5483677 as\IN\14622893 the\DT\1740 potential\JJ\1740 mechanism\NN\13446390 underlying\VBG\2604760 the\DT\1740 drug\NN\14778436 effect\NN\34213 .\.\1740
D001622_D017202 NONE In\IN\13603305 summary\NN\6722453 ,\,\1740 our\PRP$\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 <e1>betaine</e1>\NN\14712692 pretreatment\NN\1740 attenuated\VBD\224901 isoproterenol-induced\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 via\IN\1740 the\DT\1740 regulation\NN\6652242 of\IN\1740 STAT3\NN\1740 and\CC\1740 apoptotic\JJ\1740 pathways\NNS\5483677 .\.\1740
D007545_D017202 CID Acute\JJ\1740 <e2>myocardial\JJ\1740 ischemic\JJ\1740 injury</e2>\NN\14052046 was\VBD\836236 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>isoproterenol</e1>\NN\3740161 (\-LRB-\1740 85\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 for\IN\1740 two\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 .\.\1740
D007545_D017202 CID In\IN\13603305 summary\NN\6722453 ,\,\1740 our\PRP$\1740 results\NNS\34213 showed\VBD\2137132 that\IN\1740 betaine\NN\14712692 pretreatment\NN\1740 attenuated\VBD\224901 <e1>isoproterenol-induced</e1>\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 via\IN\1740 the\DT\1740 regulation\NN\6652242 of\IN\1740 STAT3\NN\1740 and\CC\1740 apoptotic\JJ\1740 pathways\NNS\5483677 .\.\1740
D001622_D020257 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>betaine</e1>\NN\14712692 (\-LRB-\1740 200\CD\1740 and\CC\1740 400\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 level\NN\4916342 of\IN\1740 cardiac\JJ\1740 marker\NN\21939 enzyme\NN\14723628 in\IN\13603305 the\DT\1740 serum\NN\5397468 and\CC\1740 prevented\VBD\1740 left\VBN\120316 <e2>ventricular\JJ\1740 remodeling</e2>\NN\1740 .\.\1740
15614572
D014196_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>trazodone</e1>\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014196_D002375 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 <e1>trazodone</e1>\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014196_D002375 NONE We\PRP\1740 also\RB\1740 investigated\VBD\644583 whether\IN\1740 <e1>trazodone</e1>\NN\3829085 induces\VBZ\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014196_D002375 NONE RESULTS\NNS\34213 :\:\1740 <e1>Trazodone</e1>\NN\3829085 at\IN\14622893 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 antagonize\VB\1787955 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 stereotypy\NN\1740 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg)-induced\JJ\1740 catalepsy\NN\14023236 .\.\1740
D014196_D002375 NONE RESULTS\NNS\34213 :\:\1740 <e1>Trazodone</e1>\NN\3829085 at\IN\14622893 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 catalepsy\NN\14023236 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 antagonize\VB\1787955 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 stereotypy\NN\1740 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg)-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D014196_D002375 NONE However\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 <e1>trazodone</e1>\NN\3829085 enhanced\VBD\227165 dexamphetamine\NN\1740 stereotypy\NN\1740 ,\,\1740 and\CC\1740 antagonized\VBD\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 ergometrine-induced\JJ\1740 WDS\NN\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 .\.\1740
D014196_D002375 NONE <e1>Trazodone</e1>\NN\3829085 at\IN\14622893 30\CD\13745420 ,\,\1740 40\CD\13745420 and\CC\1740 50\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 induced\VBN\1627355 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 antagonized\JJ\1740 apomorphine\NN\3786417 and\CC\1740 dexamphetamine\NN\1740 stereotypies\NNS\1740 .\.\1740
D014196_D002375 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 <e1>trazodone</e1>\NN\3829085 (\-LRB-\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 by\IN\1740 blocking\VBG\1476483 the\DT\1740 5-HT\NN\1740 2C\NN\1740 receptors\NNS\5225602 ,\,\1740 releases\VBZ\1435380 the\DT\1740 nigrostriatal\JJ\1740 DAergic\JJ\1740 neurons\NNS\5430628 from\IN\1740 tonic\JJ\1740 inhibition\NN\1068773 caused\VBN\1617192 by\IN\1740 5-HT\NN\1740 ,\,\1740 and\CC\1740 thereby\RB\1740 potentiates\VBZ\229605 dexamphetamine\NN\1740 stereotypy\NN\1740 and\CC\1740 antagonizes\VBZ\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D003913_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 <e1>dexamphetamine-</e1>\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003913_D002375 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 <e1>dexamphetamine-</e1>\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003913_D002375 NONE However\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 trazodone\NN\3829085 enhanced\VBD\227165 <e1>dexamphetamine</e1>\NN\1740 stereotypy\NN\1740 ,\,\1740 and\CC\1740 antagonized\VBD\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 ergometrine-induced\JJ\1740 WDS\NN\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 .\.\1740
D003913_D002375 NONE Trazodone\NN\3829085 at\IN\14622893 30\CD\13745420 ,\,\1740 40\CD\13745420 and\CC\1740 50\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 induced\VBN\1627355 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 antagonized\JJ\1740 apomorphine\NN\3786417 and\CC\1740 <e1>dexamphetamine</e1>\NN\1740 stereotypies\NNS\1740 .\.\1740
D003913_D002375 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 trazodone\NN\3829085 (\-LRB-\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 by\IN\1740 blocking\VBG\1476483 the\DT\1740 5-HT\NN\1740 2C\NN\1740 receptors\NNS\5225602 ,\,\1740 releases\VBZ\1435380 the\DT\1740 nigrostriatal\JJ\1740 DAergic\JJ\1740 neurons\NNS\5430628 from\IN\1740 tonic\JJ\1740 inhibition\NN\1068773 caused\VBN\1617192 by\IN\1740 5-HT\NN\1740 ,\,\1740 and\CC\1740 thereby\RB\1740 potentiates\VBZ\229605 <e1>dexamphetamine</e1>\NN\1740 stereotypy\NN\1740 and\CC\1740 antagonizes\VBZ\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D001058_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001058_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001058_D002375 CID METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 <e1>apomorphine-induced</e1>\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001058_D002375 CID METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001058_D002375 CID RESULTS\NNS\34213 :\:\1740 Trazodone\NN\3829085 at\IN\14622893 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 antagonize\VB\1787955 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 1.5\CD\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 stereotypy\NN\1740 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg)-induced\JJ\1740 catalepsy\NN\14023236 .\.\1740
D001058_D002375 CID RESULTS\NNS\34213 :\:\1740 Trazodone\NN\3829085 at\IN\14622893 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 catalepsy\NN\14023236 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 antagonize\VB\1787955 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 1.5\CD\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 stereotypy\NN\1740 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg)-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D001058_D002375 CID RESULTS\NNS\34213 :\:\1740 Trazodone\NN\3829085 at\IN\14622893 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 antagonize\VB\1787955 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 stereotypy\NN\1740 and\CC\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg)-induced\JJ\1740 catalepsy\NN\14023236 .\.\1740
D001058_D002375 CID RESULTS\NNS\34213 :\:\1740 Trazodone\NN\3829085 at\IN\14622893 2.5\CD\1740 -\SYM\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 catalepsy\NN\14023236 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 antagonize\VB\1787955 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 stereotypy\NN\1740 and\CC\1740 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg)-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D001058_D002375 CID Trazodone\NN\3829085 at\IN\14622893 30\CD\13745420 ,\,\1740 40\CD\13745420 and\CC\1740 50\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 induced\VBN\1627355 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 antagonized\JJ\1740 <e1>apomorphine</e1>\NN\3786417 and\CC\1740 dexamphetamine\NN\1740 stereotypies\NNS\1740 .\.\1740
D006220_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006220_D002375 CID METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006220_D002375 CID However\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 trazodone\NN\3829085 enhanced\VBD\227165 dexamphetamine\NN\1740 stereotypy\NN\1740 ,\,\1740 and\CC\1740 antagonized\VBD\1787955 <e1>haloperidol</e1>\NN\3713736 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 ergometrine-induced\JJ\1740 WDS\NN\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 .\.\1740
D006220_D002375 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 trazodone\NN\3829085 (\-LRB-\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 by\IN\1740 blocking\VBG\1476483 the\DT\1740 5-HT\NN\1740 2C\NN\1740 receptors\NNS\5225602 ,\,\1740 releases\VBZ\1435380 the\DT\1740 nigrostriatal\JJ\1740 DAergic\JJ\1740 neurons\NNS\5430628 from\IN\1740 tonic\JJ\1740 inhibition\NN\1068773 caused\VBN\1617192 by\IN\1740 5-HT\NN\1740 ,\,\1740 and\CC\1740 thereby\RB\1740 potentiates\VBZ\229605 dexamphetamine\NN\1740 stereotypy\NN\1740 and\CC\1740 antagonizes\VBZ\1787955 <e1>haloperidol</e1>\NN\3713736 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D004874_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 <e1>ergometrine-induced</e1>\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004874_D002375 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 <e1>ergometrine-induced</e1>\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004874_D002375 NONE However\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 trazodone\NN\3829085 enhanced\VBD\227165 dexamphetamine\NN\1740 stereotypy\NN\1740 ,\,\1740 and\CC\1740 antagonized\VBD\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 <e1>ergometrine-induced</e1>\JJ\1740 WDS\NN\1740 behavior\NN\407535 and\CC\1740 fluoxetine-induced\JJ\1740 penile\NN\1740 erections\NNS\14037619 .\.\1740
D005473_D009062 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 <e2>oral\JJ\1740 stereotypies</e2>\NNS\1740 ,\,\1740 on\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 <e1>fluoxetine-induced</e1>\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005473_D002375 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 effect\NN\34213 of\IN\1740 pretreatment\NN\1740 with\IN\1740 trazodone\NN\3829085 on\IN\1740 dexamphetamine-\NN\1740 and\CC\1740 apomorphine-induced\JJ\1740 oral\JJ\1740 stereotypies\NNS\1740 ,\,\1740 on\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 and\CC\1740 apomorphine\NN\3786417 (\-LRB-\1740 0.05\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 on\IN\1740 ergometrine-induced\JJ\1740 wet\JJ\1740 dog\NN\2083346 shake\NN\14786479 (\-LRB-\1740 WDS\NN\1740 )\-RRB-\1740 behavior\NN\407535 and\CC\1740 <e1>fluoxetine-induced</e1>\JJ\1740 penile\NN\1740 erections\NNS\14037619 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005473_D002375 NONE However\RB\1740 ,\,\1740 pretreatment\NN\1740 with\IN\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 trazodone\NN\3829085 enhanced\VBD\227165 dexamphetamine\NN\1740 stereotypy\NN\1740 ,\,\1740 and\CC\1740 antagonized\VBD\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 ergometrine-induced\JJ\1740 WDS\NN\1740 behavior\NN\407535 and\CC\1740 <e1>fluoxetine-induced</e1>\JJ\1740 penile\NN\1740 erections\NNS\14037619 .\.\1740
D012701_D002375 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 trazodone\NN\3829085 (\-LRB-\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 by\IN\1740 blocking\VBG\1476483 the\DT\1740 <e1>5-HT</e1>\NN\1740 2C\NN\1740 receptors\NNS\5225602 ,\,\1740 releases\VBZ\1435380 the\DT\1740 nigrostriatal\JJ\1740 DAergic\JJ\1740 neurons\NNS\5430628 from\IN\1740 tonic\JJ\1740 inhibition\NN\1068773 caused\VBN\1617192 by\IN\1740 5-HT\NN\1740 ,\,\1740 and\CC\1740 thereby\RB\1740 potentiates\VBZ\229605 dexamphetamine\NN\1740 stereotypy\NN\1740 and\CC\1740 antagonizes\VBZ\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D012701_D002375 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 trazodone\NN\3829085 (\-LRB-\1740 5\CD\13741022 ,\,\1740 10\CD\13745420 and\CC\1740 20\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 by\IN\1740 blocking\VBG\1476483 the\DT\1740 5-HT\NN\1740 2C\NN\1740 receptors\NNS\5225602 ,\,\1740 releases\VBZ\1435380 the\DT\1740 nigrostriatal\JJ\1740 DAergic\JJ\1740 neurons\NNS\5430628 from\IN\1740 tonic\JJ\1740 inhibition\NN\1068773 caused\VBN\1617192 by\IN\1740 <e1>5-HT</e1>\NN\1740 ,\,\1740 and\CC\1740 thereby\RB\1740 potentiates\VBZ\229605 dexamphetamine\NN\1740 stereotypy\NN\1740 and\CC\1740 antagonizes\VBZ\1787955 haloperidol\NN\3713736 <e2>catalepsy</e2>\NN\14023236 .\.\1740
11425091
D003042_D007235 CID Prenatal\JJ\1740 <e1>cocaine</e1>\NN\3492717 exposure\NN\5042871 and\CC\1740 cranial\JJ\1740 sonographic\JJ\1740 findings\NNS\7951464 in\IN\13603305 <e2>preterm\NN\1740 infants</e2>\NNS\9918248 .\.\1740
D003042_D007235 CID We\PRP\1740 sought\VBD\1825237 to\TO\1740 determine\VB\1645601 if\IN\1740 prenatal\JJ\1740 <e1>cocaine</e1>\NN\3492717 exposure\NN\5042871 increases\VBZ\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 subependymal\JJ\1740 cysts\NNS\14204950 in\IN\13603305 <e2>preterm\NN\1740 infants</e2>\NNS\9918248 .\.\1740
D003042_D007235 CID CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 subependymal\JJ\1740 cyst\NN\14204950 formation\NN\7938773 in\IN\13603305 <e2>preterm\NN\1740 infants</e2>\NNS\9918248 who\WP\8299493 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>cocaine</e1>\NN\3492717 prenatally\RB\1740 .\.\1740
D003042_D006470 NONE PURPOSE\NNP\5980875 :\:\1740 Prenatal\JJ\1740 <e1>cocaine</e1>\NN\3492717 exposure\NN\5042871 has\VBZ\2108377 been\VBN\836236 linked\VBN\628491 with\IN\1740 subependymal\JJ\1740 <e2>hemorrhage</e2>\NN\14285662 and\CC\1740 the\DT\1740 formation\NN\7938773 of\IN\1740 cysts\NNS\14204950 that\WDT\1740 are\VBP\836236 detectable\JJ\1740 on\IN\1740 cranial\JJ\1740 sonography\NN\901083 in\IN\13603305 neonates\NNS\9827683 born\VBN\2630189 at\IN\14622893 term\NN\6286395 .\.\1740
D003042_D003560 CID PURPOSE\NNP\5980875 :\:\1740 Prenatal\JJ\1740 <e1>cocaine</e1>\NN\3492717 exposure\NN\5042871 has\VBZ\2108377 been\VBN\836236 linked\VBN\628491 with\IN\1740 subependymal\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 the\DT\1740 formation\NN\7938773 of\IN\1740 <e2>cysts</e2>\NNS\14204950 that\WDT\1740 are\VBP\836236 detectable\JJ\1740 on\IN\1740 cranial\JJ\1740 sonography\NN\901083 in\IN\13603305 neonates\NNS\9827683 born\VBN\2630189 at\IN\14622893 term\NN\6286395 .\.\1740
D003042_D003560 CID We\PRP\1740 sought\VBD\1825237 to\TO\1740 determine\VB\1645601 if\IN\1740 prenatal\JJ\1740 <e1>cocaine</e1>\NN\3492717 exposure\NN\5042871 increases\VBZ\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>subependymal\JJ\1740 cysts</e2>\NNS\14204950 in\IN\13603305 preterm\NN\1740 infants\NNS\9918248 .\.\1740
D003042_D003560 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>subependymal\JJ\1740 cysts</e2>\NNS\14204950 in\IN\13603305 infants\NNS\9918248 exposed\VBN\2110927 to\TO\1740 <e1>cocaine</e1>\NN\3492717 prenatally\RB\1740 was\VBD\836236 44\CD\1740 %\NN\1740 (\-LRB-\1740 8\CD\13741022 of\IN\1740 18\CD\13745420 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 8\CD\13741022 %\NN\1740 (\-LRB-\1740 8\CD\13741022 of\IN\1740 99\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 unexposed\JJ\1740 group\NN\2137 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D003042_D003560 CID CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>subependymal\JJ\1740 cyst</e2>\NN\14204950 formation\NN\7938773 in\IN\13603305 preterm\NN\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>cocaine</e1>\NN\3492717 prenatally\RB\1740 .\.\1740
D003042_D001927 CID We\PRP\1740 sought\VBD\1825237 to\TO\1740 determine\VB\1645601 if\IN\1740 prenatal\JJ\1740 <e1>cocaine</e1>\NN\3492717 exposure\NN\5042871 increases\VBZ\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>subependymal\JJ\1740 cysts</e2>\NNS\14204950 in\IN\13603305 preterm\NN\1740 infants\NNS\9918248 .\.\1740
D003042_D001927 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>subependymal\JJ\1740 cysts</e2>\NNS\14204950 in\IN\13603305 infants\NNS\9918248 exposed\VBN\2110927 to\TO\1740 <e1>cocaine</e1>\NN\3492717 prenatally\RB\1740 was\VBD\836236 44\CD\1740 %\NN\1740 (\-LRB-\1740 8\CD\13741022 of\IN\1740 18\CD\13745420 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 8\CD\13741022 %\NN\1740 (\-LRB-\1740 8\CD\13741022 of\IN\1740 99\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 unexposed\JJ\1740 group\NN\2137 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D003042_D001927 CID CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>subependymal\JJ\1740 cyst</e2>\NN\14204950 formation\NN\7938773 in\IN\13603305 preterm\NN\1740 infants\NNS\9918248 who\WP\8299493 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>cocaine</e1>\NN\3492717 prenatally\RB\1740 .\.\1740
D003042_D019970 NONE Infants\NNS\9918248 were\VBD\836236 assigned\VBN\2475922 to\TO\1740 the\DT\1740 <e1>cocaine-exposed</e1>\JJ\1740 group\NN\2137 if\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 maternal\JJ\1740 history\NN\15120823 of\IN\1740 <e2>cocaine\NN\3492717 abuse</e2>\NN\418025 during\IN\1740 pregnancy\NN\14034177 or\CC\3541091 if\IN\1740 maternal\JJ\1740 or\CC\3541091 neonatal\JJ\1740 urine\NN\14853947 toxicology\NN\6054892 results\NNS\34213 were\VBD\836236 positive\JJ\1740 at\IN\14622893 the\DT\1740 time\NN\7308889 of\IN\1740 delivery\NN\315986 .\.\1740
17954033
D019259_D019694 NONE Rate\NN\13815152 of\IN\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 in\IN\13603305 <e1>lamivudine-untreated</e1>\JJ\1740 Iranian\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 infection</e2>\NN\14052046 .\.\1740
D019259_D019694 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Lamivudine</e1>\NNP\3834836 is\VBZ\836236 used\VBN\1156834 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 .\.\1740
D019259_D019694 NONE Recent\JJ\1740 studies\NNS\635850 show\VBP\2137132 that\IN\1740 the\DT\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 (\-LRB-\1740 resistant\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 )\-RRB-\1740 occur\VBP\2623529 as\IN\14622893 natural\JJ\1740 genome\NN\8456993 variability\NN\4733640 in\IN\13603305 <e1>lamivudine-untreated</e1>\JJ\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 .\.\1740
D019259_D019694 NONE In\IN\13603305 this\DT\1740 study\NN\635850 we\PRP\1740 aimed\VBD\1987160 to\TO\1740 determine\VB\1645601 the\DT\1740 rate\NN\13815152 of\IN\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 in\IN\13603305 <e1>lamivudine-untreated</e1>\JJ\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 in\IN\13603305 Iran\NNP\1740 .\.\1740
D019259_D019694 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 A\DT\13649268 total\NN\3553 of\IN\1740 77\CD\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 not\RB\1740 been\VBN\836236 treated\VBN\2376958 with\IN\1740 <e1>lamivudine</e1>\NN\3834836 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
D019259_D019694 NONE CONCLUSION\NN\5837957 :\:\1740 Although\IN\1740 the\DT\1740 natural\JJ\1740 occurrence\NN\29378 of\IN\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 in\IN\13603305 <e1>lamivudine-untreated</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 these\DT\1740 mutants\NNS\4475 were\VBD\836236 not\RB\1740 detected\VBN\2163746 in\IN\13603305 Iranian\JJ\1740 lamivudine-untreated\JJ\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 patients\NNS\9898892 .\.\1740
D019259_D019694 NONE CONCLUSION\NN\5837957 :\:\1740 Although\IN\1740 the\DT\1740 natural\JJ\1740 occurrence\NN\29378 of\IN\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 in\IN\13603305 <e1>lamivudine-untreated</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 these\DT\1740 mutants\NNS\4475 were\VBD\836236 not\RB\1740 detected\VBN\2163746 in\IN\13603305 Iranian\JJ\1740 lamivudine-untreated\JJ\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 .\.\1740
D019259_D019694 NONE CONCLUSION\NN\5837957 :\:\1740 Although\IN\1740 the\DT\1740 natural\JJ\1740 occurrence\NN\29378 of\IN\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 in\IN\13603305 lamivudine-untreated\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 these\DT\1740 mutants\NNS\4475 were\VBD\836236 not\RB\1740 detected\VBN\2163746 in\IN\13603305 Iranian\JJ\1740 <e1>lamivudine-untreated</e1>\JJ\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 patients\NNS\9898892 .\.\1740
D019259_D019694 NONE CONCLUSION\NN\5837957 :\:\1740 Although\IN\1740 the\DT\1740 natural\JJ\1740 occurrence\NN\29378 of\IN\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 in\IN\13603305 lamivudine-untreated\JJ\1740 patients\NNS\9898892 with\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 ,\,\1740 these\DT\1740 mutants\NNS\4475 were\VBD\836236 not\RB\1740 detected\VBN\2163746 in\IN\13603305 Iranian\JJ\1740 <e1>lamivudine-untreated</e1>\JJ\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE Recent\JJ\1740 studies\NNS\635850 show\VBP\2137132 that\IN\1740 the\DT\1740 YMDD\NN\1740 motif\NN\3178782 mutants\NNS\4475 (\-LRB-\1740 resistant\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 )\-RRB-\1740 occur\VBP\2623529 as\IN\14622893 natural\JJ\1740 genome\NN\8456993 variability\NN\4733640 in\IN\13603305 <e1>lamivudine-untreated</e1>\JJ\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 patients\NNS\9898892 .\.\1740
2484903
D011441_D056486 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>propylthiouracil-associated</e1>\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 methimazole-associated\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 lupus-like\JJ\1740 syndrome\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D011441_D056486 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 methimazole-associated\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e1>propylthiouracil-associated</e1>\JJ\1740 lupus-like\JJ\1740 syndrome\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D011441_D047508 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>propylthiouracil-associated</e1>\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 methimazole-associated\JJ\1740 <e2>hepatocellular\JJ\1740 necrosis</e2>\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 lupus-like\JJ\1740 syndrome\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D011441_D047508 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 methimazole-associated\JJ\1740 <e2>hepatocellular\JJ\1740 necrosis</e2>\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e1>propylthiouracil-associated</e1>\JJ\1740 lupus-like\JJ\1740 syndrome\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D011441_D008180 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>propylthiouracil-associated</e1>\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 methimazole-associated\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 <e2>lupus-like\JJ\1740 syndrome</e2>\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D011441_D008180 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 methimazole-associated\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e1>propylthiouracil-associated</e1>\JJ\1740 <e2>lupus-like\JJ\1740 syndrome</e2>\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D008713_D056486 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e1>methimazole-associated</e1>\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 lupus-like\JJ\1740 syndrome\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D008713_D047508 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e1>methimazole-associated</e1>\JJ\1740 <e2>hepatocellular\JJ\1740 necrosis</e2>\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 lupus-like\JJ\1740 syndrome\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
D008713_D008180 NONE Two\CD\13741022 cases\NNS\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 fatal\JJ\1740 <e1>methimazole-associated</e1>\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 and\CC\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 propylthiouracil-associated\JJ\1740 <e2>lupus-like\JJ\1740 syndrome</e2>\NN\5870365 are\VBP\836236 described\VBN\1001294 .\.\1740
17484470
D011433_D006333 CID Acute\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 volume\NN\33615 loading\NN\4571088 after\IN\1740 weaning\VBG\2313250 from\IN\1740 cardiopulmonary\JJ\1740 bypass\NN\3519981 ;\:\1740 an\DT\6697703 absence\NN\14449405 of\IN\1740 MR\NN\6339416 was\VBD\836236 confirmed\VBN\1011725 by\IN\1740 echocardiography\NN\177127 .\.\1740
D011433_D008944 NONE Acute\JJ\1740 heart\NN\5919034 failure\NN\66216 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 volume\NN\33615 loading\NN\4571088 after\IN\1740 weaning\VBG\2313250 from\IN\1740 cardiopulmonary\JJ\1740 bypass\NN\3519981 ;\:\1740 an\DT\6697703 absence\NN\14449405 of\IN\1740 <e2>MR</e2>\NN\6339416 was\VBD\836236 confirmed\VBN\1011725 by\IN\1740 echocardiography\NN\177127 .\.\1740
23535177
D007980_D010300 NONE The\DT\1740 plasticity\NN\5009170 of\IN\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 (\-LRB-\1740 M1\NN\13357178 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LIDs\NNS\5313679 )\-RRB-\1740 is\VBZ\836236 severely\RB\1740 impaired\JJ\1740 .\.\1740
D007980_D010300 NONE The\DT\1740 plasticity\NN\5009170 of\IN\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 (\-LRB-\1740 M1\NN\13357178 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LIDs\NNS\5313679 )\-RRB-\1740 is\VBZ\836236 severely\RB\1740 impaired\JJ\1740 .\.\1740
D007980_D004409 CID The\DT\1740 plasticity\NN\5009170 of\IN\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 (\-LRB-\1740 M1\NN\13357178 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 (\-LRB-\1740 LIDs\NNS\5313679 )\-RRB-\1740 is\VBZ\836236 severely\RB\1740 impaired\JJ\1740 .\.\1740
D007980_D004409 CID The\DT\1740 plasticity\NN\5009170 of\IN\1740 primary\JJ\1740 motor\NN\3699975 cortex\NN\5462674 (\-LRB-\1740 M1\NN\13357178 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 and\CC\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 <e2>LIDs</e2>\NNS\5313679 )\-RRB-\1740 is\VBZ\836236 severely\RB\1740 impaired\JJ\1740 .\.\1740
6585590
D004317_D066126 NONE Antitumor\NN\1740 effect\NN\34213 ,\,\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 nephrotoxicity\NN\1740 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 the\DT\1740 IgM\NN\15030481 solid\JJ\1740 immunocytoma-bearing\JJ\1740 LOU/M/WSL\NN\1740 rat\NN\2329401 .\.\1740
D004317_D066126 NONE Antitumor\NN\1740 activity\NN\30358 ,\,\1740 <e2>cardiotoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 nephrotoxicity\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 were\VBD\836236 studied\VBN\630380 in\IN\13603305 LOU/M/WSL\CD\1740 inbred\JJ\1740 rats\NNS\2329401 each\DT\1740 bearing\VBG\2630189 a\DT\13649268 transplantable\JJ\1740 solid\JJ\1740 IgM\NN\15030481 immunocytoma\NN\1740 .\.\1740
D004317_D066126 NONE Histologic\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>cardiotoxicity</e2>\NN\1740 scored\VBN\1111028 as\IN\14622893 grade\NN\7975026 III\CD\13741022 was\VBD\836236 only\RB\1740 observed\VBN\2163746 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1.0\CD\1740 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 .\.\1740
D004317_D007674 NONE Antitumor\NN\1740 effect\NN\34213 ,\,\1740 cardiotoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 the\DT\1740 IgM\NN\15030481 solid\JJ\1740 immunocytoma-bearing\JJ\1740 LOU/M/WSL\NN\1740 rat\NN\2329401 .\.\1740
D004317_D007674 NONE Antitumor\NN\1740 activity\NN\30358 ,\,\1740 cardiotoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>nephrotoxicity</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 were\VBD\836236 studied\VBN\630380 in\IN\13603305 LOU/M/WSL\CD\1740 inbred\JJ\1740 rats\NNS\2329401 each\DT\1740 bearing\VBG\2630189 a\DT\13649268 transplantable\JJ\1740 solid\JJ\1740 IgM\NN\15030481 immunocytoma\NN\1740 .\.\1740
D004317_D007674 NONE Light\JJ\1740 microscopic\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 was\VBD\836236 seen\VBN\2106506 above\IN\6392001 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.5\CD\1740 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 which\WDT\1740 resulted\VBD\2633881 in\IN\13603305 albuminuria\NN\14299637 and\CC\1740 very\RB\1740 low\JJ\1740 serum\NN\5397468 albumin\NN\14736972 levels\NNS\4916342 .\.\1740
D004317_-1 NONE Antitumor\NN\1740 effect\NN\34213 ,\,\1740 cardiotoxicity\NN\1740 ,\,\1740 and\CC\1740 nephrotoxicity\NN\1740 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 in\IN\13603305 the\DT\1740 IgM\NN\15030481 solid\JJ\1740 <e2>immunocytoma-bearing</e2>\JJ\1740 LOU/M/WSL\NN\1740 rat\NN\2329401 .\.\1740
D004317_-1 NONE Antitumor\NN\1740 activity\NN\30358 ,\,\1740 cardiotoxicity\NN\1740 ,\,\1740 and\CC\1740 nephrotoxicity\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 were\VBD\836236 studied\VBN\630380 in\IN\13603305 LOU/M/WSL\CD\1740 inbred\JJ\1740 rats\NNS\2329401 each\DT\1740 bearing\VBG\2630189 a\DT\13649268 transplantable\JJ\1740 solid\JJ\1740 IgM\NN\15030481 <e2>immunocytoma</e2>\NN\1740 .\.\1740
D004317_D009369 NONE Animals\NNS\4475 with\IN\1740 a\DT\13649268 <e2>tumor</e2>\NN\14234074 (\-LRB-\1740 diameter\NN\5129201 ,\,\1740 15.8\CD\1740 +/-\CC\1740 3.3\CD\1740 mm\NN\13649268 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 iv\NN\13741022 injections\NNS\320852 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 on\IN\1740 5\CD\13741022 consecutive\JJ\1740 days\NNS\15140892 ,\,\1740 followed\VBN\1835496 by\IN\1740 1\CD\13741022 weekly\JJ\1740 injection\NN\320852 for\IN\1740 7\CD\13741022 weeks\NNS\15113229 (\-LRB-\1740 dose\NN\3740161 range\NN\5123416 ,\,\1740 0.015\CD\1740 -\SYM\1740 4.0\CD\1740 mg/kg\NN\1740 body\NN\19128 wt\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D009369 NONE <e2>Tumor</e2>\NN\14234074 regression\NN\14501726 was\VBD\836236 observed\VBN\2163746 with\IN\1740 0.5\CD\1740 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 .\.\1740
D004317_D009369 NONE Complete\JJ\1740 disappearance\NN\42757 of\IN\1740 the\DT\1740 <e2>tumor</e2>\NN\14234074 was\VBD\836236 induced\VBN\1627355 with\IN\1740 1.0\CD\1740 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 .\.\1740
D004317_D000419 CID Light\JJ\1740 microscopic\JJ\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 damage\NN\7296428 was\VBD\836236 seen\VBN\2106506 above\IN\6392001 a\DT\13649268 dose\NN\3740161 of\IN\1740 0.5\CD\1740 mg\NN\13717155 <e1>doxorubicin/kg</e1>\NN\1740 ,\,\1740 which\WDT\1740 resulted\VBD\2633881 in\IN\13603305 <e2>albuminuria</e2>\NN\14299637 and\CC\1740 very\RB\1740 low\JJ\1740 serum\NN\5397468 albumin\NN\14736972 levels\NNS\4916342 .\.\1740
2650911
D004967_D002292 NONE Autoradiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 <e1>estrogen</e1>\NN\14745635 binding\NN\4688246 sites\NNS\8673395 in\IN\13603305 nuclei\NNS\5445668 of\IN\1740 diethylstilbesterol\NN\15058023 induced\VBD\1627355 hamster\NN\2329401 <e2>renal\JJ\1740 carcinomas</e2>\NNS\14239918 .\.\1740
D004967_D002292 NONE <e1>Estrogen</e1>\NN\14745635 binding\NN\4688246 sites\NNS\8673395 were\VBD\836236 demonstrated\VBN\2137132 by\IN\1740 autoradiography\NN\13545382 in\IN\13603305 one\CD\13741022 transplantable\NN\1740 and\CC\1740 five\CD\13741022 primary\JJ\1740 diethylstilbesterol\NN\15058023 induced\JJ\1740 <e2>renal\JJ\1740 carcinomas</e2>\NNS\14239918 in\IN\13603305 three\CD\13741022 hamsters\NNS\2329401 .\.\1740
D004967_D002292 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 published\VBN\1621555 report\NN\6470073 documenting\VBG\1000214 the\DT\1740 preferential\JJ\1740 in\FW\13603305 vivo\FW\1740 binding\NN\4688246 of\IN\1740 <e1>estrogen</e1>\NN\14745635 to\TO\1740 nuclei\NNS\5445668 of\IN\1740 cells\NNS\3080309 in\IN\13603305 estrogen\NN\14745635 induced\JJ\1740 hamster\NN\2329401 <e2>renal\JJ\1740 carcinomas</e2>\NNS\14239918 .\.\1740
D004967_D002292 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 published\VBN\1621555 report\NN\6470073 documenting\VBG\1000214 the\DT\1740 preferential\JJ\1740 in\FW\13603305 vivo\FW\1740 binding\NN\4688246 of\IN\1740 estrogen\NN\14745635 to\TO\1740 nuclei\NNS\5445668 of\IN\1740 cells\NNS\3080309 in\IN\13603305 <e1>estrogen</e1>\NN\14745635 induced\JJ\1740 hamster\NN\2329401 <e2>renal\JJ\1740 carcinomas</e2>\NNS\14239918 .\.\1740
D004054_D002292 CID Autoradiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 estrogen\NN\14745635 binding\NN\4688246 sites\NNS\8673395 in\IN\13603305 nuclei\NNS\5445668 of\IN\1740 <e1>diethylstilbesterol</e1>\NN\15058023 induced\VBD\1627355 hamster\NN\2329401 <e2>renal\JJ\1740 carcinomas</e2>\NNS\14239918 .\.\1740
D004054_D002292 CID Estrogen\NN\14745635 binding\NN\4688246 sites\NNS\8673395 were\VBD\836236 demonstrated\VBN\2137132 by\IN\1740 autoradiography\NN\13545382 in\IN\13603305 one\CD\13741022 transplantable\NN\1740 and\CC\1740 five\CD\13741022 primary\JJ\1740 <e1>diethylstilbesterol</e1>\NN\15058023 induced\JJ\1740 <e2>renal\JJ\1740 carcinomas</e2>\NNS\14239918 in\IN\13603305 three\CD\13741022 hamsters\NNS\2329401 .\.\1740
D004958_D009369 NONE Radiolabelling\NNP\1740 ,\,\1740 following\VBG\1835496 the\DT\1740 in\FW\13603305 vivo\FW\1740 injection\NN\320852 of\IN\1740 3H-17\CD\1740 beta\NN\6828818 <e1>estradiol</e1>\NN\14749794 ,\,\1740 was\VBD\836236 increased\VBN\169651 only\RB\1740 over\IN\5867413 the\DT\1740 nuclei\NNS\5445668 of\IN\1740 <e2>tumor</e2>\NN\14234074 cells\NNS\3080309 ;\:\1740 stereologic\JJ\1740 analysis\NN\633864 revealed\VBD\2137132 a\DT\13649268 4.5-\CD\1740 to\TO\1740 6.7-times\RB\1740 higher\JJR\1740 concentration\NN\4916342 of\IN\1740 reduced\VBN\441445 silver\JJ\1740 grains\NNS\14585519 over\IN\5867413 nuclei\NNS\5445668 than\IN\1740 cytoplasm\NN\5432736 of\IN\1740 these\DT\1740 cells\NNS\3080309 .\.\1740
D012834_D009369 NONE Radiolabelling\NNP\1740 ,\,\1740 following\VBG\1835496 the\DT\1740 in\FW\13603305 vivo\FW\1740 injection\NN\320852 of\IN\1740 3H-17\CD\1740 beta\NN\6828818 estradiol\NN\14749794 ,\,\1740 was\VBD\836236 increased\VBN\169651 only\RB\1740 over\IN\5867413 the\DT\1740 nuclei\NNS\5445668 of\IN\1740 <e2>tumor</e2>\NN\14234074 cells\NNS\3080309 ;\:\1740 stereologic\JJ\1740 analysis\NN\633864 revealed\VBD\2137132 a\DT\13649268 4.5-\CD\1740 to\TO\1740 6.7-times\RB\1740 higher\JJR\1740 concentration\NN\4916342 of\IN\1740 reduced\VBN\441445 <e1>silver</e1>\JJ\1740 grains\NNS\14585519 over\IN\5867413 nuclei\NNS\5445668 than\IN\1740 cytoplasm\NN\5432736 of\IN\1740 these\DT\1740 cells\NNS\3080309 .\.\1740
17297207
D011803_D001145 NONE <e1>Quinine-induced</e1>\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 malaria\NN\14178913 .\.\1740
D011803_D001145 NONE It\PRP\6125041 was\VBD\836236 reported\VBN\831651 that\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 malaria\NN\14178913 patient\NN\9898892 with\IN\1740 jaundice\NN\14299637 who\WP\8299493 presented\VBD\2137132 with\IN\1740 <e2>arrhythmia</e2>\NN\14103288 (\-LRB-\1740 premature\JJ\1740 ventricular\JJ\1740 contraction\NN\358931 )\-RRB-\1740 while\IN\15122231 getting\VBG\146138 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 was\VBD\836236 reported\VBN\831651 .\.\1740
D011803_D001145 NONE <e1>Quinine</e1>\NNP\2721948 ,\,\1740 like\UH\5839024 quinidine\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 <e2>anti-arrhythmic</e2>\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011803_D001145 NONE <e1>Quinine</e1>\NNP\2721948 ,\,\1740 like\UH\5839024 quinidine\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 <e2>pro-arrhythmic</e2>\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011803_D001145 NONE <e1>Quinine</e1>\NNP\2721948 ,\,\1740 like\UH\5839024 quinidine\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011803_D001145 NONE <e1>Quinine</e1>\NNP\2721948 ,\,\1740 like\UH\5839024 quinidine\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011803_D001145 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 <e2>pro-arrhythmic</e2>\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 heart\NN\5919034 diseases\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 electrolyte\NN\14589223 disorder\NN\14034177 (\-LRB-\1740 hypokalemia\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 vomiting\NN\116687 and\CC\1740 or\CC\3541091 diarrhea\NN\14299637 in\IN\13603305 malaria\NN\14178913 cases\NNS\7283608 .\.\1740
D011803_D016778 NONE <e1>Quinine-induced</e1>\JJ\1740 arrhythmia\NN\14103288 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 .\.\1740
D011803_D016778 NONE It\PRP\6125041 was\VBD\836236 reported\VBN\831651 that\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 patient\NN\9898892 with\IN\1740 jaundice\NN\14299637 who\WP\8299493 presented\VBD\2137132 with\IN\1740 arrhythmia\NN\14103288 (\-LRB-\1740 premature\JJ\1740 ventricular\JJ\1740 contraction\NN\358931 )\-RRB-\1740 while\IN\15122231 getting\VBG\146138 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 was\VBD\836236 reported\VBN\831651 .\.\1740
D011803_D016778 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 with\IN\1740 jaundice\NN\14299637 and\CC\1740 got\VBD\146138 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D011803_D007565 NONE It\PRP\6125041 was\VBD\836236 reported\VBN\831651 that\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 malaria\NN\14178913 patient\NN\9898892 with\IN\1740 <e2>jaundice</e2>\NN\14299637 who\WP\8299493 presented\VBD\2137132 with\IN\1740 arrhythmia\NN\14103288 (\-LRB-\1740 premature\JJ\1740 ventricular\JJ\1740 contraction\NN\358931 )\-RRB-\1740 while\IN\15122231 getting\VBG\146138 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 was\VBD\836236 reported\VBN\831651 .\.\1740
D011803_D007565 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 severe\JJ\1740 malaria\NN\14178913 with\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 got\VBD\146138 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D011803_D018879 CID It\PRP\6125041 was\VBD\836236 reported\VBN\831651 that\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 malaria\NN\14178913 patient\NN\9898892 with\IN\1740 jaundice\NN\14299637 who\WP\8299493 presented\VBD\2137132 with\IN\1740 arrhythmia\NN\14103288 (\-LRB-\1740 <e2>premature\JJ\1740 ventricular\JJ\1740 contraction</e2>\NN\358931 )\-RRB-\1740 while\IN\15122231 getting\VBG\146138 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 was\VBD\836236 reported\VBN\831651 .\.\1740
D011803_D018879 CID After\IN\1740 30\CD\13745420 hours\NNS\15118228 of\IN\1740 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 the\DT\1740 patient\NN\9898892 felt\VBD\1462928 palpitation\NN\14299637 and\CC\1740 electrocardiography\NN\177127 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 recording\NN\6791372 showed\VBD\2137132 <e2>premature\JJ\1740 ventricular\JJ\1740 contraction</e2>\NN\358931 (\-LRB-\1740 PVC\NN\15088440 )\-RRB-\1740 >\NN\1740 5\CD\13741022 x/minute\NN\1740 ,\,\1740 trigemini\NN\1740 ,\,\1740 constant\JJ\1740 type\NN\5839024 --\:\1740 sinoatrial\JJ\1740 block\NN\21939 ,\,\1740 positive\JJ\1740 U\NN\14964590 wave\NN\7309781 .\.\1740
D011803_D018879 CID After\IN\1740 30\CD\13745420 hours\NNS\15118228 of\IN\1740 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 the\DT\1740 patient\NN\9898892 felt\VBD\1462928 palpitation\NN\14299637 and\CC\1740 electrocardiography\NN\177127 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 recording\NN\6791372 showed\VBD\2137132 premature\JJ\1740 ventricular\JJ\1740 contraction\NN\358931 (\-LRB-\1740 <e2>PVC</e2>\NN\15088440 )\-RRB-\1740 >\NN\1740 5\CD\13741022 x/minute\NN\1740 ,\,\1740 trigemini\NN\1740 ,\,\1740 constant\JJ\1740 type\NN\5839024 --\:\1740 sinoatrial\JJ\1740 block\NN\21939 ,\,\1740 positive\JJ\1740 U\NN\14964590 wave\NN\7309781 .\.\1740
D011803_D018879 CID <e1>Quinine</e1>\NNP\2721948 ,\,\1740 like\UH\5839024 quinidine\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 <e2>PVC</e2>\NN\15088440 .\.\1740
D001663_D016778 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 <e1>bilirubin</e1>\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 with\IN\1740 jaundice\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D001663_D016778 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 <e1>bilirubin</e1>\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 with\IN\1740 jaundice\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D001663_D016778 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 <e1>bilirubin</e1>\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 with\IN\1740 jaundice\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D001663_D007565 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 <e1>bilirubin</e1>\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 severe\JJ\1740 malaria\NN\14178913 with\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D001663_D007565 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 <e1>bilirubin</e1>\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 severe\JJ\1740 malaria\NN\14178913 with\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D001663_D007565 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 <e1>bilirubin</e1>\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 severe\JJ\1740 malaria\NN\14178913 with\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D011188_D016778 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 <e1>potassium</e1>\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 with\IN\1740 jaundice\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D011188_D007565 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 <e1>potassium</e1>\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 severe\JJ\1740 malaria\NN\14178913 with\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 dextrose\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D005947_D016778 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>severe\JJ\1740 malaria</e2>\NN\14178913 with\IN\1740 jaundice\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 <e1>dextrose</e1>\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D005947_D007565 NONE On\IN\1740 admission\NN\49003 ,\,\1740 laboratory\NN\4602044 examination\NN\633864 showed\VBD\2137132 Plasmodium\NN\5432948 falciparum\NN\1740 (\-LRB-\1740 +\CC\1740 +\CC\1740 +\CC\1740 +\CC\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 bilirubin\NN\14756039 8.25\CD\1740 mg/dL\NN\1740 ,\,\1740 conjugated\VBN\394813 bilirubin\NN\14756039 4.36\CD\1740 mg/dL\NN\1740 ,\,\1740 unconjugated\JJ\1740 bilirubin\NN\14756039 3.89\CD\1740 mg/dL\VBN\1740 ,\,\1740 potassium\NN\14625458 3.52\CD\1740 meq/L\NN\1740 Patient\NN\9898892 was\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 severe\JJ\1740 malaria\NN\14178913 with\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 got\VBD\146138 quinine\NN\2721948 infusion\NN\14589223 in\IN\13603305 <e1>dextrose</e1>\NN\14884120 5\CD\13741022 %\NN\1740 500\CD\13745420 mg/8\NN\1740 hour\NN\15154774 .\.\1740
D011803_-1 NONE After\IN\1740 30\CD\13745420 hours\NNS\15118228 of\IN\1740 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 the\DT\1740 patient\NN\9898892 felt\VBD\1462928 <e2>palpitation</e2>\NN\14299637 and\CC\1740 electrocardiography\NN\177127 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 recording\NN\6791372 showed\VBD\2137132 premature\JJ\1740 ventricular\JJ\1740 contraction\NN\358931 (\-LRB-\1740 PVC\NN\15088440 )\-RRB-\1740 >\NN\1740 5\CD\13741022 x/minute\NN\1740 ,\,\1740 trigemini\NN\1740 ,\,\1740 constant\JJ\1740 type\NN\5839024 --\:\1740 sinoatrial\JJ\1740 block\NN\21939 ,\,\1740 positive\JJ\1740 U\NN\14964590 wave\NN\7309781 .\.\1740
D011803_D012848 NONE After\IN\1740 30\CD\13745420 hours\NNS\15118228 of\IN\1740 <e1>quinine</e1>\NN\2721948 infusion\NN\14589223 the\DT\1740 patient\NN\9898892 felt\VBD\1462928 palpitation\NN\14299637 and\CC\1740 electrocardiography\NN\177127 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 recording\NN\6791372 showed\VBD\2137132 premature\JJ\1740 ventricular\JJ\1740 contraction\NN\358931 (\-LRB-\1740 PVC\NN\15088440 )\-RRB-\1740 >\NN\1740 5\CD\13741022 x/minute\NN\1740 ,\,\1740 trigemini\NN\1740 ,\,\1740 constant\JJ\1740 type\NN\5839024 --\:\1740 <e2>sinoatrial\JJ\1740 block</e2>\NN\21939 ,\,\1740 positive\JJ\1740 U\NN\14964590 wave\NN\7309781 .\.\1740
D011188_D018879 NONE Three\CD\13741022 hours\NNS\15118228 later\RB\1740 the\DT\1740 patient\NN\9898892 felt\VBD\1462928 better\RBR\1740 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>PVC</e2>\NN\15088440 reduced\VBD\441445 to\TO\1740 4\CD\13741022 -\SYM\1740 5\CD\13741022 x/minute\NN\1740 and\CC\1740 on\IN\1740 the\DT\1740 third\JJ\1740 day\NN\15154774 ECG\NNP\7000195 was\VBD\836236 normal\JJ\1740 ,\,\1740 <e1>potassium</e1>\NN\14625458 level\NN\4916342 was\VBD\836236 3.34\CD\1740 meq/L.\NNS\1740 He\PRP\14622893 was\VBD\836236 discharged\VBN\1640855 on\IN\1740 7th\JJ\1740 day\NN\15154774 in\IN\13603305 good\JJ\1740 condition\NN\24720 .\.\1740
D011802_D001145 NONE Quinine\NNP\2721948 ,\,\1740 like\UH\5839024 <e1>quinidine</e1>\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 <e2>anti-arrhythmic</e2>\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011802_D001145 NONE Quinine\NNP\2721948 ,\,\1740 like\UH\5839024 <e1>quinidine</e1>\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 <e2>pro-arrhythmic</e2>\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011802_D001145 NONE Quinine\NNP\2721948 ,\,\1740 like\UH\5839024 <e1>quinidine</e1>\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 <e2>arrhythmias</e2>\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011802_D001145 NONE Quinine\NNP\2721948 ,\,\1740 like\UH\5839024 <e1>quinidine</e1>\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 <e2>arrhythmia</e2>\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 PVC\NN\15088440 .\.\1740
D011802_D018879 NONE Quinine\NNP\2721948 ,\,\1740 like\UH\5839024 <e1>quinidine</e1>\NN\2715941 ,\,\1740 is\VBZ\836236 a\DT\13649268 chincona\NN\1740 alkaloid\NN\14727670 that\WDT\1740 has\VBZ\2108377 anti-arrhythmic\JJ\1740 property\NN\32613 ,\,\1740 although\IN\1740 it\PRP\6125041 also\RB\1740 pro-arrhythmic\JJ\1740 that\WDT\1740 can\MD\3094503 cause\VB\1617192 various\JJ\1740 arrhythmias\NNS\14103288 ,\,\1740 including\VBG\690614 severe\JJ\1740 arrhythmia\NN\14103288 such\JJ\1740 as\IN\14622893 multiple\JJ\1740 <e2>PVC</e2>\NN\15088440 .\.\1740
D011803_D006331 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 pro-arrhythmic\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 <e2>heart\NN\5919034 diseases</e2>\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 electrolyte\NN\14589223 disorder\NN\14034177 (\-LRB-\1740 hypokalemia\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 vomiting\NN\116687 and\CC\1740 or\CC\3541091 diarrhea\NN\14299637 in\IN\13603305 malaria\NN\14178913 cases\NNS\7283608 .\.\1740
D011803_D014883 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 pro-arrhythmic\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 heart\NN\5919034 diseases\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 <e2>electrolyte\NN\14589223 disorder</e2>\NN\14034177 (\-LRB-\1740 hypokalemia\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 vomiting\NN\116687 and\CC\1740 or\CC\3541091 diarrhea\NN\14299637 in\IN\13603305 malaria\NN\14178913 cases\NNS\7283608 .\.\1740
D011803_D007008 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 pro-arrhythmic\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 heart\NN\5919034 diseases\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 electrolyte\NN\14589223 disorder\NN\14034177 (\-LRB-\1740 <e2>hypokalemia</e2>\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 vomiting\NN\116687 and\CC\1740 or\CC\3541091 diarrhea\NN\14299637 in\IN\13603305 malaria\NN\14178913 cases\NNS\7283608 .\.\1740
D011803_D014839 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 pro-arrhythmic\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 heart\NN\5919034 diseases\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 electrolyte\NN\14589223 disorder\NN\14034177 (\-LRB-\1740 hypokalemia\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 <e2>vomiting</e2>\NN\116687 and\CC\1740 or\CC\3541091 diarrhea\NN\14299637 in\IN\13603305 malaria\NN\14178913 cases\NNS\7283608 .\.\1740
D011803_D003967 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 pro-arrhythmic\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 heart\NN\5919034 diseases\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 electrolyte\NN\14589223 disorder\NN\14034177 (\-LRB-\1740 hypokalemia\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 vomiting\NN\116687 and\CC\1740 or\CC\3541091 <e2>diarrhea</e2>\NN\14299637 in\IN\13603305 malaria\NN\14178913 cases\NNS\7283608 .\.\1740
D011803_D008288 NONE Administration\NN\1133281 of\IN\1740 parenteral\JJ\1740 <e1>quinine</e1>\NN\2721948 must\MD\9367203 be\VB\836236 done\VBN\1640855 carefully\RB\1740 and\CC\1740 with\IN\1740 good\JJ\1740 observation\NN\996969 because\IN\1740 of\IN\1740 its\PRP$\6125041 pro-arrhythmic\JJ\1740 effect\NN\34213 ,\,\1740 especially\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 heart\NN\5919034 diseases\NNS\14061805 or\CC\3541091 patients\NNS\9898892 with\IN\1740 electrolyte\NN\14589223 disorder\NN\14034177 (\-LRB-\1740 hypokalemia\NN\14299637 )\-RRB-\1740 which\WDT\1740 frequently\RB\1740 occurs\VBZ\2623529 due\JJ\1740 to\TO\1740 vomiting\NN\116687 and\CC\1740 or\CC\3541091 diarrhea\NN\14299637 in\IN\13603305 <e2>malaria</e2>\NN\14178913 cases\NNS\7283608 .\.\1740
3084231
D014635_D003704 CID Reversible\JJ\1740 <e1>valproic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>dementia</e2>\NN\14395018 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D014635_D003704 CID Reversible\JJ\1740 <e1>valproic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>dementia</e2>\NN\14395018 was\VBD\836236 documented\VBN\1000214 in\IN\13603305 a\DT\13649268 21-year-old\JJ\1740 man\NN\9605289 with\IN\1740 epilepsy\NN\14085708 who\WP\8299493 had\VBD\2108377 a\DT\13649268 3-year\JJ\1740 history\NN\15120823 of\IN\1740 insidious\JJ\1740 progressive\JJ\1740 decline\NN\13458571 in\IN\13603305 global\JJ\1740 cognitive\JJ\1740 abilities\NNS\4723816 documented\VBN\1000214 by\IN\1740 serial\JJ\1740 neuropsychological\JJ\1740 studies\NNS\635850 .\.\1740
D014635_D004827 NONE Reversible\JJ\1740 <e1>valproic\JJ\1740 acid-induced</e1>\JJ\1740 dementia\NN\14395018 was\VBD\836236 documented\VBN\1000214 in\IN\13603305 a\DT\13649268 21-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>epilepsy</e2>\NN\14085708 who\WP\8299493 had\VBD\2108377 a\DT\13649268 3-year\JJ\1740 history\NN\15120823 of\IN\1740 insidious\JJ\1740 progressive\JJ\1740 decline\NN\13458571 in\IN\13603305 global\JJ\1740 cognitive\JJ\1740 abilities\NNS\4723816 documented\VBN\1000214 by\IN\1740 serial\JJ\1740 neuropsychological\JJ\1740 studies\NNS\635850 .\.\1740
D014635_D022124 CID Possible\JJ\1740 pathophysiological\JJ\1740 mechanisms\NNS\13446390 which\WDT\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 operative\JJ\1740 in\IN\13603305 this\DT\1740 case\NN\7283608 include\VBP\690614 :\:\1740 a\DT\13649268 direct\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 toxic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 ;\:\1740 a\DT\13649268 paradoxical\JJ\1740 epileptogenic\JJ\1740 effect\NN\34213 secondary\JJ\1740 to\TO\1740 the\DT\1740 drug\NN\14778436 ;\:\1740 and\CC\1740 an\DT\6697703 indirect\JJ\1740 CNS\NN\5237227 toxic\JJ\1740 effect\NN\34213 mediated\VBN\761713 through\IN\1740 valproic\JJ\1740 acid-induced\JJ\1740 <e2>hyperammonemia</e2>\NN\1740 .\.\1740
D014635_D022124 CID Possible\JJ\1740 pathophysiological\JJ\1740 mechanisms\NNS\13446390 which\WDT\1740 may\MD\15209706 have\VB\2108377 been\VBN\836236 operative\JJ\1740 in\IN\13603305 this\DT\1740 case\NN\7283608 include\VBP\690614 :\:\1740 a\DT\13649268 direct\JJ\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 toxic\JJ\1740 effect\NN\34213 of\IN\1740 valproic\JJ\1740 acid\NN\14818238 ;\:\1740 a\DT\13649268 paradoxical\JJ\1740 epileptogenic\JJ\1740 effect\NN\34213 secondary\JJ\1740 to\TO\1740 the\DT\1740 drug\NN\14778436 ;\:\1740 and\CC\1740 an\DT\6697703 indirect\JJ\1740 CNS\NN\5237227 toxic\JJ\1740 effect\NN\34213 mediated\VBN\761713 through\IN\1740 <e1>valproic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>hyperammonemia</e2>\NN\1740 .\.\1740
2083961
D012293_D058186 CID <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 due\JJ\1740 to\TO\1740 <e1>rifampicin</e1>\NN\1740 .\.\1740
D012293_D009325 NONE <e1>Rifampicin</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 thrice\NN\1740 as\IN\14622893 one\CD\13741022 of\IN\1740 the\DT\1740 3\CD\13741022 -\SYM\1740 4\CD\13741022 drug\NN\14778436 regimen\NN\5898568 and\CC\1740 each\DT\1740 time\NN\7308889 he\PRP\14622893 developed\VBD\1753788 untoward\JJ\1740 side\NN\8630039 effects\NNS\13245626 like\IN\5839024 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 and\CC\1740 fever\NN\14299637 with\IN\1740 chills\NNS\5015117 and\CC\1740 rigors\NNS\4709253 .\.\1740
D012293_D014839 NONE <e1>Rifampicin</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 thrice\NN\1740 as\IN\14622893 one\CD\13741022 of\IN\1740 the\DT\1740 3\CD\13741022 -\SYM\1740 4\CD\13741022 drug\NN\14778436 regimen\NN\5898568 and\CC\1740 each\DT\1740 time\NN\7308889 he\PRP\14622893 developed\VBD\1753788 untoward\JJ\1740 side\NN\8630039 effects\NNS\13245626 like\IN\5839024 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 and\CC\1740 fever\NN\14299637 with\IN\1740 chills\NNS\5015117 and\CC\1740 rigors\NNS\4709253 .\.\1740
D012293_D005334 NONE <e1>Rifampicin</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 thrice\NN\1740 as\IN\14622893 one\CD\13741022 of\IN\1740 the\DT\1740 3\CD\13741022 -\SYM\1740 4\CD\13741022 drug\NN\14778436 regimen\NN\5898568 and\CC\1740 each\DT\1740 time\NN\7308889 he\PRP\14622893 developed\VBD\1753788 untoward\JJ\1740 side\NN\8630039 effects\NNS\13245626 like\IN\5839024 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 and\CC\1740 <e2>fever</e2>\NN\14299637 with\IN\1740 chills\NNS\5015117 and\CC\1740 rigors\NNS\4709253 .\.\1740
23949582
D015080_D030342 NONE <e1>Mesna</e1>\NN\1740 significantly\RB\1740 reduces\VBZ\441445 IFO\NN\1740 's\POS\1740 <e2>genotoxicity</e2>\NN\1740 ,\,\1740 while\IN\15122231 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 high\JJ\1740 concentrations\NNS\4916342 it\PRP\6125041 acts\VBZ\1619354 in\IN\13603305 an\DT\6697703 inhibitory\JJ\1740 fashion\NN\4916342 on\IN\1740 the\DT\1740 cytostatic\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D007069_D030342 NONE Mesna\NN\1740 significantly\RB\1740 reduces\VBZ\441445 <e1>IFO</e1>\NN\1740 's\POS\1740 <e2>genotoxicity</e2>\NN\1740 ,\,\1740 while\IN\15122231 when\WRB\1740 administered\VBN\2436349 in\IN\13603305 high\JJ\1740 concentrations\NNS\4916342 it\PRP\6125041 acts\VBZ\1619354 in\IN\13603305 an\DT\6697703 inhibitory\JJ\1740 fashion\NN\4916342 on\IN\1740 the\DT\1740 cytostatic\JJ\1740 action\NN\30358 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
19154241
D008094_D006961 CID Long-term\JJ\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 leading\VBG\1752884 to\TO\1740 <e2>hyperparathyroidism</e2>\NN\14059928 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D008094_D006934 CID We\PRP\1740 examined\VBD\789138 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 <e1>lithium-treated</e1>\JJ\1740 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 recurrent\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 to\TO\1740 better\RBR\1740 understand\VB\588888 the\DT\1740 disease\NN\14061805 process\NN\407535 .\.\1740
D008094_D006934 CID PRACTICAL\NN\1740 IMPLICATIONS\NN\5774614 :\:\1740 As\RB\1740 much\JJ\1740 as\IN\14622893 15\CD\13745420 %\NN\1740 of\IN\1740 <e1>lithium-treated</e1>\JJ\1740 patients\NNS\9898892 become\VBP\146138 <e2>hypercalcemic</e2>\JJ\1740 .\.\1740
D008094_D049950 NONE CONCLUSION\NN\5837957 :\:\1740 <e2>Primary\JJ\1740 hyperparathyroidism</e2>\NN\14059928 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 potentially\RB\1740 life-threatening\JJ\1740 side\JJ\1740 effect\NN\34213 of\IN\1740 long-term\JJ\1740 <e1>lithium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
8318674
D003561_D011654 CID <e2>Pulmonary\JJ\1740 edema</e2>\NN\14315192 and\CC\1740 shock\NN\7510495 after\IN\1740 high-dose\JJ\1740 <e1>aracytine-C</e1>\NN\1740 for\IN\1740 lymphoma\NN\14239918 ;\:\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 TNF-alpha\NN\1740 and\CC\1740 PAF\NN\1740 .\.\1740
D003561_D012769 CID Pulmonary\JJ\1740 edema\NN\14315192 and\CC\1740 <e2>shock</e2>\NN\7510495 after\IN\1740 high-dose\JJ\1740 <e1>aracytine-C</e1>\NN\1740 for\IN\1740 lymphoma\NN\14239918 ;\:\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 TNF-alpha\NN\1740 and\CC\1740 PAF\NN\1740 .\.\1740
D003561_D012769 CID As\IN\14622893 TNF\NN\14828193 and\CC\1740 PAF\NN\1740 are\VBP\836236 thought\VBN\670261 to\TO\1740 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 septic\JJ\1740 <e2>shock</e2>\NN\7510495 and\CC\1740 adult\JJ\1740 respiratory\JJ\1740 distress\NN\7494363 syndrome\NN\5870365 ,\,\1740 we\PRP\1740 hypothesize\VBP\719734 that\IN\1740 high-dose\JJ\1740 <e1>Ara-C</e1>\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 cytokine\NN\14728724 release\NN\3748886 .\.\1740
D003561_D008223 NONE Pulmonary\JJ\1740 edema\NN\14315192 and\CC\1740 shock\NN\7510495 after\IN\1740 high-dose\JJ\1740 <e1>aracytine-C</e1>\NN\1740 for\IN\1740 <e2>lymphoma</e2>\NN\14239918 ;\:\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 TNF-alpha\NN\1740 and\CC\1740 PAF\NN\1740 .\.\1740
D003561_D008223 NONE Four\CD\13741022 out\IN\66636 of\IN\1740 23\CD\13745420 consecutive\JJ\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 high-dose\JJ\1740 <e1>Ara-C</e1>\NN\1740 for\IN\1740 <e2>lymphomas</e2>\NNS\14239918 in\IN\13603305 our\PRP$\1740 institution\NN\8008335 developed\VBD\1753788 a\DT\13649268 strikingly\RB\1740 similar\JJ\1740 syndrome\NN\5870365 during\IN\1740 the\DT\1740 perfusion\NN\320852 .\.\1740
D003561_D012128 NONE As\IN\14622893 TNF\NN\14828193 and\CC\1740 PAF\NN\1740 are\VBP\836236 thought\VBN\670261 to\TO\1740 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 septic\JJ\1740 shock\NN\7510495 and\CC\1740 <e2>adult\JJ\1740 respiratory\JJ\1740 distress\NN\7494363 syndrome</e2>\NN\5870365 ,\,\1740 we\PRP\1740 hypothesize\VBP\719734 that\IN\1740 high-dose\JJ\1740 <e1>Ara-C</e1>\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 cytokine\NN\14728724 release\NN\3748886 .\.\1740
19338378
C031942_D013921 NONE Reducing\VBG\441445 harm\NN\14052046 associated\VBN\628491 with\IN\1740 anticoagulation\NN\657604 :\:\1740 practical\JJ\1740 considerations\NNS\5770926 of\IN\1740 <e1>argatroban</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
C031942_D013921 NONE <e1>Argatroban</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 HIT\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE <e1>Argatroban</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 HIT\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE <e1>Argatroban</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 <e2>HIT</e2>\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 review\NN\5733583 is\VBZ\836236 to\TO\1740 summarize\VB\958334 practical\JJ\1740 considerations\NNS\5770926 of\IN\1740 <e1>argatroban</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 <e2>HIT</e2>\NN\36762 .\.\1740
C031942_D013921 NONE The\DT\1740 US\NNP\14964590 FDA-recommended\JJ\1740 <e1>argatroban</e1>\NN\1740 dose\NN\3740161 in\IN\13603305 <e2>HIT</e2>\NN\36762 is\VBZ\836236 2\CD\13741022 microg/kg/min\NN\1740 (\-LRB-\1740 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 hepatic\JJ\1740 impairment\NN\7296428 and\CC\1740 in\IN\13603305 paediatric\JJ\1740 patients\NNS\9898892 )\-RRB-\1740 ,\,\1740 adjusted\VBN\126264 to\TO\1740 achieve\VB\2524171 activated\VBN\1641914 partial\JJ\1740 thromboplastin\NN\15022776 times\NNS\15113229 (\-LRB-\1740 aPTTs\NNS\1740 )\-RRB-\1740 1.5\CD\1740 -\SYM\1740 3\CD\13741022 times\NNS\15113229 baseline\NN\7260623 (\-LRB-\1740 not\RB\1740 >\NNS\1740 100\CD\13745420 seconds\NNS\15154774 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE Improved\VBN\126264 familiarity\NN\5816287 of\IN\1740 healthcare\NN\654885 professionals\NNS\9605289 with\IN\1740 <e1>argatroban</e1>\JJ\1740 therapy\NN\657604 in\IN\13603305 <e2>HIT</e2>\NN\36762 ,\,\1740 including\VBG\690614 in\IN\13603305 special\JJ\1740 populations\NNS\7942152 and\CC\1740 during\IN\1740 PCI\NN\1740 ,\,\1740 may\MD\15209706 facilitate\VB\2547586 reduction\NN\351485 of\IN\1740 harm\NN\14052046 associated\VBN\628491 with\IN\1740 HIT\NN\36762 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 thromboses\NNS\1740 )\-RRB-\1740 or\CC\3541091 its\PRP$\6125041 treatment\NN\654885 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 argatroban\JJ\1740 medication\NN\3247620 errors\NNS\66216 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE Improved\VBN\126264 familiarity\NN\5816287 of\IN\1740 healthcare\NN\654885 professionals\NNS\9605289 with\IN\1740 <e1>argatroban</e1>\JJ\1740 therapy\NN\657604 in\IN\13603305 HIT\NN\36762 ,\,\1740 including\VBG\690614 in\IN\13603305 special\JJ\1740 populations\NNS\7942152 and\CC\1740 during\IN\1740 PCI\NN\1740 ,\,\1740 may\MD\15209706 facilitate\VB\2547586 reduction\NN\351485 of\IN\1740 harm\NN\14052046 associated\VBN\628491 with\IN\1740 <e2>HIT</e2>\NN\36762 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 thromboses\NNS\1740 )\-RRB-\1740 or\CC\3541091 its\PRP$\6125041 treatment\NN\654885 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 argatroban\JJ\1740 medication\NN\3247620 errors\NNS\66216 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE Improved\VBN\126264 familiarity\NN\5816287 of\IN\1740 healthcare\NN\654885 professionals\NNS\9605289 with\IN\1740 argatroban\JJ\1740 therapy\NN\657604 in\IN\13603305 <e2>HIT</e2>\NN\36762 ,\,\1740 including\VBG\690614 in\IN\13603305 special\JJ\1740 populations\NNS\7942152 and\CC\1740 during\IN\1740 PCI\NN\1740 ,\,\1740 may\MD\15209706 facilitate\VB\2547586 reduction\NN\351485 of\IN\1740 harm\NN\14052046 associated\VBN\628491 with\IN\1740 HIT\NN\36762 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 thromboses\NNS\1740 )\-RRB-\1740 or\CC\3541091 its\PRP$\6125041 treatment\NN\654885 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 <e1>argatroban</e1>\JJ\1740 medication\NN\3247620 errors\NNS\66216 )\-RRB-\1740 .\.\1740
C031942_D013921 NONE Improved\VBN\126264 familiarity\NN\5816287 of\IN\1740 healthcare\NN\654885 professionals\NNS\9605289 with\IN\1740 argatroban\JJ\1740 therapy\NN\657604 in\IN\13603305 HIT\NN\36762 ,\,\1740 including\VBG\690614 in\IN\13603305 special\JJ\1740 populations\NNS\7942152 and\CC\1740 during\IN\1740 PCI\NN\1740 ,\,\1740 may\MD\15209706 facilitate\VB\2547586 reduction\NN\351485 of\IN\1740 harm\NN\14052046 associated\VBN\628491 with\IN\1740 <e2>HIT</e2>\NN\36762 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 thromboses\NNS\1740 )\-RRB-\1740 or\CC\3541091 its\PRP$\6125041 treatment\NN\654885 (\-LRB-\1740 e.g.\FW\1740 fewer\JJR\1740 <e1>argatroban</e1>\JJ\1740 medication\NN\3247620 errors\NNS\66216 )\-RRB-\1740 .\.\1740
D006493_D013921 NONE Reducing\VBG\441445 harm\NN\14052046 associated\VBN\628491 with\IN\1740 anticoagulation\NN\657604 :\:\1740 practical\JJ\1740 considerations\NNS\5770926 of\IN\1740 argatroban\NN\1740 therapy\NN\657604 in\IN\13603305 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D006493_D013921 NONE Argatroban\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 HIT\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013921 NONE Argatroban\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 HIT\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013921 NONE Argatroban\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 thrombosis\NN\14100769 in\IN\13603305 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 <e2>HIT</e2>\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
C031942_D013927 NONE <e1>Argatroban</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 HIT\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013927 NONE Argatroban\NNP\1740 is\VBZ\836236 a\DT\13649268 hepatically\RB\1740 metabolized\VBN\1740 ,\,\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 used\VBN\1156834 for\IN\1740 prophylaxis\NN\1077350 or\CC\3541091 treatment\NN\654885 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 at\IN\14622893 risk\NN\14541044 of\IN\1740 HIT\NN\36762 undergoing\VBG\109660 percutaneous\JJ\1740 coronary\JJ\1740 intervention\NN\1239064 (\-LRB-\1740 PCI\NN\1740 )\-RRB-\1740 .\.\1740
C031942_D008107 NONE The\DT\1740 US\NNP\14964590 FDA-recommended\JJ\1740 <e1>argatroban</e1>\NN\1740 dose\NN\3740161 in\IN\13603305 HIT\NN\36762 is\VBZ\836236 2\CD\13741022 microg/kg/min\NN\1740 (\-LRB-\1740 reduced\VBN\441445 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hepatic\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 in\IN\13603305 paediatric\JJ\1740 patients\NNS\9898892 )\-RRB-\1740 ,\,\1740 adjusted\VBN\126264 to\TO\1740 achieve\VB\2524171 activated\VBN\1641914 partial\JJ\1740 thromboplastin\NN\15022776 times\NNS\15113229 (\-LRB-\1740 aPTTs\NNS\1740 )\-RRB-\1740 1.5\CD\1740 -\SYM\1740 3\CD\13741022 times\NNS\15113229 baseline\NN\7260623 (\-LRB-\1740 not\RB\1740 >\NNS\1740 100\CD\13745420 seconds\NNS\15154774 )\-RRB-\1740 .\.\1740
C031942_D009765 NONE The\DT\1740 FDA-recommended\JJ\1740 dose\NN\3740161 during\IN\1740 PCI\NN\1740 is\VBZ\836236 25\CD\13745420 microg/kg/min\NN\1740 (\-LRB-\1740 350\CD\1740 microg/kg\NNS\1740 initial\JJ\1740 bolus\NN\13899404 )\-RRB-\1740 ,\,\1740 adjusted\VBN\126264 to\TO\1740 achieve\VB\2524171 activated\VBN\1641914 clotting\NN\13518963 times\NNS\15113229 (\-LRB-\1740 ACTs\NNS\6479665 )\-RRB-\1740 of\IN\1740 300\CD\1740 -\SYM\1740 450\CD\1740 sec.\NN\1740 For\IN\1740 PCI\NN\1740 ,\,\1740 <e1>argatroban</e1>\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 investigated\VBN\644583 in\IN\13603305 hepatically\RB\1740 impaired\JJ\1740 patients\NNS\9898892 ;\:\1740 dose\NN\3740161 adjustment\NN\7357388 is\VBZ\836236 unnecessary\JJ\1740 for\IN\1740 adult\JJ\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 race/ethnicity\NN\1740 or\CC\3541091 <e2>obesity</e2>\NN\4999401 ,\,\1740 and\CC\1740 lesser\JJR\1740 doses\NNS\3740161 may\MD\15209706 be\VB\836236 adequate\JJ\1740 with\IN\1740 concurrent\JJ\1740 glycoprotein\NN\14731135 IIb/IIIa\NN\1740 inhibition\NN\1068773 .\.\1740
C031942_D006470 CID Major\JJ\1740 <e2>bleeding</e2>\VBG\104868 with\IN\1740 <e1>argatroban</e1>\NN\1740 is\VBZ\836236 0\CD\13741022 -\SYM\1740 10\CD\13745420 %\NN\1740 in\IN\13603305 the\DT\1740 non-interventional\JJ\1740 setting\NN\8567235 and\CC\1740 0\CD\13741022 -\SYM\1740 5.8\CD\1740 %\NN\1740 periprocedurally\RB\1740 .\.\1740
12948256
D004977_D009901 CID <e1>Ethambutol</e1>\NNP\1740 and\CC\1740 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D004977_D009901 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 demonstrate\VB\2137132 the\DT\1740 association\NN\8008335 between\IN\1740 <e1>ethambutol</e1>\NN\1740 and\CC\1740 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D004977_D009901 CID METHOD\NNP\5616786 :\:\1740 Thirteen\CD\13745420 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 after\IN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>ethambutol</e1>\NN\1740 for\IN\1740 tuberculosis\NN\14127211 of\IN\1740 the\DT\1740 lung\NN\5528060 or\CC\3541091 lymph\NN\5397468 node\NN\13870805 at\IN\14622893 Siriraj\NNP\1740 Hospital\NNP\3739518 between\IN\1740 1997\CD\1740 and\CC\1740 2001\CD\1740 were\VBD\836236 retrospectively\RB\1740 reviewed\VBN\644583 .\.\1740
D004977_D009901 CID RESULTS\NNS\34213 :\:\1740 All\DT\1740 patients\NNS\9898892 had\VBD\2108377 <e2>optic\JJ\1740 neuropathy</e2>\JJ\1740 between\IN\1740 1\CD\13741022 to\TO\1740 6\CD\13741022 months\NNS\15113229 (\-LRB-\1740 mean\NN\6021761 =\JJ\1740 2.9\CD\1740 months\NNS\15113229 )\-RRB-\1740 after\IN\1740 starting\VBG\2009433 <e1>ethambutol</e1>\NN\1740 therapy\NN\657604 at\IN\14622893 a\DT\13649268 dosage\NN\13576355 ranging\VBG\2604760 from\IN\1740 13\CD\13745420 to\TO\1740 20\CD\13745420 mg/kg/day\NN\1740 (\-LRB-\1740 mean\NN\6021761 =\JJ\1740 17\CD\13745420 mg/kg/day\NN\1740 )\-RRB-\1740 .\.\1740
D004977_D009901 CID CONCLUSION\NN\5837957 :\:\1740 Early\JJ\1740 recognition\NN\13932421 of\IN\1740 <e2>optic\JJ\1740 neuropathy</e2>\NN\14204950 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>ethambutol</e1>\NN\1740 therapy\NN\657604 .\.\1740
D004977_D014397 NONE METHOD\NNP\5616786 :\:\1740 Thirteen\CD\13745420 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 optic\JJ\1740 neuropathy\JJ\1740 after\IN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>ethambutol</e1>\NN\1740 for\IN\1740 <e2>tuberculosis\NN\14127211 of\IN\1740 the\DT\1740 lung\NN\5528060 or\CC\3541091 lymph\NN\5397468 node</e2>\NN\13870805 at\IN\14622893 Siriraj\NNP\1740 Hospital\NNP\3739518 between\IN\1740 1997\CD\1740 and\CC\1740 2001\CD\1740 were\VBD\836236 retrospectively\RB\1740 reviewed\VBN\644583 .\.\1740
D004977_D014388 NONE METHOD\NNP\5616786 :\:\1740 Thirteen\CD\13745420 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 optic\JJ\1740 neuropathy\JJ\1740 after\IN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>ethambutol</e1>\NN\1740 for\IN\1740 <e2>tuberculosis\NN\14127211 of\IN\1740 the\DT\1740 lung\NN\5528060 or\CC\3541091 lymph\NN\5397468 node</e2>\NN\13870805 at\IN\14622893 Siriraj\NNP\1740 Hospital\NNP\3739518 between\IN\1740 1997\CD\1740 and\CC\1740 2001\CD\1740 were\VBD\836236 retrospectively\RB\1740 reviewed\VBN\644583 .\.\1740
8312343
D004317_D002311 NONE Indications\NNS\33020 for\IN\1740 transplantation\NN\671351 were\VBD\836236 <e2>idiopathic\JJ\1740 cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 52\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 congenital\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 35\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 and\CC\1740 without\IN\1740 prior\JJ\1740 repair\NN\248977 (\-LRB-\1740 71\CD\1740 %\NN\1740 and\CC\1740 29\CD\13745420 %\NN\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 hypertrophic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D006331 NONE Indications\NNS\33020 for\IN\1740 transplantation\NN\671351 were\VBD\836236 idiopathic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 52\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>congenital\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 (\-LRB-\1740 35\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 and\CC\1740 without\IN\1740 prior\JJ\1740 repair\NN\248977 (\-LRB-\1740 71\CD\1740 %\NN\1740 and\CC\1740 29\CD\13745420 %\NN\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 hypertrophic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D002312 NONE Indications\NNS\33020 for\IN\1740 transplantation\NN\671351 were\VBD\836236 idiopathic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 52\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 congenital\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 35\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 and\CC\1740 without\IN\1740 prior\JJ\1740 repair\NN\248977 (\-LRB-\1740 71\CD\1740 %\NN\1740 and\CC\1740 29\CD\13745420 %\NN\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 <e2>hypertrophic\JJ\1740 cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D006349 NONE Indications\NNS\33020 for\IN\1740 transplantation\NN\671351 were\VBD\836236 idiopathic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 52\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 congenital\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 35\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 and\CC\1740 without\IN\1740 prior\JJ\1740 repair\NN\248977 (\-LRB-\1740 71\CD\1740 %\NN\1740 and\CC\1740 29\CD\13745420 %\NN\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 hypertrophic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D004317_D009202 CID Indications\NNS\33020 for\IN\1740 transplantation\NN\671351 were\VBD\836236 idiopathic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 52\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 congenital\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 35\CD\1740 %\NN\1740 )\-RRB-\1740 with\IN\1740 and\CC\1740 without\IN\1740 prior\JJ\1740 repair\NN\248977 (\-LRB-\1740 71\CD\1740 %\NN\1740 and\CC\1740 29\CD\13745420 %\NN\1740 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 ,\,\1740 hypertrophic\JJ\1740 cardiomyopathy\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 (\-LRB-\1740 3\CD\13741022 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 <e2>cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D015774_D003586 NONE <e2>Cytomegalovirus\NN\1338685 infections</e2>\NNS\14052046 were\VBD\836236 treated\VBN\2376958 successfully\RB\1740 with\IN\1740 <e1>ganciclovir</e1>\NN\1740 in\IN\13603305 11\CD\13745420 patients\NNS\9898892 .\.\1740
11401944
D013015_D016171 CID BACKGROUND\NN\4921011 :\:\1740 This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 phase\NN\15113229 2\CD\13741022 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 in\IN\13603305 producing\VBG\1617192 a\DT\13649268 trigger\NN\3659292 to\TO\1740 initiate\VB\1617192 <e2>torsade\NN\1740 de\FW\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 with\IN\1740 QT\NN\1740 prolongation\NN\1017987 induced\VBN\1627355 by\IN\1740 <e1>dl-sotalol</e1>\NN\1740 and\CC\1740 azimilide\NN\1740 .\.\1740
D013015_D016171 CID BACKGROUND\NN\4921011 :\:\1740 This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 phase\NN\15113229 2\CD\13741022 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 in\IN\13603305 producing\VBG\1617192 a\DT\13649268 trigger\NN\3659292 to\TO\1740 initiate\VB\1617192 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 with\IN\1740 QT\NN\1740 prolongation\NN\1017987 induced\VBN\1627355 by\IN\1740 <e1>dl-sotalol</e1>\NN\1740 and\CC\1740 azimilide\NN\1740 .\.\1740
D013015_D016171 CID An\DT\6697703 increase\NN\13576355 in\IN\13603305 TDR\NN\1740 by\IN\1740 <e1>dl-sotalol</e1>\NN\1740 facilitated\VBN\2547586 transmural\JJ\1740 propagation\NN\6253140 of\IN\1740 EADs\NNS\1740 that\WDT\1740 initiated\VBD\1617192 multiple\JJ\1740 episodes\NNS\7283608 of\IN\1740 spontaneous\JJ\1740 <e2>TdP</e2>\NN\1740 in\IN\13603305 3\CD\13741022 of\IN\1740 6\CD\13741022 rabbit\NN\2323902 left\VBD\120316 ventricles\NNS\5303402 .\.\1740
D013015_D008133 CID BACKGROUND\NN\4921011 :\:\1740 This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 phase\NN\15113229 2\CD\13741022 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 in\IN\13603305 producing\VBG\1617192 a\DT\13649268 trigger\NN\3659292 to\TO\1740 initiate\VB\1617192 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 with\IN\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 induced\VBN\1627355 by\IN\1740 <e1>dl-sotalol</e1>\NN\1740 and\CC\1740 azimilide\NN\1740 .\.\1740
D013015_D008133 CID <e1>dl-Sotalol</e1>\NN\1740 preferentially\RB\1740 prolonged\VBD\317700 action\NN\30358 potential\JJ\1740 duration\NN\15113229 (\-LRB-\1740 APD\NN\1740 )\-RRB-\1740 in\IN\13603305 M\NN\13649268 cells\NNS\3080309 dose-dependently\RB\1740 (\-LRB-\1740 1\CD\13741022 to\TO\1740 100\CD\13745420 micromol/L\NN\1740 )\-RRB-\1740 ,\,\1740 leading\VBG\1752884 to\TO\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 TDR\NN\1740 .\.\1740
D013015_D008133 CID Although\IN\1740 both\DT\1740 <e1>dl-sotalol</e1>\NN\1740 and\CC\1740 azimilide\NN\1740 rarely\RB\1740 induced\VBD\1627355 EADs\NNS\1740 in\IN\13603305 canine\NN\5282746 left\VBD\120316 ventricles\NNS\5303402 ,\,\1740 they\PRP\1740 produced\VBD\1617192 frequent\JJ\1740 EADs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 ,\,\1740 in\IN\13603305 which\WDT\1740 more\RBR\1740 pronounced\VBD\822367 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 was\VBD\836236 seen\VBN\2106506 .\.\1740
C086123_D016171 NONE BACKGROUND\NN\4921011 :\:\1740 This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 phase\NN\15113229 2\CD\13741022 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 in\IN\13603305 producing\VBG\1617192 a\DT\13649268 trigger\NN\3659292 to\TO\1740 initiate\VB\1617192 <e2>torsade\NN\1740 de\FW\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 with\IN\1740 QT\NN\1740 prolongation\NN\1017987 induced\VBN\1627355 by\IN\1740 dl-sotalol\NN\1740 and\CC\1740 <e1>azimilide</e1>\NN\1740 .\.\1740
C086123_D016171 NONE BACKGROUND\NN\4921011 :\:\1740 This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 phase\NN\15113229 2\CD\13741022 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 in\IN\13603305 producing\VBG\1617192 a\DT\13649268 trigger\NN\3659292 to\TO\1740 initiate\VB\1617192 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 with\IN\1740 QT\NN\1740 prolongation\NN\1017987 induced\VBN\1627355 by\IN\1740 dl-sotalol\NN\1740 and\CC\1740 <e1>azimilide</e1>\NN\1740 .\.\1740
C086123_D008133 NONE BACKGROUND\NN\4921011 :\:\1740 This\DT\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 phase\NN\15113229 2\CD\13741022 early\JJ\1740 afterdepolarization\NN\1740 (\-LRB-\1740 EAD\NN\1740 )\-RRB-\1740 in\IN\13603305 producing\VBG\1617192 a\DT\13649268 trigger\NN\3659292 to\TO\1740 initiate\VB\1617192 torsade\NN\1740 de\FW\1740 pointes\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 with\IN\1740 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 induced\VBN\1627355 by\IN\1740 dl-sotalol\NN\1740 and\CC\1740 <e1>azimilide</e1>\NN\1740 .\.\1740
C086123_D008133 NONE Although\IN\1740 both\DT\1740 dl-sotalol\NN\1740 and\CC\1740 <e1>azimilide</e1>\NN\1740 rarely\RB\1740 induced\VBD\1627355 EADs\NNS\1740 in\IN\13603305 canine\NN\5282746 left\VBD\120316 ventricles\NNS\5303402 ,\,\1740 they\PRP\1740 produced\VBD\1617192 frequent\JJ\1740 EADs\NNS\1740 in\IN\13603305 rabbits\NNS\2323902 ,\,\1740 in\IN\13603305 which\WDT\1740 more\RBR\1740 pronounced\VBD\822367 <e2>QT\NN\1740 prolongation</e2>\NN\1017987 was\VBD\836236 seen\VBN\2106506 .\.\1740
6517710
D011796_D003328 CID <e2>Atrial\JJ\1740 thrombosis</e2>\NN\14100769 involving\VBG\2676054 the\DT\1740 heart\NN\5919034 of\IN\1740 F-344\NN\1740 rats\NNS\2329401 ingesting\VBG\597915 <e1>quinacrine\NN\2721948 hydrochloride</e1>\NN\14817592 .\.\1740
D011796_D003328 CID Rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 500\CD\13745420 ppm\JJ\1740 <e1>quinacrine\NN\2721948 hydrochloride</e1>\NN\14817592 in\IN\13603305 the\DT\1740 diet\NN\7560652 all\DT\1740 developed\VBD\1753788 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 left\JJ\1740 <e2>atrial\JJ\1740 thrombosis</e2>\NN\14100769 .\.\1740
D011796_D003328 CID Seventy\CD\13745420 percent\NN\13815742 of\IN\1740 rats\NNS\2329401 given\VBN\2327200 250\CD\1740 ppm\NN\1740 <e1>quinacrine\NN\2721948 hydrochloride</e1>\NN\14817592 and\CC\1740 1,000\CD\1740 ppm\JJ\1740 sodium\NN\14625458 nitrite\RB\1740 simultaneously\RB\1740 in\IN\13603305 the\DT\1740 diet\NN\7560652 had\VBD\2108377 thrombosis\NN\14100769 of\IN\1740 the\DT\1740 atria\NN\5392744 of\IN\1740 the\DT\1740 heart\NN\5919034 ,\,\1740 while\IN\15122231 untreated\JJ\1740 control\NN\5190804 rats\NNS\2329401 in\IN\13603305 this\DT\1740 laboratory\NN\4602044 did\VBD\1640855 not\RB\1740 have\VB\2108377 <e2>atrial\JJ\1740 thrombosis</e2>\NN\14100769 .\.\1740
D011796_D013927 NONE Seventy\CD\13745420 percent\NN\13815742 of\IN\1740 rats\NNS\2329401 given\VBN\2327200 250\CD\1740 ppm\NN\1740 <e1>quinacrine\NN\2721948 hydrochloride</e1>\NN\14817592 and\CC\1740 1,000\CD\1740 ppm\JJ\1740 sodium\NN\14625458 nitrite\RB\1740 simultaneously\RB\1740 in\IN\13603305 the\DT\1740 diet\NN\7560652 had\VBD\2108377 <e2>thrombosis</e2>\NN\14100769 of\IN\1740 the\DT\1740 atria\NN\5392744 of\IN\1740 the\DT\1740 heart\NN\5919034 ,\,\1740 while\IN\15122231 untreated\JJ\1740 control\NN\5190804 rats\NNS\2329401 in\IN\13603305 this\DT\1740 laboratory\NN\4602044 did\VBD\1640855 not\RB\1740 have\VB\2108377 atrial\JJ\1740 thrombosis\NN\14100769 .\.\1740
D012977_D013927 NONE Seventy\CD\13745420 percent\NN\13815742 of\IN\1740 rats\NNS\2329401 given\VBN\2327200 250\CD\1740 ppm\NN\1740 quinacrine\NN\2721948 hydrochloride\NN\14817592 and\CC\1740 1,000\CD\1740 ppm\JJ\1740 <e1>sodium\NN\14625458 nitrite</e1>\RB\1740 simultaneously\RB\1740 in\IN\13603305 the\DT\1740 diet\NN\7560652 had\VBD\2108377 <e2>thrombosis</e2>\NN\14100769 of\IN\1740 the\DT\1740 atria\NN\5392744 of\IN\1740 the\DT\1740 heart\NN\5919034 ,\,\1740 while\IN\15122231 untreated\JJ\1740 control\NN\5190804 rats\NNS\2329401 in\IN\13603305 this\DT\1740 laboratory\NN\4602044 did\VBD\1640855 not\RB\1740 have\VB\2108377 atrial\JJ\1740 thrombosis\NN\14100769 .\.\1740
D012977_D003328 NONE Seventy\CD\13745420 percent\NN\13815742 of\IN\1740 rats\NNS\2329401 given\VBN\2327200 250\CD\1740 ppm\NN\1740 quinacrine\NN\2721948 hydrochloride\NN\14817592 and\CC\1740 1,000\CD\1740 ppm\JJ\1740 <e1>sodium\NN\14625458 nitrite</e1>\RB\1740 simultaneously\RB\1740 in\IN\13603305 the\DT\1740 diet\NN\7560652 had\VBD\2108377 thrombosis\NN\14100769 of\IN\1740 the\DT\1740 atria\NN\5392744 of\IN\1740 the\DT\1740 heart\NN\5919034 ,\,\1740 while\IN\15122231 untreated\JJ\1740 control\NN\5190804 rats\NNS\2329401 in\IN\13603305 this\DT\1740 laboratory\NN\4602044 did\VBD\1640855 not\RB\1740 have\VB\2108377 <e2>atrial\JJ\1740 thrombosis</e2>\NN\14100769 .\.\1740
7661171
D016595_D007674 NONE The\DT\1740 dose-dependent\JJ\1740 effect\NN\34213 of\IN\1740 <e1>misoprostol</e1>\NN\1740 on\IN\1740 indomethacin-induced\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 cirrhosis\NN\14116321 .\.\1740
D016595_D007674 NONE <e1>Misoprostol</e1>\NN\1740 (\-LRB-\1740 200\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 acutely\RB\1740 counteract\VB\2367363 the\DT\1740 indomethacin-induced\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 cirrhotic\JJ\1740 patients\NNS\9898892 .\.\1740
D016595_D005355 NONE The\DT\1740 dose-dependent\JJ\1740 effect\NN\34213 of\IN\1740 <e1>misoprostol</e1>\NN\1740 on\IN\1740 indomethacin-induced\JJ\1740 renal\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 <e2>cirrhosis</e2>\NN\14116321 .\.\1740
D016595_D005355 NONE <e1>Misoprostol</e1>\NN\1740 (\-LRB-\1740 200\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 acutely\RB\1740 counteract\VB\2367363 the\DT\1740 indomethacin-induced\JJ\1740 renal\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 <e2>cirrhotic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D016595_D005355 NONE Parameters\NNS\5858936 of\IN\1740 renal\JJ\1740 hemodynamics\NNS\6080522 and\CC\1740 tubular\JJ\1740 sodium\NN\14625458 and\CC\1740 water\NN\14618834 handling\NN\623162 were\VBD\836236 assessed\VBN\670261 by\IN\1740 clearance\NN\5089947 techniques\NNS\5660268 in\IN\13603305 26\CD\13745420 well\RB\1740 compensated\VBN\2673134 <e2>cirrhotic</e2>\JJ\1740 patients\NNS\9898892 before\IN\1740 and\CC\1740 after\IN\1740 an\DT\6697703 oral\JJ\1740 combination\NN\7951464 of\IN\1740 50\CD\13745420 mg\NN\13717155 of\IN\1740 indomethacin\NN\3828465 and\CC\1740 various\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>misoprostol</e1>\NN\1740 .\.\1740
D016595_D005355 NONE However\RB\1740 ,\,\1740 until\IN\1740 this\DT\1740 apparent\JJ\1740 ability\NN\4723816 of\IN\1740 200\CD\1740 micrograms\NNS\13717155 of\IN\1740 <e1>misoprostol</e1>\NN\1740 to\TO\1740 prevent\VB\1740 the\DT\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 indomethacin\NN\3828465 on\IN\1740 renal\JJ\1740 function\NN\13783581 is\VBZ\836236 confirmed\VBN\1011725 with\IN\1740 chronic\JJ\1740 frequent\JJ\1740 dosing\NN\1740 ,\,\1740 it\PRP\6125041 would\MD\1740 be\VB\836236 prudent\JJ\1740 to\TO\1740 avoid\VB\2452885 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>cirrhosis</e2>\NN\14116321 .\.\1740
D007213_D007674 CID The\DT\1740 dose-dependent\JJ\1740 effect\NN\34213 of\IN\1740 misoprostol\NN\1740 on\IN\1740 <e1>indomethacin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 cirrhosis\NN\14116321 .\.\1740
D007213_D007674 CID Misoprostol\NN\1740 (\-LRB-\1740 200\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 acutely\RB\1740 counteract\VB\2367363 the\DT\1740 <e1>indomethacin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 cirrhotic\JJ\1740 patients\NNS\9898892 .\.\1740
D007213_D005355 NONE The\DT\1740 dose-dependent\JJ\1740 effect\NN\34213 of\IN\1740 misoprostol\NN\1740 on\IN\1740 <e1>indomethacin-induced</e1>\JJ\1740 renal\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 <e2>cirrhosis</e2>\NN\14116321 .\.\1740
D007213_D005355 NONE Misoprostol\NN\1740 (\-LRB-\1740 200\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 acutely\RB\1740 counteract\VB\2367363 the\DT\1740 <e1>indomethacin-induced</e1>\JJ\1740 renal\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 well\RB\1740 compensated\VBN\2673134 <e2>cirrhotic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D007213_D005355 NONE Parameters\NNS\5858936 of\IN\1740 renal\JJ\1740 hemodynamics\NNS\6080522 and\CC\1740 tubular\JJ\1740 sodium\NN\14625458 and\CC\1740 water\NN\14618834 handling\NN\623162 were\VBD\836236 assessed\VBN\670261 by\IN\1740 clearance\NN\5089947 techniques\NNS\5660268 in\IN\13603305 26\CD\13745420 well\RB\1740 compensated\VBN\2673134 <e2>cirrhotic</e2>\JJ\1740 patients\NNS\9898892 before\IN\1740 and\CC\1740 after\IN\1740 an\DT\6697703 oral\JJ\1740 combination\NN\7951464 of\IN\1740 50\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>indomethacin</e1>\NN\3828465 and\CC\1740 various\JJ\1740 doses\NNS\3740161 of\IN\1740 misoprostol\NN\1740 .\.\1740
D007213_D005355 NONE However\RB\1740 ,\,\1740 until\IN\1740 this\DT\1740 apparent\JJ\1740 ability\NN\4723816 of\IN\1740 200\CD\1740 micrograms\NNS\13717155 of\IN\1740 misoprostol\NN\1740 to\TO\1740 prevent\VB\1740 the\DT\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>indomethacin</e1>\NN\3828465 on\IN\1740 renal\JJ\1740 function\NN\13783581 is\VBZ\836236 confirmed\VBN\1011725 with\IN\1740 chronic\JJ\1740 frequent\JJ\1740 dosing\NN\1740 ,\,\1740 it\PRP\6125041 would\MD\1740 be\VB\836236 prudent\JJ\1740 to\TO\1740 avoid\VB\2452885 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 therapy\NN\657604 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>cirrhosis</e2>\NN\14116321 .\.\1740
D012964_D005355 NONE Parameters\NNS\5858936 of\IN\1740 renal\JJ\1740 hemodynamics\NNS\6080522 and\CC\1740 tubular\JJ\1740 <e1>sodium</e1>\NN\14625458 and\CC\1740 water\NN\14618834 handling\NN\623162 were\VBD\836236 assessed\VBN\670261 by\IN\1740 clearance\NN\5089947 techniques\NNS\5660268 in\IN\13603305 26\CD\13745420 well\RB\1740 compensated\VBN\2673134 <e2>cirrhotic</e2>\JJ\1740 patients\NNS\9898892 before\IN\1740 and\CC\1740 after\IN\1740 an\DT\6697703 oral\JJ\1740 combination\NN\7951464 of\IN\1740 50\CD\13745420 mg\NN\13717155 of\IN\1740 indomethacin\NN\3828465 and\CC\1740 various\JJ\1740 doses\NNS\3740161 of\IN\1740 misoprostol\NN\1740 .\.\1740
11385188
D003042_D006331 NONE Prevalence\NN\4764412 of\IN\1740 <e2>heart\NN\5919034 disease</e2>\NN\14061805 in\IN\13603305 asymptomatic\JJ\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 .\.\1740
D003042_D006331 NONE To\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 of\IN\1740 <e2>heart\NN\5919034 disease</e2>\NN\14061805 in\IN\13603305 outpatient\JJ\1740 young\JJ\1740 asymptomatic\JJ\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 ,\,\1740 35\CD\1740 cocaine\NN\3492717 users\NNS\7846 and\CC\1740 32\CD\1740 age-matched\JJ\1740 controls\NNS\5190804 underwent\VBD\109660 resting\VBG\2604760 and\CC\1740 exercise\NN\621627 electrocardiography\NN\177127 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 and\CC\1740 Doppler\NNP\1740 echocardiography\NN\177127 .\.\1740
D003042_D006331 NONE To\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 of\IN\1740 <e2>heart\NN\5919034 disease</e2>\NN\14061805 in\IN\13603305 outpatient\JJ\1740 young\JJ\1740 asymptomatic\JJ\1740 chronic\JJ\1740 cocaine\NN\3492717 users\NNS\7846 ,\,\1740 35\CD\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 and\CC\1740 32\CD\1740 age-matched\JJ\1740 controls\NNS\5190804 underwent\VBD\109660 resting\VBG\2604760 and\CC\1740 exercise\NN\621627 electrocardiography\NN\177127 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 and\CC\1740 Doppler\NNP\1740 echocardiography\NN\177127 .\.\1740
D003042_D003324 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 or\CC\3541091 myocardial\JJ\1740 disease</e2>\NN\14061805 is\VBZ\836236 common\JJ\1740 (\-LRB-\1740 38\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 young\JJ\1740 asymptomatic\JJ\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 .\.\1740
D003042_D009202 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 or\CC\3541091 myocardial\JJ\1740 disease</e2>\NN\14061805 is\VBZ\836236 common\JJ\1740 (\-LRB-\1740 38\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 young\JJ\1740 asymptomatic\JJ\1740 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 .\.\1740
24091473
D004837_D066126 NONE Resuscitation\NN\1047338 with\IN\1740 lipid\NN\14944888 ,\,\1740 <e1>epinephrine</e1>\NN\14807929 ,\,\1740 or\CC\3541091 both\CC\1740 in\IN\13603305 levobupivacaine-induced\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 newborn\JJ\1740 piglets\NNS\1321854 .\.\1740
C476513_D066126 NONE Resuscitation\NN\1047338 with\IN\1740 lipid\NN\14944888 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 both\CC\1740 in\IN\13603305 <e1>levobupivacaine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 newborn\JJ\1740 piglets\NNS\1321854 .\.\1740
D004837_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 optimal\JJ\1740 dosing\NN\1740 regimens\NNS\5898568 of\IN\1740 lipid\NN\14944888 emulsion\NN\14588219 ,\,\1740 <e1>epinephrine</e1>\NN\14807929 ,\,\1740 or\CC\3541091 both\DT\1740 are\VBP\836236 not\RB\1740 yet\RB\1740 determined\VBN\1645601 in\IN\13603305 neonates\NNS\9827683 in\IN\13603305 cases\NNS\7283608 of\IN\1740 local\JJ\1740 anaesthetic\JJ\1740 systemic\JJ\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 LAST\JJ\1740 )\-RRB-\1740 .\.\1740
C476513_D002318 CID METHODS\NNS\5616786 :\:\1740 Newborn\JJ\1740 piglets\NNS\1321854 received\VBD\2210855 <e1>levobupivacaine</e1>\NN\1740 until\IN\1740 <e2>cardiovascular\JJ\1740 collapse</e2>\NN\14061805 occurred\VBD\2623529 .\.\1740
16911931
D019259_D006509 NONE Intramuscular\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 combined\VBN\2630189 with\IN\1740 <e1>lamivudine</e1>\NN\3834836 in\IN\13603305 prevention\NN\1073995 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 recurrence\NN\7342049 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D019259_D006509 NONE Intramuscular\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 combined\VBN\2630189 with\IN\1740 <e1>lamivudine</e1>\NN\3834836 in\IN\13603305 prevention\NN\1073995 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 recurrence\NN\7342049 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D019259_D006509 NONE BACKGROUND\NN\4921011 :\:\1740 Combined\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIg\NNS\1740 )\-RRB-\1740 and\CC\1740 <e1>lamivudine</e1>\NN\3834836 in\IN\13603305 prophylaxis\NN\1077350 of\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 the\DT\1740 survival\NN\13961642 of\IN\1740 HBsAg\NN\1740 positive\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE BACKGROUND\NN\4921011 :\:\1740 Combined\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIg\NNS\1740 )\-RRB-\1740 and\CC\1740 <e1>lamivudine</e1>\NN\3834836 in\IN\13603305 prophylaxis\NN\1077350 of\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 the\DT\1740 survival\NN\13961642 of\IN\1740 HBsAg\NN\1740 positive\JJ\1740 patients\NNS\9898892 .\.\1740
D006514_D006509 NONE BACKGROUND\NN\4921011 :\:\1740 Combined\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIg\NNS\1740 )\-RRB-\1740 and\CC\1740 lamivudine\NN\3834836 in\IN\13603305 prophylaxis\NN\1077350 of\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 the\DT\1740 survival\NN\13961642 of\IN\1740 <e1>HBsAg</e1>\NN\1740 positive\JJ\1740 patients\NNS\9898892 .\.\1740
D006514_D006509 NONE BACKGROUND\NN\4921011 :\:\1740 Combined\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 immune\JJ\1740 globulin\NN\14736972 (\-LRB-\1740 HBIg\NNS\1740 )\-RRB-\1740 and\CC\1740 lamivudine\NN\3834836 in\IN\13603305 prophylaxis\NN\1077350 of\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 the\DT\1740 survival\NN\13961642 of\IN\1740 <e1>HBsAg</e1>\NN\1740 positive\JJ\1740 patients\NNS\9898892 .\.\1740
20034406
D010862_D013226 CID Chemokine\NN\1740 CCL2\NN\1740 and\CC\1740 its\PRP$\6125041 receptor\NN\5225602 CCR2\NN\1740 are\VBP\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 following\VBG\1835496 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
D010862_D013226 CID In\IN\13603305 this\DT\1740 work\NN\407535 CCR2\NN\1740 and\CC\1740 CCL2\NN\1740 expression\NN\4679549 were\VBD\836236 examined\VBN\789138 following\VBG\1835496 <e2>status\NN\24720 epilepticus</e2>\NN\1740 (\-LRB-\1740 SE\NN\14724645 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 injection\NN\320852 .\.\1740
D010862_D013226 CID In\IN\13603305 this\DT\1740 work\NN\407535 CCR2\NN\1740 and\CC\1740 CCL2\NN\1740 expression\NN\4679549 were\VBD\836236 examined\VBN\789138 following\VBG\1835496 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 <e2>SE</e2>\NN\14724645 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 injection\NN\320852 .\.\1740
D010862_D013226 CID METHODS\NNS\5616786 :\:\1740 <e2>SE</e2>\NN\14724645 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 injection\NN\320852 .\.\1740
D010862_D013226 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 CCR2\NN\1740 and\CC\1740 CCL2\NN\1740 are\VBP\836236 up-regulated\VBN\1740 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 after\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>SE</e2>\NN\14724645 .\.\1740
6985297
D015764_D001919 CID Studies\NNS\635850 on\IN\1740 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 <e1>bepridil</e1>\NN\1740 .\.\1740
D015764_D001919 CID <e1>Bepridil</e1>\NNP\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 active\JJ\1740 compound\NN\5869584 for\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 anginal\JJ\1740 attacks\NNS\955060 ,\,\1740 induced\VBN\1627355 persistent\JJ\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 a\DT\13649268 non-specific\JJ\1740 anti-tachycardial\JJ\1740 effect\NN\34213 ,\,\1740 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 which\WDT\1740 were\VBD\836236 investigated\VBN\644583 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D015764_D000787 NONE <e1>Bepridil</e1>\NNP\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 active\JJ\1740 compound\NN\5869584 for\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>anginal\JJ\1740 attacks</e2>\NNS\955060 ,\,\1740 induced\VBN\1627355 persistent\JJ\1740 bradycardia\NN\14110674 and\CC\1740 a\DT\13649268 non-specific\JJ\1740 anti-tachycardial\JJ\1740 effect\NN\34213 ,\,\1740 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 which\WDT\1740 were\VBD\836236 investigated\VBN\644583 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
D015764_D013610 NONE <e1>Bepridil</e1>\NNP\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 active\JJ\1740 compound\NN\5869584 for\IN\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 anginal\JJ\1740 attacks\NNS\955060 ,\,\1740 induced\VBN\1627355 persistent\JJ\1740 bradycardia\NN\14110674 and\CC\1740 a\DT\13649268 non-specific\JJ\1740 <e2>anti-tachycardial</e2>\JJ\1740 effect\NN\34213 ,\,\1740 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 which\WDT\1740 were\VBD\836236 investigated\VBN\644583 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 .\.\1740
7949506
D003000_D054537 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 a\DT\13649268 possible\JJ\1740 adverse\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>clonidine</e1>\NN\2721160 and\CC\1740 verapamil\NN\2938514 resulting\VBG\2633881 in\IN\13603305 <e2>atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 block</e2>\NN\21939 in\IN\13603305 both\CC\1740 patients\NNS\9898892 and\CC\1740 severe\JJ\1740 hypotension\NN\14057371 in\IN\13603305 one\CD\13741022 patient\NN\9898892 .\.\1740
D003000_D054537 CID After\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 a\DT\13649268 minimal\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>clonidine</e1>\NN\2721160 (\-LRB-\1740 0.15\CD\1740 mg\NN\13717155 bid\NN\7160883 )\-RRB-\1740 ,\,\1740 she\PRP\1740 developed\VBD\1753788 complete\JJ\1740 <e2>AV\NN\15214068 block</e2>\NN\21939 and\CC\1740 severe\JJ\1740 hypotension\NN\14057371 ,\,\1740 which\WDT\1740 resolved\VBD\352826 upon\IN\1740 cessation\NN\7365849 of\IN\1740 all\DT\1740 medications.\NN\1740 A\NN\13649268 65-year-old\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 extended-release\NN\1740 verapamil\NN\2938514 240\CD\1740 mg/d\NN\1740 .\.\1740
D003000_D054537 CID After\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>clonidine</e1>\NN\2721160 0.15\CD\1740 mg\NN\13717155 bid\NN\7160883 she\PRP\1740 developed\VBD\1753788 complete\JJ\1740 <e2>AV\NN\15214068 block</e2>\NN\21939 ,\,\1740 which\WDT\1740 resolved\VBD\352826 after\IN\1740 all\DT\1740 therapy\NN\657604 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D003000_D007022 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 a\DT\13649268 possible\JJ\1740 adverse\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>clonidine</e1>\NN\2721160 and\CC\1740 verapamil\NN\2938514 resulting\VBG\2633881 in\IN\13603305 atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 block\NN\21939 in\IN\13603305 both\CC\1740 patients\NNS\9898892 and\CC\1740 severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 one\CD\13741022 patient\NN\9898892 .\.\1740
D003000_D007022 CID After\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 a\DT\13649268 minimal\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>clonidine</e1>\NN\2721160 (\-LRB-\1740 0.15\CD\1740 mg\NN\13717155 bid\NN\7160883 )\-RRB-\1740 ,\,\1740 she\PRP\1740 developed\VBD\1753788 complete\JJ\1740 AV\NN\15214068 block\NN\21939 and\CC\1740 severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 which\WDT\1740 resolved\VBD\352826 upon\IN\1740 cessation\NN\7365849 of\IN\1740 all\DT\1740 medications.\NN\1740 A\NN\13649268 65-year-old\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 extended-release\NN\1740 verapamil\NN\2938514 240\CD\1740 mg/d\NN\1740 .\.\1740
D014700_D054537 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 a\DT\13649268 possible\JJ\1740 adverse\JJ\1740 interaction\NN\37396 between\IN\1740 clonidine\NN\2721160 and\CC\1740 <e1>verapamil</e1>\NN\2938514 resulting\VBG\2633881 in\IN\13603305 <e2>atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 block</e2>\NN\21939 in\IN\13603305 both\CC\1740 patients\NNS\9898892 and\CC\1740 severe\JJ\1740 hypotension\NN\14057371 in\IN\13603305 one\CD\13741022 patient\NN\9898892 .\.\1740
D014700_D054537 CID After\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 a\DT\13649268 minimal\JJ\1740 dose\NN\3740161 of\IN\1740 clonidine\NN\2721160 (\-LRB-\1740 0.15\CD\1740 mg\NN\13717155 bid\NN\7160883 )\-RRB-\1740 ,\,\1740 she\PRP\1740 developed\VBD\1753788 complete\JJ\1740 <e2>AV\NN\15214068 block</e2>\NN\21939 and\CC\1740 severe\JJ\1740 hypotension\NN\14057371 ,\,\1740 which\WDT\1740 resolved\VBD\352826 upon\IN\1740 cessation\NN\7365849 of\IN\1740 all\DT\1740 medications.\NN\1740 A\NN\13649268 65-year-old\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 extended-release\NN\1740 <e1>verapamil</e1>\NN\2938514 240\CD\1740 mg/d\NN\1740 .\.\1740
D014700_D007022 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 a\DT\13649268 possible\JJ\1740 adverse\JJ\1740 interaction\NN\37396 between\IN\1740 clonidine\NN\2721160 and\CC\1740 <e1>verapamil</e1>\NN\2938514 resulting\VBG\2633881 in\IN\13603305 atrioventricular\JJ\1740 (\-LRB-\1740 AV\NN\15214068 )\-RRB-\1740 block\NN\21939 in\IN\13603305 both\CC\1740 patients\NNS\9898892 and\CC\1740 severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 one\CD\13741022 patient\NN\9898892 .\.\1740
D014700_D007022 CID After\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 a\DT\13649268 minimal\JJ\1740 dose\NN\3740161 of\IN\1740 clonidine\NN\2721160 (\-LRB-\1740 0.15\CD\1740 mg\NN\13717155 bid\NN\7160883 )\-RRB-\1740 ,\,\1740 she\PRP\1740 developed\VBD\1753788 complete\JJ\1740 AV\NN\15214068 block\NN\21939 and\CC\1740 severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 which\WDT\1740 resolved\VBD\352826 upon\IN\1740 cessation\NN\7365849 of\IN\1740 all\DT\1740 medications.\NN\1740 A\NN\13649268 65-year-old\JJ\1740 woman\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 extended-release\NN\1740 <e1>verapamil</e1>\NN\2938514 240\CD\1740 mg/d\NN\1740 .\.\1740
D014700_D006929 NONE CASE\NN\7283608 SUMMARIES\NN\6722453 :\:\1740 A\DT\13649268 54-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>hyperaldosteronism</e2>\NN\14059928 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>verapamil</e1>\NN\2938514 480\CD\1740 mg/d\NN\1740 and\CC\1740 spironolactone\VBD\1740 100\CD\13745420 mg/d\NN\1740 .\.\1740
D013148_D006929 NONE CASE\NN\7283608 SUMMARIES\NN\6722453 :\:\1740 A\DT\13649268 54-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>hyperaldosteronism</e2>\NN\14059928 was\VBD\836236 treated\VBN\2376958 with\IN\1740 verapamil\NN\2938514 480\CD\1740 mg/d\NN\1740 and\CC\1740 <e1>spironolactone</e1>\VBD\1740 100\CD\13745420 mg/d\NN\1740 .\.\1740
11135381
D008729_D014550 NONE Effect\NN\34213 of\IN\1740 <e1>methoxamine</e1>\NN\1740 on\IN\1740 maximum\JJ\1740 urethral\JJ\1740 pressure\NN\11419404 in\IN\13603305 women\NNS\9605289 with\IN\1740 genuine\JJ\1740 <e2>stress\NN\7083732 incontinence</e2>\NN\13473097 :\:\1740 a\DT\13649268 placebo-controlled\JJ\1740 ,\,\1740 double-blind\JJ\1740 crossover\NN\13526110 study\VBP\630380 .\.\1740
D008729_D014550 NONE Half\NN\13732295 log\NN\15098161 incremental\JJ\1740 doses\NNS\3740161 of\IN\1740 intravenous\JJ\1740 <e1>methoxamine</e1>\NN\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 saline\NN\14849367 )\-RRB-\1740 were\VBD\836236 administered\VBN\2436349 to\TO\1740 a\DT\13649268 group\NN\2137 of\IN\1740 women\NNS\9605289 with\IN\1740 genuine\JJ\1740 <e2>stress\NN\7083732 incontinence</e2>\NN\13473097 while\IN\15122231 measuring\VBG\697589 maximum\NN\13653902 urethral\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 MUP\NN\1740 )\-RRB-\1740 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 heart\NN\5919034 rate\NN\13815152 ,\,\1740 and\CC\1740 symptomatic\JJ\1740 side\NN\8630039 effects\NNS\13245626 .\.\1740
D008729_D006973 CID <e1>Methoxamine</e1>\NNP\1740 evoked\VBD\1617192 non-significant\JJ\1740 increases\NNS\13576355 in\IN\13603305 MUP\NN\1740 and\CC\1740 diastolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 but\CC\1740 caused\VBD\1617192 <e2>a\DT\13649268 significant\JJ\1740 rise\NN\7324673 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 significant\JJ\1740 fall\NN\15236475 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 at\IN\14622893 maximum\NN\13653902 dosage\NN\13576355 .\.\1740
3191389
D010862_D012640 CID Differential\JJ\1740 effects\NNS\13245626 of\IN\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010862_D012640 CID The\DT\1740 muscarinic\JJ\1740 cholinergic\NN\1740 agonist\NN\9613191 <e1>pilocarpine</e1>\NN\14712692 induces\VBZ\1627355 in\IN\13603305 rats\NNS\2329401 <e2>seizures</e2>\NNS\14081375 and\CC\1740 status\NN\24720 epilepticus\NN\1740 followed\VBN\1835496 by\IN\1740 widespread\JJ\1740 damage\NN\7296428 to\IN\1740 the\DT\1740 forebrain\NN\5462674 .\.\1740
D010862_D012640 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 5\CD\13741022 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 and\CC\1740 mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D010862_D012640 CID Indomethacin\NN\3828465 ,\,\1740 1\CD\13741022 -\SYM\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 and\CC\1740 ibuprofen\NN\3828465 ,\,\1740 10\CD\13745420 -\SYM\1740 100\CD\13745420 mg/kg\NN\1740 ,\,\1740 failed\VBD\1798936 to\TO\1740 modulate\VB\1724459 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D010862_D012640 CID Mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 26\CD\13745420 (\-LRB-\1740 22\CD\13745420 -\SYM\1740 30\CD\13745420 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 prevented\VBD\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 protected\VBD\1127795 rats\NNS\2329401 from\IN\1740 seizure-related\JJ\1740 brain\NN\5462674 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID Mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 26\CD\13745420 (\-LRB-\1740 22\CD\13745420 -\SYM\1740 30\CD\13745420 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 prevented\VBD\1740 seizures\NNS\14081375 and\CC\1740 protected\VBD\1127795 rats\NNS\2329401 from\IN\1740 <e2>seizure-related</e2>\JJ\1740 brain\NN\5462674 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 differentially\RB\1740 modulate\VBP\1724459 the\DT\1740 threshold\NN\15265518 for\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D013226 CID The\DT\1740 muscarinic\JJ\1740 cholinergic\NN\1740 agonist\NN\9613191 <e1>pilocarpine</e1>\NN\14712692 induces\VBZ\1627355 in\IN\13603305 rats\NNS\2329401 seizures\NNS\14081375 and\CC\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 followed\VBN\1835496 by\IN\1740 widespread\JJ\1740 damage\NN\7296428 to\IN\1740 the\DT\1740 forebrain\NN\5462674 .\.\1740
D012980_D012640 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 5\CD\13741022 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 ,\,\1740 <e1>sodium\NN\14625458 salicylate</e1>\NN\3828465 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 and\CC\1740 mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D010653_D012640 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 5\CD\13741022 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 ,\,\1740 <e1>phenylbutazone</e1>\NN\2721538 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 and\CC\1740 mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D007213_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 5\CD\13741022 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 <e1>indomethacin</e1>\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 and\CC\1740 mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D007213_D012640 NONE <e1>Indomethacin</e1>\NN\3828465 ,\,\1740 1\CD\13741022 -\SYM\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 and\CC\1740 ibuprofen\NN\3828465 ,\,\1740 10\CD\13745420 -\SYM\1740 100\CD\13745420 mg/kg\NN\1740 ,\,\1740 failed\VBD\1798936 to\TO\1740 modulate\VB\1724459 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D007052_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 5\CD\13741022 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 <e1>ibuprofen</e1>\NN\3828465 and\CC\1740 mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D007052_D012640 NONE Indomethacin\NN\3828465 ,\,\1740 1\CD\13741022 -\SYM\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 and\CC\1740 <e1>ibuprofen</e1>\NN\3828465 ,\,\1740 10\CD\13745420 -\SYM\1740 100\CD\13745420 mg/kg\NN\1740 ,\,\1740 failed\VBD\1798936 to\TO\1740 modulate\VB\1724459 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D008528_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 5\CD\13741022 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drugs\NNS\14778436 ,\,\1740 sodium\NN\14625458 salicylate\NN\3828465 ,\,\1740 phenylbutazone\NN\2721538 ,\,\1740 indomethacin\NN\3828465 ,\,\1740 ibuprofen\NN\3828465 and\CC\1740 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 on\IN\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 by\IN\1740 pilocarpine\NN\14712692 .\.\1740
D008528_D012640 NONE <e1>Mefenamic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 26\CD\13745420 (\-LRB-\1740 22\CD\13745420 -\SYM\1740 30\CD\13745420 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 prevented\VBD\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 protected\VBD\1127795 rats\NNS\2329401 from\IN\1740 seizure-related\JJ\1740 brain\NN\5462674 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D008528_D012640 NONE <e1>Mefenamic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 26\CD\13745420 (\-LRB-\1740 22\CD\13745420 -\SYM\1740 30\CD\13745420 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 prevented\VBD\1740 seizures\NNS\14081375 and\CC\1740 protected\VBD\1127795 rats\NNS\2329401 from\IN\1740 <e2>seizure-related</e2>\JJ\1740 brain\NN\5462674 damage\NN\7296428 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D008528_D001930 NONE <e1>Mefenamic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 26\CD\13745420 (\-LRB-\1740 22\CD\13745420 -\SYM\1740 30\CD\13745420 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 prevented\VBD\1740 seizures\NNS\14081375 and\CC\1740 protected\VBD\1127795 rats\NNS\2329401 from\IN\1740 seizure-related\JJ\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D001930 NONE Mefenamic\JJ\1740 acid\NN\14818238 ,\,\1740 26\CD\13745420 (\-LRB-\1740 22\CD\13745420 -\SYM\1740 30\CD\13745420 )\-RRB-\1740 mg/kg\NN\1740 ,\,\1740 prevented\VBD\1740 seizures\NNS\14081375 and\CC\1740 protected\VBD\1127795 rats\NNS\2329401 from\IN\1740 seizure-related\JJ\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 380\CD\1740 mg/kg\NN\1740 .\.\1740
7147232
D000255_D007022 CID Cardiovascular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>adenosine\NN\14964367 triphosphate</e1>\NN\1740 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 on\IN\1740 dogs\NNS\2083346 with\IN\1740 denervated\JJ\1740 hearts\NNS\496167 .\.\1740
D000255_D007022 CID <e1>Adenosine\JJ\1740 triphosphate</e1>\NN\1740 (\-LRB-\1740 ATP\NN\14964590 )\-RRB-\1740 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 SNP\NN\11493266 )\-RRB-\1740 are\VBP\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 to\TO\1740 induce\VB\1627355 and\CC\1740 control\NN\5190804 <e2>hypotension</e2>\NN\14057371 during\IN\1740 anesthesia\NN\14034177 .\.\1740
D000255_D007022 CID Adenosine\JJ\1740 triphosphate\NN\1740 (\-LRB-\1740 <e1>ATP</e1>\NN\14964590 )\-RRB-\1740 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 SNP\NN\11493266 )\-RRB-\1740 are\VBP\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 to\TO\1740 induce\VB\1627355 and\CC\1740 control\NN\5190804 <e2>hypotension</e2>\NN\14057371 during\IN\1740 anesthesia\NN\14034177 .\.\1740
D000255_D007022 CID <e2>Hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>ATP</e1>\NN\14964590 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 significant\JJ\1740 decreases\NNS\7296428 in\IN\13603305 mean\JJ\1740 pulmonary\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 central\JJ\1740 venous\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 peripheral\JJ\1740 resistance\NN\37396 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 body\NN\19128 oxygen\NN\14622893 consumption\NN\13440063 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 all\PDT\1740 these\DT\1740 variables\NNS\2452 returned\VBD\1835496 normal\JJ\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 after\IN\1740 ATP\NN\14964590 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D000255_D007022 CID <e2>Hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 ATP\NN\14964590 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 significant\JJ\1740 decreases\NNS\7296428 in\IN\13603305 mean\JJ\1740 pulmonary\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 central\JJ\1740 venous\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 peripheral\JJ\1740 resistance\NN\37396 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 body\NN\19128 oxygen\NN\14622893 consumption\NN\13440063 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 all\PDT\1740 these\DT\1740 variables\NNS\2452 returned\VBD\1835496 normal\JJ\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 after\IN\1740 <e1>ATP</e1>\NN\14964590 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D009599_D007022 CID Cardiovascular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 adenosine\NN\14964367 triphosphate\NN\1740 and\CC\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 on\IN\1740 dogs\NNS\2083346 with\IN\1740 denervated\JJ\1740 hearts\NNS\496167 .\.\1740
D009599_D007022 CID Adenosine\JJ\1740 triphosphate\NN\1740 (\-LRB-\1740 ATP\NN\14964590 )\-RRB-\1740 and\CC\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (\-LRB-\1740 SNP\NN\11493266 )\-RRB-\1740 are\VBP\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 to\TO\1740 induce\VB\1627355 and\CC\1740 control\NN\5190804 <e2>hypotension</e2>\NN\14057371 during\IN\1740 anesthesia\NN\14034177 .\.\1740
D009599_D007022 CID Adenosine\JJ\1740 triphosphate\NN\1740 (\-LRB-\1740 ATP\NN\14964590 )\-RRB-\1740 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 <e1>SNP</e1>\NN\11493266 )\-RRB-\1740 are\VBP\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 to\TO\1740 induce\VB\1627355 and\CC\1740 control\NN\5190804 <e2>hypotension</e2>\NN\14057371 during\IN\1740 anesthesia\NN\14034177 .\.\1740
D009599_D007022 CID During\IN\1740 <e2>hypotension</e2>\NN\14057371 produced\VBN\1617192 by\IN\1740 <e1>SNP</e1>\NN\11493266 similar\JJ\1740 decreases\NNS\7296428 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 mean\JJ\1740 pulmonary\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 central\JJ\1740 venous\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 peripheral\JJ\1740 resistance\NN\37396 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 oxygen\NN\14622893 content\NN\7951464 difference\NN\4723816 between\IN\1740 arterial\JJ\1740 and\CC\1740 mixed\JJ\1740 venous\JJ\1740 blood\NN\5397468 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 while\IN\15122231 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 cardiac\JJ\1740 output\NN\4007894 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 were\VBD\836236 increased\VBN\169651 .\.\1740
D010100_D007022 NONE <e2>Hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 ATP\NN\14964590 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 significant\JJ\1740 decreases\NNS\7296428 in\IN\13603305 mean\JJ\1740 pulmonary\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 central\JJ\1740 venous\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 peripheral\JJ\1740 resistance\NN\37396 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 body\NN\19128 <e1>oxygen</e1>\NN\14622893 consumption\NN\13440063 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ;\:\1740 all\PDT\1740 these\DT\1740 variables\NNS\2452 returned\VBD\1835496 normal\JJ\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 after\IN\1740 ATP\NN\14964590 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D010100_D007022 NONE During\IN\1740 <e2>hypotension</e2>\NN\14057371 produced\VBN\1617192 by\IN\1740 SNP\NN\11493266 similar\JJ\1740 decreases\NNS\7296428 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 mean\JJ\1740 pulmonary\JJ\1740 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 central\JJ\1740 venous\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 end-diastolic\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 total\JJ\1740 peripheral\JJ\1740 resistance\NN\37396 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>oxygen</e1>\NN\14622893 content\NN\7951464 difference\NN\4723816 between\IN\1740 arterial\JJ\1740 and\CC\1740 mixed\JJ\1740 venous\JJ\1740 blood\NN\5397468 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 while\IN\15122231 heart\NN\5919034 rate\NN\13815152 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 cardiac\JJ\1740 output\NN\4007894 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 were\VBD\836236 increased\VBN\169651 .\.\1740
24665854
D014635_D022124 CID <e1>Valproate-induced</e1>\JJ\1740 <e2>hyperammonemic</e2>\JJ\1740 encephalopathy\JJ\1740 in\IN\13603305 a\DT\13649268 renal\JJ\1740 transplanted\VBN\2013571 patient\NN\9898892 .\.\1740
D014635_D022124 CID <e1>Valproate-induced</e1>\JJ\1740 <e2>hyperammonemic</e2>\JJ\1740 encephalopathy\JJ\1740 is\VBZ\836236 an\DT\6697703 uncommon\JJ\1740 but\CC\1740 serious\JJ\1740 effect\NN\34213 of\IN\1740 valproate\NN\1740 treatment\NN\654885 .\.\1740
D014635_D022124 CID Valproate-induced\JJ\1740 <e2>hyperammonemic</e2>\JJ\1740 encephalopathy\JJ\1740 is\VBZ\836236 an\DT\6697703 uncommon\JJ\1740 but\CC\1740 serious\JJ\1740 effect\NN\34213 of\IN\1740 <e1>valproate</e1>\NN\1740 treatment\NN\654885 .\.\1740
D014635_D022124 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 15-year-old\JJ\1740 girl\NN\10787470 who\WP\8299493 was\VBD\836236 on\IN\1740 a\DT\13649268 long-term\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>valproate</e1>\NN\1740 due\IN\5174653 to\IN\1740 epilepsy\NN\14085708 and\CC\1740 revealed\VBD\2137132 impaired\JJ\1740 consciousness\NN\5669934 with\IN\1740 <e2>hyperammonemia</e2>\NN\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D014635_D001927 NONE <e1>Valproate-induced</e1>\JJ\1740 hyperammonemic\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 in\IN\13603305 a\DT\13649268 renal\JJ\1740 transplanted\VBN\2013571 patient\NN\9898892 .\.\1740
D014635_D001927 NONE <e1>Valproate-induced</e1>\JJ\1740 hyperammonemic\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 is\VBZ\836236 an\DT\6697703 uncommon\JJ\1740 but\CC\1740 serious\JJ\1740 effect\NN\34213 of\IN\1740 valproate\NN\1740 treatment\NN\654885 .\.\1740
D014635_D001927 NONE Valproate-induced\JJ\1740 hyperammonemic\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 is\VBZ\836236 an\DT\6697703 uncommon\JJ\1740 but\CC\1740 serious\JJ\1740 effect\NN\34213 of\IN\1740 <e1>valproate</e1>\NN\1740 treatment\NN\654885 .\.\1740
D014635_D004827 NONE Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 15-year-old\JJ\1740 girl\NN\10787470 who\WP\8299493 was\VBD\836236 on\IN\1740 a\DT\13649268 long-term\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>valproate</e1>\NN\1740 due\IN\5174653 to\IN\1740 <e2>epilepsy</e2>\NN\14085708 and\CC\1740 revealed\VBD\2137132 impaired\JJ\1740 consciousness\NN\5669934 with\IN\1740 hyperammonemia\NN\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D014635_D003244 CID Here\RB\1740 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 15-year-old\JJ\1740 girl\NN\10787470 who\WP\8299493 was\VBD\836236 on\IN\1740 a\DT\13649268 long-term\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>valproate</e1>\NN\1740 due\IN\5174653 to\IN\1740 epilepsy\NN\14085708 and\CC\1740 revealed\VBD\2137132 <e2>impaired\JJ\1740 consciousness</e2>\NN\5669934 with\IN\1740 hyperammonemia\NN\1740 12\CD\13745420 days\NNS\15140892 after\IN\1740 renal\JJ\1740 transplantation\NN\671351 .\.\1740
8603459
D004317_D066126 CID <e1>Doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 monitored\VBN\2169352 by\IN\1740 ECG\NNP\7000195 in\IN\13603305 freely\RB\1740 moving\VBG\2367363 mice\NNS\2329401 .\.\1740
D004317_D066126 CID In\IN\13603305 laboratory\JJ\1740 animals\NNS\4475 ,\,\1740 histology\NN\6060049 is\VBZ\836236 most\RBS\1740 commonly\RB\1740 used\VBN\1156834 to\TO\1740 study\VB\630380 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 CID These\DT\1740 findings\NNS\7951464 result\VBP\2633881 in\IN\13603305 a\DT\13649268 model\NN\5888929 that\WDT\1740 allows\VBZ\797697 the\DT\1740 testing\NN\639556 of\IN\1740 protectors\NNS\10466918 against\IN\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 as\IN\14622893 demonstrated\VBN\2137132 by\IN\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 ICRF-187\NN\1740 .\.\1740
D004317_D006984 NONE After\IN\1740 sacrifice\NN\30358 the\DT\1740 hearts\NNS\496167 of\IN\1740 <e1>doxorubicin-treated</e1>\JJ\1740 animals\NNS\4475 were\VBD\836236 enlarged\VBN\153263 and\CC\1740 the\DT\1740 atria\NN\5392744 were\VBD\836236 <e2>hypertrophic</e2>\JJ\1740 .\.\1740
D064730_D064420 NONE As\IN\14622893 this\DT\1740 schedule\NN\5898568 exerted\VBD\1158872 more\JJR\1740 <e2>toxicity</e2>\NN\13576101 than\IN\1740 needed\VBN\2604760 to\TO\1740 investigate\VB\644583 protective\JJ\1740 agents\NNS\7347 ,\,\1740 the\DT\1740 protection\NN\407535 of\IN\1740 <e1>ICRF-187</e1>\NN\1740 was\VBD\836236 determined\VBN\1645601 using\VBG\1156834 a\DT\13649268 dose\NN\3740161 schedule\NN\5898568 with\IN\1740 lower\JJR\1740 general\JJ\1740 toxicity\NN\13576101 (\-LRB-\1740 6\CD\13741022 weekly\JJ\1740 doses\NNS\3740161 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 given\VBN\2327200 i.v.\NN\1740 plus\CC\4723816 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 observation\NN\996969 )\-RRB-\1740 .\.\1740
D064730_D064420 NONE As\IN\14622893 this\DT\1740 schedule\NN\5898568 exerted\VBD\1158872 more\JJR\1740 toxicity\NN\13576101 than\IN\1740 needed\VBN\2604760 to\TO\1740 investigate\VB\644583 protective\JJ\1740 agents\NNS\7347 ,\,\1740 the\DT\1740 protection\NN\407535 of\IN\1740 <e1>ICRF-187</e1>\NN\1740 was\VBD\836236 determined\VBN\1645601 using\VBG\1156834 a\DT\13649268 dose\NN\3740161 schedule\NN\5898568 with\IN\1740 lower\JJR\1740 general\JJ\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 6\CD\13741022 weekly\JJ\1740 doses\NNS\3740161 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 doxorubicin\NN\2716866 given\VBN\2327200 i.v.\NN\1740 plus\CC\4723816 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 observation\NN\996969 )\-RRB-\1740 .\.\1740
D004317_D064420 NONE As\IN\14622893 this\DT\1740 schedule\NN\5898568 exerted\VBD\1158872 more\JJR\1740 <e2>toxicity</e2>\NN\13576101 than\IN\1740 needed\VBN\2604760 to\TO\1740 investigate\VB\644583 protective\JJ\1740 agents\NNS\7347 ,\,\1740 the\DT\1740 protection\NN\407535 of\IN\1740 ICRF-187\NN\1740 was\VBD\836236 determined\VBN\1645601 using\VBG\1156834 a\DT\13649268 dose\NN\3740161 schedule\NN\5898568 with\IN\1740 lower\JJR\1740 general\JJ\1740 toxicity\NN\13576101 (\-LRB-\1740 6\CD\13741022 weekly\JJ\1740 doses\NNS\3740161 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 <e1>doxorubicin</e1>\NN\2716866 given\VBN\2327200 i.v.\NN\1740 plus\CC\4723816 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 observation\NN\996969 )\-RRB-\1740 .\.\1740
D004317_D064420 NONE As\IN\14622893 this\DT\1740 schedule\NN\5898568 exerted\VBD\1158872 more\JJR\1740 toxicity\NN\13576101 than\IN\1740 needed\VBN\2604760 to\TO\1740 investigate\VB\644583 protective\JJ\1740 agents\NNS\7347 ,\,\1740 the\DT\1740 protection\NN\407535 of\IN\1740 ICRF-187\NN\1740 was\VBD\836236 determined\VBN\1645601 using\VBG\1156834 a\DT\13649268 dose\NN\3740161 schedule\NN\5898568 with\IN\1740 lower\JJR\1740 general\JJ\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 6\CD\13741022 weekly\JJ\1740 doses\NNS\3740161 of\IN\1740 4\CD\13741022 mg/kg\NN\1740 <e1>doxorubicin</e1>\NN\2716866 given\VBN\2327200 i.v.\NN\1740 plus\CC\4723816 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 observation\NN\996969 )\-RRB-\1740 .\.\1740
D064730_D066126 NONE These\DT\1740 findings\NNS\7951464 result\VBP\2633881 in\IN\13603305 a\DT\13649268 model\NN\5888929 that\WDT\1740 allows\VBZ\797697 the\DT\1740 testing\NN\639556 of\IN\1740 protectors\NNS\10466918 against\IN\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 as\IN\14622893 demonstrated\VBN\2137132 by\IN\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 <e1>ICRF-187</e1>\NN\1740 .\.\1740
21195121
D009569_D012640 NONE The\DT\1740 role\NN\719494 of\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 lindane\NN\14919948 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009569_D012640 NONE These\DT\1740 results\NNS\34213 support\VBP\2199590 the\DT\1740 conclusion\NN\5837957 that\IN\1740 <e1>NO</e1>\NN\7204911 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 of\IN\1740 endogenous\JJ\1740 convulsant\NN\1740 in\IN\13603305 rat\NN\2329401 model\NN\5888929 of\IN\1740 lindane\NN\14919948 <e2>seizures</e2>\NNS\14081375 .\.\1740
D001556_D012640 CID The\DT\1740 role\NN\719494 of\IN\1740 nitric\JJ\1740 oxide\NN\14818238 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 <e1>lindane</e1>\NN\14919948 in\IN\13603305 rats\NNS\2329401 .\.\1740
D001556_D012640 CID The\DT\1740 administration\NN\1133281 of\IN\1740 L-arginine\NN\1740 (\-LRB-\1740 600\CD\1740 ,\,\1740 800\CD\1740 and\CC\1740 1000\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 dose-dependent\JJ\1740 manner\NN\4916342 significantly\RB\1740 increased\VBD\169651 <e2>convulsion</e2>\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 shortened\VBD\429060 latency\NN\15269513 time\NN\7308889 to\TO\1740 first\JJ\1740 convulsion\NN\14081375 elicited\VBN\1617192 by\IN\1740 lower\JJR\1740 <e1>lindane</e1>\NN\14919948 dose\NN\3740161 (\-LRB-\1740 4\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 CID The\DT\1740 administration\NN\1133281 of\IN\1740 L-arginine\NN\1740 (\-LRB-\1740 600\CD\1740 ,\,\1740 800\CD\1740 and\CC\1740 1000\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 dose-dependent\JJ\1740 manner\NN\4916342 significantly\RB\1740 increased\VBD\169651 convulsion\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 shortened\VBD\429060 latency\NN\15269513 time\NN\7308889 to\TO\1740 first\JJ\1740 <e2>convulsion</e2>\NN\14081375 elicited\VBN\1617192 by\IN\1740 lower\JJR\1740 <e1>lindane</e1>\NN\14919948 dose\NN\3740161 (\-LRB-\1740 4\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 CID On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 pretreatment\NN\1740 with\IN\1740 L-NAME\NN\1740 (\-LRB-\1740 500\CD\13745420 ,\,\1740 700\CD\1740 and\CC\1740 900\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 decreased\VBD\169651 <e2>convulsion</e2>\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 prolonged\JJ\1740 latency\NN\15269513 time\NN\7308889 to\TO\1740 convulsion\NN\14081375 following\VBG\1835496 injection\NN\320852 with\IN\1740 a\DT\13649268 convulsive\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>lindane</e1>\NN\14919948 (\-LRB-\1740 8\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 CID On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 pretreatment\NN\1740 with\IN\1740 L-NAME\NN\1740 (\-LRB-\1740 500\CD\13745420 ,\,\1740 700\CD\1740 and\CC\1740 900\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 decreased\VBD\169651 convulsion\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 prolonged\JJ\1740 latency\NN\15269513 time\NN\7308889 to\TO\1740 <e2>convulsion</e2>\NN\14081375 following\VBG\1835496 injection\NN\320852 with\IN\1740 a\DT\13649268 convulsive\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>lindane</e1>\NN\14919948 (\-LRB-\1740 8\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 CID On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 pretreatment\NN\1740 with\IN\1740 L-NAME\NN\1740 (\-LRB-\1740 500\CD\13745420 ,\,\1740 700\CD\1740 and\CC\1740 900\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 decreased\VBD\169651 convulsion\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 prolonged\JJ\1740 latency\NN\15269513 time\NN\7308889 to\TO\1740 convulsion\NN\14081375 following\VBG\1835496 injection\NN\320852 with\IN\1740 a\DT\13649268 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>lindane</e1>\NN\14919948 (\-LRB-\1740 8\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 CID These\DT\1740 results\NNS\34213 support\VBP\2199590 the\DT\1740 conclusion\NN\5837957 that\IN\1740 NO\NN\7204911 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 of\IN\1740 endogenous\JJ\1740 convulsant\NN\1740 in\IN\13603305 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>lindane</e1>\NN\14919948 <e2>seizures</e2>\NNS\14081375 .\.\1740
D005680_D012640 NONE It\PRP\6125041 evokes\VBZ\1617192 <e2>convulsions</e2>\NNS\14081375 mainly\RB\1740 trough\VBP\1740 the\DT\1740 blockage\NN\14034177 of\IN\1740 <e1>GABA(A</e1>\NN\1740 )\-RRB-\1740 receptors\NNS\5225602 .\.\1740
D009569_D004827 NONE <e1>Nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 ,\,\1740 gaseous\JJ\1740 neurotransmitter\NN\14807410 ,\,\1740 has\VBZ\2108377 contradictor\JJ\1740 role\NN\719494 in\IN\13603305 epileptogenesis\NN\1740 due\IN\5174653 to\TO\1740 opposite\JJ\1740 effects\NNS\13245626 of\IN\1740 L-arginine\NN\1740 ,\,\1740 precursor\NN\14580897 of\IN\1740 NO\NN\7204911 syntheses\NNS\13446390 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 and\CC\1740 L-NAME\NN\1740 (\-LRB-\1740 NOS\NN\7204911 inhibitor\NN\20090 )\-RRB-\1740 observed\VBN\2163746 in\IN\13603305 different\JJ\1740 <e2>epilepsy</e2>\NN\14085708 models\NNS\5888929 .\.\1740
D009569_D004827 NONE Nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 ,\,\1740 gaseous\JJ\1740 neurotransmitter\NN\14807410 ,\,\1740 has\VBZ\2108377 contradictor\JJ\1740 role\NN\719494 in\IN\13603305 epileptogenesis\NN\1740 due\IN\5174653 to\TO\1740 opposite\JJ\1740 effects\NNS\13245626 of\IN\1740 L-arginine\NN\1740 ,\,\1740 precursor\NN\14580897 of\IN\1740 NO\NN\7204911 syntheses\NNS\13446390 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 and\CC\1740 L-NAME\NN\1740 (\-LRB-\1740 NOS\NN\7204911 inhibitor\NN\20090 )\-RRB-\1740 observed\VBN\2163746 in\IN\13603305 different\JJ\1740 <e2>epilepsy</e2>\NN\14085708 models\NNS\5888929 .\.\1740
D009569_D004827 NONE Nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 ,\,\1740 gaseous\JJ\1740 neurotransmitter\NN\14807410 ,\,\1740 has\VBZ\2108377 contradictor\JJ\1740 role\NN\719494 in\IN\13603305 epileptogenesis\NN\1740 due\IN\5174653 to\TO\1740 opposite\JJ\1740 effects\NNS\13245626 of\IN\1740 L-arginine\NN\1740 ,\,\1740 precursor\NN\14580897 of\IN\1740 <e1>NO</e1>\NN\7204911 syntheses\NNS\13446390 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 and\CC\1740 L-NAME\NN\1740 (\-LRB-\1740 NOS\NN\7204911 inhibitor\NN\20090 )\-RRB-\1740 observed\VBN\2163746 in\IN\13603305 different\JJ\1740 <e2>epilepsy</e2>\NN\14085708 models\NNS\5888929 .\.\1740
D009569_D004827 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 current\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>NO</e1>\NN\7204911 on\IN\1740 the\DT\1740 behavioral\JJ\1740 and\CC\1740 EEG\NN\7000195 characteristics\NNS\5849040 of\IN\1740 lindane-induced\JJ\1740 <e2>epilepsy</e2>\NN\14085708 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D001120_D004827 NONE Nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 ,\,\1740 gaseous\JJ\1740 neurotransmitter\NN\14807410 ,\,\1740 has\VBZ\2108377 contradictor\JJ\1740 role\NN\719494 in\IN\13603305 epileptogenesis\NN\1740 due\IN\5174653 to\TO\1740 opposite\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>L-arginine</e1>\NN\1740 ,\,\1740 precursor\NN\14580897 of\IN\1740 NO\NN\7204911 syntheses\NNS\13446390 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 and\CC\1740 L-NAME\NN\1740 (\-LRB-\1740 NOS\NN\7204911 inhibitor\NN\20090 )\-RRB-\1740 observed\VBN\2163746 in\IN\13603305 different\JJ\1740 <e2>epilepsy</e2>\NN\14085708 models\NNS\5888929 .\.\1740
D019331_D004827 NONE Nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 ,\,\1740 gaseous\JJ\1740 neurotransmitter\NN\14807410 ,\,\1740 has\VBZ\2108377 contradictor\JJ\1740 role\NN\719494 in\IN\13603305 epileptogenesis\NN\1740 due\IN\5174653 to\TO\1740 opposite\JJ\1740 effects\NNS\13245626 of\IN\1740 L-arginine\NN\1740 ,\,\1740 precursor\NN\14580897 of\IN\1740 NO\NN\7204911 syntheses\NNS\13446390 (\-LRB-\1740 NOS\NN\7204911 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>L-NAME</e1>\NN\1740 (\-LRB-\1740 NOS\NN\7204911 inhibitor\NN\20090 )\-RRB-\1740 observed\VBN\2163746 in\IN\13603305 different\JJ\1740 <e2>epilepsy</e2>\NN\14085708 models\NNS\5888929 .\.\1740
D001556_D004827 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 current\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 effects\NNS\13245626 of\IN\1740 NO\NN\7204911 on\IN\1740 the\DT\1740 behavioral\JJ\1740 and\CC\1740 EEG\NN\7000195 characteristics\NNS\5849040 of\IN\1740 <e1>lindane-induced</e1>\JJ\1740 <e2>epilepsy</e2>\NN\14085708 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 albino\NN\9606527 rats\NNS\2329401 .\.\1740
D001120_D012640 NONE The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>L-arginine</e1>\NN\1740 (\-LRB-\1740 600\CD\1740 ,\,\1740 800\CD\1740 and\CC\1740 1000\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 dose-dependent\JJ\1740 manner\NN\4916342 significantly\RB\1740 increased\VBD\169651 <e2>convulsion</e2>\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 shortened\VBD\429060 latency\NN\15269513 time\NN\7308889 to\TO\1740 first\JJ\1740 convulsion\NN\14081375 elicited\VBN\1617192 by\IN\1740 lower\JJR\1740 lindane\NN\14919948 dose\NN\3740161 (\-LRB-\1740 4\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D001120_D012640 NONE The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>L-arginine</e1>\NN\1740 (\-LRB-\1740 600\CD\1740 ,\,\1740 800\CD\1740 and\CC\1740 1000\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 dose-dependent\JJ\1740 manner\NN\4916342 significantly\RB\1740 increased\VBD\169651 convulsion\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 shortened\VBD\429060 latency\NN\15269513 time\NN\7308889 to\TO\1740 first\JJ\1740 <e2>convulsion</e2>\NN\14081375 elicited\VBN\1617192 by\IN\1740 lower\JJR\1740 lindane\NN\14919948 dose\NN\3740161 (\-LRB-\1740 4\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D019331_D012640 NONE On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>L-NAME</e1>\NN\1740 (\-LRB-\1740 500\CD\13745420 ,\,\1740 700\CD\1740 and\CC\1740 900\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 decreased\VBD\169651 <e2>convulsion</e2>\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 prolonged\JJ\1740 latency\NN\15269513 time\NN\7308889 to\TO\1740 convulsion\NN\14081375 following\VBG\1835496 injection\NN\320852 with\IN\1740 a\DT\13649268 convulsive\JJ\1740 dose\NN\3740161 of\IN\1740 lindane\NN\14919948 (\-LRB-\1740 8\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D019331_D012640 NONE On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>L-NAME</e1>\NN\1740 (\-LRB-\1740 500\CD\13745420 ,\,\1740 700\CD\1740 and\CC\1740 900\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 decreased\VBD\169651 convulsion\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 prolonged\JJ\1740 latency\NN\15269513 time\NN\7308889 to\TO\1740 <e2>convulsion</e2>\NN\14081375 following\VBG\1835496 injection\NN\320852 with\IN\1740 a\DT\13649268 convulsive\JJ\1740 dose\NN\3740161 of\IN\1740 lindane\NN\14919948 (\-LRB-\1740 8\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D019331_D012640 NONE On\IN\1740 the\DT\1740 contrary\NN\13854649 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>L-NAME</e1>\NN\1740 (\-LRB-\1740 500\CD\13745420 ,\,\1740 700\CD\1740 and\CC\1740 900\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 decreased\VBD\169651 convulsion\NN\14081375 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 and\CC\1740 prolonged\JJ\1740 latency\NN\15269513 time\NN\7308889 to\TO\1740 convulsion\NN\14081375 following\VBG\1835496 injection\NN\320852 with\IN\1740 a\DT\13649268 <e2>convulsive</e2>\JJ\1740 dose\NN\3740161 of\IN\1740 lindane\NN\14919948 (\-LRB-\1740 8\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
3864191
D012459_D007674 NONE <e1>Salicylate</e1>\NN\3828465 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 the\DT\1740 Gunn\NNP\1740 rat\NN\2329401 :\:\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 prostaglandins\NNS\5414534 .\.\1740
D011453_D007674 NONE Salicylate\NN\3828465 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 the\DT\1740 Gunn\NNP\1740 rat\NN\2329401 :\:\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 <e1>prostaglandins</e1>\NNS\5414534 .\.\1740
D011453_D007674 NONE We\PRP\1740 examined\VBD\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 <e1>prostaglandins</e1>\NNS\5414534 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 analgesic\JJ\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 the\DT\1740 Gunn\NN\1740 strain\NN\7358060 of\IN\1740 rat\NN\2329401 .\.\1740
D011453_D007674 NONE The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 aspirin-treated\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 hematuria\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 creatinine\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 aspirin-treated\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D011453_D007674 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 enhanced\VBN\227165 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 contributes\VBZ\126264 to\TO\1740 maintenance\NN\266806 of\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 morphological\JJ\1740 integrity\NN\24720 ,\,\1740 and\CC\1740 that\IN\1740 inhibition\NN\1068773 of\IN\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 may\MD\15209706 lead\VB\1752884 to\TO\1740 pathological\JJ\1740 renal\JJ\1740 medullary\JJ\1740 lesions\NNS\14204950 and\CC\1740 <e2>deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
D011453_D007674 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 enhanced\VBN\227165 prostaglandin\NN\5414534 synthesis\NN\13446390 contributes\VBZ\126264 to\TO\1740 maintenance\NN\266806 of\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 morphological\JJ\1740 integrity\NN\24720 ,\,\1740 and\CC\1740 that\IN\1740 inhibition\NN\1068773 of\IN\1740 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 may\MD\15209706 lead\VB\1752884 to\TO\1740 pathological\JJ\1740 renal\JJ\1740 medullary\JJ\1740 lesions\NNS\14204950 and\CC\1740 <e2>deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
-1_D006932 NONE The\DT\1740 homozygous\JJ\1740 Gunn\NN\1740 rats\NNS\2329401 have\VBP\2108377 unconjugated\VBN\1740 <e2>hyperbilirubinemia</e2>\NN\14204950 due\JJ\1740 to\TO\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>glucuronyl</e1>\NN\1740 transferase\NN\14732946 ,\,\1740 leading\VBG\1752884 to\TO\1740 marked\JJ\1740 bilirubin\NN\14756039 deposition\NN\13424865 in\IN\13603305 renal\JJ\1740 medulla\NN\14864360 and\CC\1740 papilla\NN\5470189 .\.\1740
D001663_D006932 NONE The\DT\1740 homozygous\JJ\1740 Gunn\NN\1740 rats\NNS\2329401 have\VBP\2108377 unconjugated\VBN\1740 <e2>hyperbilirubinemia</e2>\NN\14204950 due\JJ\1740 to\TO\1740 the\DT\1740 absence\NN\14449405 of\IN\1740 glucuronyl\NN\1740 transferase\NN\14732946 ,\,\1740 leading\VBG\1752884 to\TO\1740 marked\JJ\1740 <e1>bilirubin</e1>\NN\14756039 deposition\NN\13424865 in\IN\13603305 renal\JJ\1740 medulla\NN\14864360 and\CC\1740 papilla\NN\5470189 .\.\1740
D011453_D006417 NONE The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 damage\NN\7296428 in\IN\13603305 aspirin-treated\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>hematuria</e2>\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 creatinine\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 aspirin-treated\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D001241_D007674 CID The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 <e1>aspirin-treated</e1>\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 hematuria\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 creatinine\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 aspirin-treated\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D001241_D007674 CID The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 aspirin-treated\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 hematuria\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 creatinine\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 <e1>aspirin-treated</e1>\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D001241_D006417 NONE The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 damage\NN\7296428 in\IN\13603305 <e1>aspirin-treated</e1>\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>hematuria</e2>\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 creatinine\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 aspirin-treated\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D001241_D006417 NONE The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 damage\NN\7296428 in\IN\13603305 aspirin-treated\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>hematuria</e2>\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 creatinine\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 <e1>aspirin-treated</e1>\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D003404_D007674 NONE The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 aspirin-treated\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 hematuria\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 aspirin-treated\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D003404_D006417 NONE The\DT\1740 changes\NNS\7283608 in\IN\13603305 renal\JJ\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 were\VBD\836236 accompanied\VBN\1835496 by\IN\1740 evidence\NN\5816287 of\IN\1740 renal\JJ\1740 damage\NN\7296428 in\IN\13603305 aspirin-treated\JJ\1740 jj\NN\1740 but\CC\1740 not\RB\1740 jJ\NN\1740 rats\NNS\2329401 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 :\:\1740 increased\VBN\169651 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>hematuria</e2>\NN\14299637 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ;\:\1740 increased\VBN\169651 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 increase\VB\169651 in\IN\13603305 outer\JJ\1740 medullary\JJ\1740 histopathologic\JJ\1740 lesions\NNS\14204950 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.005\CD\1740 compared\VBN\644583 to\TO\1740 either\CC\1740 sham-treated\JJ\1740 jj\NN\1740 or\CC\3541091 aspirin-treated\JJ\1740 jJ\NN\1740 )\-RRB-\1740 .\.\1740
D011453_D058186 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 enhanced\VBN\227165 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 contributes\VBZ\126264 to\TO\1740 maintenance\NN\266806 of\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 morphological\JJ\1740 integrity\NN\24720 ,\,\1740 and\CC\1740 that\IN\1740 inhibition\NN\1068773 of\IN\1740 prostaglandin\NN\5414534 synthesis\NN\13446390 may\MD\15209706 lead\VB\1752884 to\TO\1740 <e2>pathological\JJ\1740 renal\JJ\1740 medullary\JJ\1740 lesions</e2>\NNS\14204950 and\CC\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D011453_D058186 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 enhanced\VBN\227165 prostaglandin\NN\5414534 synthesis\NN\13446390 contributes\VBZ\126264 to\TO\1740 maintenance\NN\266806 of\IN\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 morphological\JJ\1740 integrity\NN\24720 ,\,\1740 and\CC\1740 that\IN\1740 inhibition\NN\1068773 of\IN\1740 <e1>prostaglandin</e1>\NN\5414534 synthesis\NN\13446390 may\MD\15209706 lead\VB\1752884 to\TO\1740 <e2>pathological\JJ\1740 renal\JJ\1740 medullary\JJ\1740 lesions</e2>\NNS\14204950 and\CC\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
15815446
D010656_D002545 NONE Focal\JJ\1740 <e2>cerebral\JJ\1740 ischemia</e2>\NN\14195315 in\IN\13603305 rats\NNS\2329401 :\:\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 during\IN\1740 reperfusion\NN\1740 .\.\1740
D010656_D006973 CID Focal\JJ\1740 cerebral\JJ\1740 ischemia\NN\14195315 in\IN\13603305 rats\NNS\2329401 :\:\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 during\IN\1740 reperfusion\NN\1740 .\.\1740
D010656_D006973 CID After\IN\1740 180\CD\1740 min\NN\15154774 of\IN\1740 temporary\JJ\1740 middle\NN\8497294 cerebral\JJ\1740 artery\NN\5417975 occlusion\NN\14081375 in\IN\13603305 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 on\IN\1740 ischemic\JJ\1740 brain\NN\5462674 injury\NN\14052046 and\CC\1740 blood-brain\JJ\1740 barrier\NN\3839993 permeability\NN\4940146 was\VBD\836236 determined\VBN\1645601 .\.\1740
D010656_D006973 CID After\IN\1740 180\CD\1740 min\NN\15154774 of\IN\1740 temporary\JJ\1740 middle\NN\8497294 cerebral\JJ\1740 artery\NN\5417975 occlusion\NN\14081375 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 on\IN\1740 ischemic\JJ\1740 brain\NN\5462674 injury\NN\14052046 and\CC\1740 blood-brain\JJ\1740 barrier\NN\3839993 permeability\NN\4940146 was\VBD\836236 determined\VBN\1645601 .\.\1740
D010656_D020244 NONE After\IN\1740 180\CD\1740 min\NN\15154774 of\IN\1740 temporary\JJ\1740 <e2>middle\NN\8497294 cerebral\JJ\1740 artery\NN\5417975 occlusion</e2>\NN\14081375 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 on\IN\1740 ischemic\JJ\1740 brain\NN\5462674 injury\NN\14052046 and\CC\1740 blood-brain\JJ\1740 barrier\NN\3839993 permeability\NN\4940146 was\VBD\836236 determined\VBN\1645601 .\.\1740
D010656_D001930 NONE After\IN\1740 180\CD\1740 min\NN\15154774 of\IN\1740 temporary\JJ\1740 middle\NN\8497294 cerebral\JJ\1740 artery\NN\5417975 occlusion\NN\14081375 in\IN\13603305 spontaneously\JJ\1740 hypertensive\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 hypertension\NN\14057371 on\IN\1740 <e2>ischemic\JJ\1740 brain\NN\5462674 injury</e2>\NN\14052046 and\CC\1740 blood-brain\JJ\1740 barrier\NN\3839993 permeability\NN\4940146 was\VBD\836236 determined\VBN\1645601 .\.\1740
C009591_D001930 NONE Part\NN\31921 A\NN\13649268 ,\,\1740 for\IN\1740 eight\CD\13741022 rats\NNS\2329401 in\IN\13603305 each\DT\1740 group\NN\2137 <e2>brain\NN\5462674 injury</e2>\NN\14052046 was\VBD\836236 evaluated\VBN\670261 by\IN\1740 staining\VBG\283090 tissue\NN\5220461 using\VBG\1156834 <e1>2,3,5-triphenyltetrazolium\NN\1740 chloride</e1>\NN\14818238 and\CC\1740 edema\NN\14315192 was\VBD\836236 evaluated\VBN\670261 by\IN\1740 microgravimetry\NN\1740 .\.\1740
C009591_D004487 NONE Part\NN\31921 A\NN\13649268 ,\,\1740 for\IN\1740 eight\CD\13741022 rats\NNS\2329401 in\IN\13603305 each\DT\1740 group\NN\2137 brain\NN\5462674 injury\NN\14052046 was\VBD\836236 evaluated\VBN\670261 by\IN\1740 staining\VBG\283090 tissue\NN\5220461 using\VBG\1156834 <e1>2,3,5-triphenyltetrazolium\NN\1740 chloride</e1>\NN\14818238 and\CC\1740 <e2>edema</e2>\NN\14315192 was\VBD\836236 evaluated\VBN\670261 by\IN\1740 microgravimetry\NN\1740 .\.\1740
D005070_D006973 NONE <e1>Evans\NNP\1740 Blue</e1>\NNP\4959672 (\-LRB-\1740 mug\NN\13756125 g-1\NN\1740 of\IN\1740 brain\NN\5462674 tissue\NN\5220461 )\-RRB-\1740 was\VBD\836236 greater\JJR\1740 in\IN\13603305 the\DT\1740 <e2>90/HTN</e2>\JJ\1740 group\NN\2137 (\-LRB-\1740 24.4\CD\1740 +/-\CC\1740 6.0\CD\1740 )\-RRB-\1740 versus\CC\1740 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 12.3\CD\1740 +/-\CC\1740 4.1\CD\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 in\IN\13603305 turn\NN\13867641 greater\JJR\1740 than\IN\1740 the\DT\1740 15/HTN\CD\1740 group\NN\2137 (\-LRB-\1740 7.3\CD\1740 +/-\CC\1740 3.2\CD\1740 )\-RRB-\1740 .\.\1740
D005070_D006973 NONE <e1>Evans\NNP\1740 Blue</e1>\NNP\4959672 (\-LRB-\1740 mug\NN\13756125 g-1\NN\1740 of\IN\1740 brain\NN\5462674 tissue\NN\5220461 )\-RRB-\1740 was\VBD\836236 greater\JJR\1740 in\IN\13603305 the\DT\1740 90/HTN\JJ\1740 group\NN\2137 (\-LRB-\1740 24.4\CD\1740 +/-\CC\1740 6.0\CD\1740 )\-RRB-\1740 versus\CC\1740 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 12.3\CD\1740 +/-\CC\1740 4.1\CD\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 in\IN\13603305 turn\NN\13867641 greater\JJR\1740 than\IN\1740 the\DT\1740 <e2>15/HTN</e2>\CD\1740 group\NN\2137 (\-LRB-\1740 7.3\CD\1740 +/-\CC\1740 3.2\CD\1740 )\-RRB-\1740 .\.\1740
15276093
C451780_D006937 NONE <e1>Niacin\NN\15090742 extended-release/lovastatin</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 new\JJ\1740 combination\NN\7951464 product\NN\3076708 approved\VBN\803325 for\IN\1740 treatment\NN\654885 of\IN\1740 primary\JJ\1740 <e2>hypercholesterolemia</e2>\NN\14299637 and\CC\1740 mixed\JJ\1740 dyslipidemia\NN\1740 .\.\1740
C451780_D050171 NONE <e1>Niacin\NN\15090742 extended-release/lovastatin</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 new\JJ\1740 combination\NN\7951464 product\NN\3076708 approved\VBN\803325 for\IN\1740 treatment\NN\654885 of\IN\1740 primary\JJ\1740 hypercholesterolemia\NN\14299637 and\CC\1740 mixed\JJ\1740 <e2>dyslipidemia</e2>\NN\1740 .\.\1740
C451780_D050171 NONE Patients\NNS\9898892 also\RB\1740 received\VBD\2210855 dietary\JJ\1740 counseling\NN\6598915 ,\,\1740 educational\JJ\1740 materials\NNS\19613 ,\,\1740 and\CC\1740 reminders\NNS\6598915 to\TO\1740 call\VB\1029852 a\DT\13649268 toll-free\JJ\1740 number\NN\5107765 that\WDT\1740 provided\VBD\2199590 further\JJ\1740 education\NN\407535 about\IN\1740 <e2>dyslipidemia</e2>\NN\1740 and\CC\1740 <e1>niacin\NN\15090742 extended-release/lovastatin</e1>\NN\1740 .\.\1740
D003401_D009135 NONE An\DT\6697703 increase\NN\13576355 of\IN\1740 <e1>creatine</e1>\NN\14601829 phosphokinase\NN\1740 to\TO\1740 >\NNS\1740 5\CD\13741022 times\NNS\15113229 the\DT\1740 upper\JJ\1740 limit\NN\5123416 of\IN\1740 normal\JJ\1740 occurred\VBD\2623529 in\IN\13603305 0.24\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 no\DT\7204911 cases\NNS\7283608 of\IN\1740 drug-induced\JJ\1740 <e2>myopathy</e2>\NN\14204950 were\VBD\836236 observed\VBN\2163746 .\.\1740
7479194
D015662_D064420 NONE A\DT\13649268 large\JJ\1740 population-based\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 <e1>trimethoprim-sulfamethoxazole</e1>\JJ\1740 ,\,\1740 trimethoprim\VBP\1740 ,\,\1740 and\CC\1740 cephalexin\NN\2996840 for\IN\1740 uncommon\JJ\1740 serious\JJ\1740 <e2>drug\NN\14778436 toxicity</e2>\NN\13576101 .\.\1740
D014295_D064420 NONE A\DT\13649268 large\JJ\1740 population-based\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 trimethoprim-sulfamethoxazole\JJ\1740 ,\,\1740 <e1>trimethoprim</e1>\VBP\1740 ,\,\1740 and\CC\1740 cephalexin\NN\2996840 for\IN\1740 uncommon\JJ\1740 serious\JJ\1740 <e2>drug\NN\14778436 toxicity</e2>\NN\13576101 .\.\1740
D002506_D064420 NONE A\DT\13649268 large\JJ\1740 population-based\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 trimethoprim-sulfamethoxazole\JJ\1740 ,\,\1740 trimethoprim\VBP\1740 ,\,\1740 and\CC\1740 <e1>cephalexin</e1>\NN\2996840 for\IN\1740 uncommon\JJ\1740 serious\JJ\1740 <e2>drug\NN\14778436 toxicity</e2>\NN\13576101 .\.\1740
D015662_D008107 CID The\DT\1740 risk\NN\14541044 of\IN\1740 clinically\RB\1740 important\JJ\1740 idiopathic\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 was\VBD\836236 similar\JJ\1740 for\IN\1740 persons\NNS\7347 prescribed\VBN\748282 <e1>TMP-SMZ</e1>\NN\1740 (\-LRB-\1740 5.2/100,000\JJ\1740 )\-RRB-\1740 and\CC\1740 those\DT\1740 prescribed\VBN\748282 trimethoprim\NN\1740 alone\RB\1740 (\-LRB-\1740 3.8/100,000\CD\1740 )\-RRB-\1740 .\.\1740
D015662_D008107 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D008107 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 <e1>TMP-SMZ</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D006402 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D006402 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 <e1>TMP-SMZ</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D012871 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D012871 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 <e1>TMP-SMZ</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D007674 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 <e1>trimethoprim-sulfamethoxazole</e1>\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D007674 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 <e1>TMP-SMZ</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D014295_D008107 CID The\DT\1740 risk\NN\14541044 of\IN\1740 clinically\RB\1740 important\JJ\1740 idiopathic\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 was\VBD\836236 similar\JJ\1740 for\IN\1740 persons\NNS\7347 prescribed\VBN\748282 TMP-SMZ\NN\1740 (\-LRB-\1740 5.2/100,000\JJ\1740 )\-RRB-\1740 and\CC\1740 those\DT\1740 prescribed\VBN\748282 <e1>trimethoprim</e1>\NN\1740 alone\RB\1740 (\-LRB-\1740 3.8/100,000\CD\1740 )\-RRB-\1740 .\.\1740
D014295_D008107 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 <e1>trimethoprim</e1>\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D014295_D006402 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 <e1>trimethoprim</e1>\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D014295_D012871 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 <e1>trimethoprim</e1>\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D014295_D007674 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 <e1>trimethoprim</e1>\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 cephalexin\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D002506_D008107 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 <e1>cephalexin</e1>\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D002506_D006402 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 <e1>cephalexin</e1>\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D002506_D012871 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 <e1>cephalexin</e1>\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D002506_D007674 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 population-based\JJ\1740 45-day\JJ\1740 follow-up\NN\4599396 study\NN\635850 of\IN\1740 232,390\CD\1740 people\NNS\31264 who\WP\8299493 were\VBD\836236 prescribed\VBN\748282 trimethoprim-sulfamethoxazole\NN\1740 (\-LRB-\1740 TMP-SMZ\NN\1740 )\-RRB-\1740 ,\,\1740 266,951\CD\1740 prescribed\VBD\748282 trimethoprim\NN\1740 alone\RB\1740 ,\,\1740 and\CC\1740 196,397\CD\1740 prescribed\VBN\748282 <e1>cephalexin</e1>\NNS\2996840 ,\,\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 serious\JJ\1740 <e2>liver\NN\5298729 ,\,\1740 blood\NN\5397468 ,\,\1740 skin\NN\5237755 ,\,\1740 and\CC\1740 renal\JJ\1740 disorders</e2>\NNS\14034177 resulting\VBG\2633881 in\IN\13603305 referral\NN\9898892 or\CC\3541091 hospitalization\NN\15113229 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D015662_D004892 NONE Only\RB\1740 five\CD\13741022 patients\NNS\9898892 experienced\VBD\2108377 blood\NN\5397468 disorders\NNS\14034177 ,\,\1740 one\CD\13741022 of\IN\1740 whom\WP\1740 was\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>TMP-SMZ</e1>\NN\1740 ;\:\1740 of\IN\1740 seven\CD\13741022 with\IN\1740 <e2>erythema\NN\14227218 multiforme</e2>\JJ\1740 and\CC\1740 Stevens-Johnson\NN\1740 syndrome\NN\5870365 ,\,\1740 four\CD\13741022 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 TMP-SMZ\NN\1740 .\.\1740
D015662_D004892 NONE Only\RB\1740 five\CD\13741022 patients\NNS\9898892 experienced\VBD\2108377 blood\NN\5397468 disorders\NNS\14034177 ,\,\1740 one\CD\13741022 of\IN\1740 whom\WP\1740 was\VBD\836236 exposed\VBN\2110927 to\TO\1740 TMP-SMZ\NN\1740 ;\:\1740 of\IN\1740 seven\CD\13741022 with\IN\1740 <e2>erythema\NN\14227218 multiforme</e2>\JJ\1740 and\CC\1740 Stevens-Johnson\NN\1740 syndrome\NN\5870365 ,\,\1740 four\CD\13741022 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>TMP-SMZ</e1>\NN\1740 .\.\1740
D015662_D013262 CID Only\RB\1740 five\CD\13741022 patients\NNS\9898892 experienced\VBD\2108377 blood\NN\5397468 disorders\NNS\14034177 ,\,\1740 one\CD\13741022 of\IN\1740 whom\WP\1740 was\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>TMP-SMZ</e1>\NN\1740 ;\:\1740 of\IN\1740 seven\CD\13741022 with\IN\1740 erythema\NN\14227218 multiforme\JJ\1740 and\CC\1740 <e2>Stevens-Johnson\NN\1740 syndrome</e2>\NN\5870365 ,\,\1740 four\CD\13741022 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 TMP-SMZ\NN\1740 .\.\1740
D015662_D013262 CID Only\RB\1740 five\CD\13741022 patients\NNS\9898892 experienced\VBD\2108377 blood\NN\5397468 disorders\NNS\14034177 ,\,\1740 one\CD\13741022 of\IN\1740 whom\WP\1740 was\VBD\836236 exposed\VBN\2110927 to\TO\1740 TMP-SMZ\NN\1740 ;\:\1740 of\IN\1740 seven\CD\13741022 with\IN\1740 erythema\NN\14227218 multiforme\JJ\1740 and\CC\1740 <e2>Stevens-Johnson\NN\1740 syndrome</e2>\NN\5870365 ,\,\1740 four\CD\13741022 were\VBD\836236 exposed\VBN\2110927 to\TO\1740 <e1>TMP-SMZ</e1>\NN\1740 .\.\1740
D002506_D013262 CID The\DT\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e2>toxic\JJ\1740 epidermal\JJ\1740 necrolysis</e2>\NN\13509528 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 took\VBD\2367363 <e1>cephalexin</e1>\NNS\2996840 .\.\1740
8511251
D003042_D017202 CID <e1>Cocaine</e1>\NN\3492717 induced\VBD\1627355 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D003042_D017202 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 induced\VBN\1627355 by\IN\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D005996_D007511 NONE The\DT\1740 <e2>ischemia</e2>\NN\14195315 probably\RB\1740 induced\VBN\1627355 by\IN\1740 coronary\JJ\1740 artery\NN\5417975 spasm\NN\14299637 was\VBD\836236 reversed\VBN\109660 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 and\CC\1740 calcium\NN\14625458 blocking\NN\562280 agents\NNS\7347 .\.\1740
D005996_D003329 NONE The\DT\1740 ischemia\NN\14195315 probably\RB\1740 induced\VBN\1627355 by\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 spasm</e2>\NN\14299637 was\VBD\836236 reversed\VBN\109660 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 and\CC\1740 calcium\NN\14625458 blocking\NN\562280 agents\NNS\7347 .\.\1740
D002118_D007511 NONE The\DT\1740 <e2>ischemia</e2>\NN\14195315 probably\RB\1740 induced\VBN\1627355 by\IN\1740 coronary\JJ\1740 artery\NN\5417975 spasm\NN\14299637 was\VBD\836236 reversed\VBN\109660 by\IN\1740 nitroglycerin\NN\15015501 and\CC\1740 <e1>calcium</e1>\NN\14625458 blocking\NN\562280 agents\NNS\7347 .\.\1740
D002118_D003329 NONE The\DT\1740 ischemia\NN\14195315 probably\RB\1740 induced\VBN\1627355 by\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 spasm</e2>\NN\14299637 was\VBD\836236 reversed\VBN\109660 by\IN\1740 nitroglycerin\NN\15015501 and\CC\1740 <e1>calcium</e1>\NN\14625458 blocking\NN\562280 agents\NNS\7347 .\.\1740
19447152
D010042_D001714 CID Animal\JJ\1740 model\NN\5888929 of\IN\1740 <e2>mania</e2>\NN\9180259 induced\VBN\1627355 by\IN\1740 <e1>ouabain</e1>\NN\1740 :\:\1740 Evidence\NN\5816287 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 submitochondrial\JJ\1740 particles\NNS\14580897 of\IN\1740 the\DT\1740 rat\NN\2329401 brain\NN\5462674 .\.\1740
D010042_D001714 CID The\DT\1740 intracerebroventricular\NN\1740 (\-LRB-\1740 ICV\NN\1740 )\-RRB-\1740 administration\NN\1133281 of\IN\1740 <e1>ouabain</e1>\NN\1740 (\-LRB-\1740 a\DT\13649268 Na(+)/K(+)-ATPase\NN\1740 inhibitor\NN\20090 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 mimic\VB\1742886 some\DT\1740 symptoms\NNS\5823932 of\IN\1740 human\JJ\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 .\.\1740
D010042_D001714 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>ouabain-induced</e1>\JJ\1740 <e2>mania-like</e2>\JJ\1740 behavior\NN\407535 may\MD\15209706 provide\VB\2199590 a\DT\13649268 useful\JJ\1740 animal\NN\4475 model\NN\5888929 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 of\IN\1740 the\DT\1740 involvement\NN\1080366 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D010042_D001714 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>ouabain-induced</e1>\JJ\1740 mania-like\JJ\1740 behavior\NN\407535 may\MD\15209706 provide\VB\2199590 a\DT\13649268 useful\JJ\1740 animal\NN\4475 model\NN\5888929 to\TO\1740 test\VB\670261 the\DT\1740 hypothesis\NN\7162194 of\IN\1740 the\DT\1740 involvement\NN\1080366 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D012964_D001714 NONE The\DT\1740 intracerebroventricular\NN\1740 (\-LRB-\1740 ICV\NN\1740 )\-RRB-\1740 administration\NN\1133281 of\IN\1740 ouabain\NN\1740 (\-LRB-\1740 a\DT\13649268 <e1>Na(+)/K(+)-ATPase</e1>\NN\1740 inhibitor\NN\20090 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 mimic\VB\1742886 some\DT\1740 symptoms\NNS\5823932 of\IN\1740 human\JJ\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 .\.\1740
D011188_D001714 NONE The\DT\1740 intracerebroventricular\NN\1740 (\-LRB-\1740 ICV\NN\1740 )\-RRB-\1740 administration\NN\1133281 of\IN\1740 ouabain\NN\1740 (\-LRB-\1740 a\DT\13649268 <e1>Na(+)/K(+)-ATPase</e1>\NN\1740 inhibitor\NN\20090 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 has\VBZ\2108377 been\VBN\836236 suggested\VBN\1010118 to\TO\1740 mimic\VB\1742886 some\DT\1740 symptoms\NNS\5823932 of\IN\1740 human\JJ\1740 <e2>bipolar\JJ\1740 mania</e2>\NN\9180259 .\.\1740
D010042_D009069 NONE Our\PRP$\1740 findings\NNS\7951464 demonstrated\VBD\2137132 that\IN\1740 <e1>ouabain</e1>\VBP\1740 at\IN\14622893 10(-2\CD\1740 )\-RRB-\1740 and\CC\1740 10(-3)M\CD\1740 induced\VBD\1627355 <e2>hyperlocomotion</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 ,\,\1740 and\CC\1740 this\DT\1740 response\NN\11410625 remained\VBD\2604760 up\RB\1740 to\TO\1740 7\CD\13741022 days\NNS\15140892 following\VBG\1835496 a\DT\13649268 single\JJ\1740 ICV\NN\1740 injection\NN\320852 .\.\1740
733189
D000305_D015356 NONE Bilateral\JJ\1740 <e2>retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\JJ\1740 occlusion</e2>\NN\14081375 following\VBG\1835496 the\DT\1740 injection\NN\320852 of\IN\1740 long-acting\JJ\1740 <e1>corticosteroid</e1>\NN\14745635 suspensions\NNS\14586258 in\IN\13603305 combination\NN\7951464 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 :\:\1740 I.\NNP\1740 Clinical\JJ\1740 studies\NNS\635850 .\.\1740
C000873_D015356 CID Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 <e2>retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions</e2>\NNS\14081375 with\IN\1740 blindness\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 <e1>methylprednisolone\JJ\1740 acetate</e1>\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 lidocaine\NN\3681148 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 penicillin\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
C000873_D001766 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions\NNS\14081375 with\IN\1740 <e2>blindness</e2>\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 <e1>methylprednisolone\JJ\1740 acetate</e1>\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 lidocaine\NN\3681148 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 penicillin\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
D008012_D015356 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 <e2>retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions</e2>\NNS\14081375 with\IN\1740 blindness\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 methylprednisolone\JJ\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>lidocaine</e1>\NN\3681148 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 penicillin\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
D008012_D001766 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions\NNS\14081375 with\IN\1740 <e2>blindness</e2>\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 methylprednisolone\JJ\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>lidocaine</e1>\NN\3681148 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 penicillin\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
D004837_D015356 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 <e2>retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions</e2>\NNS\14081375 with\IN\1740 blindness\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 methylprednisolone\JJ\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 lidocaine\NN\3681148 ,\,\1740 <e1>epinephrine</e1>\NN\14807929 ,\,\1740 or\CC\3541091 penicillin\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
D004837_D001766 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions\NNS\14081375 with\IN\1740 <e2>blindness</e2>\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 methylprednisolone\JJ\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 lidocaine\NN\3681148 ,\,\1740 <e1>epinephrine</e1>\NN\14807929 ,\,\1740 or\CC\3541091 penicillin\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
D010406_D015356 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 <e2>retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions</e2>\NNS\14081375 with\IN\1740 blindness\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 methylprednisolone\JJ\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 lidocaine\NN\3681148 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 <e1>penicillin</e1>\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
D010406_D001766 NONE Two\CD\13741022 well-documented\JJ\1740 cases\NNS\7283608 of\IN\1740 bilateral\JJ\1740 retinal\JJ\1740 artery\NN\5417975 and\CC\1740 choriocapillaris\NN\1740 occlusions\NNS\14081375 with\IN\1740 <e2>blindness</e2>\NN\14552802 following\VBG\1835496 head\NN\5225090 and\CC\1740 neck\NN\5225090 soft-tissue\NN\1740 injection\NN\320852 with\IN\1740 methylprednisolone\JJ\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 lidocaine\NN\3681148 ,\,\1740 epinephrine\NN\14807929 ,\,\1740 or\CC\3541091 <e1>penicillin</e1>\NN\2716866 are\VBP\836236 reported\VBN\831651 .\.\1740
20566328
D003042_D028361 NONE <e2>Mitochondrial\JJ\1740 impairment</e2>\NN\7296428 contributes\VBZ\126264 to\TO\1740 <e1>cocaine-induced</e1>\JJ\1740 cardiac\JJ\1740 dysfunction\NN\14204950 :\:\1740 Prevention\NN\1073995 by\IN\1740 the\DT\1740 targeted\VBN\1151110 antioxidant\JJ\1740 MitoQ.\NN\1740
D003042_D028361 NONE This\DT\1740 uncoupling\NN\1740 effect\NN\34213 on\IN\1740 oxidative\JJ\1740 phosphorylation\NN\1740 was\VBD\836236 not\RB\1740 detectable\JJ\1740 after\IN\1740 short-term\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>cocaine</e1>\NN\3492717 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 these\DT\1740 <e2>mitochondrial\JJ\1740 abnormalities</e2>\NNS\14034177 were\VBD\836236 a\DT\13649268 late\JJ\1740 rather\RB\1740 than\IN\1740 a\DT\13649268 primary\JJ\1740 event\NN\23100 in\IN\13603305 the\DT\1740 pathological\JJ\1740 response\NN\11410625 to\TO\1740 cocaine\NN\3492717 .\.\1740
D003042_D028361 NONE This\DT\1740 uncoupling\NN\1740 effect\NN\34213 on\IN\1740 oxidative\JJ\1740 phosphorylation\NN\1740 was\VBD\836236 not\RB\1740 detectable\JJ\1740 after\IN\1740 short-term\JJ\1740 exposure\NN\5042871 to\TO\1740 cocaine\NN\3492717 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 these\DT\1740 <e2>mitochondrial\JJ\1740 abnormalities</e2>\NNS\14034177 were\VBD\836236 a\DT\13649268 late\JJ\1740 rather\RB\1740 than\IN\1740 a\DT\13649268 primary\JJ\1740 event\NN\23100 in\IN\13603305 the\DT\1740 pathological\JJ\1740 response\NN\11410625 to\TO\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D003042_D028361 NONE Taken\VBN\2367363 together\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 extend\VBP\153263 previous\JJ\1740 studies\NNS\635850 and\CC\1740 demonstrate\VBP\2137132 that\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 cardiac\JJ\1740 dysfunction\NN\14204950 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 <e2>mitochondrial\JJ\1740 defect</e2>\NN\14462666 .\.\1740
D003042_D006331 CID Mitochondrial\JJ\1740 impairment\NN\7296428 contributes\VBZ\126264 to\TO\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 :\:\1740 Prevention\NN\1073995 by\IN\1740 the\DT\1740 targeted\VBN\1151110 antioxidant\JJ\1740 MitoQ.\NN\1740
D003042_D006331 CID The\DT\1740 goal\NN\5809192 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 mitochondrial\JJ\1740 function\NN\13783581 and\CC\1740 ROS\NN\6894544 production\NN\30358 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D003042_D006331 CID Taken\VBN\2367363 together\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 extend\VBP\153263 previous\JJ\1740 studies\NNS\635850 and\CC\1740 demonstrate\VBP\2137132 that\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 mitochondrial\JJ\1740 defect\NN\14462666 .\.\1740
C476756_D028361 NONE <e2>Mitochondrial\JJ\1740 impairment</e2>\NN\7296428 contributes\VBZ\126264 to\TO\1740 cocaine-induced\JJ\1740 cardiac\JJ\1740 dysfunction\NN\14204950 :\:\1740 Prevention\NN\1073995 by\IN\1740 the\DT\1740 targeted\VBN\1151110 antioxidant\JJ\1740 <e1>MitoQ.</e1>\NN\1740
C476756_D028361 NONE <e1>MitoQ</e1>\NN\1740 ,\,\1740 a\DT\13649268 mitochondrial-targeted\JJ\1740 antioxidant\NN\14724436 ,\,\1740 was\VBD\836236 shown\VBN\2137132 to\TO\1740 completely\RB\1740 prevent\VB\1740 these\DT\1740 <e2>mitochondrial\JJ\1740 abnormalities</e2>\NNS\14034177 as\RB\1740 well\RB\1740 as\IN\14622893 cardiac\JJ\1740 dysfunction\NN\14204950 characterized\VBN\609683 here\RB\1740 by\IN\1740 a\DT\13649268 diastolic\JJ\1740 dysfunction\NN\14204950 studied\VBN\630380 with\IN\1740 a\DT\13649268 conductance\NN\11449002 catheter\NN\4493505 to\TO\1740 obtain\VB\2210855 pressure-volume\JJ\1740 data\NNS\7951464 .\.\1740
C476756_D006331 NONE Mitochondrial\JJ\1740 impairment\NN\7296428 contributes\VBZ\126264 to\TO\1740 cocaine-induced\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 :\:\1740 Prevention\NN\1073995 by\IN\1740 the\DT\1740 targeted\VBN\1151110 antioxidant\JJ\1740 <e1>MitoQ.</e1>\NN\1740
C476756_D006331 NONE <e1>MitoQ</e1>\NN\1740 ,\,\1740 a\DT\13649268 mitochondrial-targeted\JJ\1740 antioxidant\NN\14724436 ,\,\1740 was\VBD\836236 shown\VBN\2137132 to\TO\1740 completely\RB\1740 prevent\VB\1740 these\DT\1740 mitochondrial\JJ\1740 abnormalities\NNS\14034177 as\RB\1740 well\RB\1740 as\IN\14622893 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 characterized\VBN\609683 here\RB\1740 by\IN\1740 a\DT\13649268 diastolic\JJ\1740 dysfunction\NN\14204950 studied\VBN\630380 with\IN\1740 a\DT\13649268 conductance\NN\11449002 catheter\NN\4493505 to\TO\1740 obtain\VB\2210855 pressure-volume\JJ\1740 data\NNS\7951464 .\.\1740
C476756_-1 NONE <e1>MitoQ</e1>\NN\1740 ,\,\1740 a\DT\13649268 mitochondrial-targeted\JJ\1740 antioxidant\NN\14724436 ,\,\1740 was\VBD\836236 shown\VBN\2137132 to\TO\1740 completely\RB\1740 prevent\VB\1740 these\DT\1740 mitochondrial\JJ\1740 abnormalities\NNS\14034177 as\RB\1740 well\RB\1740 as\IN\14622893 cardiac\JJ\1740 dysfunction\NN\14204950 characterized\VBN\609683 here\RB\1740 by\IN\1740 a\DT\13649268 <e2>diastolic\JJ\1740 dysfunction</e2>\NN\14204950 studied\VBN\630380 with\IN\1740 a\DT\13649268 conductance\NN\11449002 catheter\NN\4493505 to\TO\1740 obtain\VB\2210855 pressure-volume\JJ\1740 data\NNS\7951464 .\.\1740
8308951
D014859_D002543 CID Cutaneous\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>warfarin-like</e1>\JJ\1740 anticoagulant\NN\3740161 causing\VBG\1617192 an\DT\6697703 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D014859_D006406 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 intercerebral\JJ\1740 <e2>hematoma</e2>\NN\14317720 due\JJ\1740 to\TO\1740 <e1>warfarin-induced</e1>\JJ\1740 coagulopathy\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D014859_D001778 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 intercerebral\JJ\1740 hematoma\NN\14317720 due\JJ\1740 to\TO\1740 <e1>warfarin-induced</e1>\JJ\1740 <e2>coagulopathy</e2>\NN\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D014859_D001778 NONE Percutaneous\JJ\1740 absorption\NN\13558490 of\IN\1740 <e1>warfarin</e1>\NN\2718259 causing\VBG\1617192 <e2>coagulopathy</e2>\JJ\1740 ,\,\1740 reported\VBD\831651 three\CD\13741022 times\NNS\15113229 in\IN\13603305 the\DT\1740 past\NN\28270 ,\,\1740 is\VBZ\836236 a\DT\13649268 significant\JJ\1740 risk\NN\14541044 if\IN\1740 protective\JJ\1740 measures\NNS\168237 ,\,\1740 such\JJ\1740 as\IN\14622893 gloves\NNS\2799897 ,\,\1740 are\VBP\836236 not\RB\1740 used\VBN\1156834 .\.\1740
D010894_D001778 NONE An\DT\6697703 adverse\JJ\1740 drug\NN\14778436 interaction\NN\37396 with\IN\1740 <e1>piroxicam</e1>\NN\3828465 ,\,\1740 which\WDT\1740 she\PRP\1740 took\VBD\2367363 occasionally\RB\1740 ,\,\1740 may\MD\15209706 have\VB\2108377 exacerbated\VBN\126264 the\DT\1740 <e2>coagulopathy</e2>\NN\1740 .\.\1740
2718706
D007741_D007022 CID Deliberate\VB\813978 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>labetalol</e1>\NNS\2721160 with\IN\1740 halothane\NN\3570838 ,\,\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D007741_D007022 CID The\DT\1740 feasibility\NN\5152150 of\IN\1740 using\VBG\1156834 <e1>labetalol</e1>\NNS\2721160 ,\,\1740 an\DT\6697703 alpha-\NN\1740 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 as\IN\14622893 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 agent\NN\7347 in\IN\13603305 combination\NN\7951464 with\IN\1740 inhalation\NN\835032 anaesthetics\NNS\3247620 (\-LRB-\1740 halothane\NN\3570838 ,\,\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 23\CD\13745420 adult\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D007741_D007022 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>labetalol</e1>\NN\2721160 induces\VBZ\1627355 easily\RB\1740 adjustable\JJ\1740 <e2>hypotension</e2>\NN\14057371 without\IN\1740 compensatory\JJ\1740 tachycardia\NN\14110674 and\CC\1740 rebound\NN\7309781 hypertension\NN\14057371 .\.\1740
D006221_D007022 CID Deliberate\VB\813978 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 <e1>halothane</e1>\NN\3570838 ,\,\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D006221_D007022 CID The\DT\1740 feasibility\NN\5152150 of\IN\1740 using\VBG\1156834 labetalol\NNS\2721160 ,\,\1740 an\DT\6697703 alpha-\NN\1740 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 as\IN\14622893 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 agent\NN\7347 in\IN\13603305 combination\NN\7951464 with\IN\1740 inhalation\NN\835032 anaesthetics\NNS\3247620 (\-LRB-\1740 <e1>halothane</e1>\NN\3570838 ,\,\1740 enflurane\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 23\CD\13745420 adult\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D006221_D007022 CID The\DT\1740 mean\NN\6021761 <e1>H</e1>\NN\14622893 concentration\NN\4916342 during\IN\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 inspiratory\JJ\1740 gas\NN\14479615 was\VBD\836236 0.7\CD\1740 +/-\CC\1740 0.1\CD\1740 vol%\NN\1740 ,\,\1740 the\DT\1740 mean\NN\6021761 E\NN\14724645 concentration\NN\4916342 1.6\CD\1740 +/-\CC\1740 0.2\CD\1740 vol%\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\NN\6021761 I\CD\14622893 concentration\NN\4916342 1.0\CD\1740 +/-\CC\1740 0.1\CD\1740 vol%\NN\1740 .\.\1740
D004737_D007022 CID Deliberate\VB\813978 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 halothane\NN\3570838 ,\,\1740 <e1>enflurane</e1>\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D004737_D007022 CID The\DT\1740 feasibility\NN\5152150 of\IN\1740 using\VBG\1156834 labetalol\NNS\2721160 ,\,\1740 an\DT\6697703 alpha-\NN\1740 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 as\IN\14622893 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 agent\NN\7347 in\IN\13603305 combination\NN\7951464 with\IN\1740 inhalation\NN\835032 anaesthetics\NNS\3247620 (\-LRB-\1740 halothane\NN\3570838 ,\,\1740 <e1>enflurane</e1>\NN\3299929 or\CC\3541091 isoflurane\NN\3570838 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 23\CD\13745420 adult\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D004737_D007022 CID The\DT\1740 mean\NN\6021761 H\NN\14622893 concentration\NN\4916342 during\IN\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 inspiratory\JJ\1740 gas\NN\14479615 was\VBD\836236 0.7\CD\1740 +/-\CC\1740 0.1\CD\1740 vol%\NN\1740 ,\,\1740 the\DT\1740 mean\NN\6021761 <e1>E</e1>\NN\14724645 concentration\NN\4916342 1.6\CD\1740 +/-\CC\1740 0.2\CD\1740 vol%\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\NN\6021761 I\CD\14622893 concentration\NN\4916342 1.0\CD\1740 +/-\CC\1740 0.1\CD\1740 vol%\NN\1740 .\.\1740
D007530_D007022 CID Deliberate\VB\813978 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 labetalol\NNS\2721160 with\IN\1740 halothane\NN\3570838 ,\,\1740 enflurane\NN\3299929 or\CC\3541091 <e1>isoflurane</e1>\NN\3570838 for\IN\1740 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D007530_D007022 CID The\DT\1740 feasibility\NN\5152150 of\IN\1740 using\VBG\1156834 labetalol\NNS\2721160 ,\,\1740 an\DT\6697703 alpha-\NN\1740 and\CC\1740 beta-adrenergic\JJ\1740 blocking\NN\562280 agent\NN\7347 ,\,\1740 as\IN\14622893 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 agent\NN\7347 in\IN\13603305 combination\NN\7951464 with\IN\1740 inhalation\NN\835032 anaesthetics\NNS\3247620 (\-LRB-\1740 halothane\NN\3570838 ,\,\1740 enflurane\NN\3299929 or\CC\3541091 <e1>isoflurane</e1>\NN\3570838 )\-RRB-\1740 was\VBD\836236 studied\VBN\630380 in\IN\13603305 23\CD\13745420 adult\JJ\1740 patients\NNS\9898892 undergoing\VBG\109660 middle-ear\JJ\1740 surgery\NN\6045562 .\.\1740
D007530_D007022 CID The\DT\1740 mean\NN\6021761 H\NN\14622893 concentration\NN\4916342 during\IN\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 inspiratory\JJ\1740 gas\NN\14479615 was\VBD\836236 0.7\CD\1740 +/-\CC\1740 0.1\CD\1740 vol%\NN\1740 ,\,\1740 the\DT\1740 mean\NN\6021761 E\NN\14724645 concentration\NN\4916342 1.6\CD\1740 +/-\CC\1740 0.2\CD\1740 vol%\NN\1740 ,\,\1740 and\CC\1740 the\DT\1740 mean\NN\6021761 <e1>I</e1>\CD\14622893 concentration\NN\4916342 1.0\CD\1740 +/-\CC\1740 0.1\CD\1740 vol%\NN\1740 .\.\1740
D007530_D007022 CID During\IN\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 the\DT\1740 serum\NN\5397468 creatinine\NN\1740 concentration\NN\4916342 rose\VBD\1835496 significantly\RB\1740 in\IN\13603305 all\DT\1740 groups\NNS\2137 from\IN\1740 the\DT\1740 values\NNS\5941423 before\IN\1740 hypotension\NN\14057371 and\CC\1740 returned\VBD\1835496 postoperatively\RB\1740 to\TO\1740 the\DT\1740 initial\JJ\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 other\JJ\1740 groups\NNS\2137 ,\,\1740 except\IN\1740 the\DT\1740 <e1>isoflurane</e1>\NN\3570838 group\NN\2137 .\.\1740
D007530_D007022 CID During\IN\1740 hypotension\NN\14057371 ,\,\1740 the\DT\1740 serum\NN\5397468 creatinine\NN\1740 concentration\NN\4916342 rose\VBD\1835496 significantly\RB\1740 in\IN\13603305 all\DT\1740 groups\NNS\2137 from\IN\1740 the\DT\1740 values\NNS\5941423 before\IN\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 returned\VBD\1835496 postoperatively\RB\1740 to\TO\1740 the\DT\1740 initial\JJ\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 other\JJ\1740 groups\NNS\2137 ,\,\1740 except\IN\1740 the\DT\1740 <e1>isoflurane</e1>\NN\3570838 group\NN\2137 .\.\1740
D003404_D007022 NONE During\IN\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 the\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 concentration\NN\4916342 rose\VBD\1835496 significantly\RB\1740 in\IN\13603305 all\DT\1740 groups\NNS\2137 from\IN\1740 the\DT\1740 values\NNS\5941423 before\IN\1740 hypotension\NN\14057371 and\CC\1740 returned\VBD\1835496 postoperatively\RB\1740 to\TO\1740 the\DT\1740 initial\JJ\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 other\JJ\1740 groups\NNS\2137 ,\,\1740 except\IN\1740 the\DT\1740 isoflurane\NN\3570838 group\NN\2137 .\.\1740
D003404_D007022 NONE During\IN\1740 hypotension\NN\14057371 ,\,\1740 the\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 concentration\NN\4916342 rose\VBD\1835496 significantly\RB\1740 in\IN\13603305 all\DT\1740 groups\NNS\2137 from\IN\1740 the\DT\1740 values\NNS\5941423 before\IN\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 returned\VBD\1835496 postoperatively\RB\1740 to\TO\1740 the\DT\1740 initial\JJ\1740 level\NN\4916342 in\IN\13603305 the\DT\1740 other\JJ\1740 groups\NNS\2137 ,\,\1740 except\IN\1740 the\DT\1740 isoflurane\NN\3570838 group\NN\2137 .\.\1740
D007741_D013610 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>labetalol</e1>\NN\2721160 induces\VBZ\1627355 easily\RB\1740 adjustable\JJ\1740 hypotension\NN\14057371 without\IN\1740 compensatory\JJ\1740 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 rebound\NN\7309781 hypertension\NN\14057371 .\.\1740
D007741_D006973 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>labetalol</e1>\NN\2721160 induces\VBZ\1627355 easily\RB\1740 adjustable\JJ\1740 hypotension\NN\14057371 without\IN\1740 compensatory\JJ\1740 tachycardia\NN\14110674 and\CC\1740 rebound\NN\7309781 <e2>hypertension</e2>\NN\14057371 .\.\1740
2400986
D002066_D020258 NONE Dose-dependent\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 of\IN\1740 high-dose\JJ\1740 <e1>busulfan</e1>\NNS\1740 in\IN\13603305 children\NNS\9622049 :\:\1740 a\DT\13649268 clinical\JJ\1740 and\CC\1740 pharmacological\JJ\1740 study\NN\635850 .\.\1740
D002066_D020258 NONE <e1>Busulfan</e1>\NNS\1740 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 <e2>neurotoxic</e2>\JJ\1740 in\IN\13603305 animals\NNS\4475 and\CC\1740 humans\NNS\31264 ,\,\1740 but\CC\1740 its\PRP$\6125041 acute\JJ\1740 neurotoxicity\NN\1740 remains\VBZ\2604760 poorly\RB\1740 characterized\VBN\609683 in\IN\13603305 children\NNS\9622049 .\.\1740
D002066_D020258 NONE <e1>Busulfan</e1>\NNS\1740 is\VBZ\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 neurotoxic\JJ\1740 in\IN\13603305 animals\NNS\4475 and\CC\1740 humans\NNS\31264 ,\,\1740 but\CC\1740 its\PRP$\6125041 acute\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 remains\VBZ\2604760 poorly\RB\1740 characterized\VBN\609683 in\IN\13603305 children\NNS\9622049 .\.\1740
D002066_D020258 NONE When\WRB\1740 the\DT\1740 total\JJ\1740 <e1>busulfan</e1>\NNS\1740 dose\NN\3740161 was\VBD\836236 taken\VBN\2367363 into\IN\1740 account\NN\6647206 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 terms\NNS\13945919 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 incidence\NN\13821570 among\IN\1740 patients\NNS\9898892 under\IN\1740 16\CD\13745420 mg/kg\NN\1740 (\-LRB-\1740 1\CD\13741022 of\IN\1740 57\CD\1740 ,\,\1740 1.7\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 patients\NNS\9898892 under\IN\1740 600\CD\1740 mg/m2\NN\1740 (\-LRB-\1740 6\CD\13741022 of\IN\1740 39\CD\1740 ,\,\1740 15.4\CD\1740 %\NN\1740 )\-RRB-\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
D002066_D020258 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 <e1>busulfan</e1>\NNS\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 dose-dependent\JJ\1740 in\IN\13603305 children\NNS\9622049 and\CC\1740 efficiently\RB\1740 prevented\VBN\1740 by\IN\1740 clonazepam\NN\1740 .\.\1740
D002066_D020258 NONE A\DT\13649268 <e1>busulfan</e1>\NNS\1740 dose\NN\3740161 calculated\VBN\632627 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 in\IN\13603305 young\JJ\1740 children\NNS\9622049 ,\,\1740 was\VBD\836236 followed\VBN\1835496 by\IN\1740 increased\VBN\169651 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 close\JJ\1740 to\IN\1740 neurotoxicity\NN\1740 incidence\NN\13821570 observed\VBN\2163746 in\IN\13603305 adults\NNS\7846 .\.\1740
D002066_D020258 NONE A\DT\13649268 <e1>busulfan</e1>\NNS\1740 dose\NN\3740161 calculated\VBN\632627 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 body\NN\19128 surface\NN\21939 area\NN\8630985 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 higher\JJR\1740 doses\NNS\3740161 in\IN\13603305 young\JJ\1740 children\NNS\9622049 ,\,\1740 was\VBD\836236 followed\VBN\1835496 by\IN\1740 increased\VBN\169651 neurotoxicity\NN\1740 ,\,\1740 close\JJ\1740 to\IN\1740 <e2>neurotoxicity</e2>\NN\1740 incidence\NN\13821570 observed\VBN\2163746 in\IN\13603305 adults\NNS\7846 .\.\1740
D002066_D009369 NONE We\PRP\1740 report\VBP\831651 here\RB\1740 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 123\CD\1740 children\NNS\9622049 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 6.5\CD\1740 years\NNS\15144371 )\-RRB-\1740 receiving\VBG\2210855 high-dose\JJ\1740 <e1>busulfan</e1>\NNS\1740 in\IN\13603305 combined\JJ\1740 chemotherapy\NN\661091 before\IN\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 for\IN\1740 malignant\JJ\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 ,\,\1740 brain\NN\5462674 tumors\NNS\14234074 excluded\VBN\471711 .\.\1740
D002066_D001932 NONE We\PRP\1740 report\VBP\831651 here\RB\1740 a\DT\13649268 retrospective\JJ\1740 study\NN\635850 of\IN\1740 123\CD\1740 children\NNS\9622049 (\-LRB-\1740 median\JJ\1740 age\NN\4916342 ,\,\1740 6.5\CD\1740 years\NNS\15144371 )\-RRB-\1740 receiving\VBG\2210855 high-dose\JJ\1740 <e1>busulfan</e1>\NNS\1740 in\IN\13603305 combined\JJ\1740 chemotherapy\NN\661091 before\IN\1740 bone\NN\5286536 marrow\NN\5286536 transplantation\NN\671351 for\IN\1740 malignant\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 <e2>brain\NN\5462674 tumors</e2>\NNS\14234074 excluded\VBN\471711 .\.\1740
D002066_D012640 CID Ninety-six\CD\1740 patients\NNS\9898892 were\VBD\836236 not\RB\1740 given\VBN\2327200 anticonvulsive\JJ\1740 prophylaxis\NN\1077350 ;\:\1740 7\CD\13741022 (\-LRB-\1740 7.5\CD\1740 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 <e2>seizures</e2>\NNS\14081375 during\IN\1740 the\DT\1740 4\CD\13741022 days\NNS\15140892 of\IN\1740 the\DT\1740 <e1>busulfan</e1>\NNS\1740 course\NN\883297 or\CC\3541091 within\IN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 the\DT\1740 last\JJ\1740 dosing\NN\1740 .\.\1740
D002066_D009461 NONE Twenty-seven\CD\13745420 patients\NNS\9898892 were\VBD\836236 given\VBN\2327200 a\DT\13649268 600-mg/m2\CD\1740 <e1>busulfan</e1>\NNS\1740 total\JJ\1740 dose\NN\3740161 with\IN\1740 continuous\JJ\1740 i.v.\NN\1740 infusion\NN\14589223 of\IN\1740 clonazepam\NN\1740 ;\:\1740 none\NN\15228378 had\VBD\2108377 any\DT\1740 <e2>neurological\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
D002998_D009461 NONE Twenty-seven\CD\13745420 patients\NNS\9898892 were\VBD\836236 given\VBN\2327200 a\DT\13649268 600-mg/m2\CD\1740 busulfan\NNS\1740 total\JJ\1740 dose\NN\3740161 with\IN\1740 continuous\JJ\1740 i.v.\NN\1740 infusion\NN\14589223 of\IN\1740 <e1>clonazepam</e1>\NN\1740 ;\:\1740 none\NN\15228378 had\VBD\2108377 any\DT\1740 <e2>neurological\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
D002066_D002493 NONE <e1>Busulfan</e1>\NNS\1740 levels\NNS\4916342 were\VBD\836236 measured\VBN\697589 by\IN\1740 a\DT\13649268 gas\NN\14479615 chromatographic-mass\NN\1740 spectrometry\NN\646833 assay\NN\5733583 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 of\IN\1740 9\CD\13741022 children\NNS\9622049 without\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 disease</e2>\NN\14061805 under\IN\1740 600\CD\1740 mg/m2\NN\1740 busulfan\NNS\1740 with\IN\1740 clonazepam\NN\1740 :\:\1740 busulfan\NNS\1740 cerebrospinal\JJ\1740 fluid\NN\19613 :\:\1740 plasma\NN\5398023 ratio\NN\13815152 was\VBD\836236 1.39\CD\1740 .\.\1740
D002066_D002493 NONE Busulfan\NNS\1740 levels\NNS\4916342 were\VBD\836236 measured\VBN\697589 by\IN\1740 a\DT\13649268 gas\NN\14479615 chromatographic-mass\NN\1740 spectrometry\NN\646833 assay\NN\5733583 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 of\IN\1740 9\CD\13741022 children\NNS\9622049 without\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 disease</e2>\NN\14061805 under\IN\1740 600\CD\1740 mg/m2\NN\1740 <e1>busulfan</e1>\NNS\1740 with\IN\1740 clonazepam\NN\1740 :\:\1740 busulfan\NNS\1740 cerebrospinal\JJ\1740 fluid\NN\19613 :\:\1740 plasma\NN\5398023 ratio\NN\13815152 was\VBD\836236 1.39\CD\1740 .\.\1740
D002066_D002493 NONE Busulfan\NNS\1740 levels\NNS\4916342 were\VBD\836236 measured\VBN\697589 by\IN\1740 a\DT\13649268 gas\NN\14479615 chromatographic-mass\NN\1740 spectrometry\NN\646833 assay\NN\5733583 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 of\IN\1740 9\CD\13741022 children\NNS\9622049 without\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 disease</e2>\NN\14061805 under\IN\1740 600\CD\1740 mg/m2\NN\1740 busulfan\NNS\1740 with\IN\1740 clonazepam\NN\1740 :\:\1740 <e1>busulfan</e1>\NNS\1740 cerebrospinal\JJ\1740 fluid\NN\19613 :\:\1740 plasma\NN\5398023 ratio\NN\13815152 was\VBD\836236 1.39\CD\1740 .\.\1740
D002998_D002493 NONE Busulfan\NNS\1740 levels\NNS\4916342 were\VBD\836236 measured\VBN\697589 by\IN\1740 a\DT\13649268 gas\NN\14479615 chromatographic-mass\NN\1740 spectrometry\NN\646833 assay\NN\5733583 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 cerebrospinal\JJ\1740 fluid\NN\19613 of\IN\1740 9\CD\13741022 children\NNS\9622049 without\IN\1740 <e2>central\JJ\1740 nervous\JJ\1740 system\NN\3575240 disease</e2>\NN\14061805 under\IN\1740 600\CD\1740 mg/m2\NN\1740 busulfan\NNS\1740 with\IN\1740 <e1>clonazepam</e1>\NN\1740 :\:\1740 busulfan\NNS\1740 cerebrospinal\JJ\1740 fluid\NN\19613 :\:\1740 plasma\NN\5398023 ratio\NN\13815152 was\VBD\836236 1.39\CD\1740 .\.\1740
D002998_D020258 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 busulfan\NNS\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 dose-dependent\JJ\1740 in\IN\13603305 children\NNS\9622049 and\CC\1740 efficiently\RB\1740 prevented\VBN\1740 by\IN\1740 <e1>clonazepam</e1>\NN\1740 .\.\1740
9782254
D007980_D010300 NONE 51\CD\1740 patients\NNS\9898892 with\IN\1740 medically\RB\1740 refractory\JJ\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 underwent\VBD\109660 stereotactic\JJ\1740 posteromedial\JJ\1740 pallidotomy\NN\1740 between\IN\1740 August\NNP\15209706 1993\CD\1740 and\CC\1740 February\NNP\15209706 1997\CD\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 bradykinesia\NN\1740 ,\,\1740 rigidity\NN\5023233 ,\,\1740 and\CC\1740 <e1>L-DOPA-induced</e1>\VBN\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D018476 NONE 51\CD\1740 patients\NNS\9898892 with\IN\1740 medically\RB\1740 refractory\JJ\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 underwent\VBD\109660 stereotactic\JJ\1740 posteromedial\JJ\1740 pallidotomy\NN\1740 between\IN\1740 August\NNP\15209706 1993\CD\1740 and\CC\1740 February\NNP\15209706 1997\CD\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 <e2>bradykinesia</e2>\NN\1740 ,\,\1740 rigidity\NN\5023233 ,\,\1740 and\CC\1740 <e1>L-DOPA-induced</e1>\VBN\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D009127 NONE 51\CD\1740 patients\NNS\9898892 with\IN\1740 medically\RB\1740 refractory\JJ\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 underwent\VBD\109660 stereotactic\JJ\1740 posteromedial\JJ\1740 pallidotomy\NN\1740 between\IN\1740 August\NNP\15209706 1993\CD\1740 and\CC\1740 February\NNP\15209706 1997\CD\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 bradykinesia\NN\1740 ,\,\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 and\CC\1740 <e1>L-DOPA-induced</e1>\VBN\1740 dyskinesias\NNS\14084880 .\.\1740
D007980_D004409 CID 51\CD\1740 patients\NNS\9898892 with\IN\1740 medically\RB\1740 refractory\JJ\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 underwent\VBD\109660 stereotactic\JJ\1740 posteromedial\JJ\1740 pallidotomy\NN\1740 between\IN\1740 August\NNP\15209706 1993\CD\1740 and\CC\1740 February\NNP\15209706 1997\CD\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 bradykinesia\NN\1740 ,\,\1740 rigidity\NN\5023233 ,\,\1740 and\CC\1740 <e1>L-DOPA-induced</e1>\VBN\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
25907210
D010755_D009369 NONE Incidence\NN\13821570 of\IN\1740 solid\JJ\1740 <e2>tumours</e2>\NNS\14234074 among\IN\1740 pesticide\NN\14806838 applicators\NNS\3183080 exposed\VBN\2110927 to\TO\1740 the\DT\1740 <e1>organophosphate</e1>\JJ\1740 insecticide\NN\14980215 diazinon\NN\1740 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 :\:\1740 an\DT\6697703 updated\JJ\1740 analysis\NN\633864 .\.\1740
D010755_D009369 NONE OBJECTIVE\NN\5980875 :\:\1740 Diazinon\NNP\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 <e1>organophosphate</e1>\JJ\1740 insecticide\NN\14980215 with\IN\1740 genotoxic\JJ\1740 properties\NNS\32613 ,\,\1740 was\VBD\836236 previously\RB\1740 associated\VBN\628491 with\IN\1740 lung\NN\5528060 cancer\NN\14239425 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 (\-LRB-\1740 AHS\NN\1740 )\-RRB-\1740 cohort\NN\8184861 ,\,\1740 but\CC\1740 few\JJ\1740 other\JJ\1740 epidemiological\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 diazinon-associated\JJ\1740 <e2>cancer</e2>\NN\14239425 risk\NN\14541044 .\.\1740
D003976_D009369 NONE Incidence\NN\13821570 of\IN\1740 solid\JJ\1740 <e2>tumours</e2>\NNS\14234074 among\IN\1740 pesticide\NN\14806838 applicators\NNS\3183080 exposed\VBN\2110927 to\TO\1740 the\DT\1740 organophosphate\JJ\1740 insecticide\NN\14980215 <e1>diazinon</e1>\NN\1740 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 :\:\1740 an\DT\6697703 updated\JJ\1740 analysis\NN\633864 .\.\1740
D003976_D009369 NONE OBJECTIVE\NN\5980875 :\:\1740 <e1>Diazinon</e1>\NNP\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 organophosphate\JJ\1740 insecticide\NN\14980215 with\IN\1740 genotoxic\JJ\1740 properties\NNS\32613 ,\,\1740 was\VBD\836236 previously\RB\1740 associated\VBN\628491 with\IN\1740 lung\NN\5528060 cancer\NN\14239425 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 (\-LRB-\1740 AHS\NN\1740 )\-RRB-\1740 cohort\NN\8184861 ,\,\1740 but\CC\1740 few\JJ\1740 other\JJ\1740 epidemiological\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 diazinon-associated\JJ\1740 <e2>cancer</e2>\NN\14239425 risk\NN\14541044 .\.\1740
D003976_D009369 NONE OBJECTIVE\NN\5980875 :\:\1740 Diazinon\NNP\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 organophosphate\JJ\1740 insecticide\NN\14980215 with\IN\1740 genotoxic\JJ\1740 properties\NNS\32613 ,\,\1740 was\VBD\836236 previously\RB\1740 associated\VBN\628491 with\IN\1740 lung\NN\5528060 cancer\NN\14239425 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 (\-LRB-\1740 AHS\NN\1740 )\-RRB-\1740 cohort\NN\8184861 ,\,\1740 but\CC\1740 few\JJ\1740 other\JJ\1740 epidemiological\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 <e1>diazinon-associated</e1>\JJ\1740 <e2>cancer</e2>\NN\14239425 risk\NN\14541044 .\.\1740
D003976_D009369 NONE We\PRP\1740 used\VBD\1156834 updated\JJ\1740 <e1>diazinon</e1>\NN\1740 exposure\NN\5042871 and\CC\1740 <e2>cancer</e2>\NN\14239425 incidence\NN\13821570 information\NN\6598915 to\TO\1740 evaluate\VB\670261 solid\JJ\1740 tumour\NN\14234074 risk\NN\14541044 in\IN\13603305 the\DT\1740 AHS\NN\1740 .\.\1740
D003976_D009369 NONE We\PRP\1740 used\VBD\1156834 updated\JJ\1740 <e1>diazinon</e1>\NN\1740 exposure\NN\5042871 and\CC\1740 cancer\NN\14239425 incidence\NN\13821570 information\NN\6598915 to\TO\1740 evaluate\VB\670261 solid\JJ\1740 <e2>tumour</e2>\NN\14234074 risk\NN\14541044 in\IN\13603305 the\DT\1740 AHS\NN\1740 .\.\1740
D003976_D009369 NONE METHODS\NNS\5616786 :\:\1740 Male\JJ\1740 pesticide\NN\14806838 applicators\NNS\3183080 in\IN\13603305 Iowa\NNP\9669125 and\CC\1740 North\NNP\13831000 Carolina\NNP\1740 reported\VBD\831651 lifetime\NN\15113229 <e1>diazinon</e1>\NN\1740 use\NN\407535 at\IN\14622893 enrolment\NN\49003 (\-LRB-\1740 1993\CD\1740 -\SYM\1740 1997\CD\1740 )\-RRB-\1740 and\CC\1740 follow-up\JJ\1740 (\-LRB-\1740 1998\CD\1740 -\SYM\1740 2005\CD\1740 )\-RRB-\1740 ;\:\1740 <e2>cancer</e2>\NN\14239425 incidence\NN\13821570 was\VBD\836236 assessed\VBN\670261 through\IN\1740 2010(North\NN\1740 Carolina)/2011(Iowa\NN\1740 )\-RRB-\1740 .\.\1740
D003976_D008175 CID OBJECTIVE\NN\5980875 :\:\1740 <e1>Diazinon</e1>\NNP\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 organophosphate\JJ\1740 insecticide\NN\14980215 with\IN\1740 genotoxic\JJ\1740 properties\NNS\32613 ,\,\1740 was\VBD\836236 previously\RB\1740 associated\VBN\628491 with\IN\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 (\-LRB-\1740 AHS\NN\1740 )\-RRB-\1740 cohort\NN\8184861 ,\,\1740 but\CC\1740 few\JJ\1740 other\JJ\1740 epidemiological\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 diazinon-associated\JJ\1740 cancer\NN\14239425 risk\NN\14541044 .\.\1740
D003976_D008175 CID OBJECTIVE\NN\5980875 :\:\1740 Diazinon\NNP\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 organophosphate\JJ\1740 insecticide\NN\14980215 with\IN\1740 genotoxic\JJ\1740 properties\NNS\32613 ,\,\1740 was\VBD\836236 previously\RB\1740 associated\VBN\628491 with\IN\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 (\-LRB-\1740 AHS\NN\1740 )\-RRB-\1740 cohort\NN\8184861 ,\,\1740 but\CC\1740 few\JJ\1740 other\JJ\1740 epidemiological\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 <e1>diazinon-associated</e1>\JJ\1740 cancer\NN\14239425 risk\NN\14541044 .\.\1740
D003976_D008175 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 observed\VBD\2163746 elevated\JJ\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 risks\NNS\14541044 (\-LRB-\1740 N=283\CD\1740 )\-RRB-\1740 among\IN\1740 applicators\NNS\3183080 with\IN\1740 the\DT\1740 greatest\JJS\1740 number\NN\5107765 of\IN\1740 LT\NN\1740 (\-LRB-\1740 RR=1.60\NN\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 1.11\CD\1740 to\TO\1740 2.31\CD\1740 ;\:\1740 Ptrend=0.02\NN\1740 )\-RRB-\1740 and\CC\1740 IW\JJ\1740 days\NNS\15140892 of\IN\1740 <e1>diazinon</e1>\NN\1740 use\NN\407535 (\-LRB-\1740 RR=1.41\NNP\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.98\CD\1740 to\TO\1740 2.04\CD\1740 ;\:\1740 Ptrend=0.08\NN\1740 )\-RRB-\1740 .\.\1740
D003976_D008175 CID CONCLUSIONS\NNS\5837957 :\:\1740 Our\PRP$\1740 updated\JJ\1740 evaluation\NN\874067 of\IN\1740 <e1>diazinon</e1>\NN\1740 provides\VBZ\2199590 additional\JJ\1740 evidence\NN\5816287 of\IN\1740 an\DT\6697703 association\NN\8008335 with\IN\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 risk\NN\14541044 .\.\1740
D010755_D008175 NONE OBJECTIVE\NN\5980875 :\:\1740 Diazinon\NNP\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 <e1>organophosphate</e1>\JJ\1740 insecticide\NN\14980215 with\IN\1740 genotoxic\JJ\1740 properties\NNS\32613 ,\,\1740 was\VBD\836236 previously\RB\1740 associated\VBN\628491 with\IN\1740 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 (\-LRB-\1740 AHS\NN\1740 )\-RRB-\1740 cohort\NN\8184861 ,\,\1740 but\CC\1740 few\JJ\1740 other\JJ\1740 epidemiological\JJ\1740 studies\NNS\635850 have\VBP\2108377 examined\VBN\789138 diazinon-associated\JJ\1740 cancer\NN\14239425 risk\NN\14541044 .\.\1740
2173761
D019806_D007022 CID Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>cromakalim</e1>\NN\1740 and\CC\1740 pinacidil\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade\NN\952963 but\CC\1740 drug-induced\JJ\1740 tachycardia\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D019806_D013610 CID Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>cromakalim</e1>\NN\1740 and\CC\1740 pinacidil\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade\NN\952963 but\CC\1740 drug-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D020110_D007022 CID Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 cromakalim\NN\1740 and\CC\1740 <e1>pinacidil</e1>\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade\NN\952963 but\CC\1740 drug-induced\JJ\1740 tachycardia\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D020110_D013610 CID Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 cromakalim\NN\1740 and\CC\1740 <e1>pinacidil</e1>\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade\NN\952963 but\CC\1740 drug-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D000319_D007022 NONE Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 cromakalim\NN\1740 and\CC\1740 pinacidil\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 <e1>beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade</e1>\NN\952963 but\CC\1740 drug-induced\JJ\1740 tachycardia\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D018727_D007022 NONE Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 cromakalim\NN\1740 and\CC\1740 pinacidil\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 <e1>beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade</e1>\NN\952963 but\CC\1740 drug-induced\JJ\1740 tachycardia\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D000319_D013610 NONE Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 cromakalim\NN\1740 and\CC\1740 pinacidil\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 <e1>beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade</e1>\NN\952963 but\CC\1740 drug-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
D018727_D013610 NONE Vasodilation\NN\365995 of\IN\1740 large\JJ\1740 and\CC\1740 small\JJ\1740 coronary\JJ\1740 vessels\NNS\5246511 and\CC\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 cromakalim\NN\1740 and\CC\1740 pinacidil\NN\1740 were\VBD\836236 not\RB\1740 affected\VBN\126264 by\IN\1740 prior\JJ\1740 combined\JJ\1740 <e1>beta\NN\6828818 adrenergic\JJ\1740 and\CC\1740 muscarinic\NN\1740 receptors\NNS\5225602 blockade</e1>\NN\952963 but\CC\1740 drug-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 abolished\VBN\1740 .\.\1740
10390729
D011188_D009069 NONE In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 <e1>K(+)-channel</e1>\NN\1740 blockers\NNS\10101634 affected\VBD\126264 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 morphine-induced\JJ\1740 secondary\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D011188_D009069 NONE In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 affected\VBD\126264 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 <e1>K(+)-channel</e1>\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 morphine-induced\JJ\1740 secondary\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D011188_D009069 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 <e1>K(+)-channels</e1>\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 hyperactivity\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D011188_D009069 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 hyperactivity\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 <e1>K(+)-channels</e1>\NN\1740 .\.\1740
D011188_D006948 NONE In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 <e1>K(+)-channel</e1>\NN\1740 blockers\NNS\10101634 affected\VBD\126264 morphine-induced\JJ\1740 hypoactivity\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 morphine-induced\JJ\1740 secondary\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D011188_D006948 NONE In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 affected\VBD\126264 morphine-induced\JJ\1740 hypoactivity\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 <e1>K(+)-channel</e1>\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 morphine-induced\JJ\1740 secondary\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D011188_D006948 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 <e1>K(+)-channels</e1>\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 hypoactivity\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D011188_D006948 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 hypoactivity\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 <e1>K(+)-channels</e1>\NN\1740 .\.\1740
D009020_D009069 NONE In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 affected\VBD\126264 <e1>morphine-induced</e1>\JJ\1740 <e2>hypoactivity</e2>\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 morphine-induced\JJ\1740 secondary\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D009020_D009069 NONE In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 affected\VBD\126264 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 <e1>morphine-induced</e1>\JJ\1740 secondary\JJ\1740 hyperactivity\NN\14052403 .\.\1740
D009020_D009069 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>hypoactivity</e2>\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 hyperactivity\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D009020_D009069 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 whereas\IN\1740 <e1>morphine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D009020_D006948 CID In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 affected\VBD\126264 <e1>morphine-induced</e1>\JJ\1740 hypoactivity\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 morphine-induced\JJ\1740 secondary\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D009020_D006948 CID In\IN\13603305 the\DT\1740 motor\NN\3699975 activity\NN\30358 test\NN\5798043 measured\VBN\697589 with\IN\1740 an\DT\6697703 Animex-activity\JJ\1740 meter\NN\13649268 neither\CC\1740 of\IN\1740 the\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 affected\VBD\126264 morphine-induced\JJ\1740 hypoactivity\NN\1740 ,\,\1740 but\CC\1740 both\DT\1740 K(+)-channel\NN\1740 blockers\NNS\10101634 prevented\VBD\1740 <e1>morphine-induced</e1>\JJ\1740 secondary\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D009020_D006948 CID It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 <e1>morphine-induced</e1>\JJ\1740 hypoactivity\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D009020_D006948 CID It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 hypoactivity\NN\1740 whereas\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D011803_D009069 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 hyperactivity\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 <e1>quinine-</e1>\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D011803_D006948 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 hypoactivity\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 <e1>quinine-</e1>\NN\1740 and\CC\1740 4-aminopyridine-sensitive\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D015761_D009069 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 <e2>hypoactivity</e2>\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 hyperactivity\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 <e1>4-aminopyridine-sensitive</e1>\JJ\1740 K(+)-channels\NN\1740 .\.\1740
D015761_D006948 NONE It\PRP\6125041 is\VBZ\836236 also\RB\1740 suggested\VBN\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 K(+)-channels\NN\1740 sensitive\JJ\1740 to\TO\1740 these\DT\1740 blockers\NNS\10101634 is\VBZ\836236 not\RB\1740 sufficient\JJ\1740 to\TO\1740 prevent\VB\1740 morphine-induced\JJ\1740 hypoactivity\NN\1740 whereas\IN\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 seems\VBZ\2604760 to\TO\1740 be\VB\836236 connected\VBN\628491 to\TO\1740 both\CC\1740 quinine-\NN\1740 and\CC\1740 <e1>4-aminopyridine-sensitive</e1>\JJ\1740 K(+)-channels\NN\1740 .\.\1740
25119790
D003474_D007674 NONE <e1>Curcumin</e1>\NN\1740 prevents\VBZ\1740 maleate-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 relation\NN\2137 to\TO\1740 hemodynamic\JJ\1740 alterations\NNS\7283608 ,\,\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 mitochondrial\JJ\1740 oxygen\NN\14622893 consumption\NN\13440063 and\CC\1740 activity\NN\30358 of\IN\1740 respiratory\JJ\1740 complex\NN\5869584 I.\NN\1740
D003474_D007674 NONE The\DT\1740 potential\JJ\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 dietary\JJ\1740 antioxidant\JJ\1740 <e1>curcumin</e1>\NN\1740 (\-LRB-\1740 120\CD\13745420 mg/Kg/day\NN\1740 for\IN\1740 6\CD\13741022 days\NNS\15140892 )\-RRB-\1740 against\IN\1740 the\DT\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 maleate\NN\2718811 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D003474_D007674 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>curcumin</e1>\NN\1740 is\VBZ\836236 able\JJ\1740 to\TO\1740 attenuate\VB\224901 in\FW\13603305 vivo\FW\1740 maleate-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 and\CC\1740 in\FW\13603305 vitro\FW\1740 cell\NN\3080309 damage\NN\7296428 .\.\1740
C030272_D007674 CID Curcumin\NN\1740 prevents\VBZ\1740 <e1>maleate-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 relation\NN\2137 to\TO\1740 hemodynamic\JJ\1740 alterations\NNS\7283608 ,\,\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 mitochondrial\JJ\1740 oxygen\NN\14622893 consumption\NN\13440063 and\CC\1740 activity\NN\30358 of\IN\1740 respiratory\JJ\1740 complex\NN\5869584 I.\NN\1740
C030272_D007674 CID The\DT\1740 potential\JJ\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 dietary\JJ\1740 antioxidant\JJ\1740 curcumin\NN\1740 (\-LRB-\1740 120\CD\13745420 mg/Kg/day\NN\1740 for\IN\1740 6\CD\13741022 days\NNS\15140892 )\-RRB-\1740 against\IN\1740 the\DT\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>maleate</e1>\NN\2718811 was\VBD\836236 evaluated\VBN\670261 .\.\1740
C030272_D007674 CID <e1>Maleate-induced</e1>\JJ\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 glucose\NN\14710501 ,\,\1740 sodium\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 kidney\NN\5333259 injury\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 necrosis\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
C030272_D007674 CID <e1>Maleate-induced</e1>\JJ\1740 renal\JJ\1740 injury\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 glucose\NN\14710501 ,\,\1740 sodium\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 <e2>kidney\NN\5333259 injury</e2>\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 necrosis\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
C030272_D007674 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 curcumin\NN\1740 is\VBZ\836236 able\JJ\1740 to\TO\1740 attenuate\VB\224901 in\FW\13603305 vivo\FW\1740 <e1>maleate-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 and\CC\1740 in\FW\13603305 vitro\FW\1740 cell\NN\3080309 damage\NN\7296428 .\.\1740
D010100_D007674 NONE Curcumin\NN\1740 prevents\VBZ\1740 maleate-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 :\:\1740 relation\NN\2137 to\TO\1740 hemodynamic\JJ\1740 alterations\NNS\7283608 ,\,\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 mitochondrial\JJ\1740 <e1>oxygen</e1>\NN\14622893 consumption\NN\13440063 and\CC\1740 activity\NN\30358 of\IN\1740 respiratory\JJ\1740 complex\NN\5869584 I.\NN\1740
C030272_D011507 CID Tubular\JJ\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 were\VBD\836236 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>maleate</e1>\NN\2718811 (\-LRB-\1740 400\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
C030272_D009336 CID <e1>Maleate-induced</e1>\JJ\1740 renal\JJ\1740 injury\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 glucose\NN\14710501 ,\,\1740 sodium\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 kidney\NN\5333259 injury\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 <e2>necrosis</e2>\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
D005947_D007674 NONE Maleate-induced\JJ\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 <e1>glucose</e1>\NN\14710501 ,\,\1740 sodium\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 kidney\NN\5333259 injury\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 necrosis\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
D005947_D007674 NONE Maleate-induced\JJ\1740 renal\JJ\1740 injury\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 <e1>glucose</e1>\NN\14710501 ,\,\1740 sodium\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 <e2>kidney\NN\5333259 injury</e2>\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 necrosis\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
D005947_D009336 NONE Maleate-induced\JJ\1740 renal\JJ\1740 injury\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 <e1>glucose</e1>\NN\14710501 ,\,\1740 sodium\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 kidney\NN\5333259 injury\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 <e2>necrosis</e2>\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
D012964_D007674 NONE Maleate-induced\JJ\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 glucose\NN\14710501 ,\,\1740 <e1>sodium</e1>\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 kidney\NN\5333259 injury\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 necrosis\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
D012964_D007674 NONE Maleate-induced\JJ\1740 renal\JJ\1740 injury\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 glucose\NN\14710501 ,\,\1740 <e1>sodium</e1>\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 <e2>kidney\NN\5333259 injury</e2>\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 necrosis\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
D012964_D009336 NONE Maleate-induced\JJ\1740 renal\JJ\1740 injury\NN\14052046 included\VBD\690614 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 in\IN\13603305 the\DT\1740 urinary\JJ\1740 excretion\NN\13466586 of\IN\1740 total\JJ\1740 protein\NN\14944888 ,\,\1740 glucose\NN\14710501 ,\,\1740 <e1>sodium</e1>\NN\14625458 ,\,\1740 neutrophil\NN\5449959 gelatinase-associated\JJ\1740 lipocalin\NN\1740 (\-LRB-\1740 NGAL\NN\1740 )\-RRB-\1740 and\CC\1740 N-acetyl\JJ\1740 b-D-glucosaminidase\NN\1740 (\-LRB-\1740 NAG\NN\9631463 )\-RRB-\1740 ,\,\1740 upregulation\NN\1740 of\IN\1740 kidney\NN\5333259 injury\NN\14052046 molecule\NN\9465459 (KIM)-1\NN\1740 ,\,\1740 decrease\VB\169651 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 claudin-2\NN\1740 expression\NN\4679549 besides\IN\1740 of\IN\1740 <e2>necrosis</e2>\NN\11444117 and\CC\1740 apoptosis\NN\11486178 of\IN\1740 tubular\JJ\1740 cells\NNS\3080309 on\IN\1740 24\CD\13745420 h.\NN\1740 Oxidative\JJ\1740 stress\NN\7083732 was\VBD\836236 determined\VBN\1645601 by\IN\1740 measuring\VBG\697589 the\DT\1740 oxidation\NN\13447361 of\IN\1740 lipids\NNS\14944888 and\CC\1740 proteins\NNS\14944888 and\CC\1740 diminution\NN\13458571 in\IN\13603305 renal\JJ\1740 Nrf2\NN\1740 levels\NNS\4916342 .\.\1740
24434397
D014148_D012640 NONE <e1>Tranexamic\JJ\1740 acid</e1>\NN\14818238 overdosage-induced\JJ\1740 generalized\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 renal\JJ\1740 failure\NN\66216 .\.\1740
D014148_D012640 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 precipitating\NN\1740 cause\NN\7323922 of\IN\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 believed\VBN\686447 to\TO\1740 be\VB\836236 an\DT\6697703 overdose\NN\1740 of\IN\1740 <e1>TNA</e1>\NNP\1740 .\.\1740
D014148_D051437 NONE <e1>Tranexamic\JJ\1740 acid</e1>\NN\14818238 overdosage-induced\JJ\1740 generalized\JJ\1740 seizure\NN\14081375 in\IN\13603305 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D014148_D006470 NONE <e1>Tranexamic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 TNA\NN\1740 )\-RRB-\1740 1\CD\13741022 g\NN\13717155 8-hourly\RB\1740 was\VBD\836236 administered\VBN\2436349 to\IN\1740 her\PRP\1740 to\TO\1740 control\VB\2422663 <e2>bleeding</e2>\VBG\104868 per\IN\1740 vaginum\NN\1740 .\.\1740
D014148_D006470 NONE Tranexamic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>TNA</e1>\NN\1740 )\-RRB-\1740 1\CD\13741022 g\NN\13717155 8-hourly\RB\1740 was\VBD\836236 administered\VBN\2436349 to\IN\1740 her\PRP\1740 to\TO\1740 control\VB\2422663 <e2>bleeding</e2>\VBG\104868 per\IN\1740 vaginum\NN\1740 .\.\1740
D014148_D004830 CID Two\CD\13741022 hours\NNS\15118228 after\IN\1740 the\DT\1740 sixth\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>TNA</e1>\NN\1740 ,\,\1740 she\PRP\1740 had\VBD\2108377 an\DT\6697703 episode\NN\7283608 of\IN\1740 generalized\JJ\1740 <e2>tonic\JJ\1740 clonic\NN\1740 convulsions</e2>\NNS\14081375 .\.\1740
D014148_D062787 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 precipitating\NN\1740 cause\NN\7323922 of\IN\1740 convulsions\NNS\14081375 was\VBD\836236 believed\VBN\686447 to\TO\1740 be\VB\836236 an\DT\6697703 <e2>overdose</e2>\NN\1740 of\IN\1740 <e1>TNA</e1>\NNP\1740 .\.\1740
8135424
D005442_D012640 CID <e1>Flumazenil</e1>\NN\1740 induces\VBZ\1627355 <e2>seizures</e2>\NNS\14081375 and\CC\1740 death\NN\7296428 in\IN\13603305 mixed\JJ\1740 cocaine-diazepam\JJ\1740 intoxications\NNS\14034177 .\.\1740
D005442_D012640 CID STUDY\NN\635850 HYPOTHESIS\NN\7162194 :\:\1740 Administration\NN\1133281 of\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 antagonist\NN\7846 <e1>flumazenil</e1>\NN\1740 may\MD\15209706 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mixed\JJ\1740 cocaine-benzodiazepine\JJ\1740 intoxication\NN\14034177 .\.\1740
D005442_D012640 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Flumazenil</e1>\NNP\1740 can\MD\3094503 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 and\CC\1740 increase\VB\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 death\NN\7296428 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 combined\JJ\1740 cocaine-diazepam\JJ\1740 intoxications\NNS\14034177 .\.\1740
D003042_D012640 CID Flumazenil\NN\1740 induces\VBZ\1627355 <e2>seizures</e2>\NNS\14081375 and\CC\1740 death\NN\7296428 in\IN\13603305 mixed\JJ\1740 <e1>cocaine-diazepam</e1>\JJ\1740 intoxications\NNS\14034177 .\.\1740
D003042_D012640 CID STUDY\NN\635850 HYPOTHESIS\NN\7162194 :\:\1740 Administration\NN\1133281 of\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 antagonist\NN\7846 flumazenil\NN\1740 may\MD\15209706 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mixed\JJ\1740 <e1>cocaine-benzodiazepine</e1>\JJ\1740 intoxication\NN\14034177 .\.\1740
D003042_D012640 CID CONCLUSION\NN\5837957 :\:\1740 Flumazenil\NNP\1740 can\MD\3094503 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 and\CC\1740 increase\VB\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 death\NN\7296428 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 combined\JJ\1740 <e1>cocaine-diazepam</e1>\JJ\1740 intoxications\NNS\14034177 .\.\1740
D003975_D012640 CID Flumazenil\NN\1740 induces\VBZ\1627355 <e2>seizures</e2>\NNS\14081375 and\CC\1740 death\NN\7296428 in\IN\13603305 mixed\JJ\1740 <e1>cocaine-diazepam</e1>\JJ\1740 intoxications\NNS\14034177 .\.\1740
D003975_D012640 CID CONCLUSION\NN\5837957 :\:\1740 Flumazenil\NNP\1740 can\MD\3094503 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 and\CC\1740 increase\VB\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 death\NN\7296428 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 combined\JJ\1740 <e1>cocaine-diazepam</e1>\JJ\1740 intoxications\NNS\14034177 .\.\1740
D001569_D012640 NONE STUDY\NN\635850 HYPOTHESIS\NN\7162194 :\:\1740 Administration\NN\1133281 of\IN\1740 the\DT\1740 <e1>benzodiazepine</e1>\NN\3771443 antagonist\NN\7846 flumazenil\NN\1740 may\MD\15209706 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mixed\JJ\1740 cocaine-benzodiazepine\JJ\1740 intoxication\NN\14034177 .\.\1740
D001569_D012640 NONE STUDY\NN\635850 HYPOTHESIS\NN\7162194 :\:\1740 Administration\NN\1133281 of\IN\1740 the\DT\1740 benzodiazepine\NN\3771443 antagonist\NN\7846 flumazenil\NN\1740 may\MD\15209706 unmask\VB\853195 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 mixed\JJ\1740 <e1>cocaine-benzodiazepine</e1>\JJ\1740 intoxication\NN\14034177 .\.\1740
24333387
D013311_D020258 NONE Glial\JJ\1740 activation\NN\13561719 and\CC\1740 post-synaptic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 :\:\1740 the\DT\1740 key\JJ\1740 events\NNS\23100 in\IN\13603305 <e1>Streptozotocin</e1>\NN\1740 (\-LRB-\1740 ICV\NN\1740 )\-RRB-\1740 induced\VBD\1627355 memory\NN\5926676 impairment\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D013311_D020258 NONE <e1>STZ</e1>\NN\1740 treatment\NN\654885 showed\VBD\2137132 decrease\NN\7296428 expression\NN\4679549 of\IN\1740 post\NN\8621598 synaptic\JJ\1740 markers\NNS\21939 CaMKIIa\NN\1740 and\CC\1740 PSD-95\NN\1740 ,\,\1740 while\IN\15122231 ,\,\1740 expression\NN\4679549 of\IN\1740 pre\JJ\1740 synaptic\JJ\1740 markers\NNS\21939 (\-LRB-\1740 synaptophysin\NN\1740 and\CC\1740 SNAP-25\VB\1740 )\-RRB-\1740 remains\VBZ\2604760 unaltered\JJ\1740 indicating\VBG\952524 selective\JJ\1740 post\NN\8621598 synaptic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D013311_D020258 NONE Oral\JJ\1740 treatment\NN\654885 with\IN\1740 Memantine\NN\1740 (\-LRB-\1740 10mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Ibuprofen\NN\3828465 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 daily\RB\1740 for\IN\1740 13\CD\13745420 days\NNS\15140892 attenuated\VBD\224901 <e1>STZ</e1>\NN\1740 induced\JJ\1740 glial\JJ\1740 activation\NN\13561719 ,\,\1740 apoptotic\JJ\1740 cell\NN\3080309 death\NN\7296428 and\CC\1740 post\VB\1356370 synaptic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 rat\NN\2329401 brain\NN\5462674 .\.\1740
D013311_D020258 NONE Present\JJ\1740 study\NN\635850 clearly\RB\1740 suggests\VBZ\1010118 that\IN\1740 glial\JJ\1740 activation\NN\13561719 and\CC\1740 post\NN\8621598 synaptic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 are\VBP\836236 the\DT\1740 key\JJ\1740 factors\NNS\7326557 in\IN\13603305 <e1>STZ</e1>\NN\1740 induced\JJ\1740 memory\NN\5926676 impairment\NN\7296428 and\CC\1740 neuronal\JJ\1740 cell\NN\3080309 death\NN\7296428 .\.\1740
D013311_D008569 CID Glial\JJ\1740 activation\NN\13561719 and\CC\1740 post-synaptic\JJ\1740 neurotoxicity\NN\1740 :\:\1740 the\DT\1740 key\JJ\1740 events\NNS\23100 in\IN\13603305 <e1>Streptozotocin</e1>\NN\1740 (\-LRB-\1740 ICV\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
D013311_D008569 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 the\DT\1740 role\NN\719494 of\IN\1740 glial\JJ\1740 activation\NN\13561719 and\CC\1740 post\VBP\1356370 synaptic\JJ\1740 toxicity\NN\13576101 in\IN\13603305 ICV\NN\1740 <e1>Streptozotocin</e1>\NN\1740 (\-LRB-\1740 STZ\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>memory\NN\5926676 impaired</e2>\JJ\1740 rats\NNS\2329401 was\VBD\836236 explored\VBN\789138 .\.\1740
D013311_D008569 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 the\DT\1740 role\NN\719494 of\IN\1740 glial\JJ\1740 activation\NN\13561719 and\CC\1740 post\VBP\1356370 synaptic\JJ\1740 toxicity\NN\13576101 in\IN\13603305 ICV\NN\1740 Streptozotocin\NN\1740 (\-LRB-\1740 <e1>STZ</e1>\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>memory\NN\5926676 impaired</e2>\JJ\1740 rats\NNS\2329401 was\VBD\836236 explored\VBN\789138 .\.\1740
D013311_D008569 CID In\IN\13603305 experiment\NN\641820 set\VBN\1850315 up\RP\1740 1\CD\13741022 :\:\1740 <e2>Memory\NN\5926676 deficit</e2>\NN\5113133 was\VBD\836236 found\VBN\2426171 in\IN\13603305 Morris\NNP\1740 water\NN\14618834 maze\NN\4377057 test\NN\5798043 on\IN\1740 14\CD\13745420 -\SYM\1740 16\CD\13745420 days\NNS\15140892 after\IN\1740 <e1>STZ</e1>\NN\1740 (\-LRB-\1740 ICV\NN\1740 ;\:\1740 3mg/Kg\NN\1740 )\-RRB-\1740 administration\NN\1133281 .\.\1740
D013311_D008569 CID Present\JJ\1740 study\NN\635850 clearly\RB\1740 suggests\VBZ\1010118 that\IN\1740 glial\JJ\1740 activation\NN\13561719 and\CC\1740 post\NN\8621598 synaptic\JJ\1740 neurotoxicity\NN\1740 are\VBP\836236 the\DT\1740 key\JJ\1740 factors\NNS\7326557 in\IN\13603305 <e1>STZ</e1>\NN\1740 induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 and\CC\1740 neuronal\JJ\1740 cell\NN\3080309 death\NN\7296428 .\.\1740
D013311_D064420 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 the\DT\1740 role\NN\719494 of\IN\1740 glial\JJ\1740 activation\NN\13561719 and\CC\1740 post\VBP\1356370 synaptic\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 ICV\NN\1740 <e1>Streptozotocin</e1>\NN\1740 (\-LRB-\1740 STZ\NN\1740 )\-RRB-\1740 induced\VBD\1627355 memory\NN\5926676 impaired\JJ\1740 rats\NNS\2329401 was\VBD\836236 explored\VBN\789138 .\.\1740
D013311_D064420 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 the\DT\1740 role\NN\719494 of\IN\1740 glial\JJ\1740 activation\NN\13561719 and\CC\1740 post\VBP\1356370 synaptic\JJ\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 ICV\NN\1740 Streptozotocin\NN\1740 (\-LRB-\1740 <e1>STZ</e1>\NN\1740 )\-RRB-\1740 induced\VBD\1627355 memory\NN\5926676 impaired\JJ\1740 rats\NNS\2329401 was\VBD\836236 explored\VBN\789138 .\.\1740
D013311_D064420 NONE <e1>STZ</e1>\NN\1740 also\RB\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 level\NN\4916342 of\IN\1740 ROS\NN\6894544 ,\,\1740 nitrite\JJ\1740 ,\,\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 and\CC\1740 reduced\VBD\441445 the\DT\1740 mitochondrial\JJ\1740 activity\NN\30358 in\IN\13603305 synaptosomal\JJ\1740 preparation\NN\407535 illustrating\VBG\955601 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 <e2>excitotoxicity</e2>\NN\1740 .\.\1740
D013311_D007249 CID <e1>STZ</e1>\NN\1740 causes\VBZ\1617192 increased\VBN\169651 expression\NN\4679549 of\IN\1740 GFAP\NN\1740 ,\,\1740 CD11b\NN\1740 and\CC\1740 TNF-a\NN\1740 indicating\VBG\952524 glial\JJ\1740 activation\NN\13561719 and\CC\1740 <e2>neuroinflammation</e2>\NN\1740 .\.\1740
D009573_D064420 NONE STZ\NN\1740 also\RB\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 level\NN\4916342 of\IN\1740 ROS\NN\6894544 ,\,\1740 <e1>nitrite</e1>\JJ\1740 ,\,\1740 Ca(2\NN\1740 +\CC\1740 )\-RRB-\1740 and\CC\1740 reduced\VBD\441445 the\DT\1740 mitochondrial\JJ\1740 activity\NN\30358 in\IN\13603305 synaptosomal\JJ\1740 preparation\NN\407535 illustrating\VBG\955601 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 <e2>excitotoxicity</e2>\NN\1740 .\.\1740
D002118_D064420 NONE STZ\NN\1740 also\RB\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 level\NN\4916342 of\IN\1740 ROS\NN\6894544 ,\,\1740 nitrite\JJ\1740 ,\,\1740 <e1>Ca(2</e1>\NN\1740 +\CC\1740 )\-RRB-\1740 and\CC\1740 reduced\VBD\441445 the\DT\1740 mitochondrial\JJ\1740 activity\NN\30358 in\IN\13603305 synaptosomal\JJ\1740 preparation\NN\407535 illustrating\VBG\955601 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 <e2>excitotoxicity</e2>\NN\1740 .\.\1740
D008559_D020258 NONE Oral\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>Memantine</e1>\NN\1740 (\-LRB-\1740 10mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 Ibuprofen\NN\3828465 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 daily\RB\1740 for\IN\1740 13\CD\13745420 days\NNS\15140892 attenuated\VBD\224901 STZ\NN\1740 induced\JJ\1740 glial\JJ\1740 activation\NN\13561719 ,\,\1740 apoptotic\JJ\1740 cell\NN\3080309 death\NN\7296428 and\CC\1740 post\VB\1356370 synaptic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 rat\NN\2329401 brain\NN\5462674 .\.\1740
D007052_D020258 NONE Oral\JJ\1740 treatment\NN\654885 with\IN\1740 Memantine\NN\1740 (\-LRB-\1740 10mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>Ibuprofen</e1>\NN\3828465 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 daily\RB\1740 for\IN\1740 13\CD\13745420 days\NNS\15140892 attenuated\VBD\224901 STZ\NN\1740 induced\JJ\1740 glial\JJ\1740 activation\NN\13561719 ,\,\1740 apoptotic\JJ\1740 cell\NN\3080309 death\NN\7296428 and\CC\1740 post\VB\1356370 synaptic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 rat\NN\2329401 brain\NN\5462674 .\.\1740
24587916
D003907_D006973 CID Antioxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 bovine\JJ\1740 lactoferrin\NN\1740 on\IN\1740 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rat\NN\2329401 .\.\1740
D003907_D006973 CID <e1>Dexamethasone-</e1>\NN\1740 (\-LRB-\1740 Dex-\NN\1740 )\-RRB-\1740 induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 associated\VBN\628491 with\IN\1740 enhanced\VBN\227165 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D003907_D006973 CID Dexamethasone-\NN\1740 (\-LRB-\1740 <e1>Dex-</e1>\NN\1740 )\-RRB-\1740 induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 associated\VBN\628491 with\IN\1740 enhanced\VBN\227165 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D003907_D006973 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 effect\NN\34213 of\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 LF\NN\5056490 on\IN\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 <e2>hypertension</e2>\NN\14057371 upon\IN\1740 <e1>Dex</e1>\NN\1740 administration\NN\1133281 .\.\1740
D003907_D006973 CID LF\NN\5056490 lowered\JJ\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 and\CC\1740 dose\NN\3740161 dependently\RB\1740 prevented\VBN\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 <e1>Dex-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D003907_D006973 CID Chronic\JJ\1740 administration\NN\1133281 of\IN\1740 LF\NN\5056490 strongly\RB\1740 reduced\VBD\441445 the\DT\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 production\NN\30358 of\IN\1740 ROS\NN\6894544 and\CC\1740 improved\VBD\126264 antioxidant\JJ\1740 capacity\NN\5202497 in\IN\13603305 <e1>Dex-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 role\NN\719494 of\IN\1740 inhibition\NN\1068773 of\IN\1740 oxidative\JJ\1740 stress\NN\7083732 as\IN\14622893 another\DT\1740 mechanism\NN\13446390 of\IN\1740 antihypertensive\JJ\1740 action\NN\30358 of\IN\1740 LF\NN\5056490 .\.\1740
D006861_D015431 NONE LF\NN\5056490 prevented\VBD\1740 body\NN\19128 <e2>weight\NN\5009170 loss</e2>\NN\13252973 and\CC\1740 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 elevated\JJ\1740 plasma\NN\5398023 <e1>H2O2</e1>\NN\1740 and\CC\1740 increased\VBD\169651 FRAP\NNP\1740 values\NNS\5941423 .\.\1740
23952588
D007980_D004409 CID Risk\NN\14541044 factors\NNS\7326557 and\CC\1740 predictors\NNS\10756433 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 among\IN\1740 multiethnic\JJ\1740 Malaysians\NNPS\9641757 with\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D004409 CID Chronic\JJ\1740 pulsatile\JJ\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 for\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 leads\VBZ\1752884 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 motor\NN\3699975 fluctuations\NNS\7345593 and\CC\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D007980_D004409 CID We\PRP\1740 studied\VBD\630380 the\DT\1740 prevalence\NN\4764412 and\CC\1740 predictors\NNS\10756433 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 among\IN\1740 multiethnic\JJ\1740 Malaysian\JJ\1740 patients\NNS\9898892 with\IN\1740 PD\NN\14625458 .\.\1740
D007980_D004409 CID <e2>Dyskinesia</e2>\NNP\14084880 was\VBD\836236 present\JJ\1740 in\IN\13603305 44\CD\1740 %\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 42\CD\1740 )\-RRB-\1740 with\IN\1740 median\JJ\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 of\IN\1740 3\CD\13741022 years\NNS\15144371 .\.\1740
D007980_D004409 CID Patients\NNS\9898892 with\IN\1740 <e2>dyskinesia</e2>\NN\14084880 had\VBD\2108377 lower\JJR\1740 onset\NN\7325190 age\NN\4916342 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 duration\NN\15113229 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 disease\NN\14061805 duration\NN\15113229 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 higher\JJR\1740 total\JJ\1740 daily\JJ\1740 levodopa\NN\14604959 dose\NN\3740161 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 higher\JJR\1740 total\JJ\1740 UPDRS\NN\1740 scores\NNS\13757724 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.005\CD\1740 )\-RRB-\1740 than\IN\1740 patients\NNS\9898892 without\IN\1740 dyskinesia\NN\14084880 .\.\1740
D007980_D004409 CID Patients\NNS\9898892 with\IN\1740 dyskinesia\NN\14084880 had\VBD\2108377 lower\JJR\1740 onset\NN\7325190 age\NN\4916342 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 duration\NN\15113229 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 disease\NN\14061805 duration\NN\15113229 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 higher\JJR\1740 total\JJ\1740 daily\JJ\1740 levodopa\NN\14604959 dose\NN\3740161 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 higher\JJR\1740 total\JJ\1740 UPDRS\NN\1740 scores\NNS\13757724 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.005\CD\1740 )\-RRB-\1740 than\IN\1740 patients\NNS\9898892 without\IN\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D007980_D004409 CID Patients\NNS\9898892 with\IN\1740 <e2>dyskinesia</e2>\NN\14084880 had\VBD\2108377 lower\JJR\1740 onset\NN\7325190 age\NN\4916342 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 duration\NN\15113229 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 disease\NN\14061805 duration\NN\15113229 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 higher\JJR\1740 total\JJ\1740 daily\JJ\1740 <e1>levodopa</e1>\NN\14604959 dose\NN\3740161 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 higher\JJR\1740 total\JJ\1740 UPDRS\NN\1740 scores\NNS\13757724 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.005\CD\1740 )\-RRB-\1740 than\IN\1740 patients\NNS\9898892 without\IN\1740 dyskinesia\NN\14084880 .\.\1740
D007980_D004409 CID Patients\NNS\9898892 with\IN\1740 dyskinesia\NN\14084880 had\VBD\2108377 lower\JJR\1740 onset\NN\7325190 age\NN\4916342 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 duration\NN\15113229 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 longer\JJR\1740 disease\NN\14061805 duration\NN\15113229 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 higher\JJR\1740 total\JJ\1740 daily\JJ\1740 <e1>levodopa</e1>\NN\14604959 dose\NN\3740161 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 higher\JJR\1740 total\JJ\1740 UPDRS\NN\1740 scores\NNS\13757724 (\-LRB-\1740 p\NN\14622893 =\JJ\1740 0.005\CD\1740 )\-RRB-\1740 than\IN\1740 patients\NNS\9898892 without\IN\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D007980_D004409 CID The\DT\1740 three\CD\13741022 significant\JJ\1740 predictors\NNS\10756433 of\IN\1740 <e2>dyskinesia</e2>\NN\14084880 were\VBD\836236 duration\NN\15113229 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 ,\,\1740 onset\NN\7325190 age\NN\4916342 ,\,\1740 and\CC\1740 total\JJ\1740 daily\JJ\1740 levodopa\NN\14604959 dose\NN\3740161 .\.\1740
D007980_D004409 CID The\DT\1740 three\CD\13741022 significant\JJ\1740 predictors\NNS\10756433 of\IN\1740 <e2>dyskinesia</e2>\NN\14084880 were\VBD\836236 duration\NN\15113229 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 ,\,\1740 onset\NN\7325190 age\NN\4916342 ,\,\1740 and\CC\1740 total\JJ\1740 daily\JJ\1740 <e1>levodopa</e1>\NN\14604959 dose\NN\3740161 .\.\1740
D007980_D004409 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 prevalence\NN\4764412 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 in\IN\13603305 our\PRP$\1740 patients\NNS\9898892 was\VBD\836236 44\CD\1740 %\NN\1740 .\.\1740
D007980_D010300 NONE Risk\NN\14541044 factors\NNS\7326557 and\CC\1740 predictors\NNS\10756433 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesia\NN\14084880 among\IN\1740 multiethnic\JJ\1740 Malaysians\NNPS\9641757 with\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D007980_D010300 NONE Chronic\JJ\1740 pulsatile\JJ\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 for\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 leads\VBZ\1752884 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 motor\NN\3699975 fluctuations\NNS\7345593 and\CC\1740 dyskinesia\NN\14084880 .\.\1740
D007980_D010300 NONE Chronic\JJ\1740 pulsatile\JJ\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 for\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 leads\VBZ\1752884 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 motor\NN\3699975 fluctuations\NNS\7345593 and\CC\1740 dyskinesia\NN\14084880 .\.\1740
D007980_D010300 NONE We\PRP\1740 studied\VBD\630380 the\DT\1740 prevalence\NN\4764412 and\CC\1740 predictors\NNS\10756433 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesia\NN\14084880 among\IN\1740 multiethnic\JJ\1740 Malaysian\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>PD</e2>\NN\14625458 .\.\1740
D007980_D010300 NONE METHODS\NNS\5616786 :\:\1740 This\DT\1740 is\VBZ\836236 a\DT\13649268 cross-sectional\JJ\1740 study\NN\635850 involving\VBG\2676054 95\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>PD</e2>\NN\14625458 on\IN\1740 uninterrupted\JJ\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 for\IN\1740 at\IN\14622893 least\JJS\1740 6\CD\13741022 months\NNS\15113229 .\.\1740
24588023
D014148_D012640 CID The\DT\1740 association\NN\8008335 between\IN\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 and\CC\1740 <e2>convulsive</e2>\JJ\1740 seizures\NNS\14081375 after\IN\1740 cardiac\JJ\1740 surgery\NN\6045562 :\:\1740 a\DT\13649268 multivariate\JJ\1740 analysis\NN\633864 in\IN\13603305 11\CD\13745420 529\CD\1740 patients\NNS\9898892 .\.\1740
D014148_D012640 CID The\DT\1740 association\NN\8008335 between\IN\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 and\CC\1740 convulsive\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 cardiac\JJ\1740 surgery\NN\6045562 :\:\1740 a\DT\13649268 multivariate\JJ\1740 analysis\NN\633864 in\IN\13603305 11\CD\13745420 529\CD\1740 patients\NNS\9898892 .\.\1740
D014148_D012640 CID Independent\JJ\1740 predictors\NNS\10756433 of\IN\1740 postoperative\JJ\1740 <e2>seizures</e2>\NNS\14081375 included\VBD\690614 age\NN\4916342 ,\,\1740 female\NN\15388 sex\NN\13440063 ,\,\1740 redo\NN\1740 cardiac\JJ\1740 surgery\NN\6045562 ,\,\1740 calcification\NN\13446390 of\IN\1740 ascending\VBG\1835496 aorta\NN\5333777 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 deep\JJ\1740 hypothermic\JJ\1740 circulatory\JJ\1740 arrest\NN\88481 ,\,\1740 duration\NN\15113229 of\IN\1740 aortic\JJ\1740 cross-clamp\NN\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D014148_D012640 CID When\WRB\1740 tested\VBN\670261 in\IN\13603305 a\DT\13649268 multivariate\JJ\1740 regression\NN\14501726 analysis\NN\633864 ,\,\1740 <e1>tranexamic\NN\1740 acid</e1>\NN\14818238 was\VBD\836236 a\DT\13649268 strong\JJ\1740 independent\JJ\1740 predictor\NN\10756433 of\IN\1740 <e2>seizures</e2>\NNS\14081375 (\-LRB-\1740 OR\NN\3541091 14.3\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 5.5\CD\1740 -\SYM\1740 36.7\CD\1740 ;\:\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D014148_D012640 CID As\IN\14622893 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 is\VBZ\836236 the\DT\1740 only\JJ\1740 modifiable\JJ\1740 factor\NN\7326557 ,\,\1740 its\PRP$\6125041 administration\NN\1133281 ,\,\1740 particularly\RB\1740 in\IN\13603305 doses\NNS\3740161 exceeding\VBG\2673965 80\CD\13745420 mg.kg(-1\CD\1740 )\-RRB-\1740 ,\,\1740 should\MD\1740 be\VB\836236 weighed\VBN\2704349 against\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 postoperative\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D014148_D006333 NONE Independent\JJ\1740 predictors\NNS\10756433 of\IN\1740 postoperative\JJ\1740 seizures\NNS\14081375 included\VBD\690614 age\NN\4916342 ,\,\1740 female\NN\15388 sex\NN\13440063 ,\,\1740 redo\NN\1740 cardiac\JJ\1740 surgery\NN\6045562 ,\,\1740 calcification\NN\13446390 of\IN\1740 ascending\VBG\1835496 aorta\NN\5333777 ,\,\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 deep\JJ\1740 hypothermic\JJ\1740 circulatory\JJ\1740 arrest\NN\88481 ,\,\1740 duration\NN\15113229 of\IN\1740 aortic\JJ\1740 cross-clamp\NN\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D014148_D007035 NONE Independent\JJ\1740 predictors\NNS\10756433 of\IN\1740 postoperative\JJ\1740 seizures\NNS\14081375 included\VBD\690614 age\NN\4916342 ,\,\1740 female\NN\15388 sex\NN\13440063 ,\,\1740 redo\NN\1740 cardiac\JJ\1740 surgery\NN\6045562 ,\,\1740 calcification\NN\13446390 of\IN\1740 ascending\VBG\1835496 aorta\NN\5333777 ,\,\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 deep\JJ\1740 <e2>hypothermic</e2>\JJ\1740 circulatory\JJ\1740 arrest\NN\88481 ,\,\1740 duration\NN\15113229 of\IN\1740 aortic\JJ\1740 cross-clamp\NN\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
24040781
C107135_D011507 CID An\DT\6697703 unexpected\JJ\1740 diagnosis\NN\152018 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>proteinuria</e2>\NN\14299637 treated\VBN\2376958 with\IN\1740 <e1>everolimus</e1>\NN\1740 :\:\1740 AL\NN\14625458 amyloidosis\NN\14061805 .\.\1740
C107135_D011507 CID In\IN\13603305 this\DT\1740 case\NN\7283608 we\PRP\1740 report\VBP\831651 the\DT\1740 unexpected\JJ\1740 diagnosis\NN\152018 of\IN\1740 amyloidosis\NN\14061805 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 pre-transplant\JJ\1740 monoclonal\JJ\1740 gammapathy\NN\1740 of\IN\1740 undetermined\JJ\1740 significance\NN\5168261 who\WP\8299493 developed\VBD\1753788 <e2>proteinuria</e2>\NN\14299637 after\IN\1740 conversion\NN\7359599 from\IN\1740 tacrolimus\NN\1740 to\TO\1740 <e1>everolimus</e1>\NN\1740 .\.\1740
C107135_D000686 CID An\DT\6697703 unexpected\JJ\1740 diagnosis\NN\152018 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 proteinuria\NN\14299637 treated\VBN\2376958 with\IN\1740 <e1>everolimus</e1>\NN\1740 :\:\1740 <e2>AL</e2>\NN\14625458 amyloidosis\NN\14061805 .\.\1740
C107135_D000686 CID An\DT\6697703 unexpected\JJ\1740 diagnosis\NN\152018 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 proteinuria\NN\14299637 treated\VBN\2376958 with\IN\1740 <e1>everolimus</e1>\NN\1740 :\:\1740 AL\NN\14625458 <e2>amyloidosis</e2>\NN\14061805 .\.\1740
C107135_D000686 CID In\IN\13603305 this\DT\1740 case\NN\7283608 we\PRP\1740 report\VBP\831651 the\DT\1740 unexpected\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>amyloidosis</e2>\NN\14061805 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 pre-transplant\JJ\1740 monoclonal\JJ\1740 gammapathy\NN\1740 of\IN\1740 undetermined\JJ\1740 significance\NN\5168261 who\WP\8299493 developed\VBD\1753788 proteinuria\NN\14299637 after\IN\1740 conversion\NN\7359599 from\IN\1740 tacrolimus\NN\1740 to\TO\1740 <e1>everolimus</e1>\NN\1740 .\.\1740
D020123_D011507 NONE <e2>Proteinuria</e2>\NNP\14299637 is\VBZ\836236 an\DT\6697703 expected\VBN\670261 complication\NN\1073995 in\IN\13603305 transplant\NN\5267548 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 <e1>rapamycin</e1>\NN\1740 inhibitors\NNS\20090 (\-LRB-\1740 mTOR-i\NNS\1740 )\-RRB-\1740 .\.\1740
D016559_D000686 NONE In\IN\13603305 this\DT\1740 case\NN\7283608 we\PRP\1740 report\VBP\831651 the\DT\1740 unexpected\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>amyloidosis</e2>\NN\14061805 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 pre-transplant\JJ\1740 monoclonal\JJ\1740 gammapathy\NN\1740 of\IN\1740 undetermined\JJ\1740 significance\NN\5168261 who\WP\8299493 developed\VBD\1753788 proteinuria\NN\14299637 after\IN\1740 conversion\NN\7359599 from\IN\1740 <e1>tacrolimus</e1>\NN\1740 to\TO\1740 everolimus\NN\1740 .\.\1740
D016559_D011507 NONE In\IN\13603305 this\DT\1740 case\NN\7283608 we\PRP\1740 report\VBP\831651 the\DT\1740 unexpected\JJ\1740 diagnosis\NN\152018 of\IN\1740 amyloidosis\NN\14061805 in\IN\13603305 a\DT\13649268 renal-transplant\JJ\1740 patient\NN\9898892 with\IN\1740 pre-transplant\JJ\1740 monoclonal\JJ\1740 gammapathy\NN\1740 of\IN\1740 undetermined\JJ\1740 significance\NN\5168261 who\WP\8299493 developed\VBD\1753788 <e2>proteinuria</e2>\NN\14299637 after\IN\1740 conversion\NN\7359599 from\IN\1740 <e1>tacrolimus</e1>\NN\1740 to\TO\1740 everolimus\NN\1740 .\.\1740
6728873
D002110_D012640 CID Five\CD\13741022 phenotypic\JJ\1740 characteristics\NNS\5849040 --\:\1740 locomotor\NN\1740 activity\NN\30358 ,\,\1740 righting\NN\1740 ability\NN\4723816 ,\,\1740 <e2>clonic\JJ\1740 seizure</e2>\JJ\1740 induction\NN\7450842 ,\,\1740 stress-induced\JJ\1740 lethality\NN\4790449 ,\,\1740 death\NN\7296428 without\IN\1740 external\JJ\1740 stress\NN\7083732 --\:\1740 were\VBD\836236 scored\VBN\1111028 at\IN\14622893 various\JJ\1740 <e1>caffeine</e1>\NN\14712692 doses\NNS\3740161 in\IN\13603305 drug-naive\JJ\1740 animals\NNS\4475 under\IN\1740 empirically\RB\1740 optimized\VBN\473572 ,\,\1740 rigidly\RB\1740 constant\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 .\.\1740
-1_D064420 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 behavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 testing\NN\639556 of\IN\1740 <e1>alkylxanthines</e1>\NNS\1740 in\IN\13603305 a\DT\13649268 single\JJ\1740 mouse\NN\2329401 strain\NN\7358060 may\MD\15209706 be\VB\836236 misleading\VBG\1999798 and\CC\1740 suggest\VBP\1010118 that\IN\1740 toxic\JJ\1740 responses\NNS\11410625 of\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 to\TO\1740 this\DT\1740 class\NN\7951464 of\IN\1740 compounds\NNS\5869584 are\VBP\836236 genetically\RB\1740 influenced\VBN\137313 in\IN\13603305 mammals\NNS\1471682 .\.\1740
3375885
D007213_D006947 CID <e2>Hyperkalemia</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 <e1>indomethacin</e1>\NN\3828465 and\CC\1740 naproxen\NN\3828465 and\CC\1740 reversed\VBN\109660 by\IN\1740 fludrocortisone\NN\1740 .\.\1740
D007213_D006947 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 <e1>indomethacin</e1>\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D007213_D006947 CID Because\IN\1740 he\PRP\14622893 was\VBD\836236 unable\JJ\1740 to\TO\1740 discontinue\VB\2609764 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drug\NN\14778436 therapy\NN\657604 ,\,\1740 fludrocortisone\NN\1740 was\VBD\836236 added\VBN\156601 ,\,\1740 correcting\VBG\138508 the\DT\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 allowing\VBG\797697 <e1>indomethacin</e1>\NN\3828465 therapy\NN\657604 to\TO\1740 be\VB\836236 continued\VBN\2367363 safely\RB\1740 .\.\1740
D009288_D006947 CID <e2>Hyperkalemia</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 indomethacin\NN\3828465 and\CC\1740 <e1>naproxen</e1>\NN\3828465 and\CC\1740 reversed\VBN\109660 by\IN\1740 fludrocortisone\NN\1740 .\.\1740
D009288_D006947 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 <e1>naproxen</e1>\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D005438_D006947 NONE <e2>Hyperkalemia</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 indomethacin\NN\3828465 and\CC\1740 naproxen\NN\3828465 and\CC\1740 reversed\VBN\109660 by\IN\1740 <e1>fludrocortisone</e1>\NN\1740 .\.\1740
D005438_D006947 NONE Because\IN\1740 he\PRP\14622893 was\VBD\836236 unable\JJ\1740 to\TO\1740 discontinue\VB\2609764 nonsteroidal\JJ\1740 anti-inflammatory\JJ\1740 drug\NN\14778436 therapy\NN\657604 ,\,\1740 <e1>fludrocortisone</e1>\NN\1740 was\VBD\836236 added\VBN\156601 ,\,\1740 correcting\VBG\138508 the\DT\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 allowing\VBG\797697 indomethacin\NN\3828465 therapy\NN\657604 to\TO\1740 be\VB\836236 continued\VBN\2367363 safely\RB\1740 .\.\1740
D008528_D001172 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D008528_D007674 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D008528_D006947 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D008528_D006994 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>mefenamic\JJ\1740 acid</e1>\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 <e2>hypoaldosteronism</e2>\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D007213_D001172 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 <e1>indomethacin</e1>\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D007213_D007674 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 <e1>indomethacin</e1>\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D007213_D006994 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 <e2>hypoaldosteronism</e2>\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 <e1>indomethacin</e1>\NN\3828465 and\CC\1740 naproxen\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D009288_D001172 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 <e1>naproxen</e1>\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D009288_D007674 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 hypoaldosteronism\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 <e1>naproxen</e1>\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D009288_D006994 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 severe\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 mefenamic\JJ\1740 acid\NN\14818238 nephropathy\NN\14573196 in\IN\13603305 whom\WP\1740 hyperkalemia\NN\14299637 and\CC\1740 inappropriate\JJ\1740 <e2>hypoaldosteronism</e2>\NN\1740 were\VBD\836236 caused\VBN\1617192 by\IN\1740 both\CC\1740 indomethacin\NN\3828465 and\CC\1740 <e1>naproxen</e1>\NN\3828465 ,\,\1740 without\IN\1740 major\JJ\1740 decline\NN\13458571 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D011453_D007674 NONE It\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 preexisting\VBG\2603699 <e2>renal\JJ\1740 disease</e2>\NN\14061805 predisposed\VBD\680841 this\DT\1740 patient\NN\9898892 to\TO\1740 type\NN\5839024 IV\CD\13741022 renal\JJ\1740 tubular\JJ\1740 acidosis\NN\14204950 with\IN\1740 <e1>prostaglandin</e1>\NN\5414534 synthetase\NN\1740 inhibitors\NNS\20090 .\.\1740
D011453_D006994 NONE It\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 preexisting\VBG\2603699 renal\JJ\1740 disease\NN\14061805 predisposed\VBD\680841 this\DT\1740 patient\NN\9898892 to\TO\1740 <e2>type\NN\5839024 IV\CD\13741022 renal\JJ\1740 tubular\JJ\1740 acidosis</e2>\NN\14204950 with\IN\1740 <e1>prostaglandin</e1>\NN\5414534 synthetase\NN\1740 inhibitors\NNS\20090 .\.\1740
9538487
D008094_D006944 CID <e2>Hyperosmolar\JJ\1740 nonketotic\JJ\1740 coma</e2>\NN\5678932 precipitated\VBN\1642924 by\IN\1740 <e1>lithium-induced</e1>\JJ\1740 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 .\.\1740
D008094_D006944 CID A\DT\13649268 45-year-old\JJ\1740 man\NN\9605289 ,\,\1740 with\IN\1740 a\DT\13649268 10-year\JJ\1740 history\NN\15120823 of\IN\1740 manic\JJ\1740 depression\NN\14373582 treated\VBN\2376958 with\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 was\VBD\836236 admitted\VBN\822367 with\IN\1740 <e2>hyperosmolar\JJ\1740 ,\,\1740 nonketotic\JJ\1740 coma</e2>\NN\5678932 .\.\1740
D008094_D018500 CID Hyperosmolar\JJ\1740 nonketotic\JJ\1740 coma\NN\5678932 precipitated\VBN\1642924 by\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 .\.\1740
D008094_D018500 CID After\IN\1740 recovery\NN\7357388 from\IN\1740 hyperglycaemia\NN\14299637 ,\,\1740 he\PRP\14622893 remained\VBD\2604760 polyuric\JJ\1740 despite\IN\7501545 normal\JJ\1740 blood\NN\5397468 glucose\NN\14710501 concentrations\NNS\4916342 ;\:\1740 water\NN\14618834 deprivation\NN\14493145 testing\NN\639556 indicated\VBD\952524 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 ,\,\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 <e1>lithium-induced</e1>\JJ\1740 .\.\1740
D008094_D001714 NONE A\DT\13649268 45-year-old\JJ\1740 man\NN\9605289 ,\,\1740 with\IN\1740 a\DT\13649268 10-year\JJ\1740 history\NN\15120823 of\IN\1740 <e2>manic\JJ\1740 depression</e2>\NN\14373582 treated\VBN\2376958 with\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 was\VBD\836236 admitted\VBN\822367 with\IN\1740 hyperosmolar\JJ\1740 ,\,\1740 nonketotic\JJ\1740 coma\NN\5678932 .\.\1740
D005947_D011141 NONE He\PRP\14622893 gave\VBD\2327200 a\DT\13649268 five-year\JJ\1740 history\NN\15120823 of\IN\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 polydipsia\NN\14040660 ,\,\1740 during\IN\1740 which\WDT\1740 time\NN\7308889 urinalysis\NN\646833 had\VBD\2108377 been\VBN\836236 negative\JJ\1740 for\IN\1740 <e1>glucose</e1>\NN\14710501 .\.\1740
D005947_D011141 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 hyperglycaemia\NN\14299637 ,\,\1740 he\PRP\14622893 remained\VBD\2604760 <e2>polyuric</e2>\JJ\1740 despite\IN\7501545 normal\JJ\1740 blood\NN\5397468 <e1>glucose</e1>\NN\14710501 concentrations\NNS\4916342 ;\:\1740 water\NN\14618834 deprivation\NN\14493145 testing\NN\639556 indicated\VBD\952524 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 ,\,\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 lithium-induced\JJ\1740 .\.\1740
D005947_D059606 NONE He\PRP\14622893 gave\VBD\2327200 a\DT\13649268 five-year\JJ\1740 history\NN\15120823 of\IN\1740 polyuria\NN\14113228 and\CC\1740 <e2>polydipsia</e2>\NN\14040660 ,\,\1740 during\IN\1740 which\WDT\1740 time\NN\7308889 urinalysis\NN\646833 had\VBD\2108377 been\VBN\836236 negative\JJ\1740 for\IN\1740 <e1>glucose</e1>\NN\14710501 .\.\1740
D005947_-1 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 <e2>hyperglycaemia</e2>\NN\14299637 ,\,\1740 he\PRP\14622893 remained\VBD\2604760 polyuric\JJ\1740 despite\IN\7501545 normal\JJ\1740 blood\NN\5397468 <e1>glucose</e1>\NN\14710501 concentrations\NNS\4916342 ;\:\1740 water\NN\14618834 deprivation\NN\14493145 testing\NN\639556 indicated\VBD\952524 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 ,\,\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 lithium-induced\JJ\1740 .\.\1740
D005947_D018500 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 hyperglycaemia\NN\14299637 ,\,\1740 he\PRP\14622893 remained\VBD\2604760 polyuric\JJ\1740 despite\IN\7501545 normal\JJ\1740 blood\NN\5397468 <e1>glucose</e1>\NN\14710501 concentrations\NNS\4916342 ;\:\1740 water\NN\14618834 deprivation\NN\14493145 testing\NN\639556 indicated\VBD\952524 <e2>nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus</e2>\NN\1740 ,\,\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 lithium-induced\JJ\1740 .\.\1740
D008094_-1 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 <e2>hyperglycaemia</e2>\NN\14299637 ,\,\1740 he\PRP\14622893 remained\VBD\2604760 polyuric\JJ\1740 despite\IN\7501545 normal\JJ\1740 blood\NN\5397468 glucose\NN\14710501 concentrations\NNS\4916342 ;\:\1740 water\NN\14618834 deprivation\NN\14493145 testing\NN\639556 indicated\VBD\952524 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 ,\,\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 <e1>lithium-induced</e1>\JJ\1740 .\.\1740
D008094_D011141 CID After\IN\1740 recovery\NN\7357388 from\IN\1740 hyperglycaemia\NN\14299637 ,\,\1740 he\PRP\14622893 remained\VBD\2604760 <e2>polyuric</e2>\JJ\1740 despite\IN\7501545 normal\JJ\1740 blood\NN\5397468 glucose\NN\14710501 concentrations\NNS\4916342 ;\:\1740 water\NN\14618834 deprivation\NN\14493145 testing\NN\639556 indicated\VBD\952524 nephrogenic\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 ,\,\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 <e1>lithium-induced</e1>\JJ\1740 .\.\1740
2239937
D002119_D006934 CID Etiology\NN\7326557 of\IN\1740 <e2>hypercalcemia</e2>\NN\14299637 in\IN\13603305 hemodialysis\JJ\1740 patients\NNS\9898892 on\IN\1740 <e1>calcium\NN\14625458 carbonate</e1>\NN\15010703 therapy\NN\657604 .\.\1740
D002119_D006934 CID Fourteen\CD\13745420 of\IN\1740 39\CD\1740 dialysis\NN\646833 patients\NNS\9898892 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 became\VBD\146138 <e2>hypercalcemic</e2>\JJ\1740 after\IN\1740 switching\NN\191142 to\TO\1740 <e1>calcium\NN\14625458 carbonate</e1>\NN\15010703 as\IN\14622893 their\PRP$\1740 principal\JJ\1740 phosphate\NN\15010703 binder\NN\3496892 .\.\1740
D010710_D006934 NONE Fourteen\CD\13745420 of\IN\1740 39\CD\1740 dialysis\NN\646833 patients\NNS\9898892 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 became\VBD\146138 <e2>hypercalcemic</e2>\JJ\1740 after\IN\1740 switching\NN\191142 to\TO\1740 calcium\NN\14625458 carbonate\NN\15010703 as\IN\14622893 their\PRP$\1740 principal\JJ\1740 <e1>phosphate</e1>\NN\15010703 binder\NN\3496892 .\.\1740
D002118_D006934 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 identify\VB\699815 risk\NN\14541044 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 indirect\JJ\1740 parameters\NNS\5858936 of\IN\1740 intestinal\JJ\1740 <e1>calcium</e1>\NN\14625458 reabsorption\NN\13526110 and\CC\1740 bone\NN\5286536 turnover\NN\13819207 rate\NN\13815152 in\IN\13603305 these\DT\1740 14\CD\13745420 patients\NNS\9898892 were\VBD\836236 compared\VBN\644583 with\IN\1740 results\NNS\34213 in\IN\13603305 14\CD\13745420 eucalcemic\JJ\1740 patients\NNS\9898892 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 length\NN\5093581 of\IN\1740 time\NN\7308889 on\IN\1740 dialysis\NN\646833 ,\,\1740 and\CC\1740 etiology\NN\7326557 of\IN\1740 renal\JJ\1740 disease\NN\14061805 .\.\1740
D002118_D006934 NONE In\IN\13603305 addition\NN\3081021 to\TO\1740 experiencing\VBG\2108377 <e2>hypercalcemic</e2>\JJ\1740 episodes\NNS\7283608 with\IN\1740 peak\JJ\1740 <e1>calcium</e1>\NN\14625458 values\NNS\5941423 of\IN\1740 2.7\CD\1740 to\TO\1740 3.8\CD\1740 mmol/L\NN\1740 (\-LRB-\1740 10.7\CD\1740 to\TO\1740 15.0\CD\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 hypercalcemic\JJ\1740 group\NN\2137 exhibited\VBD\2632167 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 mean\NN\6021761 calcium\NN\14625458 concentration\NN\4916342 obtained\VBN\2210855 during\IN\1740 6\CD\13741022 months\NNS\15113229 before\IN\1740 the\DT\1740 switch\NN\3096960 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 mean\NN\6021761 value\NN\5856066 obtained\VBN\2210855 during\IN\1740 the\DT\1740 7\CD\13741022 months\NNS\15113229 of\IN\1740 observation\NN\996969 after\IN\1740 the\DT\1740 switch\NN\3096960 (\-LRB-\1740 2.4\CD\1740 +/-\CC\1740 0.03\CD\1740 to\TO\1740 2.5\CD\1740 +/-\CC\1740 0.03\CD\1740 mmol/L\NN\1740 [\-LRB-\1740 9.7\CD\1740 +/-\CC\1740 0.2\CD\1740 to\TO\1740 10.2\CD\1740 +/-\CC\1740 0.1\CD\1740 mg/dL\NN\1740 ]\-RRB-\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D006934 NONE In\IN\13603305 addition\NN\3081021 to\TO\1740 experiencing\VBG\2108377 hypercalcemic\JJ\1740 episodes\NNS\7283608 with\IN\1740 peak\JJ\1740 <e1>calcium</e1>\NN\14625458 values\NNS\5941423 of\IN\1740 2.7\CD\1740 to\TO\1740 3.8\CD\1740 mmol/L\NN\1740 (\-LRB-\1740 10.7\CD\1740 to\TO\1740 15.0\CD\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 <e2>hypercalcemic</e2>\JJ\1740 group\NN\2137 exhibited\VBD\2632167 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 mean\NN\6021761 calcium\NN\14625458 concentration\NN\4916342 obtained\VBN\2210855 during\IN\1740 6\CD\13741022 months\NNS\15113229 before\IN\1740 the\DT\1740 switch\NN\3096960 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 mean\NN\6021761 value\NN\5856066 obtained\VBN\2210855 during\IN\1740 the\DT\1740 7\CD\13741022 months\NNS\15113229 of\IN\1740 observation\NN\996969 after\IN\1740 the\DT\1740 switch\NN\3096960 (\-LRB-\1740 2.4\CD\1740 +/-\CC\1740 0.03\CD\1740 to\TO\1740 2.5\CD\1740 +/-\CC\1740 0.03\CD\1740 mmol/L\NN\1740 [\-LRB-\1740 9.7\CD\1740 +/-\CC\1740 0.2\CD\1740 to\TO\1740 10.2\CD\1740 +/-\CC\1740 0.1\CD\1740 mg/dL\NN\1740 ]\-RRB-\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D006934 NONE In\IN\13603305 addition\NN\3081021 to\TO\1740 experiencing\VBG\2108377 <e2>hypercalcemic</e2>\JJ\1740 episodes\NNS\7283608 with\IN\1740 peak\JJ\1740 calcium\NN\14625458 values\NNS\5941423 of\IN\1740 2.7\CD\1740 to\TO\1740 3.8\CD\1740 mmol/L\NN\1740 (\-LRB-\1740 10.7\CD\1740 to\TO\1740 15.0\CD\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 hypercalcemic\JJ\1740 group\NN\2137 exhibited\VBD\2632167 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 mean\NN\6021761 <e1>calcium</e1>\NN\14625458 concentration\NN\4916342 obtained\VBN\2210855 during\IN\1740 6\CD\13741022 months\NNS\15113229 before\IN\1740 the\DT\1740 switch\NN\3096960 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 mean\NN\6021761 value\NN\5856066 obtained\VBN\2210855 during\IN\1740 the\DT\1740 7\CD\13741022 months\NNS\15113229 of\IN\1740 observation\NN\996969 after\IN\1740 the\DT\1740 switch\NN\3096960 (\-LRB-\1740 2.4\CD\1740 +/-\CC\1740 0.03\CD\1740 to\TO\1740 2.5\CD\1740 +/-\CC\1740 0.03\CD\1740 mmol/L\NN\1740 [\-LRB-\1740 9.7\CD\1740 +/-\CC\1740 0.2\CD\1740 to\TO\1740 10.2\CD\1740 +/-\CC\1740 0.1\CD\1740 mg/dL\NN\1740 ]\-RRB-\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D006934 NONE In\IN\13603305 addition\NN\3081021 to\TO\1740 experiencing\VBG\2108377 hypercalcemic\JJ\1740 episodes\NNS\7283608 with\IN\1740 peak\JJ\1740 calcium\NN\14625458 values\NNS\5941423 of\IN\1740 2.7\CD\1740 to\TO\1740 3.8\CD\1740 mmol/L\NN\1740 (\-LRB-\1740 10.7\CD\1740 to\TO\1740 15.0\CD\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 <e2>hypercalcemic</e2>\JJ\1740 group\NN\2137 exhibited\VBD\2632167 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 mean\NN\6021761 <e1>calcium</e1>\NN\14625458 concentration\NN\4916342 obtained\VBN\2210855 during\IN\1740 6\CD\13741022 months\NNS\15113229 before\IN\1740 the\DT\1740 switch\NN\3096960 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 mean\NN\6021761 value\NN\5856066 obtained\VBN\2210855 during\IN\1740 the\DT\1740 7\CD\13741022 months\NNS\15113229 of\IN\1740 observation\NN\996969 after\IN\1740 the\DT\1740 switch\NN\3096960 (\-LRB-\1740 2.4\CD\1740 +/-\CC\1740 0.03\CD\1740 to\TO\1740 2.5\CD\1740 +/-\CC\1740 0.03\CD\1740 mmol/L\NN\1740 [\-LRB-\1740 9.7\CD\1740 +/-\CC\1740 0.2\CD\1740 to\TO\1740 10.2\CD\1740 +/-\CC\1740 0.1\CD\1740 mg/dL\NN\1740 ]\-RRB-\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 0.006\CD\1740 )\-RRB-\1740 .\.\1740
D002118_D007674 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 identify\VB\699815 risk\NN\14541044 factors\NNS\7326557 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 hypercalcemia\NN\14299637 ,\,\1740 indirect\JJ\1740 parameters\NNS\5858936 of\IN\1740 intestinal\JJ\1740 <e1>calcium</e1>\NN\14625458 reabsorption\NN\13526110 and\CC\1740 bone\NN\5286536 turnover\NN\13819207 rate\NN\13815152 in\IN\13603305 these\DT\1740 14\CD\13745420 patients\NNS\9898892 were\VBD\836236 compared\VBN\644583 with\IN\1740 results\NNS\34213 in\IN\13603305 14\CD\13745420 eucalcemic\JJ\1740 patients\NNS\9898892 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 length\NN\5093581 of\IN\1740 time\NN\7308889 on\IN\1740 dialysis\NN\646833 ,\,\1740 and\CC\1740 etiology\NN\7326557 of\IN\1740 <e2>renal\JJ\1740 disease</e2>\NN\14061805 .\.\1740
2625524
D006220_D012640 NONE <e1>Haloperidol</e1>\NNP\3713736 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 amphetamine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 but\CC\1740 did\VBD\1640855 lower\JJR\1740 the\DT\1740 mortality\NN\5054863 rate\NN\13815152 at\IN\14622893 most\JJS\1740 doses\NNS\3740161 tested\VBN\670261 .\.\1740
D006220_D012640 NONE <e1>Haloperidol</e1>\NNP\3713736 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 at\IN\14622893 the\DT\1740 two\CD\13741022 highest\JJS\1740 doses\NNS\3740161 ,\,\1740 but\CC\1740 the\DT\1740 lowering\NN\351638 of\IN\1740 the\DT\1740 mortality\NN\5054863 rate\NN\13815152 did\VBD\1640855 not\RB\1740 reach\VB\2005948 statistical\JJ\1740 significance\NN\5168261 at\IN\14622893 any\DT\1740 dose\NN\3740161 .\.\1740
D006220_D012640 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 a\DT\13649268 protective\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 central\JJ\1740 dopamine\NN\14807737 blocker\NN\10101634 <e1>haloperidol</e1>\NN\3713736 against\IN\1740 death\NN\7296428 from\IN\1740 high-dose\JJ\1740 amphetamine\NN\3248958 exposure\NN\5042871 without\IN\1740 reducing\VBG\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D006220_D012640 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>haloperidol</e1>\NN\3713736 demonstrated\VBD\2137132 an\DT\6697703 ability\NN\4723816 to\TO\1740 reduce\VB\441445 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 without\IN\1740 significantly\RB\1740 reducing\VBG\441445 mortality\NN\5054863 .\.\1740
D000661_D012640 CID Haloperidol\NNP\3713736 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 but\CC\1740 did\VBD\1640855 lower\JJR\1740 the\DT\1740 mortality\NN\5054863 rate\NN\13815152 at\IN\14622893 most\JJS\1740 doses\NNS\3740161 tested\VBN\670261 .\.\1740
D000661_D012640 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 a\DT\13649268 protective\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 central\JJ\1740 dopamine\NN\14807737 blocker\NN\10101634 haloperidol\NN\3713736 against\IN\1740 death\NN\7296428 from\IN\1740 high-dose\JJ\1740 <e1>amphetamine</e1>\NN\3248958 exposure\NN\5042871 without\IN\1740 reducing\VBG\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID Haloperidol\NNP\3713736 decreased\VBD\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 at\IN\14622893 the\DT\1740 two\CD\13741022 highest\JJS\1740 doses\NNS\3740161 ,\,\1740 but\CC\1740 the\DT\1740 lowering\NN\351638 of\IN\1740 the\DT\1740 mortality\NN\5054863 rate\NN\13815152 did\VBD\1640855 not\RB\1740 reach\VB\2005948 statistical\JJ\1740 significance\NN\5168261 at\IN\14622893 any\DT\1740 dose\NN\3740161 .\.\1740
D003042_D012640 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 haloperidol\NN\3713736 demonstrated\VBD\2137132 an\DT\6697703 ability\NN\4723816 to\TO\1740 reduce\VB\441445 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 without\IN\1740 significantly\RB\1740 reducing\VBG\441445 mortality\NN\5054863 .\.\1740
D004298_D012640 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 a\DT\13649268 protective\JJ\1740 role\NN\719494 for\IN\1740 the\DT\1740 central\JJ\1740 <e1>dopamine</e1>\NN\14807737 blocker\NN\10101634 haloperidol\NN\3713736 against\IN\1740 death\NN\7296428 from\IN\1740 high-dose\JJ\1740 amphetamine\NN\3248958 exposure\NN\5042871 without\IN\1740 reducing\VBG\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
11299446
C027429_D010302 CID Worsening\NN\13457378 of\IN\1740 <e2>Parkinsonism</e2>\NNP\14085708 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>veralipride</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 menopause\NN\15116532 :\:\1740 case\NN\7283608 report\NN\6470073 .\.\1740
C027429_D010302 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 female\JJ\1740 patient\NN\9898892 with\IN\1740 stable\JJ\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 who\WP\8299493 has\VBZ\2108377 shown\VBN\2137132 a\DT\13649268 marked\JJ\1740 worsening\NN\13457378 of\IN\1740 her\PRP$\1740 motor\NN\3699975 functions\NNS\13783581 following\VBG\1835496 therapy\NN\657604 of\IN\1740 menopause\NN\15116532 related\JJ\1740 symptoms\NNS\5823932 with\IN\1740 <e1>veralipride</e1>\NN\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 improvement\NN\7359599 of\IN\1740 her\PRP$\1740 symptoms\NNS\5823932 back\RB\1740 to\TO\1740 baseline\NN\7260623 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
3831029
C037293_D006333 NONE Improvement\NN\7359599 by\IN\1740 <e1>denopamine</e1>\NN\1740 (\-LRB-\1740 TA-064\NN\1740 )\-RRB-\1740 of\IN\1740 pentobarbital-induced\JJ\1740 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 the\DT\1740 dog\NN\2083346 heart-lung\JJ\1740 preparation\NN\407535 .\.\1740
C037293_D006333 NONE Improvement\NN\7359599 by\IN\1740 denopamine\NN\1740 (\-LRB-\1740 <e1>TA-064</e1>\NN\1740 )\-RRB-\1740 of\IN\1740 pentobarbital-induced\JJ\1740 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 the\DT\1740 dog\NN\2083346 heart-lung\JJ\1740 preparation\NN\407535 .\.\1740
C037293_D006333 NONE The\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>denopamine</e1>\NN\1740 ,\,\1740 an\DT\6697703 orally\RB\1740 active\JJ\1740 beta\NN\6828818 1-adrenoceptor\NN\1740 agonist\NN\9613191 ,\,\1740 in\IN\13603305 improving\VBG\126264 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 was\VBD\836236 assessed\VBN\670261 in\IN\13603305 dog\NN\2083346 heart-lung\JJ\1740 preparations\NNS\407535 .\.\1740
C037293_D006333 NONE The\DT\1740 results\NNS\34213 warrant\VBP\1012073 clinical\JJ\1740 trials\NNS\786195 of\IN\1740 <e1>denopamine</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 .\.\1740
D010424_D006333 CID Improvement\NN\7359599 by\IN\1740 denopamine\NN\1740 (\-LRB-\1740 TA-064\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>pentobarbital-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 the\DT\1740 dog\NN\2083346 heart-lung\JJ\1740 preparation\NN\407535 .\.\1740
C037293_D001145 NONE No\DT\7204911 <e2>arrhythmias</e2>\NNS\14103288 were\VBD\836236 induced\VBN\1627355 by\IN\1740 these\DT\1740 doses\NNS\3740161 of\IN\1740 <e1>denopamine</e1>\NN\1740 .\.\1740
2974281
D011433_D006332 NONE Subacute\NN\1740 effects\NNS\13245626 of\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 B\NN\1355326 24/76\CD\1740 on\IN\1740 isoproterenol-induced\JJ\1740 rat\NN\2329401 <e2>heart\NN\5919034 hypertrophy</e2>\NN\14365950 in\IN\13603305 correlation\NN\13841213 with\IN\1740 blood\NN\5397468 pressure\NN\11419404 .\.\1740
D011433_D006332 NONE Thus\RB\1740 ,\,\1740 the\DT\1740 investigations\NNS\5797597 did\VBD\1640855 not\RB\1740 provide\VB\2199590 any\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 beta-receptor\NN\1740 blockers\NNS\10101634 <e1>propranolol</e1>\NN\1740 and\CC\1740 B\NN\1355326 24/76\CD\1740 have\VBP\2108377 the\DT\1740 potency\NN\5196375 to\TO\1740 prevent\VB\1740 isoproterenol\NN\3740161 from\IN\1740 producing\VBG\1617192 <e2>heart\NN\5919034 hypertrophy</e2>\NN\14365950 .\.\1740
D007545_D006332 CID Subacute\NN\1740 effects\NNS\13245626 of\IN\1740 propranolol\NN\1740 and\CC\1740 B\NN\1355326 24/76\CD\1740 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 rat\NN\2329401 <e2>heart\NN\5919034 hypertrophy</e2>\NN\14365950 in\IN\13603305 correlation\NN\13841213 with\IN\1740 blood\NN\5397468 pressure\NN\11419404 .\.\1740
D007545_D006332 CID The\DT\1740 studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 using\VBG\1156834 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>heart\NN\5919034 hypertrophy</e2>\NN\14365950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D006332 CID Thus\RB\1740 ,\,\1740 the\DT\1740 investigations\NNS\5797597 did\VBD\1640855 not\RB\1740 provide\VB\2199590 any\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 beta-receptor\NN\1740 blockers\NNS\10101634 propranolol\NN\1740 and\CC\1740 B\NN\1355326 24/76\CD\1740 have\VBP\2108377 the\DT\1740 potency\NN\5196375 to\TO\1740 prevent\VB\1740 <e1>isoproterenol</e1>\NN\3740161 from\IN\1740 producing\VBG\1617192 <e2>heart\NN\5919034 hypertrophy</e2>\NN\14365950 .\.\1740
D009952_D006332 NONE It\PRP\6125041 was\VBD\836236 possible\JJ\1740 to\TO\1740 suppress\VB\2510337 the\DT\1740 increased\VBN\169651 <e1>ornithine</e1>\NN\14601829 decarboxylase\NN\14732946 activity\NN\30358 with\IN\1740 both\DT\1740 beta-blockers\NNS\1740 in\IN\13603305 <e2>hypertrophied\VBN\230746 hearts</e2>\NNS\496167 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 heart\NN\5919034 mass\NN\13575869 .\.\1740
D011433_D006984 NONE Neither\DT\1740 <e1>propranolol</e1>\NN\1740 nor\CC\1740 B\NN\1355326 24/76\CD\1740 could\MD\1740 stop\VB\2452885 the\DT\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 characteristic\JJ\1740 myosin\NN\15022171 isoenzyme\NN\1740 pattern\NN\5726345 of\IN\1740 the\DT\1740 <e2>hypertrophied</e2>\VBN\230746 rat\NN\2329401 heart\NN\5919034 .\.\1740
24100257
C089750_D054549 CID <e2>Takotsubo\VBN\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 or\CC\3541091 apical\JJ\1740 ballooning\NN\302394 syndrome\NN\5870365 )\-RRB-\1740 secondary\JJ\1740 to\IN\1740 <e1>Zolmitriptan</e1>\NNP\1740 .\.\1740
C089750_D054549 CID Takotsubo\VBN\1740 syndrome\NN\5870365 (\-LRB-\1740 or\CC\3541091 <e2>apical\JJ\1740 ballooning\NN\302394 syndrome</e2>\NN\5870365 )\-RRB-\1740 secondary\JJ\1740 to\IN\1740 <e1>Zolmitriptan</e1>\NNP\1740 .\.\1740
C089750_D054549 CID Extensive\JJ\1740 literature\NN\6362953 search\NN\407535 revealed\VBD\2137132 multiple\JJ\1740 cases\NNS\7283608 of\IN\1740 coronary\JJ\1740 artery\NN\5417975 vasospasm\NN\1740 secondary\JJ\1740 to\TO\1740 <e1>zolmitriptan</e1>\NN\1740 ,\,\1740 but\CC\1740 none\NN\15228378 of\IN\1740 the\DT\1740 cases\NNS\7283608 were\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>TS</e2>\NN\14999913 .\.\1740
C089750_D008881 NONE Detailed\JJ\1740 history\NN\15120823 obtained\VBN\2210855 retrospectively\RB\1740 revealed\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 took\VBD\2367363 <e1>zolmitriptan</e1>\NN\1740 sparingly\RB\1740 only\RB\1740 when\WRB\1740 she\PRP\1740 had\VBD\2108377 <e2>migraines</e2>\NNS\14326607 .\.\1740 But\CC\1740 before\IN\1740 this\DT\1740 event\NN\23100 ,\,\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 zolmitriptan\NN\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 daily\RB\1740 for\IN\1740 several\JJ\1740 days\NNS\15140892 because\IN\1740 of\IN\1740 a\DT\13649268 persistent\JJ\1740 migraine\NN\14326607 headache\NN\5829480 .\.\1740
C089750_D008881 NONE Detailed\JJ\1740 history\NN\15120823 obtained\VBN\2210855 retrospectively\RB\1740 revealed\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 took\VBD\2367363 <e1>zolmitriptan</e1>\NN\1740 sparingly\RB\1740 only\RB\1740 when\WRB\1740 she\PRP\1740 had\VBD\2108377 migraines\NNS\14326607 .\.\1740 But\CC\1740 before\IN\1740 this\DT\1740 event\NN\23100 ,\,\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 zolmitriptan\NN\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 daily\RB\1740 for\IN\1740 several\JJ\1740 days\NNS\15140892 because\IN\1740 of\IN\1740 a\DT\13649268 persistent\JJ\1740 <e2>migraine\NN\14326607 headache</e2>\NN\5829480 .\.\1740
C089750_D008881 NONE Detailed\JJ\1740 history\NN\15120823 obtained\VBN\2210855 retrospectively\RB\1740 revealed\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 took\VBD\2367363 zolmitriptan\NN\1740 sparingly\RB\1740 only\RB\1740 when\WRB\1740 she\PRP\1740 had\VBD\2108377 <e2>migraines</e2>\NNS\14326607 .\.\1740 But\CC\1740 before\IN\1740 this\DT\1740 event\NN\23100 ,\,\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 <e1>zolmitriptan</e1>\NN\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 daily\RB\1740 for\IN\1740 several\JJ\1740 days\NNS\15140892 because\IN\1740 of\IN\1740 a\DT\13649268 persistent\JJ\1740 migraine\NN\14326607 headache\NN\5829480 .\.\1740
C089750_D008881 NONE Detailed\JJ\1740 history\NN\15120823 obtained\VBN\2210855 retrospectively\RB\1740 revealed\VBD\2137132 that\IN\1740 the\DT\1740 patient\NN\9898892 took\VBD\2367363 zolmitriptan\NN\1740 sparingly\RB\1740 only\RB\1740 when\WRB\1740 she\PRP\1740 had\VBD\2108377 migraines\NNS\14326607 .\.\1740 But\CC\1740 before\IN\1740 this\DT\1740 event\NN\23100 ,\,\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 <e1>zolmitriptan</e1>\NN\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 daily\RB\1740 for\IN\1740 several\JJ\1740 days\NNS\15140892 because\IN\1740 of\IN\1740 a\DT\13649268 persistent\JJ\1740 <e2>migraine\NN\14326607 headache</e2>\NN\5829480 .\.\1740
C089750_D003329 CID Extensive\JJ\1740 literature\NN\6362953 search\NN\407535 revealed\VBD\2137132 multiple\JJ\1740 cases\NNS\7283608 of\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 vasospasm</e2>\NN\1740 secondary\JJ\1740 to\TO\1740 <e1>zolmitriptan</e1>\NN\1740 ,\,\1740 but\CC\1740 none\NN\15228378 of\IN\1740 the\DT\1740 cases\NNS\7283608 were\VBD\836236 associated\VBN\628491 with\IN\1740 TS\NN\14999913 .\.\1740
15987266
D003513_D004827 NONE Growth-associated\JJ\1740 protein\NN\14944888 43\CD\1740 expression\NN\4679549 in\IN\13603305 hippocampal\NN\1740 molecular\JJ\1740 layer\NN\21939 of\IN\1740 chronic\JJ\1740 <e2>epileptic</e2>\JJ\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>cycloheximide</e1>\NN\1740 .\.\1740
D010862_D013226 CID To\TO\1740 investigate\VB\644583 how\WRB\1740 GAP43\NN\1740 expression\NN\4679549 (\-LRB-\1740 GAP43-ir\NN\1740 )\-RRB-\1740 correlates\VBZ\2657219 with\IN\1740 MFS\NN\5056490 ,\,\1740 we\PRP\1740 assessed\VBD\670261 the\DT\1740 intensity\NN\5090441 (\-LRB-\1740 densitometry\NN\996969 )\-RRB-\1740 and\CC\1740 extension\NN\15272029 (\-LRB-\1740 width\NN\5093581 )\-RRB-\1740 of\IN\1740 GAP43-ir\NN\1740 in\IN\13603305 the\DT\1740 inner\JJ\1740 molecular\JJ\1740 layer\NN\21939 of\IN\1740 the\DT\1740 dentate\NN\1740 gyrus\NN\5225602 (\-LRB-\1740 IML\NN\1740 )\-RRB-\1740 of\IN\1740 rats\NNS\2329401 subject\JJ\1740 to\TO\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 (\-LRB-\1740 Pilo\NN\1740 )\-RRB-\1740 ,\,\1740 previously\RB\1740 injected\VBN\81072 or\CC\3541091 not\RB\1740 with\IN\1740 cycloheximide\NN\1740 (\-LRB-\1740 CHX\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 inhibit\VB\2510337 MFS\NNP\5056490 .\.\1740
D010862_D013226 CID To\TO\1740 investigate\VB\644583 how\WRB\1740 GAP43\NN\1740 expression\NN\4679549 (\-LRB-\1740 GAP43-ir\NN\1740 )\-RRB-\1740 correlates\VBZ\2657219 with\IN\1740 MFS\NN\5056490 ,\,\1740 we\PRP\1740 assessed\VBD\670261 the\DT\1740 intensity\NN\5090441 (\-LRB-\1740 densitometry\NN\996969 )\-RRB-\1740 and\CC\1740 extension\NN\15272029 (\-LRB-\1740 width\NN\5093581 )\-RRB-\1740 of\IN\1740 GAP43-ir\NN\1740 in\IN\13603305 the\DT\1740 inner\JJ\1740 molecular\JJ\1740 layer\NN\21939 of\IN\1740 the\DT\1740 dentate\NN\1740 gyrus\NN\5225602 (\-LRB-\1740 IML\NN\1740 )\-RRB-\1740 of\IN\1740 rats\NNS\2329401 subject\JJ\1740 to\TO\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 (\-LRB-\1740 <e1>Pilo</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 previously\RB\1740 injected\VBN\81072 or\CC\3541091 not\RB\1740 with\IN\1740 cycloheximide\NN\1740 (\-LRB-\1740 CHX\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 inhibit\VB\2510337 MFS\NNP\5056490 .\.\1740
D003513_D013226 NONE To\TO\1740 investigate\VB\644583 how\WRB\1740 GAP43\NN\1740 expression\NN\4679549 (\-LRB-\1740 GAP43-ir\NN\1740 )\-RRB-\1740 correlates\VBZ\2657219 with\IN\1740 MFS\NN\5056490 ,\,\1740 we\PRP\1740 assessed\VBD\670261 the\DT\1740 intensity\NN\5090441 (\-LRB-\1740 densitometry\NN\996969 )\-RRB-\1740 and\CC\1740 extension\NN\15272029 (\-LRB-\1740 width\NN\5093581 )\-RRB-\1740 of\IN\1740 GAP43-ir\NN\1740 in\IN\13603305 the\DT\1740 inner\JJ\1740 molecular\JJ\1740 layer\NN\21939 of\IN\1740 the\DT\1740 dentate\NN\1740 gyrus\NN\5225602 (\-LRB-\1740 IML\NN\1740 )\-RRB-\1740 of\IN\1740 rats\NNS\2329401 subject\JJ\1740 to\TO\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 (\-LRB-\1740 Pilo\NN\1740 )\-RRB-\1740 ,\,\1740 previously\RB\1740 injected\VBN\81072 or\CC\3541091 not\RB\1740 with\IN\1740 <e1>cycloheximide</e1>\NN\1740 (\-LRB-\1740 CHX\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 inhibit\VB\2510337 MFS\NNP\5056490 .\.\1740
D003513_D013226 NONE To\TO\1740 investigate\VB\644583 how\WRB\1740 GAP43\NN\1740 expression\NN\4679549 (\-LRB-\1740 GAP43-ir\NN\1740 )\-RRB-\1740 correlates\VBZ\2657219 with\IN\1740 MFS\NN\5056490 ,\,\1740 we\PRP\1740 assessed\VBD\670261 the\DT\1740 intensity\NN\5090441 (\-LRB-\1740 densitometry\NN\996969 )\-RRB-\1740 and\CC\1740 extension\NN\15272029 (\-LRB-\1740 width\NN\5093581 )\-RRB-\1740 of\IN\1740 GAP43-ir\NN\1740 in\IN\13603305 the\DT\1740 inner\JJ\1740 molecular\JJ\1740 layer\NN\21939 of\IN\1740 the\DT\1740 dentate\NN\1740 gyrus\NN\5225602 (\-LRB-\1740 IML\NN\1740 )\-RRB-\1740 of\IN\1740 rats\NNS\2329401 subject\JJ\1740 to\TO\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 pilocarpine\NN\14712692 (\-LRB-\1740 Pilo\NN\1740 )\-RRB-\1740 ,\,\1740 previously\RB\1740 injected\VBN\81072 or\CC\3541091 not\RB\1740 with\IN\1740 cycloheximide\NN\1740 (\-LRB-\1740 <e1>CHX</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 inhibit\VB\2510337 MFS\NNP\5056490 .\.\1740
19728177
D000082_D017114 CID METHOD\NN\5616786 :\:\1740 Case-based\JJ\1740 observations\NNS\996969 from\IN\1740 a\DT\13649268 medical\JJ\1740 intensive\JJ\1740 care\NN\575741 unit\NN\13576101 (\-LRB-\1740 MICU\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 tertiary\JJ\1740 care\NN\575741 facility\NN\21939 in\IN\13603305 a\DT\13649268 27-year-old\JJ\1740 female\NN\15388 with\IN\1740 <e2>FHF</e2>\NN\1740 from\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 resultant\JJ\1740 cerebral\JJ\1740 edema\NN\14315192 .\.\1740
D000082_D017114 CID Initial\JJ\1740 evaluation\NN\874067 confirmed\VBD\1011725 <e2>FHF</e2>\NN\1740 from\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 cerebral\JJ\1740 edema\NN\14315192 .\.\1740
D000082_D017114 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>FHF</e2>\NN\1740 and\CC\1740 cerebral\JJ\1740 edema\NN\14315192 from\IN\1740 <e1>acetaminophen</e1>\JJ\1740 overdose\NN\1740 ,\,\1740 prolonged\JJ\1740 therapeutic\JJ\1740 hypothermia\NN\14034177 could\MD\1740 potentially\RB\1740 be\VB\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 life\NN\13954253 saving\NN\37396 therapy\NN\657604 and\CC\1740 a\DT\13649268 bridge\NN\4341686 to\TO\1740 hepatic\JJ\1740 and\CC\1740 neurological\JJ\1740 recovery\NN\7357388 .\.\1740
D000082_D001929 CID METHOD\NN\5616786 :\:\1740 Case-based\JJ\1740 observations\NNS\996969 from\IN\1740 a\DT\13649268 medical\JJ\1740 intensive\JJ\1740 care\NN\575741 unit\NN\13576101 (\-LRB-\1740 MICU\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 tertiary\JJ\1740 care\NN\575741 facility\NN\21939 in\IN\13603305 a\DT\13649268 27-year-old\JJ\1740 female\NN\15388 with\IN\1740 FHF\NN\1740 from\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 resultant\JJ\1740 <e2>cerebral\JJ\1740 edema</e2>\NN\14315192 .\.\1740
D000082_D001929 CID Initial\JJ\1740 evaluation\NN\874067 confirmed\VBD\1011725 FHF\NN\1740 from\IN\1740 <e1>acetaminophen</e1>\NN\2707683 and\CC\1740 <e2>cerebral\JJ\1740 edema</e2>\NN\14315192 .\.\1740
D000082_D001929 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 FHF\NN\1740 and\CC\1740 <e2>cerebral\JJ\1740 edema</e2>\NN\14315192 from\IN\1740 <e1>acetaminophen</e1>\JJ\1740 overdose\NN\1740 ,\,\1740 prolonged\JJ\1740 therapeutic\JJ\1740 hypothermia\NN\14034177 could\MD\1740 potentially\RB\1740 be\VB\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 life\NN\13954253 saving\NN\37396 therapy\NN\657604 and\CC\1740 a\DT\13649268 bridge\NN\4341686 to\TO\1740 hepatic\JJ\1740 and\CC\1740 neurological\JJ\1740 recovery\NN\7357388 .\.\1740
D000082_D064420 NONE RESULTS\NNS\34213 :\:\1740 Our\PRP$\1740 patient\NN\9898892 was\VBD\836236 admitted\VBN\822367 to\TO\1740 the\DT\1740 MICU\NN\1740 after\IN\1740 being\VBG\836236 found\VBN\2426171 unresponsive\JJ\1740 with\IN\1740 presumed\VBN\719734 <e2>toxicity</e2>\NN\13576101 from\IN\1740 <e1>acetaminophen</e1>\NN\2707683 which\WDT\1740 was\VBD\836236 ingested\VBN\597915 over\IN\5867413 a\DT\13649268 2-day\JJ\1740 period\NN\13575869 .\.\1740
D000082_D062787 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 FHF\NN\1740 and\CC\1740 cerebral\JJ\1740 edema\NN\14315192 from\IN\1740 <e1>acetaminophen</e1>\JJ\1740 <e2>overdose</e2>\NN\1740 ,\,\1740 prolonged\JJ\1740 therapeutic\JJ\1740 hypothermia\NN\14034177 could\MD\1740 potentially\RB\1740 be\VB\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 life\NN\13954253 saving\NN\37396 therapy\NN\657604 and\CC\1740 a\DT\13649268 bridge\NN\4341686 to\TO\1740 hepatic\JJ\1740 and\CC\1740 neurological\JJ\1740 recovery\NN\7357388 .\.\1740
D000082_D007035 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 FHF\NN\1740 and\CC\1740 cerebral\JJ\1740 edema\NN\14315192 from\IN\1740 <e1>acetaminophen</e1>\JJ\1740 overdose\NN\1740 ,\,\1740 prolonged\JJ\1740 therapeutic\JJ\1740 <e2>hypothermia</e2>\NN\14034177 could\MD\1740 potentially\RB\1740 be\VB\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 life\NN\13954253 saving\NN\37396 therapy\NN\657604 and\CC\1740 a\DT\13649268 bridge\NN\4341686 to\TO\1740 hepatic\JJ\1740 and\CC\1740 neurological\JJ\1740 recovery\NN\7357388 .\.\1740
19531695
D005424_D003693 CID <e2>Delirium</e2>\NN\14391660 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 toxic\JJ\1740 <e1>flecainide</e1>\NN\2715941 plasma\NN\5398023 concentrations\NNS\4916342 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 a\DT\13649268 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 with\IN\1740 paroxetine\NN\1740 .\.\1740
D005424_D003693 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>flecainide-induced</e1>\JJ\1740 <e2>delirium</e2>\NN\14391660 associated\VBN\628491 with\IN\1740 a\DT\13649268 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 with\IN\1740 paroxetine\NN\1740 .\.\1740
D005424_D003693 CID DISCUSSION\NN\6252138 :\:\1740 <e1>Flecainide</e1>\NNP\2715941 and\CC\1740 pharmacologically\RB\1740 similar\JJ\1740 agents\NNS\7347 that\WDT\1740 interact\VBP\2367363 with\IN\1740 sodium\NN\14625458 channels\NNS\6251781 may\MD\15209706 cause\VB\1617192 <e2>delirium</e2>\NN\14391660 in\IN\13603305 susceptible\JJ\1740 patients\NNS\9898892 .\.\1740
D005424_D003693 CID A\DT\13649268 MEDLINE\NN\4402746 search\NN\407535 (\-LRB-\1740 1966-January\JJ\1740 2009\CD\1740 )\-RRB-\1740 revealed\VBD\2137132 one\CD\13741022 in\FW\13603305 vivo\FW\1740 pharmacokinetic\JJ\1740 study\NN\635850 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 <e1>flecainide</e1>\NN\2715941 ,\,\1740 a\DT\13649268 CYP2D6\NN\1740 substrate\NN\19613 ,\,\1740 and\CC\1740 paroxetine\NN\1740 ,\,\1740 a\DT\13649268 CYP2D6\NN\1740 inhibitor\NN\20090 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 3\CD\13741022 case\NN\7283608 reports\NNS\6470073 of\IN\1740 flecainide-induced\JJ\1740 <e2>delirium</e2>\NN\14391660 .\.\1740
D005424_D003693 CID A\DT\13649268 MEDLINE\NN\4402746 search\NN\407535 (\-LRB-\1740 1966-January\JJ\1740 2009\CD\1740 )\-RRB-\1740 revealed\VBD\2137132 one\CD\13741022 in\FW\13603305 vivo\FW\1740 pharmacokinetic\JJ\1740 study\NN\635850 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 flecainide\NN\2715941 ,\,\1740 a\DT\13649268 CYP2D6\NN\1740 substrate\NN\19613 ,\,\1740 and\CC\1740 paroxetine\NN\1740 ,\,\1740 a\DT\13649268 CYP2D6\NN\1740 inhibitor\NN\20090 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 3\CD\13741022 case\NN\7283608 reports\NNS\6470073 of\IN\1740 <e1>flecainide-induced</e1>\JJ\1740 <e2>delirium</e2>\NN\14391660 .\.\1740
D005424_D003693 CID According\VBG\2657219 to\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 ,\,\1740 <e1>flecainide</e1>\NN\2715941 was\VBD\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>delirium</e2>\NN\14391660 ;\:\1740 the\DT\1740 Horn\NNP\3827536 Drug\NNP\14778436 Interaction\NNP\37396 Probability\NNP\33615 Scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 possible\JJ\1740 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 flecainide\NN\2715941 and\CC\1740 paroxetine\NN\1740 .\.\1740
D005424_D003693 CID According\VBG\2657219 to\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 ,\,\1740 flecainide\NN\2715941 was\VBD\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>delirium</e2>\NN\14391660 ;\:\1740 the\DT\1740 Horn\NNP\3827536 Drug\NNP\14778436 Interaction\NNP\37396 Probability\NNP\33615 Scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 possible\JJ\1740 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 <e1>flecainide</e1>\NN\2715941 and\CC\1740 paroxetine\NN\1740 .\.\1740
D005424_D003693 CID CONCLUSIONS\NNS\5837957 :\:\1740 Supratherapeutic\JJ\1740 <e1>flecainide</e1>\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 may\MD\15209706 cause\VB\1617192 <e2>delirium</e2>\NN\14391660 .\.\1740
D017374_D003693 CID <e2>Delirium</e2>\NN\14391660 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 toxic\JJ\1740 flecainide\NN\2715941 plasma\NN\5398023 concentrations\NNS\4916342 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 a\DT\13649268 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 with\IN\1740 <e1>paroxetine</e1>\NN\1740 .\.\1740
D017374_D003693 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 flecainide-induced\JJ\1740 <e2>delirium</e2>\NN\14391660 associated\VBN\628491 with\IN\1740 a\DT\13649268 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 with\IN\1740 <e1>paroxetine</e1>\NN\1740 .\.\1740
D017374_D003693 CID A\DT\13649268 MEDLINE\NN\4402746 search\NN\407535 (\-LRB-\1740 1966-January\JJ\1740 2009\CD\1740 )\-RRB-\1740 revealed\VBD\2137132 one\CD\13741022 in\FW\13603305 vivo\FW\1740 pharmacokinetic\JJ\1740 study\NN\635850 on\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 flecainide\NN\2715941 ,\,\1740 a\DT\13649268 CYP2D6\NN\1740 substrate\NN\19613 ,\,\1740 and\CC\1740 <e1>paroxetine</e1>\NN\1740 ,\,\1740 a\DT\13649268 CYP2D6\NN\1740 inhibitor\NN\20090 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 3\CD\13741022 case\NN\7283608 reports\NNS\6470073 of\IN\1740 flecainide-induced\JJ\1740 <e2>delirium</e2>\NN\14391660 .\.\1740
D017374_D003693 CID According\VBG\2657219 to\IN\1740 the\DT\1740 Naranjo\NNP\1740 probability\NN\33615 scale\NN\7260623 ,\,\1740 flecainide\NN\2715941 was\VBD\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>delirium</e2>\NN\14391660 ;\:\1740 the\DT\1740 Horn\NNP\3827536 Drug\NNP\14778436 Interaction\NNP\37396 Probability\NNP\33615 Scale\NN\7260623 indicates\VBZ\952524 a\DT\13649268 possible\JJ\1740 pharmacokinetic\JJ\1740 drug\NN\14778436 interaction\NN\37396 between\IN\1740 flecainide\NN\2715941 and\CC\1740 <e1>paroxetine</e1>\NN\1740 .\.\1740
D005424_D001281 NONE <e1>Flecainide</e1>\NNP\2715941 had\VBD\2108377 been\VBN\836236 started\VBN\2009433 2\CD\13741022 weeks\NNS\15113229 prior\RB\1740 for\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 .\.\1740
D012964_D003693 NONE DISCUSSION\NN\6252138 :\:\1740 Flecainide\NNP\2715941 and\CC\1740 pharmacologically\RB\1740 similar\JJ\1740 agents\NNS\7347 that\WDT\1740 interact\VBP\2367363 with\IN\1740 <e1>sodium</e1>\NN\14625458 channels\NNS\6251781 may\MD\15209706 cause\VB\1617192 <e2>delirium</e2>\NN\14391660 in\IN\13603305 susceptible\JJ\1740 patients\NNS\9898892 .\.\1740
D005424_D064420 NONE Because\IN\1740 <e2>toxicity</e2>\NN\13576101 may\MD\15209706 occur\VB\2623529 when\WRB\1740 <e1>flecainide</e1>\NN\2715941 is\VBZ\836236 prescribed\VBN\748282 with\IN\1740 paroxetine\NN\1740 and\CC\1740 other\JJ\1740 potent\JJ\1740 CYP2D6\NN\1740 inhibitors\NNS\20090 ,\,\1740 flecainide\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 with\IN\1740 commencement\NN\15180528 of\IN\1740 CYP2D6\NN\1740 inhibitors\NNS\20090 .\.\1740
D005424_D064420 NONE Because\IN\1740 <e2>toxicity</e2>\NN\13576101 may\MD\15209706 occur\VB\2623529 when\WRB\1740 flecainide\NN\2715941 is\VBZ\836236 prescribed\VBN\748282 with\IN\1740 paroxetine\NN\1740 and\CC\1740 other\JJ\1740 potent\JJ\1740 CYP2D6\NN\1740 inhibitors\NNS\20090 ,\,\1740 <e1>flecainide</e1>\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 with\IN\1740 commencement\NN\15180528 of\IN\1740 CYP2D6\NN\1740 inhibitors\NNS\20090 .\.\1740
D017374_D064420 NONE Because\IN\1740 <e2>toxicity</e2>\NN\13576101 may\MD\15209706 occur\VB\2623529 when\WRB\1740 flecainide\NN\2715941 is\VBZ\836236 prescribed\VBN\748282 with\IN\1740 <e1>paroxetine</e1>\NN\1740 and\CC\1740 other\JJ\1740 potent\JJ\1740 CYP2D6\NN\1740 inhibitors\NNS\20090 ,\,\1740 flecainide\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 should\MD\1740 be\VB\836236 monitored\VBN\2169352 closely\RB\1740 with\IN\1740 commencement\NN\15180528 of\IN\1740 CYP2D6\NN\1740 inhibitors\NNS\20090 .\.\1740
6631522
C013102_D066126 NONE Our\PRP$\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 changes\NNS\7283608 leading\VBG\1752884 to\TO\1740 an\DT\6697703 alteration\NN\7283608 of\IN\1740 myocardial\JJ\1740 dynamic\NN\9179776 imaging\NN\5765159 with\IN\1740 <e1>I-131\NN\1740 HA</e1>\NN\13888491 are\VBP\836236 not\RB\1740 the\DT\1740 initiating\VBG\1617192 factor\NN\7326557 in\IN\13603305 doxorubicin\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 CID Our\PRP$\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 changes\NNS\7283608 leading\VBG\1752884 to\TO\1740 an\DT\6697703 alteration\NN\7283608 of\IN\1740 myocardial\JJ\1740 dynamic\NN\9179776 imaging\NN\5765159 with\IN\1740 I-131\NN\1740 HA\NN\13888491 are\VBP\836236 not\RB\1740 the\DT\1740 initiating\VBG\1617192 factor\NN\7326557 in\IN\13603305 <e1>doxorubicin</e1>\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
25951420
D010126_D010300 CID Associations\NNS\8008335 of\IN\1740 <e1>Ozone</e1>\NN\14877585 and\CC\1740 PM2.5\NN\1740 Concentrations\NNPS\4916342 With\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 Disease</e2>\NNP\14061805 Among\IN\1740 Participants\NNS\9816771 in\IN\13603305 the\DT\1740 Agricultural\NNP\1740 Health\NNP\14447525 Study\NNP\635850 .\.\1740
D010126_D010300 CID OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 describes\VBZ\1001294 associations\NNS\8008335 of\IN\1740 <e1>ozone</e1>\NN\14877585 and\CC\1740 fine\JJ\1740 particulate\JJ\1740 matter\NN\5670710 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 observed\VBN\2163746 among\IN\1740 farmers\NNS\9614315 in\IN\13603305 North\NNP\13831000 Carolina\NNP\1740 and\CC\1740 Iowa\NNP\9669125 .\.\1740
D010126_D010300 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 observed\VBD\2163746 positive\JJ\1740 associations\NNS\8008335 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 with\IN\1740 <e1>ozone</e1>\NN\14877585 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 =\JJ\1740 1.39\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 0.98\CD\1740 to\TO\1740 1.98\CD\1740 )\-RRB-\1740 and\CC\1740 fine\JJ\1740 particulate\JJ\1740 matter\NN\5670710 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 =\JJ\1740 1.34\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 0.93\CD\1740 to\TO\1740 1.93\CD\1740 )\-RRB-\1740 in\IN\13603305 North\NNP\13831000 Carolina\NNP\1740 but\CC\1740 not\RB\1740 in\IN\13603305 Iowa\NNP\9669125 .\.\1740
D052638_D010300 CID OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 describes\VBZ\1001294 associations\NNS\8008335 of\IN\1740 ozone\NN\14877585 and\CC\1740 fine\JJ\1740 <e1>particulate\JJ\1740 matter</e1>\NN\5670710 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 observed\VBN\2163746 among\IN\1740 farmers\NNS\9614315 in\IN\13603305 North\NNP\13831000 Carolina\NNP\1740 and\CC\1740 Iowa\NNP\9669125 .\.\1740
D052638_D010300 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 observed\VBD\2163746 positive\JJ\1740 associations\NNS\8008335 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 with\IN\1740 ozone\NN\14877585 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 =\JJ\1740 1.39\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 0.98\CD\1740 to\TO\1740 1.98\CD\1740 )\-RRB-\1740 and\CC\1740 fine\JJ\1740 <e1>particulate\JJ\1740 matter</e1>\NN\5670710 (\-LRB-\1740 odds\NNS\4756635 ratio\NN\13815152 =\JJ\1740 1.34\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 :\:\1740 0.93\CD\1740 to\TO\1740 1.93\CD\1740 )\-RRB-\1740 in\IN\13603305 North\NNP\13831000 Carolina\NNP\1740 but\CC\1740 not\RB\1740 in\IN\13603305 Iowa\NNP\9669125 .\.\1740
11395263
D000431_D009203 NONE The\DT\1740 cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 <e1>ethanol</e1>\NN\14708720 extract\NN\14589223 of\IN\1740 Picrorrhiza\NNP\1740 kurroa\NN\1740 rhizomes\NNS\13129165 and\CC\1740 roots\NNS\13920429 (\-LRB-\1740 PK\NN\1740 )\-RRB-\1740 on\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 with\IN\1740 respect\NN\5817845 to\TO\1740 lipid\NN\14944888 metabolism\NN\13526110 in\IN\13603305 serum\NN\5397468 and\CC\1740 heart\NN\5919034 tissue\NN\5220461 has\VBZ\2108377 been\VBN\836236 investigated\VBN\644583 .\.\1740
D007545_D009203 CID The\DT\1740 cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 ethanol\NN\14708720 extract\NN\14589223 of\IN\1740 Picrorrhiza\NNP\1740 kurroa\NN\1740 rhizomes\NNS\13129165 and\CC\1740 roots\NNS\13920429 (\-LRB-\1740 PK\NN\1740 )\-RRB-\1740 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 with\IN\1740 respect\NN\5817845 to\TO\1740 lipid\NN\14944888 metabolism\NN\13526110 in\IN\13603305 serum\NN\5397468 and\CC\1740 heart\NN\5919034 tissue\NN\5220461 has\VBZ\2108377 been\VBN\836236 investigated\VBN\644583 .\.\1740
D007545_D009203 CID Oral\JJ\1740 pre-treatment\NN\1740 with\IN\1740 PK\NN\1740 (\-LRB-\1740 80\CD\13745420 mg\NN\13717155 kg(-1\NN\1740 )\-RRB-\1740 day(-1\NN\1740 )\-RRB-\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 )\-RRB-\1740 significantly\RB\1740 prevented\VBD\1740 the\DT\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 maintained\VBD\2202928 the\DT\1740 rats\NNS\2329401 at\IN\14622893 near\IN\1740 normal\JJ\1740 status\NN\24720 .\.\1740
2907577
-1_D058186 NONE Effect\NN\34213 of\IN\1740 <e1>alkylxanthines</e1>\NNS\1740 on\IN\1740 gentamicin-induced\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
-1_D058186 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 three\CD\13741022 <e1>alkylxanthines</e1>\NNS\1740 with\IN\1740 different\JJ\1740 potencies\NNS\5196375 as\IN\14622893 adenosine\NN\14964367 antagonists\NNS\7846 8-phenyltheophylline\NN\1740 ,\,\1740 theophylline\NN\2905612 and\CC\1740 enprofylline\NN\1740 ,\,\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 4\CD\13741022 daily\JJ\1740 injections\NNS\320852 of\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 200\CD\1740 mg\NN\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
-1_D058186 NONE The\DT\1740 lack\NN\14449126 of\IN\1740 any\DT\1740 consistent\JJ\1740 protective\JJ\1740 effect\NN\34213 noted\VBN\1009240 with\IN\1740 the\DT\1740 <e1>alkylxanthines</e1>\NNS\1740 tested\VBN\670261 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 indicates\VBZ\952524 that\IN\1740 adenosine\NN\14964367 plays\VBZ\1072262 little\JJ\1740 ,\,\1740 if\IN\1740 any\DT\1740 ,\,\1740 pathophysiological\JJ\1740 role\NN\719494 in\IN\13603305 gentamicin-induced\JJ\1740 <e2>ARF</e2>\NN\1740 .\.\1740
D005839_D058186 CID Effect\NN\34213 of\IN\1740 alkylxanthines\NNS\1740 on\IN\1740 <e1>gentamicin-induced</e1>\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D005839_D058186 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 three\CD\13741022 alkylxanthines\NNS\1740 with\IN\1740 different\JJ\1740 potencies\NNS\5196375 as\IN\14622893 adenosine\NN\14964367 antagonists\NNS\7846 8-phenyltheophylline\NN\1740 ,\,\1740 theophylline\NN\2905612 and\CC\1740 enprofylline\NN\1740 ,\,\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 4\CD\13741022 daily\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>gentamicin</e1>\NN\2716866 (\-LRB-\1740 200\CD\1740 mg\NN\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
D005839_D058186 CID The\DT\1740 lack\NN\14449126 of\IN\1740 any\DT\1740 consistent\JJ\1740 protective\JJ\1740 effect\NN\34213 noted\VBN\1009240 with\IN\1740 the\DT\1740 alkylxanthines\NNS\1740 tested\VBN\670261 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 indicates\VBZ\952524 that\IN\1740 adenosine\NN\14964367 plays\VBZ\1072262 little\JJ\1740 ,\,\1740 if\IN\1740 any\DT\1740 ,\,\1740 pathophysiological\JJ\1740 role\NN\719494 in\IN\13603305 <e1>gentamicin-induced</e1>\JJ\1740 <e2>ARF</e2>\NN\1740 .\.\1740
D000241_D007511 NONE <e1>Adenosine</e1>\JJ\1740 antagonists\NNS\7846 have\VBP\2108377 been\VBN\836236 previously\RB\1740 shown\VBN\2137132 to\TO\1740 be\VB\836236 of\IN\1740 benefit\NN\13278375 in\IN\13603305 some\DT\1740 <e2>ischaemic</e2>\JJ\1740 and\CC\1740 nephrotoxic\JJ\1740 models\NNS\5888929 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D000241_D007674 NONE <e1>Adenosine</e1>\JJ\1740 antagonists\NNS\7846 have\VBP\2108377 been\VBN\836236 previously\RB\1740 shown\VBN\2137132 to\TO\1740 be\VB\836236 of\IN\1740 benefit\NN\13278375 in\IN\13603305 some\DT\1740 ischaemic\JJ\1740 and\CC\1740 <e2>nephrotoxic</e2>\JJ\1740 models\NNS\5888929 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D000241_D058186 NONE <e1>Adenosine</e1>\JJ\1740 antagonists\NNS\7846 have\VBP\2108377 been\VBN\836236 previously\RB\1740 shown\VBN\2137132 to\TO\1740 be\VB\836236 of\IN\1740 benefit\NN\13278375 in\IN\13603305 some\DT\1740 ischaemic\JJ\1740 and\CC\1740 nephrotoxic\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 .\.\1740
D000241_D058186 NONE <e1>Adenosine</e1>\JJ\1740 antagonists\NNS\7846 have\VBP\2108377 been\VBN\836236 previously\RB\1740 shown\VBN\2137132 to\TO\1740 be\VB\836236 of\IN\1740 benefit\NN\13278375 in\IN\13603305 some\DT\1740 ischaemic\JJ\1740 and\CC\1740 nephrotoxic\JJ\1740 models\NNS\5888929 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 <e2>ARF</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D000241_D058186 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 three\CD\13741022 alkylxanthines\NNS\1740 with\IN\1740 different\JJ\1740 potencies\NNS\5196375 as\IN\14622893 <e1>adenosine</e1>\NN\14964367 antagonists\NNS\7846 8-phenyltheophylline\NN\1740 ,\,\1740 theophylline\NN\2905612 and\CC\1740 enprofylline\NN\1740 ,\,\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 4\CD\13741022 daily\JJ\1740 injections\NNS\320852 of\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 200\CD\1740 mg\NN\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
D000241_D058186 NONE The\DT\1740 lack\NN\14449126 of\IN\1740 any\DT\1740 consistent\JJ\1740 protective\JJ\1740 effect\NN\34213 noted\VBN\1009240 with\IN\1740 the\DT\1740 alkylxanthines\NNS\1740 tested\VBN\670261 in\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 indicates\VBZ\952524 that\IN\1740 <e1>adenosine</e1>\NN\14964367 plays\VBZ\1072262 little\JJ\1740 ,\,\1740 if\IN\1740 any\DT\1740 ,\,\1740 pathophysiological\JJ\1740 role\NN\719494 in\IN\13603305 gentamicin-induced\JJ\1740 <e2>ARF</e2>\NN\1740 .\.\1740
C028322_D058186 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 three\CD\13741022 alkylxanthines\NNS\1740 with\IN\1740 different\JJ\1740 potencies\NNS\5196375 as\IN\14622893 adenosine\NN\14964367 antagonists\NNS\7846 <e1>8-phenyltheophylline</e1>\NN\1740 ,\,\1740 theophylline\NN\2905612 and\CC\1740 enprofylline\NN\1740 ,\,\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 4\CD\13741022 daily\JJ\1740 injections\NNS\320852 of\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 200\CD\1740 mg\NN\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
D013806_D058186 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 three\CD\13741022 alkylxanthines\NNS\1740 with\IN\1740 different\JJ\1740 potencies\NNS\5196375 as\IN\14622893 adenosine\NN\14964367 antagonists\NNS\7846 8-phenyltheophylline\NN\1740 ,\,\1740 <e1>theophylline</e1>\NN\2905612 and\CC\1740 enprofylline\NN\1740 ,\,\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 4\CD\13741022 daily\JJ\1740 injections\NNS\320852 of\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 200\CD\1740 mg\NN\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
C034347_D058186 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 three\CD\13741022 alkylxanthines\NNS\1740 with\IN\1740 different\JJ\1740 potencies\NNS\5196375 as\IN\14622893 adenosine\NN\14964367 antagonists\NNS\7846 8-phenyltheophylline\NN\1740 ,\,\1740 theophylline\NN\2905612 and\CC\1740 <e1>enprofylline</e1>\NN\1740 ,\,\1740 were\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 developing\VBG\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 4\CD\13741022 daily\JJ\1740 injections\NNS\320852 of\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 200\CD\1740 mg\NN\13717155 kg-1\NN\1740 )\-RRB-\1740 .\.\1740
D014508_D009336 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 assessed\VBN\670261 by\IN\1740 biochemical\JJ\1740 (\-LRB-\1740 plasma\NN\5398023 <e1>urea</e1>\NN\14727670 and\CC\1740 creatinine\NN\1740 )\-RRB-\1740 ,\,\1740 functional\JJ\1740 (\-LRB-\1740 urine\NN\14853947 analysis\NN\633864 and\CC\1740 [3H]inulin\NN\1740 and\CC\1740 [14C]p-aminohippuric\XX\1740 acid\NN\14818238 clearances\NNS\5089947 )\-RRB-\1740 and\CC\1740 morphological\JJ\1740 (\-LRB-\1740 degree\NN\4916342 of\IN\1740 <e2>necrosis</e2>\NN\11444117 )\-RRB-\1740 indices\NNS\13850304 .\.\1740
D003404_D009336 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 assessed\VBN\670261 by\IN\1740 biochemical\JJ\1740 (\-LRB-\1740 plasma\NN\5398023 urea\NN\14727670 and\CC\1740 <e1>creatinine</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 functional\JJ\1740 (\-LRB-\1740 urine\NN\14853947 analysis\NN\633864 and\CC\1740 [3H]inulin\NN\1740 and\CC\1740 [14C]p-aminohippuric\XX\1740 acid\NN\14818238 clearances\NNS\5089947 )\-RRB-\1740 and\CC\1740 morphological\JJ\1740 (\-LRB-\1740 degree\NN\4916342 of\IN\1740 <e2>necrosis</e2>\NN\11444117 )\-RRB-\1740 indices\NNS\13850304 .\.\1740
D010130_D009336 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 assessed\VBN\670261 by\IN\1740 biochemical\JJ\1740 (\-LRB-\1740 plasma\NN\5398023 urea\NN\14727670 and\CC\1740 creatinine\NN\1740 )\-RRB-\1740 ,\,\1740 functional\JJ\1740 (\-LRB-\1740 urine\NN\14853947 analysis\NN\633864 and\CC\1740 [3H]inulin\NN\1740 and\CC\1740 <e1>[14C]p-aminohippuric\XX\1740 acid</e1>\NN\14818238 clearances\NNS\5089947 )\-RRB-\1740 and\CC\1740 morphological\JJ\1740 (\-LRB-\1740 degree\NN\4916342 of\IN\1740 <e2>necrosis</e2>\NN\11444117 )\-RRB-\1740 indices\NNS\13850304 .\.\1740
2983630
D002110_D016584 NONE Increased\VBN\169651 anxiogenic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>caffeine</e1>\NN\14712692 in\IN\13603305 <e2>panic\NN\7519253 disorders</e2>\NNS\14034177 .\.\1740
D002110_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D002110_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D002110_D016584 NONE Seventy-one\CD\1740 percent\NN\13815742 of\IN\1740 the\DT\1740 patients\NNS\9898892 reported\VBD\831651 that\IN\1740 the\DT\1740 behavioral\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>caffeine</e1>\NN\14712692 were\VBD\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 experienced\VBN\2108377 during\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 .\.\1740
D002110_D016584 NONE Because\IN\1740 <e1>caffeine</e1>\NN\14712692 is\VBZ\836236 an\DT\6697703 adenosine\NN\14964367 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 some\DT\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 patients\NNS\9898892 may\MD\15209706 have\VB\2108377 abnormalities\NNS\14034177 in\IN\13603305 neuronal\JJ\1740 systems\NNS\3575240 involving\VBG\2676054 adenosine\NN\14964367 .\.\1740
D002110_D000379 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 <e2>agoraphobia</e2>\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D008734_D000379 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1>\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 <e2>agoraphobia</e2>\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D008734_D000379 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 <e1>MHPG</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 <e2>agoraphobia</e2>\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D008734_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1>\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D008734_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 <e1>3-methoxy-4-hydroxyphenethyleneglycol</e1>\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D008734_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 <e1>MHPG</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D008734_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 <e1>MHPG</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cortisol\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D006854_D000379 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cortisol</e1>\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 <e2>agoraphobia</e2>\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D006854_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cortisol</e1>\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 <e2>panic\NN\7519253 attacks</e2>\NNS\955060 or\CC\3541091 panic\JJ\1740 disorder\NN\14034177 .\.\1740
D006854_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 on\IN\1740 behavioral\JJ\1740 ratings\NNS\5733583 ,\,\1740 somatic\JJ\1740 symptoms\NNS\5823932 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 plasma\NN\5398023 levels\NNS\4916342 of\IN\1740 3-methoxy-4-hydroxyphenethyleneglycol\JJ\1740 (\-LRB-\1740 MHPG\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cortisol</e1>\NN\14751417 were\VBD\836236 determined\VBN\1645601 in\IN\13603305 17\CD\13745420 healthy\JJ\1740 subjects\NNS\6598915 and\CC\1740 21\CD\13745420 patients\NNS\9898892 meeting\VBG\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 agoraphobia\NN\14381416 with\IN\1740 panic\NN\7519253 attacks\NNS\955060 or\CC\3541091 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D002110_D001008 CID <e1>Caffeine</e1>\NN\14712692 produced\VBD\1617192 significantly\RB\1740 greater\JJR\1740 increases\NNS\13576355 in\IN\13603305 subject-rated\JJ\1740 <e2>anxiety</e2>\NN\14373582 ,\,\1740 nervousness\RB\1740 ,\,\1740 fear\NN\7480068 ,\,\1740 nausea\NN\14299637 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 restlessness\NN\4773351 ,\,\1740 and\CC\1740 tremors\NNS\345926 in\IN\13603305 the\DT\1740 patients\NNS\9898892 compared\VBN\644583 with\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
D002110_D001008 CID Patients\NNS\9898892 with\IN\1740 <e2>anxiety\NN\14373582 disorders</e2>\NNS\14034177 may\MD\15209706 benefit\VB\2210855 by\IN\1740 avoiding\VBG\2452885 <e1>caffeine-containing</e1>\JJ\1740 foods\NNS\20090 and\CC\1740 beverages\NNS\21265 .\.\1740
D002110_D009325 CID <e1>Caffeine</e1>\NN\14712692 produced\VBD\1617192 significantly\RB\1740 greater\JJR\1740 increases\NNS\13576355 in\IN\13603305 subject-rated\JJ\1740 anxiety\NN\14373582 ,\,\1740 nervousness\RB\1740 ,\,\1740 fear\NN\7480068 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 restlessness\NN\4773351 ,\,\1740 and\CC\1740 tremors\NNS\345926 in\IN\13603305 the\DT\1740 patients\NNS\9898892 compared\VBN\644583 with\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
D002110_-1 NONE <e1>Caffeine</e1>\NN\14712692 produced\VBD\1617192 significantly\RB\1740 greater\JJR\1740 increases\NNS\13576355 in\IN\13603305 subject-rated\JJ\1740 anxiety\NN\14373582 ,\,\1740 nervousness\RB\1740 ,\,\1740 fear\NN\7480068 ,\,\1740 nausea\NN\14299637 ,\,\1740 <e2>palpitations</e2>\NNS\14299637 ,\,\1740 restlessness\NN\4773351 ,\,\1740 and\CC\1740 tremors\NNS\345926 in\IN\13603305 the\DT\1740 patients\NNS\9898892 compared\VBN\644583 with\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
D002110_D011595 NONE <e1>Caffeine</e1>\NN\14712692 produced\VBD\1617192 significantly\RB\1740 greater\JJR\1740 increases\NNS\13576355 in\IN\13603305 subject-rated\JJ\1740 anxiety\NN\14373582 ,\,\1740 nervousness\RB\1740 ,\,\1740 fear\NN\7480068 ,\,\1740 nausea\NN\14299637 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 <e2>restlessness</e2>\NN\4773351 ,\,\1740 and\CC\1740 tremors\NNS\345926 in\IN\13603305 the\DT\1740 patients\NNS\9898892 compared\VBN\644583 with\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
D002110_D014202 CID <e1>Caffeine</e1>\NN\14712692 produced\VBD\1617192 significantly\RB\1740 greater\JJR\1740 increases\NNS\13576355 in\IN\13603305 subject-rated\JJ\1740 anxiety\NN\14373582 ,\,\1740 nervousness\RB\1740 ,\,\1740 fear\NN\7480068 ,\,\1740 nausea\NN\14299637 ,\,\1740 palpitations\NNS\14299637 ,\,\1740 restlessness\NN\4773351 ,\,\1740 and\CC\1740 <e2>tremors</e2>\NNS\345926 in\IN\13603305 the\DT\1740 patients\NNS\9898892 compared\VBN\644583 with\IN\1740 healthy\JJ\1740 subjects\NNS\6598915 .\.\1740
D002110_D009421 NONE Because\IN\1740 <e1>caffeine</e1>\NN\14712692 is\VBZ\836236 an\DT\6697703 adenosine\NN\14964367 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 some\DT\1740 panic\JJ\1740 disorder\NN\14034177 patients\NNS\9898892 may\MD\15209706 have\VB\2108377 <e2>abnormalities\NNS\14034177 in\IN\13603305 neuronal\JJ\1740 systems</e2>\NNS\3575240 involving\VBG\2676054 adenosine\NN\14964367 .\.\1740
D000241_D016584 NONE Because\IN\1740 caffeine\NN\14712692 is\VBZ\836236 an\DT\6697703 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 some\DT\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 patients\NNS\9898892 may\MD\15209706 have\VB\2108377 abnormalities\NNS\14034177 in\IN\13603305 neuronal\JJ\1740 systems\NNS\3575240 involving\VBG\2676054 adenosine\NN\14964367 .\.\1740
D000241_D016584 NONE Because\IN\1740 caffeine\NN\14712692 is\VBZ\836236 an\DT\6697703 adenosine\NN\14964367 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 some\DT\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 patients\NNS\9898892 may\MD\15209706 have\VB\2108377 abnormalities\NNS\14034177 in\IN\13603305 neuronal\JJ\1740 systems\NNS\3575240 involving\VBG\2676054 <e1>adenosine</e1>\NN\14964367 .\.\1740
D000241_D009421 NONE Because\IN\1740 caffeine\NN\14712692 is\VBZ\836236 an\DT\6697703 <e1>adenosine</e1>\NN\14964367 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 some\DT\1740 panic\JJ\1740 disorder\NN\14034177 patients\NNS\9898892 may\MD\15209706 have\VB\2108377 <e2>abnormalities\NNS\14034177 in\IN\13603305 neuronal\JJ\1740 systems</e2>\NNS\3575240 involving\VBG\2676054 adenosine\NN\14964367 .\.\1740
D000241_D009421 NONE Because\IN\1740 caffeine\NN\14712692 is\VBZ\836236 an\DT\6697703 adenosine\NN\14964367 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 some\DT\1740 panic\JJ\1740 disorder\NN\14034177 patients\NNS\9898892 may\MD\15209706 have\VB\2108377 <e2>abnormalities\NNS\14034177 in\IN\13603305 neuronal\JJ\1740 systems</e2>\NNS\3575240 involving\VBG\2676054 <e1>adenosine</e1>\NN\14964367 .\.\1740
9128918
D004298_D006966 NONE Chronic\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 changes\NNS\7283608 in\IN\13603305 <e1>dopamine</e1>\NN\14807737 neurons\NNS\5430628 .\.\1740
D004298_D006966 NONE <e2>Hyperprolactinemia</e2>\NNP\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 treatment\NN\654885 with\IN\1740 haloperidol\NN\3713736 ,\,\1740 a\DT\13649268 <e1>dopamine</e1>\NN\14807737 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 and\CC\1740 Palkovits\NNS\1740 '\POS\1740 microdissection\NN\1740 technique\NN\5660268 in\IN\13603305 combination\NN\7951464 with\IN\1740 high-performance\JJ\1740 liquid\JJ\1740 chromatography\NN\13518963 was\VBD\836236 used\VBN\1156834 to\TO\1740 measure\VB\697589 neurotransmitter\NN\14807410 concentrations\NNS\4916342 in\IN\13603305 several\JJ\1740 areas\NNS\8630985 of\IN\1740 the\DT\1740 brain\NN\5462674 .\.\1740
D004298_D006966 NONE After\IN\1740 6\CD\13741022 months\NNS\15113229 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 median\JJ\1740 eminence\NN\13948441 (\-LRB-\1740 ME\NN\1740 )\-RRB-\1740 increased\VBD\169651 by\IN\1740 84\CD\1740 %\NN\1740 over\IN\5867413 the\DT\1740 control\NN\5190804 group\NN\2137 .\.\1740
D004298_D006966 NONE After\IN\1740 6\CD\13741022 months\NNS\15113229 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 ,\,\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 median\JJ\1740 eminence\NN\13948441 (\-LRB-\1740 ME\NN\1740 )\-RRB-\1740 increased\VBD\169651 by\IN\1740 84\CD\1740 %\NN\1740 over\IN\5867413 the\DT\1740 control\NN\5190804 group\NN\2137 .\.\1740
D004298_D006966 NONE Nine\CD\13741022 months\NNS\15113229 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 produced\VBD\1617192 a\DT\13649268 50\CD\13745420 %\NN\1740 increase\NN\13576355 in\IN\13603305 <e1>DA</e1>\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 ME\NN\1740 over\IN\5867413 the\DT\1740 control\NN\5190804 group\NN\2137 .\.\1740
D004298_D006966 NONE However\RB\1740 ,\,\1740 <e1>DA</e1>\NN\10484858 response\NN\11410625 was\VBD\836236 lost\VBN\1794668 if\IN\1740 a\DT\13649268 9-month\JJ\1740 long\JJ\1740 haloperidol-induced\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 1\CD\13741022 1/2\CD\1740 month-long\JJ\1740 extremely\RB\1740 high\JJ\1740 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 PRL\NN\1740 levels\NNS\4916342 produced\VBN\1617192 by\IN\1740 implantation\NN\13526110 of\IN\1740 MMQ\NN\1740 cells\NNS\3080309 under\IN\1740 the\DT\1740 kidney\NN\5333259 capsule\NN\3094503 .\.\1740
D004298_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 <e1>DA</e1>\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D004298_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 <e1>DA</e1>\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D004298_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e1>DA</e1>\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D004298_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e1>DA</e1>\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D006220_D006966 CID <e2>Hyperprolactinemia</e2>\NNP\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 treatment\NN\654885 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 ,\,\1740 a\DT\13649268 dopamine\NN\14807737 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 and\CC\1740 Palkovits\NNS\1740 '\POS\1740 microdissection\NN\1740 technique\NN\5660268 in\IN\13603305 combination\NN\7951464 with\IN\1740 high-performance\JJ\1740 liquid\JJ\1740 chromatography\NN\13518963 was\VBD\836236 used\VBN\1156834 to\TO\1740 measure\VB\697589 neurotransmitter\NN\14807410 concentrations\NNS\4916342 in\IN\13603305 several\JJ\1740 areas\NNS\8630985 of\IN\1740 the\DT\1740 brain\NN\5462674 .\.\1740
D006220_D006966 CID However\RB\1740 ,\,\1740 DA\NN\10484858 response\NN\11410625 was\VBD\836236 lost\VBN\1794668 if\IN\1740 a\DT\13649268 9-month\JJ\1740 long\JJ\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 was\VBD\836236 followed\VBN\1835496 by\IN\1740 a\DT\13649268 1\CD\13741022 1/2\CD\1740 month-long\JJ\1740 extremely\RB\1740 high\JJ\1740 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 PRL\NN\1740 levels\NNS\4916342 produced\VBN\1617192 by\IN\1740 implantation\NN\13526110 of\IN\1740 MMQ\NN\1740 cells\NNS\3080309 under\IN\1740 the\DT\1740 kidney\NN\5333259 capsule\NN\3094503 .\.\1740
D009638_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 <e1>norepinephrine</e1>\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D009638_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 <e1>norepinephrine</e1>\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D009638_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 <e1>NE</e1>\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D009638_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 <e1>NE</e1>\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D012701_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 <e1>serotonin</e1>\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D012701_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 <e1>serotonin</e1>\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D012701_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 <e1>5-HT</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D012701_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 <e1>5-HT</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D006897_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e1>5-hydroxyindoleacetic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D006897_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e1>5-hydroxyindoleacetic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 5-HIAA\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D006897_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>5-HIAA</e1>\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D006897_D006966 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 change\NN\7283608 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 DA\NN\10484858 ,\,\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 serotonin\NN\14807737 (\-LRB-\1740 5-HT\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 their\PRP$\1740 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 arcuate\JJ\1740 nucleus\NN\5445668 (\-LRB-\1740 AN\NN\6697703 )\-RRB-\1740 ,\,\1740 medial\JJ\1740 preoptic\JJ\1740 area\NN\8630985 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 caudate\NN\5497363 putamen\NNS\5497363 (\-LRB-\1740 CP\NN\1740 )\-RRB-\1740 ,\,\1740 substantia\RB\1740 nigra\JJ\1740 (\-LRB-\1740 SN\NN\14625458 )\-RRB-\1740 ,\,\1740 and\CC\1740 zona\NN\5225602 incerta\NN\1740 (\-LRB-\1740 ZI\NN\1740 )\-RRB-\1740 ,\,\1740 except\IN\1740 for\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 5-hydroxyindoleacetic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>5-HIAA</e1>\JJ\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 AN\NN\6697703 after\IN\1740 6-months\NNS\1740 of\IN\1740 hyperprolactinemia\NN\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 DA\NN\10484858 concentrations\NNS\4916342 in\IN\13603305 the\DT\1740 AN\NNP\6697703 after\IN\1740 9-months\NNS\1740 of\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
11936424
C055603_D007674 NONE <e1>Temocapril</e1>\NNP\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 modulates\VBZ\1724459 <e2>glomerular\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 nephrosis\NN\14304060 .\.\1740
C055603_D009401 NONE <e1>Temocapril</e1>\NNP\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 modulates\VBZ\1724459 glomerular\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
C055603_D009401 NONE It\PRP\6125041 appears\VBZ\2604760 that\IN\1740 <e1>temocapril</e1>\NN\1740 was\VBD\836236 effective\JJ\1740 in\IN\13603305 retarding\VBG\438495 renal\JJ\1740 progression\NN\8457976 and\CC\1740 protected\VBD\1127795 renal\JJ\1740 function\NN\13783581 in\IN\13603305 PAN\NN\3101986 <e2>neprotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D000809_D007674 NONE Temocapril\NNP\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 modulates\VBZ\1724459 <e2>glomerular\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 nephrosis\NN\14304060 .\.\1740
D000809_D009401 NONE Temocapril\NNP\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 modulates\VBZ\1724459 glomerular\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D007674 NONE Temocapril\NNP\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 modulates\VBZ\1724459 <e2>glomerular\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 nephrosis\NN\14304060 .\.\1740
D011692_D009401 CID Temocapril\NNP\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 modulates\VBZ\1724459 glomerular\JJ\1740 injury\NN\14052046 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 CID <e2>Nephrosis</e2>\NN\14304060 was\VBD\836236 induced\VBN\1627355 by\IN\1740 injection\NN\320852 of\IN\1740 <e1>PAN</e1>\NN\3101986 (\-LRB-\1740 15mg/100\CD\1740 g\NN\13717155 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D011692_D009401 CID It\PRP\6125041 appears\VBZ\2604760 that\IN\1740 temocapril\NN\1740 was\VBD\836236 effective\JJ\1740 in\IN\13603305 retarding\VBG\438495 renal\JJ\1740 progression\NN\8457976 and\CC\1740 protected\VBD\1127795 renal\JJ\1740 function\NN\13783581 in\IN\13603305 <e1>PAN</e1>\NN\3101986 <e2>neprotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
C055603_D011507 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>temocapril</e1>\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
C055603_D011507 NONE <e1>Temocapril</e1>\NN\1740 did\VBD\1640855 not\RB\1740 attenuate\VB\224901 <e2>proteinuria</e2>\NN\14299637 at\IN\14622893 8\CD\13741022 days\NNS\15140892 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 markedly\RB\1740 lower\VB\1850315 it\PRP\6125041 from\IN\1740 weeks\NNS\15113229 4\CD\13741022 to\TO\1740 20\CD\13745420 .\.\1740
C055603_D006984 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>temocapril</e1>\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 <e2>hypertrophy</e2>\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
C055603_D005921 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>temocapril</e1>\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 <e2>glomerulosclerosis</e2>\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
C055603_D009404 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>temocapril</e1>\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 <e2>nephrotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D000809_D011507 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D000809_D006984 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 <e2>hypertrophy</e2>\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D000809_D005921 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 <e2>glomerulosclerosis</e2>\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D000809_D009404 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 <e2>nephrotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D011507 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D011507 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D006984 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 <e2>hypertrophy</e2>\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D006984 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 <e2>hypertrophy</e2>\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D005921 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 <e2>glomerulosclerosis</e2>\NN\1740 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D005921 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 <e2>glomerulosclerosis</e2>\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 nephrotic\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D005921 NONE The\DT\1740 <e2>glomerulosclerosis</e2>\NN\1740 index\NN\13850304 (\-LRB-\1740 GSI\NN\1740 )\-RRB-\1740 was\VBD\836236 6.21\CD\1740 %\NN\1740 at\IN\14622893 4\CD\13741022 weeks\NNS\15113229 and\CC\1740 respectively\RB\1740 25.35\CD\1740 %\NN\1740 and\CC\1740 30.49\CD\1740 %\NN\1740 at\IN\14622893 14\CD\13745420 and\CC\1740 20\CD\13745420 weeks\NNS\15113229 in\IN\13603305 the\DT\1740 <e1>PAN</e1>\NN\3101986 group\NN\2137 .\.\1740
D011692_D009404 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 <e2>nephrotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D011692_D009404 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 whether\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 temocapril\NN\1740 ,\,\1740 a\DT\13649268 long-acting\JJ\1740 non-SH\NN\1740 group\NN\2137 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor\NN\20090 ,\,\1740 reduced\VBN\441445 proteinuria\NN\14299637 ,\,\1740 inhibited\VBD\2510337 glomerular\JJ\1740 hypertrophy\NN\14365950 and\CC\1740 prevented\VBD\1740 glomerulosclerosis\NN\1740 in\IN\13603305 chronic\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 )\-RRB-\1740 -\HYPH\1740 induced\VBN\1627355 <e2>nephrotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
24923469
7492040
D008012_D009203 NONE Clinical\JJ\1740 safety\NN\13920835 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D008012_D009203 NONE STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 .\.\1740
D008012_D009203 NONE STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-induced\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 .\.\1740
D008012_D009203 NONE PARTICIPANTS\NNS\9816771 :\:\1740 Patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>MI</e2>\NN\14207561 who\WP\8299493 received\VBD\2210855 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 .\.\1740
D008012_D009203 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 <e2>MI</e2>\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D009203 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 <e2>MI</e2>\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D009203 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 <e1>lidocaine</e1>\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>MI</e2>\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D008012_D009203 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>MI</e2>\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D003042_D009203 CID Clinical\JJ\1740 safety\NN\13920835 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003042_D009203 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 (\-LRB-\1740 MI\NN\14207561 )\-RRB-\1740 .\.\1740
D003042_D009203 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 (\-LRB-\1740 <e2>MI</e2>\NN\14207561 )\-RRB-\1740 .\.\1740
D003042_D009203 CID PARTICIPANTS\NNS\9816771 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>MI</e2>\NN\14207561 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 .\.\1740
D003042_D009203 CID RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>MI</e2>\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D003042_D009203 CID CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 <e1>cocaine</e1>\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 <e2>MI</e2>\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D003042_D009203 CID CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>MI</e2>\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D008012_D001919 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 <e2>bradydysrhythmias</e2>\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D001919 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 <e2>bradydysrhythmias</e2>\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D017180 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D017180 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D014693 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D014693 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D012640 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D012640 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D003042_D001919 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 <e2>bradydysrhythmias</e2>\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D003042_D017180 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D003042_D014693 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 seizures\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D003042_D012640 NONE RESULTS\NNS\34213 :\:\1740 Of\IN\1740 29\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 ,\,\1740 no\DT\7204911 patient\NN\9898892 died\VBD\146138 ;\:\1740 exhibited\VBD\2632167 bradydysrhythmias\NNS\1740 ,\,\1740 ventricular\JJ\1740 tachycardia\NN\14110674 ,\,\1740 or\CC\3541091 ventricular\JJ\1740 fibrillation\NN\14361664 ;\:\1740 or\CC\3541091 experienced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 administration\NN\1133281 of\IN\1740 lidocaine\NN\3681148 (\-LRB-\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0\CD\13741022 %\NN\1740 to\TO\1740 11\CD\13745420 %\NN\1740 )\-RRB-\1740 .\.\1740
D008012_D064420 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 <e1>lidocaine</e1>\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 <e2>toxicity</e2>\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D008012_D064420 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 <e2>toxicity</e2>\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D008012_D002318 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 <e1>lidocaine</e1>\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D008012_D002318 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D008012_D002493 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 <e1>lidocaine</e1>\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D008012_D002493 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D003042_D064420 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 <e1>cocaine</e1>\NN\3492717 <e2>toxicity</e2>\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D003042_D064420 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 <e2>toxicity</e2>\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity\NN\13576101 .\.\1740
D003042_D002318 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 <e1>cocaine</e1>\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D003042_D002318 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D003042_D002493 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 <e1>cocaine</e1>\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 cocaine-associated\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
D003042_D002493 NONE CONCLUSION\NN\5837957 :\:\1740 Despite\IN\7501545 theoretical\JJ\1740 concerns\NNS\5682950 that\IN\1740 lidocaine\NN\3681148 may\MD\15209706 enhance\VB\227165 cocaine\NN\3492717 toxicity\NN\13576101 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 lidocaine\NN\3681148 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 MI\NN\14207561 was\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>cardiovascular\JJ\1740 or\CC\3541091 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 .\.\1740
17035713
C004656_D007674 NONE <e1>Chloroacetaldehyde</e1>\NN\1740 as\IN\14622893 a\DT\13649268 sulfhydryl\NN\1740 reagent\NN\14779550 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 critical\JJ\1740 thiol\NN\1740 groups\NNS\2137 in\IN\13603305 ifosfamide\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
C004656_D007674 NONE <e1>Chloroacetaldehyde</e1>\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 following\VBG\1835496 anti-tumor\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
C004656_D007674 NONE Chloroacetaldehyde\NN\1740 (\-LRB-\1740 <e1>CAA</e1>\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 following\VBG\1835496 anti-tumor\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
-1_D007674 NONE Chloroacetaldehyde\NN\1740 as\IN\14622893 a\DT\13649268 <e1>sulfhydryl</e1>\NN\1740 reagent\NN\14779550 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 critical\JJ\1740 thiol\NN\1740 groups\NNS\2137 in\IN\13603305 ifosfamide\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D013438_D007674 NONE Chloroacetaldehyde\NN\1740 as\IN\14622893 a\DT\13649268 sulfhydryl\NN\1740 reagent\NN\14779550 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 critical\JJ\1740 <e1>thiol</e1>\NN\1740 groups\NNS\2137 in\IN\13603305 ifosfamide\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D007069_D007674 CID Chloroacetaldehyde\NN\1740 as\IN\14622893 a\DT\13649268 sulfhydryl\NN\1740 reagent\NN\14779550 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 critical\JJ\1740 thiol\NN\1740 groups\NNS\2137 in\IN\13603305 <e1>ifosfamide</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D007069_D007674 CID Chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 following\VBG\1835496 anti-tumor\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
D007069_D007674 CID Chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IFO</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 following\VBG\1835496 anti-tumor\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
D007069_D007674 CID Chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 following\VBG\1835496 anti-tumor\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>IFO</e1>\NN\1740 .\.\1740
D007069_D007674 CID Therefore\RB\1740 ,\,\1740 urinary\JJ\1740 acidification\NN\13518963 could\MD\1740 be\VB\836236 an\DT\6697703 option\NN\6480506 to\TO\1740 prevent\VB\1740 <e1>IFO</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 patients\NNS\9898892 .\.\1740
C004656_D009369 NONE <e1>Chloroacetaldehyde</e1>\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 renal\JJ\1740 damage\NN\7296428 following\VBG\1835496 <e2>anti-tumor</e2>\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
C004656_D009369 NONE Chloroacetaldehyde\NN\1740 (\-LRB-\1740 <e1>CAA</e1>\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 renal\JJ\1740 damage\NN\7296428 following\VBG\1835496 <e2>anti-tumor</e2>\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
D007069_D009369 NONE Chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 <e1>ifosfamide</e1>\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 renal\JJ\1740 damage\NN\7296428 following\VBG\1835496 <e2>anti-tumor</e2>\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
D007069_D009369 NONE Chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 <e1>IFO</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 renal\JJ\1740 damage\NN\7296428 following\VBG\1835496 <e2>anti-tumor</e2>\JJ\1740 therapy\NN\657604 with\IN\1740 IFO\NN\1740 .\.\1740
D007069_D009369 NONE Chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NNP\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 metabolite\NN\20090 of\IN\1740 the\DT\1740 alkylating\VBG\1740 agent\NN\7347 ifosfamide\NN\1740 (\-LRB-\1740 IFO\NN\1740 )\-RRB-\1740 and\CC\1740 putatively\RB\1740 responsible\JJ\1740 for\IN\1740 renal\JJ\1740 damage\NN\7296428 following\VBG\1835496 <e2>anti-tumor</e2>\JJ\1740 therapy\NN\657604 with\IN\1740 <e1>IFO</e1>\NN\1740 .\.\1740
C004656_D064420 NONE <e2>Toxicity</e2>\NN\13576101 of\IN\1740 <e1>CAA</e1>\NNP\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 protein\NN\14944888 content\NN\7951464 ,\,\1740 cell\NN\3080309 number\NN\5107765 ,\,\1740 LDH\NN\1740 release\NN\3748886 ,\,\1740 trypan\VBP\1740 blue\JJ\1740 exclusion\NN\13927383 assay\NN\5733583 and\CC\1740 caspase-3\NN\1740 activity\NN\30358 .\.\1740
C004656_D064420 NONE Thus\RB\1740 ,\,\1740 <e1>CAA</e1>\NNP\1740 directly\RB\1740 reacts\VBZ\2367363 with\IN\1740 cellular\JJ\1740 protein\NN\14944888 and\CC\1740 non-protein\JJ\1740 thiols\NNS\1740 ,\,\1740 mediating\VBG\761713 its\PRP$\6125041 <e2>toxicity</e2>\NN\13576101 on\IN\1740 hRPTEC\NNP\1740 .\.\1740
D014343_D064420 NONE <e2>Toxicity</e2>\NN\13576101 of\IN\1740 CAA\NNP\1740 was\VBD\836236 determined\VBN\1645601 by\IN\1740 protein\NN\14944888 content\NN\7951464 ,\,\1740 cell\NN\3080309 number\NN\5107765 ,\,\1740 LDH\NN\1740 release\NN\3748886 ,\,\1740 <e1>trypan\VBP\1740 blue</e1>\JJ\1740 exclusion\NN\13927383 assay\NN\5733583 and\CC\1740 caspase-3\NN\1740 activity\NN\30358 .\.\1740
C004656_D009336 NONE <e1>CAA</e1>\NNP\1740 reduced\VBD\441445 hRPTEC\NN\1740 cell\NN\3080309 number\NN\5107765 and\CC\1740 protein\NN\14944888 ,\,\1740 induced\VBD\1627355 a\DT\13649268 loss\NN\13252973 in\IN\13603305 free\JJ\1740 intracellular\JJ\1740 thiols\NNS\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 .\.\1740
C004656_D009336 NONE Acidification\NN\13518963 ,\,\1740 which\WDT\1740 slowed\VBD\151689 the\DT\1740 reaction\NN\13446390 of\IN\1740 <e1>CAA</e1>\NN\1740 with\IN\1740 thiol\NN\1740 donors\NNS\9608709 ,\,\1740 could\MD\1740 also\RB\1740 attenuate\VB\224901 effects\NNS\13245626 of\IN\1740 CAA\NN\1740 on\IN\1740 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 ,\,\1740 thiol\NN\1740 depletion\NN\351638 and\CC\1740 cysteine\NN\14601829 protease\NN\14732946 inhibition\NN\1068773 in\IN\13603305 living\VBG\2655135 cells\NNS\3080309 .\.\1740
C004656_D009336 NONE Acidification\NN\13518963 ,\,\1740 which\WDT\1740 slowed\VBD\151689 the\DT\1740 reaction\NN\13446390 of\IN\1740 CAA\NN\1740 with\IN\1740 thiol\NN\1740 donors\NNS\9608709 ,\,\1740 could\MD\1740 also\RB\1740 attenuate\VB\224901 effects\NNS\13245626 of\IN\1740 <e1>CAA</e1>\NN\1740 on\IN\1740 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 ,\,\1740 thiol\NN\1740 depletion\NN\351638 and\CC\1740 cysteine\NN\14601829 protease\NN\14732946 inhibition\NN\1068773 in\IN\13603305 living\VBG\2655135 cells\NNS\3080309 .\.\1740
D013438_D009336 NONE CAA\NNP\1740 reduced\VBD\441445 hRPTEC\NN\1740 cell\NN\3080309 number\NN\5107765 and\CC\1740 protein\NN\14944888 ,\,\1740 induced\VBD\1627355 a\DT\13649268 loss\NN\13252973 in\IN\13603305 free\JJ\1740 intracellular\JJ\1740 <e1>thiols</e1>\NNS\1740 and\CC\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 .\.\1740
D013438_D009336 NONE Acidification\NN\13518963 ,\,\1740 which\WDT\1740 slowed\VBD\151689 the\DT\1740 reaction\NN\13446390 of\IN\1740 CAA\NN\1740 with\IN\1740 <e1>thiol</e1>\NN\1740 donors\NNS\9608709 ,\,\1740 could\MD\1740 also\RB\1740 attenuate\VB\224901 effects\NNS\13245626 of\IN\1740 CAA\NN\1740 on\IN\1740 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 ,\,\1740 thiol\NN\1740 depletion\NN\351638 and\CC\1740 cysteine\NN\14601829 protease\NN\14732946 inhibition\NN\1068773 in\IN\13603305 living\VBG\2655135 cells\NNS\3080309 .\.\1740
D013438_D009336 NONE Acidification\NN\13518963 ,\,\1740 which\WDT\1740 slowed\VBD\151689 the\DT\1740 reaction\NN\13446390 of\IN\1740 CAA\NN\1740 with\IN\1740 thiol\NN\1740 donors\NNS\9608709 ,\,\1740 could\MD\1740 also\RB\1740 attenuate\VB\224901 effects\NNS\13245626 of\IN\1740 CAA\NN\1740 on\IN\1740 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 ,\,\1740 <e1>thiol</e1>\NN\1740 depletion\NN\351638 and\CC\1740 cysteine\NN\14601829 protease\NN\14732946 inhibition\NN\1068773 in\IN\13603305 living\VBG\2655135 cells\NNS\3080309 .\.\1740
D003545_D009336 NONE Acidification\NN\13518963 ,\,\1740 which\WDT\1740 slowed\VBD\151689 the\DT\1740 reaction\NN\13446390 of\IN\1740 CAA\NN\1740 with\IN\1740 thiol\NN\1740 donors\NNS\9608709 ,\,\1740 could\MD\1740 also\RB\1740 attenuate\VB\224901 effects\NNS\13245626 of\IN\1740 CAA\NN\1740 on\IN\1740 <e2>necrosis</e2>\NN\11444117 markers\NNS\21939 ,\,\1740 thiol\NN\1740 depletion\NN\351638 and\CC\1740 <e1>cysteine</e1>\NN\14601829 protease\NN\14732946 inhibition\NN\1068773 in\IN\13603305 living\VBG\2655135 cells\NNS\3080309 .\.\1740
D013438_D064420 NONE Thus\RB\1740 ,\,\1740 CAA\NNP\1740 directly\RB\1740 reacts\VBZ\2367363 with\IN\1740 cellular\JJ\1740 protein\NN\14944888 and\CC\1740 non-protein\JJ\1740 <e1>thiols</e1>\NNS\1740 ,\,\1740 mediating\VBG\761713 its\PRP$\6125041 <e2>toxicity</e2>\NN\13576101 on\IN\1740 hRPTEC\NNP\1740 .\.\1740
9831002
D008774_D009459 CID <e2>Neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 and\CC\1740 <e1>methylphenidate</e1>\NN\4320126 .\.\1740
D008774_D009459 CID A\DT\13649268 1-year-old\JJ\1740 female\NN\15388 presented\VBN\2137132 with\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 probably\RB\1740 caused\VBN\1617192 by\IN\1740 <e1>methylphenidate</e1>\NN\4320126 .\.\1740
D008774_D009459 CID This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 patient\NN\9898892 with\IN\1740 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 probably\RB\1740 caused\VBN\1617192 by\IN\1740 <e1>methylphenidate</e1>\NN\4320126 .\.\1740
24072398
D008694_D020258 NONE A\DT\13649268 single\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 induces\VBZ\1627355 a\DT\13649268 long-lasting\JJ\1740 depressive-like\JJ\1740 behaviour\NN\14006945 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008694_D003866 CID A\DT\13649268 single\JJ\1740 neurotoxic\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 induces\VBZ\1627355 a\DT\13649268 long-lasting\JJ\1740 <e2>depressive-like</e2>\JJ\1740 behaviour\NN\14006945 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008694_D003866 CID <e1>Methamphetamine</e1>\NNP\2704153 (\-LRB-\1740 METH\NN\2704153 )\-RRB-\1740 triggers\VBZ\1641914 a\DT\13649268 disruption\NN\1066163 of\IN\1740 the\DT\1740 monoaminergic\JJ\1740 system\NN\3575240 and\CC\1740 METH\NN\2704153 abuse\NN\418025 leads\VBZ\1752884 to\TO\1740 negative\JJ\1740 emotional\JJ\1740 states\NNS\8491826 including\VBG\690614 <e2>depressive\JJ\1740 symptoms</e2>\NNS\5823932 during\IN\1740 drug\NN\14778436 withdrawal\NN\7206096 .\.\1740
D008694_D003866 CID Methamphetamine\NNP\2704153 (\-LRB-\1740 <e1>METH</e1>\NN\2704153 )\-RRB-\1740 triggers\VBZ\1641914 a\DT\13649268 disruption\NN\1066163 of\IN\1740 the\DT\1740 monoaminergic\JJ\1740 system\NN\3575240 and\CC\1740 METH\NN\2704153 abuse\NN\418025 leads\VBZ\1752884 to\TO\1740 negative\JJ\1740 emotional\JJ\1740 states\NNS\8491826 including\VBG\690614 <e2>depressive\JJ\1740 symptoms</e2>\NNS\5823932 during\IN\1740 drug\NN\14778436 withdrawal\NN\7206096 .\.\1740
D008694_D003866 CID Methamphetamine\NNP\2704153 (\-LRB-\1740 METH\NN\2704153 )\-RRB-\1740 triggers\VBZ\1641914 a\DT\13649268 disruption\NN\1066163 of\IN\1740 the\DT\1740 monoaminergic\JJ\1740 system\NN\3575240 and\CC\1740 <e1>METH</e1>\NN\2704153 abuse\NN\418025 leads\VBZ\1752884 to\TO\1740 negative\JJ\1740 emotional\JJ\1740 states\NNS\8491826 including\VBG\690614 <e2>depressive\JJ\1740 symptoms</e2>\NNS\5823932 during\IN\1740 drug\NN\14778436 withdrawal\NN\7206096 .\.\1740
D008694_D003866 CID However\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 currently\RB\1740 unknown\JJ\1740 if\IN\1740 the\DT\1740 acute\JJ\1740 toxic\JJ\1740 dosage\NN\13576355 of\IN\1740 <e1>METH</e1>\NN\2704153 also\RB\1740 causes\VBZ\1617192 a\DT\13649268 long-lasting\JJ\1740 <e2>depressive</e2>\JJ\1740 phenotype\NN\4933544 and\CC\1740 persistent\JJ\1740 monoaminergic\JJ\1740 deficits\NNS\5113133 .\.\1740
D008694_D003866 CID Thus\RB\1740 ,\,\1740 we\PRP\1740 now\RB\1740 assessed\VBD\670261 the\DT\1740 <e2>depressive-like</e2>\JJ\1740 behaviour\NN\14006945 in\IN\13603305 mice\NNS\2329401 at\IN\14622893 early\JJ\1740 and\CC\1740 long-term\JJ\1740 periods\NNS\13575869 following\VBG\1835496 a\DT\13649268 single\JJ\1740 high\JJ\1740 <e1>METH</e1>\NN\2704153 dose\NN\3740161 (\-LRB-\1740 30\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D008694_D003866 CID This\DT\1740 <e2>depressive-like</e2>\JJ\1740 profile\NN\6999802 induced\VBN\1627355 by\IN\1740 <e1>METH</e1>\NN\2704153 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 marked\JJ\1740 depletion\NN\351638 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 ,\,\1740 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 dopamine\NN\14807737 ,\,\1740 DOPAC\NN\1740 and\CC\1740 HVA\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 and\CC\1740 serotonin\NN\14807737 ,\,\1740 observed\VBN\2163746 at\IN\14622893 both\CC\1740 3\CD\13741022 and\CC\1740 49\CD\1740 days\NNS\15140892 post-administration\JJ\1740 .\.\1740
D008694_D003866 CID These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 that\WDT\1740 a\DT\13649268 single\JJ\1740 high\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>METH</e1>\NN\2704153 induces\VBZ\1627355 long-lasting\JJ\1740 <e2>depressive-like</e2>\JJ\1740 behaviour\NN\14006945 in\IN\13603305 mice\NNS\2329401 associated\VBN\628491 with\IN\1740 a\DT\13649268 persistent\JJ\1740 disruption\NN\1066163 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 homoeostasis\NN\1740 .\.\1740
D004298_D003866 NONE This\DT\1740 <e2>depressive-like</e2>\JJ\1740 profile\NN\6999802 induced\VBN\1627355 by\IN\1740 METH\NN\2704153 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 marked\JJ\1740 depletion\NN\351638 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 ,\,\1740 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 <e1>dopamine</e1>\NN\14807737 ,\,\1740 DOPAC\NN\1740 and\CC\1740 HVA\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 and\CC\1740 serotonin\NN\14807737 ,\,\1740 observed\VBN\2163746 at\IN\14622893 both\CC\1740 3\CD\13741022 and\CC\1740 49\CD\1740 days\NNS\15140892 post-administration\JJ\1740 .\.\1740
D015102_D003866 NONE This\DT\1740 <e2>depressive-like</e2>\JJ\1740 profile\NN\6999802 induced\VBN\1627355 by\IN\1740 METH\NN\2704153 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 marked\JJ\1740 depletion\NN\351638 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 ,\,\1740 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 dopamine\NN\14807737 ,\,\1740 <e1>DOPAC</e1>\NN\1740 and\CC\1740 HVA\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 and\CC\1740 serotonin\NN\14807737 ,\,\1740 observed\VBN\2163746 at\IN\14622893 both\CC\1740 3\CD\13741022 and\CC\1740 49\CD\1740 days\NNS\15140892 post-administration\JJ\1740 .\.\1740
D006719_D003866 NONE This\DT\1740 <e2>depressive-like</e2>\JJ\1740 profile\NN\6999802 induced\VBN\1627355 by\IN\1740 METH\NN\2704153 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 marked\JJ\1740 depletion\NN\351638 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 ,\,\1740 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 dopamine\NN\14807737 ,\,\1740 DOPAC\NN\1740 and\CC\1740 <e1>HVA</e1>\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 and\CC\1740 serotonin\NN\14807737 ,\,\1740 observed\VBN\2163746 at\IN\14622893 both\CC\1740 3\CD\13741022 and\CC\1740 49\CD\1740 days\NNS\15140892 post-administration\JJ\1740 .\.\1740
D014443_D003866 NONE This\DT\1740 <e2>depressive-like</e2>\JJ\1740 profile\NN\6999802 induced\VBN\1627355 by\IN\1740 METH\NN\2704153 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 marked\JJ\1740 depletion\NN\351638 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 ,\,\1740 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 dopamine\NN\14807737 ,\,\1740 DOPAC\NN\1740 and\CC\1740 HVA\NN\1740 ,\,\1740 <e1>tyrosine</e1>\NN\14601829 hydroxylase\NN\1740 and\CC\1740 serotonin\NN\14807737 ,\,\1740 observed\VBN\2163746 at\IN\14622893 both\CC\1740 3\CD\13741022 and\CC\1740 49\CD\1740 days\NNS\15140892 post-administration\JJ\1740 .\.\1740
D012701_D003866 NONE This\DT\1740 <e2>depressive-like</e2>\JJ\1740 profile\NN\6999802 induced\VBN\1627355 by\IN\1740 METH\NN\2704153 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 marked\JJ\1740 depletion\NN\351638 of\IN\1740 frontostriatal\JJ\1740 dopaminergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 neurotransmission\NN\1740 ,\,\1740 indicated\VBN\952524 by\IN\1740 a\DT\13649268 reduction\NN\351485 in\IN\13603305 the\DT\1740 levels\NNS\4916342 of\IN\1740 dopamine\NN\14807737 ,\,\1740 DOPAC\NN\1740 and\CC\1740 HVA\NN\1740 ,\,\1740 tyrosine\NN\14601829 hydroxylase\NN\1740 and\CC\1740 <e1>serotonin</e1>\NN\14807737 ,\,\1740 observed\VBN\2163746 at\IN\14622893 both\CC\1740 3\CD\13741022 and\CC\1740 49\CD\1740 days\NNS\15140892 post-administration\JJ\1740 .\.\1740
18801087
D000638_D055370 CID <e1>Amiodarone-related</e1>\JJ\1740 <e2>pulmonary\JJ\1740 mass</e2>\NN\13575869 and\CC\1740 unique\JJ\1740 membranous\JJ\1740 glomerulonephritis\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 :\:\1740 Diagnostic\NNP\1740 pitfall\NN\5686955 and\CC\1740 new\JJ\1740 findings\NNS\7951464 .\.\1740
D000638_D055370 CID Reported\VBN\831651 herein\RB\1740 is\VBZ\836236 an\DT\6697703 autopsy\JJ\1740 case\NN\7283608 of\IN\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 ,\,\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 <e2>lung\NN\5528060 mass</e2>\NN\13575869 (\-LRB-\1740 1.5\CD\1740 cm\NNS\13649268 in\IN\13603305 diameter\NN\5129201 )\-RRB-\1740 and\CC\1740 proteinuria\NN\14299637 (\-LRB-\1740 2.76\CD\1740 g/day\NN\1740 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 for\IN\1740 a\DT\13649268 long\JJ\1740 time\NN\7308889 .\.\1740
D000638_D055370 CID The\DT\1740 <e2>lung\NN\5528060 mass</e2>\NN\13575869 was\VBD\836236 highly\RB\1740 suspected\VBN\916909 to\TO\1740 be\VB\836236 lung\NN\5528060 cancer\NN\14239425 on\IN\1740 CT\NN\901316 and\CC\1740 positron\NN\9199341 emission\NN\44455 tomography\NN\900375 ,\,\1740 but\CC\1740 histologically\RB\1740 the\DT\1740 lesion\NN\14204950 was\VBD\836236 composed\VBN\2620587 of\IN\1740 lymphoplasmacytic\JJ\1740 infiltrates\NNS\1740 in\IN\13603305 alveolar\JJ\1740 walls\NNS\3894379 and\CC\1740 intra-alveolar\JJ\1740 accumulation\NN\13497135 of\IN\1740 foamy\NN\1740 macrophages\NNS\5450888 containing\VBG\2632940 characteristic\JJ\1740 myelinoid\JJ\1740 bodies\NNS\19128 ,\,\1740 indicating\VBG\952524 that\IN\1740 it\PRP\6125041 was\VBD\836236 an\DT\6697703 <e1>amiodarone-related</e1>\JJ\1740 lesion\NN\14204950 .\.\1740
D000638_D055370 CID The\DT\1740 present\JJ\1740 case\NN\7283608 highlights\VBZ\514463 the\DT\1740 possibility\NN\5944958 that\IN\1740 differential\JJ\1740 diagnosis\NN\152018 between\IN\1740 an\DT\6697703 <e1>amiodarone-related</e1>\JJ\1740 <e2>pulmonary\JJ\1740 lesion</e2>\NN\14204950 and\CC\1740 a\DT\13649268 neoplasm\NN\14234074 can\MD\3094503 be\VB\836236 very\RB\1740 difficult\JJ\1740 radiologically\RB\1740 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 membranous\JJ\1740 glomerulonephritis\NN\14113798 might\MD\5029706 be\VB\836236 another\DT\1740 possible\JJ\1740 complication\NN\1073995 of\IN\1740 amiodarone\JJ\1740 treatment\NN\654885 .\.\1740
D000638_D055370 CID The\DT\1740 present\JJ\1740 case\NN\7283608 highlights\VBZ\514463 the\DT\1740 possibility\NN\5944958 that\IN\1740 differential\JJ\1740 diagnosis\NN\152018 between\IN\1740 an\DT\6697703 amiodarone-related\JJ\1740 <e2>pulmonary\JJ\1740 lesion</e2>\NN\14204950 and\CC\1740 a\DT\13649268 neoplasm\NN\14234074 can\MD\3094503 be\VB\836236 very\RB\1740 difficult\JJ\1740 radiologically\RB\1740 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 membranous\JJ\1740 glomerulonephritis\NN\14113798 might\MD\5029706 be\VB\836236 another\DT\1740 possible\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D000638_D015433 CID <e1>Amiodarone-related</e1>\JJ\1740 pulmonary\JJ\1740 mass\NN\13575869 and\CC\1740 unique\JJ\1740 <e2>membranous\JJ\1740 glomerulonephritis</e2>\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 :\:\1740 Diagnostic\NNP\1740 pitfall\NN\5686955 and\CC\1740 new\JJ\1740 findings\NNS\7951464 .\.\1740
D000638_D015433 CID The\DT\1740 present\JJ\1740 case\NN\7283608 highlights\VBZ\514463 the\DT\1740 possibility\NN\5944958 that\IN\1740 differential\JJ\1740 diagnosis\NN\152018 between\IN\1740 an\DT\6697703 <e1>amiodarone-related</e1>\JJ\1740 pulmonary\JJ\1740 lesion\NN\14204950 and\CC\1740 a\DT\13649268 neoplasm\NN\14234074 can\MD\3094503 be\VB\836236 very\RB\1740 difficult\JJ\1740 radiologically\RB\1740 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 <e2>membranous\JJ\1740 glomerulonephritis</e2>\NN\14113798 might\MD\5029706 be\VB\836236 another\DT\1740 possible\JJ\1740 complication\NN\1073995 of\IN\1740 amiodarone\JJ\1740 treatment\NN\654885 .\.\1740
D000638_D015433 CID The\DT\1740 present\JJ\1740 case\NN\7283608 highlights\VBZ\514463 the\DT\1740 possibility\NN\5944958 that\IN\1740 differential\JJ\1740 diagnosis\NN\152018 between\IN\1740 an\DT\6697703 amiodarone-related\JJ\1740 pulmonary\JJ\1740 lesion\NN\14204950 and\CC\1740 a\DT\13649268 neoplasm\NN\14234074 can\MD\3094503 be\VB\836236 very\RB\1740 difficult\JJ\1740 radiologically\RB\1740 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 <e2>membranous\JJ\1740 glomerulonephritis</e2>\NN\14113798 might\MD\5029706 be\VB\836236 another\DT\1740 possible\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D000638_D006349 NONE <e1>Amiodarone-related</e1>\JJ\1740 pulmonary\JJ\1740 mass\NN\13575869 and\CC\1740 unique\JJ\1740 membranous\JJ\1740 glomerulonephritis\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 :\:\1740 Diagnostic\NNP\1740 pitfall\NN\5686955 and\CC\1740 new\JJ\1740 findings\NNS\7951464 .\.\1740
D000638_D006349 NONE Reported\VBN\831651 herein\RB\1740 is\VBZ\836236 an\DT\6697703 autopsy\JJ\1740 case\NN\7283608 of\IN\1740 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 ,\,\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 lung\NN\5528060 mass\NN\13575869 (\-LRB-\1740 1.5\CD\1740 cm\NNS\13649268 in\IN\13603305 diameter\NN\5129201 )\-RRB-\1740 and\CC\1740 proteinuria\NN\14299637 (\-LRB-\1740 2.76\CD\1740 g/day\NN\1740 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 for\IN\1740 a\DT\13649268 long\JJ\1740 time\NN\7308889 .\.\1740
D000638_D001145 NONE <e1>Amiodarone</e1>\NN\2715941 is\VBZ\836236 an\DT\6697703 <e2>anti-arrhythmic</e2>\JJ\1740 drug\NN\14778436 for\IN\1740 life-threatening\JJ\1740 tachycardia\NN\14110674 ,\,\1740 but\CC\1740 various\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
D000638_D013610 NONE <e1>Amiodarone</e1>\NN\2715941 is\VBZ\836236 an\DT\6697703 anti-arrhythmic\JJ\1740 drug\NN\14778436 for\IN\1740 life-threatening\JJ\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 but\CC\1740 various\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
D000638_D011507 NONE Reported\VBN\831651 herein\RB\1740 is\VBZ\836236 an\DT\6697703 autopsy\JJ\1740 case\NN\7283608 of\IN\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 ,\,\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 lung\NN\5528060 mass\NN\13575869 (\-LRB-\1740 1.5\CD\1740 cm\NNS\13649268 in\IN\13603305 diameter\NN\5129201 )\-RRB-\1740 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 (\-LRB-\1740 2.76\CD\1740 g/day\NN\1740 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 for\IN\1740 a\DT\13649268 long\JJ\1740 time\NN\7308889 .\.\1740
D000638_D008175 NONE The\DT\1740 lung\NN\5528060 mass\NN\13575869 was\VBD\836236 highly\RB\1740 suspected\VBN\916909 to\TO\1740 be\VB\836236 <e2>lung\NN\5528060 cancer</e2>\NN\14239425 on\IN\1740 CT\NN\901316 and\CC\1740 positron\NN\9199341 emission\NN\44455 tomography\NN\900375 ,\,\1740 but\CC\1740 histologically\RB\1740 the\DT\1740 lesion\NN\14204950 was\VBD\836236 composed\VBN\2620587 of\IN\1740 lymphoplasmacytic\JJ\1740 infiltrates\NNS\1740 in\IN\13603305 alveolar\JJ\1740 walls\NNS\3894379 and\CC\1740 intra-alveolar\JJ\1740 accumulation\NN\13497135 of\IN\1740 foamy\NN\1740 macrophages\NNS\5450888 containing\VBG\2632940 characteristic\JJ\1740 myelinoid\JJ\1740 bodies\NNS\19128 ,\,\1740 indicating\VBG\952524 that\IN\1740 it\PRP\6125041 was\VBD\836236 an\DT\6697703 <e1>amiodarone-related</e1>\JJ\1740 lesion\NN\14204950 .\.\1740
D000638_D009369 NONE The\DT\1740 present\JJ\1740 case\NN\7283608 highlights\VBZ\514463 the\DT\1740 possibility\NN\5944958 that\IN\1740 differential\JJ\1740 diagnosis\NN\152018 between\IN\1740 an\DT\6697703 <e1>amiodarone-related</e1>\JJ\1740 pulmonary\JJ\1740 lesion\NN\14204950 and\CC\1740 a\DT\13649268 <e2>neoplasm</e2>\NN\14234074 can\MD\3094503 be\VB\836236 very\RB\1740 difficult\JJ\1740 radiologically\RB\1740 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 membranous\JJ\1740 glomerulonephritis\NN\14113798 might\MD\5029706 be\VB\836236 another\DT\1740 possible\JJ\1740 complication\NN\1073995 of\IN\1740 amiodarone\JJ\1740 treatment\NN\654885 .\.\1740
D000638_D009369 NONE The\DT\1740 present\JJ\1740 case\NN\7283608 highlights\VBZ\514463 the\DT\1740 possibility\NN\5944958 that\IN\1740 differential\JJ\1740 diagnosis\NN\152018 between\IN\1740 an\DT\6697703 amiodarone-related\JJ\1740 pulmonary\JJ\1740 lesion\NN\14204950 and\CC\1740 a\DT\13649268 <e2>neoplasm</e2>\NN\14234074 can\MD\3094503 be\VB\836236 very\RB\1740 difficult\JJ\1740 radiologically\RB\1740 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 membranous\JJ\1740 glomerulonephritis\NN\14113798 might\MD\5029706 be\VB\836236 another\DT\1740 possible\JJ\1740 complication\NN\1073995 of\IN\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 .\.\1740
20927253
D019386_D010146 CID Diffuse\JJ\1740 skeletal\JJ\1740 <e2>pain</e2>\NN\14299637 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>alendronate</e1>\NN\3740161 .\.\1740
D019386_D010146 CID We\PRP\1740 presented\VBD\2137132 a\DT\13649268 patient\NN\9898892 admitted\VBN\822367 to\TO\1740 our\PRP$\1740 out-patient\JJ\1740 clinic\NN\8053905 with\IN\1740 diffuse\JJ\1740 skeletal\JJ\1740 <e2>pain</e2>\NN\14299637 after\IN\1740 three\CD\13741022 consecutive\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>alendronate</e1>\NN\3740161 .\.\1740
D004164_D010024 NONE BACKGROUND\NN\4921011 :\:\1740 <e2>Osteoporosis</e2>\NN\14204950 is\VBZ\836236 caused\VBN\1617192 by\IN\1740 bone\NN\5286536 resorption\NN\13526110 in\IN\13603305 excess\NN\5119367 of\IN\1740 bone\NN\5286536 formation\NN\7938773 ,\,\1740 and\CC\1740 <e1>bisphosphonates</e1>\NNS\1740 ,\,\1740 are\VBP\836236 used\VBN\1156834 to\TO\1740 inhibit\VB\2510337 bone\NN\5286536 resorption\NN\13526110 .\.\1740
D004164_D010024 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>osteoporosis</e2>\NN\14204950 can\MD\3094503 report\VB\831651 pain\NN\14299637 ,\,\1740 and\CC\1740 <e1>bisphosphonate-related</e1>\JJ\1740 pain\NN\14299637 should\MD\1740 also\RB\1740 be\VB\836236 considered\VBN\689344 before\IN\1740 ascribing\VBG\670261 this\DT\1740 complaint\NN\14052403 to\TO\1740 osteoporosis\NN\14204950 .\.\1740
D004164_D010024 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 patients\NNS\9898892 with\IN\1740 osteoporosis\NN\14204950 can\MD\3094503 report\VB\831651 pain\NN\14299637 ,\,\1740 and\CC\1740 <e1>bisphosphonate-related</e1>\JJ\1740 pain\NN\14299637 should\MD\1740 also\RB\1740 be\VB\836236 considered\VBN\689344 before\IN\1740 ascribing\VBG\670261 this\DT\1740 complaint\NN\14052403 to\TO\1740 <e2>osteoporosis</e2>\NN\14204950 .\.\1740
D019386_D010024 NONE <e1>Alendronate</e1>\NNP\3740161 ,\,\1740 a\DT\13649268 biphosphonate\NN\1740 ,\,\1740 is\VBZ\836236 effective\JJ\1740 for\IN\1740 both\CC\1740 the\DT\1740 treatment\NN\654885 and\CC\1740 prevention\NN\1073995 of\IN\1740 <e2>osteoporosis</e2>\NN\14204950 in\IN\13603305 postmenopausal\JJ\1740 women\NNS\9605289 .\.\1740
-1_D010024 NONE Alendronate\NNP\3740161 ,\,\1740 a\DT\13649268 <e1>biphosphonate</e1>\NN\1740 ,\,\1740 is\VBZ\836236 effective\JJ\1740 for\IN\1740 both\CC\1740 the\DT\1740 treatment\NN\654885 and\CC\1740 prevention\NN\1073995 of\IN\1740 <e2>osteoporosis</e2>\NN\14204950 in\IN\13603305 postmenopausal\JJ\1740 women\NNS\9605289 .\.\1740
D004164_D010146 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 patients\NNS\9898892 with\IN\1740 osteoporosis\NN\14204950 can\MD\3094503 report\VB\831651 <e2>pain</e2>\NN\14299637 ,\,\1740 and\CC\1740 <e1>bisphosphonate-related</e1>\JJ\1740 pain\NN\14299637 should\MD\1740 also\RB\1740 be\VB\836236 considered\VBN\689344 before\IN\1740 ascribing\VBG\670261 this\DT\1740 complaint\NN\14052403 to\TO\1740 osteoporosis\NN\14204950 .\.\1740
D004164_D010146 NONE CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 conclude\VBP\628491 that\IN\1740 patients\NNS\9898892 with\IN\1740 osteoporosis\NN\14204950 can\MD\3094503 report\VB\831651 pain\NN\14299637 ,\,\1740 and\CC\1740 <e1>bisphosphonate-related</e1>\JJ\1740 <e2>pain</e2>\NN\14299637 should\MD\1740 also\RB\1740 be\VB\836236 considered\VBN\689344 before\IN\1740 ascribing\VBG\670261 this\DT\1740 complaint\NN\14052403 to\TO\1740 osteoporosis\NN\14204950 .\.\1740
24902786
D013739_D008569 NONE <e1>Testosterone</e1>\NN\14747587 ameliorates\VBZ\126264 streptozotocin-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D013739_D008569 NONE AIM\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>testosterone</e1>\NN\14747587 on\IN\1740 streptozotocin\NN\1740 (STZ)-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D013739_D008569 NONE Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 <e2>impaired\VBD\258857 the\DT\1740 memory</e2>\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e1>testosterone</e1>\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 memory\NN\5926676 impairment\NN\7296428 .\.\1740
D013739_D008569 NONE Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 impaired\VBD\258857 the\DT\1740 memory\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 <e1>testosterone</e1>\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
D013739_D008569 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Testosterone</e1>\NN\14747587 administration\NN\1133281 ameliorates\VBZ\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D013311_D008569 CID Testosterone\NN\14747587 ameliorates\VBZ\126264 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D008569 CID AIM\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 testosterone\NN\14747587 on\IN\1740 <e1>streptozotocin</e1>\NN\1740 (STZ)-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D008569 CID AIM\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 the\DT\1740 effects\NNS\13245626 of\IN\1740 testosterone\NN\14747587 on\IN\1740 streptozotocin\NN\1740 <e1>(STZ)-induced</e1>\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D013311_D008569 CID Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 <e2>impaired\VBD\258857 the\DT\1740 memory</e2>\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 <e1>STZ-</e1>\NN\1740 and\CC\1740 castration-induced\JJ\1740 memory\NN\5926676 impairment\NN\7296428 .\.\1740
D013311_D008569 CID Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 impaired\VBD\258857 the\DT\1740 memory\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 <e1>STZ-</e1>\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
D013311_D008569 CID CONCLUSION\NN\5837957 :\:\1740 Testosterone\NN\14747587 administration\NN\1133281 ameliorates\VBZ\126264 <e1>STZ-</e1>\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 in\IN\13603305 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D005485_D008569 CID Administration\NN\1133281 of\IN\1740 <e1>flutamide</e1>\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 <e2>impaired\VBD\258857 the\DT\1740 memory</e2>\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 memory\NN\5926676 impairment\NN\7296428 .\.\1740
D005485_D008569 CID Administration\NN\1133281 of\IN\1740 <e1>flutamide</e1>\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 impaired\VBD\258857 the\DT\1740 memory\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
C067431_D008569 CID Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 <e1>letrozole</e1>\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 <e2>impaired\VBD\258857 the\DT\1740 memory</e2>\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 memory\NN\5926676 impairment\NN\7296428 .\.\1740
C067431_D008569 CID Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 <e1>letrozole</e1>\NN\1740 or\CC\3541091 tamoxifen\NN\2714883 significantly\RB\1740 impaired\VBD\258857 the\DT\1740 memory\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
D013629_D008569 CID Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 <e1>tamoxifen</e1>\NN\2714883 significantly\RB\1740 <e2>impaired\VBD\258857 the\DT\1740 memory</e2>\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 memory\NN\5926676 impairment\NN\7296428 .\.\1740
D013629_D008569 CID Administration\NN\1133281 of\IN\1740 flutamide\NN\1740 ,\,\1740 letrozole\NN\1740 or\CC\3541091 <e1>tamoxifen</e1>\NN\2714883 significantly\RB\1740 impaired\VBD\258857 the\DT\1740 memory\NN\5926676 in\IN\13603305 intact\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 significantly\RB\1740 attenuated\VBD\224901 the\DT\1740 testosterone\NN\14747587 replacement\NN\196485 in\IN\13603305 improving\VBG\126264 STZ-\NN\1740 and\CC\1740 castration-induced\JJ\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 .\.\1740
8160791
D005839_D007674 CID Mechanisms\NNS\13446390 for\IN\1740 protective\JJ\1740 effects\NNS\13245626 of\IN\1740 free\JJ\1740 radical\NN\9465459 scavengers\NNS\14779550 on\IN\1740 <e1>gentamicin-mediated</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 in\IN\13603305 rats\NNS\2329401 .\.\1740
D005839_D007674 CID Studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 to\TO\1740 examine\VB\789138 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 of\IN\1740 free\JJ\1740 radical\NN\9465459 scavengers\NNS\14779550 on\IN\1740 <e1>gentamicin</e1>\NN\2716866 (GM)-mediated\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D005839_D007674 CID Studies\NNS\635850 were\VBD\836236 performed\VBN\2367363 to\TO\1740 examine\VB\789138 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 of\IN\1740 free\JJ\1740 radical\NN\9465459 scavengers\NNS\14779550 on\IN\1740 gentamicin\NN\2716866 <e1>(GM)-mediated</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D005839_D007674 CID Administration\NN\1133281 of\IN\1740 <e1>GM</e1>\NNP\13717155 at\IN\14622893 40\CD\13745420 mg/kg\NN\1740 sc\NN\14625458 for\IN\1740 13\CD\13745420 days\NNS\15140892 to\TO\1740 rats\NNS\2329401 induced\VBD\1627355 a\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 RBF\NN\1740 )\-RRB-\1740 and\CC\1740 inulin\JJ\1740 clearance\NN\5089947 (\-LRB-\1740 CIn\NNS\1740 )\-RRB-\1740 as\RB\1740 well\RB\1740 as\IN\14622893 marked\JJ\1740 <e2>tubular\JJ\1740 damage</e2>\NN\7296428 .\.\1740
D005839_D007674 CID A\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 urinary\JJ\1740 guanosine\NN\14964367 3',5'-cyclic\JJ\1740 monophosphate\NN\1740 (\-LRB-\1740 cGMP\NN\1740 )\-RRB-\1740 excretion\NN\13466586 and\CC\1740 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 cortical\JJ\1740 renin\NN\14999106 and\CC\1740 endothelin-1\NN\1740 contents\NNS\6481320 were\VBD\836236 also\RB\1740 observed\VBN\2163746 in\IN\13603305 <e1>GM-mediated</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D005839_D007674 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 1\LS\13741022 )\-RRB-\1740 both\CC\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 have\VBP\2108377 protective\JJ\1740 effects\NNS\13245626 on\IN\1740 <e1>GM-mediated</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 differ\VBP\1740 for\IN\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 ,\,\1740 and\CC\1740 3\LS\13741022 )\-RRB-\1740 superoxide\NN\14971519 anions\NNS\9315159 play\VBP\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 GM-induced\JJ\1740 renal\JJ\1740 vasoconstriction\NN\1149911 .\.\1740
D005839_D007674 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 1\LS\13741022 )\-RRB-\1740 both\CC\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 have\VBP\2108377 protective\JJ\1740 effects\NNS\13245626 on\IN\1740 GM-mediated\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 differ\VBP\1740 for\IN\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 ,\,\1740 and\CC\1740 3\LS\13741022 )\-RRB-\1740 superoxide\NN\14971519 anions\NNS\9315159 play\VBP\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 <e1>GM-induced</e1>\JJ\1740 renal\JJ\1740 vasoconstriction\NN\1149911 .\.\1740
D006152_D007674 NONE A\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 urinary\JJ\1740 <e1>guanosine\NN\14964367 3',5'-cyclic\JJ\1740 monophosphate</e1>\NN\1740 (\-LRB-\1740 cGMP\NN\1740 )\-RRB-\1740 excretion\NN\13466586 and\CC\1740 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 cortical\JJ\1740 renin\NN\14999106 and\CC\1740 endothelin-1\NN\1740 contents\NNS\6481320 were\VBD\836236 also\RB\1740 observed\VBN\2163746 in\IN\13603305 GM-mediated\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D006152_D007674 NONE A\DT\13649268 significant\JJ\1740 reduction\NN\351485 in\IN\13603305 urinary\JJ\1740 guanosine\NN\14964367 3',5'-cyclic\JJ\1740 monophosphate\NN\1740 (\-LRB-\1740 <e1>cGMP</e1>\NN\1740 )\-RRB-\1740 excretion\NN\13466586 and\CC\1740 a\DT\13649268 significant\JJ\1740 increase\NN\13576355 in\IN\13603305 renal\JJ\1740 cortical\JJ\1740 renin\NN\14999106 and\CC\1740 endothelin-1\NN\1740 contents\NNS\6481320 were\VBD\836236 also\RB\1740 observed\VBN\2163746 in\IN\13603305 GM-mediated\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
C038983_D007674 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>DMTU</e1>\NN\1740 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>tubular\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 affect\VB\126264 renal\JJ\1740 hemodynamics\NNS\6080522 and\CC\1740 vasoactive\JJ\1740 substances\NNS\20827 .\.\1740
C038983_D007674 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 1\LS\13741022 )\-RRB-\1740 both\CC\1740 SOD\NN\9335240 and\CC\1740 <e1>DMTU</e1>\NN\1740 have\VBP\2108377 protective\JJ\1740 effects\NNS\13245626 on\IN\1740 GM-mediated\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 differ\VBP\1740 for\IN\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 ,\,\1740 and\CC\1740 3\LS\13741022 )\-RRB-\1740 superoxide\NN\14971519 anions\NNS\9315159 play\VBP\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 GM-induced\JJ\1740 renal\JJ\1740 vasoconstriction\NN\1149911 .\.\1740
C038983_D007674 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 1\LS\13741022 )\-RRB-\1740 both\CC\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 have\VBP\2108377 protective\JJ\1740 effects\NNS\13245626 on\IN\1740 GM-mediated\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 differ\VBP\1740 for\IN\1740 SOD\NN\9335240 and\CC\1740 <e1>DMTU</e1>\NN\1740 ,\,\1740 and\CC\1740 3\LS\13741022 )\-RRB-\1740 superoxide\NN\14971519 anions\NNS\9315159 play\VBP\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 GM-induced\JJ\1740 renal\JJ\1740 vasoconstriction\NN\1149911 .\.\1740
D013481_D007674 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 1\LS\13741022 )\-RRB-\1740 both\CC\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 have\VBP\2108377 protective\JJ\1740 effects\NNS\13245626 on\IN\1740 GM-mediated\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 2\LS\13741022 )\-RRB-\1740 the\DT\1740 mechanisms\NNS\13446390 for\IN\1740 the\DT\1740 protective\JJ\1740 effects\NNS\13245626 differ\VBP\1740 for\IN\1740 SOD\NN\9335240 and\CC\1740 DMTU\NN\1740 ,\,\1740 and\CC\1740 3\LS\13741022 )\-RRB-\1740 <e1>superoxide</e1>\NN\14971519 anions\NNS\9315159 play\VBP\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 GM-induced\JJ\1740 renal\JJ\1740 vasoconstriction\NN\1149911 .\.\1740
8701013
D015738_D003693 CID <e1>Famotidine-associated</e1>\JJ\1740 <e2>delirium</e2>\NN\14391660 .\.\1740
D015738_D003693 CID Although\IN\1740 all\DT\1740 of\IN\1740 the\DT\1740 currently\RB\1740 available\JJ\1740 H2-receptor\JJ\1740 antagonists\NNS\7846 have\VBP\2108377 shown\VBN\2137132 the\DT\1740 propensity\NN\7498854 to\TO\1740 cause\VB\1617192 <e2>delirium</e2>\NN\14391660 ,\,\1740 only\RB\1740 two\CD\13741022 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 have\VBP\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 <e1>famotidine</e1>\NN\3522239 .\.\1740
D015738_D003693 CID The\DT\1740 authors\NNS\9610660 report\VBP\831651 on\IN\1740 six\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>famotidine-associated</e1>\JJ\1740 <e2>delirium</e2>\NN\14391660 in\IN\13603305 hospitalized\VBN\2348568 patients\NNS\9898892 who\WP\8299493 cleared\VBD\126264 completely\RB\1740 upon\IN\1740 removal\NN\383606 of\IN\1740 famotidine\NN\3522239 .\.\1740
D015738_D003693 CID The\DT\1740 authors\NNS\9610660 report\VBP\831651 on\IN\1740 six\CD\13741022 cases\NNS\7283608 of\IN\1740 famotidine-associated\JJ\1740 <e2>delirium</e2>\NN\14391660 in\IN\13603305 hospitalized\VBN\2348568 patients\NNS\9898892 who\WP\8299493 cleared\VBD\126264 completely\RB\1740 upon\IN\1740 removal\NN\383606 of\IN\1740 <e1>famotidine</e1>\NN\3522239 .\.\1740
D015738_D014456 NONE <e1>Famotidine</e1>\NNP\3522239 is\VBZ\836236 a\DT\13649268 histamine\NN\14739004 H2-receptor\NN\1740 antagonist\NN\7846 used\VBN\1156834 in\IN\13603305 inpatient\JJ\1740 settings\NNS\8567235 for\IN\1740 prevention\NN\1073995 of\IN\1740 stress\NN\7083732 <e2>ulcers</e2>\NNS\14211294 and\CC\1740 is\VBZ\836236 showing\VBG\2137132 increasing\VBG\169651 popularity\NN\4723816 because\IN\1740 of\IN\1740 its\PRP$\6125041 low\JJ\1740 cost\NN\13275288 .\.\1740
24684312
D018698_D006930 NONE Intradermal\JJ\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 injections\NNS\320852 :\:\1740 intra-\NN\1740 and\CC\1740 interindividual\JJ\1740 variability\NN\4733640 of\IN\1740 provoked\VBN\1617192 <e2>hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 .\.\1740
D018698_D006930 NONE Intradermal\JJ\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 injections\NNS\320852 :\:\1740 intra-\NN\1740 and\CC\1740 interindividual\JJ\1740 variability\NN\4733640 of\IN\1740 provoked\VBN\1617192 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 .\.\1740
D018698_D006930 NONE Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 pain\NN\14299637 models\NNS\5888929 because\IN\1740 <e2>hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 pain\NN\14299637 disorders\NNS\14034177 .\.\1740
D018698_D006930 NONE Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 pain\NN\14299637 models\NNS\5888929 because\IN\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 pain\NN\14299637 disorders\NNS\14034177 .\.\1740
D018698_D006930 NONE Secondary\JJ\1740 pinprick\NN\14406573 <e2>hyperalgesia</e2>\NN\1740 was\VBD\836236 observed\VBN\2163746 as\IN\14622893 a\DT\13649268 marked\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 visual\JJ\1740 analogue\NN\4743605 scale\NN\7260623 (\-LRB-\1740 VAS\NN\5246511 )\-RRB-\1740 response\NN\11410625 to\TO\1740 von\NN\1740 Frey\NNP\1740 gauges\NNS\3733925 60\CD\13745420 and\CC\1740 100\CD\13745420 g\NN\13717155 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 after\IN\1740 <e1>glutamate</e1>\JJ\1740 injection\NN\320852 .\.\1740
D018698_D006930 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 yield\NN\913705 reproducible\JJ\1740 <e2>hyperalgesic</e2>\JJ\1740 and\CC\1740 allodynic\JJ\1740 responses\NNS\11410625 ,\,\1740 and\CC\1740 the\DT\1740 present\JJ\1740 model\NN\5888929 is\VBZ\836236 well\RB\1740 suited\JJ\1740 for\IN\1740 basic\JJ\1740 research\NN\633864 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 for\IN\1740 assessing\VBG\670261 the\DT\1740 modulation\NN\7044917 of\IN\1740 central\JJ\1740 phenomena\NNS\29677 .\.\1740
D018698_D006930 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 yield\NN\913705 reproducible\JJ\1740 hyperalgesic\JJ\1740 and\CC\1740 <e2>allodynic</e2>\JJ\1740 responses\NNS\11410625 ,\,\1740 and\CC\1740 the\DT\1740 present\JJ\1740 model\NN\5888929 is\VBZ\836236 well\RB\1740 suited\JJ\1740 for\IN\1740 basic\JJ\1740 research\NN\633864 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 for\IN\1740 assessing\VBG\670261 the\DT\1740 modulation\NN\7044917 of\IN\1740 central\JJ\1740 phenomena\NNS\29677 .\.\1740
D002211_D006930 CID Intradermal\JJ\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 injections\NNS\320852 :\:\1740 intra-\NN\1740 and\CC\1740 interindividual\JJ\1740 variability\NN\4733640 of\IN\1740 provoked\VBN\1617192 <e2>hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\NN\1740 .\.\1740
D002211_D006930 CID Intradermal\JJ\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 injections\NNS\320852 :\:\1740 intra-\NN\1740 and\CC\1740 interindividual\JJ\1740 variability\NN\4733640 of\IN\1740 provoked\VBN\1617192 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 .\.\1740
D002211_D006930 CID Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 pain\NN\14299637 models\NNS\5888929 because\IN\1740 <e2>hyperalgesia</e2>\NN\1740 and\CC\1740 allodynia\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 pain\NN\14299637 disorders\NNS\14034177 .\.\1740
D002211_D006930 CID Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 pain\NN\14299637 models\NNS\5888929 because\IN\1740 hyperalgesia\NN\1740 and\CC\1740 <e2>allodynia</e2>\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 pain\NN\14299637 disorders\NNS\14034177 .\.\1740
D002211_D006930 CID For\IN\1740 <e1>capsaicin</e1>\NN\15032661 ,\,\1740 secondary\JJ\1740 pinprick\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 was\VBD\836236 detected\VBN\2163746 with\IN\1740 all\DT\1740 von\NN\1740 Frey\NN\1740 gauges\NNS\3733925 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D002211_D006930 CID <e1>Capsaicin</e1>\NN\15032661 injection\NN\320852 was\VBD\836236 reproducible\JJ\1740 for\IN\1740 <e2>secondary\JJ\1740 hyperalgesia</e2>\NN\1740 (\-LRB-\1740 ICC\NN\8338847 >\NN\1740 0.70\CD\1740 )\-RRB-\1740 and\CC\1740 allodynia\NN\1740 (\-LRB-\1740 ICC\NN\8338847 >\NN\1740 0.71\CD\1740 )\-RRB-\1740 .\.\1740
D002211_D006930 CID <e1>Capsaicin</e1>\NN\15032661 injection\NN\320852 was\VBD\836236 reproducible\JJ\1740 for\IN\1740 secondary\JJ\1740 hyperalgesia\NN\1740 (\-LRB-\1740 ICC\NN\8338847 >\NN\1740 0.70\CD\1740 )\-RRB-\1740 and\CC\1740 <e2>allodynia</e2>\NN\1740 (\-LRB-\1740 ICC\NN\8338847 >\NN\1740 0.71\CD\1740 )\-RRB-\1740 .\.\1740
D002211_D006930 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 yield\NN\913705 reproducible\JJ\1740 <e2>hyperalgesic</e2>\JJ\1740 and\CC\1740 allodynic\JJ\1740 responses\NNS\11410625 ,\,\1740 and\CC\1740 the\DT\1740 present\JJ\1740 model\NN\5888929 is\VBZ\836236 well\RB\1740 suited\JJ\1740 for\IN\1740 basic\JJ\1740 research\NN\633864 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 for\IN\1740 assessing\VBG\670261 the\DT\1740 modulation\NN\7044917 of\IN\1740 central\JJ\1740 phenomena\NNS\29677 .\.\1740
D002211_D006930 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 yield\NN\913705 reproducible\JJ\1740 hyperalgesic\JJ\1740 and\CC\1740 <e2>allodynic</e2>\JJ\1740 responses\NNS\11410625 ,\,\1740 and\CC\1740 the\DT\1740 present\JJ\1740 model\NN\5888929 is\VBZ\836236 well\RB\1740 suited\JJ\1740 for\IN\1740 basic\JJ\1740 research\NN\633864 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 for\IN\1740 assessing\VBG\670261 the\DT\1740 modulation\NN\7044917 of\IN\1740 central\JJ\1740 phenomena\NNS\29677 .\.\1740
D018698_D010146 NONE Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 <e2>pain</e2>\NN\14299637 models\NNS\5888929 because\IN\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 pain\NN\14299637 disorders\NNS\14034177 .\.\1740
D018698_D013001 NONE Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 capsaicin\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 pain\NN\14299637 models\NNS\5888929 because\IN\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 <e2>pain\NN\14299637 disorders</e2>\NNS\14034177 .\.\1740
D002211_D010146 NONE Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 <e2>pain</e2>\NN\14299637 models\NNS\5888929 because\IN\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 pain\NN\14299637 disorders\NNS\14034177 .\.\1740
D002211_D013001 NONE Intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 glutamate\NN\15010703 and\CC\1740 <e1>capsaicin</e1>\NN\15032661 are\VBP\836236 attractive\JJ\1740 to\TO\1740 use\VB\1156834 in\IN\13603305 human\JJ\1740 experimental\JJ\1740 pain\NN\14299637 models\NNS\5888929 because\IN\1740 hyperalgesia\NN\1740 and\CC\1740 allodynia\JJ\1740 mimic\JJ\1740 isolated\VBN\2512305 aspects\NNS\5849789 of\IN\1740 clinical\JJ\1740 <e2>pain\NN\14299637 disorders</e2>\NNS\14034177 .\.\1740
3925479
D006220_D002375 CID Evidence\NN\5816287 for\IN\1740 a\DT\13649268 cholinergic\JJ\1740 role\NN\719494 in\IN\13603305 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D006220_D002375 CID Low\JJ\1740 doses\NNS\3740161 of\IN\1740 pilocarpine\NN\14712692 caused\VBD\1617192 a\DT\13649268 pronounced\JJ\1740 enhancement\NN\248977 of\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 the\DT\1740 dopaminergic\JJ\1740 blocker\NN\10101634 ,\,\1740 <e1>haloperidol</e1>\VB\1740 .\.\1740
D006220_D002375 CID A\DT\13649268 muscarinic\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 atropine\NN\14712692 ,\,\1740 disrupted\VBN\362348 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D006220_D002375 CID Intracranial\JJ\1740 injection\NN\320852 of\IN\1740 an\DT\6697703 acetylcholine-synthesis\JJ\1740 inhibitor\NN\20090 ,\,\1740 hemicholinium\NN\1740 ,\,\1740 prevented\VBD\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 is\VBZ\836236 usually\RB\1740 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 .\.\1740
D006220_D002375 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 is\VBZ\836236 produced\VBN\1617192 by\IN\1740 neuroleptics\NNS\4470232 such\JJ\1740 as\IN\14622893 <e1>haloperidol</e1>\NN\3713736 is\VBZ\836236 actually\RB\1740 mediated\VBN\761713 by\IN\1740 intrinsic\JJ\1740 central\JJ\1740 cholinergic\NN\1740 systems\NNS\3575240 .\.\1740
D014150_D002375 NONE Experiments\NNS\641820 in\IN\13603305 mice\NNS\2329401 tested\VBD\670261 previous\JJ\1740 evidence\NN\5816287 that\IN\1740 activation\NN\13561719 of\IN\1740 cholinergic\JJ\1740 systems\NNS\3575240 promotes\VBZ\2556126 <e2>catalepsy</e2>\NN\14023236 and\CC\1740 that\IN\1740 cholinergic\NN\1740 mechanisms\NNS\13446390 need\VBP\2604760 to\TO\1740 be\VB\836236 intact\JJ\1740 for\IN\1740 full\JJ\1740 expression\NN\4679549 of\IN\1740 <e1>neuroleptic-induced</e1>\JJ\1740 catalepsy\NN\14023236 .\.\1740
D014150_D002375 NONE Experiments\NNS\641820 in\IN\13603305 mice\NNS\2329401 tested\VBD\670261 previous\JJ\1740 evidence\NN\5816287 that\IN\1740 activation\NN\13561719 of\IN\1740 cholinergic\JJ\1740 systems\NNS\3575240 promotes\VBZ\2556126 catalepsy\NN\14023236 and\CC\1740 that\IN\1740 cholinergic\NN\1740 mechanisms\NNS\13446390 need\VBP\2604760 to\TO\1740 be\VB\836236 intact\JJ\1740 for\IN\1740 full\JJ\1740 expression\NN\4679549 of\IN\1740 <e1>neuroleptic-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D014150_D002375 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 is\VBZ\836236 produced\VBN\1617192 by\IN\1740 <e1>neuroleptics</e1>\NNS\4470232 such\JJ\1740 as\IN\14622893 haloperidol\NN\3713736 is\VBZ\836236 actually\RB\1740 mediated\VBN\761713 by\IN\1740 intrinsic\JJ\1740 central\JJ\1740 cholinergic\NN\1740 systems\NNS\3575240 .\.\1740
D010862_D002375 CID Large\JJ\1740 doses\NNS\3740161 of\IN\1740 the\DT\1740 cholinomimetic\JJ\1740 ,\,\1740 <e1>pilocarpine</e1>\NN\14712692 ,\,\1740 could\MD\1740 induce\VB\1627355 <e2>catalepsy</e2>\NN\14023236 when\WRB\1740 peripheral\JJ\1740 cholinergic\NN\1740 receptors\NNS\5225602 were\VBD\836236 blocked\VBN\1476483 .\.\1740
D010862_D002375 CID Low\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>pilocarpine</e1>\NN\14712692 caused\VBD\1617192 a\DT\13649268 pronounced\JJ\1740 enhancement\NN\248977 of\IN\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 the\DT\1740 dopaminergic\JJ\1740 blocker\NN\10101634 ,\,\1740 haloperidol\VB\1740 .\.\1740
D001285_D002375 NONE A\DT\13649268 muscarinic\NN\1740 receptor\NN\5225602 blocker\NN\10101634 ,\,\1740 <e1>atropine</e1>\NN\14712692 ,\,\1740 disrupted\VBN\362348 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 .\.\1740
D000109_D002375 NONE Intracranial\JJ\1740 injection\NN\320852 of\IN\1740 an\DT\6697703 <e1>acetylcholine-synthesis</e1>\JJ\1740 inhibitor\NN\20090 ,\,\1740 hemicholinium\NN\1740 ,\,\1740 prevented\VBD\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 is\VBZ\836236 usually\RB\1740 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 .\.\1740
D006426_D002375 NONE Intracranial\JJ\1740 injection\NN\320852 of\IN\1740 an\DT\6697703 acetylcholine-synthesis\JJ\1740 inhibitor\NN\20090 ,\,\1740 <e1>hemicholinium</e1>\NN\1740 ,\,\1740 prevented\VBD\1740 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 that\WDT\1740 is\VBZ\836236 usually\RB\1740 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 .\.\1740
25084821
C069541_D009503 CID <e1>Quetiapine-induced</e1>\JJ\1740 <e2>neutropenia</e2>\NN\14196405 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 with\IN\1740 hepatocellular\JJ\1740 carcinoma\NN\14239918 .\.\1740
C069541_D009503 CID OBJECTIVE\NN\5980875 :\:\1740 <e1>Quetiapine</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 dibenzothiazepine\NN\1740 derivative\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 clozapine\NN\3713736 ,\,\1740 which\WDT\1740 has\VBZ\2108377 the\DT\1740 highest\JJS\1740 risk\NN\14541044 of\IN\1740 causing\VBG\1617192 blood\NN\5397468 dyscrasias\NNS\14052046 ,\,\1740 especially\RB\1740 <e2>neutropenia</e2>\JJ\1740 .\.\1740
C069541_D009503 CID A\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 hepatocellular\JJ\1740 carcinoma\NN\14239918 that\WDT\1740 developed\VBD\1753788 <e2>neutropenia</e2>\NN\14196405 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>quetiapine</e1>\NN\1740 is\VBZ\836236 described\VBN\1001294 here\RB\1740 .\.\1740
C069541_D009503 CID CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 <e2>neutropenia</e2>\NN\14196405 is\VBZ\836236 not\RB\1740 a\DT\13649268 common\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>quetiapine</e1>\NN\1740 ,\,\1740 physicians\NNS\10305802 should\MD\1740 be\VB\836236 cautious\JJ\1740 about\IN\1740 its\PRP$\6125041 presentation\NN\1027379 and\CC\1740 associated\VBN\628491 risk\NN\14541044 factors\NNS\7326557 .\.\1740
C069541_D001714 NONE <e1>Quetiapine-induced</e1>\JJ\1740 neutropenia\NN\14196405 in\IN\13603305 a\DT\13649268 <e2>bipolar</e2>\JJ\1740 patient\NN\9898892 with\IN\1740 hepatocellular\JJ\1740 carcinoma\NN\14239918 .\.\1740
C069541_D006528 NONE <e1>Quetiapine-induced</e1>\JJ\1740 neutropenia\NN\14196405 in\IN\13603305 a\DT\13649268 bipolar\JJ\1740 patient\NN\9898892 with\IN\1740 <e2>hepatocellular\JJ\1740 carcinoma</e2>\NN\14239918 .\.\1740
C069541_D006528 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>hepatocellular\JJ\1740 carcinoma</e2>\NN\14239918 that\WDT\1740 developed\VBD\1753788 neutropenia\NN\14196405 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>quetiapine</e1>\NN\1740 is\VBZ\836236 described\VBN\1001294 here\RB\1740 .\.\1740
C069541_D006402 NONE OBJECTIVE\NN\5980875 :\:\1740 <e1>Quetiapine</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 dibenzothiazepine\NN\1740 derivative\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 clozapine\NN\3713736 ,\,\1740 which\WDT\1740 has\VBZ\2108377 the\DT\1740 highest\JJS\1740 risk\NN\14541044 of\IN\1740 causing\VBG\1617192 <e2>blood\NN\5397468 dyscrasias</e2>\NNS\14052046 ,\,\1740 especially\RB\1740 neutropenia\JJ\1740 .\.\1740
D003024_D006402 NONE OBJECTIVE\NN\5980875 :\:\1740 Quetiapine\NNP\1740 is\VBZ\836236 a\DT\13649268 dibenzothiazepine\NN\1740 derivative\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 <e1>clozapine</e1>\NN\3713736 ,\,\1740 which\WDT\1740 has\VBZ\2108377 the\DT\1740 highest\JJS\1740 risk\NN\14541044 of\IN\1740 causing\VBG\1617192 <e2>blood\NN\5397468 dyscrasias</e2>\NNS\14052046 ,\,\1740 especially\RB\1740 neutropenia\JJ\1740 .\.\1740
D003024_D009503 NONE OBJECTIVE\NN\5980875 :\:\1740 Quetiapine\NNP\1740 is\VBZ\836236 a\DT\13649268 dibenzothiazepine\NN\1740 derivative\JJ\1740 ,\,\1740 similar\JJ\1740 to\TO\1740 <e1>clozapine</e1>\NN\3713736 ,\,\1740 which\WDT\1740 has\VBZ\2108377 the\DT\1740 highest\JJS\1740 risk\NN\14541044 of\IN\1740 causing\VBG\1617192 blood\NN\5397468 dyscrasias\NNS\14052046 ,\,\1740 especially\RB\1740 <e2>neutropenia</e2>\JJ\1740 .\.\1740
C069541_D007970 CID She\PRP\1740 developed\VBD\1753788 <e2>leucopenia</e2>\NN\14189204 after\IN\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
C069541_D008107 NONE <e2>Hepatic\JJ\1740 dysfunction</e2>\NN\14204950 may\MD\15209706 be\VB\836236 one\CD\13741022 of\IN\1740 the\DT\1740 possible\JJ\1740 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 and\CC\1740 concomitant\JJ\1740 fever\NN\14299637 may\MD\15209706 be\VB\836236 a\DT\13649268 diagnostic\JJ\1740 marker\NN\21939 for\IN\1740 adverse\JJ\1740 reaction\NN\13446390 to\IN\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
C069541_D005334 CID Hepatic\JJ\1740 dysfunction\NN\14204950 may\MD\15209706 be\VB\836236 one\CD\13741022 of\IN\1740 the\DT\1740 possible\JJ\1740 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 and\CC\1740 concomitant\JJ\1740 <e2>fever</e2>\NN\14299637 may\MD\15209706 be\VB\836236 a\DT\13649268 diagnostic\JJ\1740 marker\NN\21939 for\IN\1740 adverse\JJ\1740 reaction\NN\13446390 to\IN\1740 <e1>quetiapine</e1>\NN\1740 .\.\1740
18341442
C026098_C562694 NONE <e1>Levetiracetam</e1>\NN\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 phenobarbital\JJ\1740 treatment\NN\654885 in\IN\13603305 cats\NNS\2120997 with\IN\1740 suspected\VBN\916909 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
C026098_C562694 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 pharmacokinetics\NNS\6054892 ,\,\1740 efficacy\NN\5199286 ,\,\1740 and\CC\1740 tolerability\NN\1740 of\IN\1740 oral\JJ\1740 <e1>levetiracetam</e1>\NN\1740 administered\VBN\2436349 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 phenobarbital\JJ\1740 treatment\NN\654885 in\IN\13603305 cats\NNS\2120997 with\IN\1740 poorly\RB\1740 controlled\VBN\2422663 suspected\VBN\916909 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
C026098_C562694 NONE CONCLUSIONS\NNS\5837957 AND\CC\1740 CLINICAL\NN\1740 RELEVANCE\NN\13791389 :\:\1740 Results\NNS\34213 suggested\VBD\1010118 that\IN\1740 <e1>levetiracetam</e1>\NN\1740 is\VBZ\836236 well\RB\1740 tolerated\VBN\802318 in\IN\13603305 cats\NNS\2120997 and\CC\1740 may\MD\15209706 be\VB\836236 useful\JJ\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 phenobarbital\JJ\1740 treatment\NN\654885 in\IN\13603305 cats\NNS\2120997 with\IN\1740 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
D010634_C562694 NONE Levetiracetam\NN\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 <e1>phenobarbital</e1>\JJ\1740 treatment\NN\654885 in\IN\13603305 cats\NNS\2120997 with\IN\1740 suspected\VBN\916909 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
D010634_C562694 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 pharmacokinetics\NNS\6054892 ,\,\1740 efficacy\NN\5199286 ,\,\1740 and\CC\1740 tolerability\NN\1740 of\IN\1740 oral\JJ\1740 levetiracetam\NN\1740 administered\VBN\2436349 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 <e1>phenobarbital</e1>\JJ\1740 treatment\NN\654885 in\IN\13603305 cats\NNS\2120997 with\IN\1740 poorly\RB\1740 controlled\VBN\2422663 suspected\VBN\916909 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
D010634_C562694 NONE ANIMALS\NNS\4475 :\:\1740 12\CD\13745420 cats\NNS\2120997 suspected\VBN\916909 to\TO\1740 have\VB\2108377 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 that\WDT\1740 was\VBD\836236 poorly\RB\1740 controlled\VBN\2422663 with\IN\1740 <e1>phenobarbital</e1>\JJ\1740 or\CC\3541091 that\DT\1740 had\VBD\2108377 unacceptable\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 when\WRB\1740 treated\VBN\2376958 with\IN\1740 phenobarbital\JJ\1740 .\.\1740
D010634_C562694 NONE ANIMALS\NNS\4475 :\:\1740 12\CD\13745420 cats\NNS\2120997 suspected\VBN\916909 to\TO\1740 have\VB\2108377 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 that\WDT\1740 was\VBD\836236 poorly\RB\1740 controlled\VBN\2422663 with\IN\1740 phenobarbital\JJ\1740 or\CC\3541091 that\DT\1740 had\VBD\2108377 unacceptable\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 when\WRB\1740 treated\VBN\2376958 with\IN\1740 <e1>phenobarbital</e1>\JJ\1740 .\.\1740
D010634_C562694 NONE CONCLUSIONS\NNS\5837957 AND\CC\1740 CLINICAL\NN\1740 RELEVANCE\NN\13791389 :\:\1740 Results\NNS\34213 suggested\VBD\1010118 that\IN\1740 levetiracetam\NN\1740 is\VBZ\836236 well\RB\1740 tolerated\VBN\802318 in\IN\13603305 cats\NNS\2120997 and\CC\1740 may\MD\15209706 be\VB\836236 useful\JJ\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 <e1>phenobarbital</e1>\JJ\1740 treatment\NN\654885 in\IN\13603305 cats\NNS\2120997 with\IN\1740 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
C026098_D012640 NONE <e2>Seizure</e2>\NN\14081375 frequencies\VBZ\1740 before\IN\1740 and\CC\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 were\VBD\836236 compared\VBN\644583 ,\,\1740 and\CC\1740 adverse\JJ\1740 effects\NNS\13245626 were\VBD\836236 recorded\VBN\2225492 .\.\1740
C026098_D012640 NONE Median\JJ\1740 <e2>seizure</e2>\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>levetiracetam</e1>\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>levetiracetam</e1>\NN\1740 (\-LRB-\1740 2.1\CD\1740 <e2>seizures/mo</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>levetiracetam</e1>\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>levetiracetam</e1>\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 <e2>seizures/mo</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>levetiracetam</e1>\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 <e2>seizure</e2>\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 <e2>seizures/mo</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 <e2>seizures/mo</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 <e2>seizure</e2>\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 <e2>seizures/mo</e2>\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 <e2>seizures/mo</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 seizure\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE Median\JJ\1740 seizure\NN\14081375 frequency\NN\15286249 prior\RB\1740 to\TO\1740 treatment\NN\654885 with\IN\1740 levetiracetam\NN\1740 (\-LRB-\1740 2.1\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 median\JJ\1740 seizure\JJ\1740 frequency\NN\15286249 after\IN\1740 initiation\NN\7450842 of\IN\1740 levetiracetam\NN\1740 treatment\NN\654885 (\-LRB-\1740 0.42\CD\1740 seizures/mo\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 7\CD\13741022 of\IN\1740 10\CD\13745420 cats\NNS\2120997 were\VBD\836236 classified\VBN\657260 as\IN\14622893 having\VBG\2108377 responded\VBN\2367363 to\TO\1740 <e1>levetiracetam</e1>\NN\1740 treatment\NN\654885 (\-LRB-\1740 ie\FW\1740 ,\,\1740 reduction\NN\351485 in\IN\13603305 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 of\IN\1740 >\NNP\1740 or=50\NNP\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
24341598
D012965_D007674 NONE Comparison\NN\635850 of\IN\1740 effects\NNS\13245626 of\IN\1740 isotonic\JJ\1740 <e1>sodium\NN\14625458 chloride</e1>\NN\14818238 with\IN\1740 diltiazem\NN\2938514 in\IN\13603305 prevention\NN\1073995 of\IN\1740 contrast-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D004110_D007674 NONE Comparison\NN\635850 of\IN\1740 effects\NNS\13245626 of\IN\1740 isotonic\JJ\1740 sodium\NN\14625458 chloride\NN\14818238 with\IN\1740 <e1>diltiazem</e1>\NN\2938514 in\IN\13603305 prevention\NN\1073995 of\IN\1740 contrast-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D003287_D007674 NONE Comparison\NN\635850 of\IN\1740 effects\NNS\13245626 of\IN\1740 isotonic\JJ\1740 sodium\NN\14625458 chloride\NN\14818238 with\IN\1740 diltiazem\NN\2938514 in\IN\13603305 prevention\NN\1073995 of\IN\1740 <e1>contrast-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D003287_D007674 NONE INTRODUCTION\NN\235435 AND\CC\1740 OBJECTIVE\NN\5980875 :\:\1740 <e1>Contrast-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 CIN\NN\1740 )\-RRB-\1740 significantly\RB\1740 increases\VBZ\169651 the\DT\1740 morbidity\NN\13826959 and\CC\1740 mortality\NN\5054863 of\IN\1740 patients\NNS\9898892 .\.\1740
D003287_D058186 CID Among\IN\1740 a\DT\13649268 total\NN\3553 of\IN\1740 60\CD\13745420 patients\NNS\9898892 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 ,\,\1740 16\CD\13745420 patients\NNS\9898892 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 ARF\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 second\JJ\1740 day\NN\15154774 after\IN\1740 <e1>contrast</e1>\NN\13854649 material\NN\19613 was\VBD\836236 injected\VBN\81072 (\-LRB-\1740 26.6\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D003287_D058186 CID Among\IN\1740 a\DT\13649268 total\NN\3553 of\IN\1740 60\CD\13745420 patients\NNS\9898892 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 ,\,\1740 16\CD\13745420 patients\NNS\9898892 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 <e2>ARF</e2>\NN\1740 )\-RRB-\1740 on\IN\1740 the\DT\1740 second\JJ\1740 day\NN\15154774 after\IN\1740 <e1>contrast</e1>\NN\13854649 material\NN\19613 was\VBD\836236 injected\VBN\81072 (\-LRB-\1740 26.6\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
17028363
D000880_D058186 NONE <e2>Acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 intake\NN\13440063 of\IN\1740 slimming\VBG\1740 pills\NNS\4424218 containing\VBG\2632940 <e1>anthraquinones</e1>\NNS\1740 .\.\1740
D000880_D058186 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 23-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 prolonged\JJ\1740 use\NN\407535 of\IN\1740 a\DT\13649268 proprietary\JJ\1740 Chinese\JJ\1740 herbal\JJ\1740 slimming\NN\1740 pill\NN\4424218 that\WDT\1740 contained\VBD\2632940 <e1>anthraquinone</e1>\NN\1740 derivatives\NNS\5802185 ,\,\1740 extracted\VBN\173338 from\IN\1740 Rhizoma\NNP\1740 Rhei\NNP\1740 (\-LRB-\1740 rhubarb\NNS\7707451 )\-RRB-\1740 .\.\1740
D000880_D058186 NONE Although\IN\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 an\DT\6697703 <e1>anthraquinone-containing</e1>\JJ\1740 herbal\JJ\1740 agent\NN\7347 and\CC\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 remains\VBZ\2604760 to\TO\1740 be\VB\836236 proven\VBN\2604760 ,\,\1740 phytotherapy-associated\JJ\1740 interstitial\JJ\1740 nephropathy\NN\14573196 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 present\VBP\2137132 with\IN\1740 unexplained\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D004365_D007674 NONE <e2>Nephropathy</e2>\NNP\14573196 caused\VBN\1617192 by\IN\1740 <e1>Chinese\JJ\1740 herbs</e1>\NNS\13083586 has\VBZ\2108377 previously\RB\1740 been\VBN\836236 reported\VBN\831651 ,\,\1740 usually\RB\1740 involving\VBG\2676054 the\DT\1740 use\NN\407535 of\IN\1740 aristolochic\JJ\1740 acids\NNS\14818238 .\.\1740
D034341_D007674 NONE <e2>Nephropathy</e2>\NNP\14573196 caused\VBN\1617192 by\IN\1740 Chinese\JJ\1740 herbs\NNS\13083586 has\VBZ\2108377 previously\RB\1740 been\VBN\836236 reported\VBN\831651 ,\,\1740 usually\RB\1740 involving\VBG\2676054 the\DT\1740 use\NN\407535 of\IN\1740 <e1>aristolochic\JJ\1740 acids</e1>\NNS\14818238 .\.\1740
D004365_D058186 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 23-year-old\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 prolonged\JJ\1740 use\NN\407535 of\IN\1740 a\DT\13649268 proprietary\JJ\1740 <e1>Chinese\JJ\1740 herbal</e1>\JJ\1740 slimming\NN\1740 pill\NN\4424218 that\WDT\1740 contained\VBD\2632940 anthraquinone\NN\1740 derivatives\NNS\5802185 ,\,\1740 extracted\VBN\173338 from\IN\1740 Rhizoma\NNP\1740 Rhei\NNP\1740 (\-LRB-\1740 rhubarb\NNS\7707451 )\-RRB-\1740 .\.\1740
D004008_D058186 CID The\DT\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 was\VBD\836236 probably\RB\1740 aggravated\VBN\126264 by\IN\1740 the\DT\1740 concomitant\JJ\1740 intake\NN\13440063 of\IN\1740 a\DT\13649268 non-steroidal\JJ\1740 anti-inflammatory\JJ\1740 drug\NN\14778436 ,\,\1740 <e1>diclofenac</e1>\VBD\1740 .\.\1740
D000880_D007674 NONE Although\IN\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 an\DT\6697703 <e1>anthraquinone-containing</e1>\JJ\1740 herbal\JJ\1740 agent\NN\7347 and\CC\1740 renal\JJ\1740 injury\NN\14052046 remains\VBZ\2604760 to\TO\1740 be\VB\836236 proven\VBN\2604760 ,\,\1740 phytotherapy-associated\JJ\1740 interstitial\JJ\1740 <e2>nephropathy</e2>\NN\14573196 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 present\VBP\2137132 with\IN\1740 unexplained\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D000880_D051437 NONE Although\IN\1740 a\DT\13649268 causal\JJ\1740 relationship\NN\31921 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 an\DT\6697703 <e1>anthraquinone-containing</e1>\JJ\1740 herbal\JJ\1740 agent\NN\7347 and\CC\1740 renal\JJ\1740 injury\NN\14052046 remains\VBZ\2604760 to\TO\1740 be\VB\836236 proven\VBN\2604760 ,\,\1740 phytotherapy-associated\JJ\1740 interstitial\JJ\1740 nephropathy\NN\14573196 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 present\VBP\2137132 with\IN\1740 unexplained\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
24911645
C573355_D012640 NONE Behavioral\JJ\1740 and\CC\1740 neurochemical\JJ\1740 studies\NNS\635850 in\IN\13603305 mice\NNS\2329401 pretreated\VBN\1740 with\IN\1740 <e1>garcinielliptone\NN\1740 FC</e1>\NN\1740 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
C573355_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 <e1>GFC</e1>\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
C573355_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 <e1>GFC</e1>\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
C573355_D012640 NONE <e1>GFC</e1>\NN\1740 produced\VBD\1617192 an\DT\6697703 increased\VBN\169651 latency\NN\15269513 to\TO\1740 first\RB\1740 <e2>seizure</e2>\VB\1740 ,\,\1740 at\IN\14622893 doses\NNS\3740161 25mg/kg\NN\1740 (\-LRB-\1740 20.12\CD\1740 +\CC\1740 2.20\CD\1740 min\NN\15154774 )\-RRB-\1740 ,\,\1740 50mg/kg\NN\1740 (\-LRB-\1740 20.95\CD\1740 +\CC\1740 2.21\CD\1740 min\NN\15154774 )\-RRB-\1740 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 (\-LRB-\1740 23.43\CD\1740 +\CC\1740 1.99\CD\1740 min\NN\15154774 )\-RRB-\1740 when\WRB\1740 compared\VBN\644583 with\IN\1740 seized\JJ\1740 mice\NNS\2329401 .\.\1740
C573355_D012640 NONE The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>GFC</e1>\NN\1740 can\MD\3094503 exert\VB\1158872 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 reduce\VB\441445 the\DT\1740 frequency\NN\15286249 of\IN\1740 installation\NN\235435 of\IN\1740 pilocarpine-induced\JJ\1740 status\NN\24720 epilepticus\NN\1740 ,\,\1740 as\IN\14622893 demonstrated\VBN\2137132 by\IN\1740 increase\NN\13576355 in\IN\13603305 latency\NN\15269513 to\TO\1740 first\RB\1740 <e2>seizure</e2>\VB\1740 and\CC\1740 decrease\VB\169651 in\IN\13603305 mortality\NN\5054863 rate\NN\13815152 of\IN\1740 animals\NNS\4475 .\.\1740
D010862_D012640 CID Behavioral\JJ\1740 and\CC\1740 neurochemical\JJ\1740 studies\NNS\635850 in\IN\13603305 mice\NNS\2329401 pretreated\VBN\1740 with\IN\1740 garcinielliptone\NN\1740 FC\NN\1740 in\IN\13603305 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 GFC\NN\1740 can\MD\3094503 exert\VB\1158872 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 reduce\VB\441445 the\DT\1740 frequency\NN\15286249 of\IN\1740 installation\NN\235435 of\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 status\NN\24720 epilepticus\NN\1740 ,\,\1740 as\IN\14622893 demonstrated\VBN\2137132 by\IN\1740 increase\NN\13576355 in\IN\13603305 latency\NN\15269513 to\TO\1740 first\RB\1740 <e2>seizure</e2>\VB\1740 and\CC\1740 decrease\VB\169651 in\IN\13603305 mortality\NN\5054863 rate\NN\13815152 of\IN\1740 animals\NNS\4475 .\.\1740
D000596_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
D000596_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D005680_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 <e1>r-aminobutyric\NN\1740 acid</e1>\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
D005680_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 <e1>r-aminobutyric\NN\1740 acid</e1>\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D005680_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 <e1>GABA</e1>\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
D005680_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 <e1>GABA</e1>\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D018698_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 <e1>glutamine</e1>\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
D018698_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 <e1>glutamine</e1>\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D001224_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 <e1>aspartate</e1>\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
D001224_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 <e1>aspartate</e1>\NN\1740 and\CC\1740 glutathione\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D005978_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 <e2>seizure</e2>\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 <e1>glutathione</e1>\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 seizures\NNS\14081375 .\.\1740
D005978_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 GFC\NN\1740 effects\NNS\13245626 at\IN\14622893 doses\NNS\3740161 of\IN\1740 25\CD\13745420 ,\,\1740 50\CD\13745420 or\CC\3541091 75\CD\1740 mg/kg\NN\1740 on\IN\1740 seizure\JJ\1740 parameters\NNS\5858936 to\TO\1740 determine\VB\1645601 their\PRP$\1740 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 its\PRP$\6125041 effects\NNS\13245626 on\IN\1740 amino\NN\14621446 acid\NN\14818238 (\-LRB-\1740 r-aminobutyric\NN\1740 acid\NN\14818238 (\-LRB-\1740 GABA\NN\14601829 )\-RRB-\1740 ,\,\1740 glutamine\NN\14601829 ,\,\1740 aspartate\NN\1740 and\CC\1740 <e1>glutathione</e1>\NN\1740 )\-RRB-\1740 levels\NNS\4916342 as\RB\1740 well\RB\1740 as\IN\14622893 on\IN\1740 acetylcholinesterase\NN\1740 (\-LRB-\1740 AChE\NN\14322699 )\-RRB-\1740 activity\NN\30358 in\IN\13603305 mice\NNS\2329401 hippocampus\NN\5462674 after\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
C573355_D013226 NONE The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>GFC</e1>\NN\1740 can\MD\3094503 exert\VB\1158872 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 reduce\VB\441445 the\DT\1740 frequency\NN\15286249 of\IN\1740 installation\NN\235435 of\IN\1740 pilocarpine-induced\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 ,\,\1740 as\IN\14622893 demonstrated\VBN\2137132 by\IN\1740 increase\NN\13576355 in\IN\13603305 latency\NN\15269513 to\TO\1740 first\RB\1740 seizure\VB\1740 and\CC\1740 decrease\VB\169651 in\IN\13603305 mortality\NN\5054863 rate\NN\13815152 of\IN\1740 animals\NNS\4475 .\.\1740
D010862_D013226 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 GFC\NN\1740 can\MD\3094503 exert\VB\1158872 anticonvulsant\JJ\1740 activity\NN\30358 and\CC\1740 reduce\VB\441445 the\DT\1740 frequency\NN\15286249 of\IN\1740 installation\NN\235435 of\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 ,\,\1740 as\IN\14622893 demonstrated\VBN\2137132 by\IN\1740 increase\NN\13576355 in\IN\13603305 latency\NN\15269513 to\TO\1740 first\RB\1740 seizure\VB\1740 and\CC\1740 decrease\VB\169651 in\IN\13603305 mortality\NN\5054863 rate\NN\13815152 of\IN\1740 animals\NNS\4475 .\.\1740
1905439
D016595_D003693 CID <e2>Delirium</e2>\NN\14391660 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 woman\NN\9605289 possibly\RB\1740 associated\VBN\628491 with\IN\1740 administration\NN\1133281 of\IN\1740 <e1>misoprostol</e1>\NN\1740 .\.\1740
D016595_D003693 CID Her\PRP$\1740 <e2>delirium</e2>\NN\14391660 significantly\RB\1740 improved\VBD\126264 after\IN\1740 <e1>misoprostol</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 and\CC\1740 her\PRP$\1740 mental\JJ\1740 status\NN\24720 returned\VBD\1835496 to\TO\1740 normal\JJ\1740 within\IN\1740 a\DT\13649268 week\NN\15113229 .\.\1740
D016595_D003693 CID Because\IN\1740 no\DT\7204911 other\JJ\1740 factors\NNS\7326557 related\JJ\1740 to\TO\1740 this\DT\1740 patient\NN\9898892 changed\VBD\46534 significantly\RB\1740 ,\,\1740 the\DT\1740 <e2>delirium</e2>\NN\14391660 experienced\VBN\2108377 by\IN\1740 this\DT\1740 patient\NN\9898892 possibly\RB\1740 resulted\VBD\2633881 from\IN\1740 <e1>misoprostol</e1>\NN\1740 therapy\NN\657604 .\.\1740
D016595_D006261 NONE <e1>Misoprostol</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 adverse\JJ\1740 reactions\NNS\13446390 ,\,\1740 including\VBG\690614 gastrointestinal\JJ\1740 symptoms\NNS\5823932 ,\,\1740 gynecologic\JJ\1740 problems\NNS\14408086 ,\,\1740 and\CC\1740 <e2>headache</e2>\VB\1740 .\.\1740
12059909
D003520_D064420 NONE Delayed\VBN\439958 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 on\IN\1740 the\DT\1740 bladder\NN\5515670 of\IN\1740 DBA/2\NN\1740 and\CC\1740 C57BL/6\NN\1740 female\JJ\1740 mouse\NN\2329401 .\.\1740
D003520_D064420 NONE Early\JJ\1740 <e1>CY</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 caused\VBD\1617192 a\DT\13649268 typical\JJ\1740 haemorrhagic\JJ\1740 cystitis\NN\14566129 in\IN\13603305 both\DT\1740 strains\NNS\7358060 that\WDT\1740 was\VBD\836236 completely\RB\1740 repaired\VBN\205885 in\IN\13603305 about\RB\1740 7\CD\13741022 -\SYM\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D003520_D064420 NONE These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 delayed\VBN\439958 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>CY</e1>\NN\1740 in\IN\13603305 female\JJ\1740 DBA/2\NN\1740 mice\NNS\2329401 causes\VBZ\1617192 a\DT\13649268 bladder\NN\5515670 pathology\NN\6045562 that\WDT\1740 is\VBZ\836236 not\RB\1740 observed\VBN\2163746 in\IN\13603305 C57BL/6\NN\1740 mice\NNS\2329401 .\.\1740
D003520_D006470 CID Early\JJ\1740 <e1>CY</e1>\NN\1740 toxicity\NN\13576101 caused\VBD\1617192 a\DT\13649268 typical\JJ\1740 <e2>haemorrhagic</e2>\JJ\1740 cystitis\NN\14566129 in\IN\13603305 both\DT\1740 strains\NNS\7358060 that\WDT\1740 was\VBD\836236 completely\RB\1740 repaired\VBN\205885 in\IN\13603305 about\RB\1740 7\CD\13741022 -\SYM\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D003520_D003556 CID Early\JJ\1740 <e1>CY</e1>\NN\1740 toxicity\NN\13576101 caused\VBD\1617192 a\DT\13649268 typical\JJ\1740 haemorrhagic\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 both\DT\1740 strains\NNS\7358060 that\WDT\1740 was\VBD\836236 completely\RB\1740 repaired\VBN\205885 in\IN\13603305 about\RB\1740 7\CD\13741022 -\SYM\1740 10\CD\13745420 days\NNS\15140892 .\.\1740
D003520_D003556 CID After\IN\1740 30\CD\13745420 days\NNS\15140892 of\IN\1740 <e1>CY</e1>\NN\1740 injection\NN\320852 ulcerous\JJ\1740 and\CC\1740 non-ulcerous\JJ\1740 forms\NNS\6286395 of\IN\1740 chronic\JJ\1740 <e2>cystitis</e2>\NN\14566129 appeared\VBD\2604760 in\IN\13603305 86\CD\1740 %\NN\1740 of\IN\1740 DBA/2\NN\1740 mice\NNS\2329401 but\CC\1740 only\RB\1740 in\IN\13603305 4\CD\13741022 %\NN\1740 of\IN\1740 C57BL/6\NN\1740 mice\NNS\2329401 .\.\1740
26002693
C031763_D015464 NONE <e1>1,3-Butadiene</e1>\NN\1740 ,\,\1740 <e2>CML</e2>\NN\1740 and\CC\1740 the\DT\1740 t(9:22\NN\1740 )\-RRB-\1740 translocation\NN\13526110 :\:\1740 A\DT\13649268 reality\NN\5984584 check\VBP\644583 .\.\1740
C031763_D015464 NONE UNASSIGNED\NNS\1740 :\:\1740 Epidemiological\JJ\1740 studies\NNS\635850 of\IN\1740 <e1>1,3-butadiene</e1>\NN\1740 have\VBP\2108377 suggest\VBP\1010118 that\IN\1740 exposures\NNS\5042871 to\TO\1740 humans\NNS\31264 are\VBP\836236 associated\VBN\628491 with\IN\1740 <e2>chronic\JJ\1740 myeloid\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 CML\NN\1740 )\-RRB-\1740 .\.\1740
C031763_D015464 NONE UNASSIGNED\NNS\1740 :\:\1740 Epidemiological\JJ\1740 studies\NNS\635850 of\IN\1740 <e1>1,3-butadiene</e1>\NN\1740 have\VBP\2108377 suggest\VBP\1010118 that\IN\1740 exposures\NNS\5042871 to\TO\1740 humans\NNS\31264 are\VBP\836236 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 myeloid\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>CML</e2>\NN\1740 )\-RRB-\1740 .\.\1740
3289726
D005047_D009422 NONE <e2>Acute\JJ\1740 neurologic\JJ\1740 dysfunction</e2>\NN\14204950 after\IN\1740 high-dose\JJ\1740 <e1>etoposide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 malignant\JJ\1740 glioma\NN\14236743 .\.\1740
D005047_D005910 NONE Acute\JJ\1740 neurologic\JJ\1740 dysfunction\NN\14204950 after\IN\1740 high-dose\JJ\1740 <e1>etoposide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 <e2>malignant\JJ\1740 glioma</e2>\NN\14236743 .\.\1740
D005047_D005910 NONE This\DT\1740 complication\NN\1073995 appears\VBZ\2604760 to\TO\1740 represent\VB\2664769 a\DT\13649268 significant\JJ\1740 new\JJ\1740 toxicity\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>etoposide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 <e2>malignant\JJ\1740 glioma</e2>\NN\14236743 .\.\1740
D005047_D009369 NONE <e1>Etoposide</e1>\NN\1740 (\-LRB-\1740 VP-16\NN\1740 -\HYPH\1740 213\CD\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 and\CC\1740 hematologic\JJ\1740 malignancies\NNS\14070360 .\.\1740
D005047_D009369 NONE Etoposide\NN\1740 (\-LRB-\1740 <e1>VP-16\NN\1740 -\HYPH\1740 213</e1>\CD\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 and\CC\1740 hematologic\JJ\1740 malignancies\NNS\14070360 .\.\1740
D005047_D019337 NONE <e1>Etoposide</e1>\NN\1740 (\-LRB-\1740 VP-16\NN\1740 -\HYPH\1740 213\CD\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 and\CC\1740 <e2>hematologic\JJ\1740 malignancies</e2>\NNS\14070360 .\.\1740
D005047_D019337 NONE Etoposide\NN\1740 (\-LRB-\1740 <e1>VP-16\NN\1740 -\HYPH\1740 213</e1>\CD\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 many\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 and\CC\1740 <e2>hematologic\JJ\1740 malignancies</e2>\NNS\14070360 .\.\1740
D005047_D064420 NONE This\DT\1740 complication\NN\1073995 appears\VBZ\2604760 to\TO\1740 represent\VB\2664769 a\DT\13649268 significant\JJ\1740 new\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 high-dose\JJ\1740 <e1>etoposide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 malignant\JJ\1740 glioma\NN\14236743 .\.\1740
1615846
D015248_D006951 NONE <e1>Gemfibrozil-lovastatin</e1>\JJ\1740 therapy\NN\657604 for\IN\1740 primary\JJ\1740 <e2>hyperlipoproteinemias</e2>\NNS\14084502 .\.\1740
D008148_D006951 NONE <e1>Gemfibrozil-lovastatin</e1>\JJ\1740 therapy\NN\657604 for\IN\1740 primary\JJ\1740 <e2>hyperlipoproteinemias</e2>\NNS\14084502 .\.\1740
D015248_D006949 NONE The\DT\1740 specific\JJ\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 retrospective\JJ\1740 ,\,\1740 observational\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 long-term\JJ\1740 (\-LRB-\1740 21\CD\13745420 months/patient\JJ\1740 )\-RRB-\1740 ,\,\1740 open-label\RB\1740 ,\,\1740 <e1>gemfibrozil-lovastatin</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 80\CD\13745420 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 mixed\JJ\1740 <e2>hyperlipidemia</e2>\NN\14299637 (\-LRB-\1740 68\CD\1740 %\NN\1740 of\IN\1740 whom\WP\1740 had\VBD\2108377 atherosclerotic\JJ\1740 vascular\JJ\1740 disease\NN\14061805 )\-RRB-\1740 .\.\1740
D015248_D002340 NONE The\DT\1740 specific\JJ\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 retrospective\JJ\1740 ,\,\1740 observational\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 long-term\JJ\1740 (\-LRB-\1740 21\CD\13745420 months/patient\JJ\1740 )\-RRB-\1740 ,\,\1740 open-label\RB\1740 ,\,\1740 <e1>gemfibrozil-lovastatin</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 80\CD\13745420 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 mixed\JJ\1740 hyperlipidemia\NN\14299637 (\-LRB-\1740 68\CD\1740 %\NN\1740 of\IN\1740 whom\WP\1740 had\VBD\2108377 <e2>atherosclerotic\JJ\1740 vascular\JJ\1740 disease</e2>\NN\14061805 )\-RRB-\1740 .\.\1740
D008148_D006949 NONE The\DT\1740 specific\JJ\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 retrospective\JJ\1740 ,\,\1740 observational\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 long-term\JJ\1740 (\-LRB-\1740 21\CD\13745420 months/patient\JJ\1740 )\-RRB-\1740 ,\,\1740 open-label\RB\1740 ,\,\1740 <e1>gemfibrozil-lovastatin</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 80\CD\13745420 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 mixed\JJ\1740 <e2>hyperlipidemia</e2>\NN\14299637 (\-LRB-\1740 68\CD\1740 %\NN\1740 of\IN\1740 whom\WP\1740 had\VBD\2108377 atherosclerotic\JJ\1740 vascular\JJ\1740 disease\NN\14061805 )\-RRB-\1740 .\.\1740
D008148_D002340 NONE The\DT\1740 specific\JJ\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 retrospective\JJ\1740 ,\,\1740 observational\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 long-term\JJ\1740 (\-LRB-\1740 21\CD\13745420 months/patient\JJ\1740 )\-RRB-\1740 ,\,\1740 open-label\RB\1740 ,\,\1740 <e1>gemfibrozil-lovastatin</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 80\CD\13745420 patients\NNS\9898892 with\IN\1740 primary\JJ\1740 mixed\JJ\1740 hyperlipidemia\NN\14299637 (\-LRB-\1740 68\CD\1740 %\NN\1740 of\IN\1740 whom\WP\1740 had\VBD\2108377 <e2>atherosclerotic\JJ\1740 vascular\JJ\1740 disease</e2>\NN\14061805 )\-RRB-\1740 .\.\1740
D003401_D009220 NONE <e2>Myositis</e2>\NNP\14336539 ,\,\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 drug\NN\14778436 combination\NN\7951464 and\CC\1740 symptomatic\JJ\1740 enough\RB\1740 to\TO\1740 discontinue\VB\2609764 it\PRP\6125041 ,\,\1740 occurred\VBD\2623529 in\IN\13603305 3\CD\13741022 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 in\IN\13603305 1\CD\13741022 %\NN\1740 with\IN\1740 concurrent\JJ\1740 high\JJ\1740 <e1>creatine</e1>\NN\14601829 phosphokinase\NN\1740 (\-LRB-\1740 769\CD\1740 U/liter\NN\1740 )\-RRB-\1740 ;\:\1740 no\DT\7204911 patients\NNS\9898892 had\VBD\2108377 rhabdomyolysis\NN\1740 or\CC\3541091 myoglobinuria\NNS\14299637 .\.\1740
D003401_D012206 NONE Myositis\NNP\14336539 ,\,\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 drug\NN\14778436 combination\NN\7951464 and\CC\1740 symptomatic\JJ\1740 enough\RB\1740 to\TO\1740 discontinue\VB\2609764 it\PRP\6125041 ,\,\1740 occurred\VBD\2623529 in\IN\13603305 3\CD\13741022 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 in\IN\13603305 1\CD\13741022 %\NN\1740 with\IN\1740 concurrent\JJ\1740 high\JJ\1740 <e1>creatine</e1>\NN\14601829 phosphokinase\NN\1740 (\-LRB-\1740 769\CD\1740 U/liter\NN\1740 )\-RRB-\1740 ;\:\1740 no\DT\7204911 patients\NNS\9898892 had\VBD\2108377 <e2>rhabdomyolysis</e2>\NN\1740 or\CC\3541091 myoglobinuria\NNS\14299637 .\.\1740
D003401_D009212 NONE Myositis\NNP\14336539 ,\,\1740 attributable\JJ\1740 to\TO\1740 the\DT\1740 drug\NN\14778436 combination\NN\7951464 and\CC\1740 symptomatic\JJ\1740 enough\RB\1740 to\TO\1740 discontinue\VB\2609764 it\PRP\6125041 ,\,\1740 occurred\VBD\2623529 in\IN\13603305 3\CD\13741022 %\NN\1740 of\IN\1740 patients\NNS\9898892 ,\,\1740 and\CC\1740 in\IN\13603305 1\CD\13741022 %\NN\1740 with\IN\1740 concurrent\JJ\1740 high\JJ\1740 <e1>creatine</e1>\NN\14601829 phosphokinase\NN\1740 (\-LRB-\1740 769\CD\1740 U/liter\NN\1740 )\-RRB-\1740 ;\:\1740 no\DT\7204911 patients\NNS\9898892 had\VBD\2108377 rhabdomyolysis\NN\1740 or\CC\3541091 <e2>myoglobinuria</e2>\NNS\14299637 .\.\1740
17384765
D004113_D003072 CID <e1>Succimer</e1>\NN\1740 chelation\NN\29677 improves\NNS\1740 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation\NN\6652242 in\IN\13603305 lead-exposed\JJ\1740 rats\NNS\2329401 but\CC\1740 produces\VBZ\1617192 lasting\VBG\2704349 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 lead\JJ\1740 exposure\NN\5042871 .\.\1740
D004113_D003072 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>succimer</e1>\NN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 not\RB\1740 previously\RB\1740 exposed\VBN\2110927 to\TO\1740 Pb\NN\14625458 produced\VBN\1617192 lasting\NN\1740 and\CC\1740 pervasive\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 affective\JJ\1740 dysfunction</e2>\NN\14204950 comparable\JJ\1740 in\IN\13603305 magnitude\NN\4916342 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 higher\JJR\1740 Pb\NN\14625458 exposure\NN\5042871 regimen\NN\5898568 .\.\1740
D007854_D003072 NONE Succimer\NN\1740 chelation\NN\29677 improves\NNS\1740 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation\NN\6652242 in\IN\13603305 <e1>lead-exposed</e1>\JJ\1740 rats\NNS\2329401 but\CC\1740 produces\VBZ\1617192 lasting\VBG\2704349 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 lead\JJ\1740 exposure\NN\5042871 .\.\1740
D007854_D003072 NONE Succimer\NN\1740 chelation\NN\29677 improves\NNS\1740 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation\NN\6652242 in\IN\13603305 lead-exposed\JJ\1740 rats\NNS\2329401 but\CC\1740 produces\VBZ\1617192 lasting\VBG\2704349 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>lead</e1>\JJ\1740 exposure\NN\5042871 .\.\1740
D007854_D003072 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 succimer\NN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 not\RB\1740 previously\RB\1740 exposed\VBN\2110927 to\TO\1740 <e1>Pb</e1>\NN\14625458 produced\VBN\1617192 lasting\NN\1740 and\CC\1740 pervasive\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 affective\JJ\1740 dysfunction</e2>\NN\14204950 comparable\JJ\1740 in\IN\13603305 magnitude\NN\4916342 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 higher\JJR\1740 Pb\NN\14625458 exposure\NN\5042871 regimen\NN\5898568 .\.\1740
D007854_D003072 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 succimer\NN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 not\RB\1740 previously\RB\1740 exposed\VBN\2110927 to\TO\1740 Pb\NN\14625458 produced\VBN\1617192 lasting\NN\1740 and\CC\1740 pervasive\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 affective\JJ\1740 dysfunction</e2>\NN\14204950 comparable\JJ\1740 in\IN\13603305 magnitude\NN\4916342 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 higher\JJR\1740 <e1>Pb</e1>\NN\14625458 exposure\NN\5042871 regimen\NN\5898568 .\.\1740
D007854_D003072 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 are\VBP\836236 the\DT\1740 first\JJ\1740 data\NNS\7951464 ,\,\1740 to\TO\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 to\TO\1740 show\VB\2137132 that\IN\1740 treatment\NN\654885 with\IN\1740 any\DT\1740 chelating\VBG\2621395 agent\NN\7347 can\MD\3094503 alleviate\VB\205885 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 due\JJ\1740 to\TO\1740 <e1>Pb</e1>\NN\14625458 exposure\NN\5042871 .\.\1740
D007854_D007855 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 answer\VB\1009240 these\DT\1740 questions\NNS\7193184 ,\,\1740 using\VBG\1156834 a\DT\13649268 rodent\JJ\1740 model\NN\5888929 of\IN\1740 early\JJ\1740 childhood\NN\15144371 <e1>Pb</e1>\NN\14625458 exposure\NN\5042871 and\CC\1740 treatment\NN\654885 with\IN\1740 succimer\NN\1740 ,\,\1740 a\DT\13649268 widely\RB\1740 used\VBN\1156834 chelating\VBG\2621395 agent\NN\7347 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Pb\NN\14625458 poisoning</e2>\NN\14034177 .\.\1740
D004113_D007855 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 answer\VB\1009240 these\DT\1740 questions\NNS\7193184 ,\,\1740 using\VBG\1156834 a\DT\13649268 rodent\JJ\1740 model\NN\5888929 of\IN\1740 early\JJ\1740 childhood\NN\15144371 Pb\NN\14625458 exposure\NN\5042871 and\CC\1740 treatment\NN\654885 with\IN\1740 <e1>succimer</e1>\NN\1740 ,\,\1740 a\DT\13649268 widely\RB\1740 used\VBN\1156834 chelating\VBG\2621395 agent\NN\7347 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Pb\NN\14625458 poisoning</e2>\NN\14034177 .\.\1740
D007854_D007859 CID RESULTS\NNS\34213 :\:\1740 <e1>Pb</e1>\NN\14625458 exposure\NN\5042871 produced\VBD\1617192 lasting\VBG\2704349 <e2>impairments\NNS\7296428 in\IN\13603305 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 inhibitory\JJ\1740 control\NN\5190804 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation</e2>\NN\6652242 ,\,\1740 paralleling\VBG\2657219 the\DT\1740 areas\NNS\8630985 of\IN\1740 dysfunction\NN\14204950 seen\VBN\2106506 in\IN\13603305 Pb-exposed\JJ\1740 children\NNS\9622049 .\.\1740
D007854_D007859 CID RESULTS\NNS\34213 :\:\1740 Pb\NN\14625458 exposure\NN\5042871 produced\VBD\1617192 lasting\VBG\2704349 <e2>impairments\NNS\7296428 in\IN\13603305 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 inhibitory\JJ\1740 control\NN\5190804 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation</e2>\NN\6652242 ,\,\1740 paralleling\VBG\2657219 the\DT\1740 areas\NNS\8630985 of\IN\1740 dysfunction\NN\14204950 seen\VBN\2106506 in\IN\13603305 <e1>Pb-exposed</e1>\JJ\1740 children\NNS\9622049 .\.\1740
D007854_D019958 CID RESULTS\NNS\34213 :\:\1740 <e1>Pb</e1>\NN\14625458 exposure\NN\5042871 produced\VBD\1617192 lasting\VBG\2704349 <e2>impairments\NNS\7296428 in\IN\13603305 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 inhibitory\JJ\1740 control\NN\5190804 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation</e2>\NN\6652242 ,\,\1740 paralleling\VBG\2657219 the\DT\1740 areas\NNS\8630985 of\IN\1740 dysfunction\NN\14204950 seen\VBN\2106506 in\IN\13603305 Pb-exposed\JJ\1740 children\NNS\9622049 .\.\1740
D007854_D019958 CID RESULTS\NNS\34213 :\:\1740 Pb\NN\14625458 exposure\NN\5042871 produced\VBD\1617192 lasting\VBG\2704349 <e2>impairments\NNS\7296428 in\IN\13603305 learning\NN\5701944 ,\,\1740 attention\NN\5701944 ,\,\1740 inhibitory\JJ\1740 control\NN\5190804 ,\,\1740 and\CC\1740 arousal\JJ\1740 regulation</e2>\NN\6652242 ,\,\1740 paralleling\VBG\2657219 the\DT\1740 areas\NNS\8630985 of\IN\1740 dysfunction\NN\14204950 seen\VBN\2106506 in\IN\13603305 <e1>Pb-exposed</e1>\JJ\1740 children\NNS\9622049 .\.\1740
D004113_D019964 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>succimer</e1>\NN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 not\RB\1740 previously\RB\1740 exposed\VBN\2110927 to\TO\1740 Pb\NN\14625458 produced\VBN\1617192 lasting\NN\1740 and\CC\1740 pervasive\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 affective\JJ\1740 dysfunction</e2>\NN\14204950 comparable\JJ\1740 in\IN\13603305 magnitude\NN\4916342 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 higher\JJR\1740 Pb\NN\14625458 exposure\NN\5042871 regimen\NN\5898568 .\.\1740
D007854_D019964 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 succimer\NN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 not\RB\1740 previously\RB\1740 exposed\VBN\2110927 to\TO\1740 <e1>Pb</e1>\NN\14625458 produced\VBN\1617192 lasting\NN\1740 and\CC\1740 pervasive\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 affective\JJ\1740 dysfunction</e2>\NN\14204950 comparable\JJ\1740 in\IN\13603305 magnitude\NN\4916342 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 higher\JJR\1740 Pb\NN\14625458 exposure\NN\5042871 regimen\NN\5898568 .\.\1740
D007854_D019964 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 succimer\NN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 not\RB\1740 previously\RB\1740 exposed\VBN\2110927 to\TO\1740 Pb\NN\14625458 produced\VBN\1617192 lasting\NN\1740 and\CC\1740 pervasive\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 affective\JJ\1740 dysfunction</e2>\NN\14204950 comparable\JJ\1740 in\IN\13603305 magnitude\NN\4916342 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 the\DT\1740 higher\JJR\1740 <e1>Pb</e1>\NN\14625458 exposure\NN\5042871 regimen\NN\5898568 .\.\1740
15625689
D007980_D010300 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 characterize\VB\609683 the\DT\1740 oropharyngeal\NN\1740 dynamics\NNS\6100236 in\IN\13603305 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesia\NN\14084880 .\.\1740
D007980_D010300 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 a\DT\13649268 role\NN\719494 for\IN\1740 <e1>levodopa</e1>\NN\14604959 in\IN\13603305 the\DT\1740 oral\JJ\1740 phase\NN\15113229 of\IN\1740 deglutition\NN\838098 and\CC\1740 confirm\VBP\1011725 that\IN\1740 dysphagia\NN\14052403 is\VBZ\836236 not\RB\1740 a\DT\13649268 good\JJ\1740 predictor\NN\10756433 of\IN\1740 deglutition\NN\838098 alterations\NNS\7283608 in\IN\13603305 <e2>PD</e2>\NN\14625458 .\.\1740
D007980_D004409 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 characterize\VB\609683 the\DT\1740 oropharyngeal\NN\1740 dynamics\NNS\6100236 in\IN\13603305 PD\NN\14625458 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D007980_D004409 CID In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 <e2>dyskinetic</e2>\JJ\1740 patients\NNS\9898892 performed\VBN\2367363 better\RBR\1740 in\IN\13603305 swallowing\VBG\1156834 function\NN\13783581 ,\,\1740 which\WDT\1740 could\MD\1740 be\VB\836236 explained\VBN\831651 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 a\DT\13649268 greater\JJR\1740 <e1>levodopa</e1>\NN\14604959 dose\NN\3740161 .\.\1740
D007980_D003680 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 a\DT\13649268 role\NN\719494 for\IN\1740 <e1>levodopa</e1>\NN\14604959 in\IN\13603305 the\DT\1740 oral\JJ\1740 phase\NN\15113229 of\IN\1740 deglutition\NN\838098 and\CC\1740 confirm\VBP\1011725 that\IN\1740 <e2>dysphagia</e2>\NN\14052403 is\VBZ\836236 not\RB\1740 a\DT\13649268 good\JJ\1740 predictor\NN\10756433 of\IN\1740 deglutition\NN\838098 alterations\NNS\7283608 in\IN\13603305 PD\NN\14625458 .\.\1740
448423
D000614_D013345 NONE Recurrent\JJ\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 associated\VBN\628491 with\IN\1740 <e1>aminocaproic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 and\CC\1740 acute\JJ\1740 renal\JJ\1740 artery\NN\5417975 thrombosis\NN\14100769 .\.\1740
D000614_D007674 NONE Recurrent\JJ\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 associated\VBN\628491 with\IN\1740 <e1>aminocaproic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 artery\NN\5417975 thrombosis</e2>\NN\14100769 .\.\1740
D015119_D013345 CID <e1>Epsilon\NN\6828818 aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 to\TO\1740 prevent\VB\1740 rebleeding\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 .\.\1740
D015119_D013345 CID <e1>Epsilon\NN\6828818 aminocaproic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 EACA\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 to\TO\1740 prevent\VB\1740 rebleeding\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D015119_D013345 CID Epsilon\NN\6828818 aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 to\TO\1740 prevent\VB\1740 rebleeding\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>subarachnoid\JJ\1740 hemorrhage</e2>\NN\14285662 (\-LRB-\1740 SAH\NN\1740 )\-RRB-\1740 .\.\1740
D015119_D013345 CID Epsilon\NN\6828818 aminocaproic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>EACA</e1>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 to\TO\1740 prevent\VB\1740 rebleeding\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 subarachnoid\JJ\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>SAH</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D015119_D013345 CID These\DT\1740 complications\NNS\1073995 have\VBP\2108377 included\VBN\690614 clinical\JJ\1740 deterioration\NN\14560612 and\CC\1740 intracranial\JJ\1740 vascular\JJ\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>SAH</e2>\NN\1740 ,\,\1740 arteriolar\JJ\1740 and\CC\1740 capillary\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 syndromes\NNS\5870365 treated\VBN\2376958 with\IN\1740 <e1>EACA</e1>\NN\1740 ,\,\1740 or\CC\3541091 other\JJ\1740 thromboembolic\NN\1740 phenomena\NNS\29677 .\.\1740
D015119_D013345 CID This\DT\1740 occlusion\NN\14081375 occurred\VBD\2623529 after\IN\1740 <e1>EACA</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>SAH</e2>\NN\1740 and\CC\1740 histopathological\JJ\1740 documentation\NN\6650070 of\IN\1740 recurrent\JJ\1740 SAH\NN\1740 .\.\1740
D015119_D013345 CID This\DT\1740 occlusion\NN\14081375 occurred\VBD\2623529 after\IN\1740 <e1>EACA</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 SAH\NN\1740 and\CC\1740 histopathological\JJ\1740 documentation\NN\6650070 of\IN\1740 recurrent\JJ\1740 <e2>SAH</e2>\NN\1740 .\.\1740
D015119_D013927 CID Although\IN\1740 this\DT\1740 agent\NN\7347 does\VBZ\1640855 decrease\VB\169651 the\DT\1740 frequency\NN\15286249 of\IN\1740 rebleeding\NN\1740 ,\,\1740 several\JJ\1740 reports\NNS\6470073 have\VBP\2108377 described\VBN\1001294 <e2>thrombotic</e2>\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>EACA</e1>\NN\1740 therapy\NN\657604 .\.\1740
D015119_D013927 CID These\DT\1740 complications\NNS\1073995 have\VBP\2108377 included\VBN\690614 clinical\JJ\1740 deterioration\NN\14560612 and\CC\1740 intracranial\JJ\1740 vascular\JJ\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 SAH\NN\1740 ,\,\1740 arteriolar\JJ\1740 and\CC\1740 capillary\JJ\1740 fibrin\NN\14728724 <e2>thrombi</e2>\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 syndromes\NNS\5870365 treated\VBN\2376958 with\IN\1740 <e1>EACA</e1>\NN\1740 ,\,\1740 or\CC\3541091 other\JJ\1740 thromboembolic\NN\1740 phenomena\NNS\29677 .\.\1740
D015119_D013927 CID Since\IN\1740 intravascular\JJ\1740 fibrin\NN\14728724 <e2>thrombi</e2>\NN\5402091 are\VBP\836236 often\RB\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e1>EACA</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 disseminated\JJ\1740 intravascular\JJ\1740 coagulation\NN\13518963 or\CC\3541091 other\JJ\1740 "\``\1740 consumption\NN\13440063 coagulopathies\NNS\1740 .\.\1740 "\''\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 subtotal\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 kidney\NN\5333259 due\IN\5174653 to\TO\1740 thrombosis\NN\14100769 of\IN\1740 a\DT\13649268 normal\JJ\1740 renal\JJ\1740 artery\NN\5417975 .\.\1740
D015119_D013927 CID Since\IN\1740 intravascular\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 are\VBP\836236 often\RB\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e1>EACA</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 fibrin\NN\14728724 <e2>thrombi</e2>\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 disseminated\JJ\1740 intravascular\JJ\1740 coagulation\NN\13518963 or\CC\3541091 other\JJ\1740 "\``\1740 consumption\NN\13440063 coagulopathies\NNS\1740 .\.\1740 "\''\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 subtotal\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 kidney\NN\5333259 due\IN\5174653 to\TO\1740 thrombosis\NN\14100769 of\IN\1740 a\DT\13649268 normal\JJ\1740 renal\JJ\1740 artery\NN\5417975 .\.\1740
D015119_D020767 CID These\DT\1740 complications\NNS\1073995 have\VBP\2108377 included\VBN\690614 clinical\JJ\1740 deterioration\NN\14560612 and\CC\1740 <e2>intracranial\JJ\1740 vascular\JJ\1740 thrombosis</e2>\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 SAH\NN\1740 ,\,\1740 arteriolar\JJ\1740 and\CC\1740 capillary\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 syndromes\NNS\5870365 treated\VBN\2376958 with\IN\1740 <e1>EACA</e1>\NN\1740 ,\,\1740 or\CC\3541091 other\JJ\1740 thromboembolic\NN\1740 phenomena\NNS\29677 .\.\1740
D015119_D013923 NONE These\DT\1740 complications\NNS\1073995 have\VBP\2108377 included\VBN\690614 clinical\JJ\1740 deterioration\NN\14560612 and\CC\1740 intracranial\JJ\1740 vascular\JJ\1740 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 SAH\NN\1740 ,\,\1740 arteriolar\JJ\1740 and\CC\1740 capillary\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 syndromes\NNS\5870365 treated\VBN\2376958 with\IN\1740 <e1>EACA</e1>\NN\1740 ,\,\1740 or\CC\3541091 other\JJ\1740 <e2>thromboembolic\NN\1740 phenomena</e2>\NNS\29677 .\.\1740
D015119_D004211 NONE Since\IN\1740 intravascular\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 are\VBP\836236 often\RB\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e1>EACA</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>disseminated\JJ\1740 intravascular\JJ\1740 coagulation</e2>\NN\13518963 or\CC\3541091 other\JJ\1740 "\``\1740 consumption\NN\13440063 coagulopathies\NNS\1740 .\.\1740 "\''\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 subtotal\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 kidney\NN\5333259 due\IN\5174653 to\TO\1740 thrombosis\NN\14100769 of\IN\1740 a\DT\13649268 normal\JJ\1740 renal\JJ\1740 artery\NN\5417975 .\.\1740
D015119_D004211 NONE Since\IN\1740 intravascular\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 are\VBP\836236 often\RB\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e1>EACA</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 disseminated\JJ\1740 intravascular\JJ\1740 coagulation\NN\13518963 or\CC\3541091 other\JJ\1740 "\``\1740 <e2>consumption\NN\13440063 coagulopathies</e2>\NNS\1740 .\.\1740 "\''\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 subtotal\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 kidney\NN\5333259 due\IN\5174653 to\TO\1740 thrombosis\NN\14100769 of\IN\1740 a\DT\13649268 normal\JJ\1740 renal\JJ\1740 artery\NN\5417975 .\.\1740
D015119_D007238 NONE Since\IN\1740 intravascular\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 are\VBP\836236 often\RB\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e1>EACA</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 disseminated\JJ\1740 intravascular\JJ\1740 coagulation\NN\13518963 or\CC\3541091 other\JJ\1740 "\``\1740 consumption\NN\13440063 coagulopathies\NNS\1740 .\.\1740 "\''\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 subtotal\JJ\1740 <e2>infarction</e2>\NN\14204950 of\IN\1740 the\DT\1740 kidney\NN\5333259 due\IN\5174653 to\TO\1740 thrombosis\NN\14100769 of\IN\1740 a\DT\13649268 normal\JJ\1740 renal\JJ\1740 artery\NN\5417975 .\.\1740
D015119_D007674 CID Since\IN\1740 intravascular\JJ\1740 fibrin\NN\14728724 thrombi\NN\5402091 are\VBP\836236 often\RB\1740 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 fibrinolytic\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e1>EACA</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 fibrin\NN\14728724 thrombi\NN\5402091 in\IN\13603305 patients\NNS\9898892 with\IN\1740 disseminated\JJ\1740 intravascular\JJ\1740 coagulation\NN\13518963 or\CC\3541091 other\JJ\1740 "\``\1740 consumption\NN\13440063 coagulopathies\NNS\1740 .\.\1740 "\''\1740 This\DT\1740 report\NN\6470073 describes\VBZ\1001294 subtotal\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 kidney\NN\5333259 due\IN\5174653 to\TO\1740 <e2>thrombosis\NN\14100769 of\IN\1740 a\DT\13649268 normal\JJ\1740 renal\JJ\1740 artery</e2>\NN\5417975 .\.\1740
8755612
D004967_D009369 NONE Genetic\JJ\1740 separation\NN\24720 of\IN\1740 <e2>tumor</e2>\NN\14234074 growth\NN\13526110 and\CC\1740 hemorrhagic\JJ\1740 phenotypes\NNS\4933544 in\IN\13603305 an\DT\6697703 <e1>estrogen-induced</e1>\JJ\1740 tumor\NN\14234074 .\.\1740
D004967_D009369 NONE Genetic\JJ\1740 separation\NN\24720 of\IN\1740 tumor\NN\14234074 growth\NN\13526110 and\CC\1740 hemorrhagic\JJ\1740 phenotypes\NNS\4933544 in\IN\13603305 an\DT\6697703 <e1>estrogen-induced</e1>\JJ\1740 <e2>tumor</e2>\NN\14234074 .\.\1740
D004967_D006470 NONE Genetic\JJ\1740 separation\NN\24720 of\IN\1740 tumor\NN\14234074 growth\NN\13526110 and\CC\1740 <e2>hemorrhagic</e2>\JJ\1740 phenotypes\NNS\4933544 in\IN\13603305 an\DT\6697703 <e1>estrogen-induced</e1>\JJ\1740 tumor\NN\14234074 .\.\1740
D004967_D006470 NONE Chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>estrogen</e1>\NN\14745635 to\IN\1740 the\DT\1740 Fischer\NNP\1740 344\CD\1740 (\-LRB-\1740 F344\NN\1740 )\-RRB-\1740 rat\NN\2329401 induces\VBZ\1627355 growth\NN\13526110 of\IN\1740 large\JJ\1740 ,\,\1740 <e2>hemorrhagic</e2>\JJ\1740 pituitary\JJ\1740 tumors\NNS\14234074 .\.\1740
D004967_D010911 NONE Chronic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>estrogen</e1>\NN\14745635 to\IN\1740 the\DT\1740 Fischer\NNP\1740 344\CD\1740 (\-LRB-\1740 F344\NN\1740 )\-RRB-\1740 rat\NN\2329401 induces\VBZ\1627355 growth\NN\13526110 of\IN\1740 large\JJ\1740 ,\,\1740 hemorrhagic\JJ\1740 <e2>pituitary\JJ\1740 tumors</e2>\NNS\14234074 .\.\1740
D004054_D006470 NONE Ten\CD\13745420 weeks\NNS\15113229 of\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 (\-LRB-\1740 DES\NN\14749794 )\-RRB-\1740 treatment\NN\654885 caused\VBD\1617192 female\JJ\1740 F344\NN\1740 rat\NN\2329401 pituitaries\NNS\5329735 to\TO\1740 grow\VB\109660 to\IN\1740 an\DT\6697703 average\NN\6021499 of\IN\1740 109.2\CD\1740 +/-\CC\1740 6.3\CD\1740 mg\NN\13717155 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SE\NN\14724645 )\-RRB-\1740 versus\CC\1740 11.3\CD\1740 +/-\CC\1740 1.4\CD\1740 mg\NN\13717155 for\IN\1740 untreated\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 to\TO\1740 become\VB\146138 highly\RB\1740 <e2>hemorrhagic</e2>\JJ\1740 .\.\1740
D004054_D006470 NONE Ten\CD\13745420 weeks\NNS\15113229 of\IN\1740 diethylstilbestrol\NN\14749794 (\-LRB-\1740 <e1>DES</e1>\NN\14749794 )\-RRB-\1740 treatment\NN\654885 caused\VBD\1617192 female\JJ\1740 F344\NN\1740 rat\NN\2329401 pituitaries\NNS\5329735 to\TO\1740 grow\VB\109660 to\IN\1740 an\DT\6697703 average\NN\6021499 of\IN\1740 109.2\CD\1740 +/-\CC\1740 6.3\CD\1740 mg\NN\13717155 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SE\NN\14724645 )\-RRB-\1740 versus\CC\1740 11.3\CD\1740 +/-\CC\1740 1.4\CD\1740 mg\NN\13717155 for\IN\1740 untreated\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 to\TO\1740 become\VB\146138 highly\RB\1740 <e2>hemorrhagic</e2>\JJ\1740 .\.\1740
D004054_D006470 NONE However\RB\1740 ,\,\1740 while\IN\15122231 <e1>DES-induced</e1>\JJ\1740 pituitary\JJ\1740 growth\NN\13526110 exhibited\VBD\2632167 quantitative\JJ\1740 ,\,\1740 additive\JJ\1740 inheritance\NN\77419 ,\,\1740 the\DT\1740 <e2>hemorrhagic</e2>\JJ\1740 phenotype\NN\4933544 exhibited\VBD\2632167 recessive\JJ\1740 ,\,\1740 epistatic\JJ\1740 inheritance\NN\77419 .\.\1740
12452552
D018967_D007676 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 CRF\NN\1740 )\-RRB-\1740 developed\VBD\1753788 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 levomepromazine\NN\1740 .\.\1740
D018967_D007676 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 <e2>CRF</e2>\NN\1740 )\-RRB-\1740 developed\VBD\1753788 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 levomepromazine\NN\1740 .\.\1740
D018967_D009459 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 CRF\NN\1740 )\-RRB-\1740 developed\VBD\1753788 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 levomepromazine\NN\1740 .\.\1740
D018967_D009459 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 CRF\NN\1740 )\-RRB-\1740 developed\VBD\1753788 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>NMS</e2>\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>risperidone</e1>\NN\1740 and\CC\1740 levomepromazine\NN\1740 .\.\1740
D008728_D007676 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 CRF\NN\1740 )\-RRB-\1740 developed\VBD\1753788 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 risperidone\NN\1740 and\CC\1740 <e1>levomepromazine</e1>\NN\1740 .\.\1740
D008728_D007676 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 <e2>CRF</e2>\NN\1740 )\-RRB-\1740 developed\VBD\1753788 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 risperidone\NN\1740 and\CC\1740 <e1>levomepromazine</e1>\NN\1740 .\.\1740
D008728_D009459 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 CRF\NN\1740 )\-RRB-\1740 developed\VBD\1753788 <e2>neuroleptic\JJ\1740 malignant\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 NMS\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 risperidone\NN\1740 and\CC\1740 <e1>levomepromazine</e1>\NN\1740 .\.\1740
D008728_D009459 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 CRF\NN\1740 )\-RRB-\1740 developed\VBD\1753788 neuroleptic\JJ\1740 malignant\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>NMS</e2>\NN\13649268 )\-RRB-\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 risperidone\NN\1740 and\CC\1740 <e1>levomepromazine</e1>\NN\1740 .\.\1740
24126708
D007980_D010300 NONE Association\NN\8008335 of\IN\1740 common\JJ\1740 genetic\JJ\1740 variants\NNS\7366289 of\IN\1740 HOMER1\NN\1740 gene\NN\8459252 with\IN\1740 <e1>levodopa</e1>\NN\14604959 adverse\JJ\1740 effects\NNS\13245626 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 .\.\1740
D007980_D010300 NONE <e1>Levodopa</e1>\NN\14604959 is\VBZ\836236 the\DT\1740 most\RBS\1740 effective\JJ\1740 symptomatic\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 ,\,\1740 but\CC\1740 its\PRP$\6125041 chronic\JJ\1740 use\NN\407535 could\MD\1740 lead\VB\1752884 to\TO\1740 chronic\JJ\1740 adverse\JJ\1740 outcomes\NNS\7291312 ,\,\1740 such\JJ\1740 as\IN\14622893 motor\NN\3699975 fluctuations\NNS\7345593 ,\,\1740 dyskinesia\NN\14084880 and\CC\1740 visual\JJ\1740 hallucinations\NNS\14376855 .\.\1740
D007980_D004409 CID <e1>Levodopa</e1>\NN\14604959 is\VBZ\836236 the\DT\1740 most\RBS\1740 effective\JJ\1740 symptomatic\JJ\1740 therapy\NN\657604 for\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 ,\,\1740 but\CC\1740 its\PRP$\6125041 chronic\JJ\1740 use\NN\407535 could\MD\1740 lead\VB\1752884 to\TO\1740 chronic\JJ\1740 adverse\JJ\1740 outcomes\NNS\7291312 ,\,\1740 such\JJ\1740 as\IN\14622893 motor\NN\3699975 fluctuations\NNS\7345593 ,\,\1740 <e2>dyskinesia</e2>\NN\14084880 and\CC\1740 visual\JJ\1740 hallucinations\NNS\14376855 .\.\1740
D007980_D006212 CID <e1>Levodopa</e1>\NN\14604959 is\VBZ\836236 the\DT\1740 most\RBS\1740 effective\JJ\1740 symptomatic\JJ\1740 therapy\NN\657604 for\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 ,\,\1740 but\CC\1740 its\PRP$\6125041 chronic\JJ\1740 use\NN\407535 could\MD\1740 lead\VB\1752884 to\TO\1740 chronic\JJ\1740 adverse\JJ\1740 outcomes\NNS\7291312 ,\,\1740 such\JJ\1740 as\IN\14622893 motor\NN\3699975 fluctuations\NNS\7345593 ,\,\1740 dyskinesia\NN\14084880 and\CC\1740 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 .\.\1740
11708428
D011241_D001008 CID <e1>Prednisone</e1>\NN\2721538 induces\VBZ\1627355 <e2>anxiety</e2>\NN\14373582 and\CC\1740 glial\JJ\1740 cerebral\JJ\1740 changes\NNS\7283608 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011241_D001008 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 whether\IN\1740 <e1>prednisone</e1>\NN\2721538 (\-LRB-\1740 PDN\NN\1740 )\-RRB-\1740 produces\VBZ\1617192 <e2>anxiety</e2>\NN\14373582 and/or\CC\1740 cerebral\JJ\1740 glial\JJ\1740 changes\NNS\7283608 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011241_D001008 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 whether\IN\1740 prednisone\NN\2721538 (\-LRB-\1740 <e1>PDN</e1>\NN\1740 )\-RRB-\1740 produces\VBZ\1617192 <e2>anxiety</e2>\NN\14373582 and/or\CC\1740 cerebral\JJ\1740 glial\JJ\1740 changes\NNS\7283608 in\IN\13603305 rats\NNS\2329401 .\.\1740
D011241_D001008 CID RESULTS\NNS\34213 :\:\1740 <e2>Anxiety</e2>\NNP\14373582 was\VBD\836236 documented\VBN\1000214 in\IN\13603305 both\DT\1740 groups\NNS\2137 of\IN\1740 <e1>PDN</e1>\NN\1740 treated\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 .\.\1740
D011241_D001008 CID CONCLUSION\NN\5837957 :\:\1740 Subacute\NN\1740 exposure\NN\5042871 to\TO\1740 <e1>PDN</e1>\NN\1740 induced\VBD\1627355 <e2>anxiety</e2>\NN\14373582 and\CC\1740 reactivity\NN\5652926 of\IN\1740 microglia\NNS\5467054 .\.\1740
1858969
D004049_D004660 CID Five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>encephalitis</e2>\NN\14336539 during\IN\1740 treatment\NN\654885 of\IN\1740 loiasis\NN\1740 with\IN\1740 <e1>diethylcarbamazine</e1>\NN\1740 .\.\1740
D004049_D004660 CID Five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>encephalitis</e2>\NN\14336539 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>diethylcarbamazine</e1>\NN\1740 (\-LRB-\1740 DEC\NN\15209706 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 Congolese\JJ\1740 patients\NNS\9898892 with\IN\1740 Loa\NN\1740 loa\JJ\1740 filariasis\NN\14070360 .\.\1740
D004049_D004660 CID Five\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>encephalitis</e2>\NN\14336539 following\VBG\1835496 treatment\NN\654885 with\IN\1740 diethylcarbamazine\NN\1740 (\-LRB-\1740 <e1>DEC</e1>\NN\15209706 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 Congolese\JJ\1740 patients\NNS\9898892 with\IN\1740 Loa\NN\1740 loa\JJ\1740 filariasis\NN\14070360 .\.\1740
D004049_D008118 NONE Five\CD\13741022 cases\NNS\7283608 of\IN\1740 encephalitis\NN\14336539 during\IN\1740 treatment\NN\654885 of\IN\1740 <e2>loiasis</e2>\NN\1740 with\IN\1740 <e1>diethylcarbamazine</e1>\NN\1740 .\.\1740
D004049_D005368 NONE Five\CD\13741022 cases\NNS\7283608 of\IN\1740 encephalitis\NN\14336539 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>diethylcarbamazine</e1>\NN\1740 (\-LRB-\1740 DEC\NN\15209706 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 Congolese\JJ\1740 patients\NNS\9898892 with\IN\1740 Loa\NN\1740 loa\JJ\1740 <e2>filariasis</e2>\NN\14070360 .\.\1740
D004049_D005368 NONE Five\CD\13741022 cases\NNS\7283608 of\IN\1740 encephalitis\NN\14336539 following\VBG\1835496 treatment\NN\654885 with\IN\1740 diethylcarbamazine\NN\1740 (\-LRB-\1740 <e1>DEC</e1>\NN\15209706 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 Congolese\JJ\1740 patients\NNS\9898892 with\IN\1740 Loa\NN\1740 loa\JJ\1740 <e2>filariasis</e2>\NN\14070360 .\.\1740
6615679
D013999_D001919 CID Intraoperative\JJ\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 hypotension\NN\14057371 associated\VBN\628491 with\IN\1740 <e1>timolol</e1>\CD\2832168 and\CC\1740 pilocarpine\NN\14712692 eye\NN\5299178 drops\NNS\13899200 .\.\1740
D013999_D001919 CID A\DT\13649268 69-yr-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 concurrently\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 nitrate\NN\14818238 and\CC\1740 <e1>timolol\CD\2832168 maleate</e1>\JJ\1740 eye\NN\5299178 drops\NNS\13899200 ,\,\1740 developed\VBD\1753788 a\DT\13649268 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 became\VBD\146138 hypotensive\JJ\1740 during\IN\1740 halothane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D013999_D007022 CID Intraoperative\JJ\1740 bradycardia\NN\14110674 and\CC\1740 <e2>hypotension</e2>\NN\14057371 associated\VBN\628491 with\IN\1740 <e1>timolol</e1>\CD\2832168 and\CC\1740 pilocarpine\NN\14712692 eye\NN\5299178 drops\NNS\13899200 .\.\1740
D013999_D007022 CID A\DT\13649268 69-yr-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 concurrently\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 nitrate\NN\14818238 and\CC\1740 <e1>timolol\CD\2832168 maleate</e1>\JJ\1740 eye\NN\5299178 drops\NNS\13899200 ,\,\1740 developed\VBD\1753788 a\DT\13649268 bradycardia\NN\14110674 and\CC\1740 became\VBD\146138 <e2>hypotensive</e2>\JJ\1740 during\IN\1740 halothane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D010862_D001919 CID Intraoperative\JJ\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 hypotension\NN\14057371 associated\VBN\628491 with\IN\1740 timolol\CD\2832168 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 eye\NN\5299178 drops\NNS\13899200 .\.\1740
D010862_D001919 CID A\DT\13649268 69-yr-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 concurrently\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>pilocarpine\NN\14712692 nitrate</e1>\NN\14818238 and\CC\1740 timolol\CD\2832168 maleate\JJ\1740 eye\NN\5299178 drops\NNS\13899200 ,\,\1740 developed\VBD\1753788 a\DT\13649268 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 became\VBD\146138 hypotensive\JJ\1740 during\IN\1740 halothane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D010862_D007022 CID Intraoperative\JJ\1740 bradycardia\NN\14110674 and\CC\1740 <e2>hypotension</e2>\NN\14057371 associated\VBN\628491 with\IN\1740 timolol\CD\2832168 and\CC\1740 <e1>pilocarpine</e1>\NN\14712692 eye\NN\5299178 drops\NNS\13899200 .\.\1740
D010862_D007022 CID A\DT\13649268 69-yr-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 concurrently\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 <e1>pilocarpine\NN\14712692 nitrate</e1>\NN\14818238 and\CC\1740 timolol\CD\2832168 maleate\JJ\1740 eye\NN\5299178 drops\NNS\13899200 ,\,\1740 developed\VBD\1753788 a\DT\13649268 bradycardia\NN\14110674 and\CC\1740 became\VBD\146138 <e2>hypotensive</e2>\JJ\1740 during\IN\1740 halothane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D006221_D001919 NONE A\DT\13649268 69-yr-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 concurrently\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 nitrate\NN\14818238 and\CC\1740 timolol\CD\2832168 maleate\JJ\1740 eye\NN\5299178 drops\NNS\13899200 ,\,\1740 developed\VBD\1753788 a\DT\13649268 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 became\VBD\146138 hypotensive\JJ\1740 during\IN\1740 <e1>halothane</e1>\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D006221_D001919 NONE It\PRP\6125041 is\VBZ\836236 postulated\VBN\756338 that\IN\1740 this\DT\1740 action\NN\30358 may\MD\15209706 have\VB\2108377 been\VBN\836236 enhanced\VBN\227165 during\IN\1740 <e1>halothane</e1>\NN\3570838 anaesthesia\NN\14034177 with\IN\1740 resultant\JJ\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 hypotension\NN\14057371 .\.\1740
D006221_D007022 NONE A\DT\13649268 69-yr-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 concurrently\RB\1740 being\VBG\836236 treated\VBN\2376958 with\IN\1740 pilocarpine\NN\14712692 nitrate\NN\14818238 and\CC\1740 timolol\CD\2832168 maleate\JJ\1740 eye\NN\5299178 drops\NNS\13899200 ,\,\1740 developed\VBD\1753788 a\DT\13649268 bradycardia\NN\14110674 and\CC\1740 became\VBD\146138 <e2>hypotensive</e2>\JJ\1740 during\IN\1740 <e1>halothane</e1>\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D006221_D007022 NONE It\PRP\6125041 is\VBZ\836236 postulated\VBN\756338 that\IN\1740 this\DT\1740 action\NN\30358 may\MD\15209706 have\VB\2108377 been\VBN\836236 enhanced\VBN\227165 during\IN\1740 <e1>halothane</e1>\NN\3570838 anaesthesia\NN\14034177 with\IN\1740 resultant\JJ\1740 bradycardia\NN\14110674 and\CC\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
24088636
C098010_D009901 CID <e1>Linezolid-induced</e1>\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 .\.\1740
C098010_D014786 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 progressive\JJ\1740 <e2>loss\NN\13252973 of\IN\1740 vision</e2>\NN\5767733 associated\VBN\628491 with\IN\1740 <e1>linezolid</e1>\JJ\1740 therapy\NN\657604 .\.\1740
C098010_D014786 NONE A\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 on\IN\1740 treatment\NN\654885 with\IN\1740 multiple\JJ\1740 second-line\JJ\1740 anti-tuberculous\JJ\1740 drugs\NNS\14778436 including\VBG\690614 <e1>linezolid</e1>\JJ\1740 and\CC\1740 ethambutol\NN\1740 for\IN\1740 extensively\RB\1740 drug-resistant\JJ\1740 tuberculosis\NN\14127211 (\-LRB-\1740 XDR-TB\NN\1740 )\-RRB-\1740 presented\VBD\2137132 to\IN\1740 us\PRP\14964590 with\IN\1740 painless\JJ\1740 progressive\JJ\1740 <e2>loss\NN\13252973 of\IN\1740 vision</e2>\NN\5767733 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 .\.\1740
C098010_D054908 NONE A\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 on\IN\1740 treatment\NN\654885 with\IN\1740 multiple\JJ\1740 second-line\JJ\1740 anti-tuberculous\JJ\1740 drugs\NNS\14778436 including\VBG\690614 <e1>linezolid</e1>\JJ\1740 and\CC\1740 ethambutol\NN\1740 for\IN\1740 <e2>extensively\RB\1740 drug-resistant\JJ\1740 tuberculosis</e2>\NN\14127211 (\-LRB-\1740 XDR-TB\NN\1740 )\-RRB-\1740 presented\VBD\2137132 to\IN\1740 us\PRP\14964590 with\IN\1740 painless\JJ\1740 progressive\JJ\1740 loss\NN\13252973 of\IN\1740 vision\NN\5767733 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 .\.\1740
C098010_D054908 NONE A\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 on\IN\1740 treatment\NN\654885 with\IN\1740 multiple\JJ\1740 second-line\JJ\1740 anti-tuberculous\JJ\1740 drugs\NNS\14778436 including\VBG\690614 <e1>linezolid</e1>\JJ\1740 and\CC\1740 ethambutol\NN\1740 for\IN\1740 extensively\RB\1740 drug-resistant\JJ\1740 tuberculosis\NN\14127211 (\-LRB-\1740 <e2>XDR-TB</e2>\NN\1740 )\-RRB-\1740 presented\VBD\2137132 to\IN\1740 us\PRP\14964590 with\IN\1740 painless\JJ\1740 progressive\JJ\1740 loss\NN\13252973 of\IN\1740 vision\NN\5767733 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 .\.\1740
D004977_D054908 NONE A\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 on\IN\1740 treatment\NN\654885 with\IN\1740 multiple\JJ\1740 second-line\JJ\1740 anti-tuberculous\JJ\1740 drugs\NNS\14778436 including\VBG\690614 linezolid\JJ\1740 and\CC\1740 <e1>ethambutol</e1>\NN\1740 for\IN\1740 <e2>extensively\RB\1740 drug-resistant\JJ\1740 tuberculosis</e2>\NN\14127211 (\-LRB-\1740 XDR-TB\NN\1740 )\-RRB-\1740 presented\VBD\2137132 to\IN\1740 us\PRP\14964590 with\IN\1740 painless\JJ\1740 progressive\JJ\1740 loss\NN\13252973 of\IN\1740 vision\NN\5767733 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 .\.\1740
D004977_D054908 NONE A\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 on\IN\1740 treatment\NN\654885 with\IN\1740 multiple\JJ\1740 second-line\JJ\1740 anti-tuberculous\JJ\1740 drugs\NNS\14778436 including\VBG\690614 linezolid\JJ\1740 and\CC\1740 <e1>ethambutol</e1>\NN\1740 for\IN\1740 extensively\RB\1740 drug-resistant\JJ\1740 tuberculosis\NN\14127211 (\-LRB-\1740 <e2>XDR-TB</e2>\NN\1740 )\-RRB-\1740 presented\VBD\2137132 to\IN\1740 us\PRP\14964590 with\IN\1740 painless\JJ\1740 progressive\JJ\1740 loss\NN\13252973 of\IN\1740 vision\NN\5767733 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 .\.\1740
D004977_D014786 NONE A\DT\13649268 45-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 who\WP\8299493 was\VBD\836236 on\IN\1740 treatment\NN\654885 with\IN\1740 multiple\JJ\1740 second-line\JJ\1740 anti-tuberculous\JJ\1740 drugs\NNS\14778436 including\VBG\690614 linezolid\JJ\1740 and\CC\1740 <e1>ethambutol</e1>\NN\1740 for\IN\1740 extensively\RB\1740 drug-resistant\JJ\1740 tuberculosis\NN\14127211 (\-LRB-\1740 XDR-TB\NN\1740 )\-RRB-\1740 presented\VBD\2137132 to\IN\1740 us\PRP\14964590 with\IN\1740 painless\JJ\1740 progressive\JJ\1740 <e2>loss\NN\13252973 of\IN\1740 vision</e2>\NN\5767733 in\IN\13603305 both\DT\1740 eyes\NNS\5945642 .\.\1740
D004977_D009901 NONE <e1>Ethambutol-induced</e1>\JJ\1740 <e2>toxic\JJ\1740 optic\JJ\1740 neuropathy</e2>\NN\14204950 was\VBD\836236 suspected\VBN\916909 and\CC\1740 tablet\NN\4233405 ethambutol\NN\1740 was\VBD\836236 withdrawn\VBN\1835496 .\.\1740
D004977_D009901 NONE Ethambutol-induced\JJ\1740 <e2>toxic\JJ\1740 optic\JJ\1740 neuropathy</e2>\NN\14204950 was\VBD\836236 suspected\VBN\916909 and\CC\1740 tablet\NN\4233405 <e1>ethambutol</e1>\NN\1740 was\VBD\836236 withdrawn\VBN\1835496 .\.\1740
D004977_D015354 NONE <e2>Deterioration\NN\14560612 of\IN\1740 vision</e2>\NN\5767733 occurred\VBD\2623529 despite\IN\7501545 withdrawal\NN\7206096 of\IN\1740 <e1>ethambutol</e1>\NN\1740 .\.\1740
24727461
C005975_D028361 NONE <e1>Hydroxytyrosol</e1>\JJ\1740 ameliorates\NNS\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
C005975_D066126 NONE <e1>Hydroxytyrosol</e1>\JJ\1740 ameliorates\NNS\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
C005975_D066126 NONE Herein\RB\1740 ,\,\1740 we\PRP\1740 investigate\VBP\644583 whether\IN\1740 doxorubicin-associated\JJ\1740 chronic\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 can\MD\3094503 be\VB\836236 ameliorated\VBN\126264 with\IN\1740 the\DT\1740 antioxidant\JJ\1740 <e1>hydroxytyrosol</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
C005975_D001943 NONE <e1>Hydroxytyrosol</e1>\JJ\1740 ameliorates\NNS\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
C005975_D001943 NONE Herein\RB\1740 ,\,\1740 we\PRP\1740 investigate\VBP\644583 whether\IN\1740 doxorubicin-associated\JJ\1740 chronic\JJ\1740 cardiac\JJ\1740 toxicity\NN\13576101 can\MD\3094503 be\VB\836236 ameliorated\VBN\126264 with\IN\1740 the\DT\1740 antioxidant\JJ\1740 <e1>hydroxytyrosol</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
C005975_D001943 NONE Thirty-six\CD\1740 rats\NNS\2329401 bearing\VBG\2630189 <e2>breast\NN\5225090 tumors</e2>\NNS\14234074 induced\VBN\1627355 chemically\RB\1740 were\VBD\836236 divided\VBN\140123 into\IN\1740 4\CD\13741022 groups\NNS\2137 :\:\1740 control\NN\5190804 ,\,\1740 <e1>hydroxytyrosol</e1>\JJ\1740 (\-LRB-\1740 0.5mg/kg\CD\1740 ,\,\1740 5days/week\JJ\1740 )\-RRB-\1740 ,\,\1740 doxorubicin\NN\2716866 (\-LRB-\1740 1mg/kg/week\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 plus\CC\4723816 hydroxytyrosol\JJ\1740 .\.\1740
C005975_D001943 NONE Thirty-six\CD\1740 rats\NNS\2329401 bearing\VBG\2630189 <e2>breast\NN\5225090 tumors</e2>\NNS\14234074 induced\VBN\1627355 chemically\RB\1740 were\VBD\836236 divided\VBN\140123 into\IN\1740 4\CD\13741022 groups\NNS\2137 :\:\1740 control\NN\5190804 ,\,\1740 hydroxytyrosol\JJ\1740 (\-LRB-\1740 0.5mg/kg\CD\1740 ,\,\1740 5days/week\JJ\1740 )\-RRB-\1740 ,\,\1740 doxorubicin\NN\2716866 (\-LRB-\1740 1mg/kg/week\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 plus\CC\4723816 <e1>hydroxytyrosol</e1>\JJ\1740 .\.\1740
D004317_D028361 NONE Hydroxytyrosol\JJ\1740 ameliorates\NNS\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004317_D028361 NONE <e1>Doxorubicin</e1>\NNP\2716866 causes\VBZ\1617192 significant\JJ\1740 cardiotoxicity\NN\1740 characterized\VBN\609683 by\IN\1740 marked\JJ\1740 increases\NNS\13576355 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D004317_D066126 NONE Hydroxytyrosol\JJ\1740 ameliorates\NNS\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004317_D066126 NONE <e1>Doxorubicin</e1>\NNP\2716866 causes\VBZ\1617192 significant\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 characterized\VBN\609683 by\IN\1740 marked\JJ\1740 increases\NNS\13576355 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D004317_D066126 NONE Herein\RB\1740 ,\,\1740 we\PRP\1740 investigate\VBP\644583 whether\IN\1740 <e1>doxorubicin-associated</e1>\JJ\1740 chronic\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 can\MD\3094503 be\VB\836236 ameliorated\VBN\126264 with\IN\1740 the\DT\1740 antioxidant\JJ\1740 hydroxytyrosol\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D004317_D001943 NONE Hydroxytyrosol\JJ\1740 ameliorates\NNS\1740 oxidative\JJ\1740 stress\NN\7083732 and\CC\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D004317_D001943 NONE Herein\RB\1740 ,\,\1740 we\PRP\1740 investigate\VBP\644583 whether\IN\1740 <e1>doxorubicin-associated</e1>\JJ\1740 chronic\JJ\1740 cardiac\JJ\1740 toxicity\NN\13576101 can\MD\3094503 be\VB\836236 ameliorated\VBN\126264 with\IN\1740 the\DT\1740 antioxidant\JJ\1740 hydroxytyrosol\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D004317_D001943 NONE Thirty-six\CD\1740 rats\NNS\2329401 bearing\VBG\2630189 <e2>breast\NN\5225090 tumors</e2>\NNS\14234074 induced\VBN\1627355 chemically\RB\1740 were\VBD\836236 divided\VBN\140123 into\IN\1740 4\CD\13741022 groups\NNS\2137 :\:\1740 control\NN\5190804 ,\,\1740 hydroxytyrosol\JJ\1740 (\-LRB-\1740 0.5mg/kg\CD\1740 ,\,\1740 5days/week\JJ\1740 )\-RRB-\1740 ,\,\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 1mg/kg/week\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 plus\CC\4723816 hydroxytyrosol\JJ\1740 .\.\1740
D004317_D001943 NONE Thirty-six\CD\1740 rats\NNS\2329401 bearing\VBG\2630189 <e2>breast\NN\5225090 tumors</e2>\NNS\14234074 induced\VBN\1627355 chemically\RB\1740 were\VBD\836236 divided\VBN\140123 into\IN\1740 4\CD\13741022 groups\NNS\2137 :\:\1740 control\NN\5190804 ,\,\1740 hydroxytyrosol\JJ\1740 (\-LRB-\1740 0.5mg/kg\CD\1740 ,\,\1740 5days/week\JJ\1740 )\-RRB-\1740 ,\,\1740 doxorubicin\NN\2716866 (\-LRB-\1740 1mg/kg/week\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 plus\CC\4723816 hydroxytyrosol\JJ\1740 .\.\1740
D004317_D009369 NONE Oxidative\JJ\1740 stress\NN\7083732 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 several\JJ\1740 processes\NNS\407535 including\VBG\690614 <e2>cancer</e2>\NN\14239425 ,\,\1740 aging\NN\13526110 and\CC\1740 cardiovascular\JJ\1740 disease\NN\14061805 ,\,\1740 and\CC\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 potentiate\VB\229605 the\DT\1740 therapeutic\JJ\1740 effect\NN\34213 of\IN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
D004317_D002318 NONE Oxidative\JJ\1740 stress\NN\7083732 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 several\JJ\1740 processes\NNS\407535 including\VBG\690614 cancer\NN\14239425 ,\,\1740 aging\NN\13526110 and\CC\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 ,\,\1740 and\CC\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 potentiate\VB\229605 the\DT\1740 therapeutic\JJ\1740 effect\NN\34213 of\IN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 <e1>doxorubicin</e1>\NN\2716866 .\.\1740
C005975_D006331 NONE <e1>Hydroxytyrosol</e1>\NNP\1740 improved\VBD\126264 the\DT\1740 <e2>cardiac\JJ\1740 disturbances</e2>\NNS\407535 enhanced\VBN\227165 by\IN\1740 doxorubicin\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 percentage\NN\13815742 of\IN\1740 altered\JJ\1740 mitochondria\NN\5445668 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 .\.\1740
C005975_D006331 NONE This\DT\1740 study\NN\635850 demonstrates\VBZ\2137132 that\IN\1740 <e1>hydroxytyrosol</e1>\JJ\1740 protect\NN\1740 rat\NN\2329401 <e2>heart\NN\5919034 damage</e2>\NN\7296428 provoked\VBN\1617192 by\IN\1740 doxorubicin\NN\2716866 decreasing\VBG\169651 oxidative\JJ\1740 damage\NN\7296428 and\CC\1740 mitochondrial\JJ\1740 alterations\NNS\7283608 .\.\1740
D004317_D006331 CID Hydroxytyrosol\NNP\1740 improved\VBD\126264 the\DT\1740 <e2>cardiac\JJ\1740 disturbances</e2>\NNS\407535 enhanced\VBN\227165 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 by\IN\1740 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 percentage\NN\13815742 of\IN\1740 altered\JJ\1740 mitochondria\NN\5445668 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 .\.\1740
D004317_D006331 CID This\DT\1740 study\NN\635850 demonstrates\VBZ\2137132 that\IN\1740 hydroxytyrosol\JJ\1740 protect\NN\1740 rat\NN\2329401 <e2>heart\NN\5919034 damage</e2>\NN\7296428 provoked\VBN\1617192 by\IN\1740 <e1>doxorubicin</e1>\NN\2716866 decreasing\VBG\169651 oxidative\JJ\1740 damage\NN\7296428 and\CC\1740 mitochondrial\JJ\1740 alterations\NNS\7283608 .\.\1740
1424076
D014750_D007177 CID <e2>Syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone</e2>\NN\5404728 after\IN\1740 infusional\JJ\1740 <e1>vincristine</e1>\NN\3917455 .\.\1740
D014750_D007177 CID Evaluation\NN\874067 revealed\VBD\2137132 the\DT\1740 <e2>syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 secretion\NN\13526110 of\IN\1740 antidiuretic\JJ\1740 hormone</e2>\NN\5404728 ,\,\1740 which\WDT\1740 was\VBD\836236 attributed\VBN\670261 to\TO\1740 the\DT\1740 <e1>vincristine</e1>\NN\3917455 infusion\NN\14589223 .\.\1740
D014750_D009101 NONE A\DT\13649268 77-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 was\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 4-day\JJ\1740 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>vincristine</e1>\NN\3917455 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 4\CD\13741022 days\NNS\15140892 of\IN\1740 oral\JJ\1740 dexamethasone\NN\2721538 .\.\1740
D004317_D009101 NONE A\DT\13649268 77-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 was\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 4-day\JJ\1740 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 vincristine\NN\3917455 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 and\CC\1740 4\CD\13741022 days\NNS\15140892 of\IN\1740 oral\JJ\1740 dexamethasone\NN\2721538 .\.\1740
D003907_D009101 NONE A\DT\13649268 77-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 refractory\JJ\1740 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 was\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 4-day\JJ\1740 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 vincristine\NN\3917455 and\CC\1740 doxorubicin\NN\2716866 and\CC\1740 4\CD\13741022 days\NNS\15140892 of\IN\1740 oral\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 .\.\1740
24554916
D010758_D002779 CID <e2>Cholestatic</e2>\JJ\1740 presentation\NN\1027379 of\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 poisoning\NN\14034177 .\.\1740
D010758_D002779 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 poisoning\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 <e2>cholestasis</e2>\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 cholestasis\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 phosphorus\NN\14622893 hepatotoxicity\NN\1740 .\.\1740
D010758_D002779 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 poisoning\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 cholestasis\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 <e2>cholestasis</e2>\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 phosphorus\NN\14622893 hepatotoxicity\NN\1740 .\.\1740
D010758_D002779 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 phosphorus\NN\14622893 poisoning\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 <e2>cholestasis</e2>\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 cholestasis\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 <e1>phosphorus</e1>\NN\14622893 hepatotoxicity\NN\1740 .\.\1740
D010758_D002779 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 phosphorus\NN\14622893 poisoning\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 cholestasis\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 <e2>cholestasis</e2>\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 <e1>phosphorus</e1>\NN\14622893 hepatotoxicity\NN\1740 .\.\1740
D010758_D011041 NONE Cholestatic\JJ\1740 presentation\NN\1027379 of\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 <e2>poisoning</e2>\NN\14034177 .\.\1740
D010758_D011041 NONE <e2>Poisoning</e2>\JJ\1740 with\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 classically\RB\1740 manifests\VBZ\1015244 with\IN\1740 acute\JJ\1740 hepatitis\NN\14127211 leading\VBG\1752884 to\TO\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 which\WDT\1740 may\MD\15209706 need\VB\2604760 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D010758_D011041 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 <e2>poisoning</e2>\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 cholestasis\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 cholestasis\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 phosphorus\NN\14622893 hepatotoxicity\NN\1740 .\.\1740
D010758_D011041 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 phosphorus\NN\14622893 <e2>poisoning</e2>\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 cholestasis\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 cholestasis\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 <e1>phosphorus</e1>\NN\14622893 hepatotoxicity\NN\1740 .\.\1740
D010758_D056486 NONE Yellow\NN\4959672 <e1>phosphorus</e1>\NN\14622893 ,\,\1740 a\DT\13649268 component\NN\5867413 of\IN\1740 certain\JJ\1740 pesticide\NN\14806838 pastes\NNS\14588492 and\CC\1740 fireworks\NNS\14853392 ,\,\1740 is\VBZ\836236 well\RB\1740 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D010758_D056486 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 poisoning\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 cholestasis\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 cholestasis\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 phosphorus\NN\14622893 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D010758_D056486 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 yellow\JJ\1740 phosphorus\NN\14622893 poisoning\NN\14034177 in\IN\13603305 which\WDT\1740 a\DT\13649268 patient\NN\9898892 presented\VBN\2137132 with\IN\1740 florid\JJ\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 cholestasis\NN\14052403 highlighting\VBG\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 cholestasis\NN\14052403 can\MD\3094503 rarely\RB\1740 be\VB\836236 a\DT\13649268 presenting\JJ\1740 feature\NN\5849040 of\IN\1740 yellow\NN\4959672 <e1>phosphorus</e1>\NN\14622893 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D010758_D006505 CID Poisoning\JJ\1740 with\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 classically\RB\1740 manifests\VBZ\1015244 with\IN\1740 <e2>acute\JJ\1740 hepatitis</e2>\NN\14127211 leading\VBG\1752884 to\TO\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 which\WDT\1740 may\MD\15209706 need\VB\2604760 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D010758_D017114 CID Poisoning\JJ\1740 with\IN\1740 yellow\JJ\1740 <e1>phosphorus</e1>\NN\14622893 classically\RB\1740 manifests\VBZ\1015244 with\IN\1740 acute\JJ\1740 hepatitis\NN\14127211 leading\VBG\1752884 to\TO\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 which\WDT\1740 may\MD\15209706 need\VB\2604760 liver\NN\5298729 transplantation\NN\671351 .\.\1740
24571687
D020927_D019462 CID <e2>Vasovagal\NN\1740 syncope</e2>\NN\7478169 and\CC\1740 severe\JJ\1740 bradycardia\NN\14110674 following\VBG\1835496 intranasal\JJ\1740 <e1>dexmedetomidine</e1>\NN\1740 for\IN\1740 pediatric\JJ\1740 procedural\JJ\1740 sedation\NN\14034177 .\.\1740
D020927_D001919 CID Vasovagal\NN\1740 syncope\NN\7478169 and\CC\1740 severe\JJ\1740 <e2>bradycardia</e2>\NN\14110674 following\VBG\1835496 intranasal\JJ\1740 <e1>dexmedetomidine</e1>\NN\1740 for\IN\1740 pediatric\JJ\1740 procedural\JJ\1740 sedation\NN\14034177 .\.\1740
D020927_D001919 CID We\PRP\1740 report\VBP\831651 syncope\NN\7478169 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 an\DT\6697703 11-year-old\JJ\1740 girl\NN\10787470 following\VBG\1835496 administration\NN\1133281 of\IN\1740 intranasal\JJ\1740 <e1>dexmedetomidine</e1>\NN\1740 for\IN\1740 sedation\NN\14034177 for\IN\1740 a\DT\13649268 voiding\VBG\2477334 cystourethrogram\NN\1740 .\.\1740
D020927_D013575 NONE We\PRP\1740 report\VBP\831651 <e2>syncope</e2>\NN\7478169 and\CC\1740 bradycardia\NN\14110674 in\IN\13603305 an\DT\6697703 11-year-old\JJ\1740 girl\NN\10787470 following\VBG\1835496 administration\NN\1133281 of\IN\1740 intranasal\JJ\1740 <e1>dexmedetomidine</e1>\NN\1740 for\IN\1740 sedation\NN\14034177 for\IN\1740 a\DT\13649268 voiding\VBG\2477334 cystourethrogram\NN\1740 .\.\1740
8312983
D005473_D003693 CID <e2>Delirium</e2>\NN\14391660 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 treatment\NN\654885 .\.\1740
D005473_D003693 CID In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 hyperkinetic\JJ\1740 <e2>delirium</e2>\NN\14391660 connected\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 total\JJ\1740 <e1>fluoxetine</e1>\NN\4169152 (\-LRB-\1740 fluoxetine\NN\4169152 plus\CC\4723816 desmethylfluoxetine\NN\1740 )\-RRB-\1740 concentration\NN\4916342 .\.\1740
D005473_D003693 CID In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 hyperkinetic\JJ\1740 <e2>delirium</e2>\NN\14391660 connected\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 total\JJ\1740 fluoxetine\NN\4169152 (\-LRB-\1740 <e1>fluoxetine</e1>\NN\4169152 plus\CC\4723816 desmethylfluoxetine\NN\1740 )\-RRB-\1740 concentration\NN\4916342 .\.\1740
D015283_D006970 NONE In\IN\13603305 some\DT\1740 cases\NNS\7283608 ,\,\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 concentration\NN\4916342 of\IN\1740 <e1>citalopram</e1>\NN\1740 (\-LRB-\1740 >\NNS\1740 600\CD\1740 nmol/L\NN\1740 )\-RRB-\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 <e2>somnolence</e2>\NN\14015731 and\CC\1740 movement\NN\191142 difficulties\NNS\621627 .\.\1740
D015283_D020820 NONE In\IN\13603305 some\DT\1740 cases\NNS\7283608 ,\,\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 concentration\NN\4916342 of\IN\1740 <e1>citalopram</e1>\NN\1740 (\-LRB-\1740 >\NNS\1740 600\CD\1740 nmol/L\NN\1740 )\-RRB-\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 somnolence\NN\14015731 and\CC\1740 <e2>movement\NN\191142 difficulties</e2>\NNS\621627 .\.\1740
D005473_D006948 CID In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 <e2>hyperkinetic</e2>\JJ\1740 delirium\NN\14391660 connected\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 total\JJ\1740 <e1>fluoxetine</e1>\NN\4169152 (\-LRB-\1740 fluoxetine\NN\4169152 plus\CC\4723816 desmethylfluoxetine\NN\1740 )\-RRB-\1740 concentration\NN\4916342 .\.\1740
D005473_D006948 CID In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 <e2>hyperkinetic</e2>\JJ\1740 delirium\NN\14391660 connected\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 total\JJ\1740 fluoxetine\NN\4169152 (\-LRB-\1740 <e1>fluoxetine</e1>\NN\4169152 plus\CC\4723816 desmethylfluoxetine\NN\1740 )\-RRB-\1740 concentration\NN\4916342 .\.\1740
C036139_D006948 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 <e2>hyperkinetic</e2>\JJ\1740 delirium\NN\14391660 connected\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 total\JJ\1740 fluoxetine\NN\4169152 (\-LRB-\1740 fluoxetine\NN\4169152 plus\CC\4723816 <e1>desmethylfluoxetine</e1>\NN\1740 )\-RRB-\1740 concentration\NN\4916342 .\.\1740
C036139_D003693 NONE In\IN\13603305 this\DT\1740 report\NN\6470073 ,\,\1740 we\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 hyperkinetic\JJ\1740 <e2>delirium</e2>\NN\14391660 connected\VBN\628491 with\IN\1740 a\DT\13649268 high\JJ\1740 serum\NN\5397468 total\JJ\1740 fluoxetine\NN\4169152 (\-LRB-\1740 fluoxetine\NN\4169152 plus\CC\4723816 <e1>desmethylfluoxetine</e1>\NN\1740 )\-RRB-\1740 concentration\NN\4916342 .\.\1740
12372954
D009530_D009395 CID Acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 due\JJ\1740 to\TO\1740 <e1>nicergoline</e1>\NN\1740 (\-LRB-\1740 Sermion\NNP\1740 )\-RRB-\1740 .\.\1740
D009530_D009395 CID Acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 due\JJ\1740 to\TO\1740 nicergoline\NN\1740 (\-LRB-\1740 <e1>Sermion</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D009530_D009395 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 (\-LRB-\1740 AIN\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 <e1>nicergoline</e1>\NN\1740 (\-LRB-\1740 Sermion\NNP\1740 )\-RRB-\1740 .\.\1740
D009530_D009395 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 interstitial\JJ\1740 nephritis\NN\14113228 (\-LRB-\1740 <e2>AIN</e2>\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 <e1>nicergoline</e1>\NN\1740 (\-LRB-\1740 Sermion\NNP\1740 )\-RRB-\1740 .\.\1740
D009530_D009395 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 (\-LRB-\1740 AIN\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 nicergoline\NN\1740 (\-LRB-\1740 <e1>Sermion</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D009530_D009395 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 interstitial\JJ\1740 nephritis\NN\14113228 (\-LRB-\1740 <e2>AIN</e2>\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 nicergoline\NN\1740 (\-LRB-\1740 <e1>Sermion</e1>\NNP\1740 )\-RRB-\1740 .\.\1740
D009530_D009395 CID To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 report\NN\6470073 of\IN\1740 <e1>nicergoline-associated</e1>\JJ\1740 <e2>AIN</e2>\NN\1740 .\.\1740
D009530_D012170 NONE Before\IN\1740 admission\NN\49003 ,\,\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>nicergoline</e1>\NN\1740 and\CC\1740 bendazac\NN\1740 lysine\NN\14605787 due\JJ\1740 to\TO\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 at\IN\14622893 ophthalmologic\JJ\1740 department\NN\8220714 .\.\1740
C036067_D012170 NONE Before\IN\1740 admission\NN\49003 ,\,\1740 he\PRP\14622893 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 nicergoline\NN\1740 and\CC\1740 <e1>bendazac\NN\1740 lysine</e1>\NN\14605787 due\JJ\1740 to\TO\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 at\IN\14622893 ophthalmologic\JJ\1740 department\NN\8220714 .\.\1740
1564030
D005473_D001714 CID <e2>Mania</e2>\NNP\9180259 associated\VBN\628491 with\IN\1740 <e1>fluoxetine</e1>\NN\4169152 treatment\NN\654885 in\IN\13603305 adolescents\NNS\9622049 .\.\1740
D005473_D001714 CID Generally\RB\1740 safe\JJ\1740 and\CC\1740 well\RB\1740 tolerated\VBN\802318 by\IN\1740 adults\NNS\7846 ,\,\1740 <e1>fluoxetine</e1>\NN\4169152 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 induce\VB\1627355 <e2>mania</e2>\NN\9180259 .\.\1740
D005473_D001714 CID The\DT\1740 cases\NNS\7283608 of\IN\1740 five\CD\13741022 depressed\JJ\1740 adolescents\NNS\9622049 ,\,\1740 14\CD\13745420 -\SYM\1740 16\CD\13745420 years\NNS\15144371 of\IN\1740 age\NN\4916342 ,\,\1740 who\WP\8299493 developed\VBD\1753788 <e2>mania</e2>\NN\9180259 during\IN\1740 pharmacotherapy\NN\1740 with\IN\1740 <e1>fluoxetine</e1>\NN\4169152 ,\,\1740 are\VBP\836236 reported\VBN\831651 here\RB\1740 .\.\1740
D005473_D001714 CID Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>mania</e2>\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D005473_D001714 CID Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 <e2>hypomania</e2>\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D005473_D001714 CID Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D005473_D001714 CID Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D005473_D001714 CID Further\RB\1740 study\NN\635850 is\VBZ\836236 needed\VBN\2604760 to\TO\1740 determine\VB\1645601 the\DT\1740 optimal\JJ\1740 dosage\NN\13576355 and\CC\1740 to\TO\1740 identify\VB\699815 risk\NN\14541044 factors\NNS\7326557 that\WDT\1740 increase\VBP\169651 individual\JJ\1740 vulnerability\NN\14540765 to\TO\1740 <e1>fluoxetine</e1>\NN\4169152 induced\JJ\1740 <e2>mania</e2>\NN\9180259 in\IN\13603305 adolescents\NNS\9622049 .\.\1740
D005473_D003866 NONE <e1>Fluoxetine</e1>\NNP\4169152 ,\,\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 is\VBZ\836236 gaining\VBG\2238085 increased\VBN\169651 acceptance\NN\6193203 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 adolescent\JJ\1740 <e2>depression</e2>\NN\14373582 .\.\1740
D005473_D003866 NONE The\DT\1740 cases\NNS\7283608 of\IN\1740 five\CD\13741022 <e2>depressed</e2>\JJ\1740 adolescents\NNS\9622049 ,\,\1740 14\CD\13745420 -\SYM\1740 16\CD\13745420 years\NNS\15144371 of\IN\1740 age\NN\4916342 ,\,\1740 who\WP\8299493 developed\VBD\1753788 mania\NN\9180259 during\IN\1740 pharmacotherapy\NN\1740 with\IN\1740 <e1>fluoxetine</e1>\NN\4169152 ,\,\1740 are\VBP\836236 reported\VBN\831651 here\RB\1740 .\.\1740
D005473_D003866 NONE Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 <e2>depression</e2>\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D012701_D003866 NONE Fluoxetine\NNP\4169152 ,\,\1740 a\DT\13649268 selective\JJ\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 ,\,\1740 is\VBZ\836236 gaining\VBG\2238085 increased\VBN\169651 acceptance\NN\6193203 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 adolescent\JJ\1740 <e2>depression</e2>\NN\14373582 .\.\1740
D005473_D001289 NONE Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 <e2>attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder</e2>\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D005473_D011618 NONE Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 <e2>psychotic</e2>\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 affective\JJ\1740 disorder\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
D005473_D019964 NONE Apparent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 mania\NN\9180259 or\CC\3541091 hypomania\NN\1740 during\IN\1740 <e1>fluoxetine</e1>\NN\4169152 pharmacotherapy\NN\1740 in\IN\13603305 this\DT\1740 population\NN\7942152 were\VBD\836236 the\DT\1740 combination\NN\7951464 of\IN\1740 attention-deficit\JJ\1740 hyperactivity\NN\14052403 disorder\NN\14034177 and\CC\1740 affective\JJ\1740 instability\NN\13972797 ;\:\1740 major\JJ\1740 depression\NN\14373582 with\IN\1740 psychotic\JJ\1740 features\NNS\5849040 ;\:\1740 a\DT\13649268 family\NN\8189659 history\NN\15120823 of\IN\1740 <e2>affective\JJ\1740 disorder</e2>\NN\14034177 ,\,\1740 especially\RB\1740 bipolar\JJ\1740 disorder\NN\14034177 ;\:\1740 and\CC\1740 a\DT\13649268 diagnosis\NN\152018 of\IN\1740 bipolar\JJ\1740 disorder\NN\14034177 .\.\1740
19553912
D020123_D000740 CID Posttransplant\JJ\1740 <e2>anemia</e2>\NN\14189204 :\:\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>sirolimus</e1>\NN\1740 .\.\1740
D020123_D000740 CID <e1>Sirolimus</e1>\NNP\1740 ,\,\1740 a\DT\13649268 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 rapamycin\NN\1740 inhibitor\NN\20090 ,\,\1740 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 as\IN\14622893 playing\VBG\1072262 a\DT\13649268 special\JJ\1740 role\NN\719494 in\IN\13603305 posttransplant\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D020123_D000740 CID Sirolimus\NNP\1740 ,\,\1740 a\DT\13649268 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 <e1>rapamycin</e1>\NN\1740 inhibitor\NN\20090 ,\,\1740 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 as\IN\14622893 playing\VBG\1072262 a\DT\13649268 special\JJ\1740 role\NN\719494 in\IN\13603305 posttransplant\JJ\1740 <e2>anemia</e2>\NN\14189204 .\.\1740
D020123_D000740 CID This\DT\1740 review\NN\5733583 considers\NNS\1740 <e2>anemia</e2>\NN\14189204 associated\VBN\628491 with\IN\1740 <e1>sirolimus</e1>\NN\1740 ,\,\1740 including\VBG\690614 its\PRP$\6125041 presentation\NN\1027379 ,\,\1740 mechanisms\NNS\13446390 ,\,\1740 and\CC\1740 management\NN\1123598 .\.\1740
17496739
C085143_D012640 NONE <e1>Piperacillin/tazobactam-induced</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 rapidly\RB\1740 reversed\VBN\109660 by\IN\1740 high\JJ\1740 flux\NN\15286249 hemodialysis\NN\649760 in\IN\13603305 a\DT\13649268 patient\NN\9898892 on\IN\1740 peritoneal\JJ\1740 dialysis\NN\646833 .\.\1740
D010878_D020258 NONE Despite\IN\7501545 popular\JJ\1740 use\NN\407535 of\IN\1740 <e1>piperacillin</e1>\NN\3910033 ,\,\1740 the\DT\1740 dire\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 piperacillin\NN\3910033 still\RB\1740 goes\VBZ\2367363 unrecognized\JJ\1740 ,\,\1740 leading\VBG\1752884 to\IN\1740 a\DT\13649268 delay\NN\15271008 in\IN\13603305 appropriate\JJ\1740 management\NN\1123598 .\.\1740
D010878_D020258 NONE Despite\IN\7501545 popular\JJ\1740 use\NN\407535 of\IN\1740 piperacillin\NN\3910033 ,\,\1740 the\DT\1740 dire\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>piperacillin</e1>\NN\3910033 still\RB\1740 goes\VBZ\2367363 unrecognized\JJ\1740 ,\,\1740 leading\VBG\1752884 to\IN\1740 a\DT\13649268 delay\NN\15271008 in\IN\13603305 appropriate\JJ\1740 management\NN\1123598 .\.\1740
C085143_D007676 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 tremor\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 tonic-clonic\JJ\1740 seizure\NN\14081375 (\-LRB-\1740 GTCS\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 bronchiectasis\NN\1740 with\IN\1740 secondary\JJ\1740 infection\NN\14052046 .\.\1740
C085143_D014202 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 tonic-clonic\JJ\1740 seizure\NN\14081375 (\-LRB-\1740 GTCS\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 bronchiectasis\NN\1740 with\IN\1740 secondary\JJ\1740 infection\NN\14052046 .\.\1740
C085143_D003221 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 tremor\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 <e2>confusion</e2>\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 tonic-clonic\JJ\1740 seizure\NN\14081375 (\-LRB-\1740 GTCS\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 bronchiectasis\NN\1740 with\IN\1740 secondary\JJ\1740 infection\NN\14052046 .\.\1740
C085143_D004830 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 tremor\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 <e2>tonic-clonic\JJ\1740 seizure</e2>\NN\14081375 (\-LRB-\1740 GTCS\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 bronchiectasis\NN\1740 with\IN\1740 secondary\JJ\1740 infection\NN\14052046 .\.\1740
C085143_D004830 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 tremor\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 tonic-clonic\JJ\1740 seizure\NN\14081375 (\-LRB-\1740 <e2>GTCS</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 bronchiectasis\NN\1740 with\IN\1740 secondary\JJ\1740 infection\NN\14052046 .\.\1740
C085143_D004830 CID Despite\IN\7501545 the\DT\1740 use\NN\407535 of\IN\1740 antiepileptic\JJ\1740 agents\NNS\7347 ,\,\1740 another\DT\1740 <e2>GTCS</e2>\NN\1740 episode\NN\7283608 recurred\VBN\339934 after\IN\1740 the\DT\1740 sixth\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 .\.\1740
C085143_D001987 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 tremor\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 tonic-clonic\JJ\1740 seizure\NN\14081375 (\-LRB-\1740 GTCS\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 <e2>bronchiectasis</e2>\NN\1740 with\IN\1740 secondary\JJ\1740 infection\NN\14052046 .\.\1740
C085143_D060085 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 57-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 receiving\VBG\2210855 continuous\JJ\1740 ambulatory\JJ\1740 peritoneal\NN\1740 dialysis\NN\646833 (\-LRB-\1740 CAPD\NN\1740 )\-RRB-\1740 ,\,\1740 who\WP\8299493 developed\VBD\1753788 slurred\VBN\1724459 speech\NN\7160883 ,\,\1740 tremor\NN\345926 ,\,\1740 bizarre\JJ\1740 behavior\NN\407535 ,\,\1740 progressive\JJ\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 and\CC\1740 2\CD\13741022 episodes\NNS\7283608 of\IN\1740 generalized\VBN\634472 tonic-clonic\JJ\1740 seizure\NN\14081375 (\-LRB-\1740 GTCS\NN\1740 )\-RRB-\1740 after\IN\1740 5\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>piperacillin/tazobactam</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 g/250\NN\1740 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 given\VBN\2327200 for\IN\1740 bronchiectasis\NN\1740 with\IN\1740 <e2>secondary\JJ\1740 infection</e2>\NN\14052046 .\.\1740
D000641_D007964 NONE The\DT\1740 laboratory\NN\4602044 data\NNS\7951464 revealed\VBD\2137132 normal\JJ\1740 plasma\NN\5398023 electrolyte\NN\14589223 and\CC\1740 <e1>ammonia</e1>\JJ\1740 levels\NNS\4916342 but\CC\1740 <e2>leukocytosis</e2>\NN\14189204 .\.\1740
D010878_D001927 NONE <e1>Piperacillin-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 any\DT\1740 uremic\JJ\1740 patients\NNS\9898892 with\IN\1740 unexplained\JJ\1740 neurological\JJ\1740 manifestations\NNS\7321772 .\.\1740
D010878_D001927 NONE CAPD\NN\1740 is\VBZ\836236 inefficient\JJ\1740 in\IN\13603305 removing\VBG\2012344 <e1>piperacillin</e1>\NN\3910033 ,\,\1740 whereas\IN\1740 hemodialysis\NN\649760 can\MD\3094503 rapidly\RB\1740 terminate\VB\126264 the\DT\1740 piperacillin-induced\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D010878_D001927 NONE CAPD\NN\1740 is\VBZ\836236 inefficient\JJ\1740 in\IN\13603305 removing\VBG\2012344 piperacillin\NN\3910033 ,\,\1740 whereas\IN\1740 hemodialysis\NN\649760 can\MD\3094503 rapidly\RB\1740 terminate\VB\126264 the\DT\1740 <e1>piperacillin-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D010878_D006463 NONE <e1>Piperacillin-induced</e1>\JJ\1740 encephalopathy\JJ\1740 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 any\DT\1740 <e2>uremic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 unexplained\JJ\1740 neurological\JJ\1740 manifestations\NNS\7321772 .\.\1740
12119460
D005472_D013274 NONE High-dose\JJ\1740 <e1>5-fluorouracil</e1>\NN\1740 /\:\1740 folinic\JJ\1740 acid\NN\14818238 in\IN\13603305 combination\NN\7951464 with\IN\1740 three-weekly\JJ\1740 mitomycin\NN\2716866 C\NN\13714184 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D005472_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D005472_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 <e2>AGC</e2>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D005472_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D005472_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 <e2>AGC</e2>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D005472_D013274 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 From\IN\1740 February\NNP\15209706 ,\,\1740 1998\CD\1740 to\IN\1740 September\NNP\15209706 ,\,\1740 2000\CD\1740 we\PRP\1740 recruited\VBD\2471690 33\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>AGC</e2>\NN\1740 to\TO\1740 receive\VB\2210855 weekly\JJ\1740 24-hour\JJ\1740 <e1>5-FU</e1>\NN\1740 2,600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 preceded\VBN\2690708 by\IN\1740 2-hour\JJ\1740 FA\NN\6868043 500\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 for\IN\1740 6\CD\13741022 weeks\NNS\15113229 ,\,\1740 followed\VBN\1835496 by\IN\1740 a\DT\13649268 2-week\JJ\1740 rest\NN\13809207 period\NN\13575869 .\.\1740
D005472_D013274 NONE CONCLUSIONS\NNS\5837957 :\:\1740 High-dose\JJ\1740 <e1>5-FU/FA/MMC</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 well-tolerated\JJ\1740 outpatient\JJ\1740 regimen\NN\5898568 for\IN\1740 <e2>AGC</e2>\NN\1740 (\-LRB-\1740 objective\JJ\1740 response\NN\11410625 rate\NN\13815152 54.6\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D002955_D013274 NONE High-dose\JJ\1740 5-fluorouracil\NN\1740 /\:\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 combination\NN\7951464 with\IN\1740 three-weekly\JJ\1740 mitomycin\NN\2716866 C\NN\13714184 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D002955_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D002955_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 <e2>AGC</e2>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D002955_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>FA</e1>\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D002955_D013274 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>FA</e1>\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 <e2>AGC</e2>\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 toxicity\NN\13576101 .\.\1740
D002955_D013274 NONE PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 From\IN\1740 February\NNP\15209706 ,\,\1740 1998\CD\1740 to\IN\1740 September\NNP\15209706 ,\,\1740 2000\CD\1740 we\PRP\1740 recruited\VBD\2471690 33\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>AGC</e2>\NN\1740 to\TO\1740 receive\VB\2210855 weekly\JJ\1740 24-hour\JJ\1740 5-FU\NN\1740 2,600\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 preceded\VBN\2690708 by\IN\1740 2-hour\JJ\1740 <e1>FA</e1>\NN\6868043 500\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 for\IN\1740 6\CD\13741022 weeks\NNS\15113229 ,\,\1740 followed\VBN\1835496 by\IN\1740 a\DT\13649268 2-week\JJ\1740 rest\NN\13809207 period\NN\13575869 .\.\1740
D002955_D013274 NONE CONCLUSIONS\NNS\5837957 :\:\1740 High-dose\JJ\1740 <e1>5-FU/FA/MMC</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 well-tolerated\JJ\1740 outpatient\JJ\1740 regimen\NN\5898568 for\IN\1740 <e2>AGC</e2>\NN\1740 (\-LRB-\1740 objective\JJ\1740 response\NN\11410625 rate\NN\13815152 54.6\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D016685_D013274 NONE High-dose\JJ\1740 5-fluorouracil\NN\1740 /\:\1740 folinic\JJ\1740 acid\NN\14818238 in\IN\13603305 combination\NN\7951464 with\IN\1740 three-weekly\JJ\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 advanced\JJ\1740 <e2>gastric\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D016685_D013274 NONE CONCLUSIONS\NNS\5837957 :\:\1740 High-dose\JJ\1740 <e1>5-FU/FA/MMC</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 and\CC\1740 well-tolerated\JJ\1740 outpatient\JJ\1740 regimen\NN\5898568 for\IN\1740 <e2>AGC</e2>\NN\1740 (\-LRB-\1740 objective\JJ\1740 response\NN\11410625 rate\NN\13815152 54.6\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D005472_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D005472_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D005472_D064420 NONE In\IN\13603305 a\DT\13649268 previous\JJ\1740 phase\NN\15113229 II\CD\13741022 study\NN\635850 with\IN\1740 3-weekly\JJ\1740 bolus\NN\13899404 <e1>5-FU</e1>\NN\1740 ,\,\1740 FA\NN\6868043 and\CC\1740 mitomycin\NN\2716866 C\NN\13714184 (\-LRB-\1740 MMC\NN\1740 )\-RRB-\1740 we\PRP\1740 found\VBD\2426171 a\DT\13649268 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 rate\NN\13815152 and\CC\1740 response\NN\11410625 rates\NNS\13308999 comparable\JJ\1740 to\IN\1740 those\DT\1740 of\IN\1740 regimens\NNS\5898568 such\JJ\1740 as\IN\14622893 ELF\NN\9540430 ,\,\1740 FAM\NN\1740 or\CC\3541091 FAMTX\NNP\1740 ,\,\1740 and\CC\1740 a\DT\13649268 promising\JJ\1740 median\JJ\1740 overall\JJ\1740 survival\NN\13961642 .\.\1740
D002955_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 FA\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002955_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 24-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>FA</e1>\NN\6868043 )\-RRB-\1740 as\IN\14622893 part\NN\31921 of\IN\1740 several\JJ\1740 new\JJ\1740 multidrug\NN\1740 chemotherapy\NN\661091 regimens\NNS\5898568 in\IN\13603305 advanced\JJ\1740 gastric\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 AGC\NN\1740 )\-RRB-\1740 has\VBZ\2108377 shown\VBN\2137132 to\TO\1740 be\VB\836236 effective\JJ\1740 ,\,\1740 with\IN\1740 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002955_D064420 NONE In\IN\13603305 a\DT\13649268 previous\JJ\1740 phase\NN\15113229 II\CD\13741022 study\NN\635850 with\IN\1740 3-weekly\JJ\1740 bolus\NN\13899404 5-FU\NN\1740 ,\,\1740 <e1>FA</e1>\NN\6868043 and\CC\1740 mitomycin\NN\2716866 C\NN\13714184 (\-LRB-\1740 MMC\NN\1740 )\-RRB-\1740 we\PRP\1740 found\VBD\2426171 a\DT\13649268 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 rate\NN\13815152 and\CC\1740 response\NN\11410625 rates\NNS\13308999 comparable\JJ\1740 to\IN\1740 those\DT\1740 of\IN\1740 regimens\NNS\5898568 such\JJ\1740 as\IN\14622893 ELF\NN\9540430 ,\,\1740 FAM\NN\1740 or\CC\3541091 FAMTX\NNP\1740 ,\,\1740 and\CC\1740 a\DT\13649268 promising\JJ\1740 median\JJ\1740 overall\JJ\1740 survival\NN\13961642 .\.\1740
D016685_D064420 NONE In\IN\13603305 a\DT\13649268 previous\JJ\1740 phase\NN\15113229 II\CD\13741022 study\NN\635850 with\IN\1740 3-weekly\JJ\1740 bolus\NN\13899404 5-FU\NN\1740 ,\,\1740 FA\NN\6868043 and\CC\1740 <e1>mitomycin\NN\2716866 C</e1>\NN\13714184 (\-LRB-\1740 MMC\NN\1740 )\-RRB-\1740 we\PRP\1740 found\VBD\2426171 a\DT\13649268 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 rate\NN\13815152 and\CC\1740 response\NN\11410625 rates\NNS\13308999 comparable\JJ\1740 to\IN\1740 those\DT\1740 of\IN\1740 regimens\NNS\5898568 such\JJ\1740 as\IN\14622893 ELF\NN\9540430 ,\,\1740 FAM\NN\1740 or\CC\3541091 FAMTX\NNP\1740 ,\,\1740 and\CC\1740 a\DT\13649268 promising\JJ\1740 median\JJ\1740 overall\JJ\1740 survival\NN\13961642 .\.\1740
D016685_D064420 NONE In\IN\13603305 a\DT\13649268 previous\JJ\1740 phase\NN\15113229 II\CD\13741022 study\NN\635850 with\IN\1740 3-weekly\JJ\1740 bolus\NN\13899404 5-FU\NN\1740 ,\,\1740 FA\NN\6868043 and\CC\1740 mitomycin\NN\2716866 C\NN\13714184 (\-LRB-\1740 <e1>MMC</e1>\NN\1740 )\-RRB-\1740 we\PRP\1740 found\VBD\2426171 a\DT\13649268 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 rate\NN\13815152 and\CC\1740 response\NN\11410625 rates\NNS\13308999 comparable\JJ\1740 to\IN\1740 those\DT\1740 of\IN\1740 regimens\NNS\5898568 such\JJ\1740 as\IN\14622893 ELF\NN\9540430 ,\,\1740 FAM\NN\1740 or\CC\3541091 FAMTX\NNP\1740 ,\,\1740 and\CC\1740 a\DT\13649268 promising\JJ\1740 median\JJ\1740 overall\JJ\1740 survival\NN\13961642 .\.\1740
D002945_D006463 NONE It\PRP\6125041 may\MD\15209706 serve\VB\2669789 as\IN\14622893 an\DT\6697703 alternative\NN\5788149 to\IN\1740 <e1>cisplatin-containing</e1>\JJ\1740 regimens\NNS\5898568 ;\:\1740 however\RB\1740 ,\,\1740 it\PRP\6125041 has\VBZ\2108377 to\TO\1740 be\VB\836236 considered\VBN\689344 that\IN\1740 possibly\RB\1740 <e2>HUS</e2>\NNP\1740 may\MD\15209706 occur\VB\2623529 .\.\1740
12912689
D016190_D012175 NONE Ocular\JJ\1740 motility\NN\4773351 changes\NNS\7283608 after\IN\1740 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 chemotherapy\NN\661091 for\IN\1740 <e2>retinoblastoma</e2>\NN\14239425 .\.\1740
D016190_D012175 NONE BACKGROUND\NN\4921011 :\:\1740 Focal\JJ\1740 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 injections\NNS\320852 have\VBP\2108377 recently\RB\1740 been\VBN\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 presumably\RB\1740 toxicity-free\JJ\1740 adjunct\NN\9312645 to\TO\1740 systemic\JJ\1740 chemotherapy\NN\661091 for\IN\1740 intraocular\JJ\1740 <e2>retinoblastoma</e2>\NN\14239425 .\.\1740
D016190_D012175 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 noted\VBD\1009240 abnormal\JJ\1740 ocular\JJ\1740 motility\NN\4773351 in\IN\13603305 10\CD\13745420 consecutive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>retinoblastoma</e2>\NN\14239425 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 .\.\1740
D016190_D012175 NONE RESULTS\NNS\34213 :\:\1740 Limitation\NN\5846054 of\IN\1740 ocular\JJ\1740 motility\NN\4773351 was\VBD\836236 detected\VBN\2163746 in\IN\13603305 all\DT\1740 12\CD\13745420 eyes\NNS\5945642 of\IN\1740 10\CD\13745420 patients\NNS\9898892 treated\VBN\2376958 for\IN\1740 intraocular\JJ\1740 <e2>retinoblastoma</e2>\NN\14239425 with\IN\1740 1\CD\13741022 to\TO\1740 6\CD\13741022 injections\NNS\320852 of\IN\1740 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 multimodality\NN\1740 therapy\NN\657604 .\.\1740
D016190_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 Focal\JJ\1740 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 injections\NNS\320852 have\VBP\2108377 recently\RB\1740 been\VBN\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 presumably\RB\1740 <e2>toxicity-free</e2>\JJ\1740 adjunct\NN\9312645 to\TO\1740 systemic\JJ\1740 chemotherapy\NN\661091 for\IN\1740 intraocular\JJ\1740 retinoblastoma\NN\14239425 .\.\1740
D016190_D064420 NONE Subtenon\NNP\1740 <e1>carboplatin</e1>\NN\1740 is\VBZ\836236 not\RB\1740 free\JJ\1740 of\IN\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 its\PRP$\6125041 use\NN\407535 is\VBZ\836236 best\RBS\1740 restricted\JJ\1740 to\TO\1740 specific\JJ\1740 indications\NNS\33020 .\.\1740
D016190_D015835 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 our\PRP$\1740 clinical\JJ\1740 experience\NN\5984287 with\IN\1740 <e2>abnormal\JJ\1740 ocular\JJ\1740 motility</e2>\NN\4773351 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 chemotherapy\NN\661091 .\.\1740
D016190_D015835 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 noted\VBD\1009240 <e2>abnormal\JJ\1740 ocular\JJ\1740 motility</e2>\NN\4773351 in\IN\13603305 10\CD\13745420 consecutive\JJ\1740 patients\NNS\9898892 with\IN\1740 retinoblastoma\NN\14239425 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 subtenon\NN\1740 <e1>carboplatin</e1>\NN\1740 .\.\1740
D016190_D005355 CID CONCLUSIONS\NNS\5837957 :\:\1740 Subtenon\NNP\1740 <e1>carboplatin</e1>\NN\1740 chemotherapy\NN\661091 is\VBZ\836236 associated\VBN\628491 with\IN\1740 significant\JJ\1740 <e2>fibrosis</e2>\NN\14204950 of\IN\1740 orbital\JJ\1740 soft\JJ\1740 tissues\NNS\5220461 ,\,\1740 leading\VBG\1752884 to\TO\1740 mechanical\JJ\1740 restriction\NN\5846054 of\IN\1740 eye\NN\5299178 movements\NNS\191142 and\CC\1740 making\VBG\126264 subsequent\JJ\1740 enucleation\NN\671351 difficult\JJ\1740 .\.\1740
9158667
D014212_D013927 CID <e2>Thrombotic</e2>\JJ\1740 complications\NNS\1073995 in\IN\13603305 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 during\IN\1740 <e1>all-trans-retinoic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 .\.\1740
D014212_D015473 NONE Thrombotic\JJ\1740 complications\NNS\1073995 in\IN\13603305 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 during\IN\1740 <e1>all-trans-retinoic\JJ\1740 acid</e1>\NN\14818238 therapy\NN\657604 .\.\1740
D014212_D015473 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>all-trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D015473 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>all-trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D015473 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D015473 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D015473 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 in\IN\13603305 an\DT\6697703 <e2>APL</e2>\NN\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>ATRA</e1>\NN\1740 alone\RB\1740 .\.\1740
D014212_D015473 NONE This\DT\1740 case\NN\7283608 further\RB\1740 supports\VBZ\2199590 the\DT\1740 concern\NN\5682950 about\IN\1740 thromboembolic\NN\1740 complications\NNS\1073995 associated\VBN\628491 with\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 <e2>APL</e2>\NN\1740 patients\NNS\9898892 .\.\1740
D014212_D015473 NONE The\DT\1740 patients\NNS\9898892 ,\,\1740 a\DT\13649268 43-year-old\JJ\1740 man\NN\9605289 ,\,\1740 presented\VBD\2137132 all\PDT\1740 the\DT\1740 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 <e2>APL</e2>\NN\1740 and\CC\1740 was\VBD\836236 included\VBN\690614 in\IN\13603305 a\DT\13649268 treatment\NN\654885 protocol\NN\6652242 with\IN\1740 <e1>ATRA</e1>\NN\1740 .\.\1740
D014212_D015473 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>ATRA</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 valid\JJ\1740 therapeutic\JJ\1740 choice\NN\5788149 for\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>APL</e2>\NN\1740 ,\,\1740 although\IN\1740 the\DT\1740 procoagulant\JJ\1740 tendency\NN\6193203 is\VBZ\836236 not\RB\1740 completely\RB\1740 corrected\VBN\138508 .\.\1740
D014212_D058186 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>all-trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D058186 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D058186 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 an\DT\6697703 APL\NN\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>ATRA</e1>\NN\1740 alone\RB\1740 .\.\1740
D014212_-1 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 <e2>occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels</e2>\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>all-trans-retinoic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_-1 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 <e2>occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels</e2>\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ATRA</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014148_D058186 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014148_-1 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 <e2>occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels</e2>\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014148_D015473 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 promyelocytic\JJ\1740 leukemia</e2>\NN\14239918 (\-LRB-\1740 APL\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014148_D015473 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 due\JJ\1740 to\TO\1740 occlusion\NN\14081375 of\IN\1740 renal\JJ\1740 vessels\NNS\5246511 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 acute\JJ\1740 promyelocytic\JJ\1740 leukemia\NN\14239918 (\-LRB-\1740 <e2>APL</e2>\NN\1740 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 all-trans-retinoic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 ATRA\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 recently\RB\1740 .\.\1740
D014212_D013923 NONE This\DT\1740 case\NN\7283608 further\RB\1740 supports\VBZ\2199590 the\DT\1740 concern\NN\5682950 about\IN\1740 <e2>thromboembolic</e2>\NN\1740 complications\NNS\1073995 associated\VBN\628491 with\IN\1740 <e1>ATRA</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 APL\NN\1740 patients\NNS\9898892 .\.\1740
D006493_D013927 NONE <e2>Thrombotic</e2>\JJ\1740 events\NNS\23100 ,\,\1740 however\RB\1740 ,\,\1740 could\MD\1740 be\VB\836236 avoided\VBN\2452885 by\IN\1740 using\VBG\1156834 low-dose\JJ\1740 <e1>heparin</e1>\NN\2718259 .\.\1740
15265979
D000638_D056486 CID <e1>Amiodarone</e1>\RB\1740 ,\,\1740 an\DT\6697703 efficacious\JJ\1740 and\CC\1740 widely\RB\1740 used\VBN\1156834 antiarrhythmic\JJ\1740 agent\NN\7347 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 cause\VB\1617192 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 some\DT\1740 patients\NNS\9898892 .\.\1740
D000638_D056486 CID These\DT\1740 results\NNS\34213 provide\VBP\2199590 important\JJ\1740 new\JJ\1740 mechanistic\JJ\1740 information\NN\6598915 regarding\VBG\689344 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 and\CC\1740 indicate\VBP\952524 that\IN\1740 PPARalpha\NN\1740 protects\VBZ\1127795 against\IN\1740 amiodarone-induced\JJ\1740 hepatotoxicity\NN\1740 .\.\1740
D000638_D056486 CID These\DT\1740 results\NNS\34213 provide\VBP\2199590 important\JJ\1740 new\JJ\1740 mechanistic\JJ\1740 information\NN\6598915 regarding\VBG\689344 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 and\CC\1740 indicate\VBP\952524 that\IN\1740 PPARalpha\NN\1740 protects\VBZ\1127795 against\IN\1740 amiodarone-induced\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D000638_D056486 CID These\DT\1740 results\NNS\34213 provide\VBP\2199590 important\JJ\1740 new\JJ\1740 mechanistic\JJ\1740 information\NN\6598915 regarding\VBG\689344 the\DT\1740 <e2>hepatotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 amiodarone\NN\2715941 and\CC\1740 indicate\VBP\952524 that\IN\1740 PPARalpha\NN\1740 protects\VBZ\1127795 against\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 hepatotoxicity\NN\1740 .\.\1740
D000638_D056486 CID These\DT\1740 results\NNS\34213 provide\VBP\2199590 important\JJ\1740 new\JJ\1740 mechanistic\JJ\1740 information\NN\6598915 regarding\VBG\689344 the\DT\1740 hepatotoxic\JJ\1740 effects\NNS\13245626 of\IN\1740 amiodarone\NN\2715941 and\CC\1740 indicate\VBP\952524 that\IN\1740 PPARalpha\NN\1740 protects\VBZ\1127795 against\IN\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D000638_D006529 CID <e1>Amiodarone</e1>\NN\2715941 induced\VBD\1627355 <e2>hepatomegaly</e2>\NN\14501726 ,\,\1740 hepatocyte\NN\1740 microvesicular\JJ\1740 lipid\NN\14944888 accumulation\NN\13497135 ,\,\1740 and\CC\1740 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 serum\NN\5397468 triglycerides\NNS\14885088 and\CC\1740 glucose\NN\14710501 .\.\1740
D000638_D006529 CID The\DT\1740 absence\NN\14449405 of\IN\1740 induction\NN\7450842 of\IN\1740 these\DT\1740 genes\NNS\8459252 as\RB\1740 well\RB\1740 as\IN\14622893 <e2>hepatomegaly</e2>\NN\14501726 in\IN\13603305 PPARalpha\NN\1740 knockout\NN\10787470 [\-LRB-\1740 PPARalpha-/-\NN\1740 ]\-RRB-\1740 mice\NNS\2329401 indicated\VBD\952524 that\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 were\VBD\836236 dependent\JJ\1740 upon\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 a\DT\13649268 functional\JJ\1740 PPARalpha\NN\1740 gene\NN\8459252 .\.\1740
D014280_D006529 NONE Amiodarone\NN\2715941 induced\VBD\1627355 <e2>hepatomegaly</e2>\NN\14501726 ,\,\1740 hepatocyte\NN\1740 microvesicular\JJ\1740 lipid\NN\14944888 accumulation\NN\13497135 ,\,\1740 and\CC\1740 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 serum\NN\5397468 <e1>triglycerides</e1>\NNS\14885088 and\CC\1740 glucose\NN\14710501 .\.\1740
D005947_D006529 NONE Amiodarone\NN\2715941 induced\VBD\1627355 <e2>hepatomegaly</e2>\NN\14501726 ,\,\1740 hepatocyte\NN\1740 microvesicular\JJ\1740 lipid\NN\14944888 accumulation\NN\13497135 ,\,\1740 and\CC\1740 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 serum\NN\5397468 triglycerides\NNS\14885088 and\CC\1740 <e1>glucose</e1>\NN\14710501 .\.\1740
D000638_D015431 NONE Compared\VBN\644583 to\TO\1740 wild-type\JJ\1740 mice\NNS\2329401 ,\,\1740 treatment\NN\654885 of\IN\1740 PPARalpha-/-\NN\1740 mice\NNS\2329401 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 increased\VBN\169651 rate\NN\13815152 and\CC\1740 extent\NN\13939892 of\IN\1740 total\JJ\1740 body\NN\19128 <e2>weight\NN\5009170 loss</e2>\NN\13252973 .\.\1740
D000638_D006528 NONE The\DT\1740 inability\NN\23271 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 to\TO\1740 directly\RB\1740 activate\VB\1641914 either\CC\1740 human\JJ\1740 or\CC\3541091 mouse\NN\2329401 PPARalpha\NN\1740 transiently\RB\1740 expressed\VBN\928630 in\IN\13603305 human\JJ\1740 HepG2\NN\1740 <e2>hepatoma</e2>\NN\14242337 cells\NNS\3080309 indicates\VBZ\952524 that\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 amiodarone\NN\2715941 on\IN\1740 the\DT\1740 function\NN\13783581 of\IN\1740 this\DT\1740 receptor\NN\5225602 were\VBD\836236 indirect\JJ\1740 .\.\1740
D000638_D006528 NONE The\DT\1740 inability\NN\23271 of\IN\1740 amiodarone\NN\2715941 to\TO\1740 directly\RB\1740 activate\VB\1641914 either\CC\1740 human\JJ\1740 or\CC\3541091 mouse\NN\2329401 PPARalpha\NN\1740 transiently\RB\1740 expressed\VBN\928630 in\IN\13603305 human\JJ\1740 HepG2\NN\1740 <e2>hepatoma</e2>\NN\14242337 cells\NNS\3080309 indicates\VBZ\952524 that\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 on\IN\1740 the\DT\1740 function\NN\13783581 of\IN\1740 this\DT\1740 receptor\NN\5225602 were\VBD\836236 indirect\JJ\1740 .\.\1740
1117341
D015119_D006943 CID <e2>Hyperglycemic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>amino</e1>\NN\14621446 compounds\NNS\5869584 structurally\RB\1740 related\JJ\1740 to\TO\1740 caproate\VB\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D015119_D006943 CID The\DT\1740 chronic\JJ\1740 feeding\NN\838098 of\IN\1740 small\JJ\1740 amounts\NNS\13329641 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 %\NN\1740 of\IN\1740 diet\JJ\1740 weight\NN\5009170 )\-RRB-\1740 of\IN\1740 certain\JJ\1740 <e1>amino</e1>\NN\14621446 derivatives\NNS\5802185 of\IN\1740 caproate\NN\1740 resulted\VBD\2633881 in\IN\13603305 <e2>hyperglycemia</e2>\NN\14299637 ,\,\1740 an\DT\6697703 elevated\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 curve\NN\13863771 and\CC\1740 ,\,\1740 occasionally\RB\1740 ,\,\1740 glucosuria\NNS\14267841 .\.\1740
C037652_D006943 NONE <e2>Hyperglycemic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 amino\NN\14621446 compounds\NNS\5869584 structurally\RB\1740 related\JJ\1740 to\TO\1740 <e1>caproate</e1>\VB\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
C037652_D006943 NONE The\DT\1740 chronic\JJ\1740 feeding\NN\838098 of\IN\1740 small\JJ\1740 amounts\NNS\13329641 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 %\NN\1740 of\IN\1740 diet\JJ\1740 weight\NN\5009170 )\-RRB-\1740 of\IN\1740 certain\JJ\1740 amino\NN\14621446 derivatives\NNS\5802185 of\IN\1740 <e1>caproate</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 <e2>hyperglycemia</e2>\NN\14299637 ,\,\1740 an\DT\6697703 elevated\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 curve\NN\13863771 and\CC\1740 ,\,\1740 occasionally\RB\1740 ,\,\1740 glucosuria\NNS\14267841 .\.\1740
D015119_D006030 NONE The\DT\1740 chronic\JJ\1740 feeding\NN\838098 of\IN\1740 small\JJ\1740 amounts\NNS\13329641 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 %\NN\1740 of\IN\1740 diet\JJ\1740 weight\NN\5009170 )\-RRB-\1740 of\IN\1740 certain\JJ\1740 <e1>amino</e1>\NN\14621446 derivatives\NNS\5802185 of\IN\1740 caproate\NN\1740 resulted\VBD\2633881 in\IN\13603305 hyperglycemia\NN\14299637 ,\,\1740 an\DT\6697703 elevated\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 curve\NN\13863771 and\CC\1740 ,\,\1740 occasionally\RB\1740 ,\,\1740 <e2>glucosuria</e2>\NNS\14267841 .\.\1740
C037652_D006030 NONE The\DT\1740 chronic\JJ\1740 feeding\NN\838098 of\IN\1740 small\JJ\1740 amounts\NNS\13329641 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 %\NN\1740 of\IN\1740 diet\JJ\1740 weight\NN\5009170 )\-RRB-\1740 of\IN\1740 certain\JJ\1740 amino\NN\14621446 derivatives\NNS\5802185 of\IN\1740 <e1>caproate</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 hyperglycemia\NN\14299637 ,\,\1740 an\DT\6697703 elevated\JJ\1740 glucose\NN\14710501 tolerance\NN\5032565 curve\NN\13863771 and\CC\1740 ,\,\1740 occasionally\RB\1740 ,\,\1740 <e2>glucosuria</e2>\NNS\14267841 .\.\1740
D005947_D006943 NONE The\DT\1740 chronic\JJ\1740 feeding\NN\838098 of\IN\1740 small\JJ\1740 amounts\NNS\13329641 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 %\NN\1740 of\IN\1740 diet\JJ\1740 weight\NN\5009170 )\-RRB-\1740 of\IN\1740 certain\JJ\1740 amino\NN\14621446 derivatives\NNS\5802185 of\IN\1740 caproate\NN\1740 resulted\VBD\2633881 in\IN\13603305 <e2>hyperglycemia</e2>\NN\14299637 ,\,\1740 an\DT\6697703 elevated\JJ\1740 <e1>glucose</e1>\NN\14710501 tolerance\NN\5032565 curve\NN\13863771 and\CC\1740 ,\,\1740 occasionally\RB\1740 ,\,\1740 glucosuria\NNS\14267841 .\.\1740
D005947_D006030 NONE The\DT\1740 chronic\JJ\1740 feeding\NN\838098 of\IN\1740 small\JJ\1740 amounts\NNS\13329641 (\-LRB-\1740 0.3\CD\1740 -\SYM\1740 3\CD\13741022 %\NN\1740 of\IN\1740 diet\JJ\1740 weight\NN\5009170 )\-RRB-\1740 of\IN\1740 certain\JJ\1740 amino\NN\14621446 derivatives\NNS\5802185 of\IN\1740 caproate\NN\1740 resulted\VBD\2633881 in\IN\13603305 hyperglycemia\NN\14299637 ,\,\1740 an\DT\6697703 elevated\JJ\1740 <e1>glucose</e1>\NN\14710501 tolerance\NN\5032565 curve\NN\13863771 and\CC\1740 ,\,\1740 occasionally\RB\1740 ,\,\1740 <e2>glucosuria</e2>\NNS\14267841 .\.\1740
19108278
D011433_D001145 NONE The\DT\1740 biological\JJ\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 optical\JJ\1740 isomers\NNS\14818238 of\IN\1740 <e1>propranolol</e1>\NN\1740 and\CC\1740 their\PRP$\1740 effects\NNS\13245626 on\IN\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 .\.\1740
D011433_D001145 NONE Both\DT\1740 isomers\NNS\14818238 of\IN\1740 <e1>propranolol</e1>\NN\1740 were\VBD\836236 capable\JJ\1740 of\IN\1740 preventing\VBG\1740 adrenaline-induced\JJ\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 in\IN\13603305 cats\NNS\2120997 anaesthetized\VBN\84738 with\IN\1740 halothane\NN\3570838 ,\,\1740 but\CC\1740 the\DT\1740 mean\NN\6021761 dose\NN\3740161 of\IN\1740 (-)-propranolol\NN\1740 was\VBD\836236 0.09+/-0.02\CD\1740 mg/kg\NN\1740 whereas\IN\1740 that\DT\1740 of\IN\1740 (+)-propranolol\NN\1740 was\VBD\836236 4.2+/-1.2\CD\1740 mg/kg\NN\1740 .\.\1740
D011433_D001145 NONE Both\DT\1740 isomers\NNS\14818238 of\IN\1740 propranolol\NN\1740 were\VBD\836236 capable\JJ\1740 of\IN\1740 preventing\VBG\1740 adrenaline-induced\JJ\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 in\IN\13603305 cats\NNS\2120997 anaesthetized\VBN\84738 with\IN\1740 halothane\NN\3570838 ,\,\1740 but\CC\1740 the\DT\1740 mean\NN\6021761 dose\NN\3740161 of\IN\1740 <e1>(-)-propranolol</e1>\NN\1740 was\VBD\836236 0.09+/-0.02\CD\1740 mg/kg\NN\1740 whereas\IN\1740 that\DT\1740 of\IN\1740 (+)-propranolol\NN\1740 was\VBD\836236 4.2+/-1.2\CD\1740 mg/kg\NN\1740 .\.\1740
D011433_D001145 NONE Both\DT\1740 isomers\NNS\14818238 of\IN\1740 propranolol\NN\1740 were\VBD\836236 capable\JJ\1740 of\IN\1740 preventing\VBG\1740 adrenaline-induced\JJ\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 in\IN\13603305 cats\NNS\2120997 anaesthetized\VBN\84738 with\IN\1740 halothane\NN\3570838 ,\,\1740 but\CC\1740 the\DT\1740 mean\NN\6021761 dose\NN\3740161 of\IN\1740 (-)-propranolol\NN\1740 was\VBD\836236 0.09+/-0.02\CD\1740 mg/kg\NN\1740 whereas\IN\1740 that\DT\1740 of\IN\1740 <e1>(+)-propranolol</e1>\NN\1740 was\VBD\836236 4.2+/-1.2\CD\1740 mg/kg\NN\1740 .\.\1740
D004837_D001145 CID Both\DT\1740 isomers\NNS\14818238 of\IN\1740 propranolol\NN\1740 were\VBD\836236 capable\JJ\1740 of\IN\1740 preventing\VBG\1740 <e1>adrenaline-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 in\IN\13603305 cats\NNS\2120997 anaesthetized\VBN\84738 with\IN\1740 halothane\NN\3570838 ,\,\1740 but\CC\1740 the\DT\1740 mean\NN\6021761 dose\NN\3740161 of\IN\1740 (-)-propranolol\NN\1740 was\VBD\836236 0.09+/-0.02\CD\1740 mg/kg\NN\1740 whereas\IN\1740 that\DT\1740 of\IN\1740 (+)-propranolol\NN\1740 was\VBD\836236 4.2+/-1.2\CD\1740 mg/kg\NN\1740 .\.\1740
D004837_D001145 CID Blockade\NN\952963 of\IN\1740 <e2>arrhythmias</e2>\NNS\14103288 with\IN\1740 both\DT\1740 isomers\NNS\14818238 was\VBD\836236 surmountable\JJ\1740 by\IN\1740 increasing\VBG\169651 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>adrenaline.7</e1>\NN\1740 .\.\1740
D006221_D001145 CID Both\DT\1740 isomers\NNS\14818238 of\IN\1740 propranolol\NN\1740 were\VBD\836236 capable\JJ\1740 of\IN\1740 preventing\VBG\1740 adrenaline-induced\JJ\1740 <e2>cardiac\JJ\1740 arrhythmias</e2>\NNS\14103288 in\IN\13603305 cats\NNS\2120997 anaesthetized\VBN\84738 with\IN\1740 <e1>halothane</e1>\NN\3570838 ,\,\1740 but\CC\1740 the\DT\1740 mean\NN\6021761 dose\NN\3740161 of\IN\1740 (-)-propranolol\NN\1740 was\VBD\836236 0.09+/-0.02\CD\1740 mg/kg\NN\1740 whereas\IN\1740 that\DT\1740 of\IN\1740 (+)-propranolol\NN\1740 was\VBD\836236 4.2+/-1.2\CD\1740 mg/kg\NN\1740 .\.\1740
D011433_D017180 NONE Both\DT\1740 isomers\NNS\14818238 of\IN\1740 <e1>propranolol</e1>\NN\1740 were\VBD\836236 also\RB\1740 capable\JJ\1740 of\IN\1740 reversing\VBG\109660 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 ouabain\NN\1740 in\IN\13603305 anaesthetized\VBN\84738 cats\NNS\2120997 and\CC\1740 dogs\NNS\2083346 .\.\1740
D010042_D017180 CID Both\DT\1740 isomers\NNS\14818238 of\IN\1740 propranolol\NN\1740 were\VBD\836236 also\RB\1740 capable\JJ\1740 of\IN\1740 reversing\VBG\109660 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 <e1>ouabain</e1>\NN\1740 in\IN\13603305 anaesthetized\VBN\84738 cats\NNS\2120997 and\CC\1740 dogs\NNS\2083346 .\.\1740
1451544
D017275_D006973 NONE <e1>Isradipine</e1>\NN\1740 treatment\NN\654885 for\IN\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 general\JJ\1740 practice\NN\407535 in\IN\13603305 Hong\NNP\1740 Kong\NNP\1740 .\.\1740
D017275_D006261 CID The\DT\1740 main\JJ\1740 side-effects\NNS\1740 were\VBD\836236 <e2>headache</e2>\VBN\1740 ,\,\1740 dizziness\JJ\1740 ,\,\1740 palpitation\NN\14299637 and\CC\1740 flushing\VBG\281101 and\CC\1740 these\DT\1740 were\VBD\836236 not\RB\1740 more\RBR\1740 frequent\JJ\1740 than\IN\1740 reported\VBN\831651 in\IN\13603305 other\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>isradipine</e1>\NN\1740 or\CC\3541091 with\IN\1740 placebo\NN\3740161 .\.\1740
D017275_D004244 CID The\DT\1740 main\JJ\1740 side-effects\NNS\1740 were\VBD\836236 headache\VBN\1740 ,\,\1740 <e2>dizziness</e2>\JJ\1740 ,\,\1740 palpitation\NN\14299637 and\CC\1740 flushing\VBG\281101 and\CC\1740 these\DT\1740 were\VBD\836236 not\RB\1740 more\RBR\1740 frequent\JJ\1740 than\IN\1740 reported\VBN\831651 in\IN\13603305 other\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>isradipine</e1>\NN\1740 or\CC\3541091 with\IN\1740 placebo\NN\3740161 .\.\1740
D017275_-1 NONE The\DT\1740 main\JJ\1740 side-effects\NNS\1740 were\VBD\836236 headache\VBN\1740 ,\,\1740 dizziness\JJ\1740 ,\,\1740 <e2>palpitation</e2>\NN\14299637 and\CC\1740 flushing\VBG\281101 and\CC\1740 these\DT\1740 were\VBD\836236 not\RB\1740 more\RBR\1740 frequent\JJ\1740 than\IN\1740 reported\VBN\831651 in\IN\13603305 other\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>isradipine</e1>\NN\1740 or\CC\3541091 with\IN\1740 placebo\NN\3740161 .\.\1740
D017275_D005483 CID The\DT\1740 main\JJ\1740 side-effects\NNS\1740 were\VBD\836236 headache\VBN\1740 ,\,\1740 dizziness\JJ\1740 ,\,\1740 palpitation\NN\14299637 and\CC\1740 <e2>flushing</e2>\VBG\281101 and\CC\1740 these\DT\1740 were\VBD\836236 not\RB\1740 more\RBR\1740 frequent\JJ\1740 than\IN\1740 reported\VBN\831651 in\IN\13603305 other\JJ\1740 studies\NNS\635850 with\IN\1740 <e1>isradipine</e1>\NN\1740 or\CC\3541091 with\IN\1740 placebo\NN\3740161 .\.\1740
1395192
D001971_D009203 CID Recurrent\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 a\DT\13649268 postpartum\NN\1740 patient\NN\9898892 receiving\VBG\2210855 <e1>bromocriptine</e1>\NN\1740 .\.\1740
D001971_D009203 CID <e1>Bromocriptine</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 several\JJ\1740 previous\JJ\1740 case\NN\7283608 reports\NNS\6470073 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 the\DT\1740 puerperium\NN\15113229 .\.\1740
3475563
D001507_D002180 CID Rechallenge\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>oral\JJ\1740 candidiasis</e2>\NN\14176895 or\CC\3541091 hoarseness\JJ\1740 with\IN\1740 <e1>beclomethasone\NN\1740 dipropionate</e1>\NN\1740 .\.\1740
D001507_D002180 CID Of\IN\1740 158\CD\1740 asthmatic\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 placed\VBN\1850315 on\IN\1740 inhaled\VBN\1198101 <e1>beclomethasone</e1>\NN\1740 ,\,\1740 15\CD\13745420 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 either\CC\1740 hoarseness\NN\4988666 (\-LRB-\1740 8)\CD\1740 ,\,\1740 oral\JJ\1740 <e2>thrush</e2>\NN\14181713 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 ,\,\1740 or\CC\3541091 both\DT\1740 (\-LRB-\1740 1\CD\13741022 )\-RRB-\1740 .\.\1740
D001507_D006685 CID Rechallenge\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 oral\JJ\1740 candidiasis\NN\14176895 or\CC\3541091 <e2>hoarseness</e2>\JJ\1740 with\IN\1740 <e1>beclomethasone\NN\1740 dipropionate</e1>\NN\1740 .\.\1740
D001507_D006685 CID Of\IN\1740 158\CD\1740 asthmatic\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 placed\VBN\1850315 on\IN\1740 inhaled\VBN\1198101 <e1>beclomethasone</e1>\NN\1740 ,\,\1740 15\CD\13745420 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 either\CC\1740 <e2>hoarseness</e2>\NN\4988666 (\-LRB-\1740 8)\CD\1740 ,\,\1740 oral\JJ\1740 thrush\NN\14181713 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 ,\,\1740 or\CC\3541091 both\DT\1740 (\-LRB-\1740 1\CD\13741022 )\-RRB-\1740 .\.\1740
D001507_D006685 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 patients\NNS\9898892 may\MD\15209706 be\VB\836236 restarted\VBN\1857717 on\IN\1740 inhaled\VBN\1198101 <e1>beclomethasone</e1>\NN\1740 when\WRB\1740 clinically\RB\1740 indicated\VBN\952524 ;\:\1740 however\RB\1740 ,\,\1740 because\IN\1740 of\IN\1740 the\DT\1740 high\JJ\1740 recurrence\NN\7342049 rate\NN\13815152 ,\,\1740 patients\NNS\9898892 who\WP\8299493 develop\VBP\1753788 <e2>hoarseness</e2>\NN\4988666 should\MD\1740 not\RB\1740 be\VB\836236 re-challenged\VBN\1740 .\.\1740
D001507_D006685 CID Concomitant\JJ\1740 use\NN\407535 of\IN\1740 oral\JJ\1740 prednisone\NN\2721538 and\CC\1740 topical\JJ\1740 <e1>beclomethasone</e1>\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>hoarseness</e2>\NN\4988666 or\CC\3541091 candidiasis\NN\14176895 .\.\1740
D001507_D001249 NONE Of\IN\1740 158\CD\1740 <e2>asthmatic</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 placed\VBN\1850315 on\IN\1740 inhaled\VBN\1198101 <e1>beclomethasone</e1>\NN\1740 ,\,\1740 15\CD\13745420 (\-LRB-\1740 9.5\CD\1740 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 either\CC\1740 hoarseness\NN\4988666 (\-LRB-\1740 8)\CD\1740 ,\,\1740 oral\JJ\1740 thrush\NN\14181713 (\-LRB-\1740 6\CD\13741022 )\-RRB-\1740 ,\,\1740 or\CC\3541091 both\DT\1740 (\-LRB-\1740 1\CD\13741022 )\-RRB-\1740 .\.\1740
D011241_D006685 NONE Concomitant\JJ\1740 use\NN\407535 of\IN\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 and\CC\1740 topical\JJ\1740 beclomethasone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>hoarseness</e2>\NN\4988666 or\CC\3541091 candidiasis\NN\14176895 .\.\1740
D011241_D002177 NONE Concomitant\JJ\1740 use\NN\407535 of\IN\1740 oral\JJ\1740 <e1>prednisone</e1>\NN\2721538 and\CC\1740 topical\JJ\1740 beclomethasone\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 hoarseness\NN\4988666 or\CC\3541091 <e2>candidiasis</e2>\NN\14176895 .\.\1740
D001507_D002177 NONE Concomitant\JJ\1740 use\NN\407535 of\IN\1740 oral\JJ\1740 prednisone\NN\2721538 and\CC\1740 topical\JJ\1740 <e1>beclomethasone</e1>\NN\1740 may\MD\15209706 increase\VB\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 hoarseness\NN\4988666 or\CC\3541091 <e2>candidiasis</e2>\NN\14176895 .\.\1740
11799346
D015662_D001714 CID <e1>Cotrimoxazole</e1>\NNP\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 erythromycin\NN\2716866 were\VBD\836236 involved\VBN\2676054 in\IN\13603305 15\CD\13745420 reported\VBN\831651 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 .\.\1740
D008795_D001714 CID Cotrimoxazole\NNP\1740 ,\,\1740 <e1>metronidazole</e1>\NN\2723292 ,\,\1740 and\CC\1740 erythromycin\NN\2716866 were\VBD\836236 involved\VBN\2676054 in\IN\13603305 15\CD\13745420 reported\VBN\831651 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 .\.\1740
D004917_D001714 CID Cotrimoxazole\NNP\1740 ,\,\1740 metronidazole\NN\2723292 ,\,\1740 and\CC\1740 <e1>erythromycin</e1>\NN\2716866 were\VBD\836236 involved\VBN\2676054 in\IN\13603305 15\CD\13745420 reported\VBN\831651 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 .\.\1740
D017291_D001714 CID Cases\NNS\7283608 reported\VBN\831651 by\IN\1740 the\DT\1740 FDA\NNP\8337324 showed\VBD\2137132 <e1>clarithromycin</e1>\NN\1740 and\CC\1740 ciprofloxacin\NN\2716866 to\TO\1740 be\VB\836236 the\DT\1740 most\RBS\1740 frequently\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>mania</e2>\NN\9180259 .\.\1740
D002939_D001714 CID Cases\NNS\7283608 reported\VBN\831651 by\IN\1740 the\DT\1740 FDA\NNP\8337324 showed\VBD\2137132 clarithromycin\NN\1740 and\CC\1740 <e1>ciprofloxacin</e1>\NN\2716866 to\TO\1740 be\VB\836236 the\DT\1740 most\RBS\1740 frequently\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>mania</e2>\NN\9180259 .\.\1740
10764869
D016559_D009901 CID A\DT\13649268 case\NN\7283608 of\IN\1740 bilateral\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 on\IN\1740 <e1>tacrolimus</e1>\NN\1740 (\-LRB-\1740 FK506\NN\1740 )\-RRB-\1740 therapy\NN\657604 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D016559_D009901 CID A\DT\13649268 case\NN\7283608 of\IN\1740 bilateral\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 on\IN\1740 tacrolimus\NN\1740 (\-LRB-\1740 <e1>FK506</e1>\NN\1740 )\-RRB-\1740 therapy\NN\657604 after\IN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D016559_D009901 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 bilateral\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 <e1>tacrolimus</e1>\NN\1740 (\-LRB-\1740 FK\NN\1740 506\CD\1740 ,\,\1740 Prograf\NNP\1740 ;\:\1740 Fujisawa\NNP\1740 USA\NNP\8337324 ,\,\1740 Inc\NNP\8403787 ,\,\1740 Deerfield\NNP\1740 ,\,\1740 Illinois\NNP\9646608 )\-RRB-\1740 for\IN\1740 immunosuppression\NN\13973990 after\IN\1740 orthotropic\JJ\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D016559_D009901 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 bilateral\JJ\1740 <e2>optic\NN\5299178 neuropathy</e2>\JJ\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 tacrolimus\NN\1740 (\-LRB-\1740 <e1>FK\NN\1740 506</e1>\CD\1740 ,\,\1740 Prograf\NNP\1740 ;\:\1740 Fujisawa\NNP\1740 USA\NNP\8337324 ,\,\1740 Inc\NNP\8403787 ,\,\1740 Deerfield\NNP\1740 ,\,\1740 Illinois\NNP\9646608 )\-RRB-\1740 for\IN\1740 immunosuppression\NN\13973990 after\IN\1740 orthotropic\JJ\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
D016559_D009901 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Tacrolimus</e1>\NN\1740 and\CC\1740 other\JJ\1740 immunosuppressive\JJ\1740 agents\NNS\7347 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 <e2>optic\JJ\1740 nerve\NN\5475681 toxicity</e2>\NN\13576101 .\.\1740
D016559_D015354 NONE <e2>Deterioration\NN\14560612 of\IN\1740 vision</e2>\NN\5767733 occurred\VBD\2623529 despite\IN\7501545 discontinuation\NN\209943 of\IN\1740 the\DT\1740 <e1>tacrolimus</e1>\NN\1740 .\.\1740
24595967
D018817_D008569 CID <e2>Dysfunctional\JJ\1740 overnight\JJ\1740 memory</e2>\NN\5926676 consolidation\NN\7373803 in\IN\13603305 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 .\.\1740
D018817_D008569 CID <e1>Ecstasy</e1>\NNP\13985818 users\NNS\7846 demonstrated\VBD\2137132 <e2>impaired\JJ\1740 overnight\JJ\1740 memory</e2>\NN\5926676 consolidation\NN\7373803 ,\,\1740 a\DT\13649268 finding\NN\43195 that\WDT\1740 was\VBD\836236 more\RBR\1740 pronounced\JJ\1740 following\VBG\1835496 associative\JJ\1740 interference\NN\6660942 .\.\1740
D018817_D008569 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 <e1>ecstasy-associated</e1>\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 fronto-temporal\JJ\1740 circuitry\NN\3278248 may\MD\15209706 underlie\VB\2604760 overnight\JJ\1740 consolidation\NN\7373803 <e2>memory\NN\5926676 impairments</e2>\NNS\7296428 in\IN\13603305 regular\JJ\1740 ecstasy\NN\13985818 users\NNS\7846 .\.\1740
D018817_D008569 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 ecstasy-associated\JJ\1740 dysfunction\NN\14204950 in\IN\13603305 fronto-temporal\JJ\1740 circuitry\NN\3278248 may\MD\15209706 underlie\VB\2604760 overnight\JJ\1740 consolidation\NN\7373803 <e2>memory\NN\5926676 impairments</e2>\NNS\7296428 in\IN\13603305 regular\JJ\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 .\.\1740
D018817_D012893 CID Previous\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 have\VBP\2108377 marked\VBN\1296462 and\CC\1740 persistent\JJ\1740 neurocognitive\JJ\1740 and\CC\1740 <e2>sleep-related\JJ\1740 impairments</e2>\NNS\7296428 .\.\1740
48835
D011433_D007003 NONE Modification\NN\191142 by\IN\1740 <e1>propranolol</e1>\NN\1740 of\IN\1740 cardiovascular\JJ\1740 effects\NNS\13245626 of\IN\1740 induced\VBN\1627355 <e2>hypoglycaemia</e2>\NN\14299637 .\.\1740
17572393
D008550_D054220 NONE Neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>melatonin</e1>\NN\5407119 upon\IN\1740 the\DT\1740 offspring\VBG\1740 cerebellar\NN\1740 cortex\NN\5462674 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 BCNU-induced\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 .\.\1740
D008550_D054220 NONE This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 offspring\VBG\1740 rat\NN\2329401 cerebellum\NN\5462674 induced\VBN\1627355 by\IN\1740 maternal\JJ\1740 exposure\NN\5042871 to\TO\1740 carmustine-[1,3-bis\NN\1740 (2-chloroethyl)-1-nitrosoure\NN\1740 ]\-RRB-\1740 (\-LRB-\1740 BCNU\NNS\1740 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 exogenous\JJ\1740 <e1>melatonin</e1>\NN\5407119 upon\IN\1740 cerebellar\JJ\1740 BCNU-induced\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 ,\,\1740 using\VBG\1156834 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 analyses\NNS\633864 .\.\1740
D002330_D054220 CID Neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 melatonin\NN\5407119 upon\IN\1740 the\DT\1740 offspring\VBG\1740 cerebellar\NN\1740 cortex\NN\5462674 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>BCNU-induced</e1>\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 .\.\1740
D002330_D054220 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 offspring\VBG\1740 rat\NN\2329401 cerebellum\NN\5462674 induced\VBN\1627355 by\IN\1740 maternal\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>carmustine-[1,3-bis</e1>\NN\1740 (2-chloroethyl)-1-nitrosoure\NN\1740 ]\-RRB-\1740 (\-LRB-\1740 BCNU\NNS\1740 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 exogenous\JJ\1740 melatonin\NN\5407119 upon\IN\1740 cerebellar\JJ\1740 BCNU-induced\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 ,\,\1740 using\VBG\1156834 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 analyses\NNS\633864 .\.\1740
D002330_D054220 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 offspring\VBG\1740 rat\NN\2329401 cerebellum\NN\5462674 induced\VBN\1627355 by\IN\1740 maternal\JJ\1740 exposure\NN\5042871 to\TO\1740 <e1>carmustine-[1,3-bis\NN\1740 (2-chloroethyl)-1-nitrosoure</e1>\NN\1740 ]\-RRB-\1740 (\-LRB-\1740 BCNU\NNS\1740 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 exogenous\JJ\1740 melatonin\NN\5407119 upon\IN\1740 cerebellar\JJ\1740 BCNU-induced\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 ,\,\1740 using\VBG\1156834 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 analyses\NNS\633864 .\.\1740
D002330_D054220 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 offspring\VBG\1740 rat\NN\2329401 cerebellum\NN\5462674 induced\VBN\1627355 by\IN\1740 maternal\JJ\1740 exposure\NN\5042871 to\TO\1740 carmustine-[1,3-bis\NN\1740 (2-chloroethyl)-1-nitrosoure\NN\1740 ]\-RRB-\1740 (\-LRB-\1740 <e1>BCNU</e1>\NNS\1740 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 exogenous\JJ\1740 melatonin\NN\5407119 upon\IN\1740 cerebellar\JJ\1740 BCNU-induced\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 ,\,\1740 using\VBG\1156834 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 analyses\NNS\633864 .\.\1740
D002330_D054220 CID This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 alterations\NNS\7283608 in\IN\13603305 offspring\VBG\1740 rat\NN\2329401 cerebellum\NN\5462674 induced\VBN\1627355 by\IN\1740 maternal\JJ\1740 exposure\NN\5042871 to\TO\1740 carmustine-[1,3-bis\NN\1740 (2-chloroethyl)-1-nitrosoure\NN\1740 ]\-RRB-\1740 (\-LRB-\1740 BCNU\NNS\1740 )\-RRB-\1740 and\CC\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 exogenous\JJ\1740 melatonin\NN\5407119 upon\IN\1740 cerebellar\JJ\1740 <e1>BCNU-induced</e1>\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 ,\,\1740 using\VBG\1156834 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 analyses\NNS\633864 .\.\1740
D002330_D054220 CID Histopathologically\RB\1740 ,\,\1740 typical\JJ\1740 findings\NNS\7951464 were\VBD\836236 observed\VBN\2163746 in\IN\13603305 the\DT\1740 cerebella\NN\5462674 from\IN\1740 the\DT\1740 control\NN\5190804 groups\NNS\2137 ,\,\1740 but\CC\1740 the\DT\1740 findings\NNS\7951464 consistent\JJ\1740 with\IN\1740 early\JJ\1740 embryonic\JJ\1740 development\NN\248977 were\VBD\836236 noted\VBN\1009240 in\IN\13603305 <e1>BCNU-exposed</e1>\JJ\1740 <e2>cortical\JJ\1740 dysplasia</e2>\NN\14501726 group\NN\2137 .\.\1740
12677626
C476513_D020258 NONE <e2>Central\JJ\1740 nervous\JJ\1740 system\NN\3575240 toxicity</e2>\NN\13576101 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 for\IN\1740 lumbar\JJ\1740 plexus\NN\5225602 block\NN\21939 :\:\1740 A\DT\13649268 report\NN\6470073 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
C476513_D004830 CID We\PRP\1740 describe\VBP\1001294 2\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>grand\JJ\1740 mal\JJ\1740 seizures</e2>\NNS\14081375 following\VBG\1835496 accidental\JJ\1740 intravascular\JJ\1740 injection\NN\320852 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 .\.\1740
C476513_D004830 CID Immediately\RB\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 0.5\CD\1740 %\NN\1740 with\IN\1740 epinephrine\NN\14807929 2.5\CD\1740 microgram/mL\NN\1740 ,\,\1740 the\DT\1740 patients\NNS\9898892 developed\VBD\1753788 <e2>grand\JJ\1740 mal\JJ\1740 seizures</e2>\NNS\14081375 ,\,\1740 despite\IN\7501545 negative\JJ\1740 aspiration\NN\4836268 for\IN\1740 blood\NN\5397468 and\CC\1740 no\DT\7204911 clinical\JJ\1740 signs\NNS\6643763 of\IN\1740 intravenous\JJ\1740 epinephrine\NN\14807929 administration\NN\1133281 .\.\1740
D004837_D004830 NONE Immediately\RB\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 levobupivacaine\NN\1740 0.5\CD\1740 %\NN\1740 with\IN\1740 <e1>epinephrine</e1>\NN\14807929 2.5\CD\1740 microgram/mL\NN\1740 ,\,\1740 the\DT\1740 patients\NNS\9898892 developed\VBD\1753788 <e2>grand\JJ\1740 mal\JJ\1740 seizures</e2>\NNS\14081375 ,\,\1740 despite\IN\7501545 negative\JJ\1740 aspiration\NN\4836268 for\IN\1740 blood\NN\5397468 and\CC\1740 no\DT\7204911 clinical\JJ\1740 signs\NNS\6643763 of\IN\1740 intravenous\JJ\1740 epinephrine\NN\14807929 administration\NN\1133281 .\.\1740
D004837_D004830 NONE Immediately\RB\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 levobupivacaine\NN\1740 0.5\CD\1740 %\NN\1740 with\IN\1740 epinephrine\NN\14807929 2.5\CD\1740 microgram/mL\NN\1740 ,\,\1740 the\DT\1740 patients\NNS\9898892 developed\VBD\1753788 <e2>grand\JJ\1740 mal\JJ\1740 seizures</e2>\NNS\14081375 ,\,\1740 despite\IN\7501545 negative\JJ\1740 aspiration\NN\4836268 for\IN\1740 blood\NN\5397468 and\CC\1740 no\DT\7204911 clinical\JJ\1740 signs\NNS\6643763 of\IN\1740 intravenous\JJ\1740 <e1>epinephrine</e1>\NN\14807929 administration\NN\1133281 .\.\1740
D013874_D012640 NONE The\DT\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>sodium\NN\14625458 thiopental</e1>\NN\2792049 in\IN\13603305 addition\NN\3081021 to\TO\1740 succinylcholine\NN\3800001 in\IN\13603305 1\CD\13741022 patient\NN\9898892 .\.\1740
D013390_D012640 NONE The\DT\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 sodium\NN\14625458 thiopental\NN\2792049 in\IN\13603305 addition\NN\3081021 to\TO\1740 <e1>succinylcholine</e1>\NN\3800001 in\IN\13603305 1\CD\13741022 patient\NN\9898892 .\.\1740
C476513_D066126 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 <e1>levobupivacaine</e1>\NN\1740 may\MD\15209706 have\VB\2108377 a\DT\13649268 safer\JJR\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 profile\NN\6999802 than\IN\1740 racemic\JJ\1740 bupivacaine\NN\1740 ,\,\1740 if\IN\1740 adequate\JJ\1740 amounts\NNS\13329641 of\IN\1740 levobupivacaine\NN\1740 reach\VBP\2005948 the\DT\1740 circulation\NN\6253140 ,\,\1740 it\PRP\6125041 will\MD\5650329 result\VB\2633881 in\IN\13603305 convulsions\NNS\14081375 .\.\1740
C476513_D066126 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 levobupivacaine\NN\1740 may\MD\15209706 have\VB\2108377 a\DT\13649268 safer\JJR\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 profile\NN\6999802 than\IN\1740 racemic\JJ\1740 bupivacaine\NN\1740 ,\,\1740 if\IN\1740 adequate\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 reach\VBP\2005948 the\DT\1740 circulation\NN\6253140 ,\,\1740 it\PRP\6125041 will\MD\5650329 result\VB\2633881 in\IN\13603305 convulsions\NNS\14081375 .\.\1740
C476513_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 <e1>levobupivacaine</e1>\NN\1740 may\MD\15209706 have\VB\2108377 a\DT\13649268 safer\JJR\1740 cardiac\JJ\1740 toxicity\NN\13576101 profile\NN\6999802 than\IN\1740 racemic\JJ\1740 bupivacaine\NN\1740 ,\,\1740 if\IN\1740 adequate\JJ\1740 amounts\NNS\13329641 of\IN\1740 levobupivacaine\NN\1740 reach\VBP\2005948 the\DT\1740 circulation\NN\6253140 ,\,\1740 it\PRP\6125041 will\MD\5650329 result\VB\2633881 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 .\.\1740
C476513_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 levobupivacaine\NN\1740 may\MD\15209706 have\VB\2108377 a\DT\13649268 safer\JJR\1740 cardiac\JJ\1740 toxicity\NN\13576101 profile\NN\6999802 than\IN\1740 racemic\JJ\1740 bupivacaine\NN\1740 ,\,\1740 if\IN\1740 adequate\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>levobupivacaine</e1>\NN\1740 reach\VBP\2005948 the\DT\1740 circulation\NN\6253140 ,\,\1740 it\PRP\6125041 will\MD\5650329 result\VB\2633881 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D002045_D066126 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 levobupivacaine\NN\1740 may\MD\15209706 have\VB\2108377 a\DT\13649268 safer\JJR\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 profile\NN\6999802 than\IN\1740 racemic\JJ\1740 <e1>bupivacaine</e1>\NN\1740 ,\,\1740 if\IN\1740 adequate\JJ\1740 amounts\NNS\13329641 of\IN\1740 levobupivacaine\NN\1740 reach\VBP\2005948 the\DT\1740 circulation\NN\6253140 ,\,\1740 it\PRP\6125041 will\MD\5650329 result\VB\2633881 in\IN\13603305 convulsions\NNS\14081375 .\.\1740
D002045_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 levobupivacaine\NN\1740 may\MD\15209706 have\VB\2108377 a\DT\13649268 safer\JJR\1740 cardiac\JJ\1740 toxicity\NN\13576101 profile\NN\6999802 than\IN\1740 racemic\JJ\1740 <e1>bupivacaine</e1>\NN\1740 ,\,\1740 if\IN\1740 adequate\JJ\1740 amounts\NNS\13329641 of\IN\1740 levobupivacaine\NN\1740 reach\VBP\2005948 the\DT\1740 circulation\NN\6253140 ,\,\1740 it\PRP\6125041 will\MD\5650329 result\VB\2633881 in\IN\13603305 <e2>convulsions</e2>\NNS\14081375 .\.\1740
7727612
D008140_D009207 CID <e2>Myoclonus</e2>\NNP\14360459 associated\VBN\628491 with\IN\1740 <e1>lorazepam</e1>\NN\2830852 therapy\NN\657604 in\IN\13603305 very-low-birth-weight\NN\1740 infants\NNS\9918248 .\.\1740
D008140_D009207 CID Three\CD\13741022 young\JJ\1740 infants\NNS\9918248 ,\,\1740 all\DT\1740 of\IN\1740 birth\NN\15265518 weight\NN\5009170 <\XX\1740 1,500\CD\1740 g\NN\13717155 ,\,\1740 experienced\JJ\1740 <e2>myoclonus</e2>\NN\14360459 following\VBG\1835496 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>lorazepam</e1>\NN\2830852 .\.\1740
17543491
19293073
D001241_D003327 NONE In\IN\13603305 2002\CD\1740 ,\,\1740 the\DT\1740 U.S.\NNP\8052549 Preventive\NNP\4074482 Services\NNPS\584367 Task\NNP\575741 Force\NNP\5194151 (\-LRB-\1740 USPSTF\NN\1740 )\-RRB-\1740 strongly\RB\1740 recommended\VBD\875394 that\IN\1740 clinicians\NNS\10462860 discuss\VBP\1033527 <e1>aspirin</e1>\NN\2707683 with\IN\1740 adults\NNS\7846 who\WP\8299493 are\VBP\836236 at\IN\14622893 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>coronary\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 .\.\1740
D001241_D009203 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 benefits\NNS\13278375 and\CC\1740 harms\NNS\14052046 of\IN\1740 taking\VBG\2367363 <e1>aspirin</e1>\NN\2707683 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 <e2>myocardial\JJ\1740 infarctions</e2>\NNS\14204950 ,\,\1740 strokes\NNS\556313 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D001241_D009203 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Aspirin</e1>\NN\2707683 reduces\VBZ\441445 the\DT\1740 risk\NN\14541044 for\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 men\NNS\8208016 and\CC\1740 strokes\NNS\556313 in\IN\13603305 women\NNS\9605289 .\.\1740
D001241_D020521 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 benefits\NNS\13278375 and\CC\1740 harms\NNS\14052046 of\IN\1740 taking\VBG\2367363 <e1>aspirin</e1>\NN\2707683 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 myocardial\JJ\1740 infarctions\NNS\14204950 ,\,\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 and\CC\1740 death\NN\7296428 .\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 <e2>stroke</e2>\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 <e2>stroke</e2>\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 <e2>stroke</e2>\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D020521 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 ?\.\1740
D001241_D020521 CID Men\NNS\8208016 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 with\IN\1740 <e1>aspirin</e1>\NN\2707683 use\NN\407535 .\.\1740
D001241_D020521 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Aspirin</e1>\NN\2707683 reduces\VBZ\441445 the\DT\1740 risk\NN\14541044 for\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 in\IN\13603305 men\NNS\8208016 and\CC\1740 <e2>strokes</e2>\NNS\556313 in\IN\13603305 women\NNS\9605289 .\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 <e2>CVD</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 <e2>CVD</e2>\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 <e2>CVD</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 <e2>CVD</e2>\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 <e2>CVD</e2>\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 <e2>CVD</e2>\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D002318 NONE DATA\NN\7951464 SYNTHESIS\NN\13446390 :\:\1740 New\JJ\1740 evidence\NN\5816287 from\IN\1740 1\CD\13741022 good-quality\NN\1740 RCT\NN\1740 ,\,\1740 1\CD\13741022 good-quality\NN\1740 meta-analysis\NN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 fair-quality\JJ\1740 subanalyses\NNS\1740 of\IN\1740 RCTs\NNS\1740 demonstrates\VBZ\2137132 that\IN\1740 <e1>aspirin</e1>\NN\2707683 use\NN\407535 reduces\VBZ\441445 the\DT\1740 number\NN\5107765 of\IN\1740 <e2>CVD</e2>\NN\1740 events\NNS\23100 in\IN\13603305 patients\NNS\9898892 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 .\.\1740
D001241_D002318 NONE DATA\NN\7951464 SYNTHESIS\NN\13446390 :\:\1740 New\JJ\1740 evidence\NN\5816287 from\IN\1740 1\CD\13741022 good-quality\NN\1740 RCT\NN\1740 ,\,\1740 1\CD\13741022 good-quality\NN\1740 meta-analysis\NN\1740 ,\,\1740 and\CC\1740 2\CD\13741022 fair-quality\JJ\1740 subanalyses\NNS\1740 of\IN\1740 RCTs\NNS\1740 demonstrates\VBZ\2137132 that\IN\1740 <e1>aspirin</e1>\NN\2707683 use\NN\407535 reduces\VBZ\441445 the\DT\1740 number\NN\5107765 of\IN\1740 CVD\NN\1740 events\NNS\23100 in\IN\13603305 patients\NNS\9898892 without\IN\1740 known\VBN\2110220 <e2>CVD</e2>\NNP\1740 .\.\1740
D001241_D002318 NONE <e1>Aspirin</e1>\NN\2707683 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 affect\VB\126264 <e2>CVD</e2>\NN\1740 mortality\NN\5054863 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 either\DT\1740 men\NNS\8208016 or\CC\3541091 women\NNS\9605289 .\.\1740
D001241_D002318 NONE LIMITATIONS\NNS\5846054 :\:\1740 New\JJ\1740 evidence\NN\5816287 on\IN\1740 <e1>aspirin</e1>\NN\2707683 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 <e2>CVD</e2>\NNP\1740 is\VBZ\836236 limited\JJ\1740 .\.\1740
D001241_D006471 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 <e2>gastrointestinal\JJ\1740 bleeding</e2>\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D006471 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 <e2>gastrointestinal\JJ\1740 bleeding</e2>\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D006471 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 <e2>gastrointestinal\JJ\1740 bleeding</e2>\JJ\1740 or\CC\3541091 hemorrhagic\JJ\1740 strokes\NNS\556313 ?\.\1740
D001241_D006471 CID The\DT\1740 use\NN\407535 of\IN\1740 <e1>aspirin</e1>\NN\2707683 for\IN\1740 primary\JJ\1740 prevention\NN\1073995 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 major\JJ\1740 bleeding\JJ\1740 events\NNS\23100 ,\,\1740 primarily\RB\1740 <e2>gastrointestinal\JJ\1740 bleeding</e2>\NN\14285662 events\NNS\23100 ,\,\1740 in\IN\13603305 both\DT\1740 men\NNS\8208016 and\CC\1740 women\NNS\9605289 .\.\1740
D001241_D020300 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 <e1>aspirin</e1>\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 ?\.\1740
D001241_D020300 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 aspirin\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 ?\.\1740
D001241_D020300 CID STUDY\NN\635850 SELECTION\NN\37396 :\:\1740 English-language\JJ\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trials\NNS\786195 (\-LRB-\1740 RCTs\NNS\1740 )\-RRB-\1740 ;\:\1740 case-control\JJ\1740 studies\NNS\635850 ;\:\1740 meta-analyses\NNS\1740 ;\:\1740 and\CC\1740 systematic\JJ\1740 reviews\NNS\5733583 of\IN\1740 aspirin\NN\2707683 versus\CC\1740 control\NN\5190804 for\IN\1740 the\DT\1740 primary\JJ\1740 prevention\NN\1073995 of\IN\1740 cardiovascular\JJ\1740 disease\NN\14061805 (\-LRB-\1740 CVD\NN\1740 )\-RRB-\1740 were\VBD\836236 selected\VBN\697589 to\TO\1740 answer\VB\1009240 the\DT\1740 following\VBG\1835496 questions\NNS\7193184 :\:\1740 Does\VBZ\1640855 aspirin\NN\2707683 decrease\VB\169651 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 ,\,\1740 strokes\NNS\556313 ,\,\1740 death\NN\7296428 from\IN\1740 coronary\JJ\1740 heart\NN\5919034 events\NNS\23100 or\CC\3541091 stroke\NN\556313 ,\,\1740 or\CC\3541091 all-cause\JJ\1740 mortality\NN\5054863 in\IN\13603305 adults\NNS\7846 without\IN\1740 known\VBN\2110220 CVD\NNP\1740 ?\,\1740 Does\VBZ\1640855 <e1>aspirin</e1>\NN\2707683 increase\VB\169651 gastrointestinal\JJ\1740 bleeding\JJ\1740 or\CC\3541091 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 ?\.\1740
D001241_D020300 CID Men\NNS\8208016 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>hemorrhagic\JJ\1740 strokes</e2>\NNS\556313 with\IN\1740 <e1>aspirin</e1>\NN\2707683 use\NN\407535 .\.\1740
D001241_D006470 NONE The\DT\1740 use\NN\407535 of\IN\1740 <e1>aspirin</e1>\NN\2707683 for\IN\1740 primary\JJ\1740 prevention\NN\1073995 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 major\JJ\1740 <e2>bleeding</e2>\JJ\1740 events\NNS\23100 ,\,\1740 primarily\RB\1740 gastrointestinal\JJ\1740 bleeding\NN\14285662 events\NNS\23100 ,\,\1740 in\IN\13603305 both\DT\1740 men\NNS\8208016 and\CC\1740 women\NNS\9605289 .\.\1740
D001241_D006470 NONE <e1>Aspirin</e1>\NN\2707683 use\NN\407535 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 serious\JJ\1740 <e2>bleeding</e2>\NN\14285662 events\NNS\23100 .\.\1740
3125850
D013390_D005207 CID Increase\NN\13576355 in\IN\13603305 intragastric\JJ\1740 pressure\NN\11419404 during\IN\1740 <e1>suxamethonium-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 in\IN\13603305 children\NNS\9622049 :\:\1740 inhibition\NN\1068773 by\IN\1740 alfentanil\JJ\1740 .\.\1740
D013390_D005207 CID The\DT\1740 incidence\NN\13821570 and\CC\1740 intensity\NN\5090441 of\IN\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 caused\VBN\1617192 by\IN\1740 <e1>suxamethonium</e1>\NN\1740 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 control\NN\5190804 than\IN\1740 in\IN\13603305 the\DT\1740 alfentanil\JJ\1740 group\NN\2137 .\.\1740
D013390_D005207 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 intragastric\JJ\1740 pressure\NN\11419404 increases\VBZ\169651 significantly\RB\1740 during\IN\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 caused\VBN\1617192 by\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 healthy\JJ\1740 children\NNS\9622049 .\.\1740
D013390_D005207 CID Alfentanil\NN\1740 50\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 effectively\RB\1740 inhibits\VBZ\2510337 the\DT\1740 incidence\NN\13821570 and\CC\1740 intensity\NN\5090441 of\IN\1740 <e1>suxamethonium-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 ;\:\1740 moreover\RB\1740 ,\,\1740 intragastric\JJ\1740 pressure\NN\11419404 remains\VBZ\2604760 at\IN\14622893 its\PRP$\6125041 control\NN\5190804 value\NN\5856066 .\.\1740
D015760_D005207 NONE Increase\NN\13576355 in\IN\13603305 intragastric\JJ\1740 pressure\NN\11419404 during\IN\1740 suxamethonium-induced\JJ\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 in\IN\13603305 children\NNS\9622049 :\:\1740 inhibition\NN\1068773 by\IN\1740 <e1>alfentanil</e1>\JJ\1740 .\.\1740
D015760_D005207 NONE The\DT\1740 incidence\NN\13821570 and\CC\1740 intensity\NN\5090441 of\IN\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 caused\VBN\1617192 by\IN\1740 suxamethonium\NN\1740 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 the\DT\1740 control\NN\5190804 than\IN\1740 in\IN\13603305 the\DT\1740 <e1>alfentanil</e1>\JJ\1740 group\NN\2137 .\.\1740
D015760_D005207 NONE The\DT\1740 intragastric\JJ\1740 pressure\NN\11419404 during\IN\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 16\CD\13745420 +/-\CC\1740 0.7\CD\1740 (\-LRB-\1740 SEM\NN\1740 )\-RRB-\1740 cm\NN\13649268 H2O\NN\14618834 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 <e1>alfentanil</e1>\JJ\1740 group\NN\2137 (\-LRB-\1740 7.7\CD\1740 +/-\CC\1740 1.5\CD\1740 (\-LRB-\1740 SEM\NN\1740 )\-RRB-\1740 cm\NN\13649268 H2O\NN\14618834 )\-RRB-\1740 .\.\1740
D015760_D005207 NONE <e1>Alfentanil</e1>\NN\1740 50\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 effectively\RB\1740 inhibits\VBZ\2510337 the\DT\1740 incidence\NN\13821570 and\CC\1740 intensity\NN\5090441 of\IN\1740 suxamethonium-induced\JJ\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 ;\:\1740 moreover\RB\1740 ,\,\1740 intragastric\JJ\1740 pressure\NN\11419404 remains\VBZ\2604760 at\IN\14622893 its\PRP$\6125041 control\NN\5190804 value\NN\5856066 .\.\1740
D014867_D005207 NONE The\DT\1740 intragastric\JJ\1740 pressure\NN\11419404 during\IN\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 16\CD\13745420 +/-\CC\1740 0.7\CD\1740 (\-LRB-\1740 SEM\NN\1740 )\-RRB-\1740 cm\NN\13649268 <e1>H2O</e1>\NN\14618834 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 alfentanil\JJ\1740 group\NN\2137 (\-LRB-\1740 7.7\CD\1740 +/-\CC\1740 1.5\CD\1740 (\-LRB-\1740 SEM\NN\1740 )\-RRB-\1740 cm\NN\13649268 H2O\NN\14618834 )\-RRB-\1740 .\.\1740
D014867_D005207 NONE The\DT\1740 intragastric\JJ\1740 pressure\NN\11419404 during\IN\1740 <e2>muscle\NN\5289601 fasciculations</e2>\NNS\14361664 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 in\IN\13603305 the\DT\1740 control\NN\5190804 group\NN\2137 (\-LRB-\1740 16\CD\13745420 +/-\CC\1740 0.7\CD\1740 (\-LRB-\1740 SEM\NN\1740 )\-RRB-\1740 cm\NN\13649268 H2O\NN\14618834 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 alfentanil\JJ\1740 group\NN\2137 (\-LRB-\1740 7.7\CD\1740 +/-\CC\1740 1.5\CD\1740 (\-LRB-\1740 SEM\NN\1740 )\-RRB-\1740 cm\NN\13649268 <e1>H2O</e1>\NN\14618834 )\-RRB-\1740 .\.\1740
19655282
D003042_D002637 CID Coronary\JJ\1740 computerized\VBN\2327200 tomography\NN\900375 angiography\NN\904623 for\IN\1740 rapid\JJ\1740 discharge\NN\7283608 of\IN\1740 low-risk\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 .\.\1740
D003042_D002637 CID BACKGROUND\NN\4921011 :\:\1740 Most\JJS\1740 patients\NNS\9898892 presenting\VBG\2137132 to\IN\1740 emergency\NN\7417644 departments\NNS\8220714 (\-LRB-\1740 EDs\NNS\4377057 )\-RRB-\1740 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 are\VBP\836236 admitted\VBN\822367 for\IN\1740 at\IN\14622893 least\JJS\1740 12\CD\13745420 hours\NNS\15118228 and\CC\1740 receive\VB\2210855 a\DT\13649268 "\``\1740 rule\VB\2441022 out\RP\1740 acute\JJ\1740 coronary\JJ\1740 syndrome\NN\5870365 "\''\1740 protocol\NN\6652242 ,\,\1740 often\RB\1740 with\IN\1740 noninvasive\JJ\1740 testing\NN\639556 prior\RB\1740 to\TO\1740 discharge\VB\1640855 .\.\1740
D003042_D002637 CID It\PRP\6125041 is\VBZ\836236 unclear\JJ\1740 whether\IN\1740 a\DT\13649268 coronary\JJ\1740 CTA\NN\1740 strategy\NN\5902545 would\MD\1740 be\VB\836236 efficacious\JJ\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 as\IN\14622893 coronary\JJ\1740 vasospasm\NN\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 ischemia\NN\14195315 .\.\1740
D003042_D002637 CID We\PRP\1740 studied\VBD\630380 whether\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 could\MD\1740 identify\VB\699815 a\DT\13649268 subset\NN\7999699 safe\JJ\1740 for\IN\1740 discharge\NN\7283608 .\.\1740
D003042_D002637 CID RESULTS\NNS\34213 :\:\1740 A\DT\13649268 total\NN\3553 of\IN\1740 59\CD\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 were\VBD\836236 evaluated\VBN\670261 .\.\1740
D003042_D002637 CID CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 can\MD\3094503 result\VB\2633881 from\IN\1740 coronary\JJ\1740 vasoconstriction\NN\1149911 ,\,\1740 patients\NNS\9898892 with\IN\1740 cocaine\NN\3492717 associated\VBD\628491 <e2>chest\NN\5220461 pain</e2>\NN\14299637 ,\,\1740 a\DT\13649268 non-ischemic\JJ\1740 ECG\NN\7000195 ,\,\1740 and\CC\1740 a\DT\13649268 TIMI\NN\1740 risk\NN\14541044 score\NN\5736149 <\XX\1740 2\CD\13741022 may\MD\15209706 be\VB\836236 safely\RB\1740 discharged\VBN\1640855 from\IN\1740 the\DT\1740 ED\NN\14557898 after\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 30-day\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
D003042_D002637 CID CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 cocaine-associated\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 can\MD\3094503 result\VB\2633881 from\IN\1740 coronary\JJ\1740 vasoconstriction\NN\1149911 ,\,\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine</e1>\NN\3492717 associated\VBD\628491 <e2>chest\NN\5220461 pain</e2>\NN\14299637 ,\,\1740 a\DT\13649268 non-ischemic\JJ\1740 ECG\NN\7000195 ,\,\1740 and\CC\1740 a\DT\13649268 TIMI\NN\1740 risk\NN\14541044 score\NN\5736149 <\XX\1740 2\CD\13741022 may\MD\15209706 be\VB\836236 safely\RB\1740 discharged\VBN\1640855 from\IN\1740 the\DT\1740 ED\NN\14557898 after\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 30-day\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
D003042_D054058 NONE BACKGROUND\NN\4921011 :\:\1740 Most\JJS\1740 patients\NNS\9898892 presenting\VBG\2137132 to\IN\1740 emergency\NN\7417644 departments\NNS\8220714 (\-LRB-\1740 EDs\NNS\4377057 )\-RRB-\1740 with\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 chest\JJ\1740 pain\NN\14299637 are\VBP\836236 admitted\VBN\822367 for\IN\1740 at\IN\14622893 least\JJS\1740 12\CD\13745420 hours\NNS\15118228 and\CC\1740 receive\VB\2210855 a\DT\13649268 "\``\1740 rule\VB\2441022 out\RP\1740 <e2>acute\JJ\1740 coronary\JJ\1740 syndrome</e2>\NN\5870365 "\''\1740 protocol\NN\6652242 ,\,\1740 often\RB\1740 with\IN\1740 noninvasive\JJ\1740 testing\NN\639556 prior\RB\1740 to\TO\1740 discharge\VB\1640855 .\.\1740
D003042_D003329 NONE It\PRP\6125041 is\VBZ\836236 unclear\JJ\1740 whether\IN\1740 a\DT\13649268 coronary\JJ\1740 CTA\NN\1740 strategy\NN\5902545 would\MD\1740 be\VB\836236 efficacious\JJ\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 chest\JJ\1740 pain\NN\14299637 ,\,\1740 as\IN\14622893 <e2>coronary\JJ\1740 vasospasm</e2>\NN\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 ischemia\NN\14195315 .\.\1740
D003042_D007511 NONE It\PRP\6125041 is\VBZ\836236 unclear\JJ\1740 whether\IN\1740 a\DT\13649268 coronary\JJ\1740 CTA\NN\1740 strategy\NN\5902545 would\MD\1740 be\VB\836236 efficacious\JJ\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 chest\JJ\1740 pain\NN\14299637 ,\,\1740 as\IN\14622893 coronary\JJ\1740 vasospasm\NN\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 <e2>ischemia</e2>\NN\14195315 .\.\1740
D003042_D007511 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 can\MD\3094503 result\VB\2633881 from\IN\1740 coronary\JJ\1740 vasoconstriction\NN\1149911 ,\,\1740 patients\NNS\9898892 with\IN\1740 cocaine\NN\3492717 associated\VBD\628491 chest\NN\5220461 pain\NN\14299637 ,\,\1740 a\DT\13649268 <e2>non-ischemic</e2>\JJ\1740 ECG\NN\7000195 ,\,\1740 and\CC\1740 a\DT\13649268 TIMI\NN\1740 risk\NN\14541044 score\NN\5736149 <\XX\1740 2\CD\13741022 may\MD\15209706 be\VB\836236 safely\RB\1740 discharged\VBN\1640855 from\IN\1740 the\DT\1740 ED\NN\14557898 after\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 30-day\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
D003042_D007511 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 cocaine-associated\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 can\MD\3094503 result\VB\2633881 from\IN\1740 coronary\JJ\1740 vasoconstriction\NN\1149911 ,\,\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine</e1>\NN\3492717 associated\VBD\628491 chest\NN\5220461 pain\NN\14299637 ,\,\1740 a\DT\13649268 <e2>non-ischemic</e2>\JJ\1740 ECG\NN\7000195 ,\,\1740 and\CC\1740 a\DT\13649268 TIMI\NN\1740 risk\NN\14541044 score\NN\5736149 <\XX\1740 2\CD\13741022 may\MD\15209706 be\VB\836236 safely\RB\1740 discharged\VBN\1640855 from\IN\1740 the\DT\1740 ED\NN\14557898 after\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 30-day\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
D003042_D017202 CID CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 can\MD\3094503 result\VB\2633881 from\IN\1740 coronary\JJ\1740 vasoconstriction\NN\1149911 ,\,\1740 patients\NNS\9898892 with\IN\1740 cocaine\NN\3492717 associated\VBD\628491 chest\NN\5220461 pain\NN\14299637 ,\,\1740 a\DT\13649268 non-ischemic\JJ\1740 ECG\NN\7000195 ,\,\1740 and\CC\1740 a\DT\13649268 TIMI\NN\1740 risk\NN\14541044 score\NN\5736149 <\XX\1740 2\CD\13741022 may\MD\15209706 be\VB\836236 safely\RB\1740 discharged\VBN\1640855 from\IN\1740 the\DT\1740 ED\NN\14557898 after\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 30-day\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
D003042_D017202 CID CONCLUSIONS\NNS\5837957 :\:\1740 Although\IN\1740 cocaine-associated\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 can\MD\3094503 result\VB\2633881 from\IN\1740 coronary\JJ\1740 vasoconstriction\NN\1149911 ,\,\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine</e1>\NN\3492717 associated\VBD\628491 chest\NN\5220461 pain\NN\14299637 ,\,\1740 a\DT\13649268 non-ischemic\JJ\1740 ECG\NN\7000195 ,\,\1740 and\CC\1740 a\DT\13649268 TIMI\NN\1740 risk\NN\14541044 score\NN\5736149 <\XX\1740 2\CD\13741022 may\MD\15209706 be\VB\836236 safely\RB\1740 discharged\VBN\1640855 from\IN\1740 the\DT\1740 ED\NN\14557898 after\IN\1740 a\DT\13649268 negative\JJ\1740 coronary\JJ\1740 CTA\NN\1740 with\IN\1740 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 30-day\JJ\1740 adverse\JJ\1740 events\NNS\23100 .\.\1740
24284476
D047310_D000647 NONE Furthermore\RB\1740 ,\,\1740 <e1>apigenin</e1>\NN\1740 did\VBD\1640855 not\RB\1740 prevent\VB\1740 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 1mg/kg\CD\1740 ,\,\1740 i.p.\RB\1740 ,\,\1740 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
D012601_D000647 CID Furthermore\RB\1740 ,\,\1740 apigenin\NN\1740 did\VBD\1640855 not\RB\1740 prevent\VB\1740 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 (\-LRB-\1740 1mg/kg\CD\1740 ,\,\1740 i.p.\RB\1740 ,\,\1740 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 acquisition\NN\41899 )\-RRB-\1740 .\.\1740
10985896
D004317_D010051 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 platinum/paclitaxel-refractory\JJ\1740 <e2>ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 and\CC\1740 primary\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum\NN\5605944 .\.\1740
D004317_D010051 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D010051 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D010051 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 or\CC\3541091 primary\JJ\1740 peritoneal\JJ\1740 carcinoma\NN\14239918 with\IN\1740 platinum/paclitaxel-refractory\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D004317_D005185 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 platinum/paclitaxel-refractory\JJ\1740 <e2>ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 and\CC\1740 primary\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum\NN\5605944 .\.\1740
D004317_D005185 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 or\CC\3541091 primary\JJ\1740 peritoneal\JJ\1740 carcinoma\NN\14239918 with\IN\1740 platinum/paclitaxel-refractory\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D004317_D010534 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 platinum/paclitaxel-refractory\JJ\1740 ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers\NNS\14239425 and\CC\1740 primary\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum</e2>\NN\5605944 .\.\1740
D004317_D010534 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers\NNS\14239425 or\CC\3541091 primary\JJ\1740 <e2>peritoneal\JJ\1740 carcinoma</e2>\NN\14239918 with\IN\1740 platinum/paclitaxel-refractory\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D010984_D010051 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 <e2>ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 and\CC\1740 primary\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum\NN\5605944 .\.\1740
D010984_D010051 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 <e1>platinum-resistant</e1>\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D010984_D010051 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 or\CC\3541091 primary\JJ\1740 peritoneal\JJ\1740 carcinoma\NN\14239918 with\IN\1740 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D010984_D010051 NONE Definite\JJ\1740 ,\,\1740 although\IN\1740 limited\JJ\1740 ,\,\1740 antineoplastic\JJ\1740 activity\NN\30358 is\VBZ\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 well-defined\JJ\1740 <e1>platinum-</e1>\NN\1740 and\CC\1740 paclitaxel-refractory\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D010984_D005185 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 <e2>ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 and\CC\1740 primary\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum\NN\5605944 .\.\1740
D010984_D005185 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 or\CC\3541091 primary\JJ\1740 peritoneal\JJ\1740 carcinoma\NN\14239918 with\IN\1740 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D010984_D010534 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers\NNS\14239425 and\CC\1740 primary\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum</e2>\NN\5605944 .\.\1740
D010984_D010534 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers\NNS\14239425 or\CC\3541091 primary\JJ\1740 <e2>peritoneal\JJ\1740 carcinoma</e2>\NN\14239918 with\IN\1740 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D017239_D010051 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 <e2>ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 and\CC\1740 primary\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum\NN\5605944 .\.\1740
D017239_D010051 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 or\CC\3541091 primary\JJ\1740 peritoneal\JJ\1740 carcinoma\NN\14239918 with\IN\1740 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D017239_D010051 NONE Definite\JJ\1740 ,\,\1740 although\IN\1740 limited\JJ\1740 ,\,\1740 antineoplastic\JJ\1740 activity\NN\30358 is\VBZ\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 well-defined\JJ\1740 platinum-\NN\1740 and\CC\1740 <e1>paclitaxel-refractory</e1>\JJ\1740 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D017239_D005185 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 <e2>ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 and\CC\1740 primary\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum\NN\5605944 .\.\1740
D017239_D005185 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 <e2>ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers</e2>\NNS\14239425 or\CC\3541091 primary\JJ\1740 peritoneal\JJ\1740 carcinoma\NN\14239918 with\IN\1740 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D017239_D010534 NONE Phase\NN\15113229 2\CD\13741022 trial\NN\786195 of\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 in\IN\13603305 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 ovarian\JJ\1740 and\CC\1740 fallopian\JJ\1740 tube\NN\3089014 cancers\NNS\14239425 and\CC\1740 primary\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 peritoneum</e2>\NN\5605944 .\.\1740
D017239_D010534 NONE METHODS\NNS\5616786 AND\CC\1740 MATERIALS\NNS\19613 :\:\1740 Patients\NNS\9898892 with\IN\1740 ovarian\JJ\1740 or\CC\3541091 fallopian\JJ\1740 tube\NN\3089014 cancers\NNS\14239425 or\CC\3541091 primary\JJ\1740 <e2>peritoneal\JJ\1740 carcinoma</e2>\NN\14239918 with\IN\1740 <e1>platinum/paclitaxel-refractory</e1>\JJ\1740 disease\NN\14061805 (\-LRB-\1740 stable\JJ\1740 or\CC\3541091 progressive\JJ\1740 disease\NN\14061805 following\VBG\1835496 treatment\NN\654885 with\IN\1740 these\DT\1740 agents\NNS\7347 or\CC\3541091 previous\JJ\1740 objective\JJ\1740 response\NN\11410625 <3\IN\1740 months\NNS\15113229 in\IN\13603305 duration\NN\15113229 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 liposomal\JJ\1740 doxorubicin\NN\2716866 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 40\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D004317_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D064420 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 modified\VBN\109660 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 regimen\NN\5898568 results\VBZ\2633881 in\IN\13603305 less\JJR\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 stomatitis\NN\14336539 ,\,\1740 hand-foot\JJ\1740 syndrome\NN\5870365 )\-RRB-\1740 than\IN\1740 the\DT\1740 standard\JJ\1740 FDA-approved\JJ\1740 dose\NN\3740161 schedule\NN\5898568 .\.\1740
D004317_D060831 CID BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 <e2>erythrodysesthesia</e2>\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D060831 CID BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 <e2>hand-foot\JJ\1740 syndrome</e2>\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D060831 CID BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 <e2>erythrodysesthesia</e2>\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D060831 CID BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 <e2>hand-foot\JJ\1740 syndrome</e2>\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D004317_D060831 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 modified\VBN\109660 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 regimen\NN\5898568 results\VBZ\2633881 in\IN\13603305 less\JJR\1740 toxicity\NN\13576101 (\-LRB-\1740 stomatitis\NN\14336539 ,\,\1740 <e2>hand-foot\JJ\1740 syndrome</e2>\NN\5870365 )\-RRB-\1740 than\IN\1740 the\DT\1740 standard\JJ\1740 FDA-approved\JJ\1740 dose\NN\3740161 schedule\NN\5898568 .\.\1740
D004317_D013280 CID BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 <e2>stomatitis</e2>\NN\14336539 .\.\1740
D004317_D013280 CID BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 <e1>Doxil</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 platinum-resistant\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 <e2>stomatitis</e2>\NN\14336539 .\.\1740
D004317_D013280 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 modified\VBN\109660 liposomal\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 regimen\NN\5898568 results\VBZ\2633881 in\IN\13603305 less\JJR\1740 toxicity\NN\13576101 (\-LRB-\1740 <e2>stomatitis</e2>\NN\14336539 ,\,\1740 hand-foot\JJ\1740 syndrome\NN\5870365 )\-RRB-\1740 than\IN\1740 the\DT\1740 standard\JJ\1740 FDA-approved\JJ\1740 dose\NN\3740161 schedule\NN\5898568 .\.\1740
D010984_D064420 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 <e1>platinum-resistant</e1>\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D010984_D060831 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 <e1>platinum-resistant</e1>\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 <e2>erythrodysesthesia</e2>\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D010984_D060831 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 <e1>platinum-resistant</e1>\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 <e2>hand-foot\JJ\1740 syndrome</e2>\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 stomatitis\NN\14336539 .\.\1740
D010984_D013280 NONE BACKGROUND\NN\4921011 :\:\1740 Several\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 liposomal\JJ\1740 doxorubicin\NN\2716866 (\-LRB-\1740 Doxil\NN\1740 )\-RRB-\1740 to\TO\1740 be\VB\836236 an\DT\6697703 active\JJ\1740 antineoplastic\JJ\1740 agent\NN\7347 in\IN\13603305 <e1>platinum-resistant</e1>\JJ\1740 ovarian\JJ\1740 cancer\NN\14239425 ,\,\1740 with\IN\1740 dose\NN\3740161 limiting\NN\13796779 toxicity\NN\13576101 of\IN\1740 the\DT\1740 standard\JJ\1740 dosing\NN\1740 regimen\NN\5898568 (\-LRB-\1740 50\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 q\DT\6828818 4\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 being\VBG\836236 severe\JJ\1740 erythrodysesthesia\NN\1740 (\-LRB-\1740 "\``\1740 hand-foot\JJ\1740 syndrome\NN\5870365 "\''\1740 )\-RRB-\1740 and\CC\1740 <e2>stomatitis</e2>\NN\14336539 .\.\1740
10939760
D013411_D058186 CID Patterns\NNS\5726345 of\IN\1740 <e1>sulfadiazine</e1>\NN\4352070 <e2>acute\JJ\1740 nephrotoxicity</e2>\NN\1740 .\.\1740
D013411_D058186 CID <e1>Sulfadiazine</e1>\NN\4352070 <e2>acute\JJ\1740 nephrotoxicity</e2>\NN\1740 is\VBZ\836236 reviving\VBG\22099 specially\RB\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 use\NN\407535 in\IN\13603305 toxoplasmosis\NN\14174549 in\IN\13603305 HIV-positive\JJ\1740 patients\NNS\9898892 .\.\1740
D013411_D014123 NONE <e1>Sulfadiazine</e1>\NN\4352070 acute\JJ\1740 nephrotoxicity\NN\1740 is\VBZ\836236 reviving\VBG\22099 specially\RB\1740 because\IN\1740 of\IN\1740 its\PRP$\6125041 use\NN\407535 in\IN\13603305 <e2>toxoplasmosis</e2>\NN\14174549 in\IN\13603305 HIV-positive\JJ\1740 patients\NNS\9898892 .\.\1740
D013411_D009846 NONE Under\IN\1740 treatment\NN\654885 with\IN\1740 <e1>sulfadiazine</e1>\NN\4352070 they\PRP\1740 developed\VBD\1753788 <e2>oliguria</e2>\NN\14299637 ,\,\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 showed\VBD\2137132 multiple\JJ\1740 radiolucent\JJ\1740 renal\JJ\1740 calculi\NNS\9416076 in\IN\13603305 echography\NN\901083 .\.\1740
D013411_D015746 NONE Under\IN\1740 treatment\NN\654885 with\IN\1740 <e1>sulfadiazine</e1>\NN\4352070 they\PRP\1740 developed\VBD\1753788 oliguria\NN\14299637 ,\,\1740 <e2>abdominal\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 showed\VBD\2137132 multiple\JJ\1740 radiolucent\JJ\1740 renal\JJ\1740 calculi\NNS\9416076 in\IN\13603305 echography\NN\901083 .\.\1740
D013411_D051437 NONE Under\IN\1740 treatment\NN\654885 with\IN\1740 <e1>sulfadiazine</e1>\NN\4352070 they\PRP\1740 developed\VBD\1753788 oliguria\NN\14299637 ,\,\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 showed\VBD\2137132 multiple\JJ\1740 radiolucent\JJ\1740 renal\JJ\1740 calculi\NNS\9416076 in\IN\13603305 echography\NN\901083 .\.\1740
D013411_D007669 CID Under\IN\1740 treatment\NN\654885 with\IN\1740 <e1>sulfadiazine</e1>\NN\4352070 they\PRP\1740 developed\VBD\1753788 oliguria\NN\14299637 ,\,\1740 abdominal\JJ\1740 pain\NN\14299637 ,\,\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 showed\VBD\2137132 multiple\JJ\1740 radiolucent\JJ\1740 <e2>renal\JJ\1740 calculi</e2>\NNS\9416076 in\IN\13603305 echography\NN\901083 .\.\1740
14748761
C030852_D009369 NONE In\IN\13603305 order\NN\7168131 to\TO\1740 quantify\VB\947077 the\DT\1740 incidence\NN\13821570 of\IN\1740 these\DT\1740 cardiac\JJ\1740 events\NNS\23100 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 meta-analysis\NN\1740 of\IN\1740 clinical\JJ\1740 trials\NNS\786195 comparing\VBG\644583 <e1>VNR</e1>\NN\1740 with\IN\1740 other\JJ\1740 chemotherapeutic\JJ\1740 agents\NNS\7347 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 various\JJ\1740 <e2>malignancies</e2>\NNS\14070360 .\.\1740
C030852_D009369 NONE Randomized\JJ\1740 clinical\JJ\1740 trials\NNS\786195 comparing\VBG\644583 <e1>VNR</e1>\NN\1740 with\IN\1740 other\JJ\1740 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>cancer</e2>\NN\14239425 were\VBD\836236 searched\VBN\2131279 in\IN\13603305 Medline\NN\4402746 ,\,\1740 Embase\NN\1740 ,\,\1740 Evidence-based\JJ\1740 Medicine\NNP\6045562 Reviews\NNPS\5733583 databases\NNS\6634376 and\CC\1740 the\DT\1740 Cochrane\NNP\1740 library\NN\4105893 from\IN\1740 1987\CD\1740 to\IN\1740 2002\CD\1740 .\.\1740
C030852_D066126 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e1>VNR</e1>\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 vindesine\NN\1740 (\-LRB-\1740 VDS\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 fluorouracil\NN\2722166 ,\,\1740 anthracyclines\NNS\1740 ,\,\1740 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
D014751_D066126 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 VNR\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 <e1>vindesine</e1>\NN\1740 (\-LRB-\1740 VDS\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 fluorouracil\NN\2722166 ,\,\1740 anthracyclines\NNS\1740 ,\,\1740 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
D014751_D066126 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 VNR\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 vindesine\NN\1740 (\-LRB-\1740 <e1>VDS</e1>\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 fluorouracil\NN\2722166 ,\,\1740 anthracyclines\NNS\1740 ,\,\1740 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
D005472_D066126 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 VNR\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 vindesine\NN\1740 (\-LRB-\1740 VDS\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 <e1>fluorouracil</e1>\NN\2722166 ,\,\1740 anthracyclines\NNS\1740 ,\,\1740 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
D018943_D066126 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 VNR\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 vindesine\NN\1740 (\-LRB-\1740 VDS\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 fluorouracil\NN\2722166 ,\,\1740 <e1>anthracyclines</e1>\NNS\1740 ,\,\1740 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
C056507_D066126 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 VNR\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 vindesine\NN\1740 (\-LRB-\1740 VDS\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 fluorouracil\NN\2722166 ,\,\1740 anthracyclines\NNS\1740 ,\,\1740 <e1>gemcitabine</e1>\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
C056507_D066126 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 VNR\NN\1740 cardiac\NN\1740 events\NNS\23100 was\VBD\836236 similar\JJ\1740 to\TO\1740 vindesine\NN\1740 (\-LRB-\1740 VDS\NN\14122235 )\-RRB-\1740 and\CC\1740 other\JJ\1740 <e2>cardiotoxic</e2>\JJ\1740 drugs\NNS\14778436 [\-LRB-\1740 fluorouracil\NN\2722166 ,\,\1740 anthracyclines\NNS\1740 ,\,\1740 gemcitabine\NN\1740 (\-LRB-\1740 <e1>GEM</e1>\NN\2743547 )\-RRB-\1740 em\NN\13600404 leader\NN\7846 ]\-RRB-\1740 .\.\1740
3423103
D003000_D007022 CID Participation\NN\1080366 of\IN\1740 a\DT\13649268 bulbospinal\JJ\1740 serotonergic\NN\1740 pathway\NN\5483677 in\IN\13603305 the\DT\1740 rat\NN\2329401 brain\NN\5462674 in\IN\13603305 <e1>clonidine-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D003000_D007022 CID The\DT\1740 <e1>clonidine-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 prior\JJ\1740 spinal\JJ\1740 transection\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 bilateral\JJ\1740 vagotomy\NN\1740 .\.\1740
D003000_D007022 CID The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 a\DT\13649268 bulbospinal\JJ\1740 serotonergic\NN\1740 pathway\NN\5483677 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 development\NN\248977 of\IN\1740 <e1>clonidine-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D003000_D001919 CID Participation\NN\1080366 of\IN\1740 a\DT\13649268 bulbospinal\JJ\1740 serotonergic\NN\1740 pathway\NN\5483677 in\IN\13603305 the\DT\1740 rat\NN\2329401 brain\NN\5462674 in\IN\13603305 <e1>clonidine-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D003000_D001919 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 the\DT\1740 <e1>clonidine-induced</e1>\JJ\1740 <e2>bradycardia</e2>\NN\14110674 was\VBD\836236 antagonized\VBN\1787955 by\IN\1740 prior\JJ\1740 bilateral\JJ\1740 vagotomy\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 spinal\JJ\1740 transection\NN\1740 .\.\1740
D003000_D001919 CID Furthermore\RB\1740 ,\,\1740 selective\JJ\1740 destruction\NN\209943 of\IN\1740 the\DT\1740 spinal\JJ\1740 5-HT\NN\1740 nerves\NNS\14373582 ,\,\1740 produced\VBN\1617192 by\IN\1740 bilateral\JJ\1740 spinal\JJ\1740 injection\NN\320852 of\IN\1740 5,7-dihydroxytryptamine\NN\1740 ,\,\1740 reduced\VBD\441445 the\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 vasodepressor\NN\1740 or\CC\3541091 the\DT\1740 <e2>bradycardiac</e2>\NN\1740 responses\NNS\11410625 to\TO\1740 <e1>clonidine</e1>\NN\2721160 microinjected\VBN\1740 into\IN\1740 the\DT\1740 area\NN\8630985 near\IN\1740 the\DT\1740 ventrolateral\JJ\1740 surface\NN\21939 of\IN\1740 the\DT\1740 medulla\NN\14864360 oblongata\NNS\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003000_D001919 CID The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 a\DT\13649268 bulbospinal\JJ\1740 serotonergic\NN\1740 pathway\NN\5483677 is\VBZ\836236 involved\VBN\2676054 in\IN\13603305 development\NN\248977 of\IN\1740 <e1>clonidine-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D012701_D001919 NONE Furthermore\RB\1740 ,\,\1740 selective\JJ\1740 destruction\NN\209943 of\IN\1740 the\DT\1740 spinal\JJ\1740 <e1>5-HT</e1>\NN\1740 nerves\NNS\14373582 ,\,\1740 produced\VBN\1617192 by\IN\1740 bilateral\JJ\1740 spinal\JJ\1740 injection\NN\320852 of\IN\1740 5,7-dihydroxytryptamine\NN\1740 ,\,\1740 reduced\VBD\441445 the\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 vasodepressor\NN\1740 or\CC\3541091 the\DT\1740 <e2>bradycardiac</e2>\NN\1740 responses\NNS\11410625 to\TO\1740 clonidine\NN\2721160 microinjected\VBN\1740 into\IN\1740 the\DT\1740 area\NN\8630985 near\IN\1740 the\DT\1740 ventrolateral\JJ\1740 surface\NN\21939 of\IN\1740 the\DT\1740 medulla\NN\14864360 oblongata\NNS\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D015116_D001919 NONE Furthermore\RB\1740 ,\,\1740 selective\JJ\1740 destruction\NN\209943 of\IN\1740 the\DT\1740 spinal\JJ\1740 5-HT\NN\1740 nerves\NNS\14373582 ,\,\1740 produced\VBN\1617192 by\IN\1740 bilateral\JJ\1740 spinal\JJ\1740 injection\NN\320852 of\IN\1740 <e1>5,7-dihydroxytryptamine</e1>\NN\1740 ,\,\1740 reduced\VBD\441445 the\DT\1740 magnitude\NN\4916342 of\IN\1740 the\DT\1740 vasodepressor\NN\1740 or\CC\3541091 the\DT\1740 <e2>bradycardiac</e2>\NN\1740 responses\NNS\11410625 to\TO\1740 clonidine\NN\2721160 microinjected\VBN\1740 into\IN\1740 the\DT\1740 area\NN\8630985 near\IN\1740 the\DT\1740 ventrolateral\JJ\1740 surface\NN\21939 of\IN\1740 the\DT\1740 medulla\NN\14864360 oblongata\NNS\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
15094729
D020888_D014786 CID The\DT\1740 natural\JJ\1740 history\NN\15120823 of\IN\1740 <e1>Vigabatrin</e1>\NN\1740 associated\VBN\628491 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 in\IN\13603305 patients\NNS\9898892 electing\VBG\674607 to\TO\1740 continue\VB\2367363 their\PRP$\1740 medication\NN\3247620 .\.\1740
D020888_D014786 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 natural\JJ\1740 history\NN\15120823 of\IN\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 known\VBN\2110220 to\TO\1740 have\VB\2108377 <e1>Vigabatrin-associated</e1>\JJ\1740 changes\NNS\7283608 who\WP\8299493 elected\VBD\674607 to\TO\1740 continue\VB\2367363 the\DT\1740 medication\NN\3247620 because\IN\1740 of\IN\1740 good\JJ\1740 seizure\JJ\1740 control\NN\5190804 .\.\1740
D020888_D014786 CID CONCLUSION\NN\5837957 :\:\1740 Established\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 presumed\VBN\719734 to\TO\1740 be\VB\836236 due\JJ\1740 to\TO\1740 <e1>Vigabatrin</e1>\NN\1740 therapy\NN\657604 did\VBD\1640855 not\RB\1740 usually\RB\1740 progress\VB\252019 in\IN\13603305 spite\NN\7550369 of\IN\1740 continuing\VBG\2367363 use\NN\407535 of\IN\1740 the\DT\1740 medication\NN\3247620 .\.\1740
D020888_D014786 CID These\DT\1740 data\NNS\7951464 give\VBP\2327200 support\NN\407535 to\TO\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e1>Vigabatrin-associated</e1>\JJ\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 may\MD\15209706 be\VB\836236 an\DT\6697703 idiosyncratic\JJ\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 rather\RB\1740 than\IN\1740 dose-dependent\JJ\1740 toxicity\NN\13576101 .\.\1740
D020888_D012640 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 natural\JJ\1740 history\NN\15120823 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 patients\NNS\9898892 known\VBN\2110220 to\TO\1740 have\VB\2108377 <e1>Vigabatrin-associated</e1>\JJ\1740 changes\NNS\7283608 who\WP\8299493 elected\VBD\674607 to\TO\1740 continue\VB\2367363 the\DT\1740 medication\NN\3247620 because\IN\1740 of\IN\1740 good\JJ\1740 <e2>seizure</e2>\JJ\1740 control\NN\5190804 .\.\1740
D020888_D064420 NONE These\DT\1740 data\NNS\7951464 give\VBP\2327200 support\NN\407535 to\TO\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e1>Vigabatrin-associated</e1>\JJ\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 may\MD\15209706 be\VB\836236 an\DT\6697703 idiosyncratic\JJ\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 rather\RB\1740 than\IN\1740 dose-dependent\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
1280707
D002045_D001145 CID After\IN\1740 determining\VBG\1645601 the\DT\1740 <e1>bupivacaine</e1>\NN\1740 AD50\NN\1740 (\-LRB-\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 bupivacaine\NN\1740 that\WDT\1740 caused\VBD\1617192 50\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 beating\NN\1170962 rat\NN\2329401 heart\NN\5919034 myocyte\NN\1740 cultures\NNS\7966140 to\TO\1740 become\VB\146138 <e2>arrhythmic</e2>\JJ\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 determined\VBD\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 1-hour\NN\1740 progesterone\NN\14747338 HCl\NN\1740 exposure\NN\5042871 on\IN\1740 myocyte\NN\1740 contractile\NN\1740 rhythm\NN\15122011 .\.\1740
D002045_D001145 CID After\IN\1740 determining\VBG\1645601 the\DT\1740 bupivacaine\NN\1740 AD50\NN\1740 (\-LRB-\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 that\WDT\1740 caused\VBD\1617192 50\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 beating\NN\1170962 rat\NN\2329401 heart\NN\5919034 myocyte\NN\1740 cultures\NNS\7966140 to\TO\1740 become\VB\146138 <e2>arrhythmic</e2>\JJ\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 determined\VBD\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 1-hour\NN\1740 progesterone\NN\14747338 HCl\NN\1740 exposure\NN\5042871 on\IN\1740 myocyte\NN\1740 contractile\NN\1740 rhythm\NN\15122011 .\.\1740
D002045_D001145 CID Potentiation\NN\13564910 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 <e2>arrhythmia</e2>\NN\14103288 in\IN\13603305 myocyte\NN\1740 cultures\NNS\7966140 suggests\VBZ\1010118 that\IN\1740 this\DT\1740 effect\NN\34213 is\VBZ\836236 at\IN\14622893 least\JJS\1740 partly\RB\1740 mediated\VBN\761713 at\IN\14622893 the\DT\1740 myocyte\NN\1740 level\NN\4916342 .\.\1740
D011374_D001145 CID After\IN\1740 determining\VBG\1645601 the\DT\1740 bupivacaine\NN\1740 AD50\NN\1740 (\-LRB-\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 bupivacaine\NN\1740 that\WDT\1740 caused\VBD\1617192 50\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 beating\NN\1170962 rat\NN\2329401 heart\NN\5919034 myocyte\NN\1740 cultures\NNS\7966140 to\TO\1740 become\VB\146138 <e2>arrhythmic</e2>\JJ\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 determined\VBD\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 1-hour\NN\1740 <e1>progesterone</e1>\NN\14747338 HCl\NN\1740 exposure\NN\5042871 on\IN\1740 myocyte\NN\1740 contractile\NN\1740 rhythm\NN\15122011 .\.\1740
D006851_D001145 NONE After\IN\1740 determining\VBG\1645601 the\DT\1740 bupivacaine\NN\1740 AD50\NN\1740 (\-LRB-\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 bupivacaine\NN\1740 that\WDT\1740 caused\VBD\1617192 50\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 beating\NN\1170962 rat\NN\2329401 heart\NN\5919034 myocyte\NN\1740 cultures\NNS\7966140 to\TO\1740 become\VB\146138 <e2>arrhythmic</e2>\JJ\1740 )\-RRB-\1740 ,\,\1740 we\PRP\1740 determined\VBD\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 1-hour\NN\1740 progesterone\NN\14747338 <e1>HCl</e1>\NN\1740 exposure\NN\5042871 on\IN\1740 myocyte\NN\1740 contractile\NN\1740 rhythm\NN\15122011 .\.\1740
7477981
D007980_D004409 NONE <e1>Levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 are\VBP\836236 improved\VBN\126264 by\IN\1740 fluoxetine\NN\4169152 .\.\1740
D007980_D004409 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 seven\CD\13741022 <e1>levodopa-responsive</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D007980_D004409 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 fluoxetine\NN\4169152 may\MD\15209706 reduce\VB\441445 <e1>levodopa-</e1>\NN\1740 or\CC\3541091 dopamine\NN\14807737 agonist-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 without\IN\1740 aggravating\VBG\126264 parkinsonian\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D005473_D004409 CID Levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 are\VBP\836236 improved\VBN\126264 by\IN\1740 <e1>fluoxetine</e1>\NN\4169152 .\.\1740
D005473_D004409 CID We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>fluoxetine</e1>\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D005473_D004409 CID After\IN\1740 <e1>fluoxetine</e1>\NN\4169152 treatment\NN\654885 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 47\CD\1740 %\NN\1740 improvement\NN\7359599 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 apomorphine-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 without\IN\1740 modification\NN\191142 of\IN\1740 parkinsonian\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D005473_D004409 CID The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 <e1>fluoxetine</e1>\NN\4169152 may\MD\15209706 reduce\VB\441445 levodopa-\NN\1740 or\CC\3541091 dopamine\NN\14807737 agonist-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 without\IN\1740 aggravating\VBG\126264 parkinsonian\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D007980_D009069 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 <e1>levodopa-responsive</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D007980_D009069 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 fluoxetine\NN\4169152 may\MD\15209706 reduce\VB\441445 <e1>levodopa-</e1>\NN\1740 or\CC\3541091 dopamine\NN\14807737 agonist-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 aggravating\VBG\126264 parkinsonian\JJ\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 .\.\1740
D007980_D010300 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 <e1>levodopa-responsive</e1>\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D007980_D010300 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 fluoxetine\NN\4169152 may\MD\15209706 reduce\VB\441445 <e1>levodopa-</e1>\NN\1740 or\CC\3541091 dopamine\NN\14807737 agonist-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 aggravating\VBG\126264 <e2>parkinsonian</e2>\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D004298_D009069 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 <e1>dopamine</e1>\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D004298_D009069 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 fluoxetine\NN\4169152 may\MD\15209706 reduce\VB\441445 levodopa-\NN\1740 or\CC\3541091 <e1>dopamine</e1>\NN\14807737 agonist-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 aggravating\VBG\126264 parkinsonian\JJ\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 .\.\1740
D004298_D004409 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 <e1>dopamine</e1>\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D004298_D004409 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 fluoxetine\NN\4169152 may\MD\15209706 reduce\VB\441445 levodopa-\NN\1740 or\CC\3541091 <e1>dopamine</e1>\NN\14807737 agonist-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 without\IN\1740 aggravating\VBG\126264 parkinsonian\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D004298_D010300 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 <e1>dopamine</e1>\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D004298_D010300 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 fluoxetine\NN\4169152 may\MD\15209706 reduce\VB\441445 levodopa-\NN\1740 or\CC\3541091 <e1>dopamine</e1>\NN\14807737 agonist-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 aggravating\VBG\126264 <e2>parkinsonian</e2>\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D001058_D009069 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 <e1>apomorphine</e1>\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D001058_D009069 NONE After\IN\1740 fluoxetine\NN\4169152 treatment\NN\654885 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 47\CD\1740 %\NN\1740 improvement\NN\7359599 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 modification\NN\191142 of\IN\1740 parkinsonian\JJ\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 .\.\1740
D001058_D004409 CID We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 <e1>apomorphine</e1>\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D001058_D004409 CID After\IN\1740 fluoxetine\NN\4169152 treatment\NN\654885 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 47\CD\1740 %\NN\1740 improvement\NN\7359599 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 without\IN\1740 modification\NN\191142 of\IN\1740 parkinsonian\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D001058_D010300 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 <e1>apomorphine</e1>\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 fluoxetine\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D001058_D010300 NONE After\IN\1740 fluoxetine\NN\4169152 treatment\NN\654885 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 47\CD\1740 %\NN\1740 improvement\NN\7359599 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 modification\NN\191142 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D005473_D009069 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>fluoxetine</e1>\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D005473_D009069 NONE After\IN\1740 <e1>fluoxetine</e1>\NN\4169152 treatment\NN\654885 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 47\CD\1740 %\NN\1740 improvement\NN\7359599 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 apomorphine-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 modification\NN\191142 of\IN\1740 parkinsonian\JJ\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 .\.\1740
D005473_D009069 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 <e1>fluoxetine</e1>\NN\4169152 may\MD\15209706 reduce\VB\441445 levodopa-\NN\1740 or\CC\3541091 dopamine\NN\14807737 agonist-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 aggravating\VBG\126264 parkinsonian\JJ\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 .\.\1740
D005473_D010300 NONE We\PRP\1740 evaluated\VBD\670261 the\DT\1740 severity\NN\5036394 of\IN\1740 motor\NN\3699975 disability\NN\14547369 and\CC\1740 dyskinesias\NNS\14084880 in\IN\13603305 seven\CD\13741022 levodopa-responsive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 after\IN\1740 an\DT\6697703 acute\JJ\1740 challenge\NN\13927383 with\IN\1740 the\DT\1740 mixed\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 apomorphine\NN\3786417 ,\,\1740 before\IN\1740 and\CC\1740 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>fluoxetine</e1>\NN\4169152 (\-LRB-\1740 20\CD\13745420 mg\NN\13717155 twice\RB\1740 per\IN\1740 day\NN\15154774 )\-RRB-\1740 for\IN\1740 11\CD\13745420 +/-\CC\1740 1\CD\13741022 days\NNS\15140892 .\.\1740
D005473_D010300 NONE After\IN\1740 <e1>fluoxetine</e1>\NN\4169152 treatment\NN\654885 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 significant\JJ\1740 47\CD\1740 %\NN\1740 improvement\NN\7359599 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 of\IN\1740 apomorphine-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 modification\NN\191142 of\IN\1740 <e2>parkinsonian</e2>\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
D005473_D010300 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 increased\VBN\169651 brain\NN\5462674 serotoninergic\NN\1740 transmission\NN\121166 with\IN\1740 <e1>fluoxetine</e1>\NN\4169152 may\MD\15209706 reduce\VB\441445 levodopa-\NN\1740 or\CC\3541091 dopamine\NN\14807737 agonist-induced\JJ\1740 dyskinesias\NNS\14084880 without\IN\1740 aggravating\VBG\126264 <e2>parkinsonian</e2>\JJ\1740 motor\NN\3699975 disability\NN\14547369 .\.\1740
18165598
D002045_D010146 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 prostaglandin\NN\5414534 E2\NN\1740 release\NN\3748886 ,\,\1740 cyclooxygenase\NN\14732946 gene\NN\8459252 expression\NN\4679549 and\CC\1740 <e2>pain</e2>\NN\14299637 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 pain\NN\14299637 model\NN\5888929 .\.\1740
D002045_D010146 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 prostaglandin\NN\5414534 E2\NN\1740 release\NN\3748886 ,\,\1740 cyclooxygenase\NN\14732946 gene\NN\8459252 expression\NN\4679549 and\CC\1740 pain\NN\14299637 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 <e2>pain</e2>\NN\14299637 model\NN\5888929 .\.\1740
D002045_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 <e1>bupivacaine/rofecoxib</e1>\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 <e2>pain</e2>\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 bupivacaine/placebo\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 pain\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 PGE2\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D002045_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 <e1>bupivacaine/rofecoxib</e1>\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 pain\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 bupivacaine/placebo\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 <e2>pain</e2>\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 PGE2\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D002045_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 bupivacaine/rofecoxib\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 <e2>pain</e2>\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 <e1>bupivacaine/placebo</e1>\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 pain\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 PGE2\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D002045_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 bupivacaine/rofecoxib\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 pain\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 <e1>bupivacaine/placebo</e1>\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 <e2>pain</e2>\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 PGE2\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D002045_D010146 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>bupivacaine</e1>\NN\1740 stimulates\VBZ\137313 COX-2\NN\14737847 gene\NN\8459252 expression\NN\4679549 after\IN\1740 tissue\NN\5220461 injury\NN\14052046 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 higher\JJR\1740 PGE2\NN\1740 production\NN\30358 and\CC\1740 <e2>pain</e2>\NN\14299637 after\IN\1740 the\DT\1740 local\JJ\1740 anesthetic\JJ\1740 effect\NN\34213 dissipates\NNS\1740 .\.\1740
D008012_D010146 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 bupivacaine\NN\1740 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 prostaglandin\NN\5414534 E2\NN\1740 release\NN\3748886 ,\,\1740 cyclooxygenase\NN\14732946 gene\NN\8459252 expression\NN\4679549 and\CC\1740 <e2>pain</e2>\NN\14299637 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 pain\NN\14299637 model\NN\5888929 .\.\1740
D008012_D010146 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 bupivacaine\NN\1740 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 prostaglandin\NN\5414534 E2\NN\1740 release\NN\3748886 ,\,\1740 cyclooxygenase\NN\14732946 gene\NN\8459252 expression\NN\4679549 and\CC\1740 pain\NN\14299637 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 <e2>pain</e2>\NN\14299637 model\NN\5888929 .\.\1740
D015232_D010146 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 bupivacaine\NN\1740 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 <e1>prostaglandin\NN\5414534 E2</e1>\NN\1740 release\NN\3748886 ,\,\1740 cyclooxygenase\NN\14732946 gene\NN\8459252 expression\NN\4679549 and\CC\1740 <e2>pain</e2>\NN\14299637 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 pain\NN\14299637 model\NN\5888929 .\.\1740
D015232_D010146 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 bupivacaine\NN\1740 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 <e1>prostaglandin\NN\5414534 E2</e1>\NN\1740 release\NN\3748886 ,\,\1740 cyclooxygenase\NN\14732946 gene\NN\8459252 expression\NN\4679549 and\CC\1740 pain\NN\14299637 in\IN\13603305 a\DT\13649268 clinical\JJ\1740 <e2>pain</e2>\NN\14299637 model\NN\5888929 .\.\1740
D015232_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 bupivacaine/rofecoxib\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 <e2>pain</e2>\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 bupivacaine/placebo\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 pain\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 <e1>PGE2</e1>\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D015232_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 bupivacaine/rofecoxib\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 pain\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 bupivacaine/placebo\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 <e2>pain</e2>\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 <e1>PGE2</e1>\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D015232_D010146 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 bupivacaine\NN\1740 stimulates\VBZ\137313 COX-2\NN\14737847 gene\NN\8459252 expression\NN\4679549 after\IN\1740 tissue\NN\5220461 injury\NN\14052046 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 higher\JJR\1740 <e1>PGE2</e1>\NN\1740 production\NN\30358 and\CC\1740 <e2>pain</e2>\NN\14299637 after\IN\1740 the\DT\1740 local\JJ\1740 anesthetic\JJ\1740 effect\NN\34213 dissipates\NNS\1740 .\.\1740
D002045_D010149 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 proinflammatory\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 on\IN\1740 local\JJ\1740 prostaglandin\NN\5414534 E2\NN\1740 (\-LRB-\1740 PGE2\NN\1740 )\-RRB-\1740 production\NN\30358 and\CC\1740 cyclooxygenase\NN\14732946 (\-LRB-\1740 COX\NN\14732946 )\-RRB-\1740 gene\NN\8459252 expression\NN\4679549 that\WDT\1740 increases\VBZ\169651 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 human\JJ\1740 subjects\NNS\6598915 .\.\1740
D015232_D010149 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 proinflammatory\JJ\1740 effects\NNS\13245626 of\IN\1740 bupivacaine\NN\1740 on\IN\1740 local\JJ\1740 <e1>prostaglandin\NN\5414534 E2</e1>\NN\1740 (\-LRB-\1740 PGE2\NN\1740 )\-RRB-\1740 production\NN\30358 and\CC\1740 cyclooxygenase\NN\14732946 (\-LRB-\1740 COX\NN\14732946 )\-RRB-\1740 gene\NN\8459252 expression\NN\4679549 that\WDT\1740 increases\VBZ\169651 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 human\JJ\1740 subjects\NNS\6598915 .\.\1740
D015232_D010149 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 describe\VBP\1001294 the\DT\1740 proinflammatory\JJ\1740 effects\NNS\13245626 of\IN\1740 bupivacaine\NN\1740 on\IN\1740 local\JJ\1740 prostaglandin\NN\5414534 E2\NN\1740 (\-LRB-\1740 <e1>PGE2</e1>\NN\1740 )\-RRB-\1740 production\NN\30358 and\CC\1740 cyclooxygenase\NN\14732946 (\-LRB-\1740 COX\NN\14732946 )\-RRB-\1740 gene\NN\8459252 expression\NN\4679549 that\WDT\1740 increases\VBZ\169651 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 in\IN\13603305 human\JJ\1740 subjects\NNS\6598915 .\.\1740
C116926_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 <e1>bupivacaine/rofecoxib</e1>\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 <e2>pain</e2>\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 bupivacaine/placebo\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 pain\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 PGE2\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
C116926_D010146 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 <e1>bupivacaine/rofecoxib</e1>\JJ\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 less\RBR\1740 pain\JJ\1740 ,\,\1740 as\IN\14622893 assessed\VBN\670261 by\IN\1740 a\DT\13649268 visual\JJ\1740 analog\NN\4743605 scale\NN\7260623 ,\,\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 over\IN\5867413 the\DT\1740 first\JJ\1740 4\CD\13741022 h.\NN\1740 However\RB\1740 ,\,\1740 the\DT\1740 bupivacaine/placebo\NN\1740 group\NN\2137 reported\VBD\831651 significantly\RB\1740 more\JJR\1740 <e2>pain</e2>\NN\14299637 at\IN\14622893 24\CD\13745420 h\NN\14622893 and\CC\1740 PGE2\NN\1740 levels\NNS\4916342 during\IN\1740 the\DT\1740 first\JJ\1740 4\CD\13741022 h\NN\14622893 were\VBD\836236 significantly\RB\1740 higher\JJR\1740 than\IN\1740 the\DT\1740 other\JJ\1740 three\CD\13741022 treatment\NN\654885 groups\NNS\2137 .\.\1740
D002045_D017695 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>bupivacaine</e1>\NN\1740 stimulates\VBZ\137313 COX-2\NN\14737847 gene\NN\8459252 expression\NN\4679549 after\IN\1740 <e2>tissue\NN\5220461 injury</e2>\NN\14052046 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 higher\JJR\1740 PGE2\NN\1740 production\NN\30358 and\CC\1740 pain\NN\14299637 after\IN\1740 the\DT\1740 local\JJ\1740 anesthetic\JJ\1740 effect\NN\34213 dissipates\NNS\1740 .\.\1740
D015232_D017695 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 bupivacaine\NN\1740 stimulates\VBZ\137313 COX-2\NN\14737847 gene\NN\8459252 expression\NN\4679549 after\IN\1740 <e2>tissue\NN\5220461 injury</e2>\NN\14052046 ,\,\1740 which\WDT\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 higher\JJR\1740 <e1>PGE2</e1>\NN\1740 production\NN\30358 and\CC\1740 pain\NN\14299637 after\IN\1740 the\DT\1740 local\JJ\1740 anesthetic\JJ\1740 effect\NN\34213 dissipates\NNS\1740 .\.\1740
